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Skeletal stem cells are maintained in a Wnt-inhibitory environment within 
the resting zone of the growth plate *Shawn Hallett1, Noriaki Ono1. 1University 
of Michigan School of Dentistry, United States
Chondrocytes in the resting zone of the postnatal growth plate are characterized by their 
slow-cycling nature, which include a population of skeletal stem cells that form columnar 
chondrocytes, osteoblasts and bone marrow stromal cells over time. Slow-cycling chondro-
cytes express parathyroid hormone-related protein (PTHrP), constituting the PTHrP-indian 
hedgehog feedback loop essential for growth plate maintenance. However, the molecular 
mechanisms regulating resting chondrocyte differentiation into proliferating, columnar 
chondrocytes are unknown. Here, we utilized a genetic pulse-chase approach to isolate 
slow cycling chondrocytes (LRCs) from the postnatal growth plate resting zone using a 
chondrocyte-specific doxycycline-controllable Tet-Off system regulating expression of his-
tone-linked GFP (H2B-GFP). FACS sorting of dissected growth plates was conducted to iso-
late H2B-GFPhigh; Col2a1-creERtdTom LRCs versus H2B-GFPlow; Col2a1-creERtdTom 
non-LRCs. An RNA-seq transcriptomic analysis of LRCs identified significant enrichment 
of Wnt inhibitors and resting zone chondrocyte markers while non-LRCs were enriched for 
pre-hypertrophic and hypertrophic chondrocyte markers. To define the functional role of 
Wnt signaling on LRCs, we activated Wnt/ß-catenin signaling in PTHrP+ resting chondro-
cytes by conditionally inducing haploinsufficiency of Adenomatous polyposis coli (Apc), 
a component of the ß-catenin degradation complex, using a PTHrP-creER line and Apc-
floxed allele combined with a tdTomato reporter allowing cell-lineage analyses. Animals 
were injected with tamoxifen at postnatal day 6 (P6) and chased until P12, 21, 36 and 96. 
PTHrP+ resting chondrocytes and short (10 cells) columnar chondrocytes were quantified to 
assess PTHrP+ skeletal stem cell formation and short/long-term self-renewal capability. By 
P12 and P21, Apc-haploinsufficient PTHrP+ resting chondrocytes and the number of short 
columns were significantly reduced compared to controls. After 3 months of chase at P96, 
Apc-haploinsufficient PTHrP+ resting chondrocytes established long columns less effective-
ly than their controls. These data indicate that Wnt/ß-catenin activation impairs formation 
and short and long-term self-renewal of PTHrP+ chondrocytes. These findings reveal that 
slow-cycling chondrocytes are maintained in a canonical Wnt-inhibitory environment, un-
raveling a novel mechanism regulating self-renewal and differentiation of PTHrP+ skeletal 
stem cells of the postnatal growth plate.
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Phlpp1 inhibition improves post-traumatic osteoarthritis through 
independent effects on chondrocytes and neurons *Samantha Weaver1, Ian 
Lorang1, Xiaodong Li1, Elizabeth Bradley2, Jennifer Westendorf1. 1Mayo Clinic, 
United States, 2University of Minnesota, United States
Osteoarthritis (OA) in the knee is a debilitating condition that causes significant pain 
and morbidity. Phlpp1 and Phlpp2 are highly expressed in human OA tissue but not normal 
articular cartilage and genomic variants are associated with human OA in GWAS studies. 
Inhibition of Phlpp1 protein phosphatase has previously been shown to preserve cartilage, 
reduce allodynia, and improve function in a murine model of post-traumatic OA (PTOA). 
Phlpp1-/- mice and WT mice given an intra-articular injection of a small-molecule Phlpp 
inhibitor into the knee joint space are protected from PTOA. To investigate the specific cell 
type responsible for cartilage preservation in Phlpp1-depleted mice, Phlpp1 was deleted in 
Aggrecan-expressing (Agc+) cells at 12 weeks of age (Phlpp1-CKOAgc). At 17 weeks old, 
male mice were subjected to destabilization of the medial meniscus (DMM) surgery in the 
right knee. PTOA progression was monitored over the subsequent 12 weeks through activity 
assays, at which point mice were euthanized and limbs collected for histology. Phlpp1-CKO-
Agc mice were not protected from functional impairments as previously demonstrated in 
Phlpp1-/- mice. However, Phlpp1-CKOAgc knee articular cartilage was preserved compared 
to WT-AgcCre+ mice, with an overall lower summed OARSI score. These data suggest that 
Phlpp1 expression in chondrocytes contributes to cartilage degradation following PTOA. 
To test the effects of Phlpp1 inactivation on sensory neurons responsible for pain signal-
ing, primary rat dorsal root ganglia (DRG) were treated in culture with increasing doses of 
Phlpp inhibitor NSC117079 for 28 days. NSC117079 reduced neurite outgrowth and ex-
pression of small/medium sensory neurons (NTrk1) and neurotransmitters (Cgrp), but not 
a common neuronal gene (Uchl1) in a dose dependent manner. To translate these findings 
in vivo, Phlpp1-CKOAgc mice were given an intra-articular injection of NSC117079 into 
the DMM-operated knee 7 weeks post-surgery. Both Phlpp1-CKOAgc and WT-AgcCre+ 
administered NSC117079 spent less time resting during subsequent weekly activity assays, 
indicating improved pain. Bone sections from mice injected with NSC117079 indicated re-
duced staining of pain neurotransmitters Substance P in the subchondral bone and NF200 in 
the periosteum. Taken together, these data suggest that Phlpp1 inhibition preserves cartilage 
and improves pain during OA progression by simultaneously working in different cell types, 
including chondrocytes and neurons.
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Feedback-regulatory loop between MYC and NRF2 controls 
osteoclastogenesis and pathological bone erosion *Peter Sang Uk Park1, 
Sehwan Mun1, Steven Zeng1, Seyeon Bae1, Kyung-Hyun Park-Min2. 1Arthritis 
and Tissue Degeneration Program, David Z. Rosensweig Genomics Research 
Center, Hospital for Special Surgery, United States, 2Arthritis and Tissue 
Degeneration Program, David Z. Rosensweig Genomics Research Center, 
Hospital for Special Surgery, New York, NY, USA, United States
Osteoclasts are bone-resorbing cells that play an essential role in homeostatic bone 
remodeling, and defects in osteoclasts result in unbalanced bone resorption and pathological 
bone loss such as inflammatory arthritis and osteoporosis. Receptor activator of NF-kappa 
B ligand (RANKL) is an essential regulator of osteoclast formation and activity. Therefore, 
developing targeted therapies of the molecular pathways downstream of RANKL has been 
a promising approach to alleviating bone disease. However, the RANKL-RANK network 
is involved in various biological processes, and a deeper understanding of the molecular 
pathways specific to osteoclasts is needed. Recently, the crucial role of MYC and its down-
stream effectors in driving osteoclast differentiation and pathological bone loss has been 
demonstrated, suggesting that MYC-driven transcriptional cascade in osteoclasts is a poten-
tial treatment target downstream of RANKL. Despite these advances, upstream regulators 
of the MYC network in osteoclasts are not well defined. In this study, we identify Nuclear 
factor erythroid-derived 2 (NRF2), a transcription factor known to regulate the expression of 
phase II antioxidant enzymes, as a novel upstream regulator of MYC and promising target 
for bone diseases. We find that RANKL-induced transcription and stability of MYC are 
negatively regulated by NRF2. Pharmacological activation of NRF2 completely suppress-
es MYC expression while NRF2-deficiency increases MYC expression. Mechanistically, 
NRF2 negatively regulates MYC through suppressing RANKL-induced ERK activation, 
and blocking ERK completely inhibits NRF2 deficiency-induced osteoclast formation. To 
further understand the pathophysiological role of MYC in NRF2-mediated suppression of 
osteoclastogenesis, we generated osteoclast-specific MYC/NRF2-deficient mice. The ab-
lation of MYC in osteoclasts reverses enhanced osteoclast differentiation and activity by 
NRF2 deficiency both in vivo and in vitro. Furthermore, we also find that MYC is responsi-
ble for the accelerated arthritic bone destruction in NRF2 deficient mice in a murine model 
of inflammatory arthritis.Collectively, our results identify the functional feedback loop be-
tween MYC and NRF2 during osteoclastogenesis. Our findings also indicate that this novel 
NRF2-ERK-MYC axis could be instrumental for the fine-tuning of osteoclast formation and 
provide additional ways in which osteoclasts could be therapeutically targeted to prevent 
pathological bone erosion.
Disclosures: Peter Sang Uk Park, None
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Live Cell and Intravital Imaging of Osteoclast Resorption Dynamics and 
Osteocyte Fate During Resorption *Sarah Dallas1, Valerie Kirtley1, LeAnn 
Tiede-Lewis1, Eleanor Ray1, Yixia Xie1, Lora Shiflett1. 1University of Missouri 
Kansas City, United States
Transgenic gain and loss of function models, osteoclast culture models and naturally 
occurring mutations have advanced understanding of the mechanisms regulating osteoclast 
differentiation and function. However, only a few studies have used live cell imaging to 
determine the dynamic behaviors of osteoclasts in situ within bone. Using transgenic mice 
with fluorescently tagged osteoclasts, osteocytes and collagen, live cell and intravital imag-
ing was used to understand the dynamic and resorptive behavior of osteoclasts in bone and 
determine the fate of osteocytes undergoing resorption.Transgenic lines crossed in various 
combinations for 2-color imaging included mice with osteoclast expression of tdTomato 
(LysM-Cre/tdTom), osteocyte expression of GFP (Dmp1-AcGFPmem) or tdTomato (Dmp1-
cre/tdTom) and mice with GFPtpz-tagged type I collagen (Col-GFP). Widefield or confocal 
live cell imaging was done in calvarial explants with & without PAM3CSK4, a proinflamma-
tory stimulator of resorption, and intravital multiphoton imaging was done in 4-6wk mice. 
Live imaging in LysM-Cre/tdTom calvaria revealed that osteoclasts were highly motile, with 
maximum velocities up to 52.6+/-5.7μm/h and a mean of 13.5+/-1.4μm/h and had a highly 
branched, multi-lobed morphology, with many cell projections. Over 48h of imaging the 
osteoclast morphology continually changed, with extension & retraction of cell processes, 
amoeboid-like streaming of the cell and formation of multiple transient actin rings(sealed 
zones) that correlated with advancing resorption fronts. Some osteoclasts underwent fu-
sion with adjacent osteoclasts or fission into 2 or more osteoclasts that continued to resorb. 
PAM3CSK4 significantly reduced the maximum & mean osteoclast velocity to 38.3+/-2.1 
& 8.8+/-0.4μm/h, promoted resorption and osteoclast survival, increased the directionality 
of motion, increased the mean # of actin rings per osteoclast from 0.27+/-0.11 to 1.4+/-
0.25 and decreased fusion with a trend towards increased fission. Dual imaging of osteo-
clasts/osteocytes and collagen/osteocytes showed that ~93% of osteocytes in resorbed bone 
underwent cell death, 6% were internalized into osteoclasts and in rare cases (~1%), they 
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survived resorption by migrating out of their lacunae (n=91 osteocytes). These data provide 
new insight into the dynamic behavior of osteoclasts in the natural bone environment, how 
these dynamics are altered in inflammatory bone resorption, and reveal the fate of osteocytes 
undergoing resorption.
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Endoplasmic reticulum stress induced inhibition of mitochondrial transfer 
and cathepsin K secretion in osteocyte network - a novel mechanism 
of glucocorticoid induced bone loss *Junjie Gao1, Jun Yuan2, Delin Liu2, 
Changqing Zhang3, Minghao Zheng4. 1Perron Institute for Neurological and 
Translational Science, Nedlands, Western Australia, 6009, Australia, Australia, 
2Centre for Orthopaedic Translational Research, Medical School, University 
of Western Australia, Nedlands, Western Australia, 6009, Australia., Australia, 
3Department of Orthopaedics, Shanghai Sixth People’s Hospital, Shanghai 
Jiaotong University, Shanghai, 200233, China., China, 4Centre for Orthopaedic 
Translational Research, Medical School, University of Western Australia, 
Nedlands, Western Australia, 6009, Australia., Australia
Glucocorticoid (GC) associated osteoporosis is common but GC-triggered bone loss 
remains largely unclear. Accounting for 90% of cell population, osteocytes and their network 
may play critical role in response to GC administration. Previously we showed that endo-
plasmic reticulum (ER) regulated activity and transfer of mitochondria within osteocyte den-
dritic processes is critical for bone hemostasis. Here we showed for the first time that GC in-
hibits osteocyte homeostasis by suppressing mitochondrial transfer between osteocytes and 
induced secretion of cathepsin K through the induction of mitophagy of osteocytes. We first 
showed that dexamethasone (Dex) modified the configuration of ER in osteocytes from a tu-
bular-like form to a stressed condensed sheet-like pattern. The change of configuration lead 
to the arrest of MitoTracker® Green labelled mitochondrial movement along the dendritic 
network and compromise mitochondrial transfer within the osteocyte dendritic network. 
Degradation of Mfn2 by GC induced PINK1 activation is responsible for the inhibition of 
mitochondrial transfer evidenced by siRNA study in MLO-Y4 cells. We further showed that 
PINK1-mediated mitophagy has resulted in the induction of cathepsin K in mouse calvaria 
culture. Knocking down PINK1 gene but not Atg5 abolished the GC-triggered cathepsin K 
production suggesting that production of cathepsin K in osteocytes following GC treatment 
is mediated by a non-canonical autophagy pathway. In summary, our results indicate that 
GC-induced PINK1 modulates both of the mitochondrial transfer, and the production of 
cathepsin K in osteocytes, thereby contributing to the GC-induced bone loss.
Disclosures: Junjie Gao, None
1006
Mmp9 and Mmp14 Cooperatively Orchestrate Osteoclast Activation via 
Surface Galectin-3 Lattice Proteolysis *Lingxin Zhu1, Yi Tang2, Xiao-Yan Li2, 
Samuel Kerk3, Evan Keller4, Jung-Sun Cho2, Tamar Feinberg2, Costas Lyssiotis3, 
Stephen Weiss2. 1School and Hospital of Stomatology, Wuhan University, China, 
2Life Sciences Institute, University of Michigan, United States, 3Department of 
Molecular and Integrative Physiology, University of Michigan, United States, 
4Department of Pathology, University of Michigan, United States
During bone resorption, osteoclasts (OCs) undergo extensive transcriptional and meta-
bolic reprogramming while reorganizing cytoskeletal structure, and secreting protons along 
with proteases into resorption lacunae. We recently identified a cathepsin K-independent 
collagenolytic system in OCs that includes a functionally redundant network of the matrix 
metalloproteinases, Mmp9 and Mmp14 (Sci Transl Med 12:529, 2020). However, wheth-
er Mmp9/Mmp14 might also impact the cellular transcriptional and metabolic landscape 
of OCs remains unknown. To address this issue, we generated a myeloid-specific Mmp14 
conditional knockout mice (Csf1r-Cre/Mmp14f/f) in either Mmp9 wild-type or null back-
grounds. Primary bone marrow-derived macrophages were isolated and differentiated into 
OCs, then subjected to integrated transcriptional-metabolic profiling. Unexpectedly, over 
700 transcript changes were detected with remarkable transcriptional alterations noted in 
cytoskeleton- and carbohydrate metabolism-associated gene products in Mmp9/Mmp14 
double-knockout (DKO) OCs. Nevertheless, OC differentiation, mitochondrial abundance, 
tricarboxylic acid cycle- and glycolysis-related metabolic products were unaffected in the 
DKO OCs. Interestingly, however, the compromised sealing zone formation and hypo-re-
sorptive phenotype - observed both in vitro and in vivo - in tandem with alterations in car-
bohydrate metabolism, drew our attention to galectin-3, a putative regulator of OC function 
and a known substrate for both Mmp9 and Mmp14. Indeed, osteoclastic Mmp9 and Mmp14 
cooperatively regulated the proteolytic turnover of galectin-3, wherein the DKO OCs dis-
played significant increases in membrane-associated levels of the lectin. Consistent with 
recent studies demonstrating that Lgals3-/- mice display decreased bone mass with increased 
OC activity in vivo, we find that exogenous galectin-3 significantly inhibited sealing zone 
formation and bone resorption in wild-type OCs without affecting OC differentiation. Im-
portantly, the galectin-3 inhibitor, GCS-100, which blocks surface galectin-3 binding, sig-
nificantly reversed the defective sealing zone formation and bone resorption by DKO OCs. 
Together, these studies characterize a previously unsuspected Mmp9/Mmp14 axis that not 
only participates in mediating bone type I collagenolytic activity, but also serves to control 
transcriptional programs underlying the galectin-3-dependent regulation of sealing zone for-
mation and bone resorptive activity.
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Loss of Function of PFN1 Drives the Development of Pagetic and Primary 
Osteosarcoma *Federica Scotto di Carlo1, Sharon Russo2, Francesc Muyas3, 
Laura Pazzaglia4, Teresa Esposito1, Carmine Settembre5, Isidro Cortés-Ciriano3, 
Fernando Gianfrancesco1. 1Institute of Genetics and Biophysics, National 
Research Council of Italy, Italy, 2Institute of Genetics and Biophysics National 
Research Council of Italy, Italy, 3European Molecular Biology Laboratory, 
European Bioinformatics Institute, Wellcome Genome Campus, United 
Kingdom, 4IRCCS Istituto Ortopedico Rizzoli, Laboratory of Experimental 
Oncology, Italy, 5Telethon Institute of Genetics and Medicine (TIGEM), Italy
Osteosarcoma (OS) is an aggressive tumor of mesenchymal origin, characterized by a 
great genetic heterogeneity due to highly rearranged genomes. Rarely, it arises as degenera-
tion of Paget’s disease of bone (OS/PDB), a late-onset bone remodeling disorder, and shows 
a 5-year survival rate almost nil. We recently identified a loss-of-function mutation in the 
PFN1 gene, encoding the Profilin 1, as responsible for early-onset Paget’s disease compli-
cated by OS (Scotto di Carlo et al., J Bone Miner Res. 2020. doi: 10.1002/jbmr.3964). In-
terestingly, the analysis performed on our cohort of human tumor samples detected genomic 
loss of PFN1 in 15 out of 28 (54%) OS/PDB and 15 out of 50 (30%) primary OS, resulting in 
downregulation Profilin 1. More importantly, we observed reduced PFN1 protein levels also 
in tumors without the genomic loss of PFN1. We explained this last result through luciferase 
assay that demonstrated PFN1 as transcriptional target of p53, a well-known tumor sup-
pressor in OS.To obtain additional clues on the PFN1 pathogenic role, we generated a Pfn1 
knock-in mouse model. Micro-CT analysis revealed that heterozygous mice (n=9) as young 
as 4 months show a reduction of bone volume in their femurs by 25% (P=0,003), compared 
with wild type (n=9), further confirming the early development of bone remodeling alter-
ations. Mutant spleen-derived osteoclasts confirmed the accelerated osteoclast differentia-
tion in vitro. Intriguingly, mesenchymal cells isolated from Pfn1-KI calvariae (n=7) showed 
a 30% higher proliferation rate compared to WT cells (n=4), suggesting a predisposition 
to sarcomatous transformation. We performed whole genome sequencing (WGS) on 4 OS/
PDB and their normal counterparts, highlighting high burden of genomic rearrangements in 
tumor samples. Accordingly, MC3T3 pre-osteoblasts, engineered through CRISPR-Cas9 to 
knock-out the Pfn1 gene, acquired features of malignant transformation, namely enhanced 
proliferation and migration. These cells also exhibited nuclear abnormalities (binucleation, 
micronuclei, chromatin bridges), indicative of chromosome segregation defects and genom-
ic instability. In fact, WGS on eight independent Pfn1-KO clones confirmed extensive nu-
merical and structural chromosomal alterations, similar to what observed in OS/PDB (see 
figure). In conclusion, we describe the loss of function of PFN1 as a novel mutational event 
underlying imbalanced bone remodeling and genomic rearrangements in OS.
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Integrin alpha-5 in human breast cancer is a mediator of bone metastasis 
and a therapeutic target for the treatment of osteolytic lesions *Francesco 
Pantano1, Martine Croset2, Keltouma Driouch3, Natalia Bednarz-Knoll4, Michele 
Iulialni5, Giulia Ribelli5, Edith Bonnelye2, Harriet Wikman4, Sandra Geraci2, 
Florian Bonin3, Sonia Simonetti5, Bruno Vincenzi5, Saw See Hong6, Sofia 
Sousa2, Klaus Pantel4, Giuseppe Tonini5, Daniele Santini5, Philippe Clezardin2. 
1University of Rome, Italy, 2INSERM, UMR_S1033, University of Lyon, 
France, 3Institut Curie, France, 4University Medical Centre Hamburg-Eppendorf, 
Germany, 5Campus Bio-Medico University of Rome, Italy, 6INRA, UMR-754, 
Lyon, France
Bone metastasis remains a major cause of mortality and morbidity in breast cancer. 
Therefore, there is an urgent need to better select high-risk patients in order to adapt pa-
tient’s treatment and prevent bone recurrence. Here, we found that integrin alpha 5 (ITGA5) 
was highly expressed in bone metastases, compared to lung, liver or brain metastases. High 
ITGA5 expression in primary tumors correlated with the presence of disseminated tumor 
cells in bone marrow aspirates from early-stage breast cancer patients (n = 268; P = 0.039). 
ITGA5 was also predictive of poor bone metastasis-free survival in two separate clinical data 
sets (n = 855, HR = 1.36, P = 0.018 and n = 427, HR = 1.62, P = 0.024). This prognostic value 
remained significant in multivariate analysis (P = 0.028). Experimentally, ITGA5 silencing 
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impaired tumor cell adhesion to fibronectin, migration, and survival. ITGA5 silencing also 
reduced tumor cell colonization of the bone marrow and formation of osteolytic lesions in 
vivo. Conversely, ITGA5 overexpression promoted experimental bone metastasis. Pharma-
cological inhibition of ITGA5 with humanized monoclonal antibody M200 (volociximab) 
recapitulated inhibitory effects of ITGA5 silencing on tumor cell functions in vitro, and 
tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor 
outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted can-
cer-associated bone destruction. ITGA5 was not only expressed by tumor cells but also 
osteoclasts. Being selective to human ITGA5, this antibody did not interfere with murine 
osteoclast differentiation and activity in vitro. However, a clinically relevant concentration 
of M200 antibody was nearly as effective as the anti-RANKL antibody denosumab to inhibit 
human osteoclast differentiation and activity in vitro. Thus, in addition to its anti-tumor 
effect, M200 may also be effective at inhibiting bone resorption in vivo. Overall, this study 
identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that 
volociximab/M200 could be combined with the best standard of care for the treatment of 
ITGA5-positive breast cancer patients with bone metastases. 
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Activation of the Sympathetic Nerve System Weakens Anti-Tumoral 
Immunity in Bone via Beta 2 Adrenergic Receptors in Osteoblast and 
Myeloid-Derived Suppressor Cells, Contributing to Bone Metastasis 
Progression *Eun Jung Lee1, Kyung Jin Lee1, Serk In Park1. 1Korea University 
College of Medicine, Republic of Korea
The sympathetic nerve system (SNS) regulates bone homeostasis via β2 adrenergic re-
ceptor (Adrb2) on osteoblasts, and chronic psychological stress-induced SNS activation was 
shown to promote bone metastasis tumor growth, osteolysis, angiogenesis via osteoblastic 
cytokine expression in immunocompromised mouse models. We further investigated the ef-
fects of SNS activation on immune cells in the bone microenvironment using immune-com-
petent mouse models of breast cancer bone metastasis. Chronic immobilization stress (CIS, 
2 hours daily) increased 4T1 syngeneic breast tumor growth in bone that was reversed by 
administration of ICI-118551 (1mg/kg/day), a pharmacologic inhibitor of Adrb2. Moreover, 
CIS-treated tumors had increased CD11b+Gr1+ myeloid-derived suppressor cells (MDSC), 
a group of immature bone marrow cells with T cell suppression activity, compared with 
control-treated mice. Two-week CIS pre-treatment before intra-tibial tumor implantation in-
creased EdU+ proliferating MDSC, supporting that CIS primes the pre-metastatic niche in 
bone by tipping anti-tumoral immunity balance in favor of tumor growth. Based on previous 
publications showing that SNS activation and/or CIS effects are dependent on Adrb2 ex-
pressed on osteoblasts, we determined the effects of osteoblastic Adrb2 on MDSC function 
using in vitro co-culture system. Arginase 1 (Arg1), a functional marker of activated MDSC, 
expression in bone marrow cells increased when co-cultured with isoproterenol (an Adrb2 
agonist)-stimulated MC3T3E1 osteoblasts. In addition, isoproterenol increased C-C chemo-
kine ligand (CCL)-2, one of the known inducers of MDSC expansion, in MC3T3E1 osteo-
blasts. Our data collectively demonstrate that activation of the SNS contributes to breast 
cancer bone metastasis partly by expanding MDSC and subsequent T cell suppression. The 
SNS activation-dependent MDSC expansion is mediated by osteoblastic Adrb2 and CCL2 
expression. Further studies using osteoblast-specific Adrb2 knockout mice and CCR2-de-
pendent MDSC depletion/reconstitution experiments will provide more clear molecular 
mechanism underlying the SNS-dependent bone marrow immunity regulation.
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Stromal cell-guided transformation of MDS to AML *Álvaro Cuesta-
Domínguez1, Ioanna Mosialou2, Abdullah Ali3, Junfei Zhao4, Marta Galán-Díez5, 
Julie Teruya-Feldstein6, Ellin Berman7, Raúl Rabadán4, Azra Raza3, Stavroula 
Kousteni2. 1Department of Physiology and Cellular Biophysics, Vagelos College 
of Physicians & Surgeons, Columbia University Irving Medical Center, United 
States, 2Department of Physiology and Cellular Biophysics, Vagelos College of 
Physicians & Surgeons, Columbia University Irving Medical Center, United 
States, 3Department of Medicine, Vagelos College of Physicians & Surgeons, 
Columbia University Irving Medical Center, United States, 4Department 
of Systems Biology, Vagelos College of Physicians & Surgeons, Columbia 
University Irving Medical Center, United States, 5Department of Physiology and 
Cellular Biophysics, Vagelos College of Physicians and Surgeons, Columbia 
University Irving Medical Center, United States, 6Department of Pathology, 
Icahn School of Medicine at Mount Sinai, United States, 7Department of 
Pathology, Memorial Sloan-Kettering Cancer Center, United States
A pathogenic role of stromal cells in the bone marrow in the development of myelop-
roliferative neoplasia, myelodysplasia (MDS) and acute myeloid leukemia (AML) has been 
evidenced by a growing body of evidence. Activation of β-catenin signaling in osteoblast 
precursors induces AML in mice (βcat(ex3)2.3Col1a1 mice), is seen in approximately 38% 
of MDS/AML patients and correlates with disease severity and progression to AML. To 
examine whether it is involved in MDS to AML transformation, we constitutively activated 
β-catenin in mature osteoblasts (βcat(ex3)OCN mice). Similar to the leukemic βcat(ex3)
Col1a1 mice, βcat(ex3)OCN mice, presented with anemia, neutrophilia, thrombocytopenia, 
lymphocytopenia and dysplasia in the erythroid lineage. As opposed to 40% blasts detected 
in the bone marrow of βcat(ex3)Col1a1 mice, less than 15% blast blasts were detected in 
the bone marrow of βcat(ex3)OCN mice. In contrast to βcat(ex3)Col1a1 mice, βcat(ex3)
OCN mice showed extensive apoptosis in approximately 90% of myeloid cells in the bone 
marrow, spliceosome deregulation and increased methyltransferase expression, all hallmark 
characteristics of MDS. To gain mechanistic insight into the transformation of MDS to AML 
we compared the transcriptional profile of hematopoietic stem cell progenitors (LSK, Lin-/
cKit+/Sca+ cells)) from βcat(ex3)OCN (MDS) and βcat(ex3)Col1a1 (AML) mice as well as 
of bone marrow mononuclear cells (BM-MNCs) from 25 MDS patients and the same pa-
tients after they transformed to AML. We found that in both the mouse models and patients, 
expression of the Nucleoporin (NUP) family members was decreased with transformation to 
AML. Similarly, a comparison between the AML TCGA database and the human GEO MDS 
database indicated decreased expression of NUPs, in AML as compared to MDS samples. 
NUPs expression is also decreased in MDS cells of 58% of patients compared to healthy 
subjects; and, in LSK cells of two MDS mouse models, NUP98-HOXD13 and PU.1URE-
hetMsh2-/- mice, as compared to LSK cells from their wild type littermates. Notably, low 
NUPs expression associates with poor prognosis in TCGA AML and with enhanced β-caten-
in activity in stromal cells of MDS patients transformed to AML. These results indicate that 
downregulation of NUPs expression may be an important transformative effect of MDS to 
AML cells. This event is preferentially associated with and can be initiated by constitutive 
activation of β-catenin in mature, OCN-expressing osteoblasts
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Prostate Cancer-derived Extracellular Vesicles Negatively Affect Osteoblast 
Function *Giulia Furesi1, Martina Rauner1, Lorenz C. Hofbauer1. 1Department 
of Medicine III and Center for Healthy Aging, Dresden, Germany, Technische 
Universität Dresden, Germany, Germany
Patients with advanced prostate cancer (PCa) often develop bone metastasis. Extra-
cellular vesicles (EVs) have emerged as key players in the formation of the pre-metastatic 
niche and mediators of the crosstalk between tumor cells and the host microenvironment. 
However, the role of PCa-derived EVs in the establishment of a favorable tumor microenvi-
ronment in bone remains unclear. Here, we evaluated the effects of PCa-derived EVs on os-
teoblasts (OB) in vitro and in vivo. EVs were isolated from the murine osteotropic PCa cell 
line RM1-BM by ultracentrifugation and characterized by transmission electron microscopy, 
nanoparticle tracking analyzer, and Western blot analyses of surface markers. Internalization 
of PKH26-labeled EVs by murine primary OB was detected using fluorescence microscopy 
and flow cytometry. Additionally, OB were cultured with different concentrations (20, 50,100 
µg/ml) of PCa-derived EVs to assess dose-dependent effects on OB metabolic activity (Cell 
Titer Blue assay), vitality (crystal violet), and mineralization capacity (alizarin red staining). 
Also, RNA sequencing was performed to identify alterations in the gene expression profile 
of OB after EV treatment. Finally, the effect of PCa-derived EVs on osteogenesis in vivo 
was evaluated using BMP-2-induced bone formation in a calvarial defect mouse model. 
PCa-derived EVs displayed both the expected size of 50-100 nm as well as the expression 
of the common EV markers, CD63 and CD9. Fluorescence microscopy revealed the uptake 
of PCa-EVs into OB as early as after 1 h. After 24 h, nearly all OB contained tumor-derived 
EVs. OB treated with PCa-derived EVs showed a dose-dependent increase of cell metabol-
ic activity [+24%; +40%; +58% P<0.001] and viability [+32%; +52%; +65%; P<0.001] 
compared to untreated cells. In contrast, mineral deposition was significantly reduced [-4% 
to -37%; P<0.001]. Gene set enrichment analysis of OB treated with PCa-derived EVs ver-
sus normal OB showed a significant downregulation of osteoblastic markers [P<0.02] and 
upregulation of inflammatory factors [P<0.001]. In line with the in vitro studies, PCa-EVs 
potently inhibited BMP-2-induced bone formation in a calvaria defect model as assessed 
by µCT (P< 0.01). In summary, our results show that PCa-derived EVs impair OB activity, 
suggesting a potential role of EVs in the pre-metastatic dysregulation of bone remodeling.
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Rosen1, Thomas Andersen8, Andre van Wijnen2, Abbas Jafari3, Heather Fairfield1. 
1Maine Medical Center Research Institute, United States, 2Mayo Clininc, United 
States, 3University of Copenhagen, Denmark, 4Department of Internal Medicine, 
Division of Haematology, Vejle Hospital, Denmark, Denmark, 5Garvan Institute, 
Australia, 6Norwich University, United States, 0Garvan Institute, Australia, 
7Odense University Hospital & University of Southern Denmark, Denmark, 
8Vejle/Lillebaelt Hospital, University of Southern Denmark, Denmark
Bone marrow adipocytes (BMAds) have been implicated in accelerating bone meta-
static cancers and multiple myeloma (MM). Importantly, bone marrow (BM) adipose tissue 
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expands with aging and obesity- two key risk factors for MM- suggesting that BMAds may 
influence and be influenced by MM cells. BM biopsies showed significant loss of BM adi-
pose volume per marrow volume (AV/MV) in newly-diagnosed MM patients (n=19) versus 
healthy subjects (n=18), and significant reduction in BMAd size in MM versus MGUS or 
healthy subjects (Fig. 1). Proximal femurs from MM.1S tumor-bearing SCID-Beige mice 
(Fig. 1) had significantly fewer BMAds than naïve mice, and similar results were observed 
in the C57BL/KaLwRiJHsd-5TGM1 model (p<0.001). In vitro, murine adipocytes derived 
from 3T3-L1 cells or BM or ear mesenchymal stem cells (MSCs) had significant reduc-
tions in lipid content (p<0.0001) and adipogenic gene expression (Adipoq, Fabp4, p<0.001) 
when co-cultured with MM cells via transwell. Microarray and pathway analysis of 3T3-L1s 
co-cultured with MM cells indicated dysfunctional metabolic pathways, and the SeaHorse 
assay confirmed their defects in bioenergetic function. In human MSC-derived BMAs, 
co-culture with MM cells decreased expression of adipogenic genes and elevated expression 
of genes encoding senescence associated secretory proteins (SASPs), including: SERPINB2 
(204x), IL6 (175x), ICAM1 (33x), CXCL1 (58x), CXCL2 (39x) and VEGFA (5x), as as-
sessed by RNA sequencing. The “senescent-like” phenotype was confirmed via cytokine 
arrays and β-galactosidase staining in adipocytes exposed to MM.1S cells via transwell (p2 
FC) in MM cells co-cultured with BMAds, 3 of which are implicated in glucocorticoid re-
ceptor signaling. Our findings may help explain the dexamethasone resistance we observed 
in MM.1S cells co-cultured with BMAds, measured via flow cytometry and biolumines-
cence quantification. MM patients with higher BM AV/TV prior to dexamethasone and high 
dose melphalan followed by autologous transplant also exhibited a worse treatment response 
(-54%, p<0.05). These findings suggest that higher BMAd levels prior to treatment provides 
protection to MM cells. In summary, our findings reveal that bi-directional interactions be-
tween BMAds and MM cells have significant implications for the pathogenesis and treat-
ment of MM.
Disclosures: Michaela Reagan, None
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Control of Osteocytogenesis by a Neuronally−expressed Sp7−dependent 
Genetic Network *Jialiang Wang1, Tushar Kamath2, Evan Macosko2, Henry 
Kronenberg3, Marc Wein1. 1Massachusetts General Hospital, United States, 
2Broad Institute of MIT and Harvard, United States, 3Massachusetts Generial 
Hospital, United States
The transcription factor Sp7 coordinates cell type-specific gene expression programs at 
multiple stages in skeletal cell differentiation. Our previous data demonstrated that severe 
defects in osteocyte dendrite morphology are noted in mice lacking Sp7 during osteocyte 
differentiation. The combination of transcriptome and cistrome analyses identified 79 os-
teocyte-specific Sp7 targets. Osteocytes and neurons bear an elaborate network of cellular 
dendritic projections used for extensive inter-cellular communication. To explore links be-
tween osteocytes and neurons, we examined the enrichment of osteocyte-specific Sp7 targets 
in mouse brain at the single-cell transcriptomic level. This analysis revealed a significant 
enrichment of osteocytic Sp7 targets in neurons compared to other cell types in the mouse 
brain. These results suggest that Sp7 regulates a neuronally-enriched gene expression net-
work in order to coordinate osteocytogenesis.To capture cells undergoing osteoblast-to-os-
teocyte differentiation at single-cell resolution, we crossed Dmp1-Cre transgenic mice to 
Ai14 tdTomato reporter mice. Viable tdTomato+ cells were obtained from serial digestions 
of femora, tibiae and calvariae for single-cell RNA-seq. We successfully identified several 
osteo-lineage cell populations, including osteoblasts (marked by Bglap3), mineralized osteo-
cytes (Enpp1) and mature osteocytes (Pdpn). To understand the role of Sp7 during osteocyte 
differentiation, we compared single-cell datasets between Sp7 conditional knockout (cKO) 
mice to littermate controls. We detected striking changes in the proportions of key subpop-
ulations in Sp7 cKO mice (decrease: mineralized osteocyte; increase: mature osteocyte). 
Differential gene expression analysis revealed that terminal osteocyte markers are down-reg-
ulated in mutants across the entire population, including Pdpn, Atf3 and Ptprz1. Pseudotime 
analysis demonstrated dysregulated osteocyte differentiation in the absence of Sp7, with a 
specific block in a group of Lmo2-expressing mineralizing cells prior to becoming mature 
osteocytes. This suggests that Sp7-deficiency leads to an accumulation of mature osteocyte 
precursors and a relative paucity of mature osteocytes.Sp7 orchestrates osteocytogenesis via 
a suite of targets that promote the optimal formation of osteocyte dendrites. Findings from 
scRNA-seq analyses highlight shared transcriptome between osteocytes and neurons, and 
suggest novel steps in the treatment of osteoporosis.
Disclosures: Jialiang Wang, None
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Attenuation of Bone Loss by Activation of Connexin Hemichannels during 
Mechanical Unloading *Chao Tu1, Manuel A Riquelme1, Dezhi Zhao1, Sumin 
Gu1, Jean X Jiang1. 1Department of Biochemistry and Structural Biology, The 
University of Texas Health Science Center, San Antonio, TX 78229, USA, 
United States
Background: Emerging evidences have demonstrated that connexin 43 (Cx43)-forming 
gap junctions and hemichannels play a pivotal role in mediating mechanotransduction. How-
ever, the specific role of gap junctions and hemichannels in mechanotransduction remains 
elusive. Our previous study identified that inhibition of Cx43 hemichannels could enhance 
osteocytes apoptosis and impair periosteal bone remodeling, thereby aggregating the bone 
loss during unloading. We recently developed a monoclonal antibody, MHC2 that activates 
Cx43 hemichannels. By using this specific hemichannel-targeting MHC2, we aimed to in-
vestigate whether enhanced opening of hemichannel could attenuate the hindlimb unloading 
(HLU)-induced bone loss. Methods: 15-week-old male C57BL6 mice were tail-suspended 
or kept under ambulatory conditions for 4 weeks. Age-matched mice were randomly separat-
ed into different groups, and intraperitoneally injected with MHC2 or vehicle once per week 
at a dose of 25mg/kg. At the endpoint, the gastrocnemius and soleus muscle were weighted. 
The femurs and tibias were examined by micro-computed tomography (uCT) and histomor-
phometry, and bone turnover markers were measured by immunohistochemistry. Results: 
Mice exposed to HLU caused a significant muscle atrophy compared with non-unloaded 
counterparts. Moreover, HLU resulted in impaired cortical bone microstructure, increased 
empty osteocyte lacunae, restrained bone formation, and enhanced osteoclast activity, as 
evidenced by uCT, H&E and TRAP staining, respectively. By contrast, mice injected with 
MHC2 showed less severe muscle atrophy compared with those following vehicle treat-
ments. Notably, MHC2 contributed to elevated cortical thickness, bone volume fraction and 
BMD, and decreased empty lacunae and osteoclastogenesis in mice following HLU. Fur-
thermore, the sclerostin positive (SOST+) and apoptotic osteocytes in cortical bone caused 
by HLU were significantly decreased by MHC2 treatment. Conclusions: In this study, we 
showed that opening of hemichannel by MHC2 attenuated the catabolic function and subse-
quent bone loss during HLU, at least in part though suppression of osteocyte apoptosis and 
osteoclast activity. This study indicates an important role of hemichannels in protecting bone 
loss in response to mechanical unloading, and thus targeting Cx43 hemichannels may offer 
a new therapeutic strategy for treating bone loss and osteoporosis.
Disclosures: Chao Tu, None
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Disrupted Lacunar-Canalicular Networks and Osteocyte Mechanosensation 
in Bone with Aging and Disrupted TGFb Signaling *Charles Schurman1, 
Stefaan Verbruggen2, Tamara Alliston1. 1UCSF, United States, 2 Columbia 
University, United States
Aged bone presents several osteocyte-specific defects including a lack of mechanore-
sponsiveness, uncoupling of bone deposition and resorption, and increased bone fragility. 
Others have described an age-related degeneration of the Lacunar-Canalicular Network 
(LCN) marked by loss of osteocyte dendrites and cell bodies in mouse bone. However, 
the extent to which LCN defects impact osteocyte mechanotransduction, intercellular 
communication, and mass  transport remains unclear. Given technical constraints in ex-
perimentally dissecting these processes, we applied two in silico approaches to investigate 
the functional impact of LCN disruption resulting from aging or from osteocyte-intrinsic 
defects in TGFb signaling (TbRIIocy-/-). Using 3D reconstructed confocal images of fluo-
rescently-labeled osteocyte networks, we applied Connectomic Network Analysis to model 
mass transport and Finite Element Analysis (FEA) to model fluid dynamics and osteocyte 
mechanosensation. Relative to 2 month old wild-type mice, osteocytes from 36 month old 
C57BL/6 (WT, N=5) and 2 month old TbRIIocy-/- mice (N=5) display 43 and 34%fewer, 
more tortuous, canaliculi respectively resulting in osteocyte networks with as much as 51 
and 44% less surface area (all P<0.01). Network analysis revealed preservation of linear 
LCN order in aged and TbRIIocy-/- bone, but also localized disruptions caused by canalic-
ular shortening and loss. These blunted networks reduce predicted pericellular diffusion in 
aging and TbRIIocy-/- bone by as much as 43% (P<0.05). FEA predicts a 53% drop in fluid 
velocity and a 30-42% reduction in shear stress around aged and TbRIIocy-/- osteocytes, 
respectively (P<0.01). Modeling of flow through individual canaliculi across a range of tor-
tuosity values did not show any differences to flow parameters, suggesting flow deficits are 
driven by LCN surface area. To determine if LCN expansion, e.g. by perilacunar/canalicular 
remodeling (PLR), is sufficient to rescue flow, space around osteocytes was expanded and 
flow values became indistinguishable from young WT controls (Fig.1) Therefore, PLR reg-
ulatory pathways, such as TGFb, have potential to protect or restore function.  Accordingly, 
gene expression analysis of aged bone shows repression of genes implicated in TGFb signal-
ing and PLR. Therefore, in silico modeling shows how LCN degeneration can compromise 
mass transport and mechanotransduction, and suggests PLR as a possible target to overcome 
these age-related bone deficits.
Disclosures: Charles Schurman, None
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NADPH Oxidase 2-Mediated Reactive Oxygen Species is Necessary for 
Osteocyte Mechano-Transduction In Vitro and In Vivo *Nicole Gould1, 
Katrina Williams1, Humberto Joca2, James Lyons1, Marcus Hughes1, Ramzi 
Khairallah3, Christopher Ward1, Joseph Stains1. 1Department of Orthopaedics, 
University of Maryland School of Medicine, Baltimore, MD, 21201, USA., 
United States, 2Center for Biomedical Engineering and Technology, University 
of Maryland School of Medicine, Baltimore, MD, 21201, USA., United States, 
3Myologica, LLC, New Market, MD 21212, USA., United States
Bone senses mechanical signals and transduces them into biological changes that direct 
bone remodeling, the concerted action of bone resorbing osteoclasts and bone forming osteo-
blasts. Osteocytes, mechano-sensitive cells encased in bone, control bone remodeling in part 
through the expression of the Wnt/β-catenin antagonist, sclerostin. We recently described a 
novel osteocyte mechano-transduction pathway in vitro that controls sclerostin abundance. 
Briefly, osteocytes sense mechanical signals through microtubules, which activate NADPH 
Oxidase 2 (NOX2). NOX2-mediated reactive oxygen species (ROS) trigger calcium influx, 
activation of calcium/calmodulin-dependent kinase II (CaMKII), and rapid sclerostin pro-
tein degradation. Here, we extend these in vitro findings to show that NOX2-dependent 
ROS are both necessary and sufficient to regulate sclerostin abundance in vitro and in vivo. 
In vitro, we showed that inhibition of NOX2 function with gp91-dsTAT prevented fluid 
shear stress-induced calcium influx, CaMKII activation, and rapid sclerostin protein loss 
in Ocy454 osteocyte-like cells. Conversely, controlled production of ROS using a photo-
activated reagent, KillerRed, was sufficient to drive activation of CaMKII and sclerostin 
degradation. Using a mouse ulnar load model to stimulate mechano-activated bone forma-
tion, we showed that a single bout of mechanical load was sufficient to decrease sclerostin 
protein abundance in bone. Further, acute treatment of mice with apocynin, a NOX2 inhib-
itor, prior to ulnar loading showed a statistically significant decrease in bone formation rate 
as determined by dynamic histomorphometry. Together, these data validate the fidelity of 
the novel osteocyte mechano-sensing pathway in vivo, provide key insights into osteocyte 
mechano-transduction and the control of sclerostin, and reveal new therapeutic targets to 
improve bone mass.
Disclosures: Nicole Gould, None
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Disruption of LINC complex in skeletal stem cells results in decreased 
osteogenesis and trabecular architecture *Scott Birks1, Stacie Loisate1, 
Destiny Francis2, Sarah Manske2, Gunes Uzer1. 1Boise State University, United 
States, 2University of Calgary, Canada
Linker of Nucleoskeleton and Cytoskeleton complexes (LINC), comprised of Nesprin 
and Sun proteins coupled within the perinuclear space via the Nesprin KASH domain, play 
an integral role in mesenchymal stem cell (MSC) response to mechanical challenge. Here, 
we hypothesize disabling LINC function in vitro and in vivo will negatively impact osteo-
genesis and mechanosensitivity of MSCs.In vitro, a dominant negative form of the Nesprin 
KASH domain (DNK) was overexpressed in MSCs to disrupt LINC integrity by decoupling 
Nesprin-Sun binding. Osteogenic differentiation was then assessed at day 7 by measuring al-
kaline phosphatase (ALP) mRNA levels via qPCR. A 61% (p=0.09) decrease in mRNA ALP 
levels was found compared to empty plasmid controls suggesting a decrease in osteogenesis 
(Figure 1).In vivo, a similar DNK mechanism was achieved using a cre/lox model under the 
Prrx1 promoter. Briefly, Prx1CreER-GFP mice (+CreER) were crossed with Tg(CAG-LacZ/
EGFP-KASH2) mice (+LacZ) to produce offspring with tamoxifen inducible, cre-mediated 
EGFP overexpression localized at the KASH domain. This inhibits endogenous Nesprin-Sun 
binding, thus disabling LINC function. Tamoxifen was administered to male +CreER/+LacZ 
and control +CreER/-LacZ mice beginning at 7wks. Tibiae were collected at 7, 9, and 12wks 
(n=3/group). Compared to controls: BV/TV and TbN decreased 24% (p<.01) and 26% 
(p<.05), respectively, while TbSp was increased by 35% (p<.05) in 9 wk, +CreER/+LacZ 
mice (Figure 2).Tamoxifen has an estrogenic effect on bone and comparing tamoxifen treat-
ed +CreER/-LacZ mice to a tamoxifen independent Prrx1-Cre line (+Cre) revealed a 9% in-
crease in BV/TV at baseline with tamoxifen administration. We then crossed the +LacZ line 
with the tamoxifen independent +Cre line. While bone parameters were not different at an 
8wk baseline (n=8/grp), +Cre/+LacZ mice allowed voluntary access to a running wheel for 
4wks had reduced BV/TV (-39%) and TbN (-45%), and increased TbSp (+15%) compared 
to +Cre/-LacZ controls (n=1/grp). Four more samples/group were collected and are current-
ly being processed. This recent data implicates LINC functionality for cellular mechanical 
signal propagation in exercise challenged animals, but not in sedentary counterparts. Com-
pletion of this data will lead to a greater understanding of LINC-mediated mechanosignaling 
in bone progenitor cells.All procedures approved by Boise State University Institutional 
Animal Care and Use Committee.
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Mechanical stimulation promotes mitochondria function via Piezo1 
*Xuehua Li1, Jacob Kordsmeier1, Ha-neui Kim1, Intawat Nookaew1, Jinhu 
Xiong1. 1University of Arkansas for Medical Sciences, United States
Mechanical signal plays an essential role in bone growth and homeostasis.  Deletion of 
Piezo1, a mechanosensitive ion channel, from Dmp1-Cre-targeted cells decreases cancel-
lous and cortical bone mass and blunts the response of the skeleton to mechanical stimulus, 
demonstrating the important role of Piezo1 in skeletal mechanotransduction. However, the 
molecular mechanisms by which Piezo1 promotes bone formation is not clear. To identify 
downstream targets and pathways that respond to Piezo1, we performed RNA-seq analysis 
of MLO-Y4 cells after suppression of Piezo1 using shRNA. GO enrichment analysis indicat-
ed that several mitochondria-related categories were down-regulated in Piezo1 knock-down 
cells. The list included mitochondrial transcription, mitochondrial translation, and protein 
import to mitochondrial matrix.  Consistent with RNAseq analysis, the oxygen consump-
tion rate and ATP production were decreased in Piezo1 knock-down cells. Mitochondria 
are critical components of cells and their function has been associated with osteoblastogen-
esis and bone homeostasis in mice.  In humans, mitochondrial point mutation m.3243A>G 
leads to mitochondrial dysfunction and is associated with decreased bone mass and strength. 
In addition, fluid shear stress increased mitochondrial function in osteoblastic cells in vi-
tro.  Consistently, we found that one bout of tibia compressive loading increased expres-
sion of genes encoding subunits of the mitochondrial respiratory complex, including Cox-1, 
Cox-2, Cox-3, and CytB in cortical bone of adult mice. Therefore, we investigated whether 
Piezo1 is required for increased mitochondria function induced by mechanical stimulation. 
Yoda1, a small molecule activator of Piezo1, was used in this study because it mimics the 
effects of fluid shear stress on osteocytes.  We found that Yoda1 increased mitochondrial 
DNA content and mitochondrial mass in calvaria cells indicating increased mitochondrial 
biogenesis.  Yoda1 also increased mitochondrial function as evidenced by increased oxy-
gen consumption rate and ATP production in calvaria cells. However, these changes were 
significantly blunted in calvaria cells lacking Piezo1. These results suggest that mechanical 
stimulation promotes mitochondria function via Piezo1.
Disclosures: Xuehua Li, None
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High-dose Vitamin D Supplementation Affects Bone Density Differently 
in Females than Males *Lauren Burt1, Emma Billington1, Marianne Rose2, 
Richard Kremer 3, David Hanley1, Steven Boyd1. 1University of Calgary, Canada, 
2Alberta Health Services, Canada, 3McGill University, Canada
In a 3-year RCT of high-dose vitamin D supplementation (400 vs 4000 or 10,000 IU 
daily) in vitamin D-sufficient males and females, bone density and strength decreased as a 
function of the dose. The purpose of this study was to examine whether this response dif-
fered between males and females.Participants were healthy males and females 55-70 years 
with DXA T-scores above -2.5 and serum 25(OH)D between 30 - 125 nmol/L. Participants 
consuming <1200 mg/day of dietary calcium received calcium supplementation. Partici-
pants’ radius and tibia were scanned on high-resolution peripheral quantitative computed 
tomography (HR-pQCT) to measure total volumetric BMD (TtBMD) at baseline, 6, 12, 24 
and 36 months. Finite element analysis estimated failure load. Fasting C-telopeptide of type 
1 collagen (CTx) and amino-terminal propeptide of type I collagen (P1NP) were assessed. 
Following an intent-to-treat analysis, we used constrained linear mixed effects models to 
determine treatment group x time x sex interactions.A total of 311 participants were ran-
domized and enrolled in the study (400 IU: M=61, F=48; 4000 IU: M=51, F=49; 10,000 IU: 
M=53, F=49). Baseline, three-month, and three-year levels of 25(OH)D were 76.3, 76.7, 
and 77.4 nmol/L (400); 81.3, 115.3, and 132.2 (4000); and 78.4, 188.0, and 144.4 (10,000). 
There were significant group x time x sex interactions for TtBMD at the radius (p=0.002) 
and tibia (p=0.005). Treatment with 4000 or 10,000 compared to 400 IU resulted in greater 
TtBMD losses in females, but this was not observed with males. At study end females lost 
1.8% (400), 3.8% (4000) and 5.5% (10,000), whereas males lost 0.9% (400), 1.3% (4000) 
and 1.9% (10,000) at the radius. At the tibia, females lost 1.0% (400), 2.0% (4000) and 3.2% 
(10,000), and males lost 0.1% (400), 0.0% (4000) and 0.6% (10,000) over 3 years. There was 
no significant group x time x sex effects on bone strength. There was a trend for CTx and 
P1NP to be higher in females than males, and the females in the 10,000 IU group had higher 
CTx values than the 400 IU group.Among healthy vitamin D-sufficient females, treatment 
with 4000 or 10,000 IU of vitamin D, compared with 400 IU per day, resulted in greater 
losses of TtBMD over three years. The decline in TtBMD was not observed in males. As 
originally reported, high dose vitamin D supplementation offers no benefit for bone health, 
and this secondary analysis raises the possibility of increased bone loss for females.
Disclosures: Lauren Burt, None
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The Relationship of Total, Bioavailable, and Free 25(OH)D with Indices of 
Bone Health and Metabolism in Older Adults: A Randomized Controlled 
Trial *Malak El Sabeh1, Paola Ghanem1, Laila Al-Shaar1, Maya Rahme1, Rafic 
Baddoura2, Georges Halaby2, Ravinder J. Singh3, Roger Bouillon4, Ghada El-
Hajj Fuleihan1. 1American University of Beirut, Lebanon, 2Hotel Dieu de France, 
Lebanon, 3Mayo Clinic, United States, 4Katholieke Universiteit Leuven, Belgium
Questions regarding the superiority of free and bioavailable 25 hydroxy-vitamin D 
[25(OH)D] in predicting various health outcomes remain unresolved. This study investi-
gates the relative impact of vitamin D metabolites, free, bioavailable or total 25(OH)D, on 
indices of bone and mineral metabolism, at baseline, and in response to two vitamin D doses. 
221 elderly subjects were randomized to receive calcium and oral vitamin D3 (600IU/day 
or 3,750 IU/day) supplementation. Analyses were performed on serum levels at zero, 6 and 
12 months, for > 650 data points for each variable of interest, and on bone mineral density 
(BMD) at zero and 12 months. We used generalized linear models to account for the lack of 
independence for variables within each subject, and Bonferroni correction for multiplicity 
of testing [1]. Vitamin D binding protein was measured by radial immunodiffusion in the 
Leuven laboratory, and free and bioavailable 25(OH)D were computed using Bikle’s equa-
tion [2]. Calculated values for the metabolites using the Vermeulen equation were almost 
identical [2]. Subjects who received the higher vitamin D dose had levels that were 1.3-1.4 
folds higher than the lower dose, for all metabolites (p-value < 0.001). Serum bioavailable 
and free 25(OH)D levels were significantly associated with total 25(OH)D, with r value of 
0.942 and 0.943, respectively (p-value <0.001). PTH was negatively associated with all 
vitamin D metabolites, with correlation coefficients ranging between -0.22 and -0.25; while 
calcium, and bone turnover markers (carboxy-terminal collagen crosslinks and osteocalcin) 
were not. Only total 25(OH)D was correlated with % change BMD at the femoral neck at 
12 months, while free and bioavailable metabolites did not show any significant relationship 
with % change BMD at any of the skeletal sites. In conclusion, to-date, calculated free and 
bioavailable 25(OH)D do not appear to be superior to total 25(OH)D in predicting indices 
of bone health in an elderly population.References1. Stuart R, et al  Journal of the Royal 
Statistical Society., 2001. 50(No. 1): p. 87-95.2. Bouillon, R., et al. Front Endocrinol (Lau-
sanne), 2019. 10: p. 910.Figure legend: Relationship Between serum PTH and 25(OH)D 
expressed as Panel A: bioavailable 25(OH)D and Panel B: free 25(OH)D, each divided into 
their respective quartiles. Star (*) indicates significantly lower PTH levels in fourth quartile 
of calculated bioavailable and free 25(OH)D compared to the first quartile.
Disclosures: Malak El Sabeh, None
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Assessment of Serum and Adipose Tissue Cholecalciferol Concentrations 
to Investigate Vitamin D Metabolism *Cora Best1, Leila Zelnick1, Kenneth 
Thummel1, Simon Hsu1, Gail Cromer1, Ilona Larson2, Derek Hagman2, Howard 
Sesso3, JoAnn Manson4, Mario Kratz2, Ian de Boer1, Andrew Hoofnagle1. 
1University of Washington, United States, 2Fred Hutchinson Cancer Research 
Center, United States, 3Brigham and Women’s Hospital, United States, 4Brigham 
and Women’s Hospital, United States
The serum 25-hydroxyvitamin D (25OHD) response to vitamin D supplementation is 
greater when baseline 25OHD concentration is low. Although direct evidence is lacking, 
this is thought to result from reduced efficiency of 25-hydroxylation as vitamin D input 
increases. The disposition of the vitamin D not immediately metabolized is unclear. Adipose 
tissue contains vitamin D, but its contribution to vitamin D homeostasis is unknown.We 
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used liquid chromatography-tandem mass spectrometry to measure cholecalciferol (D3) in 
biospecimens from 3 supplementation trials. Study 1 (VITAL-DKD) was a 2x2 factorial 
randomized placebo-controlled trial (RCT) ancillary to the VITamin D and OmegA-3 TriaL 
(VITAL) that tested 2000 IU of D3 and/or 1 g of ω-3 fatty acids per day for prevention 
of diabetic kidney disease. Serum D3 and 25OHD concentrations at baseline and year 2 
were obtained for the first 200 participants. Study 2 was a pilot RCT of D3 for reduction of 
inflammation in obesity. 15 participants with 25OHD concentration < 50 nmol/L received 
2000 or 4000 IU of D3/d. Concentrations of D3 and 25OHD3 were measured in serum and 
subcutaneous adipose tissue at baseline and 3 mo. Study 3 was a pilot RCT of D3 for pre-
vention of diabetic kidney disease. 22 participants with 25OHD concentration < 75 nmol/L 
received 2000 IU of D3/d or placebo. Serum D3 and 25OHD3 were measured at baseline 
and 1, 3, 6, and 12 mo.Across studies, there was a hyperbolic relationship between serum 
D3 and 25OHD3 concentrations with a threshold evident at a 25OHD concentration ≈ 50 
nmol/L (Figure 1). In study 1, 16% of participants had baseline 25OHD < 50 nmol/L. Base-
line 25OHD < 50 nmol/L (vs. >= 50) was associated with a 16 (95% CI, 1 to 32) nmol/L 
greater serum 25OHD response but a 15 (95% CI, 2 to 28) nmol/L lesser serum D3 response 
to supplementation. In study 2, mean serum and adipose tissue D3 concentrations responded 
proportionally to the dose of D3 administered, whereas 25OHD3 concentrations responded 
less than proportionally to dose. Adipose tissue D3 was significantly correlated with serum 
25OHD3 at baseline (when vitamin D status was low) (r = 0.6) but not after supplementa-
tion.Our results support the hypotheses that 25OHD production efficiency declines as vi-
tamin D input increases and that unmetabolized vitamin D is temporarily deposited in fat. 
These data are proof-of-concept that assessment of parent vitamin D in tissues can fill gaps 
in understanding of vitamin D homeostasis. 
Disclosures: Cora Best, None
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Dairy Supplementation Reduces Fractures and Falls in Institutionalized 
Older Adults: a Cluster-Randomized Placebo-Controlled Trial *Sandra 
Iuliano1, Shirley Poon1, Judy Robbins1, Minh Bui2, Xiaofang Wang1, Lisette 
de Groot3, Marta Van Loan4, Tuan Nguyen 5, Ego Seeman6. 1Departments 
of Medicine and Endocrinology, University of Melbourne / Austin Health, 
Australia, 2School of Population and Global Health, University of Melbourne, 
Australia, 3Division of Human Nutrition, Wageningen University, Netherlands, 
4US Department of Agriculture-ARS, University of California, United States, 
5Garvan Institute of Medical Research and University of Technology Sydney, 
Australia, 6 Departments of Medicine and Endocrinology, Austin Health, 
University of Melbourne and Mary MacKillop Institute for Health Research, 
Australian Catholic University, Australia
Background:  Older adults in aged-care are at the highest risk for fractures and are 
the source of 30% of hip fractures in the community.  These individuals often have inad-
equate intakes of calcium and protein and have reduced musculoskeletal mass and func-
tion.  As dairy foods (i.e. milk, yoghurt cheese) are good source of calcium and protein we 
hypothesized that dairy supplementation would reduce the risk of fractures. Methods:  We 
undertook a 2-year cluster-randomized placebo-controlled trial in 60 aged-care facilities; 
30 randomized to provide residents with additional dairy foods to achieve 4 servings daily 
while the remaining 30 facilities continued with their usual menu. Amongst the 7133 older 
adults involved (72% females, mean; age 86.0+/-8.2 years, calcium 650 mg/day, protein < 
1g per kg body weight, 25(OH)D 73+/-27 nmol/L) falls and fractures were recorded and 
verified using incident reports and hospital x-ray reports, respectively. Dietary provision was 
determined from menu analyses and intake determined every 3 months in 10% of residents 
using validated plate waste analysis. Time to event was determined using multilevel Cox’s 
model to account for the intra-cluster covariance.Results:  Dairy supplementation provided 
an additional 562+/-166 mg/day calcium and 13+/-6 g/day protein with residents achieving 
intakes of 1153+/-444 mg/day and 69+/-20 g/day respectively, while residents in control fa-
cilities continued intakes of 636+/-267 mg/day of calcium and 57+/-16 g/day protein. Dairy 
supplementation was associated with a 54% reduction in all fractures (HR 0.46; 95CI: 
0.27 to 0.80; p=0.002),a 48% reduction in hip fractures (HR 0.60; 95%CI, 0.37 to 0.75; 
p<0.001), 9% fewer falls (HR0.91, 95%CI, 0.86 to 0.97, p<0.001) and unchanged mortality 
(HR 1.00, 95% CI, 0.41 to 2.42). Conclusion:  Correction of low calcium and protein intakes 
in aged-care residents using dairy foods is a safe and widely accessible intervention that 
reduces fractures and falls. 
Disclosures: Sandra Iuliano, None
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Vitamin D Deficiency Is Independently Associated with COVID-19 Severity 
and Mortality *Luigi Gennari1, Irene Campi2, Daniela Merlotti1, Christian 
Mingiano1, Alessandro Frosali1, Luca Giovanelli2, Camilla Torlasco3, Martino 
Pengo3, Francesca Heilbron2, Davide Soranna3, Marta Di Stefano0, Carmen 
Aresta0, Marco Bonomi2, Biagio Cangiano2, Vittoria Favero0, Letizia Fatti2, 
Giovanni Battista Perego3, Iacopo Chiodini0, Gianfranco Parati3, Luca Persani2. 
1Department of Medicine, Surgery and Neurosciences, University of Siena, 
Italy, Italy, 2Department of Endocrine and Metabolic Diseases, IRCCS, Istituto 
Auxologico Italiano, Milan, Italy, Italy, 3Department of Cardiovascular, Neural 
and Metabolic Sciences, IRCCS, Istituto Auxologico Italiano, Milan, Italy, Italy, 
0Department of Endocrine and Metabolic Diseases, IRCCS, Istituto Auxologico 
Italiano, Milan, Italy, Italy
Purpose. Vitamin D exerts well known immunomodulatory functions and there is an 
ongoing debate on the possibility that vitamin D deficiency might favor a poorer outcome 
of Coronavirus disease-19 (COVID-19). This is also sustained by epidemiology data sug-
gesting a likely relationship between COVID-19 severity and prevalence areas of vitamin 
D deficiency. We thus investigated the association between 25-hydroxyvitamin-D (25OHD) 
levels and COVID-19 severity and mortality.  Methods. We prospectively studied 103 pa-
tients (age 66.1+/-14.1 yrs) admitted to the hospital  for symptomatic COVID-19 and 52 
subjects with mildly-symptomatic SARS-CoV-2, without respiratory dysfunction. Vitamin 
D levels in SARSCoV-2 affected cases were compared to 206 age and sex matched controls 
obtained from a reference sample of 3174 consecutive subjects that underwent 25OHD mea-
surement between January 01 and March 31, 2020 in the frame of a routine health check.Re-
sults:  At hospital admission, 25OHD levels were lower in symptomatic COVID-19 patients 
(18.2+/-11.4 ng/mL) than in mildly-symptomatic SARS-CoV-2 or controls (30.3+/-8.5 ng/
mL and 25.4+/-9.4 ng/mL, respectively, p<0.0001 for both comparisons) and were inversely 
associated with IL-6 levels (β -0.284, p=0.004). After hospital admission, 54 symptomatic 
COVID-19 patients were admitted to intensive care Unit (ICU), because of severe acute re-
spiratory distress syndrome (ARDS). These patients had lower 25OHD and higher IL-6 lev-
els (14.4+/-8.6 ng/mL and 49.6+/-41.4 pg/mL, respectively), than symptomatic COVID-19 
patients not requiring ICU admission (22.4+/-12.7 ng/mL, p=0.0001 and 28.8+/-44.3 pg/
mL, p=0.016, respectively). After a mean of 19+/-9 days of hospital stay, 19 symptomatic 
COVID-19 patients (18.4%) died due to ARDS. As compared to COVID-19 cases who sur-
vived, deceased COVID-19 patients had lower 25OHD (13.2+/-6.4 vs 19.3+/-12.0 ng/mL, 
p=0.03) and higher IL-6 levels (61.0+/-45.6 vs 34.9+/-42.3 pg/mL, p=0.02). Interestingly, 
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25OHD levels were inversely associated with either ARDS requiring ICU admission [odds 
ratio, OR1.06, 95% confidence interval (95%CI) 1.01–1.12, p=0.038] or mortality (OR1.18, 
95%CI, 1.02–1.37, p=0.029), regardless of IL-6 levels and the presence of major comorbid-
ities.Conclusions. Our data, give a strong observational support to previous suggestions that 
reduced vitamin D levels may favour the appearance of severe respiratory dysfunction and 
increase the mortality risk in patients affected with COVID-19.
Disclosures: Luigi Gennari, None
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Mediterranean Diet Adherence and its Associations with Circulating 
Cytokines, Musculoskeletal Health and Incident Falls in Community-
Dwelling Older Men *Mavil May Cervo1, David Scott1, Markus Seibel2, 
Robert Cumming2, Vasi Naganathan 2, Fiona Blyth2, David Le Couteur 2, David 
Handelsman 2, Louise Waite 2, Vasant Hirani2. 1Monash University, Australia, 
2University of Sydney, Australia
Background and Aims:  Mediterranean dietary patterns may exert favourable effects on 
various health conditions. This study aimed to determine associations of adherence to Med-
iterranean diet with circulating cytokine levels, musculoskeletal health and incident falls 
in community-dwelling older men.Methods: Seven hundred ninety-four (794) communi-
ty-dwelling men with mean age 81.1+4.5 years, who participated in the five-year follow-up 
of the Concord Health and Ageing in Men Project (CHAMP) were included in the cross-sec-
tional analysis, and 616 attended follow-up three years later. Adherence to Mediterranean 
diet was assessed using MEDI-LITE (literature-derived Mediterranean diet) score which 
was obtained using a validated diet history questionnaire. Twenty-four evaluable circulating 
cytokines were analyzed using Bio-Plex Pro Human Cytokine 27-plex Assay kit. Appendic-
ular lean mass (ALM) and bone mineral density (BMD) were measured using dual-energy 
x-ray absorptiometry (DXA). Three-year changes in gait speed and hand grip strength were 
assessed by walking a 6-meter course and using a dynamometer respectively. Incident falls 
over three years were determined through telephone interviews every four months.Results: 
A higher MEDI-LITE score, indicating greater adherence to Mediterranean diet, was associ-
ated with higher appendicular lean mass adjusted for body mass index (ALMBMI) (β: 0.004 
kg/kg/m2; 95% CI: 0.000, 0.008), and lower serum interleukin-7 (IL-7) (β: -0.017 pg/mL; 
95% CI: -0.031, -0.003), and incident falls rates (IRR: 0.94; 95% CI: 0.89, 0.99). Higher 
consumption of monounsaturated fatty acids (IRR: 0.76; 95% CI: 0.59, 0.98) and mono-
unsaturated fatty acids to saturated fatty acids ratio (IRR: 0.72; 95% CI: 0.57, 0.90) were 
associated with 24%, and 28% lower falls risk in older men respectively. MEDI-LITE scores 
were not associated with BMD or physical function parameters.Conclusion: Adherence to a 
Mediterranean diet is associated with higher ALMBMI, lower levels of serum IL-7, and few-
er falls in community-dwelling older men. Monounsaturated and saturated fatty acids were 
the most important contributors to the association between Mediterranean diet and falls risk.
Disclosures: Mavil May Cervo, None
9









Sclerostin Depletion May Induce Inflammation in the Bone Marrow 
*Cristine Donham1, Jennifer Manilay1, Betsabel Chicana1, Gabriela Loots2, 
Deepa Murugesh2. 1University of California, Merced, United States, 2Lawrence 
Livermore National Laboratories, United States
Romosozumab, a humanized monoclonal antibody specific for sclerostin, has been ap-
proved in the United States for post-menopausal women with osteoporosis at high risk for 
fracture. In several Phase III clinical trials, romosozumab decreased the risk of vertebral 
fractures up to 73% and increased total hip area bone mineral density by 3.2%. Our previous 
work in 12 to 15-week-old sclerostin-knockout mice (SostKO) indicated that changes in 
immune cell development occur in the bone marrow (BM), which could be a possible side 
effect to follow in human patients. Our overall goal is to define the mechanisms that guide 
the behavior of long-term hematopoietic stem cells (LT-HSCs) after exposure to an irregular 
BM microenvironment. SOST plays an important role in maintaining bone homeostasis, as 
demonstrated by the increased ratio of bone volume to total volume observed in SostKOs. 
SOST is secreted mainly by osteocytes and could antagonize Wnt signaling by binding to the 
low-density lipoprotein related proteins 5 and 6 on other cells in the bone and BM. In this 
study, we examined the effects of Sost-deficient microenvironments on hematopoiesis using 
transplantation of wild-type LT-HSCs into an older (at least 6 months of age) cohort of Sost-
KO mice (WT→KO chimeras) and in younger mice that that received sclerostin-antibody 
(Scl-Ab) treatment for 6 weeks. As Wnt signaling is important for LT-HSC maintenance and 
self-renewal, we hypothesized that that loss of Sost in the microenvironment would result 
in an expansion and exhaustion of LT-HSCs. Our analyses revealed an increased frequency 
of hematopoietic progenitors in the BM in WT→KO and Scl-Ab treated mice, including 
myeloid-biased multipotent progenitors (MPP2 and MPP3), leading to an increased output 
of monocytes and granulocytes. The lack of Sost in the BM causes permanent changes in 
hematopoiesis, as this myeloid bias extended to extramedullary hematopoiesis in the spleen, 
where Sost is not expressed. The bias in myelopoiesis correlates with an increase in inflam-
matory cytokines TNFα, IL-1α and MCP-1 in the serum of the SostKO BM. In addition, we 
observed alterations in erythrocyte differentiation in the BM and spleen of SostKOs. Taken 
together, our current study indicates novel roles for Sost in the regulation of myelopoiesis 
and control of inflammation in the BM in older subjects. Our animal studies strongly recom-
mend tracking of hematopoietic function in patients treated with romosozumab.
Disclosures: Cristine Donham, None
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Non-activated T cells Increase Osteoclastogenesis and Breast Cancer Bone 
Metastases *Danna L. Arellano1, Juan A. Corral-Avila1, Andrea Verdugo-Meza1, 
Florian Drescher1, Samanta Jiménez2, Felipe Olvera-Rodriguez3, Patricia Juárez2, 
Pierrick GJ. Fournier2. 1Biomedical Innovation Department, CICESE, Posgrado 
de Ciencias de la Vida, CICESE, Mexico, 2Biomedical Innovation Department, 
CICESE, Mexico, 3Instituto de Biotecnología, UNAM, Mexico
Breast cancer bone metastases cannot be cured, and treatments such as T cell-based 
immunotherapy need to be tested. However, T cells can be pro-osteoclastic, which would 
support bone metastases. Thus, we aim to characterize the effect of T cells in breast cancer 
bone metastases.As a syngeneic model, we used 4T1 breast cancer cells to cause bone me-
tastases in mice. In normal Balb/C mice, osteolytic metastasis was increased when compared 
to SCID, and T-cell depleted mice (x3.6 and x1.6, respectively, p<0.05). Histomorphometry 
confirmed that the number of osteoclasts was increased at the tumor/bone interface in mice 
with T cells. Ex vivo, T cells isolated from 4T1 bone metastases increased osteoclastogene-
sis, consistent with the expression of Rankl and Tnfa mRNA. However, this pro-osteoclastic 
effect was specific of the non-activated T cells, as activated T cells inhibited the formation 
of osteoclasts ex vivo, which is consistent with the expression of Ifng and Il4 mRNA. Using 
flow cytometry, we confirmed that T cells in bone metastases are not activated, as >85% of 
T cells lacked the activation marker CD69. Thus, immunotherapy activating T cells could 
benefit patients with bone metastases.While ConA or anti-CD3/CD28 antibodies activated 
T cells from the spleen ex vivo, they failed to activate T cells from bone metastases. This 
suggests microenvironment-induced immunosuppression that could be due to an increase 
of myeloid-derived suppressor cells (MDSC), monocytic (CD11b+Ly6C+), and polymor-
phonuclear (CD11b+Ly6G+), in 4T1 bone metastases. CellROX and DAF2-DA assays 
confirmed that these MDSCs produced ROS and NO that suppress T cells.The PDE5 in-
hibitor, Sildenafil, was reported to inhibit MDSCs. However, treatment with Sildenafil did 
not decrease 4T1 bone metastases nor improved the effect of zoledronate. Thus, we looked 
for other therapeutic targets, such as immune checkpoints. Although only 27% of T cells in 
4T1 bone metastases were CTLA-4+, >70% of T cells were PD-1+, and 80% of monocyt-
ic-MDSCs were PD-L1+, which could trigger T cell suppression in bone.In conclusion, we 
found that T cells inactivated in the bone metastasis microenvironment increase osteoclast 
formation and bone metastases, while activated T cells inhibit osteoclastogenesis. Although 
targeting MDSCs with Sildenafil was not efficient, treatment with immune checkpoint inhib-
itors (antibodies against PD-1 or PD-L1) could be used for patients with bone metastases.
Disclosures: Danna L. Arellano, None
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HDAC inhibitors rescue LIFR repression driven by the bone 
microenvironment *Courtney Edwards 1, Miranda Clements2, Lawrence 
Vecchi3, Jasmine Johnson3, Rachelle Johnson3. 1Vanderbilt University Medical 
Scientist Training Program, United States, 2Vanderbilt University Graduate 
Program in Cancer Biology, United States, 3Division of Clinical Pharmacology 
Vanderbilt University Medical Center, United States
Breast cancer cells frequently disseminate to the bone marrow, where they either induce 
osteolysis or enter a dormant state. We have previously demonstrated that down-regulation 
of leukemia inhibitory factor receptor (LIFR) enables breast cancer cells to exit dormancy 
in the bone. Hypoxia, or low oxygen tensions, down-regulates LIFR in breast cancer cells 
independent of hypoxia-inducible factor (HIF) signaling, but the mechanism of hypoxic 
repression is unknown. Furthermore, we have shown that histone deacetylase (HDAC) in-
hibitors (entinostat, panobinostat, vorinostat, valproic acid, and romidepsin) stimulate LIFR 
and, in combination with bisphosphonates, promote dormancy and prevent tumor-induced 
osteolysis in mouse models of bone colonization. To confirm whether disseminated breast 
cancer cells encounter hypoxia in the bone, we performed immunostaining for pimonida-
zole (a hypoxia marker) and cytokeratin (to detect tumor cells) on serial sections and con-
firmed that approximately 50% of MCF7 breast cancer cells encountered hypoxia in the 
tibia following intracardiac inoculation. To determine if histone modifications contribute 
to the mechanism by which LIFR is repressed in hypoxia, we performed chromatin im-
munoprecipitation (ChIP) for H3K9 methylation and acetylation. ChIP analysis confirmed 
that H3K9me3, which represses gene transcription, was significantly increased (2.8-fold, 
p<0.05) in the distal LIFR promoter, and H3K9ac, which promotes transcription, was sig-
nificantly reduced (3.9-fold, p<0.01) in hypoxia (0.5% pO2 for 24 hours). Furthermore, 
entinostat and panobinostat rescued hypoxic repression and dramatically increased LIFR 
expression (up to 3.7-fold, p<0.05-0.001), and increased the known dormancy markers p38β 
(up to 2.3-fold, p<0.05-0.01) and p21 (up to 3.5-fold, p<0.05-0.01) by qPCR and Western 
blot. We previously demonstrated that parathyroid hormone-related protein (PTHrP), which 
is elevated in bone-disseminated breast cancer cells to promote osteolysis and bone coloni-
zation, significantly represses LIFR in vitro. Using ChIP, we confirmed that PTHrP binds to 
the LIFR distal promoter (up to 25-fold, p<0.0001). Furthermore, entinostat rescued LIFR 
repression by Western blot, and significantly stimulated H3K9ac in the distal LIFR promoter 
by ChIP (3.2-fold, p<0.01) when PTHrP was overexpressed. Together, these data suggest 
that HDAC inhibitors stimulate LIFR in multiple models of LIFR repression to promote 
dormancy in the bone microenvironment.
Disclosures: Courtney Edwards, None
1028
Single-cell RNA sequencing of CXCL12+ osteoprogenitors in mechanically 
loaded mouse tibiae reveals osteogenic mechanosensitive pathways *Pamela 
Cabahug-Zuckerman1, Tareq Anani2, Pablo Atria3, Anastasia Tikhonova4, Alireza 
Khodadadi-Jamayran5, Nitzan Segal6, Ioannis Aifantis4, Alesha Castillo1. 1Dept 
of Orthopaedic Surgery, New York University Grossman School of Medicine, 
Veterans Affairs New York Harbor Healthcare System, Manhattan, United 
States, 2Dept of Orthopaedic Surgery, Dept of Orthopaedic Surgery, New York 
University Grossman School of Medicine, United States, 3Dept of Orthopaedic 
Surgery, New York University Grossman School of Medicine, United States, 
4Dept of Pathology, New York University Langone Health, United States, 
5Applied Bioinformatics, New York University Langone Health, United States, 
6Dept of Biomedical Engineering, Tandon School of Engineering, New York 
University, United States
Mechanical loading (ML) is a potent anabolic stimulus in healthy adult bone [1]. A 
better understanding of cell and molecular processes in load-induced osteogenesis, including 
underlying mechanosensitive pathways, could yield effective treatment strategies for aged 
and diseased bone. Cortical bone (CB) osteocytes (OCYs) originate from LepR+ cells, of 
which 98.8% co-express CXCL12 [2]. Given that skeletal stem cells (SSCs) express an 
array of overlapping markers, including LepR and CXCL12 [2-6], we sought to determine 
how these distinct SSC populations respond to ML with regard to their number and gene 
expression profiles at the single cell level. We hypothesized that ML leads to an expansion 
of CXCL12+ and LepR+ cell populations and regulates their fate. Following NYU IACUC 
approval, adult Cxcl12tm2.1Sjm/J dsRed reporter mice (N=19) and C57BL/6 (C57, N=6) 
mice (Jackson Labs) were subjected to 4 daily bouts of tibial axial compressive loading (L) 
(6N,2Hz,120cycles) with appropriate non-loaded (NL) controls. Bone marrow (BM) and 
CB cell suspensions from L and NL tibiae were prepared for FACS and single-cell RNAseq 
(10XGenomics) as previously described [5]. FACS data are presented as %change and sig-
nificance determined by a Student’s T-test at α=0.05; expression data are presented as nor-
malized fold-change. The enriched CXCL12+ cell population was shown to highly express 
LepR. ML led to a significant increase in the number of LepR+ cells (+114%, p=0.022) in 
the BM. Differentially expressed genes in the L versus NL CXCL12-dsRed+ cells included 
upregulated osteogenic genes Wnt4 (1.32X, p<0.0001) and BMP4 (1.72X, p<0.0001), and 
downregulated adipo-associated genes PPARgamma (0.79X, p=0.037) and Apoe (0.92X, 
p<0.001). Unbiased principle component analysis (PCA) yielded 11 cell clusters, including 
reticular cells [2,5,6] and pre-osteoblasts [5,6]. Loading resulted in a significant increase in 
BMP4 (2.7X, p=0.002) and a significant decrease in sFRP expression (0.55X, p<0.0001), 
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a negative regulator of Wnt signaling [7], in reticular cells. A significant increase in Wnt4 
(1.9X, p<0.0001) was also observed in pre-osteoblasts. Our data demonstrate that loading 
promotes osteogenic differentiation via promotion of Wnt signaling, consistent with previ-
ous reports [8-10] while attenuating pro-adipogenic genes in cells expressing both LepR and 
CXCL12, which are known osteoprogenitors [2]; that is, loading effectively pushes progen-
itors towards an osteogenic fate.
Disclosures: Pamela Cabahug-Zuckerman, None
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Interaction between osteocyte SOCS3-dependent signaling and the bone 
marrow microenvironment maintains cortical bone integrity *Tsuyoshi 
Isojima1, Emma C Walker1, Blessing Crimeen-Irwin1, Ingrid J Poulton1, Narelle 
E McGregor1, Jonathan H Gooi1, T. John Martin1, Natalie A Sims1. 1St. Vincent’s 
Institute of Medical Research, Australia
Cortical structure is a crucial determinant of bone strength, yet the underlying mech-
anisms that control its organization remain poorly understood. We recently reported that 
cortical bone develops through pore closure and accumulation of high density bone by 
SOCS3-mediated suppression of gp130-STAT3 signaling in osteocytes. Since SOCS3 also 
suppresses G-CSFR signaling, we studied whether global G-CSFR (Csf3r) ablation could 
improve the structure of Dmp1Cre.Socs3f/f cortical bone.Dmp1Cre.Socs3f/f.Csf3r-/- mice 
were generated by crossing Dmp1Cre.Socs3f/f mice with Csf3r null mice on a C57BL/6 
background. Csf3r null mice exhibited no change in bone structure compared to wild type 
mice. Surprisingly, bone structure was not improved by Csf3r deletion in Dmp1Cre.Socs3f/f 
mice at 12 or 26 weeks of age. In fact, the phenotype was worsened. Dmp1Cre.Socs3f/f.Cs-
f3r-/- mice showed a further increase in cortical porosity (by 30%) compared to Dmp1Cre.
Socs3f/f. Dmp1Cre.Socs3f/f.Csf3r-/- bone had a higher proportion of low density bone than 
Dmp1Cre.Socs3f/f (increased by 23%), and very little high density bone (<5%, compared 
to 15% in Dmp1Cre.Socs3f/f and wild type). Despite this extreme defect in structure, bone 
shape was normal and femoral strength in three-point bending tests was not different from 
Dmp1Cre.Socs3f/f. Histology revealed that Dmp1Cre.Socs3f/f.Csf3r-/- cortical bone con-
tained a “double-shell” of lamellar bone separated by a channel of highly porous woven 
bone, containing 5x more osteoclasts and a 3-fold increase in blood vessel area compared to 
Dmp1Cre.Socs3f/f control. qPCR of flushed femora in Dmp1Cre.Socs3f/f.Csf3r-/- showed 
extremely high mRNA levels of osteoclast markers (Dc-stamp, Acp5), RANKL (Tnfsf11) 
and angiogenesis markers (Endomucin, Tie-1). A significant increase in the number of 
phospho-STAT1 (~15%) and phospho-STAT3 (~20%) positive osteocytes, and elevations in 
STAT1 and STAT3 target gene mRNAs (Socs1 and Bcl3), indicated that G-CSFR deletion 
further increases STAT signaling in Dmp1Cre.Socs3f/f bone.Since G-CSFR is not expressed 
in osteocytes, we suggest that G-CSFR deficiency promotes STAT signaling in osteocytes 
through its influence on the bone marrow microenvironment. In the absence of SOCS3 neg-
ative feedback, this increases cortical porosity by promoting local vascularization and bone 
resorption. This suggests that cortical bone integrity requires communication between osteo-
cytes and G-CSFR-mediated signals in the bone marrow microenvironment.
Disclosures: Tsuyoshi Isojima, None
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Requirement of Macrophage to Stromal Cell NGF-p75 Signaling in Bone 
Repair *Jiajia Xu1, Zhao Li1, Stefano Negri1, Seungyong Lee1, Yiyun Wang1, 
Ching-Yun Hsu1, Ye Tian1, Qizhi Qin1, Masnsen Cherief1, Robert Tower1, 
Thomas Clemens1, Aaron James1. 1Johns Hopkins University, United States
One of the hallmarks of bone injury is pain, yet the role of skeletal sensory nerves 
in bone repair is only recently becoming understood. In an acute bone injury, we recently 
reported that nerve growth factor (NGF) – tropomyosin receptor kinase A (TrkA) signaling 
is necessary for normal skeletal re-innervation and re-ossification. NGF has two known re-
ceptors, including the high affinity receptor TrkA and the low affinity receptor p75, the latter 
of which is expressed in bone-lining cells. Here, we assessed the role of NGF-p75 signaling 
in macrophage to stromal cell cross-talk during calvarial bone repair. A collection of NGF 
reporter animals (NGF-eGFP), pan-neuronal reporter animals (Thy1-YFP), NgfLysM condi-
tional knockout mice (Ngffl/fl; LysM-Cre), and p75Pdgfrα conditional knockout mice (Ngfr-
fl/fl; Pdgfrα-CreERT2) were subjected to calvarial bone defects (1.8 mm diameter, full thick-
ness frontal bone defects). Their bone repair phenotypes were monitored by radiographic, 
histologic and immunohistochemical means over a four week period. First, NGF and p75 ex-
pression patterns were documented after calvarial injury. NGF reporter activity was present 
both in F4/80-expressing macrophages as well as Pdgfrα-expressing stromal cells upon bone 
injury (Fig. 1A). P75 immunoreactivity was present principally in Pdgfrα-expressing stro-
mal cells and to a lesser extent in perivascular cells (Fig. 1B). Next, bone repair was assessed 
upon conditional deletion of p75 in Pdgfrα-expressing stromal cells. Results showed a sig-
nificant reduction in calvarial bone repair among p75Pdgfrα mice in comparison to p75fl/fl 
control animals (Fig. 1C-H), including a 68.3% reduction in bone volume, a 40.9% increase 
in distance between bony fronts, and a 54.8% reduction in bone fractional area at the study 
endpoint. Histochemical and immunohistochemical staining confirmed a reduction in bone 
matrix deposition and Osteocalcin+ osteoblast numbers within injured p75Pdgfrα bones. 
Cell specific deletion of Ngf in LysM-expressing monocyte/macrophages phenocopied these 
findings. In summary, it appears that NGF signaling via both its high affinity and low affinity 
receptors are critical for normal bone repair. Future studies will determine how NGF-p75 
signaling mediates mesenchymal progenitor cell migration after bone injury, and the extent 
to which conditional p75 deletion impacts skeletal re-innervation as well as repair.
Disclosures: Jiajia Xu, None
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The HIF-PHI BAY85-3934 (Molidustat) improves anemia and controls 
circulating FGF23 in a CKD mouse model *Megan Noonan1, Pu Ni1, 
Rafiou Agoro1, Elizabeth Swallow1, Matthew Allen1, Kenneth White1. 1Indiana 
University School of Medicine, United States
The phosphaturic hormone FGF23 is a critical factor in chronic kidney disease-mineral 
and bone disorder (CKD-MBD), with elevated levels in blood associated with increased odds 
for patient mortality (>6-fold). Anemia is a potent driver of FGF23 expression, and patients 
with CKD ultimately develop anemia as the kidneys lose the ability to produce erythropoie-
tin (EPO), in concert with FGF23-mediated alterations in mineral metabolism. Our goal was 
to investigate a HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitor), currently 
in clinical trials to elevate endogenous EPO, for effects on anemia-dependent FGF23 levels 
and key outcomes in a mouse model of CKD. Female C57Bl6 mice were fed a casein control 
or adenine-containing diet to induce CKD, which resulted in markedly elevated iFGF23 
and blood urea nitrogen (BUN), hyperphosphatemia, and anemia. After 12 weeks of CKD 
induction, mice were treated with the HIF-PHI BAY85-3934 (‘BAY’; Molidustat) at a hu-
man equivalent dose (20 mg/kg) every other day for 3 weeks. Compared to saline controls, 
BAY elevated serum EPO and restored CBCs to normal levels in CKD mice. iFGF23 was 
significantly elevated in saline-treated CKD mice (120-fold, p60%; p<0.05) in BAY-treat-
ed mice with CKD, coinciding with downregulated renal Egr-1 expression (p<0.01). Renal 
1,25D anabolic Cyp27b1 and catabolic Cyp24a1 mRNAs were up and downregulated, re-
spectively, in BAY-treated CKD mice. This extended treatment resulted in decreased BUN 
(p<0.01) and reduced expression of renal fibrosis markers (p<0.01). The bone marrow Erfe, 
Transferrin receptor, and EpoR mRNAs were all upregulated (p<0.05-p<0.01), and liver 
hepcidin expression was downregulated in both control and CKD groups treated with BAY 
(p<0.05-p<0.01). HIF activation in osteoblasts/osteocytes is associated with increased bone 
mass, therefore we investigated femur trabecular parameters and cortical porosity, however 
saw no effect with BAY over this time course. Serum alkaline phosphatase was significantly 
elevated in CKD-BAY mice compared to CKD controls (p<0.01), suggesting increased os-
teoblast activity. Collectively, these results support that resolving anemia using a HIF-PHI 
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improved kidney function and lowered FGF23 during CKD, potentially providing modifi-
able outcomes beyond improving iron utilization for this patient population.
Disclosures: Megan Noonan, None
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Aromatase Deficiency in Hematopoietic Cells Improves Trabecular 
Bone Quantity, Quality, and Mineralization in Bone Marrow Transplant 
Recipients *Katie Rubitschung1, Amber Sherwood1, Katya Rubinow2, Rasesh 
Kapadia3, Orhan K. Öz1. 1UT Southwestern Medical Center Department 
of Radiology, United States, 2University of Washington Diabetes Institute, 
Department of Medicine, United States, 3Scanco USA, Inc., United States
Estrogens play important roles in building and maintaining skeletal mass. While go-
nadally produced estrogens are known to be critical for maintaining bone mass, the role of 
locally produced estrogens is incompletely understood. Immune cells are hematopoietic de-
scendants that reside in the bone marrow and are known to express aromatase [1]. The aim of 
this study was to determine whether hematopoietic cell derived estrogens have a role in bone 
mass regulation.Bone marrow from 9-wk old (WT) and aromatase null (ArKO) male mice 
littermates was harvested from the femurs and tibias. Nine-week-old male WT C57BL6/J 
recipient mice (n=24) (Jackson Laboratory, Bar Harbor, ME; strain #000664) underwent 
sublethal irradiation and bone marrow transplant, receiving either WT or ArKO donor cells. 
The recipient mice were designated as WT(WT) or WT(ArKO), respectively, and sacri-
ficed 28 weeks after transplant. The lumbar spine was harvested for uCT analysis.MicroCT 
imaging of the lumbar spine was conducted on a Scanco Medical µCT 40 (Bruettisellen, 
Switzerland). Morphometric analysis focused on L4. The trabecular regions, encompassing 
about 350 slices, were contoured using a combination of manual and interpolation process. 
T-test was applied to normally distributed data while non-normal data were analyzed using 
the Mann-Whitney U-test.Compared to WT(ArKO), WT(WT) mice had lower bone vol-
ume fraction (p=0.0025), trabecular number (p=0.0073), connectivity density (p=0.0107), 
and average hydroxyapatite equivalent content (p=0.0051). In contrast, there was increased 
trabecular spacing (p=0.0087) in these mice (Fig. 1). In addition, the structure model in-
dex values between the two groups were significantly different (p=0.0003), with WT(WT) 
mice displaying trabeculae more closely resembling cylindrical rods and WT(ArKO) mice 
expressing trabeculae with a more parallel plate-like appearance.Aromatase-deficient hema-
topoietic cells transplanted into WT mice confer greater trabecular bone quantity, quality 
and mineralization compared to WT cell transplants. This study reveals the importance of 
estrogen derived from hematopoietic lineage cells and their interaction with marrow stromal 
cells. Bone marrow from aromatase deficient individuals may have clinical utility in treating 
bone disorders.Berstein, Lev M., et al. “Ability of lymphocytes infiltrating breast-cancer 
tissue to convert androstenedione.” International journal of cancer 77.4 (1998): 485-487.
Disclosures: Katie Rubitschung, None
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Phlpp1 Is Induced By Estrogen In Osteoclasts And Its Loss In Ctsk-
Expressing Cells Does Not Protect Against Ovx-Induced Bone Loss 
*Marcilline Hanson1, Ismael Karkache2, David Molstad2, Andrew Norton2, 
Kim Mansky2, Elizabeth Bradley2. 1University of Minnesota, United States, 
2University of Minnesota, United States
Prior studies demonstrated that deletion of the protein phosphatase Phlpp1 in Ctsk-Cre 
expressing cells enhances bone mass, characterized by diminished osteoclast activity and 
increased coupling to bone formation. Due to non-specific expression of Ctsk-Cre with-
in committed osteoclast and mesenchymal lineage cells, the definitive mechanism for this 
observation is unclear. To further define the role of bone resorbing osteoclasts within this 
model, we performed ovariectomy (Ovx) and Sham surgeries on Phlpp1 cKOCtsk and WT 
littermate mice. We hypothesized that if mesenchymal lineage cells were driving enhanced 
bone mass, mice would retain enhanced coupling and reduced osteoclast activity despite 
Ovx. Conversely, if osteoclast activity was dominant, elevated bone mass would be lost fol-
lowing Ovx. Micro-CT analyses confirmed enhanced BV/TV (33.3%), Tb.N (18.2%), Tb.Th 
(11.1%) and diminished Tb.Sp (12.5%) within the distal femur of Phlpp1 cKOCtsk Sham 
females (n=4). In contrast, Ovx induced bone loss (40%, 45.8%, 83.3% and 77.8% respec-
tively) with no significant difference between Phlpp1 cKOCtsk and WT mice (n=4). Histo-
morphometry of the proximal tibia confirmed that Ovx mice lacked significant differences in 
BV/TV or osteoclasts per bone surface, suggesting that E2 is required for Phlpp1 deficiency 
to have an effect. We performed high throughput unbiased transcriptional profiling of ex vivo 
generated Phlpp1 cKOCtsk osteoclasts and identified 290 differentially expressed genes. By 
cross-referencing these differentially expressed genes with all estrogen-response-element 
containing genes, we identified Igfbp4 as a potential estrogen-dependent target of Phlpp1. 
Estradiol (2nM) treatment of osteoclast progenitors induced Phlpp1 expression and reduced 
Igfbp4. Moreover, genetic deletion or chemical inhibition of Phlpp1 was correlated with 
enhanced Akt phosphorylation and levels of Igfbp4. We then assessed Igfbp4 expression 
by osteoclasts in vivo within intact 12-week old females (n=3). Modest Igfbp4 immunohis-
tochemical staining of TRAP+ osteoclasts within WT females was observed. In contrast, 
TRAP+ bone lining cells within intact Phlpp1 cKOCtsk females robustly expressed Igfbp4, 
but levels were diminished within TRAP+ bone lining cells following Ovx. These results 
demonstrate that the effects of Phlpp1 conditional deficiency are due to altered osteoclast 
activity, potentially due to estrogen-dependent regulation of Igfbp4.
Disclosures: Marcilline Hanson, None
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Secreted Frizzled Receptor Protein 4 (Sfrp4) is Required to Maintain 
Proper Ctsk+ Periosteal Stem/Progenitor Cell Niche Function. *Ruiying 
Chen1, Han Dong2, Dhairya Raval1, Roland Baron1, Matthew B. Greenblatt3, 
Francesca Gori1. 11. Division of Bone and Mineral Research, Harvard Medical 
School and Harvard School of Dental Medicine. 2. Department of Oral Medicine, 
Harvard Medical School and Harvard School of Dental Medicine., United 
States, 2Department of Cancer Immunology and Virology, Dana-Farber Cancer 
Institute and Harvard University Medical School, United States, 3Department 
of Pathology and Laboratory Medicine, Weill Cornell Medicine, United States
The periosteum contains a niche of stem cells and progenitors, which contribute to 
cortical expansion during growth, and homeostasis and repair in adults. However, in spite 
of its clinical significance our basic understanding of the local factors which regulate the 
periosteum remain elusive. We have shown that the cortical bone thinning phenotype seen 
with deletion or null mutation of the Wnt inhibitor Sfrp4 is due to deregulation of endosteal 
remodeling and low periosteal bone formation. To gain insight into the function of Sfrp4 in 
the regulation of the periosteal niche, we generated CtskCre;mTmG;wt and CtskCre;mT-
mG;Sfrp4-/- mice and investigated Cathepsin K (Ctsk+) labeled and Ctsk+;Sfrp4-/- perioste-
al cells, which include bona fide stem cells (PSCs) and non-stem progenitors (PP1 and PP2). 
Importantly, Ctsk+ periosteal cells are enriched for Wnt signaling components, and Sfrp4 is 
expressed predominantly by PP1 and PP2 progenitors. Long bone periosteum was microdis-
sected from 4 wk-old CtskCre;mTmG;wt and CtskCre;mTmG;Sfrp4-/- mice, digested and 
FACS performed to isolate and analyze the distribution of Ctsk+ PSCs, PP1 and PP2 cells. 
This analysis showed that Sfrp4 deletion leads to a significant decrease in the % of PSCs 
(13.6+0.9 vs 10+0.5, p<0.01), while markedly increasing the % of PP2 cells (13.1+2.4 vs 
12
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20+1.6, p<0.05), suggesting that Sfrp4 deletion decreases the pool of bona fide stem cells 
while favoring their transition to progenitors. To test this hypothesis, FACS isolated PSCs 
were cultured for 10 days and then reanalyzed by FACS. These studies showed that Sfrp4 
deletion significantly impaired their ability to give rise to PSCs (1.02%+0.3 vs 0.17%+0.1, 
p<0.05) and PP1 (93%+1.6 vs 69.2%+9, p<0.05) while favoring their progression into the 
PP2 non-stem progenitors (0.60%+0.13 vs 10.2%+4.7, p<0.05). Importantly, Sfrp4 deletion 
markedly decreased both the CFU-OB and CFU-Chondro potential of PSCs, PP1 and PP2 
cells as well as their ability to form bone in kidney transplantation assay. Altogether, these 
studies demonstrate a crucial role for the Wnt inhibitor Sfrp4 in the regulation of periosteal 
stem cell stemness, favoring the accumulation of periosteal progenitors with impaired capa-
bility to differentiate into mature osteoblasts. Elucidating the role of pathways regulated by 
Sfrp4, may open novel and specific therapeutic options to enhance periosteal cell activity in 
fracture repair and human diseases associated with cortical bone fragility.
Disclosures: Ruiying Chen, None
1035
The finger 2 tip loop of Activin A is required for the formation of its non-
signaling complex with ACVR1 and type II Bone Morphogenetic Protein 
receptors *Senem Aykul1, Richard A. Corpina1, Erich J. Goebel2, Camille 
J. Cunanan1, Alexandra Dimitriou1, Hyonjong Kim1, Qian Zhang1, Ashique 
Rafique3, Raymond Leidich4, Xin Wang1, Joyce McClain1, Johanna Jimenez1, 
Kalyan C. Nannuru1, Nyanza J. Rothman1, John B. Lees-Shepard1, Erik Martinez-
Hackert5, Andrew J. Murphy1, Thomas B. Thompson2, Aris N. Econmides6, 
Vincent Idone1. 1Regeneron Pharmaceuticals Inc., United States, 2University 
of Cincinnati, United States, 3Regneron Pharmaceuticals Inc., United States, 
4Regeneron Pharmacuticals Inc., United States, 5Michigan State University, 
United States, 6Regeneron Pharmaceuticals Inc., United States
Activin A functions in Bone Morphogenetic Protein (BMP) pathway signaling in two 
ways: it either engages ACVR1B to activate Smad2/3 signaling or binds ACVR1 to form a 
non-signaling complex (NSC). Although the former property has been studied extensively, 
the physiological roles of the NSC remain unexplored. The autosomal-dominant genetic dis-
order fibrodysplasia ossificans progressiva (FOP) provides a unique window into ACVR1/
Activin A signaling because in that disease FOP-mutant ACVR1 recognizes Activin A as an 
agonistic ligand, initiating signaling akin to that driven by BMPs by activating Smad1/5/8. 
We have previously shown that signaling induced by Activin A through FOP-mutant ACVR1 
is a required driver for the main pathology observed in FOP, the heterotopic ossification 
(HO) of connective tissue: inhibition of Activin A using neutralizing antibodies ameliorates 
HO in mouse models of FOP. However, given that FOP is an autosomal-dominant disorder, 
one wild type copy of ACVR1 remains, and hence can still form NSCs with Activin A (along 
with the corresponding type II receptors). Deletion of this wild type copy of Acvr1 in mouse 
FOP results in 6-fold more HO, consistent with an inhibitory role of the NSCs that can still 
form between wild type ACVR1 and Activin A in that setting. However, no direct evidence 
for physiological roles of the NSC exists to date. To set the stage to probe this question, we 
generated ‘agonist-only’ Activin A muteins that activate ACVR1B but cannot form the NSC 
with ACVR1. These muteins fail to inhibit BMP7-induced signaling via ACVR1 except to 
the level expected through competition for binding of these ligands to their type II receptors, 
a property required for any BMP family ligand to initiate signaling. We also show that these 
muteins activate ACVR1B just like wild type Activin A, but although they fail to form the 
NSC with wild type ACVR1 they still activate FOP-mutant ACVR1. Based on this evidence, 
we hypothesized that these muteins will generate more HO than wild type Activin A in an 
FOP setting, as they should activate FOP-mutant ACVR1 while simultaneously escaping the 
tempering effects of the NSC that wild type Activin can still form with the wild type copy 
of ACVR1. We show that this indeed the case (Figure 1). These results provide the first 
evidence for a biological role for the NSC in vivo and pave the way for further exploration 
of the NSC’s physiological role in corresponding knock-in mice.
Disclosures: Senem Aykul, Regeneron Pharmaceuticals Inc, Major Stock Shareholder
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HES1 is a Primary Effector of NOTCH2 Signaling in Osteoclasts *Jungeun 
Yu1, Lauren Schilling1, Ernesto Canalis1. 1UConn Health, United States
Hajdu Cheney Syndrome (HCS) is a rare genetic disorder characterized by cranio-
facial abnormalities, acroosteolysis and osteoporosis. We created a mouse model termed 
Notch2tm1.1Ecan replicating a mutation found in HCS. Notch2tm1.1Ecan mice exhibit 
marked osteopenia secondary to enhanced osteoclastogenesis and bone resorption. Hairy 
and Enhancer of Split 1 (HES1) is a transcriptional modulator and target of Notch signaling. 
Hes1 expression is significantly increased in Notch2tm1.1Ecan bone marrow-derived mac-
rophages (BMM) as they mature into osteoclasts.  However, the role of HES1 in the HCS 
phenotype and osteoclastogenesis is not known. To determine whether HES1 is responsible 
for the phenotype of Notch2tm1.1Ecan mice and the manifestations of HCS, Hes1 was inac-
tivated in osteoclasts from Notch2tm1.1Ecan mice. CtskCre/WT;Hes1loxP/loxP mice were 
crossed with Notch2tm1.1Ecan;Hes1loxP/loxP mice to inactivate Hes1 in the context of the 
Notch2 mutation. Notch2tm1.1Ecan mice displayed decreased bone volume/total volume 
(BV/TV), which was significantly increased in the context of the Hes1 inactivation so that 
the osteopenia of Notch2tm1.1Ecan mice was nearly resolved.  Moreover, the inactivation of 
Hes1 in Notch2tm1.1Ecan osteoclast precursors decreased the enhanced osteoclastogenesis 
observed in Notch2tm1.1Ecan mutant cells. To confirm a role of Hes1 in osteoclastogenesis 
and bone homeostasis, CtskCre/WT;Hes1loxP/loxP mice were crossed with Hes1loxP/loxP 
mice to generate CtskCre;Hes1Δ/Δ and littermate Hes1loxP/loxP controls. Hes1 mRNA was 
decreased 50-80% in osteoclasts and tibiae from CtskCre;Hes1Δ/Δ mice. Inactivation of 
Hes1 in Ctsk-expressing cells markedly increased BV/TV in male and to a greater extent in 
female mice which exhibited a 52% increase in femoral BV/TV compared to controls. Cul-
tures of BMMs from CtskCre;Hes1Δ/Δ mice displayed a decrease in osteoclast number and 
size, and decreased bone-resorbing capacity. In contrast, HES1 activation in Ctsk-expressing 
cells enhanced osteoclast number, size and bone resorption, resulting in osteopenia. RNAseq 
from these osteoclasts revealed that genes associated with osteoclastogenesis, particularly 
for cell movement and assembly were significantly increased, whereas inhibitors of osteo-
clastogenesis were suppressed. In conclusion, HES1 is a determinant of osteoclastogenesis 
and is a primary effector of NOTCH2 signaling and mechanistically relevant to the skeletal 
manifestation of HCS.
Disclosures: Jungeun Yu, None
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Zoledronic Acid Maintains Areal Bone Density after Denosumab 
Administration (DATA-HD Extension) *Sabashini K. Ramchand1, Natalie 
L. David1, Hang Lee2, Joy N. Tsai1, Benjamin Z. Leder1. 1Department of 
Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, 
United States, 2Biostatistics Center, Massachusetts General Hospital, Harvard 
University, United States
Background: When denosumab (DMAB) is stopped, high-turnover bone loss ensues. 
The optimal way to prevent this bone loss has not been defined. In DATA-HD, we reported 
that teriparatide (TPTD) combined with denosumab dramatically increased BMD at all an-
atomic sites. In DATA-HD Extension, we now test the hypothesis that a single dose of zole-
dronate (ZOL), given after DMAB, can preserve these large BMD gains for an additional 
27 months.Methods: In DATA-HD, postmenopausal osteoporotic women were randomized 
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to receive 9 months of either 20-µg or 40-µg of TPTD daily in combination with DMAB 
(60-mg administered at months 3 and 9). At the completion of this 15-month study, women 
enrolled in the DATA-HD Extension where they received a single dose of ZOL (5-mg i.v.) 
24-35 weeks after the last DMAB dose. BMD and bone turnover markers were assessed 
12 and 27 months after ZOL.Results: 53 women (mean age 66) completed DATA-HD and 
enrolled in DATA-HD Extension. At the femoral neck (FN) and total hip (TH), the mean 
5.6% and 5.1% gains in BMD achieved from month 0-15 were maintained both 12 and 
27 months after ZOL administration (Figure). At the spine, the mean 13.5% gain in BMD 
achieved from month 0-15 was maintained for the first 12 months but modestly decreased 
thereafter resulting in a 3.0% reduction (95% CI -2.0 to -4.0%, P<0.0001) 27 months after 
ZOL. Spine BMD remained 10.1% higher than the original DATA-HD baseline. The pattern 
of BMD changes between months 15-42 were qualitatively similar in the 20-µg and 40-µg 
groups. BMD changes were also compared among those who received ZOL early (30 weeks, 
n=15) by ANOVA. Between months 15-27, FN (but not TH or spine) BMD decreased more 
in those patients who received ZOL early versus those who received it late (P=0.04) but this 
difference did not persist to month 42. Analysis of bone turnover markers are pending due to 
lab closures during the COVID-19 pandemic.Conclusions: A single dose of ZOL effectively 
maintains the large and rapid TH and FN BMD increases achieved with combination TPTD/
DMAB therapy for at least 27 months following the transition. Spine BMD was also large-
ly, though not fully, maintained during this period. These data suggest that the DATA-HD 
Extension regimen (short-term combination DMAB/TPTD therapy follow by a single dose 
of ZOL) may be a particularly effective strategy in the long-term management of patients at 
high risk of fragility fracture.
Disclosures: Sabashini K. Ramchand, None
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Effect of Zoledronic Acid on Volumetric Bone Density and Microarchitecture 
after Denosumab Administration (DATA-HD Extension HR-pQCT 
Study) *Sabashini K. Ramchand1, Natalie L. David1, Hang Lee2, Michael 
Bruce1, Mary L. Bouxsein3, Joy N. Tsai1, Benjamin Z. Leder1. 1Department of 
Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University, 
United States, 2Biostatistics Center, Massachusetts General Hospital, Harvard 
University, United States, 3Department of Orthopedic Surgery, Harvard Medical 
School, Beth Israel Deaconess Medical Center, United States
Background: In the original DATA-HD study, we reported that 15-months of com-
bined teriparatide and denosumab resulted in large BMD gains at the hip and spine, and 
improvements in volumetric BMD (vBMD) and microarchitecture at peripheral anatomic 
sites. Based on limited evidence from bone turnover marker and areal BMD studies, con-
solidation treatment with zoledronate (ZOL) has been proposed as a potential strategy to 
mitigate post-denosumab bone loss. ZOL’s capacity to maintain improvements in peripheral 
volumetric and compartmental BMD and microarchitecture, however, have not been studied 
previously.Methods: In DATA-HD, postmenopausal osteoporotic women were randomized 
to receive 9 months of either 20-µg or 40-µg of TPTD daily in combination with DMAB 
(60-mg administered at months 3 and 9). At the completion of this 15-month study, women 
enrolled in the DATA-HD Extension where they received a single dose of ZOL (5-mg i.v.) 
24-35 weeks after the last DMAB dose. HR-pQCT of the distal radius and distal tibia were 
assessed 12 and 27 months after ZOL.Results: 53 women (mean age 66) completed DA-
TA-HD and enrolled in DATA-HD Extension. At the distal tibia, total vBMD decreased by 
1.0% (95% CI -0.6 to -1.3, P<0.0001) and 2.7% (-2.0 to -3.3, P<0.0001) 12 and 27 months 
after ZOL (Figure). Cortical vBMD was not significantly decreased at 12 months but de-
creased by 1.5% (-0.8 to -2.1, P<0.0001) 27 months after ZOL. Cortical thickness decreased 
by 3.0% (-0.5 to -5.6, P=0.02) and 3.3% (-1.7 to -5.0, P<0.001) 12 and 27 months after ZOL, 
respectively, with no significant changes in cortical porosity. Results for total vBMD, corti-
cal vBMD and cortical microstructure at the distal radius were similar (not shown). At both 
anatomic sites, trabecular vBMD, number, thickness, and separation were maintained 12 
and 27 months after ZOL administration (P=NS for all comparisons). The pattern of BMD 
changes were qualitatively similar in the 20-µg and 40-µg groups.Conclusions: A single dose 
of ZOL effectively maintains trabecular, but not cortical, vBMD and microarchitecture at 
peripheral anatomic sites after treatment with combination TPTD/DMAB. These results are 
in contrast to the largely maintained hip and spine areal BMD over this period (as reported 
separately). Alternative treatment strategies that can fully maintain improvements in periph-
eral bone parameters require further study.
Disclosures: Sabashini K. Ramchand, None
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Effects of Teriparatide on Modeling-based and Remodeling-based Bone 
Formation in the Human Femoral Neck *David Dempster1, Jeri Nieves1, Hua 
Zhou2, Mathias Bostrom3, Felicia Cosman1. 1Columbia University, United States, 
2Helen Hayes Hospital, United States, 3Hospital for Special Surgery, United 
States
Purpose: We have previously shown that a brief course of teriparatide (TPTD) stim-
ulates bone formation in the cancellous and endocortical envelope of the human femoral 
neck (1). The purpose of the present study was to determine how much of the new bone 
was formed by modeling-based formation (MBF) or remodeling-based formation (RBF).
Methods: We performed a double-blind trial of TPTD vs Placebo (PBO) in patients about to 
undergo a total hip replacement (THR) for osteoarthritis. Participants were randomized to 
receive daily TPTD 20ug or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior 
to THR. After an average of 3 weeks of study drug, double tetracycline labels were adminis-
tered per standard protocol. During the THR, an intact sample of the mid-femoral neck (FN) 
was procured; this was fixed, embedded, and sectioned transversely. Histomorphometric 
analysis was performed in the cancellous, endocortical, intracortical, and periosteal enve-
lopes, while blinded to treatment group. Sites of new bone formation were identified by the 
presence of tetracycline labels. Mineralizing surface (MS) was designated as MS.MBF if the 
underlying cement line was smooth and as MS.RBF if it was scalloped. MS over smooth 
cement lines adjacent to scalloped reversal lines was designated as overflow (MS.oRBF). 
The referent for all indices was bone surface (BS).Results: The results are shown in the 
tables below. In the cancellous and endocortical envelopes, MS.RBF/BS and MS.oRBF/BS 
were significantly higher in the TPTD-treated than the PBO-treated subjects. Differences 
were about 2 fold for MS.RBF/BS and about 6 fold for MS.oRBF/BS. There was a trend 
towards higher MS.MBF/BS in TPTD vs PBO in both envelopes. Eroded surface was not 
different between groups in either envelope. No significant differences were observed in 
any parameter in the intracortical and periosteal envelopes.Conclusion: We conclude that 
the predominant early effect of TPTD in the human femoral neck is to stimulate RBF and 
oRBF with a trend towards an increase in MBF. Despite the differences in loading between 
the FN and iliac crest, our findings in the femoral neck are very similar to those seen with 
early TPTD in the iliac crest. Given the short duration of treatment, and the lack of difference 
in eroded surface, the TPTD mediated increase in bone formation likely occurred in pre-ex-
isting remodeling units1. JCEM 2016;101:1498-1505Values in the table are Mean+/-SD; 
*Student’s t-test.
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Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation 
*David W. Dempster1, Hua Zhou1, Sudhaker D. Rao2, Chris Recknor3, Paul D. 
Miller4, Benjamin Z. Leder5, Miriam Annett6, Michael S. Ominsky6, Bruce H. 
Mitlak6. 1Regional Bone Center, Helen Hayes Hospital, United States, 2Bone & 
Mineral Research Laboratory, Henry Ford Health System, United States, 3United 
Osteoporosis Centers, United States, 4Colorado Center for Bone Research, 
United States, 5Mass General Hospital, Harvard Medical School, United States, 
6Radius Health, Inc., United States
Objective: To evaluate abaloparatide-induced changes in the bone formation indices of 
mineralizing surface (MS), bone formation rate (BFR) and mineral apposition rate (MAR); 
and to assess the effect of abaloparatide on 3 types of bone formation: modeling-based for-
mation (MBF), remodeling-based formation (RBF), and overflow MBF (oMBF) in transil-
iac bone biopsies.Methods: Twenty-three postmenopausal women with osteoporosis were 
enrolled at 4 centers in the US; all received open label abaloparatide (80 µg/day SC) for 3 
months.  Subjects were administered double fluorochrome labeling at baseline and prior to 
biopsy at 3 months.  Bone formation indices were evaluated by histomorphometry. Changes 
at 3 months from baseline were assessed for the indices on cancellous, endocortical, intra-
cortical and periosteal bone envelopes.  Sites of bone formation were designated as MBF 
if the underlying cement line was smooth, RBF if scalloped, and oMBF if formed over 
smooth cement lines adjacent to scalloped reversal lines.  Paired t-tests were used to com-
pare the differences of the indices between baseline and 3 months  in the 4 bone envelopes.
Results: Bone biopsies were obtained from 19 of the 23 subjects were enrolled in the study; 
all biopsies were evaluable. After 3 months of abaloparatide treatment, MS/ BS increased 
significantly from baseline in all of the 4 bone envelopes (p < 0.001), BFR/BS increased sig-
nificantly in cancellous, endocortical and intracortical envelopes (p < 0.001); no significant 
change was observed in MAR in the 4 bone envelopes.  Consistent with MS/BS, RBF/BS, 
MBF/BS and oMBF/BS increased significantly from baseline in the cancellous and endocor-
tical envelopes (p < 0.001), as did MBF/BS in the periosteum (p < 0.001).Conclusions: This 
study provides histomorphometric evidence that abaloparatide has a robust effect on bone 
formation in postmenopausal women with osteoporosis after 3 months of treatment.  Both 
modeling- and remodeling-based bone formation were stimulated.  This study also shows 
that abaloparatide has a favorable effect on cortical bone by increasing bone formation in 
endocortical and periosteal envelopes.
Disclosures: David W. Dempster, Radius Health, Inc., Speakers’ Bureau, Radius Health, 
Inc., Consultant, Radius Health, Inc., Grant/Research Support
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Kinetic Reconstruction of the Cancellous and Endocortical Remodeling 
Unit Reveals a Net Positive Bone Balance After 12 Months of Treatment 
with Romosozumab *Erik F Eriksen1, Rogely Waite Boyce2, Yifei Shi2, 
Jacques P Brown3, Stephane Horlait2, Cesar Libanati4, Roland Chapurlat6, 
Pascale Chavassieux6. 1Oslo University Hospital, Norway, 2Amgen Inc., United 
States, 3CHU de Quebec Research Centre, Canada, 4UCB BioPharma, Belgium, 
6Université de Lyon, United States, 6Université de Lyon, France
Purpose: EVENITY® (romosozumab-aqqg (Romo)) is a monoclonal antibody that in-
hibits sclerostin, leading to a rapid transient increase in modeling-based bone formation 
and a sustained decrease in resorption (Chavassieux JBMR 2019; Eriksen ASBMR 2019). 
To assess the effect of Romo on bone formation and resorption at the level of the basic 
multicellular unit (BMU) and determine integral effects on BMU bone balance (BB) at 12 
months, after the bone formation response has attenuated, 3D reconstruction of the cancel-
lous (Cn) and endocortical (Ec) BMU (Eriksen Bone 1986) was performed on biopsies from 
the FRAME trial (NCT01575834).Methods: In FRAME, transiliac biopsy sections were 
obtained after 12 months (M12) of Romo or placebo (Pbo) treatment; histomorphometric 
parameters were measured on Cn and Ec envelopes. Erosion depth (E.De; classified by the 
predominate resorptive cell type), osteoid thickness (O.Th), and completed and incomplete 
wall thickness (W.Th) were based on counting of lamellae in polarized light. To assess ef-
fects on the formative site at M12, O.Th/mineralized (Md) W.Th at osteoid surfaces was 
classified using a 4-sector system; the sector containing the nearly completed formative sites 
provided the reconstructed W.Th. Kinetics of remodeling phases were reconstructed accord-
ing to Steiniche (Bone 1992). The comparison of Romo vs Pbo on remodeling parameters 
was done using the Wilcoxon rank-sum test, without multiplicity adjustment.Results: On Cn 
envelope, Romo resulted in a net positive BB compared with Pbo primarily due to sustained 
reduction in resorptive cell activity throughout 12 months, resulting in a significant reduction 
in final (Pre-Ob) E.De. On Ec envelope, Romo also resulted in a net positive BB, not due to 
effects on resorption but due to positive effects on the formative site. Consequently, Romo 
significantly increased W.Th in bone packets that had completed by M12. This effect was 
not sustained in actively forming packets at the end of treatment, suggesting these positive 
effects on bone formation at the BMU occurred earlier in treatment.Conclusion: After 12 
months of Romo, a positive BB at the level of individual BMUs was evident on Cn and 
Ec envelopes, predominantly due to a net decrease in resorptive cell activity in Cn bone 
and a net increase in osteoblastic function in Ec bone. These effects likely contribute to the 
progressive increase in bone mass and microarchitectural improvements with Romo across 
12 months of treatment.
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Treatment Sequences With Romosozumab Before or After Antiresorptive 
Medication *Felicia Cosman1, David Kendler2, Bente Langdahl3, Benjamin Z 
Leder4, E. Michael Lewiecki5, Akimitsu Miyauchi6, Maria Rojeski7, Michele 
McDermott7, Mary Oates7, Cassandra E Milmont7, Cesar Libanati8, Serge 
Ferrari9. 1Columbia University, United States, 2University of British Columbia, 
Canada, 3Aarhus University Hospital, Denmark, 4Harvard Medical School, 
United States, 5New Mexico Clinical Research & Osteoporosis Center, United 
States, 6Miyauchi Medical Center, Japan, 7Amgen Inc., United States, 8UCB 
Pharma, Belgium, 9Geneva University Hospital, Switzerland
Prior studies of anabolic/antiresorptive (AR) treatment sequences indicate that using 
teriparatide (TPTD) first followed by an AR results in greater BMD gains, particularly at 
the total hip (TH), vs using an AR first followed by TPTD (Cosman JBMR 2017). Romo-
sozumab (Romo) increases bone formation while decreasing bone resorption, significantly 
increasing BMD and reducing fracture risk within 1 year. Here we summarize BMD data 
with Romo prior to or following an AR (alendronate [Aln] or denosumab [DMAb]).We 
evaluated percentage change from baseline in BMD at the TH and lumbar spine (LS) from 
four trials where patients received Romo prior to an AR (Phase 3 ARCH [Saag NEJM, 2017] 
and Phase 3 FRAME [Cosman, NEJM 2016]) or Romo following an AR (Phase 3 STRUC-
TURE [Langdahl, Lancet 2017] and Phase 2 [Kendler, OI 2019]). Percentage change from 
baseline BMD was assessed by either an ANCOVA (FRAME) or repeated measures (ARCH, 
STRUCTURE) model adjusting for baseline covariates, or as summary statistics (Phase 
2).TH BMD (Fig 1): In ARCH, BMD increased 6.2% with 1 year of Romo, and a total 
of 7.1% with the 2-year Romo/Aln sequence; and in FRAME, patients gained 6.8% with 
1 year of Romo and a total of 8.8% with the 2-year Romo/DMAb sequence. Patients in 
STRUCTURE, who were previously treated for >=1 year with Aln, gained 2.9% with 1 year 
of Romo. In a Phase 2 study, following 1 year of DMAb, 1 year of Romo increased BMD 
by 0.9%, for a total gain of 3.8% with the 2-year DMAb/Romo sequence.LS BMD (Fig 2): 
In ARCH, BMD increased 13.7% with 1 year of Romo, and a total of 15.2% with the 2-year 
Romo/Aln sequence; and in FRAME, patients gained 13.3% with 1 year of Romo and a total 
of 17.6% with the 2-year Romo/DMAb sequence. Patients in STRUCTURE (previously on 
Aln for >=1 year) gained 9.8% with 1 year of Romo. In the Phase 2 study (after 1 year of 
DMAb), 1 year of Romo increased BMD by 5.3%, for a total gain of 11.5% with the 2-year 
DMAb/Romo sequence.These data demonstrate that treatment with Romo first produces 
substantial BMD gains at the TH and LS within 1 year, and that subsequent transition to 
a potent AR can augment those gains. In patients treated with Aln or DMAb, transition to 
Romo can improve BMD, though gains are not as large as those seen when Romo is used 
first. Since BMD on treatment is a strong surrogate for bone strength, our findings support 
the concept that high-risk patients should be offered treatment with Romo first, followed by 
transition to a potent AR.
Disclosures: Felicia Cosman, Amgen Inc., Grant/Research Support, Amgen Inc., 
Consultant, Radius Health, Speakers’ Bureau, Amgen Inc., Speakers’ Bureau, Radius 
Health, Consultant
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Burosumab Led to Durable Improvements in Biochemical, Skeletal, 
and Clinical Features of Tumor-induced Osteomalacia Syndrome (TIO) 
*Suzanne Jan de Beur1, Thomas J. Weber2, Munro Peacock3, Karl Insogna4, 
Rajiv Kumar5, Paul Miller6, Diana Luca7, Tricia Cimms7, Mary Scott Roberts7, 
Thomas Carpenter4. 1Johns Hopkins University School of Medicine, United 
States, 2Duke University, United States, 3Indiana University School of Medicine, 
United States, 4Yale University School of Medicine, United States, 5Mayo Clinic 
College of Medicine, United States, 6Colorado Center for Bone Research, United 
States, 7Ultragenyx Pharmaceutical Inc, United States
TIO is a rare disease in which tumors produce FGF23, leading to renal phosphate 
wasting, impaired 1,25(OH)2D synthesis, osteomalacia, fractures, weakness, fatigue, and 
impaired mobility. In an ongoing, open-label phase 2 trial (NCT02304367), 17 adults with 
TIO or cutaneous skeletal hypophosphatemia syndrome (CSHS) were enrolled and received 
burosumab, a fully human monoclonal antibody against FGF23. Here we report safety and 
efficacy through week 144 (W144). Key endpoints: changes in serum phosphorus and osteo-
malacia assessed by bone biopsy. Two patients with X-linked hypophosphatemia diagnosed 
post-enrollment and 1 with CSHS are excluded.Serum phosphorus increased from baseline 
(BL) and was maintained through W144 (figure). Serum TmP/GFR and 1,25(OH)2D also in-
creased with burosumab.Eleven patients had paired bone biopsies at BL and W48. Mean+/-
SE osteoid volume/bone volume decreased (BL: 17.6+/-5.9%; W48: 12.1+/-4.7%; p=0.086). 
Osteoid thickness decreased (BL: 16.5+/-3.6 µm; W48: 11.3+/-2.8 µm; p<0.05). Using im-
putation (Dempster 2012), mineralization lag time decreased (BL: 1598+/-420 days; W48: 
1032+/-712 days; p=0.41). Osteoid surface/bone surface showed no change (BL: 57+/-9%; 
W48: 57+/-8%). At BL, 249 fractures/pseudofractures were identified by increased uptake 
on bone scan; 81 (33%) were fully healed and 32 (13%) were partially healed at W144.Mean 
(SD) Global Fatigue Score decreased (BL: 5.6 [2.5]; W144: 3.8 [2.2]; p<0.01), indicating 
reduced fatigue. All domains of the Brief Pain Inventory decreased (W144 Pain Severity and 
Pain Interference p<0.05), indicating reduced pain. The SF-36v2 mean (SD) physical com-
ponent summary score increased (BL: 33 [10]; W144: 41 [12]; p<0.01), indicating improved 
physical functioning. Mean (SD) number of sit-to-stand repetitions increased (BL: 6.7 [4.2]; 
W48: 8.5 [4.2]; n=10; p<0.01), indicating improved proximal muscle strength and function.
All patients had >=1 adverse event (AE). Two discontinued: 1 for chemotherapy to treat neo-
plasm progression; 1 failed to meet serum phosphorus dosing criteria and received minimal 
burosumab. There were 16 serious AEs in 7 patients, including 1 death. All were considered 
unrelated to burosumab. Six patients had a serious AE of tumor progression/compression, 5 
of whom had a history of tumor progression.In adults with TIO, burosumab was associated 
with durable improvements in phosphate metabolism, osteomalacia, fracture healing, and 
physical functioning and reduced fatigue and pain.
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Efficacy of burosumab in adults with X-linked hypophosphataemia (XLH): A 
subgroup analysis of a randomized, double-blind, placebo-controlled, phase 
3 study *Maria Luisa Brandi1, Wei Sun2, Angela Williams3, Annabel Nixon4, 
Karl Insogna5. 1Azienda Ospedaliero Universitaria Careggi, Italy, 2Kyowa Kirin 
Pharmaceutical Development, United States, 3Kyowa Kirin International, United 
Kingdom, 4Chilli Consultancy, United Kingdom, 5Yale University School of 
Medicine, United States
OBJECTIVE: XLH is a rare, lifelong, progressive phosphate wasting disorder caus-
ing substantial musculoskeletal and functional morbidities. Data demonstrate that treatment 
with burosumab in adults leads to sustained correction of serum phosphate levels, healing 
of fractures and pseudofractures, and sustained improvement in key musculoskeletal symp-
toms and impairments. The aim of the exploratory subgroup analyses is to assess wheth-
er treatment effects differed for distinct patient clusters by utilizing the data from CL303 
(NCT02526160).METHODS: CL303 is a phase 3 multicenter, randomized, double-blind, 
placebo-controlled study that evaluated the efficacy and safety of burosumab in adults with 
XLH. Subjects were randomly allocated (1:1) to burosumab or placebo, stratified by pain 
intensity and region. This comprehensive subgroup analysis was performed to assess the 
treatment effects of burosumab during a 24-week double blind placebo-controlled period 
across 14 pre-defined, clinically relevant subgroups defined before the post hoc analysis, 
including 5 pre-specified subgroups in study design (BPI worst pain at baseline, BPI average 
pain at baseline, region, gender and race group). Week 24 Primary Analysis Set was used for 
the 12 efficacy endpoints evaluated in the analysis.RESULTS: This phase 3 study had 134 
randomized subjects (68 in burosumab and 66 in placebo; 65% female; median age 41 years 
[18–65 years]). There were no statistically significant interactions between the pre-defined 
subgroups and treatment arm on serum phosphate, BPI worst pain, WOMAC stiffness or 
WOMAC physical function (p for interaction terms >0.05). Results of 12 of the pre-defined 
subgroup analyses were consistent with the results from the study population with regard to 
showing a favourable direction of effect of burosumab relative to placebo. However, for two 
subgroups variation in treatment response was observed (BFI and BPI Pain Interference).
CONCLUSIONS: Subgroup analyses with the double-blind treatment period data showed 
that burosumab was superior to placebo in the primary, key secondary and many other effi-
cacy endpoints across the pre-defined subgroups.   
Disclosures: Maria Luisa Brandi, Kyowa Kirin International, Consultant
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Three-Year Safety and Efficacy Results of Burosumab for Children Aged 
1 to 4 years with X-linked Hypophosphatemia (XLH) *Erik Imel1, Thomas 
Carpenter2, Gary Gottesman3, Angel Chen 4, Alison Skrinar4, Mary Scott 
Roberts4, Michael P Whyte5. 1Indiana University School of Medicine, United 
States, 2Yale University School of Medicine, United States, 3Shriners Hospitals 
for Children, St Louis, United States, 4Ultragenyx Pharmaceuticals Inc., United 
States, 5Washington University School of Medicine and Indiana University 
School of Medicine, United States
XLH is a rare disease involving excess FGF23 that, in children, leads to hypophospha-
temia and rickets. Burosumab, a fully human monoclonal antibody against FGF23 approved 
for XLH treatment, improved rickets in both clinical trials in children aged 5-12 yrs and 1-12 
yrs. Here, we report final, 3-year safety and efficacy data from an open label, phase 2 study of 
burosumab in children aged 1-4 yrs with XLH (NCT02750618).Eligibility criteria included 
hypophosphatemia and radiographic evidence of rickets. The primary endpoint was fasting 
serum phosphorus level. Key secondary endpoints were Thacher Rickets Severity Score 
(RSS) and Radiographic Global Impression of Change (RGI-C). Patients (pts) received SC 
burosumab every 2 weeks starting at 0.8 mg/kg for 160 weeks (64-week treatment + 96-
week extension periods).All 13 enrolled pts completed the 64-week treatment period; 12 
completed 160 weeks; 1 withdrew at week 112 (W112) to transition to commercially avail-
able burosumab. 8 pts (62%) maintained a dose of 0.8 mg/kg; 5 (38%) had dose increases 
to 1.2 mg/kg. At baseline (BL), mean (SD) age was 2.9 (1.1) yrs; 69% were male. All had 
received prior treatment with oral phosphate and active vitamin D starting at a mean (SD) 
age of 19.6 (18.0) months and a duration of 16.4 (13.8) months.Burosumab rapidly normal-
ized fasting serum phosphorus with mean (SD) levels of 2.5 (0.3) mg/dL at BL and 3.7 (0.5) 
mg/dL at W1. Levels were maintained through W160 (Table). Serum 1,25(OH)2D increased 
initially then returned to BL, as reported in other studies. Rickets significantly improved: to-
tal RSS decreased, and global RGI-C and lower limb deformity RGI-C scores were positive. 
Serum alkaline phosphatase (ALP) also improved (Table). Improvements were maintained 
through W160. Mean (SD) length/height Z-scores were maintained from BL (-1.4 [1.2]) 
through W160 (-1.5 [1.1]).The safety profile over 160 weeks was similar to previous pedi-
atric studies; no new safety concerns emerged. All pts experienced >=1 treatment-emergent 
adverse event (TEAE). All but 2 TEAEs were mild (Grade 1) or moderate (Grade 2). One pt 
had a grade 3 TEAE of food allergy, one had a grade 3 TEAE of increased serum amylase. 
One pt had a serious TEAE of dental abscess. All were considered unrelated to study drug.
Burosumab rapidly restored phosphorus homeostasis in children aged 1-4 yrs. Significant 
improvements in serum phosphorus and rickets were sustained through W160 with no new 
safety findings.
Disclosures: Erik Imel, Ultragenyx Pharmaceutical Inc, Other Financial or Material 
Support, Ultragenyx Pharmaceutical Inc, Grant/Research Support
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Palovarotene (PVO) for Fibrodysplasia Ossificans Progressiva (FOP): Data 
from the Phase III MOVE Trial *Robert J Pignolo1, Mona Al Mukaddam2, 
Geneviève Baujat3, Staffan K Berglund4, Angela M Cheung5, Carmen De Cunto6, 
Patricia Delai7, Maja Di Rocco8, Nobuhiko Haga9, Edward C Hsiao10, Peter 
Kannu11, Richard Keen12, Edna E Mancilla13, Donna R Grogan14, Rose Marino14, 
Andrew Strahs14, Frederick S Kaplan2. 1Department of Medicine, Mayo Clinic, 
United States, 2Departments of Orthopaedic Surgery & Medicine, The Center 
for Research in FOP and Related Disorders, Perelman School of Medicine, 
University of Pennsylvania, United States, 3Département de Génétique, 
Institut IMAGINE and Hôpital Universitaire Necker-Enfants Malades, France, 
4Department of Clinical Sciences, Pediatrics, Umeå University, Sweden, 
5Department of Medicine and Joint Department of Medical Imaging, University 
Health Network, University of Toronto, Canada, 6Pediatric Rheumatology 
Section, Department of Pediatrics, Hospital Italiano de Buenos Aires, Argentina, 
7Centro de Pesquisa Clinica, Hospital Israelita Albert Einstein, Brazil, 8Unit 
of Rare Diseases, Department of Pediatrics, Giannina Gaslini Institute, Italy, 
9Department of Rehabilitation Medicine, The University of Tokyo Hospital, 
Japan, 10Division of Endocrinology and Metabolism, UCSF Metabolic Bone 
Clinic, Institute of Human Genetics, and UCSF Program in Craniofacial Biology, 
Department of Medicine, University of California-San Francisco, United States, 
11Hospital for Sick children, Canada, 12Centre for Metabolic Bone Disease, 
Royal National Orthopaedic Hospital, United Kingdom, 13Children’s Hospital of 
Philadelphia, Perelman School of Medicine, University of Pennsylvania, United 
States, 14Ipsen, United States
Background: FOP is an ultra-rare, severely disabling, life-shortening genetic disorder 
characterized by progressive and cumulative heterotopic ossification (HO). PVO, an orally 
available, selective retinoic acid receptor-γ agonist, reduced HO in animal models and phase 
II trials.Objective: Assess efficacy and safety of chronic and episodic PVO in patients (pts) 
with FOP.Methods: Pts with FOP aged >=4 years were enrolled in the ongoing, 48-month, 
single-arm, open-label, phase III MOVE study (NCT03312634). PVO regimen (weight-ad-
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justed in skeletally immature pts): chronic (5 mg daily) and episodic (20 mg daily for 4 
weeks then 10 mg for >=8 weeks during flare-ups). Primary endpoint: annualized change 
in new HO volume, assessed by low-dose whole-body computed tomography (excluding 
head) vs untreated pts from a longitudinal natural history study (NHS; NCT02322255) 
using a Bayesian compound Poisson model with square-root (sqrt) transformation of new 
HO volumes. Interim efficacy analyses were planned for when all pts completed Month 12 
(IA2) and 18 (IA3) assessments. Futility was prespecified as a <5% posterior probability 
of a >=30% reduction in sqrt-transformed annualized new HO volume. Post hoc analyses 
included Bayesian analysis without sqrt transformation and weighted linear mixed effects 
models (with/without sqrt transformation). Safety is assessed throughout.Results: Futility 
criteria were met at IA2; however, Bayesian analyses of non-transformed data would have 
exceeded the prespecified boundary for early efficacy (Table). IA3 analysis set was 97 pts 
(mean age 15.1 years; 52.6% male) from MOVE; 98 from the NHS (mean age 17.8 years; 
55.1% male). At IA3, post hoc Bayesian analyses of non-transformed data continued to be 
statistically significant (p<0.025 1-sided) with a 62% reduction in mean annualized rate of 
new HO volume in PVO-treated vs untreated pts (Table). At data cut off, 100% of pts in 
MOVE had reported >=1 adverse event (AE); 97.0% reported >=1 retinoid-associated (eg 
mucocutaneous) AE. Maximum AE severity was mild in 32.3% of pts, moderate in 45.5%, 
and severe in 22.2%. Overall, 29.3% reported >=1 serious AE, including premature physeal 
closure (PPC) or epiphyseal disorder in 19 of 70 pts skeletally immature at Baseline.Conclu-
sions: Although prespecified futility criteria were met, subsequent post hoc analyses showed 
substantial efficacy suggesting that, despite the risk of PPC in a subset of pts, PVO may be 
an important therapeutic option in FOP.
Disclosures: Robert J Pignolo, Research investigator: Clementia/Ipsen, Regeneron; 
Advisory board: President of the International Clinical Council on FOP; Chair of the 
Publications Committee for the IFOPA Registry Medical Advisory Board, Other Financial 
or Material Support
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Garetosmab, an Inhibitor of Activin-A, Reduces Formation of Heterotopic 
Bone and Soft Tissue Flare-Ups in Patients with Fibrodysplasia Ossificans 
Progressiva *Maja Di Rocco1, Eduardo Forleo-Neto2, Robert Pignolo3, Richard 
Keen4, Philippe Orcel5, Thomas Funck-Brentano5, Christian Roux6, Sami 
Kolta5, Annalisa Madeo1, Judith S Bubbear4, Jacek Tabarkiewicz7, Małgorzata 
Szczepanek7, Javier Bachiller-Corral8, Angela M Cheung9, Kathryn M Dahir10, 
Esmée Botman11, Pieter G Raijmakers12, Mona Al Mukaddam13, Lianne Tile9, 
Cynthia Portal-Celhay2, Melissa Simek-Lemos2, Bret Musser2, Neena Sarkar2, 
Peijie Hou2, Anita Boyapati2, Su Liang2, Marcella Ruddy2, Scott Mellis2, Andrew 
Rankin2, Aris N. Economides2, Dinko Gonzalez Trotter2, Gary Herman2, David 
M. Weinreich2, George D. Yancopolous2, E. Marelise W. Eekhoff14, Frederick 
S. Kaplan13. 1Department of Pediatrics, Unit of Rare Diseases, IRCCS Istituto 
Giannina Gaslini, Italy, 2Regeneron Pharmaceuticals, United States, 33Department 
of Medicine, Mayo Clinic, United States, 4Centre for Metabolic Bone Disease 
Royal National Orthopaedic Hospital NHS Trust, United Kingdom, 5Service de 
Rhumatologie - DMU Locomotion, AP-HP.Nord - Université de Paris, France, 
6Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux 
de Paris, France, 7Rzeszów University, Rzeszów, Poland, 8Hospital Universitario 
Ramón y Cajal, Spain, 9University Health Network, University of Toronto, 
Canada, 10Vanderbilt University Medical Center, United States, 11Department 
Internal Medicine section Endocrinology,Amsterdam UMC, Vrije Universiteit, 
Amsterdam Bone Center, Netherlands, 12Department Radiology and Nuclear 
Medicine, Amsterdam UMC, Vrije Universiteit, Netherlands, 13Departments 
of Orthopaedics, Medicine and the Center for Research in FOP & Related 
Disorders, University of Pennsylvania Perelman School of Medicine, United 
States, 14Department Internal Medicine section Endocrinology, Amsterdam 
UMC, Vrije Universiteit, Netherlands
Background:Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disor-
der, characterized by painful flare-ups and episodic yet cumulative bone formation in soft 
tissues (Heterotopic Ossification, HO), which results in progressive immobility and early 
mortality. It has been proposed that the FOP mutation converts Activin A into an initiator of 
HO; a human monoclonal antibody against Activin A (Garetosmab, GAR) is effective in a 
humanized mouse model of FOP.Methods:LUMINA-1 (NCT03188666) evaluated the safety 
and efficacy of GAR in adult FOP patients randomized to GAR 10 mg/kg every 4 weeks 
(Q4w) IV (n=20) or placebo (PBO; n=24). The activity, size and number of HO lesions 
was assessed by 18F-sodium fluoride positron emission tomography (PET) and whole-body 
low-dose computerized tomography (CT), over 28 weeks. Flare-ups were evaluated by diary 
and investigator report.Results:Baseline demographics were similar in both groups, mean 
age (SD) was 27.6 (8.5) years and 43% male overall. Relative to placebo, GAR treatment 
decreased the total lesion activity (24.6% by PET, P =0.07) and total volume (24.9% by CT, 
P=0.37) of HO lesions (new and existing). HO burden was ameliorated by a nearly 90% 
relative reduction in the total volume of new HO lesions by CT (P =0.017) and a decrease 
in the number and rate of new HO lesions (number of new bone lesions/patient over 28 
weeks in GAR/placebo or rate ratio=0.13 by PET, P=0.006; rate ratio=0.13 by CT, P=0.009; 
Figure). Fewer patients receiving GAR developed new HO (3/20, 15%) than placebo (11/24, 
45.8%) (P=0.05). Patients receiving GAR experienced fewer flare-ups, as assessed by diary 
(relative risk [RR]=0.49, P=0.03) and investigator reports (RR=0.24, P=0.04). GAR treat-
ment was associated with an increased incidence of epistaxis, headache, acne, madarosis and 
skin infections.Conclusions:GAR substantially reduces the formation of new HO lesions and 
flare-ups and demonstrates a favorable benefit/risk profile for adults with FOP. These results 
support that activin A is a key driver of HO in FOP.IMAGE ATTACHED
Disclosures: Maja Di Rocco, None
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A Randomized Controlled Trial of Vosoritide in Children with 
Achondroplasia *Ravi Savarirayan1, Louise Tofts2, Melita Irving3, William 
Wilcox4, Carlos Bacino5, Julie Hoover-Fong6, Rosendo Ullot Font7, Paul 
Harmatz8, Frank Rutsch9, Michael Bober10, Lynda Polgreen11, Ignacio Ginebreda12, 
Klaus Mohnike13, Joel Charrow14, Daniel Hoernschmeyer15, Keiichi Ozono16, 
Yasemin Alanay17, Paul Arundel18, Shoji Kagami19, Natsuo Yasui19, Klane 
White20, Howard Saal21, Antonio Leiva-Gea22, Felipe Luna-González23, Hiroshi 
Mochizuki24, Donald Basel25, Dania Porco26, Kala Jayaram26, Elena Fisheleva26, 
Alice Huntsman-Labed26, Jonathan Day26. 1Murdoch Children’s Research 
Institute, Royal Children’s Hospital, and University of Melbourne, Australia, 
2The Children’s Hospital at Westmead, Australia, 3Guy’s and St. Thomas’ 
NHS Foundation Trust, Evelina Children’s Hospital, United Kingdom, 4Emory 
University, United States, 5Baylor College of Medicine, United States, 6Johns 
Hopkins University, United States, 7Hospital Sant Joan de Déu, Spain, 8UCSF 
Benioff Children’s Hospital, United States, 9Muenster University Children’s 
Hospital, Germany, 10AI Dupont Hospital for Children, United States, 11Lundquist 
Institute Biomedical Innovation, United States, 12Hospital Universitario Quirón 
Dexeus, Spain, 13Universitätskinderklinik Madgdeburg, Germany, 14Ann and 
Robert H. Lurie Children’s Hospital of Chicago, United States, 15University 
of Missouri-Columbia, United States, 16Osaka University, Japan, 17Acibadem 
Mehmet Ali Aydiniar University, Turkey, 18Sheffield Children’s NHS Foundation 
Trust, Sheffield Children’s Hospital, United Kingdom, 19Tokushima University 
Hospital, Japan, 20Seattle Children’s Hospital, United States, 21University of 
Cincinnati College of Medicine, United States, 22Hospital Universitario Virgen, 
Spain, 23Hospitalario de Málaga, Spain, 24Saitama Children’s Hospital, Japan, 
25Medical College of Wisconsin, United States, 26BioMarin, United States
Background: Achondroplasia is a disorder caused by specific mutations in the gene en-
coding the fibroblast growth factor receptor 3 (FGFR3) protein. Open-label, phase 2 trials in 
children with achondroplasia showed that administration of vosoritide, an analogue of C-na-
triuretic peptide, resulted in sustained increases in annualized growth velocity.Methods: This 
international, randomized, double-blind, phase 3 trial compared once-daily subcutaneous 
administration of vosoritide, at a dose of 15 mg per kg of body weight, with placebo in chil-
dren with achondroplasia aged 5 to <18 years. Eligible patients had participated, for at least 
6 months, in an observational growth study in order to calculate their baseline annualized 
growth velocity. The primary efficacy endpoint was the change from baseline in annualized 
growth velocity at week 52 of treatment. The primary analysis of the change from baseline 
in annualized growth velocity was performed using an ANCOVA model.Results: A total 
of 121 patients were randomized, with 60 assigned to receive vosoritide and 61 to receive 
placebo. A total of 119 patients completed the 52-week trial. The adjusted mean difference in 
annualized growth velocity between patients administered vosoritide and those administered 
placebo was 1.57 cm per year in favor of vosoritide (95% CI: [1.22, 1.93], two-sided p-value 
<0.001). A total of 119 patients experienced at least one adverse event (vosoritide group, 59 
[98.3%], placebo group, 60 [98.4%]).Conclusions: Daily, subcutaneous administration of 
vosoritide to children with achondroplasia resulted in a significant increase in mean annual-
ized growth velocity and similar incidence of adverse events compared to placebo.
Disclosures: Ravi Savarirayan, BioMarin, Consultant, BioMarin, Grant/Research Support
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Augmentation of BMP signaling causes midfacial defects in mice via 
suppressing glucose metabolism *Jingwen Yang1, Masako Toda2, Shawn A. 
Hallett1, Yuji Mishina1. 11. Department of Biologic and Materials Sciences, 
School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA., 
United States, 2Department of Biologic and Materials Sciences, School of 
Dentistry, University of Michigan, Ann Arbor, MI 48109, USA., United States
Midfacial malformation is the most common birth defects among craniofacial abnor-
malities in humans. The majority of craniofacial tissues are derived from cranial neural crest 
cells (CNCCs). Energy metabolism, especially aerobic glycolysis, has been recently iden-
tified to promote neural crest migration and control posterior embryonic axis elongation. 
However, the involvement of glycolysis in midfacial development remains unknown. Here 
we generated a mouse model exhibiting unexpected midfacial defects via conditional ex-
pression of a constitutively activated (ca) Acvr1, which encodes a receptor for BMPs, in 
neural crest cells (ca-Acvr1fx/+;P0-Cre, hereafter referred to as mutant). ca-ACVR1 caused 
a 1.8-fold increase of pSmad1/5/9 level in nasal processes (NPs), resulting in severe mid-
facial defects in mutant embryos, including premaxilla bone hypoplasia, duplication of the 
nasal septum, and absence of philtrum and primary palate. Interestingly, RNA-seq analysis 
revealed significant downregulation of a series of glycolytic enzymes in mutant NPs, such 
as H6pd, Gpadh, and Ldhb. Glucose consumption and lactate production were decreased in 
post-migratory CNCCs from mutant NPs compared with controls. Nevertheless, the mito-
chondria amount, protein levels of oxidative phosphorylation complexes, and mitochondria 
membrane potential were unaltered in mutant NPs. Then, we sought to determine whether 
suppressed glycolysis is involved in ca-ACVR1-induced midfacial defects. Activation of 
glycolysis via administration of HIF-1α activator Dimethyloxalyl glycine (DMOG) into 
pregnant females rescued the midfacial defects in mutants. Of note, suppression of glycol-
ysis using 2-Deoxy-D-glucose (2-DG), a competitive inhibitor of glucose metabolism, dis-
turbed the proliferation, survival, and migration of post-migratory CNCCs from control NPs. 
We have previously found that pSmad interacts with p53 thus inhibiting MDM2-mediated 
p53 degradation (Development 142:1357, 2015). Here, p53 protein level was upregulated 
in mutant NPs. We further identified that enhanced BMP signaling suppresses glycolysis 
via augmentation of p53 signaling. Blockade of p53 activity using pifithrin-α significant-
ly enhanced glycolysis activity and rescued the midfacial defects in mutants. Our results 
demonstrate that glycolysis regulated by BMP-p53 signaling axis is important for midfacial 
development and identify a novel therapeutic target for the prevention of midfacial defects.
Disclosures: Jingwen Yang, None
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αE-catenin Deletion in Skeletal Stem and Progenitor Cells (SSPCs) Increases 
their Adipogenic Potential and Protects Against Diet- or Age-induced 
Obesity and Hyperglycemia *Karen De Samblancx1, Marion Mesnieres1, 
Dana Trompet1, Naomi Dirckx1, Katrien Corbeels2, Elena Nefyodova1, Ruben 
Cardoen1, Jolanda van Hengel3, Frans van Roy3, Greetje Vande Velde4, Bart 
Van der Schueren2, Chantal Mathieu2, Christa Maes1. 1Laboratory of Skeletal 
Cell Biology and Physiology (SCEBP), Skeletal Biology and Engineering 
Research Center (SBE), Department of Development and Regeneration, KU 
Leuven, Belgium, 2Department of Chronic Diseases, Metabolism and Ageing, 
KU Leuven, Belgium, 3Department of Biomedical Molecular Biology, Ghent 
University; Inflammation Research Center, Flanders Institute for Biotechnology 
(VIB), Belgium, 4Molecular Small Animal Imaging Center (MoSAIC), 
Department of Imaging & Pathology, KU Leuven, Belgium
Links exist between bone, bone marrow adipose tissue (BMAT) and energy metabo-
lism, and understanding this interplay may impact widespread metabolic diseases such as 
osteoporosis, obesity and diabetes. Here, we generated conditional knock-out (cKO) mice 
with deletion of the intracellular cell-cell adhesion complex component αE-catenin in Prx1-
Cre+ skeletal stem/progenitor cells (SSPCs). MicroCT and histomorphometry showed that, 
compared with control littermates, αE-catenin cKO mice had reduced trabecular bone mass 
(BV/TV: 10.6+/-1.1% (control) vs 6.1+/-0.9% (cKO); p=0.006; n=8; 18-week-old) and ex-
cessive BMAT (0.15+/-0.05% vs 1.71+/-0.61%; p=0.02; n=11; 12 weeks). Increased adipo-
genesis in bone was exacerbated by high-fat diet (HFD), ageing or irradiation, and appeared 
a cell-autonomous consequence of αE-catenin loss, as mutant BMSCs in vitro showed in-
creased adipogenic differentiation.Changes in bone mass and BMAT may influence system-
ic metabolism. Hence, we investigated whether loss of skeletal αE-catenin affected energy 
metabolism. Interestingly, when challenged by HFD for 16 weeks, αE-catenin cKO mice 
were protected against the increased glycemia and glucose intolerance seen in normal mice. 
While the BW of control mice on HFD doubled compared with those fed a normal diet 
(p<0.001; n=9-10), αE-catenin cKO mice on HFD did not develop obesity. Indirect calo-
rimetry revealed increased oxygen consumption and energy expenditure in the mutant mice 
(p<0.0001; n=9-10), despite similar food intake and ambulatory activity as controls, suggest-
ing increased burning and reduced peripheral accumulation of the dietary fat. In accordance, 
peripheral fat mass was lower in HFD-fed mutants than controls, the average adipocyte size 
was 3.6-fold reduced (p=0.0012; n=4), and UCP1 mRNA levels were increased 2- to 4-fold 
in osteoblasts, BM adipocytes, white and brown fat, and muscle of αE-catenin cKO mice.
Notably, 1-year-old αE-catenin cKO mice showed a similar beneficial metabolic phenotype, 
being leaner and more glucose-tolerant than controls. Surprisingly, while increased BMAT 
was again pertinent, the ageing mutant mice had more trabecular bone than controls. Thus, 
excessive BMAT rather than bone mass correlated consistently with improved systemic me-
tabolism in αE-catenin cKO mice.In conclusion, αE-catenin deletion in Prx1-Cre+ SSPCs 
caused increased BMAT and protected against glucose intolerance and obesity, implying 
novel links between SSPC fate control, BMAT and energy metabolism.
Disclosures: Karen De Samblancx, None
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Anabolic effects of nitric oxide on osteoblast metabolism revealed by 
deficiency of argininosuccinate lyase *Zixue Jin1, Jordan Kho1, Brian Dawson1, 
Ming-Ming Jiang1, Chen Yuqing1, Saima Ali1, Lindsay Burrage1, Monica 
Grover2, Donna Palmer1, Dustin Turner1, Philip Ng1, Sandesh Nagamani1, 
Brendan Lee1. 1Baylor College of Medicine, United States, 2Stanford School of 
Medicine, United States
Previous studies have shown that nitric oxide (NO) donors may prevent bone loss and 
fractures in preclinical models of estrogen deficiency. However, the mechanisms by which 
NO modulates bone anabolism remain largely unclear. Argininosuccinate lyase (ASL) is the 
only mammalian enzyme capable of synthesizing arginine, the sole precursor for nitric oxide 
synthase (NOS)-dependent NO synthesis. Moreover, ASL is also required for channeling 
extracellular arginine to NOS for NO production. ASL deficiency (ASLD) is thus a model 
to study cell-autonomous, NOS-dependent NO deficiency. Here, we report that loss of ASL 
leads to decreased NO production and impairment of osteoblast differentiation in osteo-
blastic lineage cells and primary osteoblasts derived from a hypomorphic mouse model of 
ASLD (AslNeo/Neo). Osteoblast-lineage specific Asl knockout mice (Osteocalcin Cre;Asl-
flox/flox) have decreased bone mass and reduced bone formation. Mechanistically, we show 
that the bone phenotype is at least in part driven by the loss of NO-mediated activation 
of the glycolysis pathway in osteoblasts that leads to decreased osteoblast differentiation 
and function. Heterozygous deletion of Caveolin-1, a negative regulator of NO synthesis, 
restores NO production, osteoblast differentiation, glycolysis, and bone mass in AslNeo/Neo 
mice. The central role of ASL in bone anabolism and the translational significance of these 
preclinical studies were further reiterated by studies conducted in induced pluripotent stem 
cells (iPSCs) from an individual with ASLD. The glycolytic gene expression and the ability 
to differentiate into osteoblasts which was impaired in iPSCs generated from an individual 
with ASLD was restored in corrected, isogenic cells. Finally, in a convenient sample of 
ASLD subjects, the proportion with areal bone mineral density Z-score lower than -2.0 at 
the lumbar spine was higher as compared to the expected proportions from age- and sex-
matched data from the general population. Taken together, our findings suggest that ASLD is 
a unique genetic model for studying NO-dependent osteoblast function and that the NO-gly-
colysis pathway may be a new target to modulate bone anabolism.
Disclosures: Zixue Jin, None
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Load-induced Irisin Signaling in Healthy and Diabetic mice *Marcia Urban-
Maldonado1, Sylvia Suadicani1, Mia Thi1. 1Albert Einstein College of Medicine, 
United States
PURPOSE: Bone loss is a complication in diabetes that is often overlooked. The mech-
anisms underlying osteopenia associated with type I diabetes (T1D) are still not completely 
understood. Recently, irisin - a hormone released by muscles during exercise - has been 
shown to not only have anabolic action on bone1 but also directly regulate osteocytes2. 
Given that irisin levels in serum are positively correlated with bone mineral status in healthy 
children3, we hypothesized that altered irisin signaling is one of the factors contributing 
to diabetic bone loss. METHODS: To test this hypothesis, we used the Akita (C57BL/6J) 
mouse model of T1D and age-matched wildtype (WT) mice (8 wk old, male, n=6/group) 
that were submitted to mechanical loading by treadmill running (2 wk and 4 wk; 5 days/
wk, 300 m/day) or to normal cage control activity. All animals were euthanized immediately 
after the last running bout. Blood serum and femurs were collected and respectively assayed 
for levels of irisin using ELISA and qPCR analyses. All experiments were performed under 
IACUC approval.RESULTS: We found that serum irisin levels in young adult T1D mice 
markedly decreased during diabetes progression compared to age-matched WTs (Fig. 1A). 
From our previous studies we showed that in WT mice, load-induced skeletal responses 
occurred after 2 wks of loading, and by the end of 4 wk running bout, load-induced adap-
tation was completed4. While no apparent changes in serum irisin levels were observed in 
WT mice after 2 and 4 wks of loading, load-induced irisin levels were significantly reduced 
in T1D mice compared to loaded age-matched WT mice at both time points (Fig. 1B). This 
observation is accompanied by disruption of the Wnt/β-catenin signaling pathway, in which 
characteristic load-induced changes in mRNA levels of β-catenin (upregulation), Dkk1 and 
Sost (downregulation) that coincide with anabolic responses normally observed in WT mice, 
were dysregulated in T1D mice.CONCLUSION: These findings are in line with recent re-
ports of β-catenin regulation by irisin in osteoblasts5 and suggest that a steady level of irisin 
signaling is critical for load-induced skeletal adaptation. Observed changes in irisin levels in 
T1D bone are thus likely to alter bone mineral density and quality, and thereby lead to bone 
loss.1) Colaianni+ PNAS 2015; 2) Kim+ Cell 2018; 3) Colaianni+ Cells 2019; 4) Seref-Fer-
lengez+ Ann NY Acad Sci 2019; 5) Chen+ Int J Mol Sci 2020.
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Targeting Ferroptosis Alleviates Type 2 Diabetic Osteoporosis via 
Suppressing Osteocyte Lipotoxicity *Yiqi Yang1, Hanjun Li1, Tingting Tang1. 
1Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic 
Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University 
School of Medicine, China
Type 2 diabetes is believed to be associated with secondary osteoporosis and trabecular 
deterioration. However, the underlying pathophysiological mechanisms and effective treat-
ments of diabetic osteoporosis (DOP) remain to be investigated. Ferroptosis is a new form 
of programmed cell death induced by uncontrolled iron-dependent lipid peroxidation. Since 
type 2 diabetes is companied by hyperlipidemia, this experiment is designed to investigate 
the role of ferroptosis in DOP progression. Herein, DOP mice model was established by high 
fat diet (HFD) with low doses of streptozotocin (STZ) injection. Micro-CT and histology 
analysis showed significant decreased bone volume, which was companied by increased 
iron accumulation, morphological change of mitochondria and increased osteocyte death. 
To mimic metabolic stress in vitro, osteocyte cell line, IDG-SW3, was treated with palmitic 
acid and high glucose (PA/HG). The data demonstrated that PA/HG treatment significantly 
decreased cell viability and mineralization ability. In addition, ferroptosis was identified by 
C11-BODIPY staining and the enhanced transcription of major enzymes involved in lipid 
oxidation (Ptgs2, Acsl4 and Nox1). Scavenging of lipid peroxides rescued osteocyte viabili-
ty and promoted osteocyte function in vitro. Finally, ferroptosis inhibitors, Fer-1, further al-
leviated HFD/STZ-induced bone loss and osteocyte death via inhibiting ferroptosis in vivo. 
Hence, it is proposed that ferroptosis may play an important role in the progression of DOP 
and targeting ferroptosis could provide a new horizon for DOP treatment.  
Disclosures: Yiqi Yang, None
1054
Elevated mature osteoblastic 11β-HSD1 contributes to high-fat-diet induced 
obesity *Chuanxin Zhong1, Shengzheng Wang2, Jin Liu1, Lei Dang1, Dijie Li1, 
Nanxi Li1, Rongchen Dai1, Huarui Zhang1, Chao Liang1, Shuaijian Ni1, Aiping 
Lyu1, Fuzeng Ren3, Hong Zhou4, Ge Zhang1. 1Law Sau Fai Institute for Advancing 
Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, 
Hong Kong Baptist University, Hong Kong SAR, People’s Republic of China., 
Hong Kong, 2Department of Medicinal Chemistry, School of Pharmacy, Fourth 
Military Medical University, Xi’an, Shaanxi, People’s Republic of China., 
China, 3Department of Materials Science and Engineering, Southern University 
of Science and Technology, Shenzhen, Guangdong, People’s Republic of China., 
China, 4Bone Research Program, ANZAC Research Institute, University of 
Sydney, Sydney, Australia., Australia
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a key enzyme converting inac-
tive glucocorticoid (GC) to the physiologically active form, has become an attractive target 
for anti-obesity drug development. However, the outcomes of the systemic administration 
of the 11β-HSD1 inhibitors were not clinically satisfactory due to low anti-obesity potency 
and critical safety concerns.The published data have suggested that the role of 11β-HSD1 
in contributing to HFD-induced obesity could not be indispensable in two key metabolic 
organs (liver and adipose tissue). In addition, the most recent evidence demonstrated that 
bone behaved as an endocrine organ to influence energy metabolism. Therefore, we ex-
amined the 11β-HSD1 expression in the metabolic tissues from HFD-induced obese mice 
and their chow-fed littermates. The data demonstrated that only intraosseous 11β-HSD1 
expression was significantly higher in the HFD group (Fig. 1a). Further, we found the ex-
pression level of 11β-HSD1 was significantly higher in the mature osteoblasts in the HFD 
group (Fig. 1b&c). It implied that the 11β-HSD1 in mature osteoblasts could be involved 
in HFD induced obesity. To further explore the role of mature osteoblastic 11β-HSD1, we 
established mature osteoblasts-specific 11β-HSD1 overexpressing mice (11β-HSD1+/+) 
and induction with HFD. Interestingly, aggravating obese phenotypes were showed in the 
11β-HSD1+/+ mice after 20 weeks of induction (Fig. 2). Moreover, after intraosseous injec-
tion of 11β-HSD1 inhibitor (AZD 8329) once a week for the last four weeks during HFD 
induction, the transgenic mice showed lower body weight, gonadal fat weight and intraosse-
ous GILZ mRNA level (a mediator of GC activation by 11β-HSD1) at the end of 20th week. 
Whereas the intravenous-AZD 8329 group with the same dose showed no significant effect 
on the above-mentioned phenotype (Fig. 3).Taken together, the present study indicated that 
elevated mature osteoblastic 11β-HSD1 contributed to HFD-induced obesity. Besides, the 
clinical failure of anti-obesity 11β-HSD1 inhibitor could be explained by failure in specific 
inhibition of mature osteoblastic 11β-HSD1. It also suggested that developing the next-gen-
eration of 11β-HSD1 inhibitors specifically targeting osteoblastic 11β-HSD1 could provide 
a potential therapeutic strategy for HFD-induced obesity, which could address the safety 
concern of abnormal activation of the HPA axis as well.
Disclosures: Chuanxin Zhong, None
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Single Cell Expression Analysis of Pediatric Bone Reveals Novel Cellular 
Heterogeneity *Emily Farrow1, Tammy Brown1, Jeff Johnston1, Adam Walter1, 
Margaret Gibson1, Tomi Pastinen1, Donna Pacicca1. 1Children’s Mercy Hospital, 
United States
There are significant limitations with the use of cell lines and primary cells from ro-
dents in the study of developing human bone. Current published studies are limited to bulk 
samples, which are unable to detect underlying cellular heterogeneity. We have devised a 
reliable method for isolation of primary human bone cells and have subsequently harvested 
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these cells for single cell transcriptome analysis. Deidentified discarded bone samples from 
healthy pediatric patients (under age 18) were obtained from elective orthopaedic surgeries. 
A total of 14 individual samples (7 male, 7 female) were used for analysis and included 
trabecular, cortical, and cartilage samples. Cells were initially processed and clustered by 
Seurat v3 as described in their SCTransform-based integration workflow, resulting in 40 
independent clusters (n=41,0060 cells). Within the large cluster set, known markers of cel-
lular subtypes localized to multiple clusters. Alkaline phosphatase was detected strongly 
in clusters 18 and 26, but also in clusters 4, 11, 13, 17, 19, 21, 22, 24, 25, 32, 34, and 38. 
Trap (ACP5) expression was highest in cluster 39, but was also detected in 11, 14, 16, 26, 
27, and 38. Hemoglobin cells not fully removed during isolation were detected in cluster 
9. Interestingly, SOST was detected at very low levels in clusters 1, 7, 13, 16, 17, 19, 24, 
26, and 27 but was not statistically significant between clusters. In order to further refine 
our analyses and evaluate for novel markers of bone subtypes, we used a classic marker 
gene set to positively select for known cells types (n=11,862 cells; osteoclasts-OSCAR, 
osteoblasts-ALPL, osteocytes-PHEX, and chondrocytes-COL2A1). The positive selection 
resulted in further subclustering between cell types: Osteoclasts = 13 clusters (1359 cells); 
osteoblasts = 13 (2088 cells), osteocytes = 6 (622 cells), and chondrocytes = 23 (9943 cells). 
As expected, cellular markers such as DMP1 were detected primarily in osteocytes, but also 
in osteoblasts. Unexpectedly, PDPN was detected across all 4 cellular subtypes.This is the 
first human single cell genomics study across multiple primary bone cell / chondrocyte lin-
eages. Classic markers such as SOST may not be as relevant in primary bone. We were able 
to elucidate novel cellular markers that can be utilized in future studies to identify specific 
cell populations and will be important to study complex disease mechanisms, such as the 
impact of diabetes on bone development. 
Disclosures: Emily Farrow, Illumina, Other Financial or Material Support
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Novel Site-Specific Single-Cell RNA and Single-Nucleus ATAC sequencing 
of Ectopic Bone Progenitor Cells *Chase Pagani1, Amanda Huber1, Charles 
Hwang1, Simone Marini1, Pauline Yu1, Noelle Visser1, Nicole Patel1, Karen 
Kessel1, Kaetlin Vasquez1, Amy Strong1, Husain Rasheed1, Reagan Nelson1, 
Joseph Greenstein1, Jane Song1, Deneen Wellik2, Benjamin Levi1. 1University of 
Michigan Medical School, United States, 2University of Wisconsin - Madison, 
United States
Traumatic heterotopic ossification (HO) is the formation of ectopic bone in soft tissue 
following burn/blast wounds, orthopedic surgeries, and sports injuries. It is reported that 
mesenchymal stem cells (MSCs) undergo altered cell fate following the injury, but it is 
unclear how these cells progress through aberrant differentiation. Previous methods fail to 
mark cells effectively in a specific region, leading to confounding results. We hypothesized 
that performing an HO-forming 30% total body surface area burn with concurrent Achilles’ 
tenotomy on a Hoxa11-CreERT2;ROSA-TdTomato lineage tracing mouse that marks cells 
important in bone development and healing in the zeugopod (radius/ulna and tibia/fibula re-
gion) will allow for a site-specific in-vivo tracing of HO progenitors. We utilized single-cell 
RNA sequencing (scRNA), single nucleus ATAC sequencing (snATAC), and immunofluo-
rescent histology (IFH) across three time points to characterize and visualize the progression 
towards HO (A). Canonical analysis of uninjured, 1-week post-injury, and 6-weeks post-in-
jury time points found TdTomato transcript expression in 5 scRNA clusters, 4 of which ex-
pressed MSC lineage markers (Pdgfrα and Prrx1). Analyzing individual time points showed 
TdTomato expression shifts from a TdTomato+ Scx+ Tnmd+ cluster and TdTomato+ Pdg-
frα+ Prrx1+ cluster found priory to injury towards a cluster with both osteogenic and chon-
drogenic gene expression (Sox9, Acan, Runx2, and Spp1) 1 week following injury (B). IFH 
confirmed Hoxa11 lineage cells were within the injury site following injury and expressed 
SOX9 and RUNX2. By nine weeks following injury, IFH found Hoxa11 lineage cells within 
fully formed HO. Monocle pseudo-time analysis of the TdTomato expression clusters shows 
a stem-like branch prior to injury with an osteo/chondro differentiation branch, mainly occu-
pied by cluster 0, following injury. ScRNA clusters were mapped onto snATAC sequencing 
clusters and showed increased open chromatin regions of osteogenic, tenogenic, and chon-
drogenic differentiation genes following injury in cluster 0 (Sox9, Acan, Spp1, Sp7, Comp, 
Bglap, Ibsp, Dlx5, and Dlx6) (C). These findings suggest that Hoxa11+ bone progenitor cells 
at the site of injury undergo altered differentiation towards a combined chondrogenic/osteo-
genic cell type that eventually forms fully formed HO. This is the first study to successfully 
trace site-specific bone progenitor cells in-vivo towards ectopic bone formation.
Disclosures: Chase Pagani, None
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Single cell analysis reveals transient expansion of marrow adipogenic lineage 
precursors as the mechanism for bone marrow recovery after radiation 
*Lutian Yao1, Leilei Zhong1, Zhen Miao1, Mingyao Li1, Jaimo Ahn1, Ling Qin1. 
1University of Pennsylvania, United States
Radiotherapy treats malignant tumors effectively but also damages surrounding tissues, 
such as bone marrow. High-dose radiation often leads to fractures and lymphocytopenia. 
Bone marrow cells, including mesenchymal, hematopoietic, and endothelial cells, attempt to 
regenerate after radiation injury but the repair mechanism is still largely unknown. To inves-
tigate the acute radiation effects on bone marrow, we performed single cell RNA-sequencing 
(scRNA-seq) on Td+cells (bone marrow mesenchymal lineage cells) sorted from 1-month-
old Col2-Cre Tomato (Col2/Td) mouse femurs before and after 5 Gy focal SARRP radia-
tion (day 3). Analyzing these two datasets generated the same clustering pattern consisting 
of early mesenchymal progenitors (EMPs), late mesenchymal progenitors (LMPs), lineage 
committed progenitors (LCPs), osteoblasts, osteocytes and marrow adipose lineage precur-
sors (MALPs). Adipoq-Cre Tomato (Adipoq/Td) mice were constructed to visualize MALPs 
in bone marrow. Interestingly, these cells highly expressed adipogenic markers but had no 
lipid accumulation. Morphologically, they existed abundantly as pericytes and marrow stro-
mal cells. Computational analysis and EdU incorporation revealed that they normally do 
not proliferate but acquire highly proliferative ability after radiation, leading to a 7.4-fold 
increase of MALPs based on flow analysis. Gene enrichment analyses revealed that radiation 
upregulates pathways related to wound healing and tissue remodeling and particularly my-
ofibroblast-related genes (Acta2, Tagln, Myl9 etc) and collagen genes in MALPs. MALPs 
have a central cell body with extended cell processes (5.68+0.75/cell) that form 3D network 
in bone marrow. Shortly after radiation, MALPs lost 67% of cell processes, became more 
elongated (a 41% decrease in circularity), detached from vessels, indicating a transformation 
into myofibroblasts. This was coincided with vessel dilation and diminished bone marrow 
cellularity. At day 14 when bone marrow vessels and cellularity recover, MALPs returned 
to the baseline number and a normal reticular shape. Cell ablation of MALPs in Adipoq/Td/
DTR mice with DT injections starting right after radiation completely blocked the recovery 
of bone marrow vasculature and cellularity at day 14. In conclusion, we demonstrated that 
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radiation transiently expands a newly identified bone marrow mesenchymal subpopulation, 
MALPs, and that this expansion is crucial for bone marrow recovery after radiation injury.
Disclosures: Lutian Yao, None
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Compromised mitochondrial dynamics in osteoblasts in MDS to AML 
transformation *Rossella Labella1, Abdullah Mahmood Ali2, Ioanna Mosialou1, 
Junfei Zhao3, Paraskevi Vgenopoulou1, Andrew W Vandenberg1, Raul Rabadan4, 
Frank Oury5, Azra Raza2, Stavroula Kousteni1. 1Department of Physiology 
and Cellular Biophysics, Columbia University Irving Medical Center, New 
York, NY, United States, United States, 2Myelodysplastic Syndromes Center, 
Columbia University, New York, NY, United States, United States, 3Department 
of Biomedical Informatics and Center for Computational Biology and 
Bioinformatics, Columbia University, New York, NY, United States, United 
States, 4Department of Biomedical Informatics and Center for Computational 
Biology and Bioinformatics, New York, NY, United States, United States, 
5Institut National de la Santé et de la Recherche Médicale (INSERM) U1151, 
Institut Necker Enfants-Malades (INEM), University of Paris-Sorbonne 75015 
Paris, France, France
Cells of the endosteal niche can acquire mutational alterations that promote develop-
ment of hematological malignancies. In turn, osteoblasts and their precursors can be remod-
eled by dysplastic cells to favor their propagation. However, it is unknown whether stromal 
cell remodeling occurs and affects transformation of low to high risk disease. To study the 
role of osteoblasts in the transformation of myelodysplasia (MDS) to acute myelod leukemia 
(AML), we compared the osteoblastic transcriptome of 11 MDS patients before and after 
transformation to AML, and an additional 20 MDS and AML-transformed patients. RNA-
seq analysis revealed upregulation of genes encoding mitochondrial proteins in AML com-
pared to MDS patients. Those included components of the mitochondrial respiratory chain, 
proteins involved in mitochondrial fission, fusion, and trafficking, as well as mitochondrial 
ribosomal proteins. Consistent with this, whole exome sequencing indicated an increase in 
mtDNA and Mitotracker fluorescence was increased in bone biopsies of AML transformed 
patients. In parallel, expression of proteins representing various stages of the autophagy 
process was decreased. Among them there was a robust downregulation of mitophagy ma-
chinery proteins, such as OPTN, MFN2, PINK1, ATG13, and ATG3, involved in selective 
degradation of dysfunctional mitochondria. In line with decreased autophagy, GSEA and 
western blot analysis in human osteoblasts indicated a significant downregulation of the 
FoxO1 signaling pathway in AML transformation, an important trigger of autophagy and 
mitophagy regulation. Assessment of the functional status of the increased mitochondria of 
osteoblasts of AML transformed patients has shown compromised mitochondrial activity. To 
examine whether this metabolic dysregulation in osteoblasts affects MDS to AML progres-
sion, we investigated avenues of communication between osteoblasts and dysplastic cells. 
We found that a dense network of Tunnelling Nanotubes of actin is formed between osteo-
blasts and leukemic OCI-AML3 cells that allows transfer of mitochondria from osteoblasts 
to OCI-AML3 cells. These observations demonstrate that compromised mitophagy leads to 
dysfunctional mitochondria accumulation in osteoblasts during AML transformation. This 
event may involve exchange of damaged mitochondria with functional ones to overcome 
metabolic stress in dysplastic cells and favor their hyperproliferation as AML blasts.
Disclosures: Rossella Labella, None
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Identifying Drug Targets via Whole Exome Sequencing and CRISPR-Cas9 
*Sirui Zhou1, Laetitia Laurent1, John Kemp2, Albena Pramatarova3, Vincenzo 
Forgetta1, John Morris4, Peter Croucher5, Graham Williams6, Duncan Bassett6, 
David Goltzman7, Luca Lotta8, David Evans2, Brent Richards1. 1Lady Davis 
Institute, Jewish General Hospital, Canada, 2University of Queensland Diamantina 
Institute, Translational Research Institute, Australia, 3McGill University and 
Genome Quebec Innovation Centre, Canada, 4New York Genome Center, 
United States, 5Garvan Institute of Medical Research, Australia, 6Molecular 
Endocrinology Laboratory, Department of Medicine, Imperial College London, 
United Kingdom, 7Research Institute of the McGill University Health Centre, 
Canada, 8Cardiovascular, Metabolic and Musculoskeletal Therapeutic Genetics, 
Regeneron Genetics Center, United States
Osteoporosis leads to increased susceptibility of bone fracture for which new drugs 
are needed. A primary risk factor is low bone density; a genetically heritable and polygenic 
trait. It remains unknown whether whole-exome sequencing (WES) or target gene mapping 
using GWAS can better identify causal genes to inform drug development. To compare these 
approaches, we first identified a set of positive control genes for osteoporosis whose pertur-
bation causes a Mendelian form of osteoporosis, or which act as drug targets for approved 
osteoporosis therapies. We undertook sequence kernel association tests (SKATO) to inves-
tigate the association between 18,350 autosomal protein-coding genes and estimated bone 
mineral density (eBMD), using WES data of 42,404 white British participants from UK 
Biobank. We also performed a GWAS using imputed data in the same sample followed by 
an established target gene mapping strategy. We found that genes identified by WES were 
strongly enriched for positive control genes (odds ratio [OR] = 119, 95% CI (20.1, 502), 
P=5.2 x 10-6), and that this enrichment was 5-fold higher compared to enrichment of GWAS 
plus target gene mapping-identified genes (OR=22.5, P=5 x 10-5) (Figure). From WES data, 
we identified 38 genes with exonic variants impacting protein function, including CADM1, 
which harbored exonic variants strongly associated with eBMD (SKATO, P=1.8 x 10-9). We 
used CRISPR-Cas9 to edit CADM1 in SaOS-2 osteoblast like cell lines, suppressing protein 
abundance at the cell surface, which resulted in increased expression of early bone mark-
ers: RUNX2, COL1A1/2 and ALPL. These findings demonstrate that WES is a powerful 
approach to identify genes influencing bone density, such as CADM1, which could serve as 
targets for osteoporosis therapies.
Disclosures: Sirui Zhou, None
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Using single cell transcriptomics to characterize the potential role of RNA 
binding proteins to regulate the early stages of adult human bone marrow-
derived mesenchymal stem cell differentiation *Mason Henrich1, Robert 
Tower2, Yuanyuan Wang3, Yi Xang3, John S. Adams1, Rene Chun4. 1Department 
of Orthopedic Surgery, Orthopedic Hospital Research Center, University of 
California at Los Angeles, United States, 2Department of Orthopedic Surgery, 
Johns Hopkins School of Medicine, United States, 3Department of Pathology and 
Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 
United States, 4Department of Orthopedic Surgery, Orthopedic Hospital Research 
Center, University of California at Los Angeles, United States
Adult human bone marrow-derived mesenchymal stem cells (hMSC; CD73+/CD90+/
CD105+/CD14-/CD34-/CD45-/CD19-/HLA-/DR-) are a heterogeneous cell population that 
can undergo adipogenesis, chondrogenesis, and osteogenesis when cultured in correspond-
ing media. Understanding the regulatory mechanisms of generating bone forming cells 
from hMSC is important to the understanding of bone homeostasis and finding of targets 
for intervention in bone diseases such as osteoporosis. The mechanism of lineage-specific 
differentiation of hMSC into bone forming osteoblasts and fat accumulating adipocytes is 
an area of active investigation. While transcription factors (TF) have been proposed as the 
central regulators of lineage-specific differentiation, RNA binding protein (RBP)-directed 
alternative splicing of TF has not been examined. Most human genes undergo alternative 
splicing (AS) through the action of RNA binding proteins (RBPs). With just ~ 20,000 genes, 
the mechanism of AS expands the repertoire of proteins that is needed for the full diversity 
of cell types, tissues, and organs found in humans. To explore the role of AS in osteogenesis, 
we generated single cell RNA-sequencing (scRNA-seq) 3’ libraries on the 10x Genomics 
platform at day 0, 1 and 2 following provoked osteogenesis of hMSC. We examined the 
expression patterns of 129 RBPs with defined RNA binding motifs and detected four distinct 
populations of developing progenitors: 1) early non-committed, bipotential progenitors; 2) 
osteochrondral progenitors marked by high expression of RUNX2; 3) adipogenic progeni-
tors marked by high expression of PPARG; and 4) a purported trans osteogenic-adipogenic 
population, marked by intermediate expression of both RUNX2 and PPARG. We discovered 
four RBPs, HNRNPA2B1, FUS, SF3B4, and SRSF1, that were significantly differentially 
expressed in both scRNA-seq and a concurrently analyzed bulk RNA-seq day 0-12 hMSC 
osteogenesis time-course dataset. Additionally, using a newly developed analytical pipeline, 
these four RBPs were motif mapped to exon skipping splice sites of TF identified from the 
day 0-12 bulk-RNA-seq data. These results provide evidence of a role for differential expres-
sion of key RBPs and coupled exon skipping events in TF during the early stages of hMSC 
maturation down the osteogenic pathway.
Disclosures: Mason Henrich, None
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Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Nationwide 
Danish Analysis with Blinded Radiographic Review *Douglas Bauer1, Dennis 
Black1, Eric Vittinghoff1, Harry Genant1, Richard Dell2, Bo Fan1, Christopher 
Smith3, Martin Thomsen Ernst3, Bo Abrahamsen3. 1University of California, 
San Francisco, United States, 2Southern California Kaiser Permanente Medical 
Group, United States, 3University of Southern Denmark, Denmark
BackgroundAtypical femoral fractures (AFF) are a rare but serious complication of 
anti-resorptive treatments.  Previous studies suggest that prolonged bisphosphonate (BP) use 
is associated with higher AFF risk, but there are few population-based analyses with rigorous 
long-term documentation of medication use and radiographic validation of AFF.  The Dan-
ish National Healthcare system maintains longitudinal records of medication use, fracture 
events, and comorbidities, which allowed us to examine the prospective relationship be-
tween BP use and AFFs in the Danish population.MethodsUsing ICD-10 codes we identified 
and collected digitized pre and post-operative radiographic images from Danish adults >50 
with subtrochanteric and femoral shaft fractures between 2010-2015 (n=4973, representing 
96% of all fractures at those locations in the country).  Images were blindly reviewed by 
specially trained study radiologists to identify 2014 ASBMR major and minor criteria.  BP 
and other medication use between 1995-2015 was collected from electronic pharmacy re-
cords, and comorbidities were assessed from inpatient and outpatient administrative records. 
We identified a random sample of 35,000 Danish adults >50 and used a case-cohort design 
to evaluate the relationship between patterns of BP use and AFF outcomes, accounting for 
demographics, other medication use, comorbidities and previous fractures.   ResultsAmong 
the 1.9 million Danes >50, we confirmed 189 AFFs between 2010-15.  65 individuals with 
AFF (34%) had no exposure to BPs.  After adjustment for potential confounders, the abso-
lute risk of AFF was 0.075/10,000 person-yr in non-users, 1.77 in those with 3-5 yr of BP 
use, and 4.01 in those with >7 yr of BP use (Table).  The Danish nationwide rate of classic 
hip fracture was 43.8/10,000.  One year after BP discontinuation, the risk of AFF fell dra-
matically (RH=0.29, CI: 0.09, 0.90).  AFF risk was increased among those with rheumatoid 
arthritis or hypertension, but was unrelated to age, gender, diabetes or other medication use.
ConclusionsThis study of Danish National Healthcare data found that compared to classic 
hip fracture rates, the incidence of AFF was extremely low but BP use, particularly >5 years, 
was clearly associated with an increased risk.  One third of AFFs occurred in individuals who 
had no BP exposure.  The risk of AFF falls substantially after BP discontinuation. 
Disclosures: Douglas Bauer, None
1062
Teriparatide for the healing of incomplete Atypical Femur Fractures: The 
TAFF Trial *Lianne Tile1, Robert Bleakney2, George Tomlinson3, Aliya Khan4, 
Adrian N.C.Lau5, Rowena Ridout3, Jessica Chang6, Jasmine Lakhesar6, Judy 
Scher6, Hanxian Hu6, Jonathan D.Adachi7, Angela M. Cheung3. 1Division of 
General Internal Medicine, Department of Medicine, University of Toronto, 
Canada, 2Musculoskeletal Division, Joint Department of Medical Imaging, 
University of Toronto; Sinai Health Systems, Canada, 3University Health 
Network, University of Toronto, Canada, 4McMaster University, Canada, 
5Division of Endocrinology, Department of Medicine, University of Toronto, 
Canada, 6University Health Network, Canada, 7St Joseph’s Healthcare; McMaster 
University, Canada
Rationale: Atypical femur fractures (AFFs) are bisphosphonate-related stress frac-
tures that are difficult to heal. An incomplete AFF (iAFF) is often present prior to the com-
plete fracture, and can cause pain, ache or weakness in the thigh, especially with or after 
weight-bearing. Preliminary data suggest that teriparatide may improve healing of these 
fractures.Methods: We conducted a 2-year double-blind placebo-controlled randomized trial 
of subcutaneous teriparatide 20 mcg daily versus placebo to assess the effectiveness of teri-
paratide for the healing of incomplete AFFs (www.clinicaltrials.gov NCT01896011). Wom-
en and men over age 30 with incomplete AFFs as defined by the 2014 ASBMR AFF crite-
ria were included in the study. Exclusion criteria included peri-prosthetic, high trauma or 
pathological fractures from metastases or metabolic bone diseases other than osteoporosis, 
and contraindications to the use of teriparatide. Our primary outcome was a patient-reported 
outcome: the change in modified Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC) score from baseline to two years. The modified WOMAC is a self-admin-
istered 24-item questionnaire that assesses pain or ache (0-20), weakness (0-8) and physical 
function (0-68). Our secondary outcomes include radiographic healing, health-related quali-
ty of life short form 36 (SF-36), reintegration to normal living index (RNLI), and change in 
BMD. Continuous outcomes were compared between groups using analysis of covariance, 
with the corresponding baseline value of the outcome as the covariate at the various time 
points. Time to radiographic healing was compared using a log-rank test. For the primary 
outcome, modified WOMAC score, multiple imputation was used to handle missing data.
Results:  Thirty-four women (mean age 69.2 years; range 33.5 to 82.8yrs) participated in 
the study. Twenty-seven (27) participants had bilateral AFFs (22 with a complete AFF and 
a contralateral iAFF, and 5 with bilateral iAFFs). Seven participants had unilateral iAFFs. 
All study participants had bisphosphonate exposure, with an average duration of bisphos-
phonate use of 9.96 years (range 2.5 to 28.2 years) years. Average baseline BMD T-score at 
the lumbar spine and total hip were -1.26 and -0.83, respectively. Over two years, there were 
no differences between the two groups in modified WOMAC scores, reintegration to normal 
living, physical or mental component score of SF-36, change in BMD or radiographic heal-
ing. Of note, none of the 34 participants progressed from incomplete to complete fractures.
Conclusions: This first randomized placebo-controlled trial for the healing of incomplete 
AFFs failed to show a benefit with teriparatide.  
Disclosures: Lianne Tile, None
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Risk factors for atypical forearm fractures associated with bisphosphonate 
usage *Soo Min Cha1, Hyun Dae Shin1. 1Chungnam National University, School 
of medicine, Republic of Korea
Background: We performed a complete enumeration survey for patients under the treat-
ment of bisphosphonate (BP), aiming to find the diagnostic factors for atypical forearm frac-
tures additional to atypical femur fractures, via a retrospective case-control study.Methods: 
We identified 53 patients that met the following inclusion criteria between March 2009 and 
February 2019: a BP therapy history or ongoing administration of at least 1 year, presence 
of simple radiographs of bilateral femurs and forearms, and availability of complete medical 
records and radiological data. The patients were divided into two groups: those with any 
lesion of atypical fractures of ulna or radius, regardless of the displacement of at least one 
side extremity in simple radiographs (group 1, 20 patients); and those without any lesions 
of pathognomonic finding or fractures in either forearm in simple radiographs (group 2, 
33 patients).Results: Univariate analyses of basic demographic characteristic such as age, 
smoking, comorbidity of diabetes mellitus or any connective tissue disease needing steroid 
treatment, and BMD showed no significant differences between the groups (P > 0.05). The 
co-morbidity of malignant cancer inevitably needing BP usage was not different between the 
two groups. Multivariate analyses of the several variables that differed significantly between 
the two groups in univariate analyses demonstrated that total period and single prescribing 
physician/surgeon were significantly associated with forearm fractures. A cut-off value of 65 
months for the total period predicted the presence atypical forearm fractures.  Conclusions: 
Atypical forearm fractures are probably more common than reported in the literature to date, 
and all forearm lesions were accompanied by preceding atypical femur fractures. The period 
of BP administration had the main effect on the occurrence of atypical forearm fractures, 
particularly if more than 65 months. Also, the prescription by multiple physician was pre-
dicting factor for forearms lesion additionally to AFFs, however, more evidence-based study 
is needed to understand the effects of cancer-related BP usage on the forearm.
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BONE MATRIX QUALITY IN TRANSILIAC BIOPSIES FROM POST-
MENOPAUSAL WOMEN TREATED WITH DENOSUMAB FOR UP TO 
10 YEARS (FREEDOM and FREEDOM Extension TRIALS). *Delphine 
FARLAY1, Sébastien RIZZO1, David D. DEMPSTER2, Shuang HUANG3, Li 
CHEN3, Arkadi CHINES4, Jacques P. BROWN5, Georges BOIVIN1. 1INSERM, 
UMR 1033, Univ Lyon, University Claude Bernard Lyon 1, France, 2Department 
of Pathology and Cell Biology, Columbia University, United States, 3Clinical 
Development, Amgen Inc., United States, 4Clinical Development, Amgen Inc, 
United States, 5CHU de Quebec Research Centre, Laval University, Canada
In postmenopausal osteoporotic (PMOP) women, denosumab (DMAb) therapy through 
10 years (y) is associated with continued BMD gains and low fracture incidence1. Until 5y, 
DMAb treatment resulted in significant increases in degree of mineralization of bone (DMB) 
compared with placebo (Pbo), then plateaued through 10y in both cortical (Ct) and cancel-
lous (Cc) bone2. Our purpose is to assess the microhardness (Hv) of bone reflecting elastic 
and plastic deformations provided by DMB and the quality of mineral and organic matrix 
in bone biopsies from PMOP women treated with DMAb for up to 10y (FREEDOM and 
FREEDOM Extension Trials). Assessments were performed blindly 1) on 72 iliac bone sam-
ples from patients treated for 2/3 y either with Pbo or DMAb, and 2) on 49 iliac bone samples 
from patients treated for 5 (N=28) or 10y (N=21) with DMAb. Intrinsic quality of the min-
eral and organic matrix were assessed using Fourier transform infrared microspectroscopy. 
Hv was measured with a Vickers microindenter. Data were obtained separately in Ct and Cc. 
P-values were calculated using Wilcoxon rank sum test for pairwise comparison. After 2/3y, 
Ct Hv was significantly higher in DMAb than Pbo (Table) with increased mineral/matrix ra-
tio but without significant variation of other variables of quality of mineral and organic ma-
trix. At 5y and 10y, mineral/matrix ratio, mineral maturity (transformation of precursors into 
apatite crystals), crystallinity (size/perfection of crystals), were higher compared to 2/3y of 
DMAb, supporting transition to more mature crystals (within physiological range). Togeth-
er with the increase in DMB2 and mineral maturation, improvement in Hv was expected. 
However, Hv was significantly lower at 5y and 10y than to 2/3y while Cc collagen maturity 
was increased. In conclusion, DMAb improves bone Hv after 2/3y, mainly by changes in 
bone matrix mineralization characteristics that are consistent with DMAb’s mechanism of 
action as a potent remodeling inhibitor. However, persistently low state of bone remodeling 
at 5y and 10y is associated with reduced bone Hv, suggesting aging of the poorly remod-
eled organic matrix (non-collagenous proteins or other factors could be involved). At the 
organ level, DMAb preserves modeling-based bone formation at weight-bearing sites3 and 
leads to continued BMD gains and low fracture rate up to 10y. 1-Bone HG Lancet Diabetes 
Endocrinol 2017,5(7):513 2-Dempster DW JCEM 2018,103:2498 3-Dempster DW JBMR 
2020 Mar 12 online
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Treatment with zoledronate subsequent to denosumab in osteoporosis: a 
randomized trial *Anne Sophie Sølling1, Torben Harsløf1, Bente Langdahl1. 
1Department of Endocrinology and Internal Medicine, Aarhus University 
Hospital, Denmark
Purpose: After discontinuation of denosumab (DMAB) bone resorption increases, bone 
mass is lost and vertebral fractures have been reported. We have previously shown, that 
in 60 postmenopausal women and men treated with DMAB for an average of 4.6+/-1.6 
years (mean+/-SEM) treatment with zoledronate (ZOL) irrespective of the timing did not 
fully prevent bone loss 12 months after ZOL treatment. We now report BMD results after 
2 years. Methods: In a 2-year randomized, open label, interventional study with 60 patients 
with osteopenia, we administrated ZOL at 3 different timepoints: 6 months (6M group, 
n=20) or 9 months (9M group, n=20) after the last DMAB injection or when bone turnover 
was increased (OBS group, n=20). In the OBS group, ZOL was administered if a patient suf-
fered a low energy hip or vertebral fracture, p-carboxy-terminal collagen crosslinks (p-CTX) 
increased >= 1.26 ug/l (50% above the range for postmenopausal women and elderly men) 
or BMD decreased >= 5% 3 months after baseline. Similarly, if p-CTX increased >= 1.26 
ug/l or patient suffered a low energy hip or vertebral fracture before month 3, ZOL was ad-
ministered at that timepoint in the 9M group. All 3 groups were monitored with DXA 6, 12 
and 24 months after treatment. If BMD decreased >= 5% or s-CTX increased >= 1.26 ug/l, 
ZOL was re-administered. The last patient will attend the final visit in August 2020.Results: 
A total of 54 participants have completed the trial and are included in the results. From 
baseline to month 24 spine BMD decreased by 4.0+/-0.8%, 4.3+/-0.9%, and 4.4+/-1.7% in 
the 6M, 9M and OBS groups, respectively (p<=0.001 for all without group differences) and 
total hip BMD by 3.5+/-0.5%, 3.6+/-0.8%, and 4.4+/-1.2% in the 6M, 9M and OBS groups, 
respectively (p<0.001 for all without group differences). A total of 26 participants fulfilled 
the BMD or CTX criteria for re-treatment with ZOL; 14, 6, and 6 patients from the 6M, 
9M and OBS groups, respectively. See table 1. In all groups, mean p-CTX was within the 
premenopausal reference range during the 2nd year of the study. Seven patients suffered a 
fracture: 2 vertebral fractures and 5 non-vertebral fractures.Conclusion: Treatment with ZOL 
subsequent to DMAB in osteopenic patients did not prevent loss of bone 2 years after the 
initial ZOL treatment.
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Risk of Incident Atrial Fibrillation with Zoledronic Acid Versus 
Denosumab: A Propensity-Score Matched Cohort Study *Sara J. Cromer1, 
Kristin M. D’Silva2, Elaine W. Yu1, Michael Fischer3, Seoyoung C. Kim3. 
1Division of Endocrinology, Diabetes, and Metabolism, Massachusetts 
General Hospital, United States, 2Division of Rheumatology, Allergy, and 
Immunology, Massachusetts General Hospital, United States, 3Division of 
Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s 
Hospital, United States
Zoledronic acid is a highly effective treatment for osteoporosis and malignancy-related 
bone disease, but questions remain about a possible increased risk of atrial fibrillation (AF). 
We examined the risk of incident AF among patients receiving zoledronic acid, as compared 
to denosumab, in the first year of treatment for osteoporosis or malignancy-related bone 
disease.We performed a new user, active comparator cohort study using claims data from 
the Clinformatics Data Mart (Optum, Inc.), including privately insured Americans between 
January 1, 2010, and June 30, 2019. We examined separate propensity score (PS)-matched 
cohorts of patients with either osteoporosis or active malignancy. Inclusion criteria were age 
>50 years, incident use of either zoledronic acid or denosumab, and no prior history of ar-
rhythmia or advanced kidney disease. The primary outcome was incident AF (>=1 inpatient 
or >=2 outpatient diagnostic codes) over one year. Secondary outcomes included: 1) hospi-
talization for AF, 2) inpatient or outpatient AF diagnosis with initiation of AF medication, 
3) stroke/transient ischemic attack (TIA), and 4) non-vertebral osteoporotic fracture. Within 
each cohort, we used Cox regression to compare outcomes between patients receiving zole-
dronic acid versus denosumab.In the PS-matched osteoporosis cohort (n=16,235 pairs), the 
average age was 71 +/- 9 years, and 93% were female. There was an increased risk of AF 
with zoledronic acid compared to denosumab over one year (incidence rate [IR] 18.6 v 14.9 
per 1000 person-years; hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.04 to 1.50). 
In the PS-matched malignancy cohort (n=7,732 pairs), the average age was 70 +/- 9 years, 
and 66% were female. There was a trend towards increased AF risk with zoledronic acid 
compared to denosumab over one year (IR 46.9 v 39.0 per 1000 person-years; HR 1.19, 
95% CI 1.00 to 1.43, p=0.06). No increased risk of stroke/TIA occurred in either cohort. 
In the malignancy cohort, zoledronic acid was less effective than denosumab at preventing 
non-vertebral fractures (HR for fracture 1.32, 95% CI 1.01 to 1.74).Zoledronic acid, as com-
pared to denosumab, is associated with modestly increased risk of incident AF in the first 
year after treatment; however absolute risk remained low. Clinicians should consider AF 
risk in pre-therapy counseling and subsequent monitoring of patients initiating zoledronic 
acid therapy.
Disclosures: Sara J. Cromer, Johnson and Johnson, Other Financial or Material Support
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Effects of the recency of sentinel fractures on conventional estimates 
of fracture probability using FRAX *John Kanis1. 1Australian Catholic 
University, Australia
The recency of a prior fracture affects subsequent fracture risk. The aim of this study 
was to quantify the effect of a recent sentinel fracture, by site, on the 10-year probability 
of fracture determined with FRAX. The study used data from the Reykjavik Study fracture 
register that documented prospectively all validated fractures at all skeletal sites in a large 
sample of the population of Iceland.  Fracture probabilities were determined after a sentinel 
fracture (humeral, clinical vertebral, forearm and hip fracture) from the hazards of death and 
fracture, firstly in the context of a sentinel fracture occurring within the previous two years, 
and secondly assuming the presence of a prior osteoporotic fracture irrespective of recency. 
The probability ratios provided adjustments to conventional FRAX estimates of fracture 
probability for recent sentinel fractures.Probability ratios to adjust 10-year FRAX probabil-
ities of a major osteoporotic fracture for recent sentinel fractures were age dependent, de-
creasing with age in both men and women.   Probability ratios varied according to the site of 
sentinel fracture with higher ratios for hip and vertebral fracture than for humerus or forearm 
fracture.  For example, at the age of 50 years, a prior fracture in women from the UK using 
FRAX is associated with a 10-year fracture probability of a major osteoporotic fracture of 
7.2%.  Where a fracture occurred within the past two years, fracture probability was uplifted 
to 19, 17, 14 and 11% where the recent fracture was at the spine, hip, humerus or forearm, 
respectively.  Probability ratios to adjust 10-year FRAX probabilities of a hip fracture for re-
cent sentinel fractures were also age dependent, decreasing with age in both men and women 
(with the exception of humerus fractures). These probability ratios provide adjustments to 
conventional FRAX estimates of fracture probability for recent sentinel fractures.
Disclosures: John Kanis, None
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Surrogate threshold effect: identifying BMD change linked to different levels 
of fracture risk reduction. Study-level analysis from the FNIH Bone Quality 
Project. *Richard Eastell1, Eric Vittinghoff2, Li-Yung Lui3, Charles McCulloch2, 
Fernando Marin4, Anne de Papp5, Rachel Wagman6, Sundeep Khosla7, Jane 
Cauley8, Doug Bauer2, Mary Bouxsein9, Dennis Black2. 1University of Sheffield, 
United Kingdom, 2University of California, San Francisco, United States, 
3California Pacific Medical Center, United States, 4Eli Lilly and Co., Spain, 
5Merck and Co. Inc., Kenilworth, NJ, United States, 6Amgen Inc., United States, 
7Mayo Clinic, United States, 8University of Pittsburgh, United States, 9Harvard 
Medical School, United States
Recent work from the FNIH Bone Quality Study suggests that the change in dual-en-
ergy X-ray absorptiometry (DXA) bone mineral density (BMD) may be a useful surrogate 
for fracture endpoints, allowing for smaller and faster clinical trials for new drug approvals 
in osteoporosis. A key challenge is to identify the surrogate threshold effect (STE), defined 
as the treatment effect on the surrogate that predicts a beneficial effect on the clinical end-
point with high confidence. We have previously reported the change in total hip BMD at 24 
months that predicts any fracture benefit with 95% confidence (ASBMR 2019). In this exten-
sion, we use updated methods to estimate STEs predicting clinically meaningful reductions 
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in fracture risk. We used individual patient data (IPD) including DXA BMD and fracture 
outcomes collected as part of the FNIH Bone Quality project, a public-private partnership, 
which compiled IPD from over 150,000 participants in all major clinical trials of osteopo-
rosis therapies. The current analyses include data from 61,415 participants in 18 trials (11 
bisphosphonate, 4 SERM, 1 parathyroid hormone analogs (PTH-like), 1 denosumab and 1 
odanacatib) that measured total hip (TH) BMD. We used random effects meta-regression to 
estimate the association of the treatment effect on percent change in TH BMD from baseline 
to 24 months with the log odds- or hazard-ratio for the effect of treatment on the risk of 
fracture, accounting for the precision of the two treatment effects for each study. Upper 95% 
prediction intervals for the treatment effect on fracture risk were calculated for a fine grid of 
candidate treatment effects on BMD. STEs were estimated for TH BMD difference between 
active and placebo for different levels of minimum fracture risk reduction (Table).Thus, the 
STEs are greater the higher the minimum treatment effect and differ by fracture type. A reg-
ulatory agency or a sponsor might find the table useful in the interpretation of future clinical 
trials with total hip as the primary end point.
Disclosures: Richard Eastell, Sandoz, Consultant, CL Bio, Consultant, Haoma Medica, 
Consultant, Samsung, Consultant, IDS, Consultant, Nittobo, Consultant, Lyramid, 
Consultant, Alexion Pharmaceuticals, Grant/Research Support, Nittobo, Grant/Research 
Support, Biocon, Consultant, Viking, Consultant, Roche Diagnostics, Grant/Research 
Support
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Do Women with Lower BMD Benefit More from Anti-fracture Treatment? 
An Analysis Pooling Individual Patient Data from 134,000 Women in the 
FNIH-SABRE RCT Database. *Dennis Black1, Li-Yung Lui2, Gayle Lester3, 
Douglas Bauer1, Eric Vittinghoff1, Mary Bouxsein4, Richard Eastell5. 1University 
of California, San Francisco, United States, 2California Pacific Medical Center, 
United States, 3NIH-NIAMS, United States, 4Harvard Medical School, United 
States, 5University of Sheffield, United Kingdom
Randomized trials of alendronate, ibandronate and denosumab have shown larger re-
ductions in non-spine fracture in women with low hip BMD T-score (99% women) were at 
high fracture risk. These data were compiled as part of the FNIH/SABRE Project which is 
using these data to apply for FDA qualification for BMD change as a surrogate endpoint for 
fracture in future RCTs.We stratified data into subgroups by baseline femoral neck BMD 
-2.5. We then calculated the fracture risk reduction in vertebral, non-spine and hip fractures 
within each BMD subgroups.  We then compared and tested the differences between sub-
groups by calculating the p-value for interaction of BMD group with treatment. We also 
calculated the number needed to treat (NNT) to prevent 1 fracture within each BMD sub-
group.  As a sensitivity analysis, we performed subset analyses restricting to trials of bis-
phosphonates.The figure shows the results for the 3 fracture types.  For all 3 fracture types, 
reductions were statistically significant within both BMD subgroups and numerically larger 
among those with FN BMD T <-2.5.  The difference in fracture reduction between the two 
groups was significant for vertebral fracture (p for interaction = 0.006), not for hip fractures 
(p=0.79), with a trend for non-spine fractures (p=0.08).  NNTs were smaller in women with 
BMD T <-2.5. Results in bisphosphonate trials were similar. In summary, fracture risk was 
reduced in both BMD subgroups with significantly larger vertebral fracture reductions in 
women with BMD T <-2.5.  NNT’s for all 3 fracture types were consistently lower in women 
with BMD T <-2.5 due to higher risks. We conclude that anti-osteoporosis medications are 
effective in women below and above baseline femoral neck BMD T-score of -2.5 supporting 
the value of treating both groups of high risk women. The lower NNT in women with BMD 
T<-2.5 suggests that special consideration be given to treatment for these women.
Disclosures: Dennis Black, None
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The associations of peak bone mineral density and rate of bone mineral 
density loss during the menopause transition and early postmenopause with 
subsequent fracture: results from the Study of Women’s Health Across the 
Nation (SWAN) *Albert Shieh1, Arun Karlamangla1, Mei-Hua Huang1, Weijuan 
Han1, Gail Greendale1. 1UCLA, United States
Background. The Study of Women’s Health Across the Nation (SWAN) has demon-
strated that each standard deviation (SD) decrement of in peak lumbar (LS) or femoral (FN) 
BMD is linked to 50 and 60% greater risk of incident fracture, respectively. Whether the rate 
of BMD decline during the menopause transition (MT) contributes independently to fracture 
risk is unknown. This study examined the independent associations of peak BMD and rate 
of BMD decline during the MT and early postmenopause with incident fracture.Methods. 
This analysis included 451 participants from SWAN, a longitudinal study of the MT. The 
combined MT and early postmenopause period was defined as the interval spanning 1 year 
before to 5 years after the final menstrual period (FMP). We operationalized peak BMD as 
the last BMD measurement before 1 year prior to the FMP (BMD did not decrease before 
that time in SWAN). Rate of BMD decline (% per year) during the MT and early postmeno-
pause was calculated from the peak BMD measurement and the first BMD measurement 5 
years after the FMP. We used Cox proportional hazards regression to examine the following 
as predictors of time to first fracture after early postmenopause: 1) peak BMD; 2) rate of 
BMD decline during the MT and early postmenopause; and 3) peak BMD and rate of BMD 
decline. Models were adjusted for age, body mass index, race/ethnicity, study site, and per-
cent of time before or after the observation period that a participant took a bone-detrimental 
or beneficial medication.Results. Mean (SD) age of participants 1 year before the FMP was 
49.6 (2.4) years. 32 women sustained fractures after early postmenopause. Adjusted for co-
variates, each SD greater peak LS BMD was associated with a 44% lower hazard for fracture 
(p=0.007). Each 1% per year faster decline in LS BMD was associated with a 56% greater 
hazard for fracture (p=0.04). Peak LS BMD and rate of LS BMD decline were associated 
with fracture, independent of the other (Table). Women with a peak LS BMD below the 
sample median, and a LS BMD decline rate faster than the sample median had a 2.7-fold 
greater hazard for fracture (p=0.03). Neither peak BMD nor rate of BMD decline at the fem-
oral neck was associated with fracture.Conclusion. Peak LS BMD and rate of decline in LS 
BMD during the MT and early postmenopause are independent risk factors for subsequent 
fracture. Women with both below-median peak LS BMD and faster-than-median LS BMD 
decline have the greatest risk for future fracture.
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Osteocalcin, Muscle Function and 15-year Falls Hospitalizations in Older 
Women: The Perth Longitudinal Study of Ageing Women Study *Cassandra 
Smith1, Joshua R Lewis2, Marc Sim2, Wai H Lim3, Ee Mun Lim4, Lauren 
Blekkenhorst2, Tara C Brennan-Speranza5, Leon Adams3, Elizabeth Byrnes4, 
Gustavo Duque6, Itamar Levinger1, Richard L Prince3. 1Institute for Health and 
Sport (IHES), Victoria University, Australia, 2School of Medical and Health 
Sciences, Edith Cowan University, Australia, 3Medical School, University 
Western Australia, Australia, 4Department of Clinical Biochemistry, PathWest 
Laboratory Medicine, Queen Elizabeth II Medical Centre, Australia, 5Bosch 
Institute for Medical Research, University of Sydney, Australia, 6Australian 
Institute for Musculoskeletal Science (AIMSS), University of Melbourne and 
Western Health, Australia
Purpose: Undercarboxylated osteocalcin (ucOC) has recently been suggested to be in-
volved in muscle mass maintenance and strength, at least in animal models. In humans, the 
ucOC to total (t)OC ratio, may be related to muscle function, a combined term that includes 
muscle strength and physical function. As such, the ucOC/tOC ratio may also be related to 
falls risk, but data are limited. We tested the hypothesis that ucOC and ucOC/tOC ratio are 
associated with muscle function and 15-year falls-related hospitalizations in a cohort study 
of older women.Methods: Serum OC and ucOC was assessed in 1261 older women (mean 
age 75.2 +/- 2.7 years) at year-1 of the Calcium Intake Fracture Outcome Study trial, forming 
the Perth Longitudinal Study of Ageing Women (PLSAW, 1998 to 2013). Timed-up-and-go 
and grip strength was assessed at baseline (1998) and at 5 years. Falls-related hospitaliza-
tions over a 14.5-year follow-up was captured by the Hospital Morbidity Data Collection, 
via the Western Australian Data Linkage System. Results: Women with the highest ucOC/
tOC ratio (quartile 4) had slower timed-up-and-go test performance compared to quartile 
1 by 0.68 secs (p=0.03), grip strength was not significantly different (p>0.05). Those with 
the highest ucOC/tOC had greater falls-related hospitalizations that remained significant 
after adjusting for falls risk factors (HR 1.31, 95% CI 1.09-1.57, p=0.004).Conclusions: We 
identified many older women with high baseline ucOC/tOC ratio also have poorer muscle 
function. Higher ratio was also related to an increased risk of falls hospitalization. This data 
supports the concept that a lower ucOC/tOC ratio may be an important indicator towards 
muscle function and falls-related hospitalizations in older women. Considering links be-
tween ucOC/tOC and vitamin K sufficiency, whether this association is due to the vitamin K 
signal transduction pathway remains to be identified.
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Uncovering The Total Costs Of Osteoporosis-related Fractures In US 
Postmenopausal Women *Oth Tran1, Stuart Silverman2, Xiaoqing Xu3, 
Machaon Bonafede1, Kathleen Fox4, Michele McDermott3, Shravanthi R 
Gandra3. 1IBM Watson Health, United States, 2Cedars-Sinai Medical Center and 
David Geffen School of Medicine, United States, 3Amgen Inc., United States, 
4Strategic Healthcare Solutions, LLC, United States
Osteoporotic fractures are associated with substantial economic burden in the first year 
following a fracture regardless of fracture type. Current literature focuses on the short-term 
costs of osteoporotic fractures; however, fractures can have prolonged effects on patient 
health and both recent short-term as well as long-term data examining the cost of fracture 
are lacking. In this study, we compared direct and indirect healthcare costs between post-
menopausal osteoporotic women and demographically matched controls in the 5 years after 
incident fracture, and by fracture type in commercially insured and Medicare populations.
Using MarketScan claims data, 226,190 women (91,925 aged 50–64 years; 134,265 aged 
>=65 years) with incident osteoporotic fracture by type (hip, vertebral, and non-hip non-ver-
tebral [NHNV]) from 2008–2017 were identified. Each fracture case, by type of fracture, 
was matched to a non-fracture control (1:1) based on age, geographic region, years of fol-
low-up, and insurance type. Direct costs were assessed based on general linear models after 
adjusting for baseline costs, comorbidities, osteoporosis diagnosis, and treatment. Indirect 
costs including work loss due to absenteeism and short-term disability (STD) were assessed 
among commercially-insured patients. Costs were standardized to 2019 US dollars.Base-
line osteoporosis diagnosis and treatment rates were low among commercially-insured and 
Medicare patients. For all fracture types, commercially insured and Medicare patients in-
curred higher direct costs across all 5 years post-index compared with non-fracture controls. 
The unadjusted costs among hip fracture patients were 9.5 times higher at Year 1 and 3 times 
higher at Year 5 than matched controls (Figure). The adjusted mean incremental costs at Year 
1 for hip, vertebral, and NHNV fractures were $59,327, $29,987, and $14,390 among com-
mercially-insured patients, and $45,755, $21,169, and $19,209 among Medicare patients, 
respectively. Further, indirect costs among patients with each fracture type evaluated were 
higher than controls due to absenteeism and STD at Year 1. Patients with fracture had higher 
adjusted indirect costs due to STD (incremental cost $5,848, $2,748, and $2,596 for hip, ver-
tebral, and NHNV fracture, respectively) compared with controls during Year 1 post-index.
The significant economic burden after an osteoporosis-related fracture underscores the need 
for early patient identification and timely treatment.
Disclosures: Oth Tran, IBM Watson, Consultant
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The Stat3/mitophagy axis coordinates macrophage NLRP3 inflammasome 
activation and inflammatory bone loss *Zijun Wang 1, Lingxin Zhu1, Minquan 
Du1, Bin Peng1. 1School and Hospital of Stomatology, Wuhan University, China
Accumulating evidence indicates that the inflammasomes are implicated in a wide 
range of bone destructive diseases driven by both sterile and non-sterile inflammation. Sig-
nal transducer and activator of transcription 3 (Stat3) is a cytokine-responsive transcription 
factor involved in important immune functions including both pro- and anti-inflammatory 
responses. However, the role of Stat3 in macrophage NLRP3 inflammasome activation and 
inflammatory osteolysis remains unknown. Here, we found that Stat3 was activated in mac-
rophages during NLRP3 inflammasome activation in vitro and inflammatory osteolysis in 
vivo. We employed a Stat3 inhibitor Stattic, which inhibits the phosphorylation and DNA 
binding activity of Stat3, to target Stat3 in macrophages in vitro and inflammatory bone loss 
in vivo. The Stat3 inhibitor significantly blocked NLRP3 inflammasome activation in prima-
ry mouse bone marrow-derived macrophages in vitro, as evidenced by remarkable decrease 
of cleaved caspase-1 p20 and IL-1β p17 released into the supernatants. The cellular expres-
sion level of NLRP3, IL-1β and caspase-1 was unaffected upon Stat3 inhibition. We then 
sought to determine the molecular mechanisms underlying Stat3-regulated NLRP3 inflam-
masome activation. Unexpectedly, the Stat3 inhibition caused the notable upregulation of 
PINK1/Parkin expression and mitophagy occurrence in bone marrow-derived macrophages, 
leading to a reversed mitochondrial membrane potential collapse, which probably in turn 
inactivates the NLRP3 inflammasome. Indeed, the mitophagy inhibitor Mdivi-1 significantly 
reversed the effects of Stat3 inhibition on caspase-1 activation and IL-1β secretion in mac-
rophages, indicating the crucial dependence of Stat3 on mitophagy during inflammasome 
activation. Importantly, administration of Stat3 inhibitor significantly protected mice from 
inflammatory osteolysis models of both infection-induced periapical bone destruction and 
aseptic titanium particle-induced calvarial bone erosion, accompanied with the potent in-
duction of mitophagy, decreased macrophage infiltration and osteoclast number. Togeth-
er, these studies characterize a previously unsuspected Stat3/mitophagy axis in regulating 
macrophage inflammasome activation and inflammatory bone loss, and propose a potential 
therapeutic intervention by targeting this pathway to prevent inflammatory osteolytic bone 
diseases.
Disclosures: Zijun Wang, None
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Macrophage Lineage Hdac3 Deletion Enhances Bone Healing and Promotes 
Lcn2-Dependent Macrophage Metabolic Reprogramming *David Molstad1, 
Elizabeth Bradley1, Jennifer Westendorf2. 1University of Minnesota, United 
States, 2Mayo Clinic, United States
Macrophages play a central role in tissue regeneration, participating in both the initial 
inflammatory response and tissue healing. Although a spectrum exists, inflammatory macro-
phages (M1) are primarily involved during the initial response to injury; whereas alternative 
macrophages (e.g., M2) are the primary tissue healing effectors. Altered cellular metabolism, 
via breaks in oxidative phosphorylation, facilitates M1-associated inflammation. In contrast, 
M2 exhibits enhanced glucose metabolism that is mediated by PI3K/Akt/mTOR signaling. 
Genetic and epigenetic studies demonstrate that histone deacetylase (Hdac) 3 plays a crit-
ical role in controlling inflammation. Likewise, Hdac inhibitors suppress and conditional 
deletion of Hdac3 (Hdac3 cKOLysM) enhances M2. Hdac3 deficiency enhances collagen 
deposition within atherosclerotic lesions and stabilizes plaques, but the impact on bone 
healing is unknown. We therefore examined how Hdac3 deficiency impacts bone healing 
and alters macrophage metabolism. We induced single cortex defects in Hdac3 cKOLysM 
12-week-old mice or their control littermates and assessed bone healing 14 days after defect 
generation (n=7). Female Hdac3 cKOLysM mice showed an average 140% increase in BV/
TV within the defect site. Unbiased RNA sequencing revealed altered expression of genes 
related to inflammation and metabolism, including decreased Lipocalin2 (Lcn2), by Hdac3 
deficient bone marrow macrophages (BMMs). We confirmed these data and showed dimin-
ished Lcn2 levels by ex vivo cultured Hdac3 cKOLysM BMMs, and in vivo within the bone 
marrow of 12-week-old Hdac3 cKOLysM mice (n=6) via IHC. Moreover, BMMs treated 
with the PAN Hdac inhibitor SAHA or the Hdac3-specific inhibitor Rgfp966 exhibited in-
creased Akt/mTOR/S6K pathway activation and expression of glycolytic genes, but Lcn2 
levels were suppressed. Rgfp966 promoted glycolysis of BMMs, as measured by lactate 
production, but SAHA did not. As expected, lactate levels were increased by a two hour in-
sulin or IL4 treatment, but Hdac inhibition did not potentiate this effect. Finally, we assessed 
LCN2 levels as a function of age via IHC using a human bone marrow tissue array. LCN2 
levels were lowest in bone marrow biopsies from males and females under the age of 30, 
but were high in males and females over the age of 65. These data support that myeloid-lin-
eage Hdac3 deficiency, by promoting M2 polarization, enhances bone healing and promotes 
Lcn2-dependent metabolic reprogramming.
Disclosures: David Molstad, None
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Preosteoblasts modulate myelopoiesis in the bone marrow by producing the 
chemokines CCL3 and CCL4 *Alexander Lubosch1, Franziska Wirth1, Katrin 
Huck1, Caren Zoeller1, Hiba Ghura1, Stefan Hamelmann1, Stefan Porubsky2, 
Inaam Nakchbandi1. 1University of Heidelberg, Germany, 2University Of Mainz, 
Germany
Osteoblasts affect hematopoiesis and modulate the immune response against cancer 
(Rossnagl et al. PLoS Biology 2016), in addition to their classical role in bone formation. 
Integrin signaling modulates the ability of osteoblasts both to differentiate (Sens et al. JBMR 
2017, J Biol Chem 2017) and to modify the immune response by exposed myeloid cells. A 
Rho GTPase called CDC42 located downstream of integrin signaling is additionally able 
to integrate these signals with those originating from the wnt pathway and various growth 
factors. We therefore aimed to characterize the influence of CDC42 in osteoblasts on hema-
topoiesis.Deletion of Cdc42 in vivo in preosteoblasts using the osterix (Osx) promoter to 
drive cre expression in CDC42 floxed homozygous (conditional knockout: cKO) diminished 
osteoblast function in vitro (von Kossa staining, p<0.001) and in vivo leading to diminished 
BMD (CT: 290 vs. Osx cKO: 246 mg/cm3, p<0.0001). In addition, hematopoietic common 
myeloid progenitors (CMPs) increased in the bone marrow. These give rise to erythrocytes, 
thrombocytes, granulocytes and macrophages (CMPs increased by 17%, p<0.05). In periph-
eral blood, a rise in cells derived from these progenitors, namely erythrocytes and platelets 
was detected (Platelets increased by 18%, p<0.05). Interestingly, deletion of CDC42 in dif-
ferentiating osteoblasts using the collagen α1(I) promoter to drive cre expression in CDC42 
floxed mice also diminished BMD (Control: 262 vs. collagen cKO: 242 mg/cm3, p<0.05), 
albeit to a lesser degree than in Osx cKO. This was due to a decrease in osteoblast numbers 
and function (ObN/BS decreased by 34%, p<0.001). Hematopoiesis in the bone marrow 
and peripheral blood cells were unaffected. Thus, CDC42 expression in preosteoblasts, but 
not in differentiating osteoblasts modulates hematopoiesis in the bone marrow.To establish 
causality between CDC42 loss in preosteoblasts and changes in hematopoiesis, we isolated 
bone marrow stromal cells and treated these with a chemical CDC42 inhibitor. After removal 
of the inhibitor, pretreated stromal cells were able to advance the differentiation of sorted 
hematopoietic stem cells and increase myelopoiesis compared to untreated stromal cells 
(60% increase, p<0.005). Bone marrow stromal cells that were treated with CDC42 inhibitor 
as well as cells isolated from Osx cKO were compared to their respective controls. In the 
conditioned media of treated and cKO cells two chemokines were increased: CCL3 (4-fold 
increase, p<0.05) and CCL4 (2-fold increase, p<0.05). Inhibiting either one of the chemo-
kines in pretreated stromal cells cocultured with stem cells counteracted the increase in 
myelopoiesis (p<0.05).In summary, preosteoblasts, but not differentiating osteoblastic cells 
modulate myelopoiesis. This effect involves the Rho GTPase Cdc42 and is mediated by the 
chemokines CCL3 and CCL4. 
Disclosures: Alexander Lubosch, None
1076
Blocking of osteocyte Toll-like receptor signaling uncouples bone resorption 
from inflammation *Tetsuya Yoshimoto1, Mizuho Kittaka1, Matt Prideaux2, 
Lynda F Bonewald2, Yasuyoshi Ueki1. 1Indiana University School of Dentistry, 
Indiana Center for Musculoskeletal Health, Indiana University School of 
Medicine, United States, 2Indiana Center for Musculoskeletal Health, Indiana 
University School of Medicine, United States
It is well known that bacterial pathogens are potent inducers of bone resorption. As os-
teocytes express RANKL to activate osteoclasts, we proposed that osteocytes are the cellular 
mediators between bacterial infection and osteoclastogenesis. As we found that, like im-
mune cells, osteocytes express Toll-like receptor 2 (TLR2) and its signal transducer MYD88, 
Dmp1-Cre Myd88fl/fl mice were generated with targeted deletion of Myd88 in osteocytes. 
Injection of the TLR1/2 agonist Pam3CSK4 onto calvaria of these mice resulted in a reduc-
tion in bone erosion (67.2% males; 69.3% females) compared to control Myd88fl/fl mice. 
The Pam3CSK4-injected Dmp1-Cre Myd88fl/fl mice showed decreased osteoclast numbers 
and Rankl expression. However, there were no differences in inflammation. As interleukin-1 
receptor (IL-1R) also signals via MYD88, we next injected Pam3CSK4 to Dmp1-Cre Il1r1fl/
fl mice, but found no reduction in bone loss, suggesting that activation of TLR in osteocytes 
plays an exclusive role in osteoclast activation. To determine if this signaling mechanism 
is specific for osteocytes, both osteoblast (Ob)- and osteocyte (Ocy)-enriched cell popula-
tions were isolated from calvaria of 10-week-old C57BL/6J mice by sequential enzymatic 
digestion. Strikingly, stimulation with Pam3CSK4 induced much higher Rankl expression 
in Ocy-enriched cells compared to Ob-enriched cells (4.3 vs. 1.2-fold at 4 hours, n = 3) and 
this signaling for Rankl was blocked in the Ocy cells by inhibiting MAPKs. The co-culture 
of Ocy-enriched cells with osteoclast precursors in the presence of Pam3CSK4 showed a 
5.2-fold increase in osteoclast formation compared to co-culture with Ob-enriched cells. In-
ducing periodontitis by oral infection with P.gingivalis resulted in significantly less alveolar 
bone loss in Dmp1-Cre Myd88fl/fl mice along with a decrease in Rankl expression in the 
jawbones, but no decrease in inflammation in the gingiva. Intraperitoneal administration of 
T6167923, an MYD88 inhibitor, protected against alveolar bone loss in the wild-type mice 
with P.gingivalis periodontitis. We also found the bacteria within the Ocy lacunar-canalic-
ular system in this model. In summary, our data show that blocking of osteocytic RANKL 
uncouples bone resorption from inflammation in periodontitis and potentially other bacterial 
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infections. The osteocytic TLR-MYD88 pathway may be an emerging target to prevent and 
treat bone loss in pathogen-driven inflammatory bone diseases.
Disclosures: Tetsuya Yoshimoto, None
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Ovariectomy Induces Bone Loss Via Microbial Dependent Trafficking 
of Intestinal TNF Producing T Cells and Th17 Cells to the Bone Marrow 
*Roberto Pacifici1, Mingcan Yu2, Subhashis Pal2, Cameron Paterson3, Jau-Yi 
Li2, Abdul Malik Tyagi2, Jonathan Adams2, Craig M Coopersmith4, M. Neale 
Weitzmann5. 11 Division of Endocrinology, Metabolism and Lipids, Department 
of Medicine, Emory University, Atlanta, GA; 2 Emory Microbiome Research 
Center, Emory University, Atlanta, GA; 6 Immunology and Molecular 
Pathogenesis Program, Emory University, Atlanta, GA., United States, 21 
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, 
Emory University, Atlanta, GA; 2 Emory Microbiome Research Center, Emory 
University, Atlanta, GA., United States, 33 Department of Surgery and Emory 
Critical Care Center, Emory University School of Medicine; 4 Lieutenant, 
Medical Corps, United States Navy, NROTC Atlanta., United States, 42 Emory 
Microbiome Research Center, Emory University, Atlanta, GA; 3 Department of 
Surgery and Emory Critical Care Center, Emory University School of Medicine., 
United States, 51 Division of Endocrinology, Metabolism and Lipids, Department 
of Medicine, Emory University, Atlanta, GA; 2 Emory Microbiome Research 
Center, Emory University, Atlanta, GA; 5 Atlanta VA Medical Center, Decatur, 
GA., United States
Estrogen deficiency causes a gut microbiome dependent expansion of bone marrow 
(BM) Th17 cells and TNFa (TNF) producing (TNF+) T cells. The resulting increased BM 
levels of IL-17 and TNF stimulate RANKL expression and activity causing bone loss. How-
ever, the origin of BM Th17 cells and TNF+ T cells is unknown. We found that ovariectomy 
(ovx) expanded the pool of TNF+ T cells and Th17 cells, as well as the transcript levels 
of TNF and IL-17 in the gut and the BM suggesting that ovx may increase the trafficking 
of intestinal T cells to the BM. To directly measure T cell trafficking, Kaede mice (which 
ubiquitously express a photoconvertible protein that changes its fluorescence emission from 
green to red upon photoactivation with UV light) were sham operated or ovx. Two weeks 
later intestinal Peyer’s patches were surgically exposed and photo-converted by UV light 
exposure for 1 minute. BM red T cells were counted by flow cytometry 24 hours later. These 
experiments revealed that ovx increased by ~ 3-6 fold the homing of intestinal TNF+ T 
cells and Th17 cells into the BM. Studies using eGFP labeled Th17 cells confirmed that ovx 
increases the tropism of Th17 cells toward the BM. We found the egress of TNF+ T cells and 
Th17 cells from the intestine to the systemic circulation to be mediated by the S1P-receptor 
1 (S1PR1) expressed in T cells and circulating S1P. The influx of TNF+ T cells from the cir-
culation to the BM was mediated by the chemokine receptor CXCR3. The resulting increase 
in BM TNF levels upregulated the expression of the CXCR6 ligand CCL20 by BM cells. 
CCL20 then recruited CXCR6+ Th17 cells to the BM, causing and expansion of the pool of 
Th17 cells and the levels of IL-17 in the BM. Attesting to the functional relevance of T cell 
trafficking, the loss of trabecular bone and the increase in bone turnover induced by ovx were 
completed prevented by either: a) treatment with the S1PR1 functional antagonist FTY720, 
an agent that blocks T cell egress from the intestine, b) blockade of TNF+ T cells trafficking 
to the BM by silencing of CXCR3, or c) arrest of Th17 cells influx to the BM via treatment 
with anti CCL20 Ab. In summary, the Th17 cells and TNF+ T cells that accumulate in the 
BM of ovx mice originate in the gut. Intestinal T cells are a proximal target of sex steroid 
deficiency relevant for bone loss. Blockade of intestinal T cell migration may represent a 
therapeutic strategy for the treatment of postmenopausal bone loss.
Disclosures: Roberto Pacifici, None
1078
TNFR2 signaling pathway mediated by 14-3-3ε instructs  macrophage 
plasticity in inflammatory arthritis *Wenyu Fu1, Young-su Yi1, Aubryanna 
Hettinghouse1, Wenjun He1, Guodong Sun1, Yufei Bi1, Chuan-Ju Liu1. 1New York 
University Medical Center, United States
Inflammatory arthritis is a polyarticular chronic inflammatory disease characterized 
by deregulated immune response and bone erosion. Increasing evidences document that 
macrophages contribute significantly to the inflammation in inflammatory arthritis, thus 
therapeutic strategy targeting the unbalanced M1/M2 ratio represents an attractive target in 
treating inflammatory arthritis. Although it is well recognized that TNFR2 plays a beneficial 
anti-inflammation function in inflammatory diseases, its role in macrophage polarization, 
particularly under inflammatory arthritis, remains unknown.Here we found that activation 
of TNFR2 with its novel ligand progranulin (PGRN) markedly skewed the macrophage 
toward anti-inflammatory M2 macrophage. Using biochemical co-purification and mass 
spectrometry approaches, we isolated the signaling molecule 14-3-3ε as a novel compo-
nent of TNFR2 complexes in response to PGRN stimulation in macrophages. PGRN’s ef-
fects on macrophage polarization were largely abolished in 14-3-3ε knockout Raw264.7 
and primary BMDMs, and re-expression of 14-3-3ε restored 14-3-3ε knockout cells’ re-
sponse to PGRN, suggesting that 14-3-3ε serves as a mediator of PGRN/TNFR2 signaling. 
Global or macrophage specific 14-3-3ε deficiency resulted in an overt pro-inflammatory 
response through skewing macrophage toward M1 and unbalanced M1/M2 ratio relative to 
control littermates; in addition, PGRN’s anti-inflammation action was largely abolished in 
14-3-3ε deficient mice, suggesting that  unbalanced M1/M2 ratio played a pathologic role 
in inflammatory arthritis, and targeting macrophage plasticity through 14-3-3ε by PGRN/
TNFR2 may hold a therapeutic promise  for inflammatory arthritis.Combining transcriptome 
profiling and GSEA analysis, examination of activation status of key signaling molecules, 
along with DNA binding activity analysis revealed that TNFR2/14-3-3ε signaled through 
PI3K Akt mTOR to restrict NF-κB activation while simultaneously to stimulate C/EBPβ 
activation, thereby instructing macrophage functional plasticity (Fig. 1).In summary, our 
study identified 14-3-3ε as a novel regulator which is necessary and sufficient to mediate 
TNFR2’s regulation on macrophage polarization. This study not only provides new insights 
into TNFR2 signaling, but may also lead to the development of new interventions for various 
inflammatory diseases, particularly inflammatory diseases.
Disclosures: Wenyu Fu, None
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Fracture Risk in Type 2 Diabetes: Longitudinal Glycemic Control Based 
Prediction and the Efficacy of Medications *Bowen Wang1, Zehai Wang1, 
Atharva Poundarik1, Mohammed Zaki2, Richard Bockman3, Deepak Vashishth1. 
1Center for Biotechnology and Interdisciplinary Studies, Department of 
Biomedical Engineering, Rensselaer Polytechnic Institute, United States, 
2Department of Computer Science, Rensselaer Polytechnic Institute, United 
States, 3Division of Endocrinology and Metabolic Bone Disease, Hospital for 
Special Surgery, United States
The increased fracture risk in people with type 2 diabetes (T2D) is underestimated in 
clinical BMD-based fracture risk assessments, such as such as the FRAX tool. The loss 
of glycemic control in patients with T2D has been associated with multiple tissue modi-
fications, including bone quality alteration. In this study, we proposed to use longitudinal 
HbA1c, a serum based glycemic marker routinely measured in people with T2D over a peri-
od of time, to independently predict T2D fractures. The efficacy of longitudinal anti-diabetic 
and anti-osteoporotic medication use was also examined.The OptumLabs® Data Warehouse 
(OLDW) is a longitudinal, real-world data asset with de-identified administrative claims and 
electronic health record (EHR) data. Over the period of 01/01/2007 to 09/31/2015, a cohort 
of 154,345 patients with T2D (age >= 55 years) with available HbA1c measurements was 
identified from OLDW. Correlations were assessed based on different durations of HbA1c 
aggregate and following fracture incidences. Kaplan-Meier survival analysis and Cox pro-
portional hazard model were used to evaluate the relationship between longitudinal HbA1c, 
medications, and fracture risk. The covariates selected in the multivariate model include sex, 
age, use of three types of medication (metformin, insulin, bisphosphonates), and comorbid-
ities.A strong positive correlation was shown between one-year follow-up fracture rate and 
two-year average HbA1c (Fig. 1A, R2 = 0.97; p < 0.005). Figure 1B illustrates the survival 
curves of two-year cumulative fracture rate stratified by HbA1c bins (two-year average). 
The fracture rate between groups were significantly different (p < 0.005). With 13 covariates 
adjusted, a 1% increase in two-year average HbA1c is responsible for 2% increase in risk 
of fracture for the following two years (p=0.03). Two-year use of metformin correlated with 
decreased fracture risk, while insulin and bisphosphonates were associated with higher risk 
of fracture (all p < 0.005). We also discovered that fracture risk has a more linear response 
to longitudinal HbA1c with a lower threshold, compared to other comorbidities.Our finding 
suggests longitudinal two-year HbA1c average independently predicts the subsequent two 
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years’ fracture risk. Maintenance of glycemic control, and the use of metformin is beneficial 
in managing fracture risk in people with T2D.
Disclosures: Bowen Wang, None
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Use of Sodium-glucose Co-transporter-2 Inhibitors, Changes in Body Mass 
Index and Risk of Fracture in the United Kingdom (UK) *Nikki Werkman1, 
Judith van Dalem1, Johanna Driessen1, Bernardette Rossi2, Peter Vestergaard3, 
Joop van den Bergh4, Richard Eastell5, Andrea Burden6, Nicklas Rasmussen7, 
Olaf Klungel8, Martijn Brouwers9, Frank de Vries1. 1Department of Clinical 
Pharmacy and Toxicology, Maastricht University Medical Centre+, Netherlands, 
2Directorate Pharmaceutical Affairs, Department for Policy in Health, Ministry 
for Health, Malta, 3Aalborg University Hospital and Aalborg University, 
Denmark, 4Department of Internal Medicine, Division of Rheumatology, 
Maastricht University Medical Center+, Netherlands, 5Department of Oncology 
and Metabolism, University of Sheffield, United Kingdom, 6Department of 
Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, 
Switzerland, 7Steno Diabetes Center North Denmark, Aalborg University 
Hospital, Denmark, 8Division of Pharmacoepidemiology and Clinical 
Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Netherlands, 
9Department of Internal Medicine, division of Endocrinology and Metabolic 
Disease, Maastricht University Medical Centre+, Netherlands
Background: Type 2 diabetes (T2D) is a metabolic disorder associated with decreased 
bone quality. Clinical trials showed that sodium-glucose co-transporter 2 inhibitors (SGLT2-
Is) were associated with considerable weight loss in T2D. There is conflicting evidence 
regarding a potential reduction of bone mineral density associated with these drugs. Former 
studies presented contradicting results regarding the association of SGLT2-Is and major os-
teoporotic fracture risk. However, the potential role of weight loss due to SGLT2-I use was 
not considered.Objectives: The aim of the current study was to investigate the association 
between SGLT2-I use, changes in body mass index (BMI) and the risk of major osteoporotic 
fractures.Methods: A retrospective population-based cohort study was conducted using data 
from the UK Clinical Practice Research Datalink (CPRD) GOLD (2013-2018). The study 
population (N=34,960) consisted of T2D patients aged 18+ who received a first ever pre-
scription of a sulphonylurea (SU) or SGLT2-I. The date of the first prescription defined the 
start of follow-up. Time-varying Cox proportional hazards models were used to estimate the 
hazard ratios (HRs) of major osteoporotic fracture with current SGLT2-I use versus current 
SU use, stratified by change in BMI. Analyses were adjusted for age, sex, lifestyle variables, 
comorbidities and concomitant drug use.Results: Current use of SGLT2-Is was not associ-
ated with increased risk of major osteoporotic fracture (adjusted HR 1.19; 95% confidence 
interval 0.80-1.79) compared to SU users. This finding remained consistent after stratifica-
tion by change in BMI (see table).Conclusions: Current use of SGLT2-Is was not associated 
with osteoporotic fracture risk compared to current use of SUs. Among current SGLT2-I 
users, loss of BMI was not associated with risk of major osteoporotic fracture. These results 
suggest that SGLT2-I use is not associated with an increased risk of osteoporotic fractures, 
irrespective of change in BMI.
Disclosures: Nikki Werkman, None
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Greater Serum Carboxy‐Methyl‐Lysine (CML) is Associated with Increased 
Fracture Risk in Type 2 Diabetes: The Health, Aging and Body Composition 
Study *Ruban Dhaliwal1, Susan Ewing2, Deepak Vashishth3, Richard Semba4, 
Ann Schwartz2. 1State University of New York, Upstate Medical University, 
United States, 2University of California San Francisco, United States, 3Department 
of Biomedical Engineering, Rensselaer Polytechnic Institute, United States, 4The 
Johns Hopkins University School of Medicine, United States
Purpose: Accumulation of advanced glycation end-products (AGE) occurs with aging 
and diabetes in tissues with low turnover, including bone collagen. This accumulation alters 
collagen structure and function. Data on the relationship of fluorescent AGEs and fractures 
are not consistent. We examined the association of a non-fluorescent AGE, Carboxy-meth-
yl-lysine (CML) with incident clinical and prevalent vertebral fractures by type 2 diabetes 
(T2DM) status, in men and women ages 70-79 years from the Health, Aging, and Body 
Composition study.Methods: Determinants of T2DM were self-report, use of hypoglycemic 
medication, elevated fasting glucose (>=126 mg/dl), or impaired glucose tolerance (2-hour 
plasma glucose during oral glucose tolerance test >=200 mg/dl). Incident clinical fractures 
and baseline vertebral fractures were assessed. Cox proportional hazards models were used 
to analyze the associations between log-transformed baseline serum CML and risk of clin-
ical fractures, and logistic regression models for prevalent vertebral fractures.Results: At 
baseline, mean +/- SD age was 73.7 +/- 2.8 and 73.6 +/- 2.9 years in T2DM (n = 712) and 
non-DM (n = 2,332), respectively. Baseline CML levels were significantly higher in T2DM 
than non-DM (893 +/- 332 vs. 771 +/- 270 ng/ml, p <0.0001). Incident clinical fractures 
occurred in 136 T2DM participants over mean follow-up of 9.6 years and in 509 non-DM 
participants over mean 10.9 years. Among the subset with lateral scout data (n = 1,038), 11 
T2DM and 18 non-DM participants had prevalent vertebral fracture. In models adjusted for 
age, race, gender, and clinic, greater CML was significantly associated with higher risk of 
clinical fracture in T2DM (Hazard Ratio (HR) 1.45; 95% CI: 1.22, 1.73 per 1 SD increase 
in log CML) but not in non-DM (HR 1.07; 95% CI: 0.98, 1.16; p for interaction = 0.004). 
Further adjustment for weight, weight loss, smoking, A1c, BMD, cystatin-C, and medica-
tions had little effect (Table 1). Greater CML was also associated with increased prevalence 
of vertebral fracture in T2DM but not in non-DM (Table 1).Conclusion: Higher CML levels 
are associated with increased risk of incident clinical fractures and higher likelihood of prev-
alent vertebral fractures in T2DM, independent of BMD. These results implicate CML in the 
pathogenesis of bone fragility in diabetes.
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Dietary Advanced glycation end-products (dAGEs) and bone health: a cross-
sectional analysis in Rotterdam study *Komal Waqas1, Jinluan Chen2, Trudy 
Voortman2, Fernando Rivadeneira2, Andre G Uitterlinden2, M. Carola Zillikens3. 
1Department of internal Medicine, Erasmus Medical Centre, Netherlands, 
2Department of Epidemiology, Erasmus Medical Centre, Netherlands, 
3Department of Internal Medicine, Erasmus Medical Centre, Netherlands
We recently showed that subjects with high skin advanced glycation end products 
(AGEs) have more prevalent vertebral (VFs) and major osteoporotic fractures (MOFs). 
No studies have yet investigated the association of dietary intake of AGEs namely, Car-
boxymethyllysine (CML), in human subjects with bone mineral density and fractures. A 
cross-sectional analysis was performed in 3939 participants from Rotterdam study by using 
CML estimated from food frequency questionnaires and  a dAGE database. Bone mineral 
density (BMD) was estimated using insight dual X-ray absorptiometry. We defined MOFs 
as hip, wrist, humerus and clinical VFs; and VFs as Genant’s radiological grade 2 and 3 + 
clinically reported VFs. Multivariate linear and logistic regression models were performed 
adjusting for sex, age, RS-cohorts, physical activity, diet quality, energy intake, eGFR, dia-
betes status, smoking and BMI and subsequently BMD. Mean age of our cohort was 66.7+/-
10.5 years with 43% males and 12% subjects with diabetes. In fully adjusted models, we 
observed no association of CML with TBS (β=-0.015; p=0.48) and BMD at both femoral 
neck (β=-0.006; p=0.70) and lumbar spine (β=-0.013; p=0.38). Higher intake of CML was 
found to be associated with vertebral fractures (Odds ratio, OR=1.16, 95% confidence in-
terval, (1.02-1.32), p=0.02) and a similar but non-significant trend with MOFs (OR=1.12 
(0.98-1.27), p=0.10). Adjustment for BMD  did not change associations with fractures. Strat-
ification showed a significant association for VFs in females and subjects without diabetes. 
Top 6 food categories contributing to more than 70% of daily dietary CML intake, namely: 
Sweets, Whole grains, Unprocessed Meat, Refined grains and Processed Meat in descending 
order.  Together, CML intake of top 6 food categories were significantly associated with VFs 
(OR=1.15 (1.03-1.29), p=0.02) with almost a similar effect size as all 21 categories but not 
with MOFs (OR=1.09 (0.97-1.22), p=0.17). In conclusion, dietary intake of CML was asso-
ciated with VFs independent of BMD. CML from milk, grains and meat might impact bone 
health negatively but future studies are needed to elucidate whether associations found are 
causal and related to intake of CML alone or other constituents of these foods.
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Saturated and Unsaturated Bone Marrow Lipids Have Distinct Effects 
on Bone Density and Fracture Risk in Older Adults *Gina Woods1, Susan 
Ewing2, Sigurdur Sigurdsson3, Eric Vittinghoff2, Deborah Kado1, Trisha Hue2, 
Thomas Lang2, Tamara Harris4, Clifford Rosen5, Vilmunder Gudnason6, Anne 
Schafer2, Xiaojuan Li7, Ann Schwartz2. 1University of California, San Diego, 
United States, 2University of California, San Francisco, United States, 3Icelandic 
Heart Association, Iceland, 4National Institutes of Health, United States, 5Maine 
Medical Center Research Institute, United States, 6University of Iceland, Iceland, 
7Cleveland Clinic, United States
Greater bone marrow adiposity (MAT) is associated with low bone density (BMD) and 
vertebral fractures, yet less is known about MAT composition and bone outcomes. We stud-
ied the associations between 1H-MRS measures of vertebral MAT saturation and unsatura-
tion and bone outcomes in 465 older adults from the Age Gene/Environment Susceptibility 
(AGES)-Reykjavik study.  MAT saturation was defined as the ratio of saturated lipid (1.3 
ppm peak) to total marrow contents, and MAT unsaturation as the ratio of unsaturated lipid 
(5.3 ppm peak) to total marrow contents. Associations between MAT composition and QCT 
and DXA bone parameters were evaluated with linear regression models. Logistic regres-
sion models were used to evaluate associations with prevalent and incident radiographic 
vertebral fractures, and Cox proportional hazards models for incident clinical fractures. All 
models included both saturated and unsaturated lipids. At baseline, mean age was 81.7 (SD 
4.3) years, mean MAT unsaturation was 3.5% (SD 1.0) and mean saturation was 46.3% 
(SD 7.2). Prevalent vertebral fractures were present in 21.0% of participants, and incident 
clinical fractures occurred in 21.3% of participants over 5.1 (SD 2.4) years. Incident verte-
bral fractures occurred in 14.8% of 298 participants attending follow up visits over 3.0 (SD 
1.5) years. In cross-sectional analyses, each SD increase in MAT saturation was associated 
with lower BMD (Table). Conversely, higher MAT unsaturation was associated with higher 
BMD. Each SD increase in MAT saturation was associated with 46% greater odds (95% con-
fidence interval [CI] = 1.11-1.92) of prevalent vertebral fracture and 55% greater odds (95% 
CI = 1.03-2.34) of incident vertebral fracture, while each SD increase in MAT unsaturation 
was associated with 42% lower odds (95% CI = 0.38-0.89) of incident vertebral fracture. 
In men, there was a 45% increased risk (95% CI = 0.97-2.19) for incident clinical fracture 
per SD increase in MAT saturation versus a 45% decreased risk (95% CI = 0.37-0.83) per 
SD increase in MAT unsaturation. There was no association between MAT composition 
and incident clinical fractures in women. MAT composition was not associated with change 
in bone parameters. In conclusion, saturated and unsaturated marrow lipids have distinct 
relationships to bone density and fracture risk. Therefore, combining these peaks into total 
MAT content may not be an effective approach when evaluating the relationship between 
MAT and bone outcomes.
Disclosures: Gina Woods, None
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Role of the Gut Microbiome in Bone Metabolism in Severe Obesity and 
After Sleeve Gastrectomy *Karin Wu1, Kathryn McCauley1, Susan Lynch1, 
Anne Schafer1. 1University of California, San Francisco, United States
Sleeve gastrectomy, the most common bariatric procedure, leads to durable weight loss 
and improves obesity-related comorbidities. However, it induces abnormalities in bone me-
tabolism. One unexplored potential contributor to the negative skeletal effects is the gut 
microbiome, which influences bone metabolism and is altered after bariatric surgery. We 
characterized the relationship between the gut microbiome and skeletal outcomes in severe 
obesity and after sleeve gastrectomy.A cohort of 22 obese adults underwent skeletal health 
assessment and stool collection preoperatively, and 15 submitted stool 6 months after sleeve 
gastrectomy. Using 16S rRNA gene sequencing, stool microbial alpha diversity (richness, 
evenness), beta diversity (compositional dissimilarity), and taxon relative abundances were 
characterized. Linear mixed effect models and PERMANOVA analyses were applied to as-
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sess relationships between fecal microbiota and serum bone turnover markers (BTM) or 
areal bone mineral density (aBMD). Differential in silico prediction of bacteria functional 
pathways enrichment (Piphilin) was performed with a paired negative binomial test.Variance 
in gut microbiota beta diversity (composition) was related to serum C-telopeptide (CTX; 
p=0.04) and to procollagen-1 N-propeptide (P1NP; p=0.02) levels. Microbial diversity 
positively correlated with BTM levels. Six months after surgery, microbial beta diversity, 
relative abundance of specific bacterial taxa, and predicted microbiota function were sig-
nificantly altered. Most notably, microbiota were predicted to encode a lower capacity for 
butyrate metabolism. Concurrently, CTX and P1NP increased (by median 229% and 68%, 
both p<0.01), and femoral neck aBMD decreased (by mean 4.4 +/-4.7%, p<0.01). Those 
with greater within-subject change in microbial composition had greater increases in P1NP 
(p=0.02) and insulin-like growth factor 1 (IGF-1; p=0.045). Change in alpha diversity was 
positively associated with percent change in femoral neck aBMD (p=0.03).Gut microbial 
composition co-varied with BTM levels in severe obesity. Six months after sleeve gastrec-
tomy, microbial compositional changes were correlated with change in P1NP, and those 
with greater increases in microbial diversity had smaller declines in femoral neck BMD. 
These findings suggest that sleeve gastrectomy-induced alterations in the gut microbiome 
may influence skeletal outcomes. Microbial influences on IGF-1 and butyrate production 
are possible mechanisms.
Disclosures: Karin Wu, None
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The Stem Cell Basis of Bifurcation between Adipogenic versus Osteogenic 
Lineages *Shawon Debnath1, Alisha R. Yallowitz1, Jason Mc. Cormick2, 
Michelle Cung1, Matthew B. Greenblatt1. 1Department of Pathology and 
Laboratory Medicine, Weill Cornell Medicine, United States, 2Flow Cytometry 
Core Facility, Weill Cornell Medicine, United States
Concurrent decrease in osteoblast differentiation and increase in adipocyte differentia-
tion are a signature of nearly every disorder of low bone mass, implying that alterations in a 
bipotent progenitor able to produce both osteoblasts and adipocytes represent a convergent 
pathogenic mechanism for a wide range of skeletal disorders.  However, the cell type where 
the osteoblast and adipocyte differentiation pathways diverge and where the decision to form 
osteoblasts versus adipocytes is made are unknown under either physiologic or pathologic 
conditions.                                                Here, we have applied a combination of 16+ color 
FACS for deep cellular phenotyping with fate mapping and in vivo transplantation studies to 
identify a specific subset of skeletal stem cells (SSCs, Lin-Thy-6C3-CD200+CD105- cells) 
accounting for less than 20% of total SSCs as the only bipotent fraction of SSCs.  Specif-
ically, only this bipotent fraction of SSCs are able to both generate bone organoids after 
transplantation to the kidney capsule and reconstitute adipogenesis when implanted into 
“fatless” A-Zip/F1 mice.  In keeping with these findings, only this bipotent fraction of SSCs 
are able to both self-renew and generate all other SSC fractions in a transplantation-based 
differentiation hierarchy assay, indicating that this SSC fraction represents true stem cells. 
This bipotent SSC fraction in turn gives rise to 2 non-overlapping SSC fractions that func-
tion as committed adipocyte and committed osteoblast progenitors in organoid-based tissue 
formation assays.  Further, this bipotent SSC fraction is a key cellular effector in the ova-
riectomy model of postmenopausal osteoporosis, as after ovariectomy only this fraction of 
SSC is capable of switching from osteogenesis to adipogenesis as shown in transplantation 
based organoid formation assays.  Thus, here we identify the specific cellular point where 
the decision to form osteoblasts versus adipocytes is made, and thereby the bone versus fat 
balance of mesenchymal tissue is determined.  Additionally, only this bipotent cell displays 
full stemness features, restricting skeletal stem cells to only a small fraction of the cells 
meeting the current definitions.
Disclosures: Shawon Debnath, None
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CD10: A novel marker of bone marrow adipocyte progenitors *Abbas 
Jafari1, Asma Alshammary2, Adiba Isa2, Linda Harkness2, Alexander Rauch2, 
Michaela Tencerova3, Maria Nielsen4, Jens Andersen4, Thomas Levin Andersen5, 
Abdullah Aldahmash6, Moustapha Kassem2. 1Department of Cellular and 
Molecular Medicine, University of Copenhagen, Denmark, 2Laboratory of 
Molecular Endocrinology (KMEB), Odense University Hospital, Denmark, 
3Molecular Physiology of Bone, Institute of Physiology of the Czech Academy 
of Sciences, Czech Republic, 4Department of Biochemistry and Molecular 
Biology, University of Southern Denmark, Denmark, 5Clinical Cell Biology, 
Department of Pathology, Odense University Hospital, Denmark, 6Stem Cell 
Unit, Department of Anatomy, King Saud University, Saudi Arabia
The biological functions of human bone marrow adipocytes (BMAds) are under in-
tensive investigation. It is now accepted that BMAds are derived from skeletal (stromal 
or mesenchymal) stem cells (hBMSCs) that reside in a perivascular niche within the bone 
marrow stroma. However, lineage ontogeny of BMAds is not known due to the absence of 
prospective identification markers. Here, we employed global quantitative proteomic analy-
sis to identify surface proteins for prospective isolation of BMAd progenitors. CD10 - also 
known as neprilysin (NEP) - was found to be significantly upregulated during differentiation 
of hBMSCs to adipocyte lineage (4.7-fold on day 7, p<0.001). Single-cell RNA sequencing 
of adipogenic hBMSC cultures indicated that induction of adipocyte differentiation induc-
es CD10 expression in non-differentiated progenitor population, and CD10 expression was 
increased upon further development of the cells into mature adipocytes (650-fold, day 7, 
p<0.001). Changes of CD10 expression in adipogenic cultures were shown to be due to de 
novo chromatin remodelling and enhancer activation of cis regulatory elements in the vicin-
ity of CD10 locus, leading to upregulation of CD10 mRNA and protein levels during adipo-
genesis. Fluorescence-activated cell sorting (FACS) experiments demonstrated that CD10- 
and CD10+ hBMSC populations did not differ in terms of cell morphology or expression of 
classical hBMSC markers, whereas adipocyte differentiation potential was higher in CD10- 
cells, due to higher proliferation rate (2,3-fold, p<0.005) and accumulation of non-committed 
stem cell population. Immunohistochemical analysis of human bone specimens from healthy 
individuals indicated CD10 immunoreactivity in PPARG+ Runx2- adipocytic lineage cells 
within the bone marrow. Finally, we found increased CD10 expression (+10%, p<0.05) in 
primary hBMSC cultures established from bone marrow aspirates of obese subjects (BMI 
40.1 +/- 0.9, age 36 +/- 4) as compared to lean individuals (BMI 22.1 +/- 0.8, age: 33 +/- 5). 
Our findings demonstrate that CD10 is a marker of BMAd progenitors and thus is relevant 
for further investigations of BMAd development within the bone marrow.
Disclosures: Abbas Jafari, None
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Novel Roles of Tendon Cells in Joint Fibrocartilage Formation that is 
Regulated by Ihh Signaling *Zheng Wang1, Chi Ma2, Diane Chen1, Yan Jing1, 
Jerry Feng1. 1Texas A&M College of Dentistry, United States, 2Texas Scottish 
Rite Hospital for Children, United States
In large joints, there are two different cartilage tissues: articular cartilage (lack of type I 
collagen) and fibrocartilage (rich of type I collagen). The former receives the most research 
attention, whereas the fibrocartilage is largely unknown except that it is the common tendon 
rupture site. Additionally, osteochondrogenitors were considered as the sole source for both 
cartilages, and tendons only move joints. The aim of this study was to test a hypothesis: 
tendons directly form fibrocartilage, which is under-regulated by Ihh. To test this hypothesis, 
we 1st used immunostains to show similar ECM protein profiles such as aggrecan and Col 
X in both cartilages of humerus heads with no expressions of DMP1 and SOST (mature 
bone markers). Interestingly, fibrocartilage does not express Sox9 but express Runx2 and 
Col I (two early bone cell markers), while the articular cartilage express Sox 9 but no Runx2 
and Col I. 2nd, we traced the cell source of fibrocartilage using the tendon specific Cre 
Scx-creERT2; R26R-tdTomato line with tamoxifen induction at P3 and harvested at P7 or 
P9 or P33 or P60. The tracing data revealed only a few tendon-derived Scx+ chondrocytes 
at P7, with a gradual increase of Scx-cre+ cells in fibrocartilage at P9, P33 and the highest 
level at P60. The quantitative data showed a significant increase among these groups (n = 
4; p < 0.05) regarding the ratio of Scx+/DAPI+ cells and fibrocartilage mass (Fig a). We 
also induced Scx-CreERT2 at P30 and harvested at P60, in which there were more newly 
added Scx+ cells in the fibrocartilage, suggesting a continuous contribution to fibrocartilage 
growth. 3rd, we induced diphtheria toxin fragment A (DTA) expression in Scx-cre+ cells 
using Scx-creERT2 and showed a great reduction in the fibrocartilage ECM (Fig b). 4th, we 
conditionally deleted the Ihh gene using the Scx-CreERT2 at P3 and harvested at P14. These 
null-pups displayed few invaded Scx+ fibrocartilage cells and the original chondrocytes 
remained as they are (Fig c). Finally, we showed that 4-week treadmill exercises greatly 
increase aggrecan expression in fibrocartilage. Together, our studies support a novel theory 
(fig d): the fibrocartilage originates from tendon, which grows in and eventually replaces the 
existing cartilage. This novel finding explains why fibrocartilage is distinct from the artic-
ular cartilage and makes the tendon connection to joint extremely strong instead of simply 
connected to joints.
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RhoA Regulates the Quiescence and Cell Fate of Skeletal Stem and Progenitor 
Cells (SSPCs) *Dana Trompet1, Marian Dejaeger1, Marion Mesnieres1, Elena 
Nefyodova1, Ruben Cardoen1, Cord Brakebusch2, Jos Tournoy3, Frank Luyten4, 
Christa Maes1. 1Laboratory of Skeletal Cell Biology and Physiology (SCEBP), 
Skeletal Biology and Engineering Research Center (SBE), KU Leuven, Leuven, 
Belgium, Belgium, 2Biomedical Institute, BRIC, Faculty of Health, University 
of Copenhagen, Copenhagen, Denmark, Denmark, 3Gerontology and Geriatrics, 
University Hospitals Leuven, and Department of Chronic Diseases, Metabolism 
and Ageing, KU Leuven, Leuven, Belgium, Belgium, 4Skeletal Biology 
and Engineering Research Center (SBE), Department of Development and 
Regeneration, KU Leuven, Leuven, Belgium, Belgium
A better understanding of skeletal stem/progenitor cell (SSPC) biology, including the 
significance and regulation of intrinsic cytoskeleton-centered processes, could provide novel 
osteo-anabolic therapies. Therefore, we generated conditional knock-out (cKO) mice lack-
ing the key cytoskeletal regulator RhoA in SSPCs and osteolineage cells using Prx1-Cre and 
Osx-Cre mice.MicroCT and histomorphometry revealed that loss of RhoA led to reduced 
trabecular bone mass in both mouse models (e.g. BV/TV 12-week-old Prx1-Cre;RhoA cKO 
mice: 10.91+/-0.97% vs. 15.57+/-0.40% in controls; n=8-9; p<0.001). Interestingly, whereas 
the reduced BV/TV in Osx-Cre;RhoA mutants could be attributed to decreased osteoblast 
number and activity, Prx1-Cre;RhoA cKO mice rather showed dominant effects in the earlier 
stem and progenitor cell populations. Firstly, we found that SSC quiescence was reduced in 
Prx1-Cre;RhoA cKO mice. Mutant BMSCs showed 2-fold increased proliferation in vitro 
(n=3; p<0.05) and young Prx1-Cre;RhoA cKO bones contained 40% more CFUs than con-
trols (n=9; p<0.05). Moreover, Prx1-Cre;RhoA cKO mice grew wider bones, and generated 
larger calluses after fracture (n=16; p<0.01), indicating an increased SSC/SSPC expansion 
capacity. Compromised stem cell quiescence upon RhoA-inactivation was further supported 
by reduced long-term EdU-label-retention in vivo, and associated with increased BMSC 
senescence (p16 qRT-PCR). Moreover, the SSC/SSPC pool displayed premature exhaustion 
upon loss of RhoA as evidenced by the reduced number of CFUs and of CD45-Ter119-
CD31-CD51+Thy-6C3-CD105-CD200+ SSCs in 1-year-old Prx1-Cre;RhoA cKO mice. 
Secondly, loss of RhoA affected the cell fate and differentiation profile of SSPCs, favoring 
adipogenesis and chondrogenesis. Cultured mutant BMSCs displayed increased adipogenic 
differentiation (n=4-5; p<0.05) and Prx1-Cre;RhoA cKO mice showed increased BM adipos-
ity in vivo, which aggravated upon injury (e.g. post-fracture osmium-staining: 0.42+/-0.35% 
BMAT (control) versus 5.34+/-6.43% (cKO); n=8; p<0.05). Increased chondrogenesis was 
seen upon fracture (7.1+/-3.6% cartilage (control) versus 12.3+/-1.5% (cKO); post-fracture 
day 7; n=4-5; p<0.01) and in occasional enchondroma formation. Notably, RhoA-deficient 
cells showed changes in Wnt/β-catenin and YAP/TAZ-signaling consistent with these alter-
ations.Altogether, we conclude that loss of RhoA in SSPCs increases cellular expansion and 
alters differentiation, leading to premature SSPC exhaustion and osteopenia.
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Skeletal Abnormalities in Csf1r Knockout Rats Are Rescued by Transplant 
of Total Bone Marrow *Lena Batoon1, Melanie Caruso1, Katharine Irvine1, 
Allison Pettit1, David Hume1. 1Mater Research Institute-The University of 
Queensland, Australia
Macrophages and osteoclasts (OC) depend on colony-stimulating factor 1 receptor 
(CSF1R) signaling for proliferation, differentiation and survival. Homozygous CSF1R mu-
tations in humans are associated with flattened and diffusely dense vertebral bodies, me-
taphyseal and epiphyseal osteosclerosis, thin cortical bone in the long bones (dysosteoscle-
rosis) and hypercalcification of the skull base. Studies of the phenotypic consequences of 
Csf1r knockout (Csf1rko) in mice have been limited by early postnatal lethality. We recently 
generated Csf1rko rats which are viable as adults on an outbred background. Here, we ex-
plored the impact of Csf1rko in rats on postnatal bone growth on a defined Dark Agouti 
genetic background. These Csf1rko rats are indistinguishable at birth from littermates but 
exhibit postnatal growth retardation. However, Alcian blue-Alizarin red staining of new-
born skeletons already showed delayed mineralization of the small paw bones and digits. 
At 1 week, osteopetrosis was evident. The muscle fibers formed around the bones were also 
reduced in diameter. By 3 weeks, mutant rats had intriguing site-specific skeletal defects: 
a profound delay in rib cage ventral segment mineralization, vertebral body development, 
secondary ossification center formation in long bones and digits, and subarticular ossifica-
tion of small paw bones and carpal-tarsal bones. At 7 weeks, the cranial case of mutant rats 
lacks calcification and suture closure was impaired.  All these skeletal features were shared 
with the human CSF1R mutation. We examined macrophage and OC distribution by im-
munohistochemical localization of IBA1 and TRAP. Abundant IBA1+ macrophages in the 
paw, vertebral body and hind limbs including in both endosteal and periosteal surfaces were 
detected in 1- and 3-week old wild-type (WT) rats and were almost completely absent in the 
Csf1rko. TRAP+ OC were also undetectable. IBA1+ macrophages were partly restored in 
7-9-week old Csf1rko rats, but OC remained absent. Transplant (Tx) of WT bone marrow 
(BM) cells into unconditioned 3-week old Csf1rko rats reconstituted tissue macrophages 
and OC, reversed skeletal abnormalities as early as 7 weeks post-Tx, promoted skeletal 
and somatic growth, and long-term survival. Our findings have important implications for 
understanding the consequences of CSF1R mutation for the human skeleton and reveal the 
therapeutic potential of targeting the CSF1-CSF1R axis in related bone diseases.
Disclosures: Lena Batoon, None
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Discoidin Domain Receptor 2 (DDR2) Regulates In Vivo Skeletal Progenitor 
Cell Differentiation, Collagen Matrix Organization and Hedgehog Signaling 
*Fatma Mohamed1, Chunxi Ge1, Randy L. Cowling2, Abdul-aziz Binrayes1, Barry 
Greenberg3, Rennu Franceschi1. 1University of Michigan School of Dentistry, 
United States, 2UCSD, United States, 3UCSD School of Medicine, United States
DDR2 is a collagen-activated receptor tyrosine kinase that, together with β1-integrins, 
mediates extracellular matrix (ECM) signaling. Inactivating mutations in DDR2 cause an 
autosomal inherited human disorder characterized by dwarfism and bone growth defects 
that are largely phenocopied in globally Ddr2-deficient mice. In this study, the distribution, 
lineage and cellular function of Ddr2 was examined in transgenic mice. β-gal staining of 
Ddr2LacZ/+ mice showed strong Ddr2 expression in metaphysis, periosteum, and growth 
plate resting zones. This pattern partially overlapped with Gli1, a mediator of Hedgehog 
signaling previously identified in skeletal stem/progenitor cells. Lineage analysis using 
Ddr2mer-iCre-mer; R26RtdTomato reporter mice revealed initial tdTomato labeling of 
skeletal precursors that subsequently contributed to chondrogenic and osteogenic lineages 
including osteocytes, but not to osteoclasts. Ddr2 conditional knockout (cKO) in skeletal 
progenitors using Gli1-CreERT or Col2a1-Cre recapitulated skeletal phenotypes of global 
knockout mice including low bone mass, stunted skull growth and shortened growth plates. 
In addition, defects were observed in chondrocyte organization, proliferation, and ECM 
distribution. In wild type mice, type II collagen was uniformly detected around chondro-
cytes while in cKO animals it displayed an abnormal distribution with little staining in the 
cartilage interterritorial matrix. Conditional knockout of Ddr2 in mature osteoblasts using 
osteocalcin-Cre did not result in an observable skeletal phenotype, thereby providing fur-
ther evidence for lineage-restricted functions of Ddr2 in skeletal progenitors. Gene expres-
sion analysis showed enrichment of Ddr2 together with stem cell markers (Gli1, LepR and 
Nestin) in non-hematopoietic, non-endothelial PDGFRα+CD51+ skeletal progenitor cells. 
Ddr2 knockdown in these cells did not affect clonogenic activity; rather it reduced osteo-
genic (CFU-Ob) while enhancing adipogenic (CFU-Ad) differentiation potential. Similarly, 
Ddr2 knockout in embryonic limb bud micromass cultures reduced cartilage nodules and 
down-regulated chondrocyte differentiation markers. Ddr2 loss also markedly downreg-
ulated Ihh, Gli1 and Ptch Hedgehog signaling intermediates. These studies establish cell 
autonomous functions of Ddr2 in Gli1+ skeletal progenitor cells and chondrocytes that are 
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related to changes in ECM organization and Hedgehog signaling critical for chondrogenesis 
and osteogenesis.
Disclosures: Fatma Mohamed, None
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Loss of Transferrin Receptor 1 in Osteoclast Lineage Cells Attenuates 
Osteoclast Energy Metabolism and Cytoskeleton Organization Resulting 
in a Dramatic Increase of Trabecular Bone Mass in Long Bones of Female 
Mice *Bhaba K Das1, Lei Wang2, Toshifumi Fujiwara3, Renny Lan4, Jian Zhou2, 
Jian Q Feng5, Michael L Jennings6, Nukhet Aykin-Burns7, Weirong Xing8, 
Subburaman Mohan8, Haibo Zhao1. 1Southern California Institute for Research 
and Education, Office of Research, Tibor Rubin VA Medical Center, VA Long 
Beach Healthcare System, United States, 2Department of Orthopedics, First 
Affiliated Hospital, Anhui Medical University, China, 3Department of Orthopedic 
Surgery, Kyushu University Hospital, Japan, 4Department of Biochemistry and 
Molecular Biology, University of Arkansas for Medical Sciences, United States, 
5Department of Biomedical Sciences, Texas A&M college of Dentistry, United 
States, 6Department of Physiology and Biophysics, University of Arkansas for 
Medical Sciences, United States, 7Division of Radiation Health, Department of 
Pharmaceutical Sciences, University of Arkansas for Medical Sciences, United 
States, 8Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical 
Center, United States
Both osteoclast (OC) differentiation and bone-resorbing activities demand high ener-
gy. Fe is a nutritional element essential for mitochondrial metabolism and the biosynthesis 
of heme and Fe-S clusters, which are critical components of the mitochondrial respiratory 
complexes. Mammalian cells acquire Fe predominantly through the transferrin (Tf)/Tf re-
ceptor (TfR1)-dependent pathway. However, how the cellular iron homeostasis impacts OC 
metabolism has not been well elucidated. To address this question, we generated myeloid 
and mature OC-specific TfR1 deficient mice by crossing TfR1-floxed mice with LysM-Cre 
(TfR1ko/LysM) and Cathepsin K-Cre (TfR1ko/CTSK) mice, respectively. By µ-CT and 
histomorphometric analysis of distal femurs of 10-week old mice, we found a near three-fold 
increase in trabecular BV/TV, number, and thickness in female but not male TfR1ko/LysM 
mice compared to gender-matched control littermates. Although increased trabecular bone 
volume was seen in both TfR1ko/CTSK male and female mice, the phenotype was more 
pronounced in female mice. The OC number and serum level of TRAP in both TfR1ko/LysM 
and TfR1ko/CTSK mice were similar to controls. Surprisingly, loss of TfR1 in OCs led to 
marked increases in the osteoblast (OB) number and serum level of P1NP, suggesting that 
enhanced bone formation might also contribute to increased bone mass. In vitro mechanistic 
studies revealed that loss of TfR1 abolished Tf-dependent Fe uptake in OC precursor and 
mature cells as measured by the Tf-Fe59 uptake assay and caused a 75% decrease in mito-
chondrial respiration as assayed by the Seahorse Extracellular Flux analyzer. In consistence, 
quantitative proteomics identified a profound downregulation of proteins associated with 
mitochondrial oxidative phosphorylation in TfR1KO OCs. OC differentiation of TfR1KO 
bone marrow monocytes was normal. However, TfR1KO OCs exhibited a significant delay 
in the formation of podosome-belt and actin-ring on glass coverslips and on bone slices, 
respectively. While loss of TfR1 impaired OC bone resorption, bone marrow stromal cells 
derived from TfR1KO mice were able to differentiate into OB and form bone nodule. In 
conclusions, TfR1-dependent iron uptake plays an important role in OC energy metabolism 
and cytoskeleton organization but not OC differentiation. Deletion of TfR1 in OC lineage 
cells inhibits bone resorption and indirectly promotes bone formation leading to increased 
trabecular bone mass in a gender-dependent manner.
Disclosures: Bhaba K Das, None
1092
Osteoblastic Deletion of PKA Regulatory Subunit1A Causes Severe Bone 
Pathology in Mice *Carole Le Henaff1, Brandon Finnie1, Joshua Johnson1, 
Yasaman Nahaei1, Zhiming He1, Krishnakali Dasgupta1, Juhee Jeong1, Johanna 
Warshaw1, Henry M Kronenberg2, Lawrence S Kirschner3, Nicola C Partridge1. 
1Department of Molecular Pathobiology - College of Dentistry - New York 
University, United States, 2Endocrine Unit, Massachussetts General Hospital, 
Harvard Medical School, United States, 3Department of Cancer Biology 
and Genetics and the Division of Endocrinology, Diabetes and Metabolism - 
Department of Internal Medicine - The Ohio State University Wexner Medical 
Center, United States
Parathyroid hormone (PTH) was the first osteoanabolic hormone for treating osteo-
porosis. We have previously shown that PTH acts through PTHR1 and protein kinase A 
(PKA) activation to regulate osteoblastic gene expression. Our study aimed to elucidate the 
effects of increased PKA activity in vivo and better understand the actions of PTH (1-34) in 
bone. Tamoxifen (1mg/10g) was injected weekly to 1 or 5 month-old C57Bl/6J male col-
1CREERT/Prkar1afl/fl mice or Prkar1afl/fl mice as controls for 3-4 weeks to delete the PKA 
regulatory subunit 1A in osteoblasts and increase PKA activity. At both ages, col1CREERT/
Prkar1afl/fl mice demonstrated bone pathologies in their skulls, femurs and vertebrae and 
tumors in their tails. Deletion of Prkar1a increased bone turnover with a considerable in-
crease in osteoblast activity shown by serum-P1NP levels (6.5-13 fold), only single instead 
of double fluorescent labeling of bone and a substantial increase in osteoclast activity shown 
by CTX levels (4.4-12 fold) and TRAP staining. MicroCT showed cortical bone breakdown 
with apparent trabecular bone in the cortical area in femurs and vertebrae (Figure 1). In both 
age groups, cortical and trabecular bone RNAs showed a large increase in bone sialoprotein 
mRNA levels (3 to 6 fold) with a sharp decrease in osteocalcin (0.2-0.4 fold) showing a 
change in osteoblast differentiation. Furthermore, PTH responsive genes were significantly 
changed: SOST expression was decreased to 0.1-0.2 fold, RANKL was upregulated by 2-3 
fold and MMP13 was increased by at least 3 fold. Surprisingly, the col1CREERT/Prkar1afl/
fl skulls showed thicker but more porous and disorganized calvariae, shown by alizarin red 
staining and µCT images. At 7 weeks-old, uCT analyses showed a decrease in calvarial 
thickness (-15.7%) resulting from apparent increased trabecular bone in the calvariae and a 
16% increase in porosity. No change was observed in mandibles or teeth. At both ages, Col-
1CREERT/Prkar1afl/fl mice had tumors in their tails evident by an invasion of stromal and 
osteoclastic cells with disappearance of bone marrow and decreased growth plate but intact 
cartilage and intervertebral discs. In conclusion, elevated PKA activity in osteoblasts appears 
to be involved with high bone turnover and pathological events mimicking hyperparathy-
roidism, Jansen’s metaphyseal chondrodysplasia or McCune-Albright syndrome.
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Dynamics of Modeling- and Remodeling-Based Bone Formation in 
Response to Intermittent Parathyroid Hormone (PTH) Treatment and 
Discontinuation *Wenzheng Wang1, Wei-ju Tseng1, Hongbo Zhao1, Tala Azar1, 
Nathaniel Dyment1, Xiaowei Sherry Liu1. 1McKay Orthopaedic Research 
Laboratory, Department of Orthopaedic Surgery, Perelman School of Medicine, 
University of Pennsylvania, United States
Both modeling-based bone formation (MBF), de novo bone formation (BF) on quies-
cent surfaces without prior resorption (Fig A), and remodeling-based BF (RBF), BF coupled 
with resorption by osteoclasts (Fig B), are important mechanisms by which anabolic agents 
such as PTH rapidly improve bone mass. Despite the potent effect of PTH on promoting 
new BF, treatment benefit rapidly diminishes upon treatment discontinuation. To study the 
dynamics of activation and retention of MBF and RBF, we injected calcein (green, G), aliz-
arin complexone (red, R), and tetracycline (yellow, Y) mineral labels to ovariectomized rats 
in a G-R-Y-G sequence at days -2, 5, 12, and 19 (initiation of PTH on day 0, 20 μg/kg/
day), followed by euthanasia at day 21 (end of PTH), 28, and 42 (1- and 3- wks after PTH 
discontinuation, n=6/group). Mineral labels and cement lines on cryo-sections of tibial tra-
becular bone were used to identify BF sites as MBF (smooth cement line, Fig A) or RBF 
(scalloped cement line, Fig B) that were further stratified by activation time (within wk 1, 2, 
or 3, Fig D). We hypothesized that MBF and RBF respond differently to anabolic treatment 
and discontinuation.Mineralizing surface (MS/BS) or mineral apposition rate (MAR) did not 
differ between MBF and RBF in VEH-treated rats. Three-week PTH treatment led to greater 
MBF- and RBF- induced MS/BS (4.3- and 3.4- fold) and MAR (67% and 39%) compared 
to VEH, respectively (Fig C). PTH activated 87% of MBF surfaces during wk 1 and 13% 
by wk 2, while PTH activated 32, 66, and 2% of all RBF surfaces during wks 1, 2, and 3, 
respectively (Fig E).No BV/TV reduction was found after 1-wk discontinuation from PTH. 
However, discontinuation for 3 weeks led to a 43% reduction in total BV/TV. The BV/TV 
of MBF was unchanged while that of RBF and pre-existing bone was 81% and 34% lower 
in wk 3 vs. wk 0, respectively (Fig F). Consistently, 41% of RBF and 40% of pre-existing 
bone surfaces were TRAP+ while only 2% of MBF was TRAP+. Furthermore, 82% of MBF 
surfaces were ALP+ and 16% had mixed TRAP and ALP signal. However, only 34% of RBF 
surfaces were ALP+ and 25% had mixed signals (Fig G-K). Moreover, 60% of pre-existing 
bone surfaces remained quiescent (Fig K).In summary, PTH induces BF through rapid ac-
tivation of new MBF, followed by continuous activation of RBF. During discontinuation, 
bone loss occurs mostly at pre-existing bone and RBF sites, whereas MBF is highly resistant 
to PTH withdrawal.
Disclosures: Wenzheng Wang, None
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A Sex Dimorphic Mechanism Links Protection from Bone Loss and 
Promotion of Gut Microbiome Diversity Induced by a Nutritional 
Intervention *Amy Y Sato1, Cindy H Nakatsu2, Meloney Cregor1, Kevin 
McAndrews3, Gretel G Pellegrini3, Mario G Ferruzzi4, Mary A Lila4, Connie 
M Weaver5, Teresita M Bellido6. 1Department of Anatomy, Cell Biology, and 
Physiology, Indiana University School of Medicine, Indianapolis, IN, United 
States, 2Department of Agronomy, Purdue University, West Lafayette, IN, 
United States, 3Department of Anatomy, Cell Biology, and Physiology, Indiana 
University School of Medicine, Indianapolis, IN, United States, 4Department of 
Food Bioprocessing and Nutrition Sciences, North Carolina State University, 
Kannapolis, NC, United States, 5Department of Nutrition, Purdue University, 
West Lafayette, IN, United States, 6Department of Anatomy, Cell Biology, and 
Physiology, Indiana University School of Medicine, Indianapolis, IN; Richard 
L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN, United States
We previously showed that a blueberry-enriched diet counteracts the effects of estrogen 
deficiency in female mice on bone, skeletal muscle, and peripheral fat, and alters the gut 
microbiome. Here, we compare between female and male mice the impact of the diet on 
the skeleton and the microbiome. Four-month old B6.129X1/J mice were gonadectomized 
or sham operated, each group separated in two groups, which then were fed either control 
AIN-93M diet (C) or AIN-93M diet containing 10% lyophilized/freeze dried Montgom-
ery blueberry (MONT); N=9-20 females and N=10-26 males. In contrast to full protection 
from OVX-induced bone loss, MONT failed to prevent the loss in BMD induced by ORX. 
Further, while MONT completely prevented OVX-induced architectural deterioration of 
cancellous and cortical bone, the diet did not prevent the decrease in BV/TV, Tb.Th, Tb.N, 
Ct.Ar/Tt.Ar, and Ct.Th, quantified by micro-CT, induced by ORX. Likewise, MONT pre-
vented OVX-induced increases in circulating resorption marker CTX, but it had no effect on 
CTX levels in ORX mice. We next quantified gut microbiome diversity, by analyzing fecal 
bacterial DNA using 16S rRNA gene sequences from high throughput paired end MiSeq 
technology. OVX or ORX did not alter the variety of bacterial communities (α-diversity) 
within either C or MONT-fed mice. However, MONT increased α diversity overall, and to a 
greater extent in females than in males, measured by the Shannon Index. MONT also shift-
ed the relatedness of bacterial communities (β diversity) farther in females than in males, 
detected by two different metrics Jaccard distance (absence/presence of taxa), and weighted 
Unifrac (phylogenetic relatedness and relative taxa abundance). Moreover, MONT increased 
the prevalence of the taxon Ruminococcus1 exclusively in females and not in males, detect-
ed by Analysis of Composition of Microbiomes. In summary, the MONT diet protects from 
estrogen, but not androgen deficiency-induced bone loss and architectural deterioration; and 
promotes a healthier microbiome signature to a greater extent in females than males. These 
findings demonstrate that skeletal and microbiome responses to nutritional interventions are 
sex dimorphic and suggest a link between bone protection and gut microbiome diversity. 
Disclosures: Amy Y Sato, None
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Overexpression of antibody against oxidized phospholipids attenuates the 
age-associated, but not the ovariectomy- or unloading- induced, bone loss 
in mice *Michela Palmieri1, Teenamol E Joseph1, Aaron D Warren1, Horacio 
Gomex-acevedo2, Jinhu Xiong3, Joseph L Witztum4, Stavros C Manolagas1, 
Elena Ambrogini1. 1Center for Osteoporosis and Metabolic Bone Diseases and 
Center for Center for Musculoskeletal Disease Research, University of Arkansas 
for Medical Sciences and the Central Arkansas Veterans Healthcare System, 
United States, 2Department of Biomedical Informatics, University of Arkansas 
for Medical Sciences, United States, 3Department of Orthopaedics Surgery, 
University of Arkansas for Medical Sciences, United States, 4Department of 
Medicine, University of California San Diego, United States
Overexpression of a single chain (scFv) form of the antigen-binding domain of E06 
IgM – a natural antibody that recognizes the phosphocholine (PC) moiety of oxidized phos-
pholipids (OxPLs) – protects against atherosclerosis and hepatic steatosis. Moreover, the 
E06-scFv transgene increases cancellous and cortical bone mass in both male and female 
adult mice, by increasing bone formation. Age-related bone loss is characterized by a de-
cline in osteoblast number and bone formation and is associated with increased oxidative 
stress and lipid peroxidation. We have searched for and found that the age-associated bone 
loss seen in 22 and 24 month-old female and male wild type C57BL/6 mice was greatly 
attenuated in homozygous E06-scFv transgenic littermates, as determined by serial DXA 
BMD every 3 months. Micro-CT analysis upon euthanasia revealed that the effect of the 
E06-scFv was due to the attenuation of the age-associated decline in cancellous, but not 
cortical, bone mass. Both male and female E06-scFv transgenic mice also accumulated less 
fat mass than WT littermates during aging. As shown in histological analysis of the verte-
brae, the aged E06-scFv transgenic mice had increased osteoblasts and decreased osteoclasts 
compared to the wild type mice. Oxidative stress (OS) is involved in the bone loss caused by 
sex-steroid deficiency and elevated OS markers are found in unloading-induced bone loss, 
raising the possibility that an increase of OxPLs induced by OS might be contributing to the 
pathogenesis of these conditions as well. We, therefore, investigated whether the beneficial 
effect of the E06-scFv extends to these two other conditions. To this end, 4.5 month old 
females E06-scFv homozygous mice and WT controls were ovariectomized (OVX). Unlike 
aging, the E06-scFv transgene did not protect against OVX-induced bone loss in either the 
cancellous or the cortical compartment, as measured by DXA and micro-CT 6 weeks post- 
surgery. Lastly, we tail- suspended 5.5 month old male mice and sacrificed them 21 days 
later. E06-scFv transgenic mice had similar cortical bone loss compared to WT mice. These 
results indicate that the increase of oxidative stress with aging and the resulting increase in 
the generation of lipid peroxidation products, such PC-OxPLs, is an important pathogenetic 
mechanism for the age-associated bone loss in the cancellous bone compartment. These 
mechanisms, however, may not contribute to the OVX- or unloading –induced bone loss.
Disclosures: Michela Palmieri, None
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Osteocytes regulate bone resorption via Sclerostin and Lrp4 signaling 
through Rankl dependent and independent mechanisms *Jesus Delgado-
Calle1, Ashley Daniel1, Hayley Sabol1, Serra Ucer1, Kevin McAndrews1, 
Jessica Nelson1, Megan Sweet1, Alexander Robling1, Teresita Bellido1. 1Indiana 
University School of Medicine, United States
Earlier studies demonstrated that activation of canonical Wnt signaling in pre- and dif-
ferentiated osteoblasts versus in osteocytes (Ots) inhibits or stimulates bone resorption, re-
spectively. In both cases, osteoprotegerin (Opg) is upregulated. However, when the pathway 
is activated in Ots, receptor activator of NfKB ligand (Rankl) is also upregulated, explaining 
the increased resorption; and also Sost/sclerostin (scl) expression is increased. We hypoth-
esized that the mechanism by which canonical Wnt signaling in Ots increases resorption 
requires Sost/scl, a gene/protein expressed only in these cells. Here, we tested this hypothe-
sis in vivo by crossing mice with canonical Wnt signaling activation in Ots (daβcatOt mice) 
with SOST KO mice to generate control (C), daβcatOt, SOSTKO, and daβcatOt;SOSTKO 
littermate mice. daβcatOt mice had the expected elevated Sost and Rankl mRNA expression 
and cancellous bone mass, and more osteoclasts (Ocls) compared to C. SOSTKO mice also 
had increased cancellous bone mass but no changes in Rankl or Ocls. Sost deletion in daβca-
tOt mice increased by 25% femoral cancellous bone mass, restored to C levels the elevated 
Ocl number and decreased by 30% Rankl expression and the number of Rankl positive Ots, 
without affecting Opg. These results demonstrate that Sost/Scl regulates Rankl expression 
in Ots to stimulate bone resorption. We examined next whether Scl upregulates Rankl ex-
pression in Ots via Lrp4, known to retain and facilitate Scl’s actions. We crossed daβcatOt 
mice with mice with conditional deletion of Lrp4 in Ots (Lrp4Ot) and generated C, daβcatOt, 
Lrp4Ot, and daβcatOt;Lrp4Ot littermate mice. Lrp4Ot mice exhibited increased cancellous 
bone mass due to increases in osteoblasts (Obs) and the bone formation marker P1NP, but 
no changes in Rankl or Ocls. Deletion of osteocytic Lrp4 in daβcatOt mice increased by 
25% femoral cancellous bone mass, restored Ocl number to control levels, and reduced by 
20% the levels of the resorption marker CTX, but it did not alter their elevated Obs number. 
Surprisingly, deletion of Lrp4 in Ots did not affect Rankl (or Opg) mRNA or Rankl protein 
expression in Ots, which remained increased and similar to those found in daβcatOt mice. In 
conclusion, our findings demonstrate that Scl exerts catabolic actions in bone by increasing 
Rankl expression in Ots, and suggest that osteocytic Lrp4 signaling also stimulates bone 
resorption through autocrine mechanisms in Ots independent of Rankl regulation.
Disclosures: Jesus Delgado-Calle, None
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Bone microarchitecture and composition contribute to bone fracture risk 
in the genetically diverse diversity outbred (DO) founder mouse strains 
*Bhavya Senwar1, Michael A. Friedman2, Charles R. Farber3, Henry J. Donahue2, 
Virginia L. Ferguson1. 1University of Colorado, Boulder, CO, United States, 
2Virginia Commonwealth University, Richmond, VA, United States, 3University 
of Virginia, Charlottesville, VA, United States
Bone strength is a function of the bone mass, morphology, and material quality which 
contribute to the structural rigidity of bone. While it is understood that bone strength varies 
with genetics, how these factors contribute to bone strength and fragility remains poorly 
understood. Within low (C57BL/6J) and high (A/J) bone mass mouse strains, bone strength 
depends on both micro-architecture and bone quality, specifically cortical tissue mineral 
density (Ct.TMD; Jepsen et al., 2008, Courtland et al., 2008). We sought to evaluate if this 
relationship persists across a wider range of genetic backgrounds from the eight DO founder 
mouse strains (n=6/group; males; 19 weeks). Femurs were evaluated using micro-CT, Ra-
man spectroscopy, and three-point bending. Slenderness ratio (total area/bone length, Tt.Ar/
Le) was calculated where A/J had the most slender bones (mean Tt.Ar/Le = 0.086), followed 
by CAST (0.089), NOD (0.093), 129S1 (0.1), NZO (0.13), WSB (0.15), PWK (0.18), and 
C57BL/6 (0.35). Pearson correlations were calculated across these strains to evaluate re-
lationships between bone morphology, tissue chemistry (mineral:matrix ratio and crystal-
linity) and strength. Tt.Ar/Le negatively correlated with cortical thickness, Ct.Th (r=-0.61, 
p<0.0001), indicating that more slender bones have thicker cortices. Tt.Ar and relative corti-
cal area (RCA) were negatively correlated (r=-0.68, p<0.0001) indicating that smaller bones 
(lower Tt.Ar) had thicker cortices. Small bones with thicker cortex (Ct.Th) also had high-
er Ct.TMD (r= 0.7, p<0.0001), mineral:matrix (r=0.33, p<0.05) and crystallinity (r=0.29, 
p=0.06). These smaller bones (Tt.Ar) also had higher modulus (r=-0.73, p<0.0001) and 
lower work to fracture (r=0.61, p<0.0001). Across these strains, smaller bones had higher 
mineralization and highly organized mineral crystals, which could contribute towards ability 
of bone to bear normal, physiological loads. However, this increased mineralization could 
result in a more brittle and fracture-prone bone. These findings were earlier investigated in 
the A/J, C57BL/6J mouse strains and their recombinant inbred strains. The current study 
demonstrates these findings for a genetically diverse population of eight DO founder strains 
which motivates evaluating how specific genes associated with bone traits vary among these 
individual strains. Following this work, we aim to incorporate bone material composition 
into prediction of fracture risk for a genetically diverse population.
Disclosures: Bhavya Senwar, None
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Alterations to the Gut Microbiome Impair Bone Tissue Strength in Aged 
Mice *Macy Castaneda1, Kelsey Smith2, Jacob Nixon1, Sheldon Rowan2, 
Christopher Hernandez1. 1Cornell University, United States, 2Tufts University, 
United States
Recent studies have shown that the gut microbiome can regulate bone remodeling, bone 
quantity, bone quality and whole bone strength. Preclinical work, however, has been limited 
to young adult mice (less than 6 months of age), and it is unclear if modifications to the gut 
microbiome can also improve bone tissue strength in aged animals. Here we ask if alter-
ations to the constituents of the gut microbiome influence bone strength in older mice (1-2 
years of age).In this IACUC approved opportunistic study, male C57Bl/6 retired breeder 
mice were raised on a standard diet, divided into three groups (n=7-11/group, 28 total) and 
starting at 12-13 months of age had the starch content of their diet altered as follows: high 
glycemic index (100% amylopectin), low glycemic index (30% amylopectin/70% amylose) 
or low glycemic index diet supplemented with antibiotics to modify the constituents of the 
gut microbiome (320 mg ampicillin + 640mg neomycin /kg chow). The special diets contin-
ued until 22-24 months of age when femurs were collected to analyze diaphyseal geometry 
and strength (Fig. 1A).The low glycemic index group with altered gut microbiome showed 
reductions strength that could not be explained by geometry (section modulus) indicating 
reduced bone tissue strength (p = 0.006, Fig. 1B). No differences in tissue strength were 
observed between low- and high glycemic index groups, although the high glycemic index 
diet group had larger body mass, larger bone cross-sectional area (Fig. 1C) and moment 
of inertia, and an associated increase in whole bone stiffness (p < 0.05 each).Guss et al. 
(JBMR 2017) showed that modification to the gut microbiome caused by oral ampicillin 
and neomycin during rapid bone acquisition (1-4 months of age) led to reduced bone tissue 
strength at skeletal maturity. Here we show that the same stimulus to the gut microbiome 
applied in late adulthood (12-24 months of age), causes a similar reduction in bone tissue 
strength. Although the current study was opportunistic and is therefore limited (no baseline 
assessment, no high glycemic index Amp+Neo group), it shows that microbiome-induced 
modifications to bone tissue strength are not limited to young, rapidly growing animals. Cur-
rent osteoporosis interventions focus on enhancing bone quantity and do not directly address 
impaired bone tissue properties. Our findings raise the possibility that microbiome-based 
interventions could improve bone tissue material properties in the elderly.
Disclosures: Macy Castaneda, None
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Small changes in structure and mineral density after exercise can have 
profound effects on mechanical strength *Mariana Kersh1, Hyunggwi 
Song1, John Polk2. 1University of Illinois at Urbana-Champaign, United States, 
2University of Illinois, United States
Bone modeling occurs during development, an optimal time for adaptation due to ex-
ercise, that may have lifelong benefits. Axial loading has demonstrated a link between me-
chanical stimulation and adaptation, but their translation to exercise is challenging.Healthy 
juvenile sheep were exercised on a flat (n=11) or inclined (n=11) treadmill, and compared 
to non-exercised controls (n=8) (Fig 1A). Micro-CT analyses of subchondral (Sbch) and 
trabecular (Tb)structure and density were analyzed throughout the joint followed by me-
chanical testing. Sheep used more flexed knee angles during inclined exercise but less range 
of motion resulting in a preferential loading of a smaller region of the posterior condyle. 
Larger areas of increased Sbch and trabecular Tb and density occurred due to flat exercise 
compared to inclined exercise (Fig 1B,C). Increases in Tb thickness became larger moving 
towards the joint center (2.0+/-1.2\% to 3.4+/-1.1), while density decreased (4.9+/-2.4% 
to 3.5+/-1.4%).  Elastic modulus and yield stress was significantly greater than the con-
trol group (flat: 90% and 76%, incline: 59% and 41%, p<0.01, Fig1E). Yield strain did not 
change. The ultimate stress significantly increased by 45% (p0.1)). The ultimate strain in the 
inclined group significantly decreased to 60% of that in controls (p<0.05). Relatively small 
percent increases in subchondral and trabecular density (9 to 14%) due to exercise induced 
much larger increases in mechanical strength (41 to 90%) compared to controls. Yield and 
ultimate strength are among the most clinically important because it implies when plastic 
deformation and failure occurs. The decrease in ultimate strain due to exercise implies that 
the exercised bone is more brittle as seen in the increase in elastic moduli. However, this 
result does not imply that the exercised bone became weaker because the energy needed to 
fracture was larger in the exercise groups (see area under curves in Fig 1E). The differential 
response in mechanical properties of the two exercise groups (compared to control) suggests 
that changes in the nature of mechanical loading - here induced via inclined exercise - re-
sults in differing adaptive response.  Small changes in joint loading can result in spatially 
correlated changes to bone properties providing a mechanism for targeted exercise strategies 
aimed to improve bone health.
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Military Trainees Who are More Physically Fit Have More Favorable Tibial 
Bone Microarchitecture at Military Entry *Katelyn Guerriere1, Kristin Popp1, 
Soothesuk Kusumpa1, Leila Walker1, Melissa Richardson1, Kathryn Taylor2, 
Susan Proctor1, Stephen Foulis1, Mary Bouxsein3, Julie Hughes1. 1U.S. Army 
Research Institute of Environmental Medicine, United States, 2U.S. Army 
Research Institute of Envrionmental Medicine, United States, 3Beth Israel 
Deaconess Medical Center, United States
Physical activity (PA) history has a positive impact on bone density, structure, and frac-
ture risk. Stress fractures are a particular concern for individuals undergoing U.S. Army 
Basic Combat Training (BCT). Measures of historical PA are not taken before beginning 
BCT, however, all incoming trainees complete one or more multi-event physical fitness (PF) 
tests to determine military readiness. Purpose: The purpose of this study was to assess the re-
lationship between multi-event PF test performance and bone microstructure and density in 
young men and women entering BCT. Methods: This analysis uses a subset of data from an 
on-going prospective study collecting HR-pQCT images of the distal tibia before and after 
BCT in 4,000 trainees. Using the U.S. Army Research Institute of Environmental Medicine’s 
Soldier Performance Health and Readiness database, we obtained Occupational Physical 
Assessment Test (OPAT) and/or the first recorded Army Physical Fitness Test (APFT) scores 
from 1141 men and 630 women with pre-BCT HR-pQCT scans. The OPAT consists of a 
deadlift, standing long jump, power throw, and shuttle run with overall scores ranging from 
1 (best) to 3 (worst). The APFT consists of a 2-mile run, 2-minute sit ups, and 2-minute 
pushups with overall scores between 0 (worst) and 300 (best). We used generalized linear 
models to determine the association between PF test scores and bone parameters. Results, 
presented as effect estimates, were adjusted for age, race/ethnicity, and BMI. Results: Men 
and women enrolled in this study were similar in age and BMI. OPAT scores were signifi-
cantly inversely associated with cortical area (Ct.Ar) and thickness (Ct.Th) in men (-2.21, 
p=0.007; -0.02, p=0.042) and women (-2.54, p=0.001; -0.02, p=0.026). Ct.Ar (0.067) and 
Ct.Th (0.001) were also positively associated with APFT scores in men (p<0.001), but not 
women. Total vBMD, trabecular (Tb.) vBMD, and most Tb. parameters were also signifi-
cantly inversely associated with OPAT scores and significantly positively associated with 
APFT scores in men (p<0.04 for all), but not women. Conclusion: These results indicate 
that trainees who are more physically fit have more favorable bone microarchitecture at 
entry into BCT, although relationships may be modified by sex. Objective measures of PF 
at military entry may identify trainees at increased risk for musculoskeletal injury, although 
this remains to be demonstrated.
Disclosures: Katelyn Guerriere, None
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Low Magnitude Mechanical Signals Enhance the Effects of Zoledronic 
Acid to Reduce Osteolytic Lesion Area and Improve Cardiac Function in 
a Murine Model of Breast Cancer Bone Metastases *Gabriel M. Pagnotti1, 
Monte S. Willis1, Trupti Trivedi1, Sreemala Murthy1, Sukanya Suresh1, Yun She1, 
Clinton T. Rubin2, William R. Thompson0, Khalid S. Mohammad1, Theresa A. 
Guise1. 1Indiana University, United States, 2Stony Brook University, United 
States, 0Indiana University, United States
Breast cancer bone metastases are characterized by osteolytic lesions and associated 
with systemic skeletal muscle dysfunction. Treatment for estrogen receptor(+) disease in-
cludes complete estrogen(E2)-deprivation and osteoclast bone resorption inhibitors, such as 
bisphosphonate zoledronic acid(ZA) to suppress bone destruction. Patients can experience 
disease recurrence and muscle weakness, which may include cardiac muscle dysfunction. 
Low intensity vibrations(LIV), a low-magnitude mechanical signal, improved bone mass 
and muscle strength in the setting of complete E2-deprivation (ovariectomy(OVX)+aro-
matase inhibitor(AI) letrozole) mouse models. We hypothesized that combining LIV with 
ZA could mitigate musculoskeletal decline in the setting of complete E2-deprivation(OVX-
+AI) and bone metastases. 5w-old athymic nude mice divided into 4 tumor-bearing and 2 
non-tumor-bearing groups(n=20). Non-tumor groups were either sham or E2-deprived while 
all tumor-bearing groups were E2-deprived, receiving either no treatment, ZA alone, LIV 
alone or combined(Table1). LIV treatment(90Hz, 0.5g acceleration) began at 5w of age, 
complete E2-deprivation and ZA treatment at 9wk and intracardiac inoculation of 1x105 
MDA-MB-231 cells at 12wk. Four weeks post-tumor inoculation, radiographs showed a 
significant reduction in osteolytic lesion areas in the ZA treated group(p<0.05) versus un-
treated tumor-bearing mice. Combined treatment(LIV+ZA) reduced osteolytic lesion area 
more than either treatment alone(p<0.01). Both untreated and ZA treated tumor-bearing 
E2-deprived mice had significantly reduced grip strength, which marginally improved with 
LIV either alone or in combination with ZA. Since we observed significant effects on skel-
etal muscle function, we hypothesized that cardiac muscle function might also be affected. 
We assessed mouse cardiac function by echocardiography calculation of fractional short-
ening(FS); non-tumor(p<0.05) and tumor-bearing(p<0.01) E2-deprived mice showed a re-
duction versus sham-mice(14d post-inoculation). This was partially prevented with LIV, ZA 
or in combination, exhibiting no effects on systolic cardiac function(FS%). Together, these 
data show that osteolytic breast cancer bone metastases are associated with skeletal muscle 
weakness and cardiac muscle dysfunction, both of which are improved by LIV, ZA or in 
combination and suggest that systemic effects of the growth factors released from the bone 
matrix may affect cardiac as well as skeletal muscle.
Disclosures: Gabriel M. Pagnotti, None
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Preclinical supplementation of Human Milk Oligosaccharides (HMOs) 
during early life positively impacts long-term bone quality. *Nicolas 
Bonnet1, Kathrin Mletzko2, Michael Baruchet1, José Manuel Ramos-Nieves 1, 
Laurent Favre3, Dominique Brassart 4, Felix Schmidt2, Bjorn Busse2, Sietse-
Jan Koopmans 5, Marie Noelle Horcajada1. 1Nestlé Research, EPFL Innovation 
Park, 1015 Lausanne, Switzerland, Switzerland, 2Department of Osteology 
and Biomechanics, University Medical Center Hamburg, Germany., Germany, 
3Nestlé Research, Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland, 
4Nutrition Business Unit. Nutrition Research. Avenue Nestlé 55. 1800 Vevey. 
Switzerland, Switzerland, 5Wageningen UR Livestock Research, Wageningen, 
The Netherlands, Netherlands
Bone growth during infancy is a key period for bone strength later in life. Human milk 
oligosaccharide (HMO) supplementation rescues bone growth in malnourished infants. 
However, it is not known which specific HMOs are involved and if it is a long lasting effect. 
Hence, we tested if sialylated and/or neutral HMOs intake during early life can impact de-
terminants of bone strength later in life. Göttingen female Minipigs (n=48) were randomly 
allocated to be artificially reared with milk substitutes containing blends of either sialylated 
(2-HMOs: 3’SL and 6’SL; 0.68 g/L), neutral (4-HMOs: LNnT, LNT, 2’FL and di-FL; 4 g/L), 
both sialylated or neutral (6-HMOs: 4 g/L) or lactose as control group (C:4 g/L) from 10 
days to 11 weeks of age (weaning). A naturally-reared reference group (NR; n=8) was kept. 
At weaning, all groups received a mild-western chow diet up to 48 weeks of age (sacrifice). 
Tibial BMD, microstructure, bone quality indices (matrix maturity, mineral-to-matrix ratio, 
degree of mineralization) and strength were evaluated by DXA, microCT, FTIR, quantita-
tive backscattered electron microscopy and axial compression, respectively. Protocol was 
approved by Dutch Centrale Commissie Dierproeven, NL, N191114. Control group (C) ex-
hibit low BMD, Tb BV/TV, CtBV, failure and post failure energy and high Ct.Po (-7.3%, 
-5.6%, -8.9%, -8.5%, -22.5% and +129%, p<0.05) vs NR. 2-4 and 6-HMOs blends reduced 
Ct. Po and increased mineral-to-matrix ratio vs C in regions of interest (respectively -50%, 
-52%, -53% and +8.4%, +8.3%, +8.7% all p<0.05) without any effect on collagen maturity. 
4-HMOs blend significantly increased BMD, Tb BV/TV and Tb.N vs C (+7.7%, +4%, +27% 
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all p<0.05). This intervention decreased the degree of mineralization specifically at the peri-
oste vs C (-2.5% p<0.05), signs of higher bone formation. Similar trends were observed with 
6-HMO. As a consequence, both 4-HMO and 6-HMO increased elastic energy vs C (+29.4% 
and +20.2%; all p<0.01) and yield force (+6.3%, p=0.07 and +10.7%, p<0.05), reaching 
energy to failure levels similar to NR. In conclusion, early life lactose milk substitute is not 
as efficient as natural-rearing to promote bone strength. Addition of neutral HMO to lac-
tose rescued elastic tibial mechanical properties by improving BMD, trabecular and cortical 
bone quality. These findings further delineate the important role of HMO on long-term bone 
strength at milk substitution.
Disclosures: Nicolas Bonnet, Nestlé, Speakers’ Bureau
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FGF and Klotho Phosphate Regulatory Pathways Linking Placenta and 
Bone *Claire Stenhouse1, Katherine M Halloran1, Makenzie G Newton1, Dana 
Gaddy2, Larry J Suva3, Fuller W Bazer1. 1Department of Animal Science, 
Texas A&M University, United States, 2Department of Veterinary Integrative 
Biosciences, Texas A&M University, United States, 3Department of Veterinary 
Physiology and Pharmacology, Texas A&M University, United States
Phosphate and calcium are essential for fetal bone development and post-natal growth. 
Calcium transport across the placenta to the developing fetus is mediated by PTHrP but 
little is known regarding mechanisms of placental transport of phosphate. This study sought 
to identify whether the phosphate regulatory pathways recently uncovered in the skeleton 
have roles in the ovine endometrium and placenta throughout gestation. On Days 9, 12, 17, 
30, 70, 90, 110 or 125 of pregnancy, ewes were euthanized and hysterectomized. On Days 
9-17, the uterine horns were flushed with PBS to recover conceptuses. Sections of conceptus 
tissue (Day 17), placentae and endometria were frozen in liquid nitrogen or fixed in 4% para-
formaldehyde. Inorganic phosphate was detected spectrophotometrically in uterine flushes, 
allantoic and amniotic fluid, and homogenates of placentae and endometria. Concentrations 
of phosphate were influenced by gestational day in all samples except for amniotic fluid 
(P<0.05). Phosphate concentration was greater in placentae than endometria on Days 30, 70 
and 90 (P<0.05). On Day 125, phosphate concentrations in the endometria were greater than 
placentae (P<0.001). Next, expression of mRNA for sodium-dependent phosphate transport-
ers (SLC20A1 and SLC20A2) and klotho signaling pathway mediators (FGF21, FGF23, 
FGFR1, KL and KLB) were quantified by qPCR. Day 17 conceptuses expressed SLC20A1, 
SLC20A2, KLB, FGF21, FGF23 and FGFR1 mRNAs. Endometrial expression of FGFR1 
(P<0.001) and FGF21 (P<0.05) mRNAs was highest on Day 30, as was KL mRNA (Days 
30 and 110; P<0.001). Placental expression of KLB (P=0.06) and FGF21 (P<0.05) mR-
NAs increased between Days 110 and 125. Placental FGF23 mRNA expression increased 
with stage of gestation (P<0.01). Placental expression of FGFR1 mRNA was lowest at Day 
90 and increased by Day 125 (P=0.05). SLC20A1 mRNA expression peaked at Day 30, 
before decreasing to Day 110 (P<0.001). Further, KL and FGF23 proteins were detected 
using immunohistochemistry in conceptus trophectoderm and endoderm, uterine luminal 
and glandular epithelia, and uterine stratum compactum. KL and FGF23 were also expressed 
by placental cotyledons and caruncles in early pregnancy and localized to cotyledons in late 
pregnancy. These data suggest an important role for multiple phosphate regulatory pathways 
and direct our attention to the need to understand the impact that placental phosphate trans-
port has on both placental pathophysiology and fetal mineralization.
Disclosures: Claire Stenhouse, None
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A Neuroskeletal Atlas of the Mouse Limb *Madelyn R. Lorenz1, Jennifer 
Brazill1, Alec Beeve1, Kristann Magee1, Erica L. Scheller1. 1Washington 
University in St. Louis, United States
In addition to the well-established role of the nervous system in bone pain and vaso-
regulation, the function of nerves in and around bone has been associated with progression 
of skeletal disorders including osteoporosis, fracture, arthritis and tumor metastasis. Though 
this has renewed interest in the study of neuroskeletal disorders, isolation of the region-spe-
cific mechanisms surrounding these relationships is limited by our lack of comprehensive 
local maps of skeletal innervation.To overcome this, we used 50 µm, thick-section histology 
and confocal immuno-microscopy to map the tyrosine hydroxylase positive sympathetic 
adrenergic nerves and calcitonin gene related peptide expressing sensory peptidergic nerves 
within the mouse tibia, femur, ulna, and radius in 12-week-old C57BL6 and C3H mice. 
In the periosteum, these maps were then related to the surrounding musculature, including 
entheses and myotendinous attachments to bone, in addition to major nerve branches and 
surrounding adipose tissues.Locally, distinct patterns of innervation were detected within 
established sites that are important for bone repair and homeostasis, including regions of the 
metaphysis, mid-diaphysis, and periosteum. Within the periosteum, innervation patterns fall 
into three categories: aneural (Type I), anchored (Type II), and fascial (Type III). Finally, 
confocal imaging, tissue clearing, and light sheet microscopy were used to map aspects of 
secondary neural architecture, defining areas of myelination, Schwann cells and specialized 
mechanoreceptors, within the context of the musculoskeletal system.Overall, these results 
demonstrate that nerves are an integrated component of the skeleton with distinct spatial 
patterns of organization. This provides guidance that can be used during the design and 
implementation of future neuroskeletal studies and suggests that local differences in the neu-
roskeletal microenvironment may result in diverse, region-specific responses during skeletal 
disease and repair. This work was compiled as a resource for the field as part of the NIH 
SPARC consortium.
Disclosures: Madelyn R. Lorenz, None
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Beyond the Brain: Neurodegeneration risk-factor TREM2 R47H mutation 
causes distinct sex-dependent bone and cardiovascular phenotype in the 
absence of neuropathology *Alyson Essex1, Padmini Deosthale2, Allison 
Wagner3, John Damrath4, Joseph Wallace5, Monte Willis6, Andrea Bonetto7, 
Lilian Plotkin2. 1Department of Anatomy, Cell Biology& Physiology, Indiana 
University School of Medicine, United States, 2Department of Anatomy, Cell 
Biology&Physiology, Indiana University School of Medicine, United States, 
3Life Health Science Internship, Indiana University- Purdue University, United 
States, 4Weldon School of Biomedical Engineering, Purdue University, West 
Lafayette, Indiana, United States, 5Department of Biomedical Engineering, 
Indiana University- Purdue University Indianapolis, United States, 6Indiana 
Center for Musculoskeletal Health, Indiana University, United States, 
7Department of Surgery, Indiana University School of Medicine, United States
Age is the most critical risk factor for Alzheimer’s disease (AD). Along with its com-
plications, including osteoporosis and cardiovascular disease, AD prevalence is expected to 
increase over the next few decades due to the aging population. Clinical data shows exac-
erbated bone loss in AD, but no demonstrated mechanistic or causal links between the two 
conditions have been reported. Genome-wide analysis suggests that the Triggering Receptor 
Expressed on Myeloid Cells 2 R47H variant (TREM2R47H) confers high risk of developing 
AD.  TREM2 contributes to neuroinflammation in AD, but, interestingly, TREM2 mutant 
mice only exhibit cognitive deficits when co-expressing AD neuropathology-conferring mu-
tations. TREM2 is also critical for osteoclast differentiation and activity. Cardiomyocytes 
also express TREM2, suggesting that altered TREM2 function could also lead to deficient 
peripheral cell function, contributing to exacerbate bone and cardiovascular disease in AD 
patients. To test this possibility, TREM2 R47H variant hemizygous (TREM2R47H/+) mice 
were created by CRISPR-Cas9 on C57B6/J (WT) background. We found decreased sys-
tolic function by ultrasound echocardiography in 15-month-old (mo) TREM2R47H/+fe-
male (76.9+/-3.6 vs 85.0+/-2.3 ejection fraction, EF%) and male (78.3+/-1.3 vs 84.1+/-1.5 
EF%) mice, but not in 1mo mutants, compared to WT littermates. Left ventricular (LV) 
end diastolic and systolic diameters, indicators of dilation, were higher in female but not 
male 15mo TREM2R47H/+ mice. Femoral cortical and cancellous bone μCT analysis 
showed no change in 4mo mice, but lower cortical and cancellous BV/TV in 13mo female 
TREM2R47H/+ compared to WT mice; with no changes in males up to 20 months of age. 
Higher cortical cross-sectional area (5%), marrow area (13.5%), and endocortical bone sur-
face (4.6%) with lower cortical thickness (7.4%) indicate that the TREM2 variant may accel-
erate age-related endocortical resorption and periosteal expansion in female TREM2R47H/+ 
mice. Lower biomechanical strength [yield force (20%) and work to yield (31%)] and mate-
rial properties [stress (22%) and resilience (37%)] tested by 3-point bending were seen in fe-
male mutant compared to WT mice. Overall, our data indicate that by 13-15 months, female 
TREM2R47H/+ mice have aggravated loss of femoral bone mass and mechanical strength 
compared to age and sex-matched controls, with more profound cardiovascular dysfunction 
than males, suggesting a sex-dependent systemic role of TREM2 with aging.
Disclosures: Alyson Essex, None
1107
Transplantation of the Gut Microbiota from Healthy Mice Ameliorates Bone 
Loss in Sickle Cell Disease Recipient Mice *Liping Xiao1, Donyell Williams1, 
Marja Hurley1. 1UConn Health, United States
Although 80% of adults with sickle cell disease (SCD) have low bone mineral density, 
the molecular mechanisms of bone loss in SCD are not yet fully defined. Recent studies 
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showed gut microbiota dysbiosis in SCD in both humans and mice harboring the humanized 
sickle hemoglobin gene. Short chain fatty acids (SCFAs) are the major metabolite produced 
by gut bacteria that can affect bone growth by regulating insulin like growth factor 1 (IGF1) 
production. Serum IGF1 was low in SCD subjects and we published decreased IGF1 in bone 
and serum of SCD mice. Currently, there is no report on SCFA levels in SCD subjects or 
SCD mice. It is unknown if decreased IGF1 associated with low bone mass in SCD is due 
to reduced SCFA production by gut microbiota. Therefore, we performed fecal microbiota 
transplantation (FMT) in SCD mice. SCD female mice (3 months old, 10 mice/group) were 
fasted for 1h, then mice were subjected to bowel cleansing by oral gavage with four doses of 
200μl PEG (polyethylene glycol, Macrogol 4000) at 20min intervals to deplete the majority 
of their gut flora and then used as RECIPIENTS of the FMT. Pooled fecal matter from 8 
healthy control (Ctrl) mice (DONOR mice) was given by oral gavage 4h after last PEG treat-
ment to recipient mice. FMT was performed once per week. This is SCD-FMT group. As 
controls, Ctrl mice received FMT from Ctrl mice (Ctrl group) and SCD mice received FMT 
from SCD mice (SCD group). Six weeks post FMT, samples were collected. uCT analysis of 
femur showed significantly decreased bone volume/total volume (Fig1.A&B) and trabecular 
number, and significantly increased trabecular spacing and structure model index in SCD 
mice compared to Ctrl mice; these parameters were partially rescued in SCD-FMT group. 
Bone formation marker genes alkaline phosphatase, type-1 collagen, Dmp1, and Igf1 mRNA 
(Fig.1C) were significantly decreased in flushed tibiae from SCD mice compared with Ctrl, 
which was rescued after FMT from healthy Ctrl feces. SCFAs levels in cecal content were 
quantified by gas chromatograph coupled to a mass spectrometer detector (GC-MS). Propio-
nate and butyrate (2 types of SCFA) levels were significantly lower in SCD mice vs. Ctrl that 
was rescued after receiving FMT from healthy Ctrl mice (Fig.1D&E). These results suggest 
that the healthy gut microbiota community from healthy Ctrl mice confers protection from 
SCD bone loss by changing the production of bone growth factor IGF1 in response to altered 
bacterial metabolites SCFAs.
Disclosures: Liping Xiao, None
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Sensory Innervation in Porous Endplates by Netrin-1 from Osteoclasts 
Mediates PGE2-induced Spinal Pain *Shuangfei Ni1, Jianzhong Hu2, Xu Cao3. 
1Zhengzhou University, China, 2Central South University, China, 3Johns Hopkins 
University, United States
INTRODUCTION: Low back pain (LBP) is the leading cause of activity limitation 
and work absence as a common health problem. 90% of LBP is nonspecific LBP, however, 
its origins and underlying mechanisms remain unclear.METHODS: The lumbar spine in-
stability (LSI) and aging mouse model were established. Heterozygous male Avil-Cre mice 
were crossed with EP4flox/flox mice to knockout EP4 in sensory nerves. Heterozygous 
Dmp1-Cre mice were crossed with Ranklflox/flox to inhibit osteoclast formation. Hetero-
zygous Trap-Cre mice were crossed with Netrin-1flox/flox to delete Netrin-1 secreted by 
osteoclasts. The pressure hyperalgesia, spontaneous activity, and mechanical hyperalgesia 
of hindpaw were conducted to evaluated spinal pain-associated behaviors. All mice were 
maintained at the animal facility of The Johns Hopkins University School of Medicine. Hu-
man endplate samples were obtained from patients undergoing spine fusion surgery in the 
Department of Spine Surgery at Xiangya Hospital (China).RESULTS SECTION: Here we 
report that osteoclasts initiate the endplate sclerosis accompanied by sensory innervation 
for the LSI- and aging-induced spinal pain. Sensory innervation into the porous areas of 
sclerotic endplates was validated by retrograde and anterograde tracing. we also evaluated 
the pathological changes in the endplates of the lower lumbar spines of patients with or 
without LBP history. Severe endplate lesions were observed in patients with history of fre-
quent LBP, whereas the cartilaginous structure was preserved in patients without history of 
frequent LBP. Abundant TRAP+ osteoclasts and CGRP+PGP9.5+ nociceptive nerve fibers 
were observed in the porous endplates of patients with LBP. We show that lumbar spine 
instability (LSI) or aging induces spinal pain. Elevated levels of PGE2 activate sensory 
nerves, ultimately leading to sodium influx through Nav 1.8 channels through PKA/CREB 
signaling. Particularly, we show that knockout of PGE2 receptor 4 (EP4) in sensory nerves 
significantly reduces the spinal pain. Inhibition of osteoclast formation by knockout Rankl in 
the osteocytes significantly inhibits LSI-induced porosity of endplates, sensory innervation, 
and spinal pain. Knockout of Netrin-1 in osteoclasts abrogates sensory innervation into po-
rous endplates and spinal pain.DISCUSSION: LBP is difficult to diagnose and treat because 
of limited knowledge about its source. Importantly, endplates undergo sclerosis during aging 
and become porous, which is clinically associated with LBP. In this study, we demonstrate 
that osteoclasts initiate porosity of endplates with sensory innervation into porous areas, 
which is the potential source of spinal pain.
Disclosures: Shuangfei Ni, None
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INZ-701 prevents ectopic tissue calcification and restores growth in ENPP1 
deficient mice *ZHILIANG CHENG1, Kevin O’Brien1, Caitlin Sullivan1, 
Jennifer Howe1, Denis Schrier2, David Thompson1, Steve Jungles1. 1Inozyme 
Pharma, United States, 2Inozyme Phrma, United States
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) is the major enzyme 
that generates extracellular pyrophosphate (PPi), an inorganic metabolite with potent anti- 
calcification activity. Loss-of-function mutations lead to a state of ENPP1 deficiency and 
hypopyrophosphatemia, which in turn cause extensive calcification of the heart, arteries, and 
kidney, impaired growth and premature mortality. The acute infantile form of ENPP1 defi-
ciency (referred to as Generalized Arterial Calcification of Infancy (GACI)) presents with 
pathological mineralization in multiple tissues, arterial stenoses, growth impairment, and a 
50% mortality in the first year of life. INZ-701 is a recombinant, soluble, human ENPP1-
Fc protein being developed as potential enzyme replacement therapy for the treatment of 
ENPP1 deficiency. We performed a dose-response study to investigate the pharmacological 
effects of INZ-701 in Enpp1asj/asj mice, a murine model of acute infantile ENPP1 deficien-
cy. These mice harbor a missense mutation, p.V246D, in the Enpp1 gene, which produces 
undetectable levels and activity of ENPP1 protein and closely mimics the human condition. 
Starting from 2 weeks of age, Enpp1asj/asj mice were subcutaneously dosed either with ve-
hicle or with 0.2, 1, or 5 mg/kg of INZ-701 every other day for 8 weeks. Clinically relevant 
endpoints, including PPi levels, tissue calcium by colorimetric assay and µCT, body weight, 
and clinical signs and symptoms were measured. While plasma PPi levels in Enpp1asj/asj 
mice were confirmed to be undetectable, dosing of INZ-701 normalized PPi levels to ~2 µM 
in all 3 groups. Enpp1asj/asj mice treated with vehicle ceased to gain weight from ~4 weeks 
of age, and showed signs of hunched back, stilted gait, and impaired growth. Significant 
increases in tissue calcium levels were recorded in heart, kidney, spleen, lung, liver and 
vibrissae, and µCT revealed extensive calcification in the areas of aorta, coronary artery 
and heart in the vehicle-treated group (Figure). Our results showed that INZ-701 treatment 
at a dose of 1mg/kg or higher prevented pathological calcification in all the tested organs, 
restored growth parameters, and improved signs and symptoms of ENPP1 deficiency. In 
summary, INZ-701 restored circulating levels of PPi, a critical calcification inhibitor, and 
demonstrated a dose dependent prevention of pathological calcification and improvement of 
growth and symptoms in a murine model of ENPP1 deficiency.
Disclosures: ZHILIANG CHENG, INOZYME PHARMA, Grant/Research Support
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A MyD88 Inhibitory Peptide Reduces Endochondral Heterotopic 
Ossification in the ALK2R206H-FlEx model of FOP *Huili Lyu1, Cody 
Elkins1, Nikash Hari2, Joshua Johnson2, Carlos Serezani3, Daniel Perrien1. 
1Division of Endocrinology, Department of Medicine, Emory University, United 
States, 2Vanderbilt Center for Bone Biology, Division of Clinical Pharmacology, 
Department of Medicine, Vanderbilt University Medical Center, United States, 
3Division of Infectious Disease, Department of Medicine, Vanderbilt University 
Medical Center, United States
Fibrodysplasia ossificans progressiva (FOP) is a genetic disease caused by aberrant 
BMP signaling through mutated ACVR1/ALK2 and characterized by episodic muscle in-
flammation and endochondral heterotopic ossification (EHO) of skeletal muscles frequently 
induced by injury or inflammatory events. Hyperinflammation plays an essential role in FOP 
flares and endochondral heterotopic ossification, but the mechanisms that trigger the hyper-
inflammatory responses are not described. DAMPs and members of the IL-1 superfamily 
are among the first inflammatory signals released from damaged tissues. Their signaling 
through Toll-Like Receptors (TLRs) and IL-1 receptors, respectively, is critical to initiat-
ing the inflammatory cascade and largely dependent on the adapter protein MyD88 and 
TLR-signaling has been linked to the enhancement of canonical BMP signaling. Hence, we 
hypothesized that inhibition of MyD88 may reduce inflammation and EHO in FOP and test-
ed the hypothesis in an established mouse model of FOP. ALK2R206H-FlEx;R26creERt2/ 
creERt2 mice received tamoxifen starting at 8 days old by feeding the dam 40mg/kg/d for 8 
days followed by bilateral injury of the lower hindlimb muscles by injection of 1.5µg cardio-
toxin at 20 days old. All mice received 100µg of a palmitoylated MyD88-inhibitory peptide 
(Anti-MyD) ip or control peptide (Con) every 3 days starting 1 day before injury until sacri-
fice. Analysis of weekly radiographs revealed significantly less EHO in Anti-MyD mice vs 
Con at 14- (p<0.0001) and 21-days post-injury (p<0.001), which was confirmed by ex vivo 
μCT (p=0.0014). To determine the possibility of a direct role for MyD88 in mesenchymal 
commitment to osteogenesis, BMSCs from MyD88+/+ or MyD88-/- mice were cultured in 
non-osteogenic media with Vehicle, 100ng/ml of the TLR agonist LPS, 100ng/ml BMP2, or 
BMP2+LPS. BMP alone significantly increased the number of alkaline phosphatase positive 
cells from both MyD88+/+ (p<0.05) and MyD88-/- BMSCs. LPS alone had little effect on 
AP expression but synergistically increased the osteogenic effect of BMP2 in MyD88+/+ 
cells (p<0.01). However, in MyD88-/- cells, LPS blocked the osteogenic effect of BMP2, 
suggesting that MyD88-independent signaling pathways may antagonize osteogenic BMP 
signaling. These results suggest that MyD88-dependent pathways may be critical for EHO 
formation in FOP and that, in addition to controlling inflammation, blockade of MyD88 may 
inhibit aberrant BMP signaling in chondrogenic progenitors.
Disclosures: Huili Lyu, None
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A self-amplifying, self-propagating loop of Yap and Shh drives formation 
and expansion of heterotopic ossification *Qian Cong1, Yuchen Liu1, Taifeng 
Zhou2, Peiqiang Su3, Paul B Yu4, Yingzi Yang2. 1Department of Developmental 
Biology, Harvard School of Dental Medicine, Harvard Stem Cell Institute, 
United States, 2Department of Developmental Biology, Harvard School of Dental 
Medicine, United States, 3First Affiliated Hospital of Sun Yat-sen University, 
China, 4Department of Medicine, Brigham and Women’s Hospital, United States
Heterotopic ossification (HO) refers to extraskeletal pathological bone formation that 
occurs as a common complication after injury or as a manifestation of particular genetic 
disorders. However, limited by poor understanding of underlying cellular and molecular 
mechanisms, there is currently no effective treatment and surgical eviction ofter results in 
recurrence. We have found that in both genetic and injury-induced HO, activated ectopic 
Shh expression drives HO progression by forming a positive feedback loop that results in 
non-cell- autonomous and self-propagation of osteoblast differentiation of wild type cells. In 
mouse models of progressive osseous heteroplasia (POH), a human disease caused by null 
mutations in GNAS that encodes Gαs, we found that progressively expanded ectopic bone 
was formed by progressively recruited wild type cells. Mechanistically, Gnas-/- mesenchy-
mal cells differentiate into osteoblasts and recruit wild-type cells to form bone by activating 
Yap, a transcription factor that regulates Shh expression and secretion. Secreted Shh further 
induces Yap activation, Shh expression and osteoblast differentiation in surrounding wild 
type cells. This self-propagating positive feedback loop is both necessary and sufficient for 
ectopic bone formation and expansion and can independently of Gαs. Importantly, Yap and 
Shh activation was also found in fibrodysplasia ossificans progressive (FOP), Achilles ten-
don puncture (ATP)-induced HO mouse models and in human HO samples. Genetic removal 
of Yap and Shh abolished HO not only in POH, but also in FOP and acquired HO mouse 
models. We therefore indentify a Yap-Shh positive feedback loop as a common cellular and 
molecular mechanism underlying HO initiation and expansion. Our work highlights the im-
portance of rare genetic disease studies in identifying a shared core pathological mechanism 
underlying a class of diseases. As Shh is not required for normal bone formation, our results 
further suggest that Shh is a promising new therapeutic target for HO without affecting the 
normal bone.
Disclosures: Qian Cong, None
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Evaluation of Epigenetic Regulation of Osteogenesis Imperfecta Severity 
with Circulating microRNAs: the miROI Study *Alexandre Mercier1, 
Marjorie Millet2, Martine Croset2, Blandine Merle2, Jean-Paul Roux2, Elisabeth 
Sornay-Rendu 2, Olivier Borel2, Pawel Szulc2, Deborah Gensburger3, Emmanuelle 
Vignot4, Elisabeth Fontanges3, Roland Chapurlat1. 1Division of Rheumatology, 
Edouard Herriot University Hospital; INSERM UMR 1033, Université de Lyon, 
France, France, 2INSERM UMR 1033, Université de Lyon, France, France, 
3Division of Rheumatology, Edouard Herriot University Hospital, France, 
France, 4Division of Rheumatology, Edouard Herriot University Hospital, 
France, France
Objectives: In about 85% of individuals, Osteogenesis Imperfecta (OI) is caused by 
dominant autosomal mutations in COL1A1 and COL1A2. For the same mutated gene 
(COL1A1 or COL1A2) and for the same variant (in the same family) there is a great het-
erogeneity of phenotypic severity, without biomarker of disease severity for the physician. 
As epigenetic regulators of gene expression, circulating microRNAs (miRs) have been de-
scribed in other bone diseases as potential markers regulating gene expression. The aim of 
this study was to identify serum miRs potentially associated with the OI severity.Methods: 
Ten patients were recruited in consultation and hospitalization at the University Hospital 
Edouard Herriot Hospital in Lyon. Ten age- and sex-matched control patients from the pop-
ulation-based OFELY, MODAM and STRAMBO cohorts were involved. We measured all 
circulating microRNAs (miRome) in both groups by next generation sequencing (NGS). 
Total RNA extracted from serum was analysed by miRs sequencing on Illumina platform 
and the miRs levels were normalized by the M-trimmed mean prior to Tags-per-million 
expression and comparison between groups by the Log2(Fold Change). Multiple compari-
sons were accounted for by the false discovery rate (FDR) adjustment method of Benjami-
ni-Hochberg.Results: The mean age of OI patients was 41 (29-61) with a balanced sex-ratio. 
All patients had type I OI. We found 79 miRNAs differently expressed with FDR corrected 
p-values<0.05 and 27 miRs with corrected p<0.0005. Among these, 5 were down-regulated, 
22 were up-regulated in OI. Several miRs transcribed from physically adjacent miR genes 
clustered : miR-183/96/182 and miR-25/93/106b. After a literature review, we found 22/27 
miRs known to be involved in bone homeostasis. We used the MiRWALK database to screen 
these miRs interactions and we found 23/79 miRs predictably targeting either COL1A1 or 
COL1A2 with a probability of 100%.Conclusion: We have established the miR signature 
in OI by highlighting significant dysregulation in circulating miRs involved or potentially 
involved in the regulation of genes with a major role in the pathophysiology of OI. These 
miRs will be remeasured in a validation phase in a larger cohort to link the biological dys-
regulation to the clinical phenotype.
Disclosures: Alexandre Mercier, None
1113
Role of FGF Receptor, FGF23 Signaling in Enthesopathy of Achilles Tendon 
in High Molecular Weight FGF2 Transgenic Mice *Donyell Williams1, 
Liping Xiao1, Nathaniel Dyment2, Marja Hurley1. 1UConn Health, United States, 
2University of Pennsylvania, United States
Background: Subjects with X-linked hypophosphatemic rickets (XLH) and the Hyp 
mouse homolog of XLH develop osteomalacia and enthesopathy. FGF receptor (FGFR) in-
hibitor BGJ398 partially rescued osteomalacia in Hyp mice, which we have reported over-
express the high molecular weight isoform of fibroblast growth factor 2 (HMWFGF2) in 
osteoblasts and osteocytes. HMWFGF2Tg mice phenocopy Hyp mice with increased FGFR 
and FGF23 expression in osteoblasts and osteocytes, and BGJ398 also partially rescued 
the osteomalacia in HMWFGF2Tg mice. Therefore, in this study, we aimed to determine if 
HMWFGF2Tg mice develop enthesopathy at the Achilles tendon insertion site. Addition-
ally the effects of FGF inhibition on enthesopathy in Hyp and HMWFGF2Tg mice have 
not been reported. Thus, we also examined whether in vivo treatment with BGJ398 would 
modulate development of the enthesopathy phenotype at the Achilles tendon enthesis of 
HMWFGF2Tg mice.Methods: All Animal care and use protocols were approved by the An-
imal Care and Use Committee at UConn Health. VectorTg and HMWFGF2Tg mice (21 
days of age) were treated with vehicle (HCL 3.5 mM, DMSO 5%) or BGJ398 (2 mg/kg, 
sq daily) for 13 weeks at which time they were sacrificed. Ankles were dissected, fixed, 
and frozen undecalcified sagittal sections including the Achilles tendon were prepared for 
histology and immunohistochemistry.Results: Achilles tendon entheses from HMWFGF2Tg 
vehicle-treated mice had higher alkaline phosphatase (AP) activity but weaker Safranin O 
staining (i.e., proteoglycans) compared with VectorTg. HMWFGF2Tg vehicle-treated mice 
also had increased FGF23, phospho-ERK, and Runx2 protein expression compared with 
VectorTg. BGJ398 treatment rescued the observed abnormalities in mineralization, proteo-
glycan, and expression of FGF23, phospho-ERK and Runx2 in HMWTg entheses.Summary 
and Conclusion: This study demonstrates that overexpression of the HMWFGF2 isoform in 
Col1a1-expressing cells results in the enthesopathy of the Achilles tendon enthesis that can 
be partially rescued by FGFR inhibition.
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Activating Fgfr3 Mutation In Immature Osteoblasts Affects Appendicular 
And Cranio-facial Skeleton *Martin Biosse Duplan1, Emilie Dambroise2, 
Valentin Estibals2, Joelle Veziers3, Jerome Guicheux3, Laurence Legeai-
Mallet2. 1Université de Paris, Imagine Institute, Laboratory of Molecular 
and Physiopathological Bases of Osteochondrodysplasia. INSERM UMR 
1163. Service de Medecine Bucco-Dentaire, Hopital Bretonneau, AP-HP, 
France, 2Université de Paris, Imagine Institute, Laboratory of Molecular and 
Physiopathological Bases of Osteochondrodysplasia. INSERM UMR 1163, 
France, 3INSERM 1229, Université de Nantes, France
Achondroplasia (ACH), the most common form of dwarfism, is caused by a missense 
mutation of the gene coding for fibroblast growth factor receptor 3 (FGFR3) that leads to 
increased FGFR3 signaling. In ACH, the proliferation and differentiation of the growth plate 
chondrocytes (CCs) are disturbed, thus altering the long bone elongation. Several patients 
with ACH also show membranous bones defects and reduced bone mineral density, indi-
cating that increased FGFR3 signaling could also impair osteoblasts (OBs) differentiation 
or activity.In this study, we examined whether or not Fgfr3 overactivation in OBs leads 
to bone modifications in a mouse model of ACH. We took advantage of a model carrying 
a Fgfr3 activating mutation (Fgfr3Y367C/+) and targeted the mutation in immature OBs 
and hypertrophic CCs or in mature OBs using respectively the Osx-cre and collagen 1α1 
(2.3kb-Col1α1)-cre mouse lines.We observed that activation of Fgfr3 in immature OBs and 
hypertrophic CCs perturbed the hypertrophic CCs of the femoral growth plate resulting in a 
reduced hypertrophic zone (-22.1% compared to Osx-cre mice, p<=0.05; n>=6 for each gen-
otype, 3-week old males). Accordingly, the growth of the long bones was affected, and adult 
mutant mice had shorter femur (-28.3%, p<=0.001) and tibia (-26.1%, p<=0.001; n>=8 for 
each genotype, 3-month old males). Increased Fgfr3 signaling in immature OBs and hyper-
trophic CCs also led to osteopenia as shown by the decreased BV/TV (-46%, p<=0.005) and 
reduced cortical thickness of femurs (-19%, p<=0.05; n>=6 for each genotype, 3-month old 
males). Importantly, cranio-facial membranous bones defects were present in mutant mice, 
with a defective growth of frontal and nasal bones. In contrast, activation of Fgfr3 in mature 
OBs had very limited effects on skeletal shape, size and micro architecture of long bones 
as well as cranio-facial membranous bones. Finally, we observed that Fgfr3 activation in 
immature OBs did not affect the proliferation, viability or differentiation of the cells, but re-
duced their mineralization activity (-51%, p< 0.01; n>=6 for each genotype). In conclusion, 
immature OBs are affected by Fgfr3 overactivation and contribute to the bone modifications 
observed in ACH, independently of CCs. This study emphasizes the role of FGFR3 during 
the early steps of OB differentiation.
Disclosures: Martin Biosse Duplan, None
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3Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht. 
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Background and Purpose: Randomized clinical trials (RCTs) showed that low-dose 
glucocorticoid (GC) therapy in patients with rheumatoid arthritis (RA) was associated 
with reduced bone mineral density (BMD) loss in hands or hip. However, the effect on 
osteoporotic fractures is not yet clear and observational studies mostly reported contrasting 
results compared to the BMD studies. Thus, we investigated the use of low-dose oral GCs 
on osteoporotic fracture risk among patients with RA in the UK.Methods: This was a retro-
spective cohort study including all RA patients aged 50+ from the Clinical Practice Research 
Datalink (CPRD) between 1997-2017. Exposure to oral GCs was stratified into current (1 
year), based on the time since the most recent prescription. Current use was further stratified 
by average daily and cumulative doses. Time-dependent Cox proportional-hazards models 
estimated risk of osteoporotic fracture (included hip, vertebrae, humerus, forearm, pelvis, 
or ribs) in RA patients with current use of low-dose oral GCs (average daily dose <=7.5mg 
prednisolone equivalent dose [PED]/d) versus past use. The analyses were statistically ad-
justed for life-style parameters, comorbidities and comedications.Results: Among 15,123 
patients with RA (mean age 68.8 years, 68% females), 1640 osteoporotic fractures occurred. 
Current low-dose oral GC therapy (<=7.5mg PED/d) in RA patients was not associated with 
an increased risk of osteoporotic fractures compared with past GC use (adjusted hazard ratio 
1.14, 95%CI 0.98-1.33, Table 1). Clinical vertebral fracture was the only one among the six 
studied osteoporotic fractures that observed higher rates with low-dose GC use (adjusted 
hazard ratio 1.59, 95%CI 1.11-2.29) versus past use. High-dose (>7.5mg PED/d) long-term 
(>=1g PED) oral GC therapy in RA patients was associated with a 1.5-fold increased risk 
of osteoporotic fractures compared to past use.Conclusion: Low-dose GC therapy was not 
associated with an increased risk of osteoporotic fractures in RA patients compared with 
past GC use, except for clinical vertebral fractures. Our results are in line with findings from 
RCTs reporting a similar effect of low-dose GC use on BMD in various anatomical sites. Cli-
nicians should be aware that even in RA patients who receive low daily GC doses (<=7.5mg 
PED/d), clinical vertebral fracture risk is increased.
Disclosures: Shahab Abtahi, None
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Causal Assessment of the Association Between Bone Mineral Density and 
the Risk of Dementia *Samuel Ghatan3, Katerina Trajanoska3, Petroula Proitso2, 
Arfan Ikram3, Ling Oei4, Angela Hodges5, Fernando Rivendeneria3. 3Erasmus 
MC, Netherlands, 2Kings college London, United Kingdom, 3Erasmus MC, 
United Kingdom, 4Erasmus Mc, Netherlands, 5King’s college london, United 
Kingdom
Introduction: Evidence for an association between BMD and cognitive decline has been 
postulated for many years. As both dementia and osteoporosis are prominent age-related 
diseases the association is expected to be driven by shared comorbid factors, until proven 
otherwise. The aim of this study was to establish if there is a causal association between 
bone mineral density (BMD) and dementia. Methods: We included 5,545 participants (58% 
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females) from a prospective population-based cohort (age:66.3+/-10.3). Participants un-
derwent DXA to measure femoral neck (FN) and lumbar spine (LS) BMD. We assessed 
dementia at the time of DXA measurement and during a follow-up of maximum 12 years. 
We used time-to-event analysis to determine the observational relationship between BMD 
and incident dementia, including Alzheimer’s disease (AD) adjusted for age, sex, cohort 
effect, smoking, education, apoE (genotype) and hormone use. Next, we applied a two-sam-
ple bidirectional Mendelian Randomization approach, leveraging genetic data from large-
scale genome-wide association studies (GWAS) of AD (n = 74,046 with 25,580 cases) and 
family history of AD (n=314,278 from UK Biobank; 42,034 paternal/maternal cases; meta 
analysed against n = 74,046 with 25,580 cases), as well as, FN- and LS-BMD (n=~32,000) 
seeking to provide robust evidence of causality. Results: Among the 5,545 non-demented 
participants included in in the study 397 (7.2%) developed AD (n=264 AD cases) during 
a mean follow-up of 7 years. Lower levels ofFN-BMD were associated with higher risk of 
AD (HR:1.20) and AD (HR:1.27). In contrast, LS-BMD was not associated with incidence 
dementia (HR:1.07) or Alzheimer disease (HR:1.10). These observational results were not 
supported by the MR analysis.  A causal association was found between BMD and family 
history of AD (LS-BMD: OR=1.08, 95%: 1.02 - 1.14) (FN-BMD: OR=1.06, 95%: 1.00 – 
1.13), AD and LS-BMD were non-significant but concordant (LS-BMD: OR=1.10, 95% 
0.98 – 1.24), however FN-BMD showed no causal association (FN-BMD: OR=1.04, 95% 
0.91 – 1.19). Conclusion: The results from the MR analysis provide evidence for a causal 
association between LS-BMD levels and AD risk, but not FN-BMD. While treating BMD 
won’t be by itself an effective intervention to modify the risk of dementia, investigating 
the mechanism by which the diseases interact with each other will help us understand the 
complex aetiology of AD.
Disclosures: Samuel Ghatan, None
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Preflight Biomarkers of Bone Remodelling Predict Bone Loss on Long-
Duration Spaceflight *Leigh Gabel1, Paul Hulme1, Anna-Maria Liphardt2, 
Martina Heer3, Sara Zwart4, Jean Sibonga4, Scott Smith4, Steven Boyd1. 
1University of Calgary, Canada, 2Friedrich-Alexander University Erlangen-
Nuremberg, Germany, 3University of Bonn, Germany, 4NASA Lyndon B. 
Johnson Space Center, United States
Bone loss remains a major health concern for astronauts on long-duration spaceflight, 
despite in-flight countermeasures. This study examined changes in bone microarchitecture, 
density and strength before and after long-duration spaceflight. Seventeen astronauts (14 
men; age 38 to 60 years) had their distal tibiae and radii imaged before and after flight with 
high-resolution peripheral quantitative computed tomography (HR-pQCT; XtremeCT II; 
61µm). Postflight bone images were 3D-registered to baseline images. Finite element anal-
ysis was applied to estimate bone strength. Blood and urine biochemical markers of bone 
remodelling were acquired before, during, and after flight. Spearman correlations evaluated 
the relationship between changes in bone variables and biomarkers. Mixed effects models 
examined changes in bone and biochemical variables across time and the relationship be-
tween changes in bone variables and mission duration. At the distal tibia, median cumulative 
postflight losses in total volumetric BMD (Tt.BMD) and bone strength (F.Load) were -2 
to -4% (-0.5 to -0.8% per month), while trabecular BMD, bone volume fraction, thickness 
(Tb.BMD, BV/TV, Tb.Th) and cortical BMD (Ct.BMD) declined 1-3%. Mission duration 
ranged from 115 to 204 days and was negatively related to change in bone variables after 
flight. Tibia Tt.BMD, Ct.BMD and F.Load significantly deteriorated on missions longer than 
5-months, while Tb.BMD and BV/TV demonstrated a steeper rate of decline on missions 
longer than 6-months. Less severe postflight changes occurred at the distal radius, where 
Tt.BMD and F.Load significantly increased on missions shorter than 5.5 months and de-
creased on missions greater than 6.5-months. Bone resorption markers (carboxy- and ami-
no-terminal cross-linked telopeptides of type 1 collagen; CTx, NTx) were elevated during- 
and immediately after flight, while bone formation markers (procollagen type 1 amino-ter-
minal propeptide, P1NP; bone specific alkaline phosphatase, BSAP, osteocalcin, OC) were 
elevated from mid-flight onwards. Preflight CTx and P1NP were negatively associated with 
changes in tibia Tt.BMD and F.Load (r =-0.56 to -0.92; p<0.05), suggesting that heightened 
preflight bone remodelling may predict greater in-flight bone loss. Study findings highlight 
the integral relationship between mission duration and bone deterioration. Pre-flight markers 
of bone remodeling may help identify individuals most susceptible to bone loss on long-du-
ration spaceflight.
Disclosures: Leigh Gabel, None
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Children Living With HIV In Zimbabwe Have Impaired Trabecular 
Bone Density, Despite Treatment With Anti-Retroviral Therapy: A Cross-
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The majority of children with HIV live in sub-Saharan Africa. HIV infection has 
multi-system consequences. Whilst stunting is common, specific effects on the growing skel-
eton are unclear. We aimed to determine the effect of chronic HIV infection on bone density 
in children with HIV in Zimbabwe.We conducted a cross-sectional observational study of 
children with HIV (8-16 years) established on antiretroviral therapy (ART), and children 
without HIV, from schools serving the same population in Harare, Zimbabwe. Non-dom-
inant tibial pQCT was used to measure 4% trabecular and 38% cortical volumetric bone 
density (vBMD), cross-sectional area (CSA) and predicted bone strength (38% cross-sec-
tional moments of inertia [CSMI]). Puberty was assessed by Tanner staging. Multivariable 
linear regression assessed associations between HIV status and bone outcomes, adjusting for 
age, sex, puberty and height.We recruited 264 children with and 281 without HIV; 50.2% 
female. Children with HIV were similar in age to those living without HIV ([mean+/-SD] 
12.4+/-2.5 and 12.5+/-2.5 years), but more were prepubertal (41.8% vs. 22.1%; p<0.001). 
Mean age at ART initiation was 4.7+/-3.5 years. Children with HIV had impaired growth 
compared with those without HIV; stunting (height-for-age Z-score<-2) prevalence was 
33% vs. 7.4% (p<0.001), underweight (weight-for-age Z-score<-2) prevalence was 28% vs 
8% with a mean weight-for-age Z-score of -1.38+/-1.37 vs. -0.42+/-1.2 (p<0.001). Before 
adjustment, children with HIV had lower trabecular vBMD (mean difference -12.1 [95%CI 
-18.5, -5.73]mg/cm³; p<0.001), smaller 4% and 38% CSA (-82.6 [-116.6, -48.7]mm2 and 
-46.6 [-58.4, -34.7]mm2 respectively, both p<0.001) and lower CSMI (-1947 [-2487, -1406]
mm4; p<0.001) than those without HIV. Adjustment for age, sex and puberty did not attenu-
ate these findings. Additional height adjustment partially explained differences in bone out-
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comes. However, deficits in trabecular vBMD (-8.86 [-15.97, -1.75]mg/cm³; p=0.015, 38% 
CSA (-13.50 [-22.6, -4.9]mm2; p=0.004) and CSMI (-420 [-824.4, -16.32]mm4; p=0.041) 
persisted.This is the largest pQCT study to date, of children with HIV in Africa. We identi-
fied marked bone density and size deficits including impairment in predicted bone strength, 
despite long-term ART. These findings are concerning, as if generalizable across sub-Saha-
ran Africa they suggest impaired bone development is common, which may lead to increased 
fracture risk amongst children with HIV in Africa.
Disclosures: Cynthia Kahari, None
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Results of the PaTH Forward Phase 2 Trial Demonstrating Potential 
of TransCon PTH as a Replacement Therapy for Hypoparathyroidism 
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Background:PTH deficiency in hypoparathyroidism (HP) causes low serum calcium 
(sCa) and high phosphate (sP). Standard of Care (SoC), consisting of high doses of active 
vitamin D and calcium, raises sCa and sP and increases burden of illness on HP patients by 
worsening hypercalciuria and the CaxP product. Recently approved injections of PTH(1-
84) (t1/2 ~2-3 hrs) can raise sCa and allow partial withdrawal of SoC, but does not control 
urinary calcium (uCa) or symptomatic hypo- or hypercalcemia.1,2 TransCon PTH, an inves-
tigational prodrug of PTH(1-34) transiently bound to an inert carrier via a linker, is under 
development for the treatment of HP. At physiological temperature/pH, linker auto-cleavage 
occurs, releasing active PTH at a controlled rate with a t1/2 ~60 hrs. Methods:PaTH For-
ward is a phase 2, double-blind, placebo-controlled, multicenter trial investigating safety 
and tolerability of TransCon PTH in adult HP patients treated with SoC. TransCon PTH was 
given as daily doses of 15, 18, or 21 µg/day PTH(1-34) vs. placebo for 4 weeks followed by 
an open-label extension trial during which each subject is optimized to their individual dose 
of TransCon PTH. The primary endpoint required 1) normal sCa, and 2) normal (or >=50% 
decrease from baseline) fractional excretion of calcium (FECa), and 3) not taking active D, 
and 4) taking <=1000 mg/d of Ca. Results:At week 4, significantly more subjects (50%) on 
TransCon PTH achieved the primary endpoint vs. (15%) subjects on placebo (Table). sP 
decreased from baseline by 20% in subjects on TransCon PTH vs 1% on placebo. Increase 
from baseline in subjects meeting FECa endpoint was 42% on TransCon PTH vs. 0% on 
placebo. Free PTH showed stable levels in the lower half of the normal range at both 2 and 
4 weeks. TransCon PTH was well-tolerated; no subjects discontinued the study treatment 
or from the trial during the 4-week period, and no SAEs or severe AEs were reported. No 
subjects on TransCon PTH showed symptomatic hypocalcemia vs. 7% of subjects on pla-
cebo.  Conclusions: These data from the initial 4-week phase of the PaTH Forward Trial 
demonstrated that TransCon PTH met the primary endpoint for efficacy, potentially repre-
senting a true PTH replacement therapy for HP patients. Results from this trial help inform 
the starting dose and SoC titration schedule for the phase 3 trial. Shire Pharmaceuticals. 
2018. NATPARA (package insert)Khurana M et al. Clin Pharm Ther. 2019 105(3):710-8.
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Introduction: Fibrous dysplasia/McCune-Albright Syndrome (FD/MAS) is a rare bone 
and endocrine disorder caused by somatic GNAS mutations. Proliferation of abnormal skel-
etal stem cells results in osseous lesions that present along a broad clinical spectrum, rang-
ing from trivial to severe disease. Long bone fractures are a common, painful, and poten-
tially disabling complication. However, fracture prevalence and risk factors have not been 
well-established, making it difficult to predict which patients are at-risk for a severe course.
Methods: Clinical data and imaging were reviewed from 2 large FD/MAS cohorts (NIH and 
LUMC) to identify long bone fractures at FD sites. Skeletal burden score was quantified 
using bone scintigraphy. Multiple linear regressions were performed to identify risk factors 
for fracture rate and age at first fracture.Results: 419 total patients were included (186 NIH, 
233 LUMC). 79 (19%) had polyostotic FD and 146 (35%) had monostotic FD. 194 (46%) 
had MAS endocrinopathies. Median age at last follow-up was 30.2 years (range 3.2-84.6, 
IQR 25.5), and median skeletal burden score was 16.6 (range 0-75, IQR 33). 48 (59%) 
patients suffered >=1 lifetime fracture (median 1, range 0-70, IQR 4). Median age at first 
fracture was 8 years (range 1-76, IQR 10). Fracture rates peaked between 6-10 years of age 
and decreased thereafter. Lifetime fracture rate was associated with skeletal burden score 
(β=0.40, p7)(p<0.01).Conclusion: Higher skeletal burden score and MAS hyperthyroidism 
are primary risk factors for long bone fractures in FD/MAS. First fracture occurrence at age 
<=7 years is associated with a higher lifetime fracture risk and may predict a more severe 
clinical course. These results may allow clinicians to identify FD/MAS patients at-risk for 
severe disease who may be candidates for early therapeutic interventions.
Disclosures: Raya Geels, None
The influence of undercarboxylated osteocalcin on endothelial function in 
normal and high glucose conditions *Alexander Tacey1, Tawar Qaradakhi1, 
Alan Hayes1, Anthony Zulli1, Itamar Levinger1. 1Victoria University, Australia
Purpose: The bone derived protein undercarboxylated osteocalcin (ucOC) improves 
glucose regulation and is associated with a reduced risk of diabetes. In animals, in vivo treat-
ment with ucOC improves vascular function, but this may be due to improved glucose con-
trol rather than a direct influence on blood vessels. Moreover, there are conflicting reports on 
the role and association of ucOC with cardiovascular outcomes in humans, including reports 
of adverse effects. The aim of this study was to examine whether ucOC directly influences 
(positively or negatively) endothelial function in rabbit arteries following incubation in dif-
ferent glucose concentrations.Methods: Male New Zealand white rabbit arteries were fed a 
normal or atherogenic diet for 4-weeks. Arteries were incubated ex vivo in 11mM or 20mM 
glucose solutions for 2-hours and the vasoactivity of ucOC was assessed via several differ-
ent techniques. Isometric tension analysis was use to assess the vasoactivity of abdominal 
aortic rings to ucOC pre-incubation (10ng/ml or 30ng/ml). To replicate haemodynamic flow, 
pressure and shear stress that occur physiologically, perfusion myography techniques were 
used to assess the vasoactivity of carotid artery segments to ucOC dose response curves 
(0.3 – 45ng/ml). The immunoreactivity of nitrotyrosine (NT), endothelial nitric oxide syn-
thase (eNOS), protein kinase B (p-Akt) and mammalian target of rapamycin (p-mTOR) 
were assessed in the aorta via immunohistochemistry (IHC) following the assessment of 
vasoactivity.Results: In the abdominal aorta, both 10ng/ml and 30ng/ml doses of ucOC did 
not significantly alter endothelium-dependent (acetylcholine) (Attached figure) or endothe-
lium-independent (sodium nitroprusside) blood vessel relaxation in aortic rings following 
incubation in 11mM or 20mM glucose solutions after either the normal or atherogenic diet (p 
> 0.05). In the carotid artery, ucOC treatment did not cause any alteration in vasoactivity at 
any dose of ucOC, compared to a control treatment following either the normal or atherogen-
ic diet (p > 0.05). Further, ucOC (10ng/ml and 30ng/ml) did not alter the immunoreactivity 
of NT, eNOS, p-Akt or p-mTOR in any group (p > 0.05).Conclusion: ucOC does not have a 
direct adverse effect on endothelial function in rabbit arteries. The improvement in endothe-
lial function previously reported with ucOC is likely to be as a result of improved glucose 
regulation, an indirect effect and not a direct regulatory effect on the vasculature.
Disclosures: Alexander Tacey, None
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Validation of the Hypoparathyroidism Patient Experience Scale (HPES): 
Understanding and Assessing Burden of Disease *Meryl Brod1, David B 
Karpf2, Alden Smith2, Jill Gianettoni2, Denka Markova2, Sanchita Mourya2, 
Lori McLeod3. 1The Brod Group, United States, 2Ascendis Pharma Inc., United 
States, 3RTI Health Solutions, United States
BackgroundHypoparathyroidism (HP) is an endocrine disorder characterized by absent 
or low levels of parathyroid hormone (PTH). Patients with HP, including those on standard-
of-care therapy (SoC), report debilitating physical and cognitive symptoms and reduced 
health-related quality of life. Assessing these HP impacts are critical for the optimal man-
agement of HP. The HPES-Symptom and HPES-Impact measures were developed accord-
ing to FDA guidance on development of patient reported outcome measures (PROs). These 
measures were assessed to evaluate the HPES structure, reliability, validity, and ability to 
respond to treatment. MethodsData come from 2 sources: a noninterventional observational 
study and a phase 2, multicenter, double-blind, placebo-controlled study of TransCon PTH. 
Key inclusion/exclusion criteria for both studies: age >=18 years; confirmed diagnosis of 
post-surgical, autoimmune or idiopathic HP and stable on SoC. ResultsThe analysis data 
set included 359 patients (observational study=300, clinical trial=59). For the observational 
study, factor analysis confirmed all a priori hypothesized domains (Symptom: Physical and 
Cognitive; Impact: Physical Functioning, Daily Life, Psychological Well-being, Social Life 
and Relationships). Internal consistency Cronbach’s alphas were high for total score and 
for all domains (Symptom=0.91-0.93; Impact=0.87-0.96). Test-retest reliability for subjects 
with no treatment change was acceptable with all values for total and domains with 0.70 in-
cluded within the 95% confidence intervals, with the exception of one domain. HPES validi-
ty was strong, with all a priori construct validity hypotheses supported by moderate to strong 
correlations with the exception of one domain which had mixed results (Symptom r=0.39-
0.72; Impact r=0.46-0.77) and significant discriminant validity values for groups based on 
global ratings, calcium levels and number of comorbid issues (Symptom p< 0.004; Impact 
p< 0.003 ). For the clinical trial, both measures were highly responsive to active treatment at 
Week 4 (Symptom p=0.0001; Impact p=0.0026).ConclusionThese data show that HP, even 
when a patient is stable on SoC, has a significant impact on both patients’ reported symp-
toms, overall functioning and well-being. The HPES Symptom and Impact are reliable, valid 
and responsive PRO measures of these impacts. Assessing HPES symptoms and impacts are 
key to studying new treatments and improving clinical care for patients with HP.
Disclosures: Meryl Brod, Ascendis Pharma A/S, Consultant
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Introduction: HPP is a rare, inherited, metabolic disease caused by low activity of tis-
sue nonspecific alkaline phosphatase (ALP). Due to multiple musculoskeletal and systemic 
manifestations, HPP in adults has a heterogeneous clinical presentation that can lead to mis-
diagnosis and substantial delays in diagnosis. Methods: To better understand the most com-
mon clinical profile of adults with HPP, this study analyzed data from 270 adults with HPP 
(>=18 years of age, low ALP and/or ALPL variant) from the Global HPP Registry. Results: 
Most adults were women (75.2%). The median age at registry enrollment was 50.0 years, 
and the median ALP activity was 25.0 U/L (normal range: 40–150 U/L). Review of medical 
histories showed that pain (74.8%) was the principal symptom, followed by dental manifes-
tations (60.4%) and skeletal manifestations (47.8%). Fatigue (35.2%) and muscle weakness 
(26.3%) were also reported. For adults with quality-of-life data, the median Short-Form-
36v2 (SF-36v2) Physical Component Score was 42.4 (range: 17.9, 63.3; n=203; population 
norm score=50). The median pain interference score based on the Brief Pain Inventory-Short 
Form (BPI-SF) was 3.3 (range: 0.0, 10.0; n=196; scale ranges from 0=does not interfere to 
10=completely interferes). Of 212 adults with available data, most (66%) reported some 
disability on the Health Assessment Questionnaire Disability Index (HAQ-DI). Treatment 
with enzyme-replacement therapy (asfotase alfa) was reported in 77/270 (28.5%) adults, 
while 193/270 (71.5%) adults had never received treatment. Demographics and baseline 
ALP activity were similar between treated and untreated adults. Treated adults reported 
poorer quality of life before treatment initiation and had a higher occurrence of pain, dental 
issues, recurrent and poorly healing fractures/pseudofractures, fatigue, and muscle weakness 
compared with untreated adults. Conclusions: These results establish pain, dental manifesta-
tions, skeletal manifestations, fatigue, and muscle weakness as the principal symptoms char-
acterizing the real-world clinical profile of adults with HPP. For clinicians taking medical 
histories, it is important to recognize that the most common symptoms of HPP may not be 
immediately associated with bone disease.
Disclosures: Kathryn M. Dahir, Alexion Pharmaceuticals, Inc., Consultant
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Risk Factors for the Development of Heterotopic Ossification After Hip 
Arthroplasty: A Retrospective Review *Sukhmani Singh1, Joseph Kidane1, 
Kelly Wentworth1, Saam Morshed1, Edward Hsiao1. 1UCSF, United States
Purpose: Heterotopic ossification (HO) is a process where normal bone forms in soft 
tissue. It arises as a complication of trauma, surgery and inflammation. Risk factors for de-
velopment of HO include male gender, spinal cord injury, and bone producing diseases like 
ankylosing spondylitis [1]. We investigated other risk factors associated in the development 
of HO after total hip arthroplasty and acetabular repair.Methods: A retrospective review 
of medical records was performed for individuals who underwent total hip arthroplasty or 
acetabular repair surgeries (CPT 27130, 27076, 27137, 27220, 27222, 27226, 27227, 27228, 
27254, 29915) from September 2010 to October 2019. Demographics, anthropometrics, 
length of hospital stay, medication use and comorbid conditions were obtained. Logistic 
regression was used to identify predictors for HO development.Results: A total of 4373 pa-
tients who underwent surgery were identified (2038 men and 2335 women, mean age at 
procedure: 59.2+/-15.6 years). The incidence of HO development was 2.6% (N=115). The 
average age was 58.8+/-15.7 years in those who did not develop HO compared to 62.7+/-
13.2 years in those who did. The average length of stay was 2.92+/-3.0 days in non-HO 
group vs 3.23+/-1.7 days in the HO group. A larger proportion of individuals in the HO 
group had spinal cord injury or spine disease (20% vs 7.7%, p<0.001), osteoporosis (44.4% 
vs 16.7%, p<0.001), unspecified diabetes type (8.7% vs 2.4%, p<0.001), type 2 diabetes 
(36.5% vs 16.4%, p<0.001), prior motor vehicle accidents (9.6% vs 5.2%, p=0.042), vita-
min D deficiency (33.0% vs 10.9%, p<0.001), and were post-menopausal (40% vs 16.7%, 
p<0.001). Significant predictors for HO development were African American race (OR 4.44, 
p=0.010, 95% CI 1.42-13.87), osteoporosis (OR 2.11, p=0.006, 95% CI 1.24-3.59), diabetes 
(OR 2.38, p=0.039, 95% CI 1.04-5.44), vitamin D deficiency (OR 1.85, p-0.020, 95% CI 
1.10-3.10) and use of NSAIDs within 14 days of surgery (OR 0.58, p=0.038, 95% 0.35-
0.97). A low estrogen state (post-menopausal status and amenorrhea patients combined) was 
associated with HO development but was non-significant (OR 1.69, p=0.056, 95% CI 0.99-
2.88).Conclusions: Risk factors of African American race, diabetes, osteoporosis, vitamin D 
deficiency and potentially low estrogen states carry an increased risk for development of HO 
and may benefit from HO prophylaxis.References: [1] Kurz AZ, Leroux E, Riediger M, et 
al. Curr Rev Musculoskelet Med. 2019;12(2):147-155
Disclosures: Sukhmani Singh, None
P-004
Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients 
*Betsy Szeto1, Jason E. Zucker2, Elijah D. LaSota2, Mishaela R. Rubin2, Marcella 
D. Walker2, Michael T. Yin2, Adi Cohen2. 1Columbia University Vagelos College 
of Physicians and Surgeons, United States, 2Columbia University Irving Medical 
Center, United States
Populations severely affected by COVID-19 are also at risk for vitamin D (VitD) defi-
ciency. Common risk factors include older age, chronic illness, obesity, and non-Caucasian 
race. Countries most affected by VitD deficiency also have had the highest COVID-related 
mortality. VitD levels, deficiency and/or receptor polymorphisms may play a role in im-
mune function and have been associated with risk for respiratory infections and failure, 
susceptibility and response to therapy for enveloped virus infection, and immune-mediated 
inflammatory reaction. We hypothesized that vitD deficiency may be a risk factor for severi-
ty of COVID-19 respiratory and inflammatory complications.Among the first 700 COVID+ 
nonpregnant adults with COVID-related admissions at Columbia University Medical Cen-
ter [median (IQR): aged 63(IQR:50–74) yrs, 43% female, BMI 28.3 (IQR:24.6–33.3) kg/
m2], 22% were intubated and mortality was 21%.We searched health records for serum 
25-hydroxy VitD levels measured within 12 months of admission. VitD deficiency was 
defined as <20 ng/mL. Outcomes included discharge status, mortality, length of hospital 
stay, intubation, length of intubation, need for dialysis, and peak  levels of inflammatory 
markers: erythrocyte sedimentation rate, c-reactive protein, ferritin, interleukin 6.VitD lev-
els were available in 93/700 [vitD: 25 (IQR:17–33) ng/mL; measured 136 (IQR:75–248) 
days preadmission]. Compared to those without vitD levels, those with vitD measurements 
did not differ in age, BMI or the distribution of sex and race, but were more likely to have 
ICD-defined hypertension, diabetes, chronic kidney disease and pulmonary disease.Those 
with VitD deficiency (n=35) did not differ from those with vitD >=20ng/mL in terms of 
age, sex, race, BMI, or comorbidities. VitD deficiency tended to be associated with younger 
age and a lower frequency of preexisting pulmonary disease. There were no between-group 
differences in any outcome including intubation (29 vs 17%, p=0.2). Results were similar 
in those over 50 yrs (n=75;intubation 30 vs 17%; p=0.2) and in male/female only cohorts. 
There was no relationship between vitD as a continuous variable and any outcome, even 
after controlling for age and pulmonary disease. In summary, preliminary data do not clearly 
support a relationship between vitD status and COVID-19 clinical outcomes. Larger studies 
with VitD measurements on samples obtained at the time of hospital admission may better 
address this hypothesis.
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Diagnosis of Adult-Onset Hypophosphatasia Presenting with Metatarsal 
Stress Fracture: Proof-of-Concept for a Case Finding Strategy *Kenna 
Koehler1, Said Atway2, James Pipes2, Steven Ing3. 1The Ohio State University 
College of Medicine, United States, 2The Ohio State University Wexner Medical 
Center Department of Orthopaedics, Division of Podiatry, United States, 3The 
Ohio State University Wexner Medical Center Department of Internal Medicine, 
Division of Endocrinology, Diabetes & Metabolism, United States
Background: Hypophosphatasia (HPP) is a rare metabolic bone disorder due to loss-
of-function mutations in ALPL that encodes tissue nonspecific alkaline phosphatase (ALP), 
resulting in decreased activity of ALP, an enzyme largely responsible for skeletal mineral-
ization. Adult-onset HPP includes metatarsal stress fractures (MSF). Population prevalence 
of HPP is estimated at 1/6370 (0.016%). The primary objective was to determine how many 
cases of metatarsal fractures and low ALP levels presenting to our medical center’s podi-
atry clinic have an ALPL mutation and to phenotype their clinical course and symptoms.
Methods: We queried our Electronic Health Record (EHR) for patients (age >= 18 years) 
presenting with MSF and metatarsal fracture (MF) (by ICD-9 and ICD-10CM codes) from 
10/1/2011 to 10/1/2017 and who had a serum ALP concentration measured at some time. 
Patients with low ALP values (reference range, 38-126 U/L before and 32-126 U/L after 
6/24/2013, when a new assay platform was implemented) were eligible to receive genetic 
testing for ALPL (Prevention Genetics) and complete surveys: Short Form 36 version 2 
(SF36v2), Brief Pain Inventory-Short Form (BPI), and Health Assessment Questionnaire 
Disability Index (HAQ). Cases with and controls without ALPL pathogenic mutation were 
compared by survey scores and clinical variables relevant to the fracture. We present de-
scriptive data due to small sample size.Results: In 1611 patients with MSF/MF, 937 had ALP 
measurements and of these, 13 (1.4%) had low ALP. In 8 patients consenting to participate, 
2 had heterozygous pathogenic ALPL mutations. Pathogenic ALPL mutations were found in 
0.12% (2/1611) with MSF/MF, 0.21% (2/937) in MSF/MF & ALP value, and 15% (2/13) 
in MSF/MF & low ALP. Mean ALP in cases was 32.5 U/L (range, 30-35) and in controls 
was 29.2 U/L (range, 23-35). Cases vs. controls rated lower scores on 8/8 scales and both 
physical component (30.5 vs. 56.5) and mental component (45.1 vs. 56.8) scores on SF36v2 
(range, 0-100); higher scores for worst pain (8.0 vs. 0.8) and average pain (6.0 vs. 0.7) on 
the BPI (range, 0-10); and higher standard disability score (1.4 vs. 0) on the HAQ (range, 
0-3).Conclusion: These data provide proof-of-concept for HPP case identification in patients 
presenting to podiatry clinics with MSF/MF. Review of EHR for low ALP levels may be 
useful for consideration of HPP diagnosis and supports the need for a prospective study to 
determine an optimal case finding strategy.
Disclosures: Kenna Koehler, None
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The Voices of Hypopara Survey: Journey of Patients Living with 
Hypoparathyroidism *Danette Astolfi1, Deb Murphy1, Bob Sanders1, Loretta 
Gulley1, Ami Knoefler2, Minyoung Park2, Susana Tsao2, Sanchita Mourya2, 
Mishaela Rubin3. 1HypoPARAthyroid Association, Inc., United States, 2Ascendis 
Pharma Inc., United States, 3Columbia University, United States
BackgroundHypoparathyroidism (HP) is a rare disease that is characterized by insuf-
ficient levels of parathyroid hormone, resulting in hypocalcemia, hyperphosphatemia and 
hypercalciuria. Standard of care (SoC) consists of calcium and active vitamin D supplemen-
tation. The HypoPARAthyroidism Association (HPA) is a nonprofit organization dedicated 
to improving the lives of HP patients. The HPA developed the “Voices of Hypopara” survey 
to characterize the patient journey of HP individuals in the US.MethodsThe online survey 
was distributed to all HPA members in May 2020. Questions focused on evaluating patients’ 
experiences including diagnosis, treatment, quality of care, and impact on daily living.Re-
sultsThe survey was completed by 146 HPA members (89% female; mean age 51). The 
majority of participants (80%) were diagnosed with post-surgical HP. Diagnosis of HP was 
delayed >6 months in 55% of participants despite symptoms of chronic HP; 51% underwent 
>5 physician visits before obtaining a HP diagnosis. The most frequently cited challenges 
included the impact of HP on quality of life (87%), long-term complications (87%) and 
daily symptoms (78%).Most participants reported they are currently taking SoC (calcium in 
91%; active vitamin D in 77%). However, over half felt that this did not optimally address 
their disease and 29% were extremely concerned about hypocalcemia despite supplementa-
tion. Many (69%) felt that taking SoC was moderately to extremely burdensome. Almost all 
participants (97%) had to adjust their regimens over the course of their disease, with 61% 
adjusting >5 times since diagnosis.More than two-thirds (69%) of participants reported a 
“calcium crash” (sudden hypocalcemia symptoms requiring medical attention) in the past 
year; of these, 43% reported calcium crashes monthly or weekly. Almost half (42%) of all 
participants visited an emergency room/urgent care in the last year as a result of HP symp-
toms; of these, 56% believed that the staff was inexperienced with management of a calcium 
crash.ConclusionsThis survey, one of the largest conducted in HP patients, demonstrates key 
gaps in HP management. These findings underscore the limitations of SoC and the urgent 
need for greater disease and treatment understanding to best support patients with HP.
Disclosures: Danette Astolfi, None
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Risk Factors for Multifocal Disease in Patients with Glucocorticoid Induced 
Avascular Necrosis *Alexandra Krez1, Joseph Lane 2, Kyung Park-Min2, Kaichi 
Kaneko2, Tania Pannellini2, Derek Hansen2, Douglas Mintz2, Donald McMahon2, 
Richard Bockman2, Emily Stein1. 1Hospital for Special Surgery, United States, 
2Hospital for Special Surgery, United States
Osteonecrosis is a debilitating musculoskeletal condition that results in significant pain 
and compromised quality of life. Blood supply to bone is interrupted leading to death of 
bone cells which often results in mechanical failure and joint destruction. Patients may have 
multiple joints affected, compounding their pain and disability. While glucocorticoid (GC) 
use is a common cause of atraumatic osteonecrosis, the specific features of GC therapy that 
increase risk of multifocal disease are poorly understood. This study investigated risk factors 
for multifocal disease (MON) in patients with GC-induced osteonecrosis. We hypothesized 
that patients with the highest cumulative GC exposure have the greatest risk of MON. Fif-
ty-five adults with GC-induced osteonecrosis were prospectively enrolled. MON was de-
fined as osteonecrosis in >= 3 joints. Total cumulative dose, average dose, peak dose and 
duration were calculated separately as prednisone equivalents for oral and IV GCs. Mean 
age of subjects was 44+/-17 years, 58% women. The most common indications for GCs were 
rheumatologic disease and hematologic malignancy. Half of subjects had an additional risk 
factor for osteonecrosis: systemic lupus erythematosus (29%), acute lymphoblastic leukemia 
(11%), HIV (9%) and alcohol use > 320 g/week (4%). Mean daily oral dose of GCs was 29 
+/- 34 mg, duration 5.4 +/- 7.7 years. Average cumulative oral dose was 29,847 +/- 35,467 
mg. Half of the cohort received both IV and oral GCs. Surgical intervention was performed 
in 73%: 69% total arthroplasty and 31% core decompression. MON was found in 36%. 
Among all features of oral and IV GC exposure, the best predictor of MON was cumulative 
oral GC dose. For each increase of 1,000 mg, risk of MON increased by 3.2% (95% CI = 
1.03, 1.67). GC exposure in the first 6 months of therapy, peak dose (oral or IV) and mean 
daily dose did not independently increase risk of MON. In summary, among patients with 
GC-induced osteonecrosis cumulative oral GC dose was the best predictor of multifocal 
disease. Our findings indicate that high initial doses of IV and oral glucocorticoids, often 
necessary to rapidly reduce inflammation, may not increase risk of MON as much as total 
cumulative dose. They suggest that strategies for reducing the risk of MON in GC treated 
patients be aimed at lowering total cumulative exposure. Further research is needed to better 
define optimal strategies for prevention and treatment of MON.
Disclosures: Alexandra Krez, None
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Quantitative histone acetylation analysis of GATA3 and PAX1 transcription 
factor genes in primary hyperparathyroidism *PRIYANKA SINGH1, 
Ashutosh Arya2, Divya Dahiya3, Uma Nahar Saikia4, Jyotdeep Kaur4, Naresh 
Sachdeva3, Sanjay Bhadada4. 1PhD, India, 2PhD, India, 3Associate Professor, 
India, 4Professor, India
Introduction: Loss of histone acetylation is associated with tumorigenesis and may act 
as a potential biomarker for detecting cancer. The aim of the present study was to explore the 
histone acetylation status (H3K9ac) of the GATA3 and paired box 1 (PAX1) developmental 
transcription factor genes in a spectrum of parathyroid tumor in an Indian population.Ma-
terials and methods: A total of 40 parathyroid adenomas and 10 normal parathyroid tissue 
were recruited for the study. Gene expression analysis was done by quantitative real time 
PCR (qRT-PCR) and histone acetylation analysis was performed by chromatin immuno-
precipitation (ChIP) -qPCR.Results: The qRT-PCR analysis showed significantly reduced 
expression of GATA3 and PAX1 in parathyroid adenoma when compared to normal parathy-
roid samples with fold reduction of 0.25+/-0.22 (p <=0.0001) and 0.18+/-0.21 (p <=0.0001) 
respectively. However, expression of PAX1 was inversely related to serum calcium (r= 
-0.54; p=0.03) and plasma iPTH (r= -0.61; p = 0.01) but not with other clinicopathological 
parameters. We found active histone mark i.e. H3K9ac was decreased by 3 fold (p= 0.01) 
at GATA3 and 6.2 fold (p= 0.004) at PAX1 promoter gene in sporadic parathyroid adenoma 
compared to control parathyroid samples. A strong positive correlation between H3K9ac and 
mRNA expression of GATA3 (r= 0.58; p= 0.01) and PAX1 (r= 0.63; p= 0.003) was observed 
respectively.Conclusion: Our study reported the altered expression of GATA 3 and PAX1 in 
parathyroid adenoma. Thus, suggesting the role of histone deacetylation in altered expres-
sion of GATA3 and PAX1 might possible epigenetic regulator for parathyroid tumors and is 
crucial for diagnostic purposes.Sources of research support: DST-SERB 2018 and PGIMER 
Intramural Research Grant 2016.
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Factors associated with volumetric bone mineral density in people with 
severe obesity *Anne-Frédérique Turcotte1, Suzanne N Morin2, Fabrice Mac-
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University, Québec City, Canada, Canada, 4Department of Kinesiology and 
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Lung Institute Research Centre, Quebec City, Canada; Department of Medicine, 
Laval University, Quebec City, Canada, Canada
Context: People with severe obesity are at increased risk of fracture. The mechanisms 
of bone fragility in obesity remain unclear but factors such as higher visceral adipose tissue 
(VAT), hyperglycemia, advanced glycation end-products (AGEs) and poor muscle strength 
due to muscle fat infiltration could be implicated.Objective: We explored the association 
of the above-mentioned factors with volumetric bone mineral density (vBMD) at the lum-
bar spine and hip in people with severe obesity before bariatric surgery.Methods: We used 
baseline data from an ongoing prospective observational study investigating the impact 
of bariatric surgery on bone health. Quantitative computed tomography (QCT) was used 
to assess lumbar spine (L2-L3), total hip and femoral neck (FN) vBMD using Mindways 
QCTPro software. Spearman correlations before and after adjustment for age and sex were 
used to explore the correlations between total vBMD at each site and body weight, BMI, 
VAT (CT at L2-L3), glycemic control using glycated hemoglobin (HbA1C), AGEs levels 
by non-invasive skin auto-fluorescence (AGE Reader) and muscle strength (handgrip and 
Biodex-measured knee extensor strength).Results: 29 participants were included (22F/7M, 
mean age 47.2+/-8.2 y, mean BMI 42.9+/-6.6 kg/m2, 66% with type 2 diabetes). Significant 
inverse correlations were found between L2-L3 vBMD and visceral fat (r=-0.45, p=0.02), 
HbA1C (r=-0.51, p=0.005) and AGEs (r=-0.55, p=0.002), and a positive correlation with 
knee extensor strength (r=0.44, p=0.02). We also found a significant inverse correlation 
between total hip vBMD and HbA1C (r=-0.51, p=0.006), and a positive correlation with 
knee extensor strength (r=0.38, p=0.05). Finally, FN vBMD was inversely correlated with 
AGEs (r=-0.44, p=0.02) and visceral fat (r=-0.40, p=0.04). After adjusting for age and sex, 
correlations only remained statistically significant between L2-L3 vBMD and knee extensor 
strength (r=0.40, p=0.05), and between total hip vBMD and HbA1C (r=-0.40, p=0.05). No 
correlations were found with body weight, BMI, and handgrip strength.Conclusion: Our 
preliminary results suggest that after taking into account age and sex, lower HbA1c and 
lower limb muscle strength are associated with higher vBMD at the hip and lumbar spine in 
people with severe obesity.
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Analysis of bone status by 3D DXA measures in patients with acromegaly 
or growth hormone deficiency *Manuel Muñoz-Torres1, Sheila González-
Salvatierra2, Antonia García-Martín3, María Dolores Avilés-Pérez4, Enrique 
Moratalla-Aranda5, Diego Becerra-García5, Beatriz García-Fontana3, Luis 
Gracia-Marco6. 1Bone Metabolic Unit, Endocrinology and Nutrition Division. 
Hospital Universitario San Cecilio. Instituto de Investigación Biosanitaria 
de Granada (Ibs.GRANADA); CIBERFES, Instituto de Salud Carlos III; 
Department of Medicine. Universidad de Granada, Spain, 2Bone Metabolic 
Unit, Endocrinology and Nutrition Division. Hospital Universitario San 
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Department of Medicine. Universidad de Granada, Spain, 3Bone Metabolic 
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CIBERFES, Instituto de Salud Carlos III., Spain, 41. Bone Metabolic Unit, 
Endocrinology and Nutrition Division. Hospital Universitario San Cecilio. 
Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA); 
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Health Through Physical Activity” Research Group, Sport and Health University 
Research Institute (iMUDS), Department of Physical and Sports Education, 
Faculty of Sport Sciences, University of Granada, Spain
Purpose: Growth hormone (GH) and insulin-like growth factor-I (IGF-I) exert signifi-
cant actions on the adult skeleton. Acromegaly and adult growth hormone deficiency (GHD) 
can be associated with an increased risk of bone fragility. However, areal dual-energy x-ray 
absorptiometry (aDXA) does not capture bone quality or discriminate trabecular and cortical 
compartment. We aimed to explore the hypothesis that 3D-DXA would be useful in the bone 
evaluation of patients with GHD and acromegaly.Patients and methods: This cross-sectional 
study includes 20 patients with acromegaly (mean age 54.8 +/- 11.5.6 years; 75% women), 
14 patients with GHD (mean age 57.4 +/- 12.3 years; 78% women) and 40 healthy subjects 
matched by gender and age (mean age 56.1 +/- 12.8 years). Areal bone mineral density 
(aBMD) at femoral neck (FN), trochanter, shaft and total hip (TH) was determined by con-
ventional DXA (Hologic QDR 4500). Volumetric bone mineral density (vBMD) at corti-
cal and trabecular compartments as well as cortical surface bone mineral density (sBMD) 
and cortical thickness at total hip was evaluated using the 3D-Shaper software (v2.6, Galgo 
Medical).Results: 3D-DXA parameters showed poorer cortical vBMD (p=0.004) and inte-
gral vBMD (p=0.048) in the GHD group compared to the control group and higher cortical 
sBMD (p=0.003) and cortical vBMD (p=0.0024) in the ACRO group compared to the GHD 
group. More specifically, the cortical vBMD, integral vBMD and cortical sBMD was 7.3%, 
8.4% and 9.9% lower in the GHD group compared to the control group and; 16.2%, 8.5%, 
12.2% and 7.3% higher in the ACRO group compared to the GHD group for the cortical 
sBMD, cortical vBMD, integral vBMD and cortical thickness, respectively.Conclusions: 
According to our results, new techniques applied to DXA provide additional information on 
bone in states of deficiency or excess of GH.
Disclosures: Manuel Muñoz-Torres, None
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Frequency and Causes of Elevated Bone Mass: The French Multicentre 
Elevated Bone Mass Study *JULIEN PACCOU1, Rose-Marie Javier2, Isabelle 
Henry-Desailly3, Aurore Nottez1, Isabelle Legroux-Gérot1, Camille Ternynck1, 
Eric Lespessailles4, Pascal Guggenbuhl5, Sami Kolta6, Bernard Cortet1. 1Lille 
University Hospital, France, 2Strasbourg University Hospital, France, 3Amiens 
Picardie University Hospital, France, 4University of Orleans, France, 5University 
of Rennes, France, 6Cochin Hospital, Assistance Publique-Hôpitaux de Paris, 
France
IntroductionReports of Elevated bone mass (EBM) on routine Dual energy X-Ray Ab-
sorptiometry (DXA) scanning are not infrequent. However, epidemiological studies of EBM 
are few and definition thresholds variable. The purpose of this French multicentric study 
was to evaluate the prevalence and causes of EBM in adult patients who underwent DXA 
scanning over a 10-year period.Material and methodsThis multicentric, retrospective study 
was conducted in six French regional bone centres (Amiens, Lille, Orléans, Paris, Rennes, 
and Strasbourg). DXA databases were initially searched for individuals with a bone mineral 
density (BMD) Z-score >=+4 at any site in the lumbar spine or hip from April 1st, 2008 to 
April 30st, 2018.ResultsThe number of patients who had at least one DXA scan was 72,225, 
of which 66% were women. Of these 72,225 patients, 909 had a Z-score >=+4 at any site, i.e. 
a prevalence of 1.26% [1.18%-1.34%]. The DXA scans, imagery and medical records of 322 
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men and 587 women with EBM were reviewed to assess causes. In a few patients, EBM was 
attributed to several causes, which explains the difference between the total number of caus-
es (n=936) and the total number of patients (n=909). An artefactual cause was found in 752 
patients (80%) with EBM (mostly degenerative disease of the spine in 613 patients (65%)), 
and an acquired cause of focal EBM was found in 12 patients (1%) including sclerotic bone 
metastases (n=3), Paget’s disease (n=7), and fibrous dysplasia of bone (n=2). An acquired 
cause of generalized EBM was found in 84 patients (9%), with renal osteodystrophy (n=32), 
followed by haematological disorders (n=20, e.g. myeloproliferative syndromes and masto-
cytosis), hypoparathyroidism (n=15) and diffuse bone metastases from solid cancer (n=12). 
Of the remaining causes, rare hereditary diseases (e.g. X-linked hypophosphatemia and os-
teopetrosis) and unexplained EBM were found in 19 (2%) and 69 (7%) cases, respective-
ly. ConclusionThe prevalence of EBM (Z-score >=+4 at any site) is 1.26% [1.18%-1.34%]. 
In nearly all instances (93%) the explanation for EBM came from the medical record and 
conventional investigation. This study suggests that the main cause of EBM is degenerative 
disease of the spine. However, EBM can also reveal acquired or hereditary diseases.
Disclosures: JULIEN PACCOU, None
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Potential Interactions between SQSTM1, KEAP1 and PARK2 in Paget’s 
Disease of Bone *Yvette Oppong1, Britta Petersen1, Cynthia Alander1, Marc 
Hansen1. 1Center for Molecular Oncology, UConn School of Medicine, United 
States
Paget’s Disease of Bone (PDB) is a metabolic disease resembling excessive bone re-
modeling causing disorganized, structurally weak bone. The genetic etiology of PDB is 
heterogeneous, but a significant portion is attributed to mutations in the SQSTM1 gene. 
The SQSTM1 gene product (p62) is a 62kD protein linked to a number of cellular processes 
including autophagy. KEAP1 and PARK2 are proteins that have been shown to interact with 
p62 during autophagy. The hypothesis is that mutations in SQSTM1 associated with PDB 
could alter KEAP1 and/or PARK2 interaction with p62. A wildtype osteoblastic cell line 
(hFOB1.19) and a marrow stromal cell line developed from a pagetic lesion (PSV10) were 
treated with a combination of 15nM 1α,25-(OH)2D3 (VitD) and 1µg/ml lipopolysaccharide 
(LPS) with or without 1µM Simvastatin, a drug that blocks p62 activity in autophagy. The 
cells were then fixed and analyzed by immunofluorescence using antibodies against RELA, 
KEAP1 or PARK2. Activation of RELA (a known downstream target of p62 activation), 
KEAP1 and PARK2 were detected by changes in cellular localization of these proteins to 
the nucleus. Results, as measured by nuclear accumulation, showed activation of RELA in 
the PSV10 but not hFOB1.19 cells in response to the low dose VitD and LPS. Simvasta-
tin addition appeared to eliminate this activation. There was also nuclear accumulation of 
KEAP1 in the PSV10 cells following VitD and LPS stimulation, which was again blocked 
by Simvastatin addition. However, for PARK2, while there was nuclear accumulation in the 
PSV10 cells following LPS and VitD stimulation, Simvastatin addition did not eliminate the 
nuclear accumulation of PARK2. In conclusion, VitD and LPS appeared to activate RELA, 
KEAP1 and PARK2 in PSV10 cells but not hFOB1.19 cells. Simvastatin appeared to sup-
press activation of RELA and KEAP1 but not PARK2 in the PSV10 cells. This suggests that 
mutations in SQSTM1 associated with PDB may play different roles in activating RELA, 
KEAP1 and PARK2 and that Simvastatin affects only some of those roles.
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Vitamin D3 (D3) supplementation in subjects with primary 
hyperparathyroidism (PHPT): evaluation of safety and biochemical 
response *STHEFANIE GIOVANNA PALLONE1, Monique Nakayama Ohe1, 
Livia Marcela Santos1, Isabela Ohki Nacaguma1, Renata Elen Costa Silva0, Ilda 
Sizue Kunii1, José Gilberto Vieira1, Marise Lazaretti-Castro1. 1Federal University 
of São Paulo, Brazil, 0Federal University of São Paulo, Brazil
Introduction: Vitamin D deficiency is common in PHPT, which frequently is associat-
ed with a secondary hyperparathyroidism component. Therefore, it is essential to improve 
the levels of 25hydroxyvitamin D (25OHD), avoiding a higher elevation of PTH and its 
deleterious consequences in bone quality. However, the safety of 25OHD replacement in 
such patients is uncertain, given the risk of worsening of hypercalcemia. Objective: We 
aim to evaluate the effectivity of 14,000 UI/week D3 supplements on subjects with PHPT 
and healthy controls to achieve 25OHD levels above 30 ng/mL and the safety regarding 
hypercalcemia by analyzing (tCa) and ionized calcium (iCa). Materials and methods: We 
studied 54 patients with PHPT prior surgery and 65 healthy age-and-sex-matched subjects 
prospectively for 12 weeks with the administration of 14,000 IU of D3 weekly. Exclusion 
criteria were: taking Vitamin D supplementation in the last 3 months, creatinine clearance < 
45 and use of calcimimetics. Fasting blood samples were collected at baseline and the end 
of the study and used a general linear model with repeated measures approach to investigate 
the main effect of time and diagnosis, and diagnosis x time interactions. Results: At base-
line, 25OHD levels were similar in both groups (42.8% of subjects in the PHPT group and 
52% of healthy subjects had levels of 25OHD <20 ng / mL. p-value=0.342). The mean of 
tCa and iCa were higher in PHPT than in controls.  Diagnosis groups also differed in PTH 
values, as expected in these populations. The mean values of 25OHD increased over time 
in both groups (achieving the goal of 30 ng/mL), albeit more intensively among controls. 
The administration of D3 did not significantly change tCa, iCa, or PTH (Table 1). Conclu-
sion: Vitamin D3 14000 UI administered weekly for 12 weeks successfully raised 25OH 
D levels to a goal of 30 ng/ml without changes in calcemia in PHPT and control subjects, 
demonstrating the effectivity and the safety of this dosage in these patients. The impact of D3 
replacement on 25OHD levels differed between PHPT and controls, with a smaller increase 
among PHPT patients.
Disclosures: STHEFANIE GIOVANNA PALLONE, None
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Vitamin D, Glucose and Lipid Metabolism: Analysis in Healthy Subjects 
*Vittoria Danese1, Cristiana Cipriani1, Federica Ferrone1, Jessica Pepe1, Luciano 
Colangelo1, Mario Renella1, Valentina Piazzolla1, Viviana De Martino1, Luciano 
Nieddu2, Frank Blocki3, Salvatore Minisola1. 1Department of Clinical, Internal, 
Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 
Italy, 2Faculty of Economics, UNINT University of Rome, Italy, 3DiaSorin Inc, 
United States
Purpose. The study aimed to evaluate the mutual relationship between vitamin D, 
glucose and lipid metabolism in a large cohort of healthy subjects.Methods. We studied 
1240 blood donors (age range 18-68 years). We excluded subjects treated with drugs that 
may affect mineral metabolism. In all subjects, we measured serum 25-hydroxy-vitamin D 
[25(OH)D], parathyroid hormone (1-84PTH, hereafter PTH) and 1,25(OH)2D by chemilu-
minescence-immunoassay (LIAISON® and LIAISON XL®); ionized calcium (Ca++) and 
magnesium (Mg++) by biochemical analyzer NOVA 8; serum total and HDL cholesterol, tri-
glycerides, and plasma glucose by enzymatic test with the Cobas c 311 analyzer (Cobas®); 
serum LDL was calculated by the Friedewald formula: LDL cholesterol = total cholesterol 
- HDL - (triglycerides/5).Results. Table 1 shows demographic and anthropometric character-
istics and laboratory findings in all subjects. We observed significant negative associations 
between serum 25(OH)D and BMI (R= -0.11, p<0.0001), PTH (R= -0.16, p<0.0001), total 
cholesterol (R= -0.06, p<0.05), and triglycerides (R= -0.13, p<0.0001). Conversely, serum 
25(OH)D was positively associated with 1,25(OH)2D (R= 0.12) and creatinine (R= 0.17) 
(p<0.0001 for all). Interestingly, there was a significant direct association between serum 
PTH and total (R= 0.08, p<0.01) and LDL cholesterol (R= 0.1, p<0.001), triglycerides (R= 
0.09, p<0.01) and glucose (R= 0.15, p<0.0001); serum PTH inversely correlated with HDL 
cholesterol (R= -0.09, p<0.01). In the group of subjects with serum 25(OH)D < 20 ng/mL 
(n=670), the associations between PTH, glucose and lipid metabolism were substantially 
maintained: total (R= 0.07, p=0.06) and LDL cholesterol (R= 0.09, p<0.02), glucose (R= 
0.19, p<0.0001); HDL cholesterol (R= -0.08, p<0.05). When we divided the cohort in two 
groups according to PTH levels below (n=1155) and above (n=85) the upper limit of normal 
(36.6 pg/mL), PTH positively correlated with total (R= 0.08, p<0.01) and LDL cholesterol 
(R= 0.11, p<0.001), triglycerides (R= 0.08, p<0.01), glucose (R= 0.14, p<0.0001), and neg-
atively with HDL cholesterol (R= -0.09, p<0.01) in subjects whose PTH was < 36.6.Con-
clusions. Our study demonstrates that within the scope of the vitamin D-PTH axis, glucose 
and lipid metabolism are mutually related and influenced. Hypovitaminosis D appears to 
predispose towards worse glucose and lipid profiles, as impacted directly by the action of 
PTH. Conversely, while higher serum PTH levels per se have no relationship with glucose 
and lipid metabolism, they do associate with higher levels of bad LDL cholesterol.
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Evaluating quality of life and symptoms in primary hyperparathyroidism 
*Raghad Alyousefi1, Sunnah Aziz1, Afroze Abbas2, Rebecca Sagar2. 1University 
of Leeds, United Kingdom, 2Leeds Teaching Hospitals Trust, United Kingdom
Background: Patients with symptomatic primary hyperparathyroidism (PHPT) are 
usually considered for parathyroidectomy, the gold-standard treatment for this condition. 
Identifying symptomatic patients is challenging as symptoms are non-specific. Assessing 
quality of life is not routinely objectively evaluated pre or post-surgery. Our study aims to 
both assess evaluation of symptoms in PHPT and validate these against quality of life out-
comes. Methods: We prospectively collected data on 101 UK patients with confirmed PHPT. 
2 questionnaires were completed, 1 a validated symptom scoring tool (Pasieka, Pasieka et 
al), the other assessed quality of life (PHPQoL, Webb et al). Data analysed included demo-
graphics, biochemistry and questionnaire scores. For Pasieka the higher the score, the more 
symptomatic. A score >200 has been validated as symptomatic. Conversely, the lower the 
score in PHPQoL questionnaire, the worse the quality of life. Results: 89% of the patients 
were female. Median age was 84 years (21-91). Time since diagnosis ranged from 0-5.5 
years. Mean serum calcium at time of questionnaire was 2.68mmol/L +/- 0.1, mean PTH 
was 17.6 pmol/L +/- 9.1. 82% of patients had a Pasieka score >200, mean 529 +/- 310. 
PHPQoL mean score was 49 +/- 23. There was significant negative correlation between 
Pasieka and PHPQoL score (r2= 0.69, p<0.0001). We compared different symptom groups 
(neurocognitive, fatigue, bone pain, thirst and other). PHPQoL scores for neurocognitive 
and fatigue symptoms were significantly higher than scores for bone pain (p=0.001 and 
p=0.003 respectively). Similar results were seen in Pasieka with neurocognitive and fatigue 
symptoms the highest scoring, ‘other’ symptoms scored lowest. Calcium and PTH were not 
correlated with Pasieka (p=0.30 and p=0.74 respectively) nor PHPQoL (p=0.81 and p=0.59).
Conclusion: Our study shows the PHPQoL and Pasieka tools correlate strongly in this UK 
cohort, demonstrating the significant impact of PHPT symptoms on quality of life. Degree 
of biochemical derangement was not predictive of symptoms/quality of life. Neurocognitive 
and fatigue domains were scored more highly than others on both tools. Thus, routine use of 
PHPQoL may detect subtle neurocognitive impacts of PHPT and facilitate patient selection 
for surgery. Post-surgery, clinical focus is on normalisation of biochemical indices, but in 
the future tracking change in quality of life may better assess impact on patient well-being.
Disclosures: Raghad Alyousefi, None
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Bone Health in Type 1 Diabetes with and without Neuropathy; a Cross-
Section Study *Tatiane Vilaca1, Margaret Paggiosi1, Fatma Gossiel1, Dinesh 
Selvarajah2, Jennifer Walsh1, Richard Eastell1. 1Academic Unit of Bone 
Metabolism, The University of Sheffield, United Kingdom, 2Department of 
Oncology and Metabolism, The University of Sheffield, United Kingdom
Background Fracture risk is increased in diabetes, especially in type 1 diabetes. The 
underlying mechanisms are not fully established. Some evidence suggests that abnormalities 
in microarchitecture might be involved, especially in patients with microvascular disease.
Methods We assessed bone microarchitecture (high resolution peripheral quantitative com-
puted tomography) and bone turnover markers (CTX and PINP) in patients with type 1 
diabetes with (T1DN+, n=20) and without (T1DN-, n=20) distal symmetric polyneuropathy 
and healthy controls (n=20). Participants were scanned at the standard site and at 14% bone 
length at the radius and tibia.  Results At the 14% length site, favourable trabecular microar-
chitecture was found in T1DN- compared to controls at both radius and tibia (key findings in 
the table). At the standard site, tibial cortical porosity was 56% higher (p=0.009) in T1DN+ 
compared to T1DN-. PINP and CTX were decreased in participants with diabetes (T1DN+ 
and T1DN-) compared to controls. PINP was 34% (p=0.006) and 28% (NS) lower in T1DN- 
and T1DN+ compared to controls, while CTX was 87% (p=0.016) and 90% (p=0.011) lower, 
respectively.   DiscussionDiabetes is associated with low bone turnover, as shown by the 
decrease in bone turnover markers. This low bone turnover preserved trabecular microar-
chitecture, resulting in favourable findings at the 14% site. At the standard, more distal site, 
an increase in cortical porosity was found only at the tibia in patients with neuropathy. This 
finding suggested that microvascular complications, especially neuropathy, could affect 
bone vascularization and/or innervation and impact on cortical porosity. Overall, impaired 
microarchitecture is unlikely to be the main mechanism of bone fragility in type 1 diabetes.
Disclosures: Tatiane Vilaca, None
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Lower femoral neck bone mineral density and higher body fat are associated 
with vascular calcification in Chronic Obstructive Pulmnonary Disease 
patients *Roberta Grauman1, Vera Lúcia Szejnfeld1, Marcelo Pinheiro1, Charlles 
Castro1. 1Escola Paulista de Medicina - Universidade Federal de São Paulo, 
Brazil
Introduction: Chronic Obstructive Pulmonary Disease (COPD), a chronic disorder 
characterized by not fully reversible expiratory airflow limitation, has been associated with 
comorbidities as cardiovascular disease and osteoporosis. Higher risk for osteoporosis, ver-
tebral fractures and low lean mass and increased cardiovascular mortality have been ob-
served in COPD patients. As cardiovascular mortality due to vascular calcification and bone 
fragility might share pathophysiological mechanisms, in this study we aimed at evaluating 
the association between osteoporosis and vertebral fragility fractures with cardiovascular 
calcification in a series of patients with COPD. Patients and Methods: A total of 97 COPD 
patients underwent bone mineral density (BMD) and body composition analyses by DXA, 
spirometric evaluation and laboratorial tests. Conventional X-ray of thoracic and lumbar 
spine was used to assess vertebral fractures using semiquantitative Genant’s criteria and 
vascular calcification of abdominal aorta using Kauppila’s method. The study was approved 
by our local Ethics Committee. Results: Ninety-six patients had data available for this anal-
ysis: 44 (45.8%) were men (mean age 65.8 years-old; min 51 - max 83) and 52 (54.2%) 
were women (mean age 64.3 years-old; min 44 – max 85) with mean Kauppila’s index of 
4.8 (0-19). As compared to values below 7, a Kauppila´s index >= 7 was significantly asso-
ciated with older age (67.9 vs 63.5 years-old; p<0.05), lower femoral neck BMD (0.784 vs 
0.877 g/cm2; p<0.05) and higher serum creatinine (1.0 vs 0.8 mg/dL; p<0.05). Patients with 
Kauppila’s index >= 7 tend to have more vertebral fractures (Gentant’s grades II and III) than 
those with a Kauppila’s index < 7 (33.3% vs 17,5%; respectively; p=0.07). After adjustments 
for all confounding variables, multiple logistic regression analyses demonstrated that age 
and low femoral neck BMD for women and age and high body fat for men were the main 
determinants for having a Kauppila’s index >= 7. Conclusion: Our results demonstrate a high 
prevalence of vascular calcification in COPD patients and this outcome is associated with 
low bone mass at the femoral neck and higher rates of morphometric vertebral fractures.
Disclosures: Roberta Grauman, None
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Tumor-induced osteomalacia (TIO): Clinical Experience of a Mexican 
Reference Institution *Alfredo Adolfo Reza-Albarrán1, Ramón G De los Santos1, 
Anabel Rodríguez-Romo2, Dania L Quintanilla Flores3, Nicole M Íñiguez Ariza1, 
Arturo Angeles Angeles1. 1Instituto Nacional de Ciencias Médicas y Nutrición 
Salvador Zubirán, Mexico, 2Clínica de Especialidades Indianilla, ISSSTE, Cd. 
de México, Mexico, 3Clínica de Especialistas; Monterrey, Nuevo León, Mexico
   TIO is a rare disease caused by a FGF-23-producing tumor, usually benign; its major 
features are low serum phosphate and 1,25 (OH)2 vitamin D, along with severe osteomalacia 
and muscular weakness.   Case series: We describe 22 cases of TIO of a mexican institution 
of tertiary attention. 12 men and 10 women are included; median age was 48.6 years (+/- 
11.3); the age at onset of symptoms was 35.9 +/- 11.7. The median follow up period was 34.1 
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months (10.2-55). Generalized bone pain (100%), severe weakness (95%) and limitation 
for deambulation (95%) were the most frequent symptoms. Mean tumor size was 39.8 mm 
(+/-) 18.9 mm and location was from head to feet. Fractures were present in 21 patients (the 
most frequent sites were femur, ribs and spine). Median serum phosphate at diagnosis was 
1.51 mg/dl. Mean serum bone-specific alkaline phosphatase (BSAP) was 127.71+/- 50.04 
U/l (normal range: 9-22); mean PTH at diagnosis was 81.6 pg/ml and mean N-telopeptides 
(N-Tx) value was 91 nM/mmol cr (range of this series from 62.3-671.6; normal values 5-65). 
FGF-23 values (measured in 7 cases) was 857 RU (range from 324-1017; normal values less 
than 180). Scan with octreotide (with or without SPECT) was done in 18 patients and it was 
useful for tumor location in 15; other studies used for tumor location were CT, MRI and 
PET-CT with galium-DOTANOC. 21 patients have been treated with surgery and 19 of them 
are cured; the 2 patients without cure have tumors located in bone (5 patients from this series 
had tumor located only at bone and 4 more in soft tissue with bone infiltration). Two cases 
with tumors located in brain are cured. Histologic report was phosphaturic mesenchymal 
tumor. BSAP drecreased to normal values in 50% of cases at 23 months and N-Tx in 42% 
of cases at 21.6 months. Values of bone mineral density increased at all sites; at total hip, 
Z score increased from -3.72 to +0.19 SD. All cured patients informed improved quality of 
life and are able to walk; the 2 with surgical failure (and more than one surgical procedure 
in both) are now able to walk and also inform improved deambulation and functionality.
Discussion: We inform cure in 19 of 21 surgically treated patients. Clinical improvement 
was noted in all of them. Until 2019, only 19 cases with “intracraneal” location had been 
informed; we report 2 cured cases with tumor located inside brain and one more with tumor 
possibly located in sellar area, whose cardiopulmonary function makes surgery very risky.
Disclosures: Alfredo Adolfo Reza-Albarrán, None
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Is hyperparathyroidism associated with blood clots? Evidence from a 
systematic review and meta-analysis *Kavindra Ratnaweera1, Alexander 
Rodríguez2. 1School of Medicine, Griffith University, Australia, 2Bone and 
Muscle Health Research Group, Department of Medicine, Monash University, 
Australia
Calcium is critical in coagulation. Parathyroid hormone (PTH) maintains calcium ho-
meostasis. Patients with elevated PTH are at increased risk of cardiovascular disease, but it 
is unclear if these patients are predisposed to thrombosis which may be related to PTH action 
on calcium. We aimed to determine if PTH was associated with increased clots or markers 
of coagulation in a systematic review. We searched MEDLINE and EMBASE (29 March, 
2020) for original studies that were non-randomized; directly measured PTH levels or spe-
cifically enrolled patients with hyper/hypo-parathyroidism; measured any clotting factor; 
or reported thromboembolic or haemorrhagic events. We excluded interventional studies, 
case reports, studies of patients with surgical correction of hyperparathyroidism or receiv-
ing therapies that would interfere with mineral metabolism or haemostasis. The primary 
outcome was the association between PTH and clotting factors and the association of PTH 
with the incidence of thromboembolic or haemorrhagic events. Study quality was assessed 
using the Newcastle-Ottawa Scale. Continuous data were meta-analysed if reported in at 
least 100 patients in more than one study. Random-effects models were fitted and reported as 
standardized mean difference (SMD) with 95% confidence intervals (95%CI). Heterogeneity 
was determined by the I2 statistic. All data were computed using R (4.0.0). 2404 records 
were screened. Eight were eligible for inclusion. Seven studies were cross-sectional analyses 
of patients with primary (PHPT) or secondary (SHPT) hyperparathyroidism compared to 
controls. Study quality was poor. In pooled analyses comparing PHPT to controls, there was 
no statistical difference in fibrinogen [SMD=0.01 (-0.92–0.94); k=3 trials; n=133 patients; 
I2=86%]; D-dimer [0.46 (0.03–0.97); 3; 133; 52]; PAI [0.01 (-0.54–0.57); 3; 181; 69]. Other 
outcomes were reported in less than 100 patients as were outcomes in studies involving 
SHPT patients. One high-quality prospective study (n=27000 healthy adults) found serum 
PTH was not associated with venous thromboembolism [adjusted hazard ratio: 1.03 (0.74-
1.42)], deep vein thrombosis (1.00; 0.66-1.52) or pulmonary embolism (1.09; 0.65-1.80). 
Overall, there was little evidence to support an association between PTH and increased coag-
ulation. Prospective data are needed to understand what role if any, PTH plays in coagulation 
and if patients with elevated or reduced PTH are predisposed to clots or bleeds.
Disclosures: Kavindra Ratnaweera, None
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Risk Factors for Low Bone Mass in Spanish patients treated for HIV infection. 
*Gonzalo Allo Miguel1, Joaquín Puerma2, Gemma Villa1, José Napky1, Mercedes 
Oliet1, Mercedes Aramendi Ramos3, Rafael Rubio4, Guillermo Martínez Díaz-
Guerra1. 1Endocrinology Service. 12 de Octubre University Hospital, Spain, 
2Endocrinology Service.12 de Octubre University Hospital, Spain, 3Laboratory 
Service. 12 de Octubre University Hospital, Spain, 4Internal Medicine Service. 
12 de Octubre University Hospital, Spain
Background: Patients with human immunodeficiency virus (HIV) infection show low-
er bone mineral density (BMD) and higher rates of fragility fracture than general popula-
tion. The pathogenesis of bone disease in HIV patients remains unclear but it seems to be 
multifactorial. Low BMD has been associated with different risk factors, such as age, sex, 
smoking and anti-retroviral therapy (ART). As nowadays HIV is a chronic disease, it is 
mandatory to identify associated risk factors in those patients. Aim: This study describes 
BMD status in a group of HIV patients and evaluates potential risk factors for low BMD in 
those patients.Material and methods: 107 HIV patients were evaluated in this retrospective 
study. BMD was assessed by DXA, (densitometer QDR 4500, Hologic) at lumbar spine 
(LS), femoral neck (FN) and total hip (TH). Serum 25OHD was measured by enzyme 
immunoassay (Roche). 25OHD deficiency was defined as a 25(OH)D level of 30 ng/ml 
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were categorized as 25OHD sufficiency. ART drugs included: Tenofovir disproxil (TED); 
Tenofovir alafenamide (TAF) and Protease inhibitors (PI). Statistics: Data are expressed as 
mean+/-s.d. for continuous variables and percentages for categorical ones. Regression tech-
niques were used to evaluate the association between continuous variables. p-value <0.05 
was considered as statistically significant.Results:79 male/28 female. Mean age: 55.8+/-7.3 
years. 91(85.0%) patients were treated with TED; 15(14.0%) with TAF and 31(29.3%) with 
PI. Mean serum 25OHD was in the insufficiency range 27.09+/-12.63 ng/ml. 29(27%) pa-
tients showed 25OHD deficiency and 43 patients (40.1%) insufficiency. Mean T-score was 
in the osteopenia range in FN (-1.35+/-0.93) and LS (-1.43+/-1.26). 28(26,2%) patients suf-
fered osteoporosis. Combined treatment with TED+PI was associated with lower TH T-score 
(p=0.02). Longer duration of the disease showed statistically significant association with FN 
(p=0.01); TN (p=0.02) and LS (p=0.03) T-score. Lower 25OHD level was associated with 
lower TN T-score (p=0.02).Conclusion: Low BMD, osteoporosis and 25OHD deficiency are 
common findings in HIV patients in our group. Our study shows that long-lasting disease 
and treatment with the combination of TED+PI are associated with lower BMD. This data 
should contribute to understand the pathogenesis of bone disease in HIV patients and pro-
vide practical recommendations for its evaluation and treatment.
Disclosures: Gonzalo Allo Miguel, None
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Lower bone mineral density is associated with primary hyperparathyroidism 
patients with abnormal vitamin D metabolite ratio (VMR): A case-control 
study *Jonathan Tang1, Mushood Malik1, Jeremy Turner2, William Fraser1. 
1University of East Anglia, United Kingdom, 2Norfolk and Norwich University 
Hospital NHS, United Kingdom
Introduction The role of vitamin D and calcium metabolism has long been implicated 
in the clinical manifestation of primary hyperparathyroidism (PHPT). The skeletal response 
to the overproduction of parathyroid hormone (PTH) is less predictable, and the effect on 
bone loss can be greater in some patients. The aim of this study was to establish associa-
tions between vitamin D metabolism, including vitamin D metabolite ratio (VMR) with 
rates of  bone loss in PHPT, particularly in patients who did not undergo surgery.Methods 
An audit was conducted from the electronic health records of patients diagnosed with PHPT 
who attended the Endocrinology clinic at the Norfolk and Norwich University Hospital 
(NNUH), UK during the 2017-2019 period. The search identified cases with abnormal vita-
min D metabolism 1,25(OH)2D:24,25(OH)2D VMR of >=51, and excluded those who had 
parathyroid surgery or had received steroid therapy. For each case, the age and gender were 
matched to controls, i.e. 1,25(OH)2D:24,25(OH)2D VMR of <51, with the same exclusion 
criteria as described. Cases (n=13) were identified (age mean(range): female 70.6(50-94)yrs, 
male 73(63-79)yrs). Each case was matched to controls in the ratio of 2:1 for females, and 
1:1 for males. Laboratory measurements of serum 25OHD, adjusted calcium (ACa), phos-
phate, and plasma PTH were retrieved. In addition, we obtained the bone mineral density 
(BMD) T-score values (lumbar, left hip and left femoral neck) from DEXA scans carried out 
+/-1 month from the biochemical measurements.Results We observed a significantly lower 
Lumbar Spine T-score in the cases, mean (95%CI) -1.85 (-0.9 to -2.77) than in the matched 
controls -0.2(0.30 to -0.79), p<0.001. Whilst the left hip and left femoral neck T-scores in 
the cases were not significantly lower (Figure). 25OHD and 24,25(OH)2D were significantly 
lower in the cases than controls; mean (SEM), 42.9(6.6) v 69.4(3.9)nmol/L, p<0.01 and 
2.0(0.44) v 5.0(0.38)nmol/L, p<0.001, respectively. In contrast, the 25OHD:24,25(OH)2D 
VMR in the cases were higher 27(2.0) v 15(0.8), p<0.001. PTH, 1,25(OH)2D and ACa were 
elevated above the upper limit of the reference interval in both groups but no significant 
relationships were observed between the groups.Conclusion Our cohort of non-surgically 
managed PHPT patients presented with grossly elevated 1,25(OH)2D:24,25(OH)2D VMR 
were strongly associated with lower Lumbar Spine T-score. By using VMR we demonstrated 
an imbalance between the active and catabolic forms of vitamin D metabolites that might 
contribute to the accelerated bone loss in PHPT patients.
Disclosures: Jonathan Tang, None
P-023
Association of Testosterone, Dehydroepiandrosterone, and 17-Alpha-
Progesterone with Bone, Muscle, and Fat in Women with Congenital 
Adrenal Hyperplasia *Seung-Gyun Im1, Sung Hye Kong1, Jung Hee Kim1, 
Chan Soo Shin0. 1Seoul National University Hospital, Republic of Korea, 0Seoul 
National University Hospital, Republic of Korea
Congenital Adrenal Hyperplasia (CAH) is a disorder with disruption of cortisol synthe-
sis pathway, which leads to adrenal insufficiency and testosterone excess. It is thought that 
inadequate or excessive replacement of lifelong corticosteroid in patients with CAH exposes 
them to an increased risk of bone loss and changes in body composition. This study aimed 
to analyze the relationship of hormonal status with bone mineral density (BMD) and body 
composition in women with CAH. Women diagnosed with CAH at Seoul National Univer-
sity Hospital from 2000 to 2020 with bone densitometry scan results were included in the 
final analyses. Patients with low BMD were defined as having less than -2.0 Z-score among 
the lumbar spine, femur neck, and total hip. Lean body mass and fat mass were measured 
using bioelectrical impedance analysis, and percent lean and percent fat mass were defined 
as lean body and fat mass divided by body weight, respectively. Among a total of 138 partic-
ipants, the mean age was 26.5 years, and the mean body mass index (BMI) was 23.1 kg/m^2. 
Women with low BMD were older and had lower percent lean mass, while their BMIs were 
similar. Cumulative and daily doses of corticosteroids, ACTH, renin, 17-alpha-progesterone 
(17-α-PG), and dehydroepiandrosterone sulfate (DHEA-S) were similar between women 
with low and normal BMD. In correlation analyses, testosterone levels were positively cor-
related with the lumbar spine, femur neck, and total hip BMD after adjustments for age and 
BMI (r=0.69, p<0.001; r=0.60, p<0.001; r=0.51, p=0.001, respectively). Also, DHEA-S was 
positively correlated with the lumbar spine and total hip BMD (r=0.33, p=0.003; r=0.25, 
p=0.019, respectively), and 17-α-PG was positively correlated with lumbar spine BMD after 
adjustments (r=0.45, p=0.001), while doses of steroid replacements were insignificantly cor-
related with BMDs. The percent fat mass was positively correlated only with renin (r=0.30, 
p=0.025). Also, percent lean mass did not show significant correlation with hormonal levels 
and the amount of steroid replacement. To summarize, in women with CAH, women with 
higher testosterone and DHEA-S levels had better trabecular and cortical BMD, while those 
with higher 17-α-PG had higher trabecular BMD only. Also, women with increased renin 
levels were likely to have increased proportions of body fat. However, the degree of steroid 
replacement was not associated with BMD and body composition.
Disclosures: Seung-Gyun Im, None
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Changing Landscapes, Altered Patterns - Hungry Bone Syndrome 
following Parathyroidectomy for Primary Hyperparathyroidism *Aye Chan 
Maung1, Nurshazwani Mat Salleh1, Jeremy Chung Fai Ng2, Manju Chandran3. 
1Department of Endocrinology, Singapore General Hospital, Singapore, 
2Department of Surgery, Singapore General Hospital, Singapore, 3Osteoporosis 
and Bone Metabolism Unit, Singapore General Hospital, Singapore
Introduction: Hungry Bone Syndrome (HBS) following parathyroidectomy (PTX) for 
primary hyperparathyroidism (PHPT) has an incidence rate that varies widely from 4-87% 
depending on the country of origin of the study, with the lower rates reported from some 
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western developed countries and the highest rates from less developed ones in Asia. No 
study has explored its incidence rates in a developed country in Asia and therefore this 
was our aim.Method: 118 patients operated on for PHPT during 2012-2019 at the largest 
public hospital in the only developed country in SE Asia were retrospectively analysed. 
All patients had incidentally detected high serum Calcium (Ca) or had been admitted with 
acute symptoms of hypercalcemia or had elevated Parathyroid hormone (PTH) and high Ca 
during work-up for osteoporosis. Pre-operative clinical and laboratory parameters assessed 
were age, gender, race, radiographic bone abnormalities, BMD and use of Bisphosphonate 
(BSP), Denosumab (DMB) or vitamin D, serum corrected Ca, PTH, PO4, Alkaline Phospha-
tase (ALP) and 25(OH)D levels. HBS was defined as serum Ca <=2.1 mmol/l with normal/
raised serum PTH levels lasting more than 4 days postoperatively, requiring intravenous (IV) 
Ca.Results: Mean age(SD) of the patients was 60.92(12.01). Chinese constituted 73.7%, Ma-
lays 13.6%, Indians 8.5% and other races 4.2%. 70.3% were females. 45% had osteoporosis 
on DXA scanning. 13.5% had renal calculi. No patient had osteitis fibrosa cystica. 27% of 
the patients had ever received a BSP and 3.3% had received DMB in the 6 months prior to 
surgery. 62.7% were on vitamin D supplementation (mean dose:1607.7 IU) in the month 
prior to surgery. The mean(SD) immediate preoperative levels of PTH (0.9-6.2pmol/l) was 
25.66(30.77), corrected Ca (2.10-2.60 mmol/l) was 2.72(0.15), 25(OH)D was 20.75(7.47)
ng/ml, PO4 (0.77-1.38mmol/l) was 0.86(0.20) and ALP (32-103U/L) was 117.86(64.48). 
Only 1/118 (0.8%) developed HBS.Conclusion: The very low incidence of HBS in unse-
lected, consecutive, multi-ethnic patients undergoing PTX for PHPT at a medium volume, 
multi-surgeon, public hospital, in a developed country in SE Asia likely reflects the changing 
patterns of PHPT in the developed world. Automated measurements that include serum Ca 
and screening for PHPT amongst osteoporosis patients results in a pickup of the disease 
when it is mild or asymptomatic. The absence of severe vitamin D deficiency in our popula-
tion also likely contributed to this low incidence rate.
Disclosures: Aye Chan Maung, None
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Impact of curative treatment in symptomatic primary hyperparathyroidism 
on trabecular bone score, bone mineral density, and bone turnover markers 
- A prospective study from southern India *Jinson Paul1, Shrinath Shetty1, 
Kripa Elizabeth Cherian1, Nitin Kapoor1, Deepak Abraham1, Thomas Vizhalil 
Paul1. 1Christian Medical College, India
Background: The significance of preoperative PTH in predicting recovery of trabecular 
bone score (TBS) and other bone mineral parameters following curative parathyroidectomy 
in symptomatic primary hyperparathyroidism (PHPT) is not well studied. This prospective 
study was done to objectively assess trabecular bone score, bone mineral density (BMD) 
and bone mineral profile in Indian subjects with symptomatic PHPT and to study the influ-
ence of baseline PTH on recovery of these parameters following curative surgery.Materials 
& Methods: This was a two year prospective study conducted at a tertiary care centre in 
southern India. Baseline assessment included demographic details, mode of presentation, 
bone mineral biochemistry, BMD, TBS and bone turnover markers (BTMs). These param-
eters were reassessed at the end of the first and second years following curative parathyroid 
surgery.Results: Fifty one subjects (32 men and 19 women) with PHPT who had undergone 
curative parathyroidectomy were included in this study. The mean(SD) age was 44.6(13.7) 
years. On follow-up at two years, BTMs, BMD at femoral neck, lumbar spine and distal 
forearm as well as TBS showed significant steady improvement when compared to base-
line(P<0.05). The TBS, BTMs and BMD at lumbar spine and forearm were significantly 
worse at baseline in subjects with higher PTH(>= 250 pg/mL) when compared to the group 
with lower PTH(<250 pg/mL). However, at the end of two years the difference between high 
versus low PTH groups (mean+/-SD) persisted only for forearm BMD(0.638+/-0.093 versus 
0.698+/-0.041 g/cm2;P=0.01).Conclusion: This study found that BMD at forearm remained 
significantly worse in individuals with high PTH even at two years after surgery, while other 
parameters including TBS improved significantly from baseline.
Disclosures: Jinson Paul, None
P-026
Assessing The Impact Of Calcitonin In Management Of Hypercalcemia 
*Malik Faheem1, Fahim Abbasi2, Marina Basina1. 1Division of Endocrinology, 
Stanford University, United States, 2Division of Cardiovascular Medicine, 
Stanford University, United States
Purpose:Hypercalcemia accounts for about 0.6% of all the hospital admissions and 
hypercalcemia of malignancy, seen in up to 20% of all the malignancy cases, is the most 
common cause in the inpatient setting. Choice of therapeutic options is usually dictated by 
initial serum calcium level, rapidity of its rise and presence of hypercalcemia symptoms. 
Due to the high cost of calcitonin (minimum of $3539.20 per 48-hour therapy), we sought 
to evaluate whether calcitonin therapy with and without bisphosphates was superior to bi-
sphosphonates alone in reducing calcium levels in patients with hypercalcemia. Method: 
This is a retrospective chart review of 71 consecutive patients admitted to Stanford Hos-
pital between 10/1/2018-09/30/2019 with ICD-10 codes for hypercalcemia. Patients who 
received bisphosphonate alone (Group B), calcitonin alone (Group C) or bisphosphonates 
and calcitonin dual therapy (Group BC) were included. All patients received intravenous 
hydration. Patients receiving Denosumab were excluded due to small sample size, and no 
patients received medications known to cause hypercalcemia. Percent decline in corrected 
serum calcium was compared between the groups. One-way ANOVA followed by Bonfer-
roni pairwise comparison tests were used for statistical analysis.Results: The patients had a 
mean age of 64.3 years, 41 (57.8%) were male, and 61 (85.9%) had hypercalcemia of ma-
lignancy. Mean baseline corrected calcium was 12.2 +/- 1.5 mg/dl in bisphosphonate group 
(B), 13.4 +/- 1.7 mg/dl in calcitonin group (C) and 13.8 +/- 1.6 mg/dl in bisphosphonates + 
calcitonin group (BC). Between baseline and day 5, group C had a significantly lower mean 
percentage decrease in corrected calcium (11.8 +/- 11.6) compared to group B (28.6 +/- 4.1) 
and group BC (26.0 +/- 12.9) (p=0.02), and there was no statistically significant difference 
between group B and group BC. There was no significant difference between initial symp-
toms, baseline serum creatinine and length of stay between the three groups.Conclusion: 
Use of calcitonin, whether alone or in combination with bisphosphonates, did not provide a 
superior reduction in serum calcium levels compared to bisphosphonates alone in patients 
with hypercalcemia. Due to its high cost, calcitonin use should be limited to patients with 
severe symptomatic hypercalcemia. Further studies are warranted to determine the calcium 
level cut off when calcitonin therapy would be beneficial.Disclosure: None
Disclosures: Malik Faheem, None
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Hypercalcemia in Cirrhotic Liver Disease: A Clinical Case Series *Diana 
Athonvarangkul1, Anika Anam1, Renata Belfort de Aguiar1. 1Yale University, 
United States
Hypercalcemia due to advanced liver disease without neoplasia is a complex process 
with increasing prevalence, but its evaluation and management remains puzzling. Here, we 
present 8 patients with hypercalcemia due to cirrhosis of varying causes including viral, 
alcoholic and genetic. The peak serum corrected calcium level ranged from 12.76-14.56 mg/
dL (normal 8.8-10.2 mg/dL). As hypercalcemia due to cirrhosis is a diagnosis of exclusion, 
all patients had an extensive evaluation for other causes of hypercalcemia. All patients had 
low intact PTH, low to normal 25-hydroxyvitamin D, and low to normal 1,25-dihydroxyvi-
tamin D. Seven patients had low to normal PTHrP and one patient had elevated PTHrP in the 
context of renal dysfunction. Phosphorus level was normal to mildly elevated. Four patients 
had CTX level measured, and all were elevated. Of all patients, three had elevated total 
alkaline phosphatase (ALP); although all four patients with measured bone specific ALP 
had normal levels. No patient had evidence of hepatic neoplasm at the time of hypercalce-
mia. Six patients had negative workup for monoclonal gammopathy and one patient had a 
discrete abnormal band in the gamma region. Thyroid and cortisol hormones were normal 
in all patients. No patient had elevated vitamin A. One patient screened negative for sarcoid 
with ACE. Four patients were considered bedbound. Three patients had exogenous calcium 
intake with calcium or nutritional supplements. Three patients with DXA scans had T-scores 
in the normal to osteopenic range. For treatment of hypercalcemia, patients received calci-
tonin (n=4), bisphosphonates (n=5) and denosumab (n=1), either alone or in combination. 
One patient achieved normocalcemia after discontinuation of calcium supplements only. 
Three patients who received zolendronic acid developed hypocalcemia requiring calcium 
supplementation. Many patients were not able to tolerate intravenous fluid therapy due to 
cirrhosis related volume overload. Although the mechanism of hypercalcemia due to cirrho-
sis is unclear, it has been postulated to involve inflammatory cytokines. The presence of ele-
vated bone turnover marker CTX, but normal bsALP, preserved bone mineral density and, in 
some cases, only transient hypercalcemia, suggests that there is an acute uncoupling of bone 
remodeling favoring resorption, which may respond to bisphosphonates and denosumab. 
Additional studies are needed to determine the mechanism and to guide treatment options.
Disclosures: Diana Athonvarangkul, None
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Evaluation of Bone Mineral Density and Trabecular Bone Score (TBS) in 
X-linked hypophosphatemic patients *Pablo Florenzano1, Danisa Ivanovic-
Zuvic1, Macarena Jimenez1. 1Pontificia Universidad Catolica de Chile, Chile
X-linked hypophosphatemia, the most common cause of inherited hypophosphatemia, 
manifests as rickets in children and osteomalacia in adults. To date, Bone Mineral Density 
(BMD) reports in this population have been discordant, with a tendency towards a higher 
BMD at the lumbar spine that could be partially explained spinal by paravertebral ligament 
calcifications. The Trabecular Bone Score (TBS), an index that is determined from DXA 
scans, assesses the microarchitecture of the spine, with less influence by spinal artifacts. To 
date, no information has been published regarding TBS in this group of patients.Objective: 
To describe BMD and TBS in XLH patients, and to determine its association with clini-
cal and biochemical presentation.   Design: Cross-sectional.Methods: Adult subjects with 
PHEX-confirmed XLH were included. All patients underwent DXA scans (Lunar) at the 
lumbar spine and femoral neck. In addition, TBS values were determined. Z-scores were cal-
culated compared to NHANES. Clinical and biochemical data were obtained to determine its 
association with BMD and TBS.Results: Eighteen patients were included, 13 (72%) women, 
median age of 33 (IQR, 25-37 years). Three patients had never received calcitriol and/or 
phosphate. Median of proportion of lifetime with treatment was 0.53 (IQR, 0.12-0.75).  All 
patients were hypophosphatemic, 56% had elevated ALP and 44% had hyperparathyroidism. 
Mean BMD at lumbar spine and femoral neck were 1.45 gr/cm2 (Z-score= 2.4) and 1.02 
gr/cm2 (Z-score =0.2). BMD at lumbar spine, but not at femoral neck, was increased com-
pared to normative data (p<0.05). Mean TBS was 1.511, with a mean Z-score of 1.2+/-1.1, 
significantly higher than norm-based population. Spine BMD and TBS Z-scores exceed-
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ing 2SD were present in 44% and in 17%, respectively (p<0.05). TBS had no significant 
correlation with spine BMD. TBS Z-score, but not spine BMD, had a negative correlation 
with ALP Z-score (r=-0.47, p<0.05). Neither the proportion of lifetime with treatment nor 
other biochemical parameters, including Phosphorous Z-score, ALP Z-score, PTH, FGF23 
and CTx were associated with TBS index.Conclusions: Our population presents with high 
lumbar spine BMD and TBS compared to reference data, not associated to exposure to 
treatment.  These findings suggest that elevated spine BMD is not only explained by extra 
skeletal calcifications and highlight the need of further studies in order to elucidate the high 
lumbar bone mass phenotype in XLH.
Disclosures: Pablo Florenzano, None
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Correlations Between Preoperative Intact Parathyroid Hormone Levels 
and  Adenoma Volumes Estimated by Ultrasound or Sestamibi Scintigraphy 
in Primary Hyperparathyroidism *Sandra Haide Aguilar Maciel1, Aldo 
Ivan García Contreras1, Michelle Ninoska García González1. 1Department of 
Endocrinology, General Hospital of Mexico, Mexico City, Mexico, Mexico
Background: Primary hyperparathyroidism is a common endocrine disorder that can 
be associated with skeletal complications and nephrolithiasis. Its primary etiology is the 
parathyroid adenoma which resolves with minimally invasive surgery and requires imaging 
localization studies such as ultrasound and sestamibi scintigraphy. Purpose:This study  aims 
to determine the association between intact parathyroid hormone levels with the volume 
of parathyroid adenomas in patients with primary hyperparathyroidism caused by a single 
adenoma . Methods: Retrospective, observational study, which included 37 patients with 
primary hyperparathyroidism diagnosed in the endocrinology outpatient clinic of the Gener-
al Hospital of Mexico during a period of five years between 2013-2018. Serum parathyroid 
hormone levels were evaluated in all patients before surgery. The volume of parathyroid 
adenomas was measured by using the formula of a rotating ellipsoid in localization stud-
ies performed (ultrasound or sestamibi scintigraphy) before surgery.Results: Thirty seven 
cases, including 33 females (89%) and 4 males (10.8%) with an average age of 53.6 years 
( +/-13.21) in which the average parathyroid hormone level preoperatively was 507 pg/ml. 
A positive  correlation  was observed between the volume of parathyroid adenomas using 
ultrasound and parathyroid hormone levels with a correlation coefficient of 0.47 (p=0.004). 
The correlation between the volume of parathyroid adenomas using sestamibi scintigraphy 
and parathyroid hormone levels was also found positive with a correlation coefficient of 0.55 
(p=0.001). Additionally, a positive correlation was also observed between the parathyroid 
hormone levels and the area of the adenoma with a correlation coefficient of 0.53 (p=0.002). 
No correlation existed between serum calcium levels or phosphorus levels and the volume 
of the adenoma or its area. Although a significant positive correlation was found between the 
levels of alkaline phosphatase and the volume of parathyroid adenomas with a correlation 
coefficient of 0.432 (p=0.012).Conclusion:  Preoperative parathyroid hormone levels have 
a positive correlation with the  volume of  parathyroid adenomas using the formula of a ro-
tating ellipsoid in both ultrasound and sestamibi scintigraphy. No correlation was found be-
tween preoperative calcium or phosphorus levels and the volume of parathyroid adenomas.
Disclosures: Sandra Haide Aguilar Maciel, None
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Normocalcaemic hyperparathyroidism (NPHPT) and primary 
hyperparathyroidism (PHPT): Least significant change (LSC) for adjusted 
serum calcium *MARIAN SCHINI1, Richard Jacques2, Eleanor Oakes3, 
Nicola Peel3, Jennifer Walsh1, Richard Eastell1. 1Department of Oncology and 
Metabolism, University of Sheffield, UK, United Kingdom, 2School of Health 
and Related Research (ScHARR), University of Sheffield, UK, United Kingdom, 
3Sheffield Teaching Hospitals National Health Service Foundation Trust (STH 
NHS FT), UK, United Kingdom
The least significant change (LSC) is a term used in individuals in order to evaluate 
whether one measurement has changed significantly from the previous one. It is widely used 
when assessing bone mineral density (BMD) scans. To the best of our knowledge, there no 
such estimate available in the literature for patients with disorders of calcium metabolism. 
Our aim was to provide an estimate of the least significant change in patients with normo-
calcaemic hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT). Meth-
ods: We adjusted total serum calcium for albumin based on an equation derived from our 
laboratory and used the within-subject standard deviation calculated using the method of 
Bland and Altman (1996) in a population of NPHPT (n=11) and PHPT (n=17) for our LSC 
estimation.Results: The LSC for NPHPT and PHPT were found to be 0.25 and 0.24 mmol/L 
respectively (1.00 and 0.96 mg/dL). Intermittent hypercalcemia was present in 7 of the 11 
NPHPT patients and 6 of the 17 PHPT patients. Figure 1 shows the follow-up measurements 
from a patient with NPHPT (left panel) and PHPT (right panel), both having intermittent hy-
percalcaemia yet all results falling within the LSC (grey areas).Discussion: The least signif-
icant change calculated in this way could be used to interpret the changes in serum adjusted 
calcium in patients with NPHPT or PHPT. 
Disclosures: MARIAN SCHINI, Roche Diagnostics, Grant/Research Support
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Changes in Composition of the Gut Microbiota with Correction of Vitamin 
D Deficiency Using Cholecalciferol or Calcifediol in Young, Healthy 
Adults *Albert Shieh1, Sungeun Lee1, Jonathan Jacobs1, Carter Gottlieb1, Venu 
Lagishetty1, John Adams1. 1UCLA, United States
Background. Vitamin D may impact gut immune function and gut microbiota com-
position. We examined whether correcting vitamin D deficiency with cholecalciferol (D3) 
or calcifediol (25D3) in young, healthy adults changes gut microbiota composition. Meth-
ods. 18 adults with 25-hydroxyvitamin D [25D] <20 ng/ml were randomized to 60 mcg /
day of D3 or 20 mcg/day of 25D3 for 8 weeks with study visits every 4 weeks. Serum 
25D, 1,25(OH)2D (1,25D), and 24,25(OH)2D (24,25D) were assayed using liquid chro-
matography/tandem mass spectrometry. A vitamin D activation ratio was calculated as the 
100*(1,25D/25D. A vitamin D catabolism ratio was calculated as 24,25D/25D. Gut micro-
biota composition was assessed using 16S rRNA sequencing. α-diversity (within-individual 
diversity) was examined by species richness (Chao1), phylogenetic diversity (Faith’s PD), 
and species evenness (Shannon Index). β-diversity (between-individual diversity) was as-
sessed using DEICODE. We used a supervised, sparse Partial Least Squares Discrimination 
Analysis (sPLA-DA) to test for changes in gut microbial composition. Associations of vi-
tamin D metabolites with α-diversity, β-diversity, and individual taxa were assessed using 
multivariable linear regression or DESeq2. Results. Subjects in D3 and 25D3 groups were 
similar; mean basal 25D, BMI, and age were 17.2 ng/ml, 26.5 kg/m2 and 29.8 years, respec-
tively. After 8 weeks of D3, mean 25D and 24,25D increased significantly, but mean 1,25D 
did not (25D: 17.8 to 30.1 ng/ml [p=0.002]; 24,25D: 1.1 to 2.7 ng/ml [p=0.003]; 1,25D: 49.5 
to 53.0 pg/ml [p=0.9]). After 8 weeks of 25D3, mean 25D, 24,25D, and 1,25D all increased 
significantly (25D: 16.7 to 50.6 ng/ml [p<0.0001]; 24,25D: 1.3 to 6.2 ng/ml [p=0.0001]; 
1,25D: 56.5 to 74.2 pg/ml [p=0.05]). 25D and 24,25D were greater at weeks 4 and 8 in the 
25D3 group. Gut microbial α-diversity did not change with D3 or 25D3 supplementation. 
There was a trend towards change in gut microbial β-diversity with D3 or 25D3 supplemen-
tation (groups pooled) (p=0.09), but there were no clustering or taxonomic profile changes 
specific to supplement type. In sPLA-DA, there was a shift in some taxa after 4 weeks of 
D3 or 25D3 (groups pooled) that did not persist to week 8 (Figure). Vitamin D metabolites, 
activation and catabolism ratios were not associated with gut microbiota composition.Con-
clusion. D3 and 25D3 supplementation in vitamin D deficient, young, health adults did not 
change gut microbial composition.
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Vitamin D Metabolism after PTH Therapy in Hypoparathyroidism *Isabelle 
Piec1, Chloe Simper1, Jeremy Turner2, William D. Fraser1. 1University of East 
Anglia, United Kingdom, 2Norwich and Norfolk University Hospital, United 
Kingdom
Chronic hypoparathyroidism (hypoPT) is a rare disease characterized by insufficient 
parathyroid hormone (PTH) production/secretion, usually secondary to damage or removal 
of the parathyroid glands during head and neck surgery and often associated with hypocal-
caemia and other clinical findings.Until recently, standard therapy for this disorder consisted 
of calcium and vitamin D analog supplementation frequently associated with hypercalciuria, 
potentially resulting in long-term renal complications such as nephrocalcinosis, nephroli-
thiasis, and renal insufficiency.Recently, it has been shown that daily subcutaneous doses 
20μg of recombinant human PTH(1-34) or 50-100 µg rhPTH(1-84) (NatPar), were effective 
in maintaining serum calcium concentrations and enabling significant decreases in vita-
min D analog and oral calcium doses.We present preliminary data from a follow-up study, 
comparing vitamin D metabolism in patients on standard treatment (n=7) vs PTH (n=7).
Group comparison was performed for adjusted calcium (ACa), phosphate (PO4), 25(OHD), 
1,25(OH)2D and 24,25(OH)2D using a Mann Whitney U tests (IBM SPSS version 25.0.0.1) 
at baseline and after 2, 4, 6, 8, 12 and 16 weeks of either treatment. Within group comparison 
were performed using ANOVA with Bonferroni post-hoc using SPSS.ACa, PO4 and 25(OH)
D did not show any significant differences between the two treatments at any time point. In 
both cases. ACa increased within the reference range (2.1-2.5 mmol/L) and PO4 decreased 
to mid reference range (0.8-1.5 mmol/L). 25(OH)D concentrations decreased while those 
of the active form 1,25(OH)2D increased from baseline when treated with PTH achieving 
significant difference after 16 weeks of daily injections of PTH. 24,25(OH)2D was signifi-
cantly decreased in patients treated with PTH, resulting in a significant (p<0.05 after 8 weeks 
of treatment) difference of the ratios 25:24,25 and 1,25:24,25 vitamin D, while standard 
treatment with calcium and vitamin D showed no significant effect on these ratios.In patients 
with HypoPT, daily injection of PTH induced a significant (ANOVA, p<0.05) increase of 
1,25(OH)2D concentrations, by activating 1-alpha hydroxylase (CYP27B1) in the kidney 
and by decreasing the degradation of 25(OH)D to 24,25(OH)2D by CYP24A1. Lower con-
centrations of 24,25(OH)2D may also increase the number of available vitamin D receptors 
for 1,25(OH)2D resulting in beneficial effects such as faster and greater decrease of PO4 and 
increase of ACa.Chronic hypoparathyroidism (hypoPT) is a rare disease characterized by 
insufficient parathyroid hormone (PTH) production/secretion, usually secondary to damage 
or removal of the parathyroid glands during head and neck surgery and often associated with 
hypocalcaemia and other clinical findings.Until recently, standard therapy for this disorder 
consisted of calcium and vitamin D analog supplementation frequently associated with hy-
percalciuria, potentially resulting in long-term renal complications such as nephrocalcinosis, 
nephrolithiasis, and renal insufficiency.Recently, it has been shown that daily subcutaneous 
doses  20 μg of recombinant human PTH(1-34)  or 50-100 µg rhPTH(1-84), (NatPar) were 
effective in maintaining serum calcium concentrations and enabling significant decreases in 
vitamin D analog and oral calcium doses.We present preliminary data from a follow-up study, 
comparing vitamin D metabolism in patients on standard treatment (n=7) vs NatPar (n=7).
Group comparison was performed for adjusted calcium (ACa), phosphate (PO4), 25(OHD), 
1,25(OH)2D and 24,25(OH)2D using a Mann Whitney U tests (IBM SPSS version 25.0.0.1) 
at baseline and after 2, 4, 6, 8, 12 and 16 weeks of either treatment. Within group comparison 
were performed using ANOVA with Bonferroni post-hoc using SPSS.ACa, PO4 and 25(OH)
D did not show any significant differences between the two treatments at any time point. In 
both cases. ACa increased within the reference range (2.1-2.5 mmol/L) and PO4 decreased 
to mid reference range (0.8-1.5 mmol/L). 25(OH)D concentrations decreased while those 
of the active form 1,25(OH)2D increased from baseline when treated with PTH achieving 
significant difference after 16 weeks of daily injections of PTH.  24,25(OH)2D was signifi-
cantly lowered in patients treated with PTH, resulting in a significant (p<0.05 after 8 weeks 
of treatment) difference of the ratios 25:24,25 and 1,25:24,25 vitamin D, while standard 
treatment of calcium and vitamin D showed no significant effect on these ratios.In patients 
with HypoPT, daily injection of PTH induced significant (ANOVA, p<0.05) increased of 
1,25(OH)2D concentrations, by activating 1-alpha hydroxylase (CYP27B1) in the kidney 
thereby  decreasing the degradation of 25(OH)D to 24,25(OH)2D by CYP24A1. Lower con-
centrations of 24,25(OH)2D may also increase the number of available vitamin D receptors 
for 1,25(OH)2D resulting in beneficial effects  such as faster and greater decrease of PO4 
and increase of ACaChronic hypoparathyroidism (hypoPT) is a rare disease characterized by 
insufficient parathyroid hormone (PTH) production/secretion, usually secondary to damage 
or removal of the parathyroid glands during head and neck surgery and often associated with 
hypocalcaemia and other clinical findings.Until recently, standard therapy for this disorder 
consisted of calcium and vitamin D analog supplementation frequently associated with hy-
percalciuria, potentially resulting in long-term renal complications such as nephrocalcinosis, 
nephrolithiasis, and renal insufficiency.Recently, it has been shown that daily subcutaneous 
doses 20μg of recombinant human PTH(1-34) or 50-100 µg rhPTH(1-84) (NatPar), were ef-
fective in maintaining serum calcium concentrations and enabling significant decreases in vi-
tamin D analog and oral calcium doses.We present preliminary data from a follow-up study, 
comparing vitamin D metabolism in patients on standard treatment (n=7) vs PTH (n=7).
Group comparison was performed for adjusted calcium (ACa), phosphate (PO4), 25(OHD), 
1,25(OH)2D and 24,25(OH)2D using a Mann Whitney U tests (IBM SPSS version 25.0.0.1) 
at baseline and after 2, 4, 6, 8, 12 and 16 weeks of either treatment. Within group com-
parison were performed using ANOVA with Bonferroni post-hoc using SPSS.ACa, PO4 
and 25(OH)D did not show any significant differences between the two treatments at any 
time point. In both cases. ACa increased within the reference range (2.1-2.5 mmol/L) and 
PO4 decreased to mid reference range (0.8-1.5 mmol/L). 25(OH)D concentrations decreased 
while those of the active form 1,25(OH)2D increased from baseline when treated with PTH 
achieving significant difference after 16 weeks of daily injections of PTH. 24,25(OH)2D 
was significantly decreased in patients treated with PTH, resulting in a significant (p<0.05 
after 8 weeks of treatment) difference of the ratios 25:24,25 and 1,25:24,25 vitamin D, while 
standard treatment with calcium and vitamin D showed no significant effect on these ratios.
In patients with HypoPT, daily injection of PTH induced a significant (ANOVA, p<0.05) 
increase of 1,25(OH)2D concentrations, by activating 1-alpha hydroxylase (CYP27B1) in 
the kidney and by decreasing the degradation of 25(OH)D to 24,25(OH)2D by CYP24A1. 
Lower concentrations of 24,25(OH)2D may also increase the number of available vitamin D 
receptors for 1,25(OH)2D resulting in beneficial effects such as faster and greater decrease 
of PO4 and increase of ACa.
Disclosures: Isabelle Piec, None
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Analysis of Parathyroid Treatment in Murine Studies *Laura Zweifler1, 
Amy Koh2, Stephanie Daignault-Newton2, Laurie McCauley2. 1University of 
Michgian, United States, 2University of Michigan, United States
Parathyroid hormone (PTH) is produced by the parathyroid glands in response to low 
serum calcium concentrations where it targets bone, kidneys, and intestines. The N-termi-
nus of PTH has been investigated over decades for its ability to stimulate bone formation 
when administered intermittently and is used clinically as an effective anabolic agent for 
the treatment of osteoporosis. Despite great interest in PTH and its clinical use, the mecha-
nisms of action remain complicated and continues to be an interest for researchers. Data was 
compiled from twenty years of studies that have used PTH in murine models with a focus 
on anabolic actions in the trabecular compartment. In total, 103 studies were included that 
reported an anabolic dose of PTH. The data was stratified based on gender (male, female, or 
both), bone site (tibia, femur, vertebrae), days per week of treatment (5-5.5 days or 7 days), 
age at the start of treatment (0-2 weeks, 4-8 weeks, 9-10 weeks, 11-12 weeks, or >12 weeks), 
duration of treatment (<4 weeks, 4 weeks, 5-6 weeks, or 7-12 weeks), and dose of PTH (11 
weeks. Additionally, PTH had a greater anabolic effect when administered for a duration 
of 5-6 weeks compared to all other timepoints.  This analysis provides critical insight for 
improved future study design and interpretation.
Disclosures: Laura Zweifler, None
P-034
Calcium-phosphorus Metabolism In Patients With Cushing’s Disease 
*Alexandra Povaliaeva1, Ekaterina Pigarova1, Artem Zhukov1, Larisa Dzeranova1, 
Larisa Nikankina1, Liudmila Rozhinskaya1. 1Endocrinology Research Centre, 
Moscow, Russia, Russian Federation
Objective: to study the response of calcium-phosphorus metabolism to the cholecalcif-
erol loading dose in patients with an active Cushing’s disease in comparison with healthy 
individuals.Materials and methods: The study included 12 patients (10 female and 2 male) 
with an active Cushing’s disease, median age 39.7 [37.5;47.3] years, BMI 31.3 [27.6;33.1] 
kg/m2, 25(OH)D level 13.3 [7.8;18.7] ng/ml (immunochemiluminescent method, DEQAS 
certified), as well as 13 conditionally healthy individuals. The groups did not differ signifi-
cantly in age, sex, BMI and level of 25(OH)D. All participants were tested for PTH, total and 
ionized calcium, albumin, magnesium and creatinine blood levels as well as calcium- and 
phosphorus-creatinine ratio in single void urine before oral administration of 150 000 IU of 
an aqueous solution of cholecalciferol and 1, 3, 7 days after administration.Results: In the 
Cushing’s disease group we observed higher levels of ionized calcium at all points (p<0.05) 
and higher levels of magnesium on the 3rd and 7th day (p<0.05), lower phosphorus levels on 
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the 7th day (p<0.05). We also observed non-significant trends for higher levels of baseline 
albumin-adjusted serum calcium (p=0.07) and on day 1 (p=0.06), lower levels of baseline 
serum albumin (p=0.06), higher levels of PTH on the 3rd day (p=0.07).In the Cushing’s 
disease group phosphorus levels increased by day 1 after taking a loading dose of cholecal-
ciferol (p=0.04) and later decreased from day 3 to day 7 (p=0.04); levels of albumin-adjusted 
serum calcium decreased from day 1 to day 7 (p=0.03). In the control group we observed a 
significant increase in ionized calcium by day 3 (p=0.008), as well as a decrease in serum al-
bumin by day 3 (p=0.03), followed by an increase by day 7 (p=0.01).In the Cushing’s disease 
group magnesium levels showed significant negative correlation with total calcium levels at 
all points, as well as with ionized calcium levels at baseline and on day 7, with albumin-ad-
justed serum calcium at baseline, on day 1 and 7 (p<0.05). In the control group there were no 
such associations.Conclusion: the observed changes in calcium-phosphorus metabolism in 
patients with Cushing’s disease are probably associated with magnesium-mediated preven-
tion of an increase in blood calcium level, followed by an increase in PTH secretion, which 
led to a decrease in blood phosphorus. More studies are needed to characterize the observed 
changes accurately, including vitamin D metabolites.
Disclosures: Alexandra Povaliaeva, Russian Science Foundation (project No. 19-15-
00243), Grant/Research Support
P-035
Post-surgical permanent hypoparathyroidism: can we anticipate it? A 
cohort study *Giselle A Mumbach1, Romina Speroni1, Elbio Genovesi1, Mariana 
González Pernas1, Ana Paula Lisdero1, María Jimena Otero1, Ana Segarra1, María 
Laura García1. 1Sanatorio Dr Julio Méndez, Argentina
Introduction: Hypoparathyroidism (HypoPTH) is a disease manifested by hypocal-
cemia, hyperphosphatemia and inappropriate or low level of Parathyroid hormone (PTH). 
Common causes are thyroid or parathyroid surgery. HypoPTH could be classified: permanent 
(P) or transient (T). P-HypoPTH is the feared complication associated with high morbidity in 
follow-up . Recognize which patient has a higher risk to develop this unwanted complication 
will help us to achieve an earlier and prompt treatment.Objectives: Predict P-HypoPTH in 
post-surgical (PS) patients obtaining a cut-off value before 6 months follow-up.Methods: 
PS patients from Endocrinology Registry of Sanatorio Dr. Julio Méndez were retrospec-
tively follow-up for 12 months. We defined P-HypoPTH as hypocalcemia  and inadecuated 
or low PTH for more than 6 months post surgery. Calcium (Ca), PTH, phosphorous (P), 
vit D, magnesium and requirement of supplementation were measured a day after, a week 
and every three months. Two groups were formed and compared by Mann Whitney U Test, 
logistic regression, univariate and multivariate lineal regressions were performed as well 
as ROC curves and Logistic ROC curves. Data is expressed by variable distribution, OR 
with CI95%. p<0,05 is considered significant.Results: Seventy two patients were included. 
Logistic regressions and ROC curves were performed in order to find a predictable variable 
Table1.After several ROC curves we’ve determined a predictive diagnostic triad for P-Hy-
poPTH: week ca level of 8.9mg/dl under >=3grams of calcium supplements + 3rd month P 
level >4mg/dl; reporting S-E of 86-78% respectively AUC: 0,87 Conclusion: P-HypoPTH 
is an unwanted PS complication. Identifying a predictive data to determine which patient is 
at a higher risk to develop it will help us improve and quicken treatment response. We’ve 
found multiple risk variables and propose a diagnostic triad constructed by: Week ca level 
of 8.9mg/dl under >=3grams of calcium supplements and 3rd month P level >4mg/dl, but 
further studies with a larger number of patients is needed to confirm or improve our findings 
adding a better sensitivity and specificity.  
Disclosures: Giselle A Mumbach, None
P-036
Aldosterone is positively associated with circulating FGF23 levels in chronic 
kidney disease across four species, but does not drive FGF23 secretion 
directly *Judith Radloff1, Maximilian Pagitz1, Olena Andrukhova1, Rainer 
Oberbauer2, Iwan Burgener1, Reinhold Erben1. 1Veterinary University of Vienna, 
Austria, 2Medical University of Vienna, Austria
Chronic kidney disease (CKD) is accompanied by increases in circulating fibroblast 
growth factor 23 (FGF23) and aldosterone levels. The mechanism underlying increased se-
cretion of intact FGF23 from the skeleton in CKD still remains enigmatic. Here, we tested 
the hypothesis that aldosterone may be one of the driving forces behind increased FGF23 
secretion in CKD. Using data from a prospective study in humans (n = 14), a retrospective 
study in cats and dogs (n = 21 and 17), and an experimental study in 5/6-nephrectomized 
(5/6-Nx) mice (n = 45), we analyzed the relationship between circulating intact FGF23 and 
serum aldosterone levels in CKD across four species. To assess the effects of acute inhibition 
of aldosterone signaling on circulating FGF23, we treated mice with established CKD with 
the mineralocorticoid receptor blocker canrenone (50 mg/kg iv) and measured intact FGF23 
before and 24 h after administration of the drug. As expected, serum intact FGF23 was close-
ly associated with serum creatinine in human, canine, and feline CKD patients as well as in 
5/6-Nx mice (humans: Spearman rank correlation coefficient rS = 0.60, p = 0.0195; dogs: 
rS = 0.74, p < 0.0001; catS: rS = 0.70, p < 0.0001; mice: rS = 0.62, p < 0.0001), underscor-
ing the tight association between elevated serum intact FGF23 and declining renal function 
across all four species tested. Interestingly, we found a strikingly close association between 
circulating intact FGF23 and serum aldosterone in human, canine, and feline CKD patients, 
as well as in experimental murine CKD (humans: rS = 0.58, p = 0.0368; dogs: rS = 0.66, p = 
0.0019; cats: rS = 0.72, p = 0.0016; mice: rS = 0.49, p = 0.0004). However, injection of can-
renone in 5/6-Nx mice, 14 weeks postsurgery, did not lead to changes in the elevated intact 
FGF23 blood levels within 24 h post-injection. Hence, despite the tight positive association 
between circulating intact FGF23 and aldosterone in human, canine, and feline CKD pa-
tients as well as in experimental CKD models, the increased levels of circulating aldosterone 
in CKD are not directly driving FGF23 secretion.
Disclosures: Judith Radloff, None
P-037
Differences in Material Properties of Trabecular Bone Tissue from Modeling- 
and Remodeling-Based Bone Formation in Rats *Xiaowei Sherry Liu1, Wei-
Ju Tseng1, Wenzheng Wang1, Hongbo Zhao1, Alexander Bennett2, Lisa Mariani2, 
Yihan Li1, Tala Azar1, Nathaniel Dyment1, Do-Gyoon Kim3, Kevin Turner2. 
1McKay Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, 
Perelman School of Medicine, University of Pennsylvania, United States, 
2Department of Mechanical Engineering and Applied Mechanics, University of 
Pennsylvania, United States, 3College of Dentistry, Division of Orthodontics, 
The Ohio State University, United States
Activation of modeling-based bone formation (MBF), i.e., bone formation (BF) on qui-
escent surfaces, has been identified as an important mechanism by which anabolic agents, 
e.g. PTH1-34, rapidly elicit new BF. However, the quality of the bone tissue generated from 
MBF vs. remodeling-based BF (RBF, BF coupled with osteoclast resorption) is unclear. To 
identify MBF and RBF, we injected calcein (green, G), alizarin complexone (red, R), and tet-
racycline (yellow, Y) fluorochrome labels to 7-mo-old female rats (n=5-6/group) in a G-R-
Y-G sequence on days -2, 5, 12, and 19 (PTH 20μg/kg on days1-21), followed by euthanasia 
on day 84. Based on fluorochrome labels, cement lines, and collagen fiber alignment under 
fluorescence and second harmonic generation (SHG) microscopes, BF sites were identified 
as MBF (smooth cement line and uniform collagen fibers) or RBF (scalloped cement line 
with interrupted surrounding collagen fibers) on the 3-mm-thick PMMA sections of the rat 
tibia (Fig A-C). We hypothesize that the homogeneous collagen structure of MBF may lead 
to reduced heterogeneity of tissue material properties when compared to RBF.Compared to 
VEH, PTH treatment led to marked increases in both MBF- and RBF-induced mineralizing 
surface (MS/BS, Fig H). MS/BS was 136% greater for MBF vs. RBF with no difference in 
mineral apposition rate (MAR, Fig H). Nano-indentation tests were performed on PTH-treat-
ed specimens (10+/-2 MBF and 9+/-2 RBF sites per specimen) where BF sites were labeled 
with all 4 markers (G-R-Y-G, tissue age 10-12 wks, ~90% of BF sites). At each BF site, 
individual indents were performed first on the pre-existing bone, then on the MBF or RBF 
site, and lastly on the PMMA as internal controls (Fig D-G). While no difference in elastic 
modulus (E) or hardness (H) was found between MBF and RBF, both MBF and RBF had 
lower E (19% and 21%) and H (25% and 23%) vs. pre-existing bone (Fig I). Surprisingly, 
the full width at half maximum (FWHM) in E (EFWHM) of MBF was 27% and 28% greater 
vs. that of RBF and pre-existing bone, respectively, indicating increased heterogeneity in 
MBF. Similar results were also found for the coefficient of variance (CV) of E (ECV) and 
H (HCV).Our findings indicate greater heterogeneity in nano-scale E and H in bone tissue 
from MBF than those from RBF and pre-existing bone, rejecting our original hypothesis. 
Our results suggest that targeting MBF not only maximizes the net bone mass increase, but 
also leads to higher tissue heterogeneity.
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Whole bone geometry effects on functional compensation in the radius 
*Randee Hunter1, Karen Briley2, Amanda Agnew1. 1The Ohio State University; 
Skeletal Biology Research Laboratory, United States, 2Wright Center of 
Innovation in Biomedical Imaging, United States
Fracture prediction requires an understanding of multiple contributors to strength aug-
mented by using a systems approach. Functional compensation has been demonstrated in the 
tibia suggesting a coupling of the amount of bone and its mineralization. Furthermore, whole 
bone geometry has been shown to affect age-related changes in the radius. The purpose of 
this study is two-fold: investigate functional compensation trends as well as quantify effects 
of whole bone geometry on these trends in the radii of males and females. Quantitative 
computed tomography (QCT) was performed on bilateral radii (n=286) from post-mortem 
human subjects (n=92 males; n=51 females) ranging in age from 35-98 years at 50% and 
30% of total length (Le). Robustness (Tt.Ar/Le), a measure of whole bone geometry, and 
vBMD were quantified at each location. No significant side differences (p>0.05) were found. 
Data were analyzed by sex as well as divided into “slender” and “robust” groups using 
height-adjusted Tt.Ar/Le values. Tt.Ar/Le and vBMD were significantly different (p<0.01) 
between 30 and 50% (whether analyzed by sex or group) such that an inverse relationship 
indicates functional compensation where mineralization is increased in areas with less bone. 
After controlling for age, significant correlations between Tt.Ar/Le and vBMD were found 
in males (p=0.01, r=-0.13) and females (p=0.01, r=0.18). Robust radii demonstrated a sig-
nificant negative correlation (p<0.01, r=-0.19) whereas, there was no relationship in slender 
radii (p=0.68). Further investigation of sex-specific effects within each size group found 
only slender males (n=35) exhibited a significant inverse correlation (p=0.02, r=-0.21). 
Slender females (n=37) had a non-significant correlation within the radius and a positive 
trend (p=0.2, r=0.11) similar to trends seen in the female only group. Although the inverse 
relationship between variables in robust radii seem to demonstrate functional compensation, 
neither robust males (n=57) nor robust females (n=13) had significant correlations when 
considered separately despite obvious inverse trends (males r=-0.09; females r=-0.18). To 
maintain function, bone has the ability to synchronously alter features in response to age-re-
lated changes through mechanisms influenced by whole bone geometry. These results sug-
gest functional compensation may occur differently depending on whole bone geometry 
likely mediated by sex-specific differences.
Disclosures: Randee Hunter, None
P-039
Identifying Components of the Gut Microbiome that Regulate Bone Tissue 
Mechanical Properties *Marysol Luna1, Jason Guss1, Laura Vasquez-Bolanos1, 
Macy Castaneda1, Manuela Vargas Rojas1, Jasmin Strong1, Denise Alabi1, 
Sophie Dornevil1, Erik Taylor1, Rodrigo Bicalho1, Eve Donnelly1, Christopher 
Hernandez1. 1Cornell University, United States
Modifications to constituents of the gut microbiome can influence bone density and 
tissue strength, but the specific microbes that influence bone are not known. Here we use 
narrow spectrum oral antibiotics to selectively “knock out” distinct parts of the gut micro-
biota to help isolate the organisms responsible for modifications in bone tissue quality and 
strength.Under IACUC approval, male C57Bl/6 mice were divided into groups receiving 
oral treatment from 4-16 weeks of age to remove some or all of the gut microbial organ-
isms as follows (n=7-10/group, 57 total): 1) ampicillin; 2) neomycin; 3) vancomycin; or 4) 
metronidazole; 5) a cocktail of all 4 antibiotics with aspartame sweetener to remove 99% of 
gut microbes; 6) sweetener only control; and 7) an untreated control. Femora were collect-
ed, submitted to micro-CT for microarchitecture analysis, and tested in 3-point bending to 
determine whole bone strength. Tissue composition was obtained with FTIR spectroscopy. 
Taxonomic composition of the gut microbiota was determined by 16S rRNA sequencing and 
a subsequent PICRUSt analysis was used to predict the functional capacity of the gut micro-
biota.After accounting for differences in geometry, bone strength was reduced in the neomy-
cin group (p=0.002, Fig.1A) as was the tissue mineral:matrix ratio (Fig.1B). Taxonomy did 
not indicate differences between the neomycin and untreated groups (the vancomycin and 
sweetener groups differed from untreated, Fig.1C). However, the predicted functional capac-
ity of the gut microbiota in the neomycin group showed reduced ability to synthesize vitamin 
K (43.2 +/- 27.1% less than untreated animals). The sweetener only group showed increase 
tissue strength and metaphyseal bone volume fraction (Fig.1A,1D). This unexpected finding 
in the sweetener group suggests that sweeteners commonly used in microbiome studies may 
influence bone.Changes in the constituents of the gut microbiome caused by neomycin led to 
alterations in bone tissue strength. Our findings illustrate how taxonomy (which species are 
present, determined with 16S rRNA sequencing) may not be as good at explaining microbi-
ome-induced phenotypes as microbial functional capacity (which genes are present), which 
requires more expensive metagenomic sequencing. Furthermore, our findings are consistent 
with the idea that microbiome-derived vitamin K can influence bone tissue strength, possibly 
by modulating vitamin K dependent bone matrix proteins such as osteocalcin.
Disclosures: Marysol Luna, None
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Investigation of human trabecular bone quality in osteoporosis with and 
without type 2 diabetes *Praveer Sihota1, Ram Naresh Yadav1, Ruban Dhaliwal3, 
Jagadeesh Boss3, Vandana Dhiman4, Deepak Neradi3, Shailesh Karn3, Sidhartha 
Sharma5, Sameer Aggrawal6, Vijay Goni6, Vishwajeet Mehandia7, Deepak 
Vashishth8, Sanjay Bhadada9, Navin kumar10. 1PhD student, India, 3MD, United 
States, 3MD, India, 4PhD, India, 5Assistant Professor, Orthopedicas, PGIMER 
Chandigarh, India, 6Professor, orthopedics, PGIMER, India, 7Assistent Professor, 
IIT Ropar, India, 8Professor, RPI, United States, 9Professor,Endocrinology, 
PGIMER, India, 10Associate proffesor, IIT Ropr, India
Purpose: Individuals with type 2 diabetes (T2D) have a two to three-fold greater hip 
fracture risk than those without diabetes despite normal to high areal bone mineral density 
(aBMD). Mechanisms underlying diabetic skeletal fragility are poorly understood, making 
the clinical identification of those at risk for fractures difficult. Poor bone quality has been 
implicated in diabetic skeletal fragility but its role in altering the biomechanical proper-
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ties, associated with fracture due to lack of glycemic control over an extended period (>5 
yrs.), at the microstructural and bone matrix levels is not established.Method: Bone samples 
were taken from two groups of patients who were undergoing total hip replacement for 
low-energy hip fractures. These include patients without diabetes (n=40) and those with 
diabetes (n=30) of duration >5 years. The mean age of the diabetic and non-diabetic group 
was 67.8+/-9.2 and 71.2+/-10.8 years respectively. The mean duration of diabetes was 7.5 
+/-2.8 years. None of the patients had a history of hip fracture. The study was approved by 
the Institutional Ethics Committee (PGI/IEC/2015/171) of PGIMER, Chandigarh.Results: 
Baseline characteristics were similar for both groups. The bone quality parameters were 
found to be degraded in the diabetic group whereas no significant difference was observed in 
aBMD. Bone volume fraction was lower for the diabetic group than for non-diabetic group 
due to fewer and thinner trabeculae. Apparent-level (strength) and tissue-level (nanoinden-
tation determined) modulus and hardness were lower in those with diabetes. Compositional 
differences between the non-diabetic and diabetic groups included lower mineral to matrix 
ratio, wider mineral crystals and bone collagen modifications assessed as higher total fluo-
rescent advanced glycation end-products (fAGEs) and non-enzymatic cross-link ratio (NE-
xLR), lower enzymatic cross-link ratio (E-xLR) and altered secondary structure (Amide I 
and II bands). NE-xLR was strongly and negatively correlated with post-yield-strain, and 
fAGE was strongly and negatively correlated with post-yield-strain energy and toughness. 
These bone quality changes directly explain enhanced bone fragility in T2D.Conclusions: 
Our findings provide evidence of the detrimental effects of diabetes on trabecular bone qual-
ity at multiple scales due to lack of glycemic control over an extended period (> 5 yrs.) and 
provide new insight on skeletal fragility in individuals with diabetes.
Disclosures: Praveer Sihota, None
P-041
RAGE Removal in Developing Mice on High-Fat Diet Alters Bone Matrix 
Quality *Samuel Stephen1, Stacyann Bailey1, Divya Krishnamoorthy2, Danielle 
D’Erminio2, James Iatridis3, Deepak Vashishth1. 1Rensselaer Polytechnic 
Institute, United States, 2Ichan School of Medicine at Mount Sinai, United States, 
3Icahn School of Medicine at Mount Sinai, United States
Adolescent obesity, a growing worldwide epidemic, is related to chronic inflammation 
and elevated fracture risk. Recent work has highlighted that the receptor for advanced gly-
cation end products (RAGE), a key inflammatory mediator, affects bone metabolism. RAGE 
is believed to control reactive oxygen species synthesis, which is linked to matrix damage. 
Yet, the effect of RAGE on matrix quality in obese patients remains unknown. This study 
aimed to delineate how matrix quality is mediated by RAGE in obesity. We hypothesized 
that RAGE removal challenged with obesity would help retain bone matrix quality.Six-week 
old C57BL/6J (WT) and RAGE knockout littermates (KO, n=36; 50% Female/50% Male) 
were fed either a low fat (LF, 10% kcal) or high fat (HF, 60% kcal) diet for 12 weeks starting 
at 6 weeks of age. Tibiae and humeri (n=9/group) were excised at 18 weeks of age. Humeri 
were notched at diaphysis and loaded to failure in three-point bending to evaluate fracture 
toughness. Tibiae were scanned for cortical morphology with µCT and imaged with confocal 
Raman to assess matrix chemical composition. Two-factor ANCOVA with Tukey post-hoc 
test was used to identify any significant (p<0.05) differences between WT and KO groups 
with body mass normalized.  WT HF and KO HF females displayed reduced tibial cortical 
area, cortical thickness, and BMD over respective LF littermates (Table 1). No morphologi-
cal differences were seen in males. Mechanical testing revealed WT HF females had a higher 
toughening effect over WT LF females, but this diet effect was reversed in the KO female 
group (Fig. 1A). Raman imaging showed increased mineral-to-matrix ratio in KO groups 
over WT groups in both sexes (Fig. 1B). Additionally, WT HF females showed high pento-
sidine (PEN) and carboxymethyl-lysine (CML) over WT LF females that was not observed 
in KO female groups (Fig. 1C-D).The effects of HF diet on biomechanical properties seen in 
WT females were reversed in the RAGE KO group, implying that RAGE alters diet affects 
bone quality in a sex dependent manner. Compared to WT controls, RAGE KO groups dis-
played enhanced mineral-to-matrix ratio but attenuated glycoxidative and glycation-based 
damage in the bone matrix, seen by reduced CML and PEN. Thus, ablation of RAGE con-
serves bone quality despite degraded geometry and BMD. Therapeutic targeting of RAGE 
may have a promising role in reducing fracture risk in the obese population through man-
agement of bone quality.
Disclosures: Samuel Stephen, None
P-042
Changes in Bone Quality after One Year of Teriparatide Treatment *Florence 
Lima1, Madhumathi Rao1. 1University of Kentucky, United States
Background: We studied bone biopsies at baseline and after 1 year of treatment with 
teriparatide (TPD), in patients with low-energy fractures and low bone turnover, to exam-
ine the effect of teriparatide on bone quality using Fourier transform infrared spectrosco-
py (FTIR). FTIR assesses changes in bone mineral and matrix properties and parameters 
measured are Mineral-to-Matrix ratio (MM), Carbonate-to-Phosphate ratio (CP), Collagen 
Crosslinks (Cx) and Crystal size (C). Methods: We studied 10 patients who had paired bi-
opsies a year apart. We also evaluated bone mineral density (BMD) by DXA, bone turnover 
markers (bone specific alkaline phosphatase, n-telopeptide and osteocalcin) at baseline and 
1 year. Undecalcified bone biopsies with tetracycline labeling were obtained from iliac crest 
and evaluated by qualitative histology and quantitative histomorphometry. FTIR results were 
compared against normal control samples. Results: As expected, DXA results and BV/TV by 
histomorphometry showed a significant improvement after 1 year of TPD treatment (Lumbar 
BMD: 8.0+/-3.6%, P<0.01 and BV/TV: 50+/-57%, P<0.05). Bone turnover markers were 
significantly increased after 1 year of TPD treatment (P<0.01); bone turnover parameters by 
histomorphometry were also increased but did not reach significance (BFR/BS: 55+/-113%, 
P = 0.40 and Acf: 64+/-106%, and P = 0.14). FTIR studies showed that Mineral-to-Matrix 
ratio and Crystal size were overall increased compared to baseline (MM: 8.1+/-9.6%, P = 
0.03 and C: 4.9+/-3.5%, P<0.01, Fig. 1). At baseline, the overall Mineral-to-Matrix mean 
was lower than controls (MMbas = 4.16 vs. MMCont = 4.54, P = 0.08), while 1 year after 
TPD treatment, the overall mean values were close to the control mean value (MM1yr = 4.50 
vs. MMCont = 4.54, P = 0.80). Crystal size parameter increased after 1 year of treatment; the 
overall mean at baseline was not different from controls (CBas = 1.14 vs. CCont = 1.15, P = 
0.53, Fig. 1) while 1 year later, the overall mean was significantly higher than controls (C1yr 
= 1.19 vs. CCont = 1.15, P = 0.04, Fig. 1). CP ratio and Cx parameters were not significant-
ly different between baseline and 1 year of TPD treatment (P = 0.06 and P = 0.54, resp.). 
Conclusion: Studies on the effect of TPD on bone quality are limited. We show that TPD im-
proves bone quality and microarchitecture by increasing Mineral-to-Matrix ratio and crystal 
size. This effect occurs in addition to the improvement demonstrated in Bone Volume.
Disclosures: Florence Lima, None
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One Year of Denosumab after Two Years of Teriparatide in Premenopausal 
Idiopathic Osteoporosis (IOP): Changes in Skeletal Indices using High 
Resolution Peripheral Computed Tomography (HR-pQCT) *Sanchita 
Agarwal1, Adi Cohen1, Stephanie Shiau2, Nayoung Kil1, Mafo Kamanda-
Kosseh1, Mariana Bucovsky1, Elizabeth Shane1. 1Division of Endocrinology, 
Department of Medicine, Columbia University, United States, 2Department of 
Biostatistics & Epidemiology, Rutgers School of Public Health, United States
Premenopausal women with IOP (PreMenIOP) have marked deficits in volumetric 
BMD (vBMD), microstructure and bone strength of the peripheral skeleton by HR-pQCT. 
We previously reported that 24 months (M) of teriparatide (TPTD) improved trabecular (Tb) 
microstructure, increased cortical (Ct) area, thickness (Th) and porosity (Po) and estimated 
bone strength that were more consistent at tibia than radius in 34 women with PreMenIOP. 
In a subset of 26 TPTD-treated women, we now report sequential treatment with 12M of 
denosumab (Dmab; 60 mg SC q6M) and overall effect of treatment with 24M TPTD + 
12M Dmab. 22 women had complete data at tibia and 14 at radius (7 excluded for motion 
>3 or corruption). 11 had baseline scans on 1st-(XCT1) and follow-up on 2nd-generation 
HR-pQCT (XCT2). Common ROI generated by standard 2D matching was analyzed for 
all 3 visits. XCT2 data were calibrated to XCT1 by regression. Changes after 24M TPTD, 
12M Dmab and 24M TPTD + 12M Dmab were analyzed by paired Student’s t-tests. Primary 
outcomes were total, Ct and Tb vBMD, CtPo and stiffness. Tibia: After 24M of TPTD, 
Tb number (N) increased by 3.1% (Table; p<0.05), CtTh and Po by 2.5% and 18.6%, and 
stiffness and failure load (FL) by 2.8% and 2.3% respectively (all p<0.01); density measures 
did not change. After 12M of Dmab, total, Ct and Tb vBMD, Tb BV/TV and CtTh increased 
by 2.5%, 1.4%, 2.9%, 2.8% and 1.0% (all p<0.01), TbTh and FL increased by 1.5% and 
1.1%  (both p<0.05); CtPo did not change. Compared to baseline, TPTD+Dmab (24+12M) 
was associated with higher total vBMD and CtTh (2.4% and 3.6%; p<0.01) and TbN (4.2%; 
p<0.05). CtPo remained 16.4% above baseline (p<0.01), but stiffness increased by 3.8% 
(p<0.01). Radius: Despite improvements in Tb microstructure (increased TbN and TbTh, 
decreased TbSp, p<0.05) during TPTD, total, Ct and Tb vBMD and stiffness did not change. 
During Dmab, total and Ct vBMD increased by 2.5% and 1.7% (both p<0.01) and CtTh by 
1.2% (p<0.05). After TPTD+Dmab, there were increases in total vBMD (1.8%), Tb BV/TV 
(1.7%), TbN (6.1%) and TbTh (5.1%, all p< 0.05), with no statistically significant increase 
in stiffness or FL. In summary, we observed that sequential therapy with 24M TPTD + 12M 
Dmab resulted in improved Tb and Ct microstructure and strength at the tibia and to a lesser 
extent at the radius, possibly due to lower power in the latter. We hypothesize that Dmab per-
mits bone formed during TPTD to mineralize, thus increasing overall density and strength.
Disclosures: Sanchita Agarwal, None
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Age-changes in femoral neck cortical and trabecular traits vary with region 
and sex *Karl Jepsen1, Daniella Patton1, Erin Bigelow1, Robert Goulet1, Stephen 
Schlecht2, David Kohn1, Carrie Karvonen-Gutierrez1, Todd Bredbenner3. 
1University of Michigan, United States, 2Indiana University, United States, 
3University of Colorado Colorado Springs, United States
Hip bone mineral density (BMD) provides a simple measure of femoral neck mass but 
obscures regional changes in cortical and trabecular structures that contribute to strength 
decline. Age-related bone loss is thought to occur nonuniformly within the proximal femur 
with loss in mass of the secondary and tensile arcades preceding that of the compressive 
arcade. However, these studies were not conducted using high resolution 3D imaging. We 
mapped cortical and trabecular structure for the femoral neck and tested for regional and 
sex differences in how structure changed with age.Femoral neck cortical (Ct.BVF) and 
trabecular bone volume fraction (Tb.BV/TV) were measured for white male (n=50, 18-89 
years) and female (n=44, 21-97 years) cadavers using nanoCT (27μm). The femoral neck 
was divided into 4 cortical and 4 trabecular regions resulting in 8 regions designated as 
superior-proximal (SP), superior-distal (SD), inferior-proximal (IP), and inferior-distal (ID) 
for each bone type. There was a significant negative correlation between Tb.BV/TV and 
age in all regions for females (SP R2=0.30, p<0.001; SD R2=0.27, p<0.001; IP R2=0.11, 
p=0.026; ID R2=0.17, p=0.005) and males (SP R2=0.16, p=0.004; SD R2=0.18, p=0.003; 
ID R2=0.17, p=0.003) except for the male IP region (R2=0.04, p=0.173). Regression y-in-
tercepts (p0.4, ANCOVA) differed by sex for all regions, indicating that males had greater 
Tb.BV/TV than females but that both sexes showed similar rates of Tb.BV/TV loss with 
age. Males showed nonsignificant age associations with Ct.BVF for all regions (R2=0.002-
0.05, p=0.12-0.73). In contrast, females showed significant negative correlations with age 
in the inferior cortical regions (IP R2=0.24, p<0.001; ID R2=0.13, p=0.016). The slopes of 
the IP (p<0.001) and ID (p=0.006) regressions differed significantly by sex suggesting that 
cortical porosity increased in the inferior cortex of females at a faster rate than for males.
Regional age-changes in structure were mapped in 3D for the first time revealing similar 
rates of change in Tb.BV/TV among most regions within the proximal femur and suggesting 
that bone loss declined more uniformly than expected. Sex differences in cortical bone loss 
were localized to the inferior cortex where fractures originate. Females had lower Tb.BV/
TV across all ages including the compressive arcade; these trabecular losses combined with 
greater Ct.BVF losses (ie, increased porosity) within the inferior cortex would greatly reduce 
femoral neck fracture resistance and may contribute to the greater fracture rate of women 
compared to men.
Disclosures: Karl Jepsen, None
P-045
Voluntary Jumping Exercise Pre-Treatment Enhances Cancellous Bone 
Strength and Density in the Tibia of Hindlimb Unloaded Rats *Scott 
Lenfest1, Jon Elizondo1, Jessica Brezicha2, Amelia Looper3, Susan Bloomfield4, 
Harry Hogan1. 1Dept. of Mechanical Engineering, Texas A&M University, 
United States, 2Dept. of Biomedical Engineering, Texas A&M University, United 
States, 3College of Veterinary Medicine, Texas A&M University, United States, 
4Dept. of Health and Kinesiology, Texas A&M University, United States
            Resistance exercise is an important component of in-flight countermeasures for 
mitigating bone loss in astronauts. The hindlimb unloading rat model allows for ground-
based study of skeletal effects due to simulated microgravity, but simulating exercise is more 
challenging in this animal model. The goal of our current study was to assess the efficacy of 
a voluntary jumping exercise (VJE) protocol that uses positive reinforcement.            Adult 
male rats (5 mo.) were placed in a custom jumping cage and trained over 5 weeks to jump 
onto a 10” platform. Rats were then assigned to aging control (AC, n=63), hindlimb unload-
ing control (HU, n=27) or exercise (VJE, n=45) groups by body weight and jumping ability. 
VJE animals performed 30 jumps/d, 5 d/wk, for 4 wks at an average rate of 1 jump each 
20-25 sec. After the 28d period, HU and VJE animals did 28d of unloading. In vivo pQCT 
scans of the proximal tibia metaphysis (PTM) were taken before (d0) and after (d28) VJE 
pre-treatment, at the end of HU (d56), and at the end of 56d of recovery (d112). Reduced 
platen compression (RPC) testing was performed on the proximal tibia metaphysis of bones 
harvested on d28, d56, and d112 to assess cancellous bone.            Following exercise (d28), 
total vBMD was higher (+4.7%) for the VJE group vs. AC. Cancellous vBMD also trended 
higher for VJE (8.8%) vs. HU. After HU (d56), the VJE group had significantly higher can-
cellous vBMD (+21.2%) compared to HU. The VJE group maintained significantly higher 
cancellous vBMD compared to both AC and HU throughout recovery. RPC showed similar 
results, but the magnitude of difference was much greater. At the end of exercise (d28), the 
VJE group had higher Ultimate Stress (US, +45%) and Elastic Modulus (EM, 31%) vs. AC, 
but these differences were not significant. VJE rats had significantly higher US and EM vs. 
HU at the end of unloading (d56, +239%, +208%, resp.) and at the end of recovery (d112, 
+107%, +58%, resp.).            These data indicate that our new VJE protocol induces an 
anabolic bone response that conserved bone integrity, particularly in the cancellous com-
partment, during a subsequent period of disuse. These findings further demonstrate that the 
magnitude of change in densitometric properties underpredicts the magnitude of change in 
mechanical properties. The results have important implications for situations when patients 
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on bed rest or crew members aboard ISS are unable to exercise, as the benefits persist long 
after cessation of exercise.
Disclosures: Scott Lenfest, None
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Maximizing Precision for Estimated Bone Strength in Longitudinal Analyses 
by HR-pQCT and the Finite Element Method *Ryan Plett1, Steven Boyd2. 
1Biomedical Engineering Graduate Program, University of Calgary, Canada, 
2McCaig Institute for Bone and Joint Health, Cumming School of Medicine, 
University of Calgary, Canada
Three-dimensional (3D) imaging with high-resolution peripheral quantitative comput-
ed tomography (HR-pQCT) and micro-finite element analysis (µFEA) provides important 
insight into bone health. Longitudinal analyses of bone morphology maximize precision 
by using slice-matching or 3D rigid body registration to account for repositioning error be-
tween scans. However, the compatibility of these techniques with µFEA for longitudinal 
bone strength estimates are limited. This study develops and validates a μFEA methodology 
for HR-pQCT scans using image registration to maximize reproducibility and compares it 
to current methods.Using a standard imaging protocol, ex vivo HR-pQCT (XtremeCT II, 
Scanco Medical) distal radius images were acquired for 10 cadaveric specimens in addition 
to three serial scans of each sample. The intact forearm was repositioned with relative an-
gles (~1o, ~3o, ~6o) simulating a range of typical repositioning errors. Reaction force and 
failure load were estimated with μFEA (Faim v8.0, Numerics88 Ltd.) for three conditions: 
non-registered, the current standard slice-matched, and the newly developed 3D registered 
images. In our proposed method, only the common bone volume across serial scans is used 
for μFEA. We quantified least significant change (LSC) to estimate the precision of seri-
al measures. Since cadaveric bone was used, the gold-standard was zero change in serial 
estimates. Comparisons of precision were based on repeated-measures ANOVA (p<0.05).
Reaction force LSC significantly improved with slice-matching (74.27 N) and 3D registra-
tion (51.02 N) compared to non-registered estimates (285.28 N). Similarly, failure load LSC 
significantly improved with slice-matching (34.63 N) and 3D registration (27.57 N) com-
pared to non-registered estimates (123.96 N). LSCs did not differ significantly between 3D 
registration and slice-matching; however, at repositioning errors 3o or greater 3D-registered 
failure load was significantly improved from no registration, but slice-matching was not.We 
found that μFEA reproducibility improved using both slice-matching and 3D rigid-body im-
age registration, and that 3D registration was advantageous as repositioning error increased. 
Although 3D registration does not negate motion artifacts and aliasing, it plays an important 
role in providing the best LSC possible for longitudinal study designs and is ideally suited 
for estimating in vivo effects of interventions in longitudinal studies of bone strength.
Disclosures: Ryan Plett, None
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Metacarpal strength and porosity predict strength and porosity at other 
skeletal sites in a sex-specific manner *Erin Bigelow1, Daniella Patton1, Bonnie 
Brooker-Nolan1, Antonio Ciarelli1, Stephen Schlecht2, Todd Bredbenner3, David 
Kohn1, Carrie Karvonen-Gutierrez1, Karl Jepsen1. 1University of Michigan, 
United States, 2Indiana University, United States, 3University of Colorado 
Colorado Springs, United States
The metacarpal has been examined as a proxy of bone health at fracture prone sites 
like the proximal femur as it can be imaged at higher resolution and lower radiation dose. 
Prior work focused on metacarpal morphology and bone mineral density, but a systematic 
inter-skeletal comparison of bone strength and porosity has not been conducted. Herein, 
we tested how direct measures of metacarpal strength and porosity correlate across skeletal 
sites. We also tested whether these associations are sex-specific.Third metacarpals, radii, and 
femurs were obtained from white male (M, 18-89 years) and female (F, 21-97 years) cadav-
ers with IRB approval. Mid-shaft porosity and proximal femur trabecular bone volume frac-
tion (BV/TV) were obtained using nanoComputed Tomography. Whole bone strength was 
determined for diaphyses loaded in four-point bending and proximal femurs loaded in a side-
ways fall configuration.Metacarpal strength correlated significantly with strength measured 
at the radius (n=31, R2=0.33, p<0.001), femoral diaphysis (n=28, R2=0.51, p<0.001), and 
proximal femur (n=24, R2=0.48, p<0.001) for males (Fig 1). Likewise, metacarpal strength 
correlated with strength at the radius (n=37, R2= 0.55, p<0.001), femoral diaphysis (n=34, 
R2=0.65, p<0.001), and proximal femur (n=34, R2=0.53, p<0.001) for females. Sex-specific 
differences in the y-intercept for the radius (p<0.001) and the slope for the proximal femur 
(p=0.026) indicated that males had stronger radial diaphyses and proximal femora relative to 
the metacarpal compared to women.Metacarpal porosity for males correlated with porosity 
at the radius (R2=0.55, p<0.001) and femoral (R2=0.13, p=0.057) diaphyses, and with prox-
imal femur BV/TV (R2= 0.17, p=0.030). For females, metacarpal porosity correlated with 
porosity at the radius (R2= 0.36, p<0.001) and femoral (R2=0.15, p=0.02) diaphyses, and 
with trabecular BV/TV of the femoral neck (R2=0.33, p=0.032). Differences in the y-inter-
cept for the radius (p=0.002), and proximal femur BV/TV (p=0.014) indicated that females 
had greater radius porosity but lower femoral neck BV/TV relative to the metacarpal com-
pared to males.Thus, metacarpal strength and porosity predict strength and porosity at other 
skeletal sites with known inter-site differences in age-related bone loss patterns. Critically, 
these associations were sex-specific suggesting further research is needed to understand how 
peripheral sites can be used to monitor bone health at fracture prone sites.
Disclosures: Erin Bigelow, None
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Altered otic capsule morphology of the oim mouse model of osteogenesis 
imperfecta *Annalisa De Paolis1, Brendyn Miller2, Michael Doube3, Andrew 
J Bodey4, Christoph Rau4, Claus-Peter Richter5, Luis Cardoso1, Alessandra 
Carriero6. 1The City College of New York, United States, 2Clemson University, 
United States, 3City University of Hong Kong, Hong Kong, 4Diamond Light 
Source, United Kingdom, 5Northwestern University Feinberg School of 
Medicine, United States, 6The City college of New York, United States
Osteogenesis imperfecta (OI) is a genetic disorder caused by mutations in the encod-
ing of type I collagen. Skeletal fragility, deformities, and functional disabilities, including 
hearing loss, are typical symptoms of OI. Hearing loss in OI is progressive and in 11-31% 
of cases occurs in children below 10 years old [1-3]. There is no cure or treatment for OI 
hearing loss, and very little is known about the properties of the OI inner ear or the mecha-
nisms leading to hearing loss. In this study we investigate the morphology of the otic cap-
sule and the cochlear spiral duct in the oim mouse model of OI, which also suffers hearing 
loss [4]. High-resolution images of 8 week old oim and WT inner ears (N=6/group) were 
acquired using synchrotron microtomography at sub-micron resolution. Morphological in-
dexes were evaluated on the coronal and sagittal planes at their intersection with the cochlear 
modiolus and on two transverse planes crossing the middle and apical turn of the cochlea 
(Fig. 1a-b). Otic capsule thickness was measured on the aforementioned planes and otic 
capsule length was measured in the coronal plane. At the tissue level, cortical bone porosity, 
canals and lacunae were measured [5]. The total volume of the duct and of the helicotrema, 
and the external spiral length were quantified on 3D renderings of the fluid scalae. Duct and 
helicotrema surface area and perimeter were measured on the coronal and sagittal planes, 
turn pitches on the coronal plane, and maximum axes on the transverse planes. The morphol-
ogy of the oim inner ear is mainly preserved in the 8 week old mouse, but increased coronal 
cortical thickness and intracortical canal density, volume and connectivity affect the oim otic 
capsule (Fig. 1c-i). These results portray a state of compromised bone quality in the oim otic 
capsule which may contribute to hearing loss by making the bone tissue more susceptible 
to microfractures and/or by varying the hydrodynamics inside the cochlear duct. Further 
studies are also needed to examine the growth and development of  oim ear bones in relation 
to osteoprotegerin distribution and hearing loss.References1. Pedersen, Scand Audiol, 13:2, 
19842. Pillion et al., Genet Res Int, 20113. Ting et al., Clin Otolaryngol, 37:3, 20124. Chen 
et al., Clin Genet, 71:5, 20075. Miller et al., ORS Annual Meeting, 2017
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Two Years of Teriparatide Followed by One Year of Denosumab in 
Premenopausal Idiopathic Osteoporosis (IOP): Effect on Lumbar Spine 
Volumetric BMD by Central QCT *Sanchita Agarwal1, Thomas Lang2, 
Stephanie Shiau3, Mafo Kamanda-Kosseh1, Mariana Bucovsky1, Robert Recker4, 
Joan Lappe4, Julie Stubby4, Jennifer Larsen4, Elizabeth Shane1, Adi Cohen1. 
1Division of Endocrinology, Department of Medicine, Columbia University, 
United States, 2School of Dentistry, University of California San Francisco, 
United States, 3Department of Biostatistics & Epidemiology, Rutgers School of 
Public Health, United States, 4Department of Medicine, Creighton University 
Medical Center, United States
Premenopausal women with IOP (PreMenIOP) have large deficits in lumbar spine (LS) 
total and trabecular (Tb) volumetric BMD (vBMD) measured by central QCT (cQCT). We 
have reported that 24 months (M) of teriparatide (TPTD; 20mcg SC QD) markedly increased 
LS BMD by DXA in 41 PreMenIOP (age 36.9+/-7.6 yrs). In 32 of the 41 women, vBMD of 
L1-L2 was imaged by cQCT at baseline and after 24M of TPTD; a calibration phantom was 
scanned to convert CT Hounsfield Units to equivalent concentration of calcium hydroxy-
apatite. QCT parameters included total density (with posterior elements; Tot_vBMD), Tb 
density (Tb_vBMD) and strength index (SI; =density2*area). SI, computed from the 10mm 
mid-section of the vertebral body, approximates vertebral compressive strength. After 24M 
of TPTD, there were significant increases in all parameters (Table; within-group change 
analyzed by paired Student’s t-test). Tot_vBMD and its DXA equivalent LS BMD increased 
by 9% and 13% respectively; Tb_vBMD increased by 25% and SI by 57% (all p<0.001). 
Five women had no BMD increase by DXA (12M LS BMD change <0.026 g/cm2). These 
women had no significant increase in Tot_vBMD (3+/-5%; p=0.3), while Responders 
did (10+/-9%; p<0.01). Similarly, Tb_vBMD did not increase in Nonresponders (9+/-11; 
p=0.12), while Responders increased by 26+/-22% (p<0.01). SI increased in Nonresponders 
(26+/-25; p=0.02) and Responders (62+/-44%; p<0.01), but trended smaller in Nonrespond-
ers (p=0.12).After completing TPTD, 30 PreMenIOP took denosumab (Dmab; 60 mg SC 
q6M) for 12M; 27 had cQCT scans at all 3 timepoints (baseline, 24M TPTD, 12M Dmab). 
For each time period, changes were analyzed by paired Student’s t-test. After 12M of Dmab 
(Table), LS BMD increased further by 6%, Tot_vBMD by 4% (p<0.05), Tb_vBMD by 10%, 
and SI by 15% (all p<0.001). Compared to baseline, 24M TPTD + 12M Dmab was asso-
ciated with large and statistically significant improvements in all parameters: Tot_vBD, LS 
BMD, Tb vBMD and strength index increased by 15%, 20%, 43% and 85% respectively (all 
p<0.001).In summary, 24M of TPTD was associated with statistically significant increases 
in Tot_vBMD, Tb vBMD and SI by cQCT and LS BMD by DXA. Sequential Dmab therapy 
resulted in further statistically significant increases in all indices. Compared to pretreatment, 
24M TPTD + 12M Dmab led to marked overall improvements in vBMD and strength by 
cQCT and LS BMD by DXA. We conclude that Dmab further enhances bone mass and 
strength gains made during TPTD therapy in PremenIOP.
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Trabecular bone structural units (BSU) in the human lumbar spine decrease 
in size with age and bone volume fraction *Britney Lamarche1, Christina 
Møller Andreasen2, Jesper Skovhus Thomsen3, Thomas Levin Andersen2, 
Brent Lievers1. 1Bharti School of Engineering, Laurentian University, Canada, 
2Clinical Cell Biology, Pathology Research Unit Dept. of Molecular Medicine & 
Dept. of Clinical Research, University of Southern Denmark, Denmark, 3Dept. 
of Biomedicine, Aarhus University, Denmark
Age-related fractures are common at skeletal sites with high proportions of cancellous 
bone such as the hip and spine. Because of their ageing populations, the incidence of such 
fractures is expected to increase in industrialized countries. Previous research has shown that 
measures of bone quantity (e.g., bone mineral density) are imperfect predictors of fracture 
risk, so recent efforts have focused on combining them with measures of bone quality such 
as the microarchitecture or composition. Trabeculae are composed of a patchwork of bone 
structural units (BSU), also known as hemiosteons or trabecular packets, bonded togeth-
er by cement lines. The BSU-composition of trabeculae has received little attention. Any 
age-related changes in BSU morphometry due to remodeling can be expected to alter the 
mechanical properties and failure behaviour of cancellous bone.The present study focuses 
on whether the most recently formed BSU in vertebral cancellous bone undergo morphomet-
ric changes with age. The study was conducted on L2 vertebrae from eight young (18.5–37.6 
years) and eight old (69.1–96.4 years) females with no history of osteoporotic fractures. The 
vertebrae were scanned with µCT and embedded in plastic. Thin frontal sections (7.5 µm) 
from the centre of each vertebral specimen were prepared and immunostained for osteopon-
tin to highlight the cement lines. The cement lines of the recently formed BSU (i.e., intact 
with no new resorption or formation) were manually traced using ImageJ on high resolution 
scans of the sections. Polarized light microscopy was used to clarify any ambiguous staining. 
The area, thickness, and direct length (Fig. 1) of 4,230 BSU (181–385 per vertebra) were 
measured. A nested t-test indicated that BSU in the old group had significantly smaller area, 
thickness, and length compared to the young group (p<0.0140), and there was a negative lin-
ear correlation between age and the three measured BSU parameters (p<0.0172). The BSU 
measurements were also highly correlated to bone volume fraction (BV/TV, p<0.0017) and 
structure model index (SMI, p<0.0072) obtained by µCT. The results show that vertebral tra-
becular BSU decrease in area, thickness, and length with both increasing age and decreasing 
bone volume fraction. The mechanical consequences of the changes in BSU morphometry 
on fracture risk warrant further investigation.
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Predicting Patient-Specific Bone Atrophy using Level-Set Methods and 
HR-pQCT Measurements *Tannis Kemp1, Bryce Besler2, Lauren Burt2, 
David Hanley2, Steven Boyd2. 1Department of Mechanical and Manufacturing 
Engineering, Schulich School of Engineering, University of Calgary, Calgary, 
Canada, Canada, 2McCaig Institute for Bone and Joint Health, University of 
Calgary, Calgary, Canada, Canada
Previous studies attempted to model age-related bone atrophy; however, these studies 
used bone atrophy rates that were not specific to individual participants and therefore did not 
capture patient-specific changes.  This study aims to 1) extract patient-specific bone atrophy 
rates from serial in vivo high resolution peripheral quantitative computed tomography (HR-
pQCT) measurements, and 2) predict bone microstructure by comparing our new simulated 
bone atrophy results to ground-truth HR-pQCT data at multiple time points. A subset of 
participants (N=30) from the Calgary Vitamin D Study, investigating effects of high-dose 
vitamin D supplementation on bone quality in healthy adults (55-70 years) are used. Distal 
tibia HR-pQCT scans were taken at baseline, 6, 12, 24 and 36 months. The baseline and 
6-month scans are used to determine patient-specific atrophy rates; the remaining timepoints 
are used to compare simulated and ground-truth microstructure. Individual bone atrophy 
rates are determined using level-set methods, least squares and gradient descent to optimize 
the difference between simulated and ground-truth trabecular bone volumes. Dice coefficient 
evaluated the difference between simulated and ground-truth bone volume data, where val-
ues closer to 1 indicate good agreement. Root mean square error (RMSE) measured the error 
in trabecular bone volume fraction (Tb.BV/TV) between simulation and ground-truth. The 
results for a representative participant are presented (Fig 1). For this participant at month 6, 
the dice coefficient is 0.89 and the RMSE in Tb.BV/TV is 0.004. These results indicate the 
algorithm successfully determined atrophy rates. For this participant over months 12-36, 
the average dice coefficient is 0.80+/-0.05 (strong prediction) whereas the RMSE in Tb.BV/
TV is 0.028 (10.2% of peak Tb.BV/TV). The strong dice coefficient is likely from optimiz-
ing simulated and ground-truth bone volumes, and not optimizing for specific morphologic 
parameters such as Tb.BV/TV. To our knowledge, this is the first attempt to predict future 
bone health by determining patient-specific bone atrophy rates from serial in vivo HR-pQCT 
data.  Future work will employ strain-adaptive models and all participants will be examined 
to determine the method’s feasibility in a population.
Disclosures: Tannis Kemp, None
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The Role of Matrix Metalloproteinase-13 on Perilacunar/Canalicular 
Remodeling During Lactation *Michael Sieverts1, Cristal Yee2, Minali 
Nemani2, Tamara Alliston2, Claire Acevedo1. 1University of Utah, United States, 
2University of California, San Francisco, United States
PURPOSEPerilacunar/canalicular remodeling (PLR) is a dynamic process in which 
osteocytes resorb and replace local bone extra cellular matrix (ECM) surrounding their 
perilacunar and pericanalicular spaces by secreting matrix metalloproteases (MMPs) and 
resorptive enzymes. We and others have found that PLR is crucial to maintain bone quality, 
systemic mineral homeostasis, and the osteocyte lacuno-canalicular network (LCN). PLR 
is increased during lactation to meet the metabolic demand of supplying minerals from the 
mother’s skeleton to their offspring. This change in mineral homeostasis during lactation re-
sults in a reduction of bone mass, change in bone morphology and increase skeletal fragility. 
In addition to changes at the whole bone level, local volumetric changes also occur in the 
ECM surrounding osteocyte lacunae. Since matrix metalloproteinase-13 (MMP13) is essen-
tial for PLR and maintaining bone quality, we used MMP13 osteocyte specific cell knockout 
mice (MMP13ocy-/-) to study MMP13 osteocyte role during lactation-induced PLR.METH-
ODSFemale mice (n=4-5 mice per group) with osteocyte specific knockout of MMP13 
(DMP1Cre+;MMP13fl/fl, referred to as MMP13ocy-/-) and littermate controls (DMP-
1Cre-;MMP13fl/fl, referred to as WT) were used. For lactation study, MMP13ocy-/- and 
WT mice at 10 weeks were time-mated, allowed to be pregnant, adjusted litter size to 8-10 
pups after delivery, and lactated for 14 days. Lactated mice and 16-week-old aged-matched 
virgin mice were euthanized and tibias were harvested for imaging on the micro-computed 
tomography beamline 8.3.2 at the Advanced Light Source at Lawrence Berkley National 
Laboratory.RESULTSAt the whole bone level, significant reductions in bone volume and 
cortical thickness were observed due to lactation regardless of genotype. Bone volume of the 
WT and MMP13ocy-/- were reduced by 22% and 14% respectively. This reduction of bone 
is consistent with current knowledge of lactations effect on bone. Another common response 
to lactation is an increase in lacunar volume attributed to PLR. Analysis of lacunar volume 
showed evidence of PLR in the lactating WT mice. The lacunar volume of the WT mice 
significantly increased by 31% with lactation. In contrast, no significant difference in volume 
was observed within the MMP13ocy-/- genotype due to lactation.CONCLUSIONFindings 
indicate that MMP13 deficiency inhibits PLR during lactation. This shows that MMP13 is a 
vital gene for PLR to occur during lactation.
Disclosures: Michael Sieverts, None
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Abaloparatide Improves Bone Mass and Microarchitecture, without 
Increasing Bone Resorption, in Adult Rats Subjected to Hindlimb Unloading 
*Dian A. Teguh1, Amanda E. Craven1, Jordan L. Nustad1, Daniel J. Brooks1, 
Heike Arlt2, Beate Lanske2, Mary L. Bouxsein1. 1Beth Israel Deaconess Medical 
Center, United States, 2Radius Health, Inc, United States
Disuse osteoporosis occurs due to a reduction in mechanical loading, commonly caused 
by prolonged bed rest, paralysis, casts/braces, or microgravity exposure during spaceflight. 
Abaloparatide (ABL) is a PTHrP analog that has been shown to promote bone formation 
with limited bone resorption activity (Culler et al., 2001, Doyle et al., 2013), though its 
ability to prevent bone loss due to disuse has not been studied. Here, we assessed whether 
ABL prevents bone loss due to hindlimb unloading. Adult male rats (14 wks of age) were 
assigned to one of four groups (10-12 per group): ambulatory+vehicle (CON-VEH), ambu-
latory+ABL (CON-ABL), hindlimb unloading+vehicle (HLU-VEH), or HLU+ABL (HLU-
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ABL). Rats received a daily injection of ABL (25µg/kg/day, SC) or VEH for 28 days. We 
measured trabecular (Tb) and cortical (Ct) bone microarchitecture ex vivo using µCT (15 
µm voxel size); dynamic histomorphometry and serum markers of bone metabolism. Mi-
croCT analyses revealed that HLU led to deficits in bone microstructure that were prevented 
by ABL treatment. In particular, at the distal femur, Tb.BV/TV, Tb.Th and Tb.BMD were 
-44%, -13% and -27% lower, respectively, in HLU-VEH vs. CON-VEH (p<0.05 for all); 
whereas these same outcomes were 67%, 39%, and 50% higher, respectively, in HLU-ABL 
vs. HLU-VEH. A similar positive impact of ABL treatment on bone morphology was seen in 
the normally ambulating rats. Tb. bone formation indices (MS/BS and BFR/BS) and osteo-
blast number were significantly reduced by HLU. In contrast, bone formation increased with 
ABL treatment in both HLU and CON rats, accompanied by either a significant decrease 
or no change in osteoclast number. Serum TRAcP5b did not differ among groups, whereas 
osteocalcin had a trend of increase in both ABL-treated groups compared to VEH. Gene 
expression levels for bone formation and resorption markers are currently being tested.In 
sum, this study demonstrated positive effects of ABL on the trabecular and cortical bone 
in both normally ambulating and unloaded animals, with increases in bone formation and 
no increase in resorption. These results are consistent with prior studies showing positive 
effects of ABL on bone mass, structure and strength in OVX and ORX rats, as well as 
glucocorticoid-treated rabbits (Chandler et al., 2019a, Chandler et al., 2019b, Varela et al., 
2017), and provide a strong rationale for investigating the ability of abaloparatide to prevent 
disuse-induced bone loss in humans.
Disclosures: Dian A. Teguh, None
P-054
Alignment of the Femur with the Upper Body Protects Against Atypical 
Femoral Fractures Independent of Antiresorptive Therapy *Hanh Nguyen1, 
Catherine Shore-Lorenti1, Cherie Chiang2, Frances Milat3, Roger Zebaze1, Peter 
Ebeling1. 1Monash University, Australia, 2Austin Health, Australia, 3Hudson 
Institute of Medical Research, Australia
Bisphosphonate (BP) treatment to prevent fragility fractures is threatened by fear of 
atypical femur fractures (AFFs).  As AFFs are rare, identifying the majority who are at very 
low risk is a priority. Stress on the lateral femoral shaft from loading patterns during upright 
stance may be critical in AFF aetiology. We hypothesized that femoral alignment (FA) with 
the upper body is associated with AFFs, and the greater the FA with the upper body, the 
better the protection from AFF. In this case-control study,in 23 Caucasian postmenopausal 
women on BPs who sustained AFFs and 51 AFF-free peers [median(IQR) age: 74(67-80) vs. 
69(58-77) years, p>0.05], we computed DXA-derived spine and hip BMD, and hip structural 
parameters. Femoral alignment was quantified by a novel FA Score (FAS), expressed as a 
percentage.After adjusting for BP use and other co-variates, a higher FAS was associated 
with a lower likelihood of AFF [OR(95%CI)=0·89(0·84, 0·95), p=0·001]. Median FAS was 
lower in AFF cases (39·4% vs 51·9%, p<0·001). FAS was a better predictor of those who 
did not sustain AFFs [AUC(95%CI): 0·80(0·69, 0·90)]. The greater the FAS, the greater 
the positive predictive value (PPV) in identifying AFF-free women (R2=0·92). At a FAS of 
49·6%, the PPV was 100%, capturing 57·4% of the population who did not sustain an AFF. 
Conversely, the lower the FAS, the greater the risk for AFFs, although no threshold with a 
PPV of 100% was identified.  Body mass index, hip BMD, and structural fragility indicators 
did not predict AFF. FAS has the potential to increase the uptake of osteoporosis treatment 
by ameliorating fear of AFFs. The majority of women with FAS>49·6% can be reassured 
that antiresorptives can be initiated or continued; whilst those with a very low FAS score 
may require further screening for AFFs, or alternative treatment with anabolic drugs.
Disclosures: Hanh Nguyen, None
P-055
Micro-Geometry in Metal Scaffold Regulates Angiogenesis and Osteogenesis 
*Chengyu Yang1, Yang Liu1, Chao Liu1. 1Southern University of Science and 
Technology, China
INTRODUCTIONThe advent of precision manufacturing of metals, such as 3D print-
ing, will enable the creation of bone-interfacing implants with cell-scale geometries. Mi-
cron-sized geometric features could regulate both osteoinduction and angiogenesis. How-
ever, it is unclear how precision-manufactured structures with micron-sized features will 
affect cellular behavior. In this study, pre-osteoblasts and endothelial cells were cultured 
on stainless steel disks with microgeometries in vitro to observe the effect of micron-scale 
features on osteogenesis and angiogenesis. We hypothesized that acute angles in the pores 
of a metallic substrate will enhance angiogenesis and osteogenesis, due to the formation of 
stress concentrations within cells. METHODSMC3T3-E1 preosteoblasts and C166 endothe-
lial cells were cultured on flat stainless-steel scaffolds with 3 types of pores: isosceles trian-
gle, square, and circle. On day 4, proliferation of C166 cells was measured. Phalloidin and 
DAPI was used to stain actin and nuclei after 24 h. Actin and nucleus area was quantified. 
After culturing with different scaffolds for 4 days, osteogenic genes and angiogenic genes 
were measured by qPCR for MC3T3-E1 C166 cells respectively, and normalized to 18s. RE-
SULTSThe actin area ratio was highest in the triangular group. Proliferation was reduced in 
both endothelial cells (28.6-37.5%) and preosteoblasts (30.0-37.1%) after 4 days regardless 
of scaffold geometry. Triangular scaffold induced highest expression of angiogenic genes 
VEGFR2, VEGF-A and S1PR1 in C166 cells, and highest expression of osteogenic genes 
OPN and Runx2 in MC3T3-E1 cells. ALP mRNA expression was similar in triangle and 
square groups; with 24% reduction in the circular feature group. DISCUSSIONAcute angles 
at the micron-scale induced more actin fibrils, as well as higher expressions of angiogenic 
genes in endothelial cells and osteogenic genes in preosteoblasts. The findings represent a 
step closer in controlling bone formation at the implant interface at multiple length scales, up 
from the nano-surface texture5 to the millimeter structures. We have utilized a standard 2D 
culture protocol and geometric features on stainless steel disks, which has the drawback of 
lacking the 3D ultrastructural information from physiological conditions. Future work will 
include 3D lattice scaffold designs that are validate with in vivo experiments.
Disclosures: Chengyu Yang, None
P-056
Different relationships between cortical bone design and bone tissue mass 
and quality (mineralization) in limb bones of 3 anuran species, in relation 
with the mechanostat control of bone structure. *Miriam Corina Vera1, Jose 
Luis Ferretti2, Gustavo Roberto Cointry2, Virginia Abdala3. 1Laboratorio de 
Genética Evolutiva, Instituto de Biología Subtropical, Universidad Nacional 
de Misiones-CONICET, Misiones, Argentina, Argentina, 2Center for P-Ca 
Metabolism Studies (CEMFoC), Natl Univ of Rosario and Arg NRC (CONICET), 
Argentina, 3Cátedra de Biología General, Facultad de Ciencias Naturales e IML, 
Universidad Nacional de Tucumán, Tucumán, Argentina, Argentina
Bone mechanostat is a feedback mechanism that regulates bone structural stiffness by 
spatially orienting bone modeling accordingly with the strains induced by mechanical usage. 
The mechanostat efficiency to optimize the diaphyseal design (CSMIs) can be evaluated as 
a function of either the availability or the vBMD of cortical tissue  in negative ‘distribution/ 
quality’ (d/q) curves, or how well bone mass (BMC) is utilized to optimize diaphyseal de-
sign (CSMI) in positive ‘distribution/mass’ (d/m) curves, respectively. Anurans’ long bones 
offer a suitable model to test the efficiency of the mechanostat that way because of the 
wide variety of mechanical challenges derived from their different locomotion modes and 
habitats. We aimed to show that both d/q and d/m relationships would describe differences 
in the efficiency of the bone mechanostat under different mechanical loads, and the curves 
would show similar patterns between jumper and swimmer species and different patterns 
between these and walker frogs. To test it, we scanned by pQCT the femur and tibia-fibula 
of an arboreal-walker (Ar-W, 5 specimens), an arboreal-jumper (Ar-J, 6 specimens), and an 
aquatic-swimmer (Aq-S, 5 specimens) frog species at 9 sites placed at every 10% of their 
length.The d/q relationships showed a highly significant adjustment to common curves for 
Ar-J and Aq-S (r=0.85, p<0.001), with Aq-S data shifting to the upper-left zone of the graph, 
showing higher CSMI and lower cortical vBMD values than Ar-J. In contrast, the walking 
frogs plotted in a different region of the graph, especially in the case of data from mid diaph-
ysis, both in femur and tibia-fibula. This could be explained by the slow movement of the 
Ar-W frogs compared to the quick and powerful movement of Ar-J and Aq-S species.The 
d/m associations confirmed that idea. The Ar-J and Aq-S data were significantly adjusted to 
common correlation curves (r=0.82, p <0.001), suggesting that both movements respond 
to a common pattern, although its location in different zones would indicate some habitat 
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influence. In contrast, the Ar-W data correlated significantly (r=0.80, p <0.001) at a different 
height and with a different slope (ANCOVA p<0.001) with respect to those of Ar-J and 
Aq-S.These findings show that the movements of the jumping and swimming frogs present 
common patterns, involving higher mechanical demands than those followed by walker frog.
Disclosures: Miriam Corina Vera, None
P-057
Compound Deletion of Thrombospondin-1 and -2 Results in a Skeletal 
Phenotype not Predicted by Single Gene Knockouts *Andrea Alford1, Chris 
Stefan1, Anita Reddy1, Kenneth Kozloff1, Kurt Hankenson1. 1University of 
Michigan, United States
The trimeric thrombospondin homologs, TSP1 and TSP2, are both components of bone 
tissue and contribute in distinct ways to skeletal physiology. TSP1-null mice exhibit high tra-
becular and cortical bone mass with an osteoclast functional deficit. TSP2-null mice exhibit 
higher endocortical bone mass with increased MSC proliferation and osteoblast differentia-
tion capacity. Both TSPs affect collagen fibrillogenesis. The functional effects of combined 
TSP1 and TSP2 deficiency remain to be elucidated.  Here, we examined the spectrum of 
detergent soluble proteins in diaphyseal cortical bone of growing (6-week old) male and 
female mice deficient in both thrombospondins (double knockout (DKO)). Equal amounts 
of detergent soluble cortical bone protein were subject to Tandem Mass Tags (TMT) quan-
titative proteomics. 3,429 proteins met the selection criteria (FDR<= 1% and ³2 peptide 
spectral matches). 181 proteins were differentially abundant in both male and female DKO 
bones (>=2 fold or <=0.5 fold compared to wild-type). Physiologically relevant annotation 
terms identified in Ingenuity Pathway Analysis included “ECM degradation” and “Quan-
tity of Monocytes.” Manual inspection revealed a number of proteins with shared expres-
sion among osteoclasts and osteocytes were reduced in DKO bones. To associate changes 
in protein content with phenotype, we examined 12-week old male DKO (N=4) and WT 
(N=5) mice. Marrow-derived colony forming unit-fibroblastic was reduced in DKO mice 
(18 vs. 52 CFU per million cells plated). DKO mice were smaller than WT (22.25+/-1.9 
vs. 27.60+/- 0.5 grams p<0.001). DKO femora had reduced cross-sectional area (1.65+/-
0.3 vs. 2.13+/-0.1 mm2 p<0.01) with a flattened, less circular cross-section (0.76+/-0.1 vs. 
0.91+/-0.03 Welch’s corrected p=0.05). DKO bones were less stiff in bending (142.20+/-
25.1 vs. 201.90+/-33.2 N/mm2 p<0.05), but a disproportionate reduction in anterior-pos-
terior bending moment on nanoCT (0.103+/-0.02 vs. 0.18+/-0.01 mm4 p<0.001) lead to a 
modest increase in predicted modulus (stiffness/bending moment, p=0.07). DKO displayed 
a lower ultimate load (28.55+/-3.7 vs. 36.89+/-2.7 N p<0.01) along with a decreased ratio of 
ultimate displacement to yield displacement (1.10+/-0.02 vs. 1.39+/-0.2 Welch’s corrected 
p<0.05), which suggests a brittle bone phenotype. Tissue mineralization was not affected on 
nanoCT. Together our data suggest that when both TSP1 and TSP2 are absent, a unique bone 
phenotype not predicted by the single knockouts, is manifested.
Disclosures: Andrea Alford, None
P-058
Vitamin D receptor signaling prevents long-term glucocorticoid induced 
bone fragility by preserving several components of bone quality *Amy 
Y Sato1, Meloney Cregor1, Charlie A Schurman2, Jennifer Shutter1, Punit 
Vyas1, David Halladay1, Kevin McAndrews1, Tamara Alliston2, Teresita 
Bellido3. 1Department of Anatomy, Cell Biology, and Physiology, Indiana 
University School of Medicine, Indianapolis, IN, United States, 2Department 
of Orthopaedic Surgery, University of California San Francisco, San Francisco, 
CA, United States, 3Department of Anatomy, Cell Biology, and Physiology, 
Indiana University School of Medicine, Indianapolis, IN; Richard L. Roudebush 
Veterans Affairs Medical Center, Indianapolis, IN, United States
Bone fracture incidence with excess of glucocorticoids (GC) surpasses the risk predict-
ed by the loss of bone mineral density (BMD), implicating GC effects on other determinants 
of bone quality such as microarchitecture, remodeling rate, degree of collagen mineraliza-
tion, and mechanical properties of collagen fibrils. We showed earlier that ligands of the 
vitamin D receptor (VDR) prevent GC-induced BMD loss. We investigated here their effect 
on bone fragility at the tissue, micro, and nanoscale levels. Skeletally mature 4mo C57Bl6 
female mice (N=10) received for 8wks placebo or GC (2.1 mg/kg/d prednisolone pellets), 
and vehicle, 1,25D3 or eldecalcitol-71 (ED) (50ng/kg/d 5x/wk, gavage, starting 3d prior 
pellet implantation). GC decreased the structural (extrinsic) properties ultimate force, ener-
gy to ultimate load, and stiffness by ~20%, and the material (intrinsic) properties ultimate 
stress and toughness ~17%, tested by femoral 3-point bending. VDR ligands did not affect 
mechanical properties, but prevented all GC effects; although 1,25D3 increased ultimate 
force and GC decreased this index even with 1,25D3. We then investigated the mechanisms 
underlying bone strength preservation by the VDR ligands. GC-induced microarchitectural 
deterioration in cancellous bone (low BV/TV and Tb.N, and increased Tb.Sp) was fully 
prevented by the ligands. In contrast, ED fully protected from GC-induced cortical bone 
deterioration (low Ct.Ar/Tt.Ar, Ct.Th, and Ct.Ar, and increased Ma.Ar), but 1,25D3 did not. 
Regarding bone remodeling, both VDR ligands prevented GC-induced resorption, quantified 
by circulating CTX and osteoclast number/surface; and ED by itself markedly decreased re-
sorption. In contrast, the VDR ligands did not prevent GC-induced reduction in bone forma-
tion, quantified by circulating P1NP, osteocalcin, and MS/BS and BFR. Consistent with the 
effects on resorption, GC decreased material density measured by micro-CT and the VDR 
ligands prevented this effect. Small-Angle X-ray Scattering (SAXS) with in situ tensile test-
ing showed a GC-dependent increase in bone deformation (ultimate and yield strain), which 
was prevented by the VDR ligands. Further, VDR ligands alone decreased tissue ductility. 
Moreover, GC transferred strain away from collagen fibrils increasing collagen ductility, 
which was prevented by VDR ligands. These findings demonstrate that VDR signaling pre-
vents GC-induced bone fragility by preserving bone mass and several key components of 
bone quality.
Disclosures: Amy Y Sato, None
P-059
Effects of bone strain of rat tibia during electrical stimulation-induced muscle 
contraction on bone strength in the early stages of disuse musculoskeletal 
atrophy *Hiroyuki Tamaki1, Kengo Yotani1, Futoshi Ogita1. 1National Institute 
of Fitness and Sports in Kanoya, Japan
Mechanical loading of bone tissue is essential to maintain bone volume and muscle con-
traction force generates bone strain in vivo. We determined the in vivo bone strain magni-
tude and strain rate during electrical stimulation-induced muscle contraction (ES) and tested 
whether daily muscle ES treatment can ameliorate the decrease in tibial bone strength after 
sciatic denervation (DN) in aged rats.In vivo bone strain was measured during ES using 
thin-film strain gauges (Kyowa) attached under anesthesia to the medial surface of the tibial 
bone in adult rats (n=6). ES was applied to the tibialis anterior (TA) muscle using bipolar 
surface electrodes connected to an electrical stimulator (stimulation intensity: 1-60 V; fre-
quency: 1-100 Hz). Peak strain magnitude (με), as well as maximal and minimal strain rates 
(με/s) during the increasing and descending phases of ES, were analyzed using a time-strain 
curve. Twenty-four male rats were assigned to one of the following groups: the age-matched 
control group; the DN group; or the DN + ES group. Denervated TA muscle in the DN+ES 
group received ES at 10 Hz for 30 min/day, six days/week, for 1 week.ES-generated twitch 
and tetanic force induced bone strain for a duration of approximately 30-70 ms. Peak strain 
magnitude and strain rate increased linearly with ES intensity and frequency up to 30 V and 
50 Hz, respectively. A significant correlation was found between bone strain magnitude and 
strain rates during ES. ES at 10 Hz generated a constant repetitive bone strain at 10 cycles/s. 
ES-induced muscle contraction force mitigated denervation-induced muscle and trabecular 
bone loss and deterioration of the mechanical properties of the tibia mid-diaphysis, such as 
the stiffness, but not the maximal load, in aged rats. The TA muscle in the DN+ES group 
showed significant improvement in the myofiber cross-sectional area and muscle force rel-
ative to the DN group.These results suggest that 1) the in vivo strain magnitudes and strain 
rates of the rat tibia obtained during ES depend on the level of muscle contractile force, 2) 
low-frequency ES-induced muscle contraction treatment retards trabecular bone and muscle 
loss in aged rats in early-stage disuse musculoskeletal atrophy, and has beneficial effects on 
the functional properties of denervated skeletal muscle.
Disclosures: Hiroyuki Tamaki, None
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Mechanisms of Crack Growth Toughness in Young Osteogenesis Imperfecta 
Mouse Bone *Anxhela Docaj1, Alessandra Carriero1. 1The City College of New 
York, United States
In osteogenesis imperfecta (OI or brittle bone disease), mutations in the collagen genes 
alter the whole bone hierarchical structure and composition, increasing its vulnerability to 
spontaneous fractures and fragility [1]. We recently showed that bone fracture toughness is 
low in the oim mouse model of OI [1], already at a very young age [2], and that increases as 
the mouse grows [2]. To explain this behaviour, we examined the path of the crack during 
growth in 4 and 12 week old oim mice to determine the presence of toughness mechanisms, 
e.g. crack deflections, uncracked ligament bridging, and splitting, and their contribution to 
the bone fracture resistance.Femora from the oim and WT mice at 4 and 12 week old (N=3-6/
group) were notched and loaded in 3-point bending at 1 µm/sec using a micro-testing device 
within an environmental scanning electron microscope used in backscattering mode at 25kV 
and 35 Pa [3]. Toughness was calculated for each crack growth. The presence and occurrence 
of toughening mechanisms was examined for each crack extension and the relative tough-
ness was estimated.Examination of the crack path shows that the most common toughening 
mechanism is deflection, followed by splitting in WT bone, while in oim bone splitting and 
bridging are equally detected (Table 1). In 4 w.o. WT bone, bridging is the highest contrib-
uting mechanism to crack growth toughness, followed by deflection and splitting. In 4 w.o. 
oim bone, deflections and splitting contribute more to toughness than bridging, but less than 
in WT. In 12 w.o. mice, crack deflections, splitting and bridging are observed in WT bones, 
while they are almost absent in oim bones showing an almost flat crack path (Table 1).This 
study shows for the first time the presence of toughening mechanisms in brittle oim mouse 
bone at a young age, but not in older oim mice. Interestingly, these mechanisms could be 
beneficial to rescue oim bone from their fragility if we could increase their initiation tough-
ness. Our future studies will examine the changes in the structure and composition in oim 
bone affecting their fracture toughness during mouse growth.
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Biomechanical and MicroCT Conclusions Are Different Based on Method 
of Bodyweight Control: Pair-feeding versus Linear Regression *Mikhail 
Gurevich1, Alexander Chirokikh2, Sardar Uddin2, David Komatsu1. 1Renaissance 
School of Medicine at Stony Brook University, United States, 2Stony Brook 
University, United States
Understanding the morphometric and biomechanical properties of bone is fundamen-
tal to appreciating its overall integrity and function. Animal models are commonly used to 
study the effects of genetic perturbations or drug treatments on skeletal integrity; however, 
these interventions often alter body size as well as skeletal structures. Since morphometric 
and biomechanical properties correlate with body size, it is challenging to discern whether 
experimental outcomes are a result of direct effects on bone or are secondary to alterations in 
body mass. In past studies of the effects of methylphenidate (MP) on rat bone, we employed 
pair-feeding in an effort to control for body mass. Recently, analytical methods of body mass 
normalization, such as linear regression have been introduced, prompting us to ask if we 
would arrive at the same conclusions using these two methods. Therefore, the goal of this 
study was to compare the conclusions regarding the effects of MP treatment on bone reached 
using the pair-fed method to those acquired using the linear regression method. Four-week-
old male and female Sprague-Dawley rats were divided into 5 groups (n=12/group): Water 
(water for 8 hours), LD MP (4 mg/kg first hour, 10 mg/kg next 7 hours), LD PF (no MP, 
same food intake as LD MP), HD MP (30 mg/kg first hour, 60 mg/kg next 7 hours), and HD 
PF (no MP, same food intake as HD MP). After 13 weeks of treatment, femurs were assessed 
for longitudinal growth, microCT, and biomechanical outcomes. The HD MP group had a 
significantly lower final bodyweight relative to Water (-15.2%), LD MP (-15.1%), and LD 
PF (-14.8%) in males and relative to Water (-11.5%), LD MP (-15.8%), LD PF (-11.1%), and 
HD PF (-13.7%) in females. Without adjusting for body size, HD MP treatment significantly 
reduced energy to failure (-23.4%), stiffness (-11.5%), and ultimate force (-11.2%) in males, 
while having no significant effects in females. After normalizing with linear regression, 
significant differences among male groups were no longer present, while relatively longer 
(+3.0%) and wider femurs (+3.7%), with a greater maximum moment of inertia (+18.3%) 
were observed in the female HD MP group as compared to Water. Pair-fed comparisons 
revealed no significant differences between groups in either sex. We consider the linear re-
gression method to hold significant merit by allowing us to adjust for experimental variables 
and potentially reduce the number of animals needed to draw meaningful conclusions.
Disclosures: Mikhail Gurevich, None
P-062
A Novel Micro-FE Based Model to Investigate the Role of Osteocyte Lacunae 
in Microcracking of Human Bone *Elliott Goff1, Francesco Vicentini1, Ralph 
Müller1. 1Institute for Biomechanics, ETH Zürich, Switzerland
Microcracks propagate through the mineralized bone matrix in the vicinity of osteocyte 
lacunae. Lacunae have been shown to guide cracking, so greater understanding of this bio-
mechanical interaction is warranted. Researchers have previously created micro-finite ele-
ment (micro-FE) models to explore crack progression, yet they are oversimplified and lack 
clinical relevance. We present a novel model using clinically relevant human data to address 
crack propagation and lacunar interaction.The cortical region of a complete human iliac crest 
biopsy embedded in PMMA was imaged using a µCT50 (Scanco Medical, Switzerland) 
at a nominal voxel resolution of 1.2µm. A cubic subvolume with side length of 180µm 
was segmented, which included a vascular canal and 79 lacunae. The image volume was 
meshed using ParOSol and vertical compression was iteratively simulated in steps of 0.1% 
strain until failure with the bottom fixed. Crack initiation was defined as voxels exceeding 
a maximum principle strain of 0.8%. A directional vector was calculated accordingly and 
the immediate voxel bordering the crack tip in the vector path was deleted. The method was 
applied to several rotated versions of the original image subvolume to evaluate differences in 
cracking patterns. Lacunar volume (Lc.V), stretch (Lc.St), and oblateness (Lc.Ob) as defined 
previously were calculated using a custom Python script.As the subvolume’s angle changed, 
so did the crack pattern and the lacunae intersected. Yet, crack propagation remained parallel 
to the axis of compression while the number of intersected lacunae differed between image 
rotations. The crack in Figure 1B intersected with ten lacunae while the crack in Figures 
1A&1C intersected with three lacunae. Intersected lacunar morphometric parameters in the 
table adjacent to Figure 1 demonstrate a range of volume, stretch, and oblateness mean 
values that approximate ellipsoidal geometries.Our model confirms previous experimental 
work by demonstrating that microcracks propagate parallel to the axis of compression, orig-
inate at large canals (such as vascular canals) and are interwoven with lacunae. The mean 
Lc.St and Lc.Ob values reported suggest that these intersected lacunae approximate ellipsoi-
dal geometries. The lacunar shape could serve a mechanobiological function such as crack 
tip blunting, crack energy dissipation, or even a future biomarker for bone health.
Disclosures: Elliott Goff, None
P-063
Experimental Validation of Finite Element Models of the Proximal Tibia 
Using Digital Volume Correlation *Dylan Zaluski1, Saija Kontulainen2, James 
Johnston1. 1Department of Mechanical Engineering, University of Saskatchewan, 
Canada, 2College of Kinesiology, University of Saskatchewan, Canada
Background: Finite element (FE) models of bones incorporating geometry and material 
properties from quantitative computed tomography (QCT) (generally referred to as QCT-
FE) can help researchers understand the effects of altered bone mechanics on joint health [1]. 
Current QCT-FE models of the tibia have been experimentally validated for surface strains 
[2] but not internal bone mechanics. The objective of this study was to validate QCT-FE 
models of the tibia for internal bone displacements using digital volume correlation (DVC). 
Methods: Five embalmed cadaveric tibiae were subjected to compressive loading inside 
a high-resolution peripheral QCT (HR-pQCT) scanner using a custom mechanical testing 
rig. HR-pQCT scans (41µm voxel) were taken before load application and subsequently 
between steps of 0.5, 1.0 and 1.5mm of applied displacement. Experimental displacements 
were obtained using DVC software (DaVis 10.01, LaVision). QCT-FE models were generat-
ed from HR-pQCT scans by first downsampling to clinical QCT resolution (0.5mm voxel), 
adding noise, segmenting and converting bone voxels to linear hexahedral elements. Each 
element was assigned an elastic modulus (E) derived from bone mineral density (BMD) 
using 3 different E-BMD relationships [3-5]. Boundary conditions were replicated by map-
ping DVC displacements to nodes on the contact surface and the fixed distal end. FE mod-
els were solved using a custom MATLAB program. Agreement between FE-predicted and 
DVC-measured displacements was assessed using linear regression and root mean square 
error normalized to maximum measured displacement (RMSE%). Results: Regression in-
tercepts ranged from -0.0008 to 0.0324mm and slopes ranged from 1.00 to 1.10 (Fig. 1); all 
were significantly different from 0 and 1, respectively. RMSE% ranged from 3.5 to 5.5%, 
and all R2 were greater than 0.99. For each E-BMD tested, x and y displacement predictions 
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were nearly identical, while Nazemi et al. more accurately predicted larger magnitude z-dis-
placements (Fig. 1c). Conclusions: Internal bone displacements within the elastic regime in 
the proximal tibia are accurately predicted by QCT-FE. The E-BMD relationship of Nazemi 
et al. is recommended due to lower error for large-magnitude z-displacements. Future work 
is required to validate models for reaction forces and to develop optimized E-BMD relation-
ships. References: [1] McErlain et al. 2011; [2] Gray et al. 2008; [3] Nazemi et al. 2017; [4] 
Rho et al. 1995; [5] Morgan et al. 2003
Disclosures: Dylan Zaluski, None
P-064
Skeletal Repercussions of Concomitant Methylphenidate and Fluoxetine 
Treatment *Alexander Chirokikh1, Mikhail Gurevich1, Sardar Uddin1, 
Carly Connor2, Panayotis Thanos2, Michael Hadjiargyrou3, David Komatsu1. 
1Department of Orthopaedics, Stony Brook University, United States, 2BNNLA - 
Research Institute on Addictions, Department of Pharmacology and Toxicology, 
SUNY University at Buffalo, United States, 3Department of Biological and 
Chemical Sciences, New York Institute of Technology, United States
Concomitant administration of methylphenidate (MP) with selective serotonin reuptake 
inhibitors (SSRI) such as fluoxetine (FLX) is a common strategy used to treat attention-defi-
cit/hyperactivity disorder in pediatric patients with depression or anxiety comorbidities. Pre-
viously, our laboratory demonstrated that chronic MP treatment of male adolescent rats re-
sulted in reduced longitudinal growth, mineralization, and biomechanical integrity in appen-
dicular bones. Similarly, clinical data have shown that long-term SSRI treatment is linked to 
increased fracture risk and reduced bone mineral density, prompting the question of whether 
the skeletal repercussions associated with MP treatment are exacerbated when administered 
in combination with SSRI. As such, the objective of this study was to investigate the effects 
of MP and FLX treatment on bone morphology and biomechanical properties using a rat 
model. Four-week-old male Sprague-Dawley rats were randomly divided into the following 
4 groups (n=10/group) and administered treatments via drinking water for 8 hours per day: 
Water (water for 8 hours), HD MP (30 mg/kg first hour, 60 mg/kg next 7 hours), FLX (15mg/
kg for 8 hours), and MP+FLX (MP and FLX). Following 4 weeks of treatment, significantly 
lower bodyweights in the HD MP (-17.3%), FLX (-15.8%), and MP+FLX (-50.1%) groups 
were observed relative to Water. Since bone morphological and biomechanical properties 
are associated with animal size, data were compared directly and after normalization to 
bodyweight via linear regression. Without adjusting for bodyweight, MP+FLX animals had 
significantly shorter (-12.4%) and narrower (-17.2%), but higher density (+2.3%) femora 
compared to Water animals. The MP+FLX group also had a significantly lowered energy 
to failure (-24.8%) and ultimate force (-14.4%) relative to the Water group. In contrast, 
the MP+FLX group showed no significant differences in longitudinal growth, microCT pa-
rameters, or biomechanical outcomes relative to any other group after normalization. We 
conclude that the adverse skeletal effects of MP+FLX treatment seen via direct comparison 
are predominantly attributable to reductions in bodyweight rather than direct effects on the 
bone. Future studies will investigate MP+FLX treatment on trabecular microarchitecture and 
cortical porosity to better understand the effects on the skeleton, as well as to recognize all 
the possible sequelae for adolescents being treated with this combination therapy.
Disclosures: Alexander Chirokikh, None
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Local Bone Remodeling in Distal Radius Fracture Healing Is Not Isolated 
to the Fracture Region: A Time-lapse HR-pQCT Imaging Study *Penny 
Atkins1, Kerstin Stock2, Caitlyn Collins1, Nicholas Ohs1, Lukas Horling2, Patrik 
Christen3, Michael Blauth2, Ralph Müller1. 1Institute for Biomechanics, ETH 
Zurich, Switzerland, 2Department for Trauma Surgery, Innsbruck University 
Hospital, Innsbruck, Austria, Austria, 3Institute for Biomechanics, ETH Zurich; 
Institute for Information Systems, FHNW, Olten, Switzerland, Switzerland
Clinically, fracture healing is evaluated using 2D radiographic images; however, these 
images are only used to assess fracture bridging, without consideration for other aspects 
of bone quality post-fracture. By using a high-resolution peripheral quantitative computed 
tomography (HR-pQCT) time-lapse imaging protocol, fracture healing can be more accu-
rately monitored through microstructural bone remodeling. Therefore, we investigated local 
bone formation and resorption rates (BFR and BRR, respectively) in the region of the frac-
ture, as well as proximally and distally, hypothesizing that microstructural bone remodeling 
would be greatest in, but not isolated to, the region of the fracture.Patients (3 female, 33, 
52, and 56 years of age; 1 male, 21 years of age) with conservatively treated radius fractures 
provided informed consent prior to participation (Ethics Committee, Medical University of 
Innsbruck). HR-pQCT (XtremeCT II, Scanco Medical AG) images were acquired at 1, 3, 
5, 13, 26, and 52 weeks post-fracture. Three image stacks (504 slices, 61 μm voxels) were 
acquired to ensure full imaging of the fracture. Voxel intensities of the radius were isolat-
ed with a mask and registered using a pyramid-based approach (Python v3.7). Registered 
images were Gaussian filtered (sigma 0.8, support 1.0) and binarized (threshold 320 mg/
ccm) prior to calculation of volume-based BRR and BFR, which were quantified relative 
to images from the previous time point. Proximal, distal, and fracture regions were isolated 
using manually-defined cutting planes (ParaView v5.4; Figure 1, left).In the region of the 
fracture, maximum BRR was observed from 1-3 weeks (1.39-3.92%/day), while maximum 
BFR was observed either from 1-3 or 3-5 weeks (2.31-3.01%/day) (Figure 1, right). Cortical 
bridging was evident at 13 weeks. In the region distal to the fracture, BRR was highest from 
1-3 or 3-5 weeks (1.78-3.05%/day), while BFR was highest from 3-5 weeks (1.21-1.76%/
day). For all patients, BFR and BRR remained below 1.25%/day in the region proximal to 
the fracture site.BRR and BFR were highest in the region of the fracture, however, even 
in this relatively young cohort, we observed high BRR in the trabecular-rich distal region 
during early fracture healing. The use of this protocol to quantify fracture related remodeling 
may help to identify clinically relevant changes in bone quality post-fracture, especially in 
patients with a pre-existing imbalance of BFR and BRR (i.e. osteoporosis).
Disclosures: Penny Atkins, None
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Female Volleyball Players: A within-subject controlled model of the lower 
limb *Claudia Romero Medina1, Sena Harlley1, Daniel Den Briones1, Jorge 
Gonzalez1, Vanessa Yingling1. 1Cal State East Bay, United States
Introduction: High impact loading common in some sports affect bone structure that 
may influence bone strength across a lifetime. A within-subject controlled model for study-
ing lower limb bone adaptation to loading is needed especially in females. Weatherholt and 
Warden (2016) examined male jump athletes as a potential model reporting small side-to-
side bone strength differences in the tibia. The fibula only shares 6.4% of weight distribution 
with the ankle joint in neutral (Takebe et al, 1984). The relative disuse of the fibula may 
make it more responsive to increased loading. Volleyball may serve as a with-in subject 
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model of the lower limb due to the high-impact jumps that are common in the sport. Purpose: 
To determine bilateral differences in bone architecture and strength of the tibia and fibula. 
Methods: 16 Division II female volleyball players (age 19 yrs + 1.2, Ht 1.74 + 0.69 m, BM 
69.8 + 8.1 kg, BF% 23.9 + 5.7%) underwent peripheral quantitative computed tomography 
(pQCT) scans to measure bone strength on both the lead leg (dominant) and gather leg 
(non-dominant) tibia and fibula. Trabecular bone strength at the 4% epiphyseal site (BSIc 
mg2/mm4 =ToA x ToD2) and cortical bone strength at the 66% site (strength strain index 
(pSSI mm2) were measured. Significance was determined using two-tailed paired T-tests. 
Results: No significant differences between dominant and non-dominant limbs were detect-
ed for either the 4% or 66% site in both the tibia and the fibula. BSIc measures resulted in 
the following for tibia and fibula at the 4% site: -2.3% (95% CI = -5.7%-1.1%) and -3.8% 
(95% CI = -10.8%-3.2%). pSSI measures for tibia and fibula at the 66% site: -1.6% (95% 
CI = -4.6%-1.4%) and 7.0% (95% CI = -2.4%-16.4%). Conclusion: No significant side to 
side differences were detected in either the tibia or the fibula. The 95% CI were much larger 
compared to Weatherholt and Warden (2016) and much larger in the fibula compared to the 
tibia, suggesting a subset of the VB players could potentially reveal the effects of loading on 
the fibula depending on factors such as position played and years playing the sport. Under 
normal conditions the fibula is underloaded, therefore greater differences are expected as a 
result of sudden high impact loading; a larger sample size is needed to determine this. The 
results may also conclude that volleyball may not result in loading significant enough to 
cause large bilateral differences in the lower limb.
Disclosures: Claudia Romero Medina, None
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Preclinical evaluation of a novel 3D-printed composite scaffold using 
a rodent posterolateral spinal fusion model *Mark Plantz1, Joseph Lyons1, 
Allison Greene1, Chawon Yun1, Silvia Minardi1, Soyeon Jeong1, Kenneth Blank2, 
Robert Havey2, Muturi Muriuki2, Avinash Patwardhan2, Stuart Stock1, Wellington 
Hsu1, Erin Hsu1. 1Northwestern University Feinberg School of Medicine, United 
States, 2Edward Hines Jr. VA Hospital, United States
Despite recent advances in bone graft technology, there are significant shortcomings 
with current bone graft substitutes for spinal fusion. Options such as iliac crest bone graft 
and recombinant human bone morphogenetic protein-2 (rhBMP-2), while unquestionably 
effective for promoting bone healing, are limited by morbidity and complications, respec-
tively. Synthetic materials are promising but remain insufficiently effective. To address this 
issue, we previously developed a recombinant growth factor-free, 3D-printed composite 
material comprised of hydroxyapatite (HA) and demineralized bone matrix (DBM) for bone 
regeneration. Herein, we perform a preclinical comparative evaluation of the scaffold rela-
tive to a positive control (rhBMP-2/ACS; Infuse™) using a preclinical small animal model. 
Fifty female Sprague-Dawley rats underwent L4-L5 posterolateral spine fusion (PLF) and 
were implanted with either the HA-DBM scaffold or with 10 µg rhBMP-2/ACS (Infuse™) 
(A). Fusion was evaluated 8 weeks postoperatively. Fusion scoring was assessed by 3 blind-
ed investigators using an established scoring system where 0=no fusion (motion between 
segments), 1=unilateral fusion (motion unilaterally), and 2=bilateral fusion (no motion be-
tween segments). Spines that received an average score >=1.0 were considered successfully 
fused. Biomechanical testing quantified the segmental flexion-extension range of motion 
(ROM) and stiffness of the fused segments. The same PLF model was used for a mechanistic 
assessment of osteogenesis. Explants were removed at increasing time points up to 8 weeks 
for assessment of pro-osteogenic gene expression via qPCR and Western blotting. Fusion 
rates were not significantly different between the scaffold (93%) and Infuse™ (100%) (B); 
however, fusion scores were greater with Infuse™ (p=0.008) (C). Both treatments resulted 
in significantly reduced segmental range of motion (ROM; p<0.001) (D) and greater stiffness 
(p=0.009) when compared with non-operated controls; this effect was greater with Infuse™ 
(L4-5 flexion-extension ROM: non-operated control: 28°; scaffold: 15°; Infuse™: 4°). Pat-
terns of gene expression appeared similar between groups, with both Infuse™ and scaffold 
treatments resulting in significant elevations of several pro-osteogenic markers including 
Alp, Osx, and Runx2. The HA-DBM scaffold represents a recombinant growth factor-free 
biomaterial for promoting bone regeneration, with potential to be used as a bone graft sub-
stitute for spinal fusion.
Disclosures: Mark Plantz, None
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Deep learning-based image segmentation performs well when trained and 
tested on similar, dissimilar, and combined image data *Emilie N. Henning1, 
Ryan J. Reger1, Daniella M. Patton2, Rob W. Goulet2, Benjamin Provencher3, 
Nicolas Piché3, Mike Marsh3, Roberto J. Fajardo4, Ellen E. Quillen5, Karl J. 
Jepsen2, Todd L. Bredbenner1. 1Department of Mechanical and Aerospace 
Engineering, University of Colorado Colorado Springs, United States, 
2Department of Orthopedic Surgery, University of Michigan, United States, 
3Object Research Systems, Canada, 4Clinical and Applied Science Education, 
University of the Incarnate Word School of Osteopathic Medicine, United States, 
5Section on Molecular Medicine and Center for Precision Medicine, Wake Forest 
School of Medicine, United States
Separating bone from background is a crucial step in quantifying bone structure in 
image data. We previously demonstrated that image segmentation via deep learning with 
fully convolutional neural networks (FCNNs) outperforms methods based on global or local 
thresholding [1]. The objective of this study was to investigate the performance of FCNN-
based segmentation of human vertebral body and femoral neck data when segmented using 
similar, dissimilar, and combined data.Human L1 vertebral bodies (14 M, 25-88 yrs; 14 F, 
28-80 yrs) were imaged using microCT (53µm voxels). Human proximal femurs (15 M, 18-
89 yrs; 13 F, 24-95 yrs) were imaged using nanoCT (27µm voxels), and the femoral necks 
were isolated. Six image slices were extracted from each bone and manually segmented to 
create ground truth masks (Dragonfly 4.0, ORS). FCNNs (2D U-Net) were separately trained 
with femoral neck data, vertebral body data, and a combined dataset using a nested four-
fold cross-validation approach. Each FCNN was tested by segmenting femoral neck and 
vertebral body data. Segmentation performance was evaluated using five metrics to quantify 
similarity between segmented and ground truth masks. Nonparametric multivariate analyses 
(Wilks’ lambda test) were used to simultaneously consider all metrics in evaluating the rela-
tive segmentation performance of the FCNN models.Relative model effects were significant 
(p < 0.001), indicating differences in the segmentation performance of the FCNNs (Fig 1). 
FCNNs trained separately on femoral neck or vertebral body data both outperformed the 
FCNN trained on the combined dataset in segmenting femoral neck data. Similarly, FCNNs 
trained on femoral neck or vertebral body data outperformed the FCNN trained on com-
bined femoral neck and vertebral body data in segmenting vertebral body data. All FCNNs 
reported in the present work performed significantly better than most segmentation meth-
ods based on global or local thresholding and not significantly different than the others [1].
Simultaneous consideration of multiple performance metrics indicated that FCNNs trained 
and tested on dissimilar data performed well compared to FCNNs trained and tested on 
similar data. Further, a network trained with combined datasets (but not including the test 
data) performed well on both datasets, suggesting that deep learning-based segmentation 
may allow broad application of FCNNs trained with varied imaging data on unseen data.1. 
Patton, et al. Trans. ORS. 2020
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Mechanical Behavior of the Vertebral Endplate *Yuanqiao Wu1, Elise 
Morgan1. 1Boston University, United States
Introduction: Vertebral fractures frequently occur in or near the vertebral endplate (VEP) 
[1], a thin layer of cortical-like bone that helps transfer loads between the intervertebral disc 
and the interior of the vertebral body. Evidence of changes in the density of the VEP with 
factors such as age [2] suggests that the mechanical behavior of the VEP may influence the 
risk of vertebral fracture. In addition, clinical outcomes of vertebral fracture may be worse if 
the VEP itself becomes cracked or broken [3,4]. Thus, the goal of this study was to quantify 
the mechanical behavior of the VEP and the dependence of this behavior on VEP density. 
Methods:80 VEPs were dissected from 39 fresh-frozen human spine segments (L1-L4; M: 
24, F:15; age: 77.72+/-11.56 years). A ~30mm×12mm×1.5mm rectangular specimen was 
cut from the central region of each VEP after stripping off the cartilage endplate. Specimens 
were imaged using micro-computed tomography (μCT) (μCT40, Scanco Medical; 16μm/
voxel, 70kV, 114μA) to quantify bone volume fraction (BV/TV), apparent density (app), 
and tissue mineral density (TMD). Then each specimen underwent a four-point bend test 
(Instron 5565) to measure elastic modulus (Ε), yield stress (σy), and ultimate strain (strain at 
maximum force, εu), fracture strain (εf)). Linear regression was used to examine the depen-
dence of each mechanical property on each measure of density (JMP Pro 13, SAS Institute). 
Regressions were performed separately for specimens from the superior vs. inferior VEPs 
(defined relative to the vertebral body). The mechanical and densitometric measures were 
also compared between superior and inferior VEPs, using paired analysis where appropriate. 
Results: Both the elastic modulus and yield stress increased with increasing ρ_app and BV/
TV, in both superior and inferior VEPs (r2>0.51, p<0.001). In contrast, ultimate strain and 
fracture strain decreased with increasing BV/TV in inferior (r2>0.32, p0.08). The yield stress 
was higher in inferior vs. superior VEPs (p=0.04); no other properties differed with location 
(p>0.05). Conclusions: With decreasing density, the stiffness (modulus) and strength (yield 
stress) of the VEP decreased but the ductility (ultimate and fracture strains) decreased. These 
results suggest a potential compensatory mechanism in the VEP whereby bone loss leads to 
a more flexible and less strong VEP, yet one that is less prone to breakage. Reference:[1]
AO.Ortiz.Am J Neuroradiol,32(1):115-20.[2]Ferguson SJ. Eur Spine J,2003(12): S97-S103.
[3] S Dudley. Spine J, 14(7):1256-64. [4]AT Trout.J Bone Miner Re,21(11):1797-802.[5] 
F.-D Zhao. Bone,44(2):372-9.
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Effects of SGLT2 Inhibitor Therapy on the Fracture Resistance of Diabetic 
Mouse Bone *Jeffry Nyman1, Clay Bunn2, Sasidhar Uppuganti1, Philip Ray2, 
Iuliana Popescu2, Evangelia Kalaitzoglou2, John Fowlkes2, Kathryn Thrailkill2. 
1Vanderbilt University Medical Center, United States, 2University of Kentucky 
Medical Center, United States
As a selective sodium-dependent glucose co-transporter inhibitor (SGLT2I) that causes 
glucosuria, canagliflozin is an effective therapy to lower blood glucose (BG) levels in pa-
tients with T2D. Because hypercalciuria also results from the blocking action of the drug on 
the renal reabsorption of Na and glucose, there is concern that SGLT2I therapy could exac-
erbate the T2D-related increase in fracture risk. Using the TallyHO (TH) model (JAX #5314) 
of juvenile-onset T2D, we tested whether SGLT2I therapy improves or worsens the fracture 
resistance of diabetic bone. Female TH mice maintain normal glucose levels, while ~75% 
of male TH mice develop frank T2D. Thus, we assigned male TH mice with established 
hyperglycemia at 8-10-wk of age to chow (High-BG, n=43) or to chow supplemented with 
canagliflozin at 100 ppm (Cana, n=52). These mice, along with male TH mice with normal 
BG (Low-BG, n=16), were euthanized at 20-wk of age after collecting serum. Low-BG 
mice and Cana-treated mice gained weight between 8-wk and 20-wk, while High-BG mice 
stopped gaining weight such that their weight was 15% lower than the final weight of the 
other mice (p0.5). As expected, Cana did not restore urine glucose and calcium excretion to 
normal levels, which were both similarly elevated in Cana and High-BG compared to Low-
BG mice (p<0.0001). As assessed by μCT, the cross-sectional area (Ct.Ar, p=0.001) and cor-
tical thickness (Ct.Th, p<0.0001) of the femur mid-shaft were lower for the hyperglycemic 
than for the euglycemic mice. Cana normalized Ct.Ar to the level of Low-BG (p=0.252), but 
only partially rescued Ct.Th still being lower compared to Low-BG mice (p=0.007). The 
ultimate force endured by the femur mid-shaft during three-point bending was significantly 
lower in the High-BG than in the Low-BG group (p<0.0001). Cana-treatment increased 
this structural-dependent measurement of strength by 6.2% (p=0.033 vs. High-BG), with no 
significant difference between Cana and Low-BG (p=0.505). The ultimate stress was also 
lower for untreated mice with high BG compared to Low-BG. Cana did not significantly 
improve this estimate of material strength. Cortical tissue mineral density did not signifi-
cantly vary among the 3 groups (p=0.070), despite persistent hypercalciuria occurring in 
Cana and High-BG. There was a significant difference in the distal femur BV/TV between 
all 3 pair-wise comparisons (pCana>High-BG. Thus, the positive effects of SGLT2I on BG 
and weight partially corrects the T2D-related deterioration in bone and does not worsen the 
fracture resistance of diabetic bone.
Disclosures: Jeffry Nyman, None
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Individual Trabecula Segmentation (ITS) Based Analysis of 2nd Generation 
HR-pQCT Scans of the Human Distal Radius and Tibia Compared to 
1st Generation HR-pQCT and µCT Scans *A. Teodora Dinescu1, Yizhong 
Jenny Hu1, Sanchita Agarwal2, Elizabeth Shane2, X. Edward Guo1. 1Columbia 
University, United States, 2Columbia University Medical Center, United States
High-resolution peripheral quantitative computed tomography (HR-pQCT) has been 
used for in vivo 3D visualization of trabecular microstructure with low radiation. Sec-
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ond-generation HR-pQCT (XCTII) has been shown to have good agreement with first gen-
eration HR-pQCT (XCTI) and has an enhanced voxel size from 82 µm to 61 µm. Advanced 
Individual Trabecula Segmentation (ITS) decomposes the trabecula network into individual 
plates and rods and has been used to identify subtle bone microstructure features. ITS based 
on XCTI showed strong correlation to ITS based on micro computed tomography (µCT) 
and identified important trabecular changes in various diseases. ITS based on XCTII has 
new potentials in musculoskeletal studies but has yet to be validated. The objective of this 
study was to assess the agreement between ITS based on XCTII, ITS based on XCTI and 
ITS based on µCT to assess the capability of ITS on XCTII as a clinical tool.Twenty sets of 
fresh-frozen tibia and radius bones obtained from the Life Legacy Foundation were scanned 
in the distal region using XCTI at 82 µm, XCTII at 61 µm and µCT at 37 µm. The µCT 
image was registered to the corresponding XCTII image to ensure analysis of same regions. 
XCTII images were registered to XCTI images. A Laplace-Hamming filter was applied to 
XCTI images and a Gaussian filter applied to the XCTII and µCT images for noise reduction 
and a global threshold used to binarize the images. ITS analysis was performed on the tra-
becular region of the registered images. Bone volume fraction (pBV/TV, rBV/TV), number 
density (pTb.N, rTb.N), thickness (pTb.Th, rTb.Th) and plate-to-rod (PR) ratio (pBV/rBV) 
of trabecular plates and rods were obtained. Difference between these measurements in XC-
TII vs µCT and XCTI vs XCTII was calculated. Paired student’s t-tests were used to examine 
the difference. Linear regression was used to determine the correlation coefficient of these 
parameters.Difference and correlation coefficients of ITS based measurements are shown 
in Table 1. The XCTII parameters were statistically different from the µCT measurements 
except BV/TV in the distal tibia and rTb.N in the distal radius and the XCTI parameters 
were statistically different from the XCTII measurements except pTb.Th. The strong cor-
relation between XCTII and µCT microstructural analysis suggests that XCTII can be used 
to clinically assess changes in plate and rod microstructure and that values from XCTI can 
be corrected to XCTII parameters.
Disclosures: A. Teodora Dinescu, None
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Effect of vitamin D supplementation on hip structural geometry in the 
elderly *Aya Bassatne1, Thomas Beck 2, Ghada El-Hajj Fuleihan1. 1American 
University of Beirut, Lebanon, 2Beck Radiological Innovations, United States
Vitamin D in conjunction with calcium reduces the risk of hip fractures in institution-
alized elderly subjects but the effect on BMD is less consistent. We hypothesize that the 
beneficial effects of vitamin D supplementation on fracture risk may result from improved 
bone strength and geometry rather than BMD. We used data from a trial that randomized 257 
overweight elderly individuals to calcium citrate 1000mg daily and cholecalciferol at a daily 
equivalent dose of 600 or 3,750IU. 221 participants completed the trial. We assessed the 
effect of vitamin D on Hip Structural Analysis (HSA) parameters including cross-sectional 
area (CSA), section modulus (Z), subperiosteal width/outer diameter (OD) and buckling 
ratio (BR). The HSA program measures bone structural geometry of the femoral neck using 
conventional DXA images. Three regions are analyzed: the narrow neck (NN), the intertro-
chanter (IT) and the femoral shaft (FS). We ran unadjusted and also adjusted analyses for 
subtotal lean mass. In the overall group (combining both doses), total hip BMD, NN CSA 
and Z, IT CSA, FS CSA, subperiosteal width and Z significantly increased between baseline 
and 12 months, in the direction of increased strength. Within treatment groups, there was a 
beneficial effect of vitamin D on BMD at the total hip and HSA parameters at the IT and FS 
in the low dose arm, and on BMD at the total hip, and on HSA parameters including NN, IT 
and FS in the high dose arm. Subtotal lean mass decreased with vitamin D supplementation 
in the low dose group but did not change in the high dose group. The favorable effect of vi-
tamin D on HSA parameters at 12 months remained significant at the IT and FS and became 
significant at the NN in the low dose group after lean mass adjustments. All values at 12 
months in the high dose lost significance on adjusted analyses. The only difference in unad-
justed HSA parameters between treatment arms was for the delta BR at the intertrochanteric 
site, with a decrease in the low dose and an increase in the high dose. However, this differ-
ence disappeared in the adjusted analyses. Supplementation with 1000mg calcium citrate 
and vitamin D3 (600 IU/day) for one year had a beneficial effect on total hip BMD and pa-
rameters of bone structural geometry and strength that persisted after lean mass adjustments 
in the low dose, but not high dose arms. More vitamin D is not better, and the reduction in hip 
fracture with CaD may be mediated by structural as opposed to BMD changes.
Disclosures: Aya Bassatne, None
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A Clinically Handy Novel Mechanical Parameter to Quantify the 
Microarchitecture Effect on Apparent Modulus of Trabecular Bone 
*Yongqiang Jin1, Teng Zhang 1, Kam Yim Sze1, Jason Pui Yin Cheung1, William 
Weijia Lu1. 1The University of Hong Kong, Hong Kong
An important aspect of bone quality is the trabecular microarchitecture which can vary 
the apparent modulus (E) of trabecular bone independent of bone volume fraction (BV/TV). 
Previous studies have employed morphological/topological indices to quantify E. However, 
E itself is a mechanical quantity and those non-mechanical indices are not easily interpreta-
ble in clinical practice. This study aims to propose a novel mechanical parameter that is clin-
ically handy to quantify the microarchitecture effect on E.Fourteen human female cadaveric 
vertebrae were scanned with a µCT at 18 µm isotropic resolution. Four trabecular specimens 
(3.46×3.46×3.46 mm) were obtained from each vertebral body and converted to voxel-based 
finite element (FE) models. E value of the FE model was computed using linear FE analysis. 
The normalized apparent modulus (E*) was computed as E divided by BV/TV. Linear re-
gression was performed between E* and BV/TV. Ineffective bone mass (InBM) was defined 
as the bone mass with a negligible contribution to the load-resistance and represented by 
elements with von Mises stress less than a certain stress threshold. InBM was quantified as 
the low von Mises stress ratio (LSVMR), which is the ratio of the number of InBM elements 
to the total number of elements in the FE model. An incremental search technique with 
coarse and fine search intervals of 10 and 1 MPa, respectively, was adopted to determine the 
stress threshold for calculating LSVMR. Correlation between E* and LSVMR was analyzed 
using linear and power-law models for each stress threshold with the one producing the 
highest coefficient of determination (R2) taken as the optimal threshold. Linear regression 
was performed between E and LSVMR. Multiple linear regression of E against both BV/TV 
and LSVMR was further analyzed. E* has no significant (p = 0.75) correlation with BV/TV. 
Incremental search suggests 59 MPa to be the optimal stress threshold. BV/TV alone can 
explain 59% of the variation in E (E = 2254.64BV/TV1.04, R2 = 0.59, p < 0.001). LSVMR 
alone can explain 48% of the variation in E (E = 1696.4 – 1647.1LSVMR, R2 = 0.48, p < 
0.001). With both, 95% of the variation in E can be explained (E = 1364.89 + 2184.37BV/TV 
– 1605.38LSVMR, adjusted R2 = 0.95, p < 0.001). We conclude LSVMR can be adopted as 
the mechanical parameter to quantify the microarchitecture effect on the apparent modulus 
of trabecular bone and it is clinically handy with the interpretation of ineffective bone mass. 
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3D printed tough magnesium phosphate-based implants induce bone 
regeneration in an equine defect model *Miguel Castilho1, Nasim Golafshan1, 
Elke Vorndran2, Uwe Gbureck2, Harold Brommer3, René van Weeren3, Jos 
Malda1. 1University medical Center Utrecht, Netherlands, 2Universitätsklinik 
Würzburg, Germany, 3Utrecht University, Netherlands
Introduction: Magnesium phosphates (MgP) have shown to significantly enhance bone 
formation when compared with the standard calcium phosphate-based ceramics. However, 
such materials can hardly be shaped into large and complex geometries and more impor-
tantly lack adequate mechanical properties for the treatment of load-bearing and complex 
shape bone defects. In this study, we have engineered bone implants through extrusion as-
sisted three-dimensional (3D) printing of MgP ceramics modified with Sr2+ ions (MgPSr) 
and a medical grade polycaprolactone (PCL) polymer phase.Materials and methods: Mg-
PSr based powders were first synthesized and then combined with PCL at different weight 
ratios (70:30, 60:40, and 50:50 wt.%). Printability of MgPSr-PCL composite pastes was 
investigated using a pneumatic-driven 3D printer (regenHU, Switzerland). Full characteri-
zation of the printed materials in terms of their physico-chemical, structural and mechanical 
properties was performed. Cytotoxicity, resorbability and osteo-conductive (and inductive) 
properties of printed materials was first accessed in vitro, in the presence of equine mesen-
chymal stem cells (MSc), and then in vivo in an equine model (Shetland ponies, n=8). Bone 
tissue formation was evaluated after 6 months of implantation by micro-CT, histology and 
energy-dispersive X-ray spectroscopy combined with scanning electron microscope.Results 
and Discussion: MgPSr with 30wt.% PCL (MgPSr-PCL30) allowed the printability of rele-
vant size structures (>780 mm3) with an interconnected macroporosity (>40%) and elastic 
mechanical properties (~ 40MPa elastic modulus, ~ 300 kJ/m3 toughness) (Fig 1). Notably, 
MgPSr-PCL30 implants were able to promote in vitro bone formation without the supple-
mentation with osteo-inducing components. In addition, long-term in vivo performance of 
MgPSr-PCL30 implants in equine tuber coxae model for 6 months showed these implants 
induced bone regeneration without eliciting any negative inflammatory reaction, while no 
bone formation was observed in the empty defects (Fig 1A-C).Conclusion: Overall, the de-
veloped MgP-based composite materials and extrusion-based 3D printing process presented 
here open promising avenues to satisfy the growing need for fully resorbable and mechani-
cally competent bone implants.  
Disclosures: Miguel Castilho, None
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Are wide proximal femurs weaker? *Karl Jepsen1, Erin Bigelow1, Daniella 
Patton1, Robert Goulet1, Stephen Schlecht2, David Kohn1, Carrie Karvonen-
Gutierrez1, Todd Bredbenner3. 1University of Michigan, United States, 2Indiana 
University, United States, 3University of Colorado Colorado Springs, United 
States
In simple terms, biomechanical principles dictate that wide bones should be stronger 
than narrow since strength is proportional to outer width cubed. However, wide femoral 
necks show increased fracture risk in some studies. The biomechanical mechanism that ex-
plains this association in terms of structure-function relationships is not fully understood. 
We tested the hypothesis that wide proximal femurs will show greater loss of strength and 
structural traits with age compared to narrow.Proximal femurs were obtained for 50 white 
male cadavers (18-89 years; IRB approved). Femoral neck trabecular architecture and nar-
row-neck cortex traits were quantified from nanoCT images (27μm). Whole bone strength 
(max load) was determined by loading proximal femurs in a sideways fall configuration. 
Samples were sorted into 5 groups using total cross-sectional area (TtAr), cortical area 
(CtAr), and trabecular BV/TV (K-means cluster analysis). Two clusters containing 1-2 sam-
ples each were not examined. The three remaining clusters overlapped in CtAr and BV/
TV but not TtAr. Based on TtAr, groups were designated as narrow (n=13), intermediate 
(n=20), or wide (n=14).The wide (R2=0.41, p=0.019) and intermediate (R2=0.32, p=0.019) 
but not narrow (R2=0.12, p=0.301) groups showed significant negative associations between 
strength and age (Fig 1). TtAr showed nonsignificant associations with age for all groups. 
The wide group showed significant negative correlations with age for both CtAr (R2=0.45, 
p=0.009) and BV/TV (R2=0.38, p=0.019). In contrast, the intermediate group showed a sig-
nificant negative correlation with age only for BV/TV (R2=0.36, p=0.005), whereas the nar-
row group showed no significant associations with age for either CtAr (R2=0.06, p=0.405) 
or BV/TV (R2=0.01, p=0.713).This analysis showed that wide, male proximal femurs are 
stronger than narrow at younger ages (<65 years; p=0.006, 2-way ANOVA) consistent with 
biomechanical principles. However, age-related changes in the cortical and trabecular tis-
sues lead to a greater decline in strength of wide proximal femurs and a convergence of 
strength values at the older ages. Age-related losses of cortical and trabecular tissues varied 
among the three groups suggesting that outer bone size may predict individual trait-age tra-
jectories. Further research is needed to understand why cortical and trabecular mass decline 
with age in wide but not narrow proximal femurs and how combinations of change affect 
bone strength.
Disclosures: Karl Jepsen, None
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Pull out strength of the screw and compression force of vertebra gain with 
a 3-month course of romosozumab treatment: Prospective study using finite 
element analysis *Koji Ishikawa1, Soji Tani1, Koki Tsuchiya1, Hiro Hasegawa2, 
Takako Negishi-Koga3, Yoshifumi Kudo1, Toshiyuki Shirahata4, Takashi Nagai1, 
Tomoaki Toyone2, Katsunori Inagaki1. 1Department of Orthopaedic Surgery, 
Showa University School of Medicine, Japan, 2Department of Orthopaedic 
Surgery, Showa University School of Medicine, Japan, 3Division of Malaria 
Immunology, Department of Microbiology and Immunology, The Institute of 
Medical Science, The University of Tokyo, Japan, 4Department of Orthopaedic 
Surgery, Showa University Koto Toyosu Hospital, Japan
Introduction: Romosozumab (Romo) recieved the first in the world approval in Japan 
for the treatment of osteoporosis. Several studies have investigated the effect of osteoporosis 
treatment in patients undergoing spinal surgery. However, the lack of evidence to support 
use of Romo during spinal surgery. The aim of the present study was to investigate the effect 
of Romo on spinal surgery using FEA (finite element analysis).Methods: Fourteen patients 
(age: 73.1 +/- 6.0 years: mean +/- SD) with postmenopausal osteoporosis were included 
for this prospective study. All patients were analyzed using blood samples, DXA, and CT. 
In performing FEA analysis, each 3D model of L4 vertebra was constructed from the CT 
data. The 3D-FE models of the pedicle screw were developed separately from high solution 
micro-CT and inserted in the 3D vertebra model using traditional trajectory. Pull out strength 
(POS) of the screw and compression force of vertebra were assessed at baseline and 3 months 
following treatment.Results: Thirteen patients (92.9 %) completed 6 months follow-up with 
no fracture events. There were a significant change in TRACP-5b and total-P1NP from base-
line to 3 months (P<0.01, vs baseline: Wilcoxon). The percent LS BMD changes increased 
significantly from baseline to 6 months (14.4 %, P<0.01, vs baseline: Wilcoxon). Notably, 
percent POS changes and compression force of vertebra were significantly increased from 
baseline in only 3 months treatment (POS: 24.1%, Compression force: 13.5%, P<0.01, vs 
baseline: Wilcoxon).Discussion: In summary, our prospective biomechanical study using 
FEA showed 3 months treatment of Romo was effective in both screw fixation and compres-
sion force of vertebra. Romo may be useful for patients undergoing spine surgery.
Disclosures: Koji Ishikawa, None
P-077
Fracture Risk in Lower Extremity High Rate Loading - A Probabilistic 
Statistical Shape and Density Finite Element Analysis *Lance Frazer1, Daniel 
Nicolella1. 1Southwest Research Institute, United States
Background: Anti-vehicular landmines and improvised explosive devices (IEDs) can 
produce catastrophic lower extremity injuries. As such, lower extremity injury prevention is 
of high concern but requires a better understanding of high-rate impacts and fracture risk. In 
this study, a probabilistic finite element model of the tibia and talus was developed to pro-
duce a fracture risk assessment and was compared to experimental cadaveric testing. Meth-
ods: We developed a high-fidelity statistical shape and density model of the tibia to provide a 
means of generating physiologically plausible anatomies to investigate the effect of anatom-
ical variability on the risk of injury. Probabilistic descriptions of bone material properties for 
the tibia were taken from literature and internal sources to account for natural variation and 
uncertainty. A 7.5 kN distal tibia impact simulation was developed following the method-
ology of a previously described framework. This 7.5 kN load corresponds to nearly a 10% 
tibial fracture risk, which was experimentally derived using cadaveric specimens. Using the 
probabilistic descriptions of anatomy and material properties, a Latin Hypercube probabilis-
tic finite element analysis was performed using the 2nd percentile strain as a failure criterion. 
Results and Discussion: The probabilistic analysis resulted in a computed risk of fracture of 
10% given the 7.5 kN impact force on the distal tibia. Uncertainty and variability in the bone 
failure strain, material properties, and tibia anatomy substantially influenced fracture risk. 
The described probabilistic model reproduced experimentally derived fracture risk and can 
be used as a comprehensive surrogate to cadaveric testing for high-rate distal tibia impacts. 
This model can be used for the design of protective equipment, the identification of high-risk 
individuals, and the development of novel injury mitigation strategies.
Disclosures: Lance Frazer, None
P-078
Bilateral Asymmetry in the Healing Distal Radius: An in vivo HR-PQCT 
Micro-Finite Element Analysis Study *Caitlyn Collins1, Penny Atkins1, 
Nicholas Ohs1, Lukas Horling2, Kerstin Stock3, Patrik Christen0, Michael 
Blauth2, Ralph Müller1. 1Institute for Biomechanics, ETH Zurich, Switzerland, 
2Department for Trauma Surgery, Innsbruck University Hospital, Austria, 
3Department for Trauma Surgery, Innsbruck University Hospital, Austria, 
0Institute for Biomechanics, ETH Zurich; institute for Information Systems, 
FHNW, Switzerland
Despite evidence of inhibited recovery in non-dominant arm fractures, hand dominance 
in fracture healing remains under investigated. With the advent of high-resolution peripheral 
quantitative computed tomography (HR-pQCT), changes in microstructural and biomechan-
ical properties can be assessed in vivo. The objective of the current study was to assess the 
effect of hand dominance on fracture healing using HR-pQCT-based micro-finite element 
(microFE) analysis.Patients (3 males, 26-70 years; 8 females, 27-81 years) with a conser-
vatively treated, unilateral radius fracture provided informed consent prior to participation 
(Ethics Committee, Medical University of Innsbruck). Standard clinical HR-pQCT scans 
(XtremeCT II, Scanco Medical AG, isotropic voxel size: 61 µm) were taken of the fractured 
(F) and contralateral (C) radii (168 slices) at 1, 3, 5, 13, 26, and 52 wks post-fracture. Addi-
tional data, proximal and distal to the standard scan, were captured for the F-radii (504 total 
slices). MicroFE models, generated from registered HR-pQCT data via direct conversion 
from voxels to hexahedral elements (Python v3.7), were assigned scaled, linear elastic mate-
rial properties (Poisson’s ratio=0.3). “High friction” compression tests with a prescribed 1% 
axial displacement were performed on all models. Anterior-posterior (AP) strain ratios were 
compared after isolation of the two regions using a cutting plane with surface normal from 
the center of mass to the dorsal tubercle (Figure 1, right).Median Effective (Eff) strain was 
consistently higher (20-55%) posteriorly for both non-dominant and dominant C-radii. AP 
Strain ratio was significantly larger (p=0.027) and more consistent for the dominant C-radii 
(Figure 1, left). This behavior was irrespective of patient age. As a result of the fracture, AP 
Strain ratios (+/-sd) were inverted until 13 wk (0.84+/-0.14; 1 wk: 1.18+/-0.42) and 26 wk 
(0.98+/-0.18; 1 wk: 1.27+/-0.36) in the dominant and non-dominant F-radii, respectively.
The disparity in AP strain ratio between non-dominant and dominant C-radii suggests that 
C-radii cannot be used as a patient-specific, “healthy” reference. Full recovery after fracture 
may take more than one-year, as subjects in the current study have yet to achieve reference 
C-radii AP Strain ratios at 52 wk. Despite limited size of the current subset, the results 
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indicate that HR-pQCT-based microFE analysis is sensitive enough to detect and track dom-
inance-related contributions to bone fracture healing.
Disclosures: Caitlyn Collins, None
P-079
Effects of In Vitro Vitamin B Treatment on Advanced Glycation End-
Products and Human Cortical Bone Mechanical Properties *Taraneh 
Rezaee1, Rachana Vaidya2, Jacob Aaronson2, Lamya Karim2. 1Department 
of Bioengineering, University of Massachusetts Dartmouth, United States, 
2Department of Bioengineering, University of Massachusetts Dartmouth, United 
States
T2D patients experience 3x increased fracture risk compared to non-diabetics even with 
normal to high bone mineral density. It is likely the high risk is due to poor bone quali-
ty, which results from many factors including increased advanced glycation end-products 
(AGEs). It is important to test methods to prevent these harmful AGEs from forming. Vita-
min B6 (VitB) is an AGE inhibitor that has been used to treat diabetic complications such as 
neuropathy and cardiovascular issues1,2. Here, we investigated the effects of in vitroVitB 
treatment on bone material properties and hypothesized treatment with VitBwill decrease 
AGEs and improve bone mechanical properties.Twenty cortical beams were acquired from 
cadaveric human tibias and randomly divided into groups: vehicle, ribose (R), R + 0.5mM 
VitB, R + 5 mM VitB, and R + 50 mM VitB. Beams were incubated for 10 days at 37°C in 
solutions with 5 mM benzamidine, 25 mM e-amino-n-caproic acid, 10 mM n-ethylmaleim-
ide, and 30 mM HEPES in Hank’s Buffer. Ribose and VitB groups had 0.6 M ribose and 
respective concentrations of VitB. Beams were imaged by microCT, mechanically tested 
by cyclic Reference Point Indentation (cRPI) and 4-point bending, and assessed for total 
fluorescent AGEs.Tissue mineral density and cortical porosity were not different between 
groups. AGEs were increased in the ribose group compared to vehicle control (p<=0.05), but 
there were no differences in AGEs in Vitamin B treated groups vs ribose group. Mechanical 
testing variables by bending tests did not differ between groups. Majority of cRPI variables 
were not different between groups, except unloading slope (US) and average unloading 
slope were lower (p<=0.05) in 5 and 50 mM Vitamin B6 treated groups compared to the 
ribose group.We observed lower US and average US in VitB treated groups, indicating the 
treatment made bone less stiff, but this change was not explained by altered AGE levels. 
In contrast, a previous in vitro study showed VitB had an inhibitory effect on AGEs and 
improved indentation distance increase (IDI) in the presence of glucose3. This indicates 
1) vitamin B6 may not be as effective on ribose-derived crosslinks, or 2) we may need to 
further assess individual AGEs such as pentosidine and carboxymethyllysine in addition 
to increasing sample size to get a full understanding.References: 1) Kilhovd, et al., 1999; 
2) Jimenez, et al., 2009; 3) Abar, et al., 2018Ack:University of Massachusetts Dartmouth 
Multidisciplinary Seed Funding
Disclosures: Taraneh Rezaee, None
P-080
Effects of High-dose Bisphosphonate Therapy on the Fatigue-life of Whole-
bone and Bone Tissue *W. Brent Edwards1, Ifaz Haider1, Andrew Sawatsky1, 
Rebecca Page1. 1University of Calgary, Canada
Long-term bisphosphonate (BP) use has been linked to atypical femoral fractures (AFF) 
defined as fatigue-like fractures of the femoral shaft. The prevailing hypothesis for AFF 
is that BP related suppression of bone remodeling impairs tissue-level fatigue resistance; 
however, BPs are also associated with increases to bone mineral density and cortical thick-
ness at the whole-bone level. It remains unclear how BP-induced changes to bone across 
these different length scales influence fatigue-life measurements. In this study, we quantified 
the effects of high-dose BP therapy on the fatigue-life of whole-bone and bone tissue in 
New Zealand white rabbits treated for 6 months with alendronate (ALN; 0.15 mg/kg; n=3) 
or vehicle (VEH; n=3) via subcutaneous injection; the dosage was 50-times higher than 
the clinical dosage in humans. After treatment, whole-tibiae were imaged using computed 
tomography (CT) then cyclically loaded in zero-compression at 50% ultimate strength un-
til failure or a run-out of 500,000 cycles. Tissue-level tests were performed on 44 cortical 
beam-samples (1.1 x 1.1 x 16 mm) prepared from femora. Samples were cyclically loaded 
in four-point bending at either 140, 120 or 100 MPa until failure. After fatigue assessment, 
sections of bone near the fracture site were imaged using µCT (5 µm isotropic voxel size). 
Median volumetric bone mineral density and content were 4.1% and 14.2% higher for ALN, 
respectively, demonstrating a marked osteogenic response to drug. In general, whole-tibiae 
from ALN rabbits (median=500,000, IQR=214,631 cycles) illustrated a longer fatigue-life 
than VEH (median=28,300, IQR=76,201 cycles), with the majority of ALN bones reaching 
500,000 cycles (Figure 1); the Cohen’s d effect size between groups was large (d = 1.62). At 
the tissue-level, generalized linear modeling verified a relationship between load magnitude 
and fatigue-life (p < 0.001); however, no effect of treatment group (p=0.243) or group x load 
interaction (p=0.224) was observed. The overall porosity and size of the Haversian systems 
were lower in ALN when compared to VEH (d=0.66-1.82, depending on measure). To sum-
marize, 6-months high-dose BP therapy illustrated improvements to whole-bone fatigue-life, 
no changes to bone-tissue fatigue-life, and structural and microarchitectural changes consis-
tent with long-term BP therapy. These preliminary findings open doors to alternative hypoth-
eses for the increased risk of AFF associated with prolonged BP treatment.
Disclosures: W. Brent Edwards, None
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Why the cervical spine doesn’t break – a biomechanical examination 
by load testing the vertebrae of 13 body donors *Guido Schröder1, Sven 
Spiegel1, Marko Schulze2, Rene Trezack3, Reimer Andresen4, Hans-Christof 
Schober5. 1University Medical School Rostock, Germany, 2Institute of Anatomy, 
University Medical School Rostock, Germany, 3Faculty of Mechanical 
Engineering and Marine Engineering, Department of Construction Technology/
Lightweight Structures, University of Rostock, Germany, 4Institute of Diagnostic 
and Interventional Radiology/Neuroradiology, Westkuestenklinikum Heide, 
Academic Teaching Hospital of the Universities of Kiel, Luebeck and Hamburg, 
Germany, 5Department of Internal Medicine IV, Municipal Hospital Suedstadt 
Rostock, Academic Teaching Hospital of the University of Rostock, Germany
IntroductionOsteoporotic fractures of the cervical spine (CS) are seldom described. 
This raises the question of whether cervical cancellous bone differs in structure from that 
of thoracic (TS) and lumbar (LS) vertebrae. Structural and material characteristics of the 
cervical, thoracic and lumbar spine were compared in terms of the bone structure, structure 
model index (SMI), degree of anisotropy (DA) and failure load.MethodsCancellous bone 
was extracted using a Jamshidi Needle® from each of the cervical, thoracic and lumbar 
vertebrae of 13 body donors (Age: 84.2+/-8.5 y, 5 f, 4m). The investigations were carried 
out using a μ-CT (SKYSCAN 1172, RJL Micro & Analytic GmbH, Germany). A flat-field 
correction and a reference comparison with phantoms of density 0.25 g/cm³ and 0.75 g/cm³ 
were performed.   We measured the force required to generate a first-degree fracture (20% 
height loss) in 104 vertebral bodies using a load test. The load tests of vertebral bodies C5, 
C6, T7, T8, T9, T12, L1, L3 were performed on a servo-hydraulic testing machine (MTS 
858, MTS Systems Cooperation, Eden Prairie, USA). ResultsWith regard to SMI and DA, 
bone density (BV/TV), trabecular thickness (Tb.Th.) and trabecular separation (Tb.Sp.), sta-
tistically significant differences were found between cervical spine and thoracic spine and 
between cervical spine and lumbar spine.SMI: CS vs. TS p=0,009; CS vs. LS p=0,002; DA: 
CS vs. TS p=0,026; CS vs. LS p=0,025.  The force required to produce a first-degree fracture 
was   approximately twice as high in the cervical spine compared to the thoracic and lumbar 
spine. Failure strength CS vs. TS p= 0,002; CS v. LS p= 0,002. ConclusionCervical vertebrae 
have significantly greater load capacity before fracturing compared to thoracic and lumbar 
vertebrae due to their denser structure, higher SMI and a lesser degree of anisotropy.  These 
morphological differences may explain why osteoporotic fractures in vivo rarely occur in 
the cervical spine.
Disclosures: Guido Schröder, None
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Dietary Supplements Do Not Improve Bone Quality in C57BL/6J Female 
Mice *Amy Creecy1, Collier Smith2, Joseph Wallace2. 1Indiana University, 
United States, 2IUPUI, United States
There are multiple dietary supplements marketed for their ability to improve health 
outcomes, including reducing the symptoms of osteoarthritis or improving skin and nail 
quality. Some of these dietary supplements contain components of the extracellular ma-
trix of bone and could possibly impact bone quality. Beginning at 11 weeks of age, female 
C57BL/6J mice were given dietary supplements (hydrolyzed collagen, chondroitin sulfate, 
fish oil, or glucosamine) 5 times per week for 8 weeks (n=10 per group). Supplements were 
suspended in Milli-Q water and then deposited onto a Bacon Softie® food supplement. Mice 
had access to eat these supplements ad libitum. Control mice were given the same food 
supplement soaked with only Milli-Q water. Femurs and vertebrae were collected and stored 
in PBS-soaked gauze at -20°C. Femurs and vertebra were scanned with µ-computed tomog-
raphy (9.8 µm voxel size) to determine bone structure. Femurs were tested to failure in 3-pt 
bending to determine mechanical properties. One-way ANOVA was used for data analysis, 
followed by Dunnett’s multiple comparison tests where dietary supplement groups were 
compared to the control group if one-way ANOVA values were significant. Body weights 
were not different among the groups. Trabecular bone parameters were similar between all 
groups in both the femur and vertebrae. There were no significant changes in bone volume 
fraction (BV/TV), trabecular number or spacing. Structural model index was lower in the 
femurs for collagen-treated mice, indicating more parallel plate-like structure of trabecu-
lae. There were few differences in cortical bone structure of the femur. Marrow area and 
endocortical bone surface of glucosamine-treated mice were larger compared to controls, 
but there was no effect on cortical area or thickness. For the mechanical tests, there were no 
differences in extrinsic mechanical properties. For material properties, elastic modulus was 
lower for glucosamine-treated and fish oil-treated mice. This difference in modulus was not 
accompanied by differences in ultimate stress or toughness. Overall, dietary supplements 
had minimal effects on bone quality or quantity.
Disclosures: Amy Creecy, None
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Enhanced Formation of Carboxymethyllysine in Bone Matrix through 
Designed Glycation Reaction *Grazyna Sroga1, Deepak Vashishth1. 1Rensselaer 
Polytechnic Institute, United States
    Formation of advanced glycation end products (AGEs) is of great interest to health 
and medicine as they are formed at a slow but constant rate in human body and continue 
to accumulate with time altering key processes and functions. Due to its connection with 
the in vivo oxidative stress, carboxymethyllysine (CML) is of considerable importance to 
various oxidative stress-related diseases. Recently, it has been shown that CML accumulates 
in human aging bone [1] and correlates with fracture incidences [2]. Still, the mechanistic 
implications of CML accumulation in bone remain to be elucidated. Such studies have been 
hindered by the lack of suitable experimental strategies generating CML in bone. Thus, 
the goal of our study was to develop an in vitro strategy for enhanced formation of CML 
in bone matrix.    In vivo, CML can be formed through a number of different glycation and 
glycoxidation pathways. Of importance to this study is the in vivo oxidative route known as 
the Namiki pathway [3]. It inspired the development of our new strategy enhancing forma-
tion of CML in extracellular bone matrix based on using glyoxal and glyoxylic acid as the 
substrates.    Tibiae (posterior area) from human donors (3 age groups: young (25 y/o), mid-
dle-age (48 y/o) and elderly (84 y/o)), served as the source of cortical bone. We determined 
that on average, glyoxal led to the formation of higher levels of CML. Generally, the devel-
oped strategy produced approx. 3.1-fold higher levels of CML over the controls for glyoxal 
(Fig. 1A) and approx. 2.4-fold for glyoxylic acid (Fig. 1B). We also observed a moderate 
increase of the AGE levels either with glyoxal or glyoxylic acid, which was expected due to 
the presence of other amino acids with free functional groups (e.g., arginine, tyrosine or cys-
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teine) in matrix proteins, known to react with glyoxal and/or glyoxylic acid. We propose that 
under the developed reaction conditions, the in vitro generation of CML using glyoxal may 
be a dominant pathway towards CML formation.    In summary, we developed new strategy 
enhancing formation of CML in bone matrix. Our study presents a new experimental tool to 
investigate the role and mechanistic aspects of specific AGEs, here CML. We believe that the 
developed procedure may have general applications beyond skeletal research.    References: 
[1] Thomas et al, Bone 2018, 110: 128-133; [2] Barzilay et al, JBMR 2014, 29(5):1061-
1066; [3] Namiki N, Adv Food Res, 1988, 32: 115–184 
Disclosures: Grazyna Sroga, None
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Hypercaloric diet, polyphenols and microarchitecture of Wistar rats 
femoral neck *Beatriz Almeida Rodrigues1, Fabiana Cirinos dos Santos1, Felipe 
Peressini1, Matheus Nobile1, Mark Hurtig2, Lizandra Amoroso1. 1Universida 
Estadual Paulista “Julio de Mesquita Filho” - Faculdade de Ciências Agrarias, 
Brazil, 2Ontario Veterinary College, University of Guelph, Canada
The objective of this work was to evaluate the influence of the red orange Moro Citrus 
sinensis (L.) Osbeck and the swimming practice, on the ultrastructural aspects of the femoral 
neck of male and adult Wistar rats, treated with a high calorie diet. The experimental groups 
with twelve animals each were organized as follows: normocaloric diet (Dn), hypercaloric 
diet (Dh), normocaloric diet and phytotherapic (DnF), hypercaloric diet and phytotherapic 
(DhF), normocaloric diet and swimming (DnS), hypercaloric diet and swimming (DhS), 
hypercaloric diet, swimming and phytotherapic (DhSF). The dry extract of the red orange 
was diluted in distilled water and administered at a dose of 7mg/kg, once a day, via gavage. 
After a week of adaptation, swimming was performed for 30 min a day in a heated pool. 
After 84 days of treatment, the animals were euthanized, the femurs were dissected and 
frozen. For microCT analysis on the GE Brightspeed Elite equipment, the samples were 
thawed gradually at room temperature and kept at the same temperature during scanning. An 
80 kv power radiograph and a 4000x2624 charge-coupled device (CCD) camera were used. 
The voxel size was 5.9 μm. Then, they were placed in acrylic containers and positioned lon-
gitudinally, in the craniocaudal direction. After acquiring the 3D images, the reconstruction 
of the longitudinal sections in the program began. The material was analyzed using Parallax 
Innovations’ Microview software, with selection of the femoral neck as the area of interest 
(ROI). In the evaluation by computed microtomography (micro-CT) of the femoral neck, 
there was a greater total volume (VT) and greater bone volume (BV) in the group treated 
with a high calorie diet and swimming (DhS). Bone mineral content (BMC), bone mineral 
density (BMD), bone tissue mineral content (TMC) stood out in the DhSF group, while the 
tissue mineral density was higher in the Dh group. Higher bone volume of the femoral neck 
was observed after the group that practiced swimming and had access to the high calorie 
diet. Although there is no change in bone microarchitecture, the morphological changes and 
BMC, BMD and TMC values may reflect on beneficial effects of the phytotherapic on the 
femur, minimizing the influence of the high calorie diet on the femoral neck.
Disclosures: Beatriz Almeida Rodrigues, None
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Optimization of a High-Resolution Peripheral Quantitative Computed 
Tomography(HR-pQCT) Protocol in the Distal Tibia and Radius in Children 
and Adolescents *Kyla Kent1, Jin Long1, Mary Leonard1, Ariana Strickland1, 
Jessica Whalen1, Babette Zemel2, Keenan Brown3, Andrew Burghardt4. 
1Department of Pediatrics, Stanford University, United States, 2Department 
of Pediatrics, Children’s Hospital of Philadelphia, United States, 3Mindways 
Software, Inc., United States, 4Department of Radiology & Biomedical Imaging, 
University of California San Francisco, United States
HR-pQCT provides novel measures of bone quality that are increasingly used to study 
bone accrual in healthy children and those with chronic disease. To date, pediatric stud-
ies are hampered by lack of consistent methods for reference line placement (endplate vs. 
growth plate) or scan site (fixed or percent distance).  The goal of this study was to estab-
lish a protocol for the XCT II scanner that best captures variability in metaphyseal bone 
outcomes related to sex and maturation. First, we measured the distance from the endplate 
(tibia plafond or radius medial endplate) to the proximal margin of the distal growth plate 
in 84 participants (ages 5-29 yr), demonstrating the distance did not scale with total bone 
length in the tibia or radius (both R < 0.05). The distance scaled inversely as a percentage of 
bone length (tibia R = - 0.59; radius R = - 0.49; both p< 0.001), so use of the endplate ref-
erence will introduce significant bias with a relatively more proximal scan site in those with 
shorter bones. Accordingly, we recommend reference line placement at the proximal margin 
of the distal growth plate. Second, we acquired two consecutive stacks (336 slices over 20 
mm) beginning 2 mm proximal to the proposed reference line in 322 participants (ages 5-29 
yr).  The Figure illustrates the systematic changes in HR-pQCT outcomes within individuals 
along the length of the tibia metaphysis: e.g. trabecular thickness and cortical thickness in-
creased a mean (SD) of 17% (9.2) and 173% (33) over the scan region, respectively. We used 
multivariable regression to compare results in a single stack obtained a fixed 2 mm distance 
from the reference line vs. a single stack centered at 4%. Tests for interaction demonstrated 
that the 4% site revealed significantly greater sex and maturation effects on trabecular and 
cortical outcomes, compared with the fixed stack in the tibia: e.g. p < 0.001 for greater sex 
and Tanner maturation effects on trabecular thickness and cortical thickness at the 4% site. 
Exploratory analyses comparing stacks centered at 3, 3.5, 4, or 4.5% did not demonstrate 
consistent advantages across HR-pQCT outcomes. Similar results were observed in the radi-
us. Test-retest precision for trabecular and cortical outcomes were comparable at each scan 
site. In summary, we recommend that the HR-pQCT community adopt a standard pediatric 
protocol with reference line placement at the proximal margin of the growth plate and a 
single stack centered at 4% of bone length.
Disclosures: Kyla Kent, None
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Urinary Calcium Excretion is Negatively Associated with Bone Mineral 
Accrual in Youth with Type 1 Diabetes *David Weber1, Kimberly O’Brien2, 
Noya Rackovsky1, George Schwartz1. 1University of Rochester Medical Center, 
United States, 2Cornell University - College of Human Ecology, United States
Background: The skeletal complications of type 1 diabetes (T1D) include an increased 
risk of fracture and mild to modest deficits in bone density. The mechanism underlying 
T1D-related bone disease is unknown. Hypercalciuria has been described in conjunction 
with T1D, however its relationship with bone accrual has not been evaluated. The objec-
tive of this study was to determine if urinary calcium excretion was associated with bone 
accrual in T1D youth.  Methods: Youth with T1D of >=1 yr duration were evaluated with 
DXA, blood, and urine tests at baseline and 12-months. Whole body less head (WBLH) 
bone mineral content (BMC) was converted into age and sex specific Z-scores, adjusted 
for height Z-score. Bone accrual was assessed by WBLH BMC velocity (gm/yr), expressed 
as Z-scores adjusted for baseline BMC, age, height, weight, growth, and puberty. Urinary 
calcium excretion was assessed by spot urine calcium to creatinine ratio (Uca/Ucr). Means 
were expressed (+/- SD) and compared using t-tests; medians as (interquartile range) and 
compared using Wilcoxon rank sum. Associations between variables were tested by Spear-
man’s rho and multivariable linear regression.Results:  53 subjects (62% male, 83% white) 
aged 8-20 yr (mean 14.9+/-3.5) completed the study. Mean hemoglobin A1c (A1c) was 
8.6+/-1.5%; median duration of T1D was 6.4 (3.5-8.9) yr. WBLH BMC-Z declined from 
−0.16+/-0.83 to −0.21+/-0.90, p=0.15. Mean WBLH BMC velocity-Z was −0.31+/-0.98, 
which was significantly lower than the reference population, p=0.03. Spot Uca/Ucr was 
significantly negatively associated with WBLH BMC velocity-Z, ρ=−0.49, p=0.003 (Fig. 1). 
This relationship persisted after adjusting for sex, puberty, growth velocity, and biochemical 
markers of bone mineral metabolism. WBLH BMC velocity-Z was significantly lower in the 
6 subjects (11%) with hypercalciuria (Uca/Ucr >0.2) compared to those without hypercal-
ciuria, −0.85 (−2.04-−0.83) vs −0.07 (−0.74-0.55), p=0.02. Positive correlations were seen 
between Uca/Ucr and both urine glucose to creatinine (ρ=0.31, p=0.03) and urine sodium to 
creatinine (ρ=0.46, p=0.001) ratios. A1c, a marker of long-term glycemic control, was not 
associated with bone accrual or Uca/Ucr.Conclusions:  Greater urinary calcium excretion 
was associated with lower rate of bone accrual in T1D youth. Further studies are needed to 
76
P-087 ASBMR 2020 Annual Meeting
determine if Uca/Ucr is simply a marker of impaired bone mineral accrual or if it may be a 
potentially modifiable factor to improve bone health in T1D.
Disclosures: David Weber, None
P-087
Associations of Sex, Sexual maturation, IGF1 and Muscle Mass with Bone 
Failure Load in the Tibia and Radius Metaphysis and Diaphysis during 
Development *Tandy Aye1, Jin Long1, Kyla Kent1, Jessica Whalen1, Ariana 
Strickland1, Andrew Burghardt2, Mary Leonard1. 1Dept of Pediatrics, Stanford 
University, United States, 2Dept of Radiology and Biomedical Imaging, 
University of California San Francisco, United States
Puberty is a time of rapid growth and bone accrual and these gains influence fracture 
risk across the life course. The independent roles of sex, sexual maturation, insulin-like 
growth factor -1 (IGF1) and muscle mass on the development of the long bone metaphysis 
and diaphysis have not been established. Micro-finite element analysis (µFEA) generated 
failure load (FL) has been associated with fractures in multiple studies but has not been as-
sessed using 2nd generation HR-pQCT (XCT-II, Scanco, Inc) in children and young adults. 
The objective of this cross-sectional study in 284 healthy participants (151 females), ages 
5-30 years, was 1) to identify effects of sex and maturation on metaphysis and diaphysis 
µFEA FL in the tibia and radius; and 2) to determine the impact of adjustment for IGF1 
or muscle mass. Tibia and radius scans were obtained with 10.2 mm volumes centered at 
distances 4% (metaphysis) and 30% (diaphysis) proximal to the distal growth plate. Failure 
load was estimated for a 1% axial compression, assuming a homogenous tissue modulus of 
10 GPa and failure to occur when 7.5% of elements exceed 7000 µ. Leg and arm muscle 
mass were obtained from whole body DXA scans. All log-linear regression models for FL 
were additionally adjusted for age, age2 and bone length as covariates. At all four sites, FL 
did not differ according to sex within Tanner 1,2 independent of age and bone length. The 
figure illustrates the study findings in the tibia diaphysis as a representative example. Beyond 
Tanner 1,2, FL was progressively and significantly greater with successive Tanner stages and 
was significantly greater in males than females. Sex differences were amplified in Tanner 5 
(sex-tanner interaction, p=0.001).  IGF1 was positively associated with FL at both sites in 
the tibia (metaphysis: p<0.001; diaphysis: p<0.01), independent of sex and maturation, but 
was not significantly associated with FL in the radius. Adjustment for IGF1 did not attenuate 
the sex and sexual maturation associations with FL in the tibia (Figure). Muscle mass was 
significantly and positively associated with FL at all 4 sites (all p < 0.001), independent of 
sex and maturation. Adjustment for muscle largely attenuated the sex and maturation effects 
on FL at all 4 sites. These novel data will provide the foundation for studies of the impact 
of chronic childhood disease on bone health and studies of interventions to improve bone 
strength during growth and development. 
Disclosures: Tandy Aye, None
P-088
Type 1 Diabetes is Associated with Bone and Muscle Deficiencies in Children 
and Adolescents *Jin Long1, Hilary Seeley1, Jessica Whalen1, Ariana Strickland1, 
Kyla Kent1, Tandy Aye1, Laura Bachrach1, Mary Leonard1. 1Department of 
Pediatrics, Stanford University, Stanford, CA, United States
The bone disease in Type 1 Diabetes (T1D) is characterized by impaired bone forma-
tion, resulting in increased fracture risk across the lifespan. Biomechanical forces exerted by 
muscle are a strong anabolic stimulus to bone formation during childhood and adolescence, 
and recent data suggest that T1D compromises muscle mitochondrial oxidative capacity. 
The objective of this study was to assess bone failure load, muscle mass and muscle strength 
in 50 children and adolescents (ages 10-18 years) with T1D of at least 3 years duration, 
compared with 182 controls. Tibia and radius HR-pQCT scans (XCT-II, Scanco, Inc) were 
obtained in the metaphysis and diaphysis at a distance 4% and 30% proximal to the distal 
growth plate, respectively. Failure load (FL) was estimated using micro-finite element anal-
ysis. Leg lean mass was obtained from whole body DXA scans and isokinetic leg strength 
in knee extension from dynamometry. All bone and muscle measures were converted to 
sex-specific Z-scores relative to age based on the data in the healthy controls. Participant 
characteristics were notable for higher BMI Z-scores in the T1D females compared with 
controls (0.76 +/- 0.57 vs. 0.31 +/- 0.91, p=0.03); BMI Z-scores did not differ in T1D males 
and controls (0.24 +/- 0.94 vs. 0.26 +/- 0.98). Among males, FL in the tibia metaphysis and 
diaphysis and leg muscle strength were significantly lower in T1D, compared with controls 
(Table, all p <= 0.01). The significant bone deficits persisted in the males after adjustment 
for lower muscle mass or strength. Among females, T1D was not associated with muscle or 
bone deficits at any site. However, bone deficits were evident in the tibia diaphysis when 
adjusted for the greater BMI in the female T1D participants. IGF-1 levels were positively 
associated with tibia FL in the metaphysis and diaphysis within the controls, and were sig-
nificantly lower in T1D compared with controls (Z-score: -1.01 +/- 1.18 vs. -0.003 +/- 1.00, 
p < 0.001). However, adjustment for IGF-1 levels had negligible and inconsistent effects 
on the FL estimates summarized below. Future studies are needed to determine the impact 
of glycemic control and exercise interventions on musculoskeletal health in children and 
adolescents with T1D.
Disclosures: Jin Long, None
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Preferential maternal transmission of STX16-GNAS mutations responsible 
for autosomal dominant pseudohypoparathyroidism type Ib (PHP1B): 
another example of Transmission Ratio Distortion *Zentaro Kiuchi1, Monica 
Reyes1, Harald Jüppner2. 1Endocrine Unit, Massachusetts General Hospital 
and Harvard Medical School, United States, 2Endocrine Unit and Pediatric 
Nephrology Unit, Massachusetts General Hospital and Harvard Medical School, 
United States
The preferential transmission of a genetic mutation to the next generation, referred to 
as Transmission Ratio Distortion (TRD), has been described for several autosomal dominant 
disorders, but the underlying mechanisms remain undefined. Recently, TRD was reported 
for the offspring of patients affected by either pseudohypoparathyroidism type Ia (PHP1A) 
or pseudo-pseudohypoparathyroidism (PPHP). These individuals, who carry mutations in-
volving the maternal or the paternal GNAS exons 1-13, respectively, transmit the mutant 
allele to approximately two thirds of their children (odds ratio: ≈2:1). To determine whether 
TRD is observed also for the offspring of patients affected by autosomal dominant pseudo-
hypoparathyroidism type Ib (AD-PHP1B), we analyzed numerous cohorts in which STX16 
deletions or an inversion involving the GNAS locus leads to loss-of-methylation at GNAS 
exon A/B, if inherited from a female, thus leading to PTH-resistant hypocalcemia and hy-
perphosphatemia, and frequently resistance to other hormones that mediate their actions 
through Gsα-coupled receptors. In our studies, 72 females who are either unaffected carriers 
of the STX16/GNAS mutation (n=50) or are affected by PHP1B (n=22), had given birth to a 
total of 181 children (52.5% boys, 47.5% girls). 113 of these offspring (54.0% boys, 46.0% 
girls) had inherited the genetic defect, while 68 (50.0% boys, 50.0% girls) had inherited 
the wild-type allele; the mutation was thus transmitted to almost two thirds of the children 
(p=0.00082). Mothers with a STX16/GNAS mutation on their paternal (unaffected carri-
ers) or their maternal allele (affected by PHP1B) revealed an indistinguishable TRD. No 
evidence for TRD was observed for paternally inherited STX16/GNAS mutations. Further-
more, unaffected carriers and females affected by PHP1B showed no difference in fertility 
(2.7 and 2.0 offspring/female, respectively; p=0.14). The underlying mechanisms resulting 
in TRD for maternally transmitted mutations are unclear. It is, however, conceivable that 
maturing oocytes carrying a STX16/GNAS mutant have lower intracellular cAMP levels 
and may therefore have shortened meiotic arrest than oocytes comprising the wild-type al-
lele, thus potentially prolonging for each secondary oocyte the window for fertilization. Our 
findings provide insights into a previously not recognized aspect of AD-PHP1B, which is 
likely to have implications for genetic counseling and possibly oocyte biology.
Disclosures: Zentaro Kiuchi, None
P-090
Sex-specific Differences in Radius Bone Size, Density and Micro-Architecture 
between Children with Type 1 Diabetes and Typically Developing Children 
*Yuwen Zheng1, Anthony Kehrig1, James Johnston2, Munier Nour3, Saija 
Kontulainen1. 1College of Kinesiology, University of Saskatchewan, Canada, 
2College of Engineering, University of Saskatchewan, Canada, 3College of 
Medicine, University of Saskatchewan, Canada
Introduction: Weak bone structure at the fracture prone radius, particularly in boys, may 
underpin the greater pediatric fracture risk related to type 1 diabetes (DM1). Sex-specific 
comparisons of bone structure, micro-architecture, density and estimated strength between 
children with DM1 and typically developing children (TDC) are lacking. Our objectives 
were: 1) to assess the role of DM1 and sex in radius bone properties, micro-architecture 
and strength; 2) to characterize bone differences between children and youth with DM1 and 
TDC. Methods: We categorized 169 children and youth (6-15yrs) based on DM1 diagnosis 
into DM1 (N=35, 22F) and TDC groups (N=134, 74F). We imaged distal radius structur-
al (e.g., area), micro-architectural (e.g., porosity) properties and quantified trabecular and 
cortical bone density using high resolution peripheral quantitative computed tomography 
(HR-pQCT). We estimated bone strength (failure load and stiffness) from HR-pQCT images 
using finite element modeling. We imaged radius shaft bone structure, density and estimated 
strength (density-weight polar section modulus) as well as the surrounding muscle area at 
the forearm using pQCT. We assessed the role of group (DM1 vs. TDC) and group*sex 
interaction using MANCOVA, adjusted for maturity, forearm muscle area and body mass, 
followed by (sex-specific) between group comparison of bone outcomes. Significance was 
set at p<.05. Results: Adjusted bone outcomes at the distal radius and shaft sites differed 
between the DM1 and TDC groups (Pillai’s trace=0.740, p<.01) with a group*sex inter-
action in bone outcomes (Pillai’s trace=0.236, p<.01). At the distal radius, both sexes in 
DM1 group had 10-49% lower trabecular bone area and cortical porosity and 5-22% higher 
cortical density and thickness (p<.05, Table 1). Girls also had 8-10% lower trabecular bone 
density, volume fraction and thickness, while boys had 18% higher trabecular separation, 
14% lower total bone area and trabecular number in DM1 group (p<.05, Table 1). At the 
radius shaft, both sexes in DM1 group had 5-11% higher cortical bone density, while girls 
had 9-11% lower total and cortical bone area and boys had 8% higher cortical bone content 
in DM1 group (p<.05, Table 1). Conclusion: Bone difference in children and youth with 
DM1 are likely influenced by sex. Children with DM1 had deficits in distal radius bone size, 
trabecular bone properties and micro-architecture, but a denser and thicker cortical bone 
compared to TDC. 
Disclosures: Yuwen Zheng, None
P-091
Neonatal severe hyperparathyroidism. New analysis causes new guideline. 
*Stephen Marx2, Ninet Sinaii0. 2Office of the Scientific Director, NICHD, United 
States, 0Clinical Center, NIH, United States
Context: Neonatal severe hyperparathyroidism (NSHPT) is a rare and life-threatening 
emergency. It includes generalized hyperparathyroid bone disease and respiratory distress 
from combinations among a narrowed thorax, rib fractures, hypotonia, and biochemical dis-
turbances. Neuromotor retardation may persist after otherwise successful therapy. Early in-
tervention seems critical. NSHPT is usually caused by homozygous or heterozygous patho-
genic variant(s) of the CASR. Homozygotes and heterozygotes are often not distinguished. 
In theory, their management should differ. Optimum treatment in homozygotes is early total 
parathyroidectomy. Optimal management of heterozygotes varies from careful observation 
without surgery, to bisphosphonates and/or calcimimetics, and/or to subtotal parathyroidec-
tomy.             Evidence Acquisition: Each case met strict criteria for “severe” disease. To 
compare different immunoassays, PTH was analyzed as a ratio (thus without units) of the 
raw data divided by the upper limit of its normal range. This is a major extension on a recent 
report (JCEM April 2020). We now include many variables about presentation and thera-
py.             Evidence Synthesis: There were 98 cases with homozygous pathogenic CASR 
variants and 35 cases with heterozygous pathogenic or likely pathogenic variants. Maximal 
serum calcium was far higher in homozygotes 5.8 +/- 1.5 versus 3.2 +/- 0.2 (P<.001) (nor-
mal 2.2-2.6 mM). Maximal serum PTH as a ratio was also far higher in homozygotes 17 
+/- 12 versus 8 +/- 9 (P=.003) (normal ratio 0.3-1.0). We defined extreme hypercalcemia 
empirically as any calcium value above 4.5 mM. No heterozygote had a maximal calcium 
above 3.7 mM; however, 30 of 36 (83%) of the homozygotes had maximal calcium above 
the conservative cutoff of 4.5 mM. A more aggressive cutoff of 4.0 mM would capture 95% 
of homozygotes and no heterozygotes. The linear regression of the highest levels of extreme 
hypercalcemia versus day number confirmed frequent clustering of recognition in the first 
10 days.             Conclusions: Extreme hypercalcemia greater than 4.5 mM was newly 
identified as a conservative cutoff that was 100% predictive of homozygosity for pathogenic 
CASR variants. Extreme hypercalcemia in NSHPT is an early, facile, rapid, and inexpensive 
determinant of homozygosity. It should be sought and used as a guideline to promote early 
and definitive total parathyroidectomy in homozygotes.
Disclosures: Stephen Marx, None
P-092
Bisphosphonates for Sickle Cell Bone Morbidity: A Multicenter Canadian 
Pediatric Experience *Chelsey Grimbly1, Aisha Bruce2, Jacob L Jaremko3, 
Rose Girgis1, Marie-Eve Robinson4, Ewurabena Simpson5, R. Todd Alexander6, 
Leanne M Ward7. 1Division of Pediatric Endocrinology, Department of Pediatrics, 
University of Alberta, Canada, 2Division of Pediatric Hematology, Department 
of Pediatrics, University of Alberta, Canada, 3Department of Radiology and 
Diagnostic Imaging, University of Alberta, Canada, 4Department of Pediatrics, 
Division of Endocrinology, University of Ottawa. Children’s Hospital of 
Eastern Ontario Research Institute, Canada, 5Division of Pediatric Hematology, 
Department of Pediatrics, University of Ottawa, Canada, 6Division of Pediatric 
Nephrology, Department of Pediatrics, University of Alberta, Canada, 7Research 
Chair in Pediatric Bone Health, University of Ottawa, Canada
Purpose: Sickle Cell Disease (SCD) has severe bone morbidity, including avascular 
necrosis and bone infarcts that are often under-recognized in childhood. To date, there are no 
proven medical treatments, although bisphosphonates may be of benefit. We set out to de-
scribe the type and skeletal locations of symptomatic bone morbidity and the use of bisphos-
phonates in children with SCD being followed at two Canadian, tertiary care pediatric hos-
pitals. Methods: This was a bi-institutional, retrospective study that included children and 
adolescents with SCD and a history of symptomatic bone morbidity. Clinical data collected 
included sex, age of initial presentation, sickle cell genotype, serum 25-hydroxyvitamin D 
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(25OHD), hydroxyurea intake, the indication for bisphosphonate therapy, and the response 
to treatment. Results: We identified 32 children with Sickle Cell bone morbidity, 14 in Ed-
monton who were identified from 2014-2019, and 18 in Ottawa from 2003-2020. The mean 
+/- SD age at presentation with bone disease was 12.1 +/- 4.2 years (range 2.6-17.3). Bone 
morbidity included avascular necrosis (AVN) of the femur and humerus, vertebral end-plate 
infarcts, and bone infarcts in the femur, tibia, fibula, pelvis, jaw, and skull (See Table 1). The 
average 25OHD level was 46.8 +/- 25.8 nmol/L with 56% of 25OHD levels < 50 nmol/L and 
10% < 25 nmol/L. Ten patients were treated with intravenous (IV) bisphosphonate therapy 
(pamidronate n=2, and zoledronic acid n=8) because of bone pain. The acute phase reaction 
with the first infusion occurred in 4/10 children. There were no reports of bisphosphonate-in-
duced sickle cell crisis, or hypocalcemia requiring intervention. In all cases, children report-
ed significant or complete resolution of pain. Three children with limited mobility resumed 
full ambulation after bisphosphonate therapy. Two children underwent trans-iliac biopsies 
that demonstrated significantly elevated bone formation prior to bisphosphonates (348% and 
578% of the healthy average), with drastic reduction two years later (45% and 90%, respec-
tively). Conclusions: Long bone AVN and infarcts, as well as vertebral body, jaw and skull 
infarcts, can be symptomatic enough to warrant IV bisphosphonate therapy for children with 
SCD. Bisphosphonate therapy was well tolerated and effective in this retrospective study. 
This merits further study in prospective, controlled studies to confirm and further assess this 
promising therapy in SCD.
Disclosures: Chelsey Grimbly, None
P-093
Hip geomtery in adolescents and young adults with type 1 diabetes *sowmya 
krishnan1, Jennifer Chadwick1, Madhusmita Misra2. 1University of Oklahoma 
Health Sciences Center, United States, 2MassGeneral Children’s hospital, 
Boston, United States
Type 1 Diabetes (T1D) in adults is associated with low bone mineral density (BMD) 
and higher risk for osteoporotic fracture. The effect of T1D on the skeleton when peak bone 
mass is being laid is still uncertain. Bone mineral density obtained by dual energy x-ray 
absorptiometry (DXA) has traditionally been used as the surrogate measure for bone health 
but it is not a true measure of volumetric density and is influenced by bone size. Recently 
hip geometry measures obtained by routine DXA scans have been shown to be predictive of 
osteoporotic fractures in adults. It is uncertain if hip geometry is altered in adolescents and 
young adults with T1D. We conducted a cross-sectional pilot study to look at differences 
in BMD and hip geometry scores among adolescents and young adults with and without 
T1D.  We hypothesized that subjects with T1D would have lower BMD and unfavorable 
hip geometry scores. Due to the influence of race on BMD, only subjects who identified 
themselves as white were included in the study. Subjects with any other illness (eg: celiac 
disease, history of cancer) or medications (eg: glucocorticoids, oral contraceptive pills) that 
can influence bone health were excluded from the study.  All scans were performed on GE 
lunar iDXA. We present data on the initial 6 subjects with type 1 diabetes and 8 control 
subjects who have completed the study. Mean age of subjects with and without T1D was 
18.3 +/-1.4 and 17.9 +/-1.6 years respectively. Total body BMC, spine BMC, spine BMD 
did not differ between subjects with and without T1D (2578.4 +/- 335.4 g vs 2881.7 +/-599.4 
g; p: 0.19; 63.0 +/- 10.2g vs 73.9 +/- 13.1 g p: 0.72; 1.05 +/- 0.14 g/cm2 vs 1.20+/- 0.11 
g/cm2; p: 0.62 respectively). Similarly bone mineral apparent density at the spine did not 
differ between subjects with and without diabetes (0.32 +/- 0.05 g.cm3 vs 0.35 +/- 0.03 g/
cm3 respectively. However there was a significant difference in cross sectional area (CSA: 
index of resistance to axial forces) and cross-sectional moment of inertia (CSMI: estimate 
of resistance to bending forces in a cross-section) on hip structural analysis. CSMI was 
11376.0 +/-3057.7 mm4 vs 13917.3 +/-5720.3 mm4 (p: 0.02) while CSA was 165. 2+/-19.8 
mm2 vs 184.6 +/- 36.8 mm2 (p: 0.018) for subjects with and without diabetes respectively. 
We conclude based on this pilot study that subjects with type1 diabetes may have altered hip 
geometry that contributes to the skeletal fragility later in life.
Disclosures: sowmya krishnan, None
P-094
Bone Health in Treatment-Naïve, Ambulatory Boys with Duchenne Muscular 
Dystrophy *Stefan Jackowski1, Jinhui Ma2, Maya Scharke1, Victor Konji1, 
Jacob Jaremko3, Khaldoun Koujok4, MaryAnn Matzinger4, Nazih Shenouda4, 
Scott Walker1, Colleen Hartigan1, Hugh McMillan4, Kerry Siminoski3, Pradeep 
Bista5, Joanne Donovan5, Maria Mancini5, Leanne Ward4. 1Children’s Hospital 
of Eastern Ontario Research Institute, Canada, 2McMaster University, Canada, 
3University of Alberta, Canada, 4University of Ottawa, Canada, 5Catabasis 
Pharmaceuticals, Inc., United States
Introduction and Aims: Boys with Duchenne muscular dystrophy (DMD) are predis-
posed to low-trauma vertebral and long bone fractures due to osteoporosis. The purpose of 
this study was to determine whether clinically significant skeletal abnormalities are present 
early in the disease course, including vertebral fractures and low whole-body BMD (WB-
BMD) Z-scores. We also sought to examine the factors associated with low WB-BMD.
Methods: Baseline data were analyzed from treatment-naïve ambulatory boys 4 to 7 years 
(up to 8th birthday) with genetically-confirmed DMD not on glucocorticoids who were par-
ticipating in a global phase III trial of the NF-kB inhibitor edasalonexent (NCT03703882). 
Boys underwent functional assessments including the North Star Ambulatory Assessment 
and dual-energy x-ray absorptiometry (DXA) for Lean and Fat Mass Indices (expressed lean 
or fat mass/height2, kg/m2), and WB-BMD (less head, g/cm2). Lateral spine radiographs 
were analyzed for vertebral fractures according to the Genant semi-quantitative method.
Results: At baseline, 108 boys underwent lateral spine radiographs (mean +/- standard devi-
ation [SD] age 5.8+/-1.1 years); 72 boys also had DXA machine cross-calibrated WB-BMD 
scans (age 5.9+/-1.1 years). Three boys (2.8%) had a total of four low-trauma vertebral 
fractures (all Genant 1, mid-thoracic). WB-BMD and anthropometry measures (mean +/- 
SD) were as follows: WB-BMD Z-score -2.7+/-1.2 (p <0.001 compared with the healthy 
average; 74% with a WB-BMD Z-score ? -2.0), height Z-score -0.8+/-1.1 (p <0.001), weight 
Z-score -0.1 +/-1.0 (p =0.27), and body mass index Z-score 0.8+/-0.9 (p <0.001). A multi-
ple linear regression model controlling for age and height Z-score showed higher Fat Mass 
Index (β -0.25, 95% CI -0.46, -0.04; p=0.02), and lower Lean Mass Index (β 0.45, 95% CI 
0.20, 0.704; p=0.001) were associated with lower WB-BMD Z-scores. Logistic regression 
adjusted for age and height Z-score showed every 1 kg/m2 decrease in Lean Mass Index was 
associated with a 46% increase in the odds of a WB-BMD Z-score < -2.0 (95% CI 24%, 
90%; p=0.02).Conclusions: Mean WB-BMD Z-scores are low in young, ambulatory boys 
with DMD not on glucocorticoids. A small percentage have mild vertebral fractures, further 
supporting the negative impact of early DMD on bone health even prior to glucocorticoid 
use. In addition to lower lean mass, higher fat mass may also play a role in the abnormal 
bone strength development of pediatric DMD.
Disclosures: Stefan Jackowski, None
P-095
A Six Years Longitudinal Cohort Study on the Changes in Bone Density and 
Bone Quality up to Peak Bone Mass in Adolescent Idiopathic Scoliosis with 
and without 2 Years of Calcium and Vitamin D Supplementation *Guangpu 
YANG1, Tsz-ping LAM1, Henry PANG1, Benjamin Hon-kei YIP2, Wayne Yuk-
wai LEE1, Alec Lik-hang HUNG1, Nelson Leung-sang TANG3, Kenneth Kin-
wah To4, Yong QIU5, Jack Chun-yiu CHENG1. 1SH Ho Scoliosis Research Lab, 
Joint Scoliosis Research Center of the Chinese University of Hong Kong and 
Nanjing University, Department of Orthopaedics & Traumatology, The Chinese 
University of Hong Kong, Hong Kong, 2The Jockey Club School of Public Health 
and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, 
China, Hong Kong, 3Department of Chemical Pathology, Faculty of Medicine, 
The Chinese University of Hong Kong, Hong Kong, 4School of Pharmacy, 
Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, 5Spine 
Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical 
School, Nanjing, China, China
Introduction:Adolescent idiopathic scoliosis(AIS) is associated with low bone mass 
which could persists into adulthood. Given that AIS girls have low dietary calcium intake 
and high prevalence of Vitamin D(Vit-D) insufficiency, our group has previously reported 
the first 2-year randomized double-blinded placebo-controlled trial with calcium(Ca) and 
Vit-D supplementation to AIS girls with low bone mass (the Cal study) showing strong 
evidences of positive bone accretion effects with Ca+Vit-D supplementation.This study is 
an extension of the Cal study investigating the changes in bone density and bone quality 
at 4-year after discontinuation of Ca+Vit-D supplementation.Objective:This 6-year longi-
tudinal cohort study aimed to investigate whether improvement in BMD and bone quali-
ty induced by Ca and Vit-D supplementation (600mg Ca and 400/800IU Vit-D3 per day) 
persisted after supplement discontinuation for low bone mass in AIS girls.Methods:This 
was a randomized double-blinded placebo-controlled trial on AIS girls (11-14 years old, 
mean age = 12.9 years, Tanner stage<IV) with femoral neck aBMD Z-score<0 and Cobb 
angle>=15°. 330 subjects were randomized to Group1(placebo), Group2(600 mg Ca and 
400 IU Vit-D3 per day) or Group3(600mg Cal and 800 IU Vit-D3 per day) for 2-year treat-
ment. Investigations were done at baseline, 2-year and 6-year including High-resolution 
Peripheral Quantitative Computed Tomography(HR-pQCT) at distal radius and Dual Energy 
X-ray Absorptiometry(DXA) at proximal hips. ANCOVA was used for analysis.Results and 
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Discussion:270(81.8%) subjects completed treatment. At 2-year time-point, the increases in 
serum 25(OH)Vit-D, left femoral neck aBMD in Group3, average volumetric BMD(vBMD), 
trabecular vBMD, Trabecular BV/TV, Trabecular Number in both Group2 and 3 were sig-
nificantly greater than in Group1(p<0.05). At 6-year follow up after 4-year discontinuation 
of supplementation with a mean age of 19.15 years old, no difference was noted except in-
crease in Cortical Area and Cortical Thickness were greater only in Group3 than in Group1.
Conclusion and Significance:This study provided strong evidences that 2-year supplementa-
tion with Ca+Vit-D can improve bone health for low bone mass in AIS. At 6-year follow up 
with 4-year discontinuation of treatment, the treatment effect mostly regressed towards the 
null hypothesis indicating the need of continued supplementation to sustain the therapeutic 
effect on bone health up to the stage of peak bone mass.
Disclosures: Guangpu YANG, None
P-096
Influence of Puberty on Bone Deficits in Ambulatory Youth with Spina Bifida 
*Tishya Wren1, Nicole Mueske1, Susan Rethlefsen1, Robert Kay1, Alexander Van 
Speybroeck1, Wendy Mack2. 1Children’s Hospital Los Angeles, United States, 
2University of Southern California, United States
Pathologic fractures of the femur and tibia are common in youth with spina bifida (SB). 
These fractures may be associated with deficient bone accrual due to decreased ambulation 
and skeletal loading. This prospective cohort study used quantitative computed tomography 
(QCT) to assess three-dimensional bone properties in children and adolescents with SB. 
Eighty-three ambulatory youth with SB underwent QCT imaging of the tibia at up to 4 annu-
al visits between ages 6-16 years (294 total visits averaging 3.5 visits/patient). 177 controls 
without disability and 10 non-ambulatory youth with SB underwent imaging once. Bone 
geometric properties (cortical bone area, cross-sectional area, cortical thickness, cortical 
density, and moments of inertia) were measured at the mid-diaphysis (50% of bone length); 
cross-sectional area, cancellous density, and density-weighted area were measured in the 
proximal (13% of bone length) and distal (90% of bone length) metaphyses. Bone properties 
were compared between the ambulatory SB and control participants, among SB neuroseg-
mental subgroups (sacral, low lumbar, mid lumbar and above) as a function of pubertal 
stage (pre-pubertal, pubertal, post-pubertal), and considering SB type (myelomeningocele 
or lipomyelomeningocele) using linear mixed effects models adjusted for sex, age, height 
percentile, and body mass index percentile. Only cancellous density of both metaphyses and 
weighted area of the proximal metaphysis differed between ambulatory children with SB 
and controls before puberty. However, significant deficits in all bone properties manifest-
ed during and after puberty as moderate bone growth in the SB group failed to keep pace 
with the large increases normally observed during puberty (Figure, top). The bone deficits 
primarily affected patients with myelomeningocele, and similar deficits were observed at 
all neurosegmental levels except that cancellous density was closer to normal in the sacral 
group (Figure, middle and bottom). Descriptive analysis of the 10 non-ambulatory youth 
with SB showed greater bone deficits than ambulatory children, particularly for cancellous 
density in the distal metaphysis. Therefore, both ambulatory and non-ambulatory youth with 
spina bifda have deficits in bone, particularly during and after puberty.
Disclosures: Tishya Wren, None
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The Impact of Oral Bisphosphonate Therapy on Vertebral Morphometry 
and Fractures in Patients with Duchenne Muscular Dystrophy and 
Glucocorticoid-Induced Osteoporosis *Nat Nasomyont1, Cuixia Tian1, Lindsey 
Hornung1, Jane Khoury1, Paul Hochwalt2, Joshua Cole Tilden3, Irina Rybalsky1, 
Brenda Wong4, Meilan Rutter1. 1Cincinnati Children’s Hospital Medical Center, 
United States, 2University of Cincinnati, United States, 3Yale University, United 
States, 4University of Massachusetts Children’s Medical Center, United States
Objective: Osteoporosis and vertebral fractures are common in patients with Duchenne 
Muscular Dystrophy (DMD) treated with glucocorticoids. We aimed to evaluate the effects 
of oral bisphosphonate (BP) therapy on vertebral morphometry and fractures in patients with 
DMD and glucocorticoid-induced osteoporosis.Methods: We retrospectively studied chil-
dren and adolescents with DMD who had been treated with oral BP for glucocorticoid-in-
duced osteoporosis at a tertiary-care pediatric center from 2010-2017. Demographic data, 
and glucocorticoid and oral BP treatment histories were obtained from electronic medical 
records. Treatment outcomes were changes in lumbar (L1-L4) vertebral morphometry and 
fractures, as assessed by the Genant semi-quantitative method. Patients were included if 
they had both baseline and at least one follow-up spine radiograph available for review. 
Chi-square was used to examine change in fracture prevalence at each vertebra.Results: 
Fifty-eight patients with DMD (median age 12.2y, range 5.5-19.6y) were treated with glu-
cocorticoids for a median duration of 4.7y (range 1.3-12.6y) and 33% were non-ambulatory 
at BP start. Vertebral fractures, defined by Genant grading >=1, were present in 6%-19% of 
L1-L4 vertebrae at baseline. Among patients who had radiographs at both baseline and 1 or 
2y-post BP start, the prevalence of vertebral fractures remained stable at 1y (n=43; 5-18% 
at baseline vs 8-18% at 1y, p=0.31-1.00) and 2y of treatment (n=42; 5-23% at baseline vs 
11-33% at 2y, p=0.11-1.00). Among patients who had serial radiographs for comparison, 
longitudinal examination showed no change in Genant grading the majority of vertebrae 
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up to 5y of treatment (Figure).Conclusions: In our experience of oral BP therapy in pa-
tients with DMD, we observed stable prevalence of lumbar vertebral fractures after 1 and 
2y of treatment. Longitudinal Genant grading remained overall unchanged for up to 5y of 
treatment. Our findings suggest oral BP may be beneficial for secondary prevention of glu-
cocorticoid-induced osteoporosis in patient with DMD and may mitigate development or 
progression of vertebral fractures in the majority of patients. Longer-term data and in-depth 
quantitative analysis of vertebral fracture severity are needed to determine the efficacy of 
oral BP in children and adolescents with DMD.
Disclosures: Nat Nasomyont, None
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The Timing and Tempo of the Skeletal Maturational Spurt is Independent 
of Racial or Ethnic Background *Melanie Boeyer1, Emily Leary2, Richard 
Sherwood3, Bone Mineral Density in Childhood Study bmdcs.nichd.nih.gov4, 
Dana Duren1. 1Department of Orthopaedic Surgery, University of Missouri, 
Columbia, MO, United States, 2Department of Orthopaedic Surgery and the 
Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, 
Columbia, MO, United States, 3Department of Pathology and Anatomical 
Sciences, University of Missouri, Columbia, MO, United States, 4NICHD, 
United States
An accurate assessment of a child’s future growth and/or development is contingent, in 
part, on their skeletal maturational trajectory. Because the tempo of skeletal maturation often 
does not track linearly with chronological age, knowledge of an impending bout of rapid 
skeletal maturation (i.e., a maturational spurt) would be helpful, particularly in the treatment 
of pediatric skeletal disorders. Yet, the characterization of a maturational spurt has only been 
established for Non-Hispanic White children, and it is unknown whether the maturational 
spurt is influenced by racial and/or ethnic background. We, therefore, aimed to assess the 
maturational spurt in 420 children from four different racial and/or ethnic backgrounds from 
the Bone Mineral Density in Childhood Study (Asian or Pacific Islander, 23; Hispanic, 53; 
Black Non-Hispanic, 78; White Non-Hispanic, 266), each of whom had seven consecutive 
left hand-wrist radiographs between the chronological ages of 6 and 19 years. The relation-
ship between chronological age and skeletal age, assessed via the Fels Method, was evaluat-
ed separately in each child using a fixed effect fifth order polynomial. Milestones related to 
the maturational spurt, including the chronological age and maturational rate of onset, peak, 
and cessation, were compared between children from each racial and/or ethnic background 
using a one-way analysis of variance in both boys and girls. In boys, the chronological age 
of attainment for each maturational milestone was similar across all racial and/or ethnic 
groups. In girls, the chronological age at which onset and peak were attained in Asian or 
Pacific Islanders was significantly earlier (onset, 9.1 yr; peak, 10.9 yr) than other racial and/
or ethnic backgrounds, particularly those from Non-Hispanic White backgrounds (onset, 
11.2 yr; peak, 12.9 yr). No differences were observed in the rate of skeletal maturation at any 
milestone in either boys or girls. Although some groups had a low number of children, these 
analyses indicate that the chronological age and rate of skeletal maturation at each milestone 
may be similar in children of different racial and/or ethnic backgrounds, despite documented 
variation in milestones for other growth-related skeletal phenotypes, such as height or bone 
mineral accrual.
Disclosures: Melanie Boeyer, None
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Trends in emergency department visits for fall-related fractures among U.S. 
children 2001-2015. *Jack Orces1, Carlos Orces2. 1Nicklaus Children Hospital, 
United States, 2Laredo Medical Center, United States
Background: Although fractures in children are a major publich health problem, it is 
unknown whether fall-related fractures have decreased among children in the U.S. Objec-
tive: To examine nationwide trends in emergency department (EDs) visits for fall-related 
fractures among children beween 2001 and 2015.Methods: The National Electronic Injury 
Surveillance System-All Injury Program was used to generate national estimates of unin-
tentional fall-related fractures among children aged 0 to 19 years treated in EDs. Population 
estimates were used as the denominator to calculate age-specific fracture rates per 100,000 
persons. Fracture rates were then directly standardized to the 2000 U.S. population. The 
Joinpoint regression program software version 4.7.0.0 was used to identify points where 
a statistically significant change occurred in the linear slope of fracture rates. The results 
are presented as the average annual percent change (AAPC) with their corresponding 95% 
confidence interval (95% CI).Results: An estimated 7.9 million U.S. children were treated 
in EDs for unintentional fall-related fractures between 2001 and 2015.  Overall, upper ex-
tremity fractures accounted for 70% of the cases. Trend analysis demonstrated that fracture 
rates significantly decreased among those aged 10 to 15 years on average by -2.5% (95% CI, 
-3.4% to -1.6%) per year.  After adjusting for age, fracture rates in boys decreased annually 
by -1.9% (95% CI, -3.1% to -0.6%), whereas the decrease in rates in girls was less accentuat-
ed by - 1.4% (95% CI, -1.8% to -1.0%) per year.  As shown in Figure 1, forearm and/or wrist 
fracture rates significantly decreased by -1.6% (95% CI, -2.4% to -0.8%) during the study 
period.  Notably, a marked annual decrease in rates by -2.4% (95% CI, -2.9% to -1.9%) was 
seen from 2004 onwards.  Likewise, hand/finger fracture rates linearly decreased on average 
by -3.5 (95% CI, -4.3% to -2.8%) per year.  In contrast, shoulder, arm, and/or elbow fracture 
rates remained unchanged during the study period. Conclusions: EDs visits for fall-related 
fractures significantly decreased in U.S. children between 2001 and 2015.  This finding was 
predominantly attributed to a marked downward trend in fracture rates seen among children 
aged 10 to 14 years, boys, and forearm/wrist fractures.
Disclosures: Jack Orces, None
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Alternative splicing of CYP11B1 is involved in adrenal steroidogenesis and 
skeletal maturation of children *Olja Grgic5, Matthew R. Gazzara2, Alessandra 
Chesi3, Carolina Medina-Gomez5, Diana L. Cousminer2, Jonathan A. Mitchell4, 
Vid Prijatelj5, Enisa Shevroja5, Shana E. McCormack4, Heidi J. Kalkwarf6, Joan 
M. Lappe7, Vicente Gilsanz8, Sharon E. Oberfield9, John A. Shepherd10, Kelly 
Andrea4, Soroosh Mahboubi11, Fabio R. Faucz12, Richard A. Feelders5, Frank H. 
de Jong H. de Jong5, Andre G. Uitterlinden5, Jenny A. Visser5, Louis R. Ghanem4, 
Eppo B. Wolvius13, Leo J. Hofland5, Constantine A. Stratakis12, Babette S. 
Zemel4, Yoseph Barash2, Struan F. A. Grant 4, Fernando Rivadeneira5. 5Erasmus 
MC, University Medical Center Rotterdam, Dr Molewaterplein 40, 3015 GD, 
The Netherlands, Department of Internal Medicine;, Netherlands, 2Perelman 
School of Medicine, University of Pennsylvania, 2615 Civic Center Boulevard, 
Philadelphia, PA 19104, USA, Department of Genetics;, United States, 
3Children’s Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, 
PA 19104, USA, Center for Spatial and Functional Genomics;, United States, 
4Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center 
Boulevard, Philadelphia, PA 19104, USA, Department of Pediatrics;, United 
States, 5Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 
40, 3015 GD, The Netherlands, Department of Internal Medicine;, Switzerland, 
6Cincinnati Children’s Hospital Medical Center, University of Cincinnati College 
of Medicine, 3333 Burnet Ave, Cincinnati, OH 45229, USA, Department of 
Pediatrics;, United States, 7Creighton University, 2500 California Plaza, Omaha, 
NE 68178, USA, Division of Endocrinology;, United States, 8Children’s Hospital 
Los Angeles, Keck School of Medicine, University of Southern California, 1975 
Zonal Ave, Los Angeles, CA 90033, USA, Division of Orthopedic Surgery;, 
United States, 9Morgan Stanley Children’s Hospital, Columbia University 
Irving Medical Center, 622 West 168th Street, PH17 W 307, New York, NY 
10032, USA, Division of Pediatric Endocrinology;, United States, 10University 
of Hawai’i Cancer Center, 701 Ilalo St, Honolulu, HI 96813, USA, Cancer 
Epidemiology;, United States, 11Children’s Hospital of Philadelphia, 3401 Civic 
Center Boulevard, Philadelphia, PA 19104, USA, Department of Radiology;, 
United States, 12Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (NICHD), National Institutes of Health, 6710 Rockledge 
Dr. Bethesda, MD 20817, USA, Section on Endocrinology and Genetics;, United 
States, 13Erasmus MC, University Medical Center Rotterdam, Dr Molewaterplein 
40, 3015 GD, The Netherlands, Department of Oral and Maxillofacial Surgery;, 
Netherlands
Objectives: While aberrant splicing has been established as a cause of Mendelian dis-
eases, the effect of alternative splicing on phenotypic variability remains unclear. CYP11B1 
locus was in recent GWAS meta-analysis robustly associated with skeletal age (SA). Several 
GWS variants are located in proximity to the intron-exon boundary of the CYP11B1, and 
therefore, we hypothesized that splicing of CYP11B1 may be the mechanism underlying 
reported GWAS association. Methods: Data was obtained from 208 adrenal gland RNA-seq 
samples from GTEx (where gene showed major expression) and used to screen CYP11B1 
for splicing quantitative trait loci (sQTL). We focused on rs6410, the second most significant 
SNP in SA meta-analysis, and the one closest to the intron-exon boundary. Inclusion levels 
of alternative splice junctions were evaluated by the Modeling Alternative Junction Inclu-
sion Quantification algorithm which quantifies local splicing variations denoted as Percent 
Selected Index (PSI) - percent of transcripts that made certain splicing choice. The sQTL 
pipeline was used to test the association between rs6410 genotypes and PSI values. Reverse 
transcription polymerase chain reaction (RT-PCR) was performed using adrenal gland RNA 
samples isolated from 6 donors from the Erasmus Medical Center (EMC) and 9 donors from 
the NIH repository. Spearman correlation between rs6410 genotypes and splicing event of 
interest was then calculated. Results: The C allele of rs6410 was associated with intron 2 
retention (ΔPSI=21.1%; P=4.38x10-41), exon 2a inclusion (ΔPSI=5.3%; P=6.14x10-31), 
decreased exon 2 and 3 splicing (ΔPSI=-26.4%, P=5.29x10-43) and decreased use of the 
intron-proximal 3’ss which creates a longer exon 7 (ΔPSI=-20.3%; P=8.78x10-28). RT-PCR 
recapitulated the same conclusions with intron 2 retention levels being significantly asso-
ciated with the rs6410 C allele in samples from both EMC and NIH (r2=0.93, P=0.008 
and r2=0.95, P=7.3x10-5 respectively). Conclusion: Our study demonstrates that alternative 
splicing of CYP11B1 was the mechanism of rs6410 underlying reported association. In light 
of the already demonstrated pleiotropic effect of rs6410 on SA, height, cross-sectional area 
and hypertension, our study underpins the role of naturally occurring variation in splicing for 
both physiological traits and complex diseases. Evaluation of the impact of genomic variants 
on alternative splicing should be considered an integral part of clinical variant prioritization.
Disclosures: Olja Grgic, None
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Bone mineral density in children with cerebral palsy and spina bifida 
treated with ibandronate *Vladimir Kenis1, Andrey Sapogovskiy1, Tatiana 
Prokopenko1. 1H.Turner National Medical Research Center for Сhildren’s 
Orthopedics and Trauma Surgery, Russian Federation
Bisphosphonates has become a common method for the prevention and treatment of 
osteoporosis in children with neuromuscular diseases. Purpose. To assess mid-term changes 
of bone mineral density in patients with cerebral palsy and spina bifida treated with iband-
ronic acid. Materials and methods. 34 patients were examined and treated: 19 children with 
cerebral palsy (GMFCS levels III-IV) and 15 children with spina bifida (thoracic and upper 
lumbar neurosegmental levels), mean age 9.8 +/- 2.9 years. Ibandronic acid was adminis-
tered to all patients (3 consecutive intravenous infusions, 0.1 mg per 1 kg every 3-4 months). 
Assessment of bone mineral density was carried out using dual-energy X-ray absorptiome-
try. Results. Z-score increased from -2.55 to -2.1 (total body less head) and from -2.7 to -1.65 
(lumbar spine). Improvement of the Z-score for the lumbar spine was noted after the first, 
and for the whole body after the first two infusions. Conclusion. Ibandronic acid infusions 
improved bone mineral density in children with cerebral palsy and spina bifida for both 
the whole body and the lumbar spine. Given the data obtained, expanded weight-bearing 
excersises can be recommended 3 months after the first infusion, and dynamic exercises 
preferably expanded after 6 months.
Disclosures: Vladimir Kenis, None
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Primary Hyperparathyroidism in children and adolescents: A far cry from 
Adult Hyperparathyroidism- A series from South India *Smitha Rao1, 
Dhalapathy Sadacharan2, Shriraam Mahadevan3, Anjali Sathya4, Jayashree 
Gopal4, Shanmugasundar S4, S Murthy4. 1Senior resident in Endocrine Surgery, 
Madras Medical College, India, 2Associate Professor, Endocrine Surgery, 
Madras Medical College, India, 3Endocrinology, Diabetes & Metabolism, 
Sri Ramachandra Institute of Medical Sciences, India, 4Endocrinology & 
Metabolism, India
Background: Primary hyperparathyroidism (PHPT) is a common endocrine condition 
but rare in the paediatric and adolescent population. The presentations can be unique, un-
der cover of various differentials accounting for significant morbidity in case of untime-
ly detection.Aim: To study surgically treated paediatric PHPT retrospectively and review 
literatureMethods: We retrospectively analysed 37 surgically treated cases of PHPT with 
presenting age of up to 20 years between 2010 to 2019. All of them were operated by a high 
volume, single endocrine surgeon and team.Results: A total of 37 cases were included with 
22 males (59.5%). Mean age of the study population was 16.54 years (1-20), including 4 
cases of neonatal severe HPT (NSPHPT). Multiple Endocrine Neoplasia type 1 (MEN1) was 
diagnosed and genetically confirmed in 10 cases. Presenting manifestations were: Various 
presentations included bone pain (35.13%), renal stones (27.02%), incidental asymptomatic 
detection (18.9%), failure to thrive (10.8%) and pancreatitis (8.1%).   Mean serum calcium 
was 12.9mg/dl (highest-14.1, N-8.8-10.8mg/dl), mean parathormone levels were 386.91pg/
ml (N-10-65) and vitamin D levels ranged from 2.9-22.8ng/ml. Localization was done with 
ultrasound and 99mTc- SESTAMIBI scans. All patients underwent a bilateral neck explora-
tion and parathyroidectomy, with 14 cases having an additional thymectomy, 2 cases with 
thyroidectomy and a single case of hemithyroidectomy. The cure rate was 97.3%, with one 
case of NSPHPT of persistent disease (postop PTH-110pg/ml). Uniglandular disease was 
seen in 54.05% and the rest had multiglandular disease. All cases had a postoperative his-
topathological confirmation with an average follow up of 2 years.Conclusion: Childhood 
PHPT was more common among females with nearly one third of them having MEN1. In 
contrast to adults with more asymptomatic manifestation, bone disease followed by renal 
stones were the most common mode of presentation. Uniglandular involvement was more 
common than multi glandular disease in our series as compared to rest of the world data. 
Regular long-term follow up for MEN1 is mandatory.
Disclosures: Smitha Rao, None
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Oral Risedronate Treatment In Children With Osteogenesis Imperfecta 
*Antoine Nguyen1, Pisit Pitukcheewanont2, Anna Ryabets-Lienhard3. 
1Children’s Hospital Los Angeles (CHLA) Division of Endocrinology, Diabetes, 
and Metabolism, Los Angeles, CA, USA, United States, 2Ascendis Pharma Inc., 
Palo Alto, CA, USA, United States, 3Children’s Hospital Los Angeles (CHLA) 
Division of Endocrinology, Diabetes, and Metabolism; Keck School of Medicine, 
USC; Saban Research Institute, CHLA., Los Angeles, CA, USA, United States
To date, there are no approved pharmaceutical therapies for children with OI. Intra-
venous bisphosphonates have been used for years to treat children with OI with variable 
efficacy and tolerability. However, a few studies have evaluated the effects and tolerability of 
oral risedronate in children with OI (1)(2). In this study, we aimed to present our experience 
with oral risedronate treatment in children with OI. A retrospective chart review of patients 
with OI and history of multiple fragility fractures, who were treated with oral risedronate 
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and followed in our bone clinic between the years of 2013 and 2019. Primary outcomes 
included changes in fracture rate, urinary N-terminal telopeptide (uNTX), height z-scores, 
and lumbar and femur BMD z-scores.  Safety and tolerability of risedronate were reviewed. 
Wilcoxon matched-pairs sign-ranks test was used to assess the medians (IQR) between pre- 
and post-treatment with p value of < 0.05 set as statistically significant. A total of 17 patients 
ages 5—19 ys were reviewed (11 males, 65% type I OI, 12% type III, 18% type XI, and 
5% unknown). At the time of the review, 69% were on weekly, 19% on daily, and 12% on 
monthly risedronate treatment. Mean duration of therapy was 2.7 y ? 2.3 y, ranging 0.5 to 8 
ys.The bone resorption marker, uNTX, decreased > 30% from baseline in 93% of subjects 
within the first year of treatment, and was statistically lower by the end of treatment period 
[245 (159, 393) to 170 (39, 261), p=0.02]. Height z-score did not change with treatment, 
-0.80 (-1.20, 0.10) pre- and -0.85 (-1.60, -0.40) post-treatment, p = 0.2 in patients with Type I 
OI. There was a clinically significant reduction in the rate of fractures from baseline 0.6 per y 
(0.4, 0.8) to 0.24 (0, 0.5) by the end of the treatment period. Within a year of treatment, 80% 
of children were fracture free with improvement in bone pain and mobility. BMD pre- and 
on treatment for lumbar and femur were -2.5 (-3.43, -1.94) and -2.36 (-3.25, -1.35), and -2.05 
(-2.95, 0.3) and -1.18 (-1.73, 2.13), respectively. However, there was no statistical signifi-
cance. There was one case of reflux without erosive esophagitis, which resolved with reflux 
treatment. Overall, risedronate was well tolerated with no cases of clinically significant acute 
phase reaction, hypocalcemia, erosive esophagitis, or osteonecrosis of the jaw.Based on our 
experience, oral risedronate effectively decreased bone resorption, showed a trend towards 
decrease in fracture rate with improvement in symptoms, and was well tolerated in children 
with OI. More data are needed to systematically evaluate its long-term effects on growth, 
bone mineral density, fracture frequency, and quality of life in children with different types 
of OI.(1)Rauch et al., J Bone Miner Res. 2009; 24: 1282-1289 (2) Bishop et al., Lancet. 
2013;382(9902):1424-32.
Disclosures: Antoine Nguyen, None
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Parathyroid Hormone Response to Different Vitamin D Levels in Young 
People Living in the Arctic Region *Galina Kostrova1, Svetlana Malyavskaya1, 
Aleksandra Strelkova1, Andrey Lebedev1. 1Northern State Medical University, 
Russian Federation
Background: Low vitamin D (VD) is not always followed by a development of sec-
ondary hyperparathyroidism (SHPT). The climate-geographical specificity of the Arctic 
region provides conditions for vitamin D deficiency (geographical latitude, peculiarities of 
photoperiodicity, high geomagnetic activity, severity of weather conditions) due not only 
to the limited possibilities for natural production of vitamin D in skin but also to adaptive 
metabolic shifts. This study assesses prevalence of functional hypoparathyroidism (FHPT) 
in relation to VD deficiency/insufficiency in young people living in the city of Arkhangelsk. 
Methods: The participants of the cross-sectional (one-stage) study were 174 young peo-
ple aged 18 to 20 years, including 48 (27.6%) men and 126 (72.4%) women. The level 
of 25(OH)D in blood serum was measured by enzyme immunoassay (DRG Instruments 
kits, Germany). The levels of provision of vitamin D depending on the level of 25(OH)D 
were as follows: normal level at 30–80 ng/mL, insufficiency at 20–30 ng/mL, deficiency at 
10–19 ng/mL, and severe deficiency at less than 10 ng/mL. The level of parathormone was 
measured by enzyme immunoassay, pg/mL (normally, 16–65.0 pg/mL). Results:  Levels of 
vitamin D in young people were normal in 40 subjects (23%); 25-OH vitamin D concentra-
tion was 20–30 ng/mL in 59 subjects (34%); 10–19 ng/mL in 56 subjects (32%), and <10 ng/
mL in 19 subjects (11%). The correlation analysis has shown a weak negative relationship 
between the levels of vitamin D and total calcium (R = –0.164, p = 0.033). Increased level 
of PTH  was detected in 37 subjects (21.3%). Level of PTH was higher in the group with 
25(OH)D below 30 ng/mL. There was no correlation between the levels of PTH and vitamin 
D. More than 75% of the subjects showed normal level of PTH at the 25(OH)D levels below 
30 ng/mL and below 20 ng/mL (FHPT). There was a positive correlation between the levels 
of parathormone and total calcium (R = 0.21, p =0.018) in the group with 25(O?)D below 
30 ng/mL; the same group demonstrated a weak correlation between the levels of vitamin D 
and total calcium (R =0.18, p = 0.037). Conclusions:  Lack of parathyroid hormone response 
to vitamin D deficiency in 75% of young people may be due to desensitization and reduced 
expression of the calcium-sensitive receptor of the parathyroid glands determined by living 
in an area with low insolation and high probability of vitamin D deficiency.
Disclosures: Galina Kostrova, None
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A Case Control Study of Food Selectivity and Bone Health in Children with 
Autism Spectrum Disorder (ASD) *Karen Loechner1, Rashelle Berry2, Lindsey 
Burrell1, Scott Gillespie1, Scahill Larry1, William Sharp1. 1Emory University 
School of Medicine, United States, 2Children’s Healthcare of Atlanta, United 
States
Introduction: Provisional evidence suggest that children with ASD are at risk for de-
creased bone mineral density (BMD). High prevalence of severe food selectivity (SFS) in 
ASD may contribute to reduced BMD; however, the consequences of restricted patterns of 
intake in ASD are not well understood. In this case control pilot study, we applied a tiered 
framework to evaluate the relationship between food selectivity and BMD status. Study De-
sign: Recruitment of 30 boys (6-10 years of age) divided into 3 groups: (1) ASD and severe 
food selectivity (SFS) (n=10); (2) ASD with mild/no FS (NFS) (n=10); and (3) without ASD 
and NFS (n=10, controls). Clinical assessment/diagnostic testing confirmed ASD status. 
Presence/absence of FS involved a FS screening tool supported by a nutrition evaluation of 
regular (3-day) dietary intake. Exclusion criteria included (1) medical issues known to affect 
BMD (e.g., glucocorticoids); (2) enteral feeding (suggesting feeding disturbance beyond 
SFS), and/or 3) eating disorder (e.g., anorexia nervosa), which involves a different etiology. 
Measurement Approach: Feasibility outcomes included recruitment, attrition, and successful 
collection of clinical, BMD, and serologic/urine laboratory assessments. Study measures 
included radiological assessment involving DXA (TBLH, spine). Serologic/urine laboratory 
assessments included bone metabolism markers (25 OH vitamin D, PTH, Calcium, Magne-
sium, Phosphorus, and alkaline phosphatase (formation marker) and urine NTX (resorption 
marker), and markers of malabsorption included CRP and celiac screen. Endocrine tests 
included thyroid, growth hormone indices and testosterone. PreliminaryResults See Table 
1: Enrollment thus far involves 23/30 boys (study held due to covid restrictions). Feasibility 
outcomes indicated high retention and completion of study measures (>90%). A trend to 
lower TBLH Z-score in SFS than NFS or controls is seen and indicates larger group sizes are 
needed. Of note, no difference in vitamin D noted. Conclusion: FS is a common problem for 
children with ASD. These preliminary findings suggest that children with ASD and severe 
FS may be at risk for adverse health outcomes including decreased BMD. Increased group 
numbers will provide greater power to see if these findings are significant. Further study, in 
turn, directed to intervention models (feeding therapy; vitamin supplementation) would be 
indicated.Abbreviations: DXA: dual energy absorptiometry, TBLH: total body less head; 
NTX: N-telopeptide; PTH: parathyroid hormone
Disclosures: Karen Loechner, None
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PROPEL2: a phase 2, open-label, dose-escalation and dose-expansion study 
of infigratinib in children with achondroplasia (ACH) *Ravi Savarirayan1, 
Peter Kannu2, Carl Dambkowski3, Daniela Rogoff3, Melita Irving4. 1Murdoch 
Children’s Research Institute, Australia, 2The Hospital for Sick Children, 
Toronto, Canada, 3QED Therapeutics Inc., United States, 4Guy’s and St Thomas’ 
NHS Trust, United Kingdom
Background: ACH, the most common non-lethal form of skeletal dysplasia, is charac-
terized by defective endochondral ossification resulting from gain-of-function mutations in 
the fibroblast growth factor receptor 3 (FGFR3) gene, a negative regulator of endochondral 
bone formation. Current treatment options are non-targeted, ineffective, or painful interven-
tions aimed at preventing or treating complications. Infigratinib is an orally bioavailable and 
selective FGFR1–3 tyrosine kinase inhibitor in development for FGFR-related conditions. 
In vitro data with infigratinib showed inhibition of FGFR1–3 activity with reversal of estab-
lished growth arrest in chondrocytes. In vivo studies revealed dose-dependent improvements 
in foramen magnum and long bone length in Fgfr3Y367C/+ mice following treatment with 
infigratinib.Methods: PROPEL2 is a prospective, phase 2, open-label study of infigratinib in 
children with ACH. It consists of dose escalation with an extended treatment phase (ESC-
ET), designed as dose finding, followed by a dose-expansion phase (EXP) to confirm the 
selected dose and to provide evidence of efficacy. The primary endpoints of ESC-ET are 
treatment-emergent adverse events and change from baseline in annualized growth velocity. 
Subjects (n=40) will be enrolled in ascending dose cohorts of approximately 10 subjects/
cohort (4 cohorts planned) and treated for 6 months at their assigned dose, continuing for an 
additional 12 months with dose modifications as required. The primary endpoint of EXP is 
change from baseline in annualized growth velocity at the dose identified from ESC. Up to 
20 new subjects will be enrolled in this phase and receive infigratinib (mini-tablets, admin-
istered orally once daily) for 12 months. Secondary objectives include: safety/tolerability of 
infigratinib; changes from baseline in anthropometric parameters, including body propor-
tions; pharmacokinetic/pharmacodynamic profile of infigratinib. An exploratory objective is 
evaluation of changes in ACH disease burden. Eligible children with ACH 3–11 years of age 
who completed at least 6 months of observation in PROPEL will participate in PROPEL2.
Current status: PROPEL2 is currently enrolling; the planned total enrollment is 60 children 
with ACH (40 ESC-ET, 20 EXP). Following completion of PROPEL2, subjects have the 
opportunity to enroll in an open-label long-term extension study to assess the safety and 
efficacy of long-term administration of infigratinib in children with ACH.
Disclosures: Ravi Savarirayan, QED Therapeutics Inc., Grant/Research Support, QED 
Therapeutics Inc., Other Financial or Material Support, BioMarin, Consultant, BioMarin, 
Grant/Research Support, Ascendis, Other Financial or Material Support, BioMarin, Other 
Financial or Material Support, Ascendis, Grant/Research Support, Theracon, Grant/
Research Support
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A Randomized Double Blind Placebo Controlled Trial in Healthy School 
Children to Evaluate the Adequacy and Efficacy of Daily Supplementation 
of Milk Fortified with 1200 IU Vitamin A and D2 in one litre of Milk *Raman 
Marwaha1, Aashima Dabas2, Seema Puri3, Mani Kalaivani4, Arjun Dang5, Vineet 
Dabas2, Sangeeta Yadav2, R Pullakhandam6, Susheel Gupta7, Archana Narang8. 
1SEHEAC, India, 2Maulana Azad Medical College, India, 3Department of 
Food and Nutrition, Institute of Home Economics, University of Delhi, India, 
4Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, 
India, 5Dr Dangs Lab, India, 6Biochemistry Division, Indian Council of Medical 
Research- National Institute of Nutrition, India, 7Department of Endocrinology, 
Sanjay Gandhi Post Graduate Institute, India, 8Department of Homeopathy, BR 
Sur Homeopathic College, India
In view of high prevalence of vitamin A & D deficiencies in Indian children, we under-
took a double-blind placebo-controlled randomized trial in prepubertal children, to evaluate 
the adequacy of daily supplementation of milk fortified with 1200 IU of vitamin A & D2 
in one litre of milk. A total of 235 out of 266 children with vitamin D insufficiency were 
randomized into an intervention (n=119) and control (n=116) group. Intervention group 
was supplemented with 200 mL milk fortified with approximately 240 IU of A & D2 and 
control group with200 mL of plain milk every day for 12 weeks from Oct to December 
2019. A total of 210 children completed the study. Baseline and post supplementation fasting 
blood samples were evaluated for calcium, phosphate, alkaline phosphatase, 25 hydroxy 
vitamin D, parathyroid hormone, bone markers (CTx and PINP), retinol and urinary calci-
um/creatinine ratio. Mean? SD of baseline serum 25(OH)D level was 11.7?3.7 ng/mL with 
levels<12ng/mL in 100 (42.5%) children. The decline in control group was significantly 
greater(11.97?3.79 to 6.73?3.5ng/mL; P<0.001) than the intervention group (11.42?3.63 to 
10.81?3.45ng/mL; P=0.1) following supplementation. Secondary hyperparathyroidism sig-
nificantly increased from 18.1% to 39%in the control group and decreased from 22.7% to 
13.3%in intervention group post supplementation; P<0.001. Subclinical vitamin A deficien-
cy was recorded in 2.2% subjects. Supplementation of milk fortified with 240 IU Vitamin D2 
is not adequate to achieve vitamin D sufficiency, though it does reduce the decline in serum 
25(OH)D levels during winter in prepubertal Indian children with vitamin D deficiency.Trial 
registration: CTRI/2019/09/021073
Disclosures: Raman Marwaha, None
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PROPEL: a prospective clinical assessment study in children with 
achondroplasia (ACH) *Ravi Savarirayan1, Peter Kannu2, Carl Dambkowski3, 
Daniela Rogoff3, Melita Irving4. 1Murdoch Children’s Research Institute, 
Australia, 2The Hospital for Sick Children, Toronto, Canada, 3QED Therapeutics 
Inc., United States, 4Guy’s and St Thomas’ NHS Trust, United Kingdom
Background: ACH is the most common non-lethal form of skeletal dysplasia, affecting 
between 1 in 15,000 to 1 in 30,000 live births [Horton et al. 2007; Waller et al. 2008]. Chil-
dren and adults with ACH have disproportionate short stature, with a final height of approx. 
131 cm for males and 124 cm for females. Growth velocity for individuals with average 
stature is 1.7- to 2.2-fold higher than individuals with ACH during infancy and puberty and 
1- to 1.8-fold higher during childhood [Hoover-Fong et al. 2008]. People with ACH are 
prone to significant co-morbidities, including obstructive sleep apnea, chronic otitis media 
with conductive hearing loss, spinal stenosis, and a propensity towards obesity. In some 
infants, narrowing of the foramen magnum may result in compression of the spinal cord 
with neurologic sequelae, requiring timely neurosurgical intervention. There are currently 
no approved therapies for the treatment of ACH in either the US or the EU, and management 
is supportive in nature. There is no widely accepted consensus about treatment, and current 
treatment options are non-targeted, ineffective, or painful interventions aimed at preventing 
or treating complications of ACH [Unger et al. 2017; FDA 2018].Methods: Children with 
ACH between the ages of 2.5 and 10 years are eligible for enrollment in PROPEL, a prospec-
tive, non-interventional study examining baseline growth parameters and health status in 
children being assessed for potential enrollment into interventional studies with infigratinib, 
an oral FGFR1–3 inhibitor in development for ACH. Participants will be assessed at base-
line, month 3, month 6, and every 6 months thereafter. The primary endpoint is annualized 
height growth velocity. Secondary endpoints include change from baseline in other growth 
parameters (including body proportionality); analysis of bone biomarkers (e.g. bone alka-
line phosphatase, collagen X fragment); and the occurrence of medical events and surgical 
procedures. Participants will be enrolled in the study for a minimum of 6 months up to a 
maximum of 2 years.Current status: The PROPEL study is underway; the first participant 
was enrolled in August 2019. Planned total enrollment is 200 children with ACH. The sam-
ple size of approx. 200 participants is considered enough to characterize the natural history 
of children with ACH and lead to sufficient enrollment in a QED-sponsored Phase 2 and/or 
3 interventional trial of infigratinib in children with ACH (PROPEL2).
Disclosures: Ravi Savarirayan, QED Therapeutics Inc., Grant/Research Support, 
Ascendis, Grant/Research Support, QED Therapeutics Inc., Other Financial or Material 
Support, BioMarin, Other Financial or Material Support, BioMarin, Consultant, 
BioMarin, Grant/Research Support, Theracon, Grant/Research Support, Ascendis, Other 
Financial or Material Support
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Protocol for a Comprehensive Understanding of Bone and Muscle in 
Children with Systemic Lupus Erythematosus: a Pilot Study of Bone-muscle 
Interactions *Sarah L West1, Linda Hiraki 2, Andrea Knight2, Deborah Levy2, 
Reza Vali2, Amer Shammas2, Andy Kin On Wong3, Greg Wells2, Etienne Sochett2. 
1Trent University, The Hospital for Sick Children, Canada, 2The Hospital for 
Sick Children, Canada, 3University Health Network, Canada
Childhood-onset Systemic Lupus Erythematosus (cSLE) is a rare chronic autoimmune 
disease that can negatively impact the musculoskeletal system. Bone health is recognized 
to be compromised in cSLE, especially deficits in bone quantity and quality which place 
children at risk for current and future fracture. Muscle function may also be impaired in 
cSLE; chronic inflammation may result in impaired oxidative metabolism via free radical 
damage to mitochondria, and reduced endothelial function may disrupt blood flow and/or 
oxygen delivery to muscles. The muscle-bone interaction is an important factor contributing 
to bone health; however, no studies have examined the link between impaired bone & skel-
etal muscle metabolism/perfusion in cSLE. This study will address the knowledge gap by 
non-invasively measuring bone quantity, quality, and muscle metabolism/perfusion in cSLE. 
Our hypothesis is that bone health and muscle function (metabolism and perfusion) will be 
impaired in children with cSLE compared to healthy matched controls. We also hypothesize 
that there will be a relationship between the impairment in bone health and muscle function 
in cSLE. This study will be performed at the Hospital for Sick Children in Toronto, Canada. 
We will recruit 16 children with cSLE and 16 healthy controls (9-18 years old). After in-
formed consent, non-invasive imaging techniques will be used to measure bone and muscle 
function. More specifically, clinical bone densitometry reports (total body less head and 
spine) will be obtained. Bone quality will be measured at the non-dominant radius and tibia 
by high resolution peripheral quantitative computed tomography (HRpQCT). 31P-magnetic 
resonance spectroscopy (via magnetic resonance imaging; MRI) will be used in conjunction 
with exercise protocols (that target aerobic and anaerobic energy systems using a MRI safe 
ergometer) to assess skeletal muscle metabolism of the quadriceps muscle. Blood-oxygen 
level-dependent functional (BOLD) MRI imaging will provide a measure of blood flow/
volume and oxygen saturation (skeletal muscle perfusion). We will use T-tests, general linear 
model and regression analyses to assess outcomes, controlling for factors such as corticoste-
roid use. If we find that poor bone and muscle health are correlated in cSLE, the results will 
support a larger exercise intervention study that will aim to evaluate the impact of exercise 
on bone health and muscle function improve bone, muscle, and quality of life in cSLE.
Disclosures: Sarah L West, None
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Lactobacillus reuteri prevents Early Stages of Glucocorticoid-induced 
Avascular Necrosis of Femoral Head. *Ho Jun Kang1, Jonathan D Schepper2, 
Soumya Chennupati1, Morgan Roegner1, Narayanan Parameswaran1, Laura 
R McCabe1. 1Michigan State University, United States, 2BioTek Instruments, 
United States
Glucocorticoids (GC) are effective anti-inflammatory drugs commonly used to treat 
patients with autoimmune diseases. Over time, chronic GC treatment can negatively affect 
both gut and bone health. In the gut this leads to intestinal dysbiosis and increased gut per-
meability. In bone, this leads to glucocorticoid-induced osteoporosis and can cause osteone-
crosis (GCON, i.e., avascular necrosis of the femur head). Patients with late stages of GCON 
in the hip suffer from pain and stiffness, resulting in long-term disability and hip replace-
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ment. Identifying non-invasive ways to prevent or treat GCON would be of great benefit 
to patients. Our lab and others have shown that the gut microbiota and barrier function are 
involved in regulating bone homeostasis and density. We also identified that the probiot-
ic Lactobacillus reuteri 6475 (LR) prevented GC-induced femoral and vertebral trabecular 
bone loss in male and female mice. Based on these findings, we examined if LR treatment 
could prevent GCON of the femur head (avascularization, cell apoptosis, adiposity, abnor-
mal bone surface and architecture). Male C57BL/6J (16-weeks-old) mice were treated for 
8-weeks with subcutaneous pellets containing GC (2.5 mg/kg/day) or vehicle. Simultane-
ously, mice were orally supplemented with vehicle, the probiotic LR or a mixture of 8 strains 
of probiotics (VSL#3) at a dose of ~109 CFU bacteria/day. Femur immunohistochemistry 
examining von Willebrand factor (vWF) positive blood vessels and the gene expression 
of vWF revealed that the GC induced avascularization of the femur head was completely 
prevented by LR supplementation. Specifically, compared to controls, GC treatment caused 
more than 50% reduction in the number of the blood vessels in the marrow area of the femur 
head, whereas LR treated mice did not exhibit any change in vascularization compared to 
controls. VSL#3 treated mice had a response that was in-between controls and GC-treated 
mice (~25% reduction in vascularization). Similarly, TUNEL analyses and mRNA markers 
of apoptosis (Bax/Bcl-2, pro/anti-apoptotic) determined that LR treatment prevented GC-in-
duced apoptosis of trabecular osteoblasts and osteocytes. Also, only LR treatment prevented 
GC-induced marrow adiposity and bone architecture changes. Together, these data indicate 
that probiotic LR supplementation prevents the pathological bone effects of GCs and may be 
an effective way to prevent early stages of avascular necrosis of femoral head.
Disclosures: Ho Jun Kang, None
P-112
Ablation of TRPV1+ Afferents Decreases Periodontal Bone Destruction in 
Mice *Sheng Wang1, Man Kyo Chung1, Xiaobei Wang2, Vivek Thumbigere-
Math2. 1University of Maryland School of Dentistry, Neural and Pain Science 
Department, United States, 2University of Maryland School of Dentistry 
Advanced Oral Sciences & Therapeutics Department, United States
Objectives: Periodontal tissues are innervated by multiple subsets of sensory afferents 
including peptidergic nociceptive afferents, majority of which expresses transient receptor 
potential vanilloid 1 (TRPV1). It is well established that neuropeptides derived from sen-
sory neurons affect vascular responses (e.g., neurogenic inflammation) indicating the con-
tribution made by afferents to local inflammatory responses. Significant questions remain 
regarding the functions of peptidergic sensory nerves in periodontal host responses and al-
veolar bone remodeling. The objective of this study was to determine the roles of TRPV1+ 
peptidergic subsets of sensory afferents in alveolar bone homeostasis.Methods: In adult 
C57bl/6 mice, TRPV1+ trigeminal afferents were selectively ablated by intraganglionic in-
jection of resiniferatoxin (RTX) into trigeminal ganglia (TG). One week later, periodontitis 
was induced by tying a silk suture around the maxillary 2nd molar. Unligated contralateral 
tooth served as a control. Two weeks after ligature placement, the mice were euthanized for 
microCT followed by histology study. In a separate cohort of periodontitis-induced mice, 
maxillary alveolar bone including three molars were dissected and used for multiplex assay.
Results: In vehicle (PBS) injected group, ligature produced alveolar bone resorption around 
the second molar. In contrast, the alveolar bone resorption was significantly lower in RTX 
injected group. Tartrate-resistant acid phosphatase (TRAP) staining demonstrated signifi-
cantly increased number of osteoclasts in the ligated side, which was comparably lower in 
RTX group than vehicle group. Ligature significantly increased periodontal expression of 
RANKL, IL1β and TNFα, which was significantly lower in RTX group compared to vehi-
cle group.Conclusion: Ablation of TRPV1+ trigeminal afferents decreases proinflammatory 
cytokines and the numbers of osteoclasts in periodontium, which leads to decreased bone 
destruction in the mouse model of periodontitis. These results suggest that specific targeting 
of neuroimmune and neuroskeletal regulation can offer promising therapeutic targets for 
periodontitis.
Disclosures: Sheng Wang, None
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Minocycline-Induced Gut Dysbiosis Disrupts Metabolism and Post-Pubertal 
Skeletal Development *Matthew Carson1, Amy Warner1, Jessica Hathaway-
Schrader1, Brooks Swanson1, Joy Kirkpatrick1, Alexander Alekseyenko1, Jose 
Aguirre2, Caroline Westwater1, Chad Novince1. 1Medical University of South 
Carolina, United States, 2University of Florida, United States
Our group has shown the commensal gut microbiota critically regulates skeletal mat-
uration through liver derived mechanisms. We have also shown that broad spectrum antibi-
otic perturbation of gut microbiota dysregulates post-pubertal skeletal development. Study 
purpose was to investigate immediate and sustained effects of minocycline (MINO) therapy, 
the most common systemic antibiotic treatment (Tx) for adolescent acne, on post-pubertal 
skeletal development. Sex-matched specific-pathogen-free (SPF) C57BL/6T mice were ad-
ministered a clinically relevant dose of MINO or vehicle-control (VEH) from age 6-12wks; 
groups were euthanized at ages 12 and 18wks to assess immediate and sustained MINO Tx 
effects. In a separate experiment, germ-free (GF) C57BL/6T mice were administered MINO 
or VEH Tx from age 6-12wks. 16S rDNA analysis was performed on colon contents. Ex vivo 
µCT was performed in femurs. Tibia and vertebrae were embedded for histomorphometry. 
Livers were isolated for histopathology. Flow cytometry was carried out in gut draining 
mesenteric lymph nodes (MLNs) and liver draining lymph nodes (LLNs). In vivo µCT was 
performed to assess changes in peripheral adipose tissue volume fraction. Bone marrow 
stromal cells (BMSCs) were isolated from naïve mice to assess direct MINO Tx effects on 
osteoblastogenesis. MINO Tx induced phylum level dysbiotic shifts in the gut microbiome. 
Bone mineral density and bone volume fraction were blunted in MINO vs. VEH treated SPF 
mice at age 12wks, and these effects persisted at age 18wks. The osteopenic phenotype in 
MINO treated SPF mice was attributed to suppressed bone formation and mineral apposition 
rates, which was validated by decreased serum OCN and P1NP. Liver weight and hepatic 
glycogen content were reduced in MINO vs. VEH treated SPF mice at age 12wks, and these 
effects persisted at age 18wks. Proinflammatory TH1 and TH17 cells were elevated in LLNs 
of MINO vs. VEH treated SPF mice. There was a 3-4X greater fold increase in peripheral 
adipose tissue from age 12 to 18wks, in MINO vs. VEH treated SPF mice. Skeletal and 
metabolic outcomes were similar in MINO vs. VEH treated GF mice, and exogenous MINO 
stimulation did not alter osteoblast outcomes in vitro, which implies that MINO Tx effects 
are dependent on the microbiota. MINO-induced gut dysbiosis has detrimental effects on 
murine metabolism and skeletal maturation, which highlights potential clinical implications 
for adolescents subjected to systemic MINO Tx for acne.
Disclosures: Matthew Carson, None
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Role of Estrogen Receptor β in Bone and Muscle Crosstalk *Nuria Lara1, 
Julian Vallejo1, Mark Dallas1, Yixia Xie1, Mohammad Niroobakhsh1, Mark 
Gray1, Eleanor Ray1, Derek Nelson1, Kashif Javid1, Sarah L. Dallas1, Ganesh 
Thiagarajan1, Michael Wacker1, Mark Johnson1. 1UMKC, United States
Estrogen signaling through its two main receptors, ERα and ERβ, plays essential roles 
in bone and muscle health and we hypothesize in bone-muscle crosstalk. We investigated the 
role of ERβ mediated signaling in bone-muscle crosstalk by deleting ERβ in late osteoblast/
osteocytes (ERβ-/-oy; ERβf/f crossed with the 10-kb Dmp-1 Cre mice) or in skeletal muscle 
(ERβ-/-sm; ERβf/f crossed with the tamoxifen inducible MCM-HSA-Cre mice). Mice (m/f; 
n=3-7) were analyzed at 6 months of age. Cre negative littermates were used as controls.
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Body weight (BW) was identical over their lifespan between knockout and control mice. Fe-
murs were used for µCT and biomechanical analysis and EDL and Soleus muscles were used 
for contractility analysis. Trabecular BV/TV (3.4+/-0.8% vs 7.7+/-1.2%, p<.05) was lower 
in male ERβ-/-oy due to decreased trabecular number (0.7+/-0.1 1/mm vs 1.7+/-0.2 1/mm, 
p<.05) and increased trabecular separation (0.4+/-0.02mm vs 0.3+/-0.02mm, p<.05). Male 
ERβ-/-oy had increased elastic stiffness (200.6+/-6.4N/mm vs 174.2+/-6.8N/mm, p<.05) and 
modulus of elasticity (4.2+/-0.3GPa vs 3.2+/-0.2GPa, p<.05). Soleus muscles were smaller 
(9.5+/-0.2mg vs 10.7+/-0.4mg, p<.05) and recovered from fatigue to a lesser degree (56.7+/-
3.4%vs 72.9+/-3.6%, p<.05) in male ERβ-/-oy compared to controls. In contrast, no differ-
ences were seen in the EDL. EKG showed decrease in QT interval corrected for heart rate 
(QTc). While femurs of ERβ-/-oy females had lower modulus of elasticity (3.2+/-0.4GPa 
vs 4.5+/-0.4GPa, p<.05), no other differences were detected in bone or muscle properties. 
Soleus muscles of ERβ-/-sm males and females showed enhanced recovery from fatigue. 
Interestingly, Heart weight/BW was lower in ERβ-/-sm males, but higher in ERβ-/-sm fe-
males, which also showed a decrease in QTc. We did not observe any major difference in 
architectural or biomechanical properties in the bones of ERβ-/-sm in male or female mice.
These data identify a previously unrecognized role for ERβ in bone and show that Dmp1-Cre 
targeted deletion of ERβ in bone affects trabecular bone in males but not in females. More-
over, deleting ERβ in bone impairs Soleus muscle recovery from fatigue, suggesting a role 
for bone crosstalk with muscle adaptation to applied stress. Muscle ERβ deletion beginning 
at adulthood had effects on the soleus and heart, but not on bone properties. Together, these 
data support the hypothesis that ERβ mediated signaling plays an important role in bone to 
muscle crosstalk at the biochemical level.
Disclosures: Nuria Lara, None
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Depletion of Replicating Osteolineage Cells Leads to Fracture Nonunion 
in Col1-tk Mice *Katherine Hixon1, David Sykes1, Susumu Yoneda1, Austin 
Hensley1, Jennifer McKenzie1, Anna Miller1, Matthew Silva1. 1Washington 
University in St. Louis, United States
Nonunion is defined as the permanent failure of a bone to heal and occurs clinically in 
5% of fractures. Atrophic nonunion, characterized by failure of osteochondral callus for-
mation, is poorly understood and difficult to treat. To date, most animal models of atrophic 
nonunion involve osteotomy, periosteal stripping, etc., yet such destructive surgical methods 
are not representative of many clinical cases. Thus, there is an unmet need for a clinical-
ly relevant “failure of biology” atrophic nonunion model. Jilka et al. created the 3.6Co-
l1A1-tk (Col1-tk) mouse where treatment with the nucleoside analog ganciclovir (GCV) 
depletes replicating osteoprogenitor cells. Heterozygous Col1-tk+ mice and WT littermates, 
12-weeks old, male and female, were subjected to femur full fracture. All animals were 
dosed with GCV (8 mg/kg i.p.) twice daily starting at fracture for 2 or 4 weeks. Mice were 
sacrificed at 3 weeks for micro-CT and histology to examine an early healing timepoint. Ad-
ditional animals were monitored weekly by X-ray and micro-CT for 12 weeks post fracture 
to assess longer term outcomes; following sacrifice, micro-CT was performed and samples 
were processed for either histology or biomechanics. Weekly radiographs (n=12-18/group) 
were scored for the degree of healing using a modified Goldberg score and revealed that 
WT vs. Col1-tk mice were significantly different (Figure 1A; χ2, p < 0.05). After 3 weeks, 
WT mice had a large callus with the normal appearance of woven bone (red) and cartilage 
(blue). In contrast, Col1-tk mouse had negligible callus formation with reduced or absent 
bridging (Figure 1B). For in vivo micro-CT, the Col1-tk callus did not significantly change 
in size, whereas the WT mice saw a large increase in volume when the callus formed and a 
decrease as it remodeled (n=7-9/group; p < 0.05, ANOVA). Histologically, by 12 weeks all 
WT mice had bridged and remodeled. While the Col1-tk mice did display some bridging, 
the cortical bone remodeling/resorption was reduced and fibrotic tissue and cartilage persist-
ed (n=7/group). Finally, when the femurs were biomechanically tested, Col1-tk mice were 
significantly weaker and less stiff than WT mice (p < 0.05), indicating inferior function. In 
summary, depletion of replicating osteolineage cells in the first 2 weeks after fracture in 
Col1-tk mice leads to greatly diminished callus formation resulting in functionally impaired 
healing. This represents a new model of atrophic (or oligotrophic) nonunion.
Disclosures: Katherine Hixon, None
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Cardiovascular disease miRNAs are associated with BMD in a non-human 
primate model of osteoporosis. *Ellen Quillen1, Roberto Fajardo2, Todd 
Bredbenner3. 1Wake Forest School of Medicine, United States, 2University of the 
Incarnate Word School of Osteopathic Medicine, United States, 3University of 
Colorado Colorado Springs, United States
The overlap between cardiovascular health and bone health has been a topic of clinical 
interest for decades, with evidence suggesting a link between vascular disease, bone min-
eral density, and fracture risk. Accumulating evidence implicates circulating miRNAs as 
gene regulators across tissues and potential biomarkers of disease states. The baboon animal 
model is used in studies of cardiovascular disease, osteoporosis, and other conditions be-
cause disease processes are naturally occurring and often replicate human pathophysiology. 
To better understand the potential role of miRNAs in cardiovascular and bone health, we 
evaluated the association of miRNAs previously associated with cardiovascular disease with 
vertebral bone mineral density in the aging baboon. No work was done on living animals 
and no animals were euthanized specifically for this study. We evaluated 192 baboons (126 
female) ranging in age from 10-29 years (30-90 human-equivalent years) with a mean of 
19.4 years.RNA was extracted from whole blood samples collected at necropsy and miRNA 
libraries sequenced on the Illumina HiSeq2500. miRNAs were identified based on miR-
base alignments. miRNA counts were analyzed using the R statistical package DESeq2 to 
identify miRNAs associated with aBMD, measured using DXA in both the anterior-poste-
rior (AP) and medio-lateral (ML) orientation for the intact L2-L4 vertebrae. Six of eleven 
cardiovascular-related miRNAs investigated are associated with differences in AP aBMD 
in the baboon (p < 0.05). Four miRNAs are upregulated in animals with lower aBMD (miR-
320a, miR-197-3p, miR-191-5p, miR-27b-3p), while two are downregulated (miR-126-3p, 
miR-21-5p).Most notably, miR-320a and miR-126 are known regulators of VEGF signaling 
which regulates both angiogenesis and endochondral ossification, while miR-27b targets 
PPARγ, a transcriptional factor regulating cardiac fibrosis, glucose metabolism, and bone 
homeostasis. Additionally, miR-191 and miR-197 regulate NF-kB signaling which regulates 
both platelet activation contributing to heart disease and RANK ligand-induced osteoclas-
togenesis. Future analyses will evaluate miRNA associations with material and structural 
properties, and thus, fracture risk. We expect this work to identify miRNAs that modulate 
signaling between tissues or represent shared biomarkers of dysregulation in cardiovascular 
and skeletal diseases (e.g. arising from common dysregulation of calcium metabolism).
Disclosures: Ellen Quillen, None
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FGF23 Neutralizing Antibody Rescues Reduced Bone Nodule Formation in 
Bone Marrow Stromal Cell  Cultures from Sickle Cell Disease Mice *Marja 
Hurley1, Liping Xiao1, Donyell Williams1. 1UConn Health, United States
Osteoporosis and osteopenia are common bone complications in sickle cell disease 
(SCD), the most common genetic blood disorder in humans. The molecular mechanisms 
of bone loss in SCD are not yet fully defined. Fibroblast growth factor 23 (FGF23) is a 
phosphaturic hormone that is mainly produced by osteocytes and osteoblasts. Production of 
FGF23 is up regulated by iron deficiency, hypoxia, and high erythropoietin, which are often 
seen in SCD. In this study we examined the involvement of FGF23 in impairing bone miner-
alization in SCD mice. Since in addition to being a regulator of serum phosphate, FGF23 has 
been shown to have direct inhibitory effects on bone formation, we also assessed whether 
bone formation was decreased in SCD mice in vitro and whether FGF23 blocking anti-
body could modulate bone nodule formation in vitro. Analysis of biochemical markers in 6 
months old male control (Ctrl) and SCD littermate mice showed serum calcium was similar 
in Ctrl and SCD mice (Fig.1A). Serum phosphate was significantly decreased in SCD mice 
compared to Ctrl (Fig.1B). Serum 1,25(OH)2D was inappropriately normal in the setting of 
decreased serum Pi (Fig.1C). Serum FGF23 (intact) was significantly increased in SCD mice 
(Fig.1D). Serum ?Klotho (an essential cofactor for FGF23 signaling) was increased in SCD 
mice (Fig.1E). Bone marrow stromall cells (BMSCs) harvested from 3 months old Ctrl and 
SCD female mice were plated at 2 million cells/well in 6-well dishes and cultured for 3 days 
in proliferation media (αMEM supplemented with 10% heat-inactivated fetal bovine serum, 
100-U/mL penicillin-streptomycin), then switched to osteogenic media (proliferation media 
plus 50 ug/ml ascorbic acid and 4mM β-glycerophosphate). BMSCs from Ctrl and SCD 
were treated with control IgG (IgG, rat-anti- NGFPb-3F8-raIgG2a) or a rat anti-rat FGF23 
neutralizing antibody (FGF23Ab, clone 58.5, 100 nM) (a gift from Amgen Inc., Thousand 
Oaks, CA) throughout the 14 days of culture. After staining for alkaline phosphatase, dishes 
were re-stained for von Kossa to assess mineralized bone nodules. As shown in Fig.1F&G, 
von Kossa staining and Image J quantitative analysis showed area of mineralized bone nod-
ules was reduced in SCD cultures and was rescued by FGF23Ab. We conclude that FGF23 
contributes to the pathogenesis of abnormal phosphate homeostasis and bone loss in SCD 
mice, and there is an intrinsic mineralization defect in BMSCs from SCD mice that could be 
rescued by blocking FGF23 signaling.
Disclosures: Marja Hurley, None
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Modulation of Bone Marrow Mesenchymal Stem Cell Differentiation by 
Osteocytic Connexin Hemichannels *Jingruo Zhang1, Rui Hua1, Manuel 
Riquelme1, Sumin Gu1, Jean Jiang1. 1Department of Biochemistry and structural 
biology, UT Health San Antonio, United States
Differentiation of bone marrow mesenchymal stem cells (MSCs) in marrow cavity is 
modulated by multiple factors. Osteocytes, the most abundant bone cell type in mineral 
matrix, form an extensive cellular network and provide an extracellular tunnel connecting 
bone matrix to bone marrow cavity. The factors released from osteocytes could function 
in a paracrine manner to influence bone marrow microenvironments and MSCs. Connexin 
43 (Cx43) hemichannels richly present in osteocytes allow small molecules, such as pros-
taglandins, to release from inside cell to extracellular space. In this study, by using two 
transgenic mice models with a predominantly overexpression of Cx43 mutants in osteocytes: 
R76W mice (dominant-negative Cx43 mutant inhibiting gap junctions) and Δ130–136 mice 
(dominant-negative Cx43 mutant inhibiting both hemichannels and gap junctions), we found 
increased numbers of bone marrow adipocytes in Δ130–136 mice as compared to wild type 
(WT), while there was no change in R76W mice. In vitro MSC differentiation induction 
study showed that MSCs isolated from Δ130-136 mice bone marrow preferred adipogenic 
pathway as compared with WT and R76W mice. mRNA levels of adipogenic markers were 
also increased during adipogenic induction in Δ130-136 mice, including peroxisome prolif-
erator-activated receptor gamma (PPARγ) and adipocyte protein 2 (aP2). Contrary to Δ130-
136 mice, MSCs from R76W mice preserved a relatively normal differentiation process 
with a slightly enhanced osteogenic differentiation as compared to WT. Osteocytic Cx43 
hemichannels serve as a major portal for prostaglandin E2 (PGE2) release. The PGE2 level 
in bone marrow of Δ130-136 mice was mitigated compared to WT and R76W mice. To 
access the involvement of PGE2 released from Cx43 hemichannels in this paracrine effect, 
we treated isolated MSCs with PGE2. The adipogenic differentiation was attenuated with 
PGE2 in MSCs isolated from Δ130-136. Additionally, we observed an increase of apoptot-
ic bone marrow cells in Δ130-136 mice. PGE2 protects cells from apoptosis in many cell 
types so that the decreased PGE2 level may result in an increased apoptosis in Δ130-136 
mice bone marrow. Overall, our data suggest that Cx43 hemichannels play an important 
role in MCS differentiation in bone marrow and factor(s), possibility PGE2, released by 
Cx43 hemichannels in osteocytes may act in a paracrine manner to modulate adipogenic and 
osteogenic pathways.
Disclosures: Jingruo Zhang, None
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Chronic Treatment with Sildenafil Stimulates Bone Regeneration in a 
Calvarial Bone Defect in Rats *Esteban Matias Brenna1, Sandra Judith Renou2, 
Victoria Interlandi1, Viviana Andrea Centeno1, Pablo Alejandro Fontanetti1. 
1Universidad Nacional de Cordoba. Facultad de Odontología. Departamento de 
Biologia Oral. Cordoba, Argentina, Argentina, 2Universidad de Buenos Aires. 
Facultad de Odontología. Cátedra de Anatomía Patológica. Buenos Aires, 
Argentina, Argentina
Guided bone regeneration (GBR) is a process by which new bone is formed in an area 
where it was lost. This technique is performed by creating a space between the surface of the 
bone and surrounding soft tissues, using membranes that allow the formation of new bone 
in the created space. A factor involved in the GBR process is the vascularization of the area. 
Sildenafil citrate (SC) is a phosphodiesterase-5 inhibitor and due to its vasodilator action, it 
showed healing benefits in different experimental models.Objective: To evaluate the effect of 
SC in the GBR process in a calvarial bone defect in rats.Methods: Ten male Wistar rats aged 
30-day-old underwent surgery to perform a bone defect in calvaria. The day after surgery, 
the animals were randomly divided into two groups which were administered, by orogastric 
tube, physiological solution (Control Group (CG); n=5) or SC solution at a dose of 10mg / 
kg body weight (Sildenafil Group(SG), n=5). After 28 days of treatment animals were eutha-
nized by cervical dislocation. Prior to euthanasia, blood samples were taken to measure liver 
transaminases (GOT and GPT) and plasma Ca and P levels. Subsequently tissue samples 
were extracted from the regenerated area for histological processing. Frontal sections of 6 
µm thickness were obtained at the level of the middle defect area, which were then colored 
with H&E. On digital microphotographs of these sections, the following histomorphometric 
parameters were measured using Image ProPlus program: bone volume [BV/TV(%)] and 
soft tissue volume [SV/TV(%)]. The results were statistically analyzed by Student t test, set-
ting a p-value <0.05 for significant differences.Results: No significant differences in plasma 
levels of GOT and GPT were observed between the groups studied (p>0.05). The animals 
treated with SC showed an increase in P levels (p<0.05). Qualitatively, a more compact and 
continuous cortical was observed at the base of the bone defect in sections from the SC 
group. BV/TV(%) was significantly higher in bone defects of SG compared to CG (41.03 +/- 
11.76 vs. 18.26 +/- 3.54; p<0.01) while SV/TV(%) was significantly lower in SG compared 
to CG (28.94 +/- 11.26 vs. 42.47 +/- 5.08; p<0.05). Conclusion: The SC did not generate 
liver toxicity assessed by the absence of changes in transaminase levels. In addition, the 
results suggest that SC stimulates the bone regeneration in a calvarial bone defect in rats.
Disclosures: Esteban Matias Brenna, None
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Role of the phytoestrogen Genistein on cellular events involved in bone 
remodeling: bone-vascular cells crosstalk *Marisa J. Sandoval1, Adrián 
E. Campelo2, Sabrina B. Cepeda3, Virginia L. Massheimer4. 1Dto Biología, 
Bioqca y Farmacia, Universidad Nacional del Sur (UNS). Instituto de Ciencias 
Biológicas y Biomédicas del Sur- Consejo Nacional de Investigaciones 
Científicas y Técnicas (INBIOSUR-CONICET). Bahía Blanca, Buenos Aires, 
Argentina, Argentina, 2Instituto de Ciencias Biológicas y Biomédicas del Sur 
(INBIOSUR), Dto de Matemática-Universidad Nacional del Sur (UNS). Consejo 
Nacional de Investigaciones Científicas y Técnicas (CONICET), Bahía Blanca, 
Buenos Aires, Argentina, Argentina, 3Dto. Biología, Bioquímica y Farmacia, 
Universidad Nacional del Sur (UNS). Bahía Blanca, Buenos Aires, Argentina, 
Argentina, 4Instituto de Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), 
Dto Biología, Bioqca y Farmacia-Universidad Nacional del Sur (UNS). Consejo 
Nacional de Investigaciones Científicas y Técnicas (CONICET), Bahía Blanca, 
Buenos Aires, Argentina, Argentina
Phytoestrogens (PE) as Genistein (Gen) are proposed as natural therapy for bone loss 
prevention. We studied the mechanism of action of Gen on osteoblast (OB) differentiation; 
and on bone-vascular cells interactions with focus on angiogenesis. Aortic rings (AR, ex 
vivo assays) or murine primary cell cultures (in vitro assays) of aortic endothelial cells 
(EC) or calvarial OB exposed to 10 nM Gen were employed as experimental models. Us-
ing RT-PCR technique, we found that Gen increased  estrogen receptor alpha (ERα) and 
Runx2 mRNA levels at 3-5 days of culture (2; 20 fold a/c, respectively, p<0.05). When OB 
differentiation markers were evaluated, the evidence shows that Gen enhanced osteocalcin 
expression (immunofluorescence analysis), alkaline phosphatase activity (ALP, spectropho-
tometry) and extracellular collagen deposition (Sirius Red staining) after 11 days of culture 
(34, 40 and 60% a/c, respectively, p<0.001). In presence of the high affinity ER antagonist 
ICI182780 (10 μM) or the NO synthase (NOS) inhibitor L-NAME (10 μM) the enhance-
ments on ALP activity and collagen deposition elicited by Gen were suppressed (p<0.001). 
Cell preincubation with the ERK inhibitor PD98059 (10 µM) or the PI3K signaling pathway 
antagonist LY294002 (10 µM), completely blunted the enhancement of collagen deposi-
tion produced by Gen treatment (p<0.001), meanwhile the antagonists partially reduced the 
stimulation triggered by the PE on ALP activity (70 vs 36%; absence vs presence of the 
blockers). Since vascularization and microcirculation are events required for bone remodel-
ing, we tested whether Gen could exert an angiogenic action via an interaction between OB 
and EC. New capillaries formation depends on EC proliferation and migration. Experiments 
using conditioned medium (CM) obtained from OB exposed 24 h to Gen (CMGen) were per-
formed. The presence of CMGen increased EC proliferation and migration (1.4 and  2.5 fold, 
respectively, p<0.05). Then, new tubes formation around AR seeded on a collagen matrix 
(15 days) were evaluated using optical microscopy and ImageJ software quantification. The 
stimulation of capillaries formation exerted by Gen was significantly potentiated in pres-
ence of CMGen (95%, p<0.05). In conclusion, Gen promoted osteoblastogenesis through 
the participation of ER and NOS pathways, and the contribution of ERK or PI3K signal 
transduction pathways. Indeed, Gen stimulated angiogenesis through a crosstalk between 
bone and vascular cells.
Disclosures: Marisa J. Sandoval, None
P-121
The Changing Partners of FOXO1 Under High Serotonin Levels in 
Winnie Mouse Model of Spontaneous Chronic Colitis *Shilpa Sharma1, 
Ahmed Al Saedi1, Kulmira Nurgali2, Gustavo Duque1. 1Australian Institute for 
Musculoskeletal Science, The University of Melbourne and Western Health, 
Melbourne, Australia. Department of Medicine-Western Health, The University 
of Melbourne, Melbourne, Australia, Australia, 2Institute for Health and Sport, 
Victoria University, Melbourne, Australia, Australia
The most common extraintestinal manifestations of inflammatory bowel disease (IBD) 
are skeletal dysfunctions. It is likely that risk factors are multifactorial, such as systemic 
inflammation, malnutrition and use of glucocorticoids. Notwithstanding, large gaps remain 
in our knowledge of mechanisms underlying bone loss in IBD. The consistent feature of 
colitis is increased gut-derived serotonin (GDS) availability in the intestinal mucosa, which 
could have a negative impact on osteoblastogenesis in this model. We tested the hypothesis 
that GDS plays an important role in the pathogenesis of bone loss in IBD. Using Winnie 
mouse model of spontaneous chronic colitis, closely representing human IBD, we showed 
for the first time that elevated GDS cross talks with molecular pathways involved in bone 
formation. Winnie male mice prior to onset of colitis (6 weeks old (6wk)) and progression of 
colitis (14wk) were compared to age- and sex- matched control C57BL/6 mice. High levels 
of peripheral GDS at 14wk in Winnie male mice bind to serotonin receptors (5-HTR1B) 
on bone marrow-derived mesenchymal stem cells (BM-MSCs) to regulate transcriptional 
activity of FOXO1. This was evidenced by increased mRNA expression of 5-HTR1B and 
FOXO1 from BM-MSCs of 14wk Winnie male mice compared to 14wk male controls as 
determined by qPCR. To elucidate downstream molecular mediators of GDS in bone, im-
munohistochemical analysis unveiled dissociation of FOXO1 and CREB1 complex at 14wk 
in Winnie male mice. This relieves the suppressive effect of CREB on FOXO1, resulting in 
decreased osteoblast proliferation as compared to strong association of CREB and FOXO1 
in control group. Additionally, FOXO1 (CREB-free) association with ATF4 was observed 
in 14wk Winnie male mice, in which ATF4 promotes the transcriptional activity of FOXO1, 
contributing to suppression of osteoblast proliferation (Figure 1). In contrast, 6wk Winnie 
male mice showed no significant change in association/ dissociation of complexes with 
FOXO1 compared to 6wk male controls. This is agreeable to similar 5-HTR1B expression 
levels in 6wk Winnie male mice and age-matched male controls. These findings identify 
FOXO1 as the molecular node of an intricate transcriptional machinery that confers the sig-
naling of high GDS levels to inhibit bone formation. Further exploration of the mechanisms 
explaining this skeletal phenotype is warranted.
Disclosures: Shilpa Sharma, None
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Pathogenic role of fibroblast like synoviocyte in the particle induced 
periprosthetic osteolysis *Supriya Jagga1, Yeon-Hee Lee1, Ju-Suk Nam1, Sang-
Soo Lee1, Ashish Ranjan Sharma1. 1Hallym University, Republic of Korea
Pathogenic role of fibroblast like synoviocyte in the particle induced periprosthetic 
osteolysis Ashish Ranjan Sharma, Supriya Jagga, Yeon-Hee Lee, Ju-Suk Nam, Sang-Soo 
LeeInstitute for Skeletal Aging/Orthopedic Surgery, Hallym University-Chuncheon Sacred 
Heart Hospital, Chuncheon, South KoreaINTRODUCTION Wear debris from prosthetics 
often leads to failure of implants by causing periprosthetic osteolysis. Under inflammatory 
conditions, fibroblast-like synoviocytes (FLS) displays pathogenic behavior by releasing a 
number of pro-inflammatory cytokines and are crucial for the pathogenesis. Henceforth, the 
purpose of this study was to investigate the effect of Ti particles on FLS and the mechanism 
by which it might participate in the process of periprosthetic osteolysis. METHODS1) Ster-
ilized Ti particles (1~3 μm). 2) For viability assessment, MTT and LDH assays were per-
formed. 3) mRNA expression levels were analyzed by real-time RT-PCR. 4) TRAP staining 
was performed for osteoclastogenesis. 5)  Alkaline phosphatase activity (ALP), mineraliza-
tion, and collagen synthesis were analyzed to study changes in osteogenic activity. 6) For 
WNT and BMP signaling, Axin-2 and BRE reporter construct was utilized. 7) Western blot 
was performed to detect the activation of signaling molecules. RESULTS1. 1:400 (cells to 
Ti particles) to human FLS increased the expression of COX-2 and pro-inflammatory cyto-
kines.2. Conditioned medium (CM) collected from Ti stimulated FLS induced osteoclasto-
genesis in RAW 264.7 cells.3. Ti CM suppressed osteogenic parameters as well as WNT and 
BMP signaling activity in osteoblasts.4. Ti particles induced the mRNA expression of vari-
ous antagonists to the WNT and BMP signaling pathways in FLS.5. Inhibition of Sclerostin 
(SOST) partially recovered the Ti CM suppressed osteogenic activity in osteoblasts. CON-
CLUSIONFLS might contribute toward the bone loss as observed during periprosthetic 
osteolysis by not only stimulating osteoclastogenesis but also by suppressing bone-forming 
ability of osteoblasts. Secretion of antagonists for WNT and BMP signaling pathways like 
SOST might be helpful in understanding the participatory role of FLS in wear debris in-
duced osteolysis. In the clinical setting, targeting FLS for the secretion of antagonists like 
SOST might be a novel therapeutic approach for preventing bone loss during periprosthetic 
osteolysis.Keywords: Periprosthetic osteolysis, Wear debris, Biomaterials, Fibroblast-like 
synoviocytes, osteoblasts, Osteoclasts Acknowledgments This research was supported by 
Hallym university research Fund and by a grant from the National Research Foundation of 
Korea (NRF-2017R1A2B4012944 & NRF-2020R1C1C1008694) funded by the Ministry of 
Education, Science and Technology.
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LECT2 mediates the interaction between liver and bone by inhibiting 
osteoclastogenesis *Seong Hee Ahn1, JinMi Park1, Cho-Rong Kim1, Seongha 
Seo1, Da Hea Seo1, Yongin Cho1, So Hun Kim1, Seongbin Hong1. 1Department 
of Endocrinology and Metabolism, Inha University Hospital, Inha University 
School of Medicine, Republic of Korea
Objective: Although several clinical data suggested the deterioration of bone metabo-
lism in patients with chronic liver diseases, the direct interaction between liver and bone has 
been rarely demonstrated in vitro. We investigated the effects of hepatocyte-conditioned me-
dium (HepG2-CM), which probably contains secreted proteins from hepatocyte, and leuko-
cyte cell-derived chemotaxin 2 (LECT2), a known hepatokine, on osteoclasts.Methods: The 
conditioned medium from HepG2 cell line was collected after 48 hours of culture without 
fetal bovine serum. Osteoclasts were differentiated from mouse bone marrow macrophages 
(BMMs). HepG2-CM and LECT2 were treated on BMMs with M-CSF and RANKL. Tar-
trate resistant acid phosphatase-positive multinucleated cells were considered as osteoclasts, 
and the resorption area was determined by incubating the cells on dentine discs. Signaling 
pathways were investigated using qRT-PCR and western blot.Results: HepG2-CM inhibited 
both osteoclastogenesis and in vitro bone resorption without any significant effect on the 
viability of preosteoclasts. LECT2 also inhibited both osteoclastogenesis and in vitro bone 
resorption without any significant effect on the viability of preosteoclasts. Consistently, the 
expressions of osteoclast differentiation markers were significantly decreased by LECT2. 
Western blot analyses suggested that LECT2 inhibits p38 signaling pathways in osteoclasts.
Conclusion: LECT2 is a candidate hepatokine that connects liver and bone by inhibiting 
osteoclastogenesis.
Disclosures: Seong Hee Ahn, None
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Identify the role of osteopontin in Shn3/SLIT3 pathway of osteoblasts-type 
H endothelial cells coupling *Jia-Fwu Shyu1, Cheng-Yuan Hsiao1, Tzu-Hui 
Chu1, Ting-Han Taso1, Yu-Chih Lo1. 1Department of Biology and Anatomy, 
National Defense Medical Center, Taiwan, Province of China
Recent studies have highlighted roles for blood vessels during bone remodeling and 
fracture healing. Type H endothelial cells (ECs) express high level of junctional protein 
CD31 and endomucin. ECs are emerging as a crucial source of signals that control bone 
remodeling, thereby allowing the coupling of angiogenesis and osteogenesis during both 
development and regeneration. Schnurri-3 (SHN3) knocked out mice have unexpectedly 
identified increased bone mass due to augmented osteoblast function. Transcriptomic analy-
sis of osteoblast-lineage specific Shn3 deletion mice have identified the axon-guidance cue 
SLIT3 as a proangiogenic factor whose expression in bone is restricted to osteoblasts and is 
negatively regulated by SHN3. Osteopontin (OPN), produced by osteoblasts, is one of the 
most abundant non-collagenous proteins in extracellular matrix. OPN is an acidic phosphor-
ylated glycoprotein, which belongs to the protein family of “Small Integrin-Binding Ligand 
N-linked Glycoproteins” (SIBLINGs) and plays a decisive role in the biology of bone min-
eralization and angiogenesis. Taken together, SHN3/SLIT3 and OPN are emerging novel 
bone anabolic molecules targeting type H ECs. In this study, we set up osteoblast/HUVEC 
transwell co-culture system to examine the angiogenic effects induced by SHN3/SLIT3 and 
OPN. The angiogenesis was measured by tube formation by HUVEC in Matrigel (bottom 
well). The osteoblasts (upper well) were pre-cultured in osteogenesis medium (containing 
b-glycerophosphate and ascorbate) with or without PTH for one week. Increase tube forma-
tion was observed in HUVECs co-cultured with osteoblasts in osteogenesis medium without 
PTH. Elisa analysis showed increase expression of osteopontin but decrease expression of 
SLIT3 in PTH-stimulated osteoblast culture medium. In addition, immunofluorescent la-
beling and Western blot analysis showed increase expression of CD31 and endomucin in 
SLIT3- and OPN-stimulated HUVECs. In conclusion, these results may provide in-depth 
understanding of the osteo-angio coupling and safe and more effective treatment for osteo-
porosis and fracture healing.
Disclosures: Jia-Fwu Shyu, None
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Inhibition of PAD4 Mediated Neutrophil Extracellular Traps Prevents 
Fibrotic Osseointegration Failure in a Murine Model of Tibial Implantation 
*Emile-Victor Kuyl1, Fei Shu1, Branden Sosa1, Matthew B Greenblatt2, Mathias 
PG Bostrom1, Xu Yang1. 1Hospital for Special Surgery, United States, 2Weill 
Cornell Medicine, United States
Purpose: The formation of peptidyl arginine deiminase (PAD4) mediated neutrophil ex-
tracellular traps (NETs) are a recently discovered defense mechanism that responds to sterile 
triggers with detrimental effects in tissue healing. Patients with aseptic loosening, a cause 
of failure in uncemented total joint arthroplasty (TJA), often present with fibrotic tissue at 
the bone-implant interface. In this study, we explore the role of NETs in peri-implant fibro-
sis and osseointegration failure through a murine model of tibial implant with instability.
Methods: A 3D printed Ti-6Al-4V implant was inserted in an oversized drill-hole in the right 
proximal tibia of 8-week-old male C57BL/6J and PAD4-/- mice (n=3 per group). Fourteen 
days post-implantation, all mice were euthanized, and tibias were dissected and analyzed 
for the presentation of fibrosis at the bone-implant interface. Trabeculae were assessed by 
micro-computed tomography (microCT), hematoxylin and eosin staining and immunofluo-
rescence for extracellular DNA, citrullinated histones (CitH3) and myeloperoxidase (MPO). 
Peri-implant membrane was retrieved from patients undergoing total hip revision surgery 
for aseptic loosening and analyzed for the presence of NETs.  Results: NETs (MPO+CitH3+ 
with extracellular DNA) were present in the peri-implant area only and not in other neutro-
phil populations (MPO+citH3-) of the bone marrow (Figure 1a). NETs were identified in 
peri-implant fibrotic tissue collected from aseptic loosening patients (Figure 1b). Unstable 
implants in wild type mice failed to properly osseointegrate, as indicated by the presence 
of fibroblast-like cells and immature bone matrix in the peri-implant area (Figure 1c)and 
low bone volume fraction (BV/TV) and bone surface area (BS) around the implant (Figure 
1e). In PAD4-/- mice, we observed well-formed trabeculae, few fibroblast cells (Figure 1d), 
higher peri-implant BV/TV and BS (Figure 1f). These indicate better osseointegration in 
these mice.Discussion: NETs have been characterized in human peri-implant fibrotic tissue 
and have been identified at early time points in a murine model of unstable tibial implan-
tation, indicating a possible damage induced activation. The lack of peri-implant fibrosis 
through inhibition of NETs via PAD4 deficiency in mice indicates that NETs play a role in 
osseointegration failure, leading the way for potential therapeutic targets in treating fibrotic 
osseointegration failure and aseptic loosening.
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Deletion of Transferrin Receptor 2 (Tfr2) Aggravates Inflammation and 
Bone Loss in Serum Transfer Arthritis in Mice *Maria G. Ledesma-Colunga1, 
Ulrike Baschant1, Lorenz C. Hofbauer1, Martina Rauner1. 1Department of 
Medicine III & Center for Healthy Aging, Technische Universität Dresden, 
Dresden, Germany, Germany
Rheumatoid arthritis is an autoimmune disease characterized by chronic inflammation 
and progressive joint destruction with frequent synovial iron deposition. Transferrin receptor 
2 (Tfr2) is a focal point in the regulation of systemic iron levels and bone mass. Loss of Tfr2 
functions results in low hepcidin expression and iron overload. As neither the role of iron nor 
Tfr2 has been explored in arthritis, here, we aimed to investigate whether Tfr2 deletion and/
or iron overload impacts on the pathogenesis of inflammatory arthritis.We compared iron 
overloaded Tfr2-deficient mice (Tfr2-/-), and their wild-type (Tfr2+/+) littermate controls 
for their capacity to develop K/BxN serum transfer arthritis (STA). Arthritis severity was 
assessed by clinical scores and hind paws were collected for micro-CT, histomorphome-
try, quantitative PCR, and flow cytometry.Tfr2-/- mice developed more pronounced joint 
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swelling with enhanced mRNA expression of inflammatory markers (Il1b, Inos), synovial 
hypertrophy, and bone erosion as compared to Tfr2+/+ mice. Furthermore, the infiltration of 
myeloid cells including GR1pos neutrophils and F4/80pos macrophages/monocytes at day 
7 was increased in the joints of Tfr2-/- mice, suggesting a role of Tfr2 and/or iron overload 
in arthritis progression. To elucidate whether Tfr2 has a direct role in the pathogenesis of ar-
thritis or whether the effects are merely mediated via the systemic iron overload, we induced 
STA in mice with a conditional deletion of Tfr2 in the myeloid lineage, that have been pre-
viously described with normal iron loading. Tfr2fl/fl-LysMCre+ showed increased disease 
development with enhanced synovial hypertrophy and bone erosion in the arthritic joints 
compared to Cre- control littermates.Taken together, these findings suggest a protective role 
of endogenous Tfr2 on the progression of arthritis.
Disclosures: Maria G. Ledesma-Colunga, None
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Erythropoietin receptor in B cells plays a role in bone remodeling in mice 
*Naamit Deshet-Unger1, Albert Kolomansky1, Nathalie Ben-Califa1, Sahar 
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Anton Gorodov1, Howard S. Oster3, Moshe Mittelman3, Martina Rauner4, 
Ben Wielockx5, Drorit Neumann1, Yankel Gabet2. 1Department of Cell and 
Developmental Biology, Sackler Faculty of Medicine, Israel, 2Department of 
Anatomy and Anthropology, Sackler Faculty of Medicine, Tel Aviv University, 
Israel, 3Department of Medicine A, Tel Aviv Sourasky Medical Center, Sackler 
Faculty of Medicine, Tel Aviv University, Israel, 4Department of Medicine III, 
Dresden University Medical Center, Germany, 5Institute for Clinical Chemistry 
and Laboratory Medicine, Technische Universität Dresden, Germany
Erythropoietin (EPO) is a key regulator of erythropoiesis. However, EPO receptors 
(EPO-Rs) are also expressed on non-erythroid cell types, including myeloid and bone cells. 
Immune cells also participate in bone homeostasis. B cells produce receptor activator of 
nuclear factor kappa-Β ligand (RANKL) and osteoprotegerin (OPG), two pivotal regula-
tors of bone metabolism. Here we explored the ability of B cells to transdifferentiate into 
functional osteoclasts and examined the role of EPO in this process in a murine model.
Methods: We have combined specifically-designed experimental mouse models and in vitro 
based osteoclastogenesis assays, as well as PCR analysis of gene expression.Results: (i) 
EPO treatment in vivo increases RANKL expression in bone marrow (BM) B cells, suggest-
ing a paracrine effect on osteoclastogenesis; (ii) B cell-derived osteoclastogenesis occurs in 
vivo and in vitro, as demonstrated histologically by B cell lineage tracing in murine models, 
respectively; (iii) B-cell-derived osteoclastogenesis in vitro is restricted to Pro-B cells  ex-
pressing CD115/CSF1-R and is enhanced by EPO; (iv) EPO treatment increased the number 
of B-cell-derived preosteoclasts (β3+CD115+), suggesting a physiological rationale for B 
cell derived osteoclastogenesis; (v) finally, mice with conditional EPO-R knockdown in the 
B cell lineage (cKD) displayed a higher cortical and trabecular bone mass. Moreover, cKD 
attenuated EPO-driven trabecular bone loss, an effect that was observed despite the fact that 
cKD mice attained higher hemoglobin levels following EPO treatment.Conclusions: Our 
work highlights B cells as an important extra-erythropoietic target of EPO-EPO-R signal-
ing and suggests their involvement in the regulation of bone homeostasis and possibly in 
EPO-stimulated erythropoietic response. Importantly, we present here the first histological 
evidence for B cell-derived osteoclastogenesis in vivo.
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Assessing the host inflammatory response to a novel 3D-printed 
hydroxyapatite (HA) and demineralized bone matrix (DBM) composite 
using a rodent posterolateral spinal fusion model *Mark Plantz1, Joseph 
Lyons1, Allison Wintring1, Elianna Fred1, Eileen Phan1, James Foley1, Chawon 
Yun1, Silvia Minardi1, Soyeon Jeong1, Stuart Stock1, Wellington Hsu2, Erin 
Hsu1. 1Northwestern University Feinberg School of Medicine, United States, 
2Wellington.Hsu@nm.org, United States
A wide range of biologic bone graft materials have been assessed for spinal fusion 
applications. However, the two options that remain the most effective – iliac crest bone graft 
and recombinant human bone morphogenetic protein-2 (rhBMP-2) – are limited by morbid-
ity and complications, respectively. We recently described a recombinant growth factor-free, 
3D-printed composite material comprised of hydroxyapatite (HA) and demineralized bone 
matrix (DBM) as a potential bone graft substitute. Herein, we compare the host inflammatory 
response of our previously described 3D-printed hydroxyapatite (HA)-demineralized bone 
matrix (DBM) composite scaffold to a positive control (rhBMP-2/ACS; Infuse™) using a 
preclinical rodent posterolateral lumbar fusion (PLF) model. Sixty female Sprague-Dawley 
rats, aged 12-16 weeks, underwent bilateral posterolateral intertransverse lumbar spinal fu-
sion using 1 of 3 adjuncts: (1) type I absorbable collagen sponge (ACS) alone (n=20), (2) 
10 µg rhBMP-2/ACS (n=20), or (3) HA-DBM composite scaffold (HA-DBM) (n=20). The 
host inflammatory response was assessed at 2, 5, and 10 days post-operatively using mag-
netic resonance imaging (MRI) to quantify local edema and cytokine analysis (ELISA) of 
various pro-inflammatory markers – IL-1β, IL-18, TNF-α, MCP-1, MIP-1 – to quantify and 
compare the inflammatory response between the different treatment groups. At days 2 and 5 
post-operatively, the HA-DBM scaffold yielded significantly less soft tissue edema relative 
to rhBMP-2 (p<0.05). Additionally, the HA-DBM scaffold yielded comparable volumes of 
soft tissue edema to the ACS control at all the time points in the post-operative period. The 
concentrations of various cytokines – IL-18, TNF-α, MCP-1 – were significantly elevated in 
the rhBMP-2 group relative to the ACS control in the peri-operative period (p<0.05). This 
elevation in cytokine markers was not observed for the HA-DBM group relative to the ACS 
control. In summary, the 3D-printed HA-DBM composite has a favorable host response 
that is comparable to that of an absorbable collagen sponge, when assessed preclinically. 
The minimal inflammatory response elicited by this material provides a notable advantage 
relative to recombinant growth-factor containing materials (e.g. rhBMP-2).
Disclosures: Mark Plantz, None
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Osteal Macrophage Contributions to Post-Menopausal Osteoporosis 
Bone Pathology *Lena Batoon1, Susan Millard1, Andy Wu1, Wenhao Sun1, 
Simranpreet Kaur2, Martin Wullschleger3, Liza Raggatt1, Nathan Pavlos4, Allison 
Pettit1. 1Mater Research Institute-The University of Queensland, Australia, 2The 
University of Queensland Diamantina Institute, Australia, 3Gold Coast University 
Hospital, Australia, 4University of Western Australia, Australia
Osteal macrophages (osteomacs) support osteoblast function and promote bone anabo-
lism, but their contributions to osteoporosis have not been explored. While mouse ovariecto-
my (OVX) models have been repeatedly used, spontaneous osteoporosis in female C57Bl/6 
mice limits utility of this strain and there are no comprehensive studies confirming OVX 
recapitulated all pathological features of osteoporosis in other mouse strains. We character-
ized OVX model of post-menopausal osteoporosis in C3H/HeJ mice. OVX caused reduced 
trabecular bone volume (-46%), thickness (-21%) and number (-23%) as well as reduced 
cortical thickness (-8%) with increased cortical porosity (17.5%) at 4-weeks post-surgery. 
High resolution micro-CT revealed enlargement of cortical vascular canals post-OVX. Bone 
loss was associated with increased osteoclasts on trabecular (p<0.0001) and endocortical 
bone (p<0.0016), and decreased osteoblasts on trabecular bone (p<0.0001). While there was 
no impact on overall osteocyte number, the TRAP-expressing osteocyte frequency was in-
creased in cortical bone (p=0.0005) which is suggestive of osteocytic osteolysis, especially 
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when considered in the context of the increased cortical porosity. Unexpectedly, osteomac 
frequency was increased on both trabecular (p<0.0001) and endocortical bone (p<0.0001) 
post-OVX. Dual F4/80 (pan-macrophage marker) and TRAP staining revealed osteomacs 
frequently located in close proximity to TRAP+ osteoclasts and containing TRAP+ intracel-
lular vesicles, suggesting osteomac-mediated phagocytosis of extracellular TRAP at resorp-
tion sites. Using an in vivo inducible macrophage depletion model (CD169-DTR mouse), 
that does not simultaneously deplete osteoclasts, we observed that osteomac loss was associ-
ated with elevated serum TRAP (p=0.0017). Using in vitro high-resolution confocal imaging 
of mixed osteoclast-macrophage cultures on bone substrate, we observed macrophages jux-
taposed to osteoclast basolateral functional secretory domains scavenging degraded osteo-
clast by-products. These data demonstrate a role for osteomacs in supporting bone resorption 
through sequestering resorption byproducts. Overall, our data expose a novel role for osteo-
macs in supporting osteoclast function and provide the first evidence of their involvement in 
osteoporosis bone pathology.
Disclosures: Lena Batoon, None
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Commensal Oral Microbiota Induces Osteoimmune Response Effects that 
are Separate from the Systemic Microbiota *Jessica Hathaway-Schrader1, 
Johannes Aartun1, Nicole Poulides1, Megan Kuhn1, Blakely Graham1, Michael 
Chew1, Emily Huang1, Richard Darveau2, Caroline Westwater1, Chad Novince1. 
1Medical University of South Carolina, United States, 2University of Washington, 
United States
The commensal microbiota is a critical regulator of osteoimmune mechanisms in the 
healthy skeleton. Yet, the influence of specific commensal microbiota communities (i.e. oral, 
gut, lung, skin, urogenital) on osteoimmune response effects is unknown. Study purpose was 
to discern osteoimmunoregulatory effects imparted by the commensal oral microbiota that 
are separate from the systemic microbiota. Study outcomes were assessed at both oral and 
non-oral skeletal sites in 12wko male C57BL/6T mice bred under specific-pathogen-free 
(SPF) or germfree (GF) conditions. Trabecular/cortical bone parameters were evaluated by 
μCT, and histomorphometric analyses were performed in maxillae and tibiae. Flow cytom-
etry and nCounter gene expression were carried out in mandibular bone marrow and long 
bone marrow. SPF vs. GF mice had reduced cortical and trabecular parameters in alveo-
lar bone, while only trabecular bone outcomes were decreased at non-oral skeletal sites. 
Osteoclast numbers and size were enhanced lining alveolar bone, whereas only osteoclast 
size was increased lining non-oral skeletal sites, of SPF vs. GF mice. Consistent with the 
enhanced pro-osteoclastic phenotype, SPF mice had upregulated Nfatc1 and Rank in alve-
olar bone marrow, but not long bone marrow. Toll-like receptor(TLR) and MHC class-II 
antigen presentation pathways were upregulated in alveolar bone marrow, but not long bone 
marrow, of SPF vs. GF mice. These results were supported by elevated antigen-presenting 
cells, activated CD4+ helper T-cells, and proinflammatory TH1 and TH17 cells in alveolar 
bone marrow, but not long bone marrow, of SPF vs. GF mice. To validate the commensal 
oral microbiota has osteoimmunomodulatory effects distinct from the systemic microbiota, 
SPF mice were subjected to twice daily 0.12% chlorhexidine (CHX) oral antiseptic rinses 
from age 8-12wks. 16S rDNA analysis showed a 50% reduction in oral bacterial load, with 
no alterations in gut bacterial load, in CHX vs. saline treated mice. μCT revealed inferior 
alveolar bone parameters in saline vs. CHX treated mice. Paralleling outcomes in SPF vs. 
GF mice, TLR and MHC class-II pathways were increased in alveolar bone marrow of sa-
line vs. CHX treated mice. This research delineates that the commensal oral microbiota has 
osteoimmunomodulatory actions separate from the systemic microbiota. Findings from this 
study reveal that oral antiseptic rinses may be employed to protect against commensal oral 
microbiota driven alveolar bone loss.
Disclosures: Jessica Hathaway-Schrader, None
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Shedding “LIGHT” on the link between bone and fat in obesity in obese 
children and adolescents *Giacomina Brunetti1, Maria Felicia Faienza2, Laura 
Piacente2, Giuseppina Storlino3, Gabriele D’Amato4, Gianpaolo De Filippo5, 
Silvia Colucci1, Maria Grano3. 1Department of Basic and Medical Sciences, 
Neurosciences and Sense Organs, Section of Human Anatomy and Histology, 
University of Bari, Italy, 2Department of Biomedical Science and Human 
Oncology, Paediatric Unit, University of Bari, Italy, 3Department of Emergency 
and Organ Transplantation, Section of Human Anatomy and Histology, 
University of Bari, Italy, 4Neonatal Intensive Care Unit, Di Venere Hospital, 
Italy, 5Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré, Service 
dEndocrinologie Diabétologie Pédiatrique, France
Obesity may affect bone health, but literature reports are contradictory about the cor-
relation of body mass index (BMI) and bone markers. LIGHT, one of the immunostimula-
tory cytokines regulating the homeostasis of bone and adipose tissue, could be involved in 
obesity. Our objective was the evaluation of LIGHT/TNFSF14 levels in obese children and 
adolescents and the influence of different grades of obesity on bone status. The human study 
involved 111 obese subjects (12.21 +/- 3.71 years), and 45 age and sex-matched controls. 
Patients were subjected to the evaluation of bone status by QUS, showing that the averages 
of Ad-SoS-Z-score and BTT Z-score were within the normal range but significantly reduced 
respect to the controls (p<0.05). 25(OH) Vitamin D levels were reduced compared to the 
controls, but the difference did not reach the statistical significance. Obese patients showed 
significant high BMI-SDS, weight-SDS, and HOMA-IR that negatively correlated with the 
reduced AD-SoS-Z-score and BTT-Z-score. They also displayed significantly higher serum 
levels of LIGHT compared with healthy controls (497.30 +/- 363.45 pg/ml vs 186.06 +/- 
101.41 pg/ml, p<0.001). LIGHT levels positively correlated with age (r= 0.29, p<0.03), 
Tanner stage (r= 0.207, p<0.05), weight-SDS (r= 0.448, p<0.0001), BMI-SDS (r= 0.416, 
p<0.0002), conversely a negative correlation with 25 (OH) Vitamin D (r= -0.173, p<0.0001), 
and osteocalcin (r= -0.232, p<0.0001), Ad-Sos-Z-score (r= -0.445, p<0.02) and BTT-Z-score 
(r= -0.341, p<0.05) was found. The expression of LIGHT on monocytes, CD3+-T-cells, and 
neutrophils, was also higher in obese patients than in the controls. Furthermore, in vitro ex-
periments carried out on peripheral blood mononuclear cell (PBMCs) cultures, demonstrated 
that the addition of anti-LIGHT antibodies induced a significant inhibition of osteoclasto-
genesis. With adjustment for age multiple linear regression analysis for LIGHT as dependent 
variable showed that Tanner stage, weight-SDS, BMI-SDS, cholesterol, 25 (OH) Vitamin 
D, Osteocalcin, AD-SoS-Z-score, and BTT-Z-score are the most important predictors (r = 
0.768, p<0.0001).In conclusion, our study highlighted the elevated serum levels of LIGHT 
in obese children and adolescents, and its relationship with both the grade of obesity and 
bone impairment. Our results also emphasized the key role of the immune system in the 
cross-talk between bone and fat in obesity.
Disclosures: Giacomina Brunetti, None
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The Role of Toll-like Receptors 2 and 9 in Host Responses to Staphylococcus 
aureus Osteomyelitis *Jenna Petronglo1, Nicole Putnam 1, Caleb Ford2, 
Jacob Curry3, Jim Cassat4. 1Vanderbilt University, United States, 2Vanderbilt 
University Department of Biomedical Engineering, United States, 3Vanderbilt 
University Medical Center, United States, 4Vanderbilt University Medical Center 
Department of Pediatric Infectious Diseases, United States
Staphylococcus aureus is the most common etiologic agent of bone inflammation, or, 
osteomyelitis (OM). During S. aureus OM, treatment difficulty is compounded by inflam-
matory processes that dysregulate skeletal homeostasis, altering the differentiation and func-
tion of bone-building osteoblasts and bone-resorbing osteoclasts (OCs) to favor bone loss. 
Toll-like receptor 2 (TLR2), which detects bacterial lipoproteins, and TLR9, which detects 
bacterial CpG-DNA, have emerged as major pattern recognition receptors responsible for 
immune cell sensing of S. aureus. Thus, in this study, we sought to determine the role of 
TLR2 and TLR9 in host immune responses and dysregulation of skeletal homeostasis during 
S. aureus OM. Using in vitro assays, we discovered that S. aureus-induced osteoclastogene-
sis proceeds in a TLR2-and TLR9-dependent manner. To evaluate how TLR2 and TLR9 con-
tribute to increased osteoclastogenesis and to dysregulation of bone homeostasis during an in 
vivo infection, we surgically induced S. aureus OM in Tlr2-/- and Tlr9-/- mice. Despite our 
previous findings showing that mice deficient in the common TLR adapter protein MyD88 
incur increased bacterial dissemination and mortality, we found that TLR2 and TLR9 were 
individually dispensable for host survival and bacterial control. Moreover, in contrast to our 
in vitro findings, there were no differences in trabecular OC abundance or bone loss com-
pared to wildtype (WT). We posited that compensation between TLR2 and TLR9 masked 
the role of TLR2/9 in OM in these studies. To test this, we induced OM in Tlr2/Tlr9-/- 
mice.  We did not observe defects in local bacterial burden control or dissemination in Tlr2/
Tlr9-/- mice over an infection time course. However, we did find a significant decrease in 
reactive, cortical bone formation in Tlr2/Tlr9-/- mice compared to WT, suggesting TLR2/9 
may be involved may be involved in changes to osteoclast or osteoblast function in response 
to S. aureus. We have begun in vitro experiments to further understand how TLR2/9 func-
tions in skeletal cells responding to S. aureus. Overall, our data suggest that redundancy in 
innate immune responses to S. aureus in bone renders TLR2 and 9 individually expendable 
for the regulation of skeletal homeostasis and the control of bacterial burdens during OM, 
but also establish that TLR signaling in the skeletal niche contributes to regulation of bone 
homeostasis in infection.
Disclosures: Jenna Petronglo, None
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Deletion of von-Hippel Lindau in Dmp1-expressing cells impairs B cell 
development *Betsabel Chicana1, Joel Spencer1, Jennifer Manilay1. 1University 
of California, Merced, United States
The von-Hippel Lindau protein (VHL) regulates hypoxia-inducible factor degradation 
in response to low oxygen environments. Osteoblasts (OBs) support B cell development 
and mature into osteocytes (OCYs). We utilized Dmp1-Cre;Vhl conditional knockout mice 
(cKO), in which Vhl is deleted in OBs and OCYs. The cKO display dysregulated bone 
growth, high bone density, smaller bone marrow (BM) cavity volume and cellularity com-
pared to wild-type (WT) mice, and impaired B cell development. B cells produce antibodies, 
which are crucial for a robust adaptive immune response. Our current objective is to further 
characterize how the altered cKO bone microenvironment influences B cell development. 
Using multiparameter flow cytometry, we found that long-term hematopoietic stem cells 
(HSCs), short-term HSCs, common lymphoid progenitors, multipotent progenitors-2, 3 and 
4 and B cell progenitors were increased in % and absolute numbers in the cKO BM. In 
contrast, later stages of B cell development were decreased. As no splenic Dmp1+ cells 
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have been described, we were surprised that the % of mature peripheral B cells were also 
reduced, implying that the altered BM microenvironment in the cKO permanently affected 
B cells outside of the bone. Our observation of altered B cell development in the BM and 
in the periphery of lethally irradiated WT→cKO BM chimeras supports the idea that Vhl 
deletion in Dmp1+ cells results in cell-extrinsic changes that cannot support normal B cell 
development. We are utilizing Ai9 reporter mice to sort Vhl deficient Dmp1+ cells to test 
the hypothesis that B cell development is impaired due to reduction of key niche cells and 
decreased production of IL7, SCF, CXCL12, and Flt3. Furthermore, our preliminary intrav-
ital and ex vivo imaging studies of the cKO BM revealed abnormal structure of the marrow 
cavity, with noticeably increased vascular permeability and the appearance of an increased 
vessel density. The functional consequences of the cKO microenvironment on B cell prolif-
eration, death and output from the BM are being addressed. In future studies, we will apply 
our intravital imaging approach to perform longitudinal analyses of B cell development in 
individual cKO mice to determine how the distinct physical properties in the bone change 
and affect the progression of B cell defects in cKO bones as a function of time. This infor-
mation could be applied to future studies of the effects of bone-building drugs on BM niches 
and immune cell development.
Disclosures: Betsabel Chicana, None
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The central role of TRPM7 kinase in magnesium ion-
induced immunomodulation in macrophage during bone healing *Wei 
Qiao1, Karen H.M. Wong1, Yun Wah Lam2, Kelvin W.K. Yeung1. 1The University 
of Hong Kong, Hong Kong, 2City University of Hong Kong, Hong Kong
The use of magnesium ion (Mg2+)-modified biomaterials in bone regeneration is a 
promising and cost-effective therapeutic. Despite the widespread observation on the osteo-
genic effects of Mg2+, the diverse roles played by Mg2+ in the complex biological process 
of bone healing have not been systematically dissected. Here, we reveal a previously un-
known biphasic mode of action of Mg2+ in bone repair. In the early inflammation phase, 
Mg2+ primarily targets the monocyte-macrophage lineage to promote their recruitment, ac-
tivation, and polarization. We showed that an increase in extracellular Mg2+ contributes to 
an upregulated expression of transient receptor potential cation channel member 7 (TRPM7) 
and a TRPM7-dependent influx of Mg2+ in the monocyte-macrophage lineage, resulting in 
the cleavage and nuclear accumulation of TRPM7-cleaved kinase fragments (M7CKs). This 
then triggers the phosphorylation of Histone H3 at serine 10, in a TRPM7-dependent manner 
at the promoters of inflammatory cytokines like IL-8, leading to the formation of a pro-os-
teogenic immune microenvironment. In the later active repair/remodeling phase of bone 
healing, however, continued exposure of Mg2+ and IL-8 leads to over activation of NF-κB 
signaling in macrophages, turning the immune microenvironment into pro-osteoclastogene-
sis. Moreover, the presence of Mg2+ at this stage also decelerates bone maturation through 
the suppression of hydroxyapatite precipitation. The negative effects of Mg2+ on osteogen-
esis can override the initial pro-osteogenic benefits of Mg2+, as we found prolonged deliv-
ery of Mg2+ compromises overall bone formation. Taken together, this study establishes a 
paradigm shift in understanding the diverse and multifaceted roles of Mg2+ in bone healing.
Disclosures: Wei Qiao, None
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Sodium Benzoate (NaB) attenuates osteoporosis and enhances bone health 
via modulating host osteoimmune system *Rupesh K. Srivastava1, Leena 
Sapra1, Asha Bhardwaj1, Ayaan Ahmad1, Zaffar Azam1. 1All India Institute of 
Medical Sciences (AIIMS), India
Purpose: NaB is predominantly used as a food additive with medicinal properties. 
NaB is an FDA approved drug for treating urea cycle disorder and kidney disorders. Recent 
studies reported that administration of NaB enhances Treg cell population by up regulating 
expression of TGF-β via activating STAT6 transcription factor. But no study till date had 
delineated the immunomodulatory role of NaB in regulating bone-health in osteoporosis.The 
present study aims to elucidate the immunomodulatory role of NaB in regulating bone health 
in osteoporotic mice model.Methods Used: To investigate the same, firstly we performed in 
vitro cultures of bone marrow derived osteoclasts in the presence of NaB in a dose dependent 
manner along with examining the underlying molecular mechanism involved in osteoclasto-
genesis via Western blotting. For in vivo study female BALB/c mice were divided into three 
group’s (n=8 mice/gp) viz. Sham, Ovx and Ovx+NaB. NaB was administered orally (100 mg 
NaB/kg bw) and after 45 days mice were sacrificed and tissues analyzed for various parame-
ters via various cutting-edge technologies such as SEM, AFM, μCT, FTIR, FACS and CBA/
ELISA.Results: Our in vitro results clearly indicated that NaB inhibits osteoclastogenesis in 
a dose dependent manner by reducing the development of multi-nucleated TRAP positive 
osteoclasts. NaB ameliorated osteoclastogenesis via suppressing PI3K-Akt-mTOR mediat-
ed signaling pathway involved in differentiation of osteoclasts. From in vivo results, we 
observed that administration of NaB attenuated bone loss in Ovx mice. Both the cortical and 
trabecular bone content (BMD) and bone heterogeneity of NaB treated group was signifi-
cantly higher than Ovx group. Remarkably, the percentages of osteoclastogenic progenitors 
i.e macrophages (F4/80+CD11b+) and osteoclastogenic Th17 (CD4+Rorγt+) cells at distinct 
immunological sites such as BM, spleen, MLN and PP were significantly reduced (p < 0.01). 
On the contrary the percentages of anti-osteoclastogenic Tregs (CD4+Foxp3+ and CD8+-
Foxp3+) and Bregs (CD19+CD5+CD1d+IL-10+) were significantly enhanced (p < 0.01) in 
NaB treated group, thereby attenuating bone loss. The immunomodulatory role of NaB was 
further supported by serum cytokine data with a significant reduction in osteoclastogenic cy-
tokines (IL-6, IL-17 and TNF-α) along with enhancement in anti-osteoclastogenic cytokines 
(IL-10, IFN-γ) in NaB treated group.Conclusion: Altogether our present findings for the first 
time demonstrate that NaB has the potential to inhibit osteoclastogenesis and thereby inhibit 
bone loss in osteoporotic mice via the modulation of host immune system. The present study 
thus highlights the novel osteoprotective role NaB (an FDA approved food additive) in the 
treatment and management of osteoporosis.
Disclosures: Rupesh K. Srivastava, None
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Dose-dependent Effect of Zolendronic Acido n the Development of 
Medication-associated Jaw Osteonecrosis (MRONJ) Like-lesion in C57Bl/6 
Mice – A Histological Preliminary Study *Nataira Momesso1, Vinicius Rosa1, 
Raquel Parra1, Ramez Mahmoud1, Edilson Ervolino1, Claudia Biguetti2, Mariza 
Matsumoto1. 1Department of Basic Sciences, School of Dentistry, São Paulo State 
University (UNESP), Araçatuba, SP, Brazil, 2Bone-Muscle Research Center, 
College of Nursing and Health Innovation, University of Texas at Arlington, 
Arlington, TX 76019, USA., United States
Medication-related osteonecrosis of the jaw (MRONJ) is a potentially painful condition 
that affects patients with previous or continuous treatment with antiresorptive or antiangio-
genic agents. In this context, the cumulative use of zoledronic acid (ZL) is important dura-
tion medication-related risk factors for patients needing tooth extraction. In this preliminary 
study, we investigated the development of MRONJ-type lesions in C57Bl/6 male mice (eth-
ical committee approval n°00262-2019) at the late time point of socket healing, after contin-
uous and cumulative administration of zoledronic acid (ZL) in two different dosages. Mice 
at age of 4 to 6 months were divided, receiving intraperitoneal injection of saline solution 
(SS, control, n=3) or ZL at a concentration of 250ug / Kg (n=3) and 500ug/Kg (n=4), once 
a week, starting 4 weeks before extraction of the upper right incisor and continuing until 
day 30 after the surgery. At the end of 30 days, bone samples were collected for histological 
(H&E and Goldner Trichrome [GT] staining), histomorphometric and immunohistochemi-
cal analyzes for bone (RANKL) and inflammatory (COX-2) markers. While control group 
exhibited the dental socket filled with mature bone, ZL-250 and ZL-500 groups presented 
a significant and gradual increase in the area density of inflammatory infiltrate dependent 
of each dosage. Bone matrix area density was significantly lower in ZL-250 and ZL-500 
groups, and GT staining revealed a gradual impairment in bone matrix in ZL-250 and ZL-
500 groups compared to control (Figure 1). Area density of COX2+ cells, an inflammatory 
parameter positively related to bone neoformation, was also decreased in both treated groups 
compared to the control. On the other hand, area densities of fibroblasts, RANKL+ cells, and 
empty osteocyte lacunae were increased in ZL-250 and ZL-500 groups. Interestingly, the 
area density of detached osteoclasts, a typical characteristic of ZL effect, was higher in the 
ZL250 group compared to the SS, while ZL500 group presented a lower density of attached 
osteoclasts compared to the others. The final outcome of alveolar bone healing was signifi-
cantly affected in C57BL/6 mice using both dosages used in this study, but with increasing 
effects on histological MRONJ parameters at the higher dosage.
Disclosures: Nataira Momesso, None
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High-throughput cathelicidin bioassay utilizing HiTCA, a novel CRISPR 
Cas9-edited human monocytic cell line *Carter Gottlieb1, Rene Chun2, Jeffrey 
Wang2, Vahe Yacoubian2, John S Adams2. 1Department of Orthopaedic Surgery, 
Orthopaedic Hosital Research Center, UCLA, United States, 2Department of 
Orthopaedic Surgery, Orthopaedic Hosital Research Center, UCLA, United 
States
The purpose of this project is to create a novel serum 25-hydroxyvitamin D (25D)-driv-
en bioassay for cathelicidin gene (CAMP) expression in human innate immune cells. Cathe-
licidins are anti-microbial peptides with potent broad-spectrum activity against bacteria, 
fungi, and viral pathogens. The human CAMP gene encodes a single anti-microbial peptide, 
LL-37. CAMP is expressed by innate immune cells such as monocytes and macrophages 
(mono-macs). Owing to the insertion of a retrotransposon bearing a consensus vitamin 
D response element in the proximal CAMP promoter, only in humans and higher apes is 
CAMP expression responsive to vitamin D and limited by the 25D-deficient state of the 
host.Our lab has previously developed a CAMP expression bioassay whereby plastic-ad-
herent, primary cultures of single donor monocyte-macrophages (mono-macs) are condi-
tioned with heterologous donor serum before measuring CAMP expression by qPCR. Based 
on the concentration of 25D in the conditioning serum, this assay has proved valuable for 
measuring the ability of donor serum to alter ex vivo CAMP expression in mono-macs. 
However, the assay suffers from (1) donor variability, requiring a different mono-mac do-
nor in each experiment, (2) low throughput, and (3) contamination with a small number of 
neutrophils or other CAMP-expressing plastic-adherent cells. We circumvented these prob-
lems by creating a CRISPR-Cas9-directed knock-in of a cDNA containing the mCherry 
fluorescent reporter at the C-terminal end of the endogenous CAMP gene in the human 
VDR and CYP27B1-hydroxylase expressing SC monocytic cell line (ATCC CRL-9855), 
creating the High Throughput Cathelidicin Assay (HiTCA) cell line.  After confirming that 
mCherry inserted in the correct location and orientation, we validated the responsivity of 
HiTCA cells exposed to physiologically-relevant levels of 25D3 (1nM, 10nM, and 100nM) 
in serum-free media by observing a 25D3 dose-dependent CAMP-mCherry response (Figure 
4). The robust response to 25D3 in HiTCA cells suggests intracellular activation to I,25-di-
hydroxyvitamin D3  by endogenous CYP27B1. We then tested the HiTCA cell line using 
16 donor human serum samples (total 25D3 ranging from 6.7 to 36.2 ng/mL) and noted a 
statistically significant CAMP-mCherry expression difference (p < 0.0001) among donors. 
In conclusion, the HiTCA cell line enables a high-throughput and reproducible bioassay for 
25D-containing human sera.
Disclosures: Carter Gottlieb, None
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Regulation of macrophage polarization by IL-3 *Shubhanath Behera1, Juilee 
Karhade1, Garima Pandey1, Mohan R. Wani1. 1National Centre for Cell Science, 
India
Regulation of macrophage polarization by IL-3 Shubhanath Behera, Juilee Karhade, 
Garima Pandey, Mohan R. Wani National Centre for Cell ScienceS. P. Pune University Com-
plex, Pune 411004, IndiaMacrophages play a major role in the immune system. These cells 
can be polarized into classically activated pro-inflammatory M1 phenotype or alternatively 
activated anti-inflammatory M2 phenotype. It is recently shown that M1/M2 macrophage 
ratio is increased in bone marrow of ovariectomized osteoporotic mice and treatment with 
estrogen restore the M1/M2 ratio by preventing M2 macrophages from being differentiated 
into osteoclasts. Thus, alteration in M1/M2 macrophage ratio may participate in the patho-
genesis of postmenopausal osteoporosis. Macrophages and bone resorbing osteoclasts share 
the same myeloid cell lineage. We have recently shown that IL-3, a cytokine secreted by ac-
tivated T lymphocytes inhibits osteoclast differentiation by diverting the cells to macrophage 
lineage. IL-3 also prevents the development of inflammatory arthritis in mice and protects 
cartilage and bone destruction in the joint. In the present study we investigated the role of 
IL-3 in polarization of macrophages. When bone marrow-derived CD11b+ F4/80+ macro-
phages were incubated for 24 hours with IL-3 alone, we found that there was increase in the 
expression of  M2 macrophage markers CD206 and Arginase 1, however, the expression of 
M1 macrophage marker iNOS was unchanged by IL-3. We then induced macrophages into 
M1 phenotype by Th1 cytokines interferon gamma and/or lipopolysaccharide; and M2 phe-
notype by Th2 cytokine IL-4 in presence of IL-3. We found that IL-3 significantly increased 
the expression of CD206 and Arginase 1 induced by IL-4. IL-3 showed no effect on expres-
sion of M1 phenotype. These results indicate that IL-3 regulate macrophage polarization 
by diverting the cells towards anti-inflammatory M2 macrophages. Thus, IL-3 may play an 
important role in regulation of M1/M2 ratio in osteoporosis.  
Disclosures: Shubhanath Behera, None
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Modulation of osteoclast behaviors by the immune microenvironment 
*Margaret Durdan1, Sonya Royzenblot1, Megan Weivoda1. 1University of 
Michigan, United States
Osteoclasts (OCs) are bone resorbing cells and are increasingly recognized to exhibit 
functional heterogeneity. Understanding how OC behaviors are regulated could lead to nov-
el therapeutic targets to promote/inhibit specific activities without affecting OC numbers. 
Because OCs are closely related to macrophages (MΦ) that are phenotypically polarized by 
the immune microenvironment, we tested the effects of a subset of immune cytokines (LPS, 
IL4, and TGFβ) on mature OC gene expression. OCs were differentiated from mouse BM 
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(M-CSF and RANKL, 20 and 25ng/mL, respectively). Mature OCs were treated (tx) with 
immune cytokines for an additional 24 hrs. Following treatment, there were no differences in 
OC numbers. RNA was isolated for RT-qPCR of OC and MΦ functional gene sets. LPS po-
tently induced inflammatory MΦ genes (Adgre1, Casp1, Cd38, Fpr2, Il1b, Il6, Nlrp3, Nos2, 
Tnf), and to a lesser extent, OC genes (Acp5, Ctsk, Dcstamp, Ocstamp, Oscar). IL4 inhibited 
expression of inflammatory MΦ and OC genes and stimulated repair/resolution MΦ genes 
(Arg1, Egr2, Mrc1, Myc). TGFβ uniquely stimulated coupling-factor genes that have been 
shown to promote osteoblast proliferation, migration or differentiation (Lif, Pdgfa, Pdgfb, 
Sphk1, Vegfa, Wnt1). In addition, TGFβ reduced inflammatory MΦ genes (Adgre1, Casp1, 
Cd38, Fpr2, Il18, Nos2) and potently increased OC genes (Acp5, Ctsk, Dcstamp, Itgav, 
Itgb3, Ocstamp, Oscar). Because bone-derived TGFβ is released and activated during re-
sorption, our data suggest that TGFβ may act as negative feedback during inflammatory 
resorption and transition OC activity toward coupling. To further understand mature OC 
response to TGFβ we performed single cell RNA-seq of vehicle or TGFβ tx OCs (Fludig-
mC1). Using the Seurat toolkit, we identified two mature OC clusters (Acp5, Ctsk, Csf1r, 
Itgb3, Oscar, Tnfrsf11a), one being vehicle and the other TGFβ tx. Differential analysis of 
these clusters confirmed TGFβ qPCR data. Interestingly, whereas vehicle tx OCs exhibited 
increased lysosomal pathways and elevated Clcn7, Car2, Mmp9 expression, TGFβ tx OCs 
skewed towards phagosome and focal adhesion pathways, and increased Atp6v1g1, At-
p6v1b2, and Atp6v0e expression, suggesting potentially altered resorption mechanics. This 
is in line with previous reports of pit- vs trench-forming OCs. Thus, our current working 
hypothesis is that the immune microenvironment, including bone-derived TGFβ, regulates 
OC resorptive, inflammatory, and coupling behaviors.
Disclosures: Margaret Durdan, None
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Comparative Evaluation of 99mTc-WBC SPECT/CT and MR Imaging for 
Diagnosis of Osteomyelitis in Subjects with Diabetes and Foot Infection 
*Orhan K. Öz1, Amber Sherwood1, Katie Rubitschung1, Javier La Fontaine2, Uma 
Thakur1, Nathan Dettori1, Avneesh Chhabra1, Larry Lavery2. 1UT Southwestern 
Medical Center Department of Radiology, United States, 2UT Southwestern 
Medical Center Department of Plastic Surgery, United States
Osteomyelitis is a common complication in diabetic foot ulcers. Accurate diagnosis 
of diabetic foot osteomyelitis (DFO) is key to proper treatment and avoiding amputations. 
The best imaging approach in DFO diagnosis is an area of active investigation. Using bone 
biopsy as the diagnostic gold standard, we compare the sensitivity and specificity of radiola-
beled white blood cell imaging combined with CT (99mTc-WBC SPECT/CT) to MRI for the 
evaluation of DFO.Subjects with diabetes and foot ulcerations presenting to the Emergency 
Room of a large tertiary care facility were examined by the podiatry service. Those with 
suspected osteomyelitis were offered participation in an IRB approved protocol compar-
ing 99mTc-WBC SPECT/CT and MR imaging with and without contrast in the diagnosis 
of DFO. Bone biopsy was used as a reference standard. Forty-eight subjects consented to 
participate in the study. A total of 41 subjects completed all imaging and underwent biopsy. 
Nineteen subjects who were positive for DFO on biopsy also returned for follow up im-
aging and biopsy six weeks after initial treatment. In all cases WBC scans and MRI were 
performed within 24h of each other and prior to bone biopsy. MR scans were independently 
interpreted by two readers, a fellow and a fellowship trained musculoskeletal (MSK) ra-
diologist. In the two instances of disagreement, a third reader fellowship trained in MSK 
radiology adjudicated. The WBC SPECT/CT scans were read by a radiologist with more 
than 20 years experience in Nuclear Medicine. All readers were blinded to biopsy results. 
Pathology was performed in the hospital laboratory and interpreted by pathologist with ex-
perience in MSK infections. MRI, SPECT/CT, and pathology interpretations were coded as 
either positive or negative for osteomyelitis. Sensitivity, specificity, and predictive values 
were calculated in GraphPad Prism Version 8.0.Imaging in the diagnosis of DFO revealed 
the sensitivity and specificity of MRI was 87.9% and 31.8%, respectively (n=45), with a 
57.14% positive predictive value (PPV). The negative predictive value (NPV) of MRI was 
higher at 70.0%. 99mTc-WBC SPECT/CT performance was better overall with 90.9% sen-
sitivity, 73.7% specificity, 80.0% PPV, and 87.5% NPV (n=41).Using bone biopsy results 
as the reference standard, radiolabeled 99mTc-WBC SPECT/CT demonstrates both greater 
sensitivity and specificity for DFO when compared to MRI.
Disclosures: Orhan K. Öz, None
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Investigation of the Molecular Mechanism of TNF-α-Induced RANK on 
Osteoclast Precursors in Orthodontic Tooth Movement *Takahiro Noguchi1, 
Hideki Kitaura1, Saika Ogawa1, Fumitoshi Ohori1, Aseel Marahleh1, Yasuhiko 
Nara1, Adya Pramusita1, Ria Kinjo1, Itaru Mizoguchi1. 1Division of Orthodontics 
and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 
Japan
Osteoclasts are required for bone resorption and remodeling. Two cytokines, M-CSF 
and RANKL, are important for osteoclast formation. TNF-α has also been recognized as 
an important factor for osteoclastogenesis. It has also been reported that TNF-α plays an 
important role in osteoclastogenesis and bone resorption during orthodontic tooth movement 
(OTM). RANK is known as the receptor for RANKL. RANK is expressed in osteoclast 
precursors and osteoclasts. It has been reported that TNF-α enhances expression of RANK 
on osteoclast precursors in vitro. However, the effect of TNF-α on RANK expression in 
vivo and the role of TNF-α on RANK expression during OTM are still unclear. In this study, 
we investigated the effect of TNF-α on RANK expression in vitro, in vivo and in OTM. 
Furthermore, we investigated molecular mechanism of TNF-α-induced RANK in osteoclast 
precursors. For in vitro experiments, RANK expression was enhanced on TNF-α treated os-
teoclast precursors. NF-κB and MAPKs inhibitors significantly decreased RANK expression 
by TNF-α. Furthermore, TNF-α priming stimulates RANKL-induced osteoclast formation 
in vitro. For in vivo experiments, TNF-α was injected into mice calvariae by daily subcu-
taneous injection for 5 days. After sacrifice, RANK expression was evaluated by real-time 
PCR and immunohistochemistry. The results showed that RANK mRNA expression and the 
number of RANK-positive cells in TNF-α-injected mice are higher than PBS-injected mice. 
For OTM, a Ni-Ti closed-coil spring was fixed between the upper incisors and upper-left first 
molar to move the first molar to the mesial direction in wild-type (WT) mice and TNFR1/
TNFR2-deficient (TNFRsKO) mice to analyze the effect of TNF-α on RANK expression. 
After OTM, the number of RANK-positive cells at the compression side was evaluated by 
immunohistochemistry. RANK-positive cells increased at the compression side of the alveo-
lar bone in WT mice as a function of time by mechanical loading. In addition, the number of 
RANK-positive cells at the compression side in WT mice was significantly higher than that 
in TNFRsKO mice after OTM. These results suggest that TNF-α induced RANK expression 
in osteoclast precursors by the activation of NF-κB and MAPKs, and the enhanced expres-
sion of RANK by TNF-α might increase RANKL-induced osteoclastogenesis. Furthermore, 
TNF-α induced RANK expression at the compression side of OTM. It might enhance osteo-
clast formation at the compression side during OTM.
Disclosures: Takahiro Noguchi, None
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Possible Involvement of Elastase in Enhanced Osteoclast Differentiation 
by Neutrophils Through Degradation of Osteoprotegerin *Risa Sugisaki1, 
Yoichi Miyamoto2, Daichi Chikazu1, Ryutaro Kamijo2. 1Department of Oral 
and Maxillofacial Surgery, Tokyo Medical University, Japan, 2Department of 
Biochemistry, Showa University School of Dentistry, Japan
[Purpose] Periodontitis and rheumatoid arthritis are chronic inflammatory diseases ac-
companied by bone resorption by osteoclasts (OC). Neutrophils are one of the most abun-
dant leukocytes in the sites of lesion of inflammatory diseases such as periodontitis and 
rheumatoid arthritis. Besides the roles of reactive oxygens and proteases including elastase 
in antimicrobial activity of neutrophils, the role of these agents derived from neutrophils 
in inflammatory bone resorption has not been fully investigated. On the other hand, we 
previously reported that Kgp, a cysteine protease produced by Porphyromonas gingivalis, 
enhanced OC differentiation through degradation of osteoprotegerin (OPG), a decoy recep-
tor for nuclear factor κB (RANK) ligand (RANKL), expressed by osteoblasts. The purpose 
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of this study is to clarify the role of neutrophil elastase in OC differentiation. [Methods] We 
examined the effects of neutrophils and recombinant neutrophil elastase on osteoclast dif-
ferentiation in co-cultures of mouse calvarial osteoblasts and bone marrow cells in the pres-
ence and absence of the inhibitors of elastase. We also evaluated the degradation of human 
recombinant OPG by neutrophils isolated from human peripheral blood and recombinant 
human elastase by western blotting using an anti-OPG antibody. The primary cleavage site 
of OPG cleaved by neutrophil elastase was determined by N-terminal amino acid sequence 
analysis of the fragment. [Results] We found that human neutrophils enhanced osteoclast 
differentiation, which was significantly suppressed by elastatinal, an inhibitor of neutrophil 
elastase. Also, we found that human neutrophils degraded human recombinant osteoprote-
gerin (OPG), which was suppressed by human α1-protease inhibitor, the major endogenous 
inhibitor of neutrophil elastase. Recombinant human neutrophil elastase degraded human 
OPG in its death domain-like region. [Conclusions] These results indicated that the degrada-
tion of OPG by elastase contributed at least in part to the enhanced osteoclast differentiation 
by neutrophils. There is a possibility that neutrophils play an important role in inflammatory 
bone loss found in rheumatoid arthritis and periodontitis.
Disclosures: Risa Sugisaki, None
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Investigation of Effect of IL-33 on TNF-α-Induced Osteoclast Formation 
and Orthodontic Tooth Movement *Fumitoshi Ohori1, Hideki Kitaura1, Saika 
Ogawa1, Takahiro Noguchi1, Aseel Marahleh1, Yasuhiko Nara1, Adya Pramusita1, 
Ria Kinjo1, Itaru Mizoguchi1. 1Division of Orthodontics and Dentofacial 
Orthopedics, Tohoku University Graduate School of Dentistry, Japan
Interleukin (IL)-33 is a member of the IL-1 family, which acts as an alarmin. IL-33 is 
likely to inhibit osteoclast formation and bone resorption. Tumor necrosis factor-α (TNF-α) 
can promote osteoclast formation by directly stimulating the osteoclast precursors. It has 
been reported that TNF-α plays an important role in orthodontic tooth movement (OTM). 
However, there has been no detailed report regarding the effect of IL-33 on TNF-α-induced 
osteoclast formation and OTM. There are two objectives in this study. The first is to inves-
tigate the role of IL-33 on TNF-α-induced osteoclast formation and bone resorption. The 
second is to examine the effect of IL-33 during OTM. For in vitro analyses, osteoclast pre-
cursors, which were derived from bone marrow cells of eight-week-old male C57BL/6J 
mice, were treated with or without IL-33 in the presence of TNF-α. Tartrate-resistant acid 
phosphatase (TRAP) staining was performed to assess osteoclast formation. To investigate 
the molecular mechanism of osteoclast formation, we performed immunoblotting and im-
munofluorescence on osteoclast precursors. For in vivo analyses of mouse calvariae, TNF-α 
with or without IL-33 was subcutaneously administrated into the supracalvarial region of 
eight-week-old male C57BL/6J mice daily for 5 days (n = 4). Histological sections were 
stained for TRAP, and osteoclast numbers were determined. Using micro-CT reconstruction 
images, the ratio of bone destruction area on the calvariae was evaluated. As an OTM model, 
a Ni-Ti closed-coil spring connecting the anterior alveolar bone and upper-left first molar 
was fixed to move the first molar to the mesial direction for 12 days in eight-week-old male 
C57BL/6J mice (n = 4). IL-33 or PBS were injected on the buccal side of upper-left first 
molar at 2-day intervals. The number of osteoclasts induced by TNF-α was significantly de-
creased with IL-33. Bone resorption was also reduced. IL-33 inhibited IκB phosphorylation 
and NF-κB nuclear translocation. OTM distance was smaller in the IL-33 group than in the 
PBS group. These results suggest that IL-33 inhibited TNF-α-induced osteoclast formation 
and bone resorption. In addition, the result of OTM indicates that IL-33 inhibited tooth 
movement.
Disclosures: Fumitoshi Ohori, None
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Reprogramming Metabolism in Osteolineage and Osteoblasts by 
Inflammatory and Pro-resolution Cytokines *Rajeev Aurora1, Di Wu1, Anna 
Cline-Smith1, Elena Shashkova 1. 1Saint Louis University School of Medicine, 
United States
Studies by Albright and Reifenstein (1946) showed that estrogen (E2) loss initiates a 
rapid phase of bone loss leading to osteoporosis in half of postmenopausal women, but the 
mechanism is not fully understood. Recently we described a new pathway by which ovariec-
tomy (OVX) produced E2 loss leads to chronic low-grade production of the proinflammato-
ry cytokines: TNFα and IL-17 by memory T-cells in a IL-7 and IL-15 dependent mechanism 
(Cline-Smith, 2020). Our results provided a piece of the puzzle that has remained unsolved 
for 75 years: how does E2 loss lead to osteoporosis? Bone homeostasis is maintained by 
coupled bone resorption by osteoclasts followed by formation of new bone by osteoblasts. 
We showed previously that TNFα and IL-17 are needed to elicit uncoupled bone resorption 
observed in postmenopausal women and in OVX mice. The effect of TNFα and IL-17A 
on osteoclastogenesis is well studied. While the bone formation and mineralization rates 
increase during the acute phase, postmenopause and post-OVX, how the osteoblasts are 
restrained from matching bone resorption is not well understood. We will present results 
that show that TNFα and IL-17A restrain osteolineage differentiation pathway but increase 
osteoblast activity. Interestingly, in both instances the proinflammatory cytokines reprogram 
the cellular metabolism through differential regulation of the two mTOR complexes. These 
data provide new insights into how E2 loss restrains bone formation allowing for uncoupling 
between osteoblasts and osteoclast activity.  Our laboratory has also shown that induction of 
regulatory CD8 T-cells (TcREG) by pulsed low-dose RANKL (pRANKL) is bone anabolic. 
Interestingly, TcREG suppress osteoclasts and therefore lead to uncoupled bone formation. 
We will present data that shows that pRANKL treatment of OVX IL-10-/- mice did not 
increase bone formation and mineral apposition rates. We will also show that IL-10 repro-
grams metabolism of MSC and mature OB through regulation of mTOR complexes. Togeth-
er these data provide a fascinating view of how inflammation and resolution of inflammation 
regulates osteogenesis. 
Disclosures: Rajeev Aurora, None
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Associations between household income and proinflammatory cytokines 
related to bone early in the life-course: A Systematic Review *Stefanie Bird1, 
Jason Talevski1, Jack Feehan2, Ghazala Naureen1, Joanne May Ling Tay3, Priya 
Goyal3, Morgan Scott Berman3, Gustavo Duque1, Rachel L Duckham4, Sharon L 
Brennan-Olsen5. 1Australian Institute of Musculoskeletal Science & University 
of Melbourne, Australia, 2Australian Institute of Musculoskeletal Science & 
Victoria University, Australia, 3University of Melbourne, Australia, 4Australian 
Institute of Musculoskeletal Science & Deakin University, Australia, 5Australian 
Institute of Musculoskeletal Science & University of Melbourne & Deakin 
University, Australia
The life-course association between socioeconomic inequalities and bone health is be-
coming well-documented. Yet, little is known about the impact of socioeconomic factors on 
bone-related proinflammatory cytokines in the years before the achievement of peak bone 
mass. We aimed to systematically identify and synthesise existing data to investigate the 
relationship between household income, an important parameter of socioeconomic status 
(SES) known to influence child health, and bone-related pro-inflammatory cytokines during 
the years prior to peak bone mass attainment (ages 6 to 30 years).We applied a defined 
e-search strategy to PubMed, Ovid (Medline), EMBASE, PsycINFO and CINAHL data-
bases, with no set limits of publication date. All full-text peer-reviewed articles written in 
English that encompassed household income data and levels of proinflammatory cytokines 
associated with bone accrual (C-reactive protein [CRP], interleukin-6 [IL-6], and tumour ne-
crosis factor-alpha [TFN-α]) were screened for eligibility; epidemiological cross-sectional, 
case-control, and/or cohort studies in children and young adults aged 6-30 years, and base-
line data from randomised control trials, where relevant, were included. The Lievense et al.1 
scoring system was used to determine the level of evidence.In total, 14 studies met the inclu-
sion criteria; 4 cohort studies (from USA and Australia) and 10 cross-sectional studies (from 
USA, Puerto Rico and Canada). These studies included a total of 52,586 participants (~54% 
female). We found limited evidence for an association between low household income and 
higher levels of IL-6. However, moderate-strong evidence was observed regarding a lack of 
association between TFN- and CRP, respectively.This review suggests that an association 
may exist between low household income with increased levels of IL-6, although based on 
a paucity of data. Future analyses should investigate associations between other parameters 
of SES and proinflammatory cytokines, given the importance of early life influences on later 
life bone health.[1] Lievense A, Bierma-Zeinstra SMA, Vergahen AP, van Baar ME, Verhaar 
JAN, Koes BW (2002) Influence of obesity on the development of osteoarthritis of the hip: 
a systematic review. Rheumatol 41:1155–1162
Disclosures: Stefanie Bird, None
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The Phosphate Hypothesis: ACE2 Stabilizes Anti-polar Phenotypes of 
COVID 19 *Robert S Fredericks1. 1Endocrine-Associates, United States
    COVID 19 exposes discordance between conventional expectations and the reality 
of nature, necessitating strategies to discover transformative principles that coherently or-
ganize the data.  Engaging tactics to kill the SARS-CoV-2 virus while ignoring metabolic 
complexity of the host leaves us vulnerable to unanticipated health and economic conse-
quences.  ACE2, the viral conduit to intracellular replication, is also disrupted as a met-
abolic signal deserving of attention.    Models demonstrating a capacity to differentially 
activate innate and acquired immunity have been developed during investigation of the role 
of phosphate in manifestations of Chronic Fatigue Syndrome (CFS) that can incorporate 
ACE2 disruption as a generator of divergent phenotypes.  It is proposed that COVID 19 
pandemic severity requires both victims of cytokine storm manifesting ARDS and recurrent 
asymptomatic spreaders, plausibly mediated by enhanced innate viral killing, both stem-
ming from compromised ACE2,    Previous work demonstrated that mutations in the HFE 
gene, when homozygous responsible for hemochromatosis, are associated with divergent 
metabolic phenotypes similar to those proposed for COVID 19.  Additional validation of 
the models includes demonstrations that Grave’s disease remits with paricalcitol, Bechet’s 
improves with doxercalciferol and that severe metabolic syndrome can respond to etidro-
nate.  Recognition of heat as a fundamental metabolic signal integrating phosphate, sodium 
and calcium with FGF23/aKlotho/PTH/PTHrP signaling clarifies CFS findings relating to 
innate and acquired immunity.    Central to the phosphate hypothesis is the principle of 
anti-polarity where an initial signal produces divergent outcomes due to each individual’s 
complex signaling structure.  Mitigation of the COVID 19 pandemic appears to require 
appropriate choice of differing interventions for the victims versus asymptomatic spreaders 
with ACE2 disruption contributing to both phenotypes.    ACE2 disruption appears to negate 
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fatigue responses that could otherwise ameliorate pandemic manifestations of SARS-CoV-2 
infection.  Interventions, including SGLT2 inhibitors, vitamin D analogues, RAAS modifiers 
and renal protective agents are proposed as favorable to metabolic integrity and vaccine 
efficacy.  Recognizing the kidney as a reporter organ and the skeleton as an expression of 
systemic metabolic organization facilitates needed exploration for modeling personalized 
predispositions.
Disclosures: Robert S Fredericks, None
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Bone marrow adipogenic lineage precursors (MALPs) promote 
osteoclastogenesis in bone remodeling and pathologic bone loss *Wei Yu1, 
Leilei Zhong1, Lutian Yao1, Yulong Wei1, Tao Gui1, Ziqing Li2, Hyunsoo Kim3, 
Nathaniel Dyment1, Xiaowei Liu1, Shuying Yang4, Yongwon Choi3, Jaimo Ahn1, 
Ling Qin1. 1Department of Orthopaedic Surgery, Perelman School of Medicine, 
University of Pennsylvania, United States, 2University of Pennsylvania, United 
States, 3Department of Pathology and Laboratory Medicine, Perelman School of 
Medicine, University of Pennsylvania, United States, 4Department of Basic & 
Translational Sciences, School of Dental Medicine, University of Pennsylvania, 
Philadelphia, United States
Bone resorption by osteoclasts is a critical step in bone remodeling. It is well known 
that osteogenic cells support osteoclastogenesis via synthesizing RANKL. Recently, we 
identified a novel mesenchymal subpopulation, marrow adipogenic lineage precursors 
(MALPs), which highly expresses adipogenic markers but has no lipid accumulation, and 
demonstrated their functions in regulating marrow vessels and bone formation. In this study, 
using a single cell RNA-sequencing (scRNA-seq) dataset containing 17,494 mouse bone 
marrow mesenchymal and hematopoietic cells, we computational delineated the in vivo 
differentiation route of osteoclasts from MΦα cells, an intermediate macrophage cell type 
that also gives rise to terminally differentiated MΦβ cells. Surprisingly, ligand-receptor pair 
analysis suggested that MALPs, but not osteoblasts nor osteocytes, have the most signal 
interactions with macrophage lineage cells due to their high expression of osteoclast reg-
ulatory factors, including RANKL. Lineage tracing revealed that Adipoq-Cre only labels 
MALPs and their descendant lipid-laden adipocytes (LiLAs, which are hundred times less 
than MALPs in bone marrow) but not mesenchymal progenitors, osteoblasts, and osteocytes. 
Interestingly, nearly all osteoclasts in bone were touched by MALP cell processes. Thus, we 
constructed Adipoq-Cre Tnfsf11 flox/flox (RANKL CKOAdipoq) mice to study the role of 
RANKL from MALPs. These mice in both genders displayed a drastic increase of trabecular 
bone mass (BV/TV) in long bones (61%) and vertebrae (33%) starting from 1 mo of age 
but their growth plate and cortical bone were normal (n=6/group). At 3 mo of age, they dis-
played a more striking increase of BV/TV (1.7-fold, n=6/group). In comparison, osteoblasts/
osteocytes-specific RANKL knockdown using Dmp1-Cre merely increased tibial BV/TV 
by 18% (n=6/group, 1 mo of age). RANKL CKOAdipoq mice showed reduced osteoclast 
number (65%), osteoblast number (52%), and bone formation rate (58%) at trabecular bone 
surface (n=6/mice). MALPs also exist in calvarial bone marrow. Osteolytic lesion in calvaria 
induced by LPS injection was completely abolished in RANKL CKOAdipoq mice due to 
diminished osteoclast activation (n=6/group). In ovariectomized mice, elevated bone resorp-
tion in vertebrates was also partially attenuated in these mice (n=6/group). In summary, our 
studies identified MALPs as a critical player in controlling bone remodeling during normal 
bone metabolism and pathological bone loss.
Disclosures: Wei Yu, None
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MarrowQuant across Aging and Aplasia: A Digital Pathology Tool for 
Quantification of Bone Marrow Compartments in Histological Sections 
*Josefine Tratwal1, Ibrahim Bekri1, Chiheb Boussema1, Nicolas Kunz2, Rita 
Sarkis1, Tereza Koliqi1, Shanti Rojas-Sutterlin1, Frédérica Schyrr1, Daniel 
Naveed Tavakol1, Vasco Campos1, Erica L. Scheller3, Rossella Sarro4, Carmen 
Barcena5, Bettina Bisig6, Valentina Nardi7, Laurence de Leval4, Olivier 
Burri8, Olaia Naveiras9. 1Laboratory of Regenerative Hematopoiesis, Institute 
of Bioengineering and Institute for Experimental Cancer Research, Ecole 
polytechnique fédérale de Lausanne (EPFL), Switzerland, 2Animal Imaging 
and Technology Core, Center for Biomedical Imaging, Ecole polytechnique 
fédérale de Lausanne (EPFL), Switzerland, 3Division of Bone and Mineral 
Diseases, Department of Internal Medicine, Washington, United States, 
4Institute of Pathology, Lausanne University Hospital (CHUV) and Lausanne 
University (UNIL), Switzerland, 5Department of Pathology, University Hospital 
12 de Octubre, Spain, 6Institute of Pathology, Lausanne University Hospital 
(CHUV) and Lausanne University (UNIL), Switzerland, 7Department of 
Pathology, Massachusetts General Hospital, Harvard Medical School, United 
States, 8Bioimaging and Optics Core Facility, Ecole polytechnique fédérale de 
Lausanne (EPFL), Switzerland, 9Laboratory of Regenerative Hematopoiesis, 
Institute of Bioengineering and Institute for Experimental Cancer Research, 
Ecole polytechnique fédérale de Lausanne (EPFL) and Department of Oncology, 
Hematology Service, Lausanne University Hospital (CHUV), Switzerland
The bone marrow (BM) exists heterogeneously as hematopoietic/red or adipocytic/
yellow varying with skeletal location, age, and physiological condition. Mouse models and 
patients undergoing radio/chemotherapy or suffering acute BM failure, endure a rapid adi-
pocytic conversion of the BM (red-to-yellow transition). Following hematopoietic recovery, 
such as upon BM transplantation, functional hematopoiesis is restored (yellow-to-red transi-
tion). These changes as evaluated on histological sections of trephine biopsies are a diagnos-
tic feature of hematopoietic failure.Here we report the development of a semi-automated im-
age analysis plug-in, MarrowQuant operating through an open-source software (QuPath), to 
systematically quantify multiple bone components in hematoxylin and eosin stained sections 
in an unbiased manner. MarrowQuant reproducibly analyses the areas occupied by bone, 
hematopoietic cells, the interstitial/microvascular compartment, as well as adipocyte ghosts 
and their size distribution. BM hematopoietic cellularity analysis with MarrowQuant lies 
within the range of scoring by independent pathologists as the gold standard. Quantifica-
tion of total BM adipocyte area in murine whole bone sections compares with volumetric 
measurements of osmium-tetroxide stained lipids by micro-computerized tomography. Due 
to user-dependent variables, reproducibility in longitudinal studies is a challenge, and Mar-
rowQuant thus offers a complementary standardized approach.With our tool, we were able 
to develop a consistent map of BM hematopoietic cellularity and adiposity in mid-sections 
of murine bones in homeostatic conditions, including quantification of the highly predict-
able red-to-yellow transitions in the proximal caudal vertebrae and in the tibia. We present 
a comparative skeletal map induced by lethal irradiation, with longitudinal quantification 
of the red-to-yellow-to-red transition over two months in femurs and tibiae. Following BM 
transplantation, BM adiposity inversely correlates with kinetics of hematopoietic recovery 
conserving a proximal-to-distal gradient. Analysis of recovery in vivo with magnetic reso-
nance imaging reveals comparable kinetics. Applying MarrowQuant to acute myeloid leu-
kemic biopsies at different timepoints of treatment, confirms the plasticity of the human BM 
and a reciprocal relationship between the hematopoietic and adipocytic BM compartments. 
This opens avenues for its application in contexts requiring standardized BM evaluation.
Disclosures: Josefine Tratwal, None
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Senolytics improve the in vivo bone remodeling potential of bone marrow 
mesenchymal stem cells obtained from aged mice *Yueying Zhou1, Xiaonan 
Xin1, Li Chen2, Lichao Wang1, Ming Xu2, David Rowe2. 1UConn Health, United 
States, 2UCONN Health, United States
The in vitro osteogenic potential of bone marrow mesenchymal stem cells (BMSCs) 
declines with aging. To explore this observation, BMSCs from 27-month-old C57BL/6 male 
mice were isolated and cultured in a 6 well plate for 7 days reaching 80% confluency. Four 
wells received a senolytic cocktail (0.2µM dasatinib+20µM quercetin; D+Q) and 2 wells 
vehicle (V) for 24 hours.  One day later, the cell confluency of the D+Q treated wells fell to 
50%, but recovered to 80% after 2 additional days of culture.  The treated and control wells, 
as well as BMSCs from young donors (Y), were harvested and 5 x 105cells/defect absorbed 
into a Healos scaffold and implanted into a calvarial defect of NSG mice that also carried a 
Col3.6GFPtpz reporter. Calvarial were harvested at 6 weeks after a single i.p. injection of 
alizarine complexone (AC) 1 day prior to sacrifice. Calvarial defects were fixed in formalin, 
x-rayed and processed for cryohistology. The planar area of new bone formation relative 
to the defect size was assessed by ImageJ (Fig. A: Y = 0.88+/-0.05, V = 0.51+/-0.06 while 
D+Q = 0.82+/-0.05, p<0.001).  The transverse histological sections revealed the mineralized 
cortical shell surrounding a bone marrow space and the adjacent membraneous bone of the 
host.  Relative to the Y and D+Q treated aged cells, the V cells had wide cortices and a 
small marrow space (Fig B: marrow area/total area: Y = 0.48+/-0.05; V=0.22+/-0.03; DQ= 
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0.46+/-0.03, p<0.0001). Although AP and AC positive surfaces were similar on all samples, 
the V-treated cells had fewer TRAP positive cells on the endocortical surface and outer corti-
cal shell, and more unresorbed Healos-derived hydroxyapaptite within the cortical bone.  In 
addition, the osteoblasts expressing the Col3.6GFPtpz reporter were abundant on the endo-
cortical surfaces of the V-treated cells but rarely found in the D+Q or young donor samples. 
This histological study suggests that the D+Q treatment improves overall osteogenesis by 
enhanced bone remodeling of the woven bone that is initially deposited within the calvarial 
defect model to form a cortical shell and the environment necessary for intramarrow hema-
topoiesis. It accomplishes this outcome with little contribution from the host osteoblasts. 
The study reveals properties of osteogenesis that are not evident in primary in vitro BMSC 
cultures and provides a model for simultaneously evaluating the cellular basis for the in 
vitro and in vivo effects of senolytic agents on the aged osteogenic lineage.
Disclosures: Yueying Zhou, None
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Oxylipins Mediate Radiation-induced Marrow Adipose Tissue Expansion 
*Jason A Horton1, Aaron Maymin2, James Boyer2. 1Upstate Medical University, 
United States, 2Upstate Medical University, Dept. Orthopedic Surgery, United 
States
INTRODUCTION: Marrow adipose tissue (MAT) expansion following radiation ex-
posure may be implicated in radiation-induced bone disease. We hypothesized that radi-
ation-induced lipid oxidation could be a key factor driving marrow adipose expansion by 
activating P-PARγ which is endogenously activated by oxidized lipids. METHODS: With 
IACUC consent, bilateral hind limbs of 12-week old female c57BL/6J mice received four 
daily 5Gy fractions of 225kVp x-radiation; sham-irradiated mice served as controls. Tissues 
were harvested at 1, 3, 7 and 14 days after the final radiation exposure(n=10/group). Femurs 
were fixed and prepared for μCT-based morphometry and OsO4 enhanced imaging of MAT. 
The left tibia was homogenized in saline with 0.05% BHT, and lipids purified in C18 col-
umns for measurement of neutral lipids, PUFAs, total lipid peroxidation (Cell Biolabs), or 
quantitative oxylipin analysis by LC-MS/MS. RNA was extracted from the right tibia to as-
sess adipogenesis related gene expression (Adipogenesis PCR arrays, Qiagen). Differences 
between sham and irradiated mice were accepted as statistically significant when p<=0.05 
by ANOVA.RESULTS: Bone morphometry (table 1) showed increased trabecular bone at 
1 and 3 days post-irradiation (p<=0.0215) and gradual increase of diaphyseal cortical bone 
density (p<0.0001). MAT expansion (Ad.V/TV) was rapid, achieving significance by day 3 
(p<=0.0004); Neutral lipid content was significantly increased by days 7 and 14 (p<0.01). 
While total lipid peroxides and PUFA were reduced at 1, 3 and 7 days (p<=0.0101), several 
oxidized lipid species including P-PARγ agonist 9-HODE were increased (p<0.05) vs. con-
trols at all time points. Reactome pathway analysis revealed two dominant themes of upregu-
lated gene expression 1,3, and 7 days post irradiation, centering P-PARγ-mediated regulation 
of white adipocyte differentiation, and DNA damage signaling mediated by p53, p21 and 
FOXO1. In contrast pro-adipogenic Wnt signaling pathways, were downregulated by day 
14. DISCUSSION: This experiment identified 9-HODE as mediator of radiation-induced 
MAT expansion, likely acting via P-PARγ. Our gene expression studies suggest that MAT 
expansion may also involve p53-dependent and/or FOXO1-dependent transcription of the 
p21, known to be necessary for adipogenesis and prohibitive of osteoblastic differentiation.
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(JAH)
Disclosures: Jason A Horton, None
P-151
Differential bone effects with lipoxinA4: steady state vs. wound healing *Koh 
Amy1, Ann Decker1, Justin Do1, Hernan Roca1, Laurie McCauley1. 1University of 
Michigan, United States
LipoxinA4 (LXA4), an eicosanoid lipid mediator derivative metabolized from arachi-
donic acid, is one of the most abundant lipoxin specialized pro-resolving mediators. LXA4 
binding to its G protein coupled receptor promotes inflammation resolution and wound heal-
ing in concert with macrophages. Bone marrow F4/80+ macrophages are known to facilitate 
anabolic actions of parathyroid hormone (PTH) and PTH increases bone marrow lipoxins. 
Studies of LXA4 in bone report direct inhibitory actions on osteoclasts and enhanced mac-
rophage efferocytosis in vitro. This study investigated LXA4 effects on bone in steady state 
(growth and adult) and wound healing (tooth extraction) scenarios. C57Bl/6 male mice 
(12wk) were anesthetized and the first maxillary molar extracted. LXA4 (10ng/g) or vehicle 
(V) was administered daily for 14d. Using a growth model, pups (4d) were given daily 
LXA4 for 17d. Using an adult model, 16wk mice were given 5d of daily LXA4, then 3x/wk 
for 6wks. Bone turnover markers TRAcP5b and P1NP were determined in serum and µCT 
analyses performed of tibiae and socket bone fill. Vertebral TRAP+ osteoclast (OC) num-
bers were determined. In vitro, LXA4 effects on mCSF+RANKL induced osteoclastogenesis 
in primary bone marrow cultures was determined. After 14d of LXA4, µCT analyses re-
vealed significantly increased bone volume/total volume (BV/TV: 0.25+/-0.03 V vs 0.38+/-
0.04 LXA4) within the distal socket. There was a significant decrease in trabecular (Tb) 
number (20.6+/-0.5 V vs 18.9+/-0.2 LXA4) and increases in Tb thickness (0.044+/-0.001 
V vs 0.050+/-0.022 LXA4) and BMD (183+/-25 V vs 268+/-24 LXA4) with no change 
in Tb spacing. Tibial µCT revealed no differences in BV/TV and no differences in serum 
TRAcP5b, an indicator of OC numbers, and serum P1NP, an indicator of bone formation. 
There were no LXA4 BV/TV differences found in adult mice. In contrast, the growth mod-
el µCT revealed significantly increased BV/TV (0.21+/-0.02 V vs 0.28+/-0.02 LXA4), Tb 
number (5.96+/-0.22 V vs 7.15+/-0.34 LXA4) and BMD (124.3+/-6.6 V vs 155.18+/-9.99 
LXA4) and a trend of increased Tb thickness and decreased Tb spacing. Serum TRAcP5b 
was decreased (13.12+/-1.49 V vs 9.71+/-0.88 LXA4; p=0.07) while P1NP was unchanged. 
TRAP staining in vertebrae revealed no differences, yet OC numbers in vitro decreased 
with LXA4. These data reveal the pro-resolving mediator, LXA4, increased bone growth 
favorably in rapid growth and wound healing scenarios which may be partly attributed to an 
inhibition of bone resorption.
Disclosures: Koh Amy, None
P-152
The Influence of Interleukin-1 Receptor Antagonism and Bone Marrow 
Ablation on Vasodilator Capacity, Bone Marrow Blood Vessel Ossification, 
and Bone Microarchitecture in Old Fischer-344 Rats *Sunggi Noh1, Ryan 
Pohlig2, Rhonda Prisby1. 1The University of Texas at Arlington, United States, 
2The University of Delaware, United States
BACKGROUND: A pro-inflammatory marrow microenvironment reduces vasodilator 
capacity of bone blood vessels and increases bone marrow blood vessel (BMBV) ossifica-
tion. We theorized that bone marrow ablation and administration of an interleukin-1 receptor 
antagonist would eliminate the pro-inflammatory marrow microenvironment and reduce 
BMBV ossification.Thus, we assessed vasodilator capacity of the femoral principal nutrient 
artery (PNA), ossified BMBV, and bone microarchitecture in old rats. METHODS: Male 
Fischer-344 rats (24-mon) were assigned accordingly: Control (CON, n=15), interleukin-1 
receptor antagonism (IL-1RA, n=13), bone marrow ablation (BMA, n=13) and combined 
treatment (IL-1RA+BMA, n=11). Rats underwent surgery to create a defect in the right 
femoral shaft. The bone marrow of the BMA and IL-1RA+BMA groups was flushed with 
PBS. During 3 weeks of recovery, CON and BMA received injections of PBS (100 μl, 3 d/
wk, i.p.), while IL-1RA and IL-1RA+BMA received the antagonist (3 μg/kg, 3 d/wk, i.p.). 
At sacrifice, endothelium-dependent (ACh; 10-9-10-4 M) and independent (DEA NONOate; 
10-10-10-4 M) vasodilation in the absence and presence of marrow was assessed. MicroCT 
(μCT) was used to determine ossified vessel volume (OsVV, %) and thickness (OsV.Th, 
mm). Bone microarchitecture (i.e. BV/TV, %; Tb.N, /mm; Tb.Th, mm Tb.Sp, mm and Ct.Th, 
mm) and bone density (mg HA/ccm) were assessed via μCT. Mixed Models and ANOVAs 
were used. RESULTS: In the presence of marrow, endothelium-dependent vasodilation was 
reduced (p<0.05) in IL-1RA and BMA vs. the other groups. For endothelium-independent 
vasodilation, it was diminished (p<0.05) in the presence vs. the absence of marrow. OsVV 
and OsV.Th did not differ. Trabecular BV/TV, Tb.N and Tb.Sp did not differ among groups; 
however, Tb.Th was higher (p<0.05) in BMA (90+/-3 mm) vs. CON (79+/-2 mm). Trabec-
ular density was highest (p<0.05) in IL-1RA+BMA (1136+/-7 mg HA/ccm) vs. the other 
groups and IL-1RA (1073+/-26 mg HA/ccm) was higher (p<0.05) vs. CON (994+/-4 mg 
HA/ccm) and BMA (1022+/-7 mg HA/ccm). Ct.Th did not differ, and cortical density was 
higher (p<0.05) in IL-1RA+BMA (1325+/-3 mg HA/ccm) vs. BMA (1304+/-4 mg HA/ccm). 
CONCLUSION: The marrow microenvironment reduced endothelium-independent vasodi-
lation. Although BMBV ossification was not altered, combined treatment (i.e., IL-1RA+B-
MA) augmented bone density.
Disclosures: Sunggi Noh, None
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GNAS product XLαs, but not Gsα, exhibits variable allele-specific expression 
in bone marrow stromal samples: “next-generation” sequencing (NGS) to 
determine parental contribution. *Qiuxia Cui1, Claire Elizabeth Remillard2, 
Antonius Plagge3, Mina Gardezi4, Margret Dunlap4, Louis C Gerstenfeld4, Qing 
He5, Murat Bastepe2. 1Endocrine Unit, Department of Medicine, Massachusetts 
General Hospital and Harvard Medical School; Zhongnan Hospital, Wuhan 
University, United States, 2Endocrine Unit, Department of Medicine, 
Massachusetts General Hospital and Harvard Medical School, United States, 
3Institute of Systems, Molecular & Integrative Biology, University of Liverpool, 
United Kingdom, 4Department of Orthopaedic Surgery, Boston University 
School of Medicine, United States, 5Endocrine Unit, Department of Medicine, 
Massachusetts General Hospital and Harvard Medical School; School of 
Stomatology, Wuhan University, United States
The GNAS locus gives rise to multiple transcripts including the stimulatory G pro-
tein alpha-subunit (Gsα). GNAS mutations cause multiple inherited diseases and are found 
in various endocrine and non-endocrine tumors. Another GNAS product is the extra-large 
G-alpha protein (XLαs), which differs from Gsα in its promoter and first coding exon. XLαs 
expression has been shown to be paternal, and therefore, with the exception of those lo-
cated in Gsα exon 1, all disease-causing GNAS mutations affect XLαs when they are on 
the paternal allele. However, a previous study observed biallelic XLαs expression in bone 
marrow stromal cells (BMSCs) from normal individuals and patients from fibrous dysplasia 
of bone. We therefore investigated allelic XLαs expression in different tissues. We initially 
compared the XLαs transcript levels in paternal, maternal, or homozygous XLαs knockout 
(XLKO) mice to the levels in wild-type littermates; however, conclusive results could not 
be obtained owing presumably to the variable levels of remnant XLαs mRNA from the 
disrupted allele. We then employed “next-generation” sequencing of RT-PCR amplicons 
and a polymorphism common to both XLαs and Gsα, as well as A/B, another paternally 
expressed GNAS transcript. In mouse BMSCs, bone tissue, and cerebellum, Gsα transcripts 
were biallelically derived (48.4+/-0.3%; n=6, 53.0+/-0.7%; n=6, and 51.9+/-0.3%; n=6, 
respectively), while A/B was nearly exclusively paternal (99.8+/-0.2%; n=4, 99.6+/-0.1%; 
n=4, and 99.9+/-0.1%; n=3, respectively). In contrast, XLαs expression varied substantially 
among individual samples in each of the three tissues. Strikingly, the paternal XLαs con-
tribution in six independent BMSC samples ranged from 43.0% to 99.9% (p=0.02 vs. the 
data distribution in A/B; Wilcoxon rank-sum test). In two unrelated human BMSC samples, 
XLαs expression also appeared to be variable, albeit predominantly monoallelic (91.3% or 
99.6%). In contrast, murine calvarial osteoblasts did not show evidence of such variable 
allelic XLαs expression, even after 2 weeks of differentiation in culture (99.4+/-0.2%; n=4), 
arguing against a role of cell culture in the observed variation of allelic XLαs expression. 
Considering that BMSCs consist of multiple cell populations whose relative abundance may 
differ from sample to sample, it is possible that XLαs expression is biallelic in a certain 
subset of BMSCs. These findings have important implications in understanding the role of 
altered XLαs actions in GNAS-related diseases.
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Osteocyte Vegf-a Contributes to Myeloma-associated Angiogenesis and Is 
Regulated by Fgf23 *Patrick Mulcrone1, Daniela Petrusca1, Jesus Delgado-
Calle2, G. David Roodman1. 1Indiana University School of Medicine, United 
States, 2Indiana University School of Medicien, United States
Osteocytes regulate normal bone homeostasis and the development of multiple myelo-
ma bone disease (MMBD). Previous studies demonstrated when osteocytes interact with 
multiple myeloma cells (MM), these interactions stimulate tumor growth and production 
of osteocytic factors that increase osteoclast resorption and suppress osteoblast activity. In 
addition, the MMBD tumor microenvironment is very hypoxic, and increased bone marrow 
angiogenesis is a characteristic of patients with active MM. Further, the level of increased 
marrow angiogenesis correlates negatively with patient survival. Although osteocytes can 
produce pro-angiogenic factors during mechanical load stress and in the presence of pro-in-
flammatory cytokines, it is unclear if osteocyte-MM interactions also contribute to enhanced 
bone marrow vascularization seen with MMBD. We report that hypoxia and direct interac-
tions with MM cells increase pro-angiogenic signaling in osteocytes. Vascular endothelial 
growth factor-a (Vegf-a) increases in MLOA5 cells cultured in hypoxia compared to those 
grown under normoxic conditions. Co-culture of MM cells with MLOA5 under hypoxia in-
duces greater than two-fold increases in production of Vegf-a in osteocytes when compared 
to normoxic mono-culture, and a 42-55% increase compared to normoxic co-culture condi-
tions. Conditioned media (CM) from both hypoxic mono and co-cultures increases HUVEC 
tube length at 8hrs when compared to CM from normoxic cultures. These increases induced 
by hypoxic CM are prevented by addition of a neutralizing antibody targeting murine Vegf-a 
or using CM derived from MLOA5s lacking Vegf-a via siRNA. Angiogenic changes are 
also prevented with Ad-Cre treatment of calvarial biopsies from or primary osteocytes de-
rived from calvariae of Vegf-a flox/flox mice.  In vivo, we detected an increased number of 
Vegf-positive osteocytes in 5TGM1 MM-bearing tibiae that correlated positively with MM 
vascular area. Finally, we demonstrate a novel angiogenic role of Fgf23, an osteocyte-specif-
ic hormone. Fgf23 promotes Vegf-a expression and secretion in osteocytes via upregulation 
of the Egr1 transcription factor, and knockout of Fgf23 in osteocytes blocks MM-induced 
upregulation of Vegf-a. Together, these results demonstrate that hypoxia and MM cells trig-
ger a pro-angiogenic phenotype in osteocytes via Fgf23 and Vegf-a signaling. Our results 
support that angiogenic signals from osteocytes contribute to MM vascularization.
Disclosures: Patrick Mulcrone, None
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Differential Pathway Activation by GP130 Cytokines in Breast Cancer *Tolu 
Omokehinde1, Alec Jotte1, Rachelle Johnson2. 1Vanderbilt University, United 
States, 2Vanderbilt University Medical Center, United States
Bone-disseminated breast cancer cells oftentimes home to the osteogenic niche, where 
they are exposed to glycoprotein130 (GP130) cytokines secreted by osteoblast-lineage 
cells. Leukemia inhibitory factor (LIF), oncostatin M (OSM) and ciliary neurotropic factor 
(CNTF) are GP130 cytokines that can all signal through LIF receptor (LIFR) and are known 
to induce JAK/STAT, AKT, and ERK signaling. Our lab previously showed that breast can-
cer cell expression of LIFR and JAK/STAT signaling promotes tumor dormancy in bone, 
but it is unclear which pathways in breast cancer cells are stimulated by the LIFR-bind-
ing ligands. We hypothesized that LIF, OSM, and CNTF induce pro-dormancy signaling 
pathways and promote tumor suppression. Treatment with recombinant LIF, OSM or CNTF 
(50ng/ml) robustly stimulated pSTAT3 (up to 34-fold, p<0.01-0.0001), LIF and OSM in-
duced pERK (up to 4-fold, p<0.01-0.001), and only OSM induced pAKT (up to 9-fold, 
p<0.0001) in MCF7 breast cancer cells by Western blot. LIF and CNTF induced no signaling 
in MDA-MB-231 breast cancer cells, which have a non-functional LIFR, but OSM robust-
ly stimulated pSTAT3 and pAKT (up to 26-fold, p<0.05-0.0001) in MDA-MB-231b cells, 
suggesting OSM may signal through OSM receptor (OSMR) on breast cancer cells. Reverse 
phase protein array (RPPA) analysis of MCF7 cells treated with recombinant LIF, OSM, and 
CNTF revealed several previously unknown signaling pathways and effectors to be activat-
ed, including ATM, CREB, HSP27, and N-RAS. Overexpression of OSM in MCF7 cells re-
duced the expression of 4/18 the pro-dormancy genes BMP7, FOXA1, IGFBP5, and TGFB2 
(by 41-97.5% p<0.05-0.0001) in vitro, while treatment with recombinant cytokines or CNTF 
overexpression resulted in no significant changes. When orthotopically inoculated into mice 
(n=10/group), neither OSM nor CNTF overexpressing MCF7 cells altered the progression 
of tumor formation, tumor volume or weight in vivo. Since we were unable to generate LIF 
over-expressing MCF7 cells, possibly due to induction of dormancy, we have created a Tet-
on inducible overexpression system for LIF, OSM, and CNTF and these experiments are in 
progress. Together, these data suggest that the GP130 cytokines robustly stimulate multiple 
signaling pathways with tumor-suppressive and tumor-promoting activity, but further stud-
ies are needed to determine their effect on tumor progression and dissemination to the bone.
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Osx marks distinct subsets of CD45Neg and CD45Pos stromal populations 
in extra-skeletal tumors that enhance tumor growth *Biancamaria Ricci1, 
Eric Tycksen2, Hamza Celik3, Francesca Fontana4, Roberto Civitelli4, Roberta 
Faccio1. 1Washington University in St Louis-Department of Orthopedics, United 
States, 2Washington University in St Louis-Department of Genetics, United 
States, 3Washington University in St Louis-Department of Medicine, United 
States, 4Washington University in St Louis-Department of Internal Medicine, 
United States
The contribution of stromal populations to support tumor progression and metastasis is 
increasingly recognized. Cancer-associated fibroblasts (CAFs) are a heterogeneous popula-
tion of mesenchymal cells providing pro-tumorigenic signals, extra-cellular matrix (ECM) 
support and protection from anti-tumor therapies. While their function is well established, 
their origin and cellular phenotype remain to be fully elucidated. Osterix (Osx) is a master 
regulator of osteogenic differentiation expressed in perinatal skeletal mesenchymal stem 
cells (MSC) and post-proliferative osteoblasts. We detect Osx expression in CAFs from pri-
mary breast tumors and melanomas. By using Osx-cre/TdTomato reporter mice we confirm 
presence of 10-15% TdTOSX+ cells in extra-skeletal tumors, but also 12-20% TdTOSX+ 
cells in bone marrow (BM) and 13-18% TdTOSX+ cells in circulation. Co-injection of 
tumor-derived TdTOSX+ cells with B16 melanomas significantly increases tumor growth 
compared to tumor cells alone. Unexpectedly, the majority of TdTOSX+ cells are also pos-
itive for the hematopoietic marker CD45. RNAseq analysis and flow cytometry reveal that 
the genetic and phenotypic profiles of tumor-derived TdTOSX+CD45+ cells resemble that 
of tumor infiltrating immune cells, indicating that Osx does not mark a specific immune sub-
set. Indeed, such heterogeneity is explained by Osx expression early during hematopoiesis, 
where Osx transcripts are detected in long and short-term HSC and multipotent progenitors 
but not in the mature immune populations such as T cells, dendritic cells or macrophages. 
In contrast, RNAseq data from the TdTOSX+CD45- population show expression of genes 
involved in ECM deposition and remodeling, closely resembling the CAFs. Our results in-
dicate that Osx marks distinct subsets of tumor promoting CD45- and CD45+ stromal pop-
ulations in extra-skeletal tumors and challenge the dogma that expression of osteogenic and 
hematopoietic markers are mutually exclusive.
Disclosures: Biancamaria Ricci, None
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Autocrine and paracrine Notch receptor 3 signaling in the myeloma niche 
stimulates tumor growth and bone destruction. *Hayley Sabol1, Tania 
Amorim1, David Halladay1, Noriyoshi Kurihara1, Judith Anderson1, Meloney 
Cregor1, G David Roodman1, Teresita Bellido1, Jesus Delgado-Calle1. 1Indiana 
University School of Medicine, United States
In multiple myeloma (MM), Notch is activated in the tumor niche to stimulate MM 
proliferation and survival and bone destruction. We showed before that osteocytes (Ots) 
activate Notch, increase Notch receptor (NR) 3 expression, and stimulate proliferation in 
MM cells. To investigate the role of NR3 in MM cells and their communication with Ots, 
we used lentiviral-mediated shRNA stable gene inhibition. NR3 mRNA was undetectable in 
5TGM1 MM cells transduced with shRNA-NR3 and NR3 activation (NICD3) was reduced 
by 80% compared to control shRNA-scramble cells, whereas NR1, 2 or 4 NICD protein lev-
els remained unchanged compared to controls. NR3 knockdown decreased Notch target gene 
expression and cyclin D1, reduced proliferation by 35%, and modestly increased apoptosis 
of MM cells. Further, knockdown of NR3 decreased Rankl and increased Opg expression 
and abrogated the ability of MM cells to promote osteoclastogenesis in vitro. Together, these 
results demonstrate that autocrine NR3 signaling stimulates proliferation, favors survival, 
and increases the osteoclastogenic potential of MM cells. Next, we examined NR3’s role in 
MM-Ots communication. Direct co-culture with Ots increased MM cell proliferation by 2.7 
fold in control cells compared to only 1.6 fold in shRNA-NR3 MM cells. NR3 knockdown 
in MM cells partially prevented the upregulation of Notch target genes and cyclinD1 induced 
by contact with Ots. Inhibition of signaling downstream all NRs with GSI was required to 
fully prevent the increases in MM proliferation and gene expression induced by Ots. These 
results show that paracrine NR3 signaling mediates MM-Ots communication, but other NRs 
also contribute to Ot’s effects. Lastly, we studied the effects of NR3 knockdown in MM cells 
in ex vivo and in vivo models. Ex vivo, we found less tumor growth and lower levels of the 
resorption marker CTX in conditioned media from bones bearing shRNA-NR3 MM cells 
compared to bones bearing control cells. For the in vivo study, we injected 105 shRNA-NR3 
or shRNA-scramble 5TGM1 MM cells in the tibias of 6-wk-old C57BL/KaLwRijHsd mice. 
After 5 wks, mice bearing shRNA-NR3 cells had a 50% decrease in tumor burden, 50% 
reduction in osteolytic lesions, and exhibited 30% more cancellous bone compared to mice 
bearing control MM cells. These findings identify NR3 as a key mediator of autocrine and 
paracrine communication in the MM tumor niche and warrant future studies to target NR3 
as a therapeutic approach for the treatment of MM.
Disclosures: Hayley Sabol, None
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Non-bone metastatic cancers promote osteocytic bone destruction *Fabrizio 
Pin1, Joshua R. Huot 2, Matthew Prideaux1, Lynda F. Bonewald1, Andrea 
Bonetto2. 1Department of Anatomy, Cell Biology Physiology, Indiana University 
School of Medicine, Indianapolis, United States, 2Department of Surgery, Indiana 
University School of Medicine, Indianapolis, United States
The effects of bone metastatic cancer are well described, whereas considerably less is 
known regarding the effects of non-metastatic pro-cachexiogenic cancer on bone. In this 
study we investigated the effects of three well-characterized models of cancer cachexia in 
mice; Colon-26 adenocarcinoma (C26), ES-2 ovarian cancer and Lewis lung carcinoma 
(LLC). Even though C26, ES-2 and LLC tumor growth resulted in comparable body and 
muscle wasting, the ES-2 and LLC hosts exhibited severe bone loss by microCT analy-
sis, whereas only a modest bone loss was observed in the C26-bearing mice. In line with 
the loss of bone mass, histomorphometrical analysis showed increased osteoclast numbers 
on the femoral bone surface from ES-2 and LLC hosts (+149% and +178%, respectively, 
p<0.01), while no significant effects were observed in the mice bearing C26 tumors. TRAP+ 
osteocytes were increased in the femurs of C26 (+635%) and ES-2 bearers (+698%), along 
with increased lacunar area (+24% and +37% respectively, p<0.01) showing osteocytic os-
teolysis. In addition, C26 and ES-2 hosts displayed dramatically increased osteocyte death 
(+1569% and +4890% respectively, p<0.001), as well as empty lacunae (+108% and +93% 
respectively, p<0.001). To test the hypothesis that tumor-secreted factors were responsible 
for osteocyte cell death, IDG-SW3 cells differentiated for 21 days to acquire a mature os-
teocyte phenotype were co-cultured for 24 and 72 hours with cancer cells or 3T3 fibroblast 
as a control. Cell death was assessed by an LDH assay. An increase in LDH was observed 
in the culture medium at 24h of day 21 IDG-SW3 cells exposed to all three cancer cell 
lines (C26: +160%; ES-2: +257%; LLC: +512%; p<0.001) suggesting that all tumors were 
cytotoxic for osteocytes. Further, elevated osteoclast markers, including Acp5, CtsK, Atp-
6v0d2 and Mmp13, support the in vivo observation of osteocytic osteolysis. A reduction in 
mRNA levels for both the early osteocyte marker Dmp1 and the late marker Sost was also 
observed. Osteocytic bone destruction and extensive osteocyte cell death (osteonecrosis) 
along with muscle wasting may generate a musculoskeletal system that is incapable of full 
recovery upon eradication of tumor. Consideration of co-treatments that maintain musculo-
skeletal health while simultaneously using chemotherapy should be taken.
Disclosures: Fabrizio Pin, None
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HIF Signaling Prevents Outgrowth of Breast Cancer Cells in Lung but not 
Bone *Vera Todd1, Lawrence Vecchi2, Rachelle Johnson2. 1Vanderbilt University, 
United States, 2Vanderbilt University Medical Center, United States
As tumors enlarge and outgrow their blood supply, they frequently become hypoxic, 
activating hypoxia-inducible factor (HIF) signaling. Previous studies suggest that HIF sig-
naling in breast cancer cells promotes lung dissemination in genetic models and bone col-
onization following intracardiac inoculation, but the impact of HIF1α in the primary tumor 
on spontaneous dissemination to bone has never been evaluated. Based on these studies, we 
hypothesized that HIF1α deletion in the primary tumor would reduce spontaneous dissem-
ination to bone. To test this, we generated MMTV-Cre.Hif1αf/f.PyMT mice, which spon-
taneously develop mouse mammary carcinomas with conditional deletion of HIF1α in the 
mammary fat pad / tumors. As we reported last year, CreT/w/Hif1αf/f/PyMTT/w (Hif1α-/-) 
and Crew/w/Hif1αf/f/PyMTT/w (Hif1αf/f) littermate and cousin controls were used and 
mice sacrificed when the largest tumor reached 1cm3, which was delayed in Hif1α-/- mice 
(p<0.001). Our recent data now indicate that despite experiencing similar levels of intratu-
moral hypoxia (as assessed by pimonidazole staining), Hif1α-/- mice (n=21 mice) had an 
85% reduction in Hif1α expression in whole mammary tumors compared to Hif1αf/f mice 
(n=19 mice) (p<0.0001). Histological inspection of lung sections previously revealed that 
Hif1α-/- mice had greater incidence of macroscopic tumor nodules (n=15/21 Hif1α-/-, 
n=6/19 Hif1αf/f, p<0.05), and greater average lesion number (1.9-fold increase, p<0.05) 
and area (2.2-fold fold increase, p<0.05), and we now confirm that only one Hif1α-/- mouse 
had discernible tumor burden in the bone upon histological inspection of tibiae. Since PyMT 
mice have low baseline levels of tumor cell dissemination to bone, we used qPCR detection 
of Pymt mRNA, which is specifically expressed in mammary carcinoma cells, as an addi-
tional tool to measure tumor burden. Last year we reported a small but significant decrease 
in Pymt mRNA in the spine of Hif1α-/- mice, but with the addition of more samples and 
new statistical analyses, we now report there was no significant difference in tumor burden 
by Pymt expression in the lung, femora, spine, or brain. These data suggest that blocking 
HIF1α signaling in primary breast tumors and metastatic tumor cells may promote tumor 
cell dissemination or outgrowth in the lung, where tumor cells only encounter hypoxia as 
they grow and expand, but not in the physiologically hypoxic environment encountered in 
the bone.
Disclosures: Vera Todd, None
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FOXP1 Drives Osteosarcoma Development by Repressing P53 Signaling 
*Hanjun Li1, Tingting Tang1. 1Shanghai Key Laboratory of Orthopaedic Implants, 
Department of Orthopaedic Surgery, Shanghai Ninth People’s Hospital, Shanghai 
Jiao Tong University School of Medicine, China
Osteosarcoma has poor prognosis, and poor understanding of the genetic drivers of 
osteosarcoma hinder further improvement in therapeutic approaches. Here, we determined 
the role and regulatory mechanisms of the transcription factor forkhead box P1 (FOXP1) 
in osteosarcoma. We examined FOXP1 expression in osteosarcoma cells by qRT-PCR 
and Western blot and the pathological characteristics associated with FOXP1 expression 
through tissue microarray. FOXP1 overexpression and knockdown osteosarcoma cell lines 
were established by lentiviral transfection. Functional analyses of FOXP1 in osteosarco-
ma were performed in vitro and in vivo using cell-derived xenograft and patient-derived 
xenograft models. RNA-sequencing, chromatin immunoprecipitation, coimmunoprecipita-
tion, proximal ligation assay, and luciferase reporter assay were applied to determine the 
downstream genes, protein interactions, and upstream regulators of FOXP1. We found that 
higher FOXP1 expression correlated with malignancy in both osteosarcoma cell lines and 
clinical biopsies. FOXP1 promoted proliferation, tumor sphere formation, migration and 
invasion, and inhibited anoikis in osteosarcoma cells. FOXP1 acted as a repressor of P21 and 
RB (retinoblastoma protein) transcription, and directly interacted with the tumor suppressor 
p53, thereby inhibiting p53 activity. Extracellular signal-regulated kinase/c-Jun N-terminal 
kinase (ERK/JNK) signaling and c-JUN/c-FOS transcription factors were found to be up-
stream activators of FOXP1. Silencing of FOXP1 suppressed the development and progres-
sion of osteosarcoma in cell-derived and patient-derived xenograft animal models. In con-
clusion, we demonstrate that the FOXP1 drives osteosarcoma development by regulating the 
p53 signaling cascade, suggesting that FOXP1 is a potential target for osteosarcoma therapy.
Disclosures: Hanjun Li, None
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Macrophage Efferocytosis of Apoptotic Prostate Cancer Cells Activates TIM-
3/CEACAM1/SHP-2 Signaling to Support Bone Metastatic Progression 
*Veronica Mendoza-Reinoso1, Dah Youn Baek1, Adrianne Kurutz1, John Rubin1, 
Morgan Kuczler2, Danielle M. Zambito3, Kenneth Pienta3, Laurie K. McCauley1, 
Hernan Roca1. 1Department of Periodontics and Oral Medicine, University of 
Michigan School of Dentistry, United States, 2Department of Urology Johns 
Hopkins University School of Medicine, United States, 3Department of Urology 
Johns Hopkins University School of Medicine, United States
Apoptotic cell clearance by macrophages, aka efferocytosis, is crucial for maintaining 
tissue homeostasis. During tumor growth, millions of cancer cells undergo apoptosis and 
are cleared by macrophages. Various studies have found that efferocytosis of cancer cells 
by macrophages promotes chronic inflammation and immunosuppression supporting tumor 
growth and metastases. Little is known of the unique role that bone marrow macrophages 
play in skeletal metastasis. T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) 
is implicated in T-cell responses and cancer progression; however, TIM-3 signaling in effe-
rocytic macrophages remains to be defined. Activation of the TIM-3 signaling pathway relies 
on interaction of TIM-3 with carcinoembryonic antigen-related cell adhesion molecule 1 
(CEACAM1). TIM-3 was found to be upregulated in macrophages efferocytosing apoptotic 
prostate cancer cells. A CEACAM1 fragment was synthesized to interact with TIM-3 and 
then used to treat efferocytic bone marrow-derived macrophages. TIM-3 protein expression 
was reduced in macrophages efferocytosing cancer cells when treated with the CEACAM1 
peptide. CEACAM1 is a critical binding partner of Src-homology 2 domain-containing 
phosphatase (SHP-2) in the cytosol and SHP-2 regulates macrophage polarization and acti-
vates pro-inflammatory and immunosuppressive mechanisms. When a specific SHP2 inhib-
itor (SHP099) was used in efferocytic macrophages it significantly reduced TIM-3 expres-
sion. In addition, SHP2 inhibition led to STAT3 hyperphosphorylation suggesting STAT3 as 
a SHP-2 target in this mechanism. To investigate the potential role of TIM-3 expression in 
monocytes/macrophages in relation to prostate cancer progression, we isolated mononuclear 
CD14+ cells from blood and bone marrow samples of prostate cancer patients with vary-
ing grades of disease and analyzed TIM-3 expression. Flow cytometric analysis revealed 
a population of TIM-3+/FSChigh monocytes/macrophages that was significantly increased 
in the bone marrow but not in the matched blood samples from Grade 5 (high risk meta-
static) vs. lower grade prostate cancer patients. These results suggest that CD14+/TIM-3+/
FSChigh cell population may play a critical role in bone metastasis. Together these findings 
reveal a signaling pathway triggered in efferocytic macrophages that connects the TIM-3/
CEACAM1/SHP-2 axis, and suggests a mechanism that promotes an immunosuppressive 
microenvironment and bone metastatic cancer progression.
Disclosures: Veronica Mendoza-Reinoso, None
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Bone marrow adipocytes induce multiple myeloma cell adipomimicry and 
dexamethasone resistance *Mariah Farrell1, Anastasia D’Amico1, Heather 
Fairfield1, Connor Murphy1, Carolyne Falank1, Michaela Reagan1. 1Maine 
Medical Center Research Institute, United States
Purpose: Multiple myeloma (MM) is a cancer of plasma cells that is characterized by 
MM cell colonization of the bone marrow (BM) and painful osteolytic lesions. The rela-
tionship between bone marrow adipocytes (BMAds) and MM cells holds great promise as 
a novel therapeutic avenue. Our group and others have published that BMAds support MM 
cell survival and drug resistance, however, the mechanisms governing this are still relatively 
unknown.Approach: BMAds were differentiated from BM-MSCs for 21 days and then con-
ditioned media (CM) was collected for 48hr. Flow cytometric or bioluminescence assays as-
sessed OPM2 and MM.1S cell apoptosis, cell cycle, and proliferation after 72hr with BMAd 
CM, 80 µM dex or both. RT-PCR, adipokine arrays, and RNAseq (GSE132604) were used 
to look at adipogenic phenotype of MM cells. Finally, SCID beige mice were treated for 5 
weeks with an anti-sclerostin antibody (Scl Ab) to decrease BMAds and then inoculated 
with MM.1S cells. Scl Ab continued during MM progression and 9 mg/kg dex was given to 
mice 4x/week for 2 weeks after tumor burden was established. Controls received vehicles, 
dex alone, or Scl Ab alone.Results: MM1S cells and OPM2 cells had a 50% reduction in cell 
number and a 3-fold increase in apoptosis with dex treatment. BMAd-CM reduced dex-in-
duced apoptosis to 1.3-fold in these cells and rescued cell numbers. Dex reduced KI67%+ 
cells to 75%, but BMAd-CM recovered this level to 95%. Both an adipokine array and gene 
expression revealed an increase in adipogenic genes in MM cells exposed to BMAd CM 
(eg. FABP4, Pref-1, Leptin, IL-6, and adiponectin). RNAseq analysis revealed that many 
adipogenic genes were increased in obese MM patients relative to lean such as PPARy, 
CEBPA, and FOXO1. Mice co-treated with Scl Ab and dex had the least amount of tu-
mor burden and had significantly increased survival compared to all other treatment groups 
(Fig. 1).Conclusion: BMAd-CM supported MM cells and inhibited dex-induced apoptosis. 
MM cells increased their expression of adipokines after BMAd-CM treatment, and obese 
patients’ MM cells expressed higher levels of adipocyte genes. Our data suggest that MM 
cells may evade dex-induced apoptosis by undergoing adipomimicry. Additionally, targeting 
BMAds with Scl Ab in vivo increased efficacy of dex, resulting in decreased tumor burden 
and increased survival. Together our data demonstrate BMAds support MM cell survival and 
drug resistance, and provide translational insight for MM treatment.
Disclosures: Mariah Farrell, None
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Aberrant DNA methylation and gene expression profiles in the bone marrow 
stroma of AML patients carrying IDH1 or IDH2 mutations *Paraskevi 
Vgenopoulou1, Junfei Zhao2, Raul Rabadan2, Martin Carroll3, Stavroula 
Kousteni4. 1Department of Physiology and Cellular Biophysics, Columbia 
University Irving Medical Center, United States, 2Department of Biomedical 
Informatics and Center for Computational Biology and Bioinformatics, Columbia 
University Irving Medical Center, United States, 3Division of Hematology and 
Oncology, Perelman School of Medicine, University of Pennsylvania, United 
States, 4Department of Physiology and Cellular Biophysics, Columbia University 
Irving Medical Center, United States
Gain-of-function mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) are 
found in 3% of myelodysplasia (MDS) and 20% of acute myeloid leukemia (AML) patients. 
They drive the synthesis of the oncometabolite 2-hydroxyglutarate (2HG) which inhibits 
α-KG-dependent dioxygenases and alters histone and DNA methylation in MDS/AML cells. 
However, IDH1/2 mutations are not disease-causing by themselves and require additional 
cooperative signals to become fully transforming. We examined whether such signals could 
emanate from potential epigenetic alterations in the bone marrow (BM) stomal niche. We 
found that 2HG is present and elevated in the BM plasma of MDS or MDS/AML patients 
carrying IDH mutations as compared to patients without such mutations. It can be uptaken 
by stromal cells as treatment of BM stromal cells with 2HG leads to its detection in cell 
lysates. Methylome analysis by Enhanced Reduced Representation Bisulfite Sequencing of 
BM stromal cells showed that BM stroma of IDH-mutant AML exhibited a characteristic 
methylation pattern that was significantly different from that of IDH-wild type AML stroma. 
Gene Set Enrichment Analysis demonstrated alterations in transcription factor targets asso-
ciated with chromatin remodeling in malignancies such as acute lymphoblastic leukemia 
(LYF1), cell proliferation (SRF, HNF3, CREB), integrin beta chain associated with leuko-
cyte adhesion deficiency (LFA1), as well as pathways indicating metabolic deregulation. In 
parallel, RNAseq analysis of the same stromal cell samples revealed a robust gene expres-
sion signature associated with IDH1/2-mutant patients. Genes contained within the aberrant 
IDH-mutant gene expression and DNA methylation signatures were integrated and common 
targets were used to identify biological pathways and functions that are perturbed in the stro-
ma of IDH-mutant leukemias. Pathway analysis revealed a significant overrepresentation of 
genes involved in vascular endothelial growth factor activity, signaling by receptor tyrosine 
kinases and extracellular matrix organization and interactions, all pathways implicated in 
the interaction between stromal cells and hematopoietic stem cells (HSCs) in health and 
disease. This study unveils the epigenetic landscape of the BM stroma in IDH-mutant MDS/
AML and sets the stage for the identification of cooperating signals that drive IDH-mutant 
HSC transformation; targeting such signals, in combination with IDH1/2 inhibitors, could 
improve treatment outcome.
Disclosures: Paraskevi Vgenopoulou, None
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Treatment of established bone metastases can be achieved by  combinatorial 
osteoclast blockade and depletion of Gr1+ cell subsets *Seunghyun Lee1, 
Aude-Hélène Capietto1, Roberta Faccio0. 1Washington University in St.Louis, 
United States, 0Washington University in St.Louis, United States
The bone is the third most common site of metastasis for a variety of solid tumors in-
cluding breast, prostate, and melanoma, among others. While osteoclast (OC) blockade has 
been successful in reducing tumor growth in bone in pre-clinical settings, anti-resorptives 
failed to improve the overall survival rate of cancer patients with bone metastasis despite 
ameliorating skeletal complications. To address this unmet clinical need, we established a 
murine model of bone metastasis insensitive to the anti-tumor effects of OC blockade (Zole-
dronic acid; ZA), consisting of delayed ZA administration starting 7 days after intratibial (i.t) 
or intracardiac (i.c.) tumor cell inoculation. By using this tumor model, we interrogated what 
other cells modulate tumor growth in bone in addition to the OCs. CD11b+Gr1+ myeloid 
cells, also known as myeloid-derived suppressor cells, originate in the bone marrow and 
promote tumor progression by suppressing anti-tumor immunity. Thus, we hypothesized 
that accumulation of CD11b+Gr1+ populations might hinder ZA anti-tumor effects in the 
context of established bone metastases. To address this hypothesis, we administered an-
ti-Gr1 3x/week to mice with established B16 melanoma, PyMT carcinoma and 4T1 breast 
cancer metastases to bone or bearing subcutaneous and mammary tumors as control. While 
anti-Gr1 significantly reduced primary tumor progression, this treatment had no effects on 
bone metastases either following i.t or i.c. tumor delivery, and both in the preventive and 
curative settings. By profiling immune populations from the bone marrow and the primary 
tumor of anti-Gr1 treated mice, we found efficient depletion of CD11b+Gr1+ populations 
only at extraskeletal sites, while increased numbers in bone marrow. Subset specific analysis 
revealed that anti-Gr1 expanded a specific subset CD11b+Ly6CintLy6Gint, while depleting 
the Cd11b+/Ly6Ghigh and Ly6Chigh populations. Intriguingly, CD11b+Gr1+ cells from 
bone marrow of tumor bearing anti-Gr1 treated mice gave rise to more OCs in vitro than 
CD11b+Gr1+ cells from tumor bearing IgG controls. Based on this observation, we treated 
established metastases to bone with a combination of anti-Gr1 + ZA and found that the 
combinatorial treatment significantly reduced metastases to bone compared to each agent 
alone. In summary, we provide evidence that amelioration of established skeletal metasta-
ses can be achieved by a combination therapy consisting of depletion of Gr1+ subsets and 
osteoclast blockade.
Disclosures: Seunghyun Lee, None
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The Wnt-Inhibitor DKK-1 as a Prognostic Marker and Molecular Target 
in Human Triple-Negative Breast Cancer *Teresa Stefania Dell’Endice1, 
Andrew Browne1, Lorenz Hofbauer2, Andy Göbel1, Tilman Rachner2. 1Division 
of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III, 
TU Dresden Medical Center, Fetscherstraße 74, D-01307 Dresden, Germany, 
Germany, 2Division of Endocrinology, Diabetes and Bone Diseases, Department 
of Medicine III and Center for Healthy Aging, TU Dresden Medical Center, 
Fetscherstraße 74, D-01307 Dresden, Germany, Germany
The Wnt-signalling antagonist Dickkopf-1(DKK-1) promotes the formation of os-
teolytic bone metastases by affecting the osteoblastic function in advanced breast cancer. 
Several studies underline the importance of DKK-1 as a tumor promotor with pleiotropic 
supportive effects on cancer cell growth and disease progression. In this study, we aimed at 
clarifying the biological role and the potential as a therapeutic target of DKK-1 in human 
triple-negative breast cancer (TNBC).DKK-1 protein expression was evaluated by immuno-
histochemistry in a tissue microarray of 396 patients with primary breast cancer. Immuno-
reactivity was assessed by grading the stain intensity from 0 to 3 and multiplied by a value 
in order to calculate the percentage of the stained cancerous tissue. Patients were divided 
into DKK-1 low/negative and DKK-1 positive groups. The survival curves were plotted 
for the total number of patients, as well as subdivisions of estrogen receptor negative (ER-) 
and estrogen receptor positive (ER+) patients. Cell metabolism in MDA-MB-231 control 
and DKK-1 knock-out (KO) cells was assessed in vitro by Cell Titer Blue® viability as-
say. In vivo, normal and DKK-1 KO cells were subcutaneously inoculated into NMRI-nu 
female mice and tumour growth was assessed after 5 weeks.DKK-1 expression was signifi-
cantly increased by up to 3-fold between stages T1 and T2 compared to carcinoma in situ 
(p<0.05). When patients were stratified according to the ER- status, DKK-1 was a decisive 
predictor of survival with a significant association between positive DKK-1 expression and 
decreased survival (p<0.05) in ER- patients only. Assessment of cell viability demonstrated 
a significant reduction in the DKK-1 KO compared to the control cells (p<0.001) under 
serum-deprived culture conditions after 72 h. Subcutaneous tumor growth was significantly 
suppressed by using DKK-1 KO cells (61%, p<0.05) compared to control cells.Our findings 
show that DKK-1 expression in breast cancer is a negative prognostic factor in ER-, but not 
in ER+ patients indicating DKK-1 as a potential therapeutic target in TNBC. Furthermore, 
the growth of human MDA-MB-231 breast cancer cells is significantly reduced in NMRI-
nu mice supporting a pro-tumourigenic role of DKK1 in ER- breast cancer. These results 
warrant further research to define the role of DKK-1 in primary and metastatic breast cancer.
Disclosures: Teresa Stefania Dell’Endice, None
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Denosumab is Non-inferior to Zoledronic Acid as Bone Protection in 
Post-menopausal Breast Cancer: A 2-year Prospective Follow-up Study 
*Kristian Buch-Larsen1, Michael Andersson2, Peter Schwarz1. 1Department 
of Endocrinology, Rigshospitalet, Denmark, 2Department of Oncology, 
Rigshospitalet, Denmark
BackgroundStandard treatment for post-menopausal women with oestrogen receptor 
positive (HR+) breast cancer (BC) is aromatase inhibitors (AI), known to cause loss of 
BMD. Guidelines recommend the use of intravenous (i.v.) bisphosphonates i.e. zoledronic 
acid, which increase overall survival. Bisphosphonates reduce BMD loss and risk of frac-
tures. In this study we investigate whether denosumab is a valid second option for patients 
unable to receive standard i.v. zoledronic acid for various reasons.MethodsIn total 212 pa-
tients have been evaluated after they did not receive i.v. zoledronic acid at baseline at the 
department of Oncology and of those 199 were in AI treatment. After endocrine evalua-
tion all patients were offered zoledronic acid as first choice (N=30) or secondly denosumab 
(N=169). The patients were followed prospectively with blood tests at baseline, 1, 3, 6, 12 
and 24 months and DXA scans at baseline and 24 months.Results We saw no difference be-
tween the two treatment groups at baseline, with regard to anthropometry and standard bio-
chemistry. Plasma ionized calcium (p-Ca2+) was significantly decreased (non-symptomatic) 
after 1 month of treatment in both the denosumab (mean change -0.05 mmol/L, p <0.001) 
and zoledronic acid (-0.05 mmol/L, p<0.001) group with a corresponding p-PTH elevation. 
We observed no significant difference between the groups and p-Ca2+ was normalized after 
1 year.  Markers of bone turnover (p-P1CP, p-CTX, p-bone specific alkaline phosphatase 
and p-osteocalcin) all showed significant suppression from month 1 compared to baseline 
and remained supressed for both groups throughout the 2 years. BMD showed small and 
significant increases at the spine (0.023 g/cm2, p<0.01) and total hip (0.020 g/cm2, p<0.001) 
in the denosumab group but no change at the femoral neck (-0.012 g/cm2, p=0.14). In the 
zoledronic acid group we observed no significant change at spine (0.014 g/cm2, p=0.63) and 
total hip (-0.001 g/cm2, p=0.90) and a small and significant drop at the femoral neck (-0.037 
g/cm2, p=0.03). However, when we compared BMD change between the treatment groups, 
we found no significant difference.ConclusionOur data indicate that for post-menopausal 
HR+ BC patients in AI treatment who for various reasons cannot be treated with zoledronic 
acid, denosumab might be recommended as a safe second choice. Regarding bone protection 
denosumab is non-inferior to zoledronic acid.
Disclosures: Kristian Buch-Larsen, None
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Identification of senescent plasma cells in a mouse model of monoclonal 
gammopathy of undetermined significance *Gabriel Borges1, Sonya 
Royzenblat1, Iyabode Ajayi1, Claire Edwards2, Ming Xu3, Tamara Tchkonia4, 
James Kirkland4, Matthew Drake4, Megan Weivoda1. 1Department of Periodontics 
and Oral Medicine, School of Dentistry, University of Michigan, United States, 
2Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal 
Sciences, Botnar Research Centre, University of Oxford, United Kingdom, 
3University of Connecticut Center on Aging, University of Connecticut Health, 
United States, 4Robert and Arlene Kogod Center on Aging, Mayo Clinic, United 
States
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor condi-
tion for multiple myeloma (MM) characterized by clonal plasma cell (PC) derived monoclo-
nal antibody. Despite similar oncogenes to MM, MGUS PCs are non-proliferative and the 
mechanisms that trigger disease progression remain unclear. Because oncogene activation is 
a stressor known to cause senescence-induced growth arrest, we hypothesized that MGUS 
clonal PCs are senescent. Thus, we have employed the KaLwRij mouse model of MGUS 
to assess senescence markers in KaLwRij PCs and the response of these cells to senolytic 
therapy (dasatinib+quercetin, D+Q).Age and sex-matched KaLwRij mice (10-12 mo) were 
treated (tx) with D+Q (5, 50mg/kg) or placebo for 3 days, biweekly for 2.5 months. The re-
lated C57BL/6 mice served as controls. Blood samples were collected biweekly to measure 
serum antibody (Ab) content. Following euthanasia, bone marrow PCs were enriched via 
magnetic sorting, followed by staining for senescence-associated βGal activity (SA-βGal) 
and further isolation/analysis of PCs by fluorescence-activated cell sorting.Male and female 
KaLwRij mice exhibited significantly reduced total PC numbers compared to C57BL/6, with 
increased percentage (%) SA-βGal+ PCs. The % SA-βgal+ PCs was significantly decreased 
in female D+Q tx KaLwRij mice, and these mice exhibited a rescue in total PC number. 
Male D+Q tx KaLwRij mice showed no differences in these parameters compared to place-
bo. RT-qPCR revealed increased senescence gene expression (Bcl2, Bmi, Fas, Irf4, Nfkb1, 
Prdm1, and Relb) with reduced proliferation marker, Mki67, in SA-βGal+ PCs. D+Q tx 
significantly improved the expression of PC markers Cd40, Slamf7, and Xbp1, with trends 
for improved Sdc1 and Cd40Ig in SA-βGalNeg PCs. Serum Ab content served as a func-
tional readout of MGUS. While individual Ab isotype levels were variable, total Ab content 
significantly increased with time in placebo mice. This increase was not observed in D+Q tx 
female KaLwRij mice. The increased Ab content was driven by increased IgG1, and D+Q tx 
female KaLwRij mice exhibited a significant decrease in IgG1 percent change compared to 
placebo.Overall, these results are consistent with senescence in clonal PCs. Recent findings 
suggest senescent cells can exhibit increased genomic instability. Thus, further evaluation of 
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PC senescence phenotypes in MGUS may lead to the identification of biomarkers to predict 
risk of progression to MM.
Disclosures: Gabriel Borges, None
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Bone Loss Evaluation after One Year of Combined GnRH Agonist and 
Aromatase Inhibitors Therapy for Premenopausal Early Breast Cancers 
*XAVIER NOGUES1, Irene Petit2, Sonia Servitja3, Isabel Campodarve2, Isabel 
Aymar2, Marta Pineda-Moncusi4, Diana Ovejero4, Natalia Garcia-Giralt4. 1IMIM 
(Hospital del Mar Research Institute), Centro de Investigación Biomédica en 
Red de Fragilidad y Envejecimiento Saludable (CIBERFES);Internal Medicine 
Department, Hospital del Mar, Universitat Autònoma de Barcelona, Spain, 
2Internal Medicine Department, Hospital del Mar, Universitat Autònoma 
de Barcelona, Spain, 3Cancer Research Program, IMIM (Hospital del Mar 
Research Institute), Spain, 4IMIM (Hospital del Mar Research Institute), Centro 
de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable 
(CIBERFES), Spain
Aromatase Inhibitors (AI) have been constituted as a first line adjuvant therapy for 
estrogen receptor-positive breast cancer patients. Recent therapeutic strategies in premeno-
pausal patients involve ovarian function suppression (OFS) for menopause induction plus 
AI treatment. Even though these combined therapies increased benefits in terms of dis-
ease-free survival, several endocrine-deprivation symptoms like osteoporosis and fractures 
are raised as frequent complications. Up to day, little evidences about bone health have been 
described in these patients. The present study aimed to describe the bone mineral density 
(BMD) changes one year after AI-therapy initiation.Data of Caucasian women candidates 
for OFS plus AI (OFS+AI) were collected prospectively since January 2018. Participants 
were supplemented with 25(OH)vitD3 and those with bone antiresorptive treatments were 
excluded. The main outcomes of the study were the relative change in lumbar spine (LS), 
femoral neck (FN) and total hip (TH) BMD from baseline to one year of AI therapy. Patient 
characteristics and clinical variables were also registered at baseline and each year during 
treatment. Bone mass changes were compared between these patients and postmenopausal 
breast cancer women treated only with AI (B-ABLE cohort). T Student was used for group 
comparisons in SPSS vs23.26 patients initiated combined OFS plus AI (OFS+AI) and 758 
patients were included in the B-ABLE cohort at the beginning of AI therapy at postmeno-
pause (AI-post). Of those patients, 13 OFS+AI and 640 AI-post had BMD values at one year 
after AI starting. As it is expected, OFS+AI patients were significantly younger and thinner 
than AI-post (age mean+/-SD:46+/-6 vs 61+/-7.6; BMI mean+/-SD:24.5+/-4 vs 29+/-5.4, 
respectively; p<0.0001). No differences were found in basal BMD at three body locations, 
or in Vitamin D levels at baseline and after 1 year of treatment. OPF+AI patients suffered 
a striking bone loss (mean+/-SD) of -6.7%+/-3 at LS, -7.8%+/-4 at FN, and -5.2%+/-2.8 at 
TH. AI-post patients also underwent bone loss although it was significantly slighter (LS: 
-1.4%+/-4.1, FN: -1.3%+/-6, TH: -0.3%+/-3.7; p<0001 compared to OPF+AI patients).In 
summary, an important bone loss was detected in OFS+AI patients during the first year of 
AI therapy, even higher than AI-postmenopausal women, which need to be considered and 
monitored for clinical interventions.
Disclosures: XAVIER NOGUES, None
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Low doses of the bone-targeted Notch inhibitor BT-GSI exhibit higher 
anti-myeloma activity and preserve bone compared to unconjugated 
GSI or zolendronic acid. *Tania Amorim1, Adam Ferrari1, Hayley Sabol1, 
Judith Anderson1, Meloney Cregor1, Megan Sweet1, Venkatesan Srinivasan2, 
Frank Ebetino2, Robert Boeckman2, G David Roodman1, Teresita Bellido1, 
Jesus Delgado-Calle1. 1Indiana University School of Medicine, United States, 
2University of Rochester, United States
Multiple myeloma (MM) cells communicate with cells in the MM niche via Notch 
signaling, leading to tumor growth and bone destruction. γ-secretase inhibitors (GSIs) block 
Notch and decrease MM growth, but their clinical use is limited by severe gut toxicity. To 
overcome GSI side-effects, we generated a bone-targeted Notch inhibitor (BT-GSI). We pre-
viously showed that BT-GSI inhibits Notch in bone, decreases MM growth, and preserves 
bone without inducing gut toxicity. Here we compared BT-GSI’s anti-MM efficacy to an 
equimolar dose of systemic GSI or to zolendronic acid (ZA); and examined the effects of 
lower doses of BT-GSI on mouse models of established MM. KaLwRijHsd mice were in-
jected with 105 5TGM1 MM cells or saline (control). 3 wks after MM cell inoculation, mice 
bearing MM were randomized by tumor burden and osteolysis, and received either vehicle 
(DMSO), BT-GSI (10mg/Kg, 3x/wk), unconjugated GSI (5mg/kg, 3x/wk), bone-targeting 
moiety (BT) (5mg/kg, 3x/wk), or ZA (0.1 mg/kg, 2x/wk) for 3 more wks. Vehicle-treated 
mice exhibited a 6-fold increase in tumor burden. Similar tumor progression was seen in 
mice receiving ZA or GSI. In contrast, BT-GSI and BT decreased MM growth by 50% com-
pared to vehicle-treated mice. Futher, vehicle-treated mice had a 5-fold increase in osteolytic 
lesions. ZA, GSI, and BT reduced osteolytic number by 45%, whereas BT-GSI reduced oste-
olysis by 70%  compared to vehicle-treated mice. Morevoer, BT-GSI, BT, and ZA decreased 
the levels of the systemic bone resorption biomarker CTX, by 30-50%  while no CTX chang-
es were seen with GSI. To test the efficacy of lower doses of BT-GSI, KaLwRijHsd mice 
were injected with 105 5TGM1 cells and randomized after 3 wks as indicated above. Mice 
bearing MM received either vehicle and equimolar doses of BT-GSI (5 and 2mg/Kg) and BT 
(2.5 and 1 mg/kg) 3/wk. Mice receiving vehicle injections exhibit a 5-fold increase in tumor 
burden and 2-fold increase in osteolysis. Both doses of BT-GSI decreased tumor growth by 
50-60% and osteolytic lesions by 40-50% compared to vehicle-treated mice. In contrast, 
none of the lower BT doses affected tumor or bone disease progression. All BT-GSI and 
BT doses reduced systemic CTX levels. Collectively, these results demonstrate that BT-GSI 
inhibits MM growth and bone destruction at doses in which GSI and BT are ineffective; 
and support that bone-targeted Notch inhibition with BT-GSI is a promising therapeutic 
approach to treat MM disease.
Disclosures: Tania Amorim, None
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Zoledronic Acid Improves Bone Quality and Muscle Function in High 
Bone-Turnover State *Trupti Trivedi1, Mohamed Manaa1, Sutha John1, 
Steven Reiken2, Gabriel Pagnotti1, SreeMala Murthy1, Neha Dole3, Yun She1, 
Sukanya Suresh1, Brian Hain4, Jenna Regan1, Rachel Ofer2, Laura Wright5, 
Alex Robling6, Xu Cao7, Tamara Alliston3, Andrew Marks2, David Waning4, 
Khalid Mohammad5, Theresa Guise5. 1Indiana University School of Medicine, 
United States, 2Columbia University, United States, 3University of California 
San Francisco, United States, 4The Pennsylvania State University College 
of Medicine, United States, 5Indiana University School of Medicine, United 
States, 6Indiana University, United States, 7Johns Hopkins University School of 
Medicine, United States
Previous evidence showed that zoledronic acid (ZA), a bisphosphonate inhibitor of 
osteoclastic bone resorption, prevented the development of muscle weakness induced by 
bone-derived TGFβ in mice with osteolytic bone metastases. To determine the effects of 
ZA on bone and muscle function in a nonmalignant setting, we used mouse model Camu-
rati-Engelmann disease (CED), a bone dysplasia with TGFβ-induced accelerated bone re-
modeling. Wild-type (WT) and CED mice were treated with vehicle (V) or ZA (5μg/kg;3x/
wk) for 4 and 10wks; bone and muscle parameters were assessed. CED-V mice showed 
increased bone remodeling as indicated by increased osteoclasts number (p<0.01), osteoid 
volume (p<0.05), and BFR (p<0.05) versus WT-V. ZA treatment reduced bone remodeling 
in CED mice. MicroCT showed CED-V mice had reduced BV/TV in the tibia (p<0.05) and 
L5 vertebrae (p<0.001) with increased tibial cortical porosity (Ct.Po) (p<0.001) versus WT-
V. 3pt-bending of the femur and uniaxial compression of L5 showed decreased resistance to 
fracture in CED-V compared to WT-V mice. In CED, ZA increased BV/TV, reduced Ct.Po, 
and improved fracture resistance in the femur and L5. Collectively, ZA had significant effects 
to improve bone volume and strength in CED mice. Increased pSmad2/3 (p<0.05) in CED 
skeletal muscle indicated systemic effects of bone-derived TGFβ activity. Excess TGFβ 
in CED was associated with significant muscle weakness shown by reduced muscle fiber 
diameter (p<0.001), muscle cross-sectional area (CSA) (p<0.001), forelimb grip strength 
(p<0.01) and muscle force (p<0.01) relative to WT-V. In CED mice, 4wks and 10wks of 
ZA treatment reduced muscle pSmad2/3 (p<0.05), increased CSA (p<0.05) and fiber diame-
ter (p<0.05). There was a marginal increase in muscle force after 4wks of ZA in CED mice. 
However,10wks of preventative ZA significantly increased forelimb grip strength (p<0.05) 
and muscle force (p<0.001) in CED mice. Reduced muscle force in CED mice was due to 
Nox4 mediated oxidation of Ca+2 release channel Ryanodine Receptor1(RyR1) and loss of 
Calstabin in skeletal muscle. ZA improved muscle function by preventing oxidation of RyR1 
in CED mice. Our data highlight the profound impact of ZA in maintaining bone health and 
preserving function in an extreme state of high bone turnover, not associated with malignan-
cy. These effects on muscle are likely indirect, by blocking osteoclastic bone destruction. 
Potential direct effects cannot be ruled out and are under investigation.
Disclosures: Trupti Trivedi, None
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Syngeneic Murine Bladder Cancer Growing in Bone Responds to Anti-PD-1 
Treatment *Mari I. Suominen1, Katja Fagerlund1, Jukka P. Rissanen1, Arne 
Scholz2. 1Pharmatest Services, Finland, 2Bayer AG, Germany
The first immunotherapy treatment approved by FDA was for bladder cancer in 1990 
when intravesical introduction of weakened, live bacillus Calmette-Guérin (BCG) was found 
to reduce the cancer recurrence by stimulating an immune response. The overall 5-year sur-
vival rate of bladder cancer is 77%, so there are still patients recurring and having distant 
metastases, approximately half presenting with bone metastases. Today, also bladder cancer 
patients with metastases can be treated with immunotherapy, since 5 drugs targeting the 
PD-1/PD-L1 pathway are approved for treatment. However, the effects of immunotherapies 
in bone metastases are severely understudied. The aim of the study was to establish a novel 
syngeneic model for bladder cancer bone metastasis that could be utilized in such research.
The optimal number of murine MBT-2 bladder cancer cells inoculated into the tibia of 5-6 
week-old female C3H/HeN mice was established based on weekly observation of tumor-in-
duced bone changes by X-ray imaging and confirmed by histology. For the anti-PD-1 treat-
ment study, the mice were stratified into two groups based on similar bone lesion areas 10 
days post-inoculation and treated with anti-PD-1 therapy or isotype control. Bone changes 
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were followed by X-ray imaging one week after start of treatment and at sacrifice after three 
weeks on treatment.In the model establishment study, tumor take rate of 50% was observed. 
The tumor-induced bone reaction was osteolytic resulting in substantial local bone loss in the 
mice. The osteolytic bone lesions became visible 7-14 days post-inoculation, and the mice 
had to be euthanized 4 weeks from the cancer cell inoculations. In histology, large tumors 
and reduced bone volume of the inoculated tibia were observed. The anti-PD-1 treatment 
inhibited the increase of osteolytic area. A trend of inhibition was found already after one 
week of treatment, and significantly lower bone lesion area was observed at sacrifice.The 
established novel syngeneic bladder cancer bone metastasis model presented good response 
to anti-PD-1 therapy. These results are in concordance with the clinical efficacy of PD-1/
PD-L1 pathway inhibitors, suggesting that the intratibial MBT-2 model could be utilized to 
increase the knowledge of the effects of these pathway inhibitors in tumor - bone microenvi-
ronment. In addition, the efficacy of new immunotherapies and combination therapies could 
be tested in this model.
Disclosures: Mari I. Suominen, None
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Vitamin D regulates extracellulair vesicle communication of bone metastatic 
prostate cancer cells *Joelle A Z Klazen1, Iris J Robbesom1, Martin E van 
Royen1, Andre J van Wijnen2, Jeroen A Demmers1, M Carola Zillikens1, Johannes 
P T M van Leeuwen1, Marjolein van Driel1. 1Erasmus MC, Netherlands, 2Mayo 
Clinic, United States
The skeleton is a preferential site for metastatic invasion by cancer cells. The metastatic 
process is determined by complex interactions between cancer cells and the bone microen-
vironment.In order to unravel a potential mechanism underlying  the complexity of bone 
metastases, we studied the role of extracellular vesicles (EVs). EVs are nano-sized particles 
that transfer information from cell to cell and thereby support pre-metastatic niche formation 
in the bone.Since therapeutic intervention is not beneficial in bone metastases yet, we aimed 
to study the effects of a candidate therapeutic compound on the behavior of bone metastatic 
prostate cancer cell derived EVs. We selected 1α,25(OH2)D3 vitamin D because of its ben-
eficial effects on bone and negative effects on cancer cell growth.EVs from vitamin D (10-7 
M 1α,25-OH2D3) treated and untreated GFP-expressing human bone metastatic prostate 
cancer cells (PC-3) were isolated by ultracentrifugation (20.000 g and 100.000 g fractions) 
after one week of culture. EVs were counted by high-resolution flow cytometry (BD influx) 
and microscopy-image-guided counting (EVQuant). PC-3 EV mRNA content was analyzed 
by high-throughput next generation sequencing and confirmed by qPCR. PC-3 EV uptake by 
human osteoblasts (SV-HFO) was measured by flow cytometry (BD Accuri C6). Proteomic 
profile of PC-3 EVs was analyzed by liquid chromatography-mass spectrometry.Vitamin D 
treatment decreased the number of PC-3 cells by almost 70%. The surviving cancer cells 
produced a significantly higher number of EVs per cell in the 100,000 g fraction (increase of 
82%, p=0.0008). This 100,000 g EV fraction of the vitamin D treated PC-3 cells contained 
a different set of preferentially packaged mRNAs compared to the EVs from untreated cells. 
Interestingly, vitamin D treatment of PC-3 cells resulted in less uptake of EVs by human 
osteoblasts (15% reduction (p=0,013) for the 100.000 g and 43% (p=0.0260) for the 20.000 
g fraction). This was accompanied by a lower adhesion protein profile on the EV mem-
brane. Remarkably, despite this decreased EV uptake by osteoblasts, gene expression levels 
of the preferentially packaged EV mRNAs of the vitamin D treated PC-3 cells were highly 
upregulated (towards 200 fold) in the recipient osteoblasts.Our data identify new ways in 
which vitamin D affects the communication route of bone metastatic prostate cancer cells, 
but cannot prevent surviving cancer cells to set their landmarks for metastatic outgrowth.
Disclosures: Joelle A Z Klazen, None
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Runx2 Regulates Cytoskeletal Dynamics in Bone Metastatic Breast Cancer 
Cells *Ahmad Othman1, Marcus Winogradzki1, Jitesh Pratap1. 1Rush University 
Medical Center, United States
Bone metastasis is a significant contributor to breast cancer mortality, with no current 
treatment available. Aberrant expression of the transcriptional regulator Runx2 facilitates 
bone metastasis. Recently, Runx2 has been shown to enhance autophagy, a process of degra-
dation of damaged organelles and proteins into subunits for biosynthesis. Autophagosomes 
traffic along microtubules (MTs). Acetylation of a-Tubulin (Ac-a-Tub) stabilizes MTs and 
prevents it from buckling under the forces of traffic. High levels of Ac-a-Tub and autophagy 
are independently linked with breast cancer metastasis. We found that Runx2 promotes Ac-
a-Tub and MTs stability. However, questions regarding the mechanism of Runx2 mediated- 
Ac-a-Tub and MTs stability remain. Using patient biopsies, bone-derived breast cancer cells, 
gene and tumor arrays, we examined autophagy, Ac-a-Tub, and dynamics of MTs polymer-
ization. The tumor array showed a significant association between high levels of Runx2 and 
autophagy, while patient biopsies showed increased Ac-a-Tub staining in bone metastatic 
samples compared to primary tumors. Profiling of 168 autophagy and cytoskeletal-related 
genes revealed that the majority of the genes were unchanged with Runx2 silencing. We 
found a 2.5 fold decrease in mRNA and protein levels of Transglutaminase-2 (TGM2) in 
control cells, however, its inhibition did not change autophagy or Ac-a-Tub. Furthermore, no 
significant changes were observed in regulators of Ac-a-Tub (HDAC6, SIRT2, and ATAT1) 
with Runx2 silencing. Additionally, expression of WT and transcriptionally inactive mutant 
of Runx2 increased Ac-a-Tub and MT polymer mass, while a C-terminal deletion mutant 
failed to recapitulate these findings. These results indicate a novel transcriptional indepen-
dent regulation of Ac-a-Tub via Runx2. We tested whether Runx2 alters activity or sub-
cellular localization of regulators of Ac-a-Tub via protein-protein interaction. Inhibition of 
HDAC6 activity increased Ac-a-Tub and autophagy, while SIRT2 silencing resulted in min-
imal changes. We used Leptomycin-B to suppress protein shuttling between the nucleus and 
cytoplasm and found enhanced Ac-a-Tub in both control and Runx2 silenced cells. Taken to-
gether, these results show that Runx2 may alter localization and activity of the regulators of 
Ac-a-Tub. Our studies suggest that autophagy, Runx2, and Ac-a-Tub levels may help stratify 
bone metastatic patients for effective treatments with FDA approved MTs targeting agents.
Disclosures: Ahmad Othman, None
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Modeling Spontaneous Bone Metastasis of Human Prostate Cancer in Mice 
*Vera Labitzky1, Ann-Kristin Ahlers1, Anke Baranowsky1, Udo Schumacher1, 
Tobias Lange1. 1University Medical-Center Hamburg-Eppendorf, Germany
Purpose: The prognosis of prostate cancer (PCa) patients largely depends on whether 
or not distant metastases occur with the bone marrow (BM) being a frequent metastatic site. 
One efficient and common approach for studying BM metastasis in vivo is to inject human 
tumor cells intracardially into immunodeficient mice. However, such procedure circumvents 
early steps of the metastatic cascade due to the lack of a primary tumor. The purpose of this 
study was therefore to develop a xenograft model of human PCa in which BM metastases are 
spontaneously formed.Methods: Establishment of subcutaneous (s. c.) xenografts of human 
PCa cells (PC-3 expressing firefly luciferase (Luc2)) in SCID and NSG mice; at ~1cm³ pri-
mary tumor volume: necrospy (control group) or tumor resection (OP group); post-surgical 
monitoring of BM metastasis outgrowth by in vivo-bioluminescence imaging (BLI); detec-
tion of skeletal and pulmonary metastases by ex vivo-BLI at necropsy, corresponding histol-
ogy; quantification of spontaneous dissemination to the blood, lung and BM by Alu-PCR at 
necropsy; establishment of PC-3-Luc2 sublines by re-cultivation of xenograft primary tumor 
and BM metastasis cells.Results: The baseline level of spontaneous lung and BM metastasis 
formation (control group) was low for PC-3-Luc2 cells. For instance, we could only detect 
single disseminated tumor cells in the lung by histology while metastatic cells in the BM 
were only detectable by Alu-PCR. Primary tumor resection prolonged the life span, thereby 
enabling outgrowth of lung, but not BM metastases (OP group). Skeletal lesions could be 
identified by ex vivo-BLI, but were not visible by histology, when every 10th section (4 µm 
each) of the area of interest was examined (OP group). The overall level of circulating tumor 
cells and metastatic cells at both sites (Alu-PCR) was higher in the more immunodeficient 
NSG as compared to SCID mice. Despite the lack of detectable outgrowth of BM metasta-
ses, human PC-3-Luc2 cells could regularly be recovered from the BM of long bones after 
surgery for in vitro expansion.Conclusion: In spontaneous metastasis xenograft models of 
PC-3, higher metastasis yields can be obtained in NSG as compared to SCID mice. Primary 
tumor resection enables the outgrowth of lung, but not BM metastases. This model might be 
particularly useful for future studies on how metastatic outgrowth is regulated in a dorman-
cy-inducing (BM) vs. metastasis-permissive (lung) environment.
Disclosures: Vera Labitzky, None
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Anti-resorptive Off-medications May Yield Differential Remodeling vs. 
Exposure on Alveolus in Cancer-survivors: Analysis of the Outcome-variables 
*Yen Chun Grace Liu1, Andy Yen-Tung Teng2. 1Center for Osteoimmunology & 
Biotechnology Research (COBR) & Dept. of Oral Hygiene, School of Dentistry 
& College of Dental Medicine, Kaohsiung Medical University (KMU) & KMU-
Hospital, Kaohsiung, Taiwan, Taiwan, Province of China, 2Center for Osteo-
immunology & Biotechnology Research (COBR), College of Dental Medicine, 
Kaohsiung Medical University & Hospital, Kaohsiung, Taiwan, Taiwan, 
Province of China
Objectives: It is clear that specific anti-resorptive drugs (ARDs), including bisphospho-
nates, anti-RANKL MAbs (Prolia/Xgeva), anti-angiogenics on VEGF signaling and selec-
tive estrogen receptor modulators (SERM) are clinically associated with patients who suffer 
from adverse reactions in the maxillofacial regions, via quiescent or progressive bone or 
mucosal destruction, termed MRONJ. Thus, we proposed to correlate the clinical manifests, 
based on the therapeutic timing on off-medications(holidays) for their latency to follow-ups 
over the clinical courses where the resulting healing or improvements of bony or mucosal 
lesions with/without exposures were end-marked over time for analyses. Methods: Among 
96 MRONJ-diagnosed patients from the clinics (e.g., 40% cancer survivors, 30% osteopo-
rosis & 30% arthritis; M:64+/-5.8yrs & F:66+/-7.2yrs), clinical data were retrieved from 
established records of MRONJ, whose ARDs were dichotomized for on- or off-holidays 
(i.e., 4-to-48 months), drugs’ intervals and the effects assigned as (co)-variables for the sta-
tistical correlations with other measures, where the off-holidayed was primarily due to relat-
ed medical concerns. Student t-test was to compare variables among on- vs. off-holidayed 
MRONJ-stages (i.e.,-1,-2,-3) & timing employed, and the one-way ANOVA was to compare 
the clinical (co)-variables among all different ARDs employed. Level of significance was set 
at p<0.05; all data analyzed using SAS8.2. Results: The analyses showed that: i) the on-hol-
idayed with Prolia/Xgeva in the cancer survivors was significantly effective in alleviating 
the episodic attacks and progressive frequencies of MRONJ’s bone manifests (p<0.01) on 
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comparisons; ii) conversely, such on- or off-holidays (i.e., Prolia) was detected non-equally 
effective in MRONJ subjects with severe osteoporosis vs. osteoarthritis, in contrast to those 
amongst the cancer-survivors; iii) such differential outcomes on bone manifests in cancer 
survivors appeared significantly associated with the drugs’ dosing & timing applied (p<0.05, 
ANOVA), compared to other (co)-variables analyzed. Concludion: The present findings sug-
gest that specific ARDs (i.e., Prolia/Xgeva) were associated with specific causes on alveolus 
on distinctive bone vs. mucosal remodeling measures in cancer survivors over time (i.e., 
48-month), whose underlying mechanisms, once revealed, will facilitate the development & 
designs of the new treatment modalities/protocols with urgent needs.
Disclosures: Yen Chun Grace Liu, None
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Osteoblasts Derived from Mouse Mandible Enhance Tumor Growth of 
Prostate Cancer More Than Osteoblasts Derived from Long Bone *Yusuke 
Shiozawa1, Matthew Eber1, Sun Park1, Fang-Chi Hsu1. 1Wake Forest University 
Health Sciences, United States
Prostate cancer (PCa) metastasizes to bone, where the bone marrow microenvironment 
controls disease progression. However, the cellular interactions that result in active bone 
marrow metastases are poorly understood. A better understanding of these interactions is 
critical to success in the pursuit of effective treatments for this life ending disease. Anec-
dotally, we observe that after intracardiac injection of  PCa cells, one of the greatest tools 
to investigate the mechanisms of bone-metastatic disease, animals frequently present with 
mandible metastasis before hind limb metastasis. Therefore, in this study, we investigated 
whether the bone cells derived from the mouse mandible influence PCa progression dif-
ferently than those from the hind limb.We first validated that in the intracardiac model of 
metastatic PCa, mandible bone lesions often occur before hind limb bone lesions, which 
is anecdotally well-recognized. We then showed that cells derived from both the mandible 
and hind limb bones of mice have osteoblastic properties, and that mandible osteoblasts 
(MaOBs) have a higher potential for osteoblastic differentiation than hind limb osteoblasts 
(HLOBs) both in vitro and in vivo. Interestingly, when PCa cells were co-cultured with 
these osteoblasts, PCa cells grew significantly faster in co-culture with MaOBs compared 
to HLOBs. Consistently, PCa cells co-implanted with MaOBs into the animals grew faster 
and larger tumors than those co-implanted with HLOBs. This may be due to the observation 
that MaOBs grow faster than HLOBs, but not that MaOBs are more differentiated than 
HLOBs, as differentiation of osteoblasts through L-Ascorbic acid and β-Glycerophosphate 
supplementation failed to increase PCa growth in vitro.Together, our study demonstrated 
that faster growing osteoblasts can lead to the proliferation of PCa cells. Although further 
studies are clearly needed, these findings suggest that the proliferation status of osteoblasts 
plays a crucial role in the regulation of the growth of bone metastatic cancer cells. Therefore, 
by developing drugs that are able to alter osteoblastic proliferation, perhaps we can mitigate 
the problem of recurrence in PCa patients either by perpetuating dormancy of bone meta-
static cells indefinitely, or by releasing bone metastatic cells from dormancy and making 
them more susceptible to anti-cancer therapies that rely on proliferation pathways in order 
to eradicate the disease entirely.
Disclosures: Yusuke Shiozawa, None
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The Value of SSTR2A Immunohistochemistry in Tumor- Induced 
Osteomalacia *Seunghyun Lee1, Namki Hong2, Sang-kyum Kim3, Yumie Rhee2. 
1 Department of Internal Medicine, Severance Hospital, Endocrine Research 
Institute, Yonsei University College of Medicine, Republic of Korea, 2Department 
of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei 
University College of Medicine, Republic of Korea, 3Department of Pathology, 
Yonsei University College of Medicine, Republic of Korea
Tumor-induced osteomalacia(TIO) is a paraneoplastic disease with hypophosphatemia 
in which phosphaturic mesenchymal tumor-mixed connective tissue variant(PMT-MCT) 
secrete excessive fibroblast growth factor 23(FGF23). The localization of the tumor is im-
portant because curative surgery is possible. However, it is difficult to make a confirma-
tive diagnosis from a histologic perspective because PMT-MCT is similar in appearance 
to other tumors such as hemangiopericytoma, osteosarcoma. Therefore, a more sensitive 
histologic biomarker is needed to support the diagnosis of TIO. To date, FGF23 immuno-
histochemistry(IHC) or RT-PCR has been proposed as a useful adjunctive tool to confirm 
the diagnosis of TIO. However, the staining pattern of FGF23 IHC is often focal, limiting 
diagnostic utility, particularly in small biopsies. Recently, a 68Ga-DOTATOC scan, which 
sensitively detects expression of somatostatin receptor 2A (SSTR2A) in the tumor, demon-
strated diagnostic value in localizing TIO. Based on this finding, we compared the diag-
nostic performance of FGF23 and SSTR2A IHC in patients with TIO, along with results of 
the 68Ga-DOTATOC scan. Medical records of patients with surgically confirmed TIO in 
Severance hospital from November 2010 to July 2019 were reviewed. Unstained slides of 
13 patients (7 males, 6 females) were obtained from the pathology repository of Severance 
hospital to perform additional IHC for FGF23 and SSTR2A. Among 13 patients, 12 patients 
underwent a 68Ga-DOTATOC scan, which successfully detected suspicious lesion except 
for one case. Histological evaluation was performed by a single pathologist based on the 
H-score system using three components: the degree of dysplasia of the spindle cell, the 
presence of osteoclast type giant cell reaction, and the presence of rich vasculature. H-score 
was calculated by multiplying expression percentage and intensity with score 0 to 2 for each 
component(total score 0 to 6 points). SSTR2A showed higher H-score(median 6[IQR 6-6] 
vs. 4[2-6], p=0.009) compared to FGF23 IHC. When the nuclear pattern was counted as 
nonspecific, even greater difference of H-score was observed (SSTR2A 6 [6-6] vs. FGF23 0 
[0-2], p=0.001). Our findings suggest that SSTR2A IHC with H-score quantitation might be 
a sensitive, adjunctive diagnostic tool to ascertain the histologic diagnosis of TIO compared 
to FGF23 IHC. Further validation with negative controls is needed to evaluate the diagnostic 
accuracy of SSTR2A IHC.
Disclosures: Seunghyun Lee, None
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Serum total periostin is an independent marker of overall survival in non-
small cell lung cancer *Jean-Charles Rousseau1, Emmanuel Massy2, Madiagne 
Gueye3, Edith Bonnelye4, Marie Brevet5, Laurianne Chambard3, Michael 
Duruisseaux6, Olivier Borel1, Christelle Roger1, Raphaelle Guelminger6, Jean-
Baptiste Pialat7, Evelyne Gineyts8, Lamia Bouazza1, Marjorie Millet1, Jean-
Michel Maury9, Philippe Clezardin1, Nicolas Girard10, Cyrille Confavreux11. 
1Inserm UMR 1033, France, 2Inserm UMR1033 - Hospices Civils de Lyon 
- Université de Lyon, France, 3Service de Rhumatologie - Hospices Civils de 
Lyon, France, 4Inserm UMR1033 - CNRS ERL 6001/inserm U1232 - Institut de 
Cancérologie de l’Ouest - St Herblain, France, 5Anatomie Pathologie-Hospices 
Civils de Lyon, France, 6Service de Pneumologie - Hospices Civils de Lyon, 
France, 7Service de Radiologie - Hospices Civils de Lyon, France, 8inserm 
UMR 1033, France, 9Service de Chirurgie Thoracique, Hospices Civils de Lyon, 
France, 10Institut du Thorax Curie-Montsouris, France, 11Inserm UMR1033 - 
Hospices Civils de Lyon - Université de Lyon, France
Introduction. Lung cancer is a worldwide leading cause of mortality. At diagnosis, 30 
to 50% of non-small cell lung cancers (NSCLC) have bone metastases. The set-up of a 
metastatic niche between cancer cells and bone microenvironment is a key step of bone 
metastasis physiopathology. Periostin, an extracellular matrix protein, is expressed in bone 
in response to mechanical stress. In cancer setting, in vivo experiments have shown that 
periostin in microenvironment was an early event of the niche process favoring cancer cell 
proliferation through Wnt signaling. Moreover, some cancer cells overexpressed periostin. 
Thus, we wanted to test the prognosis value of serum total periostin level in NSCLC pa-
tients.Methods. Blood samplings were performed in NSCLC patients either with localized 
tumor or with a first bone metastasis (metastatic group). Patients were prospectively fol-
lowed. NSCLC patients were paired on age and gender to healthy controls from OFELY and 
STRAMBO cohorts. Serum periostin was assessed using Biomedica® ELISA kit. Survival 
analysis and multivariate Cox model have been conducted in the overall cancer population 
and in the bone metastatic sub-group.  Results. 133 patients, aged 64+/-11 years, have been 
enrolled into non-metastatic (n=67) and metastatic (n=65) group. Median follow-up was 
2.8 years. Median serum periostin level was 1092 pmol/L in the whole cancer population. 
Periostin level was similar between localized tumor patients and controls but significantly 
higher (+40%) in bone metastases patients (medians : 887 vs 1009 vs 1703 pmol/L respec-
tively; p<0.0001).Metastatic status and a high serum periostin level (>= 1092 pmol/mL) 
was associated with a higher risk of death (HR [95% CI]=2.80 [1.59-4.95]; p=0.0003 and 
HR=2.09 [1.06-4.13]; p = 0.03 respectively) in multivariate Cox model. In bone metastatic 
group, the Cox multivariate model including age, CRP, CTX, Ca, albumin lymphocytes 
index, showed that an elevated periostin (above the highest value of localized group) re-
mained associated with a higher risk of death (HR=3.62 [1.74-7.52]; p=0.0005). Moreover, 
using the same antibody than the ELISA, we performed immunohistochemistry on bone 
metastasis biopsies. Beyond bone matrix expression, we observed intranuclear expression 
in tumoral cells.Conclusion. Our results in NSCLC, showed that serum periostin was asso-
ciated with overall survival and that periostin might be overexpressed by lung cancer cells 
in bone metastatic niche.
Disclosures: Jean-Charles Rousseau, None
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Investigating the Effect of Yoda1 on Osteocytes Mechanoregulation of Breast 
Cancer Bone Metastasis *Chun-Yu Lin1, Liyun Wang2, Lidan You1. 1University 
of Toronto, Canada, 2University of Delaware, United States
Introduction: Bone metastasis is a severe complication causing the major mortality of 
breast cancer patients. Since metastasized breast cancer disrupts the balanced bone remodel-
ing through the crosstalk with bone cells, exercise which mediates bone remodeling through 
mechanical loading and attenuates metastatic tumor growth could act as a preventive strat-
egy. However, commonly prescribed exercise can be physically challenging for cancer pa-
tients who are frail and can increase their risk of accidental injury, keeping them from bene-
fiting from exercise. Yoda1, an activator of the mechanosensitive Piezo1 channel, provides a 
unique target to simulate bone condition under exercise without actual significant movement 
of patients by enhancing mechanosensitivity of osteocytes, the major mechanosensory bone 
cells with high expression of Piezo1 [1]. Building from our previous results showing stim-
ulated osteocytes with oscillatory fluid flow (OFF) inhibit cancer invasion using a microflu-
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idic platform [2], this project aims to study if similar inhibition could be achieved under low 
shear stress OFF stimulation combining with Yoda1.Methods: Cell viability of MLO-Y4 
osteocytes-like cells and 4T1.2 breast cancer cells under Yoda1 treatment are tested by Cal-
cein AM. Then, rescuing mechanosensitivity of MLO-Y4 under 0.5 Pa low shear stress OFF 
by various concentration of Yoda1 is evaluated by intracellular calcium imaging (flow-on for 
3 mins). Finally, using microfluidic platform, we study the inhibition of 4T1.2 extravasation 
by Yoda1 treated MLO-Y4 under low shear stress OFF. MLO-Y4 seeded in the platform is 
treated with optimized concentration of Yoda1 and stimulated by 0.5Pa OFF 2 hrs/day for 
4 days, while adjacent non-stimulated lumen channel is coated with C166 endothelial cells 
and seeded with 4T1.2. The invasion distance and percentage that 4T1.2 migrate across 
lumen into side channels are monitored by fluorescence microscope.Results: MLO-Y4 and 
4T1.2 both demonstrate high cell viability under Yoda1 treatment (Figure A). Align with 
our hypothesis, preliminary data shows pretreating MLO-Y4 with 5 µM Yoda1 increases 
osteocytes response rate under 0.5Pa OFF by 21.5 % compared with untreated group (Figure 
B). 4T1.2 extravasation distance decreases in stimulated MLO-Y4 group (Figure C). To 
conclude, this project provides a novel treatment concept to prevent bone metastases for the 
fragile population.References: [1] Li. eLife. 2019. [2] Mei. Integr Biol. 2019.
Disclosures: Chun-Yu Lin, None
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Targeting Cartilage Epidermal Growth Factor Receptor (EGFR) Pathway 
for Osteoarthritis Treatment *Yulong Wei1, Ling Qin1, Tao Gui1. 1University 
of Pennsylvania, United States
Osteoarthritis (OA) is the most common chronic condition of the joints. Despite the fact 
that OA patients have a great level of pain and disability, neither a cure nor disease-modifying 
treatment exists. Our previous studies revealed that mice lacking EGFR activity specifically 
in cartilage (Col2-Cre) have accelerated knee OA during aging or after DMM surgery. To 
test whether this pathway can be targeted as a novel OA therapy, we overexpressed HBEGF, 
an EGFR ligand, using constitutive Col2-Cre and inducible Aggrecan-Cre (Tamoxifen x 5d 
at 3 mo of age). These mice had elevated p-EGFR and p-ERK levels specifically in cartilage. 
Compared to WT, Col2-Cre HBEGFOver mice had persistently enlarged articular cartilage 
(23% and 34% increases at 1 and 5 mo of age, respectively, n=8/group), due to an expanded 
pool of chondroprogenitors (79%) with elevated proliferation ability (49%), survival rate 
(68%), and lubricant production (52%). Strikingly, after receiving DMM surgery at 3 mo 
of age, both HBEGFOver models were resistant to cartilage degeneration (Mankin Score: 
sham: 0.9; DMM WT 10.0, DMM Col-Cre 2.1, DMM Aggrecan-CreER 2.5, n=8/group) 
and OA-induced joint pain 4 mo later. Treating mice with Gefitinib, an EGFR inhibitor, 
abolished the protective action against OA in HBEGFOver mice (Mankin Score: 9.0, n=8/
group). To pharmacologically target EGFR, we conjugated TGFα, a potent EGFR ligand, 
to polymeric micellar nanoparticles (NPs) via copper-free click chemistry. Cationic diblock 
copolymer PLL-PCL was introduced into the PEG-PCL NP to reduce the surface charge 
for improved cartilage binding. The resultant TGFα-NPs were stable and non-toxic with 
superior cartilage uptake, penetration, and joint retention abilities. They bound to primary 
chondrocytes and potently activated EGFR downstream targets in a TGFα/EGFR-specific 
manner. Intra-articular delivery of TGFα-NPs once every 3 wk for 3 mo effectively attenuat-
ed DMM surgery-induced OA cartilage degeneration (Markin Score: veh 8.9, TGFα 8.1, NP 
8.4, TGFa-NP 3.3, n=8/group), subchondral bone plate sclerosis, and joint pain. Genetic or 
pharmacologic activation of EGFR revealed no obvious side effects in knee joints and major 
vital organs in mice. Taken together, our studies demonstrate the feasibility of targeting 
EGFR signaling for OA treatment as a novel therapeutic approach using nanotechnology.
Disclosures: Yulong Wei, None
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Runx3 protects articular cartilage by direct induction of Prg4 *Kosei Nagata1, 
Taku Saito1, Fumiko Yano1, Hironori Hojo2, Yasuhide Iwanaga1, Sakae Tanaka1. 
1Department of Orthopaedic Surgery Faculty of Medicine The University of 
Tokyo, Japan, 2Department of Bioengineering, The University of Tokyo, Japan
Runx transcription factor family, including Runx1, Runx2, and Runx3, modulates skel-
etal development and osteoarthritis pathogenesis. Here, we examined expression and roles of 
Runx3 in these processes.Runx3 was expressed in the hypertrophic zone of mouse epiphy-
seal cartilage, and Col2a1-Cre;Runx3fl/fl mice displayed no obvious abnormality in skeletal 
formation.In adult mouse articular cartilage, Runx3 was dominantly detected in superficial 
zone. Runx3 proteins decreased with cartilage degeneration in both mouse and human carti-
lage.We next prepared Col2a1-CreERT2;Runx3fl/fl and Prg4-CreERT2;Runx3fl/fl mice for 
Runx3 deletion in total and superficial articular cartilage after skeletal growth, respectively, 
and compared with Runx3fl/fl littermates. Notably, osteoarthritis development was signifi-
cantly accelerated in surgically-induced model by resection of medial meniscus and medial 
collateral ligament (medial model, n = 12, each) and aging model (n = 10, each) of Co-
l2a1-CreERT2;Runx3fl/fl mice. Immunohistochemistry of sham joints showed that rate of 
Runx3 positive cells and Prg4 and Aggrecan positive area were decreased in Runx3-knock-
out articular cartilage. Prg4-CreERT2;Runx3fl/fl mice also displayed enhanced osteoarthritis 
progression both in the medial model (n = 10, each) and destabilization of medial meniscus 
model (n = 8, each).To identify target genes of Runx3, we isolated superficial chondrocytes 
from Col2a1-Cre;Runx3fl/fl and Runx3fl/fl mice and performed RNA- and ChIP sequenc-
ing. Extracellular matrix formation and collagen fibril organization were indicated as the 
Runx3 roles in superficial chondrocytes. Prg4 was identified as a target gene of Runx3 in 
the superficial chondrocytes, and other extracellular matrix genes were decreased by Runx3 
knockout in deep zone chondrocytes.In primary chondrocytes, Runx3 knockout leaded to 
downregulation of anabolic genes such as Acan/Aggrecan, and Prg4/Lubricin, while Runx3 
overexpression induced these factors.Finally, we performed intra-articular administration 
of Runx3 or GFP adenoviral vectors into knee joints of wild-type mice after the medial 
model surgery (n = 10, each). Runx3 overexpression was confirmed by immunohistochem-
istry, and osteoarthritis development was significantly suppressed by Runx3 maintenance.
We conclude that Runx3 protects articular cartilage through its anabolic roles, and may be a 
potential therapeutic target for osteoarthritis.
Disclosures: Kosei Nagata, None
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Notch signaling contributes to articular cartilage homeostasis by suppressing 
differentiation of superficial zone cells *Yasuhide Iwanaga1, Kosei Nagata1, 
Fumiko Yano2, Sakae Tanaka3, Taku Saito4. 1graduate student, Japan, 2Specially 
Appointed Associate Professor, Japan, 3Professor, Japan, 4Associate Professor, 
Japan
Notch is a single-pass transmembrane cell-surface receptor that plays a crucial role in 
cell-fate determination and differentiation during development. We previously reported that 
Notch-Hes1 pathway promotes osteoarthritis (OA) development; however, there are a few 
paradoxical reports and the mechanism underlying regulation of joint homeostasis by Notch 
signaling has not been fully elucidated. Recent studies have shown that superficial zone 
(SFZ) of articular cartilage not only contributes to joint surface lubrication by producing 
lubricin/Prg4, but contains progenitors of articular chondrocytes. Here, we examined expres-
sion and functions of Notch signaling in the SFZ. mRNA levels of Notch-related molecules, 
including Notch1, 2, and Hey1, were highly expressed in SFZ cells, compared to deep zone 
cells. For in vivo experiments, we generated Prg4-CreERT2;Rbpjfl/fl (KO) mice to delete 
Rbpj, an intranuclear cofactor of Notch intercellular domain (NICD), and to suppress Notch 
signaling activity specifically in the SFZ. After tamoxifen (TM) injection for 5 days at 11 
weeks of age, surgical destabilization of medial meniscus (DMM) was conducted in the 
right knee. TM-treated KO mice displayed marked OA development, i.e., cartilage destruc-
tion and osteophyte formation, 3 months after the surgery. Similarly, OA development was 
markedly enhanced in 12-month-old KO mice which received TM injection at 9 months. We 
further mated KO mice with Ai14 reporter mice, and examined fate of Rbpj-knockout SFZ 
cells, indicated as red fluorescent protein (RFP)-positive cells. Notably, RFP-positive cells 
were broadly distributed in the deep zone, while they disappeared in the SFZ within 8 weeks. 
RFP-positive cells were also detected widely in ectopic endochondral ossification in peri-ar-
ticular regions. In explant culture of femoral heads, chondrocyte maturation, determined 
by mRNA levels of Col2a1 and Acan, were enhanced by Rbpj knockout. In contrast, these 
markers were significantly suppressed in SFZ cells by NICD overexpression. In conclusion, 
Notch signaling is essential for SFZ cells to maintain the undifferentiated nature, and con-
tributes to homeostasis of articular joints.
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A Transgenic Rat for Noninvasive Assessment of Chondrogenesis In Vivo 
*Elisabeth Ferreira1, Hong Wu2, Landon Gatrell2, Ryan Porter1. 11University of 
Arkansas for Medical Sciences, Department of Internal Medicine. 2Department 
of Orthopaedic Surgery. 3Center for Musculoskeletal Disease Research., United 
States, 2University of Arkansas for Medical Sciences, Department of Internal 
Medicine, United States
Chondroprogenitor cell (CPC) differentiation, or chondrogenesis, represents an import-
ant bottleneck in the repair of not only articular cartilage, but also appendicular bone. Rat 
models of skeletal injury and repair are frequently employed in the preclinical development 
of novel treatments for stimulating new chondrogenesis. To support these efforts, we gen-
erated a transgenic rat strain that can be used to either noninvasively report endogenous 
chondrogenesis, for correlation with endpoint measures of tissue repair, or provide a source 
of exogenous reporter CPCs for use in transplantation studies. A transgene was constructed 
in which bioluminescent (firefly luciferase) and fluorescent (mCherry) reporters were placed 
under control of regulatory sequences from rat Col2a1. This transgene was injected into 
Lewis rat embryos, transgene-positive pups were bred with wild type Lewis rats, and the 
candidate lines were imaged by serial bioluminescence imaging. For two lines, substantial 
bioluminescence signal was detected from cartilaginous regions, including the appendicu-
lar synovial joints, spine, sternum, nose, and ears. Bioluminescent radiance was intense at 
1 month of age and rapidly declined with continued development, though signal was still 
readily detected above background in 17 month old animals. For the most promising line, 
reporter activity was evaluated at 5, 8, 12, and 23 weeks of age ex vivo. Explant imaging 
and immunohistochemistry confirmed that both firefly luciferase and mCherry expression 
are localized to cartilage, while non-cartilaginous tissues (e.g., fat, muscle, kidney) exhib-
ited negligible reporter levels. Longitudinal trends in reporter mRNA levels and luciferase 
activity agreed with in vivo imaging. To determine whether this model can report de novo 
chondrogenesis, we overexpressed bone morphogenetic protein 2 within the gastrocnemius 
muscle, which leads to ectopic bone formation through an endochondral pathway. Two to 
three weeks after initiating BMP2 overexpression, bioluminescence signal was detected 
from the muscle; this signal preceded heterotopic ossification, as determined by concurrent 
X-Ray imaging. Histology of explants taken during peak bioluminescence confirmed that 
this signal was associated with ectopic cartilage in the muscle. This animal model can help 
develop new strategies for stimulating cartilage and endochondral bone formation or for 
inhibiting chondrogenesis associated with heterotopic ossification.
Disclosures: Elisabeth Ferreira, None
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The role of Sox9 SUMOylation during mouse skeletal development 
*Masafumi Inui1. 1Meiji University School of Agriculture, Japan
Sox9 is a transcription factor essential for the chondrocyte differentiation in vertebrate. 
As the skeletal morphology alters sensitively to the change of Sox9 dosage, Sox9 activity 
is tightly regulated in multiple layers including post-translational modifications (PTMs). In 
vitro studies have reported the possible inhibitory role of ubiquitination or SUMOylation on 
Sox9 transcriptional activity, but the in vivo relevance of these PTMs during the skeletal de-
velopment remains unknown. To elucidate the role of Sox9 PTMs in skeletal development, 
we introduced a point mutation to the genomic sequence of mouse Sox9 so that 396th lysine, 
an evolutionary conserved PTM target residue, is substituted to arginine. The mouse carry-
ing Sox9K396R mutation showed reduced body size, delayed endochondral ossification, and 
up-regulation of Sox9 target genes, indicating that Sox9 activity is negatively regulated by 
the PTMs on K396 during skeletal development. The long bones of Sox9K396R mouse be-
came shorter and thicker, probably due to the disturbed columnar alignment of proliferation 
zone chondrocytes. Sox9 protein level was not altered in Sox9K396R chondrocyte, implying 
that K396 was targeted by regulative modification. Consistently, K396R mutation on Sox9 
abolished its SUMOylation, but not the ubiquitination, indicated that SUMOylation is the 
major PTM on K396. We found that SUMO-fused Sox9 localized in nucleus, bound DNA, 
but could not activate the target gene expression. Furthermore, SUMO-fused Sox9 repressed 
the transcriptional activity of co-expressed non-SUMOylated Sox9 in a promoter dependent 
manner. As the SUMOylation level was reduced in mutant Sox9 that could not bind DNA, 
SUMOylation could act as a negative feedback regulation on Sox9 transcriptional activity. 
In sum, our study revealed the in vivo relevance of PTMs on Sox9 in mammalian skeletal 
development. 
Disclosures: Masafumi Inui, None
P-186
The Epigenetic Reader Brd4 Regulates Long Bone Formation *M. Lizeth 
Galvan1, Christopher Paradise1, Sofia Jerez1, Eva Kubrova1, S. Sharare Dehghani1, 
Oksana Pichurin1, Roman Thaler1, Andre van Wijnen1, Amel Dudakovic1. 1Mayo 
Clinic, United States
Formation of long bones by endochondral ossification, a process in which a cartilagi-
nous matrix is replaced by mineralized tissue, is controlled by signaling pathways that regu-
late key transcription factors, including Sox9 and Runx2. The accessibility of these factors to 
chondrogenic genes is modulated by chromatin structure which is linked to post-translation-
al modifications on histone proteins. We recently showed that the epigenetic regulator Brd4, 
a bromodomain protein that binds and interprets acetylated lysines on histones, supports 
osteogenic differentiation in vitro. Our current studies assess the functional contribution of 
Brd4 on long bone formation and chondrogenesis. Conditional (cKO) ablation of Brd4 in 
the mesenchyme (Prrx1-Cre) yields viable mice that are smaller and exhibit impairments in 
endochondral ossification. Specifically, mesenchymal Brd4 loss delays long bone formation 
(46% decline in femoral length at 3 weeks) and causes abnormal growth plate morphology. 
In support, a significant reduction in proliferative zone (25% decline at 1 week) and hyper-
trophic zone (40% decline at 1 week) within the physis and impaired formation of the sec-
ondary ossification center (60% decline at 3 weeks) is observed in Brd4 cKOPrrx1 mice. We 
also generated mice in which Brd4 function is ablated in chondrocytes (Col2a1-Cre). With 
the exception of a few survivors, the majority of Brd4 cKOCol2a1 perish immediately after 
birth. Preliminary assessment of surviving mice and embryos reveals shortened long bones, 
suggesting that chondrocyte-specific Brd4 loss impairs endochondral ossification. In vitro 
assessment of ATDC5 cells and ex vivo analysis of immature mouse articular chondrocytes 
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reveals that Brd4 supports chondrogenic differentiation and maturation, reflected by reduced 
expression of endochondral genes, Alcian Blue staining and Alizarin Red staining. Loss of 
Brd4 function significantly suppresses expression of genes that are regulated by Sox9 (e.g., 
Col2a1 and Acan) and Runx2 (e.g., Sp7/Osx and Mmp13) in differentiating chondrocytes. 
Hence, our results suggest that Brd4 is required for long bone formation and facilitates the 
transcriptional activities of Sox9 and Runx2 to support endochondral bone formation.  
Disclosures: M. Lizeth Galvan, None
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Glutamine Metabolism in Cartilage Tumors *Hongyuan Zhang1, Vijitha 
Puviindran1, Puviindran Nadesan1, Hidetoshi Tsushima2, Yuning Tang3, Leyao 
Shen1, Guofang Zhang4, Courtney Karner1, Benjamin Alman1. 1Department 
of Orthopaedic Surgery, Duke University, United States, 2Department of 
Orthopaedic Surgery, Kyushu University, Japan, 3Department of Genetics, 
Stanford University, United States, 4Duke Molecular Physiology Institute, Duke 
University, United States
INTRODUCTION: Enchondromas (ECA) are cartilage tumors that arise from growth 
plate chondrocytes that fail to undergo terminal differentiation. They affect approximately 
3% of the population causing pain, deformity, and can progress into malignant chondro-
sarcomas (CSA). There are currently no effective drugs for this condition. The majority 
of ECAs and around 50% of CSAs harbor somatic mutations in isocitrate dehydrogenases 
(IDH). Our lab reported that a chondrocyte specific Idh1 mutation was sufficient to initiate 
ECA formation and cause defects in chondrocyte differentiation during endochondral bone 
development. Mutant IDH produced the unique “oncometabolite” D-2-hydroxyglutarate 
(D-2HG), however, inhibition of the ability of mutant IDH to produce 2-HG has minimal 
effects on the tumorigenic properties of cartilage tumors. Previous studies demonstrated 
D-2HG was primarily derived from glutamine in glioma cell lines with IDH1 mutations, 
and inhibiting glutamine metabolism slows down tumor growth of glioma. In this study, 
we investigated the role of glutamine metabolism in cartilage tumors and test whether glu-
taminase (GLS), the enzyme catalyzes the first step of glutamine metabolism, could be a 
therapeutic target for enchondroma and chondrosarcoma. RESULTS: We found glutaminase 
activity in Idh1 mutant chondrocytes were significantly higher while the GLS protein level 
remained unchanged. Carbon tracing experiment showed glutamine is the primary source for 
the generation of D-2HG. Deleting Gls in Idh1 mutant chondrocytes exacerbated enchon-
droma-like phenotype in adult mice. During embryonic development, deleting Gls in Idh1 
mutant chondrocytes inhibited hypertrophic differentiation of chondrocytes and caused an 
increase in proliferation. However, in the study of chondrosarcoma, inhibiting glutaminase 
reduced cell viability of multiple patient samples in vitro and in vivo. SIGNIFICANCE: This 
study identifies the role of glutamine metabolism in cartilage tumors may differ at different 
stages of tumor development. It will help identify novel therapeutic targets for enchondroma 
and chondrosarcoma. 
Disclosures: Hongyuan Zhang, None
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Generation of a Quantitative Luciferase Reporter for Sox9 SUMOylation 
*Masafumi Inui1, Hideka Saotome1, Atsushi Kubo2. 1School of Agriculture, 
Meiji University, Japan, 2Institute of Development, Aging and Cancer, Tohoku 
University, Japan
Sox9 is a master transcription factor for chondrogenesis, which is essential for chondro-
cyte proliferation, differentiation, and maintenance. Sox9 acts in a dose-dependent manner 
in mammalian skeletal development, and its haploinsufficiency causes bone malformation 
and perinatal death in both mice and humans, while the overexpression of Sox9 also causes 
abnormalities in skeletal elements. To maintain its activity within appropriate levels, Sox9 is 
regulated by multiple layers, including post-translational modifications, such as SUMOyla-
tion. Although Sumoylation represses the Sox9 activity in the neural crest cells of Xenopus 
laevis, its role in the chondrogenic process remains unclear. As SUMOylation could be in-
volved in Sox9 dose regulation, its quantitative detection during chondrogenesis is import-
ant. However, quantitative and dynamic detection of SUMOylation of specific proteins is 
technically difficult. Therefore, a detection method for visualizing the SUMOylation in live 
cells is required to fully understand the role of Sox9 SUMOylation. To solve this probrem, 
we generated a quantitative reporter for Sox9 SUMOylation that is based on the NanoBiT 
system. The simultaneous expression of Sox9 and SUMO1 constructs that are conjugat-
ed with NanoBiT fragments induced luciferase activity in SUMOylation target residue of 
Sox9-dependent manner. In HEK293T cell, the reporter signal could be detected from both 
cell lysates and live cells. The signal from live cells could be visualized by the microscope. 
Furthermore, the signal level of our reporter responded to the co-expression of SUMOyla-
tion or deSUMOylation enzymes by several fold, showing dynamic potency of the reporter. 
The reporter was active also in ATDC5 cells, which have chondrogenic potential. Finally, us-
ing this reporter, we revealed an extracellular signal conditions that can increase the amount 
of SUMOylated Sox9. In summary, we generated a novel reporter that was capable of quan-
titatively visualizing the Sox9-SUMOylation level in live cells. It will be interesting to apply 
this reporter for detecting SUMOylation level of Sox9 during chondrocyte differentiation to 
understand the role of Sox9 regulation by SUMOylation in cartilage formation. This reporter 
will be useful for understanding the dynamism of Sox9 regulation during chondrogenesis.
Disclosures: Masafumi Inui, None
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Targeted Deletion of the Glucocorticoid Receptor in Chondrocytes 
Attenuates Cartilage Degradation in Murine Osteoarthritis *Eugenie 
Macfarlane1, Jan Tuckermann2, Markus Seibel1, Hong Zhou1. 1ANZAC Research 
Institute, University of Sydney, Australia, 2University of Ulm, Germany
Although glucocorticoids (GCs) are often used in the treatment of osteoarthritis (OA) 
for pain relief, the function of endogenous GCs in the pathogenesis of OA remains unknown. 
We have previously shown that disruption of endogenous GC signaling in osteoblasts and 
osteocytes mitigates OA in mice by reducing the severity of cartilage damage, subchon-
dral bone sclerosis and osteophyte formation. This finding led us to investigate whether 
disruption of endogenous GC signaling in chondrocytes also affects the development of 
OA.Osteoarthritis of the knee joint was induced by surgical destabilization of the medi-
al meniscus (DMM) in tamoxifen-inducible glucocorticoid receptor-knockout (chGRKO) 
mice and their wild-type (WT) littermates at 22-weeks of age (n=10-11 per group). Sham 
surgery was used as a control (n=4-5 per group). Both WT-DMM and chGRKO-DMM mice 
developed apparent OA 16-weeks after surgery, characterized by cartilage degradation, sub-
chondral bone sclerosis and osteophyte formation. No obvious signs of inflammation were 
observed histologically at this time point. Histological semiquantitative scoring revealed 
that compared to WT-DMM mice, cartilage damage was significantly less pronounced in 
chGRKO-DMM mice, particularly at the medial tibial plateau and femur condyle (Fig. 1A, 
B). Medial tibial cartilage area assessed by histomorphometry was 5912μm2 and 4632μm2 
in chGRKO-DMM and WT-DMM mice respectively (p=0.0149; Fig. 1B). Similarly, intact 
medial femoral cartilage area was 6728μm2 and 5384μm2 in chGRKO-DMM and WT-
DMM mice respectively (p=0.0116; Fig. 1B). Deletion of the glucocorticoid receptor in 
chondrocytes appeared to have no impact on subchondral bone sclerosis, osteophyte forma-
tion or synovial inflammation as no differences were observed between chGRKO-DMM and 
WT-DMM mice by either micro-CT or histomorphometry analyses (Fig. 1C).We conclude 
that endogenous GC signaling in chondrocytes promotes cartilage degradation but not ab-
normal bone formation (subchondral bone sclerosis and osteophytes) in a mouse model of 
surgically induced OA.
Disclosures: Eugenie Macfarlane, None
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Role of PHOSPHO1 in the Biogenesis and Function of Matrix Vesicles 
*Flavia Amadeu de Oliveira1, Colin Farquharson2, José Luis Millán1, Massimo 
Bottini1. 1Sanford Burnham Prebys Medical Discovery Institute, United States, 
2University of Edinburgh, United Kingdom
Matrix vesicles (MVs) are a class of extracellular vesicles released by mineral-compe-
tent cells that play a key role in the deposition of hydroxyapatite during physiologic miner-
alization and ectopic calcification1. MV-mediated mineralization is driven by a constellation 
of proteins present both on the outer surface of the MV membrane and in the MVs’ lumen 
and acting in concert to regulate the extracellular concentration of calcification inhibitors as 
well as the intraluminal concentration of Ca2+ and Pi ions. Orphan phosphatase 1 (PHOS-
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PHO1) is present in the cytosol as well as the MVs’ lumen where it produces Pi from phos-
phocholine and phosphoethanolamine generated by distinct enzymatic cascades acting upon 
the vesicle’s phospholipid membrane2. Recently, we have shown that Phospho1-/-chondro-
cytes have impaired MV biogenesis and function3 - the latter phenomenon correlated to 
the absence of a mineralization precursor, the nucleation core (NC), in the MVs’ lumen 
by AFM-based analyses4. Herein, to further assess the role of PHOSPHO1 on MV bio-
genesis and function, we used chondrocytes isolated from the growth plate of C57BL/6J 
mice cultured in osteogenic medium in the presence or absence of a PHOSPHO1 inhibitor 
(MLS-0263839). Calcium deposition, assessed by Alizarin-Red staining, showed that MLS-
0263839 significantly hampered mineralization. We then assessed the mRNA expression of 
chondrocyte markers (Runx2, Col10a1), molecules involved in nucleotide signaling (Ent-
pd1, Nt5e, P2rx7), enzymes responsible for Pi turnover on the MV surface (Alpl, Enpp1, S
pp1, Slc20a1, Slc20a2) and inside MVs (Phospho1, Enpp6, Pla2g4a, Smpd3, Chka, Etnk1), 
enzymes responsible for Ca2+ turnover (Anxa5, Anxa6), markers of mitochondrial biogene-
sis (Tfam, Ppargc1a, Nrf1), and proteins participating in autophagy (Becn1, Atg5, Map1lc3a, 
Map1lc3b) and mitophagy (Pink1, Park2, Sqstm1). Our data show that the expression of all 
these mRNAs increased in mineralizing chondrocytes with time, except for Anxa5, Anxa6, 
Nrf1 and Becn1 whose expression did not significantly change. Our data also show that the 
presence of MLS-0263839 in the culture medium blunted the expression of all these mR-
NAs, except for Anxa6, Nrf1 and Map1lc3b, without affecting cell viability. Taken together, 
our results suggest that PHOSPHO1 enzymatic activity is involved in upstream processes 
driving MV biogenesis and function.1.Bottini M et al. 20182.Dillon S et al. 20193.Yadav M 
et al. 20164.Plaut JS et al. 2019
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SLC26A11 implicated in a new sulfate transport disease *Smrithi Salian1, 
Thi Tuyet Mai Nguyen1, Justine Rousseau3, Julie Gauthier0, Jacques L Michaud0, 
Benjamin Ellezam1, Peter Glavas0, Marie Laberge-Malo0, Antonio Rossi0, 
Johan Thevelein0, Philippe M Campeau1. 1CHU Sainte-Justine Research Center, 
University of Montreal, Montreal, QC H3T 1C5, Canada, Canada, 3CHU Sainte-
Justine Research Center, University of Montreal, Montreal, QC H3T 1C5, 
Canada, Canada, 0CHU Sainte-Justine Research Center, University of Montreal, 
Montreal, QC H3T 1C5, Canada, Canada, 0Department of Molecular Medicine, 
Unit of Biochemistry, University of Pavia, 27100 Pavia, Italy, Italy, 0Laboratory 
of Molecular Cell Biology, Institute of Botany and Microbiology, KU Leuven, 
Flanders, Belgium, Belgium
Solute carrier 26 (SLC26) gene family encodes a conserved membranous protein that 
functions as anion exchangers capable of transporting a wide variety of monovalent and di-
valent anions across the plasma membrane. So far three SLC26 genes have been known to be 
implicated in Mendelian diseases: SLC26A4 in deafness with enlargement of the vestibular 
aqueduct, SLC26A3 chloride diarrhea and SLC26A2 is implicated in several skeletal dys-
plasias, including achondrogenesis, atelosteogenesis II, multiple epiphyseal dysplasia and 
diastrophic dysplasia. SLC26A11 was reported to be localized to cytoplasm and lysosome, 
where it was proposed to serve as a sulfate exporter. It is expressed broadly including in 
the brain.In this study, we have identified a mutation in SLC26A11 in a patient and we hy-
pothesize that lack of functional SLC26A11 results sulfate accumulation in lysosomes and 
a relative lack of cytoplasmic availability of sulfate essential for GAG synthesis.The patient 
was born to consanguineous Iranian parents with significant joint hypermobility at birth 
and club feet, and eventually presented microcephaly, intellectual disability, proptosis, hip 
dysplasia, coxa vara, lordosis, scoliosis and feet contractures. She was given a clinical di-
agnosis of Larsen syndrome at birth, and the current phenotype resembles musculocontrac-
tural Ehlers-Danlos. Exome sequencing revealed a homozygous missense variant c.206A>G 
(p.Tyr69Cys) in SLC26A11 (NM_173626.3). We have obtained fibroblasts from this patient 
and stably corrected them with a lentivirus encoding wildtype SLC26A11.We will analyze 
the lysosomal sulfate export as well as GAG synthesis in patient fibroblast and iPSC-derived 
chondrocytes. We generated codon-optimized constructs to express SLC26A11 in yeast to 
assess the variant’s effect on sulfate import.In conclusion, we identified a new disorder of 
sulfate transport and are actively looking for additional patients to corroborate our findings 
and define the extent of the disease.
Disclosures: Smrithi Salian, None
P-192
Chondrogenic Differentiation of Mesenchymal Stem Cell-Like KS483 
Cells *Katja Fagerlund1, Natalia Habilainen-Kirillov2, Clemens Löwik3, Alan 
Chan4, Jukka Rissanen1, Jenni Mäki-Jouppila1. 1Pharmatest Services, Finland, 
2Pharmatest Services, Finland, 3Department of Radiology, Leiden University 
Medical Center, Netherlands, 4Percuros, Netherlands
KS483 cells, a murine mesenchymal progenitor cell line, can differentiate into chon-
drocytes, adipocytes and osteoblasts and are a well-characterized model for the study of 
osteoblast differentiation and bone formation. For chondrogenic differentiation, KS483 cells 
were cultured in three-dimensional (3D) pellet culture system in 96-well plates in serum-free 
differentiation medium. The pellets were cultured in the presence and absence of BMP-6 for 
17-28 days and the medium was refreshed in 2-3 day intervals. The pellets were embedded 
in paraffin, sectioned, and stained for Safranin O and Alcain blue for assessment of sulfated 
glycosaminoglycan (sGAG) content, and processed for immunohistochemistry to visual-
ize type II collagen. For biochemical analysis, the pellets were digested with proteinase 
K and assayed for sGAG at days 17, 24 and 28. Type II collagen carboxyterminal propep-
tide (CP-II) was determined in the culture medium collected at day 17. BMP-6 showed 
concentration-dependent stimulatory effects on chondrogenic differentiation visualized by 
histological stainings, increased sGAG content of the pellets, and increased CP-II released 
into the culture medium. These results suggest that the KS483 cells can be used for in vitro 
chondrogenic differentiation model and for identifying novel chondrogenic compounds or 
compounds with inhibitory effects on chondrogenesis. The cells can be easily expanded and 
utilised for studies including large number of study groups and replicates.
Disclosures: Katja Fagerlund, None
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A Novel Regulatory Role of TRAPPC9 in Osteoarthritis *Nazar Hussein1, 
Fayez Safadi2. 1Kent State University, United States, 2Northeast Ohio Medical 
University, United States
Osteoarthritis (OA) is the most prevalent joint disease worldwide, causing chronic dis-
ability in older people. Various factors are associated with its pathogenesis, including aging, 
obesity, joint instability, and joint inflammation. The articular cartilage cells, chondrocytes, 
are responsible for maintaining homeostasis of the ECM by producing its major compo-
nents. Several activators (pro-inflammatory mediators) such as Interleukin 1 beta (IL-1β) 
is able to activate NF-kB signaling pathways. There are two distinct pathways, which can 
activate the NF-kB signaling cascades. The first one termed canonical or classical pathway, 
activation of IKKα/IKKβ/IKK?-NEMO complex will activate this pathway. On the other 
hand, the non-canonical or alternative pathway activation relies on NF-kB-inducing kinase 
(NIK). Trafficking Protein Particle Complex 9 (TRAPPC9) is a major subunit of TRAPPII 
Complex. Our data showed that TRAPPC9 binds IKKβ and NIK in chondrocytes. We be-
lieve such interaction could lead to a potential regulatory role of TRAPPC9 during NF-kB 
signaling cascades given that the role of TRAPPC9 in OA has not been studied yet. To 
explore the role of TRAPPC9 in OA, first, we assessed the gene expression/protein levels 
in primary human chondrocytes and found that TRAPPC9 expression is increased in IL-1β-
treated chondrocytes compared to controls. Next, we determined the effect of TRAPPC9 
downregulation using a viral system. TRAPPC9 downregulation might lead to positive or 
negative regulation of NF-kB signaling cascades. Studies are underway to determine the 
effects of modulating TRAPPC9 using in vivo studies, which include injection of viral par-
ticles of TRAPPC9 downregulation into the knee articular cartilage of C57BL6 mice after 
OA is surgically induced (DMM model). For OA histopathology assessment, The OARSI 
cartilage grading system will be used. Collectively, these studies are the first to report a novel 
role of TRAPPC9 in OA development.
Disclosures: Nazar Hussein, None
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Excessive mechanical strain accelerates intervertebral disc degeneration by 
disrupting the intrinsic circadian rhythm of nucleus pulposus cells *Li-Bo 
Jiang1. 1Zhongshan Hospital, Fudan University, China
Objective. Night shift workers with disordered rhythmic mechanical loading are more 
prone to have low back pain and intervertebral disc degeneration (IDD). We aim to inves-
tigate the effect of mechanical loading on the intrinsic circadian rhythm (CR) of nucleus 
pulposus (NP) cells and IDD progression.Methods. Human tissues, aged rat IVDs and a 
punctured rat intervertebral discs (IVDs) were established, collected and analyzed by RNA 
sequencing and histology. NP cells were treated with excessive cyclic tensile strain (CTS) 
to detect the intrinsic CR and the involved mechanism. An upright rat models with longtime 
light-dark (LD) shift for 12 months mimicking Night shift workers were established to detect 
the effect of mechanical loading on IDD.Results. The CR was dampened in the degenerated 
and aged NP cells. Longtime environmental CR disruption promoted IDD in rats. Moreover, 
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excessive mechanical strain disrupted the CR and inhibited the expression of core clock pro-
teins. The inhibitory effect of mechanical loading on the expression of extracellular matrix 
genes could be reversed by BMAL1 overexpression in NP cells. The Rho/ROCK pathway 
was demonstrated to mediate the effect of mechanical stimulation on CR. Prolonged me-
chanical loading, for 12 months, disrupted the intrinsic CR and induced IDD in a model 
of upright posture in a normal environment. Unexpectedly, the mechanical loading further 
accelerated the IDD in a LD cycle-disrupted environment.Conclusion. These results indicate 
that intrinsic CR disruption might be a mechanism involved in loading-induced IDD and a 
potential drug target for night shift worker.
Disclosures: Li-Bo Jiang, None
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Dietary Supplementation with Hydrolyzed Hyaline Cartilage Mitigates 
Posttraumatic Osteoarthritis: Potential Role of Shifts in Gut Microbiome 
*Yuan-Haw Wu 1, Samantha H. Landgrave2, Honey Hendesi1, Lacey J. Favazzo1, 
David A. Villani3, William Schroeder1, Stacey M. Thomas1, Karin A. Payne3, 
Janne Prawitt4, Michael J. Zuscik3. 1Department of Orthopedics, Anschutz 
Medical Campus, Aurora, Colorado, United States, 2Department of Orthopedics, 
Anschutz Medical Campus, Aurora, Colorado; Cell Biology, Stems Cells and 
Development Program, Anschutz Medical Campus, University of Colorado, 
Aurora, Colorado, United States, 3Department of Orthopedics, Anschutz 
Medical Campus, Aurora, Colorado; Cell Biology, Stems Cells and Development 
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Objective: Osteoarthritis (OA) is a leading cause of disability globally. Symptom pallia-
tion is the only option for treatment as there is no available disease-modifying therapy. It has 
recently been suggested that changes in the gut microbiome can influence OA progression; 
in fact, the chondroprotective effects of various nutraceuticals, including dietary supple-
ments comprised of cartilage components, may be due to their ability to shift the gut micro-
biome composition. One supplement in particular, known as hydrolyzed hyaline cartilage 
(hHC), has anecdotally been identified as joint protective. However, the exact mechanism 
of this protection and the potential involvement of the gut microbiome is yet to be explored. 
This study aimed to investigate the basis for joint protection conferred by hHC in OA. Meth-
od: Posttraumatic OA (PTOA) was surgically induced via destabilization of the medial 
meniscus in male C57BL/6J mice consuming a defined diet from OpenSource (D1245H). 
Injured mice were provided a daily oral supplement of hHC (0.62mg/gm body weight) or 
vehicle, beginning 2 weeks prior to injury. Three- and 12-weeks post-injury, knee joints 
were harvested, fixed, embedded in paraffin and cut sections were stained with Safranin O. 
Histomorphometry analyses were performed to measure the area of femur and tibial carti-
lages. TNF immunohistochemistry was performed to study joint inflammation and TUNEL 
staining was performed to assess chondrocyte apoptosis. Fecal material was also collected 
to support analysis of the gut microbiome via 16S rDNA sequencing. Result: Histomor-
phometry revealed that hHC-supplemented mice had more tibial and femoral uncalcified 
cartilage at both 3- and 12-week post-injury. These results may be related to suppression 
of inflammation in the hHC cohort, which displayed a trend toward reduced synovial TNF. 
This paralleled a reduction in chondrocyte apoptosis in hHC-supplemented mice. Suggesting 
a potential mechanistic association, hHC supplemented mice displayed significant shifts in 
the gut microbiome that included loss of proinflammatory Peptococcaceae family members, 
particularly the species rc4-4. Conclusion: Findings suggest that oral dietary supplementa-
tion with hHC confers joint protective effects in PTOA as well as parallel alterations in the 
gut microbiome. This sets the stage for follow-on study of the potential mechanistic link 
between the microbial shifts induced by hHC and its ability to support chondroprotection.
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Acquired Autoimmune Parathyroid Hormone (PTH) Resistance due to 
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Background: Parathyroid hormone (PTH) resistance is a hallmark of pseudohypopara-
thyroidism, an inherited genetic disorder of PTH/PTH-related Peptide (PTHrP) signaling. 
However, PTH1 receptor-related autoimmune etiology has not yet been identified as the un-
derlying mechanism for this disease.Here we describe the first case of acquired autoimmune 
PTH resistance that is secondary to PTH1R autoantibodies.Clinical Case: A 60-year-old Af-
rican-American woman, who previously had normal calcium homeostasis, presented with 
acute, symptomatic hypocalcemia, hyperphosphatemia and markedly elevated serum PTH, 
consistent with parathyroid hormone resistance. She did not have a clinical or biochemical 
phenotype suggestive of pseudohypoparathyroidism. Whole-exome sequencing and GNAS 
methylation analysis revealed no genetic or epigenetic defects of the PTH/PTHrP signaling 
pathway. Treatment with Calcitriol and Calcium supplements was initiated with good clini-
cal response. Within 10 years of follow-up, the patient developed autoimmune hypothyroid-
ism, alopecia and an unusual form of membranous glomerulonephritis, raising the suspicion 
for an autoimmune etiology for PTH resistance. Luciferase immunoprecipitation system as-
say identified antibodies against PTH1R. Using an in vitro biological assay in GP-2.3 cells, 
we found that the antibodies derived from the patient’s serum blocked PTH downstream sig-
naling via Gsalpha/cAMP/protein kinase A pathway in a concentration-dependent manner.
The patient’s autoantibody profile led to the diagnosis of additional autoimmune diseases, 
including atrophic gastritis and Sjogren syndrome. Lymphocyte immunophenotyping using 
flow cytometry revealed an overall normal B and T cell profile, but with increased frequency 
of autoreactive CD21 low CD38-negative B cell subset, which is known to be enriched in 
patients with certain immune disorders. Genes associated with autoimmune inflammatory 
disorders were sequenced but no pathologic changes were detected.Conclusions: Identifi-
cation of the first case of autoimmune PTH resistance secondary to PTH1R autoantibodies 
extends the etiologic spectrum of hypoparathyroidism and should be considered when a 
patient presents with findings consistent with pseudohypoparathyroidism, especially in the 
presence of additional autoimmune diseases. 
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Background: Juvenile onset of primary osteoporosis is a rare skeletal disorder with a 
highly heterogenous clinical presentation and complex poorly understood genetic etiolo-
gy. Low-density lipoprotein receptor-related protein 5 (LRP5), a Wnt-β-catenin pathway 
receptor involved in bone mineral density (BMD) regulation, has been reported in children 
with primary osteoporosis mainly due to missense and frame-shift mutations. To our knowl-
edge, there is only one report of in-frame deletions in exon 21 possibly being implicated in 
pregnancy related osteoporosis (1). We report the first case of a rare heterozygous de novo 
in-frame deletion in exon 21 of LRP5 gene in a girl with juvenile onset primary osteopo-
rosis.Clinical Case: A 7.5 yo previously healthy European-African-American female born 
to non-consanguineous family, was noted to have left ankle and bilateral wrists fractures 
during sport activities occurring over the span of 1 y. On exam, she was of normal stat-
ure, had normal sclerae and vision, but was found to have hypermobile joints. Initial blood 
work revealed an elevated iPTH 72 pg/mL (9-59), normal Ca 9.6 mg/dL (8.9-10.4), and 
low 25OH-Vitamin D 17 ng/mL (30-100), which normalized with supplementation to 30.4 
ng/mL. By 10.5 yo, she had sustained multiple sports related and pathologic fractures of 
long bones with progressive bone pain and functional ambulatory impairment. Radiographic 
evaluation showed osteopenia, multiple healed long bone fractures with presumed non-os-
sifying fibroma in the distal right femoral metaphysis, and subtle height loss of T4-5 verte-
brae. CT bone densitometry at 12 yo showed low mean cancellous lumbar vertebral BMD 
of 190 mg/cm3 (ref. 285 +/- 45) and normal cortical BMD of the femoral midshaft of 1977 
mg/cm3 (ref. 2000 +/- 60). Genetic testing for Osteogenesis Imperfecta returned negative 
for COL1A1 and COL1A2 mutations. Whole exome sequencing (WES) revealed a rare, de 
novo heterozygous mutation in exon 21 that involved deletion of nucleotides 4454 to 4465 
resulting in an in-frame deletion of amino acid 1485 to 1488. This mutation is predicted to 
be deleterious by in silico analysis.Conclusion: We present the first case of a young female 
with progressive pathologic fractures, functional ambulatory impairment, and low BMD 
in childhood, consistent with juvenile onset primary osteoporosis. WES revealed a rare de 
novo heterozygous in-frame deletion mutation in LRP5, providing a plausible biological 
mechanism for her clinical presentation, and further contributing to the increasing genet-
ic heterogeneity of juvenile onset primary osteoporosis and LRP5-related bone disorders.
Reference: (1) Cook, F., Mumm, S., Whyte, M., Wenkert, D. Pregnancy-associated osteo-
porosis with a heterozygous deactivating LDL receptor-related protein 5 (LRP5) mutation 
and a homozygous methylenetetrahydrofolate reductase (MTHRF) polymorphism. JBMR. 
2014;29 (4): 922-8.
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of Pennsylvani, United States
Background: Hypophosphatemia is a well-documented side effect of intravenous iron, 
mostly reported with ferrous carboxymaltose (FCM). However, associated severe osteoma-
lacia resulting in bone fractures is largely under-recognized. Herein, we report a case of 
FCM-induced hypophosphatemia complicated by multiple insufficiency fractures. Case:A 
73-year-old woman with history of Crohn’s disease, breast cancer and renal cell carcino-
ma was referred for evaluation of low bone mineral density (BMD). On evaluation, she 
was found to have hypophosphatemia. Workup revealed normal calcium (9.0 mg/dL), low 
phosphorus (1.8 mg/dL), low 1,25-dihydroxyvitamin D (19.2 pg/mL, NR: 19.9-79.3), and 
high alkaline phosphatase (200 U/L, NR: 38-126). 25 OH vitamin D (32 ng/mL) and iPTH 
(5 pmol/L, NR: 1.6-6.9) were normal. 24-hour urine phosphate was 0.533 g/d (NR: 0.6-1.2 
g/d) considered inappropriately high given low serum phosphorus. Lowest BMD was at 
the left hip with a T score of -2.9. She was started on calcitriol and phosphate supplements. 
However, she experienced non-traumatic multiple nondisplaced fractures in tarsal bones. 
Given history of malignancies and concern for tumor-induced osteomalacia, FGF23 levels 
were checked which were inappropriately normal (110 RU/mL, NR<180). Also noted to 
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have elevated C-telopeptide levels (1004 pg/mL, NR: 30 – 826). She revealed she was re-
ceiving IV iron infusions for iron-deficiency anemia, prescribed by local Hematologist, and 
had recently been switched from iron sucrose to IV FCM 700 mg/dose for total of 7 doses. 
Biochemical evaluation prior to FCM was unremarkable. FCM was discontinued and she 
was able to wean off Calcitriol and phosphate after 4 months. Phosphate levels remained 
stable, did not experience recurrent fractures and her BMD increased significantly one year 
after. Conclusion: Hypophosphatemia is a well-documented side effect of IV iron, mostly 
with FCM that causes rapid increase in active FGF23 leading to phosphate wasting. Se-
vere hypophosphatemia could last up to 12 weeks and can result in osteomalacia and bone 
fractures which are largely under-recognized. Only few studies describe long term effects 
on bone health as evident by our case. Clinicians should be aware of this complication and 
should consider using alternatives especially in patients at high risk for osteoporosis and 
fragility fractures.
Disclosures: Christie Turin, None
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Pseudohypoparathyroidism type 1A (PHP1A) is a rare disease characterized by Al-
bright’s hereditary osteodystrophy (AHO) and hormonal resistance including parathyroid 
hormone (PTH) and thyroid-stimulating hormone (TSH). PHP1A is caused by loss-of-func-
tion mutations in the imprinted GNAS gene, encoding Gsα, in the maternal allele. On the oth-
er hand, mutations in the paternal allele result in pseudopseudohypoparathyroidism (PPHP) 
characterized by AHO and no hormonal resistance. [Case 1] A 5-year-old boy with subcu-
taneous heterotopic ossification diagnosed by biopsy was referred to us since he had hypo-
calcemia and hyperphosphatemia. His height and body weight were 110.8 cm (+0.81SD) 
and 24.2 kg (+28.1%), respectively. He had AHO symptoms including round and flat face, 
brachydactyly, and knuckle sign and mild mental retardation. We started the treatment with 
active vitamin D and thyroid hormone since laboratory test showed hypocalcemia, hyper-
phosphatemia, and hypothyroidism: serum Ca 6.9 mg/dl, Pi 7.8 mg/dl, Alb 4.1 g/dl, ALP 
681 U/l, PTH 524.9 pg/ml, 25(OH)D 17 ng/ml, TSH 14.27 μIU/ml, FT4 1.2ng/dl. Genetic 
test revealed heterozygous c.1141delG (p.Asp381Thrfs23*) of his and his mother’s GNAS 
gene. [Case 2] A 1-year-old boy with subcutaneous heterotopic ossification diagnosed by 
biopsy was referred to us. He did not have any symptoms of AHO except ossification. His 
height and body weight were 69.2 cm (-0.53 SD) and 9.3 kg (+0.70 SD), respectively. The 
laboratory data were as follows: serum Ca 9.9 mg/dl, Pi 6.6 mg/dl, Alb 4.0 g/dl, ALP 449 
U/l, PTH 44 pg/ml, 25(OH)D 25.8 ng/ml, TSH 7.32 μIU/ml, FT4 0.87 ng/dl. Since hypo-
thyroidism was diagnosed, we started thyroid hormone treatment. Genetic analysis revealed 
heterozygous c.1117delC (p.Arg373Alafs*30) of his GNAS gene, although his mother did 
not harbor this mutation.These mutations we found have not been reported in the databases 
(LOVD and HGMD). The frameshift mutations introduce the addition of 23 or 30 amino 
acids in β6 strand / α5 helix of Gsa, which interact with G protein coupling receptor (GPCR) 
(Figure 1). When we predict the affinity between the Gsa with and without mutations and 
GDP by I-TASSER, there was no significant difference among these group: the confidence 
score of the prediction was 0.87, 0.83, and 0.94 in WT, c.1141delG (p.Asp381Thrfs23*), and 
c.1117delC (p.Arg373Alafs*30), respectively. Therefore, we concluded that these mutations 
do not affect the affinity with GDP but alter the association with GPCR and cause PHP1A 
or PPHP.
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Pseudo-hypoparathyroidism (PHP) is a genetic disorder characterized by end organ 
resistance to parathyroid hormone (PTH) action, resulting in hypocalcemia, hyperphospha-
temia and elevated PTH levels. PHP is sub classified into types 1A, 1B and 2. Patients with 
PHP-1A have the classical phenotypic features with short stature, round facies, and bilateral 
short 4th and 5th metacarpals. Types 1B and 2 lack this phenotypic features, but share sim-
ilar biochemical abnormalities. We present a patient with PHP-1A, with prolonged asymp-
tomatic hypocalcemia and hyperphosphatemia that resulted in alopecia due to entire scalp 
calcification.A 40y African American woman with past medical history of hypothyroidism, 
seizure disorder, scalp alopecia, and low IQ, presented to the clinic for management of hy-
pocalcemia and hyperphosphatemia. On initial evaluation, she reported worsening alopecia 
for the past several years, for which she was evaluated by dermatology and diagnosed with 
central centrifugal cicatricial alopecia after biopsy of the scalp.  She had been hypocalcemic 
for several years and reported no symptoms or seizure episodes. Her vital signs were normal: 
BP 106/72 mmHg, PR 83/m, Ht 150cm, Wt 72.8 kg, and BMI 33.8kg/m2.  On examination 
she had multiple diffusely scattered palpable small nodules on the entire scalp. Serum and 
ionized calcium levels were 6.6mg/dL (reference range[RR]: 8.6-10.4) and 0.89mmol/L (RR 
1.00-1.35), respectively, serum phosphorous was 5.7mg/dL (RR 2.5-4.5), and total and bone 
specific alkaline phosphatase 111 IU/L (RR 40-120), and 73 U/L (RR 11.6-29.6), respective-
ly. Serum intact PTH was 650pg/mL (RR 15-65), 25-hydroxyvitamin D 50ng/mL (RR >20), 
1,25-dihydroxyvitamin D 36 pg/mL (RR 20-79). BMD left femoral neck: -1.0SD, lumbar 
spine +0.2SD and forearm +0.5SD. A CT of the head showed dense calcifications of the 
basal ganglia and dentate nuclei, and unusual subcutaneous calcifications of the entire scalp. 
The diagnosis of PHP 1A was confirmed with phenotypic, biochemical, and radiological 
features, and was started on calcitriol and calcium carbonate, with eventual improvement 
in her lab abnormalities.Although intracranial calcifications are a well-known of idiopathic 
hypoparathyroidism, it is less commonly seen in post-surgical and PHP. We believe the ex-
tensive subcutaneous scalp calcifications due to underlying PHP most likely contributed to 
the progressive scarring resulting in alopecia totalis, which has not been previously reported 
in any form of hypoparathyroid states.
Disclosures: Jaspreet Hehar, None
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Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare genetic disorder with 
shared clinical features, characterized by hyperphosphatemia and recurrent ectopic  calcifi-
cations, in addition to other visceral and vascular manifestations, in absence of any inflam-
matory or neoplastic disorder.We present 3 cases of a family with two brothers and their 
uncle, with a  mutation ((homozygous c.985G>A, p.G329R) in exon 4 GALNT3G leading to 
a missense mutation), with various degrees of involvement and response to treatment.Case 
1: female, 44 years old, an episode of vertebral osteitis D11-D12Case 2: Male, 42 years old, 
moderate calcinosis in subcutaneous cellular tissue and incipient masses in hips and shoul-
ders.Case 3: Male 67 years old, type II diabetes the last 3 years, with severe calcifications 
in all large joints and severe diffuse calcification of subcutaneous cellular tissue in lower 
limbs as well as severe vascular calcifications with grade IV ischemia and left foot amputa-
tion.All three had normal serum creatinine  0.7-1.1 mg/dL (Ref 0.7-1.2) high phosphate (P) 
2-2.3 mmol/L (Ref 0.9-1.4), normal calcium, inappropriately low intact PTH 15-25 pg/mL 
(Ref 15-65) and very high FGF23 (C-Terminal FGF23 (Biomedica)) > 417 RU/mL (Ref 25-
130).  Low urinary P removal 12-18 mmol/24h (Ref 13-42) and high tubular P reabsorption 
95-97%The initial treatment with restriction of dietary P and administration of phosphate 
binders with meals (Algamate 1.5 g/8h) had a very limited effect on phosphatemia. The use 
of acetazolamide (250 mg/12h) decreased and normalized serum P in case 1, but remained 
high in cases 2 and 3. In case 3, due to the severity of the clinical picture, once obtained 
the Ethical Committee authorization, started treatment with teriparatide 20 mg SC/24h to 
promote phosphaturia and increase P uptake by the bone. The evolution of this patient (fig-
ure) was an important reduction in ectopic calcifications after 6 months of treatment. CTX 
and P1NP bone turnover markers increased from 0.11 to 0.46 ng/mL and from 22.1 to 70.2 
ng/L respectively. TRP decreased from 97 to 90%.In view of the PTH values in this family 
and the response observed in case 3, we consider whether the loss of function of FGF23 is 
limited to the renal tubule or if it could start inhibiting the secretion of PTH. In some cases of 
HFTC, the treatment with teriparatide could be an alternative or a complement to the dietary 
P restriction on, use of P  binders, acetazolamide and  thiosulfate.
Disclosures: Carlos Gomez-Alonso, None
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Eye Inflammation Associated With Bisphosphonate Treatment *Vicente 
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Bisphosphonates (BP) are first-line drugs in the treatment of osteoporosis and other 
bone diseases. Uveitis is a rare complication associated with their use.We describe 6 pa-
tients with ocular inflammation associated with BP use. The age range was between 50 and 
86 years. Four received BP for osteoporosis and two for oncologic disease. Five patients 
developed the inflammatory reaction after the first infusion of zoledronate and one patient 
after pamidronate. The time of presentation of this adverse effect varied between 12 hours 
and 7 days after infusion. In five cases anterior uveitis was diagnosed and one patient had 
posterior scleritis associated with optic perineuritis. In all patients the engagement was mon-
ocular. Three of them had received previous oral BP, without any adverse ocular reaction. 
One patient who was treated with a second zoledronate infusion repeated a new episode of 
uveitis.Patients who had anterior uveitis (n= 5) resolved with topical corticosteroids. The 
patient with posterior scleritis and perineuritis required systemic corticotherapy and hospi-
talization for pain management. All presented favorable evolution and ocular inflammation 
resolved within four weeks.Discussion:Drug induced uveitis is infrequent (<0.5%). Other 
more frequent causes include infections and systemic immune-mediated disease. BP act by 
inhibiting farnesyl pyrophosphate synthase. This leads to the accumulation of isopentenyl 
pyrophosphate which has a molecular similarity to a microbial compound and may therefore 
trigger the activation of gamma delta T cells.  This activation leads to the release of cyto-
kines and inflammatory mediators that lead to the acute phase reaction. Eye inflammation 
associated with BP treatment is an uncommon complication, but it should be suspected in 
patients who have pain, photophobia or red eye after BP application. It may recur in case of 
a new BP infusion. In our series all the patients had received intravenous BP. The evolution 
was favorable with the establishment of local or systemic corticotherapy. Early intervention 
is essential to improve pain and reduce the risk of complications. Multidisciplinary work is 
necessary for a proper diagnosis and treatment.
Disclosures: Vicente Ricardo González, None
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Background: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome 
caused by phosphaturic mesenchymal tumor (PMT) overproduction of fibroblast growth 
factor 23 (FGF23), resulting in hypophosphatemia and osteomalacia. Complete tumor re-
section is curative, with normalization of blood FGF23 and renal phosphate reabsorption, 
increase in 1,25-(OH)2-vitamin D and bone healing. Rapid postoperative changes in mineral 
homeostasis in the setting of chronic osteomalacia have the potential to induce accelerat-
ed bone mineralization associated with hypocalcemia and secondary hyperparathyroidism, 
reminiscent of the hungry bone syndrome following surgical cure of hyperparathyroidism. 
We present 2 patients with TIO who experienced postoperative hypocalcemia and second-
ary hyperparathyroidism, requiring significant calcium supplementation following curative 
PMT resection.Cases: Patient 1 was a 56 yo man who underwent complete resection of a 
chest wall PMT, with FGF23 falling from 482 RU/mL (nl < 180) to <50 RU/mL 12 hours 
after surgery. On postoperative day (POD) 2, blood calcium decreased to 8.4 mg/dL (8.6-
10.2) and PTH increased to 69.9 pg/mL (15-65) (Fig). Oral calcium was initiated to prevent 
further decline, requiring up to 5 g/d of elemental calcium. In addition to a calcium-rich diet, 
gradually decreasing doses of supplemental calcium were needed for about 2y to prevent 
elevated iPTH. His preoperative alkaline phosphatase of 222 U/L (40-129) slowly fell to 95 
U/L as his skeleton healed. Patient 2 was a 57 yo man with a rib PMT. Prior to surgery, due to 
inadequate dietary calcium, he was managed with 0.5-2g/d calcium supplementation, in ad-
ditional to calcitriol and phosphate. After PMT removal, FGF23 levels decreased from 352 
RU/mL to <50 RU/mL by POD2. Within 12 hours of surgery, calcium fell from 8.80 mg/dL 
to 7.32mg/dL and iPTH rose to 125.6 pg/mL (Fig). Calcium and PTH levels normalized on 5 
g/d of elemental calcium. Three months after surgery, he continues to require 4 g/d calcium 
to maintain a normal iPTH. In both patients, oral phosphate and calcitriol were discontinued 
at time of surgery; phosphate was given briefly for severe hypophosphatemia on POD1&2.
Conclusion: These cases of osteomalacia-induced hungry bone syndrome demonstrate the 
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expected physiological perturbation of mineral homeostasis following tumor resection in 
TIO, underscoring the importance of attentive post-surgical monitoring and calcium supple-
mentation following PMT resection.
Disclosures: Layne N. Raborn, BS, None
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A rare and challenging disease: successful treatment with pamidronate 
in Sternocostoclavicular Hyperostosis *A.T. Leerling1, A. Navas Cañete1, 
N.M. Appelman-Dijkstra1, E.M. Winter1. 1Leiden University Medical Center, 
Netherlands
Background: Sternocostoclavicular hyperostosis (SCCH) is a rare disease, constituting 
a sterile osteomyelitis with elevated bone turnover, mainly affecting the sternocostoclavicu-
lar region. It causes pain and shoulder dysfunction, and severely interferes with daily activi-
ties, work, and quality of life. SCCH has a relapse-remitting disease course, but local sclerot-
ic transformation, is slowly progressive and ultimately predisposes tissue degeneration. Low 
awareness amongst physicians and consequent diagnostic and therapeutic delay therefore 
construct a major problem, as unrecognized patients risk irreversible damage and associated 
morbidity. There is no established treatment for SCCH, but in our center we often observe 
a favorable effect of intravenous bisphosphonates. The rationale for bisphosphonates rests 
on them decreasing painfully increased bone turnover, and their anti-inflammatory effect in 
general.Clinical cases: Two adult female SCCH-patients presented with longstanding pain 
and swelling of the anterior chest wall, and compromised shoulder function. Complaints had 
existed without diagnosis for respectively 3 and 1.5 years. SPECT/CT illustrated elevated 
bone activity and sclerosis, with osteitis and hyperostosis, thereby confirming the diagno-
sis of SCCH (see attachment). Intravenous pamidronate in 3-month cycles was started for 
both, resulting in clinical remission as established by lower pain levels, improved shoulder 
function and decreased bone turnover on scintigraphy. Sclerosis persisted in one patient 
and completely resolved in the other. Conclusions and discussion: SCCH remains a rare but 
impactful bone disorder and lacks recognition. Here we described two SCCH cases treated 
with intravenous pamidronate, leading to clinical remission in both, and even complete res-
olution of sclerosis in one of them, which in our experience is a novel finding. The rationale 
for pamidronate treatment is reinforced by the clinical response together with the sclerotic 
regression, as this reversal lowers the chances of eventual permanent degeneration, associat-
ed with further disease burden and impaired quality of life.
Disclosures: A.T. Leerling, None
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Endocrinology, Department of Pediatrics, Emory University School of Medicine, 
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Introduction: Phosphate (phos) is critical for mineralization and skeletal development. 
Hypophosphatemia can result in metabolic bone disease. We describe a 9-year-old girl with 
Fanconi syndrome, hypophosphatemic rickets and nephrocalcinosis. After an allergic re-
sponse to calcitriol, Burosumab (Crysvita) was initiated. Case Discussion: She presented at 
18 months of age with renal tubular acidosis (proteinuria, glucosuria, hypercalciuria, meta-
bolic acidosis); evaluation for cystinosis, tyrosinemia, secondary causes of hypercalciuria, 
Lowe syndrome and Dent disease were negative. Hypophosphatemia (1.7-3 mg/dL) with 
phosphaturia (FeP04 50%) noted at 4 years old led to diagnosis of Fanconi syndrome. Po-
tassium citrate, phos and cholecalciferol started, yet she still progressed to nephrocalcinosis, 
weight loss and poor linear growth. At 8 years, bone pain and genu valgum, along with 
laboratory (Table 1) and radiographic evidence of metaphyseal widening/fraying (Figure 1), 
were consistent with hypophosphatemic rickets. Standard therapy with phos and calcitriol 
was started but stopped abruptly due to hives. Given bone pain and rickets, we initiated 
Burosumab (FDA approved for XLH; dosing per “prescriber packet”). Although Fanconi 
syndrome is not a known condition of FGF23 excess, we postulated that Burosumab might 
offset her phosphaturia by blocking any FGF23 contribution (pretreatment FGF23 181 RU/
mL; Mayo Clinic, reference< 230). Within 5 doses, (10mg q2 weeks) serum phosphorus 
increased (1.7 to 3.0 mg/dL) and urine phosphorus decreased (81 to 34.5 mg/dL). However, 
3 months later, serum phosphorus was again 1.7 mg/dL. We increased Burosumab (20mg q2 
weeks) but repeat phos remained 1.7 mg/dL. Clinically, bone pain improved along with ear-
ly radiological changes in rickets (Figure1). Conclusion: FGF23 diminishes Na-dependent 
phosphate reabsorption,1,25 (OH)2 vitamin D and PTH action. Burosumab, a recombinant 
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human IgG1 monoclonal antibody targeting FGF23, binds to/inhibits FGF23 and decreases 
phosphaturia and improves rickets in XLH. Our patient’s response to Burosumab suggests 
FGF23 inhibition may be clinically useful in other phosphaturic states for symptomatic relief 
and possibly bone mineralization, but it does not appear to normalize serum phos levels in 
Fanconi syndrome at recommended dosing. Abbreviations : FePO4: Fractional excretion of 
phosphate, XLH: X linked hypophosphatemic rickets, FGF 23: Fibroblast growth factor 23, 
PTH-Parathyroid hormone.
Disclosures: Nandini Vijayakanthi, None
P-206
Multiple fractures in a young woman with normal bone mineral density: 
insights from bone microarchitectural assessment *Madhuni Herath1, 
Catherine Shore-Lorenti2, Peter Ebeling1, Frances Milat3. 1Department of 
Endocrinology, Monash Health; Department of Medicine, School of Clinical 
Sciences, Monash University, Australia, 2Department of Medicine, School of 
Clinical Sciences, Monash University, Australia, 3Department of Endocrinology, 
Monash Health; Centre for Endocrinology & Metabolism, Hudson Institute 
of Research; Department of Medicine, School of Clinical Sciences, Monash 
University, Australia
Introduction: Fracture prevention in young adults with chronic disease and glucocor-
ticoid (GC) exposure is complex and limited by insufficient data. Current guidelines(1) 
recommend monitoring of bone mineral density (BMD) with dual x-ray absorptiometry 
(DXA); oral bisphosphonates are recommended over anabolic therapy for those at moder-
ate-high fracture risk.Clinical Case: A 47-year-old woman with a 30-year history of severe 
rheumatoid arthritis presented for review of osteoporosis management. She had a 20-year 
fracture history including vertebral, metatarsal and periprosthetic fractures of the left ulna 
and a more recent non-healing left patella and tibia-fibula fracture. Risk factors for fracture 
included over 20 years of GC exposure, premature ovarian insufficiency (POI) secondary 
to cyclophosphamide and pancreatitis secondary to sulfasalazine. She had received oral bi-
sphosphonates for over five years followed by four doses of zoledronic acid.  Two years 
after her final dose of zoledronic acid, she developed osteonecrosis of the jaw (ONJ) after a 
dental extraction.The patient had normal vitamin D (25-OH vitamin D 102nmol/L; 50-250), 
creatinine 63umol/L (45 – 85) and corrected calcium 2.44mmol/L (2.15-2.55) levels. Bone 
turnover markers were unremarkable: CTx 220ng/L (150-800), P1NP 50ug/L (15-70) and 
ALP 59U/L (20-105). BMD was normal on DXA: L1-L4 (LS) 1.254g/cm2, Z-score -0.3, 
left neck of femur (NOF) 0.921g/cm2, Z score -1.1 in 2010, increasing to 1.353g/cm2 LS 
and 1.142g/cm2 NOF by 2018. However, high resolution peripheral quantitative comput-
ed tomography (HR-pQCT) identified reduced trabecular and cortical bone volume and a 
7.8x6.5x6.7mm area of focal bone loss (Figure 1). While her ONJ improved, trabecular 
volumetric BMD (Tb.vBMD: 157mgHA/cm3  at radius and  144.3 mgHA/cm3 at tibia) and 
cortical volumetric BMD (Ct.vBMD; 845.3 mgHA/cm3 radius and 889.5 mgHA/cm3 tibia) 
did not, (Tbv.BMD 119.0 mgHA/cm3 radius and 114.3 mgHA/cm3 tibia, Ct.vBMD 848.4 
mgHA/cm3 radius and 889.1 mgHA/cm3 tibia) after eight months of teriparatide.Conclu-
sions: HR-pQCT provides additional insights into bone quality, enabling detailed assessment 
of cortical and trabecular bone structure and quality. This case highlights the complexity of 
bone disease encountered in young adults with chronic disease. The importance of navigat-
ing pitfalls of routine imaging modalities and utilising alternatives to obtain information and 
guide management are important learning points.
Disclosures: Madhuni Herath, None
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Symptoms of Multicentric Carpotarsal Osteolysis Respond to Anti-
inflammatory Treatment *Nina Ma1. 1Section of Endocrinology, Children’s 
Hospital Colorado and Department of Pediatrics, University of Colorado School 
of Medicine, United States
Multicentric carpotarsal osteolysis (MCTO) is a rare diagnosis associated with MAFB 
mutations and characterized by osteolysis, nephropathy and craniofacial anomalies. Affect-
ed individuals are frequently diagnosed with juvenile idiopathic arthritis (JIA) due to joint 
pain and swelling. Treatment for JIA does not prevent the progressive destruction of carpal 
and tarsal bones; consequently, “misdiagnosis” of JIA is suggested. However, we present a 
case of MCTO that responded clinically to treatment for JIA, suggesting that inflammatory 
arthropathy may co-exist with or be a feature of MCTO.A 21 mo-old child was not standing 
or walking and cried when she put weight on her feet. She learned to “walk” on her knees. 
She was healthy and her development typical otherwise. Exam was notable for bilateral 
wrist/ankle swelling, limited range of motion, metatarsal medial curvature and subtle cra-
niofacial changes (shortened palpebral fissures, periorbital fullness, narrowed nasal bridge, 
small nasal alae and long underdeveloped slit philtrum). Radiographs showed small wrist/
ankle compartments and atypical carpal/tarsal bones. Ankle MRI showed asymmetric ta-
lus bones, joint effusions and synovitis. She was diagnosed with JIA and trialed various 
treatments (NSAIDs, MTX +/- adalimumab, oral/intraarticular corticosteroids). The most 
effective treatment was MTX + tocilizumab. Treatment relieved pain and improved function. 
She began to put weight on her legs and walk independently (with orthotics). Her right foot 
remained more inverted than the left and she was unable to jump, go up or down stairs. 
On exam, she had significant improvement in range of motion and minimal active disease. 
Musculoskeletal ultrasound showed no active inflammatory arthritis or tenosynovitis. Whole 
exome sequencing later revealed a novel variant in MAFB (c.212 C>G, p.P71R). Despite 
a genetic diagnosis of MCTO, her treatment for JIA continued due to significant clinical 
improvement of symptoms and inflammation. She had no medication side effects and had 
normal renal function.Clinical Lessons: 1. Inflammatory arthropathy may co-exist with or is 
a characteristic of MCTO. Anti-inflammatory/rheumatic treatment may be adjunctive ther-
apy in some patients with MCTO1. 2. Small joint compartments and atypical carpal/tarsal 
bones may be an early clue that individuals presenting with inflammatory arthropathy have 
MCTO. 3. Small wrist/ankle compartments may support the notion that MAFB gene ex-
pression is important for chondrocyte function and the preparation for ossification in wrists/
ankles2. Thus, MCTO may not be purely an osteolytic disorder which has implications for 
treatment.References: 1. Upadia J, et al. J Pediatr Genet 2018;7(4):174-9. 2. Lazarus S, et al. 
Am J Pathol 2017;187(9):1923-34.
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Humoral Hypercalcemia of Malignancy in Recurrent Pulmonary 
Papillomatosis *Ansha Goel1, Julianna Barsony1. 1Medstar Georgetown 
University Hospital, United States
Background: Hypercalcemia is defined as serum calcium greater than 10.5 mg/dL and/
or ionized calcium greater than 1.3 mmol/L. Primary hyperparathyroidism and malignancy 
account for over 90% of all hypercalcemia cases. Humoral hypercalcemia of malignancy 
involves the secretion of parathyroid hormone-related peptide (PTHrP). Given its homology 
with PTH, PTHrP binds to the same receptors and causes hypercalcemia by increasing bone 
resorption, renal distal tubular calcium resorption, and intestinal calcium absorption. We 
present a case of humoral hypercalcemia of malignancy in a patient with recurrent respi-
ratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) where 
papillomas grow throughout the upper and lower respiratory tracts.Clinical case: Our patient 
is a 32-year-old male with a history of RRP with multiple pulmonary papillomas who has 
previously had over 350 papilloma excisions. Prior biopsies were positive for HPV 6 and 11, 
without evidence of high-grade squamous intraepithelial lesion or malignancy. He initially 
presented with shortness of breath and was found to be hypercalcemic with a serum calcium 
of 14.6 mg/dL (corrected for albumin of 2.2 gm/dL) and ionized calcium of 1.92 mmol/L. 
Additional workup revealed acute kidney injury (creatinine 1.86 mg/dL), suppressed PTH 
(6.3 pg/ml), elevated PTHrP (43 pmol/L), normal 25-hydroxyvitamin D (57.2 ng/ml), and 
normal 1,25-dihydroxyvitamin D (47.1 pg/mL). Electrocardiogram did not reveal a short-
ened Q-T interval. His clinical picture was consistent with humoral hypercalcemia of malig-
nancy, presumably due to squamous cell transformation of previous pulmonary papillomas. 
He initially received intravenous fluids, calcitonin, and Denosumab. As his renal function 
improved, he also received one dose of intravenous Zoledronic acid with subsequent im-
provement in his hypercalcemia to 12.6 mg/dL.Conclusion: Squamous cell carcinoma, via 
PTHrP secretion, is the most common cause of hypercalcemia of malignancy. Malignant 
transformation of previously benign respiratory papillomas into squamous cell carcinoma 
can occur in up to 4% of RRP cases. This illustrates the need for careful monitoring for 
malignant transformation in patients with RRP as they may possibly develop life-threatening 
hypercalcemia. A comprehensive diagnostic evaluation and urgent treatment with intrave-
nous fluids and bisphosphonate therapy may be indicated in order to prevent morbidity and 
mortality in these patients.
Disclosures: Ansha Goel, None
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Osteomalacia Secondary to Fanconi Syndrome Induced by Antiretroviral 
Drugs in a Patient with HIV/AIDS *Sara Gariela Bayas1, Francisco Umaña 
1, Luisa Plantalech1, Betiana Mabel Perez1, Mirena Buttazzoni1, Ariela Veronica 
Kitaigrodsky1, Maria Diehl1. 1Hospital Italiano de Buenos Aires, Argentina
HIV may cause an imbalance in mineral and bone metabolism. This effect is multifac-
torial and induced by pro-inflammatory molecules with an increase in osteoclast activity and 
suppression of osteoblast function. Tenofovir has been associated with Fanconi syndrome, 
accelerated bone mass loss and osteomalacia.We report a case of severe hypophosphatemia 
and osteomalacia induced by tenofovir.A 49-year-old woman consulted with invalidating 
bone and muscle pain, asthenia and multiple spontaneous fractures (vertebral, hips, tibia, 
patella, humerus, distal femur) in the last 3 years that lead her to prostation. She reported 
a history of non-Hodgkin’s lymphoma, Hepatitis C and HIV diagnosed at 31 years of age. 
She received lopinavir/ritonavir, lamivudine and tenofovir as antiretroviral therapy. Physical 
examination showed scoliosis, severe kyphosis and marked limitation in mobility of upper 
and lower limbs. Biochemical studies revealed: serum phosphate 1.4 mg/dl (NR 2.5-4.5), 
calcium 8.1mg/dl (NR 8.5-10.5), magnesium (Mg) 2 mg/dl (NR 1.9-2.5), creatinine 0.48 
mg/dl, PTH 38 pg/ml (NR 16-77.1), beta crosslaps 2.48 ng/ml (NR 0.1-0.55), bone alkaline 
phosphatase 300 ug/l  NR (3.8-22.6), 25 OH vitamin D 25 ng/ml (>30), calciuria 556 mg/
day (NR 250), calcium/creatinine urinary index 0.9 (NR 0.1-0.25), Mg fractional excretion 
2.15 (3-5%), tubular phosphorus reabsorption: 74% (NR >85). BMD showed a T- score 
of -3.6 in lumbar spine. X-rays showed severe demineralization. She received intravenous 
and oral phosphate, calcium, calcitriol, magnesium, hydrochlorothiazide and cholecalcif-
erol. Tenofovir was withdrawn. Once hypocalcemia and hypophosphatemia were corrected, 
zoledronate 4 mg was indicated. She continued with oral ibandronate for two years. Lumbar 
spine BMD improved (+27.5%) as well as X-ray images and bone markers. She evolved 
with progressive clinical improvement and is now able to walk unaided. She has not suffered 
new fractures after five years of treatment.Conclusion: In this patient with AIDS / HIV two 
metabolic bone disturbances were found, osteomalacia due to Fanconi syndrome induced by 
antiretroviral drugs with severe hypophosphatemia and devastating clinical consequences, 
treated with mineral substitution, and high bone turnover which was controlled by bisphos-
phonates. The importance of suspecting the possibility of hypophosphatemic osteomalacia 
in patients with AIDS / HIV treated with tenofovir is highlighted.
Disclosures: Sara Gariela Bayas, None
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Aneurysmal Bone Cysts: A Case Series *Milena Komornicki1, Mirena 
Butazzoni2, Maria Diehl 1, Ana María Galich1, Luisa Plantalech1. 1MD Hospital 
Italiano de Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, 
Argentina
Introduction: Aneurysmal bone cysts (ABC) are rare benign skeletal lesions. They most 
frequently involve metaphysis of long bones, pelvis or spine. They may occur as a primary 
bone tumor or secondary to preexisting bone lesions (e.g., simple bone cyst, fibrous dys-
plasia, giant cell tumor, etc.). They are usually diagnosed in the first two decades of life. 
Clinically they present with pain, swelling and palpable mass. Spinal lesions may present 
with back pain or stiffness, neurologic deficits and radicular pain. Treatment goals are to 
eradicate the lesion, minimize recurrence, relieve pain and avoid functional impairment. 
Treatment options are surgery, sclerotherapy, selective embolism, cryotherapy, etc. Recently 
bisphosphonates have been successfully used as definitive treatment.The aim of this pre-
sentation is to describe three different cases of this entity.Case 1: a 28-year-old woman pre-
sented with rib tumor and local pain. The initial histology showed a fibrohistiocytic lesion 
with multinucleated giant cells. Given the probability of being a giant cell tumor surgical 
excision was performed and fibrous dysplasia with ABC was diagnosed. Local pain resolved 
after surgery,Case 2: a 38-year-old woman with ABC in C7 and axial pain. Selective embo-
lization of the lesion was performed with partial response. Due to its location with potential 
risk of spinal cord injury, she underwent intravenous ibandronate therapy, three doses during 
six month, with symptoms improvement. RMI showed reduction in the size of the lesion 
and less bone edema. No other adjunctive therapy or surgical intervention was required.
Case 3: a 34-year-old woman, diagnosis of fibrous dysplasia with secondary ABC in sixth 
rib in posterior localization and back pain. She refused surgery and medical treatment with 
bisphosphonates was indicated. Three doses of intravenous ibandronate were administered 
within one year. She reported significant pain improvement without evidence of recurrence 
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during the follow up.Conclusions: ABC are a diagnostic and therapeutic challenge. It is im-
portant to consider this entity in patients with fibrous dysplasia. Considering its symptoms, 
location, extent, recurrence rate and benign nature, different treatment alternatives may be 
considered including surgery and antiresorptive therapy. The use of bisphosphonates could 
be a viable treatment option.
Disclosures: Milena Komornicki, None
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Chronic Treatment of Hypercalcemia caused by Methacrylate-induced 
Granulomas *Luisa Plantalech1, Maria Diehl1, Maria Eugenia Vera1, Diana 
gonzalez2, Carlos Federico Varela1. 1Hospital Italiano de Buenos Aires, 
Argentina, 2Mautalen, Argentina
Introduction: Granulomatous diseases can produce hypercalcemia mediated by 1.25 
OH2 Vitamin D due to increased activity of 1α-hydroxylase. In recent years, granulomatosis 
has been reported as a reaction to foreign bodies after the use of methacrylate for aesthetic 
purposes.Corticosteroids are a first-line therapy in granulomatosis and antiresorptive drugs 
are part of the usual treatment of hypercalcemia. Other options are hydroxychloroquine, 
ketoconazole and anti TNF alpha antibodies.The purpose of this presentation is to com-
municate the long-term treatment of a patient with granulomas induced by methacrylate 
and hypercalcemia of difficult management.Case report: A 34-year-old woman consulted 
in 2014 with hypercalcemia, lithiasis and renal failure. She had a previous injection of 
methacrylate in her lower limbs for aesthetic purposes. Laboratory tests: hypercalcemia 13 
mg/dl (8.5-10.5), phosphatemia: 4.1 mg/dl (2,5-4,5), PTH <3 pg/ml (8.7-77.1), 1.25 OH2 
Vitamin D 180 pg/ml (18-60), creatinine 2.1 mg% (0.3-1.2), alkaline phosphatase 61 (31-
100u/l), PET-CT: hypermetabolic nodular images in both buttocks and thighs. In a renal 
biopsy nephrocalcinosis and acute tubular necrosis were found. The biopsy of the gluteal 
area showed a foreign body-type granulomatous reaction. She received treatment with hy-
dration, corticotherapy, bisphosphonates and hydroxychloroquine which was suspended due 
to intolerance. Ketoconazole (400-200 mg/day) was initiated combined with meprednisone 
6 mg/day and alendronate 70 mg/week with normalization of serum calcium (9.6 mg /dl) 
and improvement of kidney function (creatinine: 1.40 mg/dl). After 5 years of treatment, 
she presented asthenia, hypotension and oligomenorrhea that was related to adrenal insuf-
ficiency due to a decrease in meprednisone to <4 mg (carried out by the patient) associated 
with ketoconazole. The patient recovered by lowering the dose of ketoconazole to 200 mg/d 
and increasing meprednisone to 6 mg/d. In the last year she had stable kidney function and 
normal calcium and PTH values.Conclusions: Treatment of granuloma-induced hypercalce-
mia associated with methacrylate application is a challenge. The combination of low doses 
of corticosteroids, ketoconazole and alendronate was effective at long-term. The dose of 
ketoconazole and meprednisone must be titrated in each patient, to be effective to inhibit the 
synthesis of calcitriol and avoid  adverses events like suppression of corticoids and sexual 
steroid synthesis
Disclosures: Luisa Plantalech, None
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A Case Of Rebound Hypercalcemia After Cessation Of Denosumab In 
Adult Patient With McCune-Albright Syndrome *Radhika Jaiswal1, Stuart 
Weinerman1. 1Long Island Jewish Medical Center, United States
Introduction: Denosumab, a fully human monoclonal antibody, is an inhibitor of 
RANKL (a cell surface protein involved in many cellular processes, including osteoclasto-
genesis, and is reported to be overexpressed in FD-like bone cells) and is mainly used for the 
treatment of postmenopausal osteoporosis and for the prevention of skeletal-related events 
from bone metastases 1,2. It is used off label in patients with McCune-Albright syndrome 
(MAS) because of its potent anti-resorptive properties 3,4. Rebound hypercalcemia follow-
ing cessation of high dose Denosumab have been reported previously in adult patients with 
osteoporosis and juvenile patients with giant cell tumor and Paget’s disease 5-7. There has 
been only one case report so far from Denosumab discontinuation causing life-threatening 
hypercalcemia requiring hospitalization in a juvenile patient with MAS 8. However, to the 
best of our knowledge, it has not been reported in an adult patient with MAS.Case descrip-
tion:A 25-year-old male with a history of MAS with polyostotic FD (who previously did not 
respond to aminobisphosphonates, being managed as outpatient with 120 mg subcutaneous 
injection of Denosumab every 1.5 months) and no prior history of hypercalcemia presented 
with worsening migraine, nausea, and vomiting for a week. His last dose of Denosumab was 
4 months ago as he had a planned tooth extraction. Initial corrected serum calcium was 15.7 
mg/dl [8.4-10.5 mg/dl]. PTH was appropriately low 9.85 pg/ml [15-65 pg/ml], vitamin D 25-
OH low 25.5 ng/ml [30-80 ng/ml] and vitamin D 1,25-dihydroxy low <5.0 pg/ml [199-79.3 
pg/ml]. PTHrP within normal range, <2.0. Serum calcium trended down to 14.4 mg/dl after 
fluids but again worsened to 15.1 mg/dl. The patient received a dose of Calcitonin 330 IU 
intramuscularly with improvement in serum calcium to 14.5 mg/dl. Further doses of Calci-
tonin were held due to an adverse reaction in form of abdominal pain, nausea and shakiness. 
Aggressive hydration was continued and a dose of Denosumab 120 mg subcutaneously was 
administered, following which the serum calcium continued to trend down and was 11.6 mg/
dl on discharge from hospital. When checked as an outpatient within a week, repeat calcium 
was 9.0 mg/dl. Patient resumed his Denosumab every 1.5 months. Multiple repeat calcium 
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have been normal since the hospital admission.Conclusion:Rebound hypercalcemia can oc-
cur in a patient with MAS upon cessation of Denosumab and thus warrants close monitoring 
for electrolyte derangements following discontinuation.
Disclosures: Radhika Jaiswal, None
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Fractures in the Intensive Care Unit (ICU): Continuous Renal Replacement 
Therapy Masking Immobility Hypercalcemia *Preethika Ekanayake1, 
Tudor Hughes2, Gina Woods3. 1University of California, San Diego Division 
of Endocrinology, Diabetes and Metabolism, United States, 2University of 
California, San Diego, Department of Radiology, United States, 3University of 
California, San Diego Division of Endocrinology, Diabetes and Metabolism; VA 
San Diego Healthcare System, United States
IntroductionContinuous renal replacement therapy (CRRT) is utilized for the treatment 
of renal failure in critically ill patients with hemodynamic instability. The citrate used in 
CRRT prevents activation of the coagulation cascade by chelating with calcium. This com-
plex is then removed by the filter, leading to calcium loss. Thus, serum calcium levels must 
be maintained via a post filter calcium infusion. Here we present a case of hypercalcemia 
and bone resorption masked by CRRT.Clinical CaseA 46-year-old woman with gastric ulcers 
and bilateral oophorectomy presented with unintentional weight loss, jaundice, cirrhosis, 
and necrotizing pancreatitis. Following a month and a half of a protracted critical illness 
requiring intubation and vasopressors, exacerbated by fluid shifts, the patient developed 
acute renal failure. CRRT with citrate anticoagulation was initiated. Prior to CRRT, her albu-
min-adjusted calcium was 9.0-9.6mg/dL and ionized calcium 1.16 (ref 1.13-1.32mmol/L). 
When CRRT was initiated, the patient received the customary calcium infusion to maintain 
her ionized calcium within the target range of 1.05-1.1mmol/L. However, within five days 
of CRRT initiation, her ionized calcium started rising above goal (1.12-1.3mmol/L) and thus 
the post filter calcium infusion was stopped. Despite ongoing citrate use with CRRT, her 
ionized calcium remained within the desired range without supplementation. After 23 days 
of CRRT, a CT scan of the chest showed incidental findings of acute sternal and bilateral rib 
fractures with severe bone demineralization. Her intact parathyroid hormone (PTHi) was el-
evated at 248 (ref 15-65pg/mL), calcitriol 16.7 (ref 19.9-79.3pg/mL), and vitamin D-OH 21 
(30-80ng/mL). Subsequent CT scans showed additional acute fractures of the thoracic and 
lumbar spine, sacrum, pubic rami, and bilateral femoral necks. Unfortunately, two months 
after CRRT was initiated, the patient expired.ConclusionIn the above case, citrate used with 
CRRT masked hypercalcemia and bone resorption until the patient suffered multiple frac-
tures. The etiology of her hypercalcemia was attributed to immobilization. Normalization 
of post filter serum calcium without supplemental calcium infusion, in a patient on CRRT 
using citrate as an anticoagulant, should raise suspicion for endogenous calcium loss via 
accelerated bone resorption.
Disclosures: Preethika Ekanayake, None
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Voriconazole Induced Periostitis *Ariela Veronica Kitaigrodsky1, Maria 
Diehl1, Aldana Maria Degrave1, Marina Scolnik1, Diana Carolina Fernandez 
Avila1, Adela Aguirre1, Mirena Buttazzoni1, Tatiana Pereira1, Ana Basquiera2. 
1Hospital Italiano de Buenos Aires, Argentina, 2Hospital Privado Universitario 
de Córdoba, Argentina
INTRODUCTIONDrug-induced periostitis is a recognized entity. Voriconazole is a 
triazole agent used in prophylaxis and treatment of fungal infections. There is recent evi-
dence that prolonged therapy with voriconazole may cause diffuse periostitis.CLINICAL 
CASEA 42-year-old woman diagnosed with high risk acute myeloid leukemia in June 2017, 
underwent bone marrow transplant with a mismatched unrelated donor in December 2017. 
Two months after transplant, gastrointestinal grade 4 graft-versus-host disease developed 
and she received treatment with high dose steroid and infliximab. As a result of severe immu-
nosuppression she suffered a mycosis by Scedosporium apiospermum with lung and brain 
compromise. She was treated with voriconazole with close monitoring of plasma levels. 
She began with arthralgias in hands and generalized bone pain after 9 months of  treatment 
with voriconazole. Physical examination showed swelling and nodular lesions in both hands 
and relative functional impotence. Bone scan revealed morphological changes at phalanges 
and metacarpal and severe periosteal reaction along with increased soft tissue. Laboratory 
showed increased levels of bone remodeling markers (bone ALP 191.8 ug/l (NR< 22.6), os-
teocalcin 152 ng/ml (NR 11-46), beta-crosslaps 4.86 ng/ml (NR < 0.573) and high levels of 
24-hour urine fluoride (17.22 mg/l, NR <3 mg/l). Calcemia, phosphatemia, and creatininemia 
were normal. Positron emission tomography determined hypermetabolic periosteal lesions 
of exophytic growth towards soft tissues in multiple axial and appendicular bone structures. 
Findings were compatible with extensive periostitis. On suspicion of voriconazole-induced 
periostitis, its use was discontinued and liposomal amphotericin was started. Days after 
discontinuing therapy, symptoms improved and radiographic abnormalities decreasedDIS-
CUSSIONVoriconazole-induced periostitis has been recently described. Fluoride included 
in  voriconazole molecule may cause elevated fluoride levels and increased osteoblastic 
activity with periosteal lesions. The history of multifocal and asymmetric bone pain and 
imaging evidence of diffuse periosteal reaction in the context of chronic treatment with 
voriconazole suggested the diagnosis. Increased fluoride levels has diagnostic utility in this 
entity. Although the suspension of therapy usually achieves rapid symptomatic improvement 
in 2 to 21 days, as in the case of our patient, radiological alterations may persist for years.
Disclosures: Ariela Veronica Kitaigrodsky, None
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Presentation of a Late Diagnosis of Larsen Syndrome with a Novel Mutation 
of the Gene Encoding Filamin B (FLNB) *Deepshree Gupta1, Deborah 
Wenkert2. 1UCLA, United States, 2Wenkert&Young, LLC, United States
Background: FLNB mutations cause autosomal dominant osteochondrodysplasias in-
cluding Spondylocarpotarsal Synostosis Syndrome, Larsen syndrome and 3 typically lethal 
disorders. Clinical case: A 65-year-old Caucasian female, referred for diagnosis and fracture 
risk assessment, had congenital anomalies (bilateral clubfeet and bilateral dislocated hips 
and knees) and patellar dislocation. Surgeries included 12 at age 50, and left femoral rodding 
of a fracture. Endocrine history: Age 45-left oophorectomy (endometriosis); Age 50-meno-
pause (no HRT). Fracture history: 2 femur fx-ages 14 and 58 yrs; wrist fx-age 51 yrs. In 
her 50s, 5 yrs of bisphosphonates, preceded 4 doses of Prolia over 4 yrs through age 63. 
Additional history: supraventricular tachycardia s/p ablation, androgenic alopecia, actinic 
keratosis, kidney stones, vertigo. Family & Social History: Ashkenazi Jewish descent, un-
married, no children. 63 yo sister has 2 children, age 32 and 43. No FH of a skeletal dyspla-
sia. Physical exam: weight 81.6 kg, height 155cm, BMI 34. Alopecia, normal lips and palate, 
no thyromegaly, mild heart murmur, and wide based gait and features of Larsen syndrome 
(Table). DXA (age 59): T&Z scores: L1-L4 Spine -1.7 & -0.3, Femoral neck -0.8 & 0.5, 
Total hip -0.8 & 0.1. A clinical diagnosis of Larsen Syndrome was confirmed by FLNB gene 
analysis (heterozygous c533G>C (Cys178Ser) mutation in exon 2 of FLNB, not present in 
dbSNP, ESP, ExAC). Discussion: Our patient’s novel mutation occurs in a highly conserved 
region in exon 2 of FLNB near the coding region of an actin binding domain (ABD) of 
filamin B. Other mutations in this region are presumed to affect actin binding, but her presen-
tation is mild for an FLNB associated disorder. This spontaneous, likely pathogenic, variant 
explains her atypical facies, bilateral clubfeet and chronic joint dislocations, but not fracture 
history which may be related to her postmenopausal status. Indeed, neither osteoporosis nor 
fractures are known features of Larsen Syndrome. She has not had respiratory, cardiac, oph-
thalmologic, nor neurologic manifestations of Larsen Syndrome and has only mild scoliosis; 
she has extremity disproportionality, but her height is normal. Significant variability occurs 
even within families with Larsen syndrome making it difficult to ascribe her milder FNLB 
associated phenotype to her novel mutation.
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The efficacy of denosumab treatment for hypercalcemia in a patient with 
primary hyperoxaluria type 1. *Liudmila Rozhinskaya1, Sofia Gronskaia1, 
Tatiana Grebennikova1, Zhanna Belaya1. 1The National Medical Research Centre 
for Endocrinology, Russian Federation
Primary hyperoxaluria type 1 (PH1) is a rare, metabolic, autosomal recessive disease, 
characterized by a deficiency of liver glyoxylate aminotransferase enzyme (AGT) and con-
sequent oxalate overproduction due to enzyme defects. These oxalate deposits lead to vari-
ous abnormalities including kidney failure and oxalate osteopathy.We report a 19-year-old 
male referred to our clinic due to complaints about severe pain in the pelvic bones, weight 
loss, low appetite, muscle and general weakness. PH1 was confirmed based on a heterozy-
gous c508 G>Amutation in exon 4 of AGXT gene. He suffered from nephrolithiasis and 
nephrocalcinosis since childhood which led to kidney failure and peritoneal dialysis at the 
age of 11; hemodialysis at the age of 17. At the age of 18 the patient underwent liver and 
kidney transplantation. At the age 19, PTH non-dependent hypercalcemia (the corrected se-
rum calcium 3.62 (2,15-2,55) mmol/L) with low PTH level 3(12-88) pg/mL) was found for 
the first time which coexisted with symptoms of severe pain in the pelvic bones. Computed 
tomography (CT) revealed severe abnormalities: diffuse sclerosis and cortical thickening 
of the vertebrae and pelvic bones, periosteal proliferation, abnormal bone texture in the 
sacroiliac joints with patchy sclerosis and several lytic lesions in the subchondral areaOn 
basal evaluation the patient had severe kyphosis, reduced mobility in the hip joints, low 
body weight (BMI 16.4kg/m2; height 1.62m; weight 43kg). According to laboratory tests 
the following changes were revealed: leukopenia 2.9 (3.9-10) 109/L with severe neutrope-
nia 0.6 (1.5-6.8)109/L, thrombocytopenia 107 (148-339) 109/L, anemia Hb-108 (132-172) 
g/L with serum iron at a normal level, hypercalcemia (calcium corrected for albumin- 3.62 
(2.15-2.55) mmol/L, serum phosphate 1.69 (0.74-1.52) mmol/L, uric acid 518 (202-416) 
µmol/L, PTH 8.12 (15-65) ng/ml, creatinine 266 (63-110) µmol/L, eGFR 30 ml/min 1.73 
m2, carboxylterminal cross-linked telopeptide of type I collagen (CTx) – 3.94 (0.01-0.6) 
ng/ml, osteocalcin - 235 (11-43) ng/ml; TSH 2.65 (0.35-4) mclU/ml, testosterone – 11.4 
(11-28.2) nmol/l.Due to kidney failure and high bone turnover, denosumab 60mg was ad-
ministered subcutaneously in order to control hypercalcemia. Three days after denosumab 
administration, the patient reported a reduction in bone pain which coincided with a decline 
in serum calcium levels and the bone resorption marker (serum calcium – 2.82 (2.15-2.55) 
mmol/L, CTx -0.64 (0.01-0.6) ng/ml, serum phosphate 0.99 (0.74-1.52) mmol/L). A month 
later biochemical parameters were within the reference range: serum calcium 2.32 mmol/L, 
serum phosphate 1.03 mmol/L with a slight improvement in creatinine levels- 184 (63-110) 
µmol/L, eGFR 45 ml/min 1.73 m2 and bone pain was alleviated.Conclusion: treatment with 
denosumab 60mg was effective at alleviating bone pain and non-PTH-dependent hypercal-
cemia in a PH1 patient.
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Atypical Parathyroid Adenoma Causing Parathyroid Crisis *Tammy Tavdy1, 
Justin Mathew1, Vafa Tabatabaie1. 1Montefiore Medical Center/Albert Einstein 
College of Medicine, United States
Background: Primary hyperparathyroidism (PHPT) is a common endocrine disorder 
that often presents as asymptomatic hypercalcemia in the setting of excess parathyroid hor-
mone (PTH) secretion. Patients with PHPT rarely present with parathyroid crisis - a sequelae 
of severe hypercalcemia with signs of multiple organ dysfunction. Parathyroid carcinoma 
and atypical parathyroid adenomas are rare diagnoses that account for approximately 2% of 
all patients with PHPT. While a definitive diagnosis for these conditions relies on pathology, 
severe hypercalcemia and PTH elevations strongly correlate with a parathyroid carcinoma. 
We describe a rare case of a patient with profound PTH-dependent hypercalcemia and para-
thyroid crisis who was found to have atypical parathyroid adenoma.Case: A 43-year-old 
woman presented with worsening abdominal pain associated with constipation and vomiting 
for one month. Laboratory results revealed hypercalcemia to 21 mg/dL (reference range 8.5-
10.5), intact PTH of 920.2 pg/mL (15.0-65.0), and creatinine 4.54 mg/dL from a baseline 
of 0.7 (30.0) and vitamin D 1,25-dihydroxy was suppressed to 8 pg/mL (18.0-72.0). PTHrP 
was normal. She had no family history of endocrinopathies and imaging did not reveal any 
jaw tumors.Neck imaging revealed a 3x2.5 cm nodule along the right posteroinferior aspect 
of the thyroid, concerning for a parathyroid carcinoma or adenoma. She was initially treated 
with aggressive intravenous fluid hydration, calcitonin, and bisphosphonates, and then start-
ed on cinacalcet. However, her hypercalcemia was refractory to medical management, and 
she underwent emergent right inferior parathyroidectomy. Pathology revealed peripheral fi-
brosis, increased mitoses, and cytologic atypia without necrosis or invasion, meeting criteria 
for atypical parathyroid adenoma.Conclusions: This case describes an aggressive biochemi-
cal presentation of an atypical parathyroid adenoma. Severe PTH-dependent hypercalcemia 
often raises concern for parathyroid carcinomas. However, standard consideration should 
also be given to atypical adenomas, an intermediate form of parathyroid neoplasms with un-
certain malignant potential and atypical histologic features. Germline mutations of CDC73 
are a common genetic anomaly and suggest that these cases could be variants of the hyper-
parathyroidism-jaw tumor syndrome. Identification of genetic markers in atypical adenomas 
is necessary to guide appropriate postoperative monitoring.
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Bilateral Atypical Femur Fractures as a Presenting Manifestation of 
Unrecognized Hypophosphatasia. *Madhav Chittimalla1, Tamara Roumayah 
Ivers1, Leika Raychouni1, Sudhaker Rao1. 1Henry Ford Health System, United 
States
Introduction: Hypophosphatasia (HPP) is a rare inherited disorder of the ALPL gene 
which leads to low serum alkaline phosphatase (ALP) levels and abnormal bone matrix min-
eralization due to accumulation of pyrophosphate, a known inhibitor of mineralization.  Al-
though severe symptoms are seen in infancy and childhood, adult onset HPP is milder and 
often asymptomatic except for low BMD, thus escapes diagnosis. Manifestations of adult 
HPP include: low serum ALP, atraumatic or pseudo-fractures of femur, and premature tooth 
loss.  We present an unusual case of previously unrecognized HPP in an otherwise healthy 
adult. Case: A 56y old man presented for evaluation of sequential bilateral atypical femur 
fractures (AFF). He had a low impact slip-and-fall in September 2019 sustaining left mid-
shaft AFF while working in China. Twelve weeks later he returned to the USA, and he 
stepped oddly while walking and felt pain in right thigh resulting in fall; x-ray showed 
mid-shaft non-displaced transverse right AFF.  He had no history of tooth loss, fractures 
or osteoporosis, nor use of bisphosphonate (BP), steroids, rheumatoid arthritis, or diabetes, 
well known predisposing factors for AFF.  Review of lab results in electronic medical record 
showed low levels of ALP for at least 9y, but he was unaware.  Despite the 2 AFFs, serum 
ALP was still inappropriately low-normal.Discussion: Review of the literature suggests that 
initial presenting symptoms of adult HPP are usually bone pain related to pseudo-fractures 
or premature loss of teeth. AFFs have been reported in the setting of undiagnosed HPP and 
concurrent bisphosphonate therapy, which is an independent risk factor for AFF. However, 
our case is unusual in whom bilateral AFFs were the only presenting manifestation of an 
underlying undiagnosed adult onset HPP in an otherwise healthy individual not taking bi-
sphosphonates.
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Coracoid Stress Fracture in a Tennis Player – A Rare Sports Injury *Clay 
Larkin1, Elijah Kakani1, Scott Mair1, Florence Lima1, Madhumathi Rao1. 
1University of Kentucky, United States
BackgroundA coracoid stress fracture is a rare injury, especially unusual in non-trau-
matic settings. In a recent systematic review, acute trauma, usually direct impact or avulsion, 
was responsible for 71% (n=15/21) of coracoid fractures, sometimes also associated with 
acromioclavicular joint injury. The remaining were fractures caused by recurrent stresses 
placed directly over the coracoid bone, such as recoil from a firearm, often referred to as 
“trap shooter’s shoulder”. This report describes a non-traumatic right coracoid stress fracture 
in a 62-year-old female, who is a life-long, predominately right-handed tennis player.Clini-
cal CaseThe patient presented to the bone clinic with acute pain located anterior to the right 
shoulder that occurred during a game of tennis.  She was diagnosed with a coracoid stress 
fracture on standard shoulder 3-view X-rays. Due to the non-displaced nature of the coracoid 
fracture, the patient was treated conservatively with a sling and cessation of sporting activi-
ties.Her past medical history was significant for post-menopausal osteoporosis complicated 
by stress fractures in the left radius and ulna, and bilateral breast cancer treated with chemo-
therapy and radiation; past surgical history was significant for surgical repair for right rotator 
cuff injury.She underwent complete workup for metabolic bone disease and was treated with 
denosumab. An anterior iliac crest bone biopsy was also performed showing normal bone 
turnover in the cortical and subcortical areas, but decreased turnover in the deeper areas.  A 
follow up x-ray at one month showed mild displacement of the base of coracoid fracture 
with minimal interval healing and persistent significant rotator cuff arthropathy. The patient 
then underwent reverse shoulder replacement. After ten months the patient was able to return 
to playing tennis at a level similar to baseline.ConclusionThis report serves as an in-depth 
account of a singular patient with a stress fracture at the base of the right coracoid process, 
a highly unusual injury. Post-menopausal osteoporosis, prior radiation to the region, chemo-
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therapy and tamoxifen, coupled with intensified mechanical stress from previously injured 
rotator cuff and continued use during tennis, culminated in this rare skeletal injury. As prior 
radiation therapy precluded the use of anabolic agents, the patient was successfully treated 
with denosumab.
Disclosures: Clay Larkin, None
P-220
Sacral Fractures in the Setting of Newly Diagnosed Rectal Cancer in 
Pregnancy: A Gravid Issue. *Parvathy Madhavan1, Samaneh Rabieihashemi1, 
Pamela Taxel1. 1University of Connecticut Health Center, United States
Introduction:Fragility fractures are rare during pregnancy and commonly occur in the 
thoracic and lumbar vertebrae during late pregnancy or early postpartum period. We discuss 
a case of a pregnant patient with bilateral sacral and SI joint insufficiency fractures and rectal 
cancer.Case:A 36-year-old female patient presented to our clinic at 31 weeks gestation after 
right sacral fracture several weeks prior. She was diagnosed with stage IIIb, locally advanced 
rectal carcinoma at 18 weeks gestation and underwent neoadjuvant chemotherapy followed 
by radiation treatment. Follow-up MRI revealed non-displaced incomplete fracture of right 
sacrum without definitive underlying pathologic lesion, retrospectively associated with 
moderate pain while walking on treadmill. A 2nd fracture of left sacral ala occurred 4-weeks 
later, and a 3rd fracture at right SI joint occurred 5-months post-partum, both atraumatic. 
MRI findings were most consistent with insufficiency fractures.Her history was significant 
for menarche at 15 years, with irregular cycles consistent with PCOS. A prior child was con-
ceived via IVF without fracture occurrence. After delivery, menstrual cycles were regular, 
and the current pregnancy spontaneous. The patient had several childhood fractures related 
to sports injuries. Family history was significant for osteopenia in her mother, without other 
metabolic bone disorders.We noted intake of prenatal vitamin and Vitamin D 2000 IU/day 
but limited calcium intake. Physical exam revealed a healthy-appearing gravid female with-
out significant lumbosacral pain and otherwise normal exam. She was counseled regarding 
the increased demand of calcium in the 3rd trimester for fetal skeletal health, with a goal 
of 1500 mg/d. Labs: See table.Due to fractures, she underwent C-section and a health boy 
was delivered. After delivery she underwent successful bowel surgery, around which she 
took enoxaparin. She is now 15 months postpartum, pain-free and without further fractures.
Conclusion:Sacral insufficiency fractures are rare in pregnancy, and in this case prompted 
suspicion for bone metastases, often seen in the pelvis or vertebrae in rectal cancer. Howev-
er, bone metastases on MRI could not be documented. This patient had several risk factors 
for insufficiency fracture, including very low calcium intake. After pregnancy, BMD gener-
ally improves within 6-12 months; thus, we will monitor her progress closely and consider 
anti-resorptive therapy if indicated. 
Disclosures: Parvathy Madhavan, None
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The Impact of Drug Therapy on Osteogenesis Imperfecta *Sarah Souza1, 
Rayanne Peinado1, Nathalia Cordeiro1, Monise Carvalho1. 1Universidade São 
Francisco, Brazil
Introduction: Osteogenesis imperfecta (OI) is a genetic disorder with heterogeneous 
manifestations, characterized mainly by fragility in the bones due to defects in the structure 
or quantity of type 1 collagen. The main clinical manifestations of this disorder are: skeletal 
deformities, blueish scleras, imperfect dentinogenesis and deafness. The diagnosis can be 
done in utero by the ultrasounds. After birth, the diagnosis becomes prominently clinical, 
with supplementary lab work and imaging scans. Treatment should be precocious and multi-
disciplinary, using drug therapy with Pamidronate Disodium in patients under 18 years old, 
with the intention of diminishing the risk of fractures. Clinical Case: M.V.S.C., 1 year and 3 
months old, female, born at 40 weeks of gestation, no family history of OI. The hypothesis 
of OI came up with the 30 week ultrasound, that showed long bones dysplasia (femur=4,4cm 
consistent with a 24 week fetus; ulna=4,47cm consistent with a 28 week fetus), and the 
suspicion of a fracture in the right femur. At birth, radiological exams highlighted fracture 
in the right femur, genu varus (Picture 1) and bone thinning, including in the skull. The case 
was forwarded to a reference service where the patient was diagnosed with OI Type III in the 
Sillence Classification. Due to the lack of availability of the medication through the public 
health system, the start of treatment with Pamidronate Disodium was delayed. In the mean 
time the patient had various fractures throughout her first year of life. At 1 year of age, the 
patient received her first dose of Pamidronate Disodium, wich is an inhibitor of bone reab-
sorption mediated by osteoclasts (1st day: 0,25mg/kg, 2nd and 3rd days: 0,5mg/kg). And 
also takes Cholecalciferol, 4 drops/day, and calcium carbonate, 500mg/day. In addition to 
the drug treatment, the patient also is also being monitored by a multidisciplinary team. After 
beginning medication, the patient hasn’t had any more fractures until now, which supports 
the importance of the drug therapy at the prognosis. Conclusion: This report is a classic 
example of how drug therapy benefits the prognosis, with the caveat of an early intervention 
being needed. However, the late start to the therapy due to the lack of availability of the 
medication through the public health system at first, leads to the worsening of the clinical 
presentation during the waiting time for the medication, resulting in various fractures during 
this period.
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Pregnancy associated Osteoporosis - Transient Osteoporosis of Hip *Krishna 
Mori1, Sathish Kumar1, Amulya Yalamanchi1, Karthik Balachandran1, Adlyne 
Reena Asirwatham1, Shriraam Mahadevan1. 1Sri Ramchandra Medical College, 
India
Introduction: Transient osteoporosis of hip (TOH) is a rare condition, often associat-
ed with pregnancy. The risk factors include pregnancy, smoking, alcohol, steroid intake, 
inflammation, vascular injury and osteogenesis imperfecta. The most important challenges 
include differentiating from avascular necrosis of hip (AVN), regional migratory osteoporo-
sis (RMO) and deciding on treatment.Presentation: 25 year old lady, G2P1L1, at term preg-
nancy presented with waddling gait and lower limb pain. She delivered a healthy neonate. 
Two weeks postpartum, her pain in left hip worsened for which she was re-evaluate and was 
found to have fracture of left neck of femur. She was operated and plate and screw fixation 
was done. On further evaluation she was found to have Vit D deficiency. Since Vit D defi-
ciency as a cause of non-traumatic hip fracture is unlikely, alternative diagnosis was sought.
DEXA scan (right hip-Z Score – 4.1 and LS spine-Z Score – 3.9) showed osteoporosis. She 
was diagnosed to have TOH, associated with pregnancy. In view of active lactation and the 
fact that the patient had already been operated, bisphosphonate therapy was avoided. She 
was given Vitamin D 60000 IU/week for 8 weeks and calcium supplementation of 1000 mg/
day. The patient showed remarkable improvement on follow up.Discussion: The pathophys-
iology of TOH is debated and is currently thought to be due to microfractures and edema 
in the marrow, with contribution from the hormonal changes occurring during and after 
pregnancy. The closest differential is AVN which is progressive and irreversible, while TOH 
is not. The other differential is index episode of RMO but it typically affects men in the fifth-
sixth decade of life. Treatment modalities for TOH include conservative management with 
rest, core decompression in the marrow edema stage and screw fixation in the presence of 
fractures.Medical treatment can potentially hasten recovery in TOH. The treatment options 
include Bisphosphonates (not preferred during lactation), Calcitonin  and Teriparatide along 
with Calcium and Vit D supplementation.Conclusion: TOH is a rare cause of acute onset hip 
pain, usually associated with pregnancy. The pathophysiology and prevalence are largely 
unknown. The condition recovers with rest and conservative management with or without 
surgery, over six months to one year. Timely detection and early initiation of anti-osteo-
porotic therapy can avert surgery or hasten recovery. Keywords: Osteoporosis, Pregnancy
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Hypercalcemia in A Young Patient: What is the Deal? *Dr. Carmen 
Cartwright, MD1, Dr. Janna Prater, MD1, Dr. Catherine Anastasopoulou, MD, 
PhD, FACE1. 1Albert Einstein HealthCare Network, United States
Introduction: Hypercalcemia can have detrimental effects leading to nephrolithiasis, 
renal dysfunction or failure, osteoporosis, cardiac arrhythmias, and a malady of symptoms 
captured in the classic medical student mnemonic of “stones, bones, groans, and psychic 
moans”. We present a case of a young patient with hypercalcemia of unclear etiology to em-
phasize the importance of understanding the underlying causes of the problem that ultimate-
ly could help in the final diagnosis and decision of appropriate treatment.Clinical Case: The 
patient is a 30-year-old male with attention deficit hyperactivity disorder, Asperger’s syn-
drome, gastroesophageal reflux disease, mixed hyperlipidemia, seizure disorder, and Bell’s 
palsy, who was found to have asymptomatic hypercalcemia since age 24. Calcium levels 
have ranged between 10.1 – 12.2 mg/dl (Normal: 8.7 -10.2), with low-normal parathyroid 
hormone (PTH) levels 18-35 pg/ml (Normal: 15-65). The patient denied any excess calcium, 
vitamin D3, or vitamin A intake. He has had mildly elevated 1,25 dihydroxy vitamin D 
levels and low-normal 25 hydroxy vitamin D levels. different laboratory tests (see Table 1) 
have ruled out familial hypocalciuric hypercalcemic syndrome, thyroid dysfunction, multi-
ple myeloma, lymphoma, sarcoidosis, tuberculosis, or other pulmonary infections that can 
lead to hypercalcemia. Imaging studies were negative for Primary Hyperparathyroidism. 
An elevated ratio of 24, 25 dihydroxy-vitamin D to 25 hydroxy-vitamin D was found. This 
was suspected to be due to relative 25 hydroxy-vitamin D deficiency and genetic testing 
was pursued but did not show evidence of mutations to CYP24A1 or SLC34A1. A trial of 
Ketoconazole was instituted due to high suspicion of an unknown mutation, but this did not 
prove to be successful. Discussion/Conclusion: The etiology of the hypercalcemia in our pa-
tient was presumed to be non-PTH mediated and an even more extensive workup is ongoing 
to cover the most unusual differential diagnoses. Endocrinologists sometimes come across 
cases where the etiology of the hypercalcemia is not attributable to well-known causes. 
These rare cases demonstrate that our knowledge of the mechanisms of hypercalcemia is far 
from complete and as we get a better understanding of the underlying processes in the patho-
genesis of hypercalcemia, it is likely that we will recognize better ways of its management.
Disclosures: Dr. Carmen Cartwright, MD, None
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An Atypical Case of Steroid Induced Bone Infarctions *Jessica Lucier1, 
Jawairia Shakil2. 1Houston Methodist Hospital, United States, 2Houston 
Methodist Hospital, United States
Introduction: Glucocorticoid use is a well known cause of bone osteonecrosis. Gluco-
corticoids have a direct toxic effect to osteoblasts and lead to increased osteoclast activity. 
Patients who have received a transplant are at an increased risk of osteonecrosis when com-
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pared to the general population. Bone infarcts in this patient population are most commonly 
seen in weight bearing long bones, specifically the femoral head. Case: A 47 year old female 
with a past medical history of double lung transplant secondary to interstitial lung disease 
and chronic anemia presented to our institution with left knee and right ankle pain. Endo-
crinology was consulted for evaluation of bone infarcts found on imaging. The patient’s 
bone pain started developing shortly after her transplant, which was three years prior to 
presentation. She had no know history of joint swelling, trauma, radiation therapy, heavy 
alcohol use, or hematological disorders. She had been on chronic steroids for her anti-re-
jection medications. Initially after her surgery she was on high dose steroids, but had now 
been on 5mg prednisone daily for two years. Her other medications included vitamin D3, 
calcium, and fosamax, which she started 3 months prior to presentation. During her hospi-
talization, she had an MRI of the spine and upper/lower extremities. She was found to have 
acute and chronic bone infracts in the distal diaphysis of the femur, proximal diaphysis of 
the tibia/fibula, anterior calcaneus, navicular, first metatarsal, and proximal diaphysis of the 
left humerus. Hematology was consulted and performed an extensive work up for possible 
hematological causes. There work up was negative for multiple myeloma, sickle cell disease, 
thalassemia, Gaucher disease and hypercoagulability. It was concluded that though atypical 
in location for steroid induced osteonecrosis, her chronic steroids were the likely underlying 
cause of her bone infarcts. Discussion: Steroids are commonly used for anti-rejection pur-
poses in the transplant population. It is important to remember that even low doses of chronic 
steroids can induce osteonecrosis. Though the femoral head is the most commonly affected 
area by steroid induced osteonecrosis, bone infarcts can occur anywhere. Patients who have 
received a transplant often also have multifocal osteonecrosis. Prompt recognition of bone 
infarctions and early treatment with bisphosphonates can greatly decrease pain and increase 
ambulation in this patient population.
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Interactions between CXCL12+ bone marrow stromal cells and 
hematopoietic cells regulate murine bone marrow adipogenesis *Yuki 
Matsushita1, Noriaki Ono1. 1University of Michigan, United States
Bone marrow stromal cells (BMSCs) expressing C-X-C motif chemokine ligand 12 
(CXCL12), generally termed as CXCL12-abundant reticular (CAR) cells, are a multifunc-
tional mesenchymal cell population that regulates hematopoiesis, osteogenesis, and adipo-
genesis. Recent studies have revealed that these CXCL12+ BMSCs are comprised of two 
distinct subsets of pre-osteoblast-like and pre-adipocyte-like cells, termed as Osteo-CAR 
and Adipo-CAR cells, respectively. The latter pre-adipocyte-like cells are dormant in physio-
logical conditions and localized to sinusoidal surfaces, with particular enrichment for hema-
topoiesis-regulating cytokines. However, the nature of interactions between CXCL12+ BM-
SCs and hematopoietic cells, and how these interactions play a role in marrow adipogenesis 
are unknown. Here we show that many CXCL12+ BMSCs marked by Cxcl12-GFP are 
physically coupled with hematopoietic cells in single cell preparation, and loss of CXCL12 
in these cells using Col2a1-cre and Cxcl12-floxed alleles leads to extensive marrow adipo-
genesis. We found in imaging cytometry that a substantial fraction of Cxcl12-GFP+ cells 
intertwined with CD45+ cells in a way indistinguishable from purely single cells, which 
rendered these cells falsely appearing in a CD45+ fraction in flow cytometry. Deletion of 
CXCL12 in CXCL12+ BMSC using Cxcl12 GFP/flox; Col2a1-cre; R26R-tdTomato tri-
ple transgenic mice led to a significant reduction of hematopoietic cells and CD45+Cx-
cl12-GFP+ cells, suggesting functional CXCL12 is important in maintaining interactions 
between CXCL12+ BMSCs and CD45+ hematopoietic cells. In addition, CXCL12 dele-
tion in BMSCs caused extensive marrow adipogenesis in adult mice, despite the fact that 
CXCL12-deficient mesenchymal progenitor cells exhibited normal capabilities for colony 
formation, self-renewal and adipocyte differentiation in cultured conditions. Our findings 
support the notion that CXCL12 inhibits an adipogenic fate of CAR cells in a non-cell-au-
tonomous manner, suggesting a link between CXCL12-dependent stromal-hematopoietic 
interactions and marrow adipogenesis. Interactions with surrounding hematopoietic cells 
might be important for bone marrow stromal cells to maintain their proper cell fates under 
normal conditions.
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Hepatocyte Nuclear Factor 4 alpha (HNF4α) is a key mediator of bone 
metabolism *Marta Martinez Calle1, Guillaume Courbon1, Connor Francis1, 
Xueyan Wang1, Bridget Hunt-Tobey1, Jadeah Spindler1, Emily Lynch1, 
Aline Martin1, Valentin David1. 1Division of Nephrology and Hypertension, 
Department of Medicine, and Center for Translational Metabolism and Health, 
Institute for Public Health and Medicine, Northwestern University Feinberg 
School of Medicine, Chicago, IL, USA, United States
Hepatocyte nuclear factor 4 alpha (HNF4α) is a transcription factor controlling the ex-
pression of genes involved in gluconeogenesis and lipid metabolism in liver. Several studies 
have shown that mutations in HNF4α are associated with osteoporosis and other bone and 
mineral metabolism outcomes, but the role of HNF4α in bone has not been studied. We tested 
the hypothesis that HNF4α is expressed in bone and regulates osteoblastogenesis and bone 
turnover.We verified expression of HNF4α in bone and generated mice harboring a condi-
tional deletion of HNF4α in osteoblasts and osteocytes by crossing HNF4αflox/flox mice 
with Oc-Cre mice (HNF4αOc-cKO). We studied the bone phenotype of wild-type (WT) and 
HNF4αOc-cKO mice at 6, 12 and 35 weeks of age. We also performed RNA sequencing 
(RNA-seq) analyses in bones and RT-PCR in primary osteoblast cultures isolated from WT 
and HNF4αOc-cKO mice and in MC3T3 cells overexpressing HNF4α (Hnf4αTg). Finally, 
we performed Chromatin Immunoprecitation Sequencing (ChIP-seq) analyzes and metab-
olomics in control and Hnf4αTg and Hnf4αKO MC3T3 osteoblasts to define the impact of 
HNF4α on osteoblastic genes and signaling pathways.We show that HNF4α is expressed in 
bone cells of mesenchymal origin (osteoblasts and osteocytes), and that HNF4α expression 
in bone declines with aging, from 6 to 35 weeks. HNF4αOc-cKO mice, showed an age 
dependent reduction in trabecular bone volume, reaching a ~40% reduction in 12-weeks-
old mice. They also showed decreased bone formation, bone resorption and mineralization, 
suggesting that HNF4α regulates bone metabolism. Consistent with the in vivo phenotype, 
HNF4α deletion reduced the number of alkaline phosphatase positive colonies and mineral 
deposits by ~50 %. ChIP-seq analyses showed that HNF4α is a transcriptional regulator of 
genes of osteoblastic differentiation, such as Runx2, osteocalcin and osterix, and Hnf4αTg 
cells showed a 3-5 fold increased expression of these genes. Finally, by RNA-seq, RT-PCR 
and metabolomics, we demonstrate that HNF4α is a master regulator of mitochondrial func-
tion and energy homeostasis in bone cells.Our results demonstrate a crucial role for HNFα 
in osteogenesis and suggest that osseous HNF4α plays a central role in bone dynamics by 
modulating the expression of osteoblastic genes and cellular energetic program.
Disclosures: Marta Martinez Calle, None
P-227
Longitudinal Changes in Visceral Adiposity are Associated with Bone 
Density, Microarchitecture and Strength:  The Framingham Osteoporosis 
Study *Douglas Kiel1, Marian Hannan1, Ching-Ti Liu2, Thomas Travison1, 
Timothy Tsai1, Mary Bouxsein3. 1Hebrew SeniorLife, United States, 2Boston 
University School of Public Health, United States, 3Beth Israel Deaconess 
Medical Center, United States
The belief that higher body weight protects the skeleton is so widely embraced in clin-
ical medicine, the FRAX® risk predictor uses BMI in place of BMD when that measure 
is not available.  Despite this view, the protective effects of increased fat mass on skele-
tal health have recently been challenged, implicating visceral obesity as having a negative 
impact on skeletal health, possibly mediated through systemic factors such as adipokines, 
cytokines, or sex steroids. To better determine the role of visceral adipose tissue (VAT) on 
bone density, microarchitecture and strength, we tested the hypothesis that longitudinal in-
creases in VAT are associated with lower volumetric density, worse microarchitecture and 
lower bone strength.We determined the association between 8-yr changes in VAT and distal 
tibia and radius measures of volumetric density, microarchitecture and strength (measured 
by micro-finite element analysis) in 1,443 men and 1,691 women from the Framingham 
Study Generation 3 cohort. Participants had both baseline and follow-up whole body DXA 
scans 8 yrs apart that were used to measure longitudinal changes in VAT, and HRpQCT 
scans (Scanco XCTII) at the follow-up visit.  Information on age, BMI, menopause status, 
self-reported physical activity, and use of estrogen was obtained from the follow-up visit. 
Multiple linear regression was used to quantify the association between changes in VAT 
(follow-up minus baseline) and distal tibial/radius measures of trabecular and cortical bone 
density, microarchitecture and strength, adjusting for baseline age, BMI, menopausal status 
and physical activity.At follow-up, the mean age was 54 yrs, mean height was 175 cm for 
men and 163 cm for women, and mean BMI was 29 kg/m2 in men and 27 kg/m2 in women. 
The mean (SD) change in VAT was 345 cm3 (800) for men, and 243 cm3 (541) for women. 
After adjustment for covariates, in men larger increases in VAT over 8 yrs were associated 
with significantly higher cortical density (CtBMD), lower cortical porosity (CtPo), lower 
cortical thickness (CtTh) and area (CtAr), trabecular density (TbBMD) and total area (TtAr), 
and most strikingly, lower failure load (FL).  For every SD gain in VAT over the 8 yrs, the 
FL declined by 234 Newtons. In women, greater increases in VAT were associated with sig-
nificantly lower CtTh, CtAr, TbBMD, TbN, Tb.BV/TV, TtBMD, TtAr and FL (a decline of 
170 Newtons).  Findings were similar for the distal radius but some measures did not reach 
statistical significance.In conclusion, after accounting for BMI and physical activity, gains in 
visceral adiposity over time are associated with unfavorable bone density, microarchitecture 
and strength, especially in women.  In both men and women lower bone strength among 
those with the greatest visceral adiposity indicates that visceral fat may be deleterious to 
bone health.
Disclosures: Douglas Kiel, None
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The role of mechanical loading in preventing obesity-induced bone loss *Xinle 
Li1, Jie Li1, Daquan Liu1, Hiroki Yokota2, Ping Zhang3. 1Department of Anatomy 
and Histology, School of Basic Medical Sciences, Tianjin Medical University, 
Tianjin 300070, China., China, 2Department of Biomedical Engineering, Indiana 
University-Purdue University Indianapolis, IN 46202, USA, United States, 
3Department of Anatomy and Histology, School of Basic Medical Sciences, 
Tianjin Medical University, Tianjin 300070, China. Department of Biomedical 
Engineering, Indiana University-Purdue University Indianapolis, IN 46202, 
USA, China
Obesity and its associated metabolic sequela are increasing globally and they are close-
ly related to bone homeostasis. The balance of adipocytes and osteoblasts from bone mar-
row mesenchymal stem cells (BM-MSCs) is linked to bone mass and fat mass in the bone 
marrow milieu. While it is reported that mechanical loading not only stimulated bone for-
mation but also inhibited obesity-associated hepatic steatosis, little is known about the load-
ing effects on obesity-associated bone loss. Using obese mice induced by high-fat diet and 
ovariectomy (OVX), we examined whether knee loading prevents bone loss associated with 
obesity through regulating the Wnt pathway. C57BL/6 female mice (~14 weeks) were sorted 
into five groups (n=22 each group): standard diet group (SC), high-fat diet group (HF), 
loading-treated HF group, HF with OVX group (HO), and loading-treated HO group. Knee 
loading was applied with 1 N force at 5 Hz for 6 min/day for 4 weeks, and femurs were har-
vested for histomorphometry analysis. Bone marrow-derived cells were isolated to examine 
the differentiation of adipocytes and osteoblasts. Western blotting was performed to evaluate 
the expression of markers for adipocytes, osteoblasts, and Wnt signaling. The results showed 
that a high-fat diet (HF and HO groups) presented higher body weight, body fat, and body 
mass index (BMI) as well as bone loss than a standard diet (SC and HF groups), in which 
the changes in OVX mice was even higher. However, knee loading significantly decreased 
body weight, fat, and BMI. It also reduced the numbers and perimeter of adipocytes and the 
differentiation of adipocytes from BM-MSCs. The expression of C/EBPα and PPARγ were 
suppressed by knee loading. The loaded group also presented a significant increase in bone 
mineral density and contents, and the circumference of trabecular bone. Regarding osteo-
blasts, knee loading enhanced the number of osteoblasts on bone surface, differentiation of 
osteoblasts, and the level of Runx2 and ALP. Furthermore, knee loading attenuated obesi-
ty-induced bone loss through regulating the Wnt pathway. Collectively, high-fat diet induced 
obesity aggravates bone loss in OVX mice. This study indicates that knee loading prevents 
obesity-related bone loss by regulating cellular fates in the differentiation of adipocytes and 
osteoblasts from BM-MSCs via the Wnt pathway. Further understanding of mechanical 
loading may contribute to developing potential therapies for obesity-associated disease.
Disclosures: Xinle Li, None
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Gli1 labels a subpopulation of FAP cells that preferentially promote muscle 
regeneration with less fat accumulation *Lutian Yao1, Elisia Tichy1, Leilei 
Zhong1, Sarthak Mohanty1, Luqiang Wang1, Foteini Mourkioti1, Ling Qin1. 
1University of Pennsylvania, United States
Skeletal muscle has a remarkable regeneration capacity after injury. Fibro-adipogen-
ic progenitors (FAPs) are critical for supporting injured muscle regeneration but their het-
erogeneity remains largely unknown. Here, using Gli1-CreER Tomato (Gli1/Td) mice, we 
found that Gli1-labeled Td+ cells are located in the interstitial area of myofibers expressing 
FAP markers PDGFRα and Sca1. Flow cytometry identified 71.3% of Td+ cells as FAPs, 
17.3% of FAPs as Td+ cells, and none of Td+ cells as satellite cells. Aging markedly de-
creased muscle Td+ cells (2 mo: 7.6%; 12 mo: 4.9%, n=4/group, p<0.01). Sorted Td+ FAPs 
formed 6.2-fold more CFU-Fs and generated much fewer adipocytes when subjected to ad-
ipogenic differentiation than Td- FAPs. Next, we created acute muscle injury by Notexin 
injection and chronic muscle injury by crossing dystrophic mdx mice with Gli1/Td mice. In 
both models, Td+ FAPs were preferentially expanded. Specifically, Notexin injury increased 
the percentage of Td+ cells in FAPs from 17% to 37% at d3 and Gli1/Td/mdx mice con-
tained 1.8-fold more Td+ cells than Gli1/Td mice (n=4/group). Cell ablation in Gli1/Td/DTA 
mice with Tam injections reduced Td+ cells by 80% and eliminated Td+ CFU-F colonies 
from muscle (n=3/group). After Notexin injury, myofibers regenerated at d7 and d28 in Gli1/
Td/DTA mice were 34.1% and 22.7%, respectively, smaller than those in Gli1/Td mice (n=5/
group), suggesting an impairment of myogenesis. Gli1 is an effector of Hedgehog (Hh) sig-
naling. Intramuscular injection of purmorphamine (pur), an Hh agonist, resulted in 1.6-fold 
larger sizes of myofibers at d30 after Notexin injury (n=4/group). Local glycerol injection 
causes muscle degeneration with fat infiltration. Interestingly, Td+ FAPs were less likely 
to become adipocytes compared to Td- FAPs and ablation of Td+ cells led to 39.9% more 
adipocytes in muscle (n=4/group). Hh signaling inhibitor, GANT61, induced 78.3% more 
adipocytes, while pur almost completely depleted adipocyte infiltration (n=5/group).Single 
cell RNA-sequencing of mouse muscle mononucleated cells showed that FAPs can be sub-
clustered into Gli1+ and Gli1- cells. Pathway analysis suggested that Gli1+ cells are more 
metabolic active and more related to tissue regeneration. In conclusion, our study revealed 
a subpopulation of FAPs that preferentially promotes muscle regeneration with less fat ac-
cumulation and implied a potential therapeutic effect of Hh signaling in muscle diseases. 
Disclosures: Lutian Yao, None
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PTHrP Overexpression in Mammary Tumors Causes Anorexia: A Possible 
Role of Lipocalin-2 *Diego Grinman1, Pamela Dann1, Marya Shanabrough1, 
Tamas Horvath1, John Wysolmerski1. 1Yale University, United States
Cancer Anorexia Cachexia Syndrome (CACS) is a life threatening complication caused 
by the release of soluble factors by tumor cells that lead to pronounced loss of weight, appe-
tite, skeletal muscle and fat mass. It occurs in up to in 26% of breast cancer patients and is 
directly responsible for 20% of all cancer deaths. CACS not only reduces quality of life, but 
also blunts responses to chemotherapy, having a dramatic impact on patient survival. One 
of the secreted factors implicated in CACS is parathyroid hormone-related protein (PTHrP), 
however, whether PTHrP contributes to CACS in breast cancer patients has not yet been ful-
ly explored. To study the metabolic effects of PTHrP in a breast cancer setting, we created a 
tetracycline-regulated model of PTHrP overexpression in mammary tumors. Administering 
doxycycline (Dox) to Tet-PTHrP;PyMT mice (10-12 weeks old)  activated human PTHLH 
cDNA expression in mammary tumors, leading to elevated circulating PTHrP levels and 
severe hypercalcemia. Tet-PTHrP;PyMT mice on Dox experienced profound anorexia, rapid 
fat wasting and weight loss. To determine whether PTHrP overexpression in mammary tu-
mors caused alterations in the central nervous system (CNS) appetite center/s, we performed 
c-Fos immunohistochemistry, a marker of neuronal activation, in coronal sections of the 
mouse brain. Tet-PTHrP;PyMT mice on Dox had a significant activation of neurons from 
the lateral parabrachial nucleus (LPBN), an area previously linked to appetite regulation. 
Also, treatment of Tet-PTHrP;PyMT mice with Dox caused more than a ten-fold increase in 
circulating levels of Lipocalin-2 (LCN2), an osteoblast secreted protein that has been shown 
to cause anorexia and is associated with reduced breast cancer patient survival. Upregulation 
of the LCN2 mRNA levels was observed in whole bones and also in mammary tumors, sug-
gesting that both tissues may contribute to the LCN2 circulating pool in response to PTHrP. 
Overall, our data suggest that mammary tumor derived PTHrP induces anorexia possibly 
through activation of neurons in the LPBN. Although more experiments are needed to de-
termine whether LCN2 is mediating the PTHrP-induced anorexia, these studies highlight a 
potential mammary tumor to bone to brain axis that could broaden our understanding of the 
suppression of appetite in CACS.
Disclosures: Diego Grinman, None
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Connexin43 Controls Body Adiposity and Glucose Tolerance in Mice via Gap 
Junction Dependent and Independent Functions *Seung-Yon Lee1, Manuela 
Fortunato 1, Marcus Watkins1, Francesca Fontana1, Roberto Civitelli1. 1Divisions 
of Bone and Mineral Diseases, Department of Medicine; Musculoskeletal 
Research Center, Washington University School of Medicine, United States
The gap junction protein, connexin43 (Cx43) is expressed in mesenchymal lineages 
including adipocytes and osteogenic cells. Others have shown that Cx43 mediates white 
adipose tissue (WAT) “beiging” in response to cold exposure, and is involved in ensur-
ing mitochondrial integrity and metabolic activity of brown adipose tissue (BAT). Using 
Twist2(Dermo1)-Cre to induce mesenchymal lineage specific ablation of Cx43 (cKOTw2), 
we asked whether lack of Cx43 affects body adiposity and energy metabolism, in addition to 
its action on bone modeling and homeostasis. In standard diet and temperature conditions, 
body weight and fat mass are only modestly reduced in cKOTw2. Likewise inguinal WAT is 
significantly reduced in cKOTw2 mice, but not other WAT depots. Notably, cKOTw2 mice 
are metabolically more active compared with control mice, based on indirect calorimetry, 
despite equal food consumption; and have better glucose tolerance on a standard chow diet. 
Importantly, significantly lower gains in body weight, fat mass, and WAT weight occur in 
cKOTw2 mice on a high fat diet (HFD) relative to control mice, and cKOTw2 mice are 
partially protected from HFD-induced glucose intolerance. Such protective effect is not seen 
with Gja1 deletion in mature adipocyte (cKOAdipoq); and Cx43 ablation in osteogenic lin-
eage cells (cKOOsx and cKODMP1) does not affect body weight and fat mass, suggesting 
that Cx43 acts at early steps of adipocyte development. Intriguingly, Tw2-Cre-driven induc-
tion of mutations that interfere with either Cx43 channel function, as in oculodentodigital 
dysplasia (cODDD), or Cx43 signaling function, as with C-terminus 5-aminoacid truncation 
(cDel5Tw2), also results in lesser body fat gains on HFD, relative to controls. Hence, Cx43 
favors WAT accumulation via both its gap junction channel and signaling functions. Intrigu-
ingly, glucose metabolism is normal in cODDD mice, whereas cDel5Tw2 mice are modestly 
glucose intolerant on standard or HFD, as are cKOAdipoq mice, suggesting that this Cx43 
effect is linked to its signaling/scaffolding function, consistent with an action in mitochon-
dria. Thus, Cx43 has multiple actions in energy metabolism, ultimately serving to decrease 
energy expenditures while maximizing glucose utilization and fat tissue metabolism. Inter-
ference with specific functions of Cx43 may help improve metabolic balance in obesity and 
during weight reduction programs, while preserving bone health.
Disclosures: Seung-Yon Lee, None
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Impaired zinc signaling is involved in muscle atrophy in type 1 diabetic 
mice *Fuka Takeuchi1, Marina Morimoto1, Yoshinori Mizuno1, Yoko Horikawa1, 
Yukinori Tamura1. 1Department of Physiology & Biochemistry, Graduate school 
of Nutrition, Kobe Gakuin University, Japan
Type 1 diabetes induces serious skeletal muscle atrophy and impaired muscle repair, 
which are important risk factors for falls and subsequent fractures. However, the detailed 
mechanisms of skeletal muscle dysfunction in diabetic state remain unclear. Zinc is an essen-
tial micronutrient for regulating metabolism, and intercellular zinc distribution is regulated 
by 24 zinc transporters (Zip1~14, ZnT1~10) located in plasma/organelle membranes. Recent 
studies suggest that changes in the expressions of zinc transporters are associated with the 
regulation of muscle cell function. In this study, we therefore investigated the role of zinc 
transporters in the pathogenesis of diabetic muscle atrophy in vivo and in vitro. Quantitative 
CT analysis showed that tibial muscle mass was decreased in streptozotocin-induced diabet-
ic female mice compared with control mice. Analysis of the gastrocnemius muscle revealed 
that protein degradation was enhanced, and protein synthesis and myogenic differentiation 
were suppressed in muscle of diabetic mice. The mRNA levels of zinc transporters, such as 
Zip1, 3, 9, 11, 13 and ZnT6, 9 were decreased in muscle of diabetic mice, suggesting that 
zinc signaling in muscle is altered in diabetic state. Moreover, oral zinc supplementation for 
4 weeks significantly ameliorated muscle loss in diabetic mice along with the increase in 
the expression of Zip9 and Zip13 in muscle. We next examined the role of Zip9 and Zip13, 
which transport zinc from the Golgi apparatus to the cytoplasm, in muscle function using 
mouse myoblastic C2C12 cells. Knockdown of Zip9 or Zip13 by specific siRNA markedly 
increased the levels of marker genes of ubiquitin proteasome system (MuRF-1, Atrogin1) in 
C2C12 cells. In addition, knockdown of Zip9 or Zip13 also markedly decreased the levels of 
myogenic genes (MyoD, Myogenin, MyHC) along with suppressed Akt phosphorylation in 
C2C12 myotubes. Moreover, knockdown of Zip13 but not Zip9 enhanced autophagy as well 
as increased protein levels of FoxO1 in C2C12 myotubes. In conclusion, our study demon-
strated that zinc signaling is altered in muscle of diabetic mice, and the down-regulation of 
Zip9 and Zip13 is associated with enhanced protein degradation and suppressed myogenesis 
through Akt/FoxO1 signaling pathway in muscle cells. These data suggest that impaired zinc 
signaling is involved in the pathogenesis of diabetic muscle atrophy, and it may be a novel 
therapeutic target in musculoskeletal disorders induced by diabetes. 
Disclosures: Fuka Takeuchi, None
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Accelerated Osteocyte Senescence and Skeletal Fragility in Mice with Type 2 
Diabetes *Japneet Kaur1, Brittany Eckhardt1, Jennifer Rowsey1, Daniel Fraser1, 
Sundeep Khosla1, David Monroe1, Joshua Farr1. 1Mayo Clinic, United States
The prevalence of type 2 diabetes (T2D) is increasing worldwide and collective evi-
dence indicates a three-fold higher fracture risk in this population despite normal to higher 
bone density. In addition to the more rapid accumulation of advanced glycation end prod-
ucts (AGEs) in T2D, recent studies have demonstrated that insulin resistance is associated 
with increased expression of p16Ink4a, a marker of cell senescence - i.e., stress-induced 
irreversible cell growth arrest, in pancreatic β-cells of mice. We previously showed that 
increased senescence mediates age-related bone loss; therefore, we hypothesized that pre-
mature cell senescence and SASP factors contribute to skeletal dysfunction in adult-onset 
T2D. To investigate this, we established T2D in adult C57BL/6N male mice using high-fat 
diet (HFD) and a single dose of streptozotocin (STZ). HFD/STZ mice demonstrated key 
features of T2D such as increased body weight, fat mass, consistently higher glucose (>=250 
mg/dL) and HbA1C levels, and reduced insulin levels and pancreatic β-cell area.  Longi-
tudinal assessments of the skeletal phenotype of T2D mice showed deteriorated cortical 
bone microarchitecture relative to control mice. Additionally, these mice displayed altered 
bone turnover markers, diminished bone strength, and impaired material properties such as 
failure load, ultimate stress, and stiffness at multiple skeletal sites as compared to controls. 
Histomorphometric assessment showed higher bone resorption and lower bone formation 
rates in T2D vs control mice. The skeletal dysfunction in T2D mice was accompanied by 
increased levels of Nε-(1-carboxymethyl)-L-Lysine (CML), an activator of the receptor for 
AGE (RAGE) pathway in serum and bone. In addition, analysis of osteocyte-enriched bone 
samples of mice with T2D showed significantly elevated mRNA expression of cell senes-
cence markers, namely p16Ink4a and p21Cip1, as well as multiple senescence-associated se-
cretory phenotype (SASP) factors, particularly metalloproteinases (Mmp3, Mmp9, Mmp12, 
and Mmp13) and NFkb1. Finally, advanced histological techniques showed a significantly 
increased percentage of senescent osteocytes in T2D as compared to control mice. Based 
on our findings, the HFD/STZ model represents a promising model for future mechanistic 
studies in mice with T2D as it mimics the typical characteristics of the human disease and 
suggests that increased cell senescence in conjunction with elevated AGEs mediate T2D-re-
lated skeletal fragility.
Disclosures: Japneet Kaur, None
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Findings to unravel the underlying mechanisms of in vivo interactions 
involving Wnt10a in bone, fat and muscle *Manabu Tsukamoto1, Ke-Yong 
Wang2, Takashi Tasaki3, Yoshiaki Yamanaka1, Eiichiro Nakamura1, Sohsuke 
Yamada4, Hiroto Izumi5, Qian Zhou6, Kagaku Azuma6, Yasuyuki Sasaguri3, 
Kimitoshi Kohno7, Akinori Sakai1. 1Department of Orthopaedic Surgery, 
University of Occupational and Environmental Health, Japan, 2Shared-Use 
Research Center, University of Occupational and Environmental Health, 
Japan, 3Department of Pathology and Cell Biology, University of Occupational 
and Environmental Health, Japan, 4Department of Pathology and Laboratory 
Medicine, Kanazawa Medical University, Japan, 5Department of Occupational 
Pneumology, University of Occupational and Environmental Health, Japan, 
6Department of Anatomy, University of Occupational and Environmental Health, 
Japan, 7Kurate Hospital, Japan
Purpose: Wnt10a is a member of the WNT family. Although deficiency of this gene 
causes symptoms related to teeth, hair, nails, and skin, we recently demonstrated a new 
phenotype of Wnt10a knockout (KO) mice involving bone and fat. The in vivo effect of the 
Wnt10a gene on bone and fat is unclear, and the relationship between bone/fat and muscle 
in Wnt10a signaling is also interesting. We aimed to evaluate the tissue changes in Wnt10a 
KO mice compared to wild-type mice and show the findings as a starting point to unravel 
the underlying mechanisms of in vivo interactions involving Wnt10a in bone, fat and mus-
cle. Methods: Experiments were performed on Wnt10a KO male mice and WT littermates. 
In vivo images of visceral and subcutaneous fat were acquired by micro CT. Mice were 
euthanized at 16 weeks of age, and blood samples, bones, fat tissues, and muscles were ob-
tained for analysis (bone histomorphometry, cell cultures, RT-PCR, Immunohistochemical 
staining, western blot and DNA microarray, etc).Results: Trabecular bone loss in the lower 
limbs of Wnt10a mice and decreased bone mineralization were observed. The adipose tissue 
in bone marrow was also decreased, and adipocyte differentiation was reduced. The body 
fat mass in Wnt10a KO mice was decreased, and white adipocytes in subcutaneous fat were 
converted to beige adipocytes. The muscle weight of the lower limbs was not decreased de-
spite trabecular bone loss, but Gdf8/myostatin expression was reduced in the subcutaneous 
fat and gastrocnemius muscles of Wnt10a KO mice. Thus, in vivo deletion of Wnt10a inhib-
ited osteogenic activity, promoted beige adipogenesis of white adipocytes and maintained 
muscle mass. These results suggest that regulation of Gdf8 by Wnt10a may help maintain 
the muscle mass of Wnt10a KO mice. Conclusions: This study was the first to histologically 
evaluate the bone, fat and muscle phenotypes of Wnt10a KO mice. The results of this study, 
which were obtained by investigating the three tissues together, could influence the under-
standing of in vivo interactions involving the Wnt10a gene.
Disclosures: Manabu Tsukamoto, None
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Endothelial cell function is mediated by BMP-2 treatment during Type 
2 Diabetes *Hanisha Battina1, Ushashi Dadwal 1, Fazal Ur Rehman Bhatti1, 
Olatundun Awosanya1, Seungyup Sun1, Caio Staut1, Stephen Mendenhall1, 
Anthony Perugini1, Conner Valuch2, Nikhil Tewari1, Rohit Nagaraj1, Murad 
Nazzal1, Rachel Blosser1, Jiliang Li2, Melissa Kacena 1. 1Department of 
Orthopaedic Surgery, Indiana University School of Medicine, IN, USA, 
United States, 2Department of Biology, Indiana University Purdue University 
Indianapolis, IN, USA, United States
Type 2 diabetes (T2D), in the presence of coexisting osteoporosis, results in increased 
fracture risk and impaired fracture healing. The latter is associated with impaired angiogen-
esis, a vital process during regeneration of bone tissue. The aim of this study was to inves-
tigate the angiogenic and proliferation potential of endothelial cells (ECs) isolated from the 
lungs (LECs) and bone marrow (BMECs) from obesity-induced mice that were treated with 
bone morphogenetic protein-2 (BMP-2, 4µg, local administration at the time of surgery) to 
heal a femoral segmental bone defect (SBD). Male C57BL/6 mice were fed a high fat diet 
(HFD, n = 27) beginning at 8 weeks of age to induce a type 2 diabetic-like phenotype. This 
phenotype was confirmed by Glucose and Insulin Tolerance testing 12 weeks later. Low fat 
diet (LFD, n = 26) fed animals served as controls. The HFD and LFD groups were treated 
with either saline or BMP-2 at the time of SBD surgery. LECs and BMECs were isolated 3 
weeks post-surgery, and their angiogenic potential was evaluated by proliferation, tube for-
mation, cell migration, and gene expression. Proliferation was examined by DAPI or crystal 
violet staining. The proliferation of LECs and BMECs was not altered by diet or BMP-2 
treatment. HFD enhanced vessel-like properties of both LECs and BMECs as demonstrated 
by tube formation assay. Three-way ANOVA results for humeri BMECs had significant ef-
fects (p£0.05) in all three migration parameters (Wound width (µm), Relative wound density 
(%), and wound confluence (%)) by time, diet, and treatment, as well as a diet by treatment 
effect. The HFD-fed mice treated with BMP-2 showed the highest migration potential. Ad-
ditionally, irrespective of diet, ECs isolated from BMP-2 treated mice exhibited increased 
migration compared to those isolated from saline treated mice. Analysis of angiogenic genes 
CD31, FLT-1, ANGPT1, and ANGPT2 showed similar changes in expression levels between 
humeri BMECs and LECs. Interestingly, BMP-2 treatment enhanced angiogenic gene ex-
pression in LFD fed mice but attenuated expression in HFD fed mice. This data demonstrates 
that LECs and BMECs undergoing HFD feeding have enhanced angiogenic potential. Taken 
together, this study shows that diet, fracture surgery, and local BMP-2 treatment all result in 
important systemic changes in angiogenesis.
Disclosures: Hanisha Battina, None
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Insulin-Like Growth Factor Binding Protein 2 Knockout Mice (Igfbp2-/-) 
Are Protected Against Vertical Sleeve Gastrectomy-Induced Bone Loss 
*Alison Pletch1, Benjamin Harris2, Phuong Le3, Clifford Rosen3. 1Maine Medical 
Center, United States, 2University of New England, United States, 3Maine 
Medical Center Research Institute, United States
Vertical Sleeve Gastrectomy (VSG) is the most common weight loss surgery in Amer-
ica. It is a successful treatment for obesity, however it leads to bone loss via undefined 
mechanisms. Previously, we have shown that Insulin-like Growth Factor Binding Protein 2 
(IGFBP2) is necessary for osteoclast proliferation and differentiation in mice, and its dele-
tion results in resistance to bone loss. Shah et al (2019) has shown that serum IGFBP2 level 
is markedly increased after VSG in humans. Based on these observations, we hypothesized 
that genetic loss of Igfbp2 would protect Igfbp2 knockout (-/-) mice from VSG-induced 
bone loss. To test this hypothesis, 36 male Igfbp2-/- mice and their littermate controls (+/+) 
were fed a 60% Kcal (high fat diet) starting at 8 weeks old. At 16 weeks, 9 Igfbp2-/- mice 
underwent VSG while 9 underwent a sham surgery. Similarly, 9 Igfbp2+/+ mice underwent 
VSG while 9 underwent a sham surgery. Mice were eye-bled and DEXA scanned at 15 and 
18 weeks. At 20 weeks, mice were DEXA scanned again and euthanized; serum was collect-
ed to measure levels of carboxy-terminal collagen crosslinks (CTx), total procollagen type 
1 N-terminal propeptide (P1NP), and IGFBP2. At 20 weeks of age, both +/+ and -/- mice 
that underwent VSG lost significant weight compared to their sham controls (+/+ VSG mean 
= 29.87g, +/+ sham mean = 37.65g, p=0.0003. -/- VSG mean = 31.65g, -/- sham mean = 
36.89g, p=0.0251). This weight loss was associated with lower fat mass (+/+ VSG mean 
= 6.578g, +/+ sham mean = 13.25g, p=0.0004. -/- VSG mean = 8.363g, -/- sham mean = 
13.57g, p=0.0082) with no change in fat free mass (data not shown). Total areal bone mineral 
density (aBMD) was significantly lower in +/+ VSG mice compared to +/+ sham (+/+ VSG 
mean = 0.04622g/cm2, +/+ sham mean = 0.04925g/cm2, p=0.0150). Femoral BMD was 
significantly lower as well (+/+ VSG mean = 0.05717g/cm2, +/+ sham mean = 0.06530g/
cm2, p=0.0313), as was femoral bone mineral content (+/+ VSG mean = 0.007667g, +/+ 
sham mean = 0.009000g, p=0.0190). Serum markers of CTx were significantly higher in 
the +/+ VSG group compared to the +/+ sham group (+/+ VSG mean = 40.35ng/mL, +/+ 
sham mean=27.54ng/mL, p=0.0127). This was also seen with serum markers of P1NP (+/+ 
VSG mean = 38.96ng/mL, +/+ sham mean=20.06ng/mL, p=0.0008). No differences were 
observed among -/- mice.  Taken together, our data suggest that Igfbp2-/- mice are protected 
from significant bone loss after VSG.
Disclosures: Alison Pletch, None
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Low bone mass in female mice fed high-fat diet is associated with elevated 
bioenergetics and ER stress in cells of the osteoblast lineage. *Veronica 
Butler1, Lakshmi Divya Kolora1, Natalie Hohos2, Yuan-Haw Wu1, Malgorzata 
Skaznik-Wikiel2, Vanessa Sherk1, Srividhya Iyer1. 1Department of Orthopedics, 
University of Colorado, School of Medicine, Anschutz Medical Campus, United 
States, 2Department of Obstetrics and Gynecology, Division of Reproductive 
Sciences, University of Colorado School of Medicine, Anschutz Medical 
Campus, United States
Obesity is detrimental to bone health, especially in children. However, the cellular me-
diators and mechanisms of this negative effect remain unclear. Differentiation of pluripotent 
stem cells is influenced by changes in energy metabolism and nutrient availability. Bioener-
getics and protein folding in the endoplasmic reticulum (ER) are closely linked. Damage due 
to accumulation of misfolded proteins results in ER stress and activates the unfolded protein 
response (UPR) by three sensor proteins: PERK, IRE1, and ATF6. ER stress mediates pro-
gression of multiple obesity-related comorbidities including glucose metabolism, liver and 
heart diseases. Previous studies have shown that elevated UPR in the osteoblast lineage in-
creases apoptosis and expression of RANKL. The purpose of this study was to determine the 
effects of high-fat diet (HFD) on osteoblast differentiation. To this end, 5-week-old C57BL/6 
female mice were fed either low-fat diet (LFD) or HFD for 10 weeks and were divided 
based on body weight into high-fat obese (HF-Ob: >25 g) and high-fat lean (HF-Ln: <22 g). 
Exposure to HFD increased body fat and blood glucose.  Importantly, this metabolic imbal-
ance was accompanied by low cancellous bone mass of the femur that was primarily due to 
decreased trabecular number and increased separation. Although the cortical thickness was 
unaffected, mice fed HFD exhibited a reduction in the mineral density at femoral midshaft. 
Furthermore, cultures of osteoblastic cells obtained from bone marrow of HF-Ln and HF-Ob 
mice had elevated glycolytic and oxygen consumption rates suggesting that excess caloric 
intake regulates their bioenergetics. We also found that elevated protein levels of PERK 
target p-eIF2a and ATF6 in bone shafts of HF-Ob mice compared to LFD controls, suggest-
ing UPR dysregulation in osteoblast lineage cells may contribute to obesity-related bone 
deficits. Our findings suggest that HFD adversely affects skeleton by acting directly on cells 
of osteoblast lineage. This is in part by regulating their bioenergetics and UPR signaling.
Disclosures: Veronica Butler, None
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Inhibition of Hypoxia Inducible Factor (HIF) Signaling Ameliorates 
Radiation Induced Marrow Adiposity *Wendi Guo1, Kassandra Spiller1, 
Colleen Wu1. 1Duke University School of Medicine, United States
While radiation therapy effectively eliminates malignant cells, damage to healthy tissue 
surrounding tumors remains a persistent clinical issue. For bone, normal tissue toxicity is 
marked by impaired hematopoietic function, diminished bone volume, and accumulation of 
marrow adipose tissue (MAT). Importantly, cancer patients who receive radiation treatment 
have an increased risk for fracture. Because marrow adiposity is associated with an increased 
risk for fracture and diminished hematopoietic stem cell frequency; we sought to identify 
strategies to prevent radiation induced expansion of MAT. Of note, the bone microenviron-
ment (BME) is characterized by low oxygen tension or hypoxia and active hypoxia inducible 
factor (HIF) signaling regulates many cellular interactions in the BME to maintain healthy 
bone. In our initial studies, histological analysis and μCT quantification of bones isolated 
from mice exposed to total body irradiation showed, unlike bone volume, that there was 
a rapid and persistent accumulation of MAT. Moreover, endomucin and CD31 staining of 
long bones revealed a disruption of the bone marrow vasculature, suggesting a perturbation 
of the hypoxic bone niche. Bone marrow adipocytes arise from multipotent mesenchymal 
progenitors (MMPs) which have the capacity to differentiate into lineage specific adipocyte 
progenitors. We next sought to determine if HIF signaling was required for radiation induced 
MAT formation. For this purpose, mice were generated in which HIFαtranscription factors 
were conditionally ablated in either MMPs or lineage specific adipocytes by crossing Lep-
RCre and aP2Cremice to mice homozygote for the conditional alleles Hif-1fl/fland Hif-2fl/
fl.Intriguingly, histological analysis and μCT quantification of osmium tetraoxide staining 
revealed radiation induced MAT was ameliorated in aP2Cre;Hif-1fl/fl;Hif-2fl/flmutant an-
imals when compared to littermate controls. In contrast, genetic ablation of HIFain LepR-
Creexpressing MMPs did not affect the expansion of marrow adiposity in irradiated bones. 
Intriguingly, after exposure to ionizing radiation examination of bones isolated from aP-
2Cre;Rosa26tdTomato/+conditional reporter mice showed tdTomato+cells localized to the 
bone marrow stroma; however, they did not co-stain for the adipocyte marker perilipin. In 
addition, co-localization of enodmucin+and tdTomato+cells in bone sections was not ob-
served. This data suggests that within the BME, aP2Cre expressing cells do not contribute 
to lipid laden adipocytes nor do they comprise cells of the vasculature. Collectively, this 
data suggests aP2Cre expressing cells in the BME constitute a population of bone marrow 
stromal cells that require HIF signaling to support radiation induced adipogenesis via a non-
cell automatous mechanism. These studies reveal the potential to exploit the HIF signaling 
pathway to protect bone against normal tissue toxicity associated with radiation exposure. 
Disclosures: Wendi Guo, None
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The L enantiomer of β-aminoisobutyric acid (BAIBA), a contracting muscle 
metabolite, has positive effects on muscle in vitro and in vivo *Fabrizio 
Pin1, Yukiko Kitase1, Anika Shimonty1, Joshua R. Huot2, Alberto Smargiassi2, 
Andrea Bonetto2, Lynda F. Bonewald1. 1Department of Anatomy, Cell Biology 
Physiology, Indiana University School of Medicine, Indianapolis, United States, 
2Department of Surgery, Indiana University School of Medicine, Indianapolis, 
United States
β-aminoisobutyric acid (BAIBA) is a non-protein amino acid produced by skeletal mus-
cle during physical activity via a PGC-1α-dependent mechanism. We have shown previously 
that L-, but not D-BAIBA is secreted by contracted mouse soleus and EDL muscle and that 
L-BAIBA is 100-1000 times more potent than D-BAIBA in protecting osteocytes from cell 
death. Others have shown that the racemic mixture of L- and D-BAIBA enhances adipose 
tissue browning, increases insulin sensitivity, and protects against diet-induced obesity, but 
effects of the pure enantiomers have not been examined. The potential autocrine effects of 
L-BAIBA on muscle were compared to the D- enantiomer by in vitro experiments using 
C2C12 myotubes and in vivo by administering it in drinking water of mice (100mg/day/kg) 
for 5 (acute) or 30 days (chronic). In vitro studies showed that 20 mM L-BAIBA increased 
C2C12 mitochondrial respiration, whereas 20 mM D-BAIBA resulted in reduced myotube 
diameter (-10%, p<0.05). In vivo, no significant effects were observed with either enan-
tiomer in the acute experiments. However, chronic administration of L-BAIBA increased 
gastrocnemius and quadriceps muscle size compared to control mice (+18%, +15%, p<0.05) 
and increased grip strength (+16%, p<0.01). We also observed a glycolytic-to-oxidative fiber 
shift (+42%, p<0.05) in the tibialis anterior muscle. An increase in protein expression of 
markers of mitochondrial biogenesis, such as PGC-1α and Cytochrome C, and markers of 
fusion, such as OPA1 (+300%, + 63% and +285% respectively, p<0.05) was also observed. 
Notably, similar to L-BAIBA, D-BAIBA increased grip strength (+15%, p<0.01). However, 
D-BAIBA had no significant effects on muscle mass, but did significantly reduce spleen size 
(19%, p<0.01). Together these in vitro and in vivo data show the positive potential autocrine 
effects of  L-BAIBA to improve oxidative metabolism resulting in increased muscle func-
tion. In mice, L-, but not D-BAIBA, acts as an exercise mimetic.
Disclosures: Fabrizio Pin, None
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Linagliptin Does Not Alter Bone Mass but Reduces Body Weight and White 
Adipose Tissue *Giulia Leanza1, Francesca Fontana2, Rocky Strollo1, Paolo 
Pozzilli1, Nicola Napoli1, Roberto Civitelli3. 1Unit of Endocrinology and Diabetes, 
Campus Bio-Medico University, Italy, 2WASHINGTON UNIVERSITY IN ST. 
LOUIS, United States, 3Division of Bone and Mineral Diseases, Washington 
University in St Louis, United States
Dipeptidyl peptidase-4 (DPP-4) inhibitors are used to lower blood glucose in type 2 
diabetes (T2D). Their mechanism of action is based on inhibiting DPP-4-mediated degrada-
tion of glucagon-like peptide-1 (GLP-1), a hormone that favors glucose utilization. Clinical 
studies suggest that DPP-4 inhibitors also reduce fracture risk among T2D patients; and 
circulating DPP4 positively correlates with body weight. In preclinical studies, GLP-1 stim-
ulates proliferation of mesenchymal stem cells and inhibits differentiation to adipocytes; 
while DPP4 expression increases with adipocyte differentiation, suggesting a role of GLP-1 
in regulating body adiposity. We tested whether linagliptin, a commonly used DPP-4 inhib-
itor, may improve bone mass and body adiposity in non-diabetic conditions. To this end, 
we randomized 6-week-old female C57BL/6J mice to receive either linagliptin (0.15 mg/
ml in drinking water; n=15) or placebo (drinking water; n=10) for 8 weeks. To minimize 
variation in baseline body weight, we used mice with body weight between 15.5 and 16.5 
g. We observed no differences in bone mineral density (BMD) and bone mineral content 
(BMC) by DXA between treatment groups at 4 and 8 weeks after starting linagliptin. Like-
wise, we found no differences between groups in lean and fat mass by DXA. By contrast, 
the linagliptin-treated group experienced a reduced gain in body weight with time relative to 
the placebo-treated group with a significant difference at the end of the observation period 
(18.1+/-1.4 vs. 19.2+/-1.1 g, respectively; p<0.05 t-test). Random blood glucose was lower 
in treated vs. control mice (144+/-10.8 vs. 172+/-20.4 mg/dl, respectively; p<0.05, t-test); 
however, no hypoglycemic episodes were observed on linagliptin. Notably at 8 weeks, 
mice treated with linagliptin showed a significant reduction in both gonadal (0.10+/-0.02 
vs. 0.19+/-0.04 g; p<0.001, t-test) and retroperitoneal white adipose tissue depots (0.017+/-
0,007 vs. 0.04+/-0.01 g; p<0.001, t-test) relative to untreated mice, even after normalization 
to body weight. In summary, linaglitptin reduces body adiposity and body weight without 
altering bone mass, suggesting a potential use of DPP-4 inhibitors in obesity and weight 
reduction programs in non-diabetic individuals, without effects on bone mass.
Disclosures: Giulia Leanza, None
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Ankle flexor torque and muscle composition are differential determinants 
of distal tibia bone strength and trabecular plate-rod morphometry *Andy 
Kin On Wong1, Eva Szabo1, Hugo Jern Wai Fung2, Adrian Chan2, Sunita Mathur2, 
Lora Giangregorio3, Angela M Cheung1. 1University Health Network, Canada, 
2University of Toronto, Canada, 3University of Waterloo, Canada
For a fixed bone volume fraction, trabecular plates contribute more to mechanical prop-
erties of trabecular bone than rods. Muscle properties are known to affect bone strength, but 
it is unclear how it affects different components of trabecular structure. Hypothesis: Peak 
torque or size of muscles around the ankle, as well as muscle and myotendinous density are 
associated with a more plate-like architecture at the distal tibia. Methods: A convenience 
sample of women and men >= 50 years old with no metal, reconstructive surgery, muscular 
dystrophies, or tendinopathies in any leg were recruited. Isometric ankle dorsi-plantarflex-
ion and inversion-eversion peak torques were measured using Biodex dynamometry. HR-
pQCT distal tibia scans were completed. Dynamometry and HR-pQCT assessments were 
completed on the same day on the non-dominant leg. Standard periosteal contouring was 
performed followed by an automated script to define the endosteal surface. Integral and 
trabecular vBMD were derived from typical analyses, failure load (FL) was obtained from 
finite element analysis, plate-specific parameters were computed from Individual Trabecula 
Segmentation (ITS) analysis, myotendinous density (MyD) and volume fraction (MyV/TV) 
were computed from soft tissue analysis. pQCT scans of the 66% mid-leg were performed 
(500 µm at a CT speed of 15 mm/s) to obtain muscle density (MD). Statistical Analysis: 
General linear models estimated how ankle flexor and extensor torque and muscle compo-
sition differentially relate, both separately and together, to whole-bone properties (integral 
vBMD, FL) and trabecular morphometry (ITS plate parameters). Models were adjusted for 
age, sex, BMI, use of glucocorticoids, current osteoarthritis, and participation in moderate 
to vigorous physical activity. Results: Among 81 women and 24 men (mean age: 63(10)y, 
BMI: 25.8(5.4) kg/m2, 25% with OA, 17% fracture history, 42% falls history), all torque 
measures, particularly ankle dorsiflexion, were determinants of plate-plate/rod junction 
density and failure load. However, muscle composition measures but not peak torque were 
associated with vBMD. The effect of greater ankle flexor-extensor torque on more intact 
bone parameters was stronger when MyD was higher (interaction p<0.001). Conclusion: 
Strength of muscles around the ankle are correlates of trabecular morphometry at the distal 
tibia, while muscle and myotendinous density surrounding it are associated with whole-bone 
density and strength.
Disclosures: Andy Kin On Wong, None
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Sympathetic Inhibition Is Associated with Lower BMD and Higher Body 
Fat in Young Female UCP1 Knockout and Wildtype Mice *Maisey Schuler1, 
Rebecca Tutino1, Miranda Cosman1, Rachel Hurwitz1, Taylor Spencer1, Alexis 
Stokel1, Isabel Hermsmeyer1, Cleo Moursi1, Maureen Devlin1. 1University of 
Michigan, United States
Brown adipose tissue (BAT) helps maintain body temperature through nonshivering 
thermogenesis, in which uncoupling protein-1 (UCP1) releases energy as heat. BAT is cor-
related with higher bone mass in humans, and experimental studies in adult rodents show 
BAT may protect the skeleton from cold-induced bone loss due to elevated sympathetic tone. 
To investigate interactions of cold stress, sympathetic tone, and BAT on body composition 
and skeletal acquisition in subadults, we studied the effects of housing temperature and sym-
pathetic inhibition in young C57BL/6J (B6) mice and UCP1 knockout (UCP1KO) mice. 
We hypothesize that 1) cold-housed UCP1KO mice will have lower BMD vs. B6 mice and 
2) sympathetic inhibition via the beta-blocker propranolol (PRO) will reduce cold-induced 
bone loss, particularly in UCP1KO mice. To test these hypotheses, male and female B6 and 
UCP1KO mice were pair housed at 26C (thermoneutrality) or 22C (mild cold stress) from 
3-12 wks of age with food and water ad lib. Half of each group were given PRO in drinking 
water (0.5 mg/mL) and half were controls (CON) (N=4-11/group). Outcomes at 12 wks of 
age included body mass, food intake, whole body bone mineral density (BMD, g/cm2), bone 
mineral content (BMC, g), and percent body fat (%) via PIXImus, and cortical and trabecular 
bone architecture at the midshaft and distal femur via µCT (results pending due to research 
hiatus). In females, BMC was lower at 12 wks and body fat was higher at 9 and 12 wks in 
UCP1KO at 22 vs. 26C, and in UCP1KO vs. B6 at 22C. In males, there were no significant 
differences in UCP1KO vs. B6 at either temperature. In B6 PRO females at 22C, BMD was 
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lower at 12 wks, BMC was lower at 9 and 12 wks, and body fat was higher at 9 wks. In UCP-
1KO PRO females at 22C, BMD was lower at 6 and 9 wks of age and BMC was lower at 6 
wks of age, and body fat was higher at 9 and 12 wks of age vs. CON. In male PRO vs. CON 
mice, there were no significant differences in bone density or body fat for either genotype or 
temperature. These data show UCP1KO mice have lower BMC, consistent with a protective 
effect of BAT on the skeleton. Contrary to our hypotheses, sympathetic inhibition was asso-
ciated with lower BMD and BMC and higher body fat in both B6 and UCP1KO females, but 
not in males, suggesting a sex-specific trade-off between bone and body fat. Future work will 
investigate whether skeletal effects of sympathetic tone differ in subadult skeletal acquisition 
vs. adult bone maintenance.
Disclosures: Maisey Schuler, None
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Effects of Chronic Hypoxia on Osteocyte Energy Metabolism, Differentiation 
and Function *Yukiko Kitase1, Matthew Prideaux1, Lynda F. Bonewald1. 
1Indiana University, United States
Chronic hypoxia, one of the contributing factors to aging- and disuse-induced osteopo-
rosis, modulates cellular energy metabolism. Osteocytes under unloaded conditions undergo 
hypoxia, however few studies have investigated the effects of chronic hypoxia on osteocyte 
energy metabolism, differentiation and function.  To determine how chronic hypoxia affects 
osteocyte energy metabolism, IDG-SW3 cells that model late osteoblast to mature osteocyte 
differentiation were treated with Roxadustat, an inhibitor of HIF prolyl-hydroxylase, known 
to cause the stabilization of HIF-α. Short-term treatments for 24 and 72h, at d15 revealed 
dysregulation of energy metabolism genes. To determine the effects on osteocyte differentia-
tion, cells at d0-15 were treated with the inhibitor and harvested on d15. Lipid droplet accu-
mulation was confirmed by Oil red O staining while Alizarin Red staining showed a dose-de-
pendent inhibition of mineralization.  Roxadustat-induced chronic hypoxia[DS3]  resulted in 
sustained induction of Glut1 mRNA (2.8-fold, Glucose uptake), Gpd1 & Pck1 (3.3 & 13.6, 
Glyceroneogenesis), Lpl, Cd36 & Fabp4 (4.5, 7.1 & 5.7, FA uptake/transport), Dgat2, Cidec 
& Plin4 (3.4, 5.2 & 4.9, Triglyceride synthesis/ lipid droplet) and PPARg (3.3, Lipogenic 
transcription factor), but not Acaca & Fasn (De novo lipogenesis). Gene expression of HIF-
2a was increased (3.9), but not HIF-1a suggesting that HIF-2a is responsible for the observed 
changes. Osteocyte differentiation, as determined by gene expression of Dmp1, Phex, and 
Mepe was inhibited but podoplanin (E11) (2.7) and Rankl (6.1) were significantly increased. 
To examine the effects of chronic hypoxia on mature osteocytes, cells were treated between 
d15-28. Roxadustat disrupted FA/lipid droplet metabolism by elevating the expression of 
Lpl (2.7), Fabp4 (2.3), Dgat2 (3.9), and Plin4 (2.0). Osteocyte genes that regulate bone 
turnover, Rankl (2.0) & Rankl/Opg ratio (1.7) showed a significant increase, while Sost/
Sclerostin (0.2/0.1) was almost completely blocked. Surprisingly, Fgf23 (10.2) was highly 
increased suggesting that phosphate metabolism is altered under chronic hypoxia.  These 
data suggest that in osteocytes chronic hypoxia may modulate FA/lipid droplet metabolism 
via HIF-2α, and alters osteocyte differentiation and function. Understanding the effects of 
chronic hypoxia on osteocyte lipid metabolism may identify novel targets for developing 
new therapeutic interventions against aging- and disuse-induced osteoporosis. 
Disclosures: Yukiko Kitase, None
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Impaired bone healing in type 2 diabetes is caused by defective bone 
microenvironment functions of skeletal progenitor cells. *FLORENCE 
FIGEAC1, MICHAELA TENCEROVA2, DALIA ALI1, THOMAS L. 
ANDERSEN3, DAN REMI APPADOO1, GREET KERCHKOFS4, JUSTYNA 
MAGDALENA KOWAL1, NICHOLAS DITZEL1, MOUSTAPHA KASSEM1. 
1KMEB, University of Southern Denmark and Odense University Hospital, 
Denmark, 2Molecular Physiology of Bone, Institute of Physiology, the Czech 
Academy of Sciences, Prague, Czech Republic, Czech Republic, 3KCB, Odense 
University Hospital, University of Southern Denmark, Denmark, 4Biomechanics 
lab, Institute of Mechanics, Materials, and Civil Engineering, UCLouvain and 
institute for experimental and clinical research and department of material 
science and engineering, Belgium
Purpose: The cellular mechanisms of obesity and type 2 diabetes (T2D)-associated im-
paired fracture healing are poorly studied. In a murine model of T2D reflecting both hyperin-
sulinemia due to high fat diet (HFD) (60% fat) and insulinopenia induced by streptozotocin 
(STZ:40mg/kg), we examined the cellular dynamics of bone healing in a tibia monocortical 
bone defect model.Methods: A cortical bone defect recapitulating phases of a stabilized frac-
ture was performed, and the dynamics of bone healing were studied using µCT-scanning and 
quantitative histology. BM-MSCs number, functions and bone marrow microenvironment 
composition were analysed employing molecular biology assays, quantitative in situ hy-
bridization and immunostaining.Results: During hyperinsulinemia, a delayed bone healing 
was observed. Newly formed bone was reduced by 28.4+/-7.7% and associated with accu-
mulation of marrow adipocytes at the defect site +124.1+/-38.7%, and increased density of 
SCA1+ (+75.0+/- 29.2%) but not Runx2+osteoprogenitor cells. We also observed increased 
in reactive oxygen species (ROS) production (+101.8+/- 33.0%), senescence gene signature 
(≈106.66+/- 34.03%) and LAMIN B1- as marker for senescent cell density (+225.2+/- 43.1 
%), suggesting accelerated senescence phenotype. During insulinopenia, a more pronounced 
delayed bone healing was observed with decreased newly formed bone to -34.9+/- 6.2% 
which was inversely correlated with glucose levels (R2=0.48, p<0.004) and callus adipose 
tissue area (R2=0.3711, p<0.01). Senescent phenotype present in hyperinsulinemic condi-
tion was absent during insulinopena. To test for the human relevance, we observed that 
sera from obese and T2D patients exerted inhibitory effects on osteoblastic differentiation 
of human marrow stromal MSC.Conclusions: Our data suggest that T2D exerts negative 
effects on bone healing through inhibitory effects of differentiation of osteoblastic stem cells 
and that the degree of hyperglycaemia and not insulin levels per se, are detrimental to bone 
healing.
Disclosures: FLORENCE FIGEAC, None
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Acute Relapse in Mice Increases Dietary Fat Retention in Cortical Bone 
*Beatriz Bermudez1, David Presby2, Ginger Johnson3, Matthew Jackman3, 
Yuan-Haw Wu3, Vanessa Sherk3. 1University of Colorado Denver, United States, 
2Harvard Medical School, United States, 3University of Colorado Anschutz 
Medical Campus, United States
Bone remodeling is known to expend energy, thereby contributing to energy balance. 
Bone marrow is an adipose depot and has a potential role as a local energy reservoir. Weight 
loss induces metabolic adaptations in non-skeletal tissues and increases the propensity for 
weight regain. It is unclear whether this also occurs in bone. Testing how energy balance 
alters nutrient trafficking in bone is crucial to understanding how undernutrition or over-
nutrition influences bone health. We aim to determine how fat trafficking and retention are 
altered by weight loss and relapse in exercise trained mice. The study design utilized mice 
over expressing human lipoprotein lipase (mckLPL) due to previously observed decreases 
in dietary and de novo derived fat retention in mckLPL mice. Wild type mice (WT) and 
mckLPL mice (6 wks old; n=14-18/grp) were fed a high-fat, high-sucrose diet for 8 weeks. 
All mice were then switched to a calorically-restricted medium fat diet and subjected to 
high intensity interval treadmill running for 3 weeks to induce and maintain 20% weight 
loss. For the final day of study, mice were randomized to either receive a food allotment to 
stay in energy balance (WtL, n=7,8/grp) or were allowed ad libitum feeding (Relapse, n=7-
10/grp). To determine trafficking of lipids, we provided food with 14C labelled oleate and 
palmitate to trace retention of dietary fat and we injected mice with 3H2O just prior to the 
final 24-hour period of study to trace de novo derived lipids. Tissues were harvested after the 
24-hour experiment and lipids were extracted from hindlimb cortical bone and plasma. Data 
are mean +/- SEM. Lean and fat mass were similar among groups. Fat intake was highest 
in Relapse groups (p<0.05, mckLPL Relapse: 449+/-42; WT Relapse: 437+/-45 vs mckLPL 
WtL: 325+/-48; WT WtL: 244+/-11 mg). Additionally, total energy expenditure and respira-
tory quotient (RQ) were highest in Relapse groups. Total lipid amount and de novo derived 
lipid product in hindlimb cortical bone were not different between groups, however dietary 
fat retention in cortical bone lipid was highest in Relapse groups (p<0.05, mckLPL Relapse: 
0.11+/-0.01; WT Relapse: 0.14+/-0.03 vs mckLPL WtL: 0.07+/-0.01; WT WtL: 0.06+/-0.01 
mg). Dietary fat retention in cortical bone was positively correlated with fat intake and RQ 
(p<0.05, r=0.61-0.66). Our results indicate that an acute relapse increases fat retention and 
exercise did not alter energy expenditure or nutrient trafficking between groups.
Disclosures: Beatriz Bermudez, None
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The Effects of High Fat Diet, Fracture Healing, and BMP-2 Treatment on 
Endothelial Cell Function in Ipsilateral and Contralateral Limbs *Olatundun 
Awosanya1, Ushashi Dadwal1, Caio Staut1, Nikhil Tewari1, Conner Valuch 
2, Stephen Mendenhall1, Rohit Nagaraj1, Rachel Blosser1, Jiliang Li2, Melissa 
Kacena 1. 1Department of Orthopaedic Surgery, Indiana University School of 
Medicine, IN, USA, United States, 2Department of Biology, Indiana University 
Purdue University Indianapolis, IN, USA, United States
Type 2 diabetes (T2D) results in physiological and structural changes in bone which 
contribute to poor fracture healing outcomes. Most prominently, T2D compromises micro-
vascular performance which negatively impacts bone regeneration as angiogenesis is re-
quired for new bone formation. Here we sought to examine the effects of locally adminis-
tered BMP-2 on femoral segmental bone defect (SBD) surgery and its angiogenic impacts 
on endothelial cells (ECs) isolated from the ipsilateral tibia or the contralateral tibia during 
T2D. Male C57BL/6 mice were fed a low fat diet (LFD, 10 kcal % fat, n=26) or high fat diet 
(HFD, 45 kcal % fat, n=27) starting at 8 weeks of age to induce a T2D-like phenotype. After 
12 weeks, the T2D phenotype was confirmed via glucose and insulin tolerance testing and 
mice underwent a femoral SBD surgery. Mice were treated with BMP-2 (4µg) or saline at 
the time of surgery. The ipsilateral and  contralateral tibia were removed 3 weeks post-sur-
gery and bone marrow ECs were isolated and their proliferation, angiogenic potential, and 
gene expression were analyzed. Crystal violet staining showed a significant 2-fold increase 
in BMP-2 treated LFD contralateral tibia ECs (p<0.05, n=3). However, no differences in 
proliferation were detected in surgical tibia ECs. Enhanced tube formation was observed in 
saline treated compared to BMP-2 treated, LFD ECs isolated from both the ipsilateral and 
contralateral tibia. Interestingly, for HFD fed mice, in both ipsilateral and contralateral tibia 
ECs, BMP-2 enhanced tube formation parameters. In LFD ipsilateral tibia ECs, BMP-2 
treatment increased expression of all angiogenic genes examined (CD31, FLT-1, ANGPT1, 
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and ANGPT2), whereas with HFD BMP-2 treatment did not alter the expression of CD31 or 
FLT1 and decreased the expression of ANGPT1 and ANGPT2. For the contralateral tibia, al-
though BMP-2 treatment resulted in no differences in CD31 or ANGPT2 expression between 
LFD and HFD ECs, significant increases were observed in HFD compared to LFD ECs in 
FLT-1 and ANGPT1 expression. As expected with impaired angiogenesis in T2D, LFD ECs 
had enhanced tube formation compared to HFD ECs. Thus, for the ipsilateral tibia ECs it 
appears that tube formation is inversely related to expression of CD31, FLT-1, ANGPT1, 
and ANGPT2 expression. However, this same trend is not observed in contralateral tibia 
ECs, perhaps suggesting that microenvironment at local versus distal sites of injury impact 
angiogenic properties.
Disclosures: Olatundun Awosanya, None
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Bone-derived PDGF-AA Promotes Pancreatic β cell Proliferation and 
Function in Aging *Xiaonan Liu1, Yu Chai1, Lei Wang1, Bin Yu1. 1Southern 
Medical University, China
The platelet-derived growth factors (PDGFs), key factors regulating pancreatic β cells 
proliferation and function, are secreted by bone tissue. However, the contribution of PDGF 
signaling from bone cells in β cells senescence and age-related type 2 diabetes remains unex-
plored. In this study, we report that the reduced number of osteoprogenitors in metaphysis of 
the long bone in aging results in a declined level of serum PDGF-AA, which contributes to 
decreased pancreatic β cell proliferation and function. 22-month-old mice had reduced level 
of both serum and pancreas PDGF-AA protein compared with 6-month-old control mice, 
which correlates with decreased serum insulin level and increased fasting glucose level, 
suggesting a declined pancreas function. RT-PCR analysis of different tissues and different 
cell types in bone marrow showed the decline in serum PDGF-AA level in aging was due to 
decreased expression of bone marrow osteoblast lineage cells. In situ immunofluorescence 
staining of bone tissue sections confirmed osterix+ osteoprogenitors are the primary source 
of PDGF-AA in bone. However, the number of osteoprogenitors, as well as their PDGF-
AA secretion, decreased as shown by immunofluorescence staining in 22-month-old mice. 
To determine whether bone-derived PDGF-AA modulates β cell proliferation and function, 
we evaluated the senescence phenotype and insulin secretion of rat insulinoma INS1 cells 
using standard medium(CON) or osterix+ osteoblast conditioned medium without(CM) or 
with (CM+AN) addition of PDGF-AA neutralizing antibody. Percentage of insulinoma INS1 
cells that expressed p16INK4a was 8.7% in CM group and increased to 23.9% in CM+AN 
group. Importantly, the expression of insulin markedly increased in CM group compared 
with CON group but was significantly lowered in CM+AN group, suggesting PDGF-AA 
secreted by osteoprogenitors promotes β cell proliferation and function. Finally, we found 
transplantation of osteoblast lineage cells directly to bone marrow increased serum PDGF-
AA level and β cell proliferation as well as function in aging mice, as shown by a reduced 
number of senescence-associated beta-galactosidase (SA-βGal)+ cells in pancreas tissue and 
improved glucose tolerance. These findings show the importance of bone-derived PDGF-AA 
in mediating pancreatic β cell proliferation and function in aging and raised the possibility of 
targeting bone secretion as a strategy to overcome age-related type 2 diabetes.
Disclosures: Xiaonan Liu, None
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Low energy availability reduces skeletal benefits in female long-distance 
triathletes as detected by HR-pQCT *Eduardo Medeiros Ferreira da Gama1, 
Leandro Kasuki2, Franscisco de Paula Paranhos Neto3, Miguel Madeira4, Laura 
Maria Carvalho Mendonça5, Annie Schtscherbyna4, Maria Lucia Fleiuss Farias4. 
1Division of Endocrinology of Clementino Fraga Filho University Hospital, 
Federal University of Rio de Janeiro (HUCFF-UFRJ), Brazil, 2Division of 
Neuroendocrinology Research Center of Clementino Fraga Filho University 
Hospital, Federal University of Rio de Janeiro (HUCFF-UFRJ), Brazil, 3Division 
of Endocrinology of Clementino Fraga Filho University Hospital, Federal 
University of Rio de Janeiro (HUCFF-UFRJ)., Brazil, 4Division of Endocrinology 
of Clementino Fraga Filho University Hospital, Federal University of Rio de 
Janeiro (HUCFF-UFRJ)., Brazil, 5Division of Rheumatology of Clementino 
Fraga Filho University Hospital, Federal University of Rio de Janeiro (HUCFF-
UFRJ)., Brazil
ABSTRACTIntroduction: The female athlete triad, initially described as the association 
of disordered eating, amenorrhea and osteoporosis, was further rede?ned to focus on low 
energy availability (EA), which has a central role in the development of hypoestrogenism 
and low bone mineral density (BMD), as measured by DXA. Objectives: To evaluate bone 
status in long-distance triathletes with and without low EA compared to non-athletes us-
ing DXA and HR-pQCT. Methods: Forty pre-menopausal women 20 years and older, 23 
triathletes and 17 non-athletes were included. The athletes denied previous menstrual al-
terations and had spontaneous regular menses or were on hormonal contraceptives at entry 
in the study. Results: Although no significant difference was detected by DXA, triathletes 
showed better bone density and microstructure than non-athletes at HR-pQCT, and median 
(range) values at distal tibia were, respectively: Total Ar=646.6 (487-869) vs 615.6 (499-
816) p=0.014; Tb.Ar=527.5 (374-764) vs 473 (384-686) p=0.018; Ct.Pm=101 (87-114) vs 
96 (87-111) p=0.011; Dtrab=167.4 (124-215) vs 131.3 (109-206) p=0.018; BV/TV=0.14 
(0.10-0.18) vs 0.11 (0.09- 0.17) p= 0.017; Tb.Sp=0.45 (0.33-0.61) vs 0.49 (0.34-0.69) 
p=0.034; Tb.Sp/N SD=0.19 (0.12-0.29) vs 0.22 (0.14-0.35) p=0.040. At distal radius sig-
nificant differences were found for Total Ar, Tb.N, Tb.Sp and Tb.Sp/N SD. The positive 
association of exercise was maintained in the subgroup of athletes with low EA as com-
pared to controls. However, athletes with low EA, as compared to those with adequate EA, 
showed increased fat mass index=6.5 (3-11) vs 3.0 (2-11) p=0.016, and lower D100=293 
(244-341) vs 344 (275-405) p=0.025, Ct.Ar=46.4 (32.2-59.2) vs 54.4 (40.5-62.4) p=0.038 
and Ct.Th=0.66 (0.48-0.85) vs 0.86 (0.62-1.01) p=0.025 at the radius and lower Dcomp=923 
(873-962) vs 950 (919-994) p=0.048 at the tibia.  Stress fractures were reported by 33% of 
athletes with low EA and by 18% of those with adequate EA. No impact on bone health was 
found between users compared to non-users of hormonal contraceptives. Conclusions: HR-
pQCT detects better bone density and microstructure in female long-distance triathletes, un-
revealed by DXA. Low EA partially compromises the beneficial effects of exercise on bone. 
These innovative findings reinforce the importance of an adequate EA in female athletes, 
irrespective of an apparently adequate BMD at DXA, to guarantee skeletal health.
Disclosures: Eduardo Medeiros Ferreira da Gama, None
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Incidence and predictors of fractures in older adults with and without obesity 
defined by body mass index versus body fat percentage *Anoohya Gandham1, 
Ayse Zengin1, Maxine P Bonham2, Tania Winzenberg3, Saliu Balogun3, Feitong 
Wu3, Dawn Aitken3, Flavia Cicuttini4, Peter R Ebeling1, Graeme Jones3, David 
Scott1. 1Department of Medicine, School of Clinical Sciences at Monash Health, 
Monash University, Clayton, Victoria, Australia, Australia, 2Department of 
Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, 
Australia, Australia, 3Menzies Institute for Medical Research, University of 
Tasmania, Hobart, Tasmania, Australia, Australia, 4Department of Epidemiology 
and Preventive Medicine, School of Public Health and Preventive Medicine, 
Monash University, Melbourne, Victoria, Australia, Australia
Purpose: To determine and compare risk factors associated with incident fractures in 
older adults with and without obesity, defined by both body mass index (BMI) and body fat 
percentage. Methods: 1,099 older adults (mean +/- standard deviation age = 63.0 +/- 7.5) 
years, participated in this prospective cohort study. Obesity status at baseline was defined 
by BMI (>=30 kg/m2) obtained by anthropometry and body fat percentage (>=30% for 
men and >=40% for women) assessed by dual-energy X-ray absorptiometry (DXA). Total 
hip and lumbar spine areal bone mineral density (aBMD) were assessed by DXA up to 
five years. Incident fractures were self-reported up to 10 years.   Results: Prevalence of 
obesity was 28% according to BMI and 43% according to body fat percentage. Obese older 
adults by BMI, but not body fat percentage, had significantly higher aBMD at the total hip 
and spine compared with non-obese (both p0.05). Mediation analysis confirmed that aBMD 
meditated the effects of BMI, but not body fat percentage, on all incident fractures. Higher 
baseline falls risk score was the only consistent predictor of increased likelihood of incident 
fractures in obese individuals only, according to both BMI and body fat percentage (both 
p-value<0.05).Conclusions: Obesity defined by body fat percentage is associated with in-
creased likelihood of incident fractures in community-dwelling older adults, whereas those 
who are obese according to BMI have reduced likelihood of incident fractures due to higher 
aBMD. Falls risk assessment may improve identification of obese older adults at increased 
risk of incident fractures.
Disclosures: Anoohya Gandham, None
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GPR109A gene deletion ameliorates gonadectomy-induced bone loss in mice 
*Jin-Ran Chen1, Oxana P. Lazarenko 1. 1Arkansas Children’s Nutrition Center, 
and the Department of Pediatrics, University of Arkansas for Medical Sciences, 
United States
Sex steroid deficiency plays critical roles in the pathophysiology of bone as the re-
sult of increased bone resorption. The G protein-coupled receptor 109A (GPR109A), also 
known as hydroxycarboxylic acid receptor 2 (HCAR2), HM74A or PUMA-G, is expressed 
in a variety of cells and tissue types, and robustly in osteoclastic precursor macrophages. 
We have previously provided evidence that suggested that GPR109A controls osteoclas-
togenesis and bone resorption, and systemic GPR109A gene deletion resulted in decreased 
osteoclast bone resorption but increased bone mass. Here, we used ovariectomized (OVX), 
orchidectomized (ORX) and GPR109A gene deletion mouse models, and investigated the 
role of GPR109A in gonadectomy-induced bone loss in female and male mice. 6 month 
old GPR109A-/- mice and their littermate wild type C57Bl6 mice were allocated to Sham 
control groups or gonadectomized groups for six weeks. Using densitometric micro-CT con-
firmed by peripheral quantitative CT (pQCT) scan on tibia and spine ex vivo, we determined 
that bone mass including bone volume, trabecular number, and bone mineral density and 
content in both trabecular and cortical site were significantly decreased in wild type OVX 
and ORX mice compared with their respective Sham control mice. While bone mass in 
GPR109A-/- Sham groups were higher compared with respective wild type Sham groups, 
gonadectomy-induced bone loss was ameliorated in GPR109A-/- mice compared with their 
respective Sham mice. In females especially, most parameters measured by micro-CT and 
pQCT had no differences between Sham and OVX groups. Bone remodeling marker mea-
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surements indicated that both bone resorption (Cathepsin K) and bone formation (bone spe-
cific ALP) markers were increased in gonadectomized mice compared with their respective 
Sham mice. However, expression of bone resorption markers (NFATc1, MMP9) were sig-
nificantly lower in GPR109A-/- mice compared with their wild type littermates. These data 
indicate that GPR109A systemic gene deletion ameliorates sex steroid deficiency-induced 
bone loss through suppressed bone resorption. Supported by USDA-ARS Project #6026-
51000-012-06S.
Disclosures: Jin-Ran Chen, None
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C3H substrain variation results in decreased bone density and fat mass in 
C3H/HeJ mice *Talia Lizotte1, Oraya Zinder2, Victoria DeMambro3, Daniel 
Brooks4, Melissa Mariano1, Eryn Harrington1, Mary Bouxsein4, Laura Reinholdt2, 
Clifford Rosen3, Kathleen Becker1. 1University of New England, United States, 
2The Jackson Laboratory, United States, 3Maine Medical Center Research 
Institute, United States, 4Beth Israel Deaconess Medical Center, United States
C3H/HeJ (HeJ) mice, a model of both high bone density and increased marrow fat, 
are commonly compared to C57BL/6J mice. HeJ mice harbor a mutation in TLR4 and an 
inversion on Chr 6 which are absent in C3H/HeOuJ (OuJ) mice. In order gain a greater 
understanding how  genetic differences in C3H substrains impact bone and adipose tissue, 
body composition was analyzed by DXA in OuJ and HeJ mice (n=15) at 8, 14, and 18 
wks of age. Female and male HeJ mice displayed decreased body mass (26% and 18% 
respectively), decreased fat mass, and increased percent fat-free mass when compared to 
OuJ mice. Inguinal and gonadal depot weights and adipocyte size were also reduced in 
HeJ mice. While no difference in food consumption was observed, HeJ mice had decreased 
energy expenditure likely resulting from changes in body composition. DXA analysis also 
indicated that total and femoral aBMD and aBMC were reduced in HeJ mice vs OuJ. When 
DXA results were normalized to body weight using a multiple linear regression model, sub-
strain differences in bone were eliminated or reversed. These data suggest that body weight 
is a major factor in regulating bone mass in C3H substrains. Bone microarchitecture was 
analyzed by µCT in femurs from OuJ and HeJ mice at 18 weeks of age (n=5). No overt 
differences in trabecular bone were present. However, Ct.Ar was decreased in HeJ mice. 
Decreases in periosteal circumference were observed only in female HeJ mice likely result-
ing in decreased pMOI, Imax, and Imin. Following adjustment for body weight, HeJ mice 
still showed decreased Ct.Ar while female mice still had decreased pMOI and Imax com-
pared to normalized OuJ data. Taken together, these results indicate that the HeJ mice have 
smaller bones than OuJ mice likely due to body weight differences. To further investigate 
differences in cell differentiation, bone marrow stromal cells (BMSCs) were differentiated 
into adipocytes and osteoblasts in vitro. No strain differences in adipogenesis were detected, 
but increased mineralization was observed by Von Kossa staining in BMSCs isolated from 
female HeJ mice. It is likely that genetic changes in HeJ mice result in increased osteogen-
esis, but body composition factors may play a major role in dictating bone density in vivo. 
Further analysis of marrow fat and gene expression may provide additional evidence to 
support a more informed choice of C3H substrains as an experimental model to study the 
genetic determinants of bone mass.
Disclosures: Talia Lizotte, None
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The Dynamics of Mice and Human Bone Marrow Adipose Tissue in 
Response to Feeding and Fasting *Gisela Pachon-Pena1, Pouneh K Fazeli2, 
Miriam A Bredella2, Elizabeth K O’Donell2, Anne Klibanski2, Clifford Rosen1. 
1MMCRI, United States, 2MGH, United States
The administration of a high fat diet (HFD) is an accelerating factor for metabolic syn-
drome, impaired glucose tolerance, and early type 2 diabetes mellitus (T2DM). The present 
study aims to assess the impact of a high fat diet or acute weight gain on human marrow adi-
pose tissue. Adipose tissue secrete numerous active substances termed adipokines, including 
adiponectin, leptin, resistin, interleukin-6, etc. Adipokines physiologically regulate devel-
opment, metabolism, fat storage, insulin sensitivity, homeostasis, blood pressure, immunity, 
and inflammation. To determine the effect of HFD on adipokines marrow adipose tissue, 
marrow/peripheral blood serum and marrow adipocytes from healthy adult human who un-
derwent either 10 days of HFD or 10 days of fasting, were collected according to published 
protocols. To analyze the expression of resistin, IL-6, TNF-α and adiponectin in human se-
rum from marrow and peripheral blood, we used DuoSet ELISA kit respectively. To analyze 
the expression of resistin, TNF-α, RCAN2 and SEMA3E/PLXND1 on marrow adipocyte, 
qRT-PCR were performed. Our results show that in paired aspirates, resistin increased mark-
edly with a HFD, but not with fasting, and not in the circulation, without significant changes 
on adiponectin neither IL-6 levels. Resistin is a cytokine produced in WAT (adipocytes in 
rodents, macrophages in human) and is thought to mediate T2DM and cardiovascular dis-
ease and to mark macrophage activation and TLR4 signaling. In our previous studies with 
mouse models, PLXIND1 is highly expressed on marrow stromal cells and has been linked 
to adiposity and type 2 diabetes. PLXIND1 also was one of the most highly expressed genes 
in MSCs from a mouse with high marrow adiposity and consistent with our finding noted 
in human volunteers. Our data show that expression of SEMA3E/PLXIND1, RCAN2 and 
TNF-α were increased on marrow adipocytes from the HFD volunteers. Also we identified 
up-regulation of the macrophage gene marker, EMR-1 (Homologous to F4/80 in mice), sug-
gestive of an inflammatory response in the marrow of normal volunteers on a HFD but not 
fasting. The bone microenviroment can be modulated by various factors including aging, 
obesity, and inflammation. Stress signal could be modulated by SEMA3E/PLXND1 axis as 
a chemoattractant for macrophages, provoking adipose tissue inflammation. Further analy-
sis is needed to understanding the immune response in the context of marrow adiposity in 
humans and mouse models.
Disclosures: Gisela Pachon-Pena, None
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Higher diet quality score increases weight loss during moderate caloric 
restriction with no greater loss of bone mineral density. *Anna Ogilvie1, 
Yvette Schlussel1, Stephen Schneider2, Sue Shapses3. 1Rutgers University, 
United States, 2Robert Wood Johnson Medical School, United States, 3Rutgers 
University and Robert Wood Johnson Medical School, United States
Purpose: Weight loss (WL) has been shown to reduce bone mineral density (BMD). 
Observational data indicate that a high-quality diet is beneficial to bone and may reduce 
fracture risk. However, whether the quality of the diet affects BMD during WL is not known.
Methods: In this prospective study design, we examined body composition, BMD, and diet 
quality in overweight/obese subjects during 6 months of WL (Osteoporosis, Weight loss 
and Endocrine; OWLE dataset). Subjects were provided nutrition counseling whether they 
were randomly assigned to weight loss (72%) or maintenance (28%); both groups were an-
alyzed together due to similar diet quality scores over 6 months. The Healthy Eating Index 
2015 (HEI) was calculated from monthly food records (11+ daily intakes/person). The HEI, 
based on the Dietary Guidelines for Americans, is a compilation of 13 food components 
that assesses nutrient density of the diet. Subjects were retrospectively separated into two 
groups by median HEI score (Higher HEI, H-HEI and Lower HEI; L-HEI; n=116/group) and 
analyzed by repeated measures ANOVA.Results: Subjects (n=232) were aged 54.5 y (53.1, 
55.8), with body mass index of 28.9 kg/m2 (28.4, 29.4), and were predominantly female 
(87%). During WL, subjects in H-HEI and L-HEI groups scored 68 (67, 69) and 54 (53, 55), 
respectively (p<0.001). Those in the H-HEI group lost more weight [-4.1 kg (-4.9, -3.4)] 
than those in the L-HEI group [-3.0 kg (-3.8, -2.1); p<0.05]. WL was associated with higher 
intake of whole grains and protein (fish/plant sources), and reduced intake of saturated fat 
and refined grains (p<0.05). Loss of total and visceral fat was greater in H-HEI versus L-HEI 
(p<0.05). As expected, there was WL-induced BMD-loss (total hip, 33% radius; p<0.001; 
and trend for lumbar spine, LS; p0.05) or a trend to attenuate BMD loss (total hip and total 
body; p=0.073, p=0.095, respectively) in the H-HEI compared to L-HEI.Conclusions: Indi-
viduals with higher diet quality scores lost more weight, and total and visceral fat. However, 
for a given amount of WL, BMD loss was similar in H-HEI and L-HEI groups. These data 
suggest the quality of the diet during caloric restriction, in addition to the amount of WL, is 
potentially another factor contributing to BMD loss.
Disclosures: Anna Ogilvie, None
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Bioactive Glass-Ceramic Granules Induce New Bone Formation in a Rat 
Preclinical Model of Type-1 Diabetes Mellitus *Fátima Gomez Gramajo1, 
Gabriela Vargas2, Rosa Alicia Araoz3, Rosa Vera Mesones2, Teresita Bellido4, 
Aldo Roberto Boccaccini5, Alejandro Gorustovich6. 1CONICET, Salta, 
Argentina, Argentina, 2Salta National University, Argentina, 3University of 
Buenos Aires, Argentina, 4Indiana University School of Medicine; University 
of Arkansas for Medical Sciences, United States, 5Institute of Biomaterials, 
Department of Materials Science and Engineering, University of Erlangen-
Nuremberg, Germany, 6Interdisciplinary Materials Group-IESIING-UCASAL, 
INTECIN UBA-CONICET, Argentina
Therapeutic strategies to increase bone formation which is defective in type-1 diabetes 
mellitus (T1DM) are sorely needed. Incorporation of therapeutic ions into the structure of 
bioactive glasses for direct stimulation of cells is a very attractive approach for bone tissue 
regeneration. Lithium (Li) has recently been identified as a biologically active ion which can 
stimulate osteoblast cell activity. Here, we evaluated the osteogenic effects of glass-ceramic 
(G-C) granules developed from bioactive glass of the 45S5 system and 5 wt% Li-doped 45S5 
glass (45S5.5Li), in a Streptozotocin-induced T1DM model. Male Wistar rats (5 weeks old) 
were assigned to two groups: control (n=10) and DM (n=10). After a week, DM was con-
firmed by quantifying fasting blood glucose levels and G-C granules (250 µm) were intraos-
seously implanted under anesthesia. Each animal was implanted with 15 mg of 45S5 G-C 
granules inside the medullary compartment of one tibia and 15 mg of 45S5.5Li G-C granules 
in the contralateral tibia. At 30 days post-treatment, glycemia levels and body weight were 
recorded and the rats then euthanized. All procedures were approved by the IACUC. Tibias 
were fixed, decalcified and embedded in paraffin. Histological sections transverse to the 
tibial longitudinal axis were subsequently obtained, stained with hematoxylin-eosin, and 
examined under optical microscope. Bone volume/tissue volume (BV/TV) of neoformed 
bone around GC granules was quantified by histomorphometry. As compared to controls 
(C), DM rats showed a significant increase (p< 0.01) in blood glucose (C 110+/-11 mg/dL, 
DM 531+/-102 mg/dL) and a significant decrease (p< 0.01) in body weight (C 263+/-23 g, 
DM 103+/-34 g). Microscopically, both groups showed lamellar bone around the G-C gran-
ules at 30 days post-implantation. The histomorphometric analysis showed similar % BV/
TV of bone around the G-C granules induced by 45S5 or 45S5.5Li granules in both C and 
DM groups (C/45S5 21+/-4, C/45S5.5Li 18+/-4; DM/45S5 14+/-1, DM/45S5.5Li 15+/-4). 
The present results demonstrate that 45S5 and 45S5.5Li G-C granules equally stimulate the 
neoformation of bone under physiological or diabetic conditions. These findings provide the 
basis for the use of bioactive glass-ceramics to promote bone regeneration in DM.
Disclosures: Fátima Gomez Gramajo, None
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Musculoskeletal and metabolic responses to low fat and high fat diet in 
athymic nude mice *Sukanya Suresh1, Laura Wright1, Sutha John1, Sreemala 
Murthy1, Yun She1, Trupti Trivedi1, Gabriel Pagnotti1, Khalid Mohammad1, 
Theresa Guise1. 1Indiana University, United States
Advanced breast cancers are frequently associated with bone metastases. Bone mar-
row microenvironment provides metastatic niche for tumor cells to survive and grow. Bone 
marrow adipose tissue (BMAT); abundant in the marrow increases with age, excess body fat 
accumulation and during adjuvant endocrine therapy, conditions which are experienced by 
breast cancer patients. Since the role of BMAT in breast cancer metastatic niche is unknown, 
it is essential to develop xenograft models of excess body fat and BMAT accumulation mir-
roring the development of obesity in humans. Athymic nude mice are T cell deficient outbred 
mice widely used in xenograft studies. Here, we characterized the effect of feeding high fat 
diet (HFD, 60 kcal % fat) or nutrient matched low-fat diet (LFD, 10 kcal % fat) on body fat, 
bone, BMAT, muscle and glucose metabolism in 9-week-old female athymic nude mice for 
4 weeks and 18 weeks. We observed no body weight differences in the initial 4 weeks, but 
from 12 weeks of age the LFD-fed mice showed more body weight gain compared to the 
HFD fed mice (p<0.05). However, between the two diet groups there was no difference in 
body fat, lean mass, glucose tolerance, insulin sensitivity, forelimb grip strength or muscle 
specific force measured by ex vivo contractility measurement of extensor digitorum longus 
muscle. Despite the lack of excess body fat accumulation, micro-CT analysis showed that 
4 weeks of HFD feeding resulted in 32% reduction in trabecular bone volume (BV/TV, 
p<0.05) and significant induction in marrow adiposity (p<0.05) compared to the LFD-fed 
mice. In contrast, 18 weeks of HFD feeding increased the trabecular BV/TV by 50% in 
the HFD fed mice relative to LFD-fed mice (p<0.05), with no induction of excess BMAT. 
Histomorphometric analysis of tibiae showed that HFD reduced bone formation rate, miner-
al apposition rate and osteoid volume at both 4 weeks (p<0.05) and 18 weeks (p<0.05) but 
reduction in osteoclasts only at 18 weeks (p<0.05). Cortical bone parameters and mechanical 
properties of the bone were unaffected by either diets.Thus, for bone metastases studies 
where impact of excess body fat, BMAT accrual and metabolic dysfunction are essential 
to study disease progression and metastases, the athymic nude mouse model is not ideal. 
Whether modifications to the model, including sex steroid deficiency, or others will improve 
responsiveness to HFD induced metabolic disruption in athymic nude mice should be as-
sessed in future studies. 
Disclosures: Sukanya Suresh, None
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Relationship between Serum PTH and Metabolic Biomarkers *Syu Mi Sam 
1, Sabashini Ramchand2, Rachel Davey2, Samantha Richardson3, Jeffrey Zajac2, 
Janine Danks2. 1RMIT University, School of Health and Biomedical Sciences, 
Australia, 2University fo Melbourne DOM, Austin Health, Australia, 3RMIT 
University, School of Science, Australia
Parathyroid hormone (PTH) is known for its classical role in calcium homeostasis and 
bone metabolism. However, evidence shows that bone, as an endocrine organ, can exert 
feedback regulation on aspects of glucose homeostasis by secreting bone-derived factors. 
For example, osteocalcin has been implicated in glucose homeostasis via the regulation of 
insulin secretion. This cross-talk between glucose and bone demonstrates the significance of 
hormones/factors which act on bone cells and could in turn contribute to the physiological 
pathways involved in glucose metabolism or vice versa. Our aim was to investigate the 
relationship between serum PTH levels and metabolic biomarkers in diabetic patients. These 
biomarkers were selected for their involvement in glucose homeostasis or calcium regula-
tion. Biochemistry blood results from 12,068 diabetic patients attending an outpatient clinic 
from 2008-2015 were examined. Only 2,032 patients from this group had their PTH level 
determined. Pearson’s correlational analyses were performed to determine the association of 
PTH with these biomarkers which included: fasting plasma glucose, C-peptide, uncorrect-
ed calcium (not adjusted to albumin), 25-hydroxy vitamin D, glycated haemoglobin, total 
cholesterol, high-density lipoprotein and low-density lipoprotein. Serum PTH levels were 
positively correlated with C-peptide, a marker of endogenous insulin production. This cor-
relation was strongest in the group of patients who had PTH levels above the normal refer-
ence interval (1.6- 6.0 pmol/L (r=0.30, p<0.01)). These findings suggest that the interaction 
of PTH with biomarkers may be affected by impaired beta-cell function. 
Disclosures: Syu Mi Sam, None
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Visceral Adipose Tissue and Major Adverse Cardio-vascular Events:A 
Systematic Review and Meta-analysis Protocol of Observational and 
Randomized Controlled Trials *Randa Saad1, Malak Ghezzawi1, John Batsis2, 
Katherine Saunders3, Marlene Chakhtoura1. 1American University of Beirut 
Medical Center, Lebanon, 2Dartmouth-Hitchcock Medical Center, United States, 
3Weill Cornell Medicine, United States
Introduction:The diagnosis of obesity has been traditionally based on using body mass 
index (BMI) which has known limitations. Visceral Adipose Tissue (VAT) assessment 
by imaging (MR, CT or Dual-energy X-ray absorptiometry (DXA)) represents a specific 
and sensitive method for measuring ectopic fat at specific sites, including central obesi-
ty.Objectives:The aim is to evaluate the association of increased VAT with major adverse 
cardiac events (MACE) (non-fatal stroke, non-fatal myocardial infarction, and cardio-
vascular death), and to identify a VAT cutoff that implies a significantly increased risk of 
MACE.  Methods:We will search MEDLINE (1946 to present), EMBASE, COCHRANE, 
and CINAHL without time or language limitation. We will include observational studies 
and trials conducted in adults (>=18 years), evaluating the association of VAT area (cm2) 
with 3-point MACE outcomes, combined (primary outcome), separately (secondary out-
come). Two reviewers (RS and MG) will review citations and abstracts, in duplicate and in-
dependently after training, and will screen full texts using a priori prepared screening forms. 
We will use the Newcastle-Ottawa Quality Assessment Scale and the Cochrane Collabora-
tion tool for risk of bias assessment of observational and randomized studies, respectively. 
We will calculate the relative risk (RR) of the 3-point MACE, comparing a specific cutoff or 
range of VAT area, or comparing different tertiles or quartiles, depending on data available in 
individual studies. Adjusted results in individual studies will be used. The primary analysis 
will be done using a random effects model, using RevMan version 5.3Results: This project 
is currently ongoing and full results will be available by September 2020. Discussion:Since 
BMI may be sometimes an insufficient parameter in the assessment of individuals with obe-
sity, additional measurements, such as VAT, may be needed to help providers risk stratify 
patients. The diagnostic threshold of abnormal visceral fat is unknown and our meta-analysis 
will provide evidence of its relationship with long-term adverse cardiovascular outcomes.
Disclosures: Randa Saad, None
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Sirt3 Deficiency Causes Hyper-acetylation of Mitochondrial Proteins and 
Mitochondrial Dysfunction in Osteoclasts of Old Mice *Wen Ling1, Kimberly 
Krager1, Aaron Warren1, Nukhet Aykin-Burns1, Stephanie Byrum1, Maria 
Almeida1, Ha-Neui Kim1. 1University of Arkansas for Medical Sciences, United 
States
Mitochondrial protein acetylation plays a key role in aging and Sirt3 is the primary 
mitochondrial protein deacetylase. Sirt3 is indispensable for the increased bone resorption 
and the accompanying enhanced mitochondrial function in osteoclasts from old mice but 
the molecular details remain elusive. We have analyzed the global proteome of bone mar-
row-derived macrophages (BMMs) and pre-osteoclasts (pOCs) from 16-month-old Sirt3 
deficient (KO) B6/Sv129 female mice and WT controls by mass spectrometry. Of a total 
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4400 identified proteins 387 were mitochondrial proteins. Gene Ontology enrichment anal-
ysis confirmed that several Sirt3 target pathways, including oxidative phosphorylation, mi-
tochondrial translation, transmembrane electron transfer carrier, and respiratory chain were 
down regulated in Sirt3 null cells. However, the overall protein-fold changes were minimal 
between genotypes, suggesting that changes in acetylation, rather than protein levels may 
be responsible for the mitochondrial dysfunction in osteoclasts of the Sirt3 null mice. Fol-
lowing data acquisition in MS/MS mode we used the Uniprot Mus musculus database to 
identify acetylated peptides and proteins. A total of 567 acetylated peptides were identified 
with a fold change of >2.5 and a p value of <0.05. RANKL enhanced 69 acetyl-lysine pep-
tides in WT cells whereas Sirt3 deletion resulted in the hyperacetylation of 305 peptides. 
In RANKL-treated Sirt3 null osteoclasts 18 mitochondrial proteins were identified with 
significant hyperacetylation at multiple sites. Importantly, five lysine residues (K49, K52, 
K62, K83, and K103) quantified in ATPIF1 – an essential protein for mitophagy – displayed 
a 3.9- to 213-fold acetylation increase in the absence of Sirt3, indicating that ATPIF1 is a 
major target of Sirt3 in osteoclasts. Consistent with this, osteoclasts lacking Sirt3 exhibit-
ed a striking decrease in the protein levels of mitophagy markers such as Bnip3 and Nix 
compared to osteoclasts from WT mice. Deletion of Sirt3 also reduced the conversion of 
LC3-I to LC3-II, indicating suppression of autophagic flux. These results demonstrate that 
Sirt3 deficiency causes significant changes in the acetylome of osteoclasts and Sirt3 target 
proteins are culprits of excessive bone resorption associated with old age.
Disclosures: Wen Ling, None
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Novel BMD Loci Identified by Whole Genome Sequencing and CRISPR 
editing in Zebrafish: The NHLBI Trans-Omics for Precision Medicine 
(TOPMED) Study *Yi-Hsiang Hsu1, Joyce W Tang2, Hanfei Xu3, Cecily 
Choy2, May Montasser4, Carolyn Crandall5, Ming-Ju Tsai1, Mao Fu4, Jeffrey R. 
O’Connell4, James Perry4, Shabnam Salimi4, Elizabeth Streeten4, Chris Delaney6, 
Anne Justice7, Charles R. Farber8, David Karasik9, David M. Evans10, Jonathan 
Tobias11, Brent Richards12, Ching-Ti Liu3, Robert Wallace13, John Blangero14, 
Kerri Wiggins15, Rebecca Jackson16, Douglas Kiel9, Braxton D. Mitchell4, 
Ronald Kwon17. 1HSL Marcus Institute for Aging Research and Harvard Medical 
School, United States, 2Institute for Stem Cell and Regenerative Medicine, Sch 
of Med, University of Washington, United States, 3Boston University, School 
of Public Health, United States, 4School of Medicine, University of Maryland, 
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The discovery of causal genetic variants creates opportunities for new disease diag-
nostics and therapies. Whole-genome sequencing (WGS) is rapidly being incorporated 
into mainstream biomedical research to provide comprehensive enumeration of sequence 
variation. To identify novel coding variants that are associated with BMD, we utilized the 
deep-coverage WGS (average 30X coverage) in 10K Caucasian participants obtained from 
Amish, CHS, FHS, SAFOS and WHI studies (the NHLBI TOPMED Program) as well as 
ALSPAC and TWINSUK studies (10X coverage). We performed gene-based collapsing 
association tests (allele-count and SKAT tests) to identify rare functional coding variants 
(MAF <= 0.5%) associated with BMD adjusting for age, age2, sex, weight, height, ancestral 
genetic background, cohort, and menopausal status (women). Only loss-of-function (LoF), 
protein-altering short insertion/deletion, and missense variants with deleterious effects 
were included. The most significant gene-based association was found in the IGHE gene 
(p=7.18x10-8) with lower lumbar spine (LS) BMD (genome-wide significance p < 4.27x10-
6 after Bonferroni correction). The other novel findings included SLC26A11, ERGIC3 and 
STMN1 genes with LSBMD and TFAP2E, CYP2B6, GDF10 and IL6 genes with FNBMD. 
Among these genes, Gdf10 and Il6 has been reported to be the most highly expressed in skel-
etal structures during early mouse development. GDF10 (growth differentiation factor 10) 
also known as BMP3B is a member of the transforming growth factor ß superfamily. In the 
GDF10 gene, four less-common potential functional variants were associated with FNBMD. 
Among them, SNP P468S is located in the mature region downstream of the RXXR cleavage 
site and predicted to be a LoF mutation that suppresses GDF10 function. To address the 
involvement of GDF10 in bone metabolism, we generated zebrafish mutants for gdf10a and 
gdf10b and analyzed them using microCT-based spinal phenomics (160 measures/animal). 
We administered CRISPR-Cas9:gRNA complexes targeting three sites on gdf10a or gdf10b. 
Sequencing analysis revealed that this produced bi-allelic out-of-frame mutations with an 
efficiency of ~90% for each gene. During early development (12 days), somatic mutants for 
both gdf10a and gdf10b exhibited increased vertebral ossification. As adults (3mo), somatic 
mutants for gdf10a exhibited reduced vertebral bone mass and mineralization. Our studies 
support a function for GDF10 in the development and growth of the skeleton.
Disclosures: Yi-Hsiang Hsu, None
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Single-cell analyses in a comparative primate skeletal cell culture model 
reveal evolutionarily divergent patterns of gene expression *Genevieve 
Housman1, Yoav Gilad1. 1University of Chicago, United States
Skeletal anatomy is important for comparative primate research, but the molecular 
mechanisms that drive the development and evolution of complex skeletal traits are not 
well characterized. Studying gene regulation in primate skeletal tissues is particularly chal-
lenging because samples are difficult to obtain, often have preservation issues, and contain 
heterogenous populations of cells. Further, human skeletal transcriptomic data have not been 
collected in consortia like GTEx. Thus, we have established a comparative primate skeletal 
cell culture model as a more accessible way of evaluating gene expression in the skeleton.
We optimized protocols for differentiating six human and six chimpanzee induced plurip-
otent stem cell lines (iPSCs) into mesenchymal stem cells (MSCs) and subsequently into 
osteoblasts; we then validated cell differentiation using standard methods. Using the 10X 
Genomics platform, we collected single-cell RNA-seq data from over 100,000 cells that 
represent samples and replicates at each stage of differentiation (n=21).Technical replicates 
were collected for each species and cell type, and the strong correlations of their average 
gene expression patterns (r=0.99 for each cell type) validate the reproducibility of collected 
data. Across all samples, humans and chimpanzees share patterns of marker gene expres-
sion that denote pluripotency in iPSCs, commitment to the mesodermal lineage in MSCs, 
and osteogenic potential in osteoblasts. Simultaneously, hundreds of genes are differentially 
expressed (DE) between humans and chimpanzees in each cell type, with some DE genes 
shared across cell types and others unique to specific cell types. DE genes present in later 
stages of skeletal cell differentiation are enriched in functions associated with extracellu-
lar matrix organization – processes essential for skeletal tissue development. Further, these 
single-cell data allow for species-specific DE gene assessment in more detailed classifica-
tions of osteogenic cells, such as preosteoblast, osteoblast, and embedding osteoblast stages.
Altogether, these gene expression patterns during primate skeletal cell development hint at 
possible evolutionarily divergent gene regulation mechanisms that may contribute to skele-
tal trait differences between species. Continued evaluation of this cell culture system using 
controlled developmental and environmental manipulations will further enhance our under-
standing of these genotype-phenotype relationships in the skeleton.
Disclosures: Genevieve Housman, None
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Peripheral bone density, microarchitecture and strength assessed by HR-pQCT is genet-
ically heritable and associated with fracture risk even after adjusting for DXA-based areal 
BMD (aBMD). Genetic studies of these phenotypes may reveal unique, novel genes that 
contribute to skeletal integrity not identifiable in previous genome-wide association studies 
(GWAS) of aBMD and CT-derived vBMD. We performed genome-wide association me-
ta-analyses to discover novel GWAS loci and replicated these novel findings in additional 
studies. The discovery GWAS meta-analysis was done in 5,692 adult Caucasians from 7 co-
hort studies (FHS, Mayo Clinic, GeRiCo, OFELY, STRAMBO, MrOS Sweden and GOOD). 
Replication was done in 2,636 adult Caucasians (MrOS US, CaMOS and Lyon QUALY-
OR). HR-pQCT (XtremeCT, Scanco Medical AG) distal radius and tibia phenotypes were 
assessed. Except for CaMOS and Qualyor (de novo genotyping for replication), SNPs in all 
other studies were genotyped by SNP chips and whole genome imputed to ~40 million SNPs. 
Multiple linear regression or mixed-effects model (family-based) were used for SNP-pheno-
type associations. Additive genetic effect models were applied, adjusted for age, sex, weight, 
height and genetic ancestry. We identified and replicated 17 GWAS loci with p < 5x10-8 
and 7 suggestive GWAS loci with 5x10-8 < p < 5x10-7. Among 17 GWAS loci, 11 were 
not reported by previous aBMD GWAS, including EFEMP1_PNPT1, FMN2, Chr3q25.2, 
CPED1, Chr9q22.2, Chr13q21.32, VAPA, DIS3L2, FGFRL1, PELO and PCDH15 genes. 
Most of these novel loci were primarily associated with bone structure phenotypes (TbTh, 
TbN, TtAr, CtPo and CtTh) and bone strength estimated via µFEA-FL. Six out of 7 sugges-
tive GWAS loci were also primarily associated with bone structure phenotypes. In contrast, 
the six previously reported aBMD GWAS loci (ZBTB40, MEF2C-AS1, WNT16-FAM3C 
and AKAP11-TNFSF11, PTHLH-CCDC91 and EN1) were associated with both density 
(e.g., TtBMD, CtBMD, TbBMD) and structure phenotypes. The most significantly associat-
ed SNP, rs10254825, was positively associated with µFEA-FL (p=5x10-26) and previously 
associated with fracture. Our findings suggest that the genetic control of bone microarchitec-
ture may provide additional insights into the pathogenesis of skeletal integrity not available 
from aBMD. Genome editing in zebrafish using the CRISPR/Cas9 on selected genes from 
the novel loci is underway to dissect their potential functional involvement in bone biology.
Disclosures: Yi-Hsiang Hsu, None
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Objectives: Osteoporosis is a metabolic skeletal disease with a strong underlying ge-
netic component. The study aimed to identify the genetic determinants of a penetrant form 
of early-onset osteoporosis in an extended Maltese family. Methods: A 3-generation ped-
igree of 29 relatives with ages ranging from 21 to 81 years was recruited. Osteoporosis 
was defined using T-score or Z-score measures of the lumbar spine and hip derived from 
DXA scans. The proband had a hip T-score of -2.9. A genome-wide linkage scan followed 
by whole exome sequencing was performed, whereas shortlisted variants were tested using 
Competitive Allele Specific PCR in a case-control collection of Maltese postmenopausal 
women. Pre-mRNA splicing aberrance was tested using an exon-trapping vector transfected 
in SaOS2 and hFOB cells. Results: Multipoint parametric linkage with dominant inheri-
tance identified two suggestive peaks with a LOD score of 2.1 mapping to chromosomes 
12p13.33-12p13.1 and 19p13.2-q13.12. Comprehensive exome variant filtering revealed the 
presence of a conserved variant rs146089604 (c.686+32G>A) in intron 7 of ZNF384 in all 
7 affected relatives, having a MAF of <=1% in gnomAD. In silico modeling predicted the 
G>A substitution to abolish an exon splicing enhancer motif and branch site. Indeed, in 
vitro functional assessment demonstrated that the A allele leads to exon 8 and part of intron 
8 to be retained, both of which were spliced out in transcripts with the G allele. Targeted 
expression profiling confirmed that ZNF384 transcripts harboring exon 8 are weakly ex-
pressed in healthy bone tissue, indicating that levels would be altered in the presence of 
the variant. Replication of ZNF384 rs146089604 in 1018 Maltese postmenopausal women 
strengthened the association with BMD and fracture susceptibility; women with the GA 
genotype (n=67) had a two-fold increased risk of low hip BMD (adjusted odds ratio: 2.0 
[95% CI 1.1-3.8]) and fractures (all-type: 2.0 [1.1-3.8], hip: 2.6 [1.0-6.4]), which was not at-
tenuated after adjusting for BMD. Only 2 women with the AA genotype were detected, both 
having a low hip BMD. Conclusion: Observations suggest that ZNF384 rs146089604 could 
be a causal variant. ZNF384 transactivates COL1A1 and matrix metalloproteinases, and 
suppresses BMP and canonical Wnt signaling. ZNF384-deficient mice had increased bone 
formation and bone volume. Thus, impaired splicing mechanisms could alter ZNF384’s 
function culminating in reduced bone quality.
Disclosures: Melissa M Formosa, None
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Age-related bone loss resulting in osteoporosis with increased fracture risk represent a 
major health problem with increased morbidity and decreased quality of life. A more com-
plete understanding of how stem cells produce bone forming cells during osteogenesis could 
be vital to discovering new therapeutic interventions. Nearly all genes of the human genome 
undergo alternative splicing (AS) through the action of RNA binding proteins (RBPs). From 
a mere ~ 20,000 genes, the mechanism of AS expands the repertoire of proteins that is 
needed for the full diversity of cell types, tissues, and organs found in humans. There has 
been no unbiased, transcriptome-wide analysis of AS of human bone marrow mesenchy-
mal stem cells (hMSC; CD73+/CD90+/CD105+/CD14-/CD34-/CD45-/CD19-/HLA-DR-) 
undergoing osteogenic differentiation. In this study, we conducted osteogenic day 0-12 time-
course differentiation of hMSC, RNA-sequencing, and bioinformatic analysis with a focus 
on RBPs and exon-skipping (SE) the most common mode of AS. As anticipated, a number 
of genes had expression that were up- and down-regulated over the time course including a 
number of RBPs. Additionally, a number of genes showed no change in expression level but 
exhibited AS. We then explored our dataset to identify RBPs whose significant differential 
expression over the time course was robustly correlated (R2 > 0.5) with SE events that had 
significant percent-spliced-in (PSI) changes with time. RBP binding motif scanning was 
then conducted on the 300-base upstream intron, exon-body, and 300-base downstream in-
tron window of sequences of these SE events. Motifs with position weight matrix scores > 
0.8 were deemed as hits. Motif hit/not-hits on foreground and background SE events were 
statistically analyzed for region specific enrichment yielding nine candidate RBPs (CPEB2, 
FUS, HNRNPA2B1, KHDRBS3, PCBP3, PTBP1, RBM38, SF3B4, SRSF1) that could be 
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potential regulators of osteogenesis. One candidate, KHDRBS3, was knocked down by siR-
NA and found to significantly reduce osteogenesis as assayed by quantitative real-time PCR 
of osteogenic markers RUNX2 and BGLAP and functional alkaline phosphatase staining in 
comparison to non-targeting siRNA negative control. The analytical pipeline also identifed 
genes with SE that maybe the targets of regulation by the candidate RBPs inferred from the 
RBP binding motif mapping. These results suggest the potential and power of AS to regulate 
the osteogenesis differentiation process.
Disclosures: Yuanyuan Wang, None
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Ongoing efforts to identify new genetic determinants of bone fragility in mice or humans 
promise to yield therapies for bone fragility in aging. However, RNA sequencing (RNAseq) 
in mouse models of fragility can yield thousands of differentially expressed genes (DEGs) 
and prioritizing new candidates for functional analyses is difficult. Human genome-wide 
association studies (GWAS) report many single variants associated with BMD and fracture, 
but GWAS alone is unable to identify causal variants. We sought to integrate data generat-
ed in mouse RNAseq and human GWAS to improve the identification of novel genes that 
are clinically relevant and functionally involved in regulating human BMD and fracture 
in aging.Unbiased RNAseq of cortical bone (marrow and periosteum removed) from 2mo, 
1, 2, and 2.5yr mice (n=4/group)  was used to identify DEGs for three aging sets: 2m-1y, 
2m-2y, and 2m-2.5y (1499, 1685, and 5525 DEGs, respectively, FDR<0.1). To determine if 
human homologs of mouse DEGs were associated with human BMD or fracture, MAGMA 
was used to calculate gene-based scores from published GWAS results from 426,824 UK 
Biobank participants. Scores were based on the most significant variant within 50kb of the 
gene region, after adjusting for several potential confounders. MAGMA was also used for 
enrichment analysis of mouse DEG sets for human BMD and fracture associations.While 
all aging mouse DEGs sets were enriched for BMD, only the 2m-2.5y set was significantly 
enriched for fracture (Fig. 1). Of this group, 1046 genes were associated with BMD and 
19 genes were associated with fracture (Bonferroni, P<0.05). Of the 19 fracture-associated 
genes, this in-silico approach identified WNT16 and LRP5, which have known functions in 
bone and clinical relevance to fracture. Several others have yet to be investigated in the skel-
eton.  These include FAM3C and CPED1, which are among 11 genes significantly associated 
with fracture at the whole genome level; and MPP3 and ERP27, which are not.Therefore, 
this approach of integrating mouse RNAseq and human GWAS prioritizes an unbiased selec-
tion of <0.5% of 5525 DEG in aging mouse bone for further mechanistic study to elucidate 
their functional relevance in bone fragility. Accordingly, we generated a publicly available 
tool (mouse2human.org) so that others can leverage new and published RNAseq and GWAS 
datasets to accelerate identification of new genetic determinants of bone fragility and, ulti-
mately, corresponding therapies. 
Disclosures: Serra Kaya, None
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Lean mass (LM), a proxy of muscle mass, predicts a range of morbidities, including 
frailty and fractures. Although genome-wide association studies (GWAS) have identified 
loci associated with whole-body (WB-) and appendicular LM, they only detect a fraction of 
genetic heritability and are unlikely to identify rare genetic variants that have larger effect 
sizes.To comprehensively discover new signals, we utilized the whole-genome sequencing 
(WGS) with average 30x in ethnically diverse (85% European-Ancestry, 7% African-Ances-
try, 8% Hispanic) participants (5744 for WB LM and 5690 for appendicular LM) from the 
Amish, CHS, FHS, SAFOS and WHI studies, members of the Trans-Omics for Precision 
Medicine (TOPMed) program. Participants had amean age of 60.7 years (SD: 14.8) and 
>65% of them were women.Lean mass residuals were generated adjusting for age, age2, 
sex, height, weight, total fat and study-specific variables. Genetic associations with inverse 
normal transformed residuals were evaluated using linear mixed-effects models adjusting for 
principal components, with random effects for relatedness. We identified four less frequent 
variants (all MAF<0.013) associated with LM at p<5x10-8 in the single-SNP analysis (Table 
1). rs76791411 (intronic of LOC101928882) was associated with WB-LM. For appendicular 
LM, intergenic rs76740061 (chr.1), as well as rs1356970370 (intronic of DLGAP2) and 
rs75017738 (intronic of AUH) were significantly associated. There were no known GWAS 
SNPs in their vicinity (+/-500K bp); these new SNPs were not analyzed in prior published 
GWAS for LM. In the gene-based association (SKAT) tests, no gene reached a stringent 
Bonferroni corrected threshold p < 1.53x10-6.We used GTEx and FUSION quantitative trait 
loci of expression (eQTLs) and DNA methylation (meQTLs of CpG sites) in human skeletal 
muscle tissue, to assess muscle function. Variants on chr.1 and in AUH gene corresponded to 
histone marks (H3K4me1_Enh and H3K27ac_Enh), suggesting these loci may function as 
enhancers in the H1 Derived Mesenchymal Stem Cells, as well as HSMM Skeletal Muscle 
Myoblasts and Cultured Satellite Cells.Additional tests are underway, including sex- and 
ancestry-specific analyses with a larger sample size, as well as replicating these results in 
other WGS cohorts. The discovery of previously not-observed genetic variants creates new 
opportunities to reveal unique pathways influencing muscle metabolism for disease diag-
nostics and therapies.
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Spaceflight adversely impacts musculoskeletal health and increases the risk of bone 
fracture and impaired healing, yet the molecular underpinnings remain elusive. Here we 
examined the effect of spaceflight on bone healing using a 2 mm femoral segmental bone 
defect (SBD) model. Forty, 9-week old, C57BL/6J male mice were randomized by cage 
into spaceflight or ground groups. In both groups 10 mice underwent SBD surgery and 10 
mice served as unoperated sham controls. Surgery/sham procedures for spaceflight mice 
occurred 4 days prior to launch. Ground control surgery/sham procedures and all subsequent 
procedures were asynchronous by 5 days to match spaceflight conditions. Mice were euth-
anized 24-28 days post-launch. The surgical femur from 5 mice/group were preserved for 
micro-computed tomography (µCT) analysis, and the callus region (corresponding area in 
sham mice) was probed by whole genome transcriptomics and metabolomics assay in the 
remaining 5 mice/group. µCT confirmed bone loss in sham spaceflight compared to ground 
femurs as well as impaired fracture healing. Concomitantly a trending sign of habituation 
to spaceflight became apparent, as gene-metabolite networks linked to cellular homeostasis 
and morbidity became activated and inhibited, respectively. The regulation of the morbidity 
signal was switched in the spaceflight surgery mice and µCT analyses revealed increased 
trabeculae spacing and decreased trabecular connectivity. Inhibited signals of cell migration 
synchronized with suppressed signals of growth factors, cytokines, and angiogenic agents 
were observed in spaceflight SBD femurs. Thus, in spaceflight there was a failure to recruit 
necessary agents for successful bone regeneration. Furthermore, the activated apoptosis sig-
nal escalated cell death. With pro-apoptotic and anti-migration characteristics, the RANK-
NFκB axis emerged as the central node in spaceflight. Concluding, the consequence of SBD 
in spaceflight was unique and customized solutions are needed to facilitate facture healing 
in spaceflight. 
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Background: Skull bone mineral density (SK-BMD) has been shown to have high her-
itability (low environmental influence) and moderately strong genetic correlation (shared 
heritability) with BMD measured at other skeletal sites. We aimed at assessing the genetic 
determinants of SK-BMD with functional follow-up of associated signals Methods: GWAS 
meta-analysis comprising 43,800 individuals from 21 different studies. SK-BMD associated 
variants were tested for pathway and tissue enrichment using DEPICT, GARFIELD and 
in-house pipelines; and examined for association on a skull shape GWAS of the UK-Bio-
Bank (N~38,000). A phenotype scan was performed on a mouse KO model of a gene un-
derlying one of the novel associated signals specific to the skull. Results: We identified 59 
genome-wide significant loci (P<=5x10-8) of which 4 were novel, explaining up to 12.5% 
of SK-BMD variance. Pathway and tissue enrichment analysis of the association signals re-
sulted in clustering within gene-sets involved in the regulation of the skeleton development; 
overexpressed in the musculoskeletal system; and enrichment in enhancer and transcribed 
regions in osteoblasts. Variants mapping to CPED1, previously associated with BMD at 
different skeletal sites and fracture, are associated not only with SK-BMD (P=1.0x10-37) 
but also presented the strongest evidence among interrogated markers for association with 
parameters of skull shape (P<1x10-16). Whereas, in-depth analysis of one of the novel as-
sociated genes, ZIC1 (P=1.2x10-10) showed that mice mutants for this gene exhibited an 
irregular pattern of skull mineralization. Conclusion: SK-BMD provides a suitable trait for 
the discovery of genes important to global bone biology and osteoporosis. The study of SK-
BMD also offers the advantage of identifying components unique to intramembranous ossifi-
cation, which cannot be captured at other skeletal sites. The genetic connection between SK-
BMD and other cranial abnormalities, could open new avenues to the understanding of the 
pathophysiology of craniofacial defects. For instance, ZIC1, a transcription factor implicated 
in craniosynostosis was shown to have a role in the regulation of skull bone mineralization. 
Disclosures: Carolina Medina Gomez, None
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Centre, Dresden, Germany;, Germany, 23Department of Endocrinology, 424 
General Military Hospital, Thessaloniki, Greece; 4Department of Medicine 
III;, Greece, 34Department of Medical Research, 251 Hellenic Air Force & 
VA General Hospital, Athens, Greece;, Greece, 41Department of Medicine III, 
2Center for Healthy Aging, Technische Universität Dresden Medical Centre, 
Dresden, Germany; 5Center for Regenerative Therapies Dresden, Technische 
Universität Dresden, Dresden, Germany;, Germany, 56Endocrinology Unit, 1st 
Department of Propaedeutic Internal Medicine, School of Medicine, National 
and Kapodistrian University of Athens, Greece, Greece
Objective: The expression of serum microRNAs (miRs) related to bone metabolism 
is potentially affected by anti-osteoporotic treatment. Here, we investigated the effect of 
sequential treatments on serum miR expression profile.Patients and Methods: This was an 
observational, open label, non-randomized clinical trial. Denosumab (Dmab) was adminis-
tered for 12 months in 37 women who were treatment-naïve (naïve-group) (n=11) or pre-
viously treated with teriparatide (TPTD-group) (n=20) or zoledronate (ZOL-group) (n=6). 
Main outcome measures were the relative serum expression of miRs linked to bone metab-
olism and secondary outcome measures were serum concentrations of the bone turnover 
markers (BTMs) pro-collagen type 1 N-terminal propeptide (PINP), C-terminal-crosslinking 
telopeptide of type 1 collagen (CTX), and tartrate-resistant acid phosphatase 5b (TRAP-5b). 
Time points were baseline, 3 and 6 months after the first Dmab injection.Results: Baseline 
relative expression of miR-21a-5p, miR-23a-3p, miR-29a-3p, and miR-338-3p was higher in 
the TPTD-group, while the relative expression of miR-21a-5p was lower in the -ZOL group 
compared to the naive-group. Dmab decreased the relative expression of miR-21a-5p at 3 
months [fold change (FC) 0.43, p<0.001] and 6 months (FC 0.34, p<0.001), and miR-338-3p 
and miR-2861 at 6 months (FC 0.31, p=0.041; FC 0.52, p=0.016, respectively) in the whole 
cohort. In subgroup analyses, Dmab decreased the relative expression of miR-21a-5p, miR-
29a-3p, miR-338-3p and miR-2861 at 3 months (FC 0.13, p<0.001; FC 0.68, p=0.044; FC 
0.46, p=0.012; FC 0.16, p<0.001, respectively), and 6 months (FC 0.1, p<0.001; FC 0.52, 
p<0.001; FC 0.04, p=0.006; FC 0.2, p<0.001, respectively) only within the TPTD group. 
Serum concentrations of CTX and TRAP-5b were positively correlated with the relative ex-
pression of several circulating miRs at both 3 and 6 months of Dmab treatment. No correla-
tion was observed between serum PINP levels and the relative expression of the tested miRs 
at 3 and 6 months after Dmab treatment in the entire cohort.Conclusions: TPTD treatment 
potentially affects the expression of the pro-osteoclastogenic miR-21a-5p and miRs relat-
ed to the expression of osteoblastic genes RUNX2 (miR23a-3p), COL1 (miR-29a-3p) and 
HDAC5 (miR-2861), while sequential treatment with Dmab acts in the opposite direction.
Disclosures: Elena Tsourdi, None
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In Silico Analysis of Limb Bud Formation in the Prrx1-Cre Anti-microRNA-
23a-27a-24-2 Cluster Mouse *Delores Stacks1, Benjamin Wildman1, Yuechuan 
Chen1, Theodore Busby1, Ashlee Williams1, Quamarul Hassan1. 1University of 
Alabama at Birmingham, United States
Objective: The microRNA cluster 23a-27a-24-2 (miR-23a cluster) inhibits osteogenesis 
by repressing the Runx2 – Ezh2 axis of osteoblast differentiation. We established a murine 
phenotype of increased trabecular and cortical bone when the miR-23a cluster was repressed 
in a Col1a1-Cre anti-miR-23a cluster mutant model. Col1a1 is expressed in committed os-
teoblasts as the collagen matrix is created prior to mineralization, which occurs in the mouse 
at days E18.5 and PN18. In this study, by changing the conditions of anti-miR-23a cluster 
expression to an earlier time course using a Prrx1-Cre, which is expressed at day E9.5, the 
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resulting offspring exhibit a unilateral rostral limb malformation phenotype that expresses 
with incomplete penetrance. Before beginning in vivo experiments to determine the cause of 
this abnormality, we surveyed mRNA seed sequences in the 3’ UTR that match the miR-23a 
cluster and its components to find possible targets for transcriptional interruption. Method: 
Here we utilized three different in silico methods of miRNA target prediction (DianaTools, 
PicTar, and TargetScan) to determine if limb bud proteins are targets of members of the 
entire miR-23a cluster. Gene ontology analysis (Panther) was used to classify genes into 
their respective functions and pathways. Results: 2988 possible miR-23a cluster gene targets 
were identified. 8 molecular functions, 21 biological processes, 14 cellular components, 21 
protein classes, and 122 pathways were recognized based on gene ontology terms. Notably, 
bone morphogenetic protein (BMP) signaling, Fibroblast growth factor signaling, Wnt sig-
naling, Hedgehog signaling, Notch signaling, and TGF-β signaling pathways are possible 
targets and are interesting due to their notoriety for being vital to osteogenesis and limb 
bud development. Conclusions: Computational prediction verifies that pathways involved in 
limb bud development are likely affected when the miR-23a cluster is repressed at an early 
embryonic stage. Future experiments include immunohistological assessment of the embry-
onic limb bud and RNA sequencing of isolated limb bud tissues. Funding statement: Re-
search reported in this publication was supported by the National Institute of Dental & Cra-
niofacial Research of the National Institutes of Health under Award Number T90DE022736. 
The content is solely the responsibility of the authors and does not necessarily represent the 
official views of the National Institutes of Health.
Disclosures: Delores Stacks, None
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Independent effects of estrogen and follicle stimulating hormone on marrow 
cell populations identified by single cell RNA-Seq analysis *Vanessa Sherk1, 
Paul MacLean1, T. Rajendra Kumar1, Douglas Adams1, Yuan-Haw Wu1, Rebecca 
Foright1, Matthew Jackman1, Ginger Johnson1, Cheryl Ackert-Bicknell1. 
1University of Colorado Anschutz Medical Campus, United States
Estrogen (E2) and follicle stimulating hormone (FSH) are purported to have indepen-
dent effects on bone loss during the menopausal transition. While FSH receptors are found 
on osteoclasts and not on osteoblasts, changes in FSH positively correlate with both for-
mation and resorption markers in peri- and postmenopausal women, suggesting that FSH 
impacts the mesenchyme in an as-of-yet undefined manner. Further, it is known that changes 
in both E2 and FSH are correlated with changes in energetics, both at the whole organism 
level and at the cellular level. The purpose of this study was to determine if treatment of rats 
with E2 and or FSH altered composite populations found within bone marrow stromal cells 
(BMSC), if cellular energy metabolism was different among these cells, and if this was cor-
related with osteoblast mineralizing potential. In a 2-factor design, adult female Wistar rats 
were ovariectomized and treated with a GnRH antagonist (Degarelix; 2mg/kg, 5% mannitol) 
+/- E2 (drinking water; 1.0μM to target ~40 pM) and +/- FSH (implanted peristaltic pump; 
6ug/kg/day) for 3 weeks. Degarelix effectively blocked FSH (<2 ng/mL). FSH treatment 
resulted in concentrations of 60+/-13 and 67+/-11 ng/mL for FSH and FSH+E2. Marrow was 
centrifuged from hindlimb bones and adherent cells were passaged 3 times and collected for 
Single cell RNA-Seq at 50,000 reads per cell and 4 replicates. Clustering and differential ex-
pression profiles were performed using the Seurat 3.0 R package. Oxygen consumption rate 
(OCR) and extracellular acidification rate (ECAR) were measured with Seahorse XFe96. 
Cell heterogeneity differed between all 4 conditions with the greatest differences observed 
for cells obtained from the E2 treated animals. Relative to the other three conditions, E2 BM-
SCs presented with an alteration in osteoblast maturation profile and a greater ability to min-
eralize as determined by Alizarin Red staining of cells. FSH treatment was also associated 
with decreased expression of genes related to IGF-1 signaling relative to all other treatments. 
Genes associated with glycogen, aerobic glycolysis, and the pentose phosphate pathway 
were most highly expressed with E2 treatment, which was in concordance with having the 
highest ECAR and state 3 OCR. Our scRNAseq analyses demonstrate that in vivo treatment 
of E2 and FSH changes the heterogeneity, identity, and gene expression of marrow-derived 
cells in a manner that may influence their metabolic phenotype and bone forming capacity.
Disclosures: Vanessa Sherk, None
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Functional Characterization of Primary Bone Transcriptome Reveals 
SOX7, CPED1, AC145124.1, FAM167A, TSLP and FCN3 as Bone Mineral 
Density Effector Genes *Vid Prijatelj1, Sjur Reppe2, Matthew Dietz3, Joost 
A. M. Verlouw1, Carolina M. Medina-Gomez1, Andre J. van Wijnen0, Kaare 
M. Gautvik2, Eppo B. Wolvius1, Fernando Rivadeneira1. 1Erasmus MC, 
University Medical Center Rotterdam, the Netherlands, Netherlands, 2Institute 
of Basic Medical Sciences, University of Oslo, Norway, Norway, 3Mayo Clinic, 
Rochester, MN, USA, Department of Orthopedic Surgery, United States, 0Mayo 
Clinic, Rochester, MN, USA, Department of Orthopedic Surgery, United States
BACKGROUND: Expression quantitative trait loci (eQTLs) are characterized by 
variants influencing messenger RNA (mRNA) expression that are often tissue-specific. We 
performed cis-eQTL analysis on primary bone tissue, with a functional follow-up analyses, 
including a summary data-based Mendelian randomization (SMR) to combine multi-om-
ics data for the prioritization of gene targets.METHODS: Donor iliac-crest biopsy samples 
(n=76) underwent microarray genotyping (Affymetrix Axiom 432) and transcriptome se-
quencing (Illumina Hiseq2000). A custom computational profiling method was utilized in 
the cis-eQTL analysis to quantify and correct blood contamination. This computational 
method offers substantial decrease in analysis time as compared to similar tools, and is pro-
vided as a shareable R programming language package. Analysis was performed in regions 
encompassing 1,000,000 base pairs upstream of transcription start sites (TSS) and down-
stream of transcription end sites (TES). Significant eQTLs were tested for enrichment of 
genomic features across several cell lines (including human osteoblasts), and amidst variants 
associated at genome-wide significant level with estimated bone mineral density (eBMD) 
from heel bone ultrasound in UK-Biobank (N=435K). Colocalization tests and multi-variant 
SMR integrative analysis (for eQTLs with Chi2 statistic >10) were performed. Bonferroni 
corrected P-value < 0.05 was considered significant.RESULTS: In total, 1277 e-genes had 
significant eQTLs. The majority of eQTLs were located around the TSS. In human osteo-
blasts, they were significantly enriched for CCCTC-binding factor (CTCF) and transcribed 
chromatin states, as well as significantly depleted for repressed chromatin states. From the 
13,126 analyzed transcripts, FAM167A (P < 0.05) and CPED1, SOX7, AC145124.1 (P 50% 
only for colocalization of TSLP and FCN3, most likely due to conditional nature of eQTLs.
CONCLUSION: We were able to integrate transcriptomic and genotyping information of 
primary bulk bone tissue to predict “unconfounded” associations between tissue specif-
ic gene expression and clinical phenotypes. CPED1 and SOX7 have established roles in 
skeletal biology, while the other prioritized eBMD genes are all related to immunological 
response, coagulation and complement activation, and autoimmune diseases. Such triangu-
lation of evidence aids the identification of implicated biologic pathways.
Disclosures: Vid Prijatelj, None
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Leveraging data from bivariate genome-wide association meta-analysis 
to unravel novel pleiotropic pathways of bone-muscle crosstalk *Katerina 
Trajanoska4, Niki Dimou2, David Karasik3, Fernando Rivadeneira1, on behalf of 
GEFOS Consortium0. 4Department of Internal Medicine, Erasmus MC University, 
Netherlands, Netherlands, 2Section of Nutrition and Metabolism, International 
Agency for Research on Cancer, France, 3Azrieli Faculty of Medicine, Bar-Ilan 
University, Israel, 1Department of Internal Medicine, Erasmus MC University, 
Netherlands, Netherlands, 0Bivariate analysis group, Netherlands
Background: The intimate relationship between bone and muscle is governed by vari-
ous mechanical and biochemical interactions; regulated by a complex network of pleiotropic 
genes with common biological pathways. We aimed to assess pleiotropy between bone and 
muscle by performing a bivariate genome-wide association study (GWAS). Methods: We 
included 20 cohorts from populations of European ancestry (Ntotal= 38,457). Total body 
bone mineral density (TB-BMD; g/cm2) and lean mass (TB-LM; kg) were measured in all 
cohorts using Dual-energy X-ray absorptiometry (DXA. Genetic variants were imputed to 
the Haplotype Reference Consortium (HRC) reference panel. In each cohort we performed 
univariate and bivariate GWAS adjusting for age, gender, height, fat percentage, and prin-
cipal components using 8,027,751 variants and results were combined in a meta-analysis. 
We defined lead significant SNPs with P< 5 × 10-8 that were independent of each other at 
r2  300 kilobases (kb) apart from each other represented independent loci.  Results: In the 
univariate TB-BMD GWAS we identified 42 signals mapping to 27 loci; all known BMD 
loci. Five loci were associated with TB-LM, three of which were novel mapping to SPEG 
(rs1810144-T, beta=0.04SD), TMEM18 (rs73139123-T, beta=0.05SD) and MYPN genes 
(rs7081213-G, beta=0.04SD). Evidence from animal models links SPEG and MYPN genes 
with muscle biology. Notably, the bivariate meta-analysis yielded 16 pleiotropic signals 
mapping in or near MEF2C, XYLB/ACvr2B, PPP6R3, RSPO3 genes among others, linked 
with both bone and muscle biology. Conclusion: Our findings provide basis for future func-
tional assessments aiming to unravel biological mechanisms underlying complex bone-mus-
cle interactions; with the potential of pinpointing strategies for the joint prevention and in-
tervention of osteoporosis and sarcopenia.
Disclosures: Katerina Trajanoska, None
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Identifying circulating biomarkers for osteoporosis *Sirui Zhou1, Erin 
Oerton2, John Morris3, Eleanor Wheeler2, Vincenzo Forgetta1, Claudia 
Langenberg2, Brent Richards1. 1Lady Davis Institute, Jewish General Hospital, 
Canada, 2MRC Epidemiology Unit, University of Cambridge, United Kingdom, 
3New York Genome Center, United States
Circulating causal protein biomarkers for osteoporosis may help risk prediction, diag-
nosis, and can be putative drug targets. In this study we used Mendelian randomization (MR) 
to identify clinically relevant circulating biomarkers for heel bone mineral density (eBMD). 
We then confirmed these findings using direct measurements of prioritized biomarkers in an-
other cohort with BMD measurement. Cis-acting SNPs associated with 863 circulating pro-
teins were identified from two studies of 6,501 individuals. These were used as instrumental 
variables in a hypothesis free, two-sample MR scan for their causal effect on eBMD from a 
GWAS of 426,824 individuals from UK Biobank. Candidate biomarkers were validated in 
the Fenland cohort (N=?11,183?) by ?their protein-level association with total body BMD 
(tBMD).?We identified 62 candidate protein biomarkers for eBMD using MR (P < 6.45 x 10-
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5), from which 17 biomarkers showed high probability of colocalization (COLOC posterior 
probability>0.7). Measuring these candidate proteins in the Fenland cohort we found that 21 
had significant associations with tBMD, where direction of effect was concordant with the 
MR finding; further analysis highlighting three prioritized biomarkers with high probability 
of colocalization in eCAVIAR with CLPP > 0.01 (MRC2, COLEC11, SEMA3C). These 
results suggest that MR can prioritize circulating protein levels as biomarkers for BMD 
outcomes. The identified biomarkers have been tested through MR and direct measurement 
and may serve as causal biomarkers and inform drug development.? ?
Disclosures: Sirui Zhou, None
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Role of Senescence in Age- and Radiation- Associated Bone Marrow 
Adiposity *Abhishek Chandra1, Anthony Lagnado1, Joshua Farr1, David 
Monroe1, Christine Hachfeld1, Sundeep Khosla1, Joao Passos1, Robert Pignolo1. 
1Mayo Clinic, United States
Clearance of senescent cells has been shown to suppress bone marrow adiposity, and 
ameliorate age- and radiation-associated bone loss, but molecular events that precede the 
occurrence of marrow adiposity are unknown. Using radiation as a model to understand 
age-associated changes in bone, we have shown that p21 peak expression on day 1 post-radi-
ation precedes major detrimental changes in radiated bones. RNA sequencing in radiated(R) 
and non-radiated(NR) femurs from mice revealed that p21, and several of the genes linked 
to adiposity, were the most significantly up-regulated in the R-bones as compared to the NR-
bones. For a longitudinal assessment of adiposity related genes, NR-and R- bones were col-
lected post sham and actual exposure, respectively, at days 1, 7, 21 and 42 for mRNA anal-
ysis and at day 1 and 7 for histology. Significantly high levels of telomere dysfunction-in-
duced foci(TIF)+ senescent osteoblasts were detected in the R-bones at day-1 and -7. The 
qRT-PCR of 20 adiposity-related genes only connected by a highly stringent String-Network 
was performed. Only Pparg was upregulated on day 1 post-radiation. Significant up-regula-
tion in adipose-related genes was observed in R-bones at day 7(Adipoq, Fabp4, Fabp5, Ghr, 
Igf-1 and -2, Lpl, Pparg, Plin-1 and -2, Rarres2 and Rxra), day 21(Cfd, Ctsc, Igf1, Mlxipl, 
Plin-1, -2 and -4, Rarres2 and Rxra) and at day 42(Adipoq, Cfd, Cidec, Ctsc, Ghr, Igf-1 and 
-2, Lpl, Lipe, Plin-1,-2 and-4, Pparg, Rarres2, Rbp4, Rxra and Scd1). In aging studies, 24 
month bone samples showed   high p21 (~6-fold increase, p=0.0002), high p16Ink4a(~3.5 
fold increase, p=0.005) and 19 out of the 20 adiposity-related genes were significantly up-
regulated, as compared to young (5m old) mouse bones. Significant down-regulation of 
microRNA(mir)-106b-5p(targeting p21 mRNA) was observed in aged bones(p=0.02) and 
across all time points in the radiated bones(day 1[p=0.09], day 7[p=0.013], day 21[p=0.006] 
and day 42[p=0.09], while mir-20a-5p(targeting p21 mRNA) was down-regulated only at 
day 21 post-radiation (p=0.006). Intriguingly, mir-27a-3p, reported to be elevated during 
obesity and in adipose tissue, was found to be elevated in aged- (p=0.04), and in R-  bones(-
day 1[p=0.005], day 21 [p=0.18] and day 42[p=0.04]. In summary, our data indicate the in-
terplay between pathways of senescence and bone marrow adiposity which follow a similar 
pattern in aging and radiation.
Disclosures: Abhishek Chandra, None
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Detection of musculoskeletal GWAS-associated lncRNAs in human, rodent 
and fish models *Bodhisattwa Banerjee1, Ines Fößl2, David Karasik3, Barbara 
Obermayer-Pietsch2. 1Bar-Ilan University, Israel, 2Medical University Graz, 
Austria, 3Bar-Ilan University; Hebrew SeniorLife, Israel
Background: The musculoskeletal (MSK) system possesses fundamental functions in 
the human body. Long non-coding RNAs (lncRNAs) are now emerging as critical regula-
tors of major biological processes affecting development, differentiation, and disease. The 
importance of lncRNAs just began to be recognized in bone (patho)physiology. Therefore, 
our study aims to prioritize candidate lncRNAs involved in MSK GWAS and determine the 
functionality of these lncRNAs in humans, mice, and zebrafish.Methods: We have mined the 
existing MSK GWAS databases and prioritized candidate lncRNAs based on their sequence 
conservancy in humans, zebrafish, and mouse. The expression of the lncRNAs in the bony 
tissues (cranium and operculum) in fish of various ages (3 and 6 months, 1 and 1.5 years) 
was tested using qPCR. Furthermore, the expression of these candidate lncRNAs in human 
plasma, serum, and bones was examined by qPCR. The qPCR data were statistically ana-
lyzed by Student’s t-test. The expression of these three lncRNAs was analyzed in RNA-seq 
data of human posterior iliac crest biopsies (GEO: GSE72815) and differentiating mouse 
osteoblasts (GEO: GSE54461).Results & Discussion: The lncRNAs MALAT1, GAS5, and 
OIP5-AS1 were selected for their potential regulatory functions in skeletal phenotypes. In 
zebrafish bones, malat1 and gas5 lncRNA expressions were significantly elevated (p <0.05) 
in young adults (3 and 6 mo) compared to the older fish (1 and 1.5 y old). Expression data 
from the human bone RNA-seq demonstrated slight upregulation of MALAT1 and GAS5 
lncRNA in younger women compared to the older. During murine osteoblast differentiation, 
Gas5 showed higher expression in the early time points (2, 4, 6 days) compared to the later 
time points (10, 14, 18 days). Therefore, it could be seen that at least one of these three 
lncRNAs, GAS5, shows a similar pattern of expression across species suggesting functional 
conservation and age-specific functions in the MSK system. Furthermore, in human serum 
and plasma, lncRNA GAS5 shows the highest expression, followed by MALAT1. The cur-
rent data do not clarify the tissue of origin of the lncRNAs or their release mechanism into 
the bloodstream. However, the presence of these two lncRNAs in serum/plasma suggested 
that they might serve as potential biomarkers. In the future, expression of GAS5 lncRNA 
during murine osteoblast differentiation will be validated by qPCR.
Disclosures: Bodhisattwa Banerjee, None
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Genetic and miRNA associations underlying beta-blocker effects on bone 
mineral density *Kathleen Nevola1, Douglas Kiel2, Katherine Motyl3, Christine 
Lary3. 1Tufts University, United States, 2Hebrew SeniorLife, United States, 
3Maine Medical Center Research Institute, United States
Many studies have shown a positive association between beta blocker (BB) use and 
bone outcomes such as fracture and bone mineral density (BMD). Response to BBs can be 
variable which may be due to genetics, with previous studies implicating beta-adrenergic re-
ceptor genes (ADRB1 and ADRB2). We hypothesized that variants in these and other genes 
in the beta adrenergic signaling mechanism on bone cells (see Figure) may influence BB 
response on BMD, and this may be due to microRNA expression (miRNA). We selected 13 
genes from this pathway that have single nucleotide polymorphisms (SNPs) with prior asso-
ciation with BMD. We measured associations between SNPs, BB use, and their interaction, 
on femoral neck BMD (FN BMD) measured via DXA in a sample of N = 1,527 members of 
the Framingham Study Offspring cohort. Genetic data were imputed to the HRC (Haplotype 
Reference Consortium), and SNPs within 2 kB upstream to 0.5 kB downstream of each gene 
were analyzed with the alternative allele dosage using a sex-stratified linear mixed effects 
model, with kinship as a random effect and covariates (age, sex, height, weight, and estrogen 
use in women). We then used conditional joint analysis with Genome-wide Complex Trait 
Analysis (GCTA) to select independent signals within each gene, identifying 11 SNPs that 
had significant interactions with BB use (p < 0.05) in ADRB1, HDAC4, PRKACB, PRK-
AR2B, RANK, and RANKL. We plan to bring 4 SNPs forward for validation: 2 in females 
(ADRB1 rs12414657 p=0.046; HDAC4 rs11124190 p=0.0093) and 2 in males (RANK 
rs34170507 p=4.4e-5; RANK rs6567268 p=0.0051). These SNPs are intron variants except 
rs12414657 which is an upstream transcript variant. To determine potential miRNA-related 
mechanisms, we analyzed the association between miRNA from whole blood with each of 
the 11 SNPs (p < 0.05), focusing on miRNAs with prior bone associations or miRNA that 
target the gene containing the SNP. For example, the SNP in ADRB1 (rs12414657) is associ-
ated with increased expression of miR-19a-3p, a miRNA associated with BB use and BMD, 
which has been shown to target ADRB1. We hypothesize that the increased expression of 
this miRNA with the alternative allele decreases ADRB1 expression, down-regulating ad-
renergic signaling in bone, leading to a decrease in bone remodeling. We plan to validate 
this and other findings in future clinical and in vivo studies. This work has implications for 
biomarkers and personalized therapy regimes for beta blocker use in bone.
Disclosures: Kathleen Nevola, None
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Improved prediction of fracture risk leveraging a genome-wide polygenic 
risk score *Tianyuan Lu1, Vincenzo Forgetta2, Julyan Keller-Baruch2, Maria 
Nethander3, Derrick Bennett4, Marie Forest2, Sahir Bhatnagar1, Robin Walters4, 
Kuang Lin4, Zhengming Chen4, Liming Li5, Magnus Karlsson6, Dan Mellström3, 
Eric Orwoll7, Eugene McCloskey8, John Kanis8, William Leslie9, Robert Clarke4, 
Claes Ohlsson3, Celia Greenwood1, Brent Richards1. 1McGill University, Canada, 
2Lady Davis Institute for Medical Research, Canada, 3University of Gothenburg, 
Sweden, 4University of Oxford, United Kingdom, 5Peking University, China, 
6Lund University, Sweden, 7Oregon Health & Science University, United States, 
8University of Sheffield, United Kingdom, 9University of Manitoba, Canada
Accurately quantifying risk of osteoporotic fracture is important for directing appropri-
ate clinical interventions. While skeletal measures such as heel quantitative speed of sound 
(SOS) and DXA bone mineral density have been shown to be able to predict risk of oste-
oporotic fracture, the utility of such measurements is subject to availability of equipment 
and human resources. Using data from 341,449 individuals of white British ancestry, we 
previously developed a genome-wide polygenic risk score (PRS), called gSOS, that captured 
25.0% of the total variance in SOS. We aim to test whether gSOS can improve fracture risk 
prediction.We examined the predictive power of gSOS in five large genome-wide genotyped 
cohorts, including 90,172 individuals of a European ancestry and 25,034 individuals of an 
Asian ancestry. We calculated gSOS for each individual and tested for association between 
gSOS and incident major osteoporotic fracture and incident hip fracture. We tested whether 
adding gSOS to risk prediction models had added value over models using other clinical risk 
factors.A standard deviation decrease in gSOS was strongly associated with an increased 
odds of incident major osteoporotic fracture in European populations, with odds ratios rang-
ing from 1.35-1.46 in four cohorts. It was also associated with a 1.26-fold (95% CI: 1.13-
1.41) increased odds of incident major osteoporotic fracture in the Asian population. We 
demonstrated that gSOS was more predictive of both incident major osteoporotic fracture 
(AUROC = 0.734; Interquartile Range (IQR): 0.727-0.740) and incident hip fracture (AU-
ROC = 0.798; IQR: 0.791-0.805) than most traditional clinical risk factors, including prior 
fracture, smoking, use of corticosteroids, rheumatoid arthritis. We also showed that adding 
gSOS to FRAX, the commonly used fracture risk prediction tool, could significantly refine 
risk prediction with a likelihood ratio test p-value < 0.05 and a positive net reclassification 
index ranging from 0.024 to 0.072.In conclusion, we generated and validated a PRS for 
SOS which is strongly associated with risk of fracture. This score provides modestly better 
fracture risk discrimination than most clinical risk factors. We propose that gSOS should be 
explored as a tool to provide better risk stratification to identify individuals at high risk of 
fracture, particularly considering that PRSs can be generated for multiple diseases from one 
single investment in genome-wide genotyping.
Disclosures: Tianyuan Lu, None
P-278
Proteomic Approach in Aorta of Rheumatoid Arthritis-Induced 5-LO KO 
Mouse Model *Cintia Kazuko Tokuhara1, Flavia Amadeu de Oliveira2, Talita 
Mendes Oliveira Ventura1, Jose Burgos Ponce3, Joao Paulo Domezi1, Adriano 
de Souza Pessoa1, Gabriela Silva Neubern de Oliveira1, Mariana Liessa Rovis 
Sanches1, Vimal Veeriah2, Mariana Rodrigues Santesso4, Marilia Afonso 
Rabelo Buzalaf1, Rodrigo Cardoso de Oliveira1. 1University of São Paulo, 
Brazil, 2Sanford Burnham Prebys Medical Discovery Institute, United States, 
3University Center of Adamantina, Brazil, 4Sao Paulo State University, Brazil
It has been established that rheumatoid arthritis (RA) mainly affects the joints, however, 
extra-articular involvement is common. Thus, it is reported that patients with RA have higher 
risk of mortality in comparison with health people, due mainly to increased cardiovascular 
disease related to both traditional risk factors and disease-induced chronic inflammation. 
Leukotrienes (LTs) are lipid mediators derived from arachidonic acid by 5-lipoxygenase 
(5-LO) pathway and play an important role in the inflammatory response. Thus, we sought 
to study in detail the role of leukotrienes on protein profile from aorta in rheumatoid arthri-
tis condition. We conducted a quantitative proteomics analysis by using mass spectrometry 
comparing 5-LO Knockout (KO) and wild type (WT) mice under arthritis-induced condi-
tion. 60-days old KO and WT mice were intravenously immunized with 1.5 mg of arthrogen 
cocktail at day 0 and 10 μg of LPS was intraperitoneally administered at day 3. After 14 
days of immunization, mice were euthanized and protein samples from aorta were isolated, 
purified and processed for proteomics analysis using LC-ESI-MS/MS. Results showed sev-
eral changes of aorta protein profile between 5-LO KO RA and WT RA. In total, over 1075 
proteins were identified by proteomic approach. Among them, 341 proteins were exclusive 
from 5-LO KO RA and 385 from WT RA and 349 proteins were identified in both groups. 
Regarding quantitative analysis, 60 and 15 proteins were up and downregulated, respectively 
in the comparison 5-LO KO RA vs. WT RA. The following proteins histone H4 and nuclear 
mitotic apparatus protein 1 were increased more than 2-fold in 5-LO KO RA and 15 proteins 
were decreased more than 2-fold in the same group. Results clearly demonstrated that ab-
sence of leukotriene causes significant changes in proteome profile of RA aorta and it may 
have important functions on metabolism and clinical implications in rheumatoid arthritis.
Disclosures: Cintia Kazuko Tokuhara, None
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Comparison of Week-by-Week Changes in Serum Levels of Bone-related 
Circulating MicroRNAs and Bone Turnover Markers *Patryk Zarecki1, 
Fatma Gossiel1, Johannes Grillari2, Miguel Debono3, Matthias Hackl4, Richard 
Eastell1. 1University of Sheffield, Department of Oncology & Metabolism, 
United Kingdom, 2Ludwig Boltzmann Institute for Experimental and Clinical 
Traumatology, Austrian Cluster for Tissue Regeneration, Austria, 3Sheffield 
Teaching Hospitals NHS Foundation Trust, United Kingdom, 4TAmiRNA 
GmbH, Austria
MicroRNAs are involved in post-transcriptional regulation of gene expression. Due 
to the regulatory role, microRNAs are differently expressed during certain conditions in 
healthy and diseased individuals and could be used as diagnostic and prognostic biomarkers 
for various diseases and conditions. We want to investigate the variability of microRNAs and 
bone turnover markers in weekly time intervals.In a single site longitudinal study, a panel 
of 19 bone-related miRNAs was measured using the osteomiR™ RT-qPCR assay in serum 
samples of 35 postmenopausal women divided into 3 groups: healthy controls (n = 9), low 
BMD (n= 14) and vertebral fractures (n= 12). Blood samples were collected once per week 
for 8 weeks at 9:00 am after overnight fasting. Bone turnover markers were measured on the 
IDS-iSYS Multi-Discipline Automated Analyser.We have analysed the data using a mixed 
model analysis of variance approach and we found no significant changes between week-by-
week time-points in any of groups. To estimate intra-individual variability between weekly 
time-points we have calculated the median coefficient of variation (CV).In healthy control 
group microRNAs median intra-individual CV was between 28.4% (hsa-miR-19b-3p) and 
80.2% (hsa-miR-214-3p); in low BMD group 33.8% (hsa-miR-188-5p) and 77.9% (hsa-
miR-127-3p); in vertebral fractures group 29.5% (hsa-miR-19b-3p) and 61.4% (hsa-miR-
214-3p). Combined assay CV including RNA isolation, reverse transcription and real-time 
qPCR was 21.3%. CTX median CV was 13.4% in healthy control group, 16.8% in low 
BMD group and 17.9% in vertebral fractures group, with assay CV of 6.5%. PINP median 
CV was 13.6% in healthy control group, 13.2% in low BMD group and 15.6% in vertebral 
fractures group, with assay CV of 7.2%. Osteocalcin median CV was 12.7% in healthy con-
trol group, 8.5% in low BMD group and 11.8% in vertebral fractures group, with assay CV 
of 6.3%. Bone alkaline phosphatase median CV was 9.2% in healthy control group, 9.8% in 
low BMD group and 11.1% in vertebral fractures group, with assay CV of 3.5%.Circulat-
ing microRNAs measured in serum seem to have higher weekly intra-individual variability 
compared to bone turnover markers. MicroRNAs with high serum levels are on average less 
variable than microRNAs with low serum levels.
Disclosures: Patryk Zarecki, None
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Comparative messenger RNA expression analysis of vitamin D receptor, 
calcium-sensing receptor, cyclin D1, and PTH in symptomatic and 
asymptomatic primary hyperparathyroidism in Asian Indians *Dwijaraj 
Hegde1, Parjeet Kaur1, Sunil Mishra1, Deepak Sarin1, Dheeraj Gautam1, 
Priyanka Singh2, Sanjay Bhadada2, Ambrish Mithal3. 1Medanta The Medicity, 
India, 2Postgraduate Institute of Medical Education and Research, India, 3Max 
superspeciality Hospital Saket, India
Background: Although classic symptoms of primary hyperparathyroidism (PHPT) have 
been reported to be common in the India, data on increasing number of asymptomatic PHPT 
cases have been emerging from this part of the world as well. The exact underlying mech-
anistic reasons for this differential clinical profile remain unknown and efforts to define the 
molecular mechanisms underlying PHPT phenotypic heterogeneity have been limited. Aim: 
To explore underlying molecular mechanisms in the pathogenesis of symptomatic and as-
ymptomatic sporadic PHPT. Methods: A prospective single centre study from India. Patients 
diagnosed with PHPT undergoing parathyroidectomy, were included. Patients lacking spe-
cific symptoms or signs traditionally associated with hypercalcemia or PTH excess were 
diagnosed as having asymptomatic PHPT. The mRNA expression of vitamin D receptor 
(VDR), calcium sensing receptor (CASR), cyclin D 1 (CD1), and parathyroid hormone 
(PTH) in parathyroid adenoma cells and controls (eight parathyroid tissues obtained from 
euthyroid patients without PHPT during thyroid surgery) was determined using quantitative 
real-time PCR (qRT-PCR) by SYBR Green I dye method (Fermentas, Life Sciences). Re-
sults: Total of 42 PHPT patients (18 men, 24 women) were studied. Mean (SD) age was 49.7 
(12.8) years. 21 patients were asymptomatic. Mean plasma PTH levels were significantly 
higher in symptomatic group compared with asymptomatic group (538.26 vs 347.47 pg/ml). 
CaSR and VDR mRNAs were significantly reduced in both symptomatic and asymptom-
atic cases compared with controls. CD1 and PTH mRNAs were significantly increased in 
symptomatic patients whereas they were not significantly different in asymptomatic PHPT 
patients compared with controls. Symptomatic PHPT patients had significantly higher ex-
pression of CD1 mRNA and significantly lower expression of CaSR mRNA compared with 
asymptomatic patients. There were no correlations between VDR, CASR, PTH and CD1 
mRNA levels and serum Ca, plasma intact PTH, 25-hydroxyvitamin D levels or adeno-
ma weight. Conclusion: This study addressed the molecular mechanisms underlying PHPT 
phenotypic heterogeneity. Asymptomatic PHPT had significantly lower expression of CD1 
mRNA and significantly higher expression of CaSR mRNA compared with symptomatic 
PHPT in Asian Indians.  
Disclosures: Dwijaraj Hegde, None
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DBP Is Required for the Utilization of Skin-Generated Vitamin D *Elizabeth 
Duchow1, Lori Plum1, Hector DeLuca1. 1University of Wisconsin-Madison, 
Department of Biochemistry, United States
The primary source of vitamin D is skin exposure to ultraviolet B light (UVB). Despite 
the importance of this source, the mechanisms surrounding the transport of cutaneously pro-
duced vitamin D into the circulation remain undefined. We tested the hypothesis that vitamin 
D binding protein (DBP) is required for the utilization of skin-generated vitamin D. Mutant 
mice lacking DBP (DBP-/-) and wild-type control mice (DBP+/+) were made vitamin D 
deficient. All mice lacked detectable serum 25-hydroxyvitamin D (25-OHD) levels and were 
equally hypocalcemic. All mice were irradiated with 8kJ of UVB daily for up to 4 days. 
Serum calcium and 25-OHD were measured using atomic absorption spectrometry and the 
DiaSorin Liason 25 OH Vitamin D Total Assay, respectively. Skin vitamin D content was an-
alyzed using a biological assay and/or high-performance liquid chromatography. All data are 
expressed as mean+/-SEM and statistical significance is defined as p<0.05. Treatment with 
UVB normalized serum 25-OHD and serum calcium in DBP+/+ mice, but had no effect on 
either in DBP-/- mice (Table 1). Vitamin D-deficient, hypocalcemic test rats responded with 
a comparable increase in serum calcium following administration of lipid extracts of skin 
from DBP+/+ and DBP-/- mice immediately following UVB treatment, indicating vitamin D 
production was normal in DBP-/- mice. Skin vitamin D levels decreased over a 2-day period 
in DBP+/+ mice but remained high in DBP-/- mice, suggesting impaired mobilization in 
the absence of DBP (40+/-2ng/g vs. 140+/-15ng/g, p<0.05 vs. DBP+/+). Repletion of DBP-
/- mice by intravenous injection of increasing amounts of recombinant DBP (2μg, 7.5μg, or 
23μg) prior to UVB restored responsiveness to UV-generated vitamin D. After two rounds 
of treatment, a significant increase in serum calcium was observed in the middle and high-
dose group compared to controls that received saline prior to UVB and controls that were 
injected with highest amount of protein but did not receive UVB. A significant decrease in 
the total amount of vitamin D retained in the skin at 48 hours following the final treatment 
was observed at all dose levels with respect to the saline control. These results demonstrate 
that DBP is required for the utilization of vitamin D produced in skin by UVB.
Disclosures: Elizabeth Duchow, None
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Secreted Frizzled Receptor Protein 4 (Sfrp4) is required for proper response 
of the periosteal stem/progenitor cells to PTH *Ruiying Chen1, Han Dong2, 
Dhairya Raval1, Shawn Berry1, Matthew B. Greenblatte3, Roland Baron1, 
Francesca Gori1. 11. Division of Bone and Mineral Research, Harvard Medical 
School and Harvard School of Dental Medicine. 2. Department of Oral Medicine, 
Harvard Medical School and Harvard School of Dental Medicine., United 
States, 2Department of Cancer Immunology and Virology, Dana-Farber Cancer 
Institute and Harvard University Medical School, United States, 3Department 
of Pathology and Laboratory Medicine, Weill Cornell Medicine, United States
The periosteum is essential in the cortical response to anabolic drugs. The identification 
of periosteal stem cells offers an opportunity to explore the mechanisms by which anabolic 
drugs such as PTH(1-34) influence the periosteum and might help identify drug targets for 
the treatment of skeletal diseases associated with cortical thinning and fragility. We have 
shown that lack of the Wnt inhibitor Sfrp4 leads to Pyle’s disease, characterized by low 
periosteal bone formation, cortical thinning and bone fragility. We found that PTH induces 
Sfrp4 in periosteal cells, suggesting that Sfrp4 might be a downstream effector of PTH in the 
periosteum. Whether PTH regulates specific pools of periosteal cells and whether Sfrp4 is 
involved is not known. To test this hypothesis, we generated CtskCre;mTmG;wt and Ctsk-
Cre;mTmG;Sfrp4-/- mice and studied the response of periosteal cells labeled by Cathep-
sin K (Ctsk+ and Ctsk+:Sfrp4-/-) to iPTH (25 nmol/kg, daily for 4-wk starting at 4-wk of 
age). Ctsk+ cells include bona fide stem cells (PSCs), with high PTH receptor expression, 
and non-stem progenitors (PP1 and PP2), the predominant source of Sfrp4. We have shown 
that Sfrp4 is required for proper maintenance and function of Ctsk+ cells. The periosteum 
of CtskCre;mTmG;wt and CtskCre;mTmG;Sfrp4-/- mice was microdissected and digested 
and Ctsk+ PSCs, PP1 and PP2 cells FACS-sorted. We found that in Ctsk-Cre;mTmG mice, 
iPTH increased the % of Ctsk+ cells (0.39+0.06 vehicle vs 0.55+0.08 iPTH, p<0.05) and 
this was due to the increase in the % of PSCs (15.5+0.3 vehicle vs 18.8+0.2, p<0.005). In 
contrast, in the absence of Sfrp4, iPTH was unable to significantly increase the pool of Ctsk+ 
cells, (0.35+0.04 vehicle vs 0.40+0.06 iPTH, NS) and the % of PSC (11+0.6 vehicle vs 
12.1+0.3 iPTH, NS). Importantly, mCT analysis showed that iPTH treatment, while signifi-
cantly increasing cortical thickness in Ctsk-Cre;mTmG tibiae (0.145+0.004 mm vehicle vs 
0.165+0.005 mm iPTH, p<0.005), failed to do so in the absence of Sfrp4 (0.095+0.002 mm 
vehicle vs 0.096+0.004 mm iPTH, NS). Our data raise the possibility that Ctsk+ bona fide 
stem cells are associated with the anabolic effect of PTH in the periosteum and that Sfrp4 
contributes to the cortical bone response to PTH. Further analysis of signaling molecules 
regulating periosteal stem cells may have clinical implications for fracture repair and the 
treatment of diseases associated with bone fragility
Disclosures: Ruiying Chen, None
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Conditional Loss of Nmp4 In Mesenchymal Stem Progenitor Cells Enhances 
PTH-Induced Bone Formation *Emily Atkinson1, Michele Adaway1, Crystal 
Korff2, Daniel Horan1, Angela Klunk1, Joseph Wallace3, Alexander Robling1, 
Joseph Bidwell1. 1Anatomy, Cell Biology & Physiology Indiana University 
School of Medicine, United States, 2Medical & Molecular Genetics, Indiana 
University School of Medicine, United States, 3Department of Biomedical 
Engineering IUPUI, United States
Activation of bone anabolic pathways is a fruitful approach for treating severe osteo-
porosis. Yet, FDA-approved osteoanabolics, e.g. parathyroid hormone (PTH) have limited 
efficacy. Improving their potency is a promising strategy for maximizing their benefits. Mice 
harboring a global loss-of-function mutation in nuclear matrix protein 4 (Nmp4) are healthy 
and exhibit an extended and enhanced bone formation response to PTH compared to wild 
type (WT) mice. This transcription factor is expressed in all tissues. To identify the cell type 
responsible for heightened PTH-induced osteoanabolism, we conditionally deleted Nmp4 
at different stages of osteoblast-lineage differentiation. Nmp4-floxed mice (Nmp4fl/fl) were 
crossed to one of three different bone-lineage Cre drivers: Prx1-Cre, which targets mesen-
chymal stem progenitor cells (MSPCs) in developing limb bud, Bglap-Cre, which targets 
mature osteoblasts, and Dmp1-Cre, which targets transitional osteocytes. PCR and Western 
analyses demonstrated genetic recombination and loss of Nmp4 protein expression in the 
appropriate Cre+ bone cells whereas Cre- control mice showed robust Nmp4 protein expres-
sion and an absence of recombination. Virgin female Cre+ and Cre- mice (10 wks of age) 
were randomly sorted into treatment groups by weight and genotype. Mice received a daily 
injection of human PTH 1–34 at 30 µg/kg, or vehicle (VEH) for 4 wks. At the end of treat-
ment areal bone mineral density (aBMD; g/cm2) was measured for the post-cranial skeleton 
by dual-energy X-ray absorptiometry. Femoral bone volume/total volume (BV/TV, %) was 
assessed with microcomputed tomography. Protocols were approved by IACUC. RESULTS: 
Nmp4fl/fl;Prx1Cre+ mice showed a significantly enhanced whole body aBMD vs. Nmp4fl/
fl;Prx1Cre- mice (VEH Cre- 0.051 +/- 0.002; PTH Cre- 0.054 +/- 0.002; VEH Cre+ 0.052 
+/- 0.002; PTH Cre+ 0.055 +/- 0.002, avg +/- SD treatment p<0.0001, genotype p=0.04, 2W 
ANOVA, n=12-16/cohort). Nmp4fl/fl;BglapCre+ and Nmp4fl/fl;Dmp1Cre+ did not show 
this effect. The Nmp4fl/fl;Prx1Cre+ mice exhibited an enhanced PTH-induced increase in 
femoral BV/TV compared to the Nmp4fl/fl;Prx1Cre- animals (Cre- VEH 2.3+/-0.7; Cre- 
PTH 5.6+/-1.7; Cre+ VEH 3.1+/-1.3; Cre+ PTH 8.4+/-3.6; avg +/- SD, treatment p<0.0001; 
genotype p= 0.0001; genotype x treatment p=0.03, 2W ANOVA, n=25-34/cohort). CON-
CLUSION: conditional loss of Nmp4 from MSPCs amplifies bone response to anabolic 
PTH. This cell-type specific pathway is a novel target for improving osteoanabolics.
Disclosures: Emily Atkinson, None
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Mechanisms Controlling The High Level Of Vitamin D Receptor Gene 
Expression In Mouse Intestine. *James Fleet1, Sylvia Christakos2, Michael 
Verzi3. 1Purdue University, United States, 2Rutgers New Jersey Medical School, 
United States, 3Rutgers University, United States
The hormone 1,25 dihydroxyvitamin D (1,25(OH)2D) is a critical regulator of calci-
um, phosphorus, and bone metabolism whose actions are mediated through the Vitamin D 
Receptor (VDR), a ligand-activated transcription factor. While VDR is expressed in many 
tissues, the highest levels of VDR are found in the intestine. We examined the DNA regions 
and sequences that control intestine-specific expression of the mouse Vdr gene. Samples 
were obtained from the three different intestinal locations: the duodenal villi, the duodenal 
crypt, and the colon. In addition, we examined three different ages: developmental (12-15 d 
post natal), adult (90 d), and aged (20 months). Samples were analyzed by ATAC-seq with 
a MACS2 peak calling protocol. Comparisons between these groups were conducted using 
DiffBind. A topologically associated domain of 240 kb containing the Vdr gene and 6 other 
genes was identified using CH12 cell Hi-C data from the 3Dgenome.org (5 kb resolution). 
15 ATAC peaks were identified in adult duodenal villi and crypt and all were within a 125 
kb region from intron 3 of the Vdr gene to -55.8 kb from exon 1. Two novel ATAC peaks 
were also found in this region for the adult colon. Peaks were similar in adult and old mouse 
intestine but peaks were missing or reduced in the developing duodenum (7 peaks) and colon 
(4 peaks). All adult duodenal villi/crypt and colon peaks overlapped with ChIP-seq peaks 
for the intestine-specific transcription factor, Cdx2 (GSM2610627). Some ATAC peaks 
also overlapped with HNF4α/γ (9 peaks, GSE112946) or SMAD4 (9 peaks, GSM1688778) 
ChIP-seq peaks while 5 ATAC peaks overlapped with ChIP-seq peaks for all three transcrip-
tion factors. Consistent with the importance of these transcription factors, Vdr mRNA levels 
fell by >70% in the intestine of Cdx2 or HNF4α/γ KO mice. Our ATAC peaks were similar 
to DNAse-Seq peaks from ENCODE for large intestine and kidney (which also had 2 novel 
peaks). However, the majority of intestine ATAC peaks were distinct from regulatory regions 
identified for other VDR expressing tissues including NIH 3T3 cells, lung alveolar macro-
phages, and MC3T3 osteoblasts. Our analysis demonstrates that the regulation of intestinal 
Vdr gene expression requires the complex interaction of multiple distal regulatory regions 
and is controlled by a combination of intestine-specific (Cdx2) and other (HNF4, SMAD4) 
transcription factors.
Disclosures: James Fleet, None
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Regulation of CRTC1/2/3 by Protein Phosphatases and Salt-inducible 
Kinases in Osteoblastic RankL Transcription *Michael Mosca1, Zhiming He1, 
Carole Le Henaff1, Nicola Partridge1. 1Department of Molecular Pathobiology, 
New York University College of Dentistry, United States
Parathyroid hormone (PTH) is a key regulator of bone homeostasis and has been used 
to treat osteoporosis. Unfortunately, prolonged treatment with PTH leads to excessive bone 
resorption through the stimulation of RankL. Denosumab has been used in trials to amelio-
rate the catabolic effects of RankL stimulated by PTH-derived treatments, but to date has 
not been proven to eliminate long term adverse effects. Current models suggest that CREB 
regulated transcription coactivators 1, 2, and/or 3 (CRTC1/2/3) are potential co-activators 
responsible for RankL transcription upon PTH-induction in osteoblasts. Our laboratory 
has previously shown that dephosphorylation of CRTC2/3 in the cytoplasm leads to their 
subsequent nuclear translocation and RankL transcription, but it is not known exactly how 
this occurs. To elucidate regulatory mechanisms involved in CRTC regulation, primary cal-
varial osteoblasts were harvested from C57BL/6J mice aged 2-3 days postnatal; calvariae 
were digested and cells were plated. siRNA knockdowns for salt-inducible kinases (SIK) 
and individual catalytic subunits of protein phosphatases (PP) of interest were performed 
(SIK1, 2 & 3; PP1, 2A, 3, 4, 5, 6 & 7) to determine their individual and combined roles on 
RankL transcription using qPCR and Western blotting. Data suggest SIK inhibition mim-
ics PTH-induction but alone is insufficient to explain CRTC1/2/3 translocation after cAMP 
signaling. PPs likely assist in removal or regulation of the phosphate group on CRTC1/2/3 
upon PTH stimulation. Initial data show specific catalytic subunits of PP1, PP2A, and PP3 
may play critical roles in this cascade as siRNA knockdowns produce significant changes 
in RankL mRNA compared to controls (p < 0.001). Additionally, we have investigated the 
direct interactions of each factor of interest with the CRTCs via co-IP using anti-CRTC2/
CRTC3 antibodies followed by Western blots. Results indicate that CRTC2/3 interact with 
PP1/PP2A upon PTH-stimulation while SIKs do not, and this interaction likely facilitates 
dephosphorylation and subsequent translocation of the CRTCs. These data lead us to believe 
that several PPs act together to regulate CRTCs after PTH-stimulated cAMP signaling and 
that understanding the exact mechanisms will illuminate novel drug targets in the treatment 
of osteoporosis.
Disclosures: Michael Mosca, None
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Beta-catenin regulates PTH receptor signaling through its armadillo residue 
to association with PTH receptor *Bin Wang1, Hong Lei1, Roger Armen1, 
Yanmei Yang1. 1Center for Translational Medicine, Department of Medicine, 
Sidney Kimmel Medical College, Thomas Jefferson University, United States
The optimal use of parathyroid hormone (PTH) therapy in osteoporosis depends in part 
on our understanding of the regulation of PTH signaling to maintain the anabolic actions 
of PTH while mitigating its catabolic effects. Although PTH receptor (PTHR) signaling 
pathways are being studied in increasing detail, the regulation of PTHR functions has not 
been fully elucidated. The anabolic PTH effects on bone are mostly mediated by the Gs/
cAMP signaling pathway, whereas Gq/PLC activation may antagonize this osteoanabolic 
action. Our data and those from other groups show that beta-catenin interacts with the PTHR 
and switches the PTHR signaling from Gs/cAMP to Gq/PLC activation in chondrocytes, 
osteoblast-like (Saos2) cells, and HEK293 cells transfected with PTHR. Beta-catenin inter-
acts with the PTHR carboxyl-terminal region, but which position of beta-catenin is bound 
by PTHR remains unknown. The primary structure of beta-catenin includes an N-terminal 
region of 130 residues, an C-terminal 100-residue segment, and a central region of 12 ar-
madillo repeats spanning (130 – 668) residues. To explore which position of beta-catenin is 
associated with the PTHR, we generated beta-catenin knockout Saos2 cells and their control 
wild-type cells using CRISPR/Cas9 technology. Knockout of beta-catenin significantly in-
creased PTH(1-34) stimulation of cAMP formation but inhibited PTH-induced intracellular 
calcium mobilization, an index of PLC activity. Knockout of beta-catenin also significantly 
facilitated PTH(1-34) stimulation of phosphorylation of the cAMP-dependent protein kinase 
PKA substrate (VASP) signal by using anti-VASP antibody. We transfected Flag-tagged full-
length beta-catenin into beta-catenin knockout Saos2 cells, and found that exogenous be-
ta-catenin could also mediate PTHR signaling switch compared with beta-catenin knockout 
cells transfected with vector plasmid. We than transfected plasmids with Flag-tagged N-ter-
minal region, central region of armadillo repeats, or C-terminal region. Our data showed that 
only central region of armadillo repeats but not N- or C- terminal region was able to mediate 
PTHR signaling switch. Molecular modeling data also suggest that the central region of 
armadillo repeats have positively charged amino acid residues that bind to multiple negative 
charged residues of C-terminal region of the PTHR. Collectively, beta-catenin through its 
armadillo residue to association with PTHR regulates PTHR signaling and targeting these 
biding sites by designing new small molecules may enhance anabolic effect of PTH for the 
treatment of osteoporosis.
Disclosures: Bin Wang, None
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Cardiac Fgf23 Production Promotes Myocardial Fibrosis In A Pressure 
Overload Model In Mice *Nejla Latic1, Ana Marek1, Ute Zeitz1, Wenhan Chang2, 
Reinhold Erben1. 1University of Veterinary Medicine, Austria, 2University of 
California San Francisco, United States
Increased cardiac expression of fibroblast growth factor (FGF23) has been observed 
in left ventricular (LV) hypertrophy in mice and men. However, the pathophysiological 
role of cardiac FGF23 secretion in the development of LV hypertrophy and dysfunction 
is unknown. To specifically ablate FGF23 in cardiomyocytes, we crossed Fgf23fl/fl mice 
with MLCv2-Cre transgenic mice, expressing Cre in cardiomyocytes. The specificity of Cre 
expression was confirmed by crossing the MLCv2-Cre mice with ROSAmT/mG reporter 
mice. Cardiac mRNA expression of FGF23 was reduced 86% in cardiomyocyte-specific 
FGF23 knock-out (Fgf23CM-KO) mice, relative to wild-type controls. Body weight and 
mineral metabolism were unchanged in Fgf23CM-KO mice.Cardiac hypertrophy was in-
duced by transverse aortic constriction (TAC), a chronic pressure overload model. TAC or 
sham surgery were performed in 5-month-old Fgf23CM-KO animals, using wild-type, Fgf-
23fl/fl, and MLCv2-Cre mice as controls. Serum levels of FGF23 were equally increased 
in all genotypes after TAC, suggesting that cardiac-derived FGF23 does not contribute to 
the rise in circulating FGF23 after TAC. Parameters of heart hypertrophy such as heart-to-
body weight ratio and cardiomyocyte size were similarly increased in all groups of TAC 
animals, 4 weeks post-surgery, showing that LV hypertrophy developed independently of 
cardiac FGF23. However, intra-arterial catheterisation revealed that mean arterial pressure 
was significantly reduced in Fgf23CM-KO TAC mice, compared to Fgf23fl/fl TAC controls. 
LV internal diameter in systole and diastole measured by echocardiography as well as LV 
diameter measured histologically were increased in Fgf23CM-KO in comparison to Fgf23fl/
fl controls, indicating more pronounced eccentric hypertrophy in Fgf23CM-KO mice after 
TAC. Interestingly, histological evaluation revealed a distinct reduction in TAC-induced car-
diac fibrosis in Fgf23CM-KO compared to Fgf23fl/fl controls. Mechanistically, treatment 
of isolated cardiac fibroblasts with recombinant FGF23 increased collagen I expression ~4-
fold. Collectively, our data suggest that local production of FGF23 promotes cardiac fibrosis 
in afterload-induced LV hypertrophy via a paracrine crosstalk between cardiomyocytes and 
fibroblasts.
Disclosures: Nejla Latic, None
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1,25-Dihydroxyvitamin D and Anti-FGF23 Blocking Antibody Treatments 
Improve Dentoalveolar Tissues in the Hyp Mouse Model of X-linked 
Hypophosphatemia *Eva Liu1, Elis Lira dos Santos2, Michael Chavez2, Tamara 
Kolli2, Brian Foster2. 1Brigham and Womens Hospital, United States, 2Ohio State 
University College of Dentistry, United States
Purpose: X-linked hypophosphatemia (XLH) is caused by PHEX mutations, leading 
to elevated serum levels of fibroblast growth factor 23 (FGF23). The high FGF23 levels 
result in decreased production of 1,25-dihydroxyvitamin D (1,25D), hypophosphatemia, and 
rickets. Patients with XLH develop dental complications, including caries and abscesses. 
Hyp mice replicate the XLH phenotype as they develop significant dentoalveolar mineral-
ization defects. We aimed to compare the effects of 1,25D monotherapy or an anti-FGF23 
blocking antibody (FGF23Ab) treatment on dentoalveolar development and mineralization 
in Hyp mice.Methods: Male Hyp mice injected subcutaneously with daily 1,25D (175 pg/g) 
or thrice weekly with FGF23 blocking antibody (35 mcg/g) from postnatal days 2 to 35 were 
compared to wild-type (WT) controls and untreated Hyp mice.  Mandibular first molar teeth 
were analyzed by high resolution micro-computed tomography (micro-CT). Decalcified first 
molar tissue morphology was assessed by hematoxylin and eosin (H&E) and picrosirius red 
(PR) stains.   Results: First molar enamel volume and density both trended lower in Hyp vs. 
WT mice, and both appeared improved with either treatment. Dentin/cementum volume and 
density were both dramatically decreased in Hyp vs. WT mice.  Dentin/cementum volumes 
increased about 20% with either 1,25D or FGF23Ab, while dentin/cementum mineral densi-
ty was not improved by either therapy.  Alveolar bone fraction (bone volume/tissue volume; 
BV/TV) and mineral density (BMD) around the first molar were both reduced in Hyp vs. 
WT mice. BV/TV increased about 10% in Hyp mice treated with either 1,25D or FGF23Ab, 
while BMD did not respond to therapy. H&E stain of the first molar demonstrates that treat-
ment of Hyp mice with either therapy improves acellular cementum morphology and reduc-
es the widened predentin, though there is still substantial osteoid present in treated molars. 
Examination of PR stained Hyp molar tissue under polarized light microscopy revealed 
disorganization of the periodontal ligament (PDL) attachment.  Both therapies improved 
PDL organization, indicating improved attachment.   Conclusions: Taken together, these 
findings demonstrate similarly limited improvements in dentoalveolar tissues with 1,25D or 
FGF23Ab therapy, suggesting 1,25D and/or phosphate partially contribute to dentoalveolar 
mineralization in XLH. They show that the defects in Hyp dentoalveolar tissue are not due 
to FGF23 specific actions.
Disclosures: Eva Liu, None
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Sex differences in skeletal development and maintenance mediated by the 
osteoblastic glucocorticoid receptor *Anuj Sharma1, Reginald Benson1, Candee 
Barris1, Jessica Pierce1, Jennifer Dorn1, Rachel Roberts1, Kanglun Yu1, Sadanand 
Fulzele1, William Hill2, Mark Hamrick3, Carlos Isales3, Xingming Shi3, Meghan 
McGee-Lawrence3. 1Augusta University, United States, 2Medical University of 
South Carolina, United States, 3Medical College of Georgia, Augusta University, 
United States
While the harmful effects of exogenous glucocorticoids (GC) on the skeleton are well 
understood, the role of endogenous GC and their glucocorticoid receptor (GR)-mediated 
signaling in bone are not clear, particularly during musculoskeletal aging. We originally 
predicted that blocking GR signaling would protect against aging-induced osteoblast dys-
function, but previously found that conditional knockout (CKO) of the GR in osteoprogeni-
tors using Osx Cre promoted low bone mass and increased marrow adiposity in young (3-6 
month old) female mice that was further exacerbated with age (21-24 month old).  This 
suggests a critical function for the GR in skeletal maintenance with aging. In the current 
study, we extended these observations into young (3-6 month old) male GR-CKO mice. 
Surprisingly, the in vivo effects of loss of the skeletal GR were sex-specific, demonstrat-
ing more harmful effects in GR-CKO females than in males. For example, marrow adi-
posity (Ad.Ar/M.Ar) and marrow adipocyte density (N.Ad/M.Ar) were increased by 747% 
and 400%, respectively, in female GR-CKO as compared to female WT mice, but only by 
176% and 59% in male GR-CKO as compared to male WT mice (genotype x sex interaction 
p-values: p=0.027 and 0.017, respectively).  To further explore this finding, we developed 
an inducible (Tet-off) Osx-Cre GR-CKO mouse model, where mice were maintained on 
doxycycline chow until 12 weeks of age and studied at 24 weeks of age to negate any de-
velopmental defects related to the Osx Cre or GR deficiency during rapid growth; the sex 
differences of GR-CKO mice persisted in this model. Despite the differences seen in vivo, 
bone marrow stromal cells (BMSCs) from young male and female GR-CKO mice cultured 
for 21 days under osteogenic conditions behaved similarly in vitro, showing increased lipid 
droplets and decreased mineralized matrix production as compared to cells from wildtype 
(WT) sex-matched mice. Similarly, mesenchymal stem cells (MSCs; cell surface marker 
sorted) from WT male mice treated with the GR antagonist RU486 developed intracellular 
lipid droplets and decreased matrix mineralization similar to BMSC isolated from GR-CKO 
mice. The similar in vitro results between sexes despite disparate findings in vivo suggest 
the involvement of hormonal mechanisms that interact with GC signaling in musculoskeletal 
aging biology. In ongoing studies, male GR-CKO mice and WT littermates are being aged to 
determine whether sex differences persist during aging.
Disclosures: Anuj Sharma, None
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Role of Endogenous Parathyroid Hormone - related Protein (PTHrP) in 
Skeletal Anabolic Actions *Takeshi Shimoide1, Loan Nguyen-Yamamoto1, 
Aimee-Lee Luco1, Lucie Canaff1, Laetitia Laurent2, Andrew C Karaplis2, David 
Goltzman1. 1Research Institute of the McGill University Health Centre, Canada, 
2Lady Davis Institute for Medical Research, Canada
Purpose: Parathyroid Hormone (PTH) acts via the type 1 PTH receptor (PTHR1). 
PTH-related protein (PTHrP), which plays a critical role in skeletal development, can act in 
a paracrine or autocrine mode either by also interacting with the PTHR1 receptor through 
its N-terminal domain, or independently of the receptor, in an intracrine fashion, through 
its nuclear localization sequence (NLS) and C-terminal region. In the present study, we 
aimed to compare the role of the N-terminal PTHR1-interacting domain relative to the NLS 
and C-terminus of PTHrP in modulating bone formation. Methods: To elucidate the role of 
PTHrP via PTHR1 in bone formation, we conditionally deleted Pthr1 and/or PthrP from cells 
of the osteoblast lineage in mice. We used mice with either a floxed Pthrp allele or Pthr1 
allele and crossed them with either osteocalcin (OC)-Cre- positive or osterix(OSX)-Cre-pos-
itive mice to create conditional knockouts specific to mature osteoblasts (PthrpOB-/- and 
Pthr1OB-/-)or immature osteoblasts (Pthrpob-/- and Pthrpob-/-) respectively. Mice were 
then crossed to create double conditional knockouts of both Pthrp and Pthr1 in mature 
osteoblasts (PthrpOB-/-;Pthr1OB-/-) or immature osteoblasts (Pthrpob-/-;Pthr1ob-/-). Cre 
negative littermates or Cre+ mice without the floxed allele were used as controls for the con-
ditional knockouts. Mice with global Pth deletion (Pth-/- mice) were derived as previously 
described. The skeletal phenotype of each strain was then analyzed in mice at 8 weeks of 
age. Growth curves, femoral bone mineral density (BMD), and femoral bone micro-archi-
tecture using micro-computed tomography (μCT) and serum biochemistry were evaluated. 
Results: Preliminary results show that Pthr1OB-/- mice were significantly smaller than their 
Cre- littermates and had significantly shorter femur lengths, and double knock-out PthrpOB-
/-;Pthr1OB-/- mice were also smaller. In contrast, PthrpOB-/- mice displayed no significant 
difference in body weight, femur length, serum calcium or phosphorus, femoral BMD or 
μCT parameters and global Pth deletion did not alter the size and femur lengths of the Pth-
/- mice. Pthrpob-/- mice, however, were smaller than controls. Conclusions: This work is 
currently ongoing to fully phenotype and elucidate the mechanism responsible for these 
phenotypes, however preliminary results suggest that the Pthrp ligand for Pthr1 in mature 
osteoblasts, may derive from less mature osteoblasts and act in a paracrine manner.
Disclosures: Takeshi Shimoide, None
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High susceptibility to collagen-induced arthritis in mice with progesterone 
receptors selectively inhibited in osteoprogenitor cells *Lixian Liu1, Junjing 
Jia1, Min Jiang1, Xueping Liu1, Chenlin Dai1, Barton Wise1, Nancy Lane1, Wei 
Yao1. 1University of California, Davis Medical Center, United States
Background. Progesterone receptor (PR) affects immunomodulation, and lack of PR in 
osteoprogenitor cells primarily affects pathways associated with immunomodulation, espe-
cially in the males. In this study, we selectively deleted PR from osteoprogenitor cells using 
Prx1-Cre to evaluate the tissue-specific effects of PR on inflammatory arthritis (IA). Meth-
ods. Collagen-induced arthritis (CIA) was used as an IA animal model, which we induced 
in PRΔPrx1 mice and their wild type (WT) littermates were immunized with collagen II 
(CII) emulsified incomplete Freund’s adjuvant (CFA) in both sexes.  Joint erosion, inflam-
mation, and cartilage damages were assessed using a semiquantitative histologic scoring 
system.  Bone volume and erosions in knee and ankle joints were quantitated using microCT. 
We found that knee and paw joint erosions developed in 37.5% and 41.7% of the WT and 
PRΔPrx1 female mice, respectively, and in 45.4 and 100%, respectively, of the male mice. 
Also, both knee and ankle joint inflammation scores, joint damage scores, and subchon-
dral bone erosions were significantly more severe in male PRcKO mice than in male WT 
mice (figure).  Although of lower severity than in male mice, female PRΔPrx1 mice also 
developed higher inflammation scores and bone erosions than the KO-normal or WT-CIA 
females.  Immunohistochemistry staining of the NLRP3 inflammasome revealed the male 
PRΔPrx1 mice had significantly higher expression of NLRP3 inflammasome in the knee 
joints. Conclusion.  Our observations indicate that the presence of PR in osteoprogenitor 
cells counteracts the development of collagen-induced arthritis and might help to explain the 
sex differences observed in human inflammatory arthritis.
Disclosures: Lixian Liu, None
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Vitamin D and bone mineral density in Argentinian patients with multiple 
sclerosis: preliminar results of a pilot study *Maria Rosa Ulla1, Carlos Vrech2, 
Elena Peralta Lopez3, Maria Jose Castro1, Florencia Martos1, Maria Angelica 
Rivoira3. 1Fundacion ILAIM, Cordoba, Argentina, Argentina, 2Sanatorio Allende, 
Argentina, 3Facultad de Ciencias Medicas, UNC, Argentina
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune, demyelinating dis-
ease of the nervous system. Currently, relapsing-remitting multiple sclerosis (RRMS) is the 
most common type of the disease. These patients are frequently exposed to high doses of 
corticosteroids, thus having risk for secondary osteoporosis, frequently aggravated by re-
striction of mobility due to physical deficit, which can predispose to fractures and cause 
further deterioration in the quality of life. Recent statistics from Argentina have shown an 
increasing prevalence of 32 patients in every 100,000 inhabitants. Since there is no similar 
study in local literature so far, we aimed at assessing bone health and vitamin D levels in 
these patients. Materials and methods: Observational, prospective, open case-control study 
evaluating serum levels of 25(OH)vitamin D as well as bone mineral density (BMD) in 
femoral neck, total hip and lumbar spine, in self-reliant patients with RRMS, compared to 
healthy controls. Thirty-six patients with RRMS (8 men and 28 women) between 20 and 59 
years of age and 36 healthy patients of similar age and sex were included. All the women 
were pre-menopausal. The patients had an Expanded Disability Status Scale less than 5.0 
and all had received a corticosteroid pulse the year prior to bone densitometry. A survey of 
physical activity and dairy consumption was carried out. Results: RRMS patients had infe-
rior serum 25(OH)vitamin D levels than controls (21.1+/-7,8 ng/mL vs 40,2+/-18.8 ng/mL, 
respectively; p<0.001). However, BMD (g/cm2) was almost the same in RRMS patients and 
controls in all the skeletal areas (Femoral neck: RRMS 0.802 vs 0.792 in controls; Total hip: 
RRMS 0.916 vs 0.921 in controls; Lumbar spine: RRMS 0.988 vs 0.970 in controls). Z-score 
BMD (expressed in media +/- standard deviation) was similar in both groups, as well (Fem-
oral neck: RRMS -0.15 +/- 1.18 vs 0.14 +/- 0.93 in controls; Total hip: RRMS -0.11 +/- 1 vs 
-0.04 +/- 0.97 in controls; Lumbar spine: RRMS -0.28 +/- 1.16 vs 0.36 +/- 1.12 in controls). 
Consumption of dairy products was low but similar in both groups (500 mg Ca/day), where-
as patients with RRMS practised physical activity more regularly. Conclusions: the inferior 
levels of vitamin D detected in patients with RRMS did not have a significant correlate on 
BMD, when compared with controls. This might be partially due to a more committed phys-
ical activity among RRMS patients. Bone parameters other than BMD remain to be studied.
Disclosures: Maria Rosa Ulla, None
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Gestational Bisphenol-A Exposure Negatively Impacts Trabecular 
Microarchitecture and Cortical Geometry in Male, but not Female, Adult 
Offspring *Rebecca Dirkes1, Rebecca Welly1, Jiude Mao1, Jessica Kinkade1, 
Victoria Vieira-Potter1, Cheryl Rosenfeld1, Pamela Bruzina1. 1University of 
Missouri, Columbia, United States
Bisphenol-A (BPA) and bisphenol-S (BPS) are estrogen disruptors found in the envi-
ronment and common household items. Estrogen is a primary hormonal regulator of bone 
growth and development; however, the impact of gestational BPA or BPS exposure on skel-
etal health of offspring remains unknown. In this longitudinal study, adult female mice were 
randomized into three groups: BPA exposure (BPA), BPS exposure (BPS) or control (CON). 
BPA/BPS/CON treatment continued through mating, gestation, and lactation. One male and 
one female offspring from each dam (n=6/group/sex) were selected and given ad lib access to 
a high-fat diet until 16 weeks of age, when body weight was measured and femora collected. 
Cortical geometry of the mid-diaphysis and trabecular microarchitecture of the distal femur 
were assessed via micro-computed tomography with a voxel size of 12 mm. Biomechanical 
strength of the femoral diaphysis was assessed via three-point bending. Two-factor ANOVA 
or ANCOVA with final body weight as a covariate were used to determine the effects of 
maternal BPA or BPS on trabecular and cortical bone outcomes, respectively. There were 
no group differences in body weight or femoral length in male or female offspring. There 
were no group differences in cortical geometry or trabecular microarchitecture in female 
offspring. Male offspring exposed to BPA had significantly lower trabecular bone volume, 
trabecular number, connectivity density and greater trabecular spacing compared to BPS or 
CON animals. Cortical thickness was also reduced in male offspring of BPA-treated dams. 
There were no group differences in biomechanical strength in male or female offspring. In 
conclusion, gestational BPA exposure significantly impairs trabecular microarchitecture and 
cortical geometry in male, but not female, adult offspring. 
Disclosures: Rebecca Dirkes, None
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Genistein improves bone healing via estrogen receptor alpha-mediated 
activation and maturation of osteoblasts *Jui-Tai Chen1, Yi-Ling Lin1, Ruei-
Ming Chen1. 1Taipei Medical University, Taiwan, Province of China
Osteoporosis-associated fractures may cause higher risks or morbidity and mortality. 
Our previous study showed that genistein, a nonsterol phytoestrogen, could induce estrogen 
receptor alpha (ERα) expression and stimulate osteoblast mineralization. This study used rat 
calvarial osteoblasts and an animal bone defect as our experimental models to evaluate the 
effects of genistein on bone healing and its possible mechanisms. Exposure of rat calvarial 
osteoblasts to genistein caused a time-dependent increase in activity of alkaline phospha-
tase (ALP), a biomarker of osteoblasts, without affecting cell survival. Levels of cytosolic 
and nuclear ERα significantly increased following genistein treatment. Subsequently, treat-
ment with genistein induced ALP mRNA and protein expressions in primary osteoblasts. 
Knocking-down ERα using RNA interference concurrently inhibited genistein-induced ALP 
mRNA expression. Moreover, genistein induced other osteogenesis-associated runt-related 
transcription factor 2 and osteocalcin mRNA and protein expressions. Attractively, admin-
istration of ICR mice suffering bone defects with genistein caused significant increases in 
the callus width, chondrocyte proliferation, and ALP synthesis. Results of micro-computed 
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tomography revealed that administration of genistein increased trabecular bone numbers 
and improved the bone thickness and volume. This study showed that genistein can improve 
bone healing via triggering ERα-mediated osteogenesis-associated gene expressions and 
subsequent osteoblast maturation.
Disclosures: Jui-Tai Chen, None
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Progesterone (Pg) and Medroxyprogesterone acetate (MPA) regulate 
same events with opposite actions in bone and vascular cells *Pablo 
Hernan Cutini1, Adrián Esteban Campelo2, Virginia Massheimer1. 1Instituto de 
Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), Universidad Nacional 
del Sur (UNS), Consejo Nacional de Investigaciones Científicas y Técnicas 
(CONICET), Bahía Blanca, Buenos Aires, Argentina., Argentina, 2Instituto de 
Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), Dpto. de Matemática, 
Universidad Nacional del Sur (UNS), Consejo Nacional de Investigaciones 
Científicas y Técnicas (CONICET), Bahía Blanca, Buenos Aires, Argentina., 
Argentina
Bone and cardiovascular diseases are multifactorial clinical entities that often coexist 
in postmenopausal women. Clinical and epidemiological studies have shown an interesting 
relationship between high bone turnover and cardiovascular disease mortality. Disorders in 
bone metabolism reversely correlate with vascular calcification (VCa). Hormone replace-
ment therapy including natural Pg or synthetic progestins such as MPA emerged as a ther-
apeutic option, although the risk/benefit of its use is controversial. VCa developed within 
atherosclerotic plaque is partly due to the osteogenic transdifferentiation of vascular smooth 
muscle cells (VSMC). The aim of this work was to investigate the effect of Pg and MPA 
on cellular/molecular events involved in VCa and in osteoblastogenesis. Primary cultures 
of calvarial osteoblasts (OB) and aortic VSMC, were in vitro exposed to 10 nM Pg or 10 
nM MPA. Measurements of matrix extracellular calcium content and alkaline phosphatase 
(ALP) activity were employed as osteoblastic differentiation markers.In order to promote 
osteoblastic differentiation, VSMC were cultured for 21 days in osteogenic medium (10 mM 
β-glycerophosphate and 4 mM CaCl2). When VSMC were cultured in osteogenic medium 
(VSMC-OB), treatment with Pg for 21 days significantly reduced ALP activity (15% below 
control, p<0.02) and calcium content (32% below control, p<0.02). Similar treatment with 
the synthetic progestin also showed a significant reduction in ALP activity (239.9 +/- 21.0 
vs. 159.6 +/- 19.1 x103 IU/mg protein, control vs MPA, p<0.02), as well as in the extracel-
lular calcium deposition (365.1 +/- 38.2 vs 253.6 +/- 21.9 µg/mg protein, control vs MPA, 
p<0.02). Conversely, exposure of OB cells to Pg or MPA significantly increased ALP activity 
(59%; 290% above control, Pg; MPA, p<0.02) and matrix calcium levels (12%; 55% above 
control, Pg; MPA, p<0.02). The mechanism of action of Pg and MPA on both cells involves 
the participation of Pg receptor (PgR), since pre-treatment of cells with RU486, a PgR an-
tagonist, completely reversed the hormonal action. However, we ruled out the involvement 
of the androgen receptor (AR), since in the presence of the AR antagonist flutamide, the 
effect of the progestogens was sustained. In conclusion, although Pg and MPA exert opposite 
effects on OB and VSMC-OB, both steroids would exhibit a potential beneficial effect by 
promoting osteoblastic differentiation and inhibiting VCa.
Disclosures: Pablo Hernan Cutini, None
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Mass spectrometry profiling of estrogens in bones derived from a rat 
model to identify potential targets for the prevention of postmenopausal 
osteoporosis *Tine Albrecht1, Daniela Pemp1, Sebastian Müller2, Lukas 
Häfner1, Günter Vollmer2, Leane Lehmann1. 1University of Würzburg, Germany, 
2University of Dresden, Germany
The impact of exogenous factors, as xenobiotics, on bone density and the risk of post-
menopausal osteoporosis, is often tested using an animal model based on ovariectomy with 
or without additional oral exposure to the estrogen 17beta-estradiol (E2) to simulate the 
postmenopausal situation. Although it is well established that estrogens significantly con-
tribute to the maintainance of the bone homeostasis, the estrogen profile in bone has not been 
determined in this model before.Thus, female mature Wistar-Hannover rats were either sham 
operated (sham group, n=18) or subjected to ovariectomy and were either fed a diet contain-
ing E2 benzoate (0.825 ppm to mimick menopausal estradiol levels; ovx+E2B group, n=15) 
or unsupplemented diet (ovx-E2B group, n=15) for 8 weeks. Then, the estrogen profile was 
analyzed in femur specimens by GC (estrone (E1), E2, 2- and 4-methoxy (MeO)-E1 and 
-E2) and UHPLC (E1-sulfate, E1-glucouronide), coupled with mass spectrometry and us-
ing deuterated internal reference standards for identification and quantification.Only E2, E1 
and 2-MeO-E1 were detected and also quantified (E2 <16-124 fmol/g; E1 <16-104 fmol/g; 
2-MeO-E1 <19-118 fmol/g). As expected, frequencies of detection of both E2 and E1 were 
significantly higher in bones derived from the sham group than from the ovx-E2B group 
(p<0.05, Fischer´s exact test). Frequency of detection of E2 did not differ between bones 
derived from ovariectomized animals with or without oral exposure to E2B. In contrast, 
frequencies of detection of E1 did not differ between bones derived from the sham and 
the ovx+E2B groups. Despite comparable levels of E1 were observed after in sham group 
and ovx+E2B group, 2-MeO-E1 was detected exclusively in specimens derived from the 
ovx+E2B group (27%). Since direct ingestion of 2-MeO-E1 was excluded (<0.05% of E2 
benzoate), differences in biotransformation between endogenous and exogenously adminis-
tered E2 seem to be reflected in the bone.In conclusion, the oxidative metabolite 2-MeO-E1 
seems only be present above limit of detection in the bone under the conditions of the animal 
model. Ovariectomy decreases levels of E2 within the bone which cannot be recovered by 
oral exposure to 0.825 ppm E2 benzoate which instead seems to restore E1 levels. The char-
acterization of the estrogen profile in the ovariectomized rat model, allows to understand 
and target the estrogen profile as a potential key factor related to changes in bone density.
Disclosures: Tine Albrecht, None
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In vivo effects of  1α25(OH)2D3-glycosides from Solanum glaucophyllum 
leaves in mice and  skeletal muscle cells *Paula Irazoqui1, Veronica Gonzalez 
Pardo1, Claudia Buitrago1, Kathrin Bühler2, Ana Russo de Boland1. 1Universidad 
Nacional del Sur-INBIOSUR, Argentina, 2Herbonis Animal Health GmbH, 
Switzerland
We have previously shown that Solanum glaucophyllum leaves extract (SGE) enriched 
with 1a,25(OH)2D3-glucosides exhibits at least equal or greater effects on early myoblast 
differentiation as synthetic 1a,25(OH)2D3 thus being an effective substitute to promote mus-
cle growth. Recently, we reported the effects of SGE compared to synthetic 1a,25(OH)2D3 
in the regulation of mitogen activated protein kinases (MAPKs), genes involved on the dif-
ferentiation of murine skeletal muscle cells C2C12, and their role on myotube formation. 
Since MAP kinase phosphatases (MKPs) deficiency impairs skeletal muscle regeneration 
and exacerbates muscular dystrophy, we further studied the effects of SGE on MKP1 and 
MKP5 which function to specifically dephosphorylate and inactivate MAPKs. SGE  did 
not statistically modified MKP-1 and MKP-5 protein levels although basal changes were 
observed. MKP-1 protein levels remained unchanged at 1, 24 and 48 hours and decreased 
at 6 and 72 hours. MKP-5 protein levels increased at differentiation onset (24-72 h). We 
found that SGE significantly induced biphasic changes in phosphatase activity, decreased 
at 1 and 24 hours (which correlates with the pro-differentiation cell arrest previously re-
ported), and increased at 6 hours. We also   investigated the effects of SGE on Akt-mTOR 
signaling during the differentiation phase. SGE, decreased Akt phosphorylation after 5-day 
and increased its phosphorylation after 7-day of treatment. However, SGE did not induced 
changes in mTOR phosphorylation during time (3-7-day). Following with this approach, we 
investigated in vivo effects of SGE on skeletal muscle function in mice. Results from the first 
in vivo pilot test, have evidenced that 2 mg SGE/kg BW for 30 days did not show statically 
significant differences in phosphorus, calcium and glucose parameters from SGE groups 
compared to control. However, SGE  leads to an increase in soleus muscle VDR protein 
expression in line with a significant decrease in 25(OH)D3 in blood serum while lower SGE 
doses did not change biochemical parameters measured in serum or protein content in mice 
muscle. These results contribute to elucidate the mechanism of action of the herbal active 
form of vitamin D when used as substitute to promote muscle growth
Disclosures: Paula Irazoqui, None
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Osteocyte Ca2+ Responses to in vivo Mechanical Loading in Mice Expressing 
Genetically Encoded Calcium Indicators with Different Sensitivities *James 
Boorman-Padgett1, David Spray2, Mia Thi2, Jelena Basta-Pljakic1, Karl Lewis3, 
Robert Majeska1, Mitchell Schaffler1. 1City College of New York, United States, 
2Albert Einstein College of Medicine, United States, 3Cornell University, United 
States
PURPOSE: Lewis+ in our laboratory recently reported the first ever studies using 
a genetically encoded calcium indicator (GECI) targeted to osteocytes (Ot) to measure 
Ca2+ responses to mechanical loading in vivo1. We discovered that increasing strain levels 
recruited more Ca2+ responding Ot following a well-defined response curve. These stud-
ies used an early GECI, GCaMP31. New GECIs, like GCaMP6f, have increased dynamic 
range and sensitivity compared to GCaMP32-4 but we do not know if Ot Ca2+responses in 
vivo are modified by the GECI used. Here, we examined how Ot Ca2+ responses to loading 
in vivo differ with GCaMP3 vs GCaMP6f. METHODS: Ot-targeted GCaMP3 or GCaMP6f 
mice were obtained from crossing DMP1-Cre with Ai38 or Ai95 mice, yielding OtGP3 and 
OtGP6 mice respectively [16-18 week old females, IACUC approved]. Under anesthesia, 
3rd metatarsals (MT3) were cyclically loaded to strains between 250 and 3000 μstrain1. 
Multiphoton microscopy was used to visualize Ot fluorescence in the mid-diaphyseal cor-
tex during loading. For each Ot, fluorescence intensity was measured (ImageJ) at baseline 
and during loading; cells >25% intensity increases were counted. Linear regression was 
used to model strain vs Ot responses.RESULTS: Within the physiological strain range (250-
2000 μstrain), Ca2+ signaling Ot in both OtGP6 and OtGP3 mice rose monotonically (r2> 
0.9 for both) (Fig). Signal intensity in OtGP6 was higher than OtGP3 cells, with ~twice 
as many responding Ot/strain level. Critically, loading-response curve slopes were equiva-
lent (ANCOVA, p>0.4).DISCUSSION: OtGP6 mice show more Ot responding to a given 
mechanical strain level than OtGP3 mice consistent with higher fluorescence intensity re-
ported in GCaMP6f. However, the Ot-loading-Ca2+ response curve slopes were equivalent, 
revealing that the recruitment relationship between Ca2+ responding Ot number vs strain 
magnitude is the same in both reporter systems, and thus represents a fundamental charac-
teristic of the system. Finally, we note that linear extrapolation of the OtGP6 response curve 
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to the y-axis implies that ~40% of cells are responding at zero load, which was not what we 
observed. We speculate a different Ot response curve might exist for very low strain loading 
(dashed line, Fig) that can now be elucidated using the higher sensitivity of the GCaMP6f 
reporter.REFERENCES: 1) Lewis+ PNAS, 2017; 2) Chen+ Nature 2013; 3) Tian+ Nat 
Methods 2009; 4) Ohkura+ PLoS One 2012
Disclosures: James Boorman-Padgett, None
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Unloading Induces Site-Specific Bone Loss in Cannabinoid Receptor 1 
(CB1) Deficient Mice *Rachel DeNapoli1, Aron Lichtman1, Henry J. Donahue1. 
1Virginia Commonwealth University, United States
The endocannabinoid system (eCBS) plays an important role in postnatal bone metab-
olism. Preliminary results from our laboratory suggest that male C57BL/6J CB1 receptor 
(CB1KO) mice show increased sensitivity to age-related epiphyseal bone loss compared 
to wild type (WT).Age-related bone loss shares many traits with unloading-induced bone 
loss; however, the role of CB1 receptor expression in unloading-induced bone loss has not 
been examined. Therefore, we tested the hypothesis that CB1KO mice are more sensitive 
to unloading-induced bone loss than WT littermates.All animal procedures were conduct-
ed with approval of Virginia Commonwealth University IACUC. Adult 20-week-old male 
C57BL/6J WT mice (n=11) and constitutive global CB1KO mice (n=8) were placed in casts 
to immobilize the left hindlimb. The right hindlimb was used as a contralateral control. 
After 21 days of immobilization, mice were sacrificed, and femurs harvested. The skeletal 
phenotype was assessed using ex vivomicro-CT scans (Bruker Skyscan 1172; 8.9 um). Cor-
tical bone at the diaphysis and cancellous bone at epiphyseal and metaphyseal regions were 
analyzed by standard micro-CT methodology. Data were compared using repeated mea-
sures 2-way ANOVA (p<0.05).At femoral diaphyseal bone sites, there were no differences 
in micro-architecture endpoints between male WT and CB1KO limbs after three weeks of 
immobilization. Unloading induced femoral epiphyseal bone loss in both WT and CB1KO 
mice. However, at femoral metaphyseal bone sites,unloading significantly decreased femo-
ral metaphyseal BV/TV, Tb.N, and Tb.Th and increased Tb.Sp in CB1KO males, but not in 
WT males (Figure 1). These data indicate that male CB1KO mice are more sensitive, rela-
tive to WT mice, to unloading induced trabecular bone loss at metaphyseal bone sites.This 
study demonstrates that CB1 receptor expression protects against bone loss from unloading. 
Therefore, activating the CB1 receptor may represent a potential therapeutic target for disuse 
and age-related bone loss.
Disclosures: Rachel DeNapoli, None
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NaQuinate: A drug that Selectively Synergizes with Mechanical Loading 
Stimuli In Vivo to Generate Greater Cortical Bone Mass and Architectural 
Modifications *Behzad Javaheri1, Amy Lock1, Robin Soper2, Alan Boyde3, 
Ruby Chang1, Stephen Hodges1, Andrew Pitsillides1. 1Royal Veterinary College, 
United Kingdom, 2Haoma Medica Ltd, United Kingdom, 3Queen Mary’s 
College, United Kingdom
Background: Response to applied mechanical loading is pivotal in the generation of 
bone mass and architecture sufficient to withstand habitual use and resist fracture. We have 
previously found that NaQuinate, a naphthoquinone carboxylic acid, contributes to main-
taining bone quality and quantity in rat and mouse ovariectomy models of rapid bone loss. 
Herein, NaQuinate’s ability to alter mechanoadaptive response in cortical and trabecular 
tibial bone following mechanical loading has been investigated.Methods: Female 12wk-
old C57/Bl6 mice (n=8/group) were randomly allocated to two groups, receiving either 
NaQuinate (750 µg/Kg/day) or vehicle 5d/wk over 3 wks. On three alternate days in the last 
2wks, the right tibia of all mice was subjected to non-invasive, dynamic axial loading (12N, 
40cycles/day, 2Hz, with 10s rest periods between cycles), with the left serving as non-loaded 
contralateral control. Three days after the last load episode, tibiae were removed and scanned 
by high-resolution micro-CT (5um) for measurement of traditional indices of bone mass and 
architecture in defined trabecular regions and along the whole of the cortex. A linear mixed 
effects model followed by Fisher’s least significant difference post-test was used for statisti-
cal analysisResults: Comparison of non-loaded tibiae in the two groups showed small, sig-
nificant NaQuinate-related increases in cross-sectional area (CSA) at restricted midshaft and 
tibio-fibular junction locations (Fig 1A/C). NaQuinate markedly enhanced mechanoadaptive 
cortical responses, generating significantly greater load-related increases in CSA, thickness 
and J score across extensive proximal tibia regions (Fig. 1B/D); revealing clear synergy, 
with increases in CSA and J significantly greater than their distinct additive effects (Fig 
1E). NaQuinate treatment also amplifies load-related increases in trabecular thickness and 
generates more vertically-orientated trabeculae when compared to load alone; which was not 
evident in contralateral tibiaeConclusions: These data reveal that NaQuinate significantly 
interacts with mechanical loading in the trabecular compartment and targeted cortical bone 
regions. This constructive interaction between NaQuinate and mechanical loading indicates 
functional utilisation of bones’ mechanostat in the regulation of bone mass and architecture 
and supports the notion that NaQuinate treatment can provide a novel therapeutic approach 
to skeletal disorders such as osteoporosis.
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β-catenin and Cx43 Interact to Mediate the Effect of Mechanical Signals 
on Osteocytes *Yue Zhang1, Caleb Ryan1, Henry Donahue1. 1Virginia 
Commonwealth University, United States
Introduction: Gap junctions (GJ) play a key role in mechanotransduction in bone. Os-
teoblast- and osteocyte-selective Cx43 deficient mice have effects in response to mechanical 
load and unloading in vivo [1, 2]. However, the mechanism is unknown. Osteocytes are the 
cells sense and communicate to bone effector cells, osteoblasts and osteoclasts. The WNT/ 
β-catenin pathway has been shown to be integral to bone response to mechanical signals 
[3]. There is also evidence that suggests β-catenin interacts with Cx43 [4].  In this study, we 
examined the hypothesis that Cx43 regulates osteocytic cell response to fluid flow through 
a β-catenin dependent mechanism.Materials and Methods: OCY454 cells were cultured at 
33°C for 3 days, then differentiated at 37°C for 12 more days. Differentiated wild type (WT) 
OCY454 cells were lysed, incubated with Phospho- or Non-phospho- β-catenin antibodies, 
precipitated, and subjected to western blot analyses with Cx43 antibody.  Mouse osteocytic 
OCY454 cells had the Cx43 gene deleted using Crispr/Cas9. Western blotting and a para-
chute assay were used to verify deletion and gap junctional communication (GJC). A Top-
flash, was used to quantify β-catenin mediated transcription. A Fobflash, a mutated Topflash, 
was used as a control. WT and Cx43 deficient cells were both co-transfected with Topflash 
or Fobflash, and TK-Renilla for 48 hours. Cells were then exposed to oscillating fluid flow 
(10dyns/cm2 at 1Hz) for 2 hours. After 2 hours later, cells were collected for dual lucifer-
ase assay. Relative luciferase activity for both WT and Cx43 KO cells was calculated as 
(TopFlow-FobFlow)/(TopCtrl-FobCtrl).Results and Discussion:  Cx43 KO cells displayed 
reduced Cx43 protein expression and GJC relative to WT cells. Co-IP results showed that 
non-phosporylated β-catenin (active form) co-precipitated with Cx43 but not the phosphory-
lated form (Fig 1). These data suggest that in osteocytes, Cx43 directly binds with the active 
form of β-catenin, reducing its availability for nuclear translocation.  Exposure to fluid flow 
significantly increased luciferase activity to a greater degree in osteocytic Cx43 KO cells 
compared to WT cells (Fig 2). This suggests that fluid flow activates β-catenin mediated 
nuclear translocation and gene transcription to a greater degree in Cx43 KO relative to WT 
cells. Taken together, these results suggest that Cx43 binds activated β-catenin and that in 
Cx43 KO cells there is more β-catenin available in response to mechanical signals. This at 
least partly explains the increased anabolic response to mechanical load in Cx43 deficient 
mice.Conclusions: Our results decreasing Cx43 expression has a strong potential to enhance 
the anabolic response of bone to mechanical load.Acknowledgements: This research was 
funded by the NIH 9R01AR068132-120.References:     1. Zhang Y PLOS 2011. 2. Lloyd SA 
JBMR 2012. 3. Kang KS. Front Endocrinol 2006. 4. Wu JC. JBC 2013.
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Skeletal disuse from unilateral hindlimb immobilization decreases the 
formation of osteocyte plasma membrane disruptions (PMD) and causes 
cortical bone loss *Anik Tuladhar1, Mackenzie Hagan1, Kanglun Yu1, Mohamed 
Awad1, Emily Parker1, Mark Hamrick1, Meghan McGee-Lawrence2. 1Augusta 
University, United States, 2Medical College of Georgia, Augusta University, 
United States
Disuse (such as from spaceflight) leads to bone loss, and better strategies to maintain 
bone health in astronauts during weightlessness and upon return to gravitational forces are 
needed.  Therapeutic approaches to enhance musculoskeletal mechanosensitivity would 
address this need, but a critical barrier to designing such an intervention is that the mecha-
nosensing osteocytes in bone cannot be properly targeted because the physical mechanism 
of load sensation by osteocytes is not fully understood; most osteocyte mechanosensation 
mechanisms observed in vitro have failed to fully explain bone’s ability to detect and adapt 
to loading in vivo.  We and others have recently reported that osteocytes utilize plasma 
membrane disruptions (PMD) as a mechanism to sense mechanical loads and initiate mech-
anotransduction cascades which direct subsequent bone adaptation, and that this mechanism 
functions in osteocytes both in vitro and in vivo. Importantly, we consistently observe that 
~20% of long bone osteocytes develop PMD with routine cage activity in mice, suggesting 
that formation of osteocyte PMD may be essential to bone’s sensation of and response to 
normal gravitational loads. Accordingly, the goal of this study was to test the effects of dis-
use on osteocyte PMD formation.  Twenty female CD-1 mice (11 weeks old) were subjected 
to unilateral hind-limb immobilization for two weeks.  Left limbs were casted using gauze 
and tape and right limbs were left untreated as loaded controls. Ten mice were sacrificed two 
weeks after cast application, five were remobilized for 24 hours prior to sacrifice, and anoth-
er five were remobilized for 72 hours prior to sacrifice. MicroCT analyses showed significant 
decreases in cortical bone thickness and area of the femur following two weeks of immobili-
zation. Histological detection of intracellular albumin staining in tibial osteocytes, indicative 
of PMD formation, showed significantly fewer PMD-labeled osteocytes in the immobilized 
left limb as compared to the control right limb (-74%, p=0.017). Mice remobilized for 24 
hours also showed significantly fewer PMD in the immobilized limb, whereas following 
72 hours of remobilization there were no differences between the immobilized and control 
limbs. These data suggest skeletal disuse results in decreased osteocyte PMD formation, 
contributing to blunted mechanotransduction and bone loss; these results further support the 
importance of osteocyte PMD formation in skeletal mechanobiology.
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NF-κB activation is required for mechanoresponsive nerve growth factor 
expression in osteoblasts *Ibtesam Rajpar1, Ryan Tomlinson1. 1Thomas 
Jefferson University, United States
In response to physiological loads, osteoblasts actively synthesize new bone tissue at 
the sites of highest mechanical strain. Recent studies have shown that mechanical loading in-
duces nerve growth factor (NGF) expression in mature osteoblasts, which subsequently sig-
nals through TrkA receptors on resident sensory nerves to support load-induced bone forma-
tion. In this study, we sought to determine whether the NF-κB signaling pathway modulates 
NGF expression and the resultant bone formation in response to loading. First, we assessed 
the time course of NGF expression following load in vitro. Monolayer cultures of the pre-os-
teoblastic MC3T3 cell line were subjected to fluid shear stress using a previously developed 
microfluidics fluid flow device. Triplicate wells were loaded at 1 mL/min for 10, 15, 30, or 
60 minutes. Significant increases in NGF gene expression were observed at 30 (+1.5 fold) 
and 60 minutes (+2.2 fold) of load as compared to non-loaded controls. To assess the require-
ment for NF-κB in NGF expression by osteoblasts in vitro, culture media was supplemented 
with the NF-κB inhibitors BAY-11-7082 or pyrrolidine dithiocarbamate (PDTC), or DMSO 
(vehicle control), starting 60 minutes before loading. NGF gene expression and protein level 
was analyzed using qRT-PCR and ELISA, and an NF-κB reporter assay was used to deter-
mine the extent of NF-κB inhibition. As compared to vehicle controls, a significant reduction 
of NGF expression and NF-κB subunits was observed in response to both inhibitors. These 
results suggested that NF-κB may be required for NGF expression and the ensuing anabolic 
load-response in adult bones. To test this hypothesis, adult mice expressing a dominant neg-
ative IkB kinase under the control of a Col1a1 promoter (Col1a1.IKK-DN) were subjected 
to three bouts of axial forelimb compression (3 N, 100 cycles, 2 Hz rest-inserted) over three 
consecutive days. Surprisingly, our preliminary results indicate no significant differences 
between Col1a1.IKK-DN mice and wildtype littermate controls in load-induced bone forma-
tion (Figure), suggesting a complex role of mechanoresponsive pathways under the control 
of NF-κB signaling as well as potential compensation for the constitutive loss of IkB kinase 
activity. In conclusion, our study reveals new understanding of the regulation of NGF-TrkA 
signaling in bone, which may enable new therapeutic options for diseases of low bone mass 
and inform the development of anti-NGF antibodies for pain relief.
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Evidence for site-specific mechanoregulation of osteocyte perilacunar/
canalicular remodeling *Courtney Mazur1, Tamara Alliston1. 1University of 
California, San Francisco, United States
Together, bone mass and bone quality determine bone strength. Bone quality metrics 
such as modulus, ultimate stress, and mineralization are improved by treadmill running or 
axial loading protocols in mice, but the cellular mechanisms linking applied loads to changes 
in quality parameters have not been identified. Osteocyte perilacunar/canalicular remodeling 
(PLR), which involves changes in gene expression, lacunar and canalicular geometry, and 
matrix mineralization, regulates bone quality. While others have investigated the effect of 
unloading on lacunar area, the effect of applied load on PLR is not understood. Therefore 
we sought to study the effect of load on the canalicular network and the genes involved in 
shaping it.We applied axial compressive load to the tibia of 8-week-old male mice (600 
cycles/day, 1 Hz, 700-1200 με peak) and compared loaded and contralateral non-loaded 
limbs. PLR outcomes were assessed in the proximal and distal tibia by blinded histologic 
analysis of canalicular length (10 days after three loading sessions) and by mRNA analysis 
of 8 acidification and proteolysis genes implicated in PLR using a custom Nanostring array 
(24 hrs post-load). Loading caused the expected repression of SOST (immunofluorescence, 
n=9, p<0.05) and the expected induction of Akt phosphorylation (Western, n=6, p<0.01) and 
bone formation (dynamic histomorphometry, MS/BS, MAR, BFR, n=6-7, p<0.02). In the 
proximal tibia, this loading regimen increased canalicular length in 5 of 6 analyzed mice by 
an average of 20%, a difference approaching significance (n=6, p=0.058, 3 mice await anal-
ysis). Likewise, loading significantly induced Atp6v0d2 mRNA levels in the proximal tibia 
(n=6, p<0.05), with induction trends for 5 other PLR genes and the Nanostring gene signa-
ture score. Parallel analysis of the distal tibia reveals site-specificity, such that no changes in 
PLR gene expression were observed in this region. Site-specific regulation of TGFβ signal-
ing provides one potential explanation, as we observed load-induced upregulation of TβRI 
and TβRII only in the proximal bone and repression of the TGFβ-responsive gene Serpine1 
only in the distal tibia (n=6, p<0.05).Load-induced PLR gene expression in the proximal 
tibia and accompanying trends in canalicular length suggest that osteocyte PLR may be 
mechanosensitive and spatially regulated. This result would indicate a role for osteocytes in 
mechanoregulation of bone quality in addition to bone mass.
Disclosures: Courtney Mazur, None
P-305
Regulation of Piezo1 in Osteoblasts using Ultrasonic Acoustic Radiation 
Force *Guangdao Zhang1, Sophie Li1, Lin Wu2, Yi-Xian Qin1. 1Stony Brook 
University, United States, 2Chinese Medical University, China
Mechanical stimulation has shown promising in bone adaptation, promoting bone for-
mation, and enhancing healing. Piezo1 is proposed as a mechanotransducer in the regulation 
of cellular response to external loading.   As an effective noninvasive method, acoustic radi-
ation force (ARF) elevated by the low-intensity pulsed ultrasound (LIPUS), has been used 
to promote bone regeneration and fracture healing. We hypothesize that Piezo1, a mechano-
sensitive ion channel, could transduce ultrasound associated mechanical signals and activate 
downstream signaling processes. The goal of this study was to evaluate the role of Piezo1 
in mouse MC3T3-E1 osteoblastic cells during ARF stimulation. We investigated the Piezo1 
expression and localization, cell migration, intracellular calcium oscillations, perinuclear 
F-actin, and the kinases 1/2 (ERK1/2) signaling in MC3T3-E1 cells and shRNA-Piezo1 
knockdown cells, respectively.  The results indicated Piezo1 protein was highly expressed 
in the MC3T3-E1 osteoblastic cells, and mainly localized on the plasma membrane and 
nucleus. Piezo1 could be knocked down by shRNA transfection. The relative expression of 
Piezo1 after knocked down was only 0.123 +/- 0.025, which was significantly lower than 
0.679 +/- 0.066 in the control cells (p<0.01) (Fig. 1A). The cell migration and proliferation 
results showed that cell-covered area of MC3T3-E1 cells was 45.91 +/- 2.29%, which was 
significantly higher than the shRNA-Piezo1 cells (32.82 +/- 1.79%, p<0.01) at 4 hours after 
LIPUS stimulation. he fluorescence intensities of the intracellular calcium of MC3T3-E1 
cells significantly increased and several calcium spikes have been observed during ARF 
stimulation, and the F-actin was also found to immediately accumulate at the perinuclear 
region after LIPUS stimulation (Fig. 1B), which persistently existed until 5-min and re-
turned to its initial level at 30-min. Corresponding to these findings, the protein expression 
of ERK1/2 after the ARF stimulation found significantly increased from 0.483 +/- 0.069 to 
0.975 +/- 0.026 (p0.05) in sh-RNA Piezo1 cells. In conclusion, Piezo1 in MC3T3-E1 osteo-
blastic cells could transduce ARF associated mechanical signals into intracellular calcium, 
and the influx of calcium acts as the second messenger in activating ERK1/2 phosphory-
lation and polymerization of perinuclear F-actin. ARF has the potential to regulate Piezo1 
channel and promote osteogenesis.
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Fluid Shear Stress Rapidly Activates TGFβ Family Signaling in Osteocytes 
*David Monteiro1, Neha Dole1, Serra Kaya1, Luke Campos1, Cassandra Belair1, 
Tamara Alliston1. 1University of California, San Francisco, United States
Bone is a dynamic tissue that constantly adapts to changing mechanical demands. The 
transforming growth factor beta (TGFβ) pathway plays several important roles in main-
taining skeletal homeostasis by coupling the bone-forming and bone-resorbing activities 
of osteoblasts and osteoclasts and participating in the anabolic response of bone to applied 
loads. However, the extent to which osteocytic TGFβ signaling is directly regulated by fluid 
shear stress (FSS) is unknown, despite work suggesting that fluid flow along canaliculi is 
a major physical cue sensed by osteocytes following bone compression. To investigate the 
effects of FSS on TGFβ signaling in osteocytes, we stimulated OCY454 cells grown within 
a microfluidic platform with FSS.Using this system, we found that OCY454 cells rapidly 
respond to 0.1 Pa FSS with increases in cytosolic Ca2+, Akt phosphorylation, and Ptgs2 
expression. Furthermore, this FSS regimen induces Smad2/3 phosphorylation and nuclear 
translocation within 30 minutes, even in the absence of added TGFβ. In fact, the dynamics 
of TGFβ signaling by FSS were comparable to treatment with 5 ng/mL TGFβ ligand. How-
ever, relative to TGFβ, FSS induced a larger increase in levels of pSmad2/3 and TGFβ target 
gene Serpine1, which was upregulated 60-fold by FSS compared to 6-fold by TGFβ after 
2 hours. The striking effect of FSS stimulation on TGFβ signaling was further augmented 
when cells were concurrently treated with TGFβ ligand, suggesting that FSS-mediated acti-
vation of latent TGFβ is insufficient to explain this enhancement.A closer investigation into 
the pSmad bands seen by Western blotting revealed subtle differences in the effects of FSS 
stimulation and treatment with TGFβ that we found to be consistent with concurrent activa-
tion of TGFβ and BMP pathways by FSS. While pretreatment with the TGFβ receptor type 
I inhibitor SB-431542 blocked Smad phosphorylation by TGFβ, it only partly attenuated its 
induction by FSS. RNA sequencing analysis revealed many biological pathways targeted by 
FSS, including TGFβ, that remained significantly upregulated even in the presence of SB-
431542, suggesting that the effects of FSS on TGFβ signaling occur through TβRI-depen-
dent and -independent mechanisms.Overall, these results show that FSS rapidly enhances 
Smad signaling through multiple arms of the TGFβ signaling pathway by activating several 
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distinct subsets of TGFβ type I receptors, implicating both TGFβ and BMP pathways in the 
osteocytic response to FSS.
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Substrate surface characteristics are transduced through a β-catenin 
mediated mechanism initiated by focal adhesion turnover and maturation 
*Otto Juhl1, Anna-Blessing Merife 1, Yue Zhang1, Christopher Lemmon1, 
Henry Donahue2. 1Virginia Commonwealth University, United States, 2Virginia 
Commonwealth University, United States
The mechanism by which osteoblast precursors and osteoblasts transduce the various 
substrate surface characteristics associated with bone implants is largely unknown. This lack 
of understanding makes the design and implementation of implants difficult, especially in 
diseases such as osteopenia, where bone formation is decreased thus limiting implant os-
teointegration.In this study, hFOB 1.19 cells, a preosteoblastic cell line, cultured on either 
tissue culture polystyrene (TCPS) or a pro-osteogenic substrate (POS) were examined for 
both enzymatic alkaline phosphatase (AP) activity and expression of key osteoblastic genes. 
In addition, changes in focal adhesion formation and maturation as well as localization and 
transcriptional activity of b-catenin on either TCPS or POS were assessed. b-catenin binding 
to TCF/LEF was then inhibited using PNU-74564 in cells on either TCPS or pro-osteogenic 
substrate. The effect of b-catenin inhibition on osteoblastic differentiation was then eval-
uated. Significance was considered as values of p < 0.05 for all studies.Cells cultured on 
the POS displayed a significant 2.5 fold increase in AP activity compared to cells cultured 
on TCPS. Moreover, there was a significant increase in all genes associated with increased 
osteoblastic differentiation after 7 days in cells cultured on the POS. Focal adhesion turnover 
and maturation increased from 24-48 hours after seeding to a greater degree in cells on POS 
relative to cells on  TCPS. Interestingly, b-catenin translocation from the membrane to the 
nucleus and transcriptional activity in cells cultured on POS was greater and more rapid (ap-
proximately 24 hours prior) than in cells cultured on TCPS. These variations also coincided 
with the observed changes in focal adhesion turnover and maturation. Inhibition of b-cat-
enin binding to TCF/LEF also inhibited the increased osteoblastic differentiation in cells 
cultured on POS such that there was no significant difference in AP activity between cells 
cultured on TCPS and the POS.These data suggest that substrate surface characteristics may 
be transduced by a focal adhesion mediated mechanism by which b-catenin translocation 
acts as a messenger molecule to regulate osteoblastic differentiation. Moreover, inhibition 
of b-catenin binding to TCF/LEF prevents the upregulation of osteoblastic differentiation 
associated with POS.
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A Novel Method for Associating Local Strain and Mineral Formation 
in Applications of Bone Tissue Engineering *Julia K. Griesbach1, Gian 
N. Schädli1, Graeme R. Paul1, Ralph Müller1, Marina Rubert1. 1Institute for 
Biomechanics, ETH Zurich, Switzerland
Dynamic mechanical loading increases bone formation both in vitro and in vivo. While 
micro-CT and micro-FE have shown a relationship linking bone formation, resorption and 
mechanical environment in vivo, current methods have several limitations. In the Schulte 
method, the association of multiple strain values to single formation voxels on concave sur-
faces leads to inaccurate remodeling probability predictions. We have therefore developed 
and validated a novel surface strain dilation (SSD) method for accurate association of local 
mechanical stimuli to mineral formation in tissue engineered bone.A remodeling image, 
obtained through registering and superimposing time-lapsed images, and local strains serve 
as input. Strain and formation are associated by dilating the surface strain onto the formation. 
The iterative layer-by-layer extrapolating of the surface data prevents original data distortion 
(Fig. 1b). Artificial validation images were created representing bone formation on uneven 
surfaces or multiple layers of formation (Fig. 1c, d) to compare the accuracy of the Schulte 
and SSD method (Fig. 1a). For real life comparison, cell-seeded scaffolds (n=6) were cul-
tured in compression bioreactors. Cyclic loading was executed 3x/week using 3% strain 
at 5Hz for 5min. Time-lapsed micro-CT was performed weekly. Images were registered, 
superimposed and converted to Young’s moduli for subsequent micro-FE to compare the two 
methods using area under the curve of the Receiver Operating Curve (AUC-ROC) scores 
and probability of formation.SSD showed the same amount of formation voxels for both 
validation images as the ground truth (c: 32, d: 56) while the Schulte method deviated vastly 
(c: 72, d: 36). Results from the in vitro study showed SSD to be accurate while the Schulte 
method showed an average absolute deviation of 108.9% (Fig. 1e). The AUC-ROC score 
of SSD was substantially better (0.65) than that of the Schulte method (0.54). The resulting 
probability plots for formation showed different behavior (Fig. 1f).We have developed and 
validated a novel algorithm that allows more accurate association of local strain and forma-
tion for uneven surfaces and large amounts of formation, facilitating the investigation of 
mechano-regulation for bone tissue engineering applications. This can lead to new insights 
in mechanical and geometrical design parameters of engineered bone scaffolds.
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3D physiological load estimation based on time-lapsed HR-pQCT images 
*Matthias Walle1, Francisco C. Marques1, Nicholas Ohs1, Ralph Müller1, Caitlyn 
J. Collins1. 1Institute for Biomechanics, ETH Zurich, Switzerland
Pathological bone morphology observed in patients with type II diabetes mellitus T2DM 
may indicate changes in cell mechanosensation. Computational models for the characteri-
zation of tissue- and cell-level biomechanical properties of bone may be used to investigate 
such changes, if physiological-mechanical loads can be estimated correctly. However, exist-
ing estimation approaches only perform moderately with HR-pQCT data as input. Here, we 
present a novel approach to improve estimation based on mechanoregulation principles and 
provide validation using bone geometries from micro-CT images adapted via a micro-struc-
tural in silico bone adaptation simulation with a highly controlled mechanical environment.
Adaptation to six different target loading conditions (Figure B; Funit=1N, and Munit=1N/
mm; α=150) were simulated for patients (n=3) using a model of homeostatic, load adaptive 
remodeling. Tissue was remodeled using a strain energy density (SED) dependent velocity 
of +/-8000 μm/year/MPa and a maximum velocity of +/-12 μm/month in regions where SED 
exceeded average tissue load (0.02 MPa) by +/-2%. From each simulation, six consecutive 
remodeling steps were selected to include several phases of the adaptation process. The 
implemented load estimation algorithms were based on independently scaling six unit loads 
(Figure C) with scaling factors α, until a target tissue load was found. The implemented 
mechanoregulation-based algorithm (MR), maximized SED in regions of bone formation, 
while minimizing SED in regions where bone was resorbed. The results were compared to a 
previously published morphology-based load estimation algorithm (MO), where a homoge-
neous target load of 0.02 MPa was assumed.MR recovered all load compositions uniquely 
without bias from initial conditions (Figure A). In comparison, MO was unable to recover 
simulated loads, resulting in a mixed-load prediction. MR-derived load magnitudes showed 
acceptable mean differences (+1.07+/-20.30%) to αtarget=150, and were underestimated by 
MO (-77.05+/-7.30%). Furthermore, mechanoregulation analysis showed that MR derived 
loading patterns explained 62.67+/-3.40% of remodeling events, while MO explained only 
50.61+/-0.70%. These preliminary results indicate that using an MR-based criterion increas-
es accuracy of the estimated loads. In the future, this algorithm may be used to better explore 
load patterns in patient cohorts furthering our understanding of mechanoregulation in os-
teo-degenerative diseases such as T2DM.
144
P-310 ASBMR 2020 Annual Meeting
Disclosures: Matthias Walle, None
P-310
Improved Initialisation of a Multiscale in Silico Model of Trabecular Bone 
Remodelling Using in Vivo Murine Data *Daniele Boaretti1, Lara Zamboni1, 
Duncan Tourolle1, Ralph Müller1. 1Institute for Biomechanics, ETH Zurich, 
Zurich, Switzerland, Switzerland
An improved understanding of bone as a mechanobiological system will accelerate the 
development of treatments for bone related diseases. Current in silico models of bone lack 
either the spatial fidelity to represent the bone microarchitecture or disregard the complex 
physiological pathways within the bone. While in vivo micro-CT images allow the use of 
real bone structures as a basis for such models, it is not possible to determine the spatial dis-
tribution of biomolecules and cells from these scans. The largest issue in applying in silico 
models of bone remodeling is the initialization of the simulations employing experimental 
data. This makes it very difficult to initialize such models with good estimates of these dis-
tributions. Here, we present a novel initialization approach using strain-specific cell seeding 
and a 1-dimensional (1D) model to determine cell population sizes and molecular concen-
trations a priori. These results are used to initialize a larger 3D coupled in silico model for 
trabecular bone remodeling.The governing equations of the in silico model were discretized 
into a 1D model composed of a set of ordinary differential equations (ODEs). Models were 
generated using micro-CT scans of mouse caudal vertebrae. The 1D model was used to com-
pute the initial concentration and receptor occupation of a cell. In the 3D model, cells were 
seeded according to the local mechanical environment, with osteoblasts (OBLs) in areas of 
higher strain and osteoclasts in areas of lower strain. We were particularly interested in the 
low-density lipoprotein receptor-related protein 6 (LRP6) receptor occupancy of OBLs and 
lining cells (LCs).The simulations with the 1D and 3D models show a very similar trend for 
LRP6 receptor occupancy for both OBLs and LCs (Fig.1, left). OBLs display a smaller range 
of free LRP6 receptors when compared to LCs for the 3D simulation. Where OBLs can be 
found on surfaces with high effective strain and have higher free LRP6 receptors, LCs can be 
found mostly on surfaces with low effective strain and have lower free LRP6 receptors at the 
end of the simulation in the 3D model (Fig.1, right).The presented method demonstrates how 
bone remodeling simulations can be initialized with appropriate biochemical concentrations 
and cell distributions. Such an approach can the current models of health and disease. This 
will facilitate investigation of population dynamics and the initialization of model agents 
involved in other signaling pathways.
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Pulsating Fluid Flow Modulates Bone Cell Shape and Mitochondrial 
Structure – Implications for Bone Cell Function? *Jianfeng Jin1, Joannes 
A.M. Korfage2, Astrid D. Bakker3, Richard T. Jaspers4, Jenneke Klein-Nulend3. 
1Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam 
(ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam 
Movement Sciences, Amsterdam, The Netherlands, Netherlands, 2Department 
of Functional Anatomy, Academic Centre for Dentistry Amsterdam (ACTA), 
University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam 
Movement Sciences, Netherlands, 3Department of Oral Cell Biology, Academic 
Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and 
Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Netherlands, 
4Laboratory for Myology, Faculty of Behavioral and Movement Sciences, Vrije 
Universiteit Amsterdam, Amsterdam Movement Sciences, Netherlands
Introduction: Bone cells respond to mechanical cues from the environment by changes 
in cellular morphology, which requires drastic rearrangements of cytoskeletal structures. 
Mitochondria form an extensive highly dynamic network undergoing fission and fusion, 
with clusters moving along the cytoskeleton. Importantly, mitochondrial form and function 
are intimately linked. However, whether mechanical factors affecting cytoskeletal organi-
zation also affect mitochondrial network structure and function in bone cells is unknown.
Purpose: To investigate whether bone cell deformation induced by mechanical loading is 
associated with changes in intracellular mitochondrial network structure.Method: Prior to 1 
h pulsating fluid flow (PFF; peak shear stress rate: 6.5 Pa/s; amplitude: 1.0 Pa; frequency: 
1 Hz), live MC3T3-E1 pre-osteoblasts were fluorescently stained for F-actin (Sir actin), 
nuclei (Sir DNA), and mitochondria (MitoTracker). Online live cell imaging was employed 
(22 cells, n=3 experiments) using LSCM before and during PFF. Cell morphology (area), 
cell movement (X,Y,Z-direction), cytoskeletal changes (F-actin fluorescence intensity), 
and mitochondrial network structure and organization (footprint/area, number of branches, 
junctions, triple/quadruple points, junction/slad/end point voxels, and branch length in live 
cell top view images; every 1 sec) were determined.Results: PFF reduced cell surface area 
gradually over time (0.85-fold, 10 min; 0.50-fold, 60 min; Fig. 1). F-actin fluorescence in-
tensity remained unchanged. PFF caused cellular up-and-down movement. PFF modulated 
mitochondrial network structure and organization, except  footprint or area (Fig. 1). The 
highest peak (value) of the network structure and organization parameters appeared at 5 sec. 
Mitochondrial movement was along the flow direction.Conclusions: PFF induced temporal 
and spatial changes in bone cell morphology, which coincided with changes in intracellular 
mitochondrial network structure. This might suggest that mechanical load-induced bone cell 
deformation may drive mitochondrial function, and likely bone cell function.Attachment: 
Figure 1: PFF affected F-actin and mitochondria in pre-osteoblasts. (A) Time course of PFF 
modulation of F-actin (yellow/red). (B) PFF reduced bone cell area.  (C) PFF modulated 
mitochondrial network structure (green). Black/red wireframe of lines: skeletonized mito-
chondria. (D) PFF did not change mitochondrial footprint (or area) values. Bar: 20 μm.
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Mechanotransduction at the Lacuna: Finite Element Modeling in 3D Using 
Confocal Fluorescence Imaging *Loretta Laughrey1, Thiagarajan Ganesh1, 
Sarah Dallas2, Mark Johnson2. 1University of Missouri-Kansas City, School of 
Computing and Engineering, United States, 2University of Missouri-Kansas 
City, School of Dentistry, United States
Bone responds to its load environment through mechanisms that are not fully under-
stood. Loading stimulates osteocytes which are key players in bone homeostasis. The effects 
of global load need to be transduced to the osteocyte in its lacuna. To date, most models have 
assumed that osteocytes respond to global bone strains homogeneously. Few models demon-
strate the complex lacunocanalicular morphology that contributes to a heterogeneous os-
teocyte response and amplification of the mechanical signals that stimulate bone formation.
To interrogate loading dynamics in bone we have developed computer models that simulate 
the complexity of lacunar and canalicular morphologies using empirical data rather than 
idealized geometries. Our models represent realistic, 3D models of a single lacuna. Confocal 
images of a 20x20x11 μm volume of FITC labeled bone, from a 4mo-old mouse femur, 
were converted into a finite element (FE) model with Materialise Innovation Suite®.Strain 
analysis was performed to examine the model response to load using FEBio Software Suite. 
The interior regions of the lacuna and canaliculi were assigned isometric elastic properties 
similar to water. Bone was assigned an elastic modulus of 5 GPa, Poisson’s ratio of 0.17, and 
density of 2 g/cm3.The results indicate that more strain at the cellular level is concentrated 
in the canaliculi rather than the lacuna (see figure). Heterogeneity of strain also occurs in the 
lacunar walls, where strain is higher near canalicular attachments. This, combined with prior 
observations that osteocyte dendrites are more sensitive to mechanical stimulation than the 
cell body, suggests that transduction of mechanical load into a biological signal could occur 
primarily in or near dendrites.The model is composed of about 2 million Tet4 elements. De-
spite its complexity strain analysis using FEBio Software Suite required less than 20 minutes 
on a desktop. Linking such models with lower resolution models from the same specimen 
could simulate the entire path of mechanotransduction from a whole bone to a single osteo-
cyte.Our procedure creates sophisticated FE models of the bone lacuna and its canaliculi for 
strain analyses based on real geometries. In the future, such models will be combined with 
multi-scale models, multiplexed images of the osteocyte, and indicators of bone formation 
to understand the heterogeneity of osteocyte responses to mechanical loading in regions of 
bone that experience similar global strains.
Disclosures: Loretta Laughrey, None
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Role of Canalicular Loss in Osteocyte Mechanobiology Due to Aging 
*Mohammadmedhi Niroobakhsh1, Sarah Dallas1, Mark Johnson1, Thiagarajan 
Ganesh1. 1University of Missouri Kansas City, United States
Prior studies from our group have demonstrated a loss of osteocyte dendrites and con-
nectivity in aged mice, which we hypothesize could explain reduced responsiveness to me-
chanical loading in the older animals. Two finite element models of idealized single osteo-
cytes in their lacunae, identical except for the number of canaliculi, were created in ANSYS 
multi-physics software using the fluid-structure interaction (FSI) approach. We examined 
the effect of the change in number of canaliculi on fluid velocity in the pericellular space 
(PCS), fluid shear stress, and bone strain. Previous studies by other groups have not exam-
ined the effect of canalicular density using computer simulations. Also, they have predicted 
that load-induced fluid flow plays an essential role in mechanotransduction through fluid 
flow shear stresses and bone strains.The osteocyte and bone tissue are solid domains, and 
fluid flows between them through the PCS. To model physiological loading, we applied a 
compressive strain of 3000 µ? as displacement to one side of the solid and the opposite side 
was fixed. A fluid inlet pressure of 300 Pa and outlet pressure of 0 Pa were assigned as fluid 
boundary conditions. The 10 canaliculi model consists of one flow inlet and nine outlets, 
while the 18 canaliculi model has 5 inlets and 13 outlets.The fluid velocity in canaliculi 
was higher than in the lacuna. The model with 18 canaliculi showed an average velocity 
of 11.7 µm/s, average fluid shear stress of 0.39 Pa, and a maximum strain of 29,820 µ? for 
the osteocyte and bone matrix. An average velocity of 16.1 µm/s, average shear stress of 
0.34 Pa, and maximum strain of 26,590 µ? were observed in the model with 10 canaliculi.
Although increasing the number of canaliculi results in lower fluid velocity, it yields higher 
shear stresses and strains. This increase in shear stress and strain may have been due to the 
incorporation of additional inlets to the model, since inlets experience higher shear stresses. 
Overall, these data suggest that increased canalicular number results in higher strains. In 
addition, these simulations support the hypothesis that higher shear stresses occur on the 
dendrite processes, rather than the cell body.Our findings indicate that it is possible to model 
aging associated changes in osteocyte morphology and that bone mechanical stimuli may be 
altered by the consequences of the reduction in PCS fluid flow when osteocyte connectivity 
changes due to aging.
Disclosures: Mohammadmedhi Niroobakhsh, None
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Prediction of Cyclic Load from Strain Measurement in a Long Bone 
using an Artificial Neural Network Algorithm *Saeed Mouloodi1, Hadi 
Rahmanpanah2, Colin Burvill2, Helen MS Davies3. 1Depts Veterinary BioSciences 
and Mechanical Engineering, The University of Melbourne, Australia, 2Dept 
Mechanical Engineering, The University of Melbourne, Australia, 3Dept 
Veterinary BioSciences, The University of Melbourne, Australia
Equine third metacarpal (MC3) bones experience a range of surface strains which are a 
measure of displacement induced by mechanical loading. Bone is a highly nonlinear, inho-
mogeneous and anisotropic material, thus determining its responses is a daunting task. In-
verse finite element analysis has to be solved to predict cyclic loading from strains measure-
ment, which most FEA packages are incapable of doing. Artificial neural network (ANN) is a 
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gold standard to be employed for prediction of load [1] in preference to relatively inaccurate, 
expensive and time-consuming tools such as FEA. In addition, examples of areas where 
such predictive capability is of great value are the design and post-operative analysis of 
orthopaedic implants [2].Nine hydrated third metacarpal bones (B1-B9) from thoroughbred 
horses were tested in ex vivo experiments. A set of strain gauges was attached to the lateral, 
dorsal, and palmar cortices of the bones. Compressive cyclic loads were applied to the bones 
using an MTS machine. Displacement of the machine ends, the values of six kinds strains, 
the applied load, and the rate of loading were recorded. The input sector had 10 variables, 
including time (t), side (left or right limb), age (y), and strains (ε). The output of the simula-
tion was the cyclic load being applied to the bone samples.The ANN model was successfully 
trained using ex-vivo measurements from B1, B3, B4, and B5. Afterwards, the ANN model 
was employed to predict the responses of B7. Figure 1a presents the comparison of the ex-vi-
vo experiments and the load prediction of the ANN. The trend of experimental results was 
consistent with the prediction of the ANN. A force-displacement curve recorded experimen-
tally and that obtained via the ANN model are demonstrated in Figure 1b. A histogram of 
errors between the ex-vivo load and the prediction of the ANN is presented in Figure 1c. The 
outcome of regression analysis between experimental results and the prediction of the ANN 
model is illustrated in Figure 1d.Artificial neural networks (nonlinear mapping approach) 
were used to solve the forward problem for the estimation of applied load. The ability of 
ANN to predict load from measurements of displacement, rate of loading, age, side (left or 
right limb), and strains was discussed. ANN is an invaluable tool for quantifying responses 
of long bones under mechanical loading.[1] A. A. Zadpoor. (2013). J Mech Behav Biomed 
Mater. 27: 249-61.[2] S. Mouloodi et al. (2020). J Mech Behav Biomed Mater. 102: 103527.
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Random Walk in 3D Model of Water Diffusion in the Human Mineralized 
Collagen Fibril *Fabiano Bini1, Andrada Pica1, Andrea Marinozzi2, Franco 
Marinozzi1. 1Department of Mechanical and Aerospace Engineering, “Sapienza” 
University of Rome, Italy, 2Orthopedy and Traumatology Area, “Campus Bio-
Medico” University, Italy
At the nanoscale bone tissue is characterized by the mineralized collagen fibril (MCF), 
a recurring structure mainly composed of apatite mineral, tropocollagen molecules (TC) and 
water. The latter has a crucial role in bone biomineralization. In this study, we aim to analyse 
the mass transport at the collagen-apatite level of porosity by means of a 3D random walk 
model.We considered a representative building block of the MCF according to [1-2]. We 
assumed a mineral volume fraction that represents an intermediate mineralized condition 
(32%vol). The geometrical dimensions of the nanocrystals and TC molecules are obtained 
with random extractions from Gaussian probability distribution functions within the range 
indicated in literature. We generated a model of the building block using the Metropolis 
algorithm in which platelets start in a regular configuration and then are subjected to random 
displacements and inclinations. The analysed arrangement of the building block is obtained 
after roughly 6·106 moves and rotations.The water diffusion within the building block is 
simulated by using a 3D random walk method. We computed the trajectory of the water 
molecule for 30k time steps Δt = 5·10-10 s and take the average over 300 water particles. 
We assume that mineral platelets and TC molecules are impermeable obstacles to water 
diffusion. Periodic boundary conditions are used to prevent error from the finite size of the 
building block.The diffusion coefficient is calculated from the mean square displacement 
of water molecules (MSD) according to the equation D=MSD/2nt, where D is the diffusion 
coefficient, n is the spatial dimension, i.e. n=3, t is the time, i.e. t = nT·Δt, with nT –number 
of time steps [3].The model provides a good prediction of the apparent diffusion coefficient, 
i.e. D = 3.25·10-10 m2/s in agreement with previous results achieved from experimental 
[4] and computational investigations [2]. The 3D random walk model is a valuable tool for 
investigating the influence of the structural hindrance on the diffusivity since the structure of 
the building block is included in the diffusion model.Insights into MCF structure and proper-
ties enhance the understanding of bone mineralization and may improve the design of smart 
structural nanomaterials.References:1. Jäger et al. (2000). Biophys. J. 79: 1737-17462. Bini 
et al. (2019). Sci. Rep. 9:26583. Stylianopoulos et al. (2010). Biophys. J. 99:3119-31284. 
Marinozzi et al. (2014). Biomatter 4:1 e28237 
Disclosures: Fabiano Bini, None
P-316
The Interactive Effects of Dynamization Time and Degree on Bone Healing 
*Ruisen Fu1, Bettina Willie2, Haisheng Yang1. 1Department of Biomedical 
Engineering, Beijing University of Technology, China, 2McGill University, 
Shriners Hospitals for Children, Canada
Introduction: Dynamization, reducing the fixation stiffness from a rigid to a more flex-
ible condition, is widely used clinically to promote fracture healing. However, the most 
effective time to apply dynamization on healing outcomes remains controversial. Preclinical 
studies have demonstrated that dynamization with a degree of ~0.1 (the ratio of the flexible 
to rigid stiffness) at an early stage of healing (e.g. one week post-osteotomy) in rat femurs 
led to delayed healing (1-2). In contrast, a clinical study observed enhanced bone healing 
with early dynamization (3). It should be noted that the baseline fixation stiffness as well 
as the dynamization degree are different between those studies. Given the critical role of 
the fixation stiffness in determining the interfragmentary movement and thus regulating the 
healing process, it is important to understand how the degree and timing of dynamization 
interactively affects the healing process. Thus, the aim of the current study was to use finite 
element modeling to quantify the combined effect of degree and timing of dynamization 
on healing outcomes in an ovine model.Methods: Based on an ovine tibial fracture healing 
model which involves a fuzzy logic-based mechano-regulated tissue differentiation algo-
rithm (4-5), we applied varied dynamization degrees (DC=0.1 to 1; 1 represents a rigid 
fixation) at 1, 2, 3, and 4 weeks (R1wF, R2wF, R3wF, R4wF) and computationally evaluated 
bone formation and biomechanical integrity during the healing process.Results: Our results 
demonstrated that early dynamization (at 1 and 2 weeks) significantly affected the healing 
process and outcomes (Fig. 1). However, the beneficial effect of early dynamization was 
dependent of the dynamization degree. Specifically, a higher dynamization degree (e.g. 0.1) 
led to a marked delay in bone formation and unrecovered stiffness whereas moderate dynam-
ization degrees (e.g. 0.3 or 0.5) significantly enhanced bone formation and biomechanical 
properties of the fractured bone (Fig. 1).Conclusions: Our results suggest that dynamization 
degree and timing interactively affects the healing process and therefore clinical application 
of dynamization should consider their interaction carefully to achieve a beneficial healing 
outcome.References: [1]. Claes et al, JOR, 2009. [2]. Willie et al, CORR, 2011. [3]. Huang 
et al, Injury, 2012. [4]. Shefelbine et al, JB, 2005. [5]. Simon et al, CMBBE, 2011. Acknowl-
edgement: NSFC (11702008), BJNSF (7202003).
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Effect of the accordion technique on bone regeneration during distraction 
osteogenesis *Ruisen Fu1, David Bertrand2, Bettina Willie2, Haisheng Yang1. 
1Department of Biomedical Engineering, Beijing University of Technology, 
China, 2McGill University, Shriners Hospitals for Children, Canada
Introduction: Distraction osteogenesis (DO) is a surgical technique used to lengthen 
bone or bridge large segmental bone defects. It is currently employed worldwide to treat 
congenital and acquired limb length discrepancies and large bone defects resulting from 
infection, trauma or malignancies. However, a major disadvantage of DO is the prolonged 
consolidation phase (10-36 months) during which patients must wear a cumbersome external 
fixator. Thus, strategies are needed to accelerate the healing process in DO. The “accordion” 
technique (AT), which uses alternating controlled distraction and compression during the 
consolidation phase of DO, has shown improved healing outcomes in a limited number of 
patients [1]. However, questions remain as to when is the most effective time to apply the 
AT following DO.Methods: We performed computational simulations to examine the effect 
of the AT applied during early, middle and late stages of the consolidation phase of DO on 
healing outcomes. A 2D axisymmetric finite element model was created based on the cortical 
and callus geometry of the ovine tibia from experimental data [2]. The initial osteotomy gap 
was set to 5 mm. Distraction (1mm/day; 0.5mm/12h) was applied to the top of the cortical 
bone and the bottom cortical end was fixed. Distraction was conducted for 10 days, followed 
by 40 days of consolidation. An adaptive tissue differentiation algorithm was used to predict 
mechanically regulated bone regeneration during DO [3]. Four groups of simulations were 
conducted: (1) Control: no AT; (2) Early AT: day 10-20; (3) Middle AT: day 20-30; (4) Late 
AT: day 30-40.Results: Results showed enhanced bone formation for the Late AT compared 
to control. Specifically, by the end of 40 days, the amount of newly formed bone in the 
callus was 37% greater for the Late AT group than the control group (Fig. 1). In contrast, the 
Early AT group showed compromised bone regeneration compared to controls. The Middle 
AT group showed comparable bone healing outcomes with the controls.Conclusion: These 
results suggest that while application of the AT during the consolidation phase of DO can 
promote bone regeneration, it is most effective at a later stage in this animal model.Refer-
ences: [1] Makhdom et al, Nanomedicine Nanotechnology, Biol. Med. 11(1): 1-18, 2015. 
[2] Claes et al, J. Bone Jt. Surg. 82(1): 142-148, 2000. [3] Niemeyer et al, PLoS One. 13(3): 
1-31, 2018. Acknowledgement: NSFC (11702008), BJNSF (7202003).
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Notum’s role in the response of bone to mechanical loading and aging 
*Vincent Marshall1, Bryan Wacker1, Julia Hum1. 1Marian University, United 
States
Osteoporosis is a silent, dangerous, pathology frequently undiagnosed until patients 
experience a major fracture. Fractures from osteoporosis lead to a 20% increase of mortality, 
revealing a need for novel anabolic therapies. Recently, mice lacking Notum protein expres-
sion were reported to have increased endocortical bone formation and strength. Notum is an 
inhibitory protein of the Wnt pathway, a major growth pathway in mammalian skeletons. 
The hypothesis for this work is Notum expression is affected by mechanical loading and 
aging. The goal of these studies is to investigate factors that could affect Notum expression, 
with the future direction of identifying factors that when pharmacologically modulated could 
promote anabolic bone growth. After establishing Notum expression in the osteocyte cell 
line, MLO-Y4, Notum protein expression in response to mechanical loading was assessed, 
mimicked via fluid shear stress for 15 min, 1hr, and 2hr. Fluid shear stress induced a decrease 
in Notum protein expression after long bouts of fluid shear stress. Notum gene expression 
was analyzed from embryonic, >8 weeks old, and <15 weeks old wild-type mice femurs. The 
aging process increases gene expression of Notum after 15 weeks of age. With these results, 
our hypothesis is supported and future studies examining the mechanism(s) of mechanical 
regulation and the aging process on Notum’s expression are underway.
Disclosures: Vincent Marshall, None
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Loading history changes the morphology and compressive force-induced 
expression of receptor activator of nuclear factor kappa B ligand/
osteoprotegerin in MLO-Y4 osteocytes *Ziyi Wang1, Yao Weng2, Yoshihito 
Ishihara3, Naoya Odagaki3, Ei Ei Hsu Hlaing1, Takashi Izawa1, Hiroshiko 
Okamura4, Hiroshi Kamioka1. 1Department of Orthodontics, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan, 
2Department of Oral Morphology, Okayama University Graduate School of 
Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, Japan, 
3Department of Orthodontics, Okayama University Hospital, Japan, 4Department 
of Oral Morphology, Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Japan
Background: In this study, we investigated the effect of the mechanical loading histo-
ry on the expression of receptor activator of nuclear factor kappa B ligand (RANKL) and 
osteoprotegerin (OPG) in MLO-Y4 osteocytes.Methods: Three h after MLO-Y4 osteocytes 
were seeded, a continuous compressive force (CCF) of 31 dynes/cm2 with or without addi-
tional CCF (32 dynes/cm2) was loaded onto the osteocytes. After 36 h, the additional CCF 
(loading history) was removed for a recovery period of 10 h. The RANKL/OPG expression, 
cell numbers, viability, and morphology were time-dependently examined at 0, 3, 6, and 10 
h. Then, the same additional CCF was applied again for 1 h to all osteocytes with or without 
the gap junction inhibitor to examine the RANKL/OPG expression.Results: The expression 
of RANKL and OPG by MLO-Y4 osteocytes without a loading history was dramatically 
decreased and increased, respectively, in response to the 1-h loading of additional weight. 
However, the expression of RANKL, OPG, and the RANKL/OPG ratio were maintained 
at the same level as in the control group in the MLO-Y4 osteocytes with a loading history 
but without gap junction inhibitor treatment. No significant difference was observed in the 
cell number or viability between the MLO-Y4 osteocytes with and without a loading his-
tory or among different time checkpoints during the recovery period. The cell morphology 
showed significant changes and was correlated with the expression of RANKL/OPG during 
the recovery period.Conclusion: Our findings indicated that the compressive force-induced 
changes in the RANKL/OPG expression could be habituated within at least 11 h by 36-h 
CCF exposure. Gap junctional intercellular communication and cell morphology may play 
roles in the storage of loading history in MLO-Y4 osteocytes.
Disclosures: Ziyi Wang, None
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Local deformation of marrow cells caused by the sinusoidal fluid pressure 
*Taekyeong Lee1, THI KHOA MY NGUYEN1, SooHyeon Hwang1, Junghwa 
Hong1. 1Korea university, Republic of Korea
The red marrow of intertrabecular pores PIT, which is a special soft tissue, contains 
various bone cells, adipocytes, extracellular fluid, and extracellular matrix composed of 
mostly collagen and proteoglycan. In the intracancellous marrow space, the marrow arte-
riole divides into capillaries. The capillaries have porous sinusoids, which are drained by 
venules. The sinusoids are average of 25um wide having thin-walled vessels, which are 
highly porous. The sinusoidal walls lined by endothelial cells are flown by fluid and tra-
versed by hematopoietic cells in both directions. Importantly, the porous sinusoids role as 
the primarily local sources and drains of fluid in the PIT. The sinusoids uniformly distribute 
in the PIT of rats as a density of 90~100 sinusoids per 3×106 micro3. The pressure of sinu-
soids is unknown. However, it is reported that the intramedullary FP in metaphysis of canine 
and murine long bone ranges from 1.78 to 2.73 kPa. Since the inner part of metaphysis 
is composed of the cancellous bone, the intramedullary FP of metaphysis could represent 
the sinusoidal FP in PIT (PITFPS). As a result, an osmotic pressure equilibrium would be 
formed in the PIT. Therefore, the sinusoidal FP would generate intramarrow fluid flow for 
metabolism of marrow cells through the extracellular gaps and matrix pores.Since the cells 
and adipocytes in the marrow are deformable, applications of the pulsatile PITFPS through 
the very porous and permeable sinusoidal wall on the boundary between the marrow and a 
sinusoid would cause local deformation of the bone cells and adipocytes. This could result 
in changes in configuration of the extracellular gaps (ECG). To understand the changes, 
murine marrow was loaded in a biochip (Fig. 1a) which has a microchannel. Then, PBS 
buffer injected to the chamber to make FP that observe the changes in configuration of the 
extracellular gaps (Fig. 1b).Even though the environment was different that inter trabecular 
conditions of bone marrow by placing in microchannel after bone marrow aspiration, but the 
significant local deformations of the marrow cells were occurred at the application line of 
pressure. In addition, the reductions of the ECG were observed at the line. These reduction 
of ECG would hinder the intramarrow fluid flow. In vivo, this would cause insufficient mass 
transport from the sinusoid to the marrow for the metabolisms, and various geneses in the 
PIT. Therefore, a substantial and assistive mechanism is required to help the intramarrow 
fluid flow for augmenting mass transport for the metabolisms and geneses of the PIT cells.
Disclosures: Taekyeong Lee, None
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Advanced Glycation End-Products Are Related With Cortical Quality And 
Increased Risk For Bone Fractures In Chronic Kidney Disease Patients 
*Noemi Roza1, Kelcia Quadros1, André Esteves1, Renata França1, Wagner 
Domingues2, Luzia Furukawa2, Rodrigo de Oliveira1. 1University of Campinas, 
Brazil, 2University of São Paulo, Brazil
INTRODUCTION: The risk of bone fractures is higher in chronic kidney disease 
(CKD) patients than general population. We aim to investigate the relationships between 
advanced glycation end-products (AGEs) and cortical bone in a cohort of CKD patients. 
MATERIALS AND METHODS: 86 CKD patients (stages 3-4, N=26; hemodialysis, N=32; 
peritoneal dialysis, N=28) were included. AGEs levels were measured in serum (pentosi-
dine and glycated hemoglobin), in skin (by AGE-Reader device) and in cortical bone by 
immunohistochemistry; receptor activator of nuclear factor kappa-Β (RANK) and its ligand 
(RANKL) and SOST mRNA expression were evaluated by quantitative real-time PCR. 
Bone histomorphometry was performed to measure cortical porosity, thickness and volume. 
Fracture risk was predicted using FRAX tool. RESULTS: Age was 51+/-13 years and body 
mass index (BMI) 26+/-5 kg/m2; 48 (56%) were male, 41 (48%) Caucasian and 16 (19%) 
diabetics; dialysis vintage was 21 (10-44) months and glomerular filtration rate 6 (5-17) mL/
min. AGEs levels in skin were 3.0+/-0.7 AU (reference: <2.0 AU), serum pentosidine 71 
(44–121) pmol/mL and glycated hemoglobin 5.4 (5-6)%; cortical bone volume, thickness 
and porosity were 22.3+/-9.8 μm2, 619+/-213 μm and 1.55 (0.9-2.7)%, respectively. AGEs 
levels in skin were correlated with age (R=0.538; P=0.0001), risk for major osteoporot-
ic fracture (R=0.562; P=0.0001) and hip fractures (R=0.49; P=0.0001). The mean area of 
AGEs deposits in the cortical bone was 5.4 (3-12.1)% and a trend of correlation was posi-
tively correlated with risk for major osteoporotic fracture (R=0.25; P=0.06); cortical thick-
ness were negatively correlated with serum pentosidine levels (R=-0.27; P=0.02) and age 
(R=-0.235; P=0.04); cortical porosity were positively correlated with glycated hemoglobin 
(R=0.278; p=0.02), SOST mRNA expression (R=0.321; p=0.03), RANKL mRNA expres-
sion (R=0.414; p=0.004). Finally, RANK mRNA expression was correlated with serum pen-
tosidine levels (R=0.304; p=0.045). CONCLUSION: AGEs were detected in cortical bone 
and skin of CKD patients and correlates with their risk for osteoporotic fractures. Serum 
pentosidine levels were associated with low thickness of cortical bone. Cortical porosity was 
associated with serum glycated hemoglobin levels, SOST and RANKL mRNA expression. 
RANK was positively influenced by serum pentosidine levels. Together these data point to a 
direct relationship between AGEs and fractures in patients with CKD.
Disclosures: Noemi Roza, None
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Hypoxia-Inducible Factor 1 Alpha Regulates FGF23 Production and 
Bone Metabolism in Chronic Kidney Disease *Guillaume Courbon1, 
Jadeah Spindler1, Bridget Hunt-Tobey1, Emily Lynch1, Xueyan Wang1, Marta 
Martinez Calle1, Aline Martin1, Valentin David1. 1Division of Nephrology and 
Hypertension, Department of Medicine, and Center for Translational Metabolism 
and Health, Institute for Public Health and Medicine, Northwestern University 
Feinberg School of Medicine, Chicago, IL, USA, United States
Renal osteodystrophy (ROD) is a complex bone disorder associated with chronic kid-
ney disease (CKD) which affects over one in ten Americans. CKD also leads to increased 
bone production of the phosphate regulating hormone, fibroblast growth factor 23 (FGF23). 
ROD and FGF23 are associated with adverse clinical outcomes, including cardiovascular 
events and death. Hypoxia-inducible factor 1 alpha (HIF1α) regulates FGF23 expression 
in osteoblasts and osteocytes, and we hypothesized that osseous HIF1α plays an important 
role in ROD and FGF23 excess in CKD.We generated mice harboring a conditional de-
letion of Hif1α in osteocytes (Hif1αDmp1-cKO) and crossed them to Col4a3KO mice, a 
mouse model of progressive CKD. We studied bone and mineral metabolism alterations of 
wild-type (WT), Hif1αDmp1-cKO, Col4a3KO and compound Col4a3KO Hif1αDmp1-cKO 
(CPD) mice. In parallel, we also treated WT and Col4a3KO mice with moderate CKD, with 
a HIF inhibitor (BAY 87-2243) for 4 weeks. Finally, we compared the differentiation and 
mineralization potential of newly generated MC3T3-E1 osteoblast cell lines overexpress-
ing Hif1α (Hif1αTg) or Hif1α shRNA (Hif1αKO) to MC3T3-E1 transfected with an empty 
vector (Ctr).As previously reported, Col4a3KO mice show a progressive decline in kidney 
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function, associated with FGF23 excess, bone loss, mineralization and turnover abnormal-
ities. Deletion of Hif1α delayed progression of CKD, as CPD mice showed reduced levels 
of BUN compared to age-matched Col4a3KO mice (-25%). In addition, CPD mice showed 
lower FGF23 levels (-80% vs. Col4a3KO) and we obtained similar results in Col4a3KO 
mice administered with a HIF inhibitor (-80% FGF23, -30% BUN, vs. Ctr-Col4a3KO). CPD 
mice also showed improved trabecular and cortical bone parameters (+50% trabecular bone 
volume, -20% cortical porosity vs. Col4a3KO). Finally, deletion of Hif1α led to increased 
alkaline phosphatase (ALP) positive colonies and mineral deposits in Hif1αKO cultures 
compared to Ctr cells, and was accompanied by a 30% reduction in Fgf23 expression. In 
contrast, Hif1αTg cells showed reduced osteogenic potential, with fewer ALP positive col-
onies and mineral deposits, together with a 2-fold increase in Fgf23 expression.Our data 
suggest that osseous HIF1α stimulates FGF23 production in CKD and is a negative regulator 
of osteoblast differentiation and function. Thus, inhibition of HIF1α in bone might represent 
a novel therapeutic strategy to improve outcomes in CKD.
Disclosures: Guillaume Courbon, None
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Reduced DMP1 expression precedes bone loss and FGF23 elevation in 
CKD *Emily Lynch1, Xueyan Wang1, Jian Q Feng2, Thomas Nickolas3, Valentin 
David1, Aline Martin1. 1Division of Nephrology and Hypertension, Northwestern 
University, United States, 2College of Dentistry, Texas A&M University, United 
States, 3Columbia University Medical Center, United States
Chronic kidney disease (CKD) is associated with major disorders of bone and min-
eral metabolism, including impaired bone turnover and mineralization, altered osteocyte 
morphology and differentiation, and increased production of the bone secreted phosphaturic 
hormone FGF23, which is independently associated with cardiovascular mortality.  Dentin 
matrix protein 1 (DMP1) is an extracellular matrix protein produced by osteocytes that stim-
ulates osteoblast differentiation and inhibits FGF23 production.  We previously showed that 
DMP1 supplementation prevents bone loss, FGF23 elevation and cardiovascular outcomes 
in mice with advanced CKD.To determine if altered DMP1 expression contributes to the 
pathogenesis of renal osteodystrophy and FGF23 elevations during CKD progression, we 
measured DMP1 expression in bone of wild-type (WT) and Col4a3KO mice with sponta-
neous and progressive CKD every 4 weeks from 4 weeks of age until their death (24 weeks). 
In parallel, we assessed kidney function, circulating levels of FGF23 and bone microarchi-
tecture. We also assessed osteocyte morphology in mice and in patients with early CKD.
Compared to age-matched WT, Col4a3KO mice showed increased albumin to creatinine ra-
tio (ACR) starting at 8 weeks and blood urea nitrogen (BUN) levels starting at 16 weeks in-
dicating onset of proteinuria and impaired kidney function (p<0.05).  Consistent with BUN 
levels, serum FGF23 levels showed sustained increases starting at 16 weeks (p<0.05).  This 
coincided with alterations in trabecular bone, including reduced trabecular volume (BV/
TV), number (Tb.N), thickness (Tb.Th), connectivity-density, and bone mineral density 
(BMD) measured by 3D-microtomography of femurs from 16 to 24 week-old Col4a3KO 
mice (p<0.05).  However, analysis of cortical (Ct) bone showed reductions in BMD, Ct.Th 
and area (Ct.Ar) as early as 12 weeks of age (p<0.05), and alterations in osteocyte morphol-
ogy as early as 10 weeks in Col4a3KO mice with early CKD and in patient with CKD stage 
1-2.  Bone DMP1 mRNA was reduced by 50% prior to the onset of proteinuria at 4 weeks 
of age and remained low at all time points throughout CKD progression (p<0.05).These data 
show that reduction in DMP1 expression occurs prior to major changes in kidney function 
and precedes altered osteocyte morphology, cortical bone loss and FGF23 elevation in CKD. 
Although further studies are needed to identify the factors that suppress DMP1 expression 
in CKD, DMP1 administration might represent an effective therapeutic strategy to prevent 
alterations in bone and mineral metabolism in early CKD.  
Disclosures: Emily Lynch, None
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Ubiquitin-specific Protease USP34 Regulates Dental Root Morphogenesis 
*Shuang Jiang1, Yuchen Guo1, Rui Sheng1, Xingying Qi1, Quan Yuan1. 1Sichuan 
University, China
Dental root morphogenesis is a dynamic process in which dental mesenchymal cells 
(DMCs) migrate and differentiate into odontoblasts and dental pulp cells, shaping the future 
root of tooth. There are complex signaling pathways involving in root formation, among 
which ubiquitin-dependent proteolysis system plays an increasingly important role. How-
ever, the precise molecular network controlling deubiquitylation in the process of root for-
mation, is yet to be determined. Here we identify deubiquitinase USP34 as a regulator of 
dental root morphogenesis.First, we delineated the pattern of USP34 expression in dental 
pulp tissues from human and mouse. USP34-expressing cells were predominantly observed 
among odontoblasts and dental pulp cells using immunohistochemical method. Then we 
found increasing mRNA and protein level of USP34 in human dental pulp stem cells (DP-
SCs) during odontoblastic induction in vitro. Furthermore, we knocked down the expression 
of USP34 by siRNA and found the odontoblastic differentiation of DPSCs was inhibited, 
with reduction of formation of mineralized nodules and intensity of ALP staining.To further 
validate the role of Usp34 in vivo, we bred Usp34f/+ mice with Sp7-Cre mice to specifi-
cally delete Usp34 from DMCs. Via histomorphometry, we observed that Usp34 deletion 
significantly inhibited root formation in mice, resulting in short root and thin dentin layer 
14 days postnatal. This data was also confirmed by micro-CT analysis. Together, we found 
that Usp34 deletion in DMCs inhibited root morphogenesis.Mechanically, we performed 
proteome analysis and noticed that knock down of USP34 downregulated the protein level of 
nuclear factor 1 C (NFIC). Therefore, we assumed that USP34 might control root formation 
via NFIC, a key regulator in odontoblastic differentiation. Then we examined ectopically 
expressed NFIC levels in the presence of CHX and observed much faster degradation of 
this protein after USP34 depletion, indicating that USP34 could regulate the stability of 
NFIC.Last, we generated DPSCs with NFIC overexpressed using lentiviruses expressing 
shRNA. Overexpression of NFIC could rescue odontoblastic differentiation, confirming by 
ALP and ARS staining. Moreover, NFIC overexpression also upregulated the mRNA levels 
of related markers.In summary, our data demonstrates that USP34 controls odontoblastic 
differentiation of DMCs during dental root morphogenesis through deubiquitinating and 
stabilizing NFIC.
Disclosures: Shuang Jiang, None
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Intestinal Vitamin D Receptor in Adult Mice is Essential to Maintain Bone 
Mass When Calcium Intake is Low but Dispensable When Calcium Intake 
is Adequate *Heng Jiang1, Sylvia Christakos2, James Fleet1. 1Dept. of Nutrition 
Science, Purdue University, United States, 2Dept. of Microbiology, Biochemistry 
and Molecular Genetics, Rutgers New Jersey Medical School, United States
During rapid bone accrual, 1,25(OH)2D/vitamin D receptor (VDR) mediated intestinal 
Ca absorption (Ca Abs) is necessary to supply adequate Ca. However, the importance of 
vitamin D-mediated intestinal Ca Abs for adult bone maintenance is unknown. We tested 
the hypothesis that 1,25(OH)2D-mediated intestinal Ca Abs has a significant role in adult 
bone health. Transgenic mice were developed to allow inducible VDR gene knockout from 
the whole intestine (Villin promoter-CreERT2+/- x VDRf/f mice, WIK) or from the large 
intestine (CDX2 promoter-CreERT2+/- x VDRf/f mice, LIK). Littermates with no CreERT2 
transgene were used as controls. At weaning, mice were fed AIN93G diet (0.5% Ca, 0.4% P, 
200 IU VD3). At 4 mo of age, mice received tamoxifen (TAM, 1 mg/20 g body weight, i.p. 
for 5 d) to induce recombination of the floxed VDR alleles. TAM caused complete VDR de-
letion along the whole intestine in WIK mice whereas LIK mice had limited recombination 
in ileum, complete recombination in cecum, and partial recombination in the proximal colon 
(PCo). After TAM, mice were randomized to AIN93M diet with either 0.5% (adequate) or 
0.2% (low) Ca for either 2 or 16 wks (n=12/group). On adequate Ca intake, WIK and LIK 
mice had similar levels of serum 1,25(OH)2D, Ca Abs, BMC and BMD as the controls. 
In control mice, low Ca intake increased serum 1,25(OH)2D level (+1.9-fold), which up-
regulated S100g gene expression and Ca Abs in the duodenum (Dd) and PCo (all p<0.05). 
Neither BMD nor BMC were altered by feeding the low Ca diet to control mice, indicating 
physiologic adaptation was sufficient to prevent bone loss. In WIK mice, the low Ca diet 
caused a more dramatic increase in serum 1,25(OH)2D (4.4-fold) but the adaptive increases 
in Dd and PCo Ca Abs and S100g mRNA were eliminated and BMC and BMD levels were 
significantly reduced (-28.2 and -23.6%, p<0.0001). LIK mice adapted to the low Ca diet by 
increasing serum 1,25(OH)2D (+2.5-fold). While Dd S100g expression and Dd Ca Abs were 
appropriately increased in the low Ca fed LIK mice, neither PCo S100g levels nor PCo Ca 
Abs were increased and there was a 12% decline in BMD and BMC. Our data suggest that 
in adult mice, vitamin D signaling plays a minimal role in regulating Ca Abs and protecting 
bone mass when dietary Ca intake is adequate. In contrast, vitamin D signaling in the whole 
intestine, and to a lesser extent the PCo, are critical to upregulate Ca Abs and protect bone 
when dietary Ca intake is low.
Disclosures: Heng Jiang, None
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In Pediatric X-linked Hypophosphatemia (XLH), Burosumab Improved 
Clinical Outcomes Versus Higher and Lower Doses of Oral Phosphate 
and/or Active Vitamin D *Erik A. Imel1, Francis H. Glorieux2, Michael P. 
Whyte3, Anthony A. Portale4, Craig F. Munns5, Ola Nilsson6, Jill H. Simmons7, 
Raja Padidela8, Noriyuki Namba9, Hae Il Cheong10, Pisit Pitukcheewanont11, 
Etienne Sochett12, Wolfgang Högler13, Koji Muroya14, Hiroyuki Tanaka15, Gary 
S. Gottesman16, Andrew Biggin5, Farzana Perwad4, Angel Chen17, Mary Scott 
Roberts17, Leanne Ward18. 1Indiana University School of Medicine, United States, 
2Shriners Hospitals for Children, Canada, McGill University, Canada, 3Shriners 
Hospitals for Children-St Louis, United States, 4Department of Pediatrics, 
University of California, San Francisco, United States, 5The University of 
Sydney Children’s Hospital Westmead Clinical School, The Children’s Hospital 
at Westmead, Australia, 6Center for Molecular Medicine, Karolinska Institutet, 
Sweden, 7Department of Pediatrics, Division of Endocrinology and Diabetes, 
Vanderbilt University School of Medicine, Vanderbilt University, United 
States, 8Department of Paediatric Endocrinology, Royal Manchester Children’s 
Hospital, United Kingdom, 9Osaka Hospital, Japan Community Healthcare 
Organization and Osaka University Graduate School of Medicine, Osaka, Japan 
currently at Tottori University Faculty of Medicine, Japan, 10Seoul National 
University Children’s Hospital, Republic of Korea, 11Center of Endocrinology, 
Diabetes and Metabolism, Children’s Hospital of Los Angeles, United States, 
12Department of Pediatrics, Hospital for Sick Children, Canada, 13Department of 
Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Austria, 
14Kanagawa Children’s Medical Center, Japan, 15Okayama Saiseikai General 
Hospital Outpatient Center, Japan, 16Shriners Hospitals for Children-St. Louis, 
United States, 17Ultragenyx Pharmaceutical Inc., United States, 18University of 
Ottawa, Canada
In a phase 3 trial in children with XLH (CL301; NCT02915705), burosumab resulted 
in greater improvements in hypophosphatemia and related morbidities than continuation 
with oral phosphate and active vitamin D (Pi/D). Here, we present a post-hoc analysis as-
sessing the response to burosumab vs higher or lower average daily doses of Pi/D over 
64 weeks. Children (1-12 years-old) with XLH receiving Pi/D with Rickets Severity Score 
>=2.0 were randomized 1:1 to 64 weeks of burosumab starting at 0.8 mg/kg subcutaneous-
ly Q2W or to resume Pi/D. Pi/D dose categories were assessed as: phosphate >40 mg/kg 
(HPi), phosphate <=40 mg/kg (LPi), alfacalcidol >60 ng/kg or calcitriol >30 ng/kg (HD), 
and alfacalcidol <=60 ng/kg or calcitriol <=30 ng/kg (LD). We used the Radiographic Global 
Impression of Change (RGI-C) to assess rickets healing at 64 weeks based on Pi/D dose 
categories before (pre-baseline) and during study. The distribution of children in the Pi/D 
dose categories pre-baseline were: 8 HPi, 21 LPi, 7 HD, and 22 LD in the burosumab group 
(n=29), and 3 HPi, 29 LPi, 7 HD, and 25 LD in the Pi/D group (n=32). On-study, the distri-
bution was 12 HPi, 20 LPi, 14 HD, and 18 LD in the Pi/D group. Regardless of Pi/D doses 
administered pre-baseline, children receiving burosumab had an approximately two-fold 
greater improvement in least square (LS) mean RGI-C score for rickets healing vs those 
continuing Pi/D (Table). Further, at Week 64, the LS mean RGI-C score with burosumab (2.1 
+/-0.1) was greater vs on-study treatment with HPi (1.0 +/-0.2), LPi (1.0 +/-0.2), HD (1.5 
+/-0.2), or LD (0.7 +/-0.2). The LS mean improvement in lower limb deformity RGI-C with 
burosumab (+1.3 +/-0.2) was greater vs HPi (+0.3 +/-0.2), LPi (+0.3 +/-0.1), HD (+0.4 +/-
0.2), or LD (+0.2 +/-0.1). The LS mean alkaline phosphatase (U/L) decrease from baseline 
with burosumab was -174 +/-14 vs HPi (-43 +/-29), LPi (-19 +/-28), HD (-59 +/-30), or LD 
(-4 +/-24). The mean parathyroid hormone (PTH) percent change from baseline with buro-
sumab was +10.5 +/-13.3 vs HPi (+45.2 +/-41.0), LPi (-9.5 +/-13.1), HD (-29.3 +/-15.5), 
or LD (+42.5 +/-27.2). Adverse events on burosumab included mild to moderate hypersen-
sitivity and injection site reactions. No discontinuations occurred. In children with XLH, 
improvements in rickets, lower limb deformity, and decreases in ALP were greater during 
burosumab than with either higher or lower on-study doses of phosphate or active vitamin 
D. The increase in PTH was greatest in the HPi and LD groups.
Disclosures: Erik A. Imel, Ultragenyx Pharmaceutical Inc., Consultant, Ultragenyx 
Pharmaceutical Inc., Grant/Research Support
P-327
Differential iron requirements of osteoblast and adipocyte differentiation 
*Erica Clinkenbeard1, Daniel Edwards III1, Christian Wright2, William 
Thompson2. 1Indiana University School of Medicine, United States, 2Indiana 
University, United States
Iron is a key mineral component for several cellular and biological processes including 
oxygen transport. Iron deficiency is highly prolific across the world and often synonymous 
with chronic kidney disease (CKD). Recent human studies demonstrated that iron deficiency 
anemia correlated with increased fracture risk independent of other known risk factors. In 
the adenine diet model of induced kidney failure, iron deficiency anemia correlates with 
development of severe cortical porosity and marrow adipocyte accumulation. Therefore, 
we hypothesized iron deficiency impairs normal osteoblast maturation and may enhance 
adipocyte differentiation. To undertake these studies we used a mouse immortalized mesen-
chymal progenitor cell (MPC-2), which proliferates continuously and maintains differenti-
ation capacity for chondrocytes, adipocytes and osteoblasts. MPC-2 cells were incubated in 
osteogenic media (OM) with increasing concentrations of deferoxamine (DFO), to mimic 
iron deficiency. After 14 days, OM control cells showed a significant induction of osteoblast 
genes including Bglap, Col1a1 and Dmp1 (p<0.05 compared to undifferentiated cells). The 
highest concentration of DFO significantly blunted the osteoblast gene expression (p<0.01 
vs OM control) and suppressed mineralized nodule formation. Hypoxia inducible factor 1α 
(HIF1α), used to adapt to iron deficient/hypoxic conditions, accumulated in the cells treated 
with DFO. Transferrin receptor (Tfrc), a known HIF1α target, increased in a DFO dose 
dependent manner. Activation of HIF1α in bone typically enhances osteoblast differentiation 
suggesting low-iron affects osteoblast function independent of HIF1α. TUNEL staining in 
these conditions confirmed no increased cell death with prolonged exposure to DFO.  MPC2 
cells were then differentiated in adipogenic media (AM) with similar DFO concentrations 
for 14 days. In contrast to the osteoblast experiments, chronic treatment with DFO had no 
effect on adipocyte differentiation. Gene expression of key factors including Pparγ, Lpl and 
AdipoQ were similar between DFO treated and AM control cells. Oil red o staining demon-
strated no deficits in the ability of the cells to accumulate lipid with or without DFO. In 
summary, osteoblast differentiation maintains a higher iron requirement for proper differen-
tiation and function compared to adipocytes. Iron deficiency could therefore be a significant 
contributing factor to bone loss, and elevated fracture risk in CKD.
Disclosures: Erica Clinkenbeard, None
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Osteocyte-specific deletion of FGF23 partially corrects bone growth and 
mineralization in DMP1KO ARHR mice *Lauriane Hivert1, Emily Lynch1, 
Jadeah Spindler1, Wenhan Chang2, Jian Q Feng3, Valentin David1, Aline Martin1. 
1Division of Nephrology and Hypertension, Northwestern University, United 
States, 2Department of Medicine, University of California San Francisco, United 
States, 3College of Dentistry, Texas A&M University, United States
Autosomal recessive hypophosphatemic rickets (ARHR) is caused by inactivating 
mutations of dentin matrix protein 1 (DMP1) that lead to primary increases in fibroblast 
growth factor 23 (FGF23) expression in osteocytes and circulating intact FGF23 (iFGF23) 
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levels, which result in hypophosphatemia, rickets and osteomalacia. To determine the role 
of osteocyte-produced FGF23 and hypophosphatemia on rickets/ostomalacia, we compared 
the bone and mineral phenotype of wild type (WT), FGF23DMP1-cKO (harboring an osteo-
cyte-specific deletion of FGF23 using DMP1-cre), DMP1KO and compound mutant DMP-
1KO/FGF23DMP1-cKO male mice at 12 weeks of age. We measured levels of markers of 
mineral metabolism in the circulation, measured bone length to evaluate bone growth and 
assessed trabecular and cortical bone microarchitecture and density by 3D-microtomogra-
phy. Compared to WT mice, FGF23DMP1-cKO mice showed a 40% reduction in serum 
iFGF23 levels and a 35% increase in serum phosphate (p<0.05). This was associated with 
reduced cortical bone porosity, increased cortical area (Ct.Ar) and bone mineral density (Ct.
BMD) (p<0.05), but similar trabecular bone phenotype and bone growth to WT mice.  As 
previously reported, DMP1KO mice showed a 20-fold increase in serum iFGF23, low se-
rum phosphate and increased PTH levels (+5-fold) (p<0.05). DMP1KO mice also showed 
impaired growth demonstrated by reduced body weight and shorter femur and tibia lengths 
(p<0.05), and all the characteristic of rickets and osteomalacia, including larger epiphyses, 
bone cross-sectional area (CSA) and marrow area (Ma.Ar), and reduced BMD, trabecular 
BV/TV, and Ct.Ar (each p<0.05).  Osteocyte-specific deletion of FGF23 in DMP1KO mice 
corrected iFGF23 levels by 80%, normalized serum phosphate, and lowered PTH levels by 
50% (p<0.05 vs. DMP1KO).  Despite the complete correction of hypophosphatemia, DMP-
1KO/FGF23DMP1-cKO mice showed only partial corrections of body weight and bone 
growth (+70% and +50%, p<0.05 vs. DMP1KO) and residual features of rickets.  BMD also 
was only partially improved (+50%, p<0.05 vs. DMP1KO) while BV/TV and Ct.Ar showed 
a near complete rescue (NS vs. WT). These data show that complete correction of hypo-
phosphatemia by the osteocyte specific deletion of FGF23 in DMP1KO mice only partially 
corrected bone growth and mineralization. Whether the residual phenotype is due directly to 
DMP1 deficiency or additional effects of FGF23 on bone remains to be determined.
Disclosures: Lauriane Hivert, None
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UK Biobank GWAS Identifies 197 Novel Loci for Serum Alkaline Phosphatase 
Concentrations *Fadil Hannan1, Mark McCarthy2, Diane Smelser3, Xin Meng1, 
Juho Asteljoki1, Taha Elajnaf1, William Rayner1, Gerda Breitwieser4, David 
Carey3, Richard Eastell5, Anubha Mahajan2, Rajesh Thakker1. 1University of 
Oxford, United Kingdom, 2Genentech, United States, 3Weis Center for Research, 
Geisinger, United States, 4Florida Atlantic University, United States, 5University 
of Sheffield, United Kingdom
Alkaline phosphatase (ALP) is a zinc-containing membrane glycoprotein, which plays 
a key role in skeletal mineralisation, and is widely used in the investigation of bone and 
liver disease. Serum ALP comprises a mixture of isoforms mainly from liver and bone, and 
partially from the intestine, especially in individuals with blood groups O and B, or who are 
secretors of blood group antigens. Serum ALP has >50% heritability, yet the genetic deter-
minants of this biomarker remain to be fully elucidated. We performed a GWAS of serum 
ALP concentrations involving 274,547 adult individuals of European ancestry from the pop-
ulation-based UK Biobank cohort. Individuals with vitamin D deficiency (25-hydroxyvita-
min D <30nmol/L), impaired kidney function (eGFR <60 ml/min/1.73m2), or alterations in 
bilirubin or gamma glutamyl transferase were excluded. Variant associations were assessed 
using a linear mixed model adjusted for age, sex, array, and relatedness in samples and 
population structure. Genome-wide significance was defined at p140,000 individuals. We 
identified 239 genome-wide significant loci, and the most significant associations were with 
the reported asialoglycoprotein receptor 1 (ASGR1)(rs55714927, p=3.3e-226), ABO blood 
group (ABO) (rs550057, p=1.7e-211) and the tissue non-specific ALP (ALPL) (rs72659192, 
p=2.7e-188) genes. 197 loci were novel and included genes with likely roles in ALP gly-
cosylation (ST3GAL3), zinc incorporation (SLC30A5) and membrane attachment (PIGV, 
PGAP3). In silico analysis was undertaken to identify gene enrichment in cellular pathways 
and expression in bone and liver. This identified novel associations between serum ALP 
and genes involved in osteoclast activation (CFOS, NFATC1) and bone resorption (MMP9), 
and in bile acid synthesis (BAAT, PROX1, AKR1C4, HSD3B7) and secretion (UGT2B7, 
SULT2A1, ITPR2). Moreover, genes were enriched in the macro-autophagy pathway, which 
mediates the clearance of cytosolic components. Thus, serum ALP was associated with 
genes involved in autophagosome formation (ATG4B, ATG7, ATG10), lysosome activation 
(TFEB), and autophagosome-lysosome fusion (RILP, UVRAG, FYCO1). In summary, these 
findings demonstrate a role for genes involved in glycoprotein processing, osteoclast acti-
vation and bile acid secretion in regulating serum ALP. In addition, this study highlights a 
novel association between serum ALP and the macro-autophagy pathway.
Disclosures: Fadil Hannan, None
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Alterations in dental hard tissues in Nogo-A mutant mice *Pierfrancesco 
Pagella1, Martin Schwab2, Thimios Mitsiadis1. 1Institute of Oral Biology, 
Center of Dental Medicine, Faculty of Medicine, University of Zurich, Zurich, 
Switzerland, Switzerland, 2Institute for Regenerative Medicine, University of 
Zurich, 8952 Schlieren, Switzerland, Switzerland
Initially discovered as a potent inhibitor of neurite outgrowth, in the last decades No-
go-A emerged as a fundamental actor of nervous system development, physiology, patholo-
gy and regeneration. In this context, Nogo-A became a promising target for central nervous 
system (CNS) regeneration- However, despite the already known widespread expression 
of Nogo-A in non-neuronal tissues, its role outside the CNS has been poorly investigated. 
We here show a completely novel function for Nogo-A during tooth development. Tooth 
formation results from a complex set of sequential and reciprocal interactions between the 
oral epithelium and the cephalic neural crest derived-mesenchyme. The epithelium folds 
around the mesenchyme that forms the dental follicle and dental pulp. Pulp cells adjacent 
to the dental epithelium differentiate into odontoblasts and secrete dentin, while epithelial 
cells adjacent to the pulp differentiate into ameloblasts and secrete enamel. We observed 
that Nogo-A was expressed in both ameloblasts and odontoblasts from early developmental 
stages. Transmission and scanning electron microscopy analysis revealed that its deletion in 
a Nogo-A KO transgenic mouse model led to a general disorganization of ameloblasts and 
the generation of defective enamel. Conditional deletion of Nogo-A in the dental epithelium 
(K14:Cre;Nogo-A) was sufficient to cause defects in enamel organization and structure, in-
dicating a completely novel, epithelium-specific role for Nogo-A. RNA sequencing analysis 
showed that, in this context, the loss of Nogo-A induced the upregulation of genes involved 
in ameloblastic differentiation. Taken together, these results indicate a completely novel set 
of functions for Nogo-A outside the neural tissues, revealing it as an important regulator of 
enamel formation.
Disclosures: Pierfrancesco Pagella, None
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Chondrocyte-specific Efnb1 expression promotes angiogenic and bone 
formation gene expression during fracture repair *Charles Rundle1, 
Subburaman Mohan2. 1VA Loma Linda Healthcare System, United States, 2VA 
Loma Linda Heathcare System, United States
The ephrin families of ligands and receptors mediate tissue development and homeosta-
sis. We have previously observed the ephrinB1 gene (Efnb1) to exhibit significant changes in 
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gene expression during endochondral bone repair. Because EFNB1 is expressed in pre-hy-
pertrophic chondrocytes during fracture repair, we examined fracture healing when Efnb1 
expression was disrupted in chondrocytes. We previously reported that Efnb1 deficiency 
in chondrocytes produced no significant differences in fracture cartilage but resulted in a 
25% reduction of the partial bone volume of the fracture callus at 3 weeks post-fracture, a 
time when the fracture cartilage is replaced by woven bone. To identify molecular pathways 
by which Efnb1 might regulate this effect, we examined fracture callus gene expression in 
Col2 chondrocyte-specific Efnb1 knockout mice at 3 weeks healing.Closed femur fractures 
were performed in chondrocyte conditional knockout (cKO), Cre+Efnb1floxed and control 
Cre+Efnb1WT mice. Total RNA was isolated from whole fracture calluses at 3 weeks after 
fracture (n=4/group) and gene expression analyzed by real-time RT-PCR for markers of bone 
formation, remodeling and angiogenesis, as well as ephrin ligands and receptors that might 
compensate for Efnb1 deficiency. Statistical analysis was performed by ANOVA with Tukey 
post-hoc confirmation.Alkaline phosphatase (Alp) expression was significantly reduced in 
the cKO mouse fractures at 3 weeks post-fracture to 0.70 of control fractures (P<0.015) but 
osteocalcin (Bglap) expression was not different from that of control fractures. None of the 
remodeling-related genes examined (Tnfsf11, Ctsk and Mmp9) displayed any significant dif-
ferences in fracture expression between cKO and control mice. Of the angiogenesis-related 
genes, von Willebrand’s Factor (Vwf) expression was down-regulated to 0.37 of the control 
fractures (P<0.015) but Hif1a expression was not different between the two genotypes. The 
cKO fracture expression of the ephrin ligand Efnb2 was down-regulated to 0.64 of control 
fractures (P<0.045), but the expression of Efnb3 and the ephrin receptor Ephb4 was not 
different between cKO and control fractures.Based on our results, we propose that: 1) Efnb1 
expressed in chondrocytes regulates fracture callus angiogenesis through Vwf, as well as the 
early stages of mineralization during bone formation through Alp. 2) Efnb1 may recruit other 
Efn family members to mediate its anabolic effects on fracture healing.
Disclosures: Charles Rundle, None
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Localization of Annexin A6 and its translocation across membrane in 
matrix vesicles during apatite formation *Ekeveliny Amabile Veschi1, Maytê 
Bolean1, Yubo Wang2, Agnieszka Strzelecka-Kiliszek3, Joanna Bandorowicz-
Pikula4, Slawomir Piluka5, Ofelia Maniti6, Thierry Granjon7, Saida Mebarek8, 
David Magne8, Ana-Paula Ramos1, Nicolas Rosato9, José Luis Millán10, He 
Tian 11, Xiao-Peng He12, Massimo Bottini9, Pietro Ciancaglini13, Rene Buchet8. 
1Departamento de Química, FFCLRP-USP, Brazil, 2East China University of 
Science and Technology, China, 3Laboratory of Biochemistry of Lipids, Nencki 
Institute of Experimental Biology, Poland, 4Laboratory of Cellular Metabolism, 
Nencki Institute of Experimental Biology, Poland, 5Laboratory of Biochemistry 
of Lipids, Nencki Institute of Experimental Biology, Poland, 6Universite de 
Lyon, ICBMS, UMR 5246, CNRS, France, 7Universite de lyon, ICBMS, UMR 
5246, CNRS, France, 8Universite de Lyon, ICBMS, UMR 5246, CNRS, France, 
9Department of Experimental Medicine, University of Rome Tor Vergata, Italy, 
10Sanford Burnham Prebys Medical Discovery Institute, United States, 11Key 
Laboratory for Advanced Materials and Joint International Research Laboratory 
of Precision Chemistry and Molecular Engineering, Feringa Nobel Prize Scientist 
Joint Research Center, East China University of Science and Technology, China, 
12Institute of Fine Chemicals, School of Chemistry & Molecular Engineering East 
China University of Science & Technology, China, 13Departamento de Química, 
Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto da Universidade de 
São Paulo (FFCLRP-USP), Brazil
Matrix vesicles (MVs) of 100-300 nm diameter are released by mineralization com-
petent cells to initiate formation of apatite. Among proteins present in MVs, annexin A6 
(AnxA6) is the largest member of the annexin family of proteins. To define functions of 
AnxA6 during mineralization, we determined its localization in MVs. MVs were extract-
ed from bone femurs of chicken embryos. Western blot on extracts of MV membranous 
fractions, indicated that AnxA6 is found in the MV-lumen, as a MV-transmembrane, on the 
internal and external leaflets of the MV bilayer. AnxA6 is selectively recruited by choles-
terol in MVs as probed by the addition of methyl-β-cyclodextrin. Thermodynamics analysis 
on monolayers and proteoliposomes composed of either dipalmitoylphosphatidylcholine 
(DPPC) to mimic the outer leaflet of the MV or a 9:1 DPPC:dipalmitoylphosphatidylser-
ine (DPPS) mixture to mimic the inner leaflet, confirmed that AnxA6 interacted differently 
with each class of phospholipids. AnxA6-lipid interaction was also Ca2+-dependent, as evi-
denced by the increase in surface pressure of negatively charged 9:1 DPPC:DPPS monolay-
ers and a decrease in enthalpy in 9:1 DPPC:DPPS proteoliposomes caused by the addition of 
AnxA6 in the presence of Ca2+ compared to DPPC zwitterionic bilayers. Protrusion of the 
protein at the surface of DPPC proteoliposomes observed by AFM suggested that AnxA6, in 
the polymeric form, interacted with the vesicle membrane. A decrease in pH inside MVs 
during apatite formation was observed. We hypothesized that acidification may render the 
protein hydrophobicity facilitating its insertion into the bilayer of MVs, which was moni-
tored with fluorophore N-4-hydroxyphenyl-N‘-phenyl dihydrodibenzo[a,c]phenazine. Ad-
dition of Anx6 to either DMPC at both pHs 7.4 and 5.4, or DMPC: DPPS (9:1) at pH 7.4 
decreased membrane fluidity, consistent with AnxA6 interactions with the surface of bilayer. 
In contrast, AnxA6 addition to DMPC: DPPS (9:1) at pH 5.4 increased the fluidity of the li-
posome membrane, suggesting insertion of AnxA6 into the bilayer, accompanied by changes 
in the protein secondary structure as observed by CD during acidification. Distinct localiza-
tion of AnxA6 during apatite formation may reflect several steps of mineralization process, 
formation of nucleation core with AnxA6 on the internal leaflet of MVs, apatite-formation 
inducing AnxA6 translocation, and MV binding to collagen with AnxA6 at the external leaf-
let of MVs.
Disclosures: Ekeveliny Amabile Veschi, None
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Prrx1-CreAlplfl/fl mice, a model for further investigations into the 
pathophysiological changes in hypophosphatemia *Victoria DeMambro1, 
Jennifer Daruszka1, Daniel Brooks2, Mary Bouxsein2, Cliff Rosen1. 1Maine 
Medical Center Research Institute, United States, 2Center for Advanced 
Orthopaedic Studies, Beth Israel Deaconess Medical Center, United States
Hypophosphatasia (HPP) is caused by loss of function mutations in the tissue-nonspe-
cific alkaline phosphatase (TNSALP) gene (Alpl) resulting in rickets, osteomalicia, bone 
fragility and lean body mass in severe childhood forms. In vitro, inhibition of TNSALP leads 
to decreased lipid accumulation suggesting TNSALP, an enzyme known for its mineralizing 
properties, may be pro-adipogenic. TNSALP may play a role in bone marrow mesenchymal 
stem cell (BMMSC) lineage determination between osteoblasts and adipocytes. Alpl-/- mice 
die postnatally, therefore, to further delineate TNSALP’s role in bone homeostasis and ad-
ipogenesis we are utilizing a Prrx1-Cre driver mated with to an Alplflfl (CreAlpflfl) mouse 
line. Male and female CreAlpflfl and control mice were evaluated for body composition and 
areal bone mineral density (aBMD) at 8, 16 and 24wks of age by DXA analysis (n=10/geno/
gender). Metabolic cage analysis was performed at 24wks of age (n=8/geno/gender). At sac-
rifice body weights, serum, inguinal fat depots (IWAT) and long bones were isolated for Mi-
croCT/histological analysis and gene expression. In vitro BMMSCs were differentiated into 
osteoblasts and adipocytes as well as the stromal vascular fraction (SVF) from the inguinal 
fat (IWAT) depot to query osteoblastic and adipogenic capacity in CreAlpflfl cells. At 8, 16 
and 24wks of age CreAlpflfl mice exhibited significantly reduced body weight and femoral 
aBMD compared to controls. CreAlpflfl fat mass was reduced at 8 and 16wks however, by 
24wks there were no differences relative to controls. Alpl expression was reduced by 70% 
in CreAlpflfl IWAT depots coupled with a reduction in adipocyte size. CreAlpflfl femurs had 
reductions in length, cortical thickness, area and BMD with increases in marrow area. Mi-
croCT imaging revealed an extremely disorganized growth plate as well as reduced trabecu-
lar bone mass, thickness, number in CreAlpflfl femurs. Metabolically, male CreAlpflfl mice 
exhibited decreased energy expenditure relative to controls, correlating with decreased 
activity levels. Preliminary BMMSCs cultures had decreased osteoblast mineralization 
coupled with increased adipogenesis in CreAlpflfl cells. Conversely, CreAlpflfl IWAT SVF 
cultures exhibited reductions in lipid accumulation. In sum, ongoing studies of Prrx1-Cre-
Alpflfl mouse model will help elucidate probable intracellular actions of TNSALP and aid in 
a greater understanding of the pathophysiological changes that occur in bone and fat in HPP. 
Disclosures: Victoria DeMambro, None
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UK Biobank GWAS Reveals Influence of Parathyroid-Bone-Kidney Axis 
on Serum Calcium and Phosphate Concentrations *Taha Elajnaf1, Fadil 
Hannan1, Mark McCarthy2, Diane Smelser3, Juho Asteljoki1, Xin Meng1, William 
Rayner1, Gerda Breitwieser4, David Carey3, Richard Eastell5, Anubha Mahajan2, 
Rajesh Thakker1. 1University of Oxford, United Kingdom, 2Genentech, United 
States, 3Weis Center for Research, Geisinger, United States, 4Florida Atlantic 
University, United States, 5University of Sheffield, United Kingdom
Mineral metabolism is tightly coordinated by interactions between the parathyroid 
glands, bone and kidneys. We further characterized the genetic determinants influencing 
this process by undertaking a genome-wide association study (GWAS) of serum calcium 
and phosphate concentrations, which are heritable traits, in >308,000 adult individuals of 
European ancestry from the population-based UK Biobank cohort. Individuals with vitamin 
D deficiency (25-hydroxyvitamin D <30nmol/L) or low estimated glomerular filtration rate 
(eGFR, <60 ml/min/1.73m2) were excluded, and serum calcium was adjusted for alterations 
in serum albumin. Directly genotyped and imputed variants were assessed using a linear 
mixed model adjusted for age, sex, array, and relatedness in samples and population struc-
ture. Genome-wide significance was defined at p140,000 individuals. These findings demon-
strate that variants in genes encoding key components of the parathyroid-bone-kidney axis 
influence both serum calcium and phosphate concentrations. Identification of these genetic 
determinants may help elucidate the pathophysiological basis of calcitropic disorders and 
highlight targets for the therapeutic modulation of mineral homeostasis.
Disclosures: Taha Elajnaf, None
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A novel GNAS duplication associated with loss-of-methylation restricted 
to exon A/B causes pseudohypoparathyroidism type Ib (PHP1B) *Monica 
Reyes1, Masayo Kagami2, Dirk Schnabel3, Maki Fukami2, Harald Jueppner4. 
1Massachusetts General Hospital, United States, 2National Research Institute 
for Child Health and Development, Japan, 3Pädiatrische Endokrinologie und 
Diabetologie Charitè, Universitätsmedizin Berlin, Germany, 4Massachusetts 
General Hospital and Harvard Medical School, United States
Pseudohypoparathyroidism type Ib (PHP1B) is characterized by resistance to para-
thyroid hormone (PTH) leading to hypocalcemia and hyperphosphatemia, and in some 
cases resistance towards additional hormones. Patients affected by this disorder all share a 
loss-of-methylation at the differentially methylated GNAS exon A/B, which reduces expres-
sion of the stimulatory G protein α-subunit (Gsα) from the maternal allele. In the proximal 
renal tubules, the paternal GNAS allele does not contribute significantly to expression of this 
signaling protein. Thus LOM at the maternal exon A/B leads to little or no Gsα thereby caus-
ing PTH-resistance in that portion of the kidney. We now describe a PHP1B patient with a de 
novo genomic GNAS duplication of approximately 88-kb, which is associated with LOM 
restricted to exon A/B. Multiplex ligation-dependent probe amplification (MLPA), compar-
ative genomic hybridization (CGH) and whole genome sequencing (WGS) established that 
the added DNA fragment extends from GNAS exon AS1 (telomeric breakpoint) to a small 
region between two imperfect repeats just up-stream of LOC105372695 (centromeric break-
point). Our novel duplication is considerably shorter than previously described duplications/
triplications in that portion of chromosome 20q13 and it does not affect methylation at exons 
AS and XL. Based on these and previous findings, it appears plausible that the identified ge-
nomic abnormality disrupts in cis the actions of a transcript that is required for establishing 
or maintaining exon A/B methylation. Our findings extend the molecular causes of PHP1B 
and provide additional insights into the structural GNAS features that are required for main-
taining maternal Gsα expression and for preventing PTH-resistance.
Disclosures: Monica Reyes, None
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An overview of the etiology, clinical manifestations, management strategies 
and complications of hypoparathyroidism from the Canadian National 
Hypoparathyroidism Registry *Hajar Abu Alrob1, Sharjil Hussain 2, Mihai 
Romanovschi2, Rafik El Werfalli2, Hisham Al Kassem1, Manoela Braga1, 
Tayyab S Khan 3, Adam Miller4, Zubin Punthakee1, J.E.M Young1, Muhammad 
Shrayyef1, Aliya Khan1. 1McMaster University, Canada, 2Bone Research and 
Education Centre, Canada, 3Western University, Canada, 4University of Toronto, 
Canada
Objective(s):The Canadian National Hypoparathyroidism Registry was formed in 2014, 
with an aim to• identify the etiology and presenting symptoms of patients with hypoPTH.• 
evaluate current treatment practice in Canada.• assess differences in presentation based on 
etiology of the disease.• compare parameters of calcium homeostasis amongst those devel-
opingcomplications of nephrolithiasis or nephrocalcinosis versus those withoutcomplica-
tions.• assess fracture risk and microstructure in Canadian patients with hypoPTH.Material 
and Methods:• Prospective observational registry of 130 patients >18 years of age. • The 
inclusion criteria:1. Chronic HypoPTH (low PTH in the presence of low serum calcium [to-
tal or ionized] for at least 6 months prior to enrolment)2. HypoPTH (including post-surgery) 
requiring calcium/calcitriol replacement to maintain normal calcium (total or ionized) level 
for at least 6 months prior to enrolment3. Pseudohypoparathyroidism with elevated PTH and 
low serum calcium (total or ionized), normal vitamin D and hyperphosphatemia•Exclusion 
criteria:1. Transient hypoPTH which resolved within <6 months of treatment.•We reviewed 
etiology, initial clinical presentation, laboratory investigations, management strategies, 
markers of skeletal health including fractures, bone mineral density (BMD), and compli-
cations including nephrolithiasis/nephrocalcinosis, and basal ganglia calcification. Fracture 
risk was determined using the Canadian Association of Radiologists and Osteoporosis Can-
ada (CAROC) toolResults: 70% (91/130) of patients had postsurgical hypoparathyroidism, 
25% had idiopathic/autoimmune disease (31/130) and 3% had pseudohypoparathyroidism 
(4/130). The mean age of onset was 41.8 years. All patients were on calcium supplements, 
85% were on calcitriol (N=111), 30 patients were on PTH(1-34) and 3 patients were on 
PTH(1-84). Nephrocalcinosis or nephrolithiasis was observed in 27% (n=14/52) of patients 
with postsurgical disease and 17% (n=4/24) of patients with nonsurgical hypoparathyroid-
ism. Among patients with postsurgical hypoparathyroidism, 15% (n=5/34) has basal ganglia 
calcification and among patients with nonsurgical hypoparathyroidism, 37% (n=7/19) had 
basal ganglia calcification. Approximately 44 patients (34.0%) required hospitalization at 
initial presentation. Patients with idiopathic/autoimmune disease were twice as likely to be 
hospitalized compared to those with postsurgical disease. Conclusion:1. HypoPTH is asso-
ciated with a significant disease burden and leads to hospitalizationin a large number of pa-
tients.2. Renal complications of nephrocalcinosis and nephrolithiasis were present in 22.1% 
of treated patients and were more commonly seen in those with hypercalciuria.3. Fracture 
risk was low in the absence of traditional osteoporosis risk factors among these patients.
Disclosures: Hajar Abu Alrob, None
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Bone Marrow Fat in Women with Post-Surgical Hypoparathyroidism 
*Davide Diacinti1, Cristiana Cipriani2, Antonio Iannacone3, Endi Kripa3, 
Martina Orlandi4, Jessica Pepe5, Luciano Colangelo5, Valentina Piazzolla5, 
Daniele Diacinti4, Salvatore Minisola5. 1Department of Oral and MaxilloFacial 
Sciences, Umberto I Hospital, University Sapienza, Rome, Italy; Department of 
Diagnostic and Molecular Imaging, Radiology and Radiotherapy, University Tor 
Vergata, Rome, Italy, Italy, 2Department of Clinical, Internal, Anesthesiological 
and Cardiovascular Sciences, “Sapienza” Rome University, Rome, Italy, Italy, 
3Department of Radiological Sciences, Oncology and Anatomo-Pathology, 
University Sapienza, Rome, Italy, Italy, 4Department of Radiological Sciences, 
Oncology and Anatomo-Pathology, University Sapienza, Rome, Italy., Italy, 
5Department of Clinical, Internal, Anesthesiological and Cardiovascular 
Sciences, “Sapienza” Rome University, Rome, Italy., Italy
Introduction:Hypoparathyroidism (HypoPT) is characterized by reduced bone remod-
eling with average normal or high normal values of bone mineral density (BMD).There are 
instead no definitive data on prevalence of fragility vertebral fractures in HypoPTpatients or 
on possible risk factors.Among its several actions on bone metabolism, parathyroid hormone 
(PTH)stimulates commitment of bone marrow mesenchimal stem cells to osteoblasts, thus 
suppressing adipogenesis. An increased adipogenesis may therefore be hypothesized in Hy-
poPT.Purpose: To assess lumbar spine Bone Marrow Fat (BMF) content in post-menopausal 
women with chronic post-surgical HypoPT using Magnetic Resonance Spectroscopy and 
evaluate how it could be related to vertebral fragility.Materials and methods: We studied 29 
post-menopausal women with post-surgical HypoPT (mean age 66 +/- 6.8 SD years) and 20 
healthy age-matched women. In all subjects we assessed: lumbar spine (L1-L4),femoral neck 
(FN) and total hip (TH) BMD by dual X-ray absorptiometry (Hologic QDR 4500A, USA); 
Trabecular Bone Score (TBS) on the L1-L4 images by the TBS-iNsight software; Vertebral 
Fracture Assessment (VFA) by iDXA (Lunar, GE, USA).BMF was measured by 3 Tesla 
L1-L5 MRI with application of the PRESS spectroscopy sequences on L3 vertebral body.
Results:HypoPT subjects had significantly higher mean BMD values than controls (1.044 vs 
0.956 g/cm²; p <0.01), andlower TBS values (1.218 vs 1.273; p <0.01). Vertebral fractures 
by VFA were observedin 6/29 (20%) of HypoPTvs 2/20 (10%) of healthy subjects.Mean 
BMF values were significantly higher in HypoPT compared to healthy subjects: 79% vs 60% 
(p<0.05). The percentage of unsaturated, residual and saturated BMF in the HypoPTgroup 
were: 5%, 6% and 68%; in healthy subjects: 9%, 3%, 48%, respectively. We observed sta-
tistically significant negative correlationsbetween BMF values and both BMD  (R=0.517; p 
<0.03) and TBS (R=0.767; p <0.03)in the HypoPT group.When only patients with vertebral 
fractures were compared, BMF was higher in HypoPT than in healthy subjects (62% vs 
78%; p<0.05).Conclusion:BMFassessed by Magnetic Resonance Spectroscopy at the lum-
bar spine is increased in postmenopausal women with chronic post-surgicalHypoPT and is 
associated with increased prevalence of fragility fractures at this level.Hence, adipogenesis 
may be stimulated in the trabecular bone in the absence of PTH and associated with skeletal 
fragility.Keywords: Bone Marrow Fat; Hypoparathyroidism;MRI 
Disclosures: Davide Diacinti, None
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Cpne7 Contributes to the Maintenance of Odontoblast Viability Under 
Stress Condition *Song Yi Roh1, Joo-Cheol Park1. 1Seoul National University, 
Republic of Korea
Precise regulation of epithelial-mesenchymal interaction (EMI) is critical during den-
tinogenesis. Cpne7, a member of calcium dependent phospholipid-binding copine family, 
was previously identified in the preameloblast conditioned medium (PA-CM). Cpne7 is 
believed to be secreted from dental epithelium and induce the differentiation of ectomesen-
chymal cells into preodontoblast and eventually into mature odontoblasts with odontoblast 
processes. Although the precise function of Cpne7 and detailed mechanisms regarding its 
role remain to be elucidated, accumulating evidence suggests Cpne7 as a key molecule that 
contributes to the formation of tubular tertiary dentin. Preliminary study showed that wild 
type mice formed reactionary dentin when dentin was slightly exposed with a high speed 
hand piece. On the other hand, Cpne7 deficient mice formed reparative dentin, in which 
odontoblast processes were absent and cell bodies were entrapped within bone-like dentin 
matrix. When recombinant CPNE7 protein was treated on the exposed dentin of Cpne7 KO 
mice, reactionary dentin was formed just as in WT mice. The goal of this study is to inves-
tigate the detailed mechanism of how Cpne7 contributes to the maintenance of odontoblast 
viability and reactionary dentin formation under stress condition. One hypothesis is that 
Cpne7 deficient cells are more vulnerable to stress therefore more likely to undergo apop-
tosis and die even under mild stress, and reparative dentin is formed as a result. The other 
hypothesis is that cpne7 deficiency disturbed odontoblast differentiation, leading to the loss 
of cell integrity and eventually, cell death. To test these hypothesis, the expression of the 
apoptosis related molecules was examined by western blotting, IF, IHC, and qPCR. Cpne7 
knockdown upregulated the protein expression of p53 and pro-apoptotic factors, including 
BAX and BID in MDPC-23 cells. Anti-apoptotic factors such as Bcl-2 and Mcl-1, however, 
were upregulated as well. Bcl-2/Bax ratio did not show any significance. These results indi-
cate that Cpne7 deficiency altered the expression of apoptotic factors but was insufficient to 
154
P-339 ASBMR 2020 Annual Meeting
cause cell death when no stress was applied. Further study is needed to examine the effects 
of Cpne7 in odontoblast differentiation and viability under stress.
Disclosures: Song Yi Roh, None
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NaQuinate, a Vitamin K Catabolite, is Found in Blood after Oral Vitamin 
K1 Administration and Reduces Osteoclast Activity Without Effecting 
Osteoclast Number in Culture *Isabel Orriss1, Elizaveta Igumnova2, Lars 
Ytrebo2, Andrew Pitsillides1, Ole-Martin Fuskevaag2, Stephen Hodges1. 1Royal 
Veterinary College, United Kingdom, 2Tromso University Hospital, Norway
Background: High dose vitamin K is used as a clinical therapeutic for osteoporosis. 
Much of the development for this was predicated on gamma-carboxylation of vitamin K-de-
pendent bone proteins. We contended that the doses that are used are substantially more 
than required for complete gamma-carboxylation of these proteins and that the active agent 
for any skeletal benefits may be derived from a minor catabolite of vitamin K, a 7-carbon, 
branched-chain carboxylic acid derivative, NaQuinate. However, the presence of NaQuinate 
in blood after ingestion of vitamin K has not previously been measured. In vivo bone forma-
tion effect of NaQuinate has been found, but the effects of NaQuinate on osteoclasts has not 
been demonstrated.Methods 1: In a preliminary experiment, blood was collected into EDTA 
vacutainers over 8h from a single volunteer under clinical supervision after taking a single 
dose of 20mg vitamin K1 in 100mL milk under local North Norway ethics (Ref: 2015/1378/
REK nord). NaQuinate was measured in whole blood (200uL) and plasma (200uL) by LC-
MS/MS methods using C13 NaQuinate stable isotope as an internal standard.Methods 2: 
Primary osteoclasts were isolated from the bone marrow of C57BL-6 mice and cultured 
on dentine discs for up to 9 days in the presence of 150ng/ml M-CSF, 3ng/ml RANKL and 
NaQuinate (1nM-10mM).  Osteoclast formation and bone resorption were assessed by bright 
field and reflective light microscopy, respectively.Results: High dose vitamin K ingestion 
releases NaQuinate into blood and appears to partition into the cell fraction before appear-
ing in plasma.The generation of osteoclasts by MCSF and RANKL on a dentine matrix is 
unchallenged by NaQuinate. In repeat experiments NaQuinate reduces total resorption and 
resorption per osteoclast by <=45% (P<0.05).  Cultures exposed at initiation show the great-
est effects, although it is interesting that replacing NaQuinate early, after 3days with fresh 
media, or introducing NaQuinate later (day 7) result in the inhibition of osteoclast activity.
Conclusion: NaQuinate, as the free acid, is generated from a single high dose vitamin K, 
suggesting it would be available to bone. In whole blood its presence is seen earlier and 
may suggest that there may be a specific cell transporter for NaQuinate. Cultured osteoclasts 
respond to NaQuinate through reduced activity, while cell number remains unchanged. The 
observation of early cell exposure at different times implies that the cells have memory of 
exposure. 
Disclosures: Isabel Orriss, Haoma Medica Ltd, Grant/Research Support
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Investigations to Identify Regulators of Phosphate Sensing *Lauren Surface1, 
Chang Liu1, Michael Mannstadt1. 1Endocrine Unit, Massachusetts General 
Hospital, Harvard Medical School, United States
Organismal phosphate (Pi) homeostasis is tightly controlled to maintain a consistent 
serum Pi level, disruption of which can have major consequences for the body. One of the 
primary regulators of this homeostasis is FGF23, a protein released by bone cells in response 
to changing serum Pi levels. How these cells are sensing these changes in Pi remains an out-
standing question in endocrinology. Using cell-based approaches, we seek to identify factors 
in osteogenic cells responsible for sensing and responding to changes in extracellular Pi con-
centration. We initially temporally profiled the transcriptional response of MC3T3-E1 and 
OCY454 cells to increases in extracellular Pi using RNA-seq and qRT-PCR following expo-
sure to high Pi media for 30 minutes, 6hr, 24hr, and 48hr, and detected clear transcriptional 
response signatures. We observed an initial induction of immediate early response genes 
within 30 min, including Egr1, Fos, and Ier2. This was followed by a late phase response at 
24-48 hours that included increased expression of EGF and MAPK signaling components 
(including Areg, Ereg and Dusp6, Spry4), as well as osteogenic genes, such as Dmp1, Spp1, 
and Enpp1. We find that the late phase response requires consistent exposure to elevated Pi, 
as a 3 hour pulse of elevated Pi followed by incubation in normal Pi media failed to induce 
expression of these genes. Consistent with previous publications, inhibition of MEK/ERK 
signaling using the small molecule U0126 was sufficient to block the early transcriptional 
response to Pi and blunt the late phase response. Using these findings, we have developed 
a fluorescent reporter system for the cellular response to increases in Pi. With this reporter, 
we are utilizing genome-wide screens to find genes that impact the sensing and response of 
osteogenic cells to changes to extracellular phosphate.
Disclosures: Lauren Surface, None
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Increased Expression of Dentin Matrix Proteins and Connexin43 is 
Associated to Reactionary Dentin Formation in Fluoride Exposed Rats 
*Pablo A. Fontanetti1, Victoria Interlandi1, Rubén H Ponce2, Raquel Gallara1, 
Viviana Centeno2. 1Universidad Nacional de Córdoba. Facultad de Odontología. 
Departamento de Biología Bucal., Argentina, 2Universidad Nacional de Córdoba. 
Facultad de Odontología. Departamento de Biología Bucal, Argentina
Excessive fluoride (F-) intake may increase the body burden of the ion and induce 
acute and chronic F- toxicity, osteo-dental fluorosis. Connexin 43, (Cx43), the most abun-
dant member of the connexin family in the dental pulp complex, controls cellular growth 
and differentiation; however, its function in dental pulp tissue in response to F- exposure 
has not been fully investigated. Previously, we showed that chronic intake of water with 
micro-molar concentrations of F- increased Cx43 and Hsp25 (Heat shock protein 25) ex-
pression in dental pulp and this effect appears to be associated with the secretory status of 
incisor odontoblasts. We evaluated if the expression of Cx43 and dentin matrix molecules 
is associated with the reactionary dentine formation in response to chronic exposure to a 
high dose of F- in rat incisors. Twelve male Wistar rats drank water with different F- con-
centrations in form of NaF during 8 weeks: a) control (n=6), 0.3 mg/L F- and b) F- exposed 
(n=6), 22 mg/L F- (50 mg/L NaF). The jaws were resected for histological processing and 
to obtain incisor pulp tissue. Cx43 protein expression was analyzed on buccolingual serial 
sections using immunohistochemistry. Number of odontoblasts/µm and nucleus/cytoplasm 
ratio were analyzed on digital photomicrographs. Total RNA was extracted from pulp tissue, 
and gene expression of Cx43, osteocalcin (OCN) and dentin sialophosphoprotein (DSPP) 
was analyzed by RT-PCR. Data were analyzed by Student t test, setting a p-value <0.05 
for significant differences. Immunoreactivity of Cx43 was higher in odontoblasts from F- 
exposed animals than in those from controls. The dose of 22 mg/L of F- did not alter the 
number of odontoblast/µm neither the predentin width. However, it increased odontoblast 
differentiation, which was evidenced by the decrease in nucleus/cytoplasm ratio (NaF: 0.150 
+/- 0.003 vs. Control: 0.177 +/- 0.007; p<0.05). The animals in F- exposed group showed 
histomorphological alterations in lower incisor dentin, as well as a significant increase in 
OCN and DSPP expression as compared to controls. In summary, these data show that high 
levels of F- in drinking water produce an alteration in dentin mineralization pattern. The 
molecular mechanism triggered by F- seems to involve events to promote an increase in the 
rate of extracellular matrix secretion resulting in the formation of reactionary dentin. These 
events apparently are associated with the status of odontoblast differentiation.
Disclosures: Pablo A. Fontanetti, None
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Abaloparatide, A Novel Selective Agonist of PTH/PTHrP Receptor, 
Increases Lumbar, Total Hip and Femoral Neck BMD in Japanese Patients 
with Osteoporosis -A Phase III Randomized Clinical Trial (ACTIVE-J)- 
*Toshio Matsumoto1, Teruki Sone2, Satoshi Soen3, Toshitsugu Sugimoto4, Sakae 
Tanaka5, Maki Mihoya6, Tetsuo Inoue7. 1Fujii Memorial Institute of Medical 
Science, Tokushima University, Japan, 2Department of Nuclear Medicine, 
Kawasaki Medical School, Japan, 3Soen Orthopaedic Clinic, Japan, 4Eikokai 
Ono Hospital, Japan, 5Department of Orthopedic Surgery, the University of 
Tokyo, Japan, 6Clinical Development Administration Department, Teijin Pharma 
Limited, Japan, 7Aoyama General Hospital, Japan
Background and Objectives: Abaloparatide (ABL) is a selective PTH/PTHrP receptor 
agonist that significantly increased lumbar and hip bone mineral density (BMD) and reduced 
new osteoporotic fractures in the multinational phase 3 ACTIVE trial. The objective of this 
randomized, double-blind, placebo-controlled, multicenter trial in Japan (ACTIVE-J) was 
to evaluate the efficacy and safety of ABL treatment for 18 months in Japanese patients 
with osteoporosis. Methods: Patients aged 55 or older with lumbar spine (LS) BMD less 
than T-score -1.77 and one or more vertebral fractures, BMD T-score less than -3.0 without 
fractures, or aged 65 years or older with BMD less than T-score -2.5 were randomly assigned 
to receive daily subcutaneous injection of 80 µg ABL or placebo (PBO) in a 2:1 ratio. The 
primary endpoint was percent change from baseline in LS BMD. The secondary endpoints 
included percent changes in total hip (TH) and femoral neck (FN) BMD, changes in bone 
turnover markers (BTM) and new vertebral and non-vertebral fractures. Results: After 18 
months, LS BMD increased 16.33% in ABL group [postmenopausal women (PMO) 122, 
male 14], and 3.78% in PBO group [PMO 64, male 6] (p<0.001). TH and FN BMD in-
creased by 4.66% and 5.13%, respectively, in ABL group, and 0.45 and 0.91%, respectively 
in PBO group (p<0.001). In male patients, ABL treatment resulted in similar increases in 
LS, TH and FN BMD as observed in the PMO patients.  With ABL, serum PINP rapidly in-
creased by over 200%, gradually decreased after 6 months and remained above PBO through 
18 months.  Serum CTX increased by over 130% at 6 months then decreased and was not 
different from PBO after 15 months. The incidence of new vertebral fractures was 4.3% in 
PBO group, but none in ABL group. New non-vertebral fractures occurred in 2.2% of ABL 
and 2.9% of PBO groups. During the 18 months of treatment, the safety profile was similar 
to that observed in the ACTIVE trial. Discussion and Conclusion: In Japanese patients with 
osteoporosis, ABL treatment robustly increased LS, TH and FN BMD and rapidly and mark-
edly increased PINP with a gradual and less prominent increase in CTX, with a good safety 
profile.  Although there is a limit for assessing the reduction in non-vertebral fracture due 
to the small number of patients, separate analyses on hip structure (HSA) and QCT demon-
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strated improvements in bone geometry and microstructure, suggesting that bone strength 
was also improved by ABL.
Disclosures: Toshio Matsumoto, Astellas, Consultant, Amgen, Consultant, Daiichi-
Sankyo, Consultant, Chugai, Speakers’ Bureau, Daiichi-Sankyo, Speakers’ Bureau, Amgen, 
Speakers’ Bureau, Asahi-Kasei Pharma, Consultant, Astellas, Speakers’ Bureau, Teijin 
Pharma, Consultant, Chugai, Consultant
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Fibroblast growth factor-23 and bone microarchitecture in ovariectomized 
rats with induced hyperthyroidism *Keunyoung Kim1, In-Joo Kim1, 
Kyoungjune Pak1, Yun Kyung Jeon1, Seong-Jang Kim1. 1Pusan National 
University Hospital, Republic of Korea
Purpose: We evaluated the effect of a thyroid stimulating hormone (TSH)-suppressive 
dose of levothyroxine (LT4) on bone mass and bone metabolism in ovariectomized (OVX) 
rats. Materials and Methods: Bilateral OVX and sham operations (Sham) were performed 
in female Sprague-Dawley virgin rats at 7 weeks of age. Rats were divided into four ex-
perimental groups as follows: 1) Sham (n=6), 2) Sham+LT4 (n=6), 3) OVX (n=8), and 
4) OVX+LT4 (n=8). After 6 weeks of treatment, the areal bone mineral density (aBMD) 
and volumetric BMD (vBMD) of the second lumbar spine were measured ex vivo using 
high-resolution DXA and μCT. Bone microarchitecture and histomorphologic analyses were 
also performed. Serum TSH, free thyroxine, fibroblast growth factor (FGF)-23, calcium, 
phosphate, osteocalcin, collagen Type-1 C-Telopeptide (CTX), and intact parathyroid hor-
mone (iPTH) levels were compared among the four experimental groups. The proinflam-
matory cytokines including interleukin (IL)-6, IL-10, IL-17, monocyte chemoattractant 
protein (MCP) -1 and tumor necrosis factor-α were compared. Spearman rank correlation 
was used to analyze the relationships between BMD, bone microarchitecture, and serum 
components, including FGF-23. Results: Significant microarchitecture deterioration in the 
OVX+LT4 group was found in the trabecular thickness. The OVX+LT4 group had solely 
elevated levels of FGF-23, osteocalcin and iPTH compared with other groups. There was no 
significant difference in phosphate as well as reduced calcium levels. The serum levels of 
IL-6 and IL-10 was increased in OVX rats, regardless of LT4 treatment. The rats with OVX-
+LT4 showed increased levels of IL-17 and MCP-1 among the evaluated proinflammatory 
cytokines compared with other rats. FGF-23 was positively correlated with parameters of 
microarchitectures, aBMD, vBMD, phosphate and IL-6 in OVX+LT4 group. Conclusion: 
This study affirmed that OVX+LT4 treatment was the significant contributor to the deteriora-
tion of bone microarchitecture and suggests that the serum levels of FGF-23 are significantly 
correlated with both bone loss and IL-6.
Disclosures: Keunyoung Kim, None
P-344
THE LEVELS OF VITAMIN D IN THE SPONDYLARTHRITIS. DOES 
THE DEFICIT CORRESPOND TO THE INFLAMMATORY ACTIVITY? 
*David Castro Corredor1. 1General University Hospital of Ciudad Real, Spain
Background: Spondyloarthritis is a group of chronic inflammatory diseases with in-
volvement of the axial skeleton (mainly), and also of peripheral joints. Patients with spon-
dyloarthritis have a significant prevalence of vitamin D levels below normal and that would 
correlate with the degree of activity of the disease.Objectives: To determine the association 
between vitamin D deficiency and the degree of activity of the disease (inflammatory ac-
tivity) in a cohort of patients with spondyloarthritis.Methods: Case-control type analytical 
observational study. We propose a retrospective review of the database of patients with 
spondyloarthritis (according ASAS2010 criteria) who were treated in the outpatient clinics 
of the Rheumatology Service of the General University Hospital of Ciudad Real during 
June 2018 to June 2019. Patients with the data will be selected. necessary for the analysis 
of the variables under study. The numerical variables of normal distribution evaluated will 
be described using measures of frequency and measures of central tendency / dispersion as 
appropriate. To assess the association between vitamin D levels and activity index, the odds 
ratio (OR) is calculated, with a 95% confidence level and the T-student for related samples.
Results: The final results of the study are presented. 115 patients were analyzed, of which 
64 were men and 51 women, with an average age of 45.97 years (+/- 13.41 DE). 47% were 
ankylosing spondylitis, 21% psoriatic arthropathy, 16% undifferentiated spondyloarthritis, 
7% spondyloarthropathy associated with inflammatory bowel disease and 9% were spon-
dyloarthropathy associated with inflammatory bowel disease. The average of the activity 
was a BASDAI of 4.57 (+/- 2.35 SD) and measured by DAPSA was 12.61 (+/- 6.76 SD). 
63 and 14 patients had activity measured by BASDAI and DAPSA, respectively. 49.56% 
patients presented an elevation of acute phase reactants. Vitamin D levels were 23.81 (+/- 
10.5 SD). 77.4% presented figures of vitamin D deficiency or insufficiency. When perform-
ing the association analysis, the vitamin D deficit / insufficiency presented an OR 10 (95% 
CI: 3.66-27.29, p=<0.0001) with the degree of activity measured with BASDAI and DAPSA 
and against the elevation of RCP it was 3.63 (95% CI 1.43-9.25, p = 0.0092) and against 
the elevation of ESR it was 2.76 (95% CI 1.09-7, 0, p = 0.0438). Regarding the compara-
tive analysis of means between vitamin D deficiency/insufficiency and BASDAI/DAPSA it 
was +3.29 (95% CI: 1.34-8.09, p=0.0084).Conclusion: Patients with spondyloarthritis, as in 
other autoimmune diseases, vitamin D deficiency is associated with increased inflammatory 
activity (BASDAI, DAPSA, RCP and ESR), measured in different time periods. Therefore, 
an optimization of vitamin D levels can imply an improvement in the patient’s clinical situa-
tion, measured by both BASDAI and DAPSA, as well as by RCP and ESR.
Disclosures: David Castro Corredor, None
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Regular Strength and Sprint Training Counteracts Bone Aging: a 10-
year Follow-up in Male Masters Athletes *Tuuli Suominen1, Markku Alén2, 
Ari Heinonen3, Hans Degens4, Jörn Rittweger5, Timo Törmäkangas1, Harri 
Suominen3, Marko Korhonen1. 1Gerontology Research Center, Faculty of Sport 
and Health Sciences, University of Jyväskylä, Finland, 2Department of Medical 
Rehabilitation, Oulu University Hospital and Center for Life Course Health 
Research, University of Oulu, Finland, 3Faculty of Sport and Health Sciences, 
University of Jyväskylä, Finland, 4Musculoskeletal Science and Sports Medicine 
Research Centre, Department of Life Sciences, Manchester Metropolitan 
University, United Kingdom, 5Institute of Aerospace Medicine, German 
Aerospace Center, Germany
According to cross-sectional and interventional studies, high-intensity strength and 
impact-type training provide a powerful osteogenic stimulus even in old age. Longitudinal 
evidence on the ability of high-intensity training to attenuate age-related bone deterioration 
is currently lacking, however. This follow-up study assessed the role of continued strength 
and sprint training on bone aging in 40- to 85-year-old male sprinters (n=69) with long-term 
training background. pQCT-derived bone structural, strength and densitometric parameters 
of the distal tibia (5% distal-proximal tibia length) and tibial midshaft (50% length) were as-
sessed at baseline and after 10 years. The groups of well-trained (actively competing, sprint 
training including strength training >=2 times/wk; n=36) and less-trained (<2 times/wk, 
no strength training, switched to endurance training; n=33) athletes were defined based on 
the self-reports at follow-up. The association of continued strength and sprint training with 
longitudinal changes in bone traits was assessed using an interaction term (group*time) in 
linear mixed models. Over the 10-year period, the mid-tibia showed a significant group*time 
interaction in cortical cross-sectional area, cortical thickness, total BMC, and BMC at the an-
terior and the posterior sites (polar mass distribution analysis) (p<0.05, raw values). At distal 
tibia, there was a significant interaction in total BMC, trabecular vBMD and compressive 
strength index (p<0.05, raw values). After adjustment for multiple comparisons, mid-tibia 
posterior BMC and distal tibia trabecular vBMD remained significant (p<0.05). Overall, 
the mean differences in changes in the bone traits in well-trained compared to less-trained 
ranged from 2 to 6%. These were reflected as improved (mid-tibia) or maintained (distal 
tibia) bone properties in well-trained and decreased in less-trained athletes over the 10-year 
period. The structural improvements at mid-tibia tended to be more pronounced among older 
(65-85-yr) well-trained, whereas the densitometric properties were best preserved among 
younger (40-64-yr) well-trained. In conclusion, our longitudinal findings indicate that con-
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tinued strength and sprint training is associated with maintained or even improved tibial 
properties in middle-aged and older male sprint athletes, suggesting that regular, intensive 
exercise counteracts bone aging.
Disclosures: Tuuli Suominen, None
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Colchicine improves muscle function, enhances bone formation, and reduces 
white adipose tissue in aged mice but not young mice. *Jenna Leser1, Nicole 
Gould1, Gouli Shi1, Nathalie Spita2, Makenzy Mull1, Ryan Riddle2, Christopher 
Ward1, Joseph Stains1. 1University of Maryland Baltimore, United States, 2Johns 
Hopkins School of Medicine, United States
The cycle of frailty is a feed forward mechanism during aging in which mechano-re-
sponsive tissues, bone and skeletal muscle, acquire a diminished capacity to respond to 
mechanical stimuli, becoming osteopenic and sarcopenic respectively, leading to reduced 
strength, mobility, and physical activity. Optimally, osteopenia and sarcopenia need to be ad-
dressed simultaneously to restore musculoskeletal deficits in the elderly. We have described 
parallel mechano-transduction pathways with shared components in responsive, young adult 
mouse bone and muscle. Mechano-sensitivity in this pathway is tuned by cytoskeletal stiff-
ness, specifically detyrosinated microtubules. With advancing age, we observed increased 
abundance of detyrosinated microtubule in muscle and bone, consistent with an attenuated 
mechano-response, pinpointing a potential therapeutic target to treat both tissues concur-
rently. Not only does this pathway affect muscle and bone, the mechano-responsive bone 
derived protein, sclerostin, increases white adipose tissue (WAT) accumulation in addition 
to inhibiting bone formation. We hypothesized increased detyrosinated microtubules con-
tribute to age dependent defects in muscle function and bone mechano-responsiveness, lead-
ing to sarcopenia and osteopenia, and accumulation of WAT. We treated 16-week (young) 
and 78-week (aged) C57BL/6 male mice with colchicine (a microtubule destabilizing drug) 
1mg/L in drinking water for 8 weeks, anticipating that targeting microtubules might restore 
mechano-transduction to increase bone formation, improve muscle function, and reduce 
WAT accumulation in aged mice. Consistent with our hypothesis, colchicine treated aged 
mice showed significantly increased bone formation on the cortical surface (300% increase, 
p=0.0496) and decreased bone derived sclerostin. Additionally, these mice exhibited im-
proved in vivo muscle contraction velocity (40% increase, p=0.0106) and power (20% in-
crease, p=0.0058). Finally, colchicine treated aged mice lost body mass (p=0.0146), showed 
reduced WAT mass (50% reduction of inguinal fat, p=0.0199, 60% reduction of gonadal 
fat, p=0.0038) and adipocyte size (30% reduction, p<0.0001). In contrast, young colchicine 
treated mice, which do not have an over-abundance of detyrosinated microtubules, had no 
significant effects on bone, muscle or WAT. These data show that targeting the aging micro-
tubule network restores mechano-responsiveness to improve aging dependent sarcopenia, 
osteopenia and diminish WAT.
Disclosures: Jenna Leser, None
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A natural small molecule targeting miR487b-Wnt5a interaction to promote 
myogenic potential in vitro *Zhenjian Zhuo1, Youyan Wan2, Shuaijian Ni2, 
Zongkang Zhang2, Ning Zhang1, Yuanyuan Yu2, Aiping Lu2, Ge Zhang2, Bao-
Ting Zhang1. 1The Chinese University of Hong Kong, Hong Kong, 2Hong Kong 
Baptist University, Hong Kong
A natural small molecule targeting miR487b-Wnt5a interaction to promote myogen-
ic potential in vitro Zhenjian Zhuo1,4, Zong-Kang Zhang1, Youyang Wan2,3,4, Shuaijian 
Ni2,3,4, Ning Zhang1, Ge Zhang2,3 & Bao-Ting Zhang11School of Chinese Medicine, Fac-
ulty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China,2Law 
Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School 
of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China,3Institute of 
Integrated Bioinformedicine and Translational Science, School of Chinese Medicine, Hong 
Kong Baptist University, Hong Kong SAR, China,4Aptacure Therapeutics Limited, Kow-
loon, Hong Kong SAR, China Sarcopenia, age-related loss of skeletal muscle mass and 
strength, is associated with serious health consequences. However, there is no clinically 
established therapy for sarcopenia to date. MicroRNAs (miRNAs) play key roles in a series 
of pathological processes by interacting with their specific target mRNAs for translation 
repression. We previously reported that miR487b, which elevated during aging and inhibited 
the expression of an important myogenic regulator Wnt5a, thereby contributed to sarcopenia 
development during aging. Mir487b could be a potential therapeutic target for sarcopenia. 
Using our recently developed virtual screening model targeting Argonaute (AGO)-medi-
ated miRNA-mRNA interactions (Zhuo et al. 2020), 10 natural small molecules (MA-1 to 
MA-10) specifically targeting miR487b-Wnt5a mRNA interaction were selected (F-1). The 
binding between the four candidates (MA-1 to MA-4) and synthesized miR487b-Wnt5a 
loop was confirmed, respectively, by streptavidin pull down assay and liquid chromatogra-
phy-mass spectrometry (LC-MS) (F-2a). AgomiR487b (a miR487b agonist) treatment could 
suppress Wnt5a expression and inhibit cell differentiation in C2C12 cells. Among the above 
four small molecule candidates, MA-4 elevated Wnt5a protein level (F-2b), but not Wnt5a 
mRNA level (F-2c) in agomiR487b-treated C2C12 cells. Moreover, MA-4 elevated the ex-
pression of myogenic marker (MyoD) (F-2d) and enhanced myotube formation (F-2e,f) in 
agomiR487b-treated C2C12 cells. To further validate the interaction between MA-4 and 
miR487b-Wnt5a loop, the interaction site in miR487b-Wnt5a loop were mutated. MA-4 
could only bind with wild-type miR487b-Wnt5a loop, instead of mutated miR487b-Wnt5a 
loop in vitro (F-3a). In addition, the MA-4-incubation-induced enhancement in the Wn-
t5a protein, MyoD, and myotube formation in agomiR487b-treated C2C12 cells could be 
abolished by wild-type miR487b-Wnt5a loop, whereas no significant change was found in 
mutated miR487b-Wnt5a loop transfection group (F-3b-f). Taken together, MA-4 could be a 
potential agent to block miR487b-Wnt5a interaction to promote myogenic potential in vitro 
(F-4). The current study could provide a novel natural small molecule drug candidate to pro-
mote myogenic potential. Acknowledgments: This study was supported by the Innovation & 
Technology Fund (UIM/328) and General Research Fund (14108816 and 14100218). Refer-
ence: Z Zhuo et al. A Loop based and AGO incorporated Virtual Screening Model Targeting 
AGO mediated miRNA-mRNA Interactions for Drug Discovery to Rescue Bone Phenotype 
in Genetically Modified Mice. Adv. Sci., 2020. DOI: 10.1002/advs.201903451.
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Musculoskeletal and cardiac defects in the Presenilin-1 (PSEN1) L166P 
KI mouse model of Alzheimer Disease. *Vidyani Suryadevara1, Amy Sato2, 
Anuradha Valiya Kambrath1, Teresita Bellido2, Monte Willis3. 1Indiana Center 
for Musculoskeletal Health, Department of Pathology & Laboratory Medicine, 
Indiana University School of Medicine, Indianapolis, IN 46202, United States, 
2Department of Anatomy Cell Biology and Physiology, Indiana University 
School of Medicine, Indianapolis, IN 46202, United States, 3Indiana Center 
for Musculoskeletal Health, Department of Pathology & Laboratory Medicine, 
Krannert Cardiology Institute, Department of Internal Medicine, Indiana 
University School of Medicine, Indianapolis, IN 46202, United States
Alzheimer Disease (AD) is the 6th leading cause of death in the US and a leading 
cause of disability and poor health. Beyond memory deficits, the systemic nature of AD 
has emerged with patients demonstrating significantly more skeletal muscle weakness, bone 
loss, and heart failure compared to age-matched controls without AD. There is currently an 
unmet need for translational models that exhibit clinically relevant muscle defects and the 
hallmark neurological characteristics of AD. We investigated skeletal and cardiac muscle 
dysfunction in a mouse knock-in model with a mutation in PSEN1 known to cause ear-
ly-onset AD in humans (PSEN1 L166P) at ages that Abeta accumulates intracellularly in 
the mouse brain (>6 mos). Skeletal and cardiac muscle function was assessed by in vivo 
DXA, plantarflexion torque, and echocardiography, respectively, in PSEN1 KI and strain-, 
sex-, and age-matched wildtype (WT) mice at 12 months of age (N=16-18). DXA analy-
sis identified a reduction in whole-body bone mineral density (BMD) in female, but not 
male, PSEN KI mice (0.0482+/-0.002, p<0.05) compared to WT control mice (0.05+/-0.001, 
p<0.05). PSEN1 KI mice demonstrated skeletal muscle weakness compared to WT mice, 
as detected by decreased plantarflexion torque and muscle contraction energy for stimula-
tion frequencies 25-300Hz (normalized by lean body mass). The time required for PSEN1 
KI skeletal muscle to relax was significantly decreased when stimulated at 125-275 Hz, 
consistent with altered re-establishment of calcium equilibrium post-contraction. Echocardi-
ography of the heart identified significant increases in left ventricular (LV) anterior and pos-
terior wall thickness and LV Mass (5.6+/-0.3 vs. 4.3+/-0.2 mg/g, normalized to body weight, 
p<0.01). No changes in systolic function (e.g., ejection fraction) were detected in PSEN1 KI 
mice. Doppler analysis of the mitral valve (MV) to identify measure diastolic function by 
determining MV E and A wave measurements. The PSEN1 KI mice had a significantly lower 
E/A ratio (0.7+/-0.2) compared to controls (2.3+/-0.3, p<0.05), revealing cardiac relaxation 
defects consistent with diastolic heart failure. These results are the first description of the 
early onset AD PSEN1 L166P mutation causing cardiac and musculoskeletal defects at an 
age that neurological defects are present. Since PSEN1 is a protein involved in neuronal 
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Notch and Wnt signaling, future studies will define how PSEN1 mutations alter these path-
ways in the tissue level.
Disclosures: Vidyani Suryadevara, None
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The gut microbiota of old mice reduces lean mass in young mice *Lina 
Lawenius1, Carrie Cowardin2, Julia M. Scheffler1, Karin L. Gustafsson1, Cecilia 
Engdahl1, Jianyao Wu1, Liesbeth Vandenput1, Ulrika Islander1, Jeffrey I. Gordon2, 
Klara Sjögren1, Claes Ohlsson1. 1Centre for Bone and Arthritis Research, Institute 
of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, 
Sweden, Sweden, 2The Edison Family Center for Genome Sciences and Systems 
Biology, Washington University in St. Louis, St. Louis, MO, USA, United States
Aging is associated with an increased risk of sarcopenia and osteoporosis. Decreases 
in gut microbiota (GM) diversity have been associated with aging. Moreover, studies have 
demonstrated that manipulation of GM composition can influence both lean body mass and 
bone mass. Therefore, we hypothesized that changes in GM composition may contribute to 
the reduced lean and/or bone mass observed in old compared to young mice. The aim of the 
present study was to determine if transplanting GM from old versus young conventional-
ly-raised C57BL/6 donor mice to young versus old recipient C57BL/6 germ-free (GF) mice 
transfers the observed decreased lean and/or bone mass.As expected, old (21-month-old) 
female GM donors had reduced relative lean mass (lean %; -29.1+/-2.0%, p<0.001) and 
trabecular bone volume fraction (BV/TV in tibia; -37.7+/-6.3%, p<0.001) compared with 
young adult (5-month-old) female GM donors.To investigate whether the age of the recipi-
ents would influence responses to colonization, old or young adult GM was used to colonize 
5-, 11- or 17-week-old germ-free (GF) recipient mice (n=12/group). 16S rDNA amplicon 
sequencing was performed on fecal samples collected at sacrifice five weeks after transplan-
tation. Lean mass percentage was determined by quantitative magnetic resonance analyses 
at baseline and after five weeks of colonization.The gut microbial communities of recipient 
animals were similar to the original donors. GM transplantation from old donors reduced the 
lean mass percentage in recipient mice relative to GM transplantation from young donors 
(Figure 1). Interestingly, this effect was observed in young growing (colonized at 5 weeks or 
11 weeks of age) but not in adult (colonized at 17 weeks of age) recipients. Two-way ANO-
VA revealed a significant interaction effect between the age of the donors and the age of the 
recipients (Figure 1). Thus, the effect of the age of the donor mice on lean mass percentage 
in recipient mice was modulated by the age of the recipient. In contrast, no significant effect 
of the age of the donor mice on bone mass parameters were observed, regardless of recipient 
age.Conclusions - Old mice had a low relative lean mass and this phenotype could be trans-
ferred to young mice by GM transplantation. This effect was dependent on the age of the 
recipient mice, suggesting that gut communities from old mice have the capacity to transfer 
this phenotype to young, growing but not to older, mature mice.
Disclosures: Lina Lawenius, None
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Musculoskeletal and cardiac defects in the microtubule associated protein 
Tau (MAPT) P301S Tg+ mouse model of Frontotemporal Dementia. 
*Anuradha Valiya Kambrath1, Vidyani Suryadevara1, Amy Sato2, Teresita 
Bellido2, Monte Willis3. 1Indiana Center for Musculoskeletal Health, Department 
of Pathology & Laboratory Medicine, Indiana University School of Medicine, 
Indianapolis, IN 46202, United States, 2Department of Anatomy Cell Biology 
and Physiology, Indiana University School of Medicine, Indianapolis, IN 46202, 
United States, 3Indiana Center for Musculoskeletal Health, Department of 
Pathology & Laboratory Medicine, Krannert Cardiology Institute, Department 
of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 
46202, United States
Frontotemporal dementia (FTD, aka Pick’s Disease) is a group of disorders caused 
by progressive nerve cell loss in the frontal or temporal lobes of the brain. In contrast to 
Alzheimer Disease, FTD has distinctive symptoms of losing the ability to understand or 
formulate words or characterized by hesitant, labored, or ungrammatical speech. Changes 
in motor function have been identified in FTD patients, but underlying causes are not clear. 
We investigated the MAPT P301S transgenic (MAPT Tg+) FTD mouse model with the 
human disease-causing mutation at time points neurological involvement (which starts at 
1-3 months) was present. mCT analysis of MAPT Tg+ femurs revealed a reduction in the 
cortical properties at 12 months of age (vs. WT?, males>females). Three-point bending tests 
revealed that the femur mechanical properties were reduced in MAPT Tg+ before the yield 
point compared to controls. However, several mechanical properties were increased after the 
yield point in a sex-dependent manner. Since human FTD is associated with muscle weak-
ness and dementias with increased heart failure and EKG changes, we next investigated skel-
etal muscle and cardiac function. MAPT Tg+ mice had significantly decreased grip strength 
(160.6+/-16.7g) compared to WT (194.3+/-12.4g, p<0.0001). Similarly, plantarflexion 
torque detected increased time to maximum in MAPT Tg+ mice (for 125, 175-300Hz), indi-
cating impairment in neuromuscular and/or motor unit recruitment. MAPT Tg+ mice exhib-
ited a decreased half relaxation time and plantarflexion torque (for 125-300 Hz). MAPT Tg+ 
hearts had significantly reduced systolic function (ejection fraction: 76.2+/-1.0%) compared 
to WT (85.2+/-1.0, p<0.0001). ECG analysis of cardiac electrophysiology identified lower 
heart rates (749.6+/-10.0 vs. 772.2+/-2.6, p<0.01), increased heart rate variability (HRV) 
(20.6+/-1.8 vs. 10.0+/-1.6 bpm), and an elongated QT interval (25.05+/-1.06 vs. 19.8+/-
1.0 ms, p<0.05) in MAPT Tg+ mice. These studies identify the first extraneuronal FTD 
phenotypes, including cardiac autonomic dysfunction (increased HRV), muscle weakness, 
and systolic heart failure at an age when neurologic and bone defects occur. These findings 
illustrate the systemic involvement of the musculoskeletal system in the pathogenesis of 
FTD, along with clinical features not previously investigated in patients (e.g., arrhythmo-
genic long QT, bone loss) that may contribute to the hypotension and increased falling risks 
reported in FTD patients.
Disclosures: Anuradha Valiya Kambrath, None
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Aminobutyric Acids: Potential Biomarkers for Musculoskeletal Health 
during Exercise and Aging? *Zhiying Wang1, Chenglin Mo1, Charalampos 
Lyssikatos2, Ziyue Liu2, Stuart Warden2, Lynda Bonwald2, Marco Brotto1. 1Bone-
Muscle Research Center, College of Nursing and Health Innovation, University 
of Texas-Arlington, United States, 2Indiana Center for Musculoskeletal Health, 
ICMH, School of Medicine, Indiana University, United States
Exercise contributes to musculoskeletal (MSK) health. MSK decline during aging cre-
ates synergistic negative effects between inactivity and aging. Healthy aging interventions 
require the identification of serum biomarkers that inform on MSK health. We reported that 
β-aminoisobutyric acid (BAIBA) and γ-aminobutyric acid (GABA) have the potential use 
for early detection of osteoporosis and MSK health during aging (Wang et. al, Commun Biol 
2020).We determined serum levels of aminobutyric acids in subjects from the ICMH-Clin-
ical Research Center FitCore Program. Human serum samples from 80 white non-Hispan-
ic individuals aged 20-85 years were used in these studies. 40 women and 40 men were 
classified as “low performers” (LP) or “high performers” (HP), according to performance 
on grip strength, repeat chair stand test, six-minute walk test (6MWT), etc. Serum concen-
trations of isomeric aminobutyric acids including α-aminobutyric acid (AABA), BAIBA, 
and GABA in serum samples were quantified using a recently customized method at the 
Bone Muscle Research Center, University of Texas-Arlington (Wang et al, 2020).The con-
centrations for D-BAIBA and L-BAIBA were 1.52 +/- 0.73 µM and 0.037 +/- 0.030 µM, 
respectively. Serum GABA levels, ranging from 0.09-0.25 µM, significantly correlated with 
age (Spearman’s correlation coefficient (ρ) 0.392, p < 0.001). Moreover, subjects in the HP 
group showed relatively higher serum GABA levels, irrespective of gender but especially in 
aged women. Serum GABA levels were 0.177 +/- 0.040 µM in HP women (age 50-65 years) 
and 0.149 +/- 0.040 µM in age-matched LP women, suggesting modulations by both exer-
cise and aging. L-AABA (7.5-41.8 µM), rarely reported in bone and exercise studies, was 
significantly and positively associated with different physical performance measures, includ-
ing usual gait speed (ρ = 0.272, p = 0.015) and 6MWT (ρ = 0.322, p = 0.046, males). Pos-
itive associations were also observed between L-AABA and bone mineral density (BMD) 
in males, including femoral neck BMD (ρ = 0.378, p = 0.016) in male subjects aged 20-85 
years and spine BMD (ρ = 0.492, p = 0.028) in young male subjects aged 20-50 years.These 
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findings suggest that serum levels of aminobutyric acids have important relationships with 
bone and muscle health during aging. Exercise may modulate these metabolites and it will 
be important to determine if they mediate the positive effects of exercise on aging in addition 
to serving as biomarkers of physical performance.
Disclosures: Zhiying Wang, None
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Elimination of Senescent Osteocytes Prevents Age-Related Bone Loss *Joshua 
Farr1, Madison Doolittle1, Brittany Eckhardt1, Jennifer Rowsey1, Daniel Fraser1, 
Parinya Samakkarnthai1, Yuji Ikeno2, Laura Niedernhofer3, Paul Robbins3, 
Robert Pignolo1, Nathan LeBrasseur1, Tamar Tchkonia1, James Kirkland1, David 
Monroe1, Sundeep Khosla1. 1Mayo Clinic, United States, 2University of Texas 
Health San Antonio, United States, 3University of Minnesota, United States
Diverse forms of stress converge to cause a cell to enter an essentially irreversible 
permanent growth arrest, termed “senescence”. The key senescence mediator, p16Ink4a, 
increases with aging in several tissues, including osteocytes among other bone-resident cell 
types. Eliminating senescent cells across tissues in old mice using p16-ATTAC, an inducible 
“suicide” transgene driven by the p16Ink4a promoter activated upon administration of a syn-
thetic drug (AP20187 [AP]), or with “senolytics” – drugs that selectively kill senescent cells, 
improves healthspan. In addition, both approaches prevent age-related bone loss in old mice 
by reducing bone resorption and having favorable effects on formation. Here we describe a 
novel Cre-loxP mouse, termed p16-LOX-ATTAC, engineered to carry a construct where the 
p16Ink4a promoter drives 3 SV40 poly(A) transcription termination sequences (3xSTOP) 
flanked by loxP sites upstream of ATTAC. In the un-recombined state (no Cre), transgene 
harboring mice do not express ATTAC; however, when crossed with a Cre, the 3xSTOP is 
removed, resulting in ATTAC expression in a senescent cell-specific manner. Importantly, 
the combination of the Cre and AP permits attaining both cell-specific and temporal (in old 
mice) control of senescent cell elimination. To determine whether clearance of senescent 
osteocytes in old mice is sufficient to prevent age-related bone loss, we crossed p16-LOX-
ATTAC mice with 8 kb Dmp1-Cre mice (thereby limiting suicide transgene expression to 
Dmp1-expressing osteocytes), and at 20-months of age, randomized the mice to four months 
of vehicle (VEH) or AP treatments. We found, using real-time qPCR, significantly reduced 
p16Ink4a mRNA expression (by -1.6-fold, p<0.05; Figure Panel A) in osteocyte-enriched 
samples of VEH- vs AP-treated mice, but no difference between groups in other tissues 
(Figure Panel A). Micro-CT revealed significantly improved spine trabecular bone volume 
fraction (BV/TV; by 42%, p<0.01; Figure Panel B) and femur cortical thickness (Ct.Th; 
by 13%, p<0.05; Figure Panel C) in AP- vs VEH-treated mice. Collectively, by specifical-
ly clearing senescent osteocytes, these data establish that osteocyte senescence is causally 
implicated in age-related bone loss and build a framework for developing and translating 
senolytics that target senescent osteocytes with superior specificity and efficacy for the pre-
vention of osteoporosis.
Disclosures: Joshua Farr, None
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Pregnancy-related change in pQCT and bone biochemistry in a population 
with habitually low calcium intake *Mícheál Ó Breasail1, Kate Ward2, Landing 
Jarjou3, Sophie Moore4, Ann Prentice1. 1MRC Nutrition and Bone Health 
Research Group, United Kingdom, 2MRC Lifecourse Epidemiology Unit, 
University of Southampton, United Kingdom, 3MRC Unit The Gambia, London 
School of Hygiene and Tropical Medicine, Gambia, 4Department of Women and 
Children’s Health, King’s College London, United Kingdom
In pregnancy, changes in maternal calcium (Ca) economy occur to satisfy fetal Ca de-
mand. Whether maternal mineral reserves facilitate these requirements in a population with 
habitually low Ca intake (~400mg/day) is difficult to quantify and no data exist from sub-Sa-
haran Africa. The aim was to determine skeletal changes using pQCT and bone biochem-
istry between early second and third trimesters. Pregnant rural Gambians aged 18-45 years 
(n=467) participating in a trial of antenatal nutritional supplements (ISRCTN49285450) 
were invited for longitudinal measurements: pQCT radius/tibia 4% total vBMD, trabecular 
vBMD, total CSA; 33%/38% radius/tibia cortical vBMD, BMC, total CSA; biochemistry 
serum collagen type 1 cross-linked β-C-telopeptide (CTX), type 1 procollagen N-terminal 
(P1NP), parathyroid hormone (PTH), and 1,25(OH)2D. Supplements were iron folic acid 
(IFA; standard care), multi-micronutrient (MMN), protein energy (PE), and PE+MMN. 
Independent t-tests tested whether within-group and pooled change differed significantly 
from 0. Multiple regression adjusting for age and supplement tested if between-visit change 
differed significantly from the IFA group. Data for change are expressed as mean[SEM]%. 
Visits occurred at mean(SD) 14 (3) and 31 (1) weeks of pregnancy. Radius trabecular and 
cortical vBMD, and BMC increased by 1.15 [0.30]%, 0.41 [0.09]%, and 0.47 [0.11]% re-
spectively (all p<0.001). At the tibia, total and trabecular vBMD increased by 0.34 [0.10]% 
and 0.46 [0.14]% (p<0.001,p<0.01), while cortical vBMD and BMC increased by 0.35 
[0.04]% and 0.55[0.07]% (both p<0.001). At the radius change in cortical vBMD in MMN 
and PE was 0.54 [0.24]% and 0.73[0.24]% lower vs IFA (p<0.05, p<0.01 respectively). 
Change in tibia total vBMD was 0.76 [0.28]% greater in PEMNN vs IFA (p<0.01). Be-
tween visits CTX, PTH, and 1,25(OH)2D increased by 23.0 [3.64%], 13.2 [2.78]%, and 21.0 
[1.65]% respectively (all p<0.001). P1NP decreased by 32.4 [2.30]% (p<0.001). Changes in 
biochemistry did not differ significantly from the IFA group. Between-visit changes in BTMs 
suggest pregnancy-related changes in maternal bone mineral homeostasis. No evidence of 
bone mobilisation was observed in the peripheral skeleton, nor were consistent differences 
found by supplement group. It remains possible that mobilisation occurs at axial sites. In this 
population, with habitually low Ca intakes, the peripheral skeleton is not mobilised as a Ca 
source for the fetus.
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Aging is associated with a progressive decline in muscle mass and function. Altered 
lipid metabolism contribute to age-related muscle atrophy and muscle weakness, and are 
responsible for significant disability in older persons. Accumulating evidence indicates that 
lipid mediators (LMs) regulate skeletal muscle mass and function, and potentially influ-
ence muscle wasting, metabolism, and functional status in response to various patholog-
ical conditions. Individual eicosanoid species [e.g., prostaglandins (PGs) and Arachidon-
ic acid (AA)-derived eicosanoids (e.g. polyunsaturated fatty acid (PUFA)] emphasize the 
biosynthesis, metabolism, and signaling pathways of many tissues and organs. The course 
to determine the molecular components that lead to mass/strength decrements in the aged 
skeletal muscle is still evolving. In this study we hypothesized that LMs play an important 
role in the regulation of basic cellular processes and thereby pathophysiological actions in 
skeletal muscle and ageing, particularly its association with bone muscle crosstalk. Profil-
ing of 29 Lipid Signaling Mediators (LMs) and quantification was performed in gastroc-
nemius muscles obtained from young (6 weeks) and (28 weeks) C57BL6 mice. We found 
gender- and/or age- related differences are present for 20 LMs identified in this study. 28 
weeks old male and female showed relatively higher LM levels [including prostaglandins 
(PGs), PGs2α (p=0.036), PGsα, Arachidonic acid (AA)(p=0.042), Eicosapentaenoic acid 
(EPA) (p=0.0057) and anandamide (AEA) (p=0.023)] than the younger mice. Similarly, with 
AA/EPA ratio (p=0.005), while AA derivatives (e.g. Lipoxin B4, a strong muscle regulator) 
showed significantly lower values compared to the young mice in both genders (p= 0.0092). 
Furthermore, Docosahexaenoic acid (DHA) autoxidation products (20-HDoHE, 11-HDoHE, 
7-HDoHE, 4-HDoHE and platelet-activating factor) were significantly higher in older mice 
than younger mice (p=0.003, p=0.020, p=0.025, p=0.045 respectively). In conclusion, even 
at relatively young age of about 6 months, a noted increase in pro-inflammatory LMs can be 
detected in female mice. These results suggest that LMs could play an earlier and long-term 
role in modulating musculoskeletal function during aging, which might relate to osteoporo-
sis. Application of these principles will help advance the understanding of skeletal muscle 
pathophysiology to study the role of LMs in health and disease.
Disclosures: Ahmed Al Saedi, None
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pQCT Muscle Density Predicts Hip Fractures Independent of FRAX, 
Falls and BMD in the Osteoporotic Fractures in Men (MrOS) Study: 
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Kwok4, Magnus Karlsson5, Björn Rosengren5, Eva Ribom6, Peggy Cawthon7, 
Kristine Ensrud8, Enwu Liu9, Kate Ward1, Cyrus Cooper1, John Kanis10, Mattias 
Lorentzon11, Claes Ohlsson11, Dan Mellström12, Helena Johansson10, Eugene 
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Health, University of Minnesota, United States, 9Mary MacKillop Institute 
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12Centre for Bone and Arthritis Research (CBAR), Sahlgrenska Academy, 
University of Gothenburg, Sweden
Muscle size decreases and muscle adiposity increases with ageing, both changes being 
associated with adverse health outcomes. DXA-measured appendicular lean mass has lim-
itations as a predictor of incident hip fracture (HF), so we wished to examine the predictive 
performance of peripheral quantitative computed tomography (pQCT) measures of both 
calf muscle size (cross sectional area, CSA) and muscle density (an established surrogate 
for muscle adiposity) for hip fracture.  pQCT (Stratec XCT2000/3000) measurements at 
the tibia were undertaken in the MrOS US, Hong Kong (HK) and Swedish Gothenburg 
(SW) cohorts.  Analyses were undertaken for each cohort and merged by meta-analysis. 
The predictive value for incident HF, using an extension of Poisson regression adjusted 
for age and follow-up time, was expressed as gradient of risk (GR=hazard ratio per SD 
increase in the exposure).   Further analyses controlled for BMD, FRAX 10-year fracture 
probability and prior falls (y/n, in the preceding 12 months).We studied 1008 (US), 1662 
(HK), 581 (SW) men, mean (SD) age 77.0 (5.1), 73.9 (4.9), 80 (3.4) years, followed for a 
mean (SD) 7.9 (2.2), 8.1 (2.3), 4.4 (1.6) years, with 31, 47, and 34 incident HF respective-
ly.  Both greater muscle CSA and greater density (suggesting lower muscle adiposity and 
higher muscle quality) were associated with a lower risk of incident HF [GR: 0.79 (95% 
CI:0.65,0.96) and 0.83 (95%CI:0.69,0.99) respectively]. The pattern of relationships was 
not materially changed by adjustment for prior falls or FRAX probability.  In contrast, after 
inclusion of femoral neck BMD T-score, the association for muscle CSA was attenuated 
[GR: 0.97 (95%CI:0.80,1.19)], whereas that for muscle density was not materially changed 
[GR: 0.74 (95%CI:0.62,0.89)].In conclusion, pQCT measures of greater muscle area and 
density were both associated with lower incidence of hip fractures, but only lower muscle 
density remained an independent risk factor for fracture after accounting for femoral neck 
BMD T-score.  These findings demonstrate a complex interplay between measures of bone, 
and muscle size and quality, in determining fracture risk.
Disclosures: Nicholas Harvey, None
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Renal-bone axis: Vitamin D status and supplementation in older adults 
*Marilena Christodoulou1, Terence Aspray2, Isabelle Piec1, Christopher 
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Bone and renal metabolism are regulated by common factors and there is extensive 
cross-talk between these organs. Ageing is associated with a decrease in estimated glomer-
ular filtration rate (eGFR) and reduced tissue sensitivity to regulating hormones. We inves-
tigated the influence of renal function on plasma concentrations of vitamin D metabolites, 
regulators of bone and mineral metabolism and their response to vitamin D supplementation 
in older people. Associations with vitamin D status were also investigated.Samples collected 
at baseline and after 12 months of supplementation from a randomised dose-ranging vitamin 
D intervention trial (VDOP; 12000, 24000, 48000IU vitamin D3/month); (n=376; >70y; 
CKD<G4) were analysed for plasma 25(OH)D (LC-MS/MS), 1,25 (OH)2D (Diasorin, Liai-
son XL), Klotho (ELISA IBL Int.), PTH (Immulite 2000, SIEMENS), SOST, DKK1 (Bio-
medica), cFGF23 and iFGF23 (Immutopics, Gen 2 ELISA). eGFR was calculated according 
to 4-variable MDRD and were pragmatically split by eGFR <60 and >=60 ml/min/1.73m2. 
Group differences were tested by ANCOVA, with vitamin D dose as a co-variate for 
post-supplementation data. ANOVA followed by regression analyses was used to test asso-
ciations with category of 25(OH)D concentration  (<=25, 25.1-50, 50.1-75, >75nmol/L).At 
baseline, 25(OH)D, 1,25(OH)2D, Klotho, DKK1 were significantly lower and PTH, SOST, 
cFGF323, iFGF23, c:iFGF23 ratio higher in the group with the lower eGFR (Table).  Plas-
ma 25(OH)D was negatively associated with PTH (β -0.143; p<0.001), cFGF23 (β -0.085; 
p<0.01) and c:iFGF23 ratio (β -0.126; p<0.001).After 12 months of supplementation, mean 
plasma concentrations of 25(OH)D, 1,25(OH)2D and cFGF23 dose-dependently increased 
and  PTH decreased (all p<0.05). There were no differences by eGFR group in 25(OH)D, 
1,25(OH)2D and Klotho, while DKK1 was significantly lower and PTH, SOST, cFGF23, 
iFGF23 and the c:iFGF23 ratio higher (p<0.05; Table). Vitamin D dose was not significant 
in these models with eGFR.  After supplementation, plasma 25(OH)D was negatively asso-
ciated with plasma PTH (β -0.201; p<0.001).Even with a moderate decline in eGFR, mark-
ers associated with bone catabolism were elevated at baseline.  Vitamin D supplementation 
reduced PTH, but increased cFGF23 and there were no effects on Klotho, SOST, DKK1 
and iFGF23.  Between eGFR group differences in 25(OH)D, 1,25(OH)2D and Klotho were 
no longer detectable. This might suggest a benefit of vitamin D supplementation on the 
renal-bone axis.
Disclosures: Marilena Christodoulou, None
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CompassTM) *Mahdi Imani1, Gustavo Duque1, Ebrahim Bani Hassan1. 
1Department of Medicine, Western Health and the Australian Institute for 
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Purpose: Accurate quantification of bone, muscle and their components (e.g. infiltrated 
fat) is still an unmet need in the musculoskeletal field, especially in newly emerging areas 
such as osteosarcopenia. Indeed, quantifying tissue volumes on 3D images using the exist-
ing software is labor-intensive and time-consuming. Hence, we developed and validated a 
software for semi-automated to automated segmentation and quantification of musculoskel-
etal tissues, which includes muscle, fat, hematopoietic marrow (HBM) and bone.Methods: 
Tissue Compass™ is a standalone software developed on MATLAB 2019b (MathWorks). 
To validate the software, slices of quantitative CT images (QCTs) (n=100 men) were used 
to quantify bone, HBM and marrow adipose tissue (MAT) in L1 vertebral body and left 
hip using Tissue Compass and the leading commercial software (SliceOmatic, TomoVision, 
CA) as a comparator.  Using the same software, QCT slices of 50 men were used to quantify 
psoas muscle volumes and their intramuscular fat (IMF) and fat-infiltrated muscle (FIM).
Mean difference and limits of agreement were calculated using Bland Altman plots. Also, 
Pearson’s correlation coefficients and intra-class correlation coefficient were calculated to 
study the agreement between both techniques.Results: Semi-automated and automated seg-
mentation techniques (that to our knowledge are unique to Tissue Compass™) accelerated 
tissue analyses by up to 10 times. Tissue Compass™ also provided a 3D visualization of 
segmented ROI with different transparency levels, making it ideal for investigating interior 
geometry and proximities of tissues by seeing them through each-other (Fig 1a & 1b).The 
two softwares showed excellent to perfect correlations (R=0.99 to 1.00) in quantification of 
all tissues.Bland Altman mean difference (limits of agreement) for hip and L1 showed excel-
lent agreement between the two software: 0.03 (-0.13, 0.20) for MAT-hip, 0.05 (-0.08, 0.18) 
for HBM-hip, and 0.05 (-0.24, 0.34) for bone-hip; and -0.02 (-0.34, 0.31) for MAT-L1, -0.14 
(-0.44, 0.17) for HBM-L1, and -0.29 (-0.62, 0.05) cm3 for bone-L1.Same excellent agree-
ments were observed for psoas muscle measurements: -0.004 (-0.013, 0.006) for IMF, -0.045 
(-0.133, 0.043) for FIM, and 0.020 (-0.326, 0.366) cm3 for muscle.Conclusion: Presented 
software using its semi-automatic segmentation and automatic quantification techniques 
provides a faster and easier tool to study musculoskeletal tissues and their components.
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Bone loss with aging is independent of age-related gut microbiome dysbiosis 
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Emerging evidence suggests an important role of the microbiome in bone health. The 
microbiome sustains a dynamic status that constantly adapts to the host physiology and 
fitness. During the aging process, the microbiome integrates and responds to aging signals 
from the host, which in turn impacts host health. However, it is unclear whether micro-
bial dysbiosis with aging contributes to age-related bone loss.Here, age-specific microbi-
al signatures were characterized and their roles in age-related bone loss were investigated 
in a murine model. 16s rRNA gene sequencing of fecal community samples from 3- and 
24-month old CB6F1 males indicated an age-dependent shift towards a Firmicutes-dominant 
community with an alteration in energy and nutrient metabolism potential. Muscipirillum, 
a pathobiont associated with host inflammation, was increased in the aged microbiome. An 
integrative analysis of 16s predicted metagenome function and LC-MS fecal metabolome 
revealed enrichment of amino acid biosynthesis pathways in aged mice. Microbial methi-
onine and S-adenosyl methionine metabolism were increased in the aged mice, which have 
previously been associated with the host aging process. Collectively, aging caused microbial 
taxonomic and functional dysbiosis in mice. We tested whether the young vs old microbiome 
differentially impacts bone turnover by colonizing 4 or 8-week old germ-free (GF) mice by 
fecal transplant from 3- or 24-month old specific-pathogen-free (SPF) mice. We assessed 
trabecular and cortical bone by micro-computed tomography 1 and 6 months after coloni-
zation.  The effect of microbial colonization on bone phenotypes was independent of the 
microbiome donor age. To assess if the gut microbiome was required for age-related bone 
loss, we compared the trabecular and cortical bone structure of 24-month old CB6F1 GF 
female mice compared to that of littermates colonized at 8-weeks of age. The 24-month old 
bone phenotype was indistinguishable between colonized and GF mice. We next examined 
bone loss from 3 to 24 months in CB6F1 GF compared to SPF mice. Neither female nor 
male GF mice were protected from age-related bone loss. In conclusion, our study indicates 
age-related bone loss occurs independent of age-related gut microbial dysbiosis.
Disclosures: Xiaomeng You, None
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Marrow adipose tissue (MAT) increases with age and several investigations have iden-
tified higher MAT as a potential risk factor for worse bone and metabolic health outcomes. 
However, few studies have been conducted to evaluate longitudinal changes in MAT. Thus, 
we aimed to characterize total, saturated and unsaturated vertebral MAT change over ap-
proximately 3 years and assess the impact of vertebral lesions on measurements in a cohort 
of older men and women in the Bone Marrow Adiposity Follow-Up (BMAF) study. BMAF 
is a longitudinal ancillary study to Age Gene/Environment Susceptibility-Reykjavik (AG-
ES-Reykjavik), a population-based cohort in Iceland. After excluding those who reported 
current bone-active medication use (n=65), a total of 143 men (mean age: 82.7 years +/- SD 
4.3) and 140 women (mean age: 81.0 years +/- 4.3), with both baseline and follow-up MAT 
measures, were included in this analysis. Vertebral (L1-L4) MAT content was measured with 
single voxel proton magnetic resonance spectroscopy (1.5T MRS) and seven-peak Voigt 
model quantification. Total, saturated, and unsaturated MAT were defined as the ratio of total 
lipids (6 lipid peaks), saturated lipid (1.3 ppm peak), and unsaturated lipid (5.3 ppm peak) 
to total marrow contents, respectively. As part of the quality control process, spectra were 
graded for relative relationship between vertebral lesions (e.g., bone marrow edema and mi-
crofractures) and MRS volume of interest (VOI) box: grade 0=no lesion, 1=lesion outside of 
box, 2=partial lesion within box; 3=entire lesion within box. Additionally, a grading system 
was developed for evaluating the visual resolution of unsaturated lipids from water peak: 
grade 0=well resolved; 1=partially resolved; 2=not resolved. Mean changes in total MAT 
were +0.16 % per year for men and -0.046 % per year for women, with a wide range of 
values. When we excluded vertebral levels with grade 3 lesions, there was little effect on the 
mean or SD for change in total, saturated, or unsaturated MAT. Change in unsaturated MAT 
also did not differ when we excluded vertebral levels with low unsaturated lipid resolution 
(grade 2). Excluding vertebra with grade 3 lesions and/or poor spectral resolution of unsat-
urated lipids did not significantly change the results and therefore, may not be necessary in 
future studies. After approximately 3 years of follow-up, changes in saturated and unsaturat-
ed MAT were small and similar between older men and women.
Disclosures: Trisha Hue, None
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An Aging-Related Bone Loss through Activation of Succinate Receptor1 
*yuqi guo1, Xin LI2. 1NYU College of Dentistry, United States, 2NYU COLLEGE 
OF DENTISTRY, United States
Mitochondrial succinate dehydrogenase (SDH) deficiency was reported to directly con-
tribute to aging. But the underlying mechanism is unknown. The deficient SDH activity 
unavoidably leads to the accumulation of succinate, an intermediate metabolite in tricarbox-
ylic acid cycle. We have observed a significant elevation of succinate, in bone cells from old 
subjects and sera from aged mice. The elevated succinate can be released to act as an extra-
cellular signaling mediator through the succinate specific receptor (SUCNR1). SUCNR1 is a 
G protein-coupled receptor and Succinate/SUCNR1 signaling has provided a new paradigm 
for the mechanism of cell stress response in organs. We have investigated on the role of 
elevated succinate and SUCNR1 activation in age-related bone loss. Our hypothesis is tar-
geting succinate receptor activation attenuates the accelerated bone loss in aging. We have 
demonstrated that succinate directly stimulates osteoclastogenesis and osteoclast activity 
through SUCNR1 in vitro and in vivo. We compared the effects of extracellular succinate 
action through SUCNR1 on bone resorption in WT and SUCNR1 KO littermate mice at 
various ages. Vehicle or succinate treated Young (1-month-old, 6-month-old), Mid-Aged 
(12-month-old), and Aged (18- month-old) male and 6-month-old sham and ovariectomized 
female mice were examined. Femur bone samples were isolated for computed tomographic 
(micro-CT) analysis. Serum levels of succinate and bone turn-over markers were measured 
with blood collected via cardiac puncture. The results revealed an age-associated decline of 
SDH activity in marrow cells, succinate elevation in aged mice and a significant reduction 
of age-related bone loss in SUCNR1 KO mice. Importantly, succinate elevation leads to an 
increase of pro-inflammatory cytokine expression and augments myelopoiesis. Our study 
underscores the potential benefits of further investigation into the SUCNR1 receptor as a 
possible therapeutic target to delay age-related skeletal degeneration.
Disclosures: yuqi guo, None
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Medical Center, Republic of Korea, 3Dongseo University, Republic of Korea, 
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The changes in femur geometry that occur with aging and lead to fragility or insuffi-
ciency fracture remain unclear. The role of the lower limb geometry, including the femur 
and femoral bowing, has become a point of discussion, especially in atypical femur frac-
ture. This study aimed to analyze femur geometry using 3-dimensional skeletonization. We 
acquired computed tomography images of both femurs obtained. A total of 1400 age- and 
sex-stratified participants were enrolled and were divided into subgroups according to age 
(by decade) and sex. The computed tomography images were used to produce 3-dimensional 
samplings of anatomical elements of the human femur using reconstruction and parametri-
zation from these datasets. The process of skeletonization was conducted to obtain compact 
representation of the femur. With the skeletonization, we were able to compare all parame-
ters according to age and sex. The femur length was 424.4 +/- 28.6 mm and were longer in 
men (P < 0.001). The minimum diameter of the medullary canal was 8.9 +/- 2.0 mm. The 
radius of curvature (ROC) was 906.9 +/- 193.3mm. Men had a larger femur length, femur 
outer diameter, and the narrowest medullary diameter (P < 0.001, respectively). Women had 
significantly smaller ROC (P < 0.001). ROC decreased by 19.4% in men and 23.6% in wom-
en between the ages of 20 to 89 years. Femur width increased over life by 11.4% in men and 
24.5% in women. Between the ages of 50 and 89 years, the medullary canal appears to have 
increased by 32.7% in women. This geometry analysis demonstrated that femoral bowing 
and femoral width increased related to aging, and that the medullary canal widened after the 
age of 50 years in women. This study revealed important age- and sex-related changes in 
femur geometry that occur with aging and osteoporosis.
Disclosures: Ik Jae Jung, None
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Purpose: To develop age- and sex-specific reference ranges for body-composition pa-
rameters using data from Hologic dual energy x-ray absorptiometry (DXA) machines in 
Australian adults. Methods: Cross-sectional analyses of healthy community-dwelling adults 
(>=18 years) who underwent a DXA scan at one of three health and wellness sites (Mobile 
DXA Pty Ltd; DXA Melbourne Pty Ltd; and EC Group Pty Ltd) in Australia. Whole-body 
scans were carried out on Hologic Discovery and Horizon machines (Hologic, Inc., Bedford, 
MA). Adult participants with a maximum height of 190cm were included. LMS method was 
used generate sex-specific, age-dependent centile curves for body-composition parameters 
[lean body mass (LBM), total body fat (TBF), appendicular lean mass (ALM), appendicular 
fat mass (AFM), ALM/BMI, ALM/height(h)2, ALM/AFM, android fat, gynoid fat]. A sub-
set of reference range (ALM/h2, ALM/BMI, TBF) results are shown here. Results: A total of 
15479 Caucasian adults (54% men) with a median age of 33 years (interquartile range: 28, 
42) were included. ALM/h2 remained stable until the 5th decade after which this parameter 
started to decline in both sexes (Figure 1). The reference values (3rd, 97th percentiles) were 
7.84-13.06 kg for men (M) and 5.89-9.99 kg  for women (W) at 30 years, 7.95-12.82 kg (M) 
and 5.93-10.16 kg (W) at 40 years, 7.83-12.47 kg (M) and 5.84-10.14 kg (W) at 50 years 
and 7.42-11.82 kg and 5.57-9.74 kg, respectively, at 60 years. ALM/BMI showed a steady 
decline from 20 years onwards in both sexes (Figure 1), the reference values were 0.90-1.45 
kg/m2 (M) and 0.62-1.13 kg/m2 (W) at 30 years, 0.87-1.42 kg/m2 (M) and 0.59-1.10 kg/m2 
(W) at 40 years, 0.85-1.38 kg/m2 (M) and 0.55-1.05 kg/m2 (W) at 50 years and 0.80-1.32 
kg/m2 and 0.51-0.98 kg/m2, respectively, at 60 years. TBF tended to increase with age in 
both sexes (Figure 1), the reference values were 7.1-37.5 kg (M) and 8.7-43.7 kg (W) at 30 
years, 7.9-40.9 kg (M) and 8.8-48.2 kg (W) at 40 years, 8.7-40.6 kg (M) and 9.1-52.0 kg (W) 
at 50 years and 9.2-41.2 kg and 10.9-49.9 kg, respectively, at 60 years. Conclusions: These 
findings will facilitate clinicians and researchers in identifying body-composition abnormal-
ities involved in various pathological states (i.e., obesity, cachexia, sarcopenia, frailty) us-
ing the most widely used DXA machine (Hologic). Adjusting ALM for BMI versus h2 also 
produced different trends, which may be clinically relevant for diagnosis of sarcopenia and 
obesity.
Disclosures: Ben Kirk, None
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Prevalence of radiographic lumbar spondylosis and its association with 
osteoporosis in an elderly Brazilian population of the community: São Paulo 
Ageing & Health (SPAH) Study *Ricardo Fuller1, Thaysa Passalini1, Rosa 
Pereira1. 1University of Sao Paulo, Brazil
Purpose: to evaluate the relationship between the radiographic lumbar spondylosis 
(LS) and osteoporosis (OP) in a representative population of Brazilian elderly. Methods: 
Cross-sectional evaluation of 616 (385 woman and 235 man) Brazilian elderly people of 
the community (65 years or older) from a cohort São Paulo Ageing & Health (SPAH) Study. 
Lateral spine radiographs (L1 to L5) were analyzed using the Kellgren & Lawrence index 
to determine: presence of spondylosis (KL> = 2 in at least one intervertebral level), KL 
total score (L1-L2 to L4-L5) and presence of vertebral fractures. Bone mineral density was 
assessed by dual energy X-ray absorptiometry (DXA) of the lumbar spine and femur. Oste-
oporosis was defined as a BMD 2.5 standard deviations or more below the mean value for 
young adults (T score<−2.5). Results: Lumbar spondylosis was present in 76.64% in women 
and 92.34% in men (p=0.000). The prevalence of LS was lower in women with vs without 
osteoporosis (respectively 69.2% vs 81.9%, p = 0.005); there was no difference for men 
(90.2% vs 91.4%, p = 0.744). There was no difference in the prevalence of LS in women with 
vs without fragility fractures (respectively 73.5% vs 75%, p = 0.763), and men (respectively 
94.6% vs 89.4%, p = 0.198). There was also no difference in the prevalence of LS when 
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vertebral and non-vertebral fractures were analyzed separately, for both women and men. 
Conclusions: The prevalence of LS was very high in elderly people of the community. The 
LS was less prevalent in women with osteoporosis
Disclosures: Ricardo Fuller, None
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Blood borne bone: Circulating Osteoprogenitors Associated with Bone and 
Muscle quality. *Jack Feehan1, Cassandra Smith2, Alexander Tacey2, Ahmed 
Al Saedi1, Gustavo Duque1, Itamar Levinger2. 1The University of Melbourne, 
Australia, 2Victoria University, Australia
Circulating osteoprogenitor (COP) cells, found within the peripheral blood, express 
characteristics of mesenchymal stem cells (MSCs) with the capacity to proliferate and differ-
entiate into bone, muscle and fat. While some aspects of their in vitro and in vivo behaviour 
as mesenchymal progenitors has been established, much remains unknown about their role 
in age-related musculoskeletal diseases such as osteoporosis and sarcopenia. In this study, 
our aim was to identify if a relationship exists between COP cells and important muscle and 
bone parameters.Thirty-eight healthy older people [mean age 72 (+/-6yrs), mean BMI 28.4] 
were recruited from the community. Exclusion criteria included recent history of fracture, 
or initiation of osteoporosis medication, type 2 diabetes mellitus, haematological, myelo-
dysplastic or myeloproliferative disorders. Participants underwent a series of assessments 
including a blood sample, anthropometry and body composition analysis via densitometry. 
Peripheral blood samples were analysed for via flow cytometry, with COP cells defined 
as peripheral blood mononuclear cells (PBMCs) co-expressing the CD45 and osteocalcin 
markers. COP cell number is expressed as a percentage of the total PBMC population. Re-
gression analysis was used to identify relationships between variables.Increased COP cell 
number was associated with increased femoral (r=0.442, p=0.008,) and total BMD (r=0.376, 
p=0.025) and tended to correlate with appendicular lean mass (r=0.314, p=0.06). These re-
sults remained consistent after adjustment for age and BMI.COP cell number is linked to 
bone and muscle parameters in vivo. This suggests the hypothesis that COP cells have a 
role in the maintenance and cross talk between these tissues. Future studies should evaluate 
whether COP cells can be used as a novel biomarker for diseases such as osteosarcopenia.
Disclosures: Jack Feehan, None
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Predictors of change in the peripheral skeletons of older adults in rural 
Gambia *Mícheál Ó Breasail1, Camille Parsons2, Ayse Zengin3, Landing 
Jarjou4, Ann Prentice1, Kate Ward2. 1MRC Nutrition and Bone Health Research 
Group, United Kingdom, 2MRC Lifecourse Epidemiology Unit, University of 
Southampton, United Kingdom, 3Department of Medicine, School of Clinical 
Sciences at Monash Health, Monash University, Australia, 4MRC Unit The 
Gambia, London School of Hygiene and Tropical Medicine, Gambia
Growing aging populations across Sub-Saharan Africa (SSA) will lead to increases in 
osteoporosis and other chronic musculoskeletal conditions, data are required to understand 
musculoskeletal aging in the region. No longitudinal studies to date describe changes in bone 
in SSA. Repeat measures were acquired from rural Gambians (n=322, 52.5% female) aged 
40-92 (mean(SD) 60(12)) years. pQCT outcomes were total area (TotA), total (TotBMD) 
and trabecular vBMD (TrBMD) from the 4% distal radius and tibia. Height (cm), weight 
(kg) and BMI (kg/m2) were recorded. Muscle function was assessed by handgrip dyna-
mometry (max grip, N/kg) and jumping mechanography (relative force (kN/kg) and max 
relative power (kW/kg)). Bone turnover markers (BTM), serum collagen type 1 cross-linked 
β-C-telopeptide (CTX) and type 1 procollagen N-terminal (P1NP), were measured. Percent-
age annual change for pQCT outcomes was calculated. Univariate analysis was performed 
to explore if baseline age, BMI, BTMs, or muscle function predicted bone change. Models 
were repeated with a sex adjustment. Results are presented as β (95% CI) where β is the 
percentage change per year per unit of the independent variable. Mean(SD) time to follow 
up was 1.8(0.3) years. At all sites Tot and TrBMD decreased and TotA increased except 
tibia TotA. Baseline age was predictor of change in radius TotBMD (-0.06(-0.10,-0.02)) and 
TotA (0.07(0.01,0.10)), and tibia TrBMD (-0.04(-0.07,-0.01)). Greater baseline grip strength 
was associated with less decrease in tibia TotBMD (0.003(0.001,0.006)) and TrBMD (0.006 
(0.002,0.009)). Similarly greater force was associated with less decrease in radius TotBMD 
(0.16(0.03,0.29)) and power with less decrease in tibia TrBMD (0.04(0.01,0.08)), and radius 
TotBMD (0.07(0.02,0.12)). Greater force and power were associated with less change in 
radius TotA (-0.17(-0.31,-0.02);-0.06(-0.11,-0.01)); whereas at the tibia greater power was 
associated with greater change in TotA (0.02(0.01,0.05)). BTMs did not predict change. 
Adjustment for sex had no material effect, except for max relative power which no longer 
predicted tibia TotA change. These novel data suggest that increasing age is the main predic-
tor of decreases in BMD in the peripheral skeleton. Better muscle function was associated 
with lower decline in vBMD. At the trabecular-rich distal radius and tibia no discernible 
sex-specific differences in change were found. These data provide important insight into 
musculoskeletal ageing in SSA.
Disclosures: Mícheál Ó Breasail, None
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Association of regional body composition and physical function using the 
Short Physical Performance Battery among Peruvian women with HIV 
*Diego Cabrera1, Mijahil Cornejo2, Yvette Pinedo2, Patricia Garcia3, Evelyn 
Hsieh4. 1Universidad Peruana Cayetano Heredia - Yale University, Peru, 
2Hospital Nacional Arzobispo Loayza, Peru, 3Universidad Peruana Cayetano 
Heredia, Peru, 4Yale University, United States
Background: The musculoskeletal (MSK) system is significantly affected by HIV and 
its treatment. Changes in body composition can reflect important changes in bone and MSK 
health, particularly among populations at risk for developing fat redistribution syndromes, 
like HIV-positive women (HpW). Although more than half of HIV-infected population 
worldwide are women, there are limited data about characteristics of women aging with 
HIV in Latin American and the Caribbean (LAC). No studies from LAC have focused on the 
relationship between body composition changes and physical function among these individ-
uals. We aimed to explore the scope of this problem among Peruvian women aging with HIV.
Methods: We enrolled HpW and HIV-negative women (HnW) >=40 years of age receiving 
care at a large HIV clinic in Lima, Peru. Dual X-ray absorptiometry (DXA) was used to mea-
sure trunk and limb lean mass (LM) and fat mass (FM). Physical performance was assessed 
with the well-established Short Physical Performance Battery (SPPB) and physical strength 
with the grip strength test (GST) using a hand dynamometer. We used linear regression to 
model associations between HIV status, body composition and physical test scores.Results: 
104 HpW and 212 HnW were enrolled with a mean age of 52.4+/-8.2 and 56.4+/-8.8 years 
(p<0.001) and BMI of 26.4+/-5.1 and 27.6+/-4.1 kg/m2 (p=0.03), respectively. Among HpW, 
the mean years since HIV diagnosis was 11.8+/-6 and everyone was on antiretroviral treat-
ment (9.9+/-5.3 years). Fat mass index (FMI) was 9.6+/-3 vs 10.9+/-2.7 kg/m2 (p<0.001) 
between HpW and HnW, respectively. Overall mean SPPB score was 9.9 vs 10.8 between 
HpW and HnW, respectively (p<0.001). Mean grip strength was 19.9+/-5.9 vs 19.8+/-5.4 kg 
(p=0.83) between HpW and HnW, respectively. In multivariate models adjusted by age and 
HIV status, increased trunk FM was independently associated with decreased SPPB score 
(p<0.001), increased arm LM was independently associated with increased GST(p<0.001) 
and increased arm %fat was independently associated with decreased GST (p<0.001).Con-
clusions: In this study, trunk FM and arm LM were independent predictors for the physical 
performance and function tests described, and HIV status was independently associated with 
SPPB score. Larger prospective studies are needed among PWH in LAC to help identify in-
dividuals at high risk for declines in physical function, and to inform prevention guidelines.
Disclosures: Diego Cabrera, None
163






Maresin 1 resolves macrophage inflammation to improve aged bone fracture 
healing *Rong Huang1, Linda Vi2, Xiaohua Zong1, Gurpreet Baht1. 1Department 
of Orthopaedic Surgery, Duke University, United States, 2Division of Physical 
Medicine and Rehabilitation, University of Toronto, Canada
Inflammaging is associated with the poor tissue regeneration observed in advanced age. 
Here, we investigated the efficacy of using Maresin 1 to improve aged fracture healing by 
resolving inflammation after acute bone injury. 24-month-old mice underwent tibial fracture 
surgery and were either treated with vehicle (Veh) or Maresin 1 (MaR1). Healing bones from 
MaR1-treated mice displayed increased bone deposition, increased structural stiffness, and 
increased force to fracture in the later stages of repair. In the early stages, MaR1 treatment 
decreased the number of pro-inflammatory macrophages within the fracture callus and de-
creased the level of inflammatory biomarkers in circulation. In tissue culture models, MaR1 
treatment of macrophages derived from the bone marrow of aged mice induced secretion of 
an osteoinductive secretome, able to enhance osteoblast differentiation. Our findings here 
identify resolution of inflammation, and MaR1 itself, to be a point of intervention to improve 
age bone healing.
Disclosures: Rong Huang, None
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Aging delays epimorphic regeneration in mice *Regina Brunauer1, Ian Xia1, 
Shabistan Asrar1, Lindsay Dawson1, Connor Dolan1, Ken Muneoka1. 1Texas 
A&M University, United States
Regenerative decline is one of the most striking effects of aging. Currently available 
studies exploring age effects on regeneration typically investigate a single tissue type and 
focus on stem cell function. Amputation of the distal mouse digit tip transects nail and skin 
epidermis, bone and connective tissue and induces an epimorphic regeneration response 
hallmarked by formation and patterned differentiation of a blastema and de novo morpho-
genesis of all involved tissues, but the effects of aging on this process are unknown. We find 
that the state of epidermal wound closure, which depends on osteoclast-dependent bone re-
sorption, determines the pace of blastema maturation and bone formation, and is postponed 
in aged digits. This delay is not due to a scarcity of progenitor cells, but a drastically reduced 
mineralization rate in aged digits. We conclude that with aging, blastema formation is intact, 
and the blastema is fully capable of regeneration, but crucial intermediate steps are temporal-
ly inhibited, resulting in a significantly delayed completion of regeneration, reminiscent of 
delayed fracture healing in aged bone. This study is the first report about the effects of aging 
on mammalian epimorphic regeneration, highlighting the importance of the spatiotemporal 
regulation of cell function in regeneration, and our findings will be instructive to identify 
aging mechanisms that hamper homeostatic and reparative tissue regeneration.
Disclosures: Regina Brunauer, None
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Smad-dependent BMP signaling in cranial neural crest cells directs their cell 
fate towards chondrogenic lineage through chromatin structural changes 
to cause midline craniosynostosis *Yuji Mishina1, Hiroki Ueharu2, Jingwen 
Yang1. 1University of Michigan School of Dentistry, United States, 2University 
of Michigan School of Dentisrty, United States
Neural crest cells (NCC) are pluripotent cell populations that differentiate into numer-
ous derivatives in the vertebrate body. We previously generated a craniosynostosis mouse 
model via conditionally express a constitutively active form of BMP type IA receptor (caB-
mpr1a) in a neural crest cells (caBmpr1a;P0-Cre). The mutant mice showed premature 
fusion of the anterior frontal (AF) suture associated with increased BMP-Smad signaling. 
Ectopic cartilages were identified in the AF suture before its fusion. These facts prompted us 
to hypothesize that increased BMP signaling in cranial NCC alters cell fate towards chon-
drogenic lineage to generate ectopic cartilage at the AF suture, thus inducing its premature 
fusion through endochondral ossification.To get mechanistic insights of how increased BMP 
signaling alters cell fate of NCCs, we used a similar model to activate BMP-Smad signaling 
via ACVR1, another type 1 receptor for BMPs (caAcvr1;P0-Cre), since this model develops 
massive endochondral ossification during craniofacial development. In vivo treatment with 
LDN-193189, a selective inhibitor of BMP type I receptor kinases, rescued ectopic cartilage 
formation, when treated at E11.5, but not E12.5. Single-cell ATAC sequence using cells 
from the first branchial arch (BA1) of E10.5 embryos demonstrated that chromatin of Sox6, 
a gene essential for chondrogenesis, is more accessible in mutants than controls, while those 
of Sp7 (osteogenesis), Pax7 (myogenesis) and Zfp423 (adipogenesis) are less accessible 
in mutants. These results strongly suggest that increased BMP signaling in cranial NCCs 
around E10.5-11.5 alters cell fate towards chondrogenesis.We set up an unbiased screening 
to identify key genes for cell fate specification by comparing cranial NCCs and trunk NCCs 
between controls and mutants, since there was no ectopic cartilage in the mutant trunk region 
despite increased BMP signaling. Single-cell RNA sequence followed by QRT-PCR and in 
situ validations revealed increased expression of expected BMP targets such as Dkk1 and 
Sox9. Interestingly, we found reduced expression of Efnb1, which encodes Ephrin B1 and 
is a causative gene for craniofacial malformations. We will discuss updated bioinformatics 
analyses to understand downstream events of increased BMP signaling in cranial NCCs for 
cell fate specification. These findings would provide a potential target for the prevention of 
premature fusions of cranial sutures caused by endochondral ossification.
Disclosures: Yuji Mishina, None
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Phlpp1 and Phlpp2 differentially regulate endochondral ossification and 
chondrogenesis *Samantha Weaver1, Shannon Flanary1, Elizabeth Zars1, 
Earnest Taylor1, Jennifer Westendorf1. 1Mayo Clinic, United States
Endochondral ossification is controlled by a coordinated network of signaling cascades. 
Phlpp1 and Phlpp2 are protein phosphatases that negatively regulate anabolic signaling in 
chondrocytes and other cell types. Phlpp1 and Phlpp2 variants are associated with height 
phenotypes in GWAS studies. Phlpp1-/- mice have shorter femurs and tibiae and lower bone 
volume than WT mice. Immature articular chondrocytes (IMCs) cultured from Phlpp1-/- 
mice are more chondrogenic, with greater production of glycosaminoglycans and increased 
signaling of anabolic enzymes pAKT, pPKC, and pERK, among others. Phlpp2 targets sim-
ilar signaling cascades, but prefers AKT1 over AKT2/3. Here, we report that Phlpp2 has 
similar chondrogenic effects as Phlpp1 in vitro, but not in vivo. At four weeks of age, femur 
and tibiae lengths in Phlpp2-/- mice were similar to WT mice. The epiphyseal growth plates 
of Phlpp2-/- mice did not have increased proliferative cell number, as previously reported 
in Phlpp1-/- mice. However, Phlpp2-/- IMCs plated in micromass had increased Alcian blue 
staining and Col2a1, Sox9, and pAKT signaling as well as elevated production of AP-1 
transcription factors JunB and FosB. Both Phlpp1-/- and Phlpp2-/- chondrocytes were more 
proliferative than WT cells in vitro, as evaluated by a growth assay over 48 hours. To exam-
ine the discrepancy between the in vitro and in vivo phenotypes, Phlpp1-CKOCol2a1 and 
Phlpp2-CKOCol2a1 mice were generated to conditionally delete Phlpp1 or Phlpp2 only in 
Col2a1-expressing cells. No growth phenotype was observed in mice from either of these 
genotypes at four weeks of age, but IMCs from both genotypes were more chondrogenic in 
vitro than WT-Col2a1Cre+ controls. These data suggest that: 1) Phlpp1 is the main regulator 
of endochondral ossification in vivo and may have a compensatory effect over Phlpp2 de-
letion in the murine growth plate and 2) the reduced growth phenotype evident in Phlpp1-/- 
mice is not due solely to Phlpp1 expression in Col2a1-expressing cells such as chondrocytes 
and bone marrow cells. Thus, Phlpp1 and Phlpp2 have complementary but non-redundant 
roles in chondrocytes and endocrine factors may control endochondral growth in Phlpp1 
deficient mice.
Disclosures: Samantha Weaver, None
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Impairment of Limb Development by Genetic Ablation of Cobra1 *Chao 
Tu1, Bin Yuan2, Huiliang Yang3, Rui Hua1, Sumin Gu1, Wentian Yang3, Rong 
Li2, Jean X Jiang1. 1Department of Biochemistry and Structural Biology, The 
University of Texas Health Science Center, San Antonio, TX 78229, USA, 
United States, 2Department of Biochemistry and Molecular Medicine, School of 
Medicine and Health Sciences, The George Washington University, Washington, 
DC 20037, USA, United States, 3Department of Orthopaedics, Brown University 
Alpert Medical School and Rhode Island Hospital, Providence, RI 02903 USA., 
United States
Background: Osteochondral progenitors (OCPs) are mesenchymal precursors that could 
differentiate into chondrocytes and osteoblasts, and thus exert important function in limb de-
velopment. COBRA1, also known as NELF-B, is a pleiotropic transcriptional cofactor that 
regulates RNA polymerase II pausing and transcription elongation, and subsequently con-
trols cell survival and growth in diverse developmental processes. However, the function of 
Cobra1 in lineage commitment of OCPs remains largely unknown. In this study, we aimed to 
investigate the role of COBRA1/NELF-B in early limb development by conditional deletion 
of Cobra1 in OCPs of the limb bud mesenchyme. Methods: We generated Prx1-cre; Cobra-
1flox/flox conditional knockout mice (cKO) and their control littermates. The lengths of long 
bones were measured. The skeletal structure and formation of newborn limbs were grossly 
and histologically evaluated by whole-mount skeletal staining, H&E, and Safranin-O stain-
ing. TUNEL assay was performed to detect the apoptotic cells. Quantitative real-time PCR, 
western blotting, and RNAscope-based in situ hybridization were utilized to determine the 
mRNA- and protein-level expression of genes related to osteogenesis and chondrogenesis. 
Results: Cobra1 cKO mice exhibited severe skeletal defects after birth, including shortened 
length in long bone and decreased cortical thickness. Histological analysis revealed remark-
able reduced bone mass density, disorganized chondrocyte column of growth plate, scattered 
distribution and compromised terminal differentiation of chondrocytes, as well as impaired 
endochondral ossification. These characteristics manifested severely restrained chondrogen-
esis and osteogenesis. In addition, Cobra1 cKO exhibited increased apoptotic chondrocytes. 
Moreover, expression levels of osteogenic markers (Col1a1, Ibsp1), chondrogenic markers 
(Acan, Col2a1), and hypertrophic markers (Col10a1, Mmp13) were significantly downregu-
lated in Cobra1 deficiency mice. Importantly, SOX9, a key regulator of chondrogenesis, was 
also markedly decreased in Cobra1 cKO mice compared to control. Conclusions: This study 
unveils a previously unrecognized role of Cobra1 in regulation of limb development, likely 
in part by regulating the chondrogenesis and osteogenesis of OCPs. 
Disclosures: Chao Tu, None
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Combinatorial CRISPR/Cas9 approach to elucidate the role of WNT16 in 
regulating bone development in zebrafish *zhen liu1, weiwei liu1, xing su1, 
ying wang2, lijun tan1, yun deng3, xiang-ding chen1. 1Laboratory of Molecular 
and Statistical Genetics, College of Life Sciences, Hunan Normal University, 
Changsha, Hunan 410081, China, China, 2The National and Local Joint 
Engineering Laboratory of Animal Peptide Drug Development, College of Life 
Sciences, Hunan Normal University, Changsha, 410081, Chin, China, 3The 
Center for Heart Development, Key Lab of MOE for Development Biology 
and Protein Chemistry, College of Life Sciences, Hunan Normal University, 
Changsha, 410081, Hunan, China, China
   Human genetic studies demonstrate that WNT16 plays important role in the regula-
tion of bone mineral density, cortical thickness, bone flexion rate, bone mass and ultimately 
fracture risk. However, the underlying mechanism is not yet fully understood. In this study, 
the role of WNT16 in skeletal development and metabolism were evaluated on a WNT16 
null mutant in zebrafish through CRISPR/Cas9-mediated gene knockout. As the result, the 
homozygous mutants exhibited mortality rate over 15% in an early embryonic stage. 20% of 
homozygous juveniles showed curved vertebra, upturned tail, lengthened jawbone, enlarged 
abdomen, slenderized caudal fin and lost caudal fin. In addition, most of them died at 19 
days post fertilization. Further Micro-CT studies revealed that the bone mineral density of 
WNT16 -/- zebrafish showed a distinct reduction compared with wild type, which is similar 
to the phenotypes of the human osteoporosis. ALP staining and TRAP staining data sug-
gested that WNT16 deficiency increase osteoclast activity but inhibit osteoblast activity. In 
summary, WNT16 is involved in the early embryonic development and the regulation of 
bone formation and resorption in zebrafish. It indicated that WNT16 might be a target for 
therapeutic interventions to improve osteoporosis treatment.
Disclosures: zhen liu, None
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Fam210a Alters Long Bone Development Through its Action in Mesenchymal 
Stem Cells and Chondrocytes *Loan Nguyen-Yamamoto1, Aimee-Lee Luco1, 
Takeshi Shimoide1, Rene St Arnaud2, David Goltzman1. 1Research Institute of 
the McGill University Health Centre, Canada, 2McGill University and Shriner’s 
Hospital for Children, Canada
Purpose: FAM210a, a nuclear-encoded mitochondrial protein has been associated 
with osteoporosis in humans, and we previously reported that, although Fam210a is not 
expressed in mature osteoblasts, global deletion of Fam210a in mice reduced BMD and 
bone formation, altered microarchitecture and decreased bone biomechanical strength, at 
least in part through its action in muscle. This suggested that Fam210a has a crucial role 
in regulating bone structure and function. In this study, we examined the role of Fam210a 
in early long bone development and endochondral bone formation.Methods: We employed 
Fam210a flox/flox mice, and Prx1-Cre or Col2-Cre mice to generate mice with specific de-
letion of Fam210a in mesenchymal stem cells (MSC) or chondrocytes (Chon) respectively. 
We examined male and female mice at 2 months of age; because mice with homozygous 
deletion of Fam210a die shortly after birth, we studied heterozygous Fam210a MSC+/- and 
Fam210a Chon+/- mice. Prx1 cre- and Col2 cre- mice were used as controls, respectively. 
We examined femoral BMD, and microarchitectural changes in femurs by μCT analysis-
Results: Compared to control mice, heterozygous female Fam210a MSC+/- mice showed 
significantly reduced BMD and femur length, and μCT analysis of femurs showed increased 
cortical BV/TV, reduced cortical porosity, reduced trabecular BV/TV, and reduced trabecular 
thickness and trabecular number. Significant changes were not, however, seen in male mice. 
In contrast, heterozygous male Fam210a Chon+/- mice showed significantly reduced BMD 
and femur length compared to control mice, with a trend toward increased cortical BV/TV 
and lower cortical porosity, and reduced trabecular BV/TV, trabecular thickness and trabec-
ular number. Female mice, however showed no change in BMD and less reduction in femur 
length. Thus, female mice with haploinsufficency of Fam210a in osteoblast precursors and/
or  immature osteoblasts were more severely affected  than males, whereas male mice  with 
haploinsufficiency of Fam210a in chondrocytes were more severely affected than females.
Conclusions: Fam210a plays an important role in long bone development through its action 
in mesenchymal stem cells and chondrocytes. This role may manifest features of sexual 
dimorphism. Further studies are ongoing to understand the mechanisms underlying these 
observations.
Disclosures: Loan Nguyen-Yamamoto, None
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Differential sensitivity to TGFβ signaling and regulatory changes to the 
Mmp13 promoter underlie species-specific variation in bone resorption and 
jaw length *Spenser Smith1, Daniel Chu1, Tiange Qu1, Goutam Krish1, Richard 
Schneider1. 1University of California, San Francisco, United States
Precise regulation of jaw length is essential for species-specific adaptation and survival. 
Jaws are often affected by size-related birth defects like hypoplasia, retrognathia, asymme-
try, and clefting. The jaw skeleton is derived from neural crest mesenchyme (NCM), and our 
prior work has shown that NCM governs species-specific jaw length through a variety of 
mechanisms, including embryonic regulation of bone resorption. By comparing jaw devel-
opment in Japanese quail and white Pekin duck, we have identified Matrix metalloproteinase 
13 (Mmp13) as a key determinant of jaw length. We have found that Mmp13 is expressed at 
substantially higher levels in the jaw primordia of quail than duck, that Mmp13 expression 
and bone resorption are NCM-mediated as revealed through quail-duck chimeras, and that 
inhibiting Mmp13 and bone resorption can lengthen the jaw. Here, we investigate molecular 
mechanisms that lead to differential regulation of Mmp13 and the ability of NCM to con-
trol bone resorption and jaw length. We focus on the TGFβ pathway, a known regulator of 
Mmp13 and bone resorption. We find significantly higher levels of TGFβ ligands, receptors, 
and effectors in the jaws of quail versus duck, indicating that quail have elevated TGFβ 
signaling. By treating jaw primordia from quail and duck with TGFβ1, we also discover 
intrinsic species-specific differences in sensitivity to TGFβ, with quail showing much stron-
ger induction of intracellular effectors (SMADs), Mmp13, and other targets like Runx2. To 
ascertain mechanisms underlying species-specific differences in TGFβ sensitivity and levels 
of Mmp13 expression, we analyze the Mmp13 promoter in quail and duck. We find that the 
Mmp13 promoter contains RUNX2 and SMAD binding sites that affect Mmp13 expression. 
We generate species-specific reporter constructs with or without these binding sites. The 
endogenous quail Mmp13 promoter responds to TGFβ1, whereas the duck promoter does 
not. Removing the SMAD binding site reduces the response in quail but adding it to the 
duck increases activity. We also identify single nucleotide polymorphisms (SNPs) adjacent 
to the RUNX2 binding site that distinguish quail from duck. Swapping these SNPs plus the 
SMAD site between species abolishes the TGFβ1 response with quail promoters but adds a 
response to duck. Overall, our results suggest that multiple levels of gene regulation in the 
TGFβ signaling pathway mediate bone resorption, and ultimately species-specific variation 
in jaw length.
Disclosures: Spenser Smith, None
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Loss of Hypoxia-Inducible Factor-1a in the Presomitic Mesoderm Impairs 
Somitogenesis and Causes Spine and Rib Abnormalities Reminiscent of 
Jarcho-Levin Syndrome *Zachary Tata1, Qing Yao1, Matthew Anderson2, 
Christophe Merceron1, Frances Farley1, Mark Lewandoski2, Ernestina Schipani3. 
1Department of Orthopedic Surgery, School of Medicine, University of 
Michigan, United States, 2Genetics of Vertebrate Development Section, Cancer 
and Developmental Biology Lab, National Cancer Institute, National Institutes of 
Health, United States, 3Department of Orthopedic Surgery, School of Medicine, 
University of Michigan; Department of Medicine, Division of Endocrinology 
and Department of Cell and Developmental Biology, University of Michigan 
Medical School, United States
Jarcho-Levin Syndrome is a disease characterized by congenital scoliosis, abnormally 
shortened trunk length, and numerous costal and vertebral defects. Approximately 25% of 
cases of Jarcho-Levin Syndrome are secondary to loss of function mutations in genes of the 
Notch Signaling Pathway. Notch signaling plays a critical role in somitogenesis, the peri-
odic segmentation of somites from the presomitic mesoderm (PSM) during embryonic axis 
extension, and these somites give rise to both the vertebrae and ribs in the fully developed 
organism. It has previously been reported that gestational hypoxia is sufficient to disrupt the 
oscillatory Notch Signaling expression normally required in the PSM for somitogenesis. 
Interestingly, hypoxia occurs naturally in embryos before the establishment of the mamma-
lian circulatory system. The key mediator of the hypoxic response in mammals is the tran-
scription factor Hypoxia-Inducible factor-1a (HIF1), which regulates expression of genes 
involved in a variety of processes including survival, differentiation and reprogramming 
of metabolism. Hypoxia increases the stability and transcriptional activity of HIF1 protein. 
However, the role of HIF1 in both somitogenesis and spinal development has yet to be in-
vestigated. To address this gap in knowledge, we conditionally inactivated HIF1 in the PSM 
using the T- (brachyury) Cre. Mutant mice displayed an abnormal curvature of the spine, as 
well as costal and vertebral defects which closely resemble those observed in Jarcho-Levin 
Syndrome. Loss of HIF1 did not affect cellular survival but led to dysregulation of the Notch 
signaling pathway in the PSM of mutant embryos. Additionally, inactivation of HIF1 in seg-
mented somites or later developmental stages did not duplicate the phenotype seen with loss 
of HIF1 in the PSM. These results demonstrate that HIF1 plays a specific developmental role 
for the spine and ribs in the PSM and acts upstream of the Notch signaling pathway in the 
regulation of somitogenesis, offering new insight into the potential etiology of Jarcho-Levin 
Syndrome. In particular, we are currently testing the hypothesis that loss of HIF1 in the 
PSM increases local hypoxia by reprogramming metabolism and augmenting mitochondrial 
respiration, which could explain why either gestational hypoxia or loss of HIF1 in the PSM 
may cause a Jarcho-Levine Syndrome phenotype.
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METTL3-mediated m6A mRNA Methylation Modulates Tooth Root 
Formation *Rui Sheng1, Yunshu Wu1, Jun Wang1, Shiwen Zhang1, Qiwen Li1, 
Danting Zhang1, Xingying Qi1, Qingyue Xiao1, Shuang Jiang1, Quan Yuan1. 
1Sichuan University, China
Purpose:N6-methyladenosine (m6A), one of the most abundant eukaryotic mRNA epi-
genetic modification catalyzed by methyltransferase-like 3 (Mettl3), influences various RNA 
processing events in RNA metabolism. However, the role of Mettl3-mediated m6A modifi-
cation in tooth development has not been revealed. In this study, we aim to reveal the func-
tion of m6A modification regulated by METTL3 during tooth root formation.Methods:we 
established Sp7-Cre; Mettl3fl/fl and Gli1-CreERT2;Mettl3fl/fl mice to investigate that how 
deletion of Mettl3 affected the development of mandibular first molar root. Next, we silenced 
METTL3 in human dental pulp cells (hDPCs) to study the influence of METTL3 on odon-
togentic differentiation. Mechanically, we performed m6A MeRIP-Seq and analysis other 
published data to identify the critical m6A targets.Results:METTL3 was highly and preva-
lently expressed, during the stage of tooth root development, especially in dental papilla and 
dental pulp near the HERS. The Sp7-Cre; Mettl3fl/fl mice which especially knockout Mettl3 
in dental pulp cells and odontoblasts showed the anomalous odontogenesis during tooth 
root formation, including short root anomaly and thinner root dentin. H&E staining sections 
and double labelling assay indicated decreasing pre-dentin secreting and mineral apposition 
rate of dentin. In addition, acid-etched SEM showed sparse odontoblast-processes in root 
area. Furthermore, The capacity of reparative dentin formation was impaired in  Sp7-Cre; 
Mettl3fl/fl mice, while it was enhanced in Sp7-Cre; Mettl3KI/KI mice. The Gli1-CreERT2; 
Mettl3fl/fl mice also showed abnormal phenotype, including short molar root and decreased 
bone mass of alveolar bone. Depletion of METTL3 in hDPCs also crippled the ability of 
proliferation and mineralization. Mechanically, we revealed that specific and enriched m6A 
peak near translation stop codon of NFIC. Moreover, software prediction using published 
m6A-seq data from other cells also confirmed that NFIC was modified. Deletion METTL3 
impaired the protein translation of NFIC, and the defect partially rescued by NFIC overex-
pression. These evidences suggested that METTL3 was crucial for tooth root development.
Conclusion:In conclusion, we demonstrated m6A modification in odontogenetic cells regu-
lated by METTL3 could affect NFIC translation and modulate odontogenesis or mineraliza-
tion during tooth root formation.
Disclosures: Rui Sheng, None
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Opposite Effects of Cntnap4 Knockout in Cranial Neural Crest Cells of 
Cranial Base and Vault *Pin Ha1, Chenshuang Li2, Samantha Lee1, Nuo Dong1, 
Zhong Zheng1, Kang Ting1, Chia Soo3, Xinli Zhang1. 1Division of Growth and 
Development, School of Dentistry, University of California, Los Angeles, United 
States, 2Department of Orthodontics, School of Dental Medicine, University 
of Pennsylvania, United States, 3Department of Orthopaedic Surgery and the 
Orthopaedic Hospital Research Center, University of California, Los Angeles, 
United States
Contactin-associated protein-like 4 (Cntnap4), a member of the neurexin superfamily of 
transmembrane molecules that have critical functions in neuronal cell communication, has 
been identified as a specific receptor of an osteogenic protein, Nell-1 for osteogenesis. This 
opens up a new revenue for Cntnap4 functional studies beyond its putative roles in brain. 
Our previous reports showed that Cntnap4flox/flox; Wnt1-Cre (Cntnap4Wnt1KO) mice and 
Nell-1flox/flox; Wnt1-Cre (Nell-1Wnt1KO) mice developed very similar craniofacial dys-
plasia phenotype, which includes frontonasal, maxilla and mandibular bone defects, prema-
ture ossification/fusion of the intrasphenoidal synchondrosis (ISS), and an obvious increased 
incidence of postnatal hydrocephalus. To unravel the cellular and molecular mechanisms of 
a contradictory craniofacial skeletal phenotype of vault and base, primary Cntnap4-deficient 
cranial neural crest cells (CNCCs) were isolated separately from both frontonasal bones 
and cranial base sphenoidal bones. Cntnap4-deficient CNCCs from cranial vault (cvCNCC) 
demonstrated a significant reduction in osteogenic differentiation and non-responsive to 
Nell-1’s stimulation compared to wild-type (WT) cells. Surprisingly, Cntnap4-deficient 
CNCCs from cranial base (cbCNCC) presented the opposite effects with significant increase 
in osteogenic differentiation, but without significant further augmentation by Nell-1 protein. 
Since ISS premature ossification/fusion and hydrocephalus of Cntnap4Wnt1KO mice usual-
ly occur at week-3 old, tissue sections of cranial base were obtained at this stage for histolo-
gy and immunostaining. Coincidently, these in vivo analyses demonstrated that a significant 
accelerated ossification at both ISS and spheno-occipital synchondrosis (SOS) with elevated 
levels of Col 1, Col10 and OCN, along with tremendously increased cell proliferation in the 
bone marrow of pre- and basi-sphenoid bones in Cntnap4Wnt1KO over WT mice. Mecha-
nistically, the differential activations of Wnt/β-catenin and Ihh signalings were observed in 
Cntnap4-deficient cvCNCCs and cbCNCCs that are responsible for intramembranous and 
endochondral type of bone formations, respectively. In aggregate, Cntnap4 was not only a 
novel key regulator of CNCCs, but also executing a striking opposite effect on cbCNCCs 
from cvCNCCs, which underscores the unique craniofacial phenotypes of calvarial hypo-
plasia and premature ossification of synchondrosis in Cntnap4Wnt1KO mice (see Fig. A-C).
Disclosures: Pin Ha, None
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Evaluating the Role(s) of Wnt Receptor Frizzled 2 in Limb and Craniofacial 
Development *Megan Michalski1, Cassandra Diegel1, Alex Zhong1, Gabrielle 
Foxa1, Bart Williams1. 1Van Andel Institute, United States
Heterozygous mutations in Frizzled 2 (FZD2), a Wnt ligand receptor, are associated 
with two syndromes which present with limb reductions and craniofacial anomalies: Rob-
inow syndrome and autosomal dominant omodysplasia. We utilized two Fzd2 mouse models 
to study the role of Fzd2 in craniofacial and limb development: Fzd2tm1.1Nat (global knock-
out) and Fzd2FloxMOR (conditional-ready). While homozygosity for the Fzd2tm1.1Nat al-
lele results in partial penetrance of cleft palate and delayed neonatal growth (consistent with 
previous reports), we did not note limb reductions. We found that the Fzd2tm1.1Nat allele 
retains a small fragment of the CDS encoding the Fzd2 C-terminus and noted an in-frame 
ATG, associated with a strong Kozak sequence near the 5’ end of this FZD2 fragment that 
could drive expression of a 531bp in-frame CDS. We found this FZD2 fragment to retain 
signaling function. Conditional heterozygous deletion of the Fzd2FloxMOR allele using 
Prx1-cre and Wnt1-cre2 resulted in limb reductions and craniofacial anomalies respectively. 
The Fzd2FloxMOR allele was thought to contain loxP sites surrounding the protein coding 
sequence of Fzd2. However, cre-mediated recombination of the Fzd2FloxMOR allele did 
not result in significant loss of FZD2 protein or mRNA. We carried out whole genome se-
quencing of Fzd2FloxMOR mice and found that this allele contains two copies of the Fzd2 
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gene, exogenous bacterially-derived sequence, and duplication of endogenous sequence. 
Due to the unexpected issues noted in the above models, we have recently generated a new 
floxed allele of Fzd2 (Fzd2Flox-VAI) by injecting 2-cell embryos with purified Cas9-strepta-
vidin fusion protein and biotinylated repair templates designed to incorporate loxP sites sur-
rounding the Fzd2 gene. From 85 potential founders, we identified 4 containing loxP sites 
incorporated into both the 5’ and 3’ sites. After crossing these animals to C57Bl/6J mice, 
both the 5’ and 3’ loxP sites were transmitted in cis within the germline. Our preliminary 
data shows successful cre-mediated recombination when crossed with CMV-cre. Overall, we 
successfully simultaneously inserted 2 loxP sites using this method and significantly reduced 
the cost and time burden to generate floxed mice. Fzd2 is likely an important mediator of 
craniofacial and limb development and we are in the process of utilizing our new mouse 
model to gain a deeper understanding of the mechanism by which Fzd2 controls develop-
ment of these structures.
Disclosures: Megan Michalski, None
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Hydrolyzed collagen and vitamin D3 accelerate bone regeneration in adult 
zebrafish *Nili Vasserman1, Chen Shochat Carvalho1, David Karasik1. 1Bar Ilan 
university, Israel
Bone regeneration is an important process that allows healing of bone tissue after trau-
ma, fractures, or surgical removal. There are clinical cases in which bone regeneration is 
needed in large quantity. Therefore, there is a need to develop novel, more potent, drugs, 
especially of anabolic nature. Due to its fast bone regeneration, zebrafish (Danio rerio, ZF) is 
a popular in-vivo model for such a study.Our aim was to assess the in-vivo and in-vitro effect 
of a collagen hydrolysate (CH) and 1α,25-Dihydroxyvitamin D3 (VitD) supplementation on 
bone regeneration, using ZF jawbone model. After bone resection, 6-mo-old ZF were fed 
fish food supplemented with low, medium, or high dose of either CH or VitD (Table 1). Jaw 
bone gap at resection site was measured by microCT scans and averaged (n=4) to estimate 
bone regeneration rate. The smallest gap, i.e. fastest regeneration rate, was observed at 14 
and 28 days post resection, at low dose of VitD, while at 35 days post resection, the smallest 
gap was observed with CH treatments compared to VitD and control (Table 1). In addition 
to the gap’s closure there was an overgrowth of the new bone. After 60 days, in the highest 
dose of CH, the shape of the mandible resembled that of a wild type ZF.In-vitro: the effect 
of 3 doses of CH and VitD was studied on MC3T3-E1 osteoblast and RAW264.7 osteoclast 
cell lines by cell-specific staining and functional assays. The expressions of osteogenic and 
osteoclastogenic genes were measured by qPCR. The medium dose of CH increased osteo-
blast proliferation and calcium deposition and decreased the size of osteoclasts, while VitD 
in all doses increased ALP activity but not ALP gene expression. Additionally, CH increased 
osteoblast expression of RUNX2, while the expression of all 3 osteoclast genes, RANKL, 
TRAP and CTSK was increased by VitD and CH.Our results indicate that CH and VitD 
have an anabolic therapeutic potential in bone regeneration.  Gap closure after resection was 
similarly accelerated by CH and VitD treatments even after 2 weeks of feeding, but in the 
long term, it was more significant with CH treatment.  Our findings demonstrate that CH can 
upregulate osteoblast and osteoclasts activity (the latter activity is necessary to remodeling 
process). In conclusion, we suggest that CH could represent a promising treatment for bone 
healing, but at the same time, the effect of combining both treatments should be examined.
Disclosures: Nili Vasserman, None
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Global deficiency of chaperone mediated autophagy leads to low cancellous 
bone mass in young mice *Nisreen Akel1, Milena Dimori1, Ryan Macleod2, 
Stuart Berryhill1, Julie Crawford1, Melda Onal1. 1University of Arkansas for 
Medical Sciences, United States, 2university of Arkansas for Medical Sciences, 
United States
Chaperone-mediated autophagy (CMA) is a protein degradation pathway that eliminates 
soluble cytoplasmic proteins that are damaged, incorrectly folded, or targeted for selective 
proteome remodeling. CMA has been proposed to contribute to DNA repair, cellular repro-
graming, and the cellular stress response. However, the role of CMA in skeletal remodeling 
under physiological and pathophysiological conditions is unknown. To determine whether 
CMA contributes to skeletal homeostasis, we deleted the CMA receptor Lamp2a from the 
mouse genome, thereby producing mice that lack CMA in all tissues. MicroCT analysis 
at five-weeks-of age revealed that female LAMP2A global knockout (L2AgKO) mice had 
lower vertebral cancellous bone mass compared to wild type (WT) controls. Bones of female 
CMA-deficient mice exhibited higher mRNA levels of the osteoclast marker genes Trap and 
Cathepsin K compared to controls. Unlike the female mice, bone mass of five-week-old 
male L2AgKO mice was not different from controls. Previous studies by others have shown 
that in young mice lack of CMA in liver tissue is partially compensated for by an increase in 
other proteostasis mechanisms. However, this partial compensation has been shown to dissi-
pate as mice mature and leads to a premature aging phenotype in this tissue. Consistent with 
this, our ex vivo studies showed that CMA-deficient osteoblasts exhibited a slight increase 
in the ubiquitin-proteasome system. To determine whether a functional role of CMA for 
bone tissue becomes more pronounced as mice mature, we analyzed the skeletal phenotype 
of young adult mice at eighteen weeks of age. MicroCt analysis revealed that both male and 
female L2AgKO mice had lower vertebral cancellous bone mass compared to WT controls. 
At this age, gene expression analysis performed at the whole bone level did not show any 
significant differences in mRNA levels of osteoclast or osteoblast marker genes. However, 
ex vivo analysis of bone marrow progenitors showed that CMA deficient progenitors have 
an increased ability to produce osteoclasts and a decreased ability to form alkaline phos-
phatase-positive osteoblast colonies compared to WT progenitors. Whether these ex vivo 
changes are the underlying cause of the low bone mass phenotype of L2AgKO mice needs 
to be determined. Taken together our results suggest that CMA gains importance as mice ma-
ture and that lack of CMA leads to low vertebral cancellous bone mass in young adult mice.
Disclosures: Nisreen Akel, None
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Sex Differences in the Skeletal Phenotype of the African Spiny Mouse 
(Acomys cahirinus) *Kirby Sherman1, Alyssa Falck1, Shannon Huggins1, 
Lindsay A Dawson1, Ken Muneoka1, Dana Gaddy1, Malcolm Maden2, Larry J 
Suva3. 1Texas A&M University, United States, 2Univeristy of Florida, United 
States, 3Department of Veterinary Physiology and Pharmacology, United States
Although similar in appearance to mice of the genus Mus, “African spiny mice” of the 
genus Acomys are distinct and have unusually stiff guard hairs and possess brittle, easily torn 
skin allowing the animals to escape predators by discarding extensive patches of skin. In 
response to such profound injuries, Acomys completely regenerate hair follicles, sebaceous 
glands, dermis and fur with no evidence of scarring, unlike Mus. Based on the profound 
regenerative capabilities of Acomys, and an absence of skeletal data, the baseline Acomys 
bone phenotype was determined. Tibiae and femurs were harvested from adult male and 
female 2 and 4-6 month old Acomys as well as from 3-to-6-month-old Mus (C57/Bl6). The 
baseline Acomys skeletal phenotype were ascertained using microCT, histology, and immu-
nohistochemistry. Interestingly in younger Acomys, females had significantly higher BV/
TV, Tb.Th, and decreased Tb.Sp. than age-matched male Acomys. Cortical bone analysis 
revealed that female Acomys have significantly increased Ct.Th. and larger cortical CSA 
than males. Interestingly, these significant differences between male and female bone mi-
croarchitecture and geometry were not maintained in the older Acomys, perhaps indicative 
of earlier attainment of peak adult bone mass in females. Indeed, although young female 
Acomys had higher BV/TV than age-matched young males, no significant differences were 
noted when either young or old females were compared to older males. This supports the 
idea that female Acomys attain peak adult bone mass earlier than males. Acomys females 
at all ages have significantly greater BV/TV than either 3 or 6 month old male C57/Bl6 
mice. Histologically, Acomys bone marrow demonstrates different cellular organization 
relative to Mus, with Acomys having significantly fewer bone marrow adipocytes, distinct 
cuboidal-like morphology of marrow cells, robust cell proliferation along bone surfaces, 
prominent megakaryocytes, and large osteoclasts decorating the Acomys’ growth plate. The 
significantly increased bone volume, microarchitecture and altered geometry in adult female 
Acomys likely provides an evolutionary advantage to the females, who are typically more 
aggressive and dominant compared to their male counterparts. Our ongoing efforts seek to 
accurately define the Acomys bone and bone marrow phenotype and identify the molecu-
lar pathways controlling bone regeneration in order to enhance mammalian regenerative 
capabilities.
Disclosures: Kirby Sherman, None
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LepR-expressing stem cells are essential for alveolar bone regeneration 
*Shiwen Zhang1, Danting Zhang 1, Jun Wang1, Qiwen Li1, Quan Yuan1. 1State 
Key Laboratory of Oral Diseases & National Clinical Research Center for Oral 
Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 
China, China
Purpose:  Stem cells play a critical role in alveolar-bone repair. Several populations 
of skeletal stem cells (SSCs) have been identified in the long bone, while their identity and 
function in alveolar bone remain poorly understood, due to the lack of specific in vivo mark-
ers. Previously, we found that LepR+ cells were expressed in the alveolar bone and stayed 
quiescent, but activated and differentiated into osteoblasts in response to tooth extraction. 
In this study, we sought to find out whether LepR+ cells represent a population of alveo-
lar bone SSCs and investigate the role and mechanism of LepR+ SSCs regulating alveolar 
bone regeneration.Methods:LepR-Cre;tdTomato;Col2.3-GFP reporter mice was generated 
and the mandible was collected at different time points to follow the fate of LepR+ lineage 
cells. Next we created a tooth extraction model in LepR-Cre;tdTomato;Col2.3-GFP mice 
and LepR-Cre;tdTomato;iDTR mice to investigate the contribution of LepR+ cells to alve-
olar bone regeneration through mirco-CT, frozen section and double labeling. Further, we 
generated parabiosis models to investigate whether LepR+ cells in the extraction sockets are 
derived from peripheral blood circulation. In order to explore the potential mechanism that 
regulates LepR+ cell response, we performed RNA-Seq through sorting the LepR+ cells 
from the tooth sockets and injured alveolar bone and found a high expression of Pth1r gene. 
Then we created LepR-Cre;Pth1rfl/fl;tdTomato mice to further study PTH/PTH1R signaling 
regulating LepR+ cells.Results:Tracing data showed that LepR+ cells gradually differenti-
ated to osteoblasts with age in alveolar bone. LepR+ cells were maintained in a quiescent 
state, but activated in response to tooth extraction and generated most of the new bone. By 
post-tooth extraction day 28, 47.84% of Col2.3-GFP+ osteoblasts were tdTomato+, whereas 
only 13.29% of double positive cells in the uninjured controls. Micro-CT and double label-
ing results demonstrated that ablation of LepR+ cells suppressed extraction socket healing. 
Intermittent PTH treatments significantly induced LepR+ cells increasing and differentiating 
into osteoblasts both in physiology condition as well as in injured model. In addition, condi-
tional knockout Pth1r in the LepR+ cell lineage resulted in impaired bone healing. Conclu-
sions:we demonstrate LepR+ cells, a postnatal SSCs population, are essential for alveolar 
bone regeneration, which is regulated by PTH/PTH1R signaling. 
Disclosures: Shiwen Zhang, None
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A Positive Feedback Loop Between PTH1R and ZFP467 Mediates the Linage 
Allocation in the Bone Marrow Niche *Hanghang Liu1, Phuong Le1, Lama 
Alabdulaaylly2, Yosta Vegting3, Isabella Calle1, Francesca Gori2, Beate Lanske2, 
Roland Baron2, Clifford Rosen1. 1Maine Medical Center Research Institute, 
Maine Medical Center, United States, 2Harvard School of Dental Medicine, 
United States, 3University of Amsterdam, Amsterdam UMC, Meibergdreef 9, 
Netherlands
We previously reported that deletion of Pth1r in mesenchymal progenitors reduced 
osteoblast differentiation and bone mass while enhancing adipogenesis and bone marrow 
adipose tissue. Mechanistically, we found that PTH suppressed the expression of Zfp467, 
a pro-adipogenic zinc finger transcription factor. Consequently, Pthr1 deficiency in mes-
enchymal progenitors leads to increased Zfp467 expression. Based on these observations, 
we hypothesized that genetic loss of Zfp467 would lead to an increase in bone mass by 
shifting marrow progenitor cell fate towards osteogenesis. To test this hypothesis, we gen-
erated Zfp467-/- mice. At 16wks of age, Zfp467-/- mice (-/-) were significantly smaller 
than Zfp467+/+ mice (+/+). μCT of tibial trabecular (Tb.) bone showed that Tb.BV/TV, 
Tb.BMD, Tb.N, and Conn.D were significantly higher in -/- vs. +/+ (p<0.002) with lower 
SMI (p=0.005). Cortical (Ct.) parameters showed smaller Ma.Ar and higher Ct.Ar/Tt.Ar 
in -/- (p<0.03). Additionally, Ct. Porosity was significantly lower in -/- vs. +/+ (p=0.003). 
Histomorphometry showed higher structural parameters of Tb.BV/TV, Tb.N, and Tb.Th 
in -/- (p<0.0175). Furthermore, MS/BS, MAR, and BFR/BV were higher in -/- vs. +/+ 
(p<0.005). Oc.S/BS was significantly higher in -/- (p<0.05). Femoral gene expression in-
cluding Alpl, Sp7, and Acp5 were increased in -/- (p< 0.018). Adiponectin, Cebpa, Lepr, and 
Ppra? mRNA were lower in -/- vs. +/+ (p<0.01). Similarly, Fabp4 and Lep in the inguinal 
depot were also decreased in -/- (p<0.05). Marrow adipocyte numbers were reduced in -/- 
(p=0.0074). In vitro, COBs and BMSCs-/- showed more positive ALP and Alizarin Red 
staining and a decrease in ORO droplets. Interestingly, Pth1r and Creb mRNA and protein 
levels were increased in -/- COBs and BMSCs (p<0.05). Additionally, -/- COBs exhibited 
enhanced endogenous levels of cAMP vs. control cells (p=0.0003), and the pro-osteogenic 
effect of Zfp467-/- could be blocked by a PKA inhibitor (p<0.01). Furthermore, Zfp467-
/- cells showed greater glycolytic activity vs. control cells (p<0.05), but no differences in 
mitochondrial respiration. Taken together, these results show that global deletion of Zfp467 
leads to increase osteogenesis and bone mass and decreased adipogenesis in female mice as 
well as an increased basal level of PTH1R expression in osteoblasts. These data support a 
critical role for Zfp467 in early lineage allocation and provide a novel potential mechanism 
by which PTH acts in an anabolic manner.
Disclosures: Hanghang Liu, None
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Chondrocyte Dedifferentiation: An Alternate Fate For Hypertrophic 
Chondrocytes *Jason Long1, Abigail Leinroth1, Yihan Liao1, Anthony Mirando1, 
Yinshi Ren2, Deepika Sharma1, Colleen Wu1, Courtney Karner1, Kathryn Cheah3, 
Matthew Hilton1. 1Duke University, United States, 2Texas Scottish Rite Hospital, 
United States, 3The University of Hong Kong, China
Skeletal stem and progenitor cells (SSPCs) have the capacity to become osteoblasts, 
chondrocytes, and adipocytes during normal bone development, aging, and regeneration. 
SSPCs reside within the periosteum surrounding cortical bone and the intramedullary bone 
marrow. However, whether these SSPCs have a distinct origin and/or function remains to be 
determined. Recent in vivo lineage tracing and genetic reporter studies determined that many 
marrow associated osteoblasts are derived from hypertrophic chondrocytes of the growth 
plate cartilage, thereby raising questions as to whether these cells undergo trans-differen-
tiation to directly generate committed osteoblasts or rather a de-differentiation process to 
generate SSPCs that ultimately give rise to osteoblasts and/or other cell types. Using similar 
lineage tracing and reporter analyses (Col10a1Cre; R26-tdTomato and Col10a1CreERT2; 
R26-tdTomato), we determined that hypertrophic chondrocytes undergo de-differentiation 
to generate SSPCs that likely give rise to osteoblasts, osteocytes, and adipocytes within the 
marrow during skeletal development. Colony forming unit – fibroblast (CFU-F) assays per-
formed using the bone marrow harvested from these reporter mice indicate that as many as 
50% of the CFU-Fs (a general measure of SSPCs) may be derived from the growth plate, and 
bulk RNA-sequencing of tdTomato positive and negative colonies demonstrated uniquely 
expressed genes within these populations, suggesting alternative origins and/or functions. 
Further, single cell RNA-sequencing of marrow associated tdTomato+ cells from reporter 
mice determined that hypertrophic chondrocytes give rise to two osteoblast populations, 
while also generating at least 3 populations of SSPCs that share common markers but also 
exhibit uniquely expressed genes. Ongoing studies are aimed at determining the spatial and 
functional significance of these unique bone marrow associated SSPC populations.  
Disclosures: Jason Long, None
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Mfap4 Expression Marks Mesenchymal Cells in the Mouse Calvaria *Didem 
Goz Ayturk1, Eun Sung Suh1, Ugur M Ayturk1. 1Hospital for Special Surgery, 
United States
Bone tissue-resident macrophages (also referred to as osteomacs) regulate fracture heal-
ing and osteoblast differentiation (Chang et al., J Immunol, 2008; Batoon et al., Biomate-
rials, 2019). We recently described osteomacs, along with osteoblasts and their precursors 
in the neonatal mouse calvaria with single cell RNA-seq (Ayturk et al., J Bone Miner Res, 
2020). We found that primary calvarial cells consist of multiple, transcriptionally distinct 
cell populations, predominantly including osteoblasts (Bglap+) and a population resembling 
osteoblast-precursors (Bglap-, Col1a1+, Mfap4+), as well as a small group of macrophages 
(F4/80+, less than 5% of all cells). In the present study, our goal was to determine the spa-
tial locations of macrophages and osteoblast-lineage cells in vivo, and identify and validate 
genetically modified mice that could be useful in studying osteoprogenitors in the mouse 
calvaria. Our single cell RNA-seq data indicated that Mfap4-expression distinctly marks os-
teoprogenitors among calvarial cells. We therefore obtained the Tg(Mfap4-EGFP)HF313G-
sat reporter mouse (i.e. Mfap4.eGFP, GENSAT) and imaged calvarial tissue in this mouse 
strain at P5 and P16. We detected strong and comprehensive GFP expression in all layers of 
the calvarial periosteum and endosteum, except for the bone-lining layers that presumably 
consist of mature osteoblasts (Figure 1). To determine if GFP+ cells include any non-mes-
enchymal populations, we performed FACS and immunohistochemistry analyses for CD45, 
F4/80 and CD31 expression, but found no overlap between these markers and GFP-expres-
sion. In contrast, we found that Mfap4-driven GFP expression is limited to connective tissue 
(such as the patellar tendon and cruciate ligaments) and hematopoietic populations of the 
bone marrow in the limbs. When we stained calvariae of Mfap4.eGFP mice for macrophage 
markers F4/80 or CD169, we found that labeled macrophages were positioned immediately 
adjacent to Mfap4-expressing cells in the periosteum endosteum (Figure 1). Our data indi-
cate that Mfap4-expression marks periosteal and endosteal cells (that are likely osteopro-
genitors) in the calvaria but not the long bones. Furthermore, these cells are intertwined with 
macrophages that might be required for bone formation; future experiments might reveal 
mechanisms of signaling between the two cell types.
Disclosures: Didem Goz Ayturk, None
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Biglycan Regulates Structural Integrity and Bone Regeneration *Reut 
Shainer1, Vardit Kram1, Tina M. Kilts1, Li Li1, Andrew Doyle2, Carl G. Simon 
Jr3, Liliana Schaefer4, Marian F. Young1. 1Molecular Biology of Bones and Teeth 
Section, NIDCR, NIH, United States, 2Cell Biology Section, NIDCR, NIH, 
United States, 3Biosystems and Biomaterials Division, NIST, United States, 
4Institut für Allgemeine Pharmakologie und Toxikologie, Goethe University, 
Germany
Bone healing involves a complex sequence of physiological events starting with an in-
flammatory response at the fracture site, followed by activation and proliferation of skeletal 
stem cells in the periosteum. To identify new factors that further control bone regeneration, 
immunohistochemistry and RNA analysis were performed and showed that Biglycan (Bgn), 
an extracellular matrix proteoglycan, is greatly enhanced in the periosteum in response to 
injury. Here, we used WT and Bgn deficient (KO) mice in order to examine the role of 
Bgn in the bone.µCT analysis showed that compared with WT bones, Bgn KO bones had 
a reduction in cortical thickness and trabecular number. The structural integrity of the Bgn 
KO bones was found to be compromised as second harmonic generation microscopy demon-
strated irregular structure and spacing between the collagen fibers of the Bgn KO bones. 
This molecular structural change was coupled with a reduction in the hardness of the Bgn 
KO bones.Next, we examined bone regeneration by fracturing the bones. Bgn KO mice 
showed reduced inflammation and macrophage infiltration around the fracture site. In ad-
dition, RNAseq analysis showed an enhanced expression of genes involved in suppressing 
inflammation. The periosteum of Bgn KO did not expand to the same extent as WT after 
fracture, leading to reduced callus formation, which regained its original (pre-fracture) shape 
faster.  Since periosteal-derived cells (PDCs) have an important role in fracture healing, we 
decided to investigate whether they can be used to enhance or improve the healing process. 
We isolated and cultured PDCs from the long bones of WT mice, using a 3D system to mimic 
the native environment of the cells. We found that PDCs create a distinct microenvironment 
that favors cartilage formation in vitro. When the 3D scaffolds containing PDCs were trans-
planted subcutaneously into mice, they differentiated into calcified cartilage. Finally, we 
cultured WT PDCs in the 3D scaffold and wrapped it around the fracture site in WT and Bgn 
KO mice. Here we show that the 3D scaffolds with PDCs enhanced the recovery of the frac-
tured bone in both WT and Bgn KO mice.Overall our results demonstrate that Bgn deletion 
impairs bone formation and fracture repair, and highlight the importance of biglycan and 
periosteal cells in skeletal tissue in both homoeostasis and during bone healing.
Disclosures: Reut Shainer, None
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Periosteal cells labeled by VEGFR2 (KDR) and CCR5 are a subset of long-
term repopulating adult skeletal stem cells in mouse and human *Youngjae 
Jeong1, Laura Ortinau1, Kevin Lei1, Lorenzo Deveza1, Dongsu Park1. 1Baylor 
College of Medicine, United States
Skeletal stem cells (SSCs) are heterogeneous in population and have multipotent capac-
ity to differentiate into bone, adipocyte, cartilage and marrow stromal cells. In particularly, 
they continuously supply chondrocytes and osteoblasts for cartilage and bone formation, 
respectively, during skeletal development and bone regeneration/repair process throughout 
lifetime. Due to the limited number, heterogeneity, and wide tissue distribution of SSC pop-
ulation in adult bones, it is challenging to identify and characterize the selective markers to 
distinguish rare periosteal (ourter surface of bone) SSCs in vivo. Recent advancement in 
SSC fields allowed discovery of a few molecular markers that specifically define subsets of 
population, and yet their functional roles are not still clear. Especially, common selective 
markers for periosteal SSCs in both mouse and human and their differential function com-
pared to bone marrow SSCs (BM-SSCs) are largely unknown. In the following study, we 
have used Prx1CreER-EGFP mouse model to demonstrate that VEGFR2 (KDR) is selective-
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ly expressed in endogenous periosteal SSCs (CD45-CD31-Ter119-CD150+CD140a+GFP+) 
by flow cytometry. Immunofluorescent imaging analysis showed Prx1-GFP+ periosteal cells 
in the femoral periosteum were KDR positive. From our recent study, we revealed that the 
combination of Mx1 and αSMA-GFP can selectively label endogenous periosteal SSCs in 
mouse models. These cells highly express CCR5, a chemokine receptor for CCL5, and have 
migratory function toward the injury site upon bone defect. In the current study, flow cy-
tometry analysis demonstrated Prx1-GFP+ endogenous periosteal SSCs express both KDR 
and CCR5. We also defined that human periosteal cells express KDR and CCR5. Notably, 
the expression of CCR5 appeared in early post-natal periosteal SSCs and their expression 
sustained in adult bones, implicating that periosteal SSCs acquire their unique markers and 
function postnatally and the KDR and CCR5 combination can distinguish both mouse and 
human periosteal SSC subsets that preserve long-term repopulating capability. Identifying 
and understanding the functional mechanism of periosteum-resident SSC subsets constitutes 
a promising therapeutic approach to develop more effective treatment for degenerative bone 
disease and bone defects.   
Disclosures: Youngjae Jeong, None
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Phagocytosis by mesenchymal stromal cells: A facultative process that 
induces senescence *Emily Quarato1, Allison Li1, Charles Smith1, Roman 
Eliseev1, Laura Calvi1. 1University of Rochester, United States
Mesenchymal stromal cell (MSC) dysfunction is implicated in multiple settings includ-
ing age-induced bone loss, radiation injury, and dysfunction of the hematopoietic stem cell 
niche in hematologic malignancies. Our laboratory studies the supporting role of MSCs and 
macrophages within the hematopoietic system and recently reported their role in the aged 
microenvironment. Aged marrow macrophages were found to be expanded but defective 
in their ability to phagocytose apoptotic cells (efferocytosis), resulting in increased inflam-
matory signals and expansion of dysfunctional MSCs. Since MSCs have previously been 
reported to be facultative phagocytes during embryonic development when macrophages 
are defective, we hypothesized that MSCs possess efferocytic capacity that impairs their 
function and fate determination. In vivo, we observed the phagocytic activity of MSCs and 
quantified efferocytosis of fluorescently labeled apoptotic neutrophils to be 5%. Notably, all 
phagocytic activity in MSCs was increased in aged mice and in a murine model of myeloid 
malignancy. Through in vitro assays utilizing a murine bone marrow stromal cell line (ST2) 
we analyzed the extent of phagocytic and efferocytic capabilities in MSCs given both bio-
logical and non-biological cargo and determined the consequences to fate determination post 
a phagocytic event. We observed that 2μm carboxylated beads were phagocytosed by most 
MSCs, while, with senescent neutrophils, 5% of the MSCs actively conduct efferocytosis in 
vitro, similar to the rate observed in vivo. In the MSCs that are actively engulfing, there was 
a significant increase to the rate of senescence over controls and their non-engulfing coun-
terparts, and we observed global depression in differentiation potential to the osteoblastic 
and adipocytic lineages. As both phagocytosis and MSC differentiation are accompanied 
by changes in mitochondrial dynamics, we sought to determine if increased phagocytosis in 
MSC is a result of mitochondrial changes. Utilizing in vitro culture, MSCs’ oxidative and 
glycolytic functions were decreased by phagocytosis and efferocytosis. Collectively, these 
data support the hypothesis that efferocytic activity by MSCs compromises their function 
and fate determination with disruption of mitochondrial activity, and therefore may serve as 
a therapeutic target to mitigate MSC damage in the setting of aging, radiation and hemato-
logic malignancies.
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Identification of a novel population of stem cells in mouse muscle: potential 
for bone regeneration *Yu Liu1, Louis Gerstenfeld2, Beth Bragdon1. 1Boston 
University School of Medicine, Department of Orthopaedic Surgery, United 
States, 2Boston University School of Medicine, Department of Orthopaedic 
Surgery, United States
Acquired heterotopic bone, which is bone formation within the musculature in response 
to injury, implies the existence of stem cells with osteogenic potential in the muscle. Pub-
lished work and our studies showed the paired related homeobox gene1 (Prx1) express-
ing cells connote a postnatal skeletal stem cell (SSC) population that contributes to bone 
homeostasis and wound repair. While Prx1 is widely expressed in mesenchymal tissues, 
questions remain whether Prx1+ muscle cells can contribute to bone formation and whether 
stem cells from different locations are functionally the same.To address this, 8-10 week old 
Prx1CreER;Rosa26tdTomato ;Rag mice received two doses of tamoxifen in 72 hours to 
induce fluorescent labeling of the Prx1 cells. 2 days after injection, bone marrow, periosteum 
and muscle were harvested and processed for fluorescence-activated cell sorting. Antibodies 
for CD45 (hematopoietic), CD105 and CD200 were used to isolate SSC (Prx1+ CD105- 
CD200+ CD45-) and two progenitor populations1 (CD105- CD200- and CD105+). Cells 
were then cultured and differentiated toward the osteo-, adipo- and chondro-genic lineages 
to directly characterize and compare the sub-populations of Prx1.Results showed the highest 
percentage of Prx1+ cells were found in the muscle followed by periosteum, while the bone 
marrow showed the least. Percentage of SSC within the non-hematopoietic population from 
muscle, periosteum and bone marrow were 3.73+/-0.72%, 0.79+/-0.30%, 0.05+/-0.02% re-
spectively (Figure A). Muscle SSCs showed greater proliferative capacities and tri-lineage 
differentiation potentials than periosteal SSCs, while bone marrow SSCs were not able to 
form colonies even when plated at high density (Figure B). Bulk RNA-sequencing analysis 
demonstrated SSC populations were distinct from their progenitors while tissue source had 
a lesser influence on the uniqueness of stem cells.These results suggest that the Prx1 pop-
ulation consists of both stem and progenitor cells. The high percentage and regenerative 
potential of muscle SSCs indicate that mesenchymal tissues consist of multiple distinct pools 
of stem cells. The identification of the novel population of muscle-derived stem cells raises 
the possibility that it may serve as a promising source for bone regeneration. 1. Debnath, S. 
et al. Discovery of a periosteal stem cell mediating intramembranous bone formation. Nature 
562, 133–139 (2018).
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A Subset of Osteocytes Contribute to Intramedullary Bone Formation 
during Fracture Repair *Yongmei Wang1, Anna Celli2, Sun Hee Won Kim1, 
Daniel Bikle1. 1Endocrine Unit, University of California, San Francisco/ San 
Francisco VA Health Care System, United States, 2Laboratory for Cell Analysis 
Core Facility, Helen Diller Family Comprehensive Cancer Center, University of 
California, San Francisco, United States
Fracture (Fx) repair is a complex process including intramembranous bone formation 
(BF), endochondral BF and intramedullary BF. Intramedullary bone formation (IMBF) oc-
curs within the marrow of the ends of fractured bones, and the mechanisms of its repair 
remain unknown.  To address this issue, we investigated the origin of the progenitors and 
mechanism of progenitor differentiation involved in IMBF by histology, lineage tracing and 
multi-photon microscopy. A unilateral closed mid tibial Fx was made in 12 wks old wild 
type  mice by 3 point-bending. Histological staining showed that at day 5 (D5) post Fx, only 
granulation tissues appeared in the intramedullary (IM) area;  neither bone nor cartilage had 
yet formed in this area. No Sox2 positive cells were observed in the area as well. At D10 post 
Fx, bone formed in the IM area, accompanied by vascular invasion, as indicated by CD31 
and VEGF expression, and marrow space formation within the newly formed bone. At D28 
post Fx, no trabecular bone was observed at the IM area, indicating the transient nature of 
IMBF during Fx repair. We then determined progenitors contribute to IMBF by tracing the 
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cell fate of type II collagen (Col2) expressing cells in the mice by crossing tamoxifen (tam) 
regulated  tam regulated Col2 cre-recombinase (Col2 cre) with Rosa TdTomato (TdT) ex-
pressing mice. Tam was given 1 day prior to Fx. At D10 post Fx, TdT labeled cells appeared 
in the IM area as well as in the cortical bone (CB) of the fractured bone ends (FBE) as 
osteocytes.  Immunohistochemistry (IHC)  identified that in the CB, TdT labeled osteocytes 
continuously  expressed Col2 and co-expressed the stem cell marker Sox2, while in the IM 
area, the TdT labeled cells no longer expressed Sox2, but expressed the osteoblastic gene os-
teocalcin and  osteocytic gene DMP-1. Multi-photon microscopy (Zeiss LSM780, Carl Zeiss 
microscopy), reconstructed 3D images demonstrated that TdT  labeled cells were located 
inside the lacunae in the CB of the FBE  and on the bone surface in the IM area. Interestingly, 
blood vessels originating from the lacunae containing TdT labeled cells crossed the CB and 
connected to the newly formed IM bone with the TdT  labeled cells.  Our data indicate that 
during Fx repair, IMBF is a transient process, Col2 expressing osteocytes from the broken 
bone ends appear to reprogram, migrate to the intramedullary area via the cortical vessel 
network, differentiate into osteoblasts, and contribute to IMBF.
Disclosures: Yongmei Wang, None
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Nox4 is critical for early but not late stages of osteoblastic stem cell 
renewal *Jin-Ran Chen1, Oxana P. Lazarenko1, James Watt2, Martin J. Ronis 
2. 11Department of Pediatrics, University of Arkansas for Medical Sciences, 
and 2Arkansas Children’s Nutrition Center, United States, 23Department of 
Pharmacology and Experimental Therapeutics, Louisiana State University 
Health Sciences Center, United States
Reactive oxygen species (ROS) can be generated by several sources, the tightly con-
trolled and cell-specific NADPH-oxidases (Nox) represent one of the major sources of ROS 
signaling molecules, including superoxide, hydrogen peroxide, and hydroxyl radicals in 
many cell types. We have previously identified that osteoblastic cells do not express Nox3 
but do express Nox 1, 2 and 4, with isoforms 4 and 2 being relatively abundant. We have 
characterized the role of Nox2 in bone cells during bone development by using a mouse 
model in which its co-factor p47phox was knocked out. In contrast, Nox4 has never been 
examined to determine if it plays a role during osteoblast self-renewal, proliferation and 
postnatal bone development. We have generated systemic Nox4 gene deletion mouse model 
(Nox4-/-), osteoblast specific Nox4 gene deletion mouse model (Nox4flox/flox/Prx1-Cre+, 
CKO) and control mouse model (Nox4flox/flox). Using these mouse models, we investi-
gated the role Nox4 in osteoblast stem cell renewal and late stage cell proliferation and 
postnatal bone development. Bone marrow stromal cells and non-adherent hematopoietic 
cells were isolated from 18 weeks old above three genotypic mouse groups (n=3). We found 
colony forming units-fibroblasts (CFU-F) were significantly lower in samples from CKO 
(56.0+/-12.3) and Nox4-/- (59.7+/-4.7) compared with those from Nox4flox/flox control 
(76.0+/-5.0). This was accompanied by significantly lower osteoblast stromal cell prolifer-
ation and senescence associated β-galactosidase activity in CKO and Nox4-/- groups com-
pared Nox4flox/flox control group. We have passaged and re-cultured those osteoblast stro-
mal cells and repeated assays for more than 12 times. We found that after 9 passages, those 
suppressed osteoblast stem self-renewal and proliferation in CKO and Nox4 groups caught 
up to control group. In passage 10, there were no differences on cell proliferation among 
groups, CKO (2.64+/-0.1 cells/well x 104) and Nox4-/- (2.67+/-0.1 cells/well x 104) com-
pared with Nox4flox/flox control (2.61+/-0.2 cells/well x 104). Osteoclastogenesis assays 
showed no differences among groups, however, β-Catenin mRNA expression in osteoclast 
progenitors was lower in CKO and Nox4-/- groups compared Nox4flox/flox control group. 
We have collected bone samples from 3 weeks old, 13 weeks old and 32 weeks old of all ge-
notypic groups (at least 6 per group), bone growth and bone mass in tibia and spine are under 
assessment using micro-CT and peripheral quantitative computerized tomography (pQCT) 
and histologic methods. These data suggested that Nox4 expression in bone osteoblastic 
cells might play different roles during osteoblast differentiation, maturation and prolifera-
tion. This study was supported by NIH grant R37 AA18282 to MJR.
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Knockdown of Zbtb40 disrupts mesenchymal differentiation and likely acts 
as a cell fate determination gene *Madison Doolittle1, Robert D Maynard2, 
Dana A Godfrey2, Charles R Farber3, Cheryl L Ackert-Bicknell2. 1Center for 
Musculoskeletal Research, University of Rochester, United States, 2Departament 
of Orthopedics, University of Colorado, United States, 3Center for Public Health 
Genomics, University of Virginia, United States
Zinc Finger and BTB Domain containing 40 (Zbtb40) is an under-characterized DNA 
binding protein that has been implicated in the regulation of bone mineral density (BMD) 
by genome-wide association studies (GWASs).  We previously showed that knockdown of 
Zbtb40 in vitro reduces mineralized nodule formation in MC-3T3 cells subjected to osteo-
blast differentiation and mice homozygous for a Zbtb40 truncation mutation have decreased 
trabecular bone volume in the vertebrae.  Other members of the ZBTB gene family act 
as regulators of stem cell differentiation. In this work we sought to determine if Zbtb40 
played a role in mesenchymal stem cell (MSC) differentiation. In MC-3T3 cells ZBTB40 
was bound to the promoter of the early MSC differentiation factor Msx2, suggesting that 
indeed Zbtb40 may act to impact the three main MSC lineages. To test if ZBTB40 impacted 
chondrogenesis we knocked down Zbtb40 in C3H10T ½ cells via siRNA and subjected these 
cells to DMEM:F12 media and 100ng of BMP-2.  Knockdown of Zbtb40 resulted in de-
creased expression of Sox9 (p<0.05), but interestingly expression of Col2a1 was increased 
(p<0.001) at day 3 post differentiation, compared to cells treated with scramble siRNA. 
At day 7 we saw an increase in Col10a1 (p<0.01) and Acan (Aggrecan, p<0.01). Next, we 
tested if Zbtb40 was involved in adipocyte differentiation. We knocked-down expression 
of this gene in C3H10T ½ cells, but this time treated them with high glucose DMEM, 1uM 
dexamethasone 0.5uM IMBX and 10 ug/ml of insulin. We saw a reduction in mRNA levels 
for Pparg (p<0.01), but no change in PPARG protein. We observed a reduction of Fabp4 
mRNA (p<0.01) and substantial reduction of FABP4 protein (P<0.0001), which may in part 
explain the lack of reduction of PPARG protein levels.  ZBTB40 did bind to the promoter of 
Pparg.  Further, Oil Red O staining was reduced in the Zbtb40 knockdown cells relative to 
the scramble siRNA treated cells after 8 days of differentiation. These data suggest ZBTB40 
may be an inhibitor of chondrogenesis and activator of adipogenesis. If these data are taken 
together with our previous work where we showed that knockdown or mutation of Zbtb40 
impacted osteoblastogenesis, these data collectively suggest that ZBTB40 plays a role in 
early MSC commitment and or differentiation.  Future studies will be needed to determine 
how ZBTB40 impacts adipose and cartilage formation in vivo.
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Physiological And Nutrition-related Effects On Bone Marrow Adipocyte 
Formation *George Soultoukis1, Marina Leer2, Charlotte Rinne2, Nicole 
Dittberner2, Katharina Schmidt-Bleek3, Tim Julius Schulz2. 1Leibniz Association, 
Germany, 2German Institute of Human Nutrition, Germany, 3Charité - 
Universitätsmedizin Berlin Julius Wolff Institut, Germany
IntroductionBone marrow fat comprises of adipocytes that are important components 
of the regenerative niche in bone. Unlike the more traditional brown and white adipose de-
pots throughout the body, marrow fat can expand in response to both nutrient shortage (e.g. 
caloric restriction) and nutrient excess (e.g. high fat diet). Marrow adipocytes are formed 
by a distinct population of committed adipogenic progenitor cells which in turn arise from 
a specialized population of the cellular stroma of the bone marrow. Under normal physio-
logical conditions long-bone derived mesenchymal stromal cells appear to mainly play a 
regulatory role, but they also increasingly undergo adipogenic lineage commitment under 
pathological conditions (e.g. obesity) and with age. However, the precise transcriptional and 
niche changes modulating these events are not fully understood. This work aims to elucidate 
these phenomena further. MethodsWe use a mouse model and immortalized murine bone-de-
rived stem cell lines to investigate how bone regeneration is influenced by aging, nutrition, 
and sitagliptin. We perform single-cell RNA-sequencing analysis, and profile the defined 
stem/progenitor cell populations to trace lineage commitment as a function of age and diet. 
We validate our findings through in vitro and in vivo analyses targeting identified candidate 
genes found to modulate cellular fate determination. ResultsWe find that adipogenic lineage 
fate determination is highly sensitive to specific nutrition-related signals. We show that dis-
tinct nutrients, alone or in conjunction with Bone Morphogenetic Protein (BMP) signaling, 
regulate osteogenic and adipogenic progenitor cell specialization, while related molecules 
promote the expansion of ectopic marrow fat. Commited adipogenic lineage cells highly 
express the protease DPP4, and inhibition of DPP4 by its antagonist sitagliptin abolishes 
its negative effects on bone healing mineralization via modulation of osteogenic progenitor 
cells. Finally, we also uncover a novel regulatory role of the alarmin cytokine IL-33. Con-
clusionsOur results expose critical changes in the bone marrow niche and elucidate novel 
mechanisms modulating bone regeneration as a function of age and diet. Loss of appropriate 
stem and progenitor cell formation contributes to the age- and diet-related loss of bone tissue 
integrity and regenerative capacity, and targeting molecules secreted by adipogenic progen-
itor cells can reverse these detrimental processes.
Disclosures: George Soultoukis, None
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Horizontal fissuring at the osteochondral interface: a novel and unique 
pathological feature in patients with obesity-related osteoarthritis *Lianzhi 
Chen1, Christopher Mitchell1, chriswjones@health.wa.gov.au Jones2, Minghao 
Zheng1. 1University of Western Australia, Australia, 2Fiona Stanley Hospital, 
Australia
Obesity is a well-recognized risk factor for osteoarthritis (OA). We aim to investigate 
if obesity is the causal antecedent of early joint replacement in patients with OA and charac-
terize the body mass index (BMI)-associated pathological changes in the osteochondral unit. 
We analyzed the impact of BMI on the age at which patients undergo total knee replacement 
(TKR). 616,469 cases of TKR from the Australian Orthopaedic Association National Joint 
Replacement Registry (AOANJRR) and the British National Joint Registry (NJR) were as-
sessed. It revealed that there was a significant progressive reduction in the age at which pa-
tients with increased BMI underwent TKR. The mean age of TKR in obese class III patients 
was 8 years younger than normal-weight patients. We then investigated the effect of BMI 
on pathological changes of the knee joint in a representative subset of 88 cases undergoing 
TKR. Histopathological examination revealed, for the first time, that horizontal fissuring at 
the osteochondral interface (Figure 1) was the major pathological feature of obesity-related 
171





OA. The frequency of horizontal fissure was strongly associated with increased BMI in the 
predominant compartment. An increase in one unit of BMI (1 kg/m2) increased the odds 
of horizontal fissures by 14.7%. Over 80% of the horizontal fissures were attributable to 
obesity. Reduced cartilage degradation and alteration of subchondral bone microstructure 
were also associated with increased BMI. In conclusion, obesity is strongly associated with 
a younger age of TKR. Due to differences in the mechanical properties of cartilage, calci-
fied cartilage and subchondral bone, secondary shear stress generated by high body weight 
in obesity-related OA induces horizontal fissures at the osteochondral interface. This key 
pathological feature may be the cause of earlier TKR in patients with obesity. This find-
ing will draw considerable attention to the osteochondral interface as a therapeutic target 
for obesity-related OA.Figure 1. Osteochondral interface of patients with normal weight 
(A), cartilage is firmly attached to calcified cartilage. In patients with obese class III (B), a 
horizontal fissure is observed at the osteochondral interface between the articular cartilage 
(AC) and subchondral bone (SCB). Free bone debris (black arrowhead) and cartilage erosion 
(empty arrow) are presented within the fissure.
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Effect of Denosumab on Osteoclast Activity within Osteolytic Lesions after 
Total Hip Arthroplasty: A Proof of Concept Trial *Mohit M Mahatma1, 
Raveen L Jayasuriya1, David Hughes2, Simon C Buckley2, Andrew Gordon2, 
Andrew J Hamer2, M Wassim Tomouk2, Robert M Kerry2, J Mark Wilkinson1. 
1University of Sheffield, United Kingdom, 2Sheffield Teaching Hospitals NHS 
Foundation Trust, United Kingdom
Osteolysis, leading to aseptic loosening, causes recurrent pain and disability after total 
hip arthroplasty (THA), and for which there are no established pharmacological alternatives 
to revision surgery. In this phase 2 clinical trial (EudraCT 2011-000541-20) we examined 
the effect of denosumab versus placebo on osteolytic lesion activity in patients undergoing 
revision surgery after THA. Men and women >= 30 years old scheduled for revision surgery 
for symptomatic, radiologically-confirmed osteolysis were randomised (1:1) to receive ei-
ther denosumab 60mg or placebo subcutaneously eight weeks prior to operation. At surgery, 
biopsies from the osteolytic membrane-bone interface were taken for histomorphometric 
analysis of osteoclast number, the primary outcome measure. Secondary outcome mea-
sures included other static histomorphometric indices and systemic bone turnover markers. 
Adverse events and patient-reported clinical outcome scores were recorded as safety end-
points. Of the 24 subjects enrolled, 22 completed the study (10 denosumab) and comprise 
the per-protocol analysis. There were no differences in baseline characteristics and bone 
turnover markers between groups (p>0.05). The denosumab group had 78% fewer osteo-
clasts at osteolytic lesion sites (95% CI -61 to -95, P=0.011), 81% lower osteoclast surface 
(-70 to -95, P=0.009), and 73% lower eroded surface (-54 to -92, P=0.020) compared to the 
placebo group. Number of osteoblasts and osteoblast surface were also reduced by 81% 
(-62 to -100, p=0.021) and 82% (-64 to -101, p=0.017), respectively. Immunocytochemistry 
for cell proliferation (Ki67) and apoptosis (Caspase 3) identified no differences between 
the groups (p>0.05). At surgery, serum CTX-I, TRAP5b and PINP were 80% (-65 to -95, 
p<0.001), 65% (-40 to -90, p<0.001), and 53% (-41 to -65, p0.05). In this phase 2 clinical 
trial, a single dose of denosumab reduced osteoclast activity within osteolytic lesions and 
was safe to administer. These data provide a biological basis for a definitive phase 3 clinical 
trial using clinical outcomes of pain, function and prosthesis survival as the study endpoints.
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Mitigation of Osteoarthritis Progression by Inhibiting Connexin 
Hemichannels *Rui Hua1, Yi Tian1, Manuel Riquelme1, Liang Ma1, Sumin Gu1, 
Jean X. Jiang1. 1Department of Biochemistry and Structural Biology, UT Health 
San Antonio, United States
Osteoarthritis (OA) is a joint disease characterized by degeneration of articular car-
tilage, subchondral bone remodeling and synovial inflammation, which causes pain and 
limited mobility. Connexin43 (Cx43) acts as a vital homeostatic regulator in the muscu-
loskeletal system and its expression is increased in the cartilage and synovial tissue of OA 
patients. Emerging evidence suggests that Cx43 contributes to the production of catabolic 
and inflammatory factors and exacerbates joint destruction. Cx43 forms hemichannels (HCs) 
that mediate the release of small molecules, such as ATP and prostaglandin E2 (PGE2), 
into the extracellular environment. The open probability of HCs is low under physiological 
conditions, while their activation is regulated by multiple factors, including proinflamma-
tory cytokines. We have developed a monoclonal antibody, which specifically inhibits the 
activity of Cx43 HCs. In primary mouse chondrocytes, ethidium bromide dye uptake assay 
indicated that this antibody blocked the IL-1β treatment induced HCs opening. To investi-
gate its function in OA progression, post-traumatic OA model was induced in male C57BL/6 
mice by surgically destabilization of the medial meniscus (DMM). Antibody or saline was 
administered by intraperitoneal injection twice during 8 weeks post-surgery. Cartilage deg-
radation and synovial inflammation were analyzed by histology and immunohistochemis-
try. Compared to saline group, Cx43 antibody treatment significantly improved cartilage 
integrity as quantified by the OARSI scoring system, decreased degree of synovitis, along 
with reduction of Mmp13 and Collagen X levels. Microcomputed tomography (μCT) of 
subchondral bone sclerosis showed a decrease in BV/TV, Tb.Th and an increase in Tb.Sp 
after inhibition of Cx43 HCs. In addition, Von Frey filament and open-field tests exhibited 
ameliorated OA associated pain symptoms in DMM mice with antibody treatment, while 
no difference was observed between saline and antibody treated sham mice. We found the 
antibody was primarily localized to the synovium region, and the signal was detectable even 
at 2 weeks after antibody administration. In vivo dye uptake and immunofluorescence assay 
further validated the role of antibody in blocking OA induced HCs opening in synoviocytes 
that express Cx43. Taken together, our study suggests that targeting Cx43 HCs is a potential, 
novel therapeutic strategy to mitigate the catabolic and inflammatory environment of the 
joint during OA progression.
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Mechanosensitive Control of Articular Cartilage and Subchondral Bone 
Homeostasis Requires Osteocytic TGFβ Signaling *Karsyn Bailey1, Jeffrey 
Nguyen2, Cristal Yee1, Neha Dole1, Alexis Dang1, Tamara Alliston1. 1University 
of California, San Francisco, United States, 2California State University, Long 
Beach, United States
Osteoarthritis (OA) is characterized by the irreversible disruption of multiple joint tis-
sues including articular cartilage and subchondral bone. While cartilage degeneration and 
subchondral bone changes are established hallmarks of OA, the causal mechanisms driving 
the coordinated loss of homeostasis in these two tissues remains unclear. The transforming 
growth factor beta (TGFβ) signaling pathway is known to play a complex tissue-specific 
and non-linear role in OA. The chondrocytic- and MSC-intrinsic contributions of TGFβ 
signaling to OA have been studied, but the role of osteocyte-intrinsic TGFβ signaling in joint 
homeostasis is unknown. Recent evidence demonstrates a new role for osteocytes in human 
and mouse OA, and we sought to identify the osteocytic contributions of TGFβ signaling 
to OA.We used male and female mice (n = 7-11 mice per group) with an osteocyte-intrinsic 
ablation of TGFβ type II receptor (DMP1Cre+; TβRIIfl/fl abbreviated as TβRIIocy-/-) and 
their control littermates (DMP1Cre-; TβRIIfl/fl), and assessed defects in cartilage degener-
ation, subchondral bone plate (SBP) thickness, and SBP sclerostin expression. To further 
investigate these mechanisms in male mice, we perturbed joint homeostasis using the medi-
al meniscal/ligamentous injury (MLI) model, which preferentially disrupts the mechanical 
environment of the joint on the medial side to induce OA. In all contexts, independent of 
sex, genotype, or medial or lateral joint compartment, increased SBP thickness and SBP 
sclerostin expression were spatially associated with cartilage degeneration. Male TβRIIo-
cy-/- mice, but not female TβRIIocy-/- mice, have significantly increased cartilage degener-
ation, increased SBP thickness, and higher levels of SBP sclerostin relative to Cre- controls, 
demonstrating that the role of osteocytic TGFβ signaling on joint homeostasis is sexually 
dimorphic. With changes in joint mechanics due to injury, injured Cre- control mice signifi-
cantly increase SBP thickness, subchondral bone volume, and SBP sclerostin expression. 
TβRIIocy-/- mice, however, are insensitive to subchondral bone changes with injury, sug-
gesting that mechanosensation at the SBP requires osteocytic TGFβ signaling. Our results 
provide new evidence that osteocytic TGFβ signaling is required for a mechanosensitive 
response to injury, and that osteocytes control SBP homeostasis to maintain cartilage health, 
uncovering osteocytic TGFβ signaling as a novel therapeutic target for OA.
Disclosures: Karsyn Bailey, None
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Tibial Bone Quality in Former Bariatric Surgery Patients with Knee 
Osteoarthritis *Breanne S. Baker1, Chantelle C. Bozynski1, Emily V. 
Leary1, Richard J. Sherwood2, James A. Keeney1, James L. Cook1, Dana L. 
Duren2. 1Department of Orthopaedic Surgery and Thompson Laboratory of 
Regenerative Orthopaedics, Missouri Orthopaedic Institute – University of 
Missouri, Columbia, MO, United States, 2Department of Orthopaedic Surgery 
and Thompson Laboratory of Regenerative Orthopaedics, Missouri Orthopaedic 
Institute – University of Missouri, Columbia, MO and Department of Pathology 
and Anatomical Sciences – University of Missouri, Columbia, MO, United States
The recent rise in bariatric weight loss surgery poses a unique set of challenges for or-
thopaedic surgeons. While bariatric surgery can be an effective means for rapid weight loss 
prior to procedures such as total knee arthroplasty (TKA) for severely overweight patients, 
it can also be associated with substantial bone resorption, potentially jeopardizing TKA 
prostheses fixation and/or ingrowth. This study sought to determine if TKA patients with 
history of bariatric surgery exhibit different subchondral bone quality compared to matched 
controls. Approval for this study was granted by the University of Missouri Institutional 
Review Board and was in accordance with the Declaration of Helsinki. Former bariatric sur-
gery patients (BS n=12) and sex-, age-, weight-, height-, and BMI-matched controls (CON 
n=10) completed Patient-Reported Outcomes Measurement Information System (PROMIS) 
surveys and underwent elective TKA at the Missouri Orthopaedic Institute. Tibial plateau 
osteochondral tissues that would otherwise be discarded were recovered after standard of 
care surgical resection and immediately processed. The central portions of the medial and 
lateral tibial plateaus were cut into 1 x 2 cm samples. These samples were scanned using mi-
croCT at 10.007–10.060 µm and analyzed using ImageJ and BoneJ software. Next, the same 
medial and lateral specimens underwent plastic embedding of undecalcified bone in methyl 
methacrylate. Two sections from each specimen were prepared for histologic sectioning, 
stained with Goldner’s trichrome, and histomorphometric measures of bone quality were 
analyzed using Clemex Vision PE software. Paired t-tests with a Bonferroni correction were 
performed and effect sizes (ES) were calculated for all measures between groups. BS pa-
tients reported more pain interference with daily tasks (p=0.044, ES=0.98) and poorer phys-
ical function (p=0.013, ES=1.28) compared to CON (see Figure 1).  No differences were 
found between BS and CON patients when comparing microCT (all p>0.195, all ES0.239, 
all ES<0.58). These results suggest that despite reporting greater difficulties with pain and 
physical function than control peers, former bariatric surgery patients who presented with 
endstage knee osteoarthritis requiring TKA did not exhibit altered bone microarchitecture 
or histomorphometry.
Disclosures: Breanne S. Baker, None
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Identification of Gli1 as A Progenitor Cell Marker for Meniscus 
Development and Injury repair *Yulong Wei1, Ling Qin1, Tao Gui1. 1University 
of Pennsylvania, United States
Meniscal tears, the most common injury of the knee, are associated with a high risk of 
osteoarthritis (OA). Stem cell transplantation has been proposed to repair injured menis-
cus. However, meniscus-specific progenitors remained largely unknown. Gli1, an effector 
of hedgehog (Hh) pathway, was recently recognized as a mesenchymal progenitor marker 
in bone. In this study, we constructed Gli1-CreER Tomato (Gli1ER/Td) mice for lineage 
tracing studies. Td did not label meniscus in newborn pups. In 2-wk-old mice, Td initial-
ly labeled the entire anterior horn and gradually concentrated at the superficial cells by 8 
wk of age. Td started to label posterior horn in 4-wk-old mice and later also focused on 
superficial cells. In adult mice, Td+ cells only occurred in the superficial layer of meniscal 
horns and long-term tracing did not detect their expansion. Td+ cells were co-stained with 
mesenchymal progenitor markers (Sca1, CD90, CD200, and PDGFRα) and lubricant Prg4. 
Sorted Td+ meniscal cells generated 2.6-fold more CFU-Fs and grew much faster than Td- 
cells. They also differentiate better into osteoblasts, chondrocytes, and meniscal cells than 
Td- cells in vitro. Hh activator (Purmorphamine, Pur) stimulated proliferation, migration, 
and differentiation of meniscus progenitors, while inhibitor (GANT-61) suppressed them. 
After transection of meniscal anteriomedial horn, Td+ cells quickly emerged at the injury 
ends and proliferated. This is line with human degenerated meniscus, in which Gli1 appeared 
in cell clusters with Ki67+ staining. Normally, the two ends of mouse meniscus remained 
separated 3 mo later (Repair score, RS: 3.9, n=8/group). However, injection of Td+ cells, 
but not Td- cells, from Gli1ER/Td meniscus into the joint capsule of WT mice right after 
injury resulted in the reconnection of two ends within 1 mo (4.8, n=8/group). Intraarticular 
injection of Pur also exhibited a strong repair effect (4.9, n=7/group). Knee OA develops 
2 mo later after meniscus injury. Strikingly, injection of Td+ cells or Pur right after injury 
greatly reduced cartilage degeneration and attenuated OA-related pain (Mankin Score: veh 
6.9, Gli1+ cells 4.5, and Pur 3.3; n=8/group, p<0.001). Taken together, our work establish-
es Gli1+ cells as a novel progenitor population contributing to meniscus development and 
injury response and indicates a new therapeutic target for repairing injured meniscus and 
preventing OA propagation.
Disclosures: Yulong Wei, None
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Understanding causal pathways between bone mineral density, body mass 
index and osteoarthritis using bidirectional and multivariable Mendelian 
randomization *April Hartley1, Eleanor Sanderson1, Raquel Granell1, Lavinia 
Paternoster1, Jie Zheng1, George Davey Smith1, Lorraine Southam2, Konstantinos 
Hatzikotoulas2, Cindy G Boer3, Joyce van Meurs3, Eleftheria Zeggini2, Celia L 
Gregson1, Jon H Tobias1. 1University of Bristol, United Kingdom, 2Institute of 
Translational Genomics, Helmholtz Zentrum Munchen, Germany, 3Erasmus 
Medical College, Netherlands
Objectives: Observational and Mendelian randomization (MR) analyses suggest that 
high Bone Mineral Density (BMD) is a risk factor for osteoarthritis (OA); however, it is 
unclear whether this represents a direct causal effect or shared aetiology. Moreover, con-
founding by body mass index (BMI) might contribute to this relationship, due to causal 
effects on both OA and BMD. We performed bidirectional MR to elucidate causal pathways 
between BMD, BMI and OA, and multivariable (MV)MR to determine if the causal path-
way from BMD to OA is BMI-independent.Methods: One-sample (1S)MR estimates were 
generated by two-stage least-squares regression, adjusted for sex, genotyping chip and 10 
principal components. Unweighted allele scores instrumented each exposure. Two-sample 
(2S)MR estimates were generated using inverse-variance weighted fixed-effects meta-anal-
ysis. Steiger filtering was performed prior to 2S analysis to remove SNPs explaining a great-
er proportion of variation in the outcome than the exposure. 1S MVMR, including BMD 
and BMI instruments in the same model, determined the BMI-independent causal pathway 
from BMD to OA. Instruments used for each analysis are summarized in Table 1. Latent 
causal variable (LCV) analysis, using weight-adjusted femoral neck BMD and hip/knee OA 
summary statistics, determined whether genetic correlation explained the causal effect of 
BMD on OA.Results: 1SMR provided strong evidence that higher eBMD causes hip and 
knee OA (ORhip=1.28[1.05,1.57], ORknee=1.40[1.20,1.63], OR per SD increase). 2SMR 
effect sizes were consistent in direction (Table 1). 1SMR suggested that causal pathways 
between eBMD and OA were bidirectional (βhip=1.10[0.36,1.84], βknee=4.16[2.74,5.57], 
β=SD increase per doubling in risk). BMI was strongly causally related to both hip & knee 
OA and eBMD in both 1S and 2SMR, but a causal effect of eBMD on BMI was not observed 
(Table 1). MVMR identified a BMI-independent causal pathway between eBMD and hip & 
knee OA (ORhip=1.26[1.03,1.54], ORknee=1.36[1.16,1.59]). LCV suggested that genetic 
correlation (i.e. shared genetic aetiology) did not fully explain causal effects of BMD on hip 
& knee OA.Conclusions: Our results provide evidence for a BMI-independent causal effect 
of BMD on OA. Despite evidence of bidirectional effects, the effect of BMD on OA did not 
appear to be fully explained by shared genetic aetiology, suggesting a direct action of bone 
on joint deterioration.
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Image-Based Bone Remodeling in Patients Achieving a Favourable Clinical 
Response to Biologic Therapies *Scott C Brunet1, Justin J Tse1, Micheal 
T Kucynski1, Steven K Boyd1, Cheryl Barnabe2, Sarah L Manske1. 1McCaig 
Institute for Bone and Joint Health, Biomedical Engineering Graduate Program, 
and Department of Radiology; Cumming School of Medicine, University of 
Calgary, Canada, 2McCaig Institute for Bone and Joint Health, Department of 
Community Health Sciences, Department of Medicine; Cumming School of 
Medicine, University of Calgary, Canada
Purpose: High resolution-peripheral quantitative computed tomography (HR-pQCT) 
imaging of patients with rheumatoid arthritis (RA) has suggested that biologic therapies may 
lead to the repair of bone damage in the hands, but this has not been assessed using a quan-
titative image-based bone remodeling analysis. The purpose of this study was to use HR-
pQCT to assess bone formation and resorption for patients that demonstrated a good clinical 
response to biologic therapy, and to examine if there are differences in bone remodeling 
across different biologic mechanisms of action.Methods: Ninety participants who met the 
2010 ACR/EULAR classification for RA and achieved a moderate or good EULAR response 
within 3 months of initiating biologic therapy were recruited. HR-pQCT images of the 2nd 
and 3rd metacarpophalangeal (MCP) joints were obtained at the time of their EULAR re-
sponse achievement and again 9 months later. After registering the follow-up image to the 
baseline, image-based bone remodeling analysis of the metacarpal head was performed to 
calculate bone formation (BF/TV) and resorption fractions (BR/TV), as well as net change 
(BF/TV – BR/TV). The average BF/TV and BR/TV across both joints were compared. We 
assessed differences in BF/TV and BR/TV by biologic therapy mechanism of action (an-
ti-TNF, anti-IL6, or T-cell co-stimulatory inhibitor).Results: Image-based bone remodeling 
analysis was successfully performed in at least one MCP joint of 46 patients. Thirty-three 
participants were lost to follow-up and 11 were excluded due to motion or inability to reg-
ister in both joints. BR/TV was significantly higher (0.57%) than BF/TV (0.47%) (p0.05).
Conclusions: This study demonstrates that biologic therapy results in minimal levels of bone 
remodeling in the metacarpal head of RA patients over the course of 9 months. This suggests 
that biologic therapy stabilizes bone remodeling but does not necessarily lead to systemic 
bone formation. There is visual evidence of local change in some patients (Figure 1), but the 
relationship with biologic therapy is unclear at this time. Future research should investigate 
local bone remodeling in eroded regions to determine if biologic therapy can lead to the local 
repair of RA erosions.
Disclosures: Scott C Brunet, None
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Association Between Serum Vitamin D Level and Osteoarthritis in Korean 
Elderly Population *Hee Sook Lim1, Kyo Il Suh2, Dong Won Byun2, Hyeong 
Kyu Park2, Hye Jeong Kim2, Sang Joon Park2. 1Department of Food and 
Nutrition, Yeonsung University, Republic of Korea, 2Division of Endocrinology 
and Metabolism, Department of Internal Medicine, Soonchunhyang University 
College of Medicine, Republic of Korea
Background and Purpose: Vitamin D is important in bone health and its relationship 
with osteoarthritis has been reported. Osteoarthritis (OA) and osteoporosis are common dis-
eases in the elderly and are known to be negatively associated, but their relationships in 
Koreans are not known. This study aimed to assess the risk of osteoarthritis by vitamin D 
and bone mineral density (BMD) status using a nationally representative database. Meth-
od: A total of 3,156 participants aged >=60 years were selected from the Korean National 
Health and Nutrition Examination Survey 2010-2013. We classified into two groups (nor-
mal: 2,431, OA: 725) according to arthritis presence. Radiographic osteoarthritis defined 
as Kellgren-Lawrence (KL) grade >=2. Bone health was classified according to T-score for 
osteoporosis or in tertiles. Socio-economic factors and health behaviors were compared into 
two groups. Results: The prevalence of osteoarthritis was 41.6% in males and was 58.4% 
in females. Subjects with osteoarthritis regardless of site tended to be older, have lower in-
come, lower education level, higher BMI, lower strength exercise frequency. Quality of life 
(EQ-5D) was also significantly lower in the osteoarthritis group. Medium vitamin D status 
was associated with a lower compared to those with higher vitamin D status both males and 
females. In BMD tertiles, osteoarthritis was lower in those with BMDs of T1 compared to 
T3 at the total femur and lumbar spine in females. Conclusion: Vitamin D level and bone 
mineral density were positively associated with osteoarthritis in elderly people.
Disclosures: Hee Sook Lim, None
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Possibities of Trabecular Bone Score to Reflect Activity and Progression 
of Ankylosing Spondilitis in Young Patients *Konstantin Kolpakov1, Julia 
Ubshaeva1, Vitaly Omelchenko1, Maxim Korolev1. 1RICEL - Branch of IC&G 
SB RAS, Russian Federation
I. INTRODUCTION Ankylosing spondylitis (AS) is a systemic inflammatory disease, 
with primary lesion of spine. Inflammation is developing mainly in lumbar vertebrae, lead-
ing to its degradation. Meanwhile, it is proliferating in AS resulting in syndesmophytes 
formation. Dual-energy X-ray absorptiometry (DXA) is used to measure bone mineral 
density (BMD), but it is invalid in AS, because of osteophytosis. Trabecular bone score 
(TBS) is another tool to evaluate bone properties. While BMD represents quantity of the 
bone tissue, TBS represents its quality. So, TBS does not lose its value in the presence of 
syndesmophytes. The aim of this work is to investigate TBS correlation with BMD, clinical 
and laboratory disease activity and structural progression of AS in the males before 50. II. 
MATERIALS AND METHODS 21 AS male patients before 50 were included in investiga-
tion. The following parameters were collected: age, duration of the disease, BASDAI and 
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ASDAS scores, consumption of corticosteroids, smoking status, history of fractures. Eryth-
rocyte sedimentation rate (ESR), C-reactive protein (CRP) and fibrinogen were also evalu-
ated. The degree of structural progression of AS was determined by the stage of sacroiliitis 
according to Kellgren. BMD was measured in the lumbar spine, right and left femurs and 
femoral necks. TBS in the lumbar spine was determined using an iNsight software package. 
All the results are presented as Median (Me) +/- Standard Deviation (SD). The relationships 
between variables were studied using Spearman correlation analysis. III. RESULTS The 
median age is 36+/-6.8 years, the BASDAI index is 2.3+/-0.9. Two patients had a history of 
vertebral fractures. 19.0% of patients have stage 2 sacroiliitis, 33.3% have stage 3 and 47.7% 
have stage 4. The median TBS in the group was 1.407+/-0.131, BMD in the lumbar spine - 
1.184+/-0.136, in the right and left femurs - 1.012+/-0.127 and 1.006+/-0.126, respectively, 
in the right and left necks of the femur - 0.980+/-0.152 and 0.957+/-0.132, respectively. 
A negative correlation was revealed between the stage of sacroiliitis and TBS values (r=-
0.49; p<0.05). There was no correlation between either TBS or stage of sacroiliitis and age. 
Patients with a history of vertebral fractures had the lowest TBS values in the entire group 
(1.167 and 1.121). No one parameter of AS activity correlated with TBS or BMD. IV. CON-
CLUSION TBS, unlike BMD, reflects structural progression of AS, but do not correlate with 
clinical or laboratory activity.
Disclosures: Konstantin Kolpakov, None
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Development of a precision medicine-based therapeutic strategy 
forrheumatoid arthritis *Chao Liang1, Duoli Xie1. 1Hong Kong Baptist 
University, Hong Kong
Bone erosion is a central feature of rheumatoid arthritis (RA). Traditional concept holds 
that chronic inflammation causes bone erosion in RA. Thus, most of the anti-RA drugs are 
designed for targeting inflammation to attenuate bone erosion. Among these drugs, Lefluno-
mide has been used for almost twenty years. However, only 40-50% RA patients show good 
response to Leflunomide in attenuating bone erosion.Recently, we found that RA patients 
with either good or limited response to Leflunomide in attenuating bone erosion had equiv-
alent basal inflammation. Surprisingly, these two subgroups of patients showed comparable 
immunosuppression after Leflunomide treatment. C-reactive protein (CRP) is synthesized 
by liver and commonly considered as an inflammation marker. However, emerging evidenc-
es reveal that there are large genetic variations of CRP, which are irrelevant to inflammation 
status in RA. Further, it has been reported that CRP could directly regulate osteoclastic 
activity. We found that RA patients with good response to Leflunomide showed relatively 
low basal serum CRP (CRPlow), whereas the others with limited response demonstrated 
high basal CRP (CRPhigh). We observed the similar relationship between the high basal 
CRP and the limited response to Leflunomide in established collagen-induced arthritis (CIA) 
rats. CRP silencing compensated the limited efficacy of Leflunomide, leading to adequate 
attenuation of bone erosion in the CRPhigh CIA rats. We concluded that in addition to in-
flammation, high CRP was another factor responsible for inducing bone erosion in CRPhigh 
RA.CRP has two isoforms: native CRP (nCRP) and monomeric CRP (mCRP). nCRP is 
normally present as a pentamer of five identical subunits in serum, which is inefficient for 
osteoclastic activity. However, nCRP dissociates into monomeric CRP (mCRP) upon enter-
ing inflammatory sites. Studies have shown that mCRP directly induces osteoclastic differ-
entiation in vitro. We found that there was excessive mCRP in both CRPlow and CRPhigh 
RA patients and CIA rats. 1,6-bis(phosphocholine)-hexane has been reported to be a small 
molecular CRP inhibitor, which could suppress dissociation of nCRP to mCRP. In vitro 
proper inhibition of nCRP dissociation by 1,6-bis-PC decreased osteoclastic differentia-
tion. Combination of 1,6-bis-PC with Leflunomide could compensate the limited efficacy 
of Leflunomide, leading to adequate attenuation of bone erosion in CRPhigh CIA rats.This 
study would present a precision medicine-based therapeutic strategy for RA. Combination 
of Leflunomide with 1,6-bis-PC will be a promising approach for adequately attenuating 
bone erosion in CRPhigh RA. This study was supported by grants from the Natural Science 
Foundation Council of China (81700780 and 81922081).
Disclosures: Chao Liang, None
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Conditional Knockout of SHP2 in Mice Reveals Its Indispensable Role in 
Osteogenic Maturation and Bone Mineral Homeostasis *Huiliang Yang1, 
Lijun Wang1, Jiahui Huang1, Douglas Moore1, Wentian Yang1. 1Brown University 
Alpert Medical School and Rhode Island Hospital, United States
Purpose: The maturation and function of osteoblasts (OBs) heavily rely on the revers-
ible phosphorylation of signaling proteins. To date, most of the work on OBs has been fo-
cused on phosphorylation by protein kinases, whereas little has been studied on dephosphor-
ylation by protein tyrosine phosphatases (PTPase). SHP2 (encoded by Ptpn11) is an ubiq-
uitously expressed PTPase. Previous studies show that SHP2 mutations are associated with 
human Noonan syndrome (NS) and metachondromatosis (MC); both display bone and car-
tilage manifestations. The role of SHP2 in skeletal cells remains incompletely understood. 
To investigate whether and how SHP2 functions in skeletal cells, we generated OB-specific 
SHP2 deficient mutant mice.Methods: OB-specific SHP2 deficient mice (SHP2KOBglap) 
and littermate controls (SHP2CTRBglap) were generated by crossing mice bearing Ptpn11 
floxed allele to Tg(Bglap-Cre) mice. Tg(Rosa26ZsG) allele served as a Cre reporter. Mice 
were sacrificed at the indicated time points and underwent X-ray, µ-CT, histological, bio-
chemical, and biological analyses per the protocols approved by IACUC. Results: SHP2KO-
Bglap mice appeared normal and indistinguishable from the SHP2CTRBglap mice up to 10 
weeks. However, the mobility of SHP2KOBglap mutants became progressively restricted 
as they aged. Analysis of skeletal morphology with radiographs revealed a striking skeletal 
phenotype in SHP2KOBglap mutants featuring scoliosis, reduced bone mineral density, and 
growth of osteochondromas and enchondromas adjacent to the metaphysis of multiple joints. 
Further phenotypic studies showed that SHP2 deletion in OBs leads to significant osteopenia 
in both trabecular and cortical bones (Fig.1A, 1B) due to failed bone cell maturation and 
function (Fig. 1C), and enhanced osteoclast activity (Fig. 1D). SHP2 deficient but Bglap+ 
chondrocytes were found to contribute to the onset of enchondromas and osteochondro-
mas in old mice. Mechanistically, SHP2 was found to promote osteoblastic differentiation 
by promoting RUNX2/OSTERIX signaling and suppress osteoclastogenesis by inhibiting 
STAT3-mediated RANKL production by osteoblasts and osteocytes.Conclusions: Our study 
uncovered an indispensable role for SHP2 in regulating OB maturation and function, local 
osteoclastogenesis, and bone mineral homeostasis. These findings also explain why the skel-
etal system is compromised in NS and MC patients and inform the development of novel 
therapeutics to combat skeletal disorders.
Disclosures: Huiliang Yang, None
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SLC1A5 regulates osteoblast differentiation by providing glutamine used 
for de novo amino acid synthesis. *Deepika Sharma1, Guo-fang Zhang1, Yilin 
Yu2, Courtney Karner1. 1Duke University, United States, 2duke University, 
United States
Osteoblasts are bone forming cells whose primary function is to synthesize and secrete 
Type I Collagen and other proteins that comprise the bone matrix. A constant supply of 
amino acids is required to sustain high rates of protein synthesis associated with bone anab-
olism. To meet this requirement, osteoblasts must maximize the production or acquisition 
of amino acids. Indeed, recent reports have linked the regulation of amino acid uptake and 
metabolism to osteoblast function and bone formation. For example, osteoblast progenitors 
increase glutamine uptake and metabolism necessary for osteoblast differentiation. Howev-
er, little is known about specific amino acid transporters mediating glutamine uptake, nor 
their regulation during osteoblast differentiation.  Here we identify the amino acid trans-
porter Slc1a5 as the primary glutamine transporter in osteoblasts. To determine the role 
of Slc1a5 during bone development, we generated a novel floxed Slc1a5 allele (Slc1a5fl) 
using homologous recombination to insert lox P sites flanking exon 2. Deletion of Slc1a5 
in specified osteoblasts using Sp7Cre significantly reduced glutamine uptake and resulted in 
defective intramembranous and endochondral ossification. Sp7Cre;Slc1a5fl/fl animals were 
characterized by reduced protein expression of both Osterix (encoded by Sp7) and Type I 
Collagen despite normal Sp7 and Col1a1 mRNA expression. Consistent with this, inhibiting 
Slc1a5 dependent glutamine uptake reduced the rate of general protein synthesis as well as 
collagen synthesis in vitro. Mechanistically, Slc1a5 dependent glutamine uptake is critical 
to maintain intracellular amino acid homeostasis.  Stable isotopomer analysis indicated that 
glutamine carbon and nitrogen are used for de novo synthesis of many amino acids includ-
ing glutamate, proline and aspartate which are directly incorporated into newly synthesized 
protein. Importantly, inhibiting glutamine catabolism significantly reduced the concentration 
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of glutamine derived amino acids as well as protein and collagen synthesis. Collectively, our 
data indicates Slc1a5 provides osteoblasts with glutamine used for de novo synthesis of ami-
no acids that are rapidly incorporated into protein to support bone matrix production. Thus, 
our data strongly suggest that manipulation of Slc1a5 activity may provide a therapeutic 
approach for normalizing deranged bone anabolism associated with human bone diseases.
Disclosures: Deepika Sharma, None
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FAK promotes early osteoprogenitor cell proliferation by enhancing 
mTORC1 signaling *Shuqun Qi5, Xiumei Sun5, Han Kyoung Choi5, Jinfeng 
Yao5, Li Wang5, Guomin Wu5, Yun He5, Jian Pan3, Jun-lin Guan4, Fei Liu5. 
5Department of Biologic & Materials Sciences and Prosthodontics, University of 
Michigan School of Dentistry, Ann Arbor, MI 48109, USA, China, 5Department 
of Biologic & Materials Sciences and Prosthodontics, University of Michigan 
School of Dentistry, Ann Arbor, MI 48109, USA, Republic of Korea, 3Department 
of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, 
Sichuan University, Chengdu, Sichuan 610041, China, China, 4Department of 
Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH 
45267, USA, United States, 5Department of Biologic & Materials Sciences and 
Prosthodontics, University of Michigan School of Dentistry, Ann Arbor, MI 
48109, USA, United States
Focal adhesion kinase (FAK) is an intracellular non-receptor tyrosine kinase and a ma-
jor mediator of signal transduction by integrins. The goal of this study was to determine the 
impact and mechanism of FAK inhibition in osteoblast lineage cells on bone homeostasis. 
µCT and histomorphometry analyses showed that mice lacking FAK in Dermo1-expressing 
cells exhibited low bone mass and decreased osteoblast number. By generating compound 
mice using Ai14 fluorescence reporter mice, we were able to specifically analyze the ef-
fect of Fak deletion on the Dermo1-expressing bone marrow stromal cells (BMSCs). Our 
data showed that Dermo1-targeted FAK-deficient early osteoprogenitor cells had decreased 
proliferation and reduced colony formation ability. Mechanistically, FAK-deficient early os-
teoprogenitor cells had significantly reduced mammalian/mechanistic target of rapamycin 
complex 1 (mTORC1) signaling, a central regulator of cell growth and proliferation, shown 
by a significant decrease in the levels of phospho-mTOR and phospho-S6 by western blot 
and immunofluorescence analyses. Furthermore, our data showed that the pharmacological 
inhibition of FAK kinase function alone was sufficient to decrease the proliferation and com-
promise the mineralization of early osteoprogenitor cells in vitro. In contrast to the Fak dele-
tion in early osteoprogenitor cells, FAK loss in Col3.6 Cre-targeted osteoblasts did not cause 
bone loss, and Fak deletion in osteoblasts did not affect proliferation, differentiation, and 
mTORC1 signaling but increased the level of active proline-rich tyrosine kinase 2 (PYK2), 
which belongs to the same non-receptor tyrosine kinase family as FAK. Importantly, if 
FAK kinase was inhibited in BMSCs at the early osteogenic differentiation stage, mTORC1 
signaling was reduced without any change in active PYK2 level and mineralization was 
compromised. In contrast, if FAK kinase was inhibited at a later osteogenic differentiation 
stage, mTORC1 signaling was not affected but active PYK2 was upregulated, however, the 
concomitant inhibition of both FAK kinase and PYK2 kinase reduced mTORC1 signaling 
and mineralization. In summary, our data suggest that FAK promotes early osteoprogenitor 
cell proliferation by enhancing mTORC1 signaling via its kinase-dependent function and the 
loss of FAK in osteoblasts can be compensated by the upregulated active PYK2. Together 
with previous work, we conclude that FAK has differential roles in osteoblast lineage cells 
(Fig 1).
Disclosures: Shuqun Qi, None
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Slc38a2 provides proline to fulfill energetic and biosynthetic demands 
associated with osteoblast differentiation and bone formation *Leyao Shen1, 
Yilin Yu2, Guo-Fang Zhang3, Courtney Karner1. 1Department of Orthopaedic 
Surgery, Department of Cell Biology, Duke University, United States, 
2Department of Orthopaedic Surgery, Duke University, United States, 3Duke 
Molecular Physiology Institute, United States
Osteoblasts are the chief bone forming cell responsible for producing and secreting 
the Type I Collagen rich extracellular matrix. Protein synthesis is very demanding from an 
energetic and biosynthetic standpoint, requiring copious amounts of ATP and amino acids 
amongst other metabolites. Thus, bone matrix production is predicted to burden osteoblasts 
with unique biosynthetic and energetic demands to maintain high rates of protein synthe-
sis associated with bone anabolism. To understand how osteoblasts fulfill these metabolic 
demands, we devised a computational method to predict important amino acids and how 
amino acid demand changes during osteoblast differentiation. This method identified pro-
line as a potentially important amino acid whose demand increases during osteoblast dif-
ferentiation. For example, proline is significantly enriched in important osteoblast proteins 
including RUNX2, OSX, COL1A1 and OCN. Consistent with this, proline uptake increases 
concomitantly with induction of these proteins during differentiation indicating proline may 
be a critical regulator of osteoblast differentiation. Unfortunately little is known about how 
osteoblasts obtain or utilize proline. Here we identify the amino acid transporter Slc38a2 
as the primary proline transporter in osteoblasts. Conditional deletion of a floxed allele of 
Slc38a2 (Slc38a2fl) in either mesenchymal progenitors using Prx1Cre or preosteoblasts us-
ing Sp7Cre resulted in defects in both intramembranous and endochondral ossification due 
to defective osteoblast differentiation highlighted by a specific reduction of proline enriched 
proteins (e.g. OSX and COL1A1). Mechanistically, Slc38a2 provides proline to support 
osteoblast differentiation via two major modes. First, stable isotopomer analysis indicates 
proline is directly incorporated into nascent protein and does not contribute to amino acid 
biosynethsis or TCA cycle anaplerosis. Second, proline oxidation provides electrons to the 
electron transport chain to fuel ATP production necessary for cellular activity. Collectively, 
these data highlight a bipartite mechanism by which proline fulfills the energetic and bio-
synthetic demands associated with osteoblast differentiation and bone matrix production.
Disclosures: Leyao Shen, None
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Runx2 defines the osteoblast chromatin landscape in skeletal development 
*Hironori Hojo1, Taku Saito1, Shoko Onodera2, Toshifumi Azuma2, Ung-il 
Chung1, Masahide Seki1, Yutaka Suzuki1, Andrew McMahon3, Shinsuke Ohba4. 
1The University of Tokyo, Japan, 2Tokyo Dental College, Japan, 3University of 
Southern California, United States, 4Nagasaki University, Japan
Runx2 is an essential transcription factor for both osteoblast specification and chon-
drocyte hypertrophy. At the 2019 ASBMR annual meeting, we presented our finding that 
Runx2 acted on accessible chromatin regions in a cell-type-distinct manner in osteoblasts 
and chondrocytes. However, it remains to be clarified whether Runx2 is involved in the 
establishment of the chromatin accessibility. To address this question in an in vivo setting, 
we generated Sp7-GFP::Cre;Runx2fl/fl;R26Rtdtomato compound mice. This mouse line 
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enabled us to perform both conditional ablation of Runx2 and genetic marking with Td-
tomato in the Runx2-deficient cells simultaneously upon CRE expression driven by Sp7 
activation. As Runx2 is genetically upstream of Sp7, Runx2 was transiently expressed in 
osteoblast progenitors, but was ablated at Sp7-positive stage in the Runx2-deficient cell lin-
eage. We confirmed that skeletal formation was severely impaired in the conditional Runx2 
homozygous-knockout mice (Runx2 cKO) at E18.5 as previously reported (Takarada T. et 
al., Development 143, 2016). We performed ATAC-seq with the Tdtomato positive cells 
purified from E18.5 Runx2 cKO calvaria. The assay revealed that chromatin accessibili-
ty was significantly decreased in 2,643 genomic regions in Runx2 cKO cells compared to 
the Runx2 heterozygous-knockout cells. Gene ontology analysis, de novo motif analysis 
and integrative analysis with a Runx2-DNA binding profile revealed that the Runx2-depen-
dent accessible regions were primarily bound by Runx2 through a Runx consensus motif, 
and were highly associated with genes related to skeletal development. Next, to identify 
Runx2-mediated functional enhancers, we conducted a CROP-seq assay (Datlinger P. et 
al., Nat Methods 14, 2017). In this assay, multiplexed CRISPR-based enhancer knockout 
was combined with single-cell RNA-sequencing, giving both the genotype as guide RNA 
sequence and the phenotype as transcriptome at single-cell resolution. This assay identified 
a functional osteoblast enhancer called Enh-Ob. Reporter assays and EMSA confirmed that 
Runx2 transactivated the Enh-Ob through a Runx motif. Finally, a reporter transgenic assay 
and enhancer knockout study revealed that the Enh-Ob was specifically activated in skeletal 
tissues and was required for normal osteogenesis. Collectively, these results suggest that 
Runx2 is required for maintenance of chromatin accessibility at osteoblast cis-regulatory 
modules, which underlies osteoblast specification.
Disclosures: Hironori Hojo, None
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Aromatase Deficiency in Osteoblasts Causes Decrease Bone Mass Accrual 
in Young Mice *Amber Sherwood1, Katie Rubitschung1, Orhan K. Öz1. 1UT 
Southwestern Medical Center Department of Radiology, United States
Estrogens have a regulatory role in bone metabolism. Peripheral estrogen synthesis 
is thought to be important in post-menopausal women and men. Using a novel transgenic 
mouse model, we evaluate changes in bone mineral density by DXA in young osteoblast 
specific aromatase knockout mice (ObArKO).The ObArKO model was generated using a 
conditional Cre recombinase driven by the Col1a1-2.3 promoter1 and a floxed Cyp19a1 
Exon 2 allele. Homozygous floxed (Aromfl/fl) female mice were bred to hemizygous 
Col2.3-Cre Aromfl/fl males. Mice were maintained on a C57BL/6J background and fed a 
normal chow diet. DXA imaging was performed on male and female ObArKO and Aromfl/
fl littermates at 4, 8, 12, and 16 weeks of age. Animal weight and nose-anal length were 
recorded at each time point. Upon sacrifice, gonads were characterized to assess ectopic 
Cre expression. There were at least n=8/group.Uterine weight and testicular weights were 
not different between groups. Nose-anal length and body fat % were comparable to con-
trols. Significant decreases in whole body BMD were observed in female ObArKO mice 
at 4, 8, 12, and 16 weeks of age (p=0.014 or better). Spinal BMD was also significantly 
decreased in ObArKO females at 4 and 8 weeks, but was comparable to controls thereafter. 
ObArKO females showed decreased femoral BMD at 4, 8, 12, and 16 weeks (p=0.001, 
0.0002, 0.002, and 0.120). ObArKO females displayed significantly abated body weight 
at 4, 8, and 12 weeks (p=0.016 or better). The differences were resolved at 16 weeks. Male 
ObArKO mice exhibited low whole body BMD only at 8 weeks of age (p=0.017). Spinal 
and femoral BMD was reduced at 4 weeks (p=0.014 and p=0.005) and 8 weeks (p=0.011 
and p=0.010, respectively), although no differences were seen at 12 or 16 weeks. Nose-anal 
length was less in male ObArKO at 8 weeks (p=0.037). Body fat % was similar between 
groups.Here we present a reproductively sound mouse model to facilitate investigation into 
the role of osteoblast derived estrogen in bone metabolism. Male and female ObArKO mice 
demonstrated significant decreases in BMD compared to control littermates, suggesting that 
estrogen synthesized by osteoblasts is necessary for early bone mass accrual in mice. The 
normal % body fat and uterine weights are distinct from the global aromatase knockout. 
Underlying mechanisms of impaired bone mass accrual warrant further examination.1Liu F. 
et al. (2004). Int J Dev Biol. 48:645–653.
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Overexpressing miR-125b in Osteoblasts Confers a Significant Survival 
Benefit in Mice with Bone Metastasis *Shohei Kohno1, Nushrat Sarmin1, 
Tomoko Minamizaki1, Yuji Yoshiko1. 1Department of Calcified Tissue Biology, 
Graduate School of Biomedical & health Sciences, Hiroshima University, Japan
We have previously shown that miRNAs encased in matrix vesicles (MVs) budding 
from osteoblasts accumulate in bone matrix. Of these, miR-125b inhibits osteoclast forma-
tion by downregulating its target Prdm1, a transcription repressor, resulting in increased ex-
pression of anti-osteoclastogenesis factors including MAFB and IRF8. Transgenic (Tg) mice 
overexpressing miR-125b by using human osteocalcin promoter exhibit high bone mass with 
a decreased number of osteoclasts. Taken together with the fact that miR-125b is known to 
act as a tumor suppressor, these results lead us to determine whether miR-125b as MV cargo 
abrogates osteolytic bone metastasis. First, we treated cancer cell lines (the human prostate 
cancer PC-3 and breast cancer MCF-7 and the murine mammary carcinoma Py8119) with 
mouse MVs, resulting in suppression of cancer cell proliferation, migration and invasion in 
vitro. These effects were mimicked by ectopic overexpression of miR-125b in cancer cells. 
To determine whether miR-125b as a MV cargo can suppress cancer metastasis in vivo, 
Py8119 cells tagged with luciferase (Py-Luc cells) were injected into wild-type (WT) and 
Tg mice via the caudal artery. In vivo imaging demonstrated that Luc activity was detected 
in femurs as early as 17 days post-injection (pi) and then spread across multiple sites in WT 
mice and only in femurs in Tg mice at 21 days pi. Micro-CT could detect bone loss in the 
proximal femurs as early as 10 days pi. Concomitant with these, less severe bone defects 
in the metastatic lesions were histologically proven in Tg vs WT mice. A large number of 
TRAP-positive multinuclear cells (osteoclasts) could be detected in the interface between 
bone and metastatic Py-Luc in both genotypes, and ROI analysis revealed that the number of 
osteoclasts in Tg mice was less than that in WT mice. To assess whether overexpression of 
miR-125b in osteoblasts show a significant survival benefit, Tg mice and WT mice injected 
with and without Py-Luc cells were grown under normal conditions. All WT mice received 
Py-Luc cells died by 28 days pi, while some of Tg mice with Py-Luc cells survived more 
than 40 days. In this study, we demonstrated that overexpression of miR-125b in osteoblasts 
suppress bone metastasis via its possible dual actions by inhibiting osteoclastogenesis and 
blocking cancer cell activities. Our findings may provide a potential therapeutic strategy for 
osteolytic bone metastasis.
Disclosures: Shohei Kohno, None
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Cell Trafficking and Regulation of Osteoblastogenesis by Extracellular 
Vesicle Intralumenal Bone Morphogenetic Protein-2 *Saigopalakrishna 
Yerneni1, Juraj Adamik2, Lee Weiss3, Phil Campbell1. 1Department of Biomedical 
Engineering, Carnegie Mellon University, United States, 2Department of 
Hematology/Oncology, School of Medicine, University of Pittsburgh, United 
States, 3The Robotics Institute, Carnegie Mellon University, United States
Extracellular vesicles (EVs), which are found in all body fluids as well as immobilized 
within the tissue extracellular matrix, contain a wide array of both surface-bound and intralu-
menal signaling cargo, including growth factors. Whereas EV surface-bound growth factors 
can directly access their receptors on target cell surfaces, the cell signaling mechanism(s) 
associated with intraluminal EV growth factor regulation of cell function remains unknown. 
To help gain insight into this mechanism, we investigated trafficking and regulation of os-
teoblastogenesis by bone morphogenetic protein-2 (BMP2), as a paradigm growth factor, 
loaded directly into the lumen of J774A.1-derived EVs (BMP2-EVs) using sonification or 
indirectly collected as an EV product of BMP2 recycling experiments with C2C12 cells. 
Bioactivity of BMP2-EVs was then assessed using C2C12 cell culture. ‘Free’ uncomplexed 
BMP2 was used as a control. Trafficking studies were performed using 125I-BMP2 or 
125I-EVs. Both were readily internalized by C2C12 cells, with similar intracellular and cell 
surface-bound fractions of ~90% and ~10%, respectively. Recycling experiments to deter-
mine the fate of internalized BMP2 and EVs showed rapid externalization of both BMP2 
and EVs in as little as 2 min, with an eventual release of 23-40% of internalized BMP2 or 
EVs by 30 min. Recycled BMP2 or EVs were minimally proteolytically degraded, with 10% 
of each being retained on the cell surface and 90% being released into the extracellular mi-
croenvironment. Approximately 65% of recycled BMP2 was associated with EVs, whereas 
~75% of recycled EVs remained intact and capable of cell signaling. Based on gene and 
protein expression experiments, BMP2-EVs regulated osteoblastogenesis similarly to free 
BMP2. Finally, cell culture experiments with added noggin, an inhibitory BMP2 extracellu-
lar binding protein, demonstrated that BMP2-EVs could still regulate osteoblastogenesis via 
intracellular signaling since any recycled, extracellular free BMP2 did not play a significant 
role in inducing osteoblastic differentiation. Collectively, these experiments show that EV 
intraluminal BMP2 can bypass BMP2 cell surface receptors and deliver BMP2 directly into 
the intracellular compartment via EV internalization processes where BMP2 signaling is 
apparently initiated from within the cell. It also raises the question do other EV intralumenal 
growth factors utilize similar cell signaling processes?
Disclosures: Saigopalakrishna Yerneni, None
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Analysis of BMP2-dependent Gene Regulatory Network Revealed New 
Perspective of Klf4 as a Novel Transcription Factor Governing Osteoblast 
Differentiation *Shuaitong Yu1, Huan Liu1, Zhi Chen1. 1School of Stomatology 
Wuhan University, China
Transcription factors turn on/off the expression of target genes, which, in turn, allow for 
changes in cell morphology or activities needed for cell fate determination and differentia-
tion. BMP signaling have been widely regarded as one of the most important topics in ver-
tebrate skeletal biology, of which BMP2 is a potent inducer governing osteoblast differenti-
ation of bone marrow stromal cells (BMSCs). However, how BMP2 initiate its downstream 
transcription factor to determine differentiation direction remain largely unknown. Here, we 
used RNA-seq, ATAC-seq and animal models to illustrate BMP2-dependent gene regulatory 
network governing osteoblast lineage commitment. We firstly generated Bmp2f/fSp7-Cre 
mice (Bmp2-cKO). We did not observe any significant difference between Bmp2-cKO and 
their siblings in newborn mice. However, as early as 2 weeks of age, these mice were small 
in size compared with control. Micro-CT analyses revealed Bmp2-cKO mice exhibited de-
creased bone density. Histological analyses also found obvious defects in the number of 
osteoblasts. In vitro experiment showed BMSCs isolated from Bmp2-cKO mice exhibiting 
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impacted osteoblast differentiation. BMSCs were harvested from Bmp2f/f (Bmp2-WT) and 
Bmp2-cKO mice and induced with osteogenic medium for 7 days, which were then subject-
ed to RNA-seq and ATAC-seq analysis to reveal BMP2-dependent gene regulatory network 
governing osteoblast differentiation. Combined with previous reported H3K27Ac ChIP-seq 
for osteoblast differentiation, we identified xxx chromatin regions of active enhancers were 
closed with the loss of BMP2 resulting the down-regulation of 2352 genes and up-regulation 
of 2231 genes. We further identified over 80% of these cis-regulatory elements were directly 
targeted by Runx2, Dlx5, Mef2c, Oasis and Klf4. We further chose Klf4 as a novel research 
target and also generated Klf4f/fSp7-Cre mice to investigate the role of KLF4 in osteo-
blast differentiation of mBMSCs. However, most of Klf4f/fSp7-Cre mice (Klf4-cKO) died 
after birth, Klf4f/+Sp7-Cre (Klf4-Het) survived to adulthood and exhibited smaller body 
size accompanied by defective incisors like Bmp2-cKO mice. In addition, histology and 
cytobiology analyses showed Klf4-Het had fewer osteoblasts and lower osteogenic ability. 
In conclusion, our current work outlined a comprehensive BMP2-dependent gene regulatory 
network in which Klf4 was a novel transcription factor specifically governing osteoblast 
differentiation of Sp7+ lineage.
Disclosures: Shuaitong Yu, None
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MicroRNA-101, which Inhibits the Epigenetic Suppressor Ezh2, Increases 
Trabecular Bone Volume in Male Mice *Sofia Jerez1, Amel Dudakovic1, Janet 
Denbeigh1, Padmini Deosthale2, Christopher Paradise1, Martina Gluscevic1, 
Pengfei Zan1, Oksana Pichurin1, Farzaneh Khani1, Roman Thaler1, Lilian 
Plotkin2, Andre van Wijnen1. 1Mayo Clinic, United States, 2Indiana University, 
United States
High-throughput microRNA sequencing was used to identify novel miRs that regulate 
osteoblast differentiation. We established that miR-101, which targets the epigenetic enzyme 
Ezh2, is highly up-regulated in differentiated MC3T3 cells (~7 fold) and robustly expressed 
in primary mouse calvarial osteoblasts. We have shown previously that loss of Ezh2 function 
enhances osteogenic differentiation in vitro and bone formation in vivo. Thus, we tested the 
attractive mechanistic model that increased miR-101 expression may suppress Ezh2 expres-
sion to stimulate osteogenesis and bone formation. Indeed, transient miR-101 over-expres-
sion suppresses Ezh2 protein levels and also reduces tri-methylation on lysine 27 of histone 
3 (H3K27me3), a heterochromatic mark catalyzed by Ezh2. Importantly, over-expression 
of miR-101 stimulates osteogenic differentiation of MC3T3 cells as quantified by alizarin 
red staining. Therefore, we examined transgenic doxycycline-inducible miR-101 expressing 
mice that permit robust induction of miR-101 by an order of magnitude. Experimental con-
trol and mir-101 over-expressing mice were exposed to doxycycline during pregnancy and 
postnatal stages (phenotyping at 8 weeks) to maximize penetrance of skeletal phenotypes. 
Our analyses revealed that miR-overexpressing male mice are bigger as measured by total 
body weight and exhibit an increase in long bone length. These mice exhibit significant in-
creases in trabecular bone volume fraction, trabecular number, trabecular thickness, as well 
as a reduction in trabecular spacing based on microCT analysis. Histomorphometric exam-
ination established a significant reduction in osteoid volume to bone volume and osteoid sur-
face to bone surface. These findings suggest that the enhancement in trabecular bone may be 
due to accelerated bone mineralization in miR-101 over-expressing male mice. Remarkably, 
while female mice exhibit a significant increase in bone length, no significant changes were 
noted by microCT (trabecular bone parameters) and histomorphometry (osteoid parameters). 
We conclude that miR-101 upregulation during osteoblast maturation enhances trabecular 
bone parameters in male mice. Thus, miR-101 and Ezh2 may form part of an intricate epi-
genetic feed-forward mechanisms that controls bone formation.   
Disclosures: Sofia Jerez, None
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Discoidin Domain Receptor 2 is a Novel Inducer of Bone Regeneration 
*Chunxi Ge1, Abdulaziz Binrayes1, Fatma Mohamed2, Kenneth Kozloff2, Renny 
Franceschi 2. 1University of Michigan, United States, 2University of Michigan, 
United States
Bone loss caused by trauma, neoplasia, congenital defects or periodontal disease is a 
major cause of disability and human suffering. Skeletal progenitor/stem cell:extracellular 
matrix (ECM) interactions are critical for bone regeneration. This project will focus on dis-
coidin domain receptor 2 (DDR2), an understudied, but important bone-associated collagen 
receptor. Ddr2 loss-of-function mutations in humans and mice cause severe craniofacial and 
skeletal defects. In this study, we examine the role of DDR2 in bone regeneration. Cal-
varial subcritical-size defects and tibial fractures were generated in Ddr2 deficient mice. 
For calvarial defects, complete bridging, seen in wild type (WT) mice at 4 weeks post-sur-
gery, was not observed in Ddr2 deficient mice, which failed to heal defects even after 12 
weeks. For tibial fractures, complete union was observed after 6 weeks in WT mice, but 
was severely reduced in Ddr2-deficient animals. This was manifested as significant reduc-
tions in callous volume and modified radiographic union scoring tibial fracture (mRUST) 
score. Ddr2 expression, measured by LacZ activity in Ddr2+/LacZ mice, was restricted to 
periosteal surfaces of uninjured calvarial bone and tibia. Within 2 days of injury, expression 
expanded into regeneration areas and continued throughout the healing process. Lentivi-
ral mediated overexpression of DDR2 and shRNA knockdown of DDR2 were performed 
in a mesenchymal cell line (ST2 cells). We found that overexpression of DDR2 increased 
osteoblast differentiation while knockdown of DDR2 was inhibitory. Furthermore specific 
triple helical peptides containing DDR2 or b1 integrin binding regions of fibrillar collagens 
were synthesized and used to coat tissue culture surfaces. DDR2 peptide strongly stimulated 
osteoblast differentiation as measured by induction of mineralization and osteoblast marker 
mRNAs. b1 integrin peptide was also stimulatory, but to a lesser extent than the DDR2 
peptide. Most interestingly, the combination of both peptides synergistically enhance osteo-
blast differentiation and activation of DDR2 and integrin signals. This study shows DDR2 
is required for bone regeneration in surgically-induced bone defect models. Stimulation of 
DDR2 activity either by overexpression or activation with DDR2-binding peptides may pro-
vide novel strategies for bone regeneration. 
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Egr1 Regulates Prx1 Expression through CXCL12 Signaling in Fracture 
Repair *Alessandra Esposito1, Mariana Lima-Miranda2, Lily Yu3, Anna 
Spagnoli1. 1Rush University Medical Center, United States, 2Rush University 
Medical Centerq, United States, 3Rush University medical Center, United States
Studies, including from our laboratory, have reported that Paired Related Homeobox 
1 (Prx1) regulates mesenchymal stromal cells differentiation and is postnatally expressed 
within the periosteum and endosteum. Our in vitro and in vivo studies have previously re-
ported that Prx1 is a downstream target of CXCL12 signaling during BMP2-induced fracture 
healing, and a downregulation of Prx1 is required for osteoblast differentiation. However, 
little is known about the mechanism of such regulation. Notably, studies have been reported 
that Egr-1 (Early growth response gene 1) plays a key role in differentiation and angiogene-
sis and loss of Egr1 results in impaired endochondral bone repair. Here, we hypothesize that 
BMP2-CXCL12 axis regulates Prx1 expression during osteoblast differentiation through 
Egr1 expression in fracture. For in-vivo experiments, BMP2flox/flox mice were crossed with 
Prx1-Cre transgenic males to generate BMP2cKO/+ mice. For treatment with AMD3100, 
mice were i.p.-injected with 2.5 mg/g AMD3100-PBS solution twice per day, 2 days once 
prior to fracture and then 6 times beginning 2 days after fracture (day 2 through day 7) fol-
lowed by harvest at 14 days postfracture (PFD). Tibias were dissected at 1, 3, 7, 10, 14, and 
21 PFD and subjected to immunofluorescence (IF). For in vitro experiments, BMP2cKO/+ 
mice were crossed with BMP2flox/flox mice to produce BMP2cKo/cKO. Endosteal cells 
were isolated from the bone marrow of tibias and femurs of BMP2cKo/cKO. Osteoblastic 
differentiation was carried out using StemXVivo osteogenic base media and supplement. 
For in vitro AMD3100 treatment of confluent endosteal cells, beginning on day 7, 400 µM 
of AMD3100 dissolved in water was added to the cells every 3 days until day 14 when cells 
were harvested. To support our hypothesis, we found that mice haploinsufficient for BMP2 
in Prx1 expressing cells (BMP2cKO/+), that have impaired fracture healing, have increased 
Egr1, as well as Prx1, mRNA levels and such increase positively correlated with increased 
levels of CXCL12. Furthermore, in WT fractured calluses Egr1 mRNA expression, as well 
as Prx1’s, increased rapidly right after fracture and decline by day 21. Impaired fracture heal-
ing of BMP2cKO/+ mice was rescued when mice were systemically treated with AMD3100, 
an inhibitor of CXCL12 signaling, that led to a downregulation of CXCL12 and Prx1 mRNA 
expressions, as well as Egr1’s. Isolated endosteal cells from BMP2cKO/cKO mice failed 
to differentiate into osteoblasts and showed increased Egr1 mRNA levels, as well as Prx1 
and CXCL12; AMD3100 treatment restored osteogenic differentiation and normalized their 
mRNA expressions. Our findings unveil a novel role of Egr1 in regulating Prx1 expression 
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through CXCL12 signaling that is critical in fracture healing. Studies are in progress to 
further characterize the nature of such regulation.
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The effect of SNP rs2887571 (located in an estrogen receptor α binding site) 
on WNT5B function in bone *Sarocha Suthon1, Gustavo A. Miranda-Carboni1, 
Susan A. Krum1. 1UTHSC, United States
Osteoporosis is a bone metabolic disease in which there is a loss of bone mineral den-
sity (BMD). WNTs, including WNT5A, promote osteogenesis; in contrast, WNT5B shows 
the opposite effect as high-throughput knockout of Wnt5b increased BMD in mice (Brom-
mage et al., 2014). Expression levels of WNT5B continuously increase during osteogenesis 
(Kemp et al., 2014), suggesting that WNT5B has a role in osteoblasts. A GWAS revealed 
SNP rs2887571 is associated with lower BMD (Estrada et al., 2012). This SNP showed over-
lap with an estrogen receptor alpha (ERα) binding site from ChIP-sequencing (Krum et al., 
2008) and is located 45 kilobases upstream of WNT5B. However, the relationship between 
SNP rs2887571 and WNT5B is unclear, as is the function of WNT5B in bone. We hypoth-
esize that SNP rs2887571 alters ERα binding to suppresses level of WNT5B which inhibits 
osteogenesis. 110 samples of human osteoblasts (hOBs) were genotyped for SNP rs2887571 
and compared to the expression of nearby genes (WNT5B, ERC1 and FBXL14). The cor-
relation between genotypes and gene expression was plotted and homozygous AA had sig-
nificantly higher expression than homozygous GG for only WNT5B. 10 nM E2 decreased 
mRNA and protein expression of WNT5B in hOBs, human osteosarcoma U2OS-ERα cells 
and mouse osteoblasts (mOBs), as well as ovariectomized mice showed higher WNT5B lev-
els compared to sham operated mice by IHC. ERα directly represses WNT5B, as ERα bound 
at SNP rs2887571 and H3K27 was tri-methylated when treated with E2 in U2OS-ERα cells. 
Therefore, a decreased amount of WNT5B due to the GG allele or decreased E2 is correlat-
ed with lower BMD. Mechanistically, WNT5B functions through a β-catenin-independent 
signaling pathway by activating phospho-JNK and repressing β-catenin. Mouse mesenchy-
mal stem cells were treated with 50 ng/mL recombinant mouse WNT5B and showed that 
WNT5B increased proliferation and adipogenesis, while it inhibited osteogenesis. Although 
WNT5B did not affect proliferation and migration in pre-osteoblasts, WNT5B inhibited os-
teoblast differentiation and mineralization by suppressing levels of Alpl and Bglap (osteo-
calcin) expression. WNT5B also suppressed E2-induced osteoblast differentiation in mOBs 
and U2OS-ERα cells by recruiting SIN3A, which is part of the histone deacetylase com-
plex, to ALPL enhancers. Taken together, this data reveal the mechanistic functions of SNP 
rs2887571 and WNT5B on bone mineral density.
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Irisin Downregulates the Senescent Marker p21 in Osteoblasts in vitro and 
its Serum Levels Positively Correlates with a Lower Rate of Age-Related 
Osteoporosis *Graziana Colaianni1, Lorenzo Sanesi1, Angela Notarnicola2, 
Monica Celi3, Roberta Zerlotin1, Giuseppina Storlino1, Patrizia Pignataro2, 
Mariella Errede2, Vito Pesce2, Umberto Tarantino3, Biagio Moretti2, Maria 
Grano1. 1Department of Emergency and Organ Transplantation,University of 
Bari, Italy, 2Department of Basic Medical Sciences, Neuroscience and Sense 
Organs, University of Bari, Italy, 3Department of Orthopedics and Traumatology, 
Tor Vergata University of Rome, Italy
Irisin is a myokine produced by skeletal muscle during exercise in both mice and hu-
mans. We previously showed that Irisin treatment ameliorates disuse-induced osteoporosis 
and muscular atrophy in mice. Data in humans showed a positive association between Irisin 
and bone mineral density in athletes and a population of healthy children. However, the role 
of this myokine regarding the state of muscle and bone in the same population remained to 
be determined.For this purpose, 62 patients (age 68.71+/- 12.31 years) undergoing total hip 
or knee replacement were recruited. Our results showed that irisin serum levels negatively 
correlated with age (r=-0.515; p<0.001) and positively correlated with femoral bone mineral 
density (BMD) (r=0.619; p<0.001) and vertebral BMD (r=0.201; p<0.001). Irisin was also 
positively associated with Fndc5 mRNA in muscle biopsies (r=0.248; p<0.01), as well as 
with Osteocalcin (Ocn) mRNA in bone biopsies (r=0.708; p<0.001). In skeletal muscle, 
FNDC5 positive fibers positively correlate with BMD of the total femur (r=0.765; p<0.001) 
and BMD of the femoral neck (r=0.575; p<0.05). Interestingly, by analyzing patients divided 
by their T score, we found lower irisin levels (p<0.01) in patients with osteopenia/osteoporo-
sis (OP) compared to healthy controls matched for age and sex. By analyzing the senescence 
marker p21, we found a significant increase in its mRNA expression in the bone biopsies of 
OP patients compared to control ones. Therefore, we investigated in vitro whether rec-iri-
sin had a direct effect on this senescence marker, showing that p21 mRNA expression was 
significantly down-regulated in osteoblasts by the treatment with irisin.Overall, these results 
indicate that higher irisin levels are associated with a lower rate of age-related osteoporosis 
and that irisin could be effective in delaying the osteoblast aging process, suggesting a po-
tential senolytic action of this myokine.
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Dio3os influences neighboring Dio3 gene expression and in trans regulates 
osteoblastogenesis *QUAMARUL HASSAN1, Yuechuan Chen2, Benjamin 
Wildman1, Delores Stacks1, Mohammad Rehan1. 1School of Dentistry, University 
of Alabama, United States, 2School of Dentistry, University of Alabama, 
Birmingham AL, United States
LncRNAs are classified as a unique class of long RNA transcripts, lack of translation-
al potential, and influence the chromatin state of protein-coding genes. A few of these ln-
cRNAs have been shown to regulate osteoblastogenesis. In the current research we have 
studied lncRNA Dio3os to decipher a molecular regulation that is unique for thyroid hor-
mone metabolism and osteogenesis. Human LncRNA library was screened with murine 
osteoblast cDNA to identify unique lncRNAs specific for bone formation. CRISPR-Cas9/
dCAS9-CRAB technologies were used to knock-out exons and suppress expression. ChIP 
and promoter activity assays were used to study the transcriptional status of the chromatin 
state. RNA-IP was used to study lncRNA-protein interactions. We uncovered a novel ln-
cRNA named Dio3os in the proximity of iodothyronine deiodinase 3 (Dio3) gene and its 
expression is significantly decreased during osteoblast differentiation. The bi-direction-
al Dio3 promoter initiates transcription of Dio3os in opposite direction. T4 and Vitamin 
D significantly activate Dio3/Dio3os bidirectional promoter activity. ChIP and promoter 
activity assays indicated HIF1a and HDAC1 directly binds and induced, however RUNX2, 
BRG1 repressed both Dio3 and Dio3os transcription. Dio3os overexpression activates 
neighboring Dio3 expression, while inhibits osteoblast progression and maturation in trans. 
Transcriptional repression of Dio3os by dCAS9-KRAB negatively regulates the expression 
of immediate neighbor Dio3 gene while increased osteogenesis. CRISPR Knockdown of Di-
o3os exons 1, 2 and 3 decreased Dio3 however increased osteoblast gene expression to sup-
port osteoblast differentiation. Taken together, these findings directly suggest that the local 
control of Dio3 chromatin state by lncRNA Dio3os linked to T4 inactivation which results in 
inhibition osteoblast differentiation.
Disclosures: QUAMARUL HASSAN, None
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miR-199a-5p located at the Osteoporosis GWAS Implicated DNM3 Loci 
Regulates Human Osteoblast Differentiation *Yadav Wagley1, Alessandra 
Chesi2, Matthew E. Johnson2, Solomon Chang1, James A. Pippin2, Andrew 
D. Wells2, Struan F. A. Grant2, Kurt D. Hankenson1. 1University of Michigan, 
United States, 2Children’s Hospital of Philadelphia, United States
By intersecting genome-wide promoter focused Capture C and ATAC-seq data derived 
from differentiating human osteoblasts, we recently reported consistent contacts between 
multiple candidate causal variants underpinning GWAS-implicated BMD loci and putative 
target effector gene promoters. Functional assays using siRNA knockdown led to identi-
fication of ING3 (at the ‘CPED-WNT16’ locus) and EPDR1 (at the ‘STARD3NL’ locus) 
as effector genes during human osteoblastogenesis. Here, we explored the ‘DNM3’ locus 
which harbors DNM3OS and the embedded MIR199A2 as candidate target genes. Bone 
morphogenetic protein-2 (BMP2) stimulation of human mesenchymal stem cells (hMSCs) 
reduced DNM3OS and corresponding MIR199A2 expression in a time-dependent fashion. 
Of the two mature microRNAs, miR-199a-5p and miR-199a-3p, both of which are expressed 
from MIR199A2, we elected to focus on the miR-199a-5p in this study. As observed with 
the MIR199A2 precursor, significant reduction of the mature miR-199a-5p was observed 
after 24 hours of BMP2 stimulation in hMSCs, suggesting that its downregulation coincides 
with osteoblast commitment. hsa-miR-199a-5p mimetic was introduced into hMSCs and 
cells were stimulated with BMP2. Interestingly, cells overexpressing miR-199a-5p mimetic 
revealed a unique morphological change, along with failure to efficiently undergo mineral-
ization despite having no effect on ALPL expression compared to control cells. Immunoblot 
analysis revealed that miR-199a-5p mimetic overexpressing cells had higher levels of the os-
teoblastic transcription factor RUNX2 after BMP2 stimulation, whilst Osterix protein levels 
did not significantly differ from the control cells. Given the morphological change observed 
after miR-199a-5p mimetic overexpression, we hypothesized that the mimetic was inducing 
differentiation to a chondrogenic fate. Expression levels of ACAN, COMP and COL10A1 
were significantly higher in cells overexpressing the microRNA mimetic, with further in-
creases following BMP2 stimulation. Additionally, in control cells, the levels of chondrocyte 
specific transcription factor SOX9 was transiently upregulated in response to BMP2 and 
returned to baseline within 72 hours; however, in contrast, SOX9 protein levels remained el-
evated in cells overexpressing miR-199a-5p. Since BMP signaling intersects with the Notch 
pathway to induce hMSC osteoblast differentiation and SOX9 harbors an antagonistic rela-
tion with the Notch pathway, we examined whether Notch processing is altered after miR-
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199a-5p mimetic overexpression. As suspected, Notch processing was reduced upon BMP2 
stimulation of miR-199a-5p mimetic overexpressing cells. Exposing miR-199a-5p mimetic 
overexpressing cells to immobilized Jagged1 rescued the mineralization defect within 10 
days. Taken together, while miR-199a-5p impedes BMP-induced osteoblast differentiation, 
promoting a chondrogenic fate over osteoblastogenesis, Notch signaling bypasses the miR-
199a-5 inhibition of osteoblast differentiation.
Disclosures: Yadav Wagley, None
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Identification of Molecular Players in Phosphate-Induced Signaling 
Cascade Initiating the Mineralization Process. *Dobrawa Napierala1, Sana 
Khalid1, Mairobys Socorro1, Juan Taboas1. 1University of Pittsburgh School of 
Dental Medicine, United States
Phosphate (Pi) is a signaling molecule that supports osteogenic differentiation of skel-
etal and dental progenitor cells and stimulates formation of mineralized extracellular matrix 
(ECM) by differentiated cells. The importance of Pi for the development and homeostasis 
of all mineralizing tissues is underscored by bone, cartilage, dentin and periodontal com-
plex pathologies in genetic and acquired disorders affecting Pi availability. However little 
is known about Pi-induced signaling cascade in cells producing mineralizing ECM, and the 
key players, such as Pi receptors/sensors, kinases transmitting the Pi signal inside the cell 
and transcription factors regulating gene expression in response to Pi are largely unknown. 
The goal of our research is to delineate the signaling cascade that initiates mineralization in 
response to extracellular Pi. 17IIA11 and MLO-A5 committed osteogenic cell lines were 
used as two different models of cells supporting mineralization. Activation and inhibition 
of specific molecules was accomplished either by genetic modification of model cells or 
pharmacologically. Using ChIP assay, we detected that Pi changes binding of the mineraliza-
tion-regulating transcription factor Trps1 to its target regulatory elements. On the other hand, 
Trps1 deficiency results in loss of activation of extracellular signal-regulated kinase Erk1/2 
in response to Pi. Gene expression analyses detected significantly decreased expression of 
parathyroid hormone/ parathyroid hormone related protein receptor1 (Pth1r) in Trps1-defi-
cient 17IIA11 cells. Furthermore, the depletion of Pth1r from either 17IIA11 or MLO-A5 
cells was sufficient to abolish activation of Erk1/2 and expression of classic Pi-responsive 
genes Dmp1 and Spp1 (Opn). Analyses of signaling cascades downstream of Pth1r identified 
phospholipase C (PLC) and protein kinase C (PKC) as mediators of Pi signaling in osteo-
genic cells. In conclusion, we identified Pth1r/PLC/PKC signaling pathway and the Trps1 
transcription factor as new players in the Pi-induced signaling cascade in cells producing 
mineralized ECM.
Disclosures: Dobrawa Napierala, None
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Zinc Finger Homeobox 3 (ZFHX3) Transcription Factor is a Novel Negative 
Regulator of Osteoblast Differentiation *Gustavo Gomez1, Weirong Xing 1, 
Sheila Pourteymoor1, Jasmine Lau1, Subburaman Mohan1. 1VALLHS, United 
States
Bone formation is the fundamental process of skeletal development in vertebrates that 
is strictly regulated by a complex transcriptional network which is incompletely understood. 
Based on the established importance of homeobox transcription factors in bone formation, 
we tested a role for a zinc finger homeobox (Zfhx) protein about which nothing is known. 
Zfhx3, also known as AT motif binding factor 1 (ATBF1), was originally identified as a tu-
mor suppressor as loss of heterozygosity at Zfhx3 locus frequently occurs in gastric cancer. 
By immunohistochemistry, we found that Zfhx3 was predominantly expressed in Osterix 
(Osx) expressing chondrocytes and osteoblasts at the primary and secondary spongiosa of 
long bones of mice.  In vitro studies revealed that Zfhx3 is highly expressed in pre-osteo-
blasts and that its expression remained unchanged during ascorbic acid-induced osteoblast 
differentiation, as measured by real time RT-PCR.  To evaluate the role of Zfhx3, we over-
expressed PCDNA 3.1 vector containing the full length cDNA clone of human Zfhx3 or 
GFP control by electroporation in MC3T3-E1 osteoblasts and confirmed nearly 100-fold 
overexpression by real time PCR using primers that are specific to human Zfhx3.  Overex-
pression of Zfhx3 caused a two-fold increase in cell proliferation (P<0.001) vs PCDNA 3.1-
GFP control.  In contrast, expression levels of osteoblast differentiation markers, ALP and 
BSP were decreased by 70% and 65% (both P<0.01) respectively, compared to GFP control. 
To determine the mechanism for negative effect of Zfhx3 on osteoblast differentiation, we 
measured expression levels of Runx2, Osx, β-catenin, Dlx3, Dlx5 and Dlx6 by real RT-PCR 
in Zfhx3 overexpressing and GFP control MC3T3-E1 cells. We found that while expression 
of Osx and Dlx5 were reduced by 37% and 17% (both P<0.05) respectively, expression 
levels of other transcription factors were not affected by Zfhx3 overexpression.  Based on 
these data, we propose that ZFHX3 is a negative regulator of osteoblast differentiation that 
mediates its effects in part via regulating Osx expression.    
Disclosures: Gustavo Gomez, None
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Functional evidence of bone regulation of WNT16 through upstream 
enhancers within CPED1 *Núria Martínez-Gil1, Neus Roca-Ayats1, Carlos 
Herrera1, Nicola Gritti2, Nerea Ugartondo1, Natàlia Garcia-Giralt3, Diana 
Ovejero3, Xavier Nogués3, Jordi Garcia-Fernandez1, Daniel Grinberg1, Susanna 
Balcells1. 1Department of Genetics, Microbiology and Statistics, Faculty of 
Biology, Universitat de Barcelona, CIBERER, IBUB, IRSJD, Barcelona, Spain., 
Spain, 2European Molecular Biology Laboratory (EMBL) Barcelona, 08003 
Barcelona,Spain, Spain, 3Musculoskeletal Research Group, IMIM (Hospital del 
Mar Medical Research Institute), Centro de Investigación Biomédica en Red en 
Fragilidad y Envejecimiento Saludable (CIBERFES), ISCIII, Barcelona, Spain, 
Spain
WNT16 stands up as an essential gene of bone homeostasis due to its role in regulation 
of cortical bone and its consistency as a bone mineral density (BMD) GWAS signal. Here, 
we present new evidences through in vitro functional experiments, of two WNT16 variants: a 
common CT insertion (rs142005327) associated with BMD and a rare variant (rs190011371) 
found only in three women of the BARCOS cohort (n = 1490), all three with BMD below the 
50th percentile (Martínez-Gil, N. et al. Sci Rep. 8:10951, 2018). The rs142005327 variant 
is located in a proximal region of intron 2 containing chromatin enhancer/promoter marks 
in osteoblasts (ENCODE). Through a 4C chromatin conformation analysis in 3 bone cell 
lines (Saos2, hFOB and MSC), we identified physical interactions between this intron 2 
region and several putative regulatory regions within the CPED1 gene known to be active in 
osteoblasts (Genehancer database; Maynard RD et al. Gene 674:127-133, 2018). Moreover, 
luciferase assays indicated that a region close to the variant exhibited promoter activity in 
Saos2 cells (See figure 1). Analysis of previously published RNA-seq data from hFOB cells 
showed expression of a region located downstream of this promoter, which would be a novel 
transcript of the gene. Regarding the 3’UTR-variant rs190011371, by means of a reporter 
assay we described the partial loss-of-function for the minor allele, which is in agreement 
with the low BMD phenotype of the carriers of the rare variant. Our results confirm the role 
of WNT16 in BMD determination and suggest a novel regulatory mechanism of WNT16 in 
bone, mediated by physical interaction with various enhancer regions within CPED1.Figure 
1. Relative luciferase activity of different intron 2 fragments cloned into the pGL3-basic 
vector: PFull, Pins, P1, P2, Pvar, Pcons, Ppic. For reference, the structure of WNT16 exon2, 
intron 2 and exon 3 is depicted, above the graph where the asterisk marks the position of SNP 
rs142005327. Values are normalized to the activity of the empty vector, arbitrarily set at 1. 
****p<0.0001 and ***p<0.001. Error bars indicate s.d.
Disclosures: Núria Martínez-Gil, None
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The evaluation of bone union activity of freeze-dried platelet-rich plasma 
*Hideyuki Kinoshita1, Sumihisa Orita1, Kazuhide Inage1, Yasuhiro Shiga1, Seiji 
Ohtori1. 1Department of Orthopaedic Surgery, Graduate School of Medicine, 
Chiba University, Japan
Fresh platelet-rich plasma (PRP) accelerates bone union in rat model. However, fresh 
PRP has a short half-life. We suggested freeze-dried PRP (FD-PRP) prepared in advance 
and investigated its efficacy in vivo. Spinal posterolateral fusion was performed on 8-week-
old male Sprague-Dawley rats divided into six groups based on the graft materials (n = 
10 per group): sham control, artificial bone (A hydroxyapatite–collagen composite) –alone, 
autologous bone, artificial bone + fresh-PRP, artificial bone + FD-PRP preserved 8 weeks, 
and artificial bone + human recombinant bone morphogenetic protein 2 (BMP) as a positive 
control. At 4 and 8 weeks after the surgery, we investigated their bone union–related charac-
teristics including amount of bone formation, histological characteristics of trabecular bone 
at remodeling site, and biomechanical strength on 3-point bending. Comparable radiological 
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bone union was confirmed at 4 weeks after surgery in 80% of the FD-PRP groups, which 
was earlier than in other groups (p < 0.05). Histologically, the trabecular bone had thinner 
and more branches in the FD-PRP. Moreover, the biomechanical strength was comparable 
to that of autologous bone. FD-PRP accelerated bone union at a rate comparable to that of 
fresh-PRP and BMP by remodeling the bone with thinner, more tangled, and rigid trabecular 
bone. Next, we evaluated the pharmacological activity of growth factors (GFs) in FD-PRP 
in vitro after storage for four weeks. The platelet counts in both the fresh-PRP and FD-PRP 
samples were approximately 10-fold higher than those in peripheral blood samples. The 
phosphorylation and activation of platelet-derived growth factor (PDGF) receptor and ex-
tracellular signal-regulated kinase (ERK) were evenly induced by fresh-PRP and FD-PRP 
stimulation. Both fresh-PRP and FD-PRP significantly induced osteoblast proliferation in 
MTT cell viability assays. Furthermore, osteoblast PDGF receptor knockdown attenuated 
the downstream ERK activation by fresh PRP and FD-PRP. In conclusion, we demonstrated 
that FD-PRP promoted bone union in vitro and in vivo. If FD-PRP is clinically applicable, it 
could be used to promote bone fusion in bone fracture surgery and induce interbody fusion 
with the appropriate scaffold in spine surgery without intraoperative blood collection.
Disclosures: Hideyuki Kinoshita, None
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Agrin drives osteoblast differentiation through Wnt and BMP signaling 
modulation *Alann Thaffarell Portilho de Souza1, Fabiola Singaretti de 
Oliveira2, Denise Weffort2, Helena Bacha Lopes2, Gileade Pereira Freitas2, 
Maria Paula Oliveira Gomes2, Roger Rodrigo Fernandes2, Adalberto Luiz Rosa2, 
Marcio Mateus Beloti2. 1Bone Research Lab, School of Dentistry of Ribeirao 
Preto, University of Sao Paulo / Baron-Gori Lab, Department of Oral Medicine, 
Infection and Immunity, Harvard School of Dental Medicine, Brazil, 2Bone 
Research Lab, School of Dentistry of Ribeirao Preto, University of Sao Paulo, 
Brazil
The extracellular matrix protein Agrin has been detected in chondrocytes and endos-
teal osteoblasts but its function in osteoblast differentiation has not been investigated yet. 
Thus, we hypothesized that Agrin regulates osteoblast differentiation and, due to Agrin and 
wingless-related integration site (Wnt) sharing the same receptor, transmembrane low-den-
sity lipoprotein receptor–related protein 4 (Lrp4), and the crosstalk between Wnt and bone 
morphogenetic protein (BMP) signaling, both pathways could be involved in this regulation. 
To show if and how the expression of Agrin occurs during osteoblast differentiation, the tem-
poral gene expression of Agrin and osteocalcin (Oc) as well as of Agrin receptors Lrp4 and 
α-dystroglycan (Dag1) was evaluated by real-time PCR in mouse pre-osteoblastic cell line 
MC3T3-E1 subclone 14, mouse osteoblasts differentiated from bone marrow-derived mes-
enchymal stromal cells and mouse calvarial-derived osteoblasts, cultured under osteogenic 
conditions. Moreover, protein expression of AGRIN was detected by immunofluorescence 
labeling. To determine the influence of Agrin on osteoblast differentiation, Agrin was 
knocked down in MC3T3-E1 cells by transfection with small interfering RNA (siRNA). 
Then, the Agrin silencing effects were evaluated on gene expression of Agrin receptors and 
the bone markers runt-related transcription factor 2 (Runx2), osterix, alkaline phosphatase 
(Alp), bone sialoprotein, Oc and α-1 type I collagen, as well as on protein expression of 
RUNX2 and ALP activity. In addition, genes related to Wnt and BMP signaling pathways 
were evaluated in order to explore the possible mechanisms involved in the Agrin-mediated 
osteoblast differentiation. We have shown that Agrin and its receptors Lrp4 and Dag1 are 
expressed during osteoblast differentiation in the three well-established cell culture models. 
Moreover, the disruption of Agrin by siRNA impaired the expression of its receptors and 
inhibited osteoblast differentiation evidenced by the downregulation of the bone markers 
RUNX2 and ALP activity. Furthermore, Agrin knockdown also downregulated the expres-
sion of genes related to Wnt and BMP signaling pathways. In conclusion, our data uncover 
the role of Agrin in regulating osteoblast differentiation and suggest that an Agrin-Wnt-BMP 
circuit is involved in this process. These findings make Agrin a candidate as a target for 
developing new therapeutic strategies to treat bone-related diseases and injuries.
Disclosures: Alann Thaffarell Portilho de Souza, None
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In Vitro Bone Tissue Model in a Well Plate Capture Molecular Regulation of 
Bone Remodeling *Yongkuk Park1, Jungwoo Lee1. 1University of Massachusetts 
Amherst, United States
Bone is dynamic tissue undergoes repeated bone remodeling for the maintenance of 
bone integrity throughout the lifetime, which include bone-forming osteoblasts and bone-re-
sorbing osteoclasts. This process is under the regulation of local growth factors and cyto-
kines by interaction between bone cells. However, one of the main limitations is difficult 
to study the detailed mechanism of molecular and cellular process of bone remodeling due 
to anatomical inaccessibility of the inner bone surface. It is necessary to develop relevant 
experimental model for in vitro bone biology study. Here, we report a new class of in vitro 
bone tissue model using a demineralized bone slice that retains intrinsic complexity of bony 
extracellular matrix with semi-optical transparency. We devised sequential method to fabri-
cate (10-20 µm) sectioned demineralized bone matrix from a bovine femur. The bone pieces 
in 1.2 M hydrochloric acid were located in the hydrostatic pressure chamber at 4-bar to ac-
celerate the demineralization step. Next, a demineralized bone block was cryosectioned and 
tailored in a circular shaped to be fit in multi-well plates. Primary osteogenic progenitors and 
marrow hematopoietic cells were retrieved from transgenic DsRed and eGFP mice. Demin-
eralized bone slice directed osteoblasts to develop structurally mineralized bone tissue and 
subsequently acquire a resting state bone lining cell phenotype with gap junction. Vitamin 
D3 and prostaglandin E2 stimulation reverted lining cells to activated osteoblasts, which can 
induce differentiation of bone marrow mononuclear cells into mature osteoclasts. The func-
tions of bone cells on the bone slice were confirmed by the real-time imaging and enzyme 
immunoassay. Finally, we created tissue-inspired trabecular bone model in a well plate by 
co-layering stimulated and resting bone tissue surface together, reproducing cellular connec-
tion and communication between osteoblast and osteoclast. We envision that the established 
bone tissue model will facilitate to pursue a better understanding in bone remodeling biology 
with high experimental control and access.
Disclosures: Yongkuk Park, None
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Dullard/Ctdnep1 negatively regulates Smad2/3 protein level and TGF-β 
signaling in osteoblastic cells. *Iori Nozawa1, Yasuhiro Arasaki1, Takuro 
Akiya1, Masafumi Inui2, Masaki Noda3, Yoichi Ezura4, Tadayoshi Hayata1. 
1Department of Molecular Pharmacology, Graduate School of Pharmaceutical 
Sciences and Faculty of Pharmaceutical Sciences, Tokyo University of Science, 
Japan, 2Laboratory of Animal Regeneration Systemology, Department of Life 
Sciences, School of Agriculture, Meiji University, Japan, 3Department of 
Molecular Pharmacology, Medical Research Institute, Tokyo Medical & Dental 
University (TMDU), Japan, 4Department of Judo Therapy, Faculty of Medical 
Technology, Teikyo University, Japan
Transforming growth factor-β (TGF-β) is a pivotal cytokine that controls behavior and 
fate of many different types of cells. In early skeletal development, TGF-β signaling is re-
quired for sternum formation, perichondrium development, and joint morphogenesis. Impor-
tantly, TGF-β signaling is suppressed or terminated by various phosphatases and ubiquitin li-
gases after the onset of TGF-β signaling. We previously showed that the phosphatase Dullard 
(Ctdnep1) is an important negative regulator of TGF-β signaling during endochondral ossi-
fication. However, the role of Dullard in the regulation of TGF-β signaling during osteoblast 
differentiation remains elusive. In this study, we wished to study relationship between Dull-
ard and TGF-β signaling using osteoblastic MC3T3-E1 cells and HEK293T cells as model 
systems. Western blot analysis showed that siRNA-mediated knockdown of Dullard mRNA 
resulted in increased Smad2/3 protein level in MC3T3-E1 cells, whereas overexpression of 
Dullard reduced Smad2/3 protein level. To examine whether Dullard physically interact with 
the components of TGF-β signaling pathway, we conducted co-immunoprecipitation assay 
using HEK293T cells. However, interaction of Dullard with Smad2, SMAD4 and TGF-βRII 
was not detected. Overexpression of Dullard suppressed TGF-β-responsive (CAGA)12-lu-
ciferase reporter activity induced by TGF-β1 treatment, whereas Dullard knockdown upreg-
ulated the reporter activity in MC3T3-E1 cells. Regarding osteoblast differentiation, Dullard 
knockdown impaired osteoblast differentiation as revealed by the alkaline phosphatase and 
mineralization assay. These data suggest that Dullard/Ctdnep1 negatively regulates TGF-β 
signaling pathway, at least in part, by downregulating Smad2/3 protein level and is required 
for osteoblast differentiation.
Disclosures: Iori Nozawa, None
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NMUR1 is not required for Neuromedin U (NMU)-mediated regulation 
of bone remodeling *Kelli Jestes1, Tara Zukosky2, Maria Squire2, Julia Hum1, 
Corinne Metzger3, Matthew Allen3, Jonathan Lowery1. 1Marian University, 
United States, 2University of Scranton, United States, 3Indiana University School 
of Medicine, United States
Neuromedin-U (NMU) is an evolutionarily conserved peptide that regulates varying 
physiologic effects including blood pressure, stress and allergic responses, metabolic and 
feeding behavior, pain perception, neuroendocrine functions. Recently, several lines of in-
vestigation implicate NMU in regulating bone remodeling. For instance, global loss of NMU 
expression in male and female mice leads to high bone mass due to elevated bone formation 
rate with no alteration in bone resorption rate or observable patterning defect. Additionally, 
NMU treatment reduces osteoblastic differentiation of bone marrow stromal cells in vitro. 
Taken together, these findings suggest that targeting the NMU pathway may be a beneficial 
strategy for increasing bone mass. It is unclear at present, however, which receptor is utilized 
by NMU to mediate bone-specific effects as it signals via two G-protein-coupled receptors 
(GPCRs), NMU Receptor 1 (NMUR1) and NMU Receptor 2 (NMUR2), and both are ex-
pressed in the postnatal skeleton. Here, we tested the hypothesis that NMUR1 is required 
for the NMU-mediated regulation of bone remodeling by examining bone mass in global 
Nmur1 mutant mice. These results reveal that bone mass in femora and tibiae of twelve-
week-old male Nmur1 mutants is unchanged compared to controls with no defects observed 
in osteoblast or osteoclast-related histological parameters. These results suggest that 1) the 
effects of NMU on bone remodeling in vivo are accomplished via NMUR2 or 2) the absence 
of NMUR1 is compensated by NMUR2. Future studies are required to distinguish between 
these possibilities and determine the downstream pathway utilized by NMU to regulate bone 
remodeling in vivo.
Disclosures: Kelli Jestes, None
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METTL7A Promotes Cell Survival and Enhances Osteogenic Differentiation 
*Eugene Lee1, Juyoung Kim1, Tae-kyung Kim1, Gun-Il Im1. 1Dongguk University, 
Republic of Korea
In transplanting adult stem cells for the treatment of bone disease, in the case of ex-
tensive loss of damaged blood vessels, the expected effect is not obtained because the 
transplanted cells do not receive blood supply and are mostly necrotic in the early stage 
of transplantation. To increase the effectiveness of stem cell transplantation, the survival 
of transplanted stem cells must be considered, and the problem found consistently in many 
studies is that the most of transplanted cells are hypoxic, inflammatory, oxidative stress, 
and no glucose is supplied. Cells are exposed to these environments, fail to engraft in the 
early stage, die at least 90% in the early stage, and disappear. To date, little is known about 
cell survival in the clinical microenvironment that occurs during bone healing. This study 
suggests that glucose can be the key factor to stem cell survival and bone differentiation. 
To support this, an in vitro mimics was created in which the microenvironmental stress of 
glucose deficiency, which cells may be exposed to during transplantation, was previously 
regulated. Furthermore, the METTL7A gene, bone regeneration marker, has been newly dis-
covered by genetic analysis of the model. In this study, bone marrow stem cells induced by 
overexpression of the METTL7A gene were applied to a bone-deficient animal model, and 
the problem of early necrosis of stem cell transplantation could be alleviated by regulation 
of methylation. Finally, this study is the first study revealing the association and mechanism 
of METTL7A gene and bone regeneration signaling pathway, and confirmed the potential as 
a new model for improving cell survival and bone differentiation in stem cell transplantation 
therapy.
Disclosures: Eugene Lee, None
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Effects of mesenchymal stromal cells from healthy rats on the impaired 
osteoblast differentiation of mesenchymal stromal cells from osteoporotic 
and diabetic rats *Alann Thaffarell Portilho de Souza1, Gileade Pereira Freitas2, 
Helena Bacha Lopes2, Denise Weffort2, Fabiola Singaretti de Oliveira2, Letícia 
Faustino Adolpho2, Márcio Mateus Beloti2, Adalberto Luiz Rosa2. 1Bone 
Research Lab, School of Dentistry of Ribeirao Preto, University of Sao Paulo / 
Baron-Gori Lab, Department of Oral Medicine, Infection and Immunity, Harvard 
School of Dental Medicine, Brazil, 2Bone Research Lab, School of Dentistry of 
Ribeirao Preto, University of Sao Paulo, Brazil
Osteoporosis and diabetes mellitus are systemic diseases that impaired osteoblast dif-
ferentiation of mesenchymal stromal cells (MSCs). Considering the cell therapy applica-
tions to treat bone defects under osteoporotic and diabetic conditions, where MSCs from 
healthy donors (HE-MSCs) interact with MSCs from osteoporotic (ORX-MSCs) and diabet-
ic (DM-MSCs) receptors, we hypothesized that HE-MSCs would counteract the deleterious 
effects of these diseases on the ability of ORX-MSCs and DM-MSCs to differentiate into 
osteoblasts. Thus, the aim of this study was to evaluate the influence of HE-MSCs on the 
osteoblast differentiation of both ORX-MSCs and DM-MSCs, using an indirect co-culture 
model. Osteoporosis and diabetes mellitus were induced in rats by orchiectomy surgery and 
streptozotocin injection, respectively. Then, MSCs were isolated and cultured from bone 
marrow of healthy, osteoporotic and diabetic rats. HE-MSCs were co-cultured with ORX-
MSCs (HE-MSCs→ORX-MSCs) or DM-MSCs (HE-MSCs→DM-MSCs) under osteogenic 
conditions, and Runx2 gene expression (n = 3) and alkaline phosphatase (ALP) activity (n 
= 5) were evaluated on day 10 and extracellular matrix mineralization (n = 5), on day 14. 
Co-cultures of MSCs at the same condition (HE-MSCs→HE-MSCs, ORX-MSCs→ORX-
MSCs or DM-MSCs→DM-MSCs) were used as controls. The data were compared by 
ANOVA (p <= 0.05). In osteoporosis, the gene expression of Runx2 was HE-MSCs→ORX-
MSCs > HE-MSCs→HE-MSCs > ORX-MSCs→ORX-MSCs (p = 0.001), ALP activity 
was HE-MSCs→HE-MSCs > HE-MSCs→ORX-MSCs > ORX-MSCs→ORX-MSCs 
(p=0.001) and mineralization was HE-MSCs→HE-MSCs = HE-MSCs→ORX-MSCs > 
ORX-MSCs→ORX-MSCs (p = 0.001). In diabetes, the gene expression of Runx2 was 
HE-MSCs→HE-MSCs HE-MSCs→DM-MSCs > DM-MSCs→DM-MSCs (p =  0.001) 
(Figure). Together, the data indicated that MSCs derived from healthy rats partially recover 
the osteogenic potential of MSCs from rats with osteoporosis and diabetes mellitus. These 
findings suggest that the use of MSCs from healthy donors may be an interesting strategy 
in cell therapy approaches to repair bone tissue under osteoporotic and diabetic conditions.
Disclosures: Alann Thaffarell Portilho de Souza, None
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Gprc5a is a novel target gene of teriparatide involved in osteoblastic cell 
proliferation. *Kosuke Kato1, Yasuhiro Arasaki1, Takuro Akiya1, Masaki Noda2, 
Yoichi Ezura3, Tadayoshi Hayata1. 1Department of Molecular Pharmacology, 
Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical 
Sciences, Tokyo University of Science, Japan, 2Department of Molecular 
Pharmacology, Medical Research Institute, Tokyo Medical & Dental University 
(TMDU), Japan, 3Department of Judo Therapy, Faculty of Medical Technology, 
Teikyo University, Japan
Objective. Osteoporosis is caused by an imbalance between bone formation by osteo-
blasts and bone resorption by osteoclasts. Teriparatide is one of the therapeutic drugs for 
osteoporosis that promotes bone formation. However, its mechanism of action is not fully 
understood. In an exhaustive search for teriparatide target genes, we focused on Gprc5a, one 
of the G protein-coupled receptors (GPCRs) considering the effectiveness of GPCR in drug 
discovery. In this study, we wished to characterize function of Gprc5a in osteoblastic cells.
Methods & Results. Gene expression analysis revealed that treatment of rat osteosarcoma 
ROS17/2.8 cells and mouse osteoblastic MC3T3-E1 cells with 100 nM teriparatide for 1 
hour resulted in a significant increase in Gprc5a expression. Gprc5a expression was also 
significantly increased in femurs of 4-week-old rats 1 hour after injection of teriparatide (80 
µg/kg body weight). Time-course experiment using MC3T3-E1 cells revealed that Gprc5a 
expression was maximized at the 1-hour time point after 100 nM teriparatide treatment and 
then attenuated. To examine the subcellular localization of Gprc5a, Gprc5a-HA expression 
plasmid was transfected into MC3T3-E1 for immunofluorescence study. The results showed 
that the localization pattern of Gprc5a-HA was consistent with plasma membrane localiza-
tion pattern. We also examined the effects of Gprc5a siRNA transfection in MC3T3-E1 cells 
on cell proliferation, and we found that siRNA-mediated knockdown of Gprc5a significantly 
reduced the cell proliferation.Conclusion. These findings suggest that Gprc5a is one of the 
possible target genes of teriparatide, responsible for osteoblastic cell proliferation.
Disclosures: Kosuke Kato, None
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Effect of Fucoidan, a Sulfated Polysaccharide, Extracted from the Algae 
Macrocystis pyrifera, Sargassum muticum, and Undaria pinnatifida on 
Bone Remodeling *Brenda Iduarte1, Jessica Landeros1, Enrique Hernández2, 
Rodrigo Beas3, Pierrick Fournier1, Patricia Juárez1. 1CICESE, Mexico, 2CRIAP-
Ensenada, Mexico, 3UABC, Mexico
Bone is a dynamic tissue that is in constant repair and remodeling, however, the im-
balance in this process causes bone diseases such as osteoporosis. In this work, we experi-
mented if the sulfated polysaccharides of the Macrocystis pyrifera, Sargassum muticum and 
Undaria pinnatifida algae from Todos Santos Island, BC, can modulate the bone remodeling 
process. Sulfated polysaccharides were extracted by the acid hydrolysis method. Extract 
characterization was performed using in vitro and ex vivo tests to study cell proliferation 
and differentiation in order to evaluate the modulatory effect of sulfated polysaccharides at 
different stages of bone development. At an early stage, osteoblast precursors (MC3T3-E1 
cells) were treated with different concentrations of sulfated polysaccharides demonstrating 
a dose-dependent proliferation inhibitory effect. Differentiation assays with MC3T3-E1 
cells treated with sulfated polysaccharides stimulated osteoblast cells to produce areas of 
bone mineralization. These results were consistent with osteoblastogenesis studies using ex 
vivo bone marrow assays of Balb/c mice, while in osteoclastogenesis they maintained an 
inhibitory effect, demonstrating that these compounds have the ability to stimulate differ-
entiated and undifferentiated cells to mineralize bone. Furthermore, gene expression assays 
of MC3T3-E1 treated with the sulfated polysaccharides indicated significant expression 
of Osteoprotegerin (OPG), a RANKL antagonist protein. Our results suggest that sulfated 
polysaccharides from the marine algae studied are compounds capable of promoting bone 
formation demonstrating their potential as an anabolic therapeutic agent.
Disclosures: Brenda Iduarte, None
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κ-Carrageenan-Functionalization of Octacalcium Phosphate-Coated 
Titanium Discs Enhances Pre-Osteoblast Behavior and Osteogenic 
Differentiation *Wei Cao1, Gang Wu2, Nathalie Bravenboer3, Marco N. 
Helder4, Engelbert A.J.M. Schulten4, Jianfeng Jin1, Lester Geonzon5, Shingo 
Matsukawa5, Rommel G. Bacabac6, Christiaan M. ten Bruggenkate4, Jenneke 
Klein-Nulend1. 1Department of Oral Cell Biology, Academic Centre for 
Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit 
Amsterdam, Amsterdam Movement Sciences, Netherlands, 2Department of 
Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry 
Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit 
Amsterdam, Amsterdam Movement Sciences, Netherlands, 3Department of 
Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit 
Amsterdam, Amsterdam Movement Sciences, Netherlands, 4Department 
of Oral and Maxillofacial Surgery/Oral Pathology, Amsterdam University 
Medical Centers and Academic Centre for Dentistry Amsterdam (ACTA), 
Vrije Universiteit Amsterdam, Amsterdam Movement Sciences, Netherlands, 
5Department of Food, Science & Technology, Tokyo University of Marine 
Science & Technology, Japan, 6Department of Physics, Medical Biophysics 
Group, University of San Carlos, Philippines
Introduction: A highly bioactive coating is promising to improve osteointegration and 
long-term prognosis of dental implants. Carrageenan is highly hydrophilic and biocompat-
ible seaweed-derived sulfated-polysaccharide. Whether carrageenan can be used to func-
tionalize octacalcium phosphate (OCP)-coatings to enhance osseointegration of titanium 
dental implants is unclear.Purpose:To characterize carrageenan-functionalized biomimetic 
OCP-coated titanium, and to test the effect of carrageenan on pre-osteoblast behavior and 
osteogenic differentiation.Method:Preparation and characterization of k-carrageenan-func-
tionalized OCP-coating: OCP-solution containing k-carrageenan at 0.125, 0.25, 0.5, 1, and 
2 mg/ml was used to precipitate OCP-coating onto titanium discs. Characterization was per-
formed using SEM, EDX, XRD, Raman spectroscopy, and contact angle measurements.
MC3T3-E1 pre-osteoblast behavior: Cell adhesion and spreading were determined using 
fluorescent staining (1,2 h), and cell metabolic activity by PrestoBlue® assay, and prolif-
eration by CyQuant® cell proliferation assay kit (day 1,2,3).Osteogenic differentiation: Al-
kaline phosphatase activity, osteogenic gene expression, and matrix mineralization alizarin 
red staining) were determined.Statistics: ANOVA (n=3-5), statistical significance: p<0.05. 
Results:k-Carrageenan (all concentrations) in OCP-coating changed the titanium disc coat-
ing’s morphology/microstructure by decreasing porosity compared to controls. k-Carrageen-
an (2 mg/ml only) increased OCP interplanar crystal distance (~1.5-fold). k-Carrageenan 
did not affect hydrophilicity. k-Carrageenan (0.5 and 2 mg/ml) significantly increased (6-
7-fold) cell adhesion and spreading. All concentrations tested dose-dependently increased 
proliferation (max. 1.3-fold, day 3), metabolic activity (max. 1.5-fold, day 3), alkaline phos-
phatase activity (max. 1.8-fold, day 4), and matrix mineralization (max. 2.6-fold, day 28).
Conclusions:k-Carrageenan modified morphology and microstructure of OCP-coating, and 
enhanced pre-osteoblast metabolic activity, proliferation, and osteogenic differentiation. 
This suggests that k-carrageenan might improve dental implant osseointegration in vivo.
Figure 1. k-Carrageenan dose-dependently stimulates metabolic activity (day 3), alkaline 
phosphatase activity (day 4), and mineralized nodule formation (alizarin red; day 28) of 
MC3T3-E1 pre-osteoblasts.
Disclosures: Wei Cao, None
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Osteoblastic cell differentiation and the quest for energy for calcium 
synthesis *Claudia Medeiros1, Joseph Wallace1. 1IUPUI, United States
Bone quality is essential for proper bone function. The quality of bone tissue is mea-
sured by material properties, geometry, and mass. Bone is a flexible tissue that can withstand 
mechanical loading by dynamic processes of modelling and remodeling as a mechano-re-
sponse to stress. Therefore, the more we exercise, the more we improve bone content and 
function. Over time, disease states alter bone matrix composition and compromises bone’s 
ability to resist fracture. Bone diseases have been associated with altered bone metabolism. 
Energy production is mitochondria’s main role. Mitochondria is also responsible for calcium 
homeostasis. Calcium is an important component of bone function found in the mineral 
phase formed during osteoblast deposition. Osteoblastic cells are known to utilize both gly-
colysis and oxidative phosphorylation for energy production. However, as it differentiates, 
the metabolic needs shift to accommodate the demands required for mineralization. Here, we 
investigate the energy metabolism during osteoblast differentiation. Through Alizarin stain-
ing, we detected calcium accumulation by microscopy (Fig.1A) and quantitative analysis 
(Fig.1B). Using molecular analyses, we determined relative mitochondrial DNA (mtDNA) 
content during mineral synthesis. Mitochondrial copy number increased as mineralization 
accumulated in the matrix, suggesting that differentiated osteoblastic cells require more 
energy. Additional work is needed to characterize expression of key components of tricar-
boxylic acid (TCA) cycle, the central metabolic pathway in mitochondria, during osteoblast 
maturation. Further analysis of biochemical TCA markers is underway. 
Disclosures: Claudia Medeiros, None
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Prostate transmembrane protein androgen induced-1 and Nedd4 Regulate 
Bone Resorption by Promoting Proton Production in Osteoclasts *Hirohito 
Hirata1, Xianghe Xu2, Masatoshi Murayama1, Makoto Shiraki1, Toshio Kukita3, 
Masaaki Mawatari4, Akiko Kukita2. 1Department of Pathology and Microbiology, 
Department of Orthopedic Surgery, Faculty of Medicine, Saga University, 
Japan, 2Department of Pathology and Microbiology, Faculty of Medicine, Saga 
University, Japan, 3Department of Molecular Cell Biology & Oral Anatomy, 
Faculty of Dentistry, Kyushu University, Japan, 4Department of Orthopedic 
Surgery, Faculty of Medicine, Saga University, Japan
Prostate transmembrane protein androgen induced 1 (Pmepa1), is a binding protein 
with Nedd4 family of E3 ubiquitin ligases, which is mainly localized to vesicle membrane, 
and is involved in regulation of cell proliferation, metastasis, autophagy, and lysosomal 
stability in cancer cells. We have previously reported that Pmepa1 is highly expressed in 
osteoclasts on bone and is involved in bone resorption. In this study, we investigated the role 
and the regulatory mechanism of bone resorption via Pmepa1 using Pmepa1 mutant mice 
and involvement of Nedd4 in bone resorption. Mutant mice which lack membrane and cyto-
plasmic Nedd4 binding domains of Pmepa1 were generated by CRISPR/Cas9 system. Micro 
CT Analysis revealed that bone volume was relatively increased in Pmepa1 mutant mice 
compared to wild type (WT). Bone histomorphometry of lumbar vertebrae showed Pmepa1 
mutation slightly increased osteoblast numbers, but significantly decreased osteoclast num-
bers on bone surface and decreased erosion depth of osteoclasts. In vitro culture of bone mar-
row macrophages with RANKL showed that there was no difference in osteoclastogenesis 
between Pmepa1 mutant and WT mice, whereas bone resorption activity of Pmepa1 mutant 
osteoclasts was markedly decreased. The proton produced by osteoclasts was analyzed using 
an acid-sensitive fluorescent probe. Analysis by confocal laser microscopy showed proton 
production of Pmepa1 mutant osteoclasts was significantly decreased. In the previous study, 
we found Pmepa1 was localized to lysosome, but intracellular localization and role of Nedd4 
in osteoclasts has not been investigated. Analysis by immunofluorescence with Airyscan 
super resolution microscopy showed that Nedd4 is localized to lysosome with V0a3 or V0d2 
subunits of V-ATPase, and Pmepa1 was highly colocalized with Nedd4 in osteoclasts. In 
addition, knockdown of Nedd4 expression in osteoclasts markedly reduced bone resorp-
tion and proton production of osteoclasts. Finally, analysis by genomewide expression of 
osteoclasts showed that regulatory genes involved in vesicular trafficking was decreased in 
Pmepa1 mutant osteoclasts in comparison with those in WT osteoclasts. Collectively, our 
data show that both Pmepa1 and Nedd4, which are localized to lysosome with components 
of V-ATPase regulate bone resorption by affecting proton production. Our results show that 
together with Pmepa1, Nedd4 is a possible target for bone resorption.
Disclosures: Hirohito Hirata, None
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TAF12, a Member of TFIID Transcription Factor Complex, Contributes 
to Osteoclast Differentiation and Bone Resorption In Vivo *Kazuaki 
Miyagawa1, Yasuhisa Ohata1, Jumpei Teramachi1, Jiro Miura2, Mark A Subler3, 
John M Chirgwin3, Jolene J Windle 3, G. David Roodman1, Noriyoshi Kurihara4. 
1Division of Hematology and Oncology, Department of Medicine, Indiana 
University, United States, 2Division for Interdisciplinary Dentistry, Osaka 
University, Japan, 3Department of Human and Molecular Genetics, Virginia 
Commonwealth University, United States, 4Division of Hematology and 
Oncology, Department of Medicine, Indiana University, United States
We reported that TAF12 is expressed at higher levels in osteoclasts (OCLs) than os-
teoblasts (OBs), and contributed to OCL formation, particularly in OCLs of patients with 
Paget’s disease (Cell Metab,2012). However, TAF12’s role in normal bone remodeling is 
unclear, in part because global knockout of TAF12 is embryonic lethal in mice. Therefore, 
we generated mice with targeted heterozygous deletion of Taf12 (Taf12flox/- mice), using 
CRISPR/Cas9 technology and bred them to Trap-Cre mice to generate Trap-Cre/Taf12flox/- 
mice with targeted deletion of Taf12 in the OCL lineage. TAF12 protein levels in highly 
purified OCLs from Trap-Cre(+)/Taf12flox/- (TC(+)/Taf12) mice were decreased by 60% 
compared to OCLs from 8-month-old Trap-Cre(-)/Taf12flox/- (TC(-)/Taf12) and WT mice 
. Histomorphometric analysis of femurs revealed that BV/TV in 8-month-old TC(+)/Taf12 
mice was increased 1.6-fold compared to TC(-)/Taf12 mice. OCLs number and surface were 
also decreased by 20% in TC(+)/Taf12 mice compared to TC(-)/Taf12 mice, while OB num-
bers and surface were unchanged. These findings suggested that targeted deletion of TAF12 
in OCLs enhances bone volume due to the inhibition of OCL formation/ resorption during 
bone-remodeling. Consistent with these results, OCL formation and bone resorption induced 
by RANKL in cultures of TC(+)/Taf12  bone marrow were reduced by 40% and 60% re-
spectively, compared to OCL of TC(-)/Taf12 mice. Further, expression levels of NFATc1 
and Cathepsin K (CTSK) in OCLs from TC(+)/Taf12  mice were decreased by 50% and 
75% respectively, compared with TC(-)/Taf12. CTSK expression in OCLs in bone sections 
of TC(+)/Taf12 mice was similarly decreased. Since autophagy regulates bone resorption 
and secretion of proteases to the ruffled border in OCLs (DeSelm CJ et al, Dev Cell, 2011), 
we examined the effects of loss of TAF12 on autophagic molecule expression in OCLs. 
We found that syntaxin17 expression, which is involved in autophagosome formation, was 
significantly lower on  Western blots and by immunohistochemistry of OCLs from TC(+)/
Taf12 mice vs. TC(-)/Taf12 mice . Transmission electron microscopy of OCLs resorbing 
bone showed that the  ruffled borders of OCLs from TC(+)/Taf12 mice  were poorly  formed 
compared to TC(-)/Taf12 mice. These results suggest that TAF12 contributes to OCL dif-
ferentiation, bone resorption, and CTSK secretion in vivo and may be a novel target for 
blocking bone resorption.
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Sterol Regulatory Element Binding Transcription Factor 2 (SREBF2) 
Negatively Regulates Osteoclastogenesis and Pathological Bone Erosion 
*Haemin Kim1, Seyeon Bae2, Sehwan Mun2, Steven Zeng2, Kyung-Hyun Park-
Min1. 1Hospital for Special Surgery/Weill Cornell Medical College, United 
States, 2Hospital for Special Surgery, United States
Osteoclasts are the sole bone resorbing cells, and their dysregulation leads to patholog-
ical bone destruction. Recently, the importance of metabolic reprogramming in osteoclast 
differentiation and bone remodeling is increasingly appreciated and is an emerging area of 
research. However, its role in osteoclasts remains to be determined. Lipids, including cho-
lesterol and fatty acids, have greatly impacted on skeleton and bone cells. Previously, the 
close correlation between plasma lipids and bone mineral density has been well established. 
SREBFs are a key transcription factor for regulating lipid biosynthesis and are sensors for 
intracellular lipids. To investigate the role of SREBF2-mediated lipid metabolism in os-
teoclasts, we generated osteoclast-specific SREBF2 deficient mice (SF2 cKO). Strikingly, 
SF2 cKO mice exhibit reduced bone mass compared to control mice and show accelerated 
osteoclastogenesis. Consistent with data from mouse osteoclasts, SREBF2 knockdown by 
siRNAs in human osteoclasts promotes osteoclastogenesis, and overexpression of SREBF2 
completely suppresses osteoclast differentiation, suggesting that SREBF2 is a negative 
regulator of both human and mouse osteoclastogenesis. During the osteoclastogenesis, the 
levels of intracellular cholesterol significantly increase in a time-dependent manner, and the 
genes associated with cholesterol biosynthesis are induced during receptor activator of NF-
κB ligand (RANKL)-mediated osteoclastogenesis. Nuclear SREBF2 is also highly induced 
by RANKL. However, SREBF2 mediated regulation of osteoclast differentiation is inde-
pendent of intracellular cholesterol. Small molecule inhibitors targeting SREBF2 activation 
also enhance osteoclastogenesis. Moreover, SREBF2 deficiency accelerates pathological 
bone erosion in a murine inflammatory arthritis model. Using ChIP sequencing and RNA 
sequencing, we revealed that SREBF2 regulates osteoclastogenesis in part by targeting the 
interferon signaling pathway. Taken together, our findings have elucidated the effect of lipid 
metabolism and SREBFs on osteoclastogenesis and bone homeostasis and also open up a 
new avenue to therapeutically target pathological bone destruction.
Disclosures: Haemin Kim, None
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Cellular Origin and Functions of Osteoclast Progenitors in Inflammatory 
Arthritis *Christian Jacome-Galarza1, Julia Charles1. 1Brigham and Women’s 
Hospital, United States
Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints resulting 
in osteoclast (OC) mediated bone and cartilage destruction, leading to physical disability. 
However, the precise cellular origins of OC and the mechanisms that regulate their forma-
tion in IA are poorly understood. Myeloid lineages including OC can derive from either 
hematopoietic stem cells (HSC) or erythro-myeloid progenitors (EMP). Previous studies 
suggest that, in IA, HSC-derived monocytes differentiate into OC and others showed that 
macrophages (macs) can form OC under the influence of inflammatory cytokines in vitro. 
We hypothesized that EMP-derived macs and HSC-derived monocytes can independent-
ly contribute to the formation of OC in IA. To test this hypothesis, we used Flt3Cre;Ros-
a26LSL-YFP mice to label HSC-derived cells and Cx3cr1CreERT2;Rosa26LSL-tdTomato 
mice, pulsed with tamoxifen at E9.75, to label EMP-derived cells. We harvested ankle joints 
and examined synovium and periosteal bone by histology and confocal microscopy to detect 
fluorescent proteins (lineage-tracer), OC and macs. Histology of ankle joints from healthy 
Flt3Cre;Rosa26LSL-YFP embryos at E16.5, newborn at P0 and 8 week-old mice showed 
that ~7 % of synovial F4/80+ or CD68+ cells were of HSC origin, suggesting that EMPs are 
the major source of synovial macs. We confirmed, using Cx3cr1CreERT2;Rosa26LSL-tdTo-
mato mice, that numerous F4/80+ synovial macs were TdTomato+, showing for the first time 
an EMP-origin. To test the HSC origin of OC in IA, adult Flt3Cre;Rosa26LSL-YFP  mice 
were treated with K/BxN arthritogenic serum and ankle joints were harvested at day 10 
(peak inflammation). Unexpectedly, we found that only 56% of OC were YFP-positive, in-
dicating that a large proportion of synovial OC are not HSC-derived. Further, we identified 
CD68+TRAP+ cells localized to periosteal surfaces as candidate progenitors of synovial 
OC. Consistent with the dual origin of synovial OC, CD68+TRAP+ progenitors derive from 
both HSC (27%) and non-HSC (73%) lineages.We are currently confirming the EMP-origin 
of OC in arthritic mice, more precisely defining the phenotype of OCPs and investigating 
their transcriptional profile by scRNA sequencing. A better understanding of the transcrip-
tional mechanisms that regulate OC formation in IA will allow us to decipher pathogenic 
mechanisms and identify cell specific molecules to develop new therapeutic targets to inhibit 
OC formation and prevent bone and cartilage erosions.
Disclosures: Christian Jacome-Galarza, None
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β-adrenergic Receptors in Osteoclasts Regulate Differentiation and 
Resorption Activity in vitro *Audrey Bergeron1, Audrie Langlais1, Deborah 
Barlow2, Karen Houseknecht2, Katherine Motyl1. 1Maine Medical Center 
Research Institute, United States, 2University of New England, United States
Sympathetic nervous system (SNS) signaling via β-adrenergic receptors (βAR) leads 
to uncoupled remodeling and bone loss. Therefore, βAR antagonists (β-blockers, BB) may 
be used to treat or prevent osteoporosis. Our recent finding that the non-selective β-block-
er propranolol (Pro) prevents resorption in vivo without influencing RANKL suggests that 
βARs play a direct role in osteoclasts (OCLs).Therefore, we hypothesized that βAR sig-
naling directly promotes OCL differentiation/function. To test this, we injected 3 mg/kg 
sc of the βAR agonist salbutamol (Sal) daily for 4 wks in BL/6 female mice. Both µCT 
and ELISA showed striking Sal-induced bone resorption in vivo with marked trabecular 
bone loss in the distal femur (BV/TV was reduced by 35% compared to veh, p<0.001) and 
L5 vertebra. Sal increased serum levels of CTx (137%, p<0.001) without changing P1NP 
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levels (p=0.9), suggesting enhanced resorption but no changes in formation. Next, using 
RNAscope, we were able to detect both Adrb1 and Adrb2 transcripts in femur. Importantly, 
both Adrb1 and Adrb2 transcripts colocalize with Acp5 positive cells lining trabecular bone 
surfaces, indicating that both are expressed in OCLs in vivo. In vitro, we further confirmed 
low levels of Adrb1 gene expression (Ct values >30) and moderate Adrb2 gene expression in 
primary bone marrow stromal cells and RAW264.7 cells differentiated to OCLs (Ct values = 
29.8/26.3, respectively). We observed β1AR and β2AR protein in OCL cultures using IHC 
(but not in OCLs from Adrb1/2 global KO mice). We next treated primary OCLs with Pro 
or Sal at concentrations comparable to those achieved in vivo in the bone marrow of dosed 
mice; 1 µM Pro inhibited OCL differentiation (# TRAP positive multinucleated cells) by 
18% (p=0.005) and reduced resorption (OsteoAssay Surface) by 45% (p=0.05) while 1 µM 
Sal enhanced OCL differentiation by 51% (p<0.0001) and increased resorption by 139% 
(p=0.03). Consistent with this, Pro inhibited mid-to-late stage differentiation markers while 
Sal enhanced these markers (including Acp5, Fam102a, Fos, and Nfatc1).  Interestingly, in 
OCLs derived from Adrb1/2 global KO mice, Pro reduced OCL numbers (but to a lesser 
degree than in WT cells) while Sal did not increase OCL numbers; indicating that Pro may 
exhibit β1AR and β2AR-independent effects on OCL differentiation while Sal targets βARs 
more specifically. In summary, these data suggest that BB may serve as a therapy targeting 
OCLs in bone pathologies.
Disclosures: Audrey Bergeron, None
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Regulation of Osteoclast Differentiation by MEF2A *Andrew Norton 1, 
Nicholas Blixt1, Brian Spencer1, Cory Baumann1, Dawn Lowe1, Kim Mansky1. 
1University of Minnesota, United States
Osteoclasts are large multinuclear cells that are responsible for breaking down bone. 
Myocyte enhancer factor 2 (MEF2) is a family of transcription factors, Mef2a, b, c and 
d, that regulate gene transcription in multiple cell types. Research from other groups has 
demonstrated that MEF2 regulates chondrocytes, osteoblasts and osteocytes; however, little 
work to date has been done to demonstrate if MEF2 plays a role in regulating osteoclast dif-
ferentiation.  We initially determined that MEF2A, C and D are expressed during osteoclast 
differentiation. To study MEF2A’s role in regulating osteoclast differentiation, we created a 
conditional mouse model of MEF2A in which Mef2a floxed mice (A-WT) were bred to mice 
expressing c-Fms-Cre (A-cKO). At three months of age, femurs from female A-cKO mice 
have increased BV/TV and decreased CTX and decreased number of osteoclasts compared 
to female A-WT mice. We did not observe a skeletal phenotype or change in bone biomark-
ers in the male mice that were conditional for Mef2a. In vitro cultures of osteoclasts from 
male or female A-cKO mice form smaller and less active osteoclasts compared to A-WT 
mice. MEF2C has been shown to regulate expression and activity of the estrogen receptor in 
cardiac cells via the interaction of class IIA HDACs with MEF2C. Thus, we hypothesize that 
sex specific effects on osteoclasts that we measure in female A-cKO mice is due to changes 
in the expression and/or activity of the estrogen receptor. We measured a 3-fold increase 
in Esr1, the gene for estrogen receptor-alpha, in A-cKO osteoclasts. We sham-operated or 
ovariectomized (OVX) 8 to 10-week old female A-WT or A-cKO female mice. We measured 
approximately a 45% reduction in the BV/TV of femurs from A-WT OVX vs. A-WT sham 
mice. BV/TV of A-cKO OVX mice was reduced 55% compared to A-cKO sham mice. Ad-
ditionally, BV/TV of the A-cKO OVX mice was not significantly different than A-WT sham 
mice supporting the hypothesis that dysregulation of estrogen signaling is the mechanism 
for the increased BV/TV in female A-cKO mice. Lastly, we measured a 3-fold increase in 
Mef2c expression and a 3-fold decrease in Hdac9 expression in osteoclasts from A-cKO 
mice suggesting that MEF2A may regulate estrogen receptor expression and activity thor-
ough modulation of Mef2c and Hdac9 expression.
Disclosures: Andrew Norton, None
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Hem1 Promotes Osteoclast Fusion and Bone Resorption in Mice *Xiaoyan 
Wang1, Lijian Shao2, Nukhet Aykin-Burns1, Daohong Zhou3, Maria Almeida1, 
Ha-Neui Kim1. 1University of Arkansas for Medical Sciences, United States, 
2University of Illinois Chicago, United States, 3University of Florida, United 
States
Hem1 (Hematopoietic protein 1), a hematopoietic cell-specific member of the Hem 
family of cytoplasmic adaptor proteins, is essential for lymphopoiesis and innate immu-
nity via actin polymerization as well as the transition of fetal liver hematopoiesis to the 
bone marrow. Hem1 is indispensable for the Arp2/3 complex-induced cell migration and the 
accompanying enhanced mitochondrial function in yeast, but little is known about Hem1 
regulation of mitochondrial function in mammalian cells. Here we report that Hem1 con-
tributes to the fusion of pre-osteoclasts in mice. Five-week-old male or female mice with 
global deletion (KO) of Hem1 gene had higher cancellous bone volume and BMD in femur 
than wild-type littermate controls (WT). This change was due to an increase in trabecular 
number and a decrease in trabecular spacing while trabecular thickness was not affected as 
determined by micro-CT. The high bone mass phenotype was associated with decreased 
CTx levels in the serum. To examine the cellular mechanisms responsible for the decrease 
in bone resorption, we used bone marrow-derived macrophage (BMM) cultures and induced 
osteoclast formation with RANKL. In the cells from WT mice, Hem1 mRNA and protein 
levels were greatly increased during the transition of BMMs to mature osteoclasts in the 
presence of RANKL. Osteoclast progenitors from Hem1 KO mice differentiated normal-
ly into TRAP-positive osteoclasts albeit with impaired resorptive function due to defects 
in actin ring formation. Osteoclasts lacking Hem1 exhibited a striking decrease in oxygen 
consumption rate and mitochondrial ATP production as compared to osteoclasts from WT 
mice. Osteoclast resorbing activity was increased in BMM cultures from wild-type C57BL6 
mice transduced with retroviral vectors expressing the murine Hem1. Hem1 overexpression 
increased RANKL-induced DC-stamp and ATP6v0d2, known osteoclast fusion markers, 
suggesting that, consistent with its polymerization properties of actin, Hem1 promotes osteo-
clastogenesis by regulating actin ring organization. Transplantation of Hem1 KO mice with 
normal hematopoietic cells (Lin-CD45+) restored cancellous bone volume and microarchi-
tecture in the distal femur, as well as the levels of serum CTx and actin ring formation in 
osteoclasts. Taken together, these results indicate that Hem1 activation in mice stimulates 
osteoclast fusion and its resorbing activity, most likely by promoting mitochondrial function; 
and thereby decreases bone mass.
Disclosures: Xiaoyan Wang, None
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Genetic and pharmacological activation of Hedgehog signaling suppresses 
osteoclastogenesis and hinders titanium particle-induced osteolysis via 
inhibiting the JNK/c-Fos-NFATc1 cascade *Liwei Zhang1, Yanjun Yang1, Zirui 
Liao1, Meng Li1, Xinhaun Lei2, Chiting Yuan2, Jianquan Chen1. 1Department 
of Orthopaedics, the First Affiliated Hospital of Soochow University, China, 
2Orthopedic Department, Taizhou Hospital Affiliated to Wenzhou Medical 
University, China
Aseptic loosening is a major long-term complication after total joint arthroplasty and 
has become the first cause for further revision surgery. Proinflammatory cytokines release 
resulting from engulfing implant debris by macrophages and subsequent stimulation of os-
teoclast differentiation and bone resorption are considered as the mechanism of periprosthet-
ic osteolysis (PPO). Thus, therapeutic approaches of suppressing osteoclast formation and 
activity are considered to be of great potential to prevent and treat this osteolytic disease. 
Hedgehog (Hh) signaling has been shown to play a critical role in skeletal development and 
metabolism with promoting osteoblast differentiation and inhibiting adipogenesis. While 
Hh signaling is also implicated in regulating osteoclastogenesis indirectly, whether it can 
inhibit osteoclast differentiation and bone resorption remains controversial. In this study, 
we explored the cell-autonomous role of Hh signaling in regulating osteoclastogenesis and 
its therapeutic potential in preventing wear particle-induced osteolysis.Hh signaling activa-
tion in macrophages was resulted from conditional ablation of negative regulator suppressor 
of fused (Sufu) using LysM-Cre or Smo-agonist purmorphamine (PM) treatment. Firstly, 
RANKL-induced osteoclast formation and bone resorption were strongly inhibited after Hh 
signaling activation detected by TRAP staining, F-actin ring immunofluorescence and scan-
ning electron microscope. Meanwhile, the down-regulated expressions of osteoclast-specific 
genes including Nfatc1, c-Fos, Ctsk, Dcstamp, Acp5, Oscar, Atp6v0a3, and Atp6v0d2 were 
assessed by RT-qPCR. Ti particle-induced osteolysis models were established to assess os-
teoclastogenesis and bone resorption in vivo and the samples were analyzed using Micro-CT 
and histomorphometry, which confirmed the protective effect of Hh signaling activation on 
osteolysis. The mechanistic study by western blot revealed that activation of Hh signaling 
suppressed RANKL-induced JNK phosphorylation and downregulated protein levels of two 
key osteoclastic transcriptional factors, c-Fos and its downstream target NFATc1.Hh signal-
ing activation caused by Sufu ablation and PM treatment inhibited osteoclastogenesis and 
Ti particle-induced osteolysis through suppressing JNK/NFATc1/c-Fos signaling, indicating 
it may serve as a novel candidate for therapeutic intervention in PPO and other osteolytic 
diseases.
Disclosures: Liwei Zhang, None
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STAT3 controls osteoclast differentiation and bone homeostasis by regulating 
NFATc1 transcription *Yang Yiling1, Jiang Lingyong1, Dai Qinggang1, Zhou 
Siru1. 1Shanghai Jiaotong University School of Medicine, China
The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) 
plays a central role in cell survival and function. STAT3 has been demonstrated to partic-
ipate in maintenance of bone homeostasis in osteoblasts, but its role in osteoclasts in vivo 
remains poorly defined. Here we generated a conditional knockout mouse model in which 
Stat3 was deleted in osteoclasts using a Cathepsin K-Cre (Ctsk-Cre) driver. We observed 
osteoclast-specific Stat3 deficiency caused increased bone mass in mice, which we attribut-
ed to impaired bone catabolism by osteoclasts. Stat3-deficient bone marrow macrophages 
(BMMs) showed decreased expression of nuclear factor of activated T cells, cytoplasmic 
1 (NFATc1) and reduced osteoclast differentiation determined by decreases in osteoclast 
number, TRAP activity and expression of osteoclast marker genes. Enforced expression of 
NFATc1 in Stat3-deficient BMMs rescued the impaired osteoclast differentiation. Mech-
anistically, we revealed that STAT3 could drive the transcription of NFATc1 by binding 
to its promoter. Furthermore, preventing STAT3 activation using an inhibitor of upstream 
phosphorylases, AG490, also impaired osteoclast differentiation and formation in a similar 
way to gene deletion of Stat3. In summary, our data provide the first evidence that STAT3 is 
significant in osteoclast differentiation and bone homeostasis in vivo, and may be identified 
as a potential pharmacological target for the treatment of bone metabolic diseases through 
regulation of osteoclast activity.
Disclosures: Yang Yiling, None
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F-actin mediates suppression of bone resorption and prevention of 
ovariectomy-induced bone loss by a C-glycoside isoflavonoid *Ling Li1, 
Zuocheng Qiu1, Xinluan Wang1. 1Translational Medicine R&D Center, Institute 
of Biomedical and Health Engineering, Shenzhen Institutes of Advanced 
Technology, Chinese Academy of Sciences, China
Given the limitations of current anti-resorption agents for postmenopausal osteoporosis, 
there is a need for alternatives without impairing coupling crosstalk between bone resorption 
and bone formation. In this study, we evaluated the effects of puerarin, a natural C-glyco-
side isoflavonoid, on bone resorption using an ovariectomized (OVX)-rat model and further 
investigated its underlying molecular mechanism of action in vitro. Puerarin significantly 
inhibited F-actin ring formation and bone resorption, without affecting osteoclastgenesis or 
apoptosis. In terms of mechanism, it down-regulated c-Fos, TRAP and CAII gene expres-
sion, but not suppressed osteoclastogenesis-related proteins TRAF6, NFATc1 and p-NF-kap-
pa B (p65), decreased protein of integrin-beta 3 and phosphorylations of Src, Pyk2 and Cbl, 
but not inhibited Src kinase activity. Oral administration of 150 mg/kg/day of puerarin pre-
vented OVX-induced trabecular bone loss of proximal tibia and significantly improved bone 
strength of femur diaphysis in rats. Moreover, puerarin significantly decreased TRAP-pos-
itive osteoclast numbers and serum TRAP-5b, CTx, without affecting bone formation rate. 
Taken together, we present novel findings that puerarin prevents the bone loss in OVX rat 
through suppression of osteoclast activation and bone resorption, by disrupting F-actin ring 
formation of osteoclast via inhibiting integrin-beta3-Pyk2/Cbl/Src signaling pathway, with-
out affecting osteoclasts formation or apoptosis. These results demonstrate the unique mech-
anism of puerarin on bone metabolism and provide a novel natural C-glycoside isoflavonoid 
as potential agent for prevention of postmenopausal osteoporosis.
Disclosures: Ling Li, None
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Deletion of Sirt3 increases bone mass and alleviates estrogen deficiency-
induced bone loss through suppressing osteoclast activity *Qiangqiang 
LI1, Haixing WANG2, Jiajun Zhang1, Alice Pik Shan KONG3, Tsz-ping LAM1, 
Wayne Yuk Wai LEE1. 1Department of Orthopaedics and Traumatology, SH Ho 
Scoliosis Research Laboratory, The Chinese University of Hong Kong, Hong 
Kong, 2Department of Orthopaedics and Traumatology, The Chinese University 
of Hong Kong, Hong Kong, 3Department of Medicine & Therapeutics, The 
Chinese University of Hong Kong, Hong Kong
Purpose: Sirt3 is a NAD+-dependent deacetylase and plays important roles in mito-
chondrial function and energy homeostasis. Osteoclasts (OC) consist of large amounts of 
mitochondria owing to high energy demand for bone-resorption activity. Previous study 
demonstrated the regulatory effect of Sirt3 on OC formation in vitro only. In this study, 
we aimed to study the biological function of Sirt3 in OC activity in aging and ovariectomy 
(OVX)-induced osteoporosis mice models.Methods: First, Sirt3 expression was investigat-
ed during OC differentiation in vitro by using primary bone marrow-derived macrophages 
(BMM), and in fresh bone tissue and bone marrow cells collected from ovariectomized mice 
and sham group. Next, we knockdown Sirt3 expression in RAW264.7 cell line to determine 
its effect on osteoclast differentiation. Moreover, female mice with global deletion (KO) 
of Sirt3 gene were used for the characterization of bone phenotypes at different ages (5 
weeks, 3 months and 6 months old). Finally, the impact of Sirt3 deficiency on OVX-induced 
bone loss was investigated. Results: Cellular study demonstrated that Sirt3 mRNA level was 
greatly increased during the differentiation of BMMs to mature OCs and inhibition of Sirt3 
significantly decreased osteoclastogenesis. Sirt3 mRNA in bone tissue and bone marrow 
cells was also significantly increased following OVX in wildtype (WT) mice. Compared 
to WT mice, Sirt3 deletion in KO mice resulted in increased femoral cortical thickness and 
higher trabecular bone mineral density in femur, which could be attributed to lower OC 
activity following Sirt3 deletion as indicated by suppressed osteoclastogenic differentiation 
and decreased serum level of TRACP-5b level. Finally, we observed OVX markedly deplet-
ed bone mass in WT mice but this decline was less obvious in Sirt3 KO mice. TRAP staining 
and ELISA assay showed that OC activities was markedly enhanced in the WT OVX group 
when compared to WT sham group, while no significant difference was observed in bone 
resorption parameters between Sirt3 KO sham group and Sirt3 KO OVX group. Conclusion: 
Sirt3 has important roles in the bone homeostasis and estrogen deficiency-induced bone loss 
by modulating OC activity, suggesting that inhibiting Sirt3 and its downstream targets might 
be novel therapeutic targets to modulate osteoresorptive disorders.
Disclosures: Qiangqiang LI, None
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Specific role of Hh signaling pathway in bone resorption *Ryuma Haraguchi1, 
Yukihiro Kohara1, Riko Kitazawa2, Yuuki Imai3, Sohei Kitazawa1. 1Department 
of Molecular Pathology, Ehime University Graduate School of Medicine, 
Japan, 2Department of Diagnostic Pathology, Ehime University Hospital, Japan, 
3Proteo-Science Center, Ehime University, Japan
 The functional role of the Hedgehog (Hh) signaling pathway has been widely investi-
gated in bone physiology/development.  Previous studies have, however, focused primarily 
on Hh functions in bone formation, while its effects on bone resorption have not been ful-
ly elucidated.  Here, we found that cyclopamine (Smoothened [Smo] inhibitor), GANT-58 
(GLI1 inhibitor) or GANT-61 (GLI1/2 inhibitor), significantly inhibited RANKL-induced 
osteoclast differentiation of bone marrow-derived macrophages.  Although the inhibitory 
effects were exerted by cyclopamine or GANT-61 treatment over 0-48 h (early-stage of 
osteoclast differentiation) or 48-96 h (late-stage of osteoclast differentiation) after RANKL 
stimulation, GANT-58 suppressed osteoclast formation only during the early stage.  These 
results suggest that the Smo-GLI1/2 axis mediates the whole process of osteoclastogenesis, 
and that GLI1 activation is requisite only during early cellular events of osteoclastogenesis. 
Additionally, macrophage/osteoclast-specific deletion of Smo in mice was found to attenuate 
the aging phenotype characterized by trabecular low bone mass, suggesting that blockage of 
the Hh signaling pathway in the osteoclast lineage plays a protective role against age-related 
bone loss.  Our findings reveal a specific role of the Hh signaling pathway in bone resorption, 
and highlight that its inhibitors show potential as therapeutic agents that block osteoclast 
formation in the treatment of senile osteoporosis.
Disclosures: Ryuma Haraguchi, None
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Sexual dimorphism in early osteoclasts demonstrates enhanced inflammatory 
pathway activation in female cells *Se Hwan Mun1, Sandra Jastrzebski2, 
Judy Kalinowski3, Steven Zeng1, Seyeon Bae1, Eugenia Giannopoulou1, Nazir 
M Khan4, Hicham Drissi4, Bongjin Shin3, Sun-Kyeong Lee3, Joseph Lorenzo3, 
Kyung-Hyun Park-Min1. 1Hospital for Special Surgery, United States, 2University 
of Connecticut Health Center, United States, 3University of Connecticut Health, 
United States, 4Emory University, United States
Sexual dimorphism of the skeleton is well-documented. At maturity, the male (M) skel-
eton is larger and has a higher bone density than the female (F). However, the underlying 
mechanisms for these differences remain incompletely understood. We examined sexual di-
morphism in the formation of osteoclasts (OC) between cells from F and M mice. In vivo we 
found that the number of OC in bones was greater in F (typically 2.5-3 x greater, p<0.01). 
Similarly, in vitro osteoclast differentiation and pit formation were accelerated in cultures 
of F highly purified osteoclast precursor (OCP) cells or bone marrow macrophages, treated 
with M-CSF and RANKL (typically ~ 1.5 - 2 x greater in F, P<0.01). To further character-
ize sex differences between F and M early OC, we performed unbiased RNA-sequencing 
analysis of cultured, murine bone marrow OCPs, which were treated for 3 days with M-CSF 
and RANKL. We found 125 differentially expressed genes (DEGs) that were significant-
ly regulated in a sex-dependent manner. Only 9 DEGs were located on sex chromosomes. 
Transcriptional sexual dimorphism was found to be predominately mediated by genes in-
volved in innate immune and inflammatory response pathways. Gene set enrichment analy-
sis (GSEA) showed that the pathways related to inflammatory response, allograft rejection, 
IL6_JAK_STAT3 signaling, UV-response up, and interferon gamma response were enriched 
in sex-dimorphic genes in early OCs. Upstream regulator analysis of Ingenuity Pathway 
Analysis also showed that the responses to inflammatory mediators were higher in F early 
OCs compared to M early OCs. We then used GSEA to identify transcription factor-bind-
ing motifs that are enriched in the promoters of sex-dimorphic genes. The binding motifs 
for Ets2, PU.1, EN1, NF-?B, and NFATc1 were significantly enriched in the promoters of 
sex-dimorphic genes. Although both RANK expression and the proximal RANKL-signal-
ing pathways were comparable between females and males, accumulation of both nuclear 
p65 and NFATc1 was significantly increased in female OCPs compared to male OCPs on 
day 1 after RANKL stimulation, which partially explains the differences in transcriptom-
ic sexual-dimorphism in OCs. Collectively, our findings identify a sex-dependent intrinsic 
difference in early osteoclasts, which results from an altered response to osteoclastogenic 
stimulation. In humans, these differences could contribute to the lower peak bone mass and 
increased risk of osteoporosis of females relative to males.
Disclosures: Se Hwan Mun, None
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Dectin-2, a Fc receptor gamma-harboring receptor, regulates foreign body 
reaction by interfering with intracellular calcium oscillation. *Hiroyuki 
Okada1, Hiroshi Kajiya2, Yasunori Omata3, Koji Okabe2, Takeshi Miyamoto4, 
Sakae Tanaka3. 1Center of Disease Biology and Integrative Medicine, Faculty 
of Medicine, the University of Tokyo, Japan, 2Department of Physiological 
Science and Molecular Biology, Fukuoka Dental College, Japan, 3Department 
of Orthopaedic Surgery, The University of Tokyo, Japan, 4Department of 
Orthopaedic Surgery, Faculty of Life Science, Kumamoto University, Japan
Dectin-2, a mannose receptor expressed in dendritic cells and macrophages, is cou-
pled with Fc receptor gamma (FcRγ), an immunoreceptor tyrosine-based activation motif 
(ITAM) adaptor. Dectin-2 has an important role in host defense against Candida and Myco-
bacterium. Recent report showed that Dectin-2 in tissue macrophage has a crucial role in the 
pathogenesis of aortitis. However, the role of Dectin-2 in the differentiation of osteoclasts 
(OCs) and foreign body giant cells (FBGCs) remains unknown.Methods: OCs were induced 
from murine bone marrow macrophages (BMMs) by four-day treatment with M-CSF and 
RANKL, and FBGCs by three-day treatment with GM-CSF and IL-4. Gene expression of 
Dectin-2 was evaluated by RT-PCR. Intracellular localization of Dectin-2 was confirmed by 
immunocytochemistry. The role of Dectin-2 on osteoclastogenesis in vivo was examined by 
bone densitometry, and the role in FBGCs was histologically examined using an intraperi-
toneal sponge grafting model. Finally, calcium oscillation in BMMs, a downstream signal 
of ITAM receptors, was analyzed using calcium indicator Fura-2. BMMs form Dectin-2 
KO and FcRγ KO mice were also used.Results and Discussion: Expression of Dectin-2 was 
increased in both OCs and FBGCs, especially in FBGCs, during the course of their differen-
tiation. Dectin-2 was colocalized with FcRγ on the plasma membrane. BMD of Dectin-2 KO 
and FcRγKO mice was not changed compared to wild type mice. In contrast, foreign body 
reaction caused by intraperitoneal sponge grafting was reduced in Dectin-2 KO and FcRγKO 
mice. Finally, the analysis of frequency of calcium oscillations in BMMs showed that slow 
waves were increased in FcRγ KO BMMs before GM-CSF and IL-4 stimulation, and in Dec-
tin-2 KO mice after stimulation with cytokines.In this study, we found that Dectin-2 was lo-
calized on cellular membrane and interfered with downstream calcium oscillations. Dectin-2 
had an important role especially in the differentiation of FBGCs and foreign body reaction.
Disclosures: Hiroyuki Okada, None
P-450
Acetylcholinesterase in osteoclastogenesis and osteoporosis via ACh-
independent pathway *Xiaohe LUO1, Chunyi WEN1. 1The Hong Kong 
Polytechnic University, Hong Kong
PurposeAcetylcholinesterase (AChE), originally known as an enzyme to hydrolyze 
ACh, has been demonstrated to regulate skeletogenesis via both cholinergic[1] and non-cho-
linergic pathways[2]. Recent research claims that cholinergic activity favors bone mass by 
inhibiting AChE[3]. However, AChE in bone regulation via ACh-independent pathway re-
mains largely unknown. Moreover, osteoclasts-mediated bone resorption plays a pivotal role 
in bone homeostasis and diseases. Compared to osteogenesis and bone development, AChE 
in osteoclastogenesis and bone degeneration is still poorly understood.Here, we aimed to 
investigate the expression pattern of endogenous AChE during osteoclastogenesis; the ef-
fects of exogenous AChE/heat-inactivated AChE in osteoclastogenesis; the pharmaceutical 
inhibition of AChE both in vitro and in vivo.Methods15 ng/ml soluble RANKL was used to 
induce osteoclastogenesis of RAW 264.7 cells. Recombinant AChE, AChE inhibitors Do-
nepezil and Galantamine were added during osteoclastogenesis respectively. Sham/OVX 
Balb/C mice were treated with Donepezil. Quantitative RT-PCR of TRAP, RANK, MMP9 
and ACHE; TRAP and IF staining were performed.Results and ConclusionDuring differen-
tiation, mRNA and protein levels of endogenous AChE first increased (Fig.A,B), sharing a 
same trend of mRNA expression of osteoclast-markers (TRAP, RANK and MMP9), sug-
gesting AChE may play an emerging role in regulating osteoclastogenesis.By TRAP stain-
ing, larger size osteoclasts were observed in AChE/heat-inactivated AChE groups, indicat-
ing the non-enzymatic effect of AChE in osteoclastogenesis. Higher concentration of AChE/
heat-inactivated AChE were associated with increased nuclear NO. in single TRAP+ cell and 
mRNA levels of cell-cell fusion markers (OC-STAMP, DC-STAMP), pointing that AChE 
may contribute to cell-cell fusion of OCs (Fig.D-F).AChE inhibitor Donepezil could inhibit 
osteoclastogenesis in vitro, decreased NO. of OCs was observed in Donepezil-treated OVX 
mice, indicating the potential therapeutics of osteoporosis by inhibiting AChE. (Fig.G,H)
Donepezil but not Galantamine inhibited osteoclastogenesis in vitro. Donepezil binds to 
both catalytic and peripheral site of AChE, while Galantamine only binds to the catalytic 
site, suggesting the peripheral site may contribute to cell-cell fusion of OCs. (Fig.I,J)Refer-
ences1.Eimar, H., J Musculoskelet Neuronal Interact, 2013.2.Spieker, J., PLOS one, 2016. 
3.Ma, Y. & F. Elefteriou, J Bone Miner Res, 2020.
Disclosures: Xiaohe LUO, None
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Regulatory network mediated by RBP-J/NFATc1-miR182 controls 
inflammatory bone resorption. *Kazuki INOUE1, Xiaoyu Hu2, Baohong 
Zhao1. 1HOSPITAL FOR SPECIAL SURGERY, United States, 2 Institute for 
Immunology and School of Medicine, Tsinghua University, China
Bone resorption is a severe consequence of inflammatory diseases associated with os-
teolysis, such as rheumatoid arthritis (RA), often leading to disability in patients. In physi-
ological conditions, the differentiation of bone-resorbing osteoclasts is delicately regulated 
by the balance between osteoclastogenic and anti-osteoclastogenic mechanisms. Inflamma-
tion has complex impact on osteoclastogenesis and bone destruction, and the underlying 
mechanisms of which, especially feedback inhibition, are underexplored. Here, we identify 
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a novel regulatory network mediated by RBP-J/NFATc1-miR182 in TNF-induced osteo-
clastogenesis and inflammatory bone resorption. This network includes negative regulator 
RBP-J and positive regulators, NFATc1 and miR182, of osteoclast differentiation. In this 
network, miR182 is a direct target of both RBP-J and NFATc1. RBP-J represses, while 
NFATc1 activates miR182 expression through binding to specific open chromatin regions in 
the miR182 promoter. Inhibition of miR182 by RBP-J servers as a critical mechanism that 
limits TNF-induced osteoclast differentiation and inflammatory bone resorption. Inflamma-
tion, such as that which occurs in RA, shifts the expression levels of the components in this 
network mediated by RBP-J/NFATc1-miR182-FoxO3/PKR (previously identified miR182 
targets) towards more osteoclastogenic, rather than healthy conditions. Treatment with TNF 
inhibitors in RA patients reverses the expression changes of the network components and 
osteoclastogenic potential. Thus, this network controls the balance between activating and 
repressive signals that determine the extent of osteoclastogenesis. These findings collective-
ly highlight the biological significance and translational implication of this newly identified 
intrinsic regulatory network in inflammatory osteoclastogenesis and osteolysis.
Disclosures: Kazuki INOUE, None
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Zoledronic acid is not equally potent on osteoclasts generated from different 
individuals – osteoclasts from smokers are less sensitive *Anaïs MJ Møller1, 
Jean-Marie Delaisse2, Jacob B Olesen2, Troels Bechmann3, Jonna S Madsen4, 
Kent Søe2. 1Clinical Cell Biology, University Hospital of Southern Denmark, 
Dept. of Regional Health Research, University of Southern Denmark, Denmark, 
2Clinical Cell Biology, Odense University Hospital, Dept. of Clinical Research, 
University of Southern Denmark, Denmark, 3Dept. of Oncology, Lillebaelt 
Hospital, University Hospital of Southern Denmark, University of Southern 
Denmark, Denmark, 4Dept. of Immunology and Biochemistry, Lillebaelt 
Hospital, University Hospital of Southern Denmark, University of Southern 
Denmark., Denmark
Zoledronic acid is a bisphosphonate, commonly used to treat bone diseases such as 
osteoporosis and cancer induced bone disease. However, patients show a variable sensitivity 
to zoledronic acid and the reason remains unclear. The objective of this study was to obtain 
more knowledge in this regard. We hypothesized that osteoclasts generated from different 
individuals will show a variable sensitivity to zoledronic acid in vitro. Osteoclasts were gen-
erated using monocytes from 46 healthy female blood donors (40-66 years). Matured osteo-
clasts were reseeded onto bone slices pre-coated with different concentrations of zoledronic 
acid and e.g. IC50 and maximum inhibition values were determined based on the eroded 
bone surface after 3 days of resorption. We found that the IC50 for inhibition of osteoclastic 
bone resorption varied from 0.06 to 12.57 µM zoledronic acid (median of 0.26 µM) and 
the dose for maximum inhibition varied from 0.3 to 50 µM (median of 2 µM), thus a more 
than 200- and 167-fold difference, respectively, in sensitivity to zoledronic acid among os-
teoclasts from different healthy individuals. Multiple linear regression analyses showed that 
the determined IC50 correlated with: 1. smoking habits – osteoclasts from smokers were 
less sensitive than those of non-smokers; 2) the average number of nuclei per osteoclast in 
vitro – more nuclei made osteoclasts less sensitive. Further analyses showed that: 3. increas-
ing protein levels of mature cathepsin K in osteoclast cultures rendered the osteoclasts less 
sensitive to zoledronic acid; 4. surprisingly, neither gene nor protein expression of farnesyl 
diphosphate synthase was found to correlate with the sensitivity to zoledronic acid; 5. in 1/3 
of the cultures, zoledronic acid had no negative impact on the metabolic activity neither at 
IC50 nor at maximum inhibition; 6. trench-forming osteoclasts were found to be more sen-
sitive to zoledronic acid than those making pits in the same cell culture; Thus, we conclude 
that there indeed is a high degree of variation in the potency of zoledronic acid on osteoclasts 
when generated from different individuals. We propose that these findings may explain at 
least some of the variance observed in patients. These findings may therefore be of clinical 
importance, which is currently being investigated in a clinical trial combining in vitro and 
in vivo investigations.
Disclosures: Anaïs MJ Møller, None
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Galectin-8 is Involved in Osteoclastic Formation and Activity *Michèle 
ROY1, Elizabeth STEPHENS1, Sophie BOUHOUR1, Sophie ROUX1. 
1Sherbrooke University, Canada
Introduction: The best characterized functions of galectin-8, a β-galactoside-binding 
lectin encoded by LGALS8, are performed extracellularly, where it binds glycans to modu-
late cell-matrix interactions and triggers signaling cascades mediated by integrin and organi-
zation of the cytoskeleton. The functions of intracellular galectin-8 are less well known, but 
cytosolic galectin-8 is a danger recognition receptor, which has been implicated in selective 
autophagy. While an increase in osteoclastogenesis and bone resorption has been reported in 
transgenic mice overexpressing galectin-8 secondary to an increase in RANKL production 
by osteoblasts (Vinik et al, 2015), we wondered if galectin-8 could have a direct impact on 
osteoclasts, in particular by modulating the processes associated with vesicle trafficking such 
as autophagy or bone resorption. Indeed, we have previously demonstrated a differential 
expression of galectin-8 splicing variants in the osteoclasts of Paget’s disease of bone char-
acterized by overactivity of these cells.Methods: Using human osteoclasts generated in vitro 
from cord blood monocytes, this study was aimed to characterize galectin-8 involvement in 
osteoclastic formation, bone resorbing activity and basal autophagy. All experiments were 
performed after specific knock-down of LGALS8 expression using DsiRNA transfected in 
mature osteoclasts.Results: Inhibiting galectin-8 expression was associated with a signifi-
cant decrease in the bone resorption area, and in the number of multinucleated cells (MNCs) 
compared to cells transfected with a negative control (bone resorption: -58%; MNCs -45%, 
both p<0.05), or to non-transfected cells. By immunoblots, we also evaluated LC3II/LC3I 
ratio, a reliable marker of autophagic vesicles, and observed a significant increase in this 
ratio in basal conditions in LGALS8 knock-down cells compared to cells transfected with a 
negative control (+52%, p<0.05), and in non-transfected cells as well. This increased in bas-
al autophagy could be due to the inactivation of mTORC1, as a trend to decrease in 4EBP1 
phosphorylation, a well-known substrate of mTOR, was also observed in the same condi-
tions (-55%, LGALS8 DsiRNA vs negative control, ns).Conclusion:  Galectin-8 appears as a 
new player in human osteoclast biology that could be involved in the regulation of osteoclast 
formation and bone resorption. Galectin-8 might impact osteoclastic activity through mTOR 
signaling, although mechanisms remain to be elucidated.
Disclosures: Michèle ROY, None
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Senescence-dependent increase of CpG methylation at receptor activator 
NF-κB (RANK) gene promoter impairs osteoclastogenesis by decreasing 
RANK-positive osteoclast precursors *Riko Kitazawa1, Ryuma haraguchi2, 
Yukihiro Kohara2, Sohei Kitazawa2. 1Ehime University Hospital, Division of 
Diagnostic Pathology, Japan, 2Ehime University Graduate School of Medicine, 
Department of Molecular Pathology, Japan
  Receptor activator of NF-κB (RANK) is a member of the tumor necrosis factor recep-
tor (TNFR) family expressed in osteoclast precursors, and RANK-RANK ligand (RANKL) 
signaling plays a central role in differentiation, activation and survival of osteoclasts.  The 
5’-flanking region of the mouse RANK gene lacks canonical TATA-box but contains four 
continuous Sp-1 binding sites with clustered CpG-loci (CpG-island) around the transcrip-
tion and translation start sites.  In this study, the passage-dependent and age-related change 
in osteoclastogenesis and RANK expression relative to the methylation status of its gene 
promoter was investigated.  Quantitative RT-PCR disclosed that the steady-state expression 
of RANK mRNA of RAW cells was lower at passage 40 (P40) than at P18; also, RANKL-in-
duced osteoclastogenesis as well as the expression of TRACP and CTSK mRNA was sig-
nificantly lower at P40 than at P18. Mirroring the passage-dependent reduction in osteoclas-
togenesis, both methylation-specific PCR and bisulfite mapping of the CpG-island region 
(-150 /+110, adjacent to transcription and translation start sites) showed a higher frequency 
of CpG methylation at P40 than at P18.  Morphologic detection of sequence-specific meth-
ylated cytosine by the newly established ICON-probe technique revealed that the number 
of cells positive for RANK gene promoter methylation increased significantly at P40.  Con-
versely, pre-treatment with demethylating agent 5-Aza-dC restored the expression of RANK 
gene and RANKL-induced osteoclastogenesis at P40.  Reflecting the in vitro passage-depen-
dent increase of CpG methylation of the cultured RAW cells, RANK gene promoter meth-
ylation in mono-nucleated cells of mouse spleen and bone marrow tissue disclosed a higher 
rate of methylation-positive and RANK-negative populations in 12-month-old mice than in 
10.5-week-old ones.    These data suggest that DNA methylation at CpG-island in the RANK 
gene promoter occurs in an age-related manner (the so-called type-A methylation), which 
may explain, in part, the impairment of bone resorption activity by reduced osteoclastogene-
sis, namely impairment of the coupling of bone resorption and bone formation, in the elderly.
Disclosures: Riko Kitazawa, None
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An Uncommon Cause of Toothache: A New Perspective on Eagle Syndrome 
*Sanne Treurniet1, Jeroen Jansen2, Leo van Ruijven3, Ton Langeveld2, Tim 
Forouzanfar4, Nathalie Bravenboer5, Elisabeth Eekhoff1. 1Department of Internal 
Medicine, Amsterdam University Medical Center, location VUmc, Amsterdam 
Movement Sciences, Amsterdam, The Netherlands, Netherlands, 2Department 
of otolaryngology, Leiden University Medical Center, Leiden, The Netherlands, 
Netherlands, 3Department of Oral Cell Biology and Functional Anatomy, 
ACTA-University of Amsterdam and VU University, Amsterdam Movement 
Sciences, Amsterdam, The Netherlands, Netherlands, 4Department of Oral and 
Maxillofacial Surgery/Pathology, Amsterdam University Medical Centers, 
location VUmc, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, 
Netherlands, 5Department of Clinical Chemistry, Bone and Calcium Metabolism 
Lab, Amsterdam University Medical Centers, location VUmc, Amsterdam 
Movement Sciences, Amsterdam, The Netherlands, Netherlands
Introduction. A 44-year old woman presented with pain and nerve compression in the 
face due to Eagle syndrome. Eagle syndrome was diagnosed after many years of unexplained 
toothache, pain in the neck and hearing loss. The Eagle syndrome is due to elongation of the 
styloid process or calcification of the stylohyoid ligament. In this patient, Eagle syndrome 
was diagnosed on both sides of the neck, which is very rare. Previously performed surgery, 
at the age of 39, to relieve complaints was not successful. At the age of 42, a second surgery 
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took place to remove calcified tissue matching with Eagle syndrome on the right side of the 
neck. Two years later, surgical removal of the calcified tissue on the left side of the neck was 
performed successfully.Purpose. Follow-up of the clinical symptoms and analysis of the 
removed tissue from the neck.Method. A [18F]NaF PET/CT scan was conducted preopera-
tively. Histologic examination and microCT was performed on the removed tissue.Results. 
Prior to surgery an [18F]NaF PET/CT scan showed no increased uptake of [18F]NaF in the 
styloid hyoid region, indicating no active bone formation at this site. The tissue removed 
during surgery is classified as calcified tissue. Histologic examination and microCT revealed 
cortical and trabecular bone and some areas of cartilage tissue.Conclusion. The molecular 
mechanism leading to calcification in the styloid region in Eagle syndrome is still unknown. 
This case-report suggested an endochondral process of bone formation. Further examination 
of the calcified tissue will take place to investigate the properties of this material.
Disclosures: Sanne Treurniet, None
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RNA-binding protein Cpeb4 is required for osteoclastogenesis. *Masamichi 
Li1, Yasuhiro Arasaki1, Takuro Akiya1, Iori Nozawa1, Yoichi Ezura2, Tadayoshi 
Hayata1. 1Department of Molecular Pharmacology, Graduate School of 
Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Tokyo 
University of Science, Japan, 2Department of Judo Therapy, Faculty of Medical 
Technology, Teikyo University, Japan
It has been shown that useful therapeutic agents such as an anti-RANKL antibody de-
nosumab could be developed from the identification of osteoclast differentiation factors. 
As one of the possible factors regulating the osteoclast differentiation, we previously re-
ported that expression of Cytoplasmic polyadenylation element binding protein 4 (Cpeb4), 
an RNA-binding protein, is increased during osteoclast differentiation. Cpeb4 is involved 
in various biological aspects and pathogenesis including cancer, fatty liver, erythroid cell 
differentiation. Cpeb4 mis-splicing is also related to autism-like phenotype. However, the 
function of Cpeb4 in osteoclast differentiation is unknown. In this study, we aimed to eluci-
date the function of Cpeb4 in osteoclast differentiation. First, to determine which transcript 
variants are expressed in RAW264.7 cells, we performed RT-PCR experiment using primer 
set to amplify exons 2 to 5. We found that variant 2 and variant 3 were expressed out of 4 
variants and variant 2 was expressed more abundantly than variant 3. Next, we attempted 
to generate a stable cell line expressing short hairpin RNA (shRNA) against Cpeb4 using 
mouse macrophage cell line RAW264.7. We successfully generated a stable cell line ex-
pressing Cpeb4 shRNA with approximately 37% reduction of Cpeb4 expression compared 
to that expressing control shRNA. To determine the function of Cpeb4 during osteoclast 
differentiation, we treated those cells with RANKL. TRAP staining experiment revealed that 
depletion of Cpeb4 resulted in a dramatic decrease in osteoclast numbers. Gene expression 
study also demonstrated that knockdown of Cpeb4 strongly repressed the mRNA induction 
of Atp6v0d2, Cathepsin K, Dcstamp, Nfatc1, RANK and Acp5 (TRAP) by RANKL, sup-
porting a role of Cpeb4 in RANKL-induced osteoclast formation. Thus, our findings suggest 
that Cpeb4 is a novel essential regulator for osteoclastogenesis.
Disclosures: Masamichi Li, None
P-457
Role of Lrp1 in RAW264 cells on osteoclast differentiation *Yukihiro Kohara1, 
Ryuma Haraguchi1, Riko Kitazawa2, Sohei Kitazawa1. 1Department of Molecular 
Pathology, Ehime University Graduate School of Medicine, Japan, 2Department 
of Diagnostic Pathology, Ehime University Hospital, Japan
Low density lipoprotein receptor-related protein 1 (LRP1; also known as CD91), a 
member of the low-density lipoprotein receptor family, functions as a receptor for sever-
al ligands such as α-2 macroglobulin, Apolipoprotein E and tissue plasminogen activator. 
In human studies, LRP1 single nucleotide polymorphism (SNP) is associated with bone 
mineral density. While LRP1 is thought to be a suppressor of osteoclast differentiation at 
late stages, its function at early stages remains unclear. In this study, we generated Lrp1 
gene-stable knockdown macrophage cell line RAW264 cells by the lentiviral short hairpin 
RNA (shRNA) vector to gain insight into the function of Lrp1 in osteoclast precursors. Lrp1 
gene stable knockdown RAW264 cells inhibited RANKL-induced osteoclast formation and 
osteoclastic master transcription factor Nfatc1 mRNA expression as assessed by quantitative 
RT-PCR. Furthermore, to investigate osteoclast-osteoblast interactions, the conditioned-me-
dium (CM) from Lrp1 knockdown RAW264 cells was harvested during 48-96 h after 
RANKL stimulation and used in bone marrow stromal cell line ST2 cultures. Surprisingly, 
the CM of Non-Mammalian shRNA RAW264 cells inhibited alkaline phosphatase (ALP) ac-
tivity induced by ascorbic acid and β-glycerophosphate compared with the untreated control, 
whereas the CM of Lrp1 knockdown RAW264 cells nullified the inhibitory effects on ALP 
activity, suggesting that osteoclast-derived humoral factors inhibit osteoblast differentiation, 
and that the expression or secretion of these factors is mediated by LRP1. Thus, we propose 
that LRP1 in macrophages mediates both differentiation into osteoclasts and osteoclast-os-
teoblast interactions.
Disclosures: Yukihiro Kohara, None
P-458
RNA-binding protein Cpeb4 is localized in nuclei during osteoclast 
differentiation. *Yasuhiro Arasaki1, Masamichi Li1, Takuro Akiya1, Iori 
Nozawa1, Yoichi Ezura2, Tadayoshi Hayata1. 1Department of Molecular 
Pharmacology, Graduate School of Pharmaceutical Sciences and Faculty of 
Pharmaceutical Sciences, Tokyo University of Science, Japan, 2Department of 
Judo Therapy, Faculty of Medical Technology, Teikyo University, Japan
Little attention has been paid to the mechanism of osteoclast differentiation by post-tran-
scriptional regulation such as splicing, stability or translation of mRNA. Here we focused 
on RNA-binding protein Cpeb family consisting of Cpeb1, Cpeb2, Cpeb3 and Cpeb4 as 
one of the possible factors regulating the osteoclast differentiation through post-transcrip-
tional mechanisms. Quantitative RT-PCR analysis revealed that only Cpeb4 expression 
out of 4 members was upregulated two days after RANKL stimulation in RAW264.7 cells. 
Immunofluorescence analysis revealed that Cpeb4 was localized in cytoplasm in untreated 
RAW264.7 cells, whereas Cpeb4 was localized in nuclear bodies by RANKL stimulation in 
addition to the cytoplasm. Similar results were also obtained for RANKL-stimulated mouse 
bone marrow macrophages. To determine the property of the nuclear bodies where Cpeb4 
is localized, we performed immunofluorescence analysis using antibodies identifying the 
nuclear speckle and Cajal bodies. However, Cpeb4 was not colocalized in either of them. 
Time-course experiment revealed that nuclear localization of Cpeb4 was detected at least 
9 hours after RANKL stimulation. Finally, we investigated the downstream pathway of 
RANKL signaling that may contribute to nuclear localization of Cpeb4 using various inhibi-
tors. The results showed that PI3K-Akt signaling and Nfatc1 activation are important for the 
localization. Thus, these results suggest that Cpeb4 may be involved in post-transcriptional 
regulation of differentiating osteoclasts in the nuclei.
Disclosures: Yasuhiro Arasaki, None
P-459
Deletion of the Matrix-Degrading Enzymes MMP13 and Cathepsin K in 
Osteocytes Regulates Osteocytic Osteolysis and Bone Mass, Protecting the 
Skeleton in Lactating Mice *Yinbo Niu1, Jiaming Zhang1, Ai Orimoto1, Shuang 
Liang1, Dorothy Hu1, Pamela Dann2, Daniel Brooks3, Mary L. Bouxsein3, John 
Wysolmerski4, Francesca Gori5, Roland Baron6. 1Division of Bone and Mineral 
Research, Harvard School of Dental Medicine;, United States, 2Endocrine 
Section, Yale School of Medicine, United States, 3Dept of Orthopedics, Beth 
Israel Deaconess Hospital, United States, 4: Endocrine Section, Yale School 
of Medicine, United States, 5Division of Bone and Mineral Research, Harvard 
School of Dental Medicine, United States, 6Division of Bone and Mineral 
Research, Harvard School of Dental Medicine;, United States
Cathepsin K (Ctsk) and MMP13 are extra-cellular matrix-degrading enzymes  secreted 
by osteocytes (Ocy) in the peri-lacunar space. We showed that targeted deletion of Ctsk in 
Ocy (Ctskocy) prevented lacunae (Lac) enlargement and bone loss during lactation but did 
not affect the skeleton at steady state. Since MMP13 is up-regulated by Ctskocy deletion and 
by lactation, we generated: 1) MMP13ocy mice and 2) MMP13:Ctskocy mice to delete Ctsk 
from the MMP13ocy mice (Ctsk may compensate for the lack of MMP13). We explored 
Ocy osteolysis (Olysis), bone remodeling, skeletal homeostasis and Ocy gene expression at 
steady state (12 wk old females) and in response to 12 days of lactation. μCT and dynamic 
histomorphometry showed that MMP13ocy mice exhibited a pronounced increase in Tb 
BV/TV but no changes in bone formation or resorption, suggesting changes that occurred 
earlier. In contrast, the cortex showed only a marked increase in Ocy Lac area (LacA, p30μ2, 
p< 0.01) by back scattered electron microscopy, but no changes in Ocy canalicular organi-
zation by silver stain. Cortical bone qRT-PCR showed a significant decrease in OPG with 
unchanged RANKL. Bone strength was increased and, importantly, MMP13ocy mice were 
protected from bone loss during lactation. Deletion of Ctsk in the MMP13ocy mice resulted 
in a further increase in Tb BV/TV compared to MMP13ocy mice (p<0.0001). In contrast 
to MMP13ocy mice, MMP13:Ctskocy mice had larger cortical volume, thickness and to-
tal area, suggesting enhanced periosteal bone formation. Importantly, Ocy LacA and the 
number of large Lac, both increased in MMP13ocy mice, returned to normal after deletion 
of Ctsk, suggesting a role of Ctsk in the Lac enlargement observed in MMP13ocy mice. 
In contrast with the lack of changes observed in MMP13ocy mice, MMP13:Ctskocy mice 
showed a significant increase in MAR (p<0.01) and decrease in osteoclasts (p<0.05). Like 
Ctskocy and MMP13ocy, MMP13:Ctskocy mice were protected from bone loss during lac-
tation, despite a significant increase in serum PTH. MMP13ocy RNA Seq analysis of Ocy 
identified changes in several signaling pathways known to affect bone cells and remodeling.
These results suggest that in Ocy, MMP13 and Ctsk are involved in the regulation of Oly-
sis but also of bone homeostasis. Deleting these enzymes in the Ocy micro-environment 
prevents peri-lacunar matrix degradation, favors bone mass and prevents the loss of bone 
induced by lactation.
Disclosures: Yinbo Niu, None
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Kalirin regulates Osteocyte Dendrite Connectivity and Function *Jung Min 
Hong1, Kornchanuk Joy Wayakanon1, Loan Do1, Tehrune Tyler1, Sung-Kyung 
Kin2, Kawak Stephanie2, Su Huang1, Angela Bruzzaniti1. 1Indiana University 
School of Dentistry, United States, 2Indiana University, United States
Communication among bone cells, especially osteocytes, is important for the main-
tenance of bone mass.  However, the intracellular proteins that control the morphology 
and function of osteocytes, and their ability to communicate with other bone cells are still 
unknown. Kalirin is a multi-domain GDP/GTP-exchange factor protein that activates the 
Rho GTPases. A rare missense mutation in the Kalirin gene (KALRN) in female and male 
siblings was shown to cause short stature and delayed bone age, among other abnormalities. 
Previously, we found that lack of Kalirin (Kal-KO) leads to the loss of trabecular and cortical 
bone mass, consistent with the human findings. In addition to its expression in osteoblasts 
and osteoclasts, our data revealed Kalirin expression in osteocytes, where it was localized to 
the perinuclear region and to the dendritic processes. Moreover, mRNA expression of Dmp1, 
Sost, Phex and RANKL was decreased in Kal-KO long bones (marrow flushed).  Based on 
the possible role of Kalirin on the morphology and function of osteocytes, we examined the 
role of Kalirin in regulating osteocyte connectivity and the mechanism of osteocyte dendritic 
elongation.  Analysis of the lacunar-canalicular system with basic fuchsine staining revealed 
shorter canaliculi in Kal-KO mice, compared to wild-type (WT), although lacunar density 
was similar between genotypes. Ex vivo analysis of osteocytes from collagenase-digest-
ed long bones also revealed shorter and fewer dendrites in Kal-KO osteocytes, which was 
associated with a dramatic decrease in both ERK levels and RhoA activation, compared 
with WT osteocytes. We identified the GTP-exchange factor domain 1 (GEF1) of Kalirin 
as the predominate dendrite-lengthening domain. Overexpression of GEF1 caused dendrite 
elongation in MLO-Y4 cells via activation of ERK and RhoA, while chemical inhibition of 
these pathways led to dendrite shortening. Overall, these results suggest that Kalirin controls 
osteocytic connectivity and function in part by regulating cytoskeletal remodeling through 
the activity of ERK and RhoA.  Consequently, Kalirin may control the bone remodeling 
cycle by regulating osteocyte signaling to osteoclasts and osteoblasts.
Disclosures: Jung Min Hong, None
P-461
Deletion of Gata4 from cells of the osteoblast lineage increases bone mass 
in mice and blunts the stimulation of RANKL expression by pro-senescence 
signals *Ha-Neui Kim1, Aaron Warren1, Elisabeth Ferreira1, Wen Ling1, 
Srividhya Iyer2, Charles O’Brien1, Maria Almeida1. 1University of Arkansas for 
Medical Sciences, United States, 2University of Colorado School of Medicine, 
United States
As in humans, aging in mice leads to cortical thinning and increased cortical porosi-
ty associated with increased bone remodeling. Production of the osteoclastogenic cytokine 
RANKL by osteocytes increases with age in mice and is essential for the loss of cortical 
bone and increase in cortical porosity. The age-related increase in RANKL expression is as-
sociated with increased markers of cellular senescence in osteocyte-enriched cortical bone, 
including increased levels of Gata4, a transcription factor that mediates expression of the 
senescence associated secretory phenotype (SASP). However, the molecular mechanisms 
responsible for the increased RANKL expression and osteoclast number in cortical bone 
with age are unclear. To determine whether cellular senescence can stimulate RANKL pro-
duction, we examined the ability of several well-established inducers of senescence, such 
as irradiation, etoposide, and H2O2, to stimulate RANKL expression in cultured osteoblas-
tic cells and osteocyte-enriched organ cultures. Induction of cellular senescence increased 
RANKL production in each of these murine culture models as well as in human fibroblasts, 
suggesting a potential explanation for elevated RANKL levels with age. The increase in 
RANKL was associated with higher protein levels of Gata4 and elements of the SASP. 
Moreover, over-expression of Gata4 stimulated RANKL expression in primary cultures of 
murine osteoblastic cells. To determine whether Gata4 in osteocytes is required for the se-
nescence-induced expression of RANKL, we generated mice lacking Gata4 in the entire 
osteoblast lineage using Osx1-Cre (Gata4ΔOsx1). Irradiation of femoral shaft organ cultures 
from 3-month-old Osx1-Cre control littermate mice increased RANKL protein levels but 
this effect was prevented in organ cultures from Gata4ΔOsx1 mice. Three-month-old female 
Gata4ΔOsx1 mice had higher femoral and spinal BMD than Osx1-Cre littermates as deter-
mined by DXA. In contrast, Gata4ΔOsx1 male mice had no changes in BMD. Micro-CT 
analysis of L5 vertebra and femur from female mice revealed increased BV/TV associated 
with increase trabecular number and trabecular thickness. Overall, these findings support the 
working hypothesis that Gata4 in osteocytes stimulates RANKL expression to promote bone 
remodeling during growth and aging.
Disclosures: Ha-Neui Kim, None
P-462
Increased bone mass, bone formation, and bone resorption caused by adult 
onset compound deletion of Sik2 and Sik3 in mice *Marc Wein1, Christian D 
Castro Andrade1, Kathy Cheng-Chia Tang1, Daniel J Brooks1, Janaina da Silva 
Martins1, Marc Foretz2, Mary L Bouxsein1. 1Massachusetts General Hospital, 
Harvard Medical School, United States, 2Université de Paris, Institut Cochin, 
France
Background:Salt inducible kinases (SIK) control parathyroid hormone action in osteo-
cytes downstream of cAMP and protein kinase A. Previous work by our lab demonstrated 
that in vivo combined deletion of Sik2 and Sik3 in osteocytes and osteoblasts using DMP1-
Cre showed dramatic increase in bone mass, increased bone turnover, and gene expression 
changes similar to those seen with constitutive PTH signalling. These results suggest that 
SIK2/3 inhibitors may represent a new class of PTH-like small molecules. However, the 
organism-wide consequences of deleting these kinases in postnatal mice remains to be 
determined. Here, we addressed this problem by breeding Sik2/3 floxed mice to ubiqui-
tin-CreERt2 animals to achieve ubiquitous deletion of these kinases in a tamoxifen-depen-
dent manner.Methods:6 week old control (Sik2f/f ; Sik3f/f) or Sik2/3 DKO (Sik2f/f ; Sik-
3f/f ; ubiquitin-CreERt2) mice were treated with tamoxifen (1 mg, IP, Q48H, 3 doses total). 
Animals were sacrificed 21 days after the first tamoxifen injection and skeletal phenotypes 
were assessed by micro-CT, histology, histomorphometry, and serum bone turnover markers.
Results:Combined Sik2/3 deletion in adult mice led to a dramatic increase in trabecular bone 
mass and growth plate expansion by micro-CT (Figure) without causing overt health effects. 
Fasting serum turnover biomarkers showed accelerated bone turnover with elevated P1NP 
(bone formation, p<0.0001) and CTX (bone resorption, p=0.00017) levels in Sik2/3 DKO 
mice. Other skeletal parameters such as Trabecular BV/TV (p=0.0012), trabecular number 
(Tb.N) (p=0.0001), trabecular thickness (Tb.Th) (p=0.0148), trabecular spacing (Tb.Sp) 
(p=0.00089) and cortical porosity (p=0.0185) are also significantly higher in Sik2/3 mutants 
versus tamoxifen-treated control mice. Also, elevated tartrate-resistant acid phosphatase 
(TRAP) staining was observed in the mutant mice compared to tamoxifen-treated control 
animals, consistent with increased bone resorption. Furthermore, histomorphometry anal-
ysis showed significant higher numbers of osteoblasts (N.Ob/T.Ar) (p=0.0006) and osteo-
clasts (N.Oc/T.Ar) (p=0.001) per tissue area. Bone formation rate (BFR/TV) (p=0.0053) 
and fibrocyte volume (Fb.V/TV) (p=0.0012) per tissue volume are also significantly in-
creased in Sik2/3 DKO mice versus tamoxifen-treated controls. Finally, serum analysis 
of Sik2/3 DKOs showed elevated levels of alkaline phosphatase (p<0.0001) and calcium 
(p=0.0245) without affecting phosphorus levels.Conclusion:Global loss of Sik2 and Sik3 in 
vivo using the tamoxifen-induced CreERt2 under the control of ubiquitin promoter led to 
significantly increased bone mass, bone formation and bone resorption. Differences at the 
level of bone resorption exist between genetic Sik2/3 deletion and our previous results using 
pharmacologic SIK inhibitors, supporting sthe notion that Sik2/3 inhibitors may represent a 
promising new class of pharmacologic agents for osteoporosis treatment. 
Disclosures: Marc Wein, Galapagos NV, Grant/Research Support, Radius Health, Inc, 
Grant/Research Support
P-463
PTH protects osteocytes from oxidative stress-induced death and senescence 
*Yuhei Uda1, Roberto Santos1, Alejandro Kochen1, Carly Newell1, Anna Tse1, 
Paola Divieti Pajevic1. 1Henry M. Goldman School of Dental Medicine, Boston 
University, United States
Osteoporosis, one of the major skeletal disorders during aging, is characterized by un-
coupled osteoblast and osteoclast activities. Parathyroid hormone (PTH) is widely used in 
the clinic to treat osteoporosis due to its anabolic actions on bone, which require signaling 
via the PTH receptor (PPR). PPR is highly expressed in cells of the osteoblastic lineage, 
including osteocytes. Osteocytes are the most abundant cells in bone and serve as a key 
regulator of bone remodeling. Despite the significant role of PPR signaling in skeletal ho-
meostasis, its function during aging remains unclear. Preliminarily, we have demonstrated 
that mice lacking PPR in osteocytes (Dmp1-PPRKO) display marked age-related bone loss 
driven by increased bone resorption and suppressed bone formation. In these mice, with 
aging, there is a significant decrease in osteoprogenitors and an increase in bone marrow 
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adiposity, reminiscent of skeletal senescence. We hypothesized that PPR signaling protects 
osteocytes from senescence and oxidative stress. To test this hypothesis, we designed an 
in vitro approach and established an osteocytic cell line in which the PPR expression was 
ablated using CRISPR/Cas9 technique. Ocy454-PPRKO and Ocy454-PPRCtrl cells were 
used to examine whether PTH protects osteocytes from oxidative stress. Cells were treated 
with PTH prior to exposure to hydrogen peroxide (H2O2) and cell viability was measured 
by resazurin-based assays. PTH treatment significantly suppressed the increase in H2O2-in-
duced death in PPRCtrl cells. As expected, the protective effect of PTH was not observed in 
PPRKO cells. High levels of reactive oxygen species (ROS), including hydrogen peroxide, 
promote protein and DNA oxidation, resulting in cell death. We analyzed the production 
of ROS using a fluorescent probe and found that PTH treatment significantly reduced the 
increase in ROS levels induced by H2O2 treatment, suggesting an antioxidant function of 
PTH in osteocytes. Oxidative stress is one of the causes of senescence. To further investigate 
if PTH prevents osteocytes from oxidative stress-induced senescence, we examined senes-
cence-associated (SA) β-galactosidase activity in cells treated with PTH and exposed to low 
doses of H2O2. Compared to untreated and PPRKO groups, treatment with the hormone 
significantly decreased the number of SA-βgal positive cells, demonstrating that PPR sig-
naling protects osteocytes, and possibly other osteoblastic cells, from H2O2-induced cellular 
senescence.
Disclosures: Yuhei Uda, None
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PPARG in Osteocytes Regulates Sclerostin Expression, Bone Mass and 
Marrow Adiposity *Sudipta Baroi1, Piotr Czernik1, Amit Chougule1, Patrick 
Griffin2, Beata Lecka-Czernik1. 1University of Toledo, College of Medicine and 
Life Sciences, United States, 2The Scripps Research Institute, United States
Peroxisome proliferator activated receptor gamma (PPARG) is a transcription factor 
known for regulating energy metabolism and insulin sensitivity; however, its role in regula-
tion of osteocyte function is largely unknown. In this study, we report that PPARG is abun-
dantly expressed in osteocytes, as compared to endosteal osteoblasts, and is transcriptionally 
essential for sclerostin production. Mice lacking PPARG primarily in osteocytes (γOTKO) 
have increased bone mass and decreased marrow fat, and there is an excellent correlation 
of sclerostin protein level in osteocytes with the level of PPARG deletion. This is paralleled 
by increased WNT signaling and bone forming activity of endosteal osteoblasts. Moreover, 
osteocyte conditioned medium depleted of sclerostin decreases adipogenesis in recipient 
bone marrow stromal cells consistent with decreased marrow adiposity in γOTKO mice. 
Examination of 8 kb sequence upstream of Sost gene transcription start site (TSS), using po-
sition weighted matrix prediction for transcription factors binding sites (JASPAR), revealed 
multiple PPARG binding elements (PPREs). Two of them, with highest scores for consensus 
PPARG binding sequence, were chosen for further analysis. Chromatin immunoprecipita-
tion assays (ChIP) showed that PPARG binds to both PPREs. Interestingly, pharmacologic 
modulation of PPARG activity with full agonist rosiglitazone increases PPARG binding to 
both PPREs and increases sclerostin mRNA and protein expression. Consistently, γOTKO 
mice are at least partially resistant to the negative effects of rosiglitazone on bone. These 
findings indicate that transcriptional activities of PPARG are essential for sclerostin expres-
sion in osteocytes and support consideration of targeting PPARG activities with selective 
modulators to treat osteoporosis.
Disclosures: Sudipta Baroi, None
P-465
ABT263 attenuate irradiation-induced bone loss in mice through cleaning 
senescent osteocytes and inhibiting SASP production *Qinghe Geng5, Shen 
Wang2, Han Huan3, Juan Zhai1, Huabei Sun0, Yilong Guo0, Ke Heng4, Hanjun 
Guo5, Huaiyuan Zhai6, Hongwei Li0, Guangliang Su7, Qing Zhang5, Junnian 
Zheng0. 5Central Lab, Pizhou Hospital, Xuzhou Medical University, China, 
2Guangxi Medical Universtiy, China, 3Nanjing University of Chinese Medicine, 
China, 1Central Lab, Pizhou Hospital, Xuzhou Medical University, China, 
0Central Lab, Pizhou Hospital, Xuzhou Medical University, China, 4Changzhou 
Second Hospital, Nanjing Medical University, China, 5Xuzhou Medical 
University, China, 6Ruidong Hospital of Nanjing, China, 0Xuzhou Medical 
University, China, 7Yongcheng City Hospital, Henan, China
Radiotherapy widely treats life-threatening cancers effectively in clinic, but also in-
juries neighboring healthy tissues, in which skeletal system is usually involved. Cellular 
senescence of osteocytes and senescence-associated secretory phenotype (SASP) plays a 
causative role in pathogenesis of radiation-induced osteoporosis, suggesting great benefits 
of senolytic drugs in preventing radiation-induced bone loss through clearance of senescent 
cells. To determine the effects of ABT263, a specific inhibitor of anti-apoptotic protein BCL-
2 and BCL-xL, on senescent osteocyte clearance and radiation-induced bone loss, 2-m-old 
C57 mice were irradiated focusing on femoral metaphyseal region with a single dose of 
24 Gy and treated with vehicle or ABT263, and followed by molecular, histomorphomet-
ric and biomechanical tests 8 weeks after focal radiation treatment (FRT). We found that 
senescence-associated beta-galactosidase (SA-β-gal) activity, cellular senescence markers, 
including p16Ink4a, p21, and p53, and SASP factors were significantly higher in irradiated 
femoral bone tissue of irradiated mice than non-irradiated control mice, while bone miner-
al density (BMD) and trabecular bone mass were lower than non-irradiated control mice, 
suggesting success establishment of FRT mouse model. Notably, the irradiated mice treated 
with ABT263 had reduced senescent-cell burden, including fewer SA-β-gal+ osteocytes and 
lower expression of senescence markers (p16Ink4a, p21 and p53) and SASP factors, and 
higher BMD than that of vehicle-treated irradiated mice. Consist with this, biomechanical 
tests of irradiated femora revealed that maximum load, yield load, ultimate displacement, 
yield displacement, stiffness, and energy absorption of femora were lower in irradiated mice 
than non-irradiated mice. While this decrease was significantly reversed in ABT263-treated 
irradiated mice than vehicle-treated mice. Therefore, our data indicate a radioprotective role 
of ABT263 in radiation-induced osteoporosis through clearing senescent osteocytes and in-
hibiting SASP production.
Disclosures: Qinghe Geng, None
P-466
Late Osteoblast- and Osteocyte-Derived NOTUM Regulates Cortical 
Bone Mass in Mice *Karin H. Nilsson1, Petra Henning1, Maha Abdelghaffar1, 
Jianyao Wu1, Ulf H. Lerner1, Claes Ohlsson1, Sofia Movérare-Skrtic1. 1Centre 
for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy at 
University of Gothenburg, Gothenburg, Sweden, Sweden
Osteoporosis is a common skeletal disease, leading to increased risk of fractures. Cur-
rent osteoporosis treatments primarily reduce risk of fracture in the vertebrae, mainly de-
pendent on trabecular bone, while most fractures occur at non-vertebral bone sites, mainly 
dependent on cortical bone. WNT signaling is a crucial regulator of bone homeostasis. The 
activity of WNTs is inhibited by NOTUM, which is a secreted WNT lipase highly expressed 
by osteoblast lineage cells in the cortical bone. We previously demonstrated that conditional 
inactivation of NOTUM in all osteoblast lineage cells using the Runx2-Cre mouse model 
specifically increased the cortical bone thickness, with an unchanged trabecular bone phe-
notype(1). To determine if NOTUM with an impact on cortical bone is mainly derived from 
osteoblast precursors/early osteoblasts or from late osteoblasts/osteocytes, we developed a 
mouse model where NOTUM is inactivated only in late osteoblasts/osteocytes expressing 
the dentin matrix protein 1 (Dmp1) promoter. We observed a specific increase in cortical 
bone area and thickness in both femur and tibia, but no change in trabecular bone volume 
fraction (BV/TV) in adult female Dmp1-creNotumflox/flox mice as compared to control 
mice. In conclusion, NOTUM expressed by late osteoblasts and osteocytes regulates the cor-
tical bone mass, and we suggest that NOTUM inhibition might be an interesting pharmaco-
logical target for increasing cortical bone mass.1. Moverare-Skrtic S, Nilsson KH, Henning 
P, et al. Osteoblast-derived NOTUM reduces cortical bone mass in mice and the NOTUM 
locus is associated with bone mineral density in humans. FASEB J: 2019;33(10):11163-79.
Disclosures: Karin H. Nilsson, None
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Piezo1 expression in both osteoblasts and osteocytes contributes to bone 
homeostasis *Xuehua Li1, Jacob Kordsmeier1, Jinhu Xiong1. 1University of 
Arkansas for Medical Sciences, United States
Mechanical loading plays an essential role in bone growth and homeostasis. The identi-
ty of the cells responsible for directly sensing changes in mechanical loading of the skeleton 
is unclear. Although osteocytes are commonly thought to perform this function, in vitro 
evidence suggested that osteoblasts are also sensitive to mechanical stimulation and pro-
duce the same molecules in response as osteocytes, such as prostaglandins. Therefore, both 
osteoblasts and osteocytes are potential mechanosensors in bone. In recent studies, deletion 
of Piezo1, a mechanosensitive ion channel, from Dmp1-Cre-targeted cells decreased cancel-
lous and cortical bone mass and blunted the response of the skeleton to mechanical stimulus, 
demonstrating the important role of Piezo1 in skeletal mechanotransduction.  However, in 
addition to osteocytes, the Dmp1-Cre transgene used in our work also causes recombination 
in mature osteoblasts. To determine whether Piezo1 promotes bone formation via its expres-
sion in osteoblasts, osteocytes, or both, we deleted the Piezo1 gene using Sost-Cre transgenic 
mice, which express the Cre recombinase in osteocytes but not in osteoblasts. Mice lacking 
the Piezo1 gene in SOST-Cre expressing cells, hereafter referred to as SOST-Cre;Piezo1f/f 
mice, exhibited normal body weight but low bone mineral density at 12 weeks of age com-
pared to littermate controls. Micro-CT analysis revealed decreased cancellous bone mass 
in the femur and vertebra of 12-week-old male and female SOST-Cre;Piezo1f/f mice. Cor-
tical thickness in the femur was also significantly decreased in SOST-Cre;Piezo1f/f mice 
at 12 weeks of age. Longitudinal femoral length was not affected by the Piezo1 deletion. 
In contrast to Dmp1-Cre;Piezo1f/f mice, periosteal and endocortical circumferences in the 
midshaft of femur were unaltered in SOST-Cre;Piezo1f/f mice.  In addition, the decreases in 
cancellous bone mass and cortical thickness in SOST-Cre;Piezo1f/f mice were not as large 
as those observed in Dmp1-Cre;Piezo1f/f mice. These results suggest that Piezo1 expression 
in both osteoblasts and osteocytes contributes to the maintenance of bone mass, and that 
osteoblasts, in addition to osteocytes, sense changes in mechanical loading in vivo.  
Disclosures: Xuehua Li, None
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Osteocytic Wnt protects unloading-induced bone loss via increased 
endochondral ossification *Xiaolin Tu1, Saima Khan1, Syed Zain Azher1, 
Teresita Bellido2, Wei Huang3. 1Chongqing Medical University, China, 2Indiana 
University, United States, 3The First Affiliated Hospital of Chongqing Medical 
University, China
Osteocytes, the terminal stage cells of osteoblast differentiation orchestrates Wnt ana-
bolic action even with upregulated expression of Sost/sclerostin (PNAS 2015, 112:E478). 
We hypothesized that osteocytic Wnt protects bone loss induced by unloading (unL), in-
dependent of Sost/sclerostin. This study aims to examine the consequence of unL in mice 
with dominant activation of Wnt/β-catenin signaling in osteocytes (daβcatOt). Mice were 
generated by a cross of DMP1-Cre mice with Catnb lox (ex3) mice. UnL was performed by 
tail suspension in 12-wk-old mice with 30 degree of head-down tilted body and cage surface 
for 2 wks. Bone mass was gained in daβcatOt mice with more lumbar vertebral BMD by 
unL than normal loading (NL, 13.7% versus 4.2%), not like control mice (-15.1% versus 
8.6%). daβcatOt mice robust raised femoral BMD by 10.3% via unL, equivalent to that done 
by NL in either daβcatOt (11.1%, n.s.) or control (9.8%, n.s.) mice. As expected, control 
mice dramatically lost femoral BMD by unL (-8.3%). Both X-ray radiography and μCT 
imaging displayed significant loss of cancellous bone by unL under primary spongiosa only 
in controls; however, this did not happen in daβcatOt mice. In control mice, unL decreased 
BV/TV about 7-fold, lowered Tb.N but increased Tb.Sp about 2-fold each without changes 
in Tb.Th as compared to NL counterparts; however, in daβcatOt mice, unL didn’t change 
any of these parameters. Neither NL nor unL changed cortical bone area in any mice. Bone 
histomorphometry further confirmed such changes in cancellous bone microarchitecture. 
UnL lowered osteoblasts lining on the trabeculae of control mice, but not in daβcatOt mice 
with even higher N.Ob/Tr. Serum bone formation marker, osteocalcin level was maintained 
in daβcatOt mice, which was lower in controls of unL compared to NL. The expression of 
osteoblast genes Alp, Ocn, Col1, Runx2, and Osx behaved as the changes of bone mass. 
TRAPase-staining revealed increase in N.Oc/BS and Oc.S/BS only in control unL  mice as 
compared to NL; whereas such alternations were shown between daβcatOt groups. Serum 
CTX-level was robust increased by 46.1% in the controls before and after unL, much higher 
than that in NL control (2.5%). However, there is no significant difference in serum CTX 
levels between daβcatOt groups, unL versus NL. Conclusion: osteocytic Wnt 100% protects 
unL-induced bone loss possibly by the enhancement of endochondral ossification.
Disclosures: Xiaolin Tu, None
P-469
Naproxen affects the osteocyte dendritic network and perilacunar 
remodeling in mouse bone *Alexandra Ciuciu1, Ryan Tomlinson2. 1Thomas 
Jefferson University, United States, 2Thomas Jefferson University, United States
Osteocytes orchestrate mechanosensation, bone remodeling, and mineral homeostasis 
by acting through a complex network of dendritic projections that connect them to each 
and other bone cells, known as the lacunocanalicular system. Our lab recently reported that 
regular administration of the non-steroidal anti-inflammatory drug (NSAID) naproxen to 
mice for two weeks significantly decreased femoral bone toughness, consistent with clinical 
reports of increased fatigue injuries in patients taking NSAIDs. However, our understanding 
of the mechanisms by which NSAIDs, such as naproxen, may reduce bone toughness is lim-
ited. Since previous mouse models of diminished bone toughness have illustrated alterations 
in the osteocyte dendritic network, we hypothesized that NSAIDs diminish bone toughness 
by actions on the lacunocanalicular system. Here, naproxen sodium (10.9 mg/kg) or vehicle 
control (DI water) was administered through drinking water for 15 days to adult mice. Two 
days before the last day of treatment, mice were injected with calcein (10 mg/kg). Both 
femurs, tibias, and forelimbs, were harvested and fixed with 10% NBF overnight. One group 
was decalcified in 14% EDTA at 4ºC, sunk in 30% sucrose, and embedded in OCT before 
sectioning. Osteocyte dendrites were visualized using phalloidin-stained 20 µm thick sec-
tions imaged by confocal microscopy (Zeiss LSM800) at 40x magnification. Quantification 
of dendrite number and length using FIJI revealed that naproxen-treated osteocytes had a 
lower average number of dendrites and a greater variance in dendrite length, as compared to 
control osteocytes (Figure 1). Immunohistochemistry against MMP13 on 10 µm thick sec-
tions showed significantly fewer MMP13-positive osteocytes in naproxen-treated osteocytes 
as compared to control (p=0.0004). Separately, a group of undecalcified bones was dehydrat-
ed in graded ethanol, embedded in MMA, and sectioned at 100 µm using a low speed saw. 
Each section was imaged using confocal microscopy (Zeiss LSM800) at 20x. These images 
revealed significantly fewer calcein labeled osteocytes in bones harvested from mice treated 
with naproxen as compared to vehicle control (p=0.042). In summary, our results reveal that 
naproxen significantly alters the osteocyte dendritic network and diminishes perilacunar re-
modeling. These observations provide new insight into the mechanisms by which naproxen 
affects bone toughness and increases stress fracture risk. 
Disclosures: Alexandra Ciuciu, None
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TGFβ activates canonical Wnt signaling in osteocytes: Regulation via miR-
100 *Neha Dole1, Jihee Yoon1, David Monteiro1, Courtney Mazur2, Jason Yang3, 
Cassandra Belair1, Tamara Alliston1. 1UCSF, United States, 2Massachusetts 
General Hospital, Harvard, United States, 3UC Berkley, United States
Skeletal responses to loading and unloading are tightly calibrated by the mechanosen-
sory function of osteocytes. We and others have shown TGFβ and Wnt signaling to be key in 
mediating mechanotransduction; however, how these distinct molecular networks converge 
to fine-tune osteocyte responses remains elusive. Our previous studies implicated post-tran-
scriptional mechanisms in coupling TGFβ and Wnt pathways to mechanical load. Since, mi-
croRNAs (miRs), are known to post-transcriptionally regulate multiple signaling cascades 
simultaneously, we aimed to identify mechanosensitive miRs that integrate TGFβ and Wnt 
signaling in osteocytes.Using an unbiased small RNA-seq detecting miR transcriptomal 
changes in OCY454 osteocytic cells with fluid shear stress (FSS, 10 dynes/cm2, 2-hours), 
we revealed 60 differentially expressed mechanosensitive miRs. Of these, miR-100 was 
shown to mediate crosstalk between TGFβ and Wnt pathways in hematopoietic cells. This 
led us to focus on candidate miR-100 and unravel its function in integrating TGFβ and 
Wnt signaling during osteocyte mechanotransduction.Using primary BMSCs and MC3T3E1 
cells, we showed that miR-100 is suppressed during osteogenic differentiation due to its 
inhibitory activity on the expression of osteogenic markers Runx2, osteocalcin, and bone 
sialoprotein. In osteocytes, FSS caused a 40% reduction in miR-100 expression, while in-
ducing TGFβ, Wnt, and load responsive genes (i.e. Serpine1, Tcf4, Ptgs2). This load-induced 
repression of miR-100 in osteocytes was also confirmed in vivo in C57BL/6 mouse bones 
subjected to hindlimb loading (3.5N, 600 cycles, 1Hz, one load session).We then studied 
the cooperation between TGFβ, miR-100, and Wnt pathways in OCY454 osteocytes. We 
found that TGFβ signaling repressed miR-100 expression while augmenting Wnt signaling. 
Inhibition of miR-100 increased expression of Wnt-responsive genes Ctnnb1 and Tcf4 and 
enhanced active β-catenin protein levels. Using a Wnt-luciferase reporter (TOPFlash) we 
found that inhibiting miR-100 activity amplifies Wnt signaling by 5-fold. Inhibition of Wnt 
signaling by miR-100 was attributed to its direct binding and repression of Wnt receptors, 
frizzled (FZD)-4, -5, and -8 in osteocytes, shown by luciferase- 3’UTR constructs, gene 
expression, and protein analyses. Overall, our study identifies a novel mechanism by which 
TGFβ activates canonical Wnt signaling by suppressing miR-100, a negative regulator of the 
Wnt pathway, during mechanotransduction.
Disclosures: Neha Dole, None
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Osteocytes as main responders to Low Intensity Pulsed Ultrasound for the 
treatment of fracture healing *Tatsuya Shimizu1, Fujita Naomasa2, Sato Mari3, 
Tsuji-Tamura Kiyomi3, Kitagawa Yoshimasa1, Fujisawa Toshiaki2, Tamura 
Masato3. 1Oral Diagnosis and Medicine, Department of Oral Pathobiological 
Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, 
Hokkaido University, Japan, 2 Dental Anesthesiology, Department of Oral 
Pathobiological Science, Faculty of Dental Medicine and Graduate School of 
Dental Medicine, Hokkaido University, Japan, 3Oral Biochemistry and Molecular 
Biology, Department of Oral Health Science, Faculty of Dental Medicine and 
Graduate School of Dental Medicine, Hokkaido University, Japan
Skeletal tissue is known to respond to mechanical stress. Ultrasound stimulation is one 
of mechanical stress and low intensity pulsed ultrasound (LIPUS) devices have been clin-
ically utilized to promote the fracture healing. However, it is still not clear which skeletal 
cells mainly respond to LIPUS and how they contribute to fracture healing. To examine 
that, we utilized medaka and zebrafish as an in vivo model for fracture healing. Medaka 
are known to have bones without embedded osteocytes, while zebrafish are known to have 
bones with embedded osteocytes. To investigate whether osteocytes are necessary for frac-
ture healing in response to LIPUS, the tail bones of medaka and zebrafish were fractured and 
given LIPUS until fracture have been completely recovered. Interestingly, fracture healing 
was accelerated by ultrasound stimulation in zebrafish but not in medaka. Thus, osteocytes 
are important to receive the ultrasound stimulation and modulate fracture healing. Next, 
to examine the molecular events induced by LIPUS in osteocyte, we performed RNA-se-
quencing analysis in the murine MLO-Y4 cells exposed to LIPUS. Among 16,476 genes, 
179 genes were significantly changed by LIPUS. Since most of bone-related genes were not 
changed, LIPUS may contribute to fracture healing through not direct effect on osteogenic 
genes. As a result of functional annotation analysis, annotation such as “Immunity”, “An-
tiviral defense”, “Cytoplasm”, “Secreted”, “Extracellular matrix”, “Transcription” were in-
cluded in top ranks. Furthermore, the same tendency was observed in the clustering analysis. 
These results suggest that osteocytes respond to LIPUS with these 179 genes and may affect 
fracture healing via regulation of neighbor tissues/cells with secreted factors and/or control 
inflammatory immune response partially regulated by transcriptional factors. To examine 
whether genes contained in above three clusters are also modulated by LIPUS in vivo, we 
isolated RNA from zebrafish tail given bone fracture and measured the gene expression.” Al-
though Secreted factors were not altered, inflammatory genes Ptgs2 and four transcriptional 
genes such as Egr1, Egr2, Nr4a1 and Fosb were significantly changed by LIPUS in zebrafish 
tail. Taken together, bone-embedded osteocytes[KT1]  are necessary to respond to LIPUS 
and give effects on fracture healing probably through osteocyte-derived factors induced by 
Egrs, Nr4a1 and Fosb and control of inflammation.
Disclosures: Tatsuya Shimizu, None
P-472
Increased Glycolytic Flux is Associated With Extracellular Matrix 
Mineralization and Acquisition of a Mature Osteocyte-Like Phenotype 
*Matthew Prideaux1, Yukiko Kitase1, Lynda Bonewald1, Tom O’Connell1. 
1Indiana University, United States
The differentiation of osteoblasts into osteocytes is accompanied by dramatic chang-
es in cell morphology, extracellular matrix mineralization and the expression of osteocyte 
marker genes. However, whether changes in energy metabolism regulate osteocyte differen-
tiation remains unexplored. To investigate this, we used the IDG-SW3 cell line, which differ-
entiate from osteoblasts into mature osteocyte-like cells in long term culture. An untargeted 
NMR-based metabolomics approach was applied on cell extract and culture media taken at 
days representing the early osteoblast (d4), osteoid osteocyte (d9), mineralizing osteocyte 
(d18) and mature osteocyte (d28). Changes in metabolites were correlated with gene expres-
sion profiles by RNA Seq.Glycolysis was the most strongly upregulated metabolic pathway 
during differentiation, with a 3-fold increase in glucose consumption and 2-fold increase in 
lactate secretion between day 9 and 18 (P<0.001). This glycolytic flux was accompanied by 
increased mRNA expression of key enzymes for glycolysis (Hk2, Pfkfb3, Pgam1/2, Pkm) 
(2-22 fold increase), lactate production and transport (Ldha, Pdk1, Slc16a3) (2.5-110 fold) 
and osteocyte markers (Dmp1, Sost, Mepe) (120-500 fold) (P<0.001). Quantitative PCR 
analysis on cells harvested every 3 days of differentiation identified a key time period be-
tween day 12 and 18 where the onset of mineralization correlated with increased glucose 
utilization, lactate secretion, and elevated expression of glycolytic enzymes and osteocyte 
markers.To confirm the role of this glycolytic flux, 50-500 µM 2-Deoxy-D-Glucose (2DG) 
or 1-20 µM of the Pfkfb3 inhibitor PFK158 was used to inhibit glycolysis in IDG-SW3 cells 
between day 9 and 21 of differentiation. Both inhibitors significantly decreased mineraliza-
tion (P<0.001), as well as Alpl mRNA expression by 3-4 fold (P<0.001). Both inhibitors 
dose dependently inhibited the mRNA expression of glycolytic/lactate enzymes Hk2 (2-3 
fold), Pkm (2-fold), Ldha (2-3 fold), Pdk1 (2.5-fold) and Slc16a3 (50-fold) (P<0.001). Fur-
thermore, 500 µM 2DG strongly inhibited the late osteocyte markers Sost (6-fold) and Mepe 
(14-fold) (P<0.001). Therefore, our data suggests that osteocytes, unlike most other cell 
types, use glycolysis rather than the more efficient oxidative phosphorylation as the predom-
inant energy source during differentiation. Current therapeutic strategies to inhibit glycolysis 
in diseases such as cancer may thus have detrimental effects on bone health. 
Disclosures: Matthew Prideaux, None
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Bone Loss is Associated with Direct Effects of Progranulin on Osteoblast 
Lineage Cells *Liping Wang1, Robert Nissenson1. 1San Francisco VA Health 
Care System, United States
Progranulin (PGRN) is a cytokine that can display either pro- or anti-inflammatory 
properties depending on the tissue context. We recently reported that macrophage-derived 
PGRN uncouples bone turnover in aging female mice by promoting bone resorption and 
suppressing bone formation. Treatment of primary cultures of osteoblasts or macrophages 
with PGRN (500 ng/ml) significantly increased the expression of proinflammatory genes 
including Nlrp3, Il-1, and TNF-α. Since osteocytes serve as master regulators of bone re-
sorption and bone formation, we tested whether PGRN might have direct effects on gene 
expression in Ocy454 cells (Ocys). We compared these effects with those of PTH which 
(like PGRN) is pro-osteoclastogenic but (unlike PGRN) is anti-anabolic. KEGG analysis 
demonstrated that PGRN treatment for 4 hrs was associated with altered expression of genes 
associated with osteoclast differentiation (p=1.7x10-4). PGRN increased Rankl (3.1-fold), 
Ccl2 (10.3-fold), and Csf1 (2.2-fold).  By comparison, treatment with 100 nM PTH(1-34) 
for 4 hrs increased the expression of Rankl (16.4-fold), Ccl2 (1.9-fold), and Csf1 (1.8-fold). 
The most significant pathway association identified by KEGG analysis of PGRN-treated 
Ocys was the TNF signaling pathway (p=8.1x10-12). Of the 23 genes in this pathway that 
were affected by PGRN, 22 were up-regulated. Among the noteworthy proinflammatory 
genes induced by PGRN were serum amyloid A3 (Saa3, 26-fold), lipocalin2 (Lcn2, 11-fold), 
proteoglycan4 (Prg4, 17-fold), Cxcr6 (13-fold), and Steap4 (20-fold). These results suggest 
that PGRN may inhibit bone formation through a direct TNF-α-like effect on osteoblast 
lineage cells (OBLs). Treatment of Ocys with PGRN for 24 hrs altered the expression of 
genes associated with Wnt signaling (KEGG analysis, p=8.5x10-4). PGRN down-regulated 
the expression of Wnt4 (-2.3-fold), Wnt7b (-2.9-fold), Tcf7 (-1.9-fold), and Axin2 (-1.6-
fold). Furthermore, comparison of WT to PGRN KO mice indicated that the loss of PGRN 
increased the exprssion of Wnt4 (1.3-fold, p<0.05) and decreased the expression of Saa3 
(8-fold, p<0.05), Prg4 (63-fold, p<0.05), Cxcr6 (2.2-fold, p<0.05), Lcn2 (2.6-fold, p=0.09), 
and Steap4 (4.6-fold, p<0.01) in 6 month old female mouse bone. These results suggest that 
direct effects of PGRN on OBLs may contribute to its bone resorption action and that PGRN 
may inhibit bone formation by producing proinflammatory TNF-α-like effects on OBLs re-
sulting in the suppression of Wnt signaling.
Disclosures: Liping Wang, None
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Conditional Deletion of CaMKK2 Alters the Osteocyte Secretome to 
Promote Bone Accrual in a Sex-Dependent Manner *Uma Sankar1, Justin 
Williams 1. 1Indiana University School of Medicine, United States
One in two women and one in four men will experience osteoporotic fractures. Anabol-
ic therapies that stimulate bone accrual are in high clinical demand. Ca2+/CaM-dependent 
protein kinase kinase 2 (CaMKK2) is a potent regulator of bone remodeling and fracture 
healing. Genetic ablation or pharmacological inhibition of CaMKK2 elicits a profound bone 
anabolic response by stimulating osteoblast-mediated bone formation and inhibiting osteo-
clast-mediated bone resorption. CaMKK2 inhibition protects female mice from ovariecto-
my-induced osteoporosis, and reverses age-associated bone loss and accelerates bone heal-
ing in male mice. The aim of our current work is to determine the cell-intrinsic role of CaM-
KK2 in osteocytes (OCY), the most abundant cell type in bone. Our recent studies indicate 
that deletion of CaMKK2 from osteocytes results in enhanced bone microarchitecture only 
in female mice by modulating osteoblasts and osteoclasts. Moreover, female CaMKK2-de-
ficient osteocytes expressed significantly reduced Sost and enhanced Opg mRNA, and their 
conditioned media reduced WT OC function in vitro.  Based on these findings we hypoth-
esized that deletion of CaMKK2 from osteocytes alters their secretory profile to promote 
bone accrual in a sex dependent-manner. Conditional deletion of CaMKK2 from OCYs was 
accomplished by generating dentin matrix protein1 (Dmp1-8kb)-Cre+::Camkk2fl/fl (Cam-
kk2OCY) mice and Dmp1-8kb-Cre+::Camkk2+/+ (CtlOCY) littermates were used as con-
trols. We performed label-free quantitative proteomics on serum-free osteocyte CM from 12 
w/o Camkk2OCY and CtlOCY mice (n=3/group/sex) using liquid chromatography coupled 
with tandem mass spectrometry (LC-MS/MS). Approximately 1140 extracellular proteins 
were identified using SEQUEST HT, with a false discovery rate of <1%. LC-MS/MS data 
was cross-referenced with the Uniprot mouse proteome using the FASTA database and all 
samples were normalized to total peptide amount to account for random errors. Functional 
annotation analysis was performed using DAVID. Proteins of interest were selected based 
on the relative abundance ratio of Camkk2OCY and CtlOCY osteocyte CM collected from 
either sex. Our top candidates were selected based on at least a 10-fold (maximum of 100-
fold) increase or decrease in CaMKK2-deficient female osteocyte CM relative to control 
CM, while observing no change in abundance among CM from male osteocytes. Currently 
we are validating the top 10 factors using ELISA-based approaches.
Disclosures: Uma Sankar, None
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Role of primary cilia and parathyroid hormone (PTH) receptor type 1 
(PTH1R)  in osteocyte- osteoclast communication. *Irene Tirado-Cabrera1, 
Eduardo Martín-Guerrero1, Sara Heredero-Jiménez1, Irene Buendia1, Juan A. 
Ardura1, Arancha R Gortazar1. 1Bone Physiopathology laboratory, Applied 
Molecular Medicine Institute (IMMA), Universidad San Pablo-CEU, CEU 
Universities, Campus Monteprincipe, Spain
Primary cilia have been described as potential mechanosensors in bone cells, such as 
osteocytes and mesenchymal osteoprogenitors. Certain osteogenic responses induced by flu-
id flow in vitro are decreased by primary cilia inhibition in MC3T3 osteoblastic cells and 
MLO-Y4 osteocytes. The parathyroid hormone receptor type 1 (PTH1R) is expressed along 
the osteoblast lineage and controls several bone cell functions during the process of bone 
remodeling and homeostasis. PTH1R modulates osteoblast, osteoclast and osteocyte effects 
during bone remodeling upon activation by PTH or PTH-related protein (PTHrP). We and 
others have described that some actions of PTH1R can be triggered directly by mechanical 
stimulation in a ligand independent manner. We hypothesize that PTH1R forms a signaling 
complex in the primary cilium that is essential for mechanotransduction in osteocytes and 
affects osteocyte-osteoclast communication. We aim to describe the role of primary cilia and 
PTH1R on the secretion of osteoclastic precursor recruiting signals by mechanically-stim-
ulated osteocytes.MLO-Y4 osteocytes were mechanically stimulated with fluid flow (FF) 
or with PTHrP(1-37). PTH1R and primary cilia signaling were inhibited using PTH1R or 
primary cilia specific siRNAs, respectively. Conditioned media (CM) and total protein ex-
tracts were collected. CM-induced migration of the murine monocyte/macrophage cell line 
RAW 264.7 was analyzed. The expression of monocyte pro-migratory MCP-1 and RANTES 
chemokines was studied by western blot. Proteomic analysis of CM obtained from MLO-Y4 
cells in static conditions (SC) or stimulated with FF with or without PTH1R silencing was 
performed.CM obtained from mechanically- or PTHrP-stimulated MLO-Y4 cells decreased 
RAW 264.7 cell migration compared to CM from MLO-Y4 kept under SC. However, these 
effects were inhibited in primary cilia- and PTH1R-silenced conditions. Furthermore, both 
mechanical stimulation and PTHrP(1-37) inhibited MCP-1 and RANTES protein expression 
and secretion in MLO-Y4 cells. Proteomic analysis of the secretomes revea1ed secretion of 
1.323 proteins. Comparing SC and FF secretomes 27 proteins increased while a total of 37 
proteins decreased. If we compare SC with SC and PTH1R-silenced secretomes, 28 pro-
teins increased, and 15 proteins decreased. Comparing secretomes of mechanical stimulus 
with PTH1R-silenced and FF conditions, 10 proteins increased and 5 decreased. Regarding, 
PTH1R-silenced and SC with mechanical stimulus conditions, 40 proteins showed a signif-
icant increase and 1 protein a decrease. Twenty-two proteins were related to inflammatory 
processes or to recruitment of osteoclast precursors, such as Serum amyloid A-3 protein, 
Complement C3, and Dickkopf-related protein 3. Our results indicate that mechanisms de-
pendent of PTH1R and primary cilia in osteocytes are involved in the recruitment of osteo-
clast precursors.
Disclosures: Irene Tirado-Cabrera, None
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Connexin 43 Deficiency Inhibits Osteocyte Differentiation and Sclerostin 
Secretion *Evan Buettmann1, Gabriel Hoppock2, Aaron Vincent1, Michael 
Friedman2, Yue Zhang1, Henry Donahue2. 1Virginia Commonwealth University, 
United States, 2Virginia Commonwealth University, United States
Mutations in Connexin 43 (Cx43) result in various clinical skeletal abnormalities. Pre-
clinical studies have shown that loss of osteocytic Cx43 in vivo leads to increased peri-
osteal bone apposition and decreased SOST expression. Although these effects are largely 
attributed to the significant osteocyte apoptosis occurring, few studies have directly inves-
tigated the role of Cx43 in osteocyte differentiation and sclerostin secretion in vitro. We 
hypothesized that Cx43 deficiency directly inhibits osteocytic differentiation and soluble 
sclerostin production.Wildtype (WT) Ocy454 cells (from Boston University, Pajevic Lab)
and Cx43 knockout (Cx43 KO) cells generated by CRISPR were seeded into collagen coated 
3D Alvetex inserts (500,000 cells/insert; Reprocell). The osteocytes were cultured at 37°C in 
αMEM (10% FBS) to induce differentiation and harvested at 3, 6, 10 and 14 days. Osteocyte 
apoptosis (Ddit3 expression) and differentiation (Dmp1 expression) were assessed by qPCR. 
Proliferation was quantified by PicoGreen DNA Assay (Invitrogen). Soluble sclerostin was 
assayed from conditioned media by ELISA (R&D Systems). Data were analyzed by 2-way 
ANOVA with Tukey’s post-hoc test (p<0.05).WT osteocytes demonstrated no significant 
increases in Ddit3 expression or proliferation throughout differentiation (Figure 1A-C). In 
contrast, Cx43 KO osteocytes showed significantly higher Ddit3 expression, relative to WT 
osteocytes, at days 10 and 14. Concurrent with this increased Ddit3 expression, Cx43 KO 
osteocytes showed significantly increased cell proliferation compared to WT osteocytes. 
Dmp1 expression significantly increased in WT and Cx43 KO osteocytes until day 6 but 
expression was significantly lower in Cx43 KO osteocytes at all timepoints (Figure 1B). 
Soluble sclerostin levels were significantly elevated from baseline at day 14 in WT osteo-
cytes and 4-fold greater than levels in Cx43 KO osteocytes (Figure 1D).Our results support 
our hypothesis and demonstrate that osteocyte differentiation and soluble sclerostin produc-
tion are significantly inhibited with Cx43 deficiency. Furthermore, these changes occurred 
despite no significant decreases in cell number in Cx43 KO osteocytes. These novel in vitro 
results indicate that the enhanced periosteal bone formation in Cx43 deficient mice may not 
simply be simply due to a loss of osteocytes, but also due to a potent inhibition of osteocytic 
differentiation, thereby causing a decrease in sclerostin secretion.
Disclosures: Evan Buettmann, None
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Serum Vitamin-D Levels and Osteocyte Lacunar Properties in 
Postmenopausal Women *Mohammed Akhter1, Sue Bare1, Joan Lappe1, Robert 
Recker1. 1Creighton University, United States
The serum vitamin-D (25OHD(2) and 25OHD(3)) levels have been shown to be a factor 
in skeletal health. The project presents data with regards to osteocyte lacunar properties as 
a function of low and high levels of serum vitamin-D in healthy postmenopausal women. 
Our work continues to understand the bone tissue’s intrinsic properties that may also be 
affected by other factors that include serum level vitamin-D status. The overall objective 
is to examine features/causes of osteoporosis-related skeletal fragility in humans by ob-
taining additional information concerning the intrinsic properties of bone tissue (including 
osteocyte lacunar properties) to develop better treatments for osteoporosis. This preliminary 
project used the MicroXCT-200 (Carl Zeiss) system to quantify osteocyte lacunar properties 
in transilial bone biopsy specimens from healthy post-menopausal women representing Low 
level (n=3, Low 53.9+/-5.7 ng/mL) and high serum vitamin-D (n=3, High 148.1+/-11.5 ng/
mL). Each biopsy specimen was prepared with a maximum thickness of 0.4mm for opti-
mal image quality. Two cortical [Cort] and trabecular [Trab] sites (2 nodal regions) were 
selected for 0.6µm pixel resolution (PR) scanning (Figure-1). The field of view (FOV) was 
0.6mmx0.6mm (1000x1000 pixels). Avizo (9.1 FEI, MA) software was used to segment the 
lacunar voids. Using the one-way ANOVA, (SPSS), the serum vitamin D status (Low vs 
High) related differences were analyzed. An average of 3000 segmented lacunae/specimen 
in the cortical region and 1500 lacunae/specimen in the trabecular region were analyzed 
(Figure-2). While osteocyte lacunar volume (LcV) and surface area (LcSA) for cortical bone 
were significantly smaller, and for trabecular bone, they tended to be smaller in Low than 
High vitamin-D group (Table-1). The lacunar density (LcD) was not different between the 
two groups both in cortical and trabecular bone tissue. These preliminary data (Table-1) 
suggest that osteocyte lacunae are smaller in women with low serum vitamin-D (Low) than 
those with high vitamin-D levels (High). These are the first preliminary data looking into the 
relationship between osteocyte lacunar properties and serum vitamin-D levels. Larger sized 
lacunae may provide increased heterogeneity and better intrinsic mechanical strength prop-
erties. Further investigation with additional data is needed to better understand the effects of 
various health conditions on bone intrinsic properties.
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Hyperglycemia and Collagen Glycation Alter Gene Expression of Sclerostin 
and RANKL in Osteocytes *Rachana Vaidya1, Jacob Aaronson1, Paola Pajevic2, 
Lamya Karim1. 1Department of Bioengineering, University of Massachusetts 
Dartmouth, United States, 22Department of Translational Dental Medicine, 
Boston University, Boston, MA, United States
Patients with type 2 diabetes (T2D) have 3X higher fracture risk than healthy adults 
despite having normal or high bone density. One contributing factor to poor bone tissue qual-
ity in T2D are the changes in bone cell functions induced by hyperglycemia and increased 
non-enzymatic glycation of the collagen matrix. Osteocytes secrete sclerostin and recep-
tor activator of nuclear factor-κB (RANKL), two proteins that aid in bone resorption and 
formation. We hypothesized exposure of osteocytes to high glucose and glycated collagen 
would alter SOST and RANKL expression to indicate an imbalance in remodeling.The os-
teocytic cell line Ocy454 was grown 1) in complete α-MEM media with 5.56mM(Control), 
14mM (2X), or 22mM (4X) glucose with 25mM HEPES to maintain pH, or 2) on glycated 
vs non-glycated collagen substrate. For glycation, rat tail type I collagen was treated with 
257mM methylglyoxal in 100mM sodium phosphate, pH 7.4, for 6h at 22°C and dialyzed 
against 0.02M acetic acid at 4°C. Collagen (glycated and non-glycated) was used to coat six 
well plates at a concentration of 5 μg/cm2. Cells were grown for 12 days before measure-
ment of gene and protein expression. RT-qPCR for SOST and RANKL was performed using 
SYBR green and β-actin was used as housekeeping gene. Protein expression was determined 
in cell supernatants using ELISA kits.After 12 days in culture, SOST expression was sig-
nificantly upregulated in 14mM glucose (p<=0.05), with a similar trend in 22mM glucose 
(p=0.069) relative to control, with a corresponding increase in sclerostin protein expression 
(p<=0.05) in the medium. There was no change in RANKL gene or protein expression after 
12 days in 14mM or 22mM glucose. RANKL expression was significantly increase after 5 
days of exposure to glycated collagen (p<=0.05) (Figure 1) whereas SOST expression was 
unaffected. Moreover, both sclerostin and RANKL protein expression were unchanged upon 
exposure to glycated vs non-glycated collagen.High sugar treatments changed the expres-
sion of sclerostin, but glycated collagen treatment only effected RANKL gene expression. 
These results suggest that Ocy454 cells are modified by conditions representative of T2D. 
Their altered behavior has the potential to cause disruptions in the bone remodeling cycle, 
causing a deterioration in the bone tissue quality that may contribute to increased fracture 
risk. Further work is needed to clarify how bone remodeling signaling factors from Ocy454 
changes in T2D.Acknowledgements: The Ocy454 cell line was provided by the MGH Cen-
ter for Skeletal Research P30 Core (P30AR066261). This study was funded by NIH-NIAMS 
(K01AR069685) and the ASBMR Rising Star Award.
Disclosures: Rachana Vaidya, None
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Connexin 43 Deficiency in Osteocytes Promotes Bone Catabolism but Makes 
Osteocytes More Sensitive to Anabolic Effects of Mechanical Loading 
*Michael Friedman1, Yue Zhang1, Evan Buettmann1, Henry Donahue1. 1Virginia 
Commonwealth University, United States
Introduction: Anabolic mechanical loading increases bone mass, strength, and quality. 
Osteocytes are the main mechanosensing cells in bone that transduce mechanical signals into 
changes in bone metabolism. The gap junction protein Connexin 43 (Cx43) is part of bone’s 
mechanosensing mechanism. Deletion of Cx43 in osteoblasts and osteocytes decreases bone 
volume but increases responsiveness to mechanical loading in mice1. It remains unclear 
how loading results in a greater anabolic response in Cx43-deficient bone. We hypothesized 
that loss of Cx43 in osteocytes exposed to loading in vitro via oscillating fluid flow would 
increase expression of genes responsible for bone anabolism.Methods: Mouse osteocytic 
OCY454 cells had the Cx43 gene deleted by CRISPR. Wildtype (WT) and Cx43-deficient 
(Cx43KO) cells were seeded on glass slides at 15,000 cells/slide and incubated in al-
pha-MEM media at 33°C for 3 days of proliferation. The cells were then transferred to 37°C 
for 10 days of differentiation. Cells were exposed to 2 hours of oscillating fluid flow (1Hz, 
10 dyne/cm2) using a Flexcell Streamer and Osci-Flow controller. Static control cells were 
placed into the streamer without fluid flow. Then, cells were incubated in fresh media for 2 
hours. Cells were harvested, and gene expression was analyzed by RT-qPCR. Conditioned 
media samples from the post-flow incubation were analyzed by ELISA for RANKL, OPG, 
and sclerostin. Two-Way ANOVAs with Tukey’s tests were used to determine significance 
(p<0.05). Results: Gene expression of RANKL and RANKL/OPG ratio were significantly 
increased in Cx43KO cells compared to WT cells under static and flow conditions (Fig 1). 
Sclerostin gene expression was not affected. Conditioned media from Cx43KO cells had 
increased sclerostin and decreased OPG compared to conditioned media from WT cells. 
Fluid flow decreased media sclerostin and OPG only in Cx43KO cells.Discussion: Cx43 de-
ficiency alone increased signals leading to osteoclastogenesis and decreased signals leading 
to osteoblastogenesis in vitro. Mechanical signals decreased the catabolic marker sclerostin 
but only in Cx43KO cells. These results support the observed phenotype in Cx43KO bones 
which have low bone mass, increased turnover and increased sensitivity to loading. Our 
results suggest Cx43 regulates bone metabolism and responsiveness to mechanical loading. 
Cx43 may be a novel target to increase bone mass.Reference: 1. Bivi et al. J Orthop Res 
2013.
Disclosures: Michael Friedman, None
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A mathematical and computational model of an osteocyte immersed in flow 
with experimental validation *Jared Barber1, Luoding Zhu1, Sungsoo Na1, 
Hiroki Yokota1. 1Indiana University-Purdue University Indianapolis, United 
States
In order to produce a tool that can be used to better understand osteocyte mechanics, a 
three-dimensional mathematical and computational model for an osteocyte in viscous flow is 
developed. The initial model consists of a membrane, cytoskeleton, and nucleus and is mod-
eled by an interlinked viscoelastic fiber network.  The network is created by constructing a 
triangularization of the cell’s surface, using a meshing tool to convert that triangularization 
into a tetrahedralization of the cell’s volume, and then using the edges of the tetrahedra to de-
fine the interlinked network of linearly viscoelastic elements or fibers (dashpots and springs 
in parallel).  The fiber size and various mechanical properties (e.g. viscosity and elasticity) 
for the membrane, cytoskeleton, and nucleus are adjusted to match results from literature 
and experiment.  The lattice Boltzmann equations (the D3Q19 model) are used to model the 
viscous incompressible flow.  Forces due to the cellular structures are estimated using the 
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principal of virtual work combined with bending and elongational elastic energy estimates, 
volume and surface area conservation associated energies, and viscous energy dissipation. 
The immersed boundary (IB) method framework models the interaction between the fluid 
and osteocyte structures.  By developing the model using an idealized ellipsoidal geometry, 
the numerical and physiological capabilities are initially assessed.  The model uses methods 
that are highly parallelizable and the model can be run on multiple cores simultaneously 
in order to produce simulations in a feasible amount of time.  The model is also capable of 
producing cell motions qualitatively similar to those seen in experiment as well as force esti-
mates, which can be more difficult to obtain from experiment.  Additional simulations using 
more realistic cell shapes and cytoskeletal networks further support the model’s capability 
to produce reasonable cell motions and force distributions.  These results suggest that this 
three-dimensional model is a tool capable of providing insight into more realistic scenarios. 
Such scenarios include in vitro laboratory experiments involving varying shear flow rates, 
the problem of in vivo strain amplification in bone (whereby microscale geometry amplifies 
small macroscopic strains into large microscopic strains), and osteocyte-cancer cell interac-
tions, all subjects for future work.
Disclosures: Jared Barber, None
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Effect of Yerba Mate (Ilex paraguariensis) on Osteocytic Cells *Florencia 
D`Andrea1, Natasha Sanz 1, Mercedes Lombarte 1, María J Rico2, Viviana 
Rozados 2, O. Graciela Scharovsky 2, Verónica E Di Loreto 1, Lilian I Plotkin3, 
Lucas Ricardo BRUN1. 1Bone Biology Laboratory. School of Medicine. Rosario 
National University., Argentina, 2Instituto de Genética Experimental. School of 
Medicine. Rosario National University, Argentina, 3Department of Anatomy, Cell 
Biology & Physiology, Indiana University School of Medicine, United States
Yerba mate (YM) infusion is frequently drank in several Latin American countries. 
Several active phytochemicals including caffeine and polyphenols have been identified in 
YM solution. Whereas caffeine has shown a negative impact on BMD in healthy postmeno-
pausal women in particular when it is associated with low calcium diet, polyphenols have 
shown positive bone effects due to their antioxidant properties. In addition, we found that 
YM significantly increased MC3T3E1 osteoblastic cells viability in vitro and positive effect 
on BMD, trabecular bone biomechanical properties, and alkaline phosphatase levels in vivo. 
However, whether the infusion also affects osteocytes is not known. To examine this possi-
bility, we evaluate the effect of YM components on MLO-Y4 osteocytic cells in vitro. Cell 
viability (Cell Proliferation Reagent WST-1, Roche) was evaluated before exposing cells (48 
hours) to YM components (caffeine and two polyphenols: rutin and chlorogenic acid) in two 
different experiments: 1. caffeine (C 0.66, 1.66 and 3.33 µg/ml), chlorogenic acid (AC 1, 5 
and 10 µg/ml) and their combinations (n=8/group). 2. caffeine (C 0.66, 1.66 and 3.33 µg/
ml), rutin (R 1, 5 and 10 µg/ml) and their combinations (n=8/group). A qualitative analysis 
of the cell morphology according to treatment was made. Differences between groups were 
analyzed using one-way ANOVA test and it was considered significant if p<0.05. No appar-
ent changes in cell morphology were observed with the treatments. A significant increase in 
osteocytic cells viability was observed with low rutin concentration (R1 µg/ml = 114.3+/-
5.1% vs. control) and highest caffeine concentrations (C1.66 µg/ml = 120.2+/-7.4%, C3.33 
µg/ml = 113.3+/-5.4% vs. control). All rutin/caffeine combinations showed a positive effect 
on cell viability, in particular, the combination R10/C0.66 (118%) that has the normal ratio 
polyphenols/caffeine (15/1) found in YM. On the other hand, chlorogenic acid did not show 
any effect on cell viability. We conclude that caffeine and rutin -components of YM- individ-
ually and in combination have a positive effect, increasing osteocytic viability in cell culture. 
Chlorogenic acid individually or combined with caffeine has no effect on osteocytic cells, 
suggesting an inhibitory effect of the polyphenol on the survival effect of caffeine. Our data 
suggests that the positive effects of YM at the bone level previously described, could be -at 
least in part- due to the increased survival of osteocytes.
Disclosures: Florencia D`Andrea, None
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Development of an Electrical Stimulation Environment for Osteocytes 
*Taylor deVet1, Roshan Bashar1, Hubert deBruin 1, Gregory Wohl1. 1McMaster 
Univeristy, Canada
Bone remodelling is a relatively well-understood process. However, there is debate over 
the mechanisms of activation and communication of the cells, specifically osteocytes. The 
hypothesis is that osteocytes sense mechanical stimuli and generate a biochemical response 
to control remodelling. Studies have shown that the application of direct electrical current 
has positive effects on osteogenesis, indicating that bone cells are sensitive to an electrical 
environment. However, this is currently under-researched, specifically in the case of osteo-
cytes. The goal of our work is to improve our understanding of how osteocytes respond to 
electrical stimulation.To investigate osteocytes in vivo, we developed a miniaturized elec-
trical stimulation device that fits into a 12-well cell culture plate. Platinum electrodes were 
used to characterize the electrical properties of the cell culture media to try and maximize 
cellular stimulation while minimizing changes to the media. A DC current was applied with 
an increasing magnitude from 100 to 800 µAmps using a constant current. We measured the 
resistance of the medium in two commonly used cell media – McCoy’s and DMEM.Our 
results show that electrical stimulation of culture media causes changes in the media that 
increase with the applied current. There are changes to the pH of the medium instantaneously 
upon the application of current visible through the media’s built in pH indicator. The pH 
change depends on the polarity of the electrode with the positive electrode creating a basic 
environment and the negative electrode creating an acidic one. This separation disperses 
between 60-120 minutes. There are also changes in the resistance of the media depending 
on the stimulating current and the amount of time stimulation occurs.To probe the field 
strength across the stimulation field, we are developing an electrode array on the base of each 
cell culture well consisting of more platinum electrodes. This will allow us to measure the 
amount of stimulation that is getting to the cells in the bottom of the well.These experiments 
have given insight into the stability of cell culture medium with the introduction of direct 
electrical stimulation which will allow us to decipher if the behaviour of osteocytes under 
electrical stimulation is coming from the stimulation or the electrochemical reactions in the 
culture media. This is a first step into creating a stable electrical environment for osteoblast 
and osteocyte cells in culture.
Disclosures: Taylor deVet, None
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General Comorbidity Indicators Contribute to Fracture Risk Independent 
of FRAX: A Registry-Based Cohort Study. *William Leslie1, Suzanne 
Morin2, Lisa Lix1, Eugene McCloskey3, Helena Johansson3, Nicholas Harvey4, 
John Kanis3. 1University of Manitoba, Canada, 2McGill University, Canada, 
3University of Sheffield, United Kingdom, 4University of Southampton, United 
Kingdom
BACKGROUND: FRAX® estimates 10-year fracture probability from osteoporo-
sis-specific risk factors. General comorbidity indicators are associated with fracture risk 
and can be assessed at the population level using easily-obtained administrative healthcare 
information. Whether these general indicators contribute to fracture risk independently 
from those included in FRAX is uncertain.OBJECTIVE: To examine the associations be-
tween two general comorbidity indicators (Johns Hopkins Aggregated Diagnosis Groups™, 
ADGs® or the number of hospitalizations in the preceding 3 years) and the risk of major 
osteoporotic fracture (MOF) and hip fracture (HF) outcomes adjusted for FRAX probabili-
ty without/with competing mortality.METHODS: We used the population-based Manitoba 
Bone Mineral Density (BMD) Program registry to identify women and men age 40 years or 
older with at least 3 years of prior health care data undergoing baseline BMD assessment 
with FRAX scores. Using linked population-based administrative healthcare information, 
we constructed ADG scores and tabulated the total number of hospitalizations in the prior 
3 years for each individual. We identified subsequent incident MOF and HF, and performed 
Cox regression analysis to determine associations between increasing ADG score (mildly 
increased=3-5, moderately increased 6-8, markedly 9+ increased vs low=0-2) or number of 
hospitalizations (1, 2, 3+ vs 0) and fracture outcomes. There was no evidence of collinearity 
therefore both indicators were included in the final models.RESULTS: The study population 
included 83,461 individuals (mean age 64.6 years, 90% women) with 8,416 MOF and 2,665 
HF during average follow up 9 years. ADG score was low in 18.9%, mildly increased in 
44.1%, moderately increased in 26.3%, and markedly increased in 10.8%. Hospitalizations 
in the previous 3 years were distributed as none in 79.9%, 1 in 8.4%, 2 in 7.1% and 3+ 
in 4.6%. Increasing ADG score and number of hospitalizations showed a gradient of in-
creasing MOF and HF risk adjusted for age and sex (TABLE). ADG score was unaffected 
by adjustment for FRAX and when competing mortality was considered. Hospitalizations 
were partially attenuated by adjustment for FRAX and no longer significant when com-
peting mortality was considered.CONCLUSIONS: A general comorbidity indicator (Johns 
Hopkins ADG score) but not the number of hospitalizations in the preceding 3 years was a 
FRAX-independent risk factor for incident MOF and hip fracture.
Disclosures: William Leslie, None
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Identifying Patients at High Risk of Hip Fracture — Combining CT-based 
Vertebral Fracture Assessment and Biomechanical Computed Tomography 
Analysis *Tony M. Keaveny1, David C. Lee2, Heidi Fischer3, Annette L. Adams3, 
David L. Kopperdahl2. 1University of California, Berkeley, United States, 2O.N. 
Diagnostics LLC, United States, 3Kaiser Permanente Southern California, 
United States
Addressing the need to identify more patients at high and very high risk of hip fracture, 
here we investigated hip fracture discrimination in a real-world setting via combining CT-
based Vertebral Fracture Assessment (VFA) with hip BMD T-scores and femoral strength 
from Biomechanical Computed Tomography analysis (BCT), all measured from the same 
CT scan. Using a case-cohort design sampled from 111,694 Kaiser patients (both sexes) 
aged 65 or older who had a hip-containing CT scan for any indication, a DXA within 3 years 
of the CT, and no prior hip fracture, we compared those with subsequent hip fracture with 
randomly selected sex-stratified controls and analyzed their CT scans blinded to all other 
data. For BCT, we investigated two binary classifications: patients with either a hip BMD 
T-score <= -2.5 or with femoral strength less than the threshold for fragile bone strength 
(“or” logical, oBCT); or patients testing positive for both criteria (“and” logical, aBCT). For 
VFA, we investigated three binary classifications: presence of any vertebral fracture (Genant 
grade 1–3); presence of any moderate or severe vertebral fracture (grade 2–3); or a total 
fracture grade of 4 or more, summed over all vertebrae. The VFA and BCT binary classifi-
cations were then combined using “or” or “and” logicals. The outcome was an incident hip 
fracture after any imaging; DXA (spine or hip osteoporosis) without any VFA was used as 
a reference. Overall, combining VFA with BCT did not improve the BCT prediction but did 
provide various levels of competing sensitivity and specificity (Table). For the women, the 
presence of at least one vertebral fracture of any grade performed at least as well as spinal 
osteoporosis by DXA; when combined using an “or” logical with oBCT, it identified patients 
at slightly higher risk of hip fracture than did clinical osteoporosis by DXA (age- BMI- and 
race/ethnicity-adjusted Hazard Ratio 3.53 vs. 2.04; diagnostic odds ratio 4.33 vs. 2.77) and 
with high sensitivity (80%) but modest specificity (53%); and when combined using an 
“and” logical with aBCT, it identified patients at over two-fold higher risk of hip fracture 
than did clinical osteoporosis by DXA (HR 4.84 vs. 2.04; diagnostic odds ratio 7.25 vs. 
2.77) and at high specificity (95%) but low sensitivity (29%). Similar trends occurred for the 
men but required the presence of a moderate or severe vertebral fracture. We conclude that 
combining VFA with BCT may have clinical utility.
Disclosures: Tony M. Keaveny, Amgen, Consultant, O.N. Diagnostics, Other Financial or 
Material Support, Bone Health Technologies, Consultant
P-485
Independent Performance Evaluation of the Garvan Fracture Risk 
Calculator: A Registry-Based Cohort Study. *William Leslie1, Tuan Nguyen2, 
Suzanne Morin3, Lisa Lix1, John Eisman2. 1University of Manitoba, Canada, 
2Garvan Institute of Medical Research, Australia, 3McGill University, Canada
BACKGROUND: Absolute risk estimation is the preferred approach for assessing frac-
ture risk and treatment decision making, but the optimal model remains controversial. The 
Garvan Fracture Risk Calculator (FRC) is a simple prediction model derived from the Dub-
bo Osteoporosis Study (DOES) cohort from Australia.OBJECTIVE: To evaluate the pre-
dictive performance of the Garvan FRC in a large clinical registry from Manitoba, Canada.
METHODS: Using the population-based Manitoba Bone Mineral Density (BMD) registry, 
we identified women and men age 50-95 years undergoing baseline BMD assessment from 
September 1, 2012 onwards, with registry linkage and self-reported falls in the prior 12 
months. 5-year Garvan FRC predictions were generated from clinical risk factors (CRFs) 
without BMD and again with femoral neck BMD. We identified subsequent non-traumatic 
incident osteoporotic fractures (OF, any fracture excluding craniofacial, hand/foot, ankle) 
and hip fractures (HF) from population-based healthcare data sources to March 31, 2018. 
Overall risk stratification was assessed from area under the receiver operating characteristic 
curve (AUROC). Cox regression analysis and calibration ratios (5-year observed / predicted) 
was assessed for risk quintiles. All analyses were sex stratified.RESULTS: The study pop-
ulation consisted of 16,682 women (mean age 66.6 +/- SD 8.7 years) and 2,839 men (mean 
age 68.7 +/- SD 10.2 years). During mean observation time of 2.6 years there were incident 
OF in 681 women and 140 men; incident HF in 199 women and 22 men. AUROC showed 
significant fracture risk stratification with the Garvan FRC; predictions from the tool using 
CRFs were better than from age or weight alone, predictions the tool with BMD were better 
than age and BMD alone (TABLE). Garvan FRC used with BMD was better than predictions 
from CRFs, especially for HF prediction (AUROC 0.86 in women, 0.82 in men). There was 
a strong gradient of increasing risk for Garvan FRC quintiles (highest vs lowest, hazard 
ratios women 5.75 [95% CI 4.32-7.76] and men 3.43 [1.95-6.04] for any OF; women 101.6 
[14.2-727.5] for HF, insufficient numbers for men). Calibration differences were noted with 
Garvan FRC both over- and underestimating risk.CONCLUSIONS: A simple fracture risk 
prediction model, Garvan FRC, outperformed clinical risk factors or BMD alone for fracture 
risk stratification, particularly for hip fractures, but may require recalibration for accurate 
predictions in this population.
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Assessment of machine-learning technologies for predicting major 
osteoporotic fracture in 25,772 postmenopausal women with genomic and 
phenotypic data *Qing Wu1. 1University of Nevada, Las Vegas, United States
The performance of existing fracture risk assessment tools in fracture prediction re-
mains suboptimal. But recent innovations in genomic data and machine learning (ML) tech-
nologies have shown great potential in improving fracture prediction performance. Artificial 
neural networks (ANN) and support vector machines (SVM) are widely used ML approach-
es in prediction research; however, their performance for fracture prediction, especially with 
genomic data, has been rarely studied.  This study aimed to develop ANN and SVM mod-
els from genomic and phenotypic data, determine if these ML models perform better than 
conventional logistic regression, and ascertain which method performs the best in fracture 
prediction. We used genomic and phenotypic data from the Women’s Health Initiative Clin-
ical Trial and Observational Study (N=25,772) as the data source and conducted genotype 
imputation at the Sanger Imputation Server. We identified 1,103 associated SNPs from the 
genomic data and derived the corresponding genetic risk score (GRS) for each participant. 
Major osteoporotic fractures (MOF) was used as the outcome variable, and clinical fracture 
risk factors were included in the modeling. The data were normalized and then randomly 
split into a training set (70%) and a validation set (30%). The model was built using ANN, 
SVM, and logistic regression separately. For the model training, the adaptive synthetic over-
sampling technique was used to account for the low fracture rate in the data, and the 10-fold 
stratified cross-validation was employed for hyper-parameters optimization. The fracture 
prediction performance of each model was assessed by area under the ROC curve (AUC) 
and accuracy in the testing set. We found that the performance of ANN in predicting fracture 
was the best, with an accuracy of 0.752 and an AUC of 0.830. The performance of SVM 
and logistic regression in MOF prediction was similar. SVM and logistic regression had an 
accuracy of 0.705 and 0.708, and both methods had AUC of 0.750. The performance of ANN 
remained the best in MOF prediction in sensitivity analyses when we limited the study sam-
ple to the control or interventional group in the data. We also observed that GRS is a signif-
icant predictor of MOF, and GRS significantly improved the accuracy and AUC of each ML 
method. Therefore we concluded that ANN performed the best for the prediction of MOF in 
postmenopausal women, and genomic variants can significantly improve fracture prediction.
Disclosures: Qing Wu, None
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Comparison of Short-Term and 10-year Probabilities to Characterise 
Fracture Risk After a Recent Sentinel Fracture *Helena Johansson4, John A 
Kanis4, Nicholas C Harvey2, Vilmundur Gudnason3, Gunnar Sigurdson3, Kristin 
Siggeirsdottir3, Mattias Lorentzon4, Enwu Liu4, Liesbeth Vandenput4, William D 
Leslie5, Eugene V McCloskey6. 4Mary McKillop Institute for Health Research, 
Australian Catholic University, Australia, 2MRC Lifecourse Epidemiology Unit, 
University of Southampton, United Kingdom, 3Icelandic Heart Association 
Research Institute, Iceland, 4Mary McKillop Institute for Health Research, 
Australian Catholic University, Iceland, 5Department of Medicine, University of 
Manitoba, Canada, 6Centre for Integrated research in Musculoskeletal Ageing, 
Mellanby Centre for bone research, Department of Oncology and Metabolism, 
University of Sheffield, United Kingdom
Purpose The recency of a prior fracture affects subsequent fracture risk (imminent risk), 
leading some to suggest that short term probability calculations might be more useful than 
10-year probabilities to identify patients for treatment.  The aim of this analysis was to quan-
tify the effect of a recent sentinel fracture, by site, on future fracture probability expressed 
over periods of 2, 5 and 10 years.Methods The Reykjavik Study fracture register prospec-
tively captured all fractures at all skeletal sites in a large sample of the population of Iceland. 
Fracture probabilities were determined after a sentinel fracture (humeral, clinical vertebral, 
forearm and hip fracture), occurring within the previous two years, and probabilities for a 
prior osteoporotic fracture irrespective of recency.  The probability ratios were used to adjust 
fracture probabilities calculated over 2-, 5- and 10-year time horizons.Results Probability 
ratios to adjust probabilities of a hip or major osteoporotic fracture (MOF) following a sen-
tinel fracture were age dependent, decreasing with age in both men and women, and varied 
according to the site of sentinel fracture. For the outcome of MOF the ratio was 1.09 if the 
sentinel fracture was a forearm fracture (for a woman aged 70 for 10-year probability) and 
1.50 if the sentinel fracture was a vertebral fracture. While probability ratios for a sentinel 
fracture were higher with a shorter time horizon, particularly over 2 years, the final absolute 
fracture probability was much lower (Figure). The ratios between probability with sentinel 
and any previous fracture for a woman aged 70 years were 1.50 for 10-year probability, 
1.99 for 5-year and 2.55 for 2-year probability. At all ages, the 10-year probability was 
much higher than the 2-year probability, ranging from 3.8-fold at the age of 40 to 1.7-fold 
at the age of 90. The 5-year probability gave intermediate values.Conclusion Probability 
ratios provide adjustments to conventional FRAX estimates of fracture probability for re-
cent sentinel fractures.  Ten-year probability of fractures captures the impact of recency of 
fracture with magnitudes of change and final probability that can readily inform clinical de-
cision making.  Figure.  10-year, 5-year and 2-year probability of major osteoporotic fracture 
(MOF) in women from Iceland with a recent vertebral fracture.
Disclosures: Helena Johansson, None
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Predicting Mortality and Re-fracture Following an Initital Fracture *Thao 
P. Ho-Le2, Thach S. Tran2, Hanh M. Pham2, Steven A. Frost2, Jacqueline Center2, 
John A. Eisman2, Tuan V. Nguyen2. 2Healthy Aging Theme, Garvan Institute 
of Medical Research, Australia, 2Healthy Aging Theme, Garvan Institute of 
Medical Research, Viet Nam
Background and Aim. An initial fracture signifies increased risks of subsequent fracture 
andmortality. There is, however, a large variation between individuals in terms of adverse 
healthstates following a fracture. This study sought to define the pattern of, and determinants 
for, thetransition between fracture, refracture, and mortality.Methods. This cohort study in-
volved 2046 women and 1205 men, aged 60 years and olderwhose fracture status and health 
outcomes had been continuously monitored for up to 20 years. Fragility fractures were as-
certained using X-ray report and circumstance of fracture. The incidence of mortality was 
ascertained from the state birth, death and marriage registry. Femoral neck bone mineral 
density (BMD, GE-Lunar Prodigy) was measured at baseline. A multistate Markov style of 
the Cox’s proportional hazards model was used to estimate the transition probabilities and 
transition time between 5 statuses (ie no fracture, initial fracture,second fracture, third frac-
ture, and mortality).Results. Approximately 22.4% of women and 9.2% of men had osteo-
porosis (FN BMD T-scores <= -2.5). Among women without a fracture, approximately 51% 
would remain fracture-free during the study time; 12% would suffer a fracture, and 1% went 
on to re-fracture. Amongmen without a fracture, 52% would remain fracture-free during 
the study period; 5.6% wouldsuffer a fracture, and 3.4% went on to re-fracture. Five-year 
probability of transition from nofracture to initial fracture was 6% and 13.9% for a woman 
without and with osteoporosis,respectively. For a man without and with osteoporosis, the 
respective five-year risk was 3.5%and 8.3%.Conclusion. Individuals with an initial fracture 
have an increased risk of subsequent fractureand mortality, and the risk of fracture-associat-
ed mortality in men is greater than in women.The predictive model developed here can aid 
patients and doctors to reach an informed decision concerning treatment in individuals with 
an initial fracture to reduce fracture and mortality inthe general population.
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Automated Workflow for Vertebral Deformity Measurements on CT and 
MRI Scans Using Artificial Intelligence *Abhinav Suri1, Grace Ng1, Brandon 
Jones1, Nancy Anabaraonye1, Patrick Beyrer1, Grace Choi1, Nikita Bastin1, 
Thomas Leichner1, Sungho Kim1, Amanda Jankelovits1, Helene Chesnais1, Andy 
Chen1, Alisha Agarwal1, James Parente1, Jacquelyn Golden1, Samantha Turner1, 
Alexandra Rizaldi1, Emily Tu1, Lauren Rodio1, Nima Missaghian1, Eusha Hasan1, 
Chamith Rajapakse1. 1University of Pennsylvania, United States
PURPOSEVertebral fractures comprise almost 50% of osteoporotic fractures in the 
United States. Vertebral deformity fractures can be classified as wedge, biconcave, or crush, 
depending on the anterior (Ha), middle (Hm), and posterior (Hp) heights of each vertebral 
body. However, determining these measurements is time-consuming and resource intensive. 
Artificial Intelligence algorithms offer the ability to automatically determine Ha, Hm, and 
Hp and segment vertebral bodies for 3D bone quality assessment. We report the develop-
ment and testing of a deep learning neural network implementation for analyzing sagittal 
spine CT and MR images. METHODSSagittal spine MR (T1) and CT scans (MR = 998 
subjects, age 67 +/- 11yrs; CT = 35 subjects, age 64 +/- 3yrs; all female) were used to train 
two networks (Fig.1). A key-point detection network was trained with 4622 labeled verte-
bral bodies--augmented to 5667 vertebrae (4398 MR, 1269 CT)--to find relevant points for 
height calculations. A 3D segmentation network was trained with labelled scans (68 MR, 
35 CT) to extract volumes of vertebral bodies and discs. Accuracy of the neural networks 
were measured using two parameters: 2D/3D Dice score (ranges from 0 to 1 where 1 means 
predicted segmentation = labelled ground truth) and error distance (distance of predicted 
key-point location to true location). Each network was evaluated with 238 MR and 15 CT 
scans. RESULTSThe network was able to predict relevant key-points and segmentation 
masks. The neural network achieved an overall 2D Dice coefficient of 0.97, 3D Dice coeffi-
cient of 0.94, and error distance of 0.97 mm. Mean percent error in Ha, Hm, and Hp height 
calculations was 0.13%. Each scan slice was processed by the neural network with a mean 
time of 0.973 seconds. CONCLUSIONSThe neural network was able to determine morpho-
metric measurements for detecting spinal deformities with high accuracy on sagittal MR and 
CT images. Additionally, it was able to extract 3D volumes for vertebral bodies and discs. 
Thus we were able to show AI algorithms are able to automatically extract measurements 
for rapid quantification of vertebral bone health. This approach could simplify the screening, 
detection of changes, and surgical planning in patients with vertebral deformities and frac-
tures by reducing the burden on radiologists who have to do these measurements manually.
Disclosures: Abhinav Suri, None
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Adjusting Fracture Probability for the Effects of Recent Fracture: A 
Registry-Based Cohort Study. *William Leslie1, Suzanne Morin2, Lisa Lix1, 
Eugene McCloskey3, Helena Johansson3, Nicholas Harvey4, John Kanis3. 
1University of Manitoba, Canada, 2McGill University, Canada, 3University of 
Sheffield, United Kingdom, 4University of Southampton, United Kingdom
BACKGROUND: FRAX® estimates 10-year fracture probability from multiple risk 
factors, including prior fracture. Prior fracture in FRAX does not consider fracture site or 
time since fracture, and has been reported to underestimate fracture risk after recent frac-
tures (less than 2 years) and some fracture sites (especially vertebral and hip). Site-specific 
multipliers to adjust FRAX for the effect of a recent fracture were developed in the Icelandic 
population but have not been validated in other populations.OBJECTIVE: To examine the 
effect of recent fracture (less than 2 years) on fracture risk predictions from FRAX and the 
validity of adjusting predictions with the Icelandic risk multipliers.METHODS: Using the 
population-based Manitoba Bone Mineral Density (BMD) Program registry, we identified 
women and men age 40 years or older with a major osteoporotic fracture (MOF) in the prior 
two years, baseline FRAX assessments (without and with BMD), and fracture outcomes. We 
estimated calibration ratios for observed 10-year cumulative MOF and hip fracture probabil-
ity (with competing mortality) versus conventional FRAX predictions, and compared these 
with the Icelandic multipliers for recent fracture.RESULTS: The study population included 
5,056 women (mean age 66.8 years) and 963 men (mean age 68.8 years) with MOF in the 
prior 2 years. MOF Icelandic multipliers decreased with advancing age for women (from 
mean 2.79 age 40-49 to 1.03 age 80+ years) and men (from mean 2.77 age 40-49 to 1.05 age 
80+ years). This paralleled the age-related decrease in the calibration ratios for empirically 
observed 10-year cumulative MOF probability and unadjusted FRAX predictions (Table). 
There was corresponding improved MOF prediction for women ages 40-49 and 50-59 and 
men ages 40-49, 50-59, 60-69 and 70-79 with adjusted compared with conventional FRAX 
scores. The multipliers were numerically smaller for women age 60 years or older and did 
not significantly improve risk prediction. When analyzed by prior fracture site, the multi-
pliers showed the largest improvement in MOF prediction following recent vertebral and 
humerus fracture. Assessment of hip fracture was limited by smaller numbers and wide con-
fidence intervals, but the multipliers improved hip fracture prediction in women age 50-59 
years and men ages 60-69 and 70-79.CONCLUSIONS: Risk multipliers for recent fracture 
meaningfully improved prediction of 10-year fracture risk in some age subgroups of women 
and men.
Disclosures: William Leslie, None
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Risk of fragility fractures in patients with Type 1 diabetes mellitus may be 
associated with diabetes-specific clinical parameters *Pavithra Natarajan1, 
Jacob Mather1, Saifuddin Kassim 2, Rebecca Sagar2, Afroze Abbas2. 1University 
of Leeds, United Kingdom, 2Leeds Teaching Hospitals Trust, United Kingdom
Background: Type 1 Diabetes Mellitus (T1DM) is associated with impaired bone health 
and increased risk of fragility fractures. The pathophysiology of this is considered to be 
multi-factorial. However, clinical management guidelines for T1DM rarely mention bone 
health, and the suspicion is that fracture risk is underestimated in this cohort. This study 
aims to assess and stratify fracture risk in patients with T1DM, within a UK tertiary hos-
pital setting.Methods: A retrospective analysis of 497 patients aged 50 to 98 with T1DM 
was conducted. Data were collected including; demographics, medications, biochemistry, 
fracture history, bone mineral density, microvascular complications (neuropathy, retinopa-
thy & microalbuminuria) and HbA1c levels. The validated Fracture Risk Assessment tool 
(FRAX) was used to calculate 10-year major osteoporotic and hip fracture risk, respective 
risk categories according to National Osteoporosis Guidelines Group (NOGG) recommen-
dations were also recorded.  Relevant statistical analysis was performed using Prism version 
8.3.1. Results: As expected, results showed that 10-year major osteoporotic and hip fracture 
risk was significantly greater in females (p<0.001) and increased with age (p<0.001). Frac-
ture risk was greater with a lower eGFR (p<0.001) and fell with rising BMI (p78mmol/mol), 
the proportion requiring investigation for osteoporosis or active treatment was significantly 
higher than those with better glycaemic control (p=0.04). Mean fracture risk was positively 
correlated with an increasing number of microvascular complications (major osteoporotic; 
p= 0.009, hip; p=0.004). Patients with microalbuminuria had greater FRAX risk than those 
with no complications (major osteoporotic; p= 0.04, hip; p=0.007), those with retinopathy 
and neuropathy were not found to have a significantly increased risk. Conclusion Our find-
ings demonstrate the potential for diabetes-specific clinical risk factors (elevated HbA1c, 
low eGFR, presence of multiple microvascular complications and presence of microalbu-
minuria)  to be used alongside conventional risk factors for fracture (e.g. age, sex, BMI) 
to effectively identify patients with T1DM who may be most at risk of fracture. This has 
implications for clinical practice in the future management of patients with T1DM, which 
may help to reduce the risk of fragility fractures in this group.
Disclosures: Pavithra Natarajan, None
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Crystal Bone: Personalized, Short-term Fracture Risk Prediction With 
Natural Language Processing Methods *Yasmeen Almog1, Angshu Rai1, 
Anirban Mishra1, Amanda Moulaison1, Ross Powell1, Kerry Weinberg1, Celeste 
Hamilton1, Mary Oates1, Eugene McCloskey2, Steven R. Cummings3. 1Amgen 
Inc., United States, 2University of Sheffield, United Kingdom, 3University of 
California San Francisco, United States
Fractures due to osteoporosis are common and associated with significant clinical, per-
sonal, and economic burden; however, osteoporosis remains widely underdiagnosed and 
undertreated. Common fracture risk assessment tools, such as FRAX and Garvan, confer 
risk over the long-term but do not provide short-term risk estimates necessary to identify 
very high-risk patients likely to fracture in 1–2 years. Further, these tools use cross-sectional 
data representing a subset of all available clinical risk factors for risk prediction. These 
methods are generalized across patient populations and may not fully utilize patient histories 
commonly found in electronic health records (EHRs) that contain temporal information for 
thousands of unique features.We used the Optum® de-identified EHR dataset (2007–2018) 
to develop Crystal Bone, a method that applies machine learning techniques commonly used 
in natural language processing to the temporal nature of patient histories to predict fracture 
risk over a 1–2-year timeframe. We repurposed deep-learning models typically applied to 
language-based prediction tasks which learn the meanings of words and sentences to clas-
sify them. Crystal Bone uses context-based embedding techniques to learn an equivalent 
“semantic” meaning of various medical events. Similar to how language models predict the 
next word in a given sentence or the topic of an overall document, Crystal Bone can predict 
that a patient’s future trajectory may contain a fracture or that the “signature” of the patient’s 
overall journey is similar to that of a typical fracture patient.We applied Crystal Bone to 
two datasets, one enriched for fracture patients and one representative of a typical hospital 
system. In both datasets, when predicting likelihood of fracture in the next 1–2 years, Crystal 
Bone had an area under the receiver operating characteristic (AUROC) score ranging from 
72%–83% on a test (hold-out) dataset. These results suggest performance similar to that of 
FRAX and Garvan, which have 10-year fracture risk prediction AUROC scores of 64.4% 
+/– 3.7%.Our results suggest it is possible to use each patient’s unique medical history as 
it changes over time to predict patients at risk for fracture in 1–2 years. Furthermore, it is 
theoretically possible to integrate a model like Crystal Bone directly into an EHR system, 
enabling “hands-off” fracture risk prediction, which could lead to improved identification of 
patients at very high risk for fracture.
Disclosures: Yasmeen Almog, Amgen Inc., Other Financial or Material Support
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Hip Fracture Risk Modeling using DXA and Artificial Intelligence *Yannik 
Glaser1, Peter Sadowski2, Thomas Wolfgruber3, Li-Yung Lui4, Steven Cummings 
4, John Shepherd3. 1Information and Computer Sciences University of Hawai’i 
at Mānoa, United States, 2Information and Computer Sciences University of 
Hawai’i at Mānoa, United States, 3University of Hawai’i Cancer Center, United 
States, 4University of California, San Francisco Coordinating Center, United 
States
Bone density and geometry measures of the hip from Dual-Energy X-ray absorptiome-
try (DXA) scans are highly predictive of hip fracture. However, these approaches are limited 
to using specific bone regions and features without consideration of surrounding tissues. In 
this study, we ask if deep learning can enable us to use DXA scans to better predict fracture 
risk and eliminate quality problems associated with ROI placement. We model four clini-
cal-relevant scenarios with increasing a priori risk information: from none to the equivalent 
of the FRAX model.We trained and evaluated our model on patient data from the Health, 
Aging and Body Composition study (Health ABC), a prospective cohort study of 3075 white 
and black men and women aged 70 to 79 years; Health ABC DXA scans were collected 
using a Hologic system (Hologic Inc., MA). Participants were separated into training (70%) 
and validation (10%) sets for model tuning, and a test (20%) data set for final evaluation. 
Neural networks were trained for each of the following scenarios: 1-Opportunistic Screen-
ing: only demographic information used without imaging data; 2-Advanced Screening: de-
mographic information and low-energy DXA image to approximate populations with only 
demographics and a clinical femur X-ray scan; 3-Full Diagnostic Workup without DXA 
(17 additional data-fields per patient including blood markers, disability status, and general 
indicators of fitness); 4-Full Diagnostic with DXA: model 3 with both low and high energy 
DXA images, femur-neck bone mineral density (BMD). For each model, the neural network 
fracture predictions are probabilistic, with the network output parameterizing an exponential 
distribution from which we can derive a risk score and estimate time-to-fracture.We used 
4197 DXA hip scans from all 3075 participants followed up for 15-years period . On the 
test data, the opportunistic model achieved an AUROC of 0.70 using demographic variables 
only. The Advanced Screening model marginally improved performance with inclusion of 
the low-energy DXA images (AUROC = 0.71). The full diagnostic model without and with 
the full DXA scans achieved AUROC values of 0.73 and 0.77 respectively.We conclude that 
deep learning can improve hip fracture prediction models that already include demographic, 
bone density, and clinical risk factors. Further, deep learning can be applied to DXA images 
without post acquisition analysis eliminating a major error source for DXA hip scans.
Disclosures: Yannik Glaser, None
201






Replication of a Novel Hip Structural Assessment Measure for Incident 
Hip and Other Fractures in the Study of Osteoporotic Fractures Cohort 
*BCC Khoo1, JR Lewis2, J Schousboe3, K Brown4, RL Prince1, K Ensrud5. 
1University of Western Australia, Australia, 2Edith Cowan University, Australia, 
3Park Nicollet Osteoporosis Centre and HealthPartners Institute, United States, 
4Mindways Software Inc, United States, 5University of Minnesota, United States
The internal distribution of bone within the proximal femur is known to be related to 
resistance to fracture. However areal bone density (aBMD) only assesses total bone in the 
scanned area. We have developed a four variable analytical method for hip DXA images 
termed Minimal Analysis (MA) measured at 1cm sections through the Femoral Neck (FN), 
Trochanter (TR) and Shaft (S) regions of the hip(1). The MA has two internal structural 
variables, Sigma, related to bone distribution and Delta, the difference between the geo-
metric and mineral mass centres, in addition to aBMD and bone Width of the cross sections 
(1). Previous analysis of data from the Perth Longitudinal Study of Ageing in Women (PL-
SAW) identified predictive benefit from the addition of the MA variable TRSigma to age 
and proximal femur aBMD (THaBMD) on net reclassification improvement (NRI) (2). We 
now replicate the evaluation of MA in prediction of hip fracture in the SOF cohort based on 
a prespecified analytical protocol. The analytical approach was to firstly test the additional 
benefit of TRSigma only and secondly all 12 MA variables in improving hip fracture predic-
tion in addition to age and THaBMD, using logistic and Cox proportional hazard regression 
and ROC.The participants were 7330 women, mean baseline age 73.3 (5.06) Mean (SD) 
years, 854 of whom sustained a hip fracture in the15 years after baseline. In the first logistic 
analysis, when added to age and THaBMD, TR sigma significantly improved AUC-ROC 
for hip fracture (C-statistic 0.70 and 0.72, P<0.001).  To illustrate effect size of TRSigma 
tertiles were created and compared in Cox regression. Compared to the lowest tertile of the 
HR (95% CI) for hip fracture in the second and third tertile were 1.61 (1.24 – 2.08) and 
2.66 (2.09 – 3.37) respectively.  In the second logistic analysis when compared to age and 
THaBMD alone (C-statistic 0.70) the addition of forward stepwise regression identified sev-
en of the 12 MA variables (Table) that contributed to improved prediction (C-statistic 0.73, 
P<0.001). These data identify additional clinical benefit of using structural data related to 
the internal distribution of bone in predicting resistance to hip fracture In addition, software 
is available for current DXA machines to allow reporting of the Minimal Analysis variables 
and thus a potentially improved hip fracture risk for individuals.(1) Khoo et al. J Clin Densi-
tom. 201417(1): 38-46(2) Khoo et al. Osteoporos Int. 2016; 27(1): 241-8
Disclosures: BCC Khoo, None
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HIGH RESOLUTION PERIPHERAL QCT (HR-pQCT) PREDICTS 
FRACTURES FOR ALL AGE GROUPS IN OLDER ADULTS – THE 
BOMIC CONSORTIUM *Pawel Szulc1, Mary Bouxsein2, Steven Boyd3, 
Emmanuel Biver4, Roland Chapurlat 1, Serge Ferrari4, David Goltzman5, Marian 
Hannan6, Sundeep Khosla7, Elisabeth Sornay-Rendu1, Douglas Kiel8, Elizabeth 
Samelson9. 1INSERM UMR1033, University of Lyon, Hospices Civil de Lyon, 
France, 2Beth Israel Deaconess Medical Center, Harvard Medical School, United 
States, 3University of Calgary, Canada, 4Geneva University Hospital and Faculty 
of Medicine, Switzerland, 5McGill University, Canada, 6HSL Marcus Institute 
for Aging Research and Harvard Medical School, United States, 7Mayo Clinic 
College of Medicine, United States, 8Harvard Medical School, Hinda and Arthur 
Marcus Institute for Aging Research, Hebrew SeniorLife, United States, 9Hebrew 
SeniorLife, Harvard Medical School, United States
Areal bone mineral density (aBMD) is used to assess fracture risk; however, its predic-
tive value may decrease with age. Our aim was to determine if the association of HRpQCT 
indices with fracture risk varies by age.Participants included 6,836 men and women aged 
40-96 yrs from 7 cohorts (Framingham, CaMos, Mayo, QUALYOR, GeRiCo, OFELY, 
STRAMBO). We used Cox models to estimate age-specific hazard ratios (HRs) and 95%CIs 
for associations between incident fracture and HR-pQCT bone indices, adjusted for age, sex, 
weight, height, cohort and femoral neck (FN) aBMD. We evaluated two fracture outcomes, 
all osteoporotic fractures and major osteoporotic fractures (MOF). We repeated the analyses 
adjusting for FRAX corrected for FN aBMD and cohort.During the median follow-up of 49 
months, 719 individuals had incident fragility fractures. Distal radius trabecular volumetric 
BMD (Tb.vBMD) and number (Tb.N) were associated with similar increases in fracture 
risk in all the age groups (Table). After adjustment for FRAX corrected for FN aBMD and 
cohort, distal radius Tb.vBMD and Tb.N remained associated with a similar increase in frac-
ture risk across age groups. In the analyses limited to 369 MOF, the patterns were similar in 
both the statistical models, e.g. distal radius Tb.vBMD was associated with higher fracture 
risk similarly in all the age groups. HRpQCT indices varied in their associations with the 
fracture risk (those at distal radius being more predictive than those at distal tibia), but each 
of them showed similar associations across age groups (interactions with age p>0.05).Thus, 
in a large group of men and women followed up prospectively, the link between HRpQCT 
indices and fracture risk did not vary across age groups. The patterns were similar regardless 
of the skeletal site of the scan, HRpQCT measure, statistical model and type of fracture. Our 
data show that above and beyond aBMD and FRAX, trabecular density and microarchitec-
ture provides important fracture prediction information for all age groups.
Disclosures: Pawel Szulc, None
P-497
Clinical characteristics of patients with wrist fracture attending a Bone 
Health Unit in Ireland *Maire Rafferty1, Nessa Fallon2, Georgina Steen2, 
Niamh Maher2, Claire O Carroll2, James Bernard Walsh2, Kevin McCarroll2. 1Sj 
James Hospital, Ireland, 2St James Hospital, Ireland
IntroductionFragility fracture of the wrist is the most common osteoporotic fracture. 
Identifying patients at risk for wrist and other fractures is central to the assessment of older 
adults and fracture liaison services. The aim of this study was to identify retrospectively the 
baseline characteristics of patients presenting to our bone health service with wrist fractures. 
In particular, we aimed to explore parameters of bone health including US heel and also 
establish the point prevalence of osteoporosis/osteopenia using standard DXA criteria.Meth-
odsData regarding all patients attending our service with a wrist fracture between 2014-2018 
were obtained from a database at our unit. This included demographic details and clinical 
characteristics at the time of their presentation such as a results of blood tests, DXA with 
Vertebral Fracture Assessment (VFA) and US heel. Statistical analysis were performed using 
SPSSv26.Results1724 patients were identified and 86% were female. Mean age was 67.6+/-
13.1 and BMI 25.6+/-5.0. 15.2% had a history of hip fracture. 36% were taking >5 medica-
tions with about one third (36.1%) on anti-resorptives or anabolic therapy at the time of their 
first visit. The majority (70.2%) had a 25(OH)D level > 50 nmol/l and 17.2% had an eGFR 
<60 ml/min. Based on DXA, 57.9% had osteoporosis and 33.2% osteopenia with 24.7% hav-
ing a vertebral fracture on VFA. US heel correctly identified 57.5% of those with osteoporo-
sis. Those with a diagnosis of osteoporosis were more likely to be female ( p<0.001), older 
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(p<0.001) and have a lower BMI (p<0.001), worse eGFR (p=0.015) and a previous fracture 
(p=0.001). Predictors of osteoporosis treatment included being female (p<0.001) and having 
lower T scores at all sites (p<0.001).ConclusionsAbout 60% of those with wrist fracture had 
osteoporosis which is similar to other international studies. Importantly a high proportion 
had a history of other fractures including hip (15.2%) and vertebral fracture (24.7%) high-
lighting the importance of targeting future fracture prevention in this group. In particular, 
those with wrist fractures who had lower BMD (and thereby at higher risk of future fracture) 
were older, female, had a previous fracture and had lower BMI and worse renal function. US 
of heel did not identify a substantial number who had osteoporosis by DXA criteria.
Disclosures: Maire Rafferty, None
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The reversal-resorption phase is further extended in glucocorticoid-induced 
osteoporosis compared to postmenopausal controls and osteoporotic 
patients *Lisbeth Koch Thomsen1, Majken I Kejser1, Line L Sørensen1, Pia R 
Jensen2, Ellen-Margrethe Hauge3, Jens Bollerslev4, Lene W T Boel5, Jean-Marie 
Delaissé1, Christina M Andreasen1, Thomas L Andersen1. 1Clinical Cell Biology, 
Department of Clinical Pathology, Odense University Hospital & Research 
Unit of Pathology, Department of Clinical Research, Department of Molecular 
Medicine, University of Southern Denmark, Denmark, 2Department of Clinical 
Cell Biology (KCB), Vejle Hospital, IRS, University of Southern Denmark, 
Denmark, 3Department of Rheumatology, Aarhus University Hospital, Denmark, 
4Section of Specialized Endocrinology, Medical Clinic B, Oslo University 
Hospital, Norway, 5Faculty of Medicine, University of Oslo, Norway
Studies have shown an age-induced increased cortical porosity due to an accumulation 
of eroded type 2 pores (remodeling of existing pores) reflecting an extended reversal-re-
sorption phase. The present study addresses the histomorphometric changes in cortical bone 
remodeling within postmenopausal osteoporosis (PMO) and glucocorticoid-induced osteo-
porosis (GIO) compared to controls.In this study we analysed 7-µm-thick Goldner-Masson 
trichrome stained sections from transiliac bone biopsies from i) postmenopausal women 
with GIO (n=19, age 71+/-5 years), ii) women with PMO, but no prior glucocorticoid treat-
ment (n=17, age 71+/-6 years), and iii) postmenopausal women with no prior osteoporosis 
diagnosis (controls, n=21, age 71+/-7 years).We found statistically significantly thinner cor-
tices (~40%) in both GIO and PMO relative to controls (p<0.001). Only in controls cortical 
thickness decreased with age (rp=-0.49, p<0.05, -0.02% per year), while GIO and PMO 
showed no significant age correlation. In the remaining cortices, PMO had a borderline sig-
nificantly decreased cortical porosity compared to controls (p=0.054) and GIO (p=0.066). 
In all three groups the cortical porosity correlated with mean pore diameter (GIO: rp=0.88, 
p<0.0001, PMO: rp=0.93, p<0.0001, controls: rp=0.54, p<0.05), but not pore density. The 
percentage of cortical porosity reflecting non-quiescent pores was high in all three groups, 
but even higher in PMO (88.2%, p=0.051) and GIO (89.2%, p<0.05) compared to controls 
(79.5%). Most of the porosity from non-quiescent pores was due to a higher prevalence of 
eroded pores. Especially in GIO, a significant higher percentage of the porosity is reflecting 
eroded pores compared to PMO (p<0.05) and controls (p<0.01). On the other hand, GIO had 
a significantly lower percentage of porosity reflecting eroded-formative pores than in PMO 
(p<0.05). Moreover, the pore diameter of quiescent osteons was lower in PMO (p<0.001) 
and GIO (p=0.053) compared to controls, suggesting an improved BMU balance. Interest-
ingly, none of the investigated parameters in GIO showed a significant correlation with dos-
age or treatment-time, possibly due to the late stage in GC-treatment at biopsy collection (6.0 
+/- 5.1 years).In conclusion, GIO and PMO have a very pronounced cortical thinning, and 
the cortical porosity of the remaining cortices reflects cortical remodelling with an extended 
reversal-resorption phase in all groups, but especially in GIO – not a negative BMU balance.
Disclosures: Lisbeth Koch Thomsen, None
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External Validation of FREM in 74,828 Patients from Manitoba, Canada: 
A Registry-Based Cohort Study. *William Leslie1, Sören Möller2, Michael 
Skjødt3, Lin Yan1, Bo Abrahamsen2, Lisa Lix1, Eugene McCloskey4, Helena 
Johansson4, Nicholas Harvey5, John Kanis4, Katrine Rubin2. 1University of 
Manitoba, Canada, 2University of Southern Denmark and Odense University 
Hospital, Denmark, 3Holbæk Hospita, Denmark, 4University of Sheffield, United 
Kingdom, 5University of Southampton, United Kingdom
BACKGROUND: FREM is a tool developed from Danish public health registers (hos-
pital diagnoses) to identify individuals over age 45 years at high imminent risk of major 
osteoporotic fractures (MOF) and hip fracture (HF). The tool was internally validated within 
the Danish population, but generalizability to other populations and robustness with respect 
to non-hospital data sources has not been reported.OBJECTIVE: To examine the ability 
of FREM to identify individuals at high imminent fracture risk in women and men from 
Manitoba, Canada.METHODS: Using the population-based Manitoba Bone Mineral Den-
sity (BMD) Program registry, we identified women and men age 45 years or older under-
going baseline BMD assessment with 2 years of follow up data (1996-2016). From linked 
population-based data sources we constructed FREM scores using up to 10 years of prior 
healthcare information (full 10 years available in >93% of the population). Scores were 
based upon hospitalization diagnoses alone (FREM-H), physician claims diagnoses alone 
(FREM-P) or both sources (FREM-HP). We identified subsequent incident MOF and HF 
over 1- and 2-years, and assessed risk stratification (area under the curve, AUC) and calibra-
tion (observed vs predicted for 1-year outcomes). We used age alone as a minimum lower 
bound comparator and FRAX® with BMD as the optimal upper bound comparator. All anal-
yses were sex-stratified.RESULTS: The study population comprised 74,828 subjects (67,930 
women, mean age 65.1 years; 6,898 men, mean age 67.4 years. Over the 2 years of obser-
vation there were 1,612 incident MOF and 299 incident HF. The TABLE shows significant 
fracture risk stratification for all FREM scores, with performance better than age alone but 
still below that from FRAX® with BMD. The inclusion of physician claims data (FREM-HP 
and FREM-P) gave slightly better performance than hospitalization data alone (FREM-H). 
Overall calibration for 1-year MOF prediction was reasonable (observed/predicted ratios 
FREM-HP 0.88, FREM-H 1.09, FREM-P 0.93) but HF prediction was underestimated (ob-
served/predicted ratios FREM-HP 0.36, FREM-H 0.48, FREM-P 0.39).CONCLUSIONS: 
The FREM algorithm showed significant fracture risk stratification when applied to an in-
dependent clinical population from Manitoba, Canada. Physician claims data enhanced the 
performance of FREM in this population. Calibration for MOF prediction was good but HF 
risk was systematically underestimated indicating the need for recalibration.
Disclosures: William Leslie, None
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Phenotypic cluster analysis of HR-pQCT parameters for assessment of 
fragility fracture risk *Danielle Whittier1, Elizabeth Samelson2, Marian 
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Sundeep Khosla6, Serge Ferrari3, Mary Bouxsein7, Doug Kiel2, Steven Boyd1. 
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2Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical 
School, United States, 3Division of Bone Diseases, Geneva University Hospitals 
and Faculty of Medicine, University of Geneva, Switzerland, 4INSERM 
UMR1033, Université de Lyon, Hôpital Edouard Herriot, France, 5Department 
of Medicine, McGill University and McGill University Health Centre, Canada, 
6Mayo Clinic College of Medicine and Science, United States, 7Department of 
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Purpose: Previous studies have found that HR-pQCT measures provide additive 
predictive power to DXA for evaluating fracture risk. However, improvement is limited, 
and distinguishing fracture risk remains a challenge. There are reoccurring patterns of mi-
croarchitectural features that appear in a population, but are not explicitly captured with 
individual HR-pQCT measures. Unsupervised machine learning is capable of identifying 
clusters in complex data, and when applied to HR-pQCT imaging, it may provide insight 
into bone phenotypes. This study applies machine learning to HR-pQCT to identify bone 
“phenotypes” in the population and determines the associated fracture risk.Methods: A total 
of 5,780 individuals (71% women, mean age of 68 +/- 9 years) from the Bone Microar-
chitecture International Consortium (BoMIC) across 7 cohorts were included. Participants 
had HR-pQCT (XtremeCT, Scanco Medical AG) scans of the distal radius and tibia, and 
were followed for incident major osteoporotic fractures (wrist, hip, spine, humerus) over an 
average 4.7 +/- 2.4  years. Parameters used for cluster analysis included total, cortical and 
trabecular BMD; cortical and trabecular microarchitecture; and estimated failure load, from 
the tibia and radius. Clusters were identified separately for each sex using hierarchical ag-
glomerative clustering. Model tuning parameters and number of clusters were chosen from 
dendrogram diagrams and optimizing for the silhouette coefficient. Hazard ratios (HRs) for 
association between cluster and fracture were estimated using Cox models, adjusted for age 
and cohort.Results: We identified 3 female and 2 male clusters. Female clusters revealed 
unique phenotypes that we designated as “healthy bone”, “osteoporotic trabecular bone”, 
and “osteoporotic cortical bone”. The osteoporotic clusters had significantly higher fracture 
risk relative to the healthy cluster; HR of 2.03 (95% CI: 1.40, 2.93) and 3.19 (2.05, 4.96) for 
osteoporotic trabecular and cortical clusters, respectively. One male cluster had worse HR-
pQCT measures overall and significantly higher fracture risk relative to the other healthier 
male cluster; HR of 2.91 (1.51, 5.59).Conclusion: We identified unique bone phenotypes in a 
large prospective multi-center study, and demonstrated relevance to  fracture risk. Grouping 
the population into bone phenotypes using cluster analysis is a novel method that may be 
more effective than using individual HR-pQCT measures for assessing fracture risk.
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Biochemical Markers of Bone Turnover in Postmenopausal Women with 
and without Atypical Femur Fracture Following Long-term Bisphosphonate 
Therapy: A Nested Case-Controlled Study *Ruban Dhaliwal1, Bernard Cook2, 
Elizabeth Warner2, Shijing Qiu2, Sudhaker Rao2. 1Division of Endocrinology, 
State University of New York Upsate Medical University, United States, 2Henry 
Ford Health System, United States
Purpose: Atypical femur fracture (AFF), a rare but serious complication of long-term 
bisphosphonate (BP) therapy, is considered to be a consequence of severe suppression of 
bone turnover thereby compromising bone biomechanical properties.Methods: We com-
pared serum bone formation markers [osteocalcin (OC) and N-terminal propeptide (PINP)] 
and bone resorption marker, C-terminal telopeptide of type 1 collagen (CTX) in a nested 
case control, age-, sex- and race matched postmenopausal women on long term BP therapy: 
17 non-AFF and 17 with AFF.Results: The Mean age was 67.2 +/- 7.4 years in non-AFF 
group compared to 67.5 +/- 7.7, p > 0.05). Mean duration of BP use was 7.3 +/- 4.7 years in 
non-AFF group compared to 11.1 +/- 5.0 (p < 0.05). The mean level of serum PINP was 31.6 
+/- 19.8 pg/L in the non-AFF group and 64.2 +/- 48.5 pg/L in the AFF group (p=0.015); se-
rum CTX was 257.5 +/- 192.7 ng/L vs 265.8 +/- 137.3 ng/L; and serum OC was 15.4 +/- 6.6 
vs 16.2 +/- 7.2 respectively. There were no between group differences in CTX or OC.Con-
clusion: Our preliminary data suggest no differences in circulating levels of bone turnover 
markers (BTMs) between AFF and non-AFF postmenopausal women on long term BP ther-
apy. However, despite a major fracture (AFF) there was no expected increase in BTMs, 
implying that bone turnover might have been much lower in AFF patients before the fracture 
than in non-AFF patients. Additionally, the lack of difference between groups may be related 
to the duration of BP therapy and baseline levels of BTMs prior to BP therapy, which we 
did not have. Further studies in larger number of patients with and without AFF are needed 
to fully understand the role of BTMs in monitoring BP therapy and for surveillance of AFF.
Disclosures: Ruban Dhaliwal, None
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A novel non-ionizing technology for bone densitometry and fracture risk 
prediction *Francesco Conversano1, Delia Ciardo1, Fiorella Lombardi1, Paola 
Pisani1, Sergio Casciaro1. 1National Research Council, Institute of Clinical 
Physiology, Italy
Purpose The aim is to present the available data concerning a novel non-ionizing ap-
plication in the context of osteoporosis diagnosis, fracture risk prediction and bone strength 
assessment, named Radiofrequency Echographic Multi-Spectrometry (REMS) technology. 
Methods The available literature, including full papers, reviews and abstracts about REMS 
technology published before May 25th 2020 has been reviewed. Results REMS novelty 
relies on a non-ionizing approach, based on the automatic processing of the raw unfiltered 
signals obtained by an ultrasound scan of reference sites, i.e. femoral neck and lumbar spine 
[1]. It has been clinically validated through the comparison of the bone mineral density 
(BMD) and T-score values calculated by REMS with the corresponding dual X-ray absorpti-
ometry (DXA) ones. This study, involving over 1900 women, demonstrated the high accura-
cy, sensibility and specificity in the identification of osteoporotic/non-osteoporotic patients 
as well as high repeatability and reproducibility of REMS [1]. A multicenter clinical study 
on over 1300 patients has shown the ability of T-score values calculated by REMS to predict 
incident fragility fractures, with comparable performance to DXA in case of femoral neck 
analysis and superior than DXA in case of lumbar spine [2]. Other studies have shown that 
REMS is able to evaluate BMD with higher accuracy than DXA in particular conditions, i.e. 
patients with arthrosis, vertebral collapses, vertebroplasty, presence of artifacts, etc. [3,4]. 
Recently, this technology has been object of a consensus paper by the European Society 
for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal 
Diseases (ESCEO), that underlined the validity of REMS for osteoporosis diagnosis and 
fracture risk prediction, in view of an improved management for osteoporotic patients [5]. 
Conclusion REMS allows to overcome the main drawbacks of DXA, measuring the BMD 
value and giving insight of the bone micro-architecture using a non-ionizing approach. The 
demonstrated performance allows for the application of REMS in short-term monitoring, 
widespread access to early diagnosis and evaluation in specific populations of patients, such 
as pregnant women and paediatrics. References1. Osteoporos Int 2018;30:391–402 2. Bone 
2020 May;134:115297 3. Exp Ther Med 2019;18(3):1661-68 4. Abstract accepted for oral 
presentation at ISCD 2020 Annual Meeting 5. Aging Clin Exp Res 2019;31(10):1375–89
Disclosures: Francesco Conversano, None
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Visceral Fat Metabolic Activity Evaluated by 18F-FDG PET/CT Predicts 
Osteoporosis in Healthy Postmenopausal Korean Women *Kisoo Pahk1, 
Yeongkeun Kwon1, Sungsoo Park1, Sungeun Kim1. 1Korea University Anam 
Hospital, Republic of Korea
Purpose: Traditionally, obesity is believed to be protective against osteoporosis. How-
ever, recent accumulating evidences suggest that visceral obesity increases the risk of osteo-
porosis and obesity-driven dysfunctional metabolic activity in visceral adipose tissue (VAT) 
is considered as a possible underlying mechanism for the development of obesity-related 
osteoporosis. 18F-fluorodeoxyglucose positron emission tomography/computed tomogra-
phy (18F-FDG PET/CT) is an established method to assess the degree of VAT metabolic 
activity. We aimed to investigate the predictive role of VAT metabolic activity evaluated by 
18F-FDG PET/CT for osteoporosis in healthy postmenopausal Korean women.Materials 
and methods: A total of 115 postmenopausal women who underwent routine health check-up 
between January 2016 and December 2018 were enrolled in this study, retrospectively. They 
all underwent dual-energy X-ray absorptiometry and 18F-FDG PET/CT. Osteoporosis was 
defined as bone mineral density (BMD) T-score <= -2.5 at either lumbar spine or femoral 
neck. Metabolic activity of VAT was defined as the maximum standardized uptake value 
(SUVmax) of VAT divided by the SUVmax of subcutaneous adipose tissue (V/S ratio).Re-
sults: The participants with osteoporosis showed significantly higher V/S ratio than the par-
ticipants without osteoporosis. V/S ratio of 1.33 was proposed as an optimal cut-off value for 
predicting osteoporosis (sensitivity; 93%, specificity; 43.1%, area under the curve; 0.716, p 
< 0.001). Furthermore, V/S ratio was significantly associated with osteoporosis in postmeno-
pausal woman by uni-and multivariate analyses. Interestingly, V/S ratio showed significant 
positive correlation with high sensitivity C-reactive protein, which is a surrogate marker of 
systemic inflammatory condition.Conclusions: VAT metabolic activity as measured by V/S 
ratio predicts osteoporosis in healthy postmenopausal Korean women.
Disclosures: Kisoo Pahk, None
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Bone Material Properties are Related to Accumulation of Advanced Glycation 
Endproducts whereas Cortical Porosity is Related to Microvascular Disease 
in Type 2 Diabetes Mellitus Patients *Parinya Samakkarnthai1, Jad Sfeir1, 
Elizabeth J. Atkinson1, Sara J. Achenbach1, Paul W. Wennberg1, Peter J. Dyck1, 
Amanda J. Tweed1, Tammie L. Volkman1, Shreyasee Amin1, Joshua N. Farr1, 
Adrian Vella1, Matthew T. Drake1, Sundeep Khosla1. 1Mayo Clinic, United States
Reduced bone material strength index (BMSi) and increased cortical porosity (CtPo) 
have emerged as potentially contributing to fragility fracture risk in type 2 diabetes melli-
tus (T2DM), as these patients generally have normal DXA BMD and preserved trabecular 
bone microarchitecture. However, data are conflicting regarding whether BMSi or CtPo are 
consistently altered in T2DM. Thus, we sought to identify determinants of BMSi and CtPo 
in T2DM by relating them to conventional diabetic complications, thereby potentially iden-
tifying subsets of T2DM patients with reduced BMSi or increased CtPo. We recruited an 
age-stratified, random sample of 171 T2DM patients (75 postmenopausal women and 96 
men >= 50 yrs) and age-matched controls (63 women and 45 men) who underwent extensive 
phenotyping: BMSi using in vivo microindentation (OsteoProbe®); skin advanced glycation 
endproducts (AGEs) using autofluorescence (AGE Reader®); HRpQCT at the distal radius 
and tibia; and, in the T2DM patients, detailed assessment of diabetic microvascular com-
plications including urine microalbuminuria, retinopathy, neuropathy, and vascular disease 
(ankle brachial index [ABI], and transcutaneous oxygen tension [TcPO2]).  All analyses 
were adjusted for age, sex, and BMI.In this cohort, BMSi did not differ between T2DM 
(mean+/-SEM, 74.8+/-0.8) and control (75.0+/-1.0; p = 0.843) subjects, but AGEs were 
significantly (+17%; p < 0.001) higher in the T2DM patients versus controls. Of note, skin 
AGEs were negatively correlated with BMSi in both T2DM (r= -0.30, p < 0.001) and con-
trol (r= -0.23, p=0.020) subjects. In relating diabetic complications to CtPo, we found that 
204
P-505 ASBMR 2020 Annual Meeting
T2DM patients with clinically significant peripheral vascular disease (TcPO2 <= 40 mm Hg 
on the dorsum of the foot) had significantly higher (+21.0%, p = 0.031) CtPo at the distal 
tibia as compared to controls; in these subjects, CtPo was negatively correlated with TcPO2 
at both the distal tibia (r = -0.39, p = 0.041) and radius (r = -0.41, p = 0.029).Our findings 
thus demonstrate that BMSi is related to AGE accumulation, regardless of diabetes status, 
while CtPo in T2DM is linked to TcPO2, a measure of peripheral microvascular blood flow. 
These data may explain the conflicting findings regarding whether these measures differ be-
tween T2DM and control subjects, as only those T2DM patients with high AGEs may have 
reduced BMSi, whereas only those T2DM patients with significant peripheral microvascular 
disease may have increased CtPo.
Disclosures: Parinya Samakkarnthai, None
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Longitudinal evolution of bone microarchitecture and strength in type 
2 diabetic postmenopausal women with and without history of fragility 
fractures - a 5-year follow-up study using HR-pQCT *Ursula Heilmeier1, 
Gabby B. Joseph2, Pasco Courtney3, Julio Carballido-Gamio4, Nhan Dinh3, 
Soheyla Torabi3, Karin Darakananda3, Jiwon Youm3, Andrew J. Burghardt3, 
Thomas M. Link3, Galateia Kazakia3. 1University of California San Francisco, 
Musculoskeletal Quantitative Imaging Group, United States, 2University of 
California, San Francisco, Musculoskeletal Quantitative Imaging Research 
Group, United States, 3University of California San Francisco, Musculoskeletal 
Quantitative Imaging Research Group, United States, 4Department of Radiology, 
University of Colorado Anschutz Medical Campus, United States
Introduction: Type 2 diabetic (T2D) bone disease is characterized by an increased fra-
gility fracture risk that cross-sectional clinical studies partly attribute to severe deficits in 
cortical bone quality such as a higher cortical porosity. However, the temporal evolution of 
bone microarchitecture, strength and particularly of cortical porosity in diabetic bone disease 
is still unknown. Here, we aimed to prospectively characterize via high resolution peripheral 
quantitative computed tomography (HR-pQCT) the 5-year changes in bone microarchitec-
ture, cortical porosity and strength seen in T2D postmenopausal women with (DMFx, n=12) 
and without history of fragility fractures (DM, n=10) and to compare those to nondiabetic 
fracturefree controls (Co, n=10). Methods: 32 postmenopausal women underwent a baseline 
HR-pQCT scan of the ultradistal tibia and a FU-scan 4-5 years after. Cortical parameters in-
cluding cortical porosity (Ct.Po), pore volume (Ct.Po.V), tissue mineral density (Ct.TMD-an 
inverse marker for subresolution microporosity) and bone strength estimates via µFEA were 
calculated for each timepoint and annualized. GLM were run for intergroup comparisons. 
Results: All 3 groups were similar in age (60+/-1 y) and BMI (27+/-0.8 kg/m2). At baseline, 
DMFx exhibited the highest macroporosity of the 3 groups (71.9% greater Ct.PoV, p=0.02, 
66.3% greater Ct.Po%, p=0.02 than DM), and had a significantly higher cortical micropo-
rosity (inverse Ct.TMD) than DM (p=0.037). Longitudinally, both micro- (inverse Ct.TMD) 
and macroporosity (Ct.Po) increased significantly over time (0.012<p<0.004) in all 3 groups 
and at similar annual rates, while bone strength indices decreased yearly 14x (failure load F) 
and 22x (stiffness K) more in DMFx versus Co (0.017<=p<=0.004) and 4x (F) and 6.7x (K) 
more in DMFx versus DM (0.025<=p<=0.010). Conclusion: Our data suggest that despite 
different baseline levels in cortical porosity, T2D women with and without fractures exhib-
ited long-term porosity increases at a rate similar to non-diabetics. However, the annual loss 
in bone strength was by far strongest in T2D women with history of a fragility fractures. 
This suggests a potentially non-linear course of cortical porosity development in T2D: major 
porosity development may occur rather early in the course of disease, followed by a smaller 
steady annual increase in porosity which in turn can still have a detrimental effect on bone 
strength - depending on the amount of early cortical predamage.
Disclosures: Ursula Heilmeier, None
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Clinical Utility of TBS versus Lumbar DXA at a Single Academic Center 
Osteoporosis Clinic *Sophie Cannon1, Jian Shen1, Reema Patel1, David Wing1, 
Lauren Claravall1, Jeanne Nichols1, Deborah Kado1. 1University of California 
San Diego, United States
Trabecular Bone Score (TBS) is a validated independent tool for analyzing lumbar 
bone microarchitecture and assessing fracture risk, but it is not widely used in U.S. clin-
ical practice. The current gold standard for analyzing bone mass and fracture risk is DXA 
BMD. While each independently predicts fracture, TBS and DXA are not strongly correlated 
with each other (r ~ 0.30).Thus, at a single academic institution, we investigated how DXA 
with TBS testing may add value to the diagnosis and management of patients referred to 
an osteoporosis clinic. Using a convenience sample of the first 121 patients referred for 
TBS testing (5/2016-2/2019), we conducted a cross-sectional analysis of DXA BMD versus 
TBS in association with clinical characteristics of age, sex, BMI, history of fracture at >50 
years, medication use, health behaviors, and chronic medical conditions obtained from the 
electronic medical record.Patients were a mean age of 62.4 (SD = 10.9, range 22-94) and 
had an average BMI of 23.6 kg/m2 (SD = 4.2). One hundred (83%) were female, 103 (85%) 
were Caucasian, 14 (12%) Asian, 3 (2.5%) Hispanic, and one listed Other. Most had been 
prescribed osteoporosis medications (74.4%) and 58 (48%) reported a fracture at age > 50, of 
which 23 (19%) had a spine fracture, and 5 (4%) had a hip fracture. The mean TBS score was 
1.30 (SD = 0.11, range 0.94-1.53). After adjusting for age and BMI, the Spearman Partial 
Correlation Coefficient (r) was 0.23 (p = 0.01) between TBS and lumbar spine BMD.  After 
excluding patients under age 50 (n = 14) and stratifying by history of fracture at age >50, in 
those with a fracture history, r was only 0.22 (p = 0.12) compared to those with no fracture 
history (r = 0.37, p = 0.003) (Figure). The mean TBS score was lower in those with a fracture 
history vs not (1.27 vs. 1.30, p = 0.02), but this difference was no longer significant after 
adjusting for age and BMI (p = 0.20). Lumbar spine DXA values were no different between 
those who did and did not report a fracture (p = 0.35). Of the other clinical measures, there 
were significant correlations between TBS and 24-hour urinary calcium excretion (r = -0.26, 
p = 0.03) and PTH (r = 0.23, p = 0.02), findings not seen with other DXA BMD measures. 
In conclusion, compared to traditional spine DXA, TBS score was more strongly correlated 
with a history of fracture and other fracture risk factors, suggesting that TBS testing adds 
clinical utility in the real-world setting.
Disclosures: Sophie Cannon, None
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Longer Duration of Type 2 Diabetes Mellitus Associated with Poor Bone 
Microarchitecture Assessed by Trabecular Bone Score (TBS) *Mohammed 
Almohaya1, Abdullah Almuqawed1, Alwaleed Alaskar1, Uhoud Almohareb1, 
David Kendler2. 1King Fahad Medical City, Saudi Arabia, 2University of British 
Columbia, Canada
Type 2 diabetes mellitus (T2DM) is associated with increased osteoporotic fractures 
with the greatest fracture risk observed in those with T2DM longer than 10 years. Lumber 
spine areal bone mineral density (LS-BMD) is paradoxically increased compared to non-
diabetics. TBS estimates trabecular microarchitecture, which is an independent predictor 
of fracture in patients with T2DM. Data concerning the effect of T2DM duration on TBS 
is lacking.  We retrospectively reviewed consecutive patients older than 50 years and in 
whom Lumbar Spine Bone Mineral Density (LS-BMD) and TBS data were available at 
a tertiary referral center in Riyadh, Saudi Arabia.  Individuals were categorized as with 
T2DM or without diabetes (no-DM). The T2DM group was subdivided based on duration 
of diabetes to those were diagnosed within 4 years (New-DM), moderate duration between 
4 to 10 years (Mod-DM) and longer duration of more than 10 years (LT-DM). Patients were 
considered to have very poor glycemic control if hemoglobin A1C (HgbA1c) was over 9.5% 
(very poor-control T2DM), poorly-controlled T2DM when HgbA1c was 7.5% to 9.5% and 
well-controlled T2DM when HgbA1c was below 7.5%.  A total of 211 patients were includ-
ed (195 females, 16 males), mean age was 65.4 +/- 9.1years. There were 104 patients diag-
nosed with T2DM (49.2%) of whom 64 patients were LT-DM. LS-BMD was significantly 
higher in T2DM (mean 0.934 g/cm2 in T2DM vs. 0.881 g/cm2 in no-DM; p = 0.01). Mean 
TBS trended lower in T2DM (1.264 in T2DM vs. 1.290 in non-T2DM; p = 0.11). T2DM 
had higher BMI (32.4 vs. 28.8; p <0.001). Within T2DM, age, BMI and prior fractures were 
similar; HgBA1c in LT-DM was higher compared to New-DM (mean +1.65%). TBS was 
significantly lower in subjects with LT- DM compared to New-DM (-0.085, p 0.02) and 
no-DM (-0.056, p 0.01). 78% of LT-DM had TBS < 1.320 (degraded). Poor-control T2DM 
was associated with lower TBS compared to New-DM and no-DM (decreased by average of 
0.007 and 0.092 respectively, both p <0.005). TBS positively correlated with BMD (Pearson 
r= 0.45) but negatively correlated with duration of T2DM (r= -0.14) and HgbA1c (r= -0.26).
Since TBS is a marker for vertebral trabecular architecture, these data indicate that there 
is greater architectural deterioration in individuals with LT-DM and poor control T2DM. 
Such changes are independent of changes in LS-BMD. This may help explain the increased 
fracture risk at higher BMD in T2DM patients and in particular those with longer and poor 
control T2DM. 
Disclosures: Mohammed Almohaya, None
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Comparison of hip structure analysis and 3D-SHAPERTM images in 
post-kidney transplant recipients with denosumab treatment. *Yasumasa 
Yoshino3, Eisuke Tomatsu1, Sahoko Sekiguchi-Ueda1, Megumi Shibata1, 
Takeshi Takayanagi1, Hiroshi Toyama0, Renaud Winzenrieth0, Atsushi Suzuki1, 
Yohei Asada1. 3Department of Endocrinology and Metabolism, Fujita Health 
University, Japan, 1Department of Endocrinology and Metabolism, Fujita Health 
University, Japan, 0Department of Radiology, Fujita Health University, Japan, 
0Galgo Medical S.L. Barcelona, Spain
Background: 3D-SHAPERTM Software generates a 3D QCT model from a patient’s 
hip DXA scan, and measures separately cortical and trabecular bone density. We have previ-
ously reported that 3D-SHAPERTM could give us more precise information in post-kidney 
transplantation (KTx) patients treated with denosmab (Dmab), an anti-RANKL antibody.  In 
this study, we further analyze 2D-DXA image in these patients and compare the change of 
3D bone measurements and hip structure analysis (HSA) data.Methods: Novel KTx patients 
were recruited (n=35, M/F=22/13, age=53.6 +/- 2.3 years). All patients were treated with glu-
cocorticoids (GCs) during the study period. Dmab was administrated every 6 months during 
first year after KTx in 28 cases regardless of BMD at the time of KTx. Among them, 24 cases 
(Dmab-C) stopped Dmab, and 4 cases (Dmab-D) were continuously administered Dmab 
for 3 years. 7 other patients received no anti-osteoporosis medicine during the study period 
(Control). BMD at total femur (TF BMD) was measured using a Discovery A densitometer 
(Hologic, Inc., MA, USA) after KTx, at 6, 12, 24 and 36 months and total femur DXA 
image was analyzed retrospectively using 3D-SHAPERTM software (v2.9, Galgo Medical, 
Spain), and by the parameters of HSA from same DXA images.Results1. 3D-ShaperTM 
analysis: Control showed continuous decline of both cortical surface BMD (Cort sBMD)
(-6.2%) and trabecular volumetric BMD (Tb vBMD) (-15.8%). On the contrary, Dmab-D 
showed the increase of both Cort sBMD (+8.0%) and Tb vBMD (+5.2%).  Dmab-C showed 
transient increase of Cort sBMD at total femur at 12 months and returned to baseline at 36 M 
(+0.4%), while its Tb vBMD decreased (-6.4%).2. HSA: Both Dmab-C and Dmab-D main-
tained baseline levels of CSA, CSMI and Z modules at femoral neck. At intertrochanteric 
region, all parameters showed positive changes in Dmab-D but not in Dmab-C.  Control 
patients showed decrease of all parameters at any site.Discussion:  KTx patients with GCs 
exhibited rapid decrease of BMD. 12 months of Dmab is protective enough to balance with 
GCs negative effect on the cortical bone at femoral neck and intertrochanteric region at 36 
months but does not compensate the trabecular loss linked to GCs.Conclusion: New imaging 
technologies, such as 3D-SHAPERTM, in accordance with HSA, seems to give us more 
precise assessment of bone structure in KTx patients.
Disclosures: Yasumasa Yoshino, None
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Fracture Risk Assessment (FRAX) without BMD and Risk of Major 
Osteoporotic Fractures in Adults with Type 1 Diabetes *Viral Shah1, Anagha 
Champakanath1, Amena KESHAWARZ1, Janet Snell-Bergeon1. 1Barbara Davis 
Center for Diabetes, United States
Purpose: The risk for major osteoporotic fractures (MOF) in people with type 1 diabe-
tes (T1D) is three- to four-fold higher compared to adults without diabetes and cannot be 
explained by DXA-measured bone mineral density (BMD) alone. Fracture risk assessment 
tool (FRAX) underreports fracture probability in patients with type 2 diabetes who are also 
at increased risk for fractures. There are no studies to verify FRAX applicability in T1D 
population and therefore, we aimed to evaluate the predictability of FRAX without BMD 
for MOF risk in a prospective cohort of adults with T1D compared to adults without dia-
betes.Methods:  Participants were enrolled into the Coronary Artery Calcification in Type 1 
Diabetes (CACTI) study between 2000-2002, and were followed prospectively over three 
visits: 3, 6 and 14 years later.  At the 14-year follow-up examination, participants reported 
the age and location of all fractures they had sustained.  FRAX scores were calculated at 
the 6-year examination, using race-specific FRAX tools.  Native Americans and those with 
missing race information but non-Hispanic ethnicity had FRAX scores calculated using the 
Caucasian tool.  Individuals younger than 40 were entered into the FRAX tool with their age 
set to 40, since the calculator does not include younger ages.  New MOF were defined as 
fractures to the hip, forearm, humerus, or spine occurring between the 6- and 14-year visits. 
Risk for MOF was examined using Cox proportional hazards survival analysis.Results:  346 
T1D (mean age 43.3 +/- 9, BMI 26.4 +/- 5, diabetes duration 29.4 +/- 8.6 years, A1c 7.8 
+/- 1.1) and 411 controls (mean age 46.9 +/- 9 years, BMI 26.3 +/- 5 kg/m2, A1c 5.5 +/- 0.4) 
were analyzed in this study. T1D was a significant predictor of new MOF [unadjusted HR 1.8 
(95% CI 1.0-3.3)], even after adjusting for age and sex [HR 2.0 (1.1-3.8), p=0.02]. However, 
T1D was not a significant predictor of new MOF after adjusting for FRAX without BMD 
[HR 1.5 (0.8-2.8), p=0.2] or after adjusted for age, sex and FRAX without BMD [HR 1.6 
(0.8-3.0, p=0.2)] [Figure].  A sensitivity analysis excluding people under 40 years of age 
showed similar results.Conclusion:  FRAX without BMD accurately identified individuals 
at higher risk of MOF in adults with T1D and its clinical use would facilitate therapeutic 
decision-making in this population.
Disclosures: Viral Shah, None
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Pelvic Bone Density is Lower than Proximal Femur Bone Density in 
Postmenopausal Women *Mahshid Mohseni1, Shannon Stum1, Bridgett 
Toennies1, Seth Eisen2, Roberto Civitelli1. 1Divison of Bone and Mineral 
Diseases, Washington University School of Medicine, United States, 2Divison 
Rheumatology, Washington University School of Medicine, United States
 Pelvic fractures represent 7% of all fragility fractures and are commonly (> 50%) 
associated with loss of independence in the elderly. The incidence of pelvic fractures has 
increased significantly over the past 3 decades; however, little is known about the rela-
tionship between bone mineral density (BMD) and pelvic fractures. We conducted a pilot, 
cross-sectional study to establish a method of measuring pelvic BMD and to correlate BMD 
of the pelvis with BMD at other skeletal sites. Postmenopausal women without a history of 
pelvis and hip fragility fractures were enrolled.  Hip, spine, and pelvis DXA scans were ob-
tained using a Hologic DXA machine. Pelvic BMD was calculated using Hologic Research 
Software from 3 areas of the pelvis (R1: public symphysis, R2: inferior pubic ramus, and 
R3: superior pubic ramus), corresponding to common fracture locations.  Pelvis BMD was 
the average of the 3 pelvis sites.  104 postmenopausal women were enrolled in the study. 
Precision error was calculated using the root mean square method, as recommended by In-
ternational Society of Clinical Densitometry.  BMD precision error was 0.011g/cm2 which is 
slightly lower than the precision total hip BMD at our center (0.007 g/cm2). BMD of R1, R2, 
and R3 pelvic areas were measured as 0.44+/-0.15, 0.41+/- 0.15, and 0.62 +/-0.19 g/cm2, 
respectively. Notably, BMD of R3 was significantly higher than the other 2 areas (P<0.001, 
ANOVA). Pelvic BMD (0.49+/-0.14 g/cm2) was significantly lower than BMD of femoral 
neck (0.72+/- 0.16 g/cm2), total proximal femur (0.86+/-17 g/cm2) and spine (0.97+/- 19 g/
cm2) (P <0.001). Pelvic BMD correlated with BMD of proximal femur (R2:0.73), femoral 
neck (R2: 0.51), and spine (R2:0.64). Women with osteoporosis in both spine and hip areas 
had significantly lower BMD of pelvis but osteoporosis at one location (only spine or hip) 
was not associated with lower pelvic BMD. Type 2 DM was associated with increase BMD 
of spine and total hip but not with increased pelvic BMD. In summary, we report a precise 
method of measuring BMD of commonly fractured areas of the pelvis. Pelvis BMD is lower 
than hip, femoral neck, and spine. Bone density of the pelvis correlates most with BMD of 
total proximal femur.  The results of this pilot study can be used for future studies to deter-
mine whether pelvic BMD could help identify patients at risk for pelvic fragility fractures 
better than proximal femur BMD, which may change how osteoporosis is defined based on 
DXA tests.
Disclosures: Mahshid Mohseni, None
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Performance of the Garvan Fracture Risk Calculator in Individuals with 
Diabetes: A Registry-Based Cohort Study. *William Leslie1, Tuan Nguyen2, 
Suzanne Morin3, Lisa Lix1, John Eisman2. 1University of Manitoba, Canada, 
2Garvan Institute of Medical Research, Australia, 3McGill University, Canada
BACKGROUND: The Garvan Fracture Risk Calculator (FRC) is a simple prediction 
model derived from the Australian Dubbo Osteoporosis Study (DOES) cohort. Diabetes in-
creases fracture risk and also falls risk. The Garvan FRC includes prior falls as an input 
variable. Whether the Garvan FRC captures diabetes-associated fracture risk is uncertain.
OBJECTIVE: To evaluate the performance of the Garvan FRC in individuals with versus 
without diabetes.METHODS: Using the population-based Manitoba Bone Mineral Density 
(BMD) registry, we identified women and men age 50-95 years undergoing baseline BMD 
assessment from September 1, 2012 onwards with registry linkage, diagnosed diabetes, and 
self-reported falls in the prior 12 months. 5-year Garvan FRC predictions were generated 
from clinical risk factors (CRFs) without BMD and again with femoral neck BMD. We iden-
tified subsequent non-traumatic incident osteoporotic fractures (OF, any fracture excluding 
craniofacial, hand/foot, ankle) and hip fractures (HF) from population-based healthcare data 
sources to March 31, 2018 (mean observation time of 2.6 years). Overall risk stratification 
was assessed from area under the receiver operating characteristic curve (AUROC). Cox 
regression analysis was performed to examine the effect of diagnosed diabetes on fracture 
outcomes adjusted for Garvan FRC predictions (log-transformed to correct for a skewed 
distribution). All analyses were sex stratified.RESULTS: The study population consisted of 
2,618 women with and 14,064 women without diabetes; 636 men with and 2,201men with-
out diabetes. The Garvan FRC provided significant OF and HF risk stratification in women 
with diabetes, similar to those without diabetes (TABLE). Analyses of OF in men were 
limited by smaller numbers but did not show a significant difference between those with and 
without diabetes (insufficient HF in men for analysis). Cox regression showed that OF risk 
was 23% greater in women with diabetes adjusted for Garvan FRC including BMD (hazard 
ratio 1.23, 95% confidence interval [CI] 1.01-1.49) suggesting that the Garvan FRC slightly 
underestimated risk. An increased point estimate was also seen for diabetes-related HF risk 
in women (hazard ratio 1.37, 95%CI 0.88-2.15) but this was not statistically significant.
CONCLUSIONS: The Garvan FRC shows similar fracture risk stratification in individuals 
with vs without diabetes, but may underestimate this risk.
Disclosures: William Leslie, None
P-512
Non-linear FE is more predictive of femoral fractures in the AGES RS 
cohort than aBMD or linear FE *Ingmar Fleps1, Halldór Pálsson2, Alexander 
Baker1, William Enns-Bray1, Hassan Bahaloo2, Navrag Singh1, William R. 
Tayler1, Stephen J. Ferguson1, Sigurdur Sigurdsson 3, Vilmundur Gudnason3, 
Benedikt Helgason1. 1Institute for Biomechanics, ETH Zürich, Switzerland, 
Switzerland, 2School of Engineering and Natural Sciences, University of Iceland, 
Reykjavik, Iceland, Iceland, 3The Icelandic Heart Association Research Institute, 
Kopavogur, Iceland, Iceland
Hip fractures in the elderly are a major socioeconomic burden. Clinical fracture risk 
assessment based on areal bone mineral density (aBMD) is known to only identify about 
50% of individuals that will later fracture their hip. Finite element models (FEMs) based on 
CT scans are more predictive of ex-vivo measured proximal femoral strength than aBMD. 
However, improved hip fracture risk assessment with FEMs in clinical cohorts using only 
information gathered at baseline has not been demonstrated. Only studies that used data col-
lected post-fracture [1] or with biased cohorts that do not include subjects with normal bone 
T-score [2] have found FEMs to be significantly better at assessing fracture risk than aBMD. 
In this study, we compare the ability of FEMs to classify hip fractures to that of aBMD in 
the AGES Reykjavik Study (RS) cohort.CT-based FEMs were built for 602 subjects (362 
females and 239 males) of the AGES RS. Of these subjects, 201 suffered a hip fracture 
during the subsequent 5-7 year follow up period. Material properties were assigned to the 
FEMs based on CT grey scale values [3]. Each femur was loaded under 12 sideways fall im-
pact alignments (Figure 1). Simulations were performed with linear (FEMsLinear) and with 
non-linear (FEMsNonlin) material properties. Classification of hip fractures was assessed 
with the area under the receiver-operator curve (AUC). Non-parametric bootstrapping was 
used to test for significance and a Benjamini-Hochberg correction procedure for multiple 
hypotheses testing was applied. Squared Spearman’s coefficient of correlation (RS2) was 
used to quantify the variance in ranking for hip fracture classification depending on loading 
alignments.The AUC based on FEMsNonlin was found to be significantly higher than for 
aBMD for all 12 loading conditions (Figure 1). FEMsNonlin were significantly more predic-
tive of hip fractures than FEMsLinear. The rankings based on femoral strength FEMsNonlin 
and FEMsLinear were highly correlated RS2 = 0.76-0.86. Using only baseline information 
from a large clinical cohort, we have shown a significant improvement in AUC for FEM-de-
rived proximal femur strength compared to aBMD. This study adds credibility to the use of 
FEM-based hip fracture risk assessment in clinical settings. These models can be valuable 
for future development of in-silico selection of personalized preventive treatment options.
Quasim et al, Osteoporos Int, 27:2815-2822, 2016.Sarvi et al, J Biomech, 88:64-71, 2019. 
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Biomechanical CT predicts vertebral stiffness in a cohort of Chinese 
cadavers *Wentian Feng1, Yi Wei2, Zuchang Li0, Haisheng Yang1. 1Department 
of Biomedical Engineering, Beijing University of Technology, China, China, 
2Beijing Jishuitan Hospital, China, China, 0Beijing Jishuitan Hospital, China, 
China
Introduction: Osteoporotic spine fracture is a global issue affecting a great percentage of 
elderly population, and it is particularly serious in China which has the largest aging popula-
tion and the fastest speed of aging. Accurate fracture risk prediction is the key for preventing 
osteoporotic vertebral fractures. Currently, bone mineral density (BMD) measurement based 
on dual-energy X-ray absorptiometry (DXA) is the clinical standard for vertebral strength 
(or related fracture risk) assessment [1]. While BMD works well for the hip at fracture risk 
prediction, it is far less successful for the spine. The biomechanical CT (i.e. QCT-based 
finite element (FE) analysis), which measures facture-related mechanical characteristics of 
the vertebra, has shown improved results in predicting vertebral fracture risk over BMD 
[2]. However, there is little evidence on its application in Chinese population. Thisstudy 
was motivated to develop a QCT-FE model to predict the vertebral stiffness for a cohort 
of Chinese cadavers and evaluate the accuracy of the FE predictions by comparing with 
mechanical testing results.Methods: QCT scans were taken for 13 vertebral bodies excised 
from 6 cadavers (T10–L4; age: 72-98 years; Male=4, Female=2). BMD of each vertebra was 
measured from the QCT scans. Each vertebral specimen was tested in compression until fail-
ure. The stiffness and strength of the vertebrae were measured from the load-displacement 
curves. FE models were created with voxel-based hexahedron elements and assigned with 
BMD-based heterogeneous material properties. Linear elastic FE analyses were performed.
Results: Results showed high correlations (R²=0.83, p<0.05) between FEA-predicted and 
experimentally measured stiffness values. The correlation between BMD and the measured 
stiffness was sightly lower, (R²=0.76, p<0.05). The correlation between FEA-predicted stiff-
ness and experimentally measured strength (R²=0.52) was also stronger than that between 
BMD and experimental strength (R²=0.39).Conclusion: These results show the effectiveness 
of QCT-FEA in assessing mechanical properties of vertebrae in Chinese and could provide 
support for future application of biomechanical CT for risk prediction of osteoporotic spine 
fractures in Chinese population.References: [1] Allaire B T et al., 2018, Osteoporosis In-
ternational. [2] Keaveny T M et al., 2020, Osteoporosis International.Acknowledgement: 
BJNSF (7202003), NSFC (11702008).
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Defining incident vertebral compression fractures: comparison of three CT-
derived and DXA-derived morphometric approaches *WING P. CHAN1, 
Ai-Ling Hsu1. 1Department of Radiology, Wan Fang Hospital, Taipei Medical 
University, Taiwan, Province of China
Defining incident vertebral compression fractures: comparison of three CT-derived and 
DXA-derived morphometric approaches*Wing P. Chan and Ai-Ling Hsu, Department of 
Radiology, Wan Fang Hospital, Taipei Medical University, Taiwan.Background: We hypoth-
esized that the lowest parts of vertebral body heights cannot be obtained by two- dimensional 
vertebral fracture assessment (VFA) images from dual-energy X-ray absorptiometry (DXA) 
scans. The aim of this study was to assess the discrepancies between DXA-derived and series 
of thin-cut sagittal CT-derived images in measuring and classifying vertebral compression 
fractures using Genant’s grade.Methods: We recruited 35 patients aged over 50 years (13 
men, mean age 71.2+/-10.8; 22 women, 72.7+/-9.4) who had routine CT including lumbar 
spine and DXA scans. Patients who received spinal surgery or had metallic implants or sco-
liosis were excluded. A CT radiological technologist reformatted axial images into mid-sag-
ittal views with a slice thickness of 2.50 mm, resulting in 235 sagittal reformatted slices of 
the vertebral columns. A radiologist with 28 years of experience in spine imaging manually 
marked 6 points on vertebral inner square corner (excluding cortical bone) of each mid-sagit-
tal reformatted CT image, and the Genant’s grade were automatically measured and calculat-
ed. We compared the “consistent / inconsistent” ratios of the CT-derived and DXA-derived 
morphometric approaches for each vertebral body. To classify each vertebral fracture grade, 
the CT scan of each patient was categorized by 3 methods: 1) Classical Method: Select the 
mildest grade from a series of images on a CT scan; 2) Consensus Method: Select the most 
prevalent grade from a series of images on a CT scan; and 3) Global Search Method: Select 
the most severe grade from a series of images on a CT scan.Results: In total, 165 vertebrae 
(T12 to L4) were analyzed. There was no statistically significant difference between the re-
sults of the DXA method and those of the CT-derived Classical Method (p = 0.069), but the 
DXA results were different from those of the other two CT-derived methods (p <0.001). The 
classification of compression fractures of Genant’s grades 0, 1, 2, and 3 were75.8%, 6.1%, 
9.1%, and 9.1%, respectively, for DXA; 69.1%, 7.9%, 11.5%, and 11.5%, respectively, for 
the CT-derived Classical Method; 44.2%, 21.8%, 17.0%, and 17.0%,respectively, for the 
CT-derived Consensus Method; and 22.4%, 26.7%, 29.1%, and 21.8%, respectively, for the 
CT-derived Global Search Method.Conclusion: The DXA method was unable to capture the 
lowest parts of vertebral body heights as defined by series of thin-cut sagittal CT-derived im-
ages, thereby underestimating the severity of vertebral compression fractures.Disclosures: 
The authors declare that they have no competing interest.
Disclosures: WING P. CHAN, None
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Development of Spine Radiography-Based Fracture Prediction Model 
Using Convolutional Neural Network *Sung Hye Kong1, Jung Hee Kim1, Jae 
Won Lee2, Byeong Uk Bae2, Jin Kyeong Sung2, Kyu Hwan Jung2, Chan Soo 
Shin3. 1Department of Internal Medicine, Seoul National University College of 
Medicine, Republic of Korea, 2Vuno Inc, Republic of Korea, 3Seoul National 
University College of Medicine, Republic of Korea
Traditionally, bone mineral density has been used to define osteoporosis and to predict 
the risk of osteoporotic fractures. Deep-learning techniques from images have been rapidly 
developing, which may give us a novel insight into the bone quality, along with density. 
Therefore, we aimed to develop a spine radiography-based fracture prediction model using 
deep-learning methods. From 2012 to 2019 at Seoul National University Hospital, 2450 
participants aged 50-75 years who had at least 2 lumbosacral radiographs without fracture 
at the baseline were included. Among them, 742 participants with radiographs inappropriate 
for the analysis and 113 followed up for < 6 months were excluded, which leaves 1595 par-
ticipants in the final analyses. Positive cases were defined as participants who developed os-
teoporotic fractures during follow-up, and negative cases as those who did not. Two models 
using a convolutional neural network (CNN) and one model using naïve-Bayes were trained 
using the baseline radiographs, to predict the occurrence of osteoporotic fracture. The first 
CNN model used a key-point detection network to extract a region of interest of L1-5 verte-
bral bodies, which gives a bounding box of the whole lumbar spine. The second CNN model 
used segmented areas of each vertebral body to minimize the effect of confounders, such as 
aortic calcification or bowel gas. A naïve-Bayes model was trained using the information of 
age and sex of the participants. The performance was evaluated using the area under the re-
ceiver operating curves (AUCs) with 5-fold cross-validation. In a total of 1595 participants, 
1188 were women, and the mean age was 60.5 years. The mean follow-up duration was 
40.7 months, and there were 120 positive cases. The AUCs were 0.72+/-0.02, 0.80+/-0.03, 
and 0.72+/-0.02, and the sensitivities were 0.61, 0.74, and 0.65 in the first, second model of 
CNN, and the naïve-Bayes model, respectively. The specificities were 0.77 in all models. 
The CNN model using segmented images showed the highest AUC and sensitivity among 
models (both p<0.001). In conclusion, the CNN model with segmented vertebral images out-
performed the CNN model with non-segmented images and naïve-Bayes model in predicting 
osteoporotic fractures using baseline lumbosacral radiographs.
Disclosures: Sung Hye Kong, None
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Classification of Motion Artifact Severity in High-Resolution Peripheral 
Quantitative Computed Tomography Using Deep Convolutional Neural 
Network *Jin Long1, Jessica Whalen1, Derek Yang1, Ariana Strickland1, Kyla 
Kent1, Saeed Seyyedi2, Mary Leonard1, Andrew Burghardt3. 1Department of 
Pediatrics, Stanford University, Stanford, CA, United States, 2Department of 
Radiology, Stanford University, Stanford, CA, United States, 3Department of 
Radiology & Biomedical Imaging, University of California San Francisco, San 
Francisco, CA, USA, United States
In vivo bone imaging techniques, including conventional and high-resolution peripheral 
quantitative computed tomography (HR-pQCT), are susceptible to motion artifacts, partic-
ularly in fidgety pediatric populations. While some attempts have been made to implement 
motion correction in lower resolution peripheral cone beam CT, these techniques have not 
been adapted to HR-pQCT specifically. Visual inspection is widely used to subjectively cat-
egorize scans into 5 grades of motion artifact severity, from completely acceptable (1) to 
completely unusable (5), following the scaling method by Pialat et al. The scoring scale has 
been adopted in recent consensus guidelines; however, it is time-consuming, highly sub-
jective and operator dependent. We report an innovative deep learning method to classify 
motion artifact severity in HR-pQCT scans of the metaphyseal and diaphyseal tibia and 
radius obtained in children and adolescents. A total of 10,000 2D images were randomly 
sampled from 5627 3D scans (168 images/scan) performed in 320 participants and random-
ized into training (60%), validation (20%) and testing (20%) datasets. Annotations using 
the standard 5-grade scale were performed by one highly-experienced observer and used as 
the ground truth. To give each motion grade an equal chance for the machine to learn, scans 
with grades 4 and 5 were oversampled from the scan pool to create 5 equally distributed 
samples. Multiple unique images were sampled from each scan. Neural networks are good 
at dealing with this within-scan correlation by processing each input image independently 
(e.g. flipping, distorting and randomly cropping). To avoid the use of correlated data across 
training, validation, and testing datasets, randomization at the scan level was used. The ini-
tial results in 1,000 annotated images demonstrated the best performance for a 161-layer 
DenseNet model that was pretrained on ImageNet and then further trained and tuned on 
our HR-pQCT data. This transfer learning classifier achieved an overall accuracy of 93% 
(kappa=0.94), with high accuracy across motion grades 1 to 3 (grade 1: 85%; grade 2: 78%; 
grade 3: 96%). Notably, the accuracy of the classifier was 100% for the grades 4 and 5, which 
are conventionally excluded from analyses. Deep convolutional neural networks can provide 
rapid automated classification of motion artifact severity, representing an important tool for 
operational efficiency and quality in multi-center clinical studies.
Disclosures: Jin Long, None
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Rapid Detection of Vertebral Deformities and Lumbar Scoliosis from Spine 
DXA Scans *Abhinav Suri1, Sisi Tang1, Ashley Terry1, Anjali Gupta1, Iman 
Fathali1, Charis Ma1, Abigail Manion1, Anita Kalluri1, Winnie Xu1, Anna Feng1, 
Elyse Migdal1, Eric Ji1, Christian Fernandes1, Uchechi Nwogwugwu1, Soomin 
Lee1, Vikram Balasubramanian1, Kelly Moyer1, Devna Chopra1, Albert Chen1, 
Elijah Li1, Chamith Rajapakse1. 1University of Pennsylvania, United States
PURPOSELumbar spinal deformities are highly prevalent among older patients with 
osteoporosis and other degenerative bone diseases. Furthermore, these deformities cause a 
curvature of the spine (scoliosis), leading to a higher risk of fracture and pain in patients. 
Currently, DXA scans report vertebrae specific BMD scores; however, they do not report 
vertebral deformities or presence of lumbar curvature. We report the development of a com-
puter vision algorithm for rapid automated morphometric measurement of Spine DXA scans.
METHODSSpine DXA reports (1282 subjects, age 64.5+/-10.7yrs, female) were processed 
to isolate the relevant DXA image. From the DXA scan, lines were detected using Hough 
Line transforms (similar lines were consolidated using K-Means clustering on endpoints) 
and intersections were found between reconstructed lines and the contour of the spine out-
line (Fig 1). From these intersection points, corner points for each vertebral body (n=6410) 
were isolated, allowing for the measurement of vertebral body lateral heights (right lateral 
vs left lateral height) and Cobb angles in the coronal plane. The algorithm was evaluated 
using a key-point error distance metric that measures distance of predicted corner points to 
manually marked corner points of vertebral bodies.RESULTSThe algorithm was able to de-
tect relevant corner points rapidly and with high accuracy. On a set of 1000 scans, each scan 
was processed in an average of 0.035 +/- 0.012 seconds. Average key-point error distance 
was 0.13mm when evaluated on a testing set of 100 manually annotated scans (age 64.3+/-
5.3yrs, female).CONCLUSIONSThe computer vision algorithm was able to determine mor-
phometric measurements for detecting vertebral body corner points with high accuracy on 
DXA images. Additionally, it was able to do so quickly. These corner points can be used to 
calculate vertebral deformities and Cobb angles for scoliosis grading. Thus, we were able to 
show this algorithm is able to automatically extract measurements for rapid quantification of 
vertebral bone health and potential risk of fracture. This automated approach could simplify 
the screening, detection of changes, further cross-sectional imaging workup, and surgical 
planning in patients with vertebral deformities and fractures by reducing the burden on ra-
diologists who have to do these measurements manually.
Disclosures: Abhinav Suri, None
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Interval Bone Mineral Density Loss in Osteopenic Patients: A Limitation 
of FRAX *Charles Intenzo1, Aishwarya Gulati1, John Bilezikian2. 1Thomas 
Jefferson Univ., United States, 2Columbia Univ., United States
Background:Bone mineral density (BMD), considered to be a gold standard for the 
diagnosis of osteoporosis, is most commonly measured by dual-energy x-ray absorptiometry 
(DXA).  For patients with osteopenia, the Fracture Risk Assessment Tool (FRAX) incor-
porates acknowledged other risk factors to assess overall fracture risk, and aid in patient 
management. If the FRAX score in in an osteopenic patient predicts a 10-year fracture risk of 
>20% for a major osteoporotic fracture, or >3% for a hip fracture, pharmacologic therapy is 
indicated.. However, FRAX does not include an assessment of a significant decline in BMD 
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over time.Methods:Our goal was to determine the frequency with which BMD declines in 
patients  with osteopenia by DXA, but whose FRAX score coninues to be below treatment 
thresholds.Results:Over a 2-year interval, 1,112 (15.59%) of 7,133 patients with osteopenia 
by DXA experienced a significant decrease in BMD, but had FRAX scores remain in the 
subtherapeutic range.Conclusion:Since a decline in BMD is, by itself, a clinical risk factor, 
FRAX assessment may therefore potentially underestimate true fracture risk if a significant 
decline in BMD is measured.
Disclosures: Charles Intenzo, None
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New technology REMS demonstrated good accuracy for the diagnosis of 
osteoporosis defined by DXA, in Brazilian adult women. *Débora Meira 
Ramos Amorim1, Eliane Naomi Sakane 1, Sérgio Setsuo Maeda1, Marise 
Lazaretti Castro1. 1Federal University of Sao Paulo, Brazil
Background: Dual energy X-ray absorption (DXA) is the standard method used to 
define osteoporosis, according to the criteria created by the World Health Organization in 
1995. However, DXA has some limitations that other new methodologies try to overcome. 
A new technology is the Radiofrequency Echographic Multi Spectrometry(REMS), which 
uses sound waves instead of ionizing radiation, in addition to the advantages of portability 
and lower cost. To better understand the utility of this method, we compared bone mass 
density (BMD) measured using both REMS and DXA in Brazilian women recruited at the 
School-Hospital’s DXA Service in Sao Paulo, Brazil. The short-term intra-operator and in-
ter-operator CV% were also performed. Results: A total of 343 patients were included. Due 
to poor quality on acquisitions, we had to exclude 67 lumbar spines and 63 femoral neck 
from the REMS exams, and 41 lumbar spines and 31 proximal femurs from the DXA exams. 
In addition, 22 exams were excluded for other technical reasons. In the resulting dataset 
(227 spines and 238 femurs) there were high correlations between both methodologies for 
BMD values (r=0,75, p<0.001 for lumbar spine and r=0.78, p<0.001 for femoral neck). 
The comparison between REMS outcomes and DXA showed that the average difference 
in BMD (expressed as bias +/- 1.96 SD) was -0.026 +/- 0.1758 g/cm2 for the spine and 
-0.027 +/- 0.1525 for the femoral neck.The good correlation between the two methods also 
is showed by standard error of the estimate (SEE) of 8.3% for the spine and 10.3% for the 
femur. RMS-CV% was 0.33% for spine and 0.29% for femoral neck. For the diagnosis of 
osteoporosis in women older than 40 years, REMS approach effectively discriminated the 
osteoporotic patients from the non-osteoporotic for both lumbar spine(sensitivity = 84%, 
specificity=94.6%) and femoral neck (sensivitity= 92.6%,specificity 93.5%), by accepting a 
0.3 tolerance on T-score value of “borderline” patients. Evaluating REMS precision by CV-
RMS%,the result was 0.943 for BMD lumbar spine and 1.175 for BMD femoral neck. With 
regard to REMS repeatability by CV-RMS%, it resulted in 0.671 for BMD lumbar spine and 
0,706 for BMD femoral neck. Conclusions: The REMS approach can be used for non-ioniz-
ing osteoporosis diagnosis directly on the lumbar spine and femoral neck with a good level 
of accuracy and precision.
Disclosures: Débora Meira Ramos Amorim, None
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Bone Fragility Parameters do not Fiffer Significantly in Patients with 
Primary and Subsequent Distal Radius Fracture *Jongjin Lee1, Young Ho 
Shin1. 1Department of Orthopedic Surgery, Asan Medical Center, University of 
Ulsan College of Medicine, Republic of Korea
Purpose: The characteristics of patients who experienced subsequent distal radius frac-
ture (DRF) after initial DRF have not been determined. The purpose of this study was to 
investigate the characteristics of patients with subsequent DRF and to compare bone fragil-
ity parameters of patients with primary and subsequent distal DRF.Methods: We compared 
demographic characteristics and bone fragility parameters, including bone mineral density 
(BMD), trabecular bone score (TBS), hip geometry parameters, and bicortical thickness 
(BCT) of the distal radius in 215 patients with primary and 26 with subsequent DRF. To 
reduce bias, patients with subsequent DRF were propensity score matched in a 1:2 manner 
with patients with primary DRF and additional comparison was done.Results: The mean 
time to subsequent DRF after initial DRF was 121.9 mo +/- 85.3 mo (range, 1 to 240 mo). 
Subsequent DRF group was older than primary DRF group, but it was not statistically sig-
nificant (p=0.077). The portion of patients exposed to osteoporosis medications was sig-
nificantly higher in the subsequent DRF group (38.5% vs. 19.1%, p=0.022).Bone fragility 
parameters, including BMDs, TBS, hip geometry parameters and BCT did not differ signifi-
cantly in the two groups. Similar results were observed in comparison between propensity 
score matched primary and subsequent DRF group.Conclusions: Despite patients in the 
subsequent DRF group being older, bone fragility parameters did not differ significantly in 
patients with primary and subsequent DRF. These findings suggest that the occurrence of 
subsequent DRF is due to multiple factors, not to bone fragility alone.
Disclosures: Jongjin Lee, None
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Deep Learning for Rapid High-Resolution Proximal Femur MRI Scans 
*Brandon Jones1, Carlos Osuna1, Srikant Iyer1, Olivia Sandvold1, Nicholas 
Josselyn1, Matthew MacLean1, Gregory Chang2, Walter Witschey1, Hee Kwon 
Song1, Felix Wehrli1, Chamith Rajapakse1. 1University of Pennsylvania, United 
States, 2New York University, United States
Introduction:Hip fractures affect one in six postmenopausal women during their life-
time and cause the greatest mortality and morbidity among fractures, with the one-year 
mortality rate reaching 20%. While existing osteoporotic medications have been shown to 
reduce fracture risk by half, they are not prescribed to everyone who would benefit from 
them. As such, there is a clear need for improved methods for clinical assessment of bone 
quality-both in terms of diagnostic accuracy and cost. In recent years, MRI has shown strong 
potential for quantifying hip fracture risk due to its ability to image both trabecular and cor-
tical microarchitecture in vivo. One of the existing MRI protocol for microstructural imaging 
of the proximal femur involves a 16-minute Spoiled Gradient Recalled Echo (SPGR) se-
quence which is too long to be clinically viable. Therefore, the present abstract investigated 
feasibility of reducing this scan time through the application of deep convolutional neural 
networks (CNNs) for Compressed Sensing.Methods: A Monte Carlo algorithm retrospec-
tively subsampled k-space data in 2D from fully sampled MR images of the proximal femur. 
The subsampled k-space was then naïvely Fourier transformed with zero padding and the 
resultant artefactual image was used as input to the CNN. We employed a 2D U-Net with 
9 layers consisting of 4 feature contracting and 4 feature expanding segments, each with a 
series of convolutions followed by Rectified Linear Unit (ReLU). The network was trained 
for 500 epochs at 5 times acceleration factor (AF), which means only 102 lines of k-space 
frequency encoding was included out of 512 total, but was evaluated for both AF of 3 and 
5. We used a custom loss defined as the sum of the mean squared error (MSE) in image 
space, the MSE between the measured and predicted k-space within the MC mask, and the 
MSE of horizontal gradients.Results: Reconstructed images are shown in Fig 1. The CNN 
removes the majority of artefacts are both acceleration factor (AF) of 3x and 5x. At 5x AF, 
the CNN improved the structural similarity index, normalized root-mean-squared error, and 
peak SNR (p<0.0001 for all).Discussion:The present abstract comprises the first preliminary 
results that CNNs can reconstruct high-resolution bone MRI scans which are sampled below 
the Nyquist criterion. Ongoing work will develop a concurrent model which to interpolate 
missing data in k-space, as well as extend the models to work for 3-D and parallel imaging.
Disclosures: Brandon Jones, None
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Assessment of Gender Differences in Bone Metabolism Using [18F]NaF 
PET/CT in the Spine *Helene Chesnais1, Sylvia Rhodes1, Poul Høilund-
Carlsen2, Abass Alavi1, Chamith Rajapakse1. 1Penn Medicine, United States, 
2Odense University, Denmark
Structural imaging modalities such as DXA are currently used to assess bone quality 
in osteoporosis but may lack the sensitivity to detect changes in metabolic activity. The 
use of [18F]NaF PET/CT is increasing as a marker of bone metabolism. The purpose of 
this study was to analyze gender differences in the lumbar and thoracic spines of healthy 
males and females as measured by [18F]NaF PET/CT. This retrospective study included136 
participants (68 females and 68 males, ages 21-75) that had undergone [18F]NaF PET/CT. 
The operator guided computer software PMOD software (PMOD Technologies LLC, Swit-
zerland) was used to segment individual vertebra, and calculate SUV. Bone metabolism 
of the thoracolumbar spine, lumbar spine and thoracic spine was compared using linear 
regressions with age and BMI in all subjects, then stratified by gender, and by Young (<50) 
and Old (>=50) age categories. In females but not males, bone metabolism was negatively 
correlated with age (r=-0.51, P<.001). In females but not males, bone metabolism was pos-
itively correlated with BMI (r=0.44, P<.001).Bone metabolism was correlated with BMI 
in young and old females, but not young and old males, Figure 1. Bone metabolism as 
measured by SUV demonstrated more consistent trends with age and BMI in females than 
in males. This can inform the analysis of future healthy, mixed-age and mixed-BMI cohorts 
for [18F]NaF PET/CT.
Disclosures: Helene Chesnais, None
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Towards explainable AI: Can Visualizations via Saliency Maps Support 
Understanding a Neural Network’s Decision on 3D CT Vertebral Fracture 
Discrimination? *Eren Bora Yilmaz1, Alexander Oliver Mader2, Tobias Fricke3, 
Jaime A. Peña4, Carsten Meyer5, Claus-Christian Glüer4. 1Department of 
Computer Science, Kiel University, Germany, 2Institute of Computer Science, 
Kiel University of Applied Sciences, Kiel, Germany, Germany, 3Klinik für 
Radiologie und Neuroradiologie des Universitätsklinikums Schleswig-Holstein, 
Campus Kiel, Germany, 4Section Biomedical Imaging, Dept. of Radiology and 
Neuroradiology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, 
Germany, 5Kiel University of Applied Sciences, Institute of Computer Science, 
Kiel, Germany AND Kiel University, Faculty of Engineering, Department of 
Computer Science, Kiel, Germany AND Philips Research, Department of Digital 
Imaging, Hamburg, Germany, Germany
Automated evaluation of vertebral fracture status on computed tomography (CT) scans 
acquired for various purposes (opportunistic CT) may substantially enhance vertebral frac-
ture detection rate. Deep neural networks (NNs) have shown promising performance in a 
number of classification tasks but their black box nature may hinder acceptance by radiol-
ogists and clinicians. We aim: (a) to develop and evaluate a convolutional NN architecture 
for osteoporotic vertebral fracture discrimination based on 3D CT data as part of a pipeline 
localizing (Mader et al., MICCAI 2019) and classifying individual vertebrae with regard to 
their fracture status and (b) to compute saliency maps to visualize areas that majorly influ-
ence the network’s decision. Low-dose CT images of 159 patients (136 female), typically 
T5–L4, from 7 participating centers were annotated with vertebral coordinates and per-ver-
tebra fracture status by a trained radiologist. A total of 132 of 1,943 vertebrae in the dataset 
showed osteoporotic fractures based on the Genant classification method. Experiments were 
conducted using a VGG-like network with 4 convolutional layers and 5.6 million trainable 
parameters. The network was trained in a random four-fold cross-validation setup for the 
task of osteoporotic fracture discrimination, based on 3D image patches containing a single 
vertebra, using the cross-entropy loss (plus additional regularization terms taking into ac-
count the radiologist’s vertebral height gradings). Saliency maps were computed using the 
Grad-Cam and Guided BackProp algorithms. As proposed by Adebayo et al., NIPS 2019, 
the maps were qualitatively compared to those of models with randomly initialized weights 
and those of models trained on random labels to ensure meaningfulness of the maps. After 
training for less than 30 minutes on a high-end GPU the vertebra level models achieved 
areas under the ROC curve (AUC) between 0.966 and 0.999 across different folds. Thus, 
CT-based NN permit highly accurate discrimination of osteoporotic vertebral fracture status 
of individual vertebrae. Saliency maps (see figure) seem to highlight vertebral end plates and 
borders, i.e., fracture-relevant features, but were qualitatively found to depend on the model 
architecture (not shown) and the algorithm used to compute the maps. Thus, more research 
is needed on the calculation and interpretation of saliency maps as a means to visualize the 
complex decision process of a NN.
Disclosures: Eren Bora Yilmaz, None
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Impact of Trabecular Bone Score on Fracture Risk in Postmenopausal 
Women With Type 2 Diabetes Compared to Those Without Type 2 Diabetes 
*Shamsuddin Shaik1, Ibtehal Shamleffer2, M Raihan Azad3, Diann Jones4, Shemra 
Rizzo5, Fiona Cook4. 1Lehigh Valley Health Network, United States, 2LeBauer 
Endocrinology, United States, 3Physicians East Endocrinology, United States, 
4East Carolina University, United States, 5Independent Researcher, United States
BackgroundRecent literature indicates that patients with Type 2 diabetes (T2DM) have 
higher fracture risk despite higher bone mineral density (BMD) than non-diabetic patients 
and that this involves adverse effects of T2DM on bone quality. Trabecular Bone Score 
(TBS) is a noninvasive test of bone quality. Previous studies have found an association with 
T2DM and lower TBS. Our aim was to compare the impact of adding TBS to the calculation 
of 10-year fracture risk (FRAX) in post-menopausal (PM) women with or without T2DM.
MethodsRecords of 1,504 women of age>55 on the same DXA machine within the preced-
ing 10 years were systematically screened. Those with BMD of the femoral neck and at least 
2 valid lumbar vertebrae and lowest T score -2.5 were included. TBS was analyzed on valid 
vertebrae. Information on fracture risk factors and diabetes was found in medical records. 
Patients with GFR <30 ml/min, causes of secondary osteoporosis, or use of drugs affect-
ing bone metabolism were excluded. A validated calculator (www.sheffield.ac.uk/FRAX) 
was used to determine major osteoporotic (MOP) and hip FRAX for each eligible case. Lo-
gistic regression was used to assess the association of T2DM status with having an increased 
FRAX score when including TBS.ResultsThe study included 109 patients with T2DM and 
112 without DM. Significant differences were found in age, BMI, and race between the 
groups. The DM group was 63% African American (AA), with mean age 69 and mean BMI 
33. The non DM group was 66% Caucasian (W), with mean age 67 and mean BMI 31. In un-
adjusted models, inclusion of TBS was more likely to increase MOP FRAX and hip FRAX 
in the T2DM than the non DM group. This finding lost significance after adjustment for age, 
race, and BMI. In the adjusted model, inclusion of TBS was more likely to increase MOP 
FRAX and hip FRAX in AA than W and less likely to increase MOP FRAX and hip FRAX 
with increase in BMI. Inclusion of TBS was less likely to increase hip FRAX with increase 
in age. (see Table)ConclusionThis study does not clarify the impact of TBS on FRAX in 
PM women with osteopenia and T2DM due to age, race, and BMI differences between the 
groups. However, the study does demonstrate that age, race, and BMI significantly influence 
the impact of TBS on FRAX. Since T2DM is prevalent in AA and Hispanic patients, it will 
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be important to consider race in future studies investigating the reasons for the association of 
T2DM with increased fracture risk.
Disclosures: Shamsuddin Shaik, None
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Effects of Risedronate on Trabecular and Cortical Volumetric Bone Density 
of the Hip after Sleeve Gastrectomy: a Pilot Randomized Controlled Trial 
*Katelyn Greene1, Kylie Reed2, Kristen Beavers2, Daniel Beavers1, Adolfo 
Fernandez3, Jamy Ard3, Sarah Wherry4, Ashley Weaver1. 1Wake Forest School 
of Medicine, United States, 2Wake Forest University, United States, 3Wake 
Forest Baptist Health, United States, 4University of Colorado Anschutz Medical 
Campus, United States
Purpose: Bone mineral density (BMD) loss and increased fracture risk following bar-
iatric surgery indicate a need for effective strategies to minimize bone loss, particularly at 
the hip. Bisphosphonates may be effective in mitigating surgical weight loss-associated 
bone loss, which can comprehensively assess bone in each compartment using quantita-
tive computed tomography (QCT).Methods: This 6-month pilot randomized controlled trial 
(NCT03411902) enrolled 24 older sleeve gastrectomy (SG) patients to examine the efficacy 
of 150 mg once monthly risedronate (versus placebo) in the prevention of surgical weight 
loss-associated bone loss. Helical QCT scans of the left hip were performed at baseline 
(prior to SG) and at 6 months post-SG with a bone calibration phantom (Mindways Inc.). 
Trabecular and cortical volumetric BMD (vBMD) of the total hip, femoral neck, and tro-
chanter were measured using QCT Pro v6.1. Group treatment effects were estimated using 
a general linear model adjusted for baseline values of each outcome.Results: Of 24 partic-
ipants randomized, 20 (n=7, risedronate; n=13, placebo) completed baseline QCT testing 
and 17 completed 6-month QCT testing. At baseline, average age was 57+/-7 years, 85% 
were female (65% postmenopausal), and 15% were black. Compared to the placebo group, 
the risedronate group had a higher baseline body mass index (46.6+/-8.0 vs 41.9+/-3.8 kg/
m2) and osteopenia incidence (2 vs 0). No statistically significant differences were observed 
in any vBMD outcomes between treatment groups. However, the directionality of treatment 
effect estimates suggests preserved trabecular vBMD in the risedronate group versus placebo 
at the total hip [mean (SE): -7.3 (5.1) vs -9.3 (3.3) mg/cm3] and femoral neck [3.7 (6.8) vs 
-5.0 (4.4) mg/cm3], but not at the trochanter [-5.5 (2.0) vs -4.5 (1.3) mg/cm3]; (see Figure 
1). Treatment effect estimates suggest a trend in the opposite direction for cortical vBMD, 
with higher losses in the risedronate group vs placebo at the total hip [-5.0 (13.5) vs 21.0 
(8.5) mg/cm3], femoral neck [-109.6 (50.9) vs -15.5 (32.7) mg/cm3], and trochanter [14.7 
(51.5) vs 21.7 (31.7) mg/cm3].Conclusion: Data from this pilot study do not show risedro-
nate treatment significantly affects compartmental vBMD change following SG. However, 
the direction and magnitude of change observed suggest risedronate may minimize short-
term trabecular vBMD loss at the hip and femoral neck, but not necessarily protect against 
cortical vBMD loss.
Disclosures: Katelyn Greene, None
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Towards a Generalized Convolutional Neural Network for Automated 
Identification of Vertebral Compression Fractures: The Manitoba Bone 
Mineral Density Registry *Barret A. Monchka1, Douglas Kimelman1, Lisa M. 
Lix1, William D. Leslie1. 1University of Manitoba, Canada
Background: Automated identification of vertebral compression fractures with accuracy 
comparable to human experts is possible through the use of convolutional neural networks 
(CNNs). Due to technical differences between GE dual-energy (DE) vertebral fracture as-
sessment (VFA) images and Hologic single-energy (SE) VFA scans, CNNs trained on one 
scan mode may not generalize well to another.Aim: To evaluate the ability of CNNs to 
generalize between DE and SE VFA scan modes.Methods: 12,742 VFAs were obtained from 
the Manitoba Bone Mineral Density Program between 2010 and 2017 (GE Lunar Prodigy 
and iDXA). VFAs were classified by expert readers as fracture present vs. absent using 
the modified algorithm-based qualitative (ABQ) method. Scans were randomly divided into 
independent training (60%), validation (10%), and test (30%) sets. Three CNN models were 
constructed by training separately on DE only, SE only, and a composite dataset comprised 
of both SE and DE VFAs. All three trained CNN models were separately evaluated against 
both SE and DE test datasets (6 combinations). Accuracy, sensitivity, specificity, and area 
under the receiver operating characteristic curve (AUC) were used to evaluate predictive 
performance compared with the human reference.Results: Good performance was seen for 
CNNs trained and evaluated on the same scan mode. DE scans used for both training and 
evaluation achieved accuracy 87.5%, sensitivity 87.9%, specificity 87.4%, AUC 0.94. SE 
scans used for both training and evaluation achieved accuracy 87.4%, sensitivity 79.4%, 
specificity 89.0%, AUC 0.91. Conversely, CNNs performed poorly when evaluated on scan 
modes that differed from their training sets (DE-trained model evaluated against SE VFAs 
AUC=0.58; SE-trained model evaluated against DE VFAs AUC=0.58). However, a compos-
ite CNN trained simultaneously on both SE and DE VFAs gave performance comparable to 
DE/DE; and significantly better than SE/SE, DE/SE, and SE/DE, whether evaluated against 
DE VFAs (accuracy=92.3%, sensitivity=82.4%, specificity=94.3%, AUC=0.95) or SE VFAs 
(accuracy=90.6%, sensitivity=82.2%, specificity=92.3%, AUC=0.94).Conclusion: CNNs 
for vertebral fracture identification are highly sensitive to scan mode and do not generalize 
when trained on only one scan mode. Training CNNs on a composite dataset, comprised of 
both DE and SE VFAs, allows CNNs to generalize to both scan modes and improves auto-
mated fracture identification in SE VFA scans.
Disclosures: Barret A. Monchka, None
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Global impact of COVID-19 on osteoporosis management: A retrospective, 
longitudinal descriptive analysis of access to online FRAX fracture risk 
assessments. *Eugene McCloskey1, Nicholas Harvey2, Helena Johansson3, 
Mattias Lorentzon4, Liesbeth Vandenput5, Enwu Liu5, John Kanis3. 1Centre for 
Integrated research in Musculoskeletal Ageing, University of Sheffield, United 
Kingdom, 2MRC Lifecourse Epidemiology Unit, University of Southampton, 
United Kingdom, 3Centre for Metabolic Bone Diseases, University of Sheffield, 
United Kingdom, 4Sahlgrenska Academy, University of Gothenburg, Sweden, 
5Mary McKillop Health Institute, Australian Catholic University, Australia
The COVID-19 pandemic and its management is impacting on the care of patients 
with osteoporosis. We have quantified the international impact by examining changes in the 
usage of online fracture risk assessments before and after the declaration of the COVID-19 
pandemic on March 11th.A retrospective, longitudinal analysis using GoogleAnalytics data 
on daily sessions on the FRAX® fracture risk calculator website from November 2019 to 
April 2020, based on country of origin (IP address location) and a comparison with the same 
period in 2019. The main outcome was change in session number between the months of 
February, March and April 2020. Detailed results are presented for 66 countries compris-
ing 98% of all sessions. During the 3-month period, the FRAX website recorded 460,495 
sessions from 184 countries, with 210,656 sessions recorded in February alone. In March 
and April, the number of sessions fell by 23.1% and 58.3% respectively (Figure). No such 
pattern was observed over the same period in 2019. There were smaller reductions in Asia 
than elsewhere, partly related to earlier and less-marked nadirs in some countries (China, 
Taiwan, Hong Kong, South Korea and Vietnam). In Europe, the majority of countries (24/31, 
77.4%) reduced usage by at least 50% in April. Seven countries showed smaller reductions 
(range -2.85% to -44.1%) including Poland, Slovakia, Czech Republic, Germany, Norway, 
Sweden and Finland. There was no significant relationship between the reduction in FRAX 
usage and measures of disease burden such as deaths per million of the population.This 
study documents a marked impact of the COVID-19 pandemic on the management of oste-
oporosis using a globally applicable assessment. The impact appears unrelated to the burden 
of disease, suggesting that it may relate more to the societal and healthcare measures taken 
to ameliorate the pandemic.
Disclosures: Eugene McCloskey, None
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The correlation between bone mineral density/trabecular bone score 
and body mass index, height, and weight *Jin Hwan Kim1. 1Department of 
Orthopaedics, Ilsan Paik Hospital of Inje University, Republic of Korea
Objectives: This study investigated the correlation between bone mineral density 
(BMD)/trabecular bone score (TBS) and body mass index (BMI), height and weight in Ko-
rean adults.Methods: We enrolled 2555 female participants in their 20s - 80s and 1631 male 
participants in their 20s - 70s. Participants with history of previous vertebral surgeries or 
current vertebral diseases were excluded. Female and male participants were divided into 
osteoporosis group (n = 136 and n= 31, respectively), osteopenia group (n = 822 and n = 460, 
respectively), and normal group (n = 1596 and n = 1140, respectively) based on their BMD 
T-score. Dual-energy X-ray absorptiometry image analysis and linear regression analysis 
were conducted on each participant in each group to determine the P value and the correla-
tion between BMD T-score/TBS T-score and BMI, weight, and height.Results: We found a 
significant correlation between BMI and TBS in both male and female participants. In the 
male participants, the correlation coefficient increased progressively from the normal group 
to the osteoporosis group. In the female group, we observed a significant positive correlation 
between height and TBS, and in the male group a significant negative correlation between 
weight and TBS was observed.Conclusions: BMI and weight are closely correlated to body 
fat content. BMD was positively correlated to BMI and weight, while TBS was negatively 
correlated to BMI and weight. Therefore, although BMI causes an increase in BMD, it ap-
pears to be negatively affecting bone quality.
Disclosures: Jin Hwan Kim, None
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REMS technology a new diagnostic approach in patients with spine artifacts 
*Maria Dea Tomai Pitinca1, Carla Caffarelli1, Stefano Gonnelli1. 1Department of 
Medicine, Surgery and Neuroscience. University of Siena, Italy
Bone Densitometry performed by DEXA technology is the Gold Standard in the evalua-
tion of BMD. It is well known that some conditions (arthrosis, vertebral collapses, vertebro-
plasty) can result in an overestimation of the spinal BMD measured by DEXA.The purpose 
of this work is to evaluate the REMS (Radiofrequency Echographic Multi-Spectrometry) 
technology in patients with alterations of the spine (osteophytes, vertebral fractures, verte-
broplasty). 86 female patients (mean age 70.44 +/- 9.1), with vertebral alterations that could 
affected the spine BMD were considered.Patients, after obtaining informed consent, under-
went DEXA  and REMS examination on the reference sites (proximal femur and Lumbar 
vertebrae). The bone mineral density assessed by REMS technology showed lower values 
??in the spine compared to the densitometric test performed with DEXA technology for both 
the BMD (0.772 +/- 0.065 vs 1.067 +/- 0.210) and the T-score (-2.5 +/- 0.6 vs 0.2 +/- 1.8). 
The BMD and T-score values ??measured with REMS and DEXA at ??the femoral site were 
highly correlated and this correlation reached statistical significance (p <0.01). Furthermore, 
a high correlation was shown between the BMD and the T-score measured with the DEXA 
technology  at the femoral sites (FN and TH) and those measured at the lumbar site with 
the REMS method (p <0.01).The high correlation between the values ??of femoral BMD, 
T-score FN and T-score TH in the two methods confirms that the REMS technology is a 
highly reliable examination in the evaluation of BMD and fracture risk. Furthermore the 
data obtained on lumbar scans shows that REMS technology is able to evaluate BMD more 
accurately than DEXA in patients with conditions that can make the DEXA exam less reli-
able. These data open new possible scenarios from both research and  clinical point of view 
and for fracture prevention.
Disclosures: Maria Dea Tomai Pitinca, None
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Radiofrequency Echographic Multi Spectrometry (REMS) technology: 
repeatability and precision assessment for short-term monitoring 
application *Paola Pisani1, Fiorella Lombardi1, Delia Ciardo1, Francesco 
Conversano1, Sergio Casciaro1. 1National Research Council, Institute of Clinical 
Physiology, Italy
PURPOSE The assessment of bone health through densitometric techniques is based on 
the evaluation of bone mineral density (BMD) at reference axial sites, i.e. femur or lumbar 
spine. In a setting of patients (pts) undergoing pharmacological treatments with non-phys-
iological BMD reduction as a side effect, the evaluation of BMD loss must be accurately 
performed with repeated examinations over time. The aim is to review the intra-operator (i.e. 
short-term precision), inter-operator and inter-device repeatability of Radiofrequency Echo-
graphic Multi-Spectrometry (REMS), a non-ionizing approach for osteoporosis diagnosis 
[1], in view of short-term BMD monitoring in breast cancer (BC) pts undergoing aromatase 
inhibitors (AIs) with or without Denosumab administration. METHODS Following the in-
dications of the ISCD [2], the parameters of interest were assessed on groups of 30-patient 
each. All subjects underwent 2 REMS scans at lumbar spine or femoral neck, performed 
by the same operator (for intra-operator repeatability) or by 2 different operators (for in-
ter-operator repeatability) or by the same operator using 2 different devices (for inter-device 
repeatability). The results are expressed as percentage coefficient of variation (RMS-CV) 
and least significant change for a 95% confidence level (LSC). The performance of lumbar 
spine REMS scans for the short-term monitoring of the effect of AIs with/without denosum-
ab in BC pts has been evaluated. RESULTS The results, obtained from a literature review 
[3,4], have shown a high precision of REMS for both axial sites, with intra- and inter-op-
erator RMS-CV lower than 0.55%. These results correspond to an LSC lower than 1.3% 
for femoral neck and 1.6% for lumbar spine. As concerning the inter-device repeatability, 
RMS-CV in the range 0.4%-0.6% were observed, with corresponding LSC of 1.1%-1.5%. 
The assessment of bone health-related parameters by REMS in BC pts every 6 months from 
the onset of the therapies, showed a statistically significant increasing trend of BMD in 
pts assuming AIs and Denosumab and a decreasing trend for patients undergoing AIs only. 
CONCLUSION The high repeatability and precision, with the low LSC values, associated 
with the non-ionizing approach, show that REMS is eligible for short-term monitoring of 
BMD. REFERENCES1. Aging Clin Exp Res 2019;31(10):1375–89 2. Osteoporos Int 2019; 
30:3–44. 3. Osteoporos Int 2018;30:391-402 4. Ann Rheum Dis 2020; 79, S1:1826.
Disclosures: Paola Pisani, None
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Hip Spine Discordance in Bone Mineral Density: Prevalence and Significance 
in Indian Patients *Amulya yalamanchi1, Karthik balachandran2, Adlyne Reena 
Asirwatham3, Shriraam Mahadevan3, Krishna Mori3, Sathish Kumar3. 1Sri 
ramachandra medical college, India, 2Sri ramachandra medical college, India, 
3Sriramachandra medical college, India
Abstract: Introduction: The WHO recommends that osteoporosis be diagnosed based 
on the lowest T score in hip, spine or distal 33% radius. Indian guidelines also emphasize T 
score based diagnosis and treatment of osteoporosis. One of the reasons for measuring bone 
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density is to account for differences in bone density between sites. The data on discordance 
in bone density between the hip, spine and distal radius is scarce in India - despite DXA 
scanning being available in India for the last 20 years. If there’s a significant discordance 
between hip and spine, this can potentially have impact on the diagnosis of osteoporosis. 
Objective: To study the prevalence of hip and spine discordance in BMD and its predictors 
in Indian patients. Materials and Methods: This was a retrospective study in which individ-
uals who underwent BMD measurement and FRAX scoring at Sri Ramachandra Medical 
Centre, Chennai during the time period July 2016 to July 2018 were included. Those who 
have already received treatment with US Food and Drug Administration (USFDA) approved 
drugs for osteoporosis were excluded. Results: The study included 808 adults, both men and 
women, above the age of 50. The mean age(sd) was 58.7 (6.2) years. The group had 56.8% 
men. None of the patients were taking any osteoporosis medications. 41.9% of patients tend 
to have discordance between their hip and spine, regardless of the normative data used for 
classification. discordance is minor in 39.9% minor and major in 2% . Conclusions: Discor-
dance between hip and spine classification by DXA is common (roughly 4 out of 10 patients) 
while major discordance is rare(2 out of 100 patients). Optimizing vertebral fracture detec-
tion and choice of anti-osteoporosis therapy are clinically significant implications of hip 
spine discordance, which need to be explored in future prospective studies. Keywords: Hip 
spine discordance, Bone mineral density, T score, DXA, Indian patients.
Disclosures: Amulya yalamanchi, None
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Phthalates and bone mineral density change in the Women’s Health 
Initiative *KATHERINE REEVES1. 1University of Massachusetts Amherst, 
United States
BackgroundPhthalates are endocrine-disrupting chemicals, often used in food pack-
aging materials and other consumer goods, that could disrupt normative physiologic func-
tion, triggering detrimental impacts on bone. Longitudinal associations between phthalate 
exposure and bone mineral density (BMD) have not been explored.MethodsWe evaluated 
associations between urinary phthalate biomarkers and BMD in postmenopausal women 
participating in the prospective Women’s Health Initiative (WHI). WHI participants who 
were enrolled in the BMD substudy (N=11,020) and were included in a nested case-control 
study of phthalates and breast cancer (N=1257, 419 cases and 838 matched controls) were 
included in these analyses. We measured thirteen phthalate biomarkers and creatinine in 2-3 
urine samples per participant collected over 3 years, when all participants were cancer-free. 
Total hip and femoral neck BMD were measured at baseline and year 3, concurrent with the 
time of urine collection, via dual energy x-ray absorptiometry (Hologic QDR 2000, 2000+ 
or 4500). We fit multivariable generalized estimating equation models and linear mixed ef-
fects models to estimate cross-sectional and longitudinal associations, respectively, between 
phthalate biomarkers and BMD measures, with stratification on postmenopausal hormone 
therapy (HT) use.ResultsIn multivariable cross-sectional analyses urinary concentrations of 
mono-benzyl phthalate, mono-3-carboxypropyl phthalate, and the sum of di-isobutyl phthal-
ate metabolites were inversely associated with total hip BMD among women not using HT, 
but not among HT users. Multivariable longitudinal analyses showed greater declines in total 
hip BMD among women not using HT and with highest concentrations of mono-carboxyoc-
tyl phthalate (MCOP) (-1.48%, 95% CI -2.45 – -0.51%) or mono-carboxynonyl phthalate 
(MCNP) (-1.45%, 95% CI -2.35 – -0.55%); similar associations were observed with femoral 
neck BMD in this group. Among women using HT, phthalate biomarkers were not associated 
with total hip or femoral neck BMD change.ConclusionsWe report, for the first time, that 
MCOP and MCNP are associated with greater percent decreases in total hip and femoral 
neck BMD. Phthalate exposure may have clinically important effects on BMD, and poten-
tially fracture risk.
Disclosures: KATHERINE REEVES, None
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Cross-sectional associations between visceral adipose tissue and bone 
mineral density in the UK Biobank Imaging Study *Victoria Bland1, Yann 
Klimentidis1, Jennifer Bea1, Denise Roe1, Scott Going1. 1University of Arizona, 
United States
While the strong positive relationship between body mass, particularly lean mass, with 
areal bone mineral density (aBMD) in adults is well established, the relationship between 
aBMD and adipose tissue distribution is not well understood. Consequently, our aim was to 
characterize the association of MRI-derived abdominal visceral adipose tissue (VAT) with 
DXA-derived whole body (WB), lumbar spine (LS), and femoral neck (FN) aBMD in males, 
premenopausal females, and postmenopausal females. We used data from 3177 individuals 
aged 44-77 years old from the UK Biobank who took part in the imaging study and had 
available DXA and abdominal MRI data. Linear regression analysis was used to assess the 
relationship between abdominal VAT (liters) and aBMD (g/cm2), controlling for age, race, 
DXA total body lean mass, height, BMI class (normal weight: < 25 kg/m2, overweight: >= 
25 and < 30 kg/m2, obese: >= 30 kg/m2), physical activity, smoking, and oral contracep-
tive/hormone replacement therapy use (females only). In postmenopausal females, VAT was 
positively associated with WB (β: 0.013, p = 0.009), LS (β: 0.030, p < 0.0001), and FN 
aBMD (β: 0.016, p = 0.003). In males and premenopausal females, a significant interaction 
(p < 0.05) between VAT and BMI class was identified for WB aBMD and LS aBMD bone 
outcomes. In males, the interactions showed a positive relationship between VAT and aBMD 
in normal weight men, but a negative relationship between VAT and aBMD in obese men. 
In premenopausal females, the interaction indicated a positive relationship between VAT 
and aBMD in normal weight women, but a negative relationship in overweight and obese 
women. No significant relationship between VAT and FN aBMD was identified in males (p 
= 0.63), but VAT was positively associated with FN aBMD in premenopausal females (β: 
0.024, p = 0.007). These results indicate that VAT may positively influence aBMD in normal 
weight individuals, likely due to a mechanical influence on bone, but could be detrimental 
to bone density in overweight and obese individuals, especially among males and premeno-
pausal females. Future analyses are needed to determine if there is a threshold at which VAT 
might become detrimental to aBMD.
Disclosures: Victoria Bland, None
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Does Serial Bone Density Measurement Meaningfully Improve Incident 
Fracture Risk Prediction in Postmenopausal Women? Results from 
the Women’s Health Initiative Observational Study and Clinical Trials 
*CAROLYN CRANDALL1, Joseph Larson2, Nicole Wright3, Deepika Laddu4, 
Marcia Stefanick5, Andrew Kaunitz6, Nelson Watts7, Jean Wactawski-Wende8, 
Catherine Womack9, Karen Johnson10, Laura Carbone11, Rebecca Jackson12, 
Kristine Ensrud13. 1University of California, Los Angeles, United States, 2Fred 
Hutchinson Cancer Research Center, United States, 3University of Alabama 
at Birmingham, United States, 4University of Illinois, United States, 5Stanford 
University School of Medicine, United States, 6University of Florida College of 
Medicine, United States, 7Mercy Health Osteoporosis and Bone Health Services, 
Cincinnati, United States, 8University at Buffalo, the State University of New 
York, United States, 9The University of Tennessee Health Science Center, United 
States, 10University of Tennessee Health Science Center, Memphis, United 
States, 11Medical College of Georgia at Augusta University, United States, 12The 
Ohio State University, Columbus, OH, United States, 13University of Minnesota 
and Veterans Affairs Health Care System, Minneapolis, United States
Background. Whether repeated osteoporosis screening improves fracture prediction is 
controversial. Objectives. To determine whether a second BMD measurement an average of 
3 years after the initial assessment adds to the prediction of fracture risk beyond baseline 
BMD measurement alone. Design. Women’s Health Initiative (WHI), a prospective obser-
vational study, mean 12.1 years follow-up Setting. 3 clinical centers Participants. Postmeno-
pausal women aged >=50 years (n = 7,419). Measurements. BMD was measured at baseline 
and 3 years later Methods. We calculated area under the receiver operating characteristic 
curve (AUC) for baseline BMD, absolute change in BMD, and the combination of baseline 
BMD and change in BMD to predict incident hip fracture or major osteoporosis fracture 
(MOF) during follow-up. Results. During follow-up, 139 hip fractures and 732 MOF oc-
curred. For prediction of hip fractures, AUC values were 0.79 (95% confidence interval 
[CI] 0.75, 0.82) for baseline total hip BMD, 0.77 (0.74, 0.81) for change in total hip BMD, 
and 0.79 (0.76, 0.83) for the combination of baseline total hip BMD and change in total hip 
BMD. Femoral neck and lumbar spine BMD predicted hip fracture in a similar manner. 
For prediction of MOF, AUC values were 0.67 (0.65, 0.69) for baseline total hip BMD, 
0.66 (0.64, 0.68) for change in total hip BMD, and 0.67 (0.65, 0.69) for the combination 
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of baseline total hip BMD and change in total hip BMD. Femoral neck and lumbar spine 
BMD predicted MOF in a similar manner. Limitations. Observational design, self-reported 
fractures. Conclusion. A second BMD measure after 3 years does not meaningfully improve 
the prediction of hip or major osteoporotic fracture beyond baseline BMD alone. Funding. 
National Institutes of Health.
Disclosures: CAROLYN CRANDALL, None
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Major osteoporotic fracture to hip fracture incidence rate ratios: a 
systematic review of observational studies. *Marlene Chakhtoura 1, Hiba 
Dagher1, Sima Lynn Sharara1, Ziyad Mahfoud1, Jane Cauley2, Ghada El Hajj 
Fuleihan1. 1American University of Beirut - Lebanon, Lebanon, 2University of 
Pittsburgh, United States
BackgroundThe Fracture Risk Assessment Tool (FRAX) is central to many osteoporo-
sis guidelines. Country specific FRAX calculators are made possible with country specific 
hip fracture incidence and life expectancy data. The calculator provides 10-year probabilities 
for hip and major osteoporotic fracture (MOF), and uses MOF/hip fracture incidence rate 
ratios (IRR) from Malmo Sweden for the latter, in most countries. However, the risk of 
osteoporotic fractures varies by age, gender, and geography.AimEvaluate the IRR [and 95% 
confidence interval (CI)] of MOF/hip fractures, by gender and age categories, in studies ex-
tending >1 year, across continents.MethodsWe conducted a systematic search in 3 databases 
targeting observational studies on MOF (forearm, vertebral, proximal humerus, hip) and hip 
fractures in men and women >50 years (CRD42019129259). We used relevant MeSh terms/
keywords, and did not apply language nor time restriction until May 2018. One reviewer 
completed title/abstract and full text screening, and 2 reviewers completed duplicate and 
independent data abstraction. We assessed studies quality based on population representa-
tiveness, study design, definition of ethnicity and fracture. We calculated the MOF/hip IRR 
and its 95% CI using incident fractures, by gender and age category, using Rothman’s for-
mula (1).ResultsWe included 27 studies, from Europe (15), US and Canada (7), Asia (3) and 
Australia (2). Calculations were done for four countries, awaiting needed data from authors 
of other studies. The MOF/hip IRR is higher in younger age categories, and higher in women 
compared to men, across all countries. This is driven by low hip fracture incidence at young 
ages. The IRR at 50-54 years is 3-12 folds higher than the IRR at 85+ years in women, and 
2.3-10.3 folds higher in men. The difference between men and women is larger at younger 
ages, and varies across countries. The IRR is 1.3-3.3 folds higher at 50-54 years in women 
compared to men. At ages 85-90+, the IRR in both genders become almost similar, with few 
exceptions. The MOF/hip IRR vary across countries; differences are larger at younger ages 
(see Table for selected countries from different continents).ConclusionThe variability in the 
MOF/hip fracture IRR may affect the 10-year MOF fracture risk prediction in FRAX using 
ratios from Malmo Sweden ratios. This would depend on the impact of observed differences 
on derived FRAX estimates. Further research is needed to elucidate the clinical implication 
of our findings.(1)Rothman 2008
Disclosures: Marlene Chakhtoura, None
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Associations between Seasonal Influenza, Fractures and Fall Injuries - a 
National Retrospective Cohort Study *Kristian Axelsson1, Henrik Litsne1, 
Mattias Lorentzon1. 1Geriatric Medicine, Institute of Medicine, Sahlgrenska 
Academy, University of Gothenburg, Sweden
Background: Fractures and fall injuries often lead to disability, increased morbidity 
and mortality. Older adults are at higher risk of influenza related complications such as 
pneumonia, cardiovascular events and deaths, but the risk of fractures and fall injuries is 
unclear. The primary objective of this study was to investigate if the risk of fractures and fall 
injuries is increased in older patients diagnosed with seasonal influenza compared to propen-
sity score matched controls.Methods: In this retrospective cohort study of 6 692 older adults 
(70 years or older) with seasonal influenza diagnosed at Swedish hospitals (from December 
1st, 2015 to December 31st, 2017) and 6 692 propensity score matched controls derived 
from the general population, the risk of fracture or fall injury was investigated.Results: The 
mean (SD) age of the 6 692 influenza patients was 82.3 (7.1) years, 50.9% were women and 
the mean (SD) Charlson Comorbidity Index was 2.2 (2.3). During the first 14 days after 
baseline, there were 217 fractures or fall injuries among the patients with influenza and 32 
among the propensity score matched controls corresponding to incident rates of 900 (95% 
CI, 788-1028) and 127 (95% CI, 90.1-180) fractures or fall injuries per 1000 person-years, 
respectively, translating to an increased risk of fracture or fall injury in a logistic regression 
model (odds ratio 6.98 (95% CI, 4.81-10.13)) in influenza patients. The incidence among the 
influenza patients was higher also in the subsequent period (day 15 to 60) than in the con-
trols, with incident rates of 195 (95% CI, 165-230) and 112 (95% CI, 90.4-138), respectively, 
corresponding to an increased risk in influenza patients in a Cox model (hazard ratio 1.74 
(95% CI, 1.33-2.28)).Conclusions: Among older adults with influenza diagnosis, the risk of 
fracture or fall injury was increased substantially, providing additional evidence to support 
the prevention of influenza and of injurious falls in those affected by the disease.
Disclosures: Kristian Axelsson, None
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Treat-to-Target in Osteoporosis: Total Hip BMD T-Score as an Indicator 
of Fracture Risk in Bisphosphonate-Treated Postmenopausal Women from 
Real‏-World Data *Gustaf Ortsäter1, Jonas Banefelt1, Emma Söreskog1, Jen 
Timoshanko3, Alireza Moayyeri3, Kristina Åkesson4, Anna Spångéus5, Östen 
Ljunggren6, Cesar Libanati3. 1Quantify Research, Sweden, 3UCB Pharma, 
United Kingdom, 3UCB Pharma, Belgium, 4Lund University, Skåne University 
Hospital, Sweden, 5Linköping University Hospital, Sweden, 6Uppsala University 
Hospital, Sweden
PurposeThe association between bone mineral density (BMD) and fracture (fx) risk is 
well established. The importance of total hip (TH) BMD T-score in determining fx risk ob-
served in recent studies has reignited discussion on whether a BMD target could be suitable 
in a treat-to-target approach in patients (pts) with osteoporosis (OP).1,2 We use real-world 
data to extend the evidence confirming a relationship between TH T-score and fx risk in 
postmenopausal women with prior bisphosphonate (BP) treatment (tx).MethodsIn this ret-
rospective cohort study, all women aged >=55 years (yrs) with >=1 TH T-score measured 
between 2006–2013 at 1 of 3 Swedish OP clinics with prior BP tx and without Paget’s dis-
ease or malignancy were identified. Pt data were linked to fx and BP tx data from national 
health registers.The index date was set to the first BMD measurement; cumulative incidence 
of any clinical and non-vertebral (NV) fx was assessed 12 and 24 months following this 
date. The association between T-score and fx risk was estimated using proportional hazards 
regression; restricted cubic splines were added to illustrate any potential non-linear rela-
tionship. 4 subgroups were considered: any prior BP tx; BP tx for >=3 yrs; any prior BP 
tx but no dispensations during the last yr; and any prior BP tx with >=1 dispensation in the 
last yr.ResultsOf 3,422 included pts, the mean (SD; range) age was 71.5 (8.6; 55–98) yrs 
and median (IQR; range) TH T-score was –1.7 (1.4; -7.7–3.0). 22.6% had a TH BMD<=-
2.5; 34.4% had a prior fx. At 12 and 24 months respectively, cumulative incidence (95% 
CI) of any clinical fx was 4.44% (3.79–5.17) and 8.39% (7.49–9.35), and NV was 3.83% 
(3.22–4.51) and 7.31% (6.47–8.21). In women with prior BP tx, TH T-score was inversely 
related with 12-month clinical and NV fx incidence [Figure]; the association was similar at 
24 months. This relationship was maintained overall and similar across subgroups.Conclu-
sionsIn BP-treated women, TH T-score is associated with 12- and 24-month fx risk, similar 
to that reported from clinical trials with other therapeutic agents.1,3 These real-world data 
provide additional evidence supporting the use of BMD in a treat-to-target approach for 
pts at increased fx risk receiving OP tx.References1. Ferrari S. JBMR 2019;34:1033–40; 2. 
Cummings SR. JBMR 2016;32:3–10; 3. Cosman F. JBMR 2018;33(Suppl 1):25.Acknowl-
edgementsThis study was funded by UCB Pharma and Amgen Inc. Medical writing services 
were provided by Costello Medical.
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Height Loss in Old Age and Hip Fracture Risk Among Men in Late Life: 
Findings from the Osteoporotic Fractures in Men (MrOS) Study *Kristine 
Ensrud1, John Schousboe2, Allyson Kats3, Tien Vo3, Brent Taylor1, Peggy 
Cawthon4, Jane Cauley5, Nancy Lane6, Andrew Hoffman7, Lisa Langsetmo3. 1VA 
Health Care System / University of Minnesota, United States, 2HealthPartners 
Institue / University of Minnesota, United States, 3University of Minnesota, 
United States, 4California Pacific Medical Center Research Institute, United 
States, 5University of Pittsburgh, United States, 6University of California - Davis, 
United States, 7Stanford University, United States
Height loss in older adults is associated with a higher risk of all-cause mortality. Thus, 
the competing risk of mortality (unrelated to hip fracture) may modify the relationship of 
height loss with hip fracture risk, especially in late life. To determine the association of 
height loss in old age with subsequent risk of hip fracture in men late in life while accounting 
for the competing risk of mortality, we used data from 3498 men (mean [SD] age 79.2 [5.2] 
years) participating in the Year 7 (Y7) MrOS exam. Height was measured at the baseline and 
Y7 exams with a Harpenden stadiometer. Height loss (cm) was expressed as a categorical 
variable (<1 cm [referent group], >=1 and <2 cm, >=2 and <3 cm, and >=3 cm). Men were 
contacted every 4 months after Y7 to ask about hip fractures (confirmed by radiographic re-
ports) and ascertain vital status (deaths verified by death certificates). Cumulative incidence 
was estimated considering mortality as competing risk. Hazard ratios (HR) were calculated 
using Fine-Gray models accounting for death as a competing risk. Mean (SD) height loss 
between baseline and Y7 exam was 1.4 (1.4) cm. During a maximum follow-up of 10 years 
after Y7, 158 (4.5%) men experienced a hip fracture and 1418 (40.6%) died before experi-
encing this event. The absolute probability of hip fracture at 10 years steadily increased with 
greater height loss; the probability (95% CI) was 2.7% (1.9-3.7%) among men with height 
loss <1 cm increasing to 11.6% (7.9-16.0%) among men with height loss >=3 cm. After 
adjusting for age, race and enrollment site, hip fracture risk after Y7 increased in a graded 
manner with greater height loss between baseline and Y7 (subdistribution HR 1.61 among 
men with loss >=1 cm and <2 cm, 1.95 among men with loss >=2 cm and <3 cm, and 3.45 
among men with loss >=3 cm) (Model 1, Table). The association was somewhat attenuated 
but persisted after further adjustment for fall history, multimorbidity, baseline height, weight 
change between baseline and Y7 exam and FN BMD (Model 2). Additional adjustment for 
incident radiographic vertebral fracture between baseline and Y5 exam did not alter the 
results (Model 3). In conclusion, height loss of 3 cm or more in old age is a strong risk factor 
for hip fracture in men in late life, even after accounting for traditional risk factors and con-
sidering the competing risk of mortality.
Disclosures: Kristine Ensrud, None
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Frailty Phenotype and Risk of Fracture Among Women Late in Life: Impact 
of Traditional Risk Factors and Competing Mortality *John Schousboe1, 
Lisa Langsetmo2, Allyson Kats2, Tien Vo2, Deborah Kado3, Stone Katie4, Brent 
Taylor2, Kristine Ensrud2. 1HealthPartners Institute, United States, 2University of 
Minnesota, United States, 3University of California, San Diego, United States, 
4California Pacific Medical Center, United States
Frailty phenotype is traditionally defined as frail, pre-frail, or robust by five Cardiovas-
cular Health Study (CHS) criteria (slow gait speed, low grip strength, poor energy, weight 
loss, low physical activity). Alternatively, three Study of Osteoporotic Fractures (SOF) cri-
teria (weight loss, low energy, inability to rise from a chair 5 times without use of the arms) 
have been proposed to identify frailty status in the busy clinical practice setting. CHS and 
SOF Frailty phenotypes are associated with increased fracture risk, but competing risk of 
mortality may mitigate this risk, especially in the very old.Our objective was to estimate 
the associations of the frailty phenotype with hip and non-spine fracture risks over 5-years 
of follow-up  in women >80 years using Cox proportional hazards models and Fine-Gray 
subdistribution hazards models to account for competing mortality. Models were adjusted 
for age and race, followed by adjustment for traditional risk factors (e.g. femoral neck BMD, 
prior clinical fracture, prevalent radiographic vertebral fracture, body mass index, fall histo-
ry, parental hip fracture, current smoking) with a cut-off p-value <0.10. The referent group 
in the analyses was robust women.Among 2638 women at the SOF year 16 visit (mean age 
83.2 years), 187 (7.1%) had a subsequent hip fracture, 439 (16.6%) had a non-spine fracture, 
and 430 (16.3%) died without having a fracture over the 5-years of follow-up. Adjusted 
for age and race, SOF defined frailty was associated increased risks of hip and non-spine 
fractures, and CHS defined frailty was associated with a higher risk of non-spine fracture 
(Table). These associations were similarly attenuated after considering competing mortality 
or after adjusting for traditional risk factors. After adjusting for both competing mortality 
and traditional risk factors, these associations were further attenuated and no longer signif-
icant. In contrast, femoral neck BMD remained strongly associated and prevalent vertebral 
fracture or self-reported falls were moderately associated with hip and non-spine fractures, 
regardless of competing mortality.In conclusion, after accounting for competing mortality 
risk and traditional risk factors, frailty defined by phenotypic criteria is not a strong fracture 
risk factor in late life women. BMD, vertebral fracture and fall history retained significance, 
confirming the importance of identifying and appropriately treating those with osteoporosis 
and falls.
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FRAX probabilities generally do not change much over time. A prospective 
analysis from the OFELY cohort. *elisabeth SORNAY-RENDU1, francois 
DUBOEUF1, Roland Chapurlat1. 1INSERM UMR1033 and Université de Lyon, 
France
Introduction: The Fracture Risk Assessment Tool (FRAX) identifies the probability of 
Major Osteoporotic Fractures (MOF) and/or Hip Fractures (HF) in the next 10 years, but 
the evolution of FRAX has not been evaluated so far.Materials and Methods: We have col-
lected incident fracture in 579 women (mean age, 67 +/- 11 years) from the 14th to the 20th 
annual follow-up visit of the OFELY prospective study and calculated the change in FRAX 
probabilities over these 6 years. We examined whether the change in FRAX would predict 
incident fracture. Fragility fractures, all confirmed by radiographs, were prospectively regis-
tered.Results: The FRAX probabilities were highly correlated 6 years apart with a Spearman 
coefficient between 0.90 and 0.97 for MOP and HF with and without BMD. The median 
(interquartile range [IQ]) variation of FRAX probabilities expressed in absolute difference 
was 1.7 [0.1-4.3] for MOP FRAX with BMD, 0.7 [0.1-1.9] for MOP FRAX without BMD, 
1.7 [0.5-3.5] for HF FRAX with BMD and 1.7 [0.2-4.3] for HF FRAX without BMD.The 
highest increases in FRAX probabilities (e.g., highest quartile of absolute difference for 
MOP without BMD) were moderately associated with older age with an OR [95%CI] of 1.24 
[1.19-1.30] per year and lower BMI (0.93 [0.89-0.98] per unit), and strongly with Fx sus-
tained since the prior evaluation of FRAX 6 years earlier (22.2 [8.4-58.6]). During a median 
(interquartile range [IQ]) of 7.0 years (6.9–7.3 years) of follow-up, 104 women sustained 
incident fragility fractures including 14 HF, 28 vertebral Fx and 63 nonHipnonVert Fx. Us-
ing a Cox model, the highest quartile of absolute difference for MOP FRAX without BMD 
(6.5-54) was associated with an increased risk of incident Fx with an Hazard Ratio (95%CI) 
of 2.5 (1.7-3.7), p<0.0001. Among 502 women below the French intervention threshold for 
the MOP FRAX with BMD, only 20 women (4%) were above the threshold 6 years later.
Conclusions: Over 6 years, the FRAX tracks for most women. Incident fragility fracture is 
the main predictor of increasing FRAX probabilities. Without incident fracture, recalculat-
ing FRAX after 6 years will not change treatment decision in most instances.
Disclosures: elisabeth SORNAY-RENDU, None
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Geographic Variations in Bone Mineral Density and Prevalent Fractures 
in Canada *Nazila Hassanabadi1, Claudie Berger2, Alexandra Papaioannou3, 
Angela M Cheung4, Elham Rahme1, William D Leslie5, David Goltzman1, 
Suzanne N Morin1. 1McGill University, Canada, 2Research Insitute of the McGill 
University Health Centre, Canada, 3McMaster University, Canada, 4University of 
Toronto, Canada, 5University of Manitoba, Canada
Purpose: The prevalence of osteoporosis and fractures differs across countries and re-
gions. We aimed to describe sex-specific bone mineral density (BMD) and prevalent fracture 
patterns across geographical regions in Canada.Methods: We used baseline data of 27,244 
Canadians (13,828 women and 13,416 men) aged 50 years+ participating in the Canadian 
Longitudinal Study of Aging from 7 provinces across the country (2012-15). We created lin-
ear and logistic regression models to determine associations between province of residence 
and total hip BMD and prevalent self-reported major osteoporotic fractures (MOF) stratified 
by sex adjusting for age, body mass index (BMI), height, vitamin D level, comorbidities and 
physical performance measures. Results: The mean (SD) age of participants was 64.4 (9.4) 
years in women and 64.8 (9.4) in men. Mean BMI was lowest (27.4 kg/m2 [5.1]) in British 
Columbia (BC) and highest (29.0 kg/m2 [6.1]) in Manitoba (MB).  The mean total hip BMD 
was lowest in BC (0.908 g/cm2 [0.141]) and highest in Newfoundland and Labrador (NL) 
(0.944 g/cm2 [0.149]) and Ontario (ON) (0.936 g/cm2 [0.145]). The overall prevalence of 
osteoporosis (T-score  £-2.5 femoral neck) was 7.0% in women and 1.5% in men and of 
MOF was 4.6%; ranging from 3.1% in BC to 5.8% in MB. The mean (SD) FRAX score was 
10% (7) in women and 6% (3) in men, and was noted to be 4% lower in women from BC and 
between 4 to 11 % lower in men from BC, MB, NS and NL compared to women and men 
from ON. Alberta (AB) (12.3%) and Quebec (QC) (12.0%) had the highest proportion of 
participants reporting falls (previous 12 months), while MB (8.6%) had the fewest.Adjusted 
linear regressions demonstrated significant differences in total hip BMD across provinces; 
women and men from BC and AB, and women from MB and NS had lower BMD than ON 
(Table). Adjusted Odds Ratios (OR) for prevalent MOF were significantly lower in women 
(OR 0.56; 95% CI: 0.40- 0.79) and men (OR 0.35; 95% CI 0.21- 0.58) from BC and men 
from NS, (OR 0.52; 95% CI: 0.28-0.98) compared to ON. Results were similar when re-
stricting the analyses to participants of White ancestry only. Conclusion: Though prevalence 
of osteoporosis and MOF was low in this cohort, significant geographic variations in total 
hip BMD and fractures were observed. Future work will examine the determinants of these 
variations and how they have evolved over time by contrasting our results with those pub-
lished by the Canadian Multicenter Osteoporosis Study.
Disclosures: Nazila Hassanabadi, None
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Increase in C-reactive Protein is Associated with Increased Rate of 
Bone Loss: Study of Women’s Health Across the Nation (SWAN) *Arun 
Karlamangla1, Nicholas Jackson1, WeiJuan Han1, Mei-Hua Huang1, Jane Cauley2, 
Carrie Karvonen-Gutierrez3, Gail Greendale1. 1UCLA, United States, 2University 
of Pittsburgh, United States, 3University of Michigan, United States
Purpose: Greater levels of inflammation marker, C-reactive protein (CRP), have been 
associated with less BMD in some investigations, but longitudinal studies of the association 
between CRP and bone loss are lacking.  We set out to determine whether within-woman 
change in serum CRP in midlife, before, during, and after the menopause transition (MT), is 
related to within-woman change in BMD decline rate. Methods: We measured serum CRP 
level and BMD by DXA every 1-2 years over a 21-year period, in 2365 women, starting at 
age 42–52 when they were in premenopause or early perimenopause.  We excluded CRP 
values significantly higher than the woman’s CRP in other visits, since these likely represent 
acute, not chronic, inflammation. We censored women when they started hormone therapy. 
1431 women had 2 or more visits (total, 7700 visits) with valid CRP and BMD measured 
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concurrently, and a follow up BMD measurement 1.5-3.5 years following each such visit (for 
BMD decline rate calculation). To eliminate all confounding by woman-specific, time-fixed 
characteristics (even those not measured) and focus exclusively on within-woman changes, 
we used individual fixed effects (IFE) models to estimate the association of log CRP with 
BMD decline rate over the following 1.5–3.5 years. We included the following time-varying 
covariates: MT stage (1: pre or early perimenopause, 2: late peri- or early postmenopause, 3: 
late postmenopause), BMI, diabetes, smoking, alcohol, and medication use.  Results: Mean 
BMD decline rate over all visits was 0.76% per year at the LS and 0.67% per year at the FN. 
The geometric mean of CRP over all visits was 1.53 mg/L. CRP was greater in MT stage 
2 than in 1 (p<0.001), but not different in stages 2 vs. 3. BMD decline at both LS and FN 
was faster in MT stage 2 than both other stages (all p < 0.001). In unadjusted IFE models, 
every within-woman doubling of CRP was associated with 0.13% per year faster decline in 
FN BMD but was not associated with LS BMD decline. In adjusted IFE models, MT stage 
modified this relationship (interaction p value < 0.05, stage 1 vs. 2, 2 vs 3; LS and FN). 
Each within-woman doubling of CRP was associated with 0.09% faster decline per year in 
FN BMD in MT stages 1 and 3, and 0.10% faster decline in LS BMD in MT stage 3 only 
(Table).Conclusions: Within-woman increase in CRP is associated with faster BMD decline 
before and after the MT, but not during the MT when bone loss may be primarily driven by 
sex hormone changes.
Disclosures: Arun Karlamangla, None
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Geographic Variation in Prevalence of Osteoporosis Diagnosis and 
Utilization of Anti-Osteoporosis Therapies Among Commercially Insured 
Women Aged 50 Years and Older with Fragility Fractures in the United 
States *Andrea J. Singer1, E. Michael Lewiecki2, Pallavi B. Rane3, Xin Wang4, 
Timothy Hill4, Kainan Sun4, Rolin L. Wade4, Michele McDermott3, Shravanthi R. 
Gandra3. 1MedStar Georgetown University Hospital, United States, 2University 
of New Mexico Health Sciences Center, United States, 3Amgen Inc, United 
States, 4IQVIA, United States
Background: There is limited real-world evidence on geographic variation in fragil-
ity-fracture related outcomes among commercially insured women in the US.Objective: 
To describe geographic variation in distribution of fragility fractures among commercially 
insured women aged >=50 years in the US, and in rates of osteoporosis diagnosis and treat-
ment in these women.Methods: This retrospective cohort study utilized a nationally repre-
sentative commercial claim database (IQVIA). Women aged >=50 years were identified on 
the first occurrence of a fragility fracture of hip, vertebra, or non-hip non-vertebral in inpa-
tient or outpatient setting, between Jan 2015 - Aug 2018. Fracture-related age-standardized 
measures in the 1-year period preceding and following the fracture, including diagnosis of 
osteoporosis (identified using ICD9/10 diagnosis codes for osteoporosis), use of anti-resorp-
tive or anabolic agents, and subsequent fracture events were described at the sub-national 
level.Results: 40,377 commercially insured women were identified who met study eligibility 
criteria and had >=1 fragility fracture. Their mean[SD] age was 63.4[9.6] years, 33.9% were 
from southern regions and their mean[SD] Charlson comorbidity index score was 2.3[2.6]. 
Their most common index fracture type was non-hip non-vertebral (54.4%), followed by 
vertebral (32.5%) and hip (13%); with 36.6% of all index fractures reported in an inpatient 
setting. In the 1-year pre-index period, 10.7% women had received a bone mineral density 
test, 13.4% had a diagnosis of osteoporosis, and 8.6% were receiving any anti-resorptive 
or anabolic agents. Despite experiencing fragility fractures, these values later increased to 
21.1%, 27.4%, and 15.9%, respectively; and 11.9% of women had a subsequent fragili-
ty fracture (with 53% presenting with a hip fracture) in the 1-year following the fracture. 
There was geographic variation across the different states for fracture related measures as 
described in Table 1.Conclusion: Osteoporosis is an underdiagnosed and undertreated con-
dition among commercially insured women with fragility fractures in the US, who remain at 
risk for subsequent fractures. There is geographic variation across different states in the US 
for osteoporosis diagnosis and treatment.
Disclosures: Andrea J. Singer, Amgen Inc., Consultant
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Estimated glomerular filtration rate (eGFR) based on cystatin C predicts 
fragility fractures better than eGFR based on creatinine in women but not 
in men: The Tromsø Study *Sofie Karoliina Nordvåg1, Frida Igland Nissen1, 
Tove Tveitan Borgen2, Camilla Andreasen3, Ragnar Martin Joakimsen1, Toralf 
Melsom1, Martin Dahl Solbu1, Åshild Bjørnerem1. 1UiT The Arctic University 
of Norway, Tromsø, Norway, 2Vestre Viken Hospital Trust, Drammen Hospital, 
Norway, 3UiT The Arctic University of Norway, Tromsø, Norway
Patients with end-stage kidney disease have a higher fracture risk than the general pop-
ulation. Previous studies on whether early kidney dysfunction is associated with low bone 
mineral density and increased fracture risk have yielded ambiguous results. The results of 
these studies may have been confounded by the use of creatinine based estimates of the 
glomerular filtration rate (eGFRcre), because creatinine levels correlates with muscle mass, 
an important risk factor for fractures. Moreover, few population-based prospective studies 
have reported the importance of reduced eGFR and risk of fracture other than hip fracture. 
We tested the hypothesis that decreased eGFR based on serum cystatin C (eGFRcys) or both 
cystatin C and creatinine (eGFRcrecys) predict fractures better than eGFR based on creat-
inine (eGFRcre).At baseline in the Tromsø Study in 1994-95, a total of 3016 women and 
2836 men aged 50-94 years were included in this study. eGFRcre, eGFRcys and eGFRcrecys 
were estimated using the Chronic Kidney Disease Epidemiology Collaboration equations. 
Hazard ratio (HR) was calculated in Cox’s proportional hazards models and adjusted for age, 
height, body mass index, bone mineral density, diastolic blood pressure, smoking, physical 
activity, previous fracture, diabetes and cardiovascular disease. During a median of 14.6 
years follow-up, and 34,851 person-years, 232, 135, 394 and 669 of 3016 women suffered 
incident hip, proximal humerus, wrist and fragility fractures (hip, proximal humerus and/or 
wrist). During 33,442 person-years, 118, 35, 65 and 201 of 2836 men suffered incident hip, 
proximal humerus, wrist and fragility fractures. In women, lower eGFRcre did not predict 
any type of fracture. A 1 SD lower eGFRcys increased the risk for hip, proximal humerus 
and fragility fracture (HR 1.36; 95% CI 1.16-1.60, HR 1.33; 95% CI 1.08-1.63 and HR 1.12; 
95% CI 1.02-1.23), respectively. A 1 SD lower eGFRcrecys increased the risk for hip and 
proximal humerus fracture (HR 1.25; 95% CI 1.08-1.45 and HR 1.30; 95% CI 1.07-1.57), 
respectively. Women with eGFRcys in the lowest quartile had doubled risk of hip fracture 
compared with those in the upper quartile (HR 2.09; 95% CI 1.15-3.78). In men, lower 
eGFRcre, eGFRcys or eGFRcrecys did not predict any fracture. In conclusion, lower eGFR 
based on cystatin C increased the risk of hip, proximal humerus and fragility fracture in 
women. Neither eGFR based on cystatin C, creatinine or both, predicted any type of fracture 
in men.
Disclosures: Sofie Karoliina Nordvåg, None
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Concomitant Use of Oral Glucocorticoids and Proton Pump Inhibitors and 
Risk of Osteoporotic Fractures among Patients with Rheumatoid Arthritis: 
A Population-based Cohort Study *Shahab Abtahi1, Johanna H.M. Driessen1, 
Andrea M. Burden2, Patrick Souverein3, Joop P. van den Bergh4, Tjeerd van 
Staa3, Annelies Boonen4, Frank de Vries1. 1Department of Clinical Pharmacy 
and Toxicology, MUMC+, Netherlands, 2Institute of Pharmaceutical Sciences, 
Department of Chemistry and Applied Biosciences, ETH-Zurich, Switzerland, 
3Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht. 
Institute for Pharmaceutical Sciences, Netherlands, 4Department of Internal 
Medicine, Division of Rheumatology, MUMC+, Netherlands
Background and Purpose: Patients with rheumatoid arthritis (RA) commonly use oral 
glucocorticoids (GCs) and proton pump inhibitors (PPIs). Both drugs are associated with os-
teoporotic fractures, where the underlying biological mechanism is known for oral GCs but 
not yet understood for PPIs. We investigated the association between concomitant use of oral 
GCs and PPIs and the risk of osteoporotic fractures among patients with RA.Methods: This 
was a retrospective cohort study including all RA patients aged 50+ from the Clinical Prac-
tice Research Datalink (CPRD) between 1997-2017. Exposure to oral GCs and PPIs was 
stratified into current (1 year), based on the time since the most recent prescription. Current 
use was further stratified by average daily and cumulative dose and duration of use. Time-de-
pendent Cox proportional-hazards models estimated risk of osteoporotic fractures (included 
hip, vertebrae, humerus, forearm, pelvis, or ribs) in RA patients with concomitant current 
use of oral GCs and PPIs versus non-use. The analyses were statistically adjusted for life-
style parameters, comorbidities and comedications.Results: Among 12,351 patients with RA 
(mean age 68 years, 69% females), 1411 osteoporotic fractures were observed. Concomitant 
current use of oral GCs and PPIs was associated with a 1.6-fold increased risk of osteopo-
rotic fracture compared with non-use (adjusted hazard ratio 1.60, 95%CI 1.35-1.89, Table 
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1). This was statistically different from a 1.2-fold increased osteoporotic fracture risk as-
sociated with oral GC or PPI use alone. Most individual fracture sites were significantly 
associated with concomitant use of oral GCs and PPIs. Among concomitant users, fracture 
risk was not increased with higher daily dose or longer duration of PPI use. Current PPI use 
was associated with 1.3-fold increased risk of osteoporotic fractures versus non-use.Conclu-
sions: Concomitant use of oral GCs and PPIs was associated with a 1.6-fold elevated risk 
of osteoporotic fracture compared with non-use. This increased risk seems to emerge from 
separate mechanisms of action of GCs and PPIs on bone or falling risk, since the observed 
HRs with oral GC or PPI use alone seem to be additive. Considering the increasing life 
expectancies and high consumption of PPIs among elderly patients, these findings may be 
clinically relevant in RA patients treated with oral GCs in combination with PPIs.
Disclosures: Shahab Abtahi, None
P-547
High Prevalence of Osteoporosis in Older Male Veterans Receiving Hip-
Containing Computed Tomography Scans *Polly Fu, MD1, Janet Chiang, 
MD1, Anne Schafer, MD1, Preeti Sukerkar, MD PhD2, Tony Keaveny, PhD3, 
Daniel Bikle, MD PhD1. 1Division of Endocrinology and Metabolism, University 
of California, San Francisco; Endocrine Research Unit, San Francisco Veterans 
Affairs Health Care System, United States, 2Departments of Radiology and 
Biomedical Imaging, University of California, San Francisco, United States, 
3Departments of Mechanical Engineering and Bioengineering, University of 
California, Berkeley, United States
Osteoporosis care in men is suboptimal due to low rates of DXA testing. Biomechan-
ical computed tomography analysis (BCT) can be applied “opportunistically” to prior 
hip-containing CT scans to measure femoral bone strength using finite-element analysis and 
DXA-equivalent femoral neck BMD, both of which are independently associated with in-
cident hip fracture in men. In this study, we used BCT in older male Veterans with prior ab-
dominal/pelvic CT performed for unrelated indications to investigate their prevalence of os-
teoporosis, as defined by either hip BMD (T-score <= -2.5) or fragile bone strength (<= 3500 
N). Additionally, we identified which clinical parameters are associated with osteoporosis in 
these men.Out of 4,209 abdominal/pelvic CT scans performed between 2017 and 2019 in 
men age >= 65 in the San Francisco Veterans Affair Health Care System, 625 de-identified 
CT scans were randomly selected for BCT analysis, stratified by age. Scans were excluded 
if the femoral coverage or image quality was insufficient. Blinded from the BCT analysis, 
data from the electronic health record were collected on demographics, medical history, 
prescriptions, labs, and prior imaging. These data were then associated with osteoporosis 
using multivariate logistic regression.After exclusions, we obtained BCT results from 557 
men. Mean age was 77.2 +/- 7.6 years; 69.1% were white; mean BMI was 26.9 +/- 5.4 kg/
m2. Most CTs were performed in an outpatient setting (62.1%); cancer (47.8%), chronic 
kidney disease (36.6%), and diabetes (30.3%) were the most common comorbidities. As 
expected, prevalence of osteoporosis increased with age (Fig 1). In those with osteoporosis, 
42.6% had a history of major osteoporotic fracture, 38.0% had a prior DXA ever, and 18.6% 
had received antiresorptive/anabolic therapy. In those without a prior osteoporosis diagnosis 
or treatment (n = 482) and after adjusting for age, BMI, race, and inpatient vs. outpatient 
CT, osteoporosis was associated with end stage renal disease (OR 7.4 [95%CI 2.3-23.8], 
p=0.001), COPD (OR 2.2 [1.2-4.0], p=0.009), exposure to high-dose inhaled steroids (OR 
3.7 [1.2-11.8, p=0.03), and presence of bone metastasis (OR 3.0 [1.1-8.6], p=0.04).These 
results suggest that performing BCT in men with prior CT would be valuable in identifying 
those at high risk of hip and major osteoporotic fractures, particularly those with specific 
risk factors such as advanced age, end stage renal disease, COPD, or high-dose inhaled 
steroid use.
Disclosures: Polly Fu, MD, None
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Racial Differences in Musculoskeletal Health in Elderly Population from 
the WHICAP cohort *Sanchita Agarwal1, Carmen Germosen1, Nayoung 
Kil1, Mariana Bucovsky1, John Williams1, Marcella Walker1. 1Division of 
Endocrinology, Department of Medicine, Columbia University, United States
There are racial differences in risk of fracture that are not explained by differences in 
Bone Mineral Density (BMD) by Dual X-ray Absorptiometry (DXA). Fracture rates are 
higher in White vs. Black men and women. Some data suggest intermediate fracture risk in 
Hispanics, while other work shows rates similar to Whites, a finding that may be skeletal 
site-specific. We enrolled adults >= age 65 from a multi-ethnic (34% Black, 25% White, 
41% Hispanic) population-based study in New York City. Bone health was assessed us-
ing DXA, High Resolution peripheral Quantitative Computed Tomography (HRpQCT), 
Trabecular Bone Score (TBS), Vertebral Fracture Assessment (VFA) and grip strength in 
265 participants (mean age 76+/-6 yrs). Weight was higher in Black vs. White and Hispan-
ic women while Hispanic women and men were shorter vs. the other groups (all p<0.05). 
Calcium intake was lower in Black vs. White and Hispanic women and Hispanic vs. White 
men (all p<0.05), while vitamin D intake did not differ. White women had twice as many 
historical fractures vs. both groups (both p<0.05), but no difference in vertebral fracture by 
VFA (p=0.85). Age and weight-adjusted BMD by DXA was higher at the femoral neck and 
radius in Black vs. White women (all p<0.05). In contrast at the spine, adjusted BMD was 
higher in White and Black vs. Hispanic women (all p<0.05), while adjusted TBS was higher 
in White vs. Hispanic women only (p<0.05). By HRpQCT, adjusted cortical indices tended 
to be lower in White vs. Hispanic and Black women at both sites, while White women had 
more trabeculae and lower separation vs. Hispanic women (both p<0.05). Differences result-
ed in higher adjusted stiffness in Black vs. white women at radius (p<0.05). In contrast, age 
and weight-adjusted HRpQCT trabecular indices tended to be deteriorated in Hispanic men 
at both sites, while Black men had lower indices at the tibia vs. white men, but there were 
no differences in cortical indices or stiffness. Falls, body composition and physical activity 
did not differ by race, but grip strength was lower in Hispanic vs. Black women (p<0.01). In 
summary, White women had cortical bone loss while Hispanic women had trabecular dete-
rioration leading to higher stiffness in Black women. Non-white men, particularly Hispanic 
men, tended to have trabecular deterioration vs. White men. Sex, site, and compartment-spe-
cific racial differences in microstructure may contribute to racial differences in fracture rates.
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The association of tea intake with BMD and fractures in White women and 
men of the Canadian Multicentre Osteoporosis Study (CaMos) *Suzanne 
N Morin1, Claudie Berger2, Weiyi Liu1, Jerilynn C Prior3, Angela M Cheung4, 
David A Hanley5, Steven K Boyd5, Andy KO Wong4, Alexandra Papaioannou6, 
Elham Rahme1, David Goltzman1. 1McGill University, Canada, 2Research 
Institute of the McGill University Health Centre, Canada, 3University of British 
Columbia, Canada, 4University of Toronto, Canada, 5University of Calgary, 
Canada, 6McMaster University, Canada
Purpose: Previous reports support the beneficial effect of tea consumption on BMD 
and hip fracture in women. Data are lacking on its impact on BMD change over time, on 
incident fractures, and in men. Methods: We included 7398 White participants aged 50+ 
(5355 women, 2043 men) from the population-based longitudinal cohort study CaMos at 
baseline (1995-97), among which 4386 women and 1561 men had a 5-year follow-up. Daily 
tea intake was categorized: no tea (NoT), moderate <= 2cups (MoT), and high >2 cups 
(HiT). Incident major osteoporotic fractures (MOF) were assessed yearly. We used regres-
sion models to study the association between tea intake and baseline total hip BMD (linear), 
%-change in total hip BMD over 5 years (linear), prevalent MOF (logistic) and 5-year in-
cident MOF (logistic).Results: The median daily tea intakes were 1.6 cups (IQR: 0.0-2.6) 
in women and 1.4 cups (IQR: 0.0-2.0) in men. The distribution of daily tea intake (with 
caffeinated tea representing 87%) was 22.3% in NoT, 51.1% in MoT and 26.6% in HiT for 
women, and was 27.7% in NoT, 51.4% in MoT and 21.0% in HiT in men. Compared to NoT, 
HiT consumers were older (67.8 years [SD=9.2] vs. 65.8 years [9.4]), smoked less (13% vs. 
21%) and exercised more regularly (56% vs. 51%). The average baseline total hip BMD was 
lowest in HiT (0.867g/cm2 [0.157]) and highest in MoT consumers (0.889g/cm2 [0.161]). 
The prevalence of MOF was 13.6% in women and 8.3% in men and did not differ by group 
of tea intake. In the subsample of participants with a 5-year follow-up, the total hip BMD 
decreased by 1.9% (5.2) over 5 years in HiT compared to 1.2% (4.8) in NoT. The proportion 
of incident MOF was 5.0% in women and 1.7% in men and differed by tea intake groups 
only in women. Adjusted linear regression models (Table) demonstrated that compared to 
NoT consumers, women with MoT intake had a higher baseline BMD (+ 0.013g/cm2 (95% 
confidence interval: 0.005; 0.021); however, those with a HiT intake showed a greater BMD 
loss and a higher incidence of MOF. In men, we also noted a greater loss in adjusted total 
hip BMD in HiT vs NoT consumers at 5 years. Conclusion: Our results support a favorable 
effect of moderate tea consumption in men and women. However, more than 2 cups of tea 
per day was associated with greater BMD loss over time in both men and women, and with 
increased risk for incident MOF in women.
Disclosures: Suzanne N Morin, None
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Current, but not Past Smoking, is Associated with Sex-Specific Skeletal 
Deficits *Sanchita Agarwal1, Carmen Germosen1, Nayoung Kil1, Mariana 
Bucovsky1, Natalie Cusano2, John Williams1, Marcella Walker1. 1Division of 
Endocrinology, Department of Medicine, Columbia University, United States, 
2Division of Endocrinology, Department of Medicine, Lenox Hill Hospital, 
United States
Smoking is a risk factor for fracture. The mechanism by which smoking increases frac-
ture risk and its effect on skeletal microstructure is unclear. We compared musculoskeletal 
health in current, past and non-smokers from a population-based multiethnic cohort of older 
adults in New York City, the Washington Heights-Hamilton Heights-Inwood Columbia Ag-
ing Project. Of N=265 subjects, most smokers were non-White (42% Black, 38% Mixed). 
Dual X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed To-
mography (HRpQCT), Trabecular Bone Score (TBS), Vertebral Fracture Assessment (VFA), 
and grip strength were assessed. Participants mean age was 76+/-6 years, mostly female 
(67%) with a mean smoking exposure of 22+/-21 pack-years. In men, weight and calcium 
intake were 18% and 49% lower in current (n=8) vs. past (n=39) smokers, respectively (both 
p<0.05). Age and weight-adjusted BMD by DXA did not differ at any site. Current male 
smokers had 11 % lower age and weight-adjusted TBS compared to past and non-smokers 
(both p<0.05). By HRpQCT, age and weight-adjusted trabecular (Tb) volumetric BMD was 
28-30% lower and Tb separation was higher by 22% in male current vs. past and non-smok-
ers at the radius (all p<0.05). Tb number and thickness were 16% and 8% lower in current 
vs. never smokers (both p<0.05). There were no differences in cortical indices. There were 
similar findings at the tibia. Additionally, age and weight-adjusted tibial stiffness was 25% 
lower in current vs. non-smokers (p=0.01). Grip strength was lower in current smokers vs. 
past and non-smokers (p<0.05). There were no between-group differences in age, physical 
activity, vitamin D intake, falls, or vertebral fractures by VFA in men. In women (n=177), 
current smokers were younger than both groups and non-smokers were shorter than past 
smokers (p<0.05). There were no differences by DXA, but cortical porosity by HRpQCT 
was twice as high in current (n=8) vs. past and non-smokers at the radius and 40% higher 
vs. non-smokers at the tibia (both p<0.05). There was no difference in Tb indices in women. 
Pack-years was not associated with skeletal indices. In summary, current but not past smok-
ing, is associated with trabecular skeletal microstructural deficits at the spine and peripheral 
skeleton in men and cortical deficits in women. Smoking may have sex-specific effects. The 
association with current, but not past smoking, suggests that effects of tobacco use may be 
reversible with smoking cessation.
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Gut microbiota and bone status in postmenopausal women – pilot study 
*Pawel Szulc1, Victoria Meslier2, Christian Morabito2, Nathalie Galleron2, 
Mamadou Gabou Thiam2, Nicolas Pons2, Stanislav Dusko Ehrlich2, Joël Doré2, 
Roland Chapurlat1, Hugo Roume2, Philippe Wagner3. 1INSERM UMR 1033, 
University of Lyon, Hospices Civils de Lyon, France, 2Université Paris-Saclay, 
INRAE, Metagenopolis, France, 3INSERM UMR1033 University of Lyon, 
Hospices Civils de Lyon, France
Data from clinical and experimental studies show that gut microbiota is involved in 
the regulation of bone loss after menopause in women and after ovariectomy in mice. Our 
aim was to assess cross-sectionally the association between bone status and gut microbiota 
composition in postmenopausal women. Four groups of volunteer postmenopausal wom-
en aged 60 and over were examined:A – 38 women aged 70+/-6 years with normal bone 
mineral density (BMD) defined by T-score> –1.5 at the lumbar spine, total hip and femoral 
neck (all three),B – 38 women aged 71+/-5 years with normal BMD and fractures (at least 
one prevalent vertebral fracture on a lateral DXA scan or self-reported prior fragility frac-
ture),C – 38 women aged 69+/-6 years with osteoporosis (T-score< –2.5 at one skeletal site 
at least) without fracture,D – 38 women aged 71+/-6 years with osteoporosis and fractures.
BMD measurementss and lateral scans were obtained using a Hologic Discovery A device. 
Microbial diversity and composition of the gut microbiota were assessed by standardized 
quantitative metagenomic pipeline. Metagenomic Species was used to identify and quantify 
microbial species by comparing to the 10.4 IGC2 gene reference catalogue.At the order 
rank, Christensenellales were less abundant and Burkholderiales were more abundant in 
Group B vs. other groups (p<0.05). Victivallales and Oscillospirales were more abundant in 
women with osteoporotic BMD vs. those with normal BMD (p<0.01).At the rank of Metag-
enomic Species, Akermansia muciniphila was most abundant in Group A and, somewhat 
unexpectedly, in Group D. Allisonella histaminiformans was enriched in Group B vs. other 
groups (p<0.005). Anaerostipes hadrus was enriched in women with osteoporotic BMD vs. 
those with normal BMD (p<0.01). One unclassified Methanomethylophilaceae species was 
enriched in Group D vs. other groups (p<0.001).Our preliminary data suggest that, in post-
menopausal women, BMD and fracture status seem to be associated with specific compo-
nents of gut microbiota. Further studies are needed to better characterize potential pathways 
underlying these associations, e.g. good general health status (Akermansia muciniphila, 
Christensenellales), leanness (Oscillospirales, Victivallales), inflammation (Allisonella his-
taminiformans, Methanomethylophilaceae), synthesis of short chain fatty acids (Akermansia 
muciniphila, Anaerostipes hadrus), high dietary fiber and protein intake (Christensenellales).
Disclosures: Pawel Szulc, None
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A Prospective Observational Study of Bone Mineral Density in 
Premenopausal Women with Uterine Fibroids *Michael R. McClung1, 
Arthur Santora2, Ayman Al-Hendy3, Juan Camilo Arjona Ferreira4, Yulan Li4, 
Laura McKain4, Rachel B. Wagman4. 1Oregon Osteoporosis Center, United 
States, 2Kinexum Services LLC, United States, 3Department of Obstetrics and 
Gynecology, University of Illinois/Chicago, United States, 4Myovant Sciences 
Inc., United States
Purpose: Uterine fibroids (UF) may cause heavy menstrual bleeding (HMB) and neg-
atively impact daily living and quality of life. Gonadotropin-releasing hormone (GnRH) 
agonists and antagonists treat UF-associated bleeding but are associated with bone loss. The 
aim of this prospective study was to characterize longitudinal bone mineral density (BMD) 
in untreated premenopausal women with UF over a 52-week observational period and to 
evaluate factors correlated with changes in BMD.Methods: Premenopausal women aged 
18–50 years with ultrasound-confirmed UF, were enrolled contemporaneously at a subset 
of sites conducting trials assessing the efficacy and safety of relugolix combination therapy 
(relugolix 40 mg, a GnRH antagonist, estradiol 1 mg and norethindrone acetate 0.5 mg) for 
women with HMB associated with UF (Al-Hendy, 2019). HMB was not a requirement for 
inclusion. BMD was measured by dual energy X-ray absorptiometry at the lumbar spine 
(LS), total hip (TH), and femoral neck (FN) at screening, Weeks 24 and 52. Mean % change 
in BMD from baseline was summarized by anatomic location. Trends for age, body mass 
index (BMI), and racial subgroups were examined.Results: A total of 262 participants, mean 
age 41.8 (SD: 5.5) years, were enrolled in the United States; 58% were Black/African Amer-
ican; 37% were White. Mean BMI was 31.6 kg/m2 (SD: 8.0). Baseline mean BMD at the 
LS was 1.21 g/cm2 (SD: 0.18) and the mean % changes from baseline (95% CI) were 0% 
(–0.32%, 0.31%) and –0.41% (–0.77%, –0.05%) at Weeks 24 and 52, respectively. Baseline 
mean BMD was 1.05 g/cm2 (SD: 0.15) at TH and 0.97 g/cm2 (SD: 0.19) at FN with simi-
lar minimal changes observed over 52 weeks. A histogram of % change from baseline LS 
BMD at Week 52 showed a symmetrical distribution with women who both gained and lost 
bone mass. Evaluation of subgroups, BMI < 30 kg/m2 vs >= 30 kg/m2 or Black/African 
American vs White, showed consistent results with the overall population. In the youngest 
women (age 18–34 years subgroup), gains in BMD were observed through Week 52, while 
no change or non-significant decline was observed in other age subgroups (Figure).Conclu-
sion: In this novel set of longitudinal data in premenopausal women with UF, BMD changes 
over 52 weeks were consistent with results of cross-sectional studies of BMD in women of 
reproductive age. Although age-related differences were observed, race and BMI did not 
influence BMD over time.
Disclosures: Michael R. McClung, Amgen, Speakers’ Bureau, Amgen and Myovant, 
Consultant
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Effects of Vitamin D Analogues on Fracture Incidence in Chronic Kidney 
Disease: A Systematic Review and Meta-Analysis of Randomized Clinical 
Trials *Nada Khelifi1, Louis-Charles Desbiens2, Aboubacar Sidibé2, Fabrice 
Mac-Way2. 1CHU de Quebec Research Center, Faculty and Department, Canada, 
2CHU de Quebec Research Center, Faculty and Department of Medicine, Laval 
University, Quebec City, Canada, Canada
Background: We performed a systematic review and meta-analysis of randomized clini-
cal trials (RCTs) to evaluate the effect of vitamin D analogues on fracture incidence and bone 
mineral density (BMD) in adult patients with chronic kidney disease (CKD).Methods: We 
searched MEDLINE, EMBASE, CENTRAL, ClinicalTrials.gov, and the WHO’s Interna-
tional Clinical Trials Registry Platform databases from inception to October 16, 2019. Two 
reviewers independently screened all identified references in order to include RCTs compar-
ing active vitamin D analogues, alone or in combination, to placebo or another medication, 
in adults with CKD requiring or not dialysis. Trials involving kidney transplant recipients 
and/or comparing vitamin D analogues to anti-resorptive or anabolic bone therapy were 
excluded. Primary outcome was fracture at any anatomical site (total fractures). Secondary 
outcomes were BMD at femoral neck, lumbar spine, and/or total hip. Pre-specified sub-
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group analyses were conducted according to baseline demographics, overall risk of bias and 
follow-up time. Risk of bias was assessed with the Cochrane Risk of Bias tool. Meta-anal-
ysis was conducted with random-effects models.Results: From 6 293 references retrieved, 
9 RCTs were eligible (1 615 participants), 7 of which were used in the meta-analyses. All 
of these studies used placebo as comparator. Vitamin D analogues were not associated with 
a significant reduction in total fractures (RR= 0.92 [95% CI 0.45, 1.86], I2= 0%, 7 trials, 
1 553 patients) in overall and in pre-specified subgroup analyses. Only two trials reported 
BMD thus, a meta-analysis could not be performed. Eight RCTs were at high risk of bias, 
notably due to incomplete outcome data and pharmaceutical funding.Conclusions: Current 
evidence from RCTs is insufficient to associate vitamin D analogues with bone protection in 
CKD. Additional large and long-term studies specifically designed to evaluate the efficacy 
of vitamin D analogues on bone outcomes are thus required.Registration: CRD42020154915
Disclosures: Nada Khelifi, None
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Sex-specific differences in bone mass are maintained following spinal cord 
injury *Courtney Mazur1, W. Brent Edwards2, Ifaz Haider2, Ying Fang3, Leslie 
Morse4, Thomas Schnitzer5, Karen Troy6. 1Massachusetts General Hospital, 
United States, 2University of Calgary, Canada, 3University of Northern Arizona, 
United States, 4University of Minnesota Medical School, United States, 
5Northwestern University, United States, 6Worcester Polytechnic Institute, 
United States
Spinal cord injuries (SCI) cause rapid, severe bone loss in the distal femur and proximal 
tibia and increase risk of low-impact fracture. The rate of bone loss and the affected sites are 
distinct from osteoporosis following menopause or aging, so SCI-induced bone loss requires 
specific attention. While women are at higher risk of osteoporosis than men, current studies 
of SCI-induced bone loss do not enroll enough women to discern sex-specific patterns fol-
lowing SCI. We analyzed QCT scans from four clinical trials with nearly identical imaging 
protocols to test the hypothesis that there are sex-specific differences in bone loss following 
SCI.In this cross-sectional study of 137 people (31 female) with varying duration of SCI, 
we used baseline QCT scans from four clinical trials. Protocols were approved by the IRB 
at each study site, and all participants provided informed consent. Scans were segmented to 
include all tissue inside the periosteal boundary of the proximal tibia or distal femur (0.15 g/
cm2 threshold). Regions of interest (epiphysis, metaphysis, diaphysis) were assigned as suc-
cessive 10% bone length sections.As in prior analyses, we found that integral bone volume 
(BV) in both bones and all regions does not change after SCI, while bone mineral content 
(BMC) rapidly declines until reaching a plateau approximately 3 years post-injury. In all 
regions of interest, female BV was 72-77% of that in males (Fig 1A, p<0.0001). The decline 
in BMC over time in each region of interest was well described by separate single-phase 
exponential decay curves for each sex (Fig 1B, p<0.001), which were primarily determined 
by lower mean values for females in the early (3 years post-SCI) phases. From the early to 
the plateau phase, BMC in the epiphysis, metaphysis and diaphysis was reduced by approx-
imately 63%, 54%, and 40%, respectively, for both sexes. The number of female subjects 
between 0.5-2 years post-SCI was insufficient to detect sex-specific changes in the rate of 
BMC change. As expected with lower BV and BMC, the bending strength index (BSI) in 
female bones was significantly lower than in males over time, particularly in the metaphysis 
and diaphysis (Fig 1C, p<0.001). These data suggest that the magnitude of SCI-induced 
bone loss is similar in males and females, but due to consistently lower BV, BMC, and BSI, 
special attention should be paid to female patients to prevent low-impact fractures.
Disclosures: Courtney Mazur, None
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Incidence and Risk Factors for Osteoporotic Non-vertebral Fracture in 
Low-Income Community-dwelling Elderly: a Population-based Prospective 
Cohort Study in Brazil. The São Paulo Ageing & Health (SPAH) Study. 
*Diogo Souza Domiciano1, Luana Gergeim Machado1, Camille Pinto 
Figueiredo1, Valéria Caparbo1, Ricardo M Oliveira2, Paulo Rossi Menezes3, 
Rosa Maria Rodrigues Pereira1. 1Bone Metabolism Laboratory, Rheumatology 
Division, Faculdade de Medicina da Universidade de São Paulo., Brazil, 2RDO 
Diagnósticos Médicos, Brazil, 33Department of Preventive Medicine, Faculdade 
de Medicina da Universidade de São Paulo., Brazil
Introduction. No data on incidence of osteoporotic non-vertebral fracture have been 
reported in low- income countries where the population’s aging has been faster. Even in 
developed countries, currently available prospective data on major fractures rates beyond 
hip are scarce. Thus, we sought describe the incidence and risk factors for non-vertebral 
fracture in a longitudinal prospective Brazilian population-based elderly cohort.Methods. 
707 older adults (449 women, 258 men) were evaluated at baseline and after a mean fol-
low-up of 4.3+/-0.8 years. Clinical questionnaire, bone mineral density (BMD) and labora-
tory tests were performed at baseline. New non-vertebral fracture (hip, proximal humerus, 
rib, forearm) was determined during the follow-up. Multivariate Poisson regression mod-
els were used to identify independent predictors of fracture.Results. The age-standardized 
incidence of non-vertebral fracture was 1706.1/100,000 person-years (pyr) in women and 
632.8/100,000 in men. Concerning to hip fractures, the incidence was 421.2/100,000 pyr 
in women and 89.9/100,000 in men. In a multivariate analysis, age (RR 2.07, 95% CI 1.13-
3.82, p=0.019, per each 10-year increase), prior non-vertebral fracture (RR 3.08, 95% CI 
1.36-6.95, p=0.007) and total hip BMD (RR 1.68, 95% CI 1.11-2.56, p=0.015, per each 1 SD 
decrease) were predictors of new non-vertebral fracture. In men, fitting a model of risk fac-
tors for fracture was prevented by the limited number of events in male sample.Conclusion. 
This is the first population-based study to ascertain the incidence of major non-vertebral 
fractures in elderly Latin Americans, confirming the high frequency of the disorder. Age, 
prior fracture and hip BMD were predictors of the short-term incidence of fracture.
Disclosures: Diogo Souza Domiciano, None
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How do risk factors for incident fracture differ in obese and non-obese 
community-dwelling older men? The Concord Health and Ageing in Men 
Project *David Scott1, Markus Seibel2, Robert Cumming2, Vasi Naganathan2, 
Fiona Blyth2, David Le Couteur2, David Handelsman2, Benjumin Hsu2, Louise 
Waite2, Vasant Hirani2. 1Monash University, Australia, 2University of Sydney, 
Australia
Background: Obese older adults have higher bone mineral density (BMD) than non-
obese counterparts but other characteristics of obesity, including increased falls risk, met-
abolic disorders and hypogonadism, may predispose these individuals to fracture. Further-
more, high body mass index (BMI), which is generally used to define obesity, is associated 
with better BMD and reduced fracture risk, whereas high fat mass per se may not be. The 
primary aim of this study was to compare clinical risk factors for incident fracture in com-
munity-dwelling older men with and without obesity, defined according to body fat percent-
age.Methods: BMI and body fat percentage were assessed at baseline by anthropometry 
and dual-energy X-ray absorptiometry, respectively, in 1,625 community-dwelling men aged 
>=70 years. Categories for non-obese and obese were <30kg/m2and >=30kg/m2 for BMI, 
and <30% and >=30% for body fat percentage. Sociodemographic, medical, physical func-
tion and blood biochemistry parameters were collected at baseline. Self-reported incident 
fractures of any type and cause (excluding pathological fractures and fractures of hands, 
fingers, feet, toes and the skull) were confirmed by radiographic reports and recorded up to 9 
years. Hip fractures were also followed for 14 years using data linkage.Results: Prevalence 
of obesity was lower when defined according to BMI (27%) than when defined according to 
body fat percentage (44%). There were no differences in incidence of any fracture between 
non-obese and obese men by BMI (10.7 vs 9.3%, respectively; P>0.05) or body fat percent-
age (10.2 vs 10.6%, respectively; P>0.05). When obesity was defined according to body fat 
percentage, significant interactions were observed demonstrating that prevalent dementia 
at baseline increased hazard for incident any and hip fracture in non-obese men (adjusted 
hazard ratio 7.08; 95% CI 3.27-15.36 and 8.36; 3.13-22.31, respectively) but not for obese 
men. Past-year falls increased hazard for any fracture in obese men (2.86; 95% CI 1.60-5.10) 
but not for non-obese men, while higher luteinizing hormone concentrations reduced hazard 
for hip fracture in obese men (0.91; 0.85-0.97 per IU/L) but not for non-obese men.Conclu-
sions: Community-dwelling older men with obesity, regardless of the definition applied, do 
not demonstrate reduced risk for incident fracture compared with non-obese counterparts. 
Assessments of falls history and gonadotrophin levels, in addition to established clinical 
risk factors for fracture, may contribute to improvements in fracture prediction in obese 
older men.
Disclosures: David Scott, None
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Long-Term Changes in Bone Mineral Density and Trabecular Bone Score 
among Chinese Patients with HIV on Antiretroviral Therapy *Wenmin 
Guan1, Wei Pan2, Wei Yu3, Xiaojing Song2, Yanling Li2, Taisheng Li2, Evelyn 
Hsieh4. 1Department of Radiology, Peking Union Medical College Hospital, 
Chinese Academy of Medical Sciences and Peking Union Medical College, 
China, 2Department of Infectious Diseases, Peking Union Medical College 
Hospital, Chinese Academy of Medical Sciences, China, 3Department of 
Radiology, Peking Union Medical College Hospital, Chinese Academy of 
Medical Sciences, China, 4Rheumatology, Yale School of Medicine, United 
States
PurposeAntiretroviral therapy (ART) has been associated in several studies with low 
bone mineral density (BMD) in persons with HIV (PWH). However, BMD measured by 
dual-energy X-ray absorptiometry (DXA) only provides information about bone mineral 
quantity. Trabecular bone score (TBS) is a textural index that estimates bone microarchitec-
ture from lumbar spine DXA images. Few studies have reported long-term changes in TBS 
in PWH.Materials and MethodsWe conducted a retrospective chart review of adult PWH 
receiving care at a large tertiary care center in Beijing. Patients were included in this analysis 
if they had a DXA scan prior to ART initiation and at least one follow-up DXA after ART 
initiation. We collected information regarding demographic and clinical history, HIV treat-
ment, BMD and TBS information.ResultsA total of 459 PWH were included in this analysis 
(mean age: 36.1+/-11.3 years). Among 391 patients <50 years of age, 10 (2.6%) had a BMD 
below the expected range for age (Z score <=-2.0). Among 68 patients >=50 years, low bone 
density (-2.5< T score <-1) was diagnosed in 15 (22.1%) and only 1 (1.5%) had osteoporosis 
(T score <=-2.5). TBS of 107 patients (23.3%) and 6 patients (1.3%) were partially degraded 
(1.200< TBS <1.350) and degraded (TBS <=1.200), respectively. Mean percent change in 
lumbar spine BMD from 0 to 48 weeks (-3.0%) was larger than the percent change observed 
from 0 to 96, 144, and 192 weeks (-2.4%, -1.1%, and -1.3%, respectively, p<0.002). The 
mean percent change from 0 to 240 weeks was not statistically significant. Femoral neck 
BMD decreased by -3.5% from 0 to 48 weeks, and by -4.6% from 0 to 96 weeks. Thereafter 
the percent change from baseline remained stable (p=0.595). The percent change in total 
hip BMD was similar to that of femoral neck BMD at each timepoint. In terms of TBS, the 
largest percent change was observed from 0 to 48 weeks (-1.6%), compared with -1.1% to 
-1.2% change observed between week 0 and subsequent timepoints (Figure 1).ConclusionAt 
baseline, among PWH with normal BMD, 20%-40% of them were identified as having par-
tially degraded or degraded TBS respectively. After three years of ART, the percent change 
from baseline in BMD and TBS remained stable. Lumbar spine BMD returned to baseline 
levels at 240 weeks, but femoral neck / total hip BMD and TBS did not recover.
Disclosures: Wenmin Guan, None
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Osteoporotic Fractures in the Arab region A Systematic Review *Maya 
Barake1, Rozana El Eid2, Marlene Chakhtoura2, Lokman Meho3, Tala Mahmoud4, 
Jessica Atieh3, Abla Mehio SIbai5, Sara Ajjour2, Ghada El Hajj Fuleihan2. 
1Clemenceau Medical Center, Lebanon, 2American University of Beirut Medical 
Center, Lebanon, 3American University of Beirut, Lebanon, 4University of 
Balamand, Lebanon, 5American University of Beirut, Lebanon
Asia is projected to account for the largest proportion of the rising burden of osteopo-
rotic fractures worldwide. Data from the Middle East is scarce. We performed a systematic 
review on the epidemiology of vertebral and hip osteoporotic fractures in 22 Arab League 
countries, using Scopus, Pubmed and Embase. We identified 64 relevant publications, of 
which 37 were in Q1 Scopus-rated journals, mostly of fair quality. Of the 17 eligible hip 
fracture studies, only 6 provided hip fracture incidence data. Mean age of hip fractures pa-
tients was 70-74 years, female to male ratio was 1.2-1.35. Age-standardized incidence rates, 
to the UN 2010 population, were 200 to 300/100,000 for women from Kuwait and Lebanon, 
and lower in Morocco. Risk factors included lower BMD or BMI, taller stature, intake of 
anxiolytics and sleeping pills. Most patients were not tested nor treated, and mortality 1-2 
years post-fracture varied between 12-47%. Of the 18 Q1 papers on vertebral fractures, 14 
based on 10 cohorts presented data on prevalent fractures. In women, the prevalence of 
morphometric vertebral fractures varied, possibly due to differences in population selection, 
patients’ mean age or fracture detection. Excluding grade I fractures, 7.9-25.6% of women, 
from Lebanon and Morocco, mean age 58-74 years, had prevalent vertebral fractures; and 
12-14% of men from the same countries, mean age of 62-74 years, had. Risk factors included 
age, gender, smoking, multiparity, years since menopause, low BMD, bone markers, high 
sclerostin, low IgF1, hypovitaminosis D, Abdominal Aortic Calcification (AAC) score and 
Vitamin D Receptor (VDR) gene polymorphisms. Vertebral fracture incidence in women 
from Saudi Arabia, mean age 61 years, with low baseline risk, was 6.3% at 5 years. Prospec-
tive population-based studies on incidence and prevalence, predictive models, and fracture 
outcomes from Arab countries are lacking. They are the key for addressing the staggering 
osteoporosis burden and closing the care gap of this deadly disease.
Disclosures: Maya Barake, None
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Associations Between Lipid Concentrations and Bone Mineral Density in 
a Cohort of Patients With History of Fractures. *Charilaos Chourpiliadis1, 
Evangelos Karvounis2, Harikleia Hourpiliadi1, Dionysios Papachristou3, 
Georgia Antoniou4, Juan Jaume5, Rodis Paparodis5. 1Private Practice, Greece, 
2Department of Endocrine Surgery, EuroclinicGeneral Hospital, Greece, 
3University of Patras School of Medicine, Greece, 4Department of Orthopaedics, 
Evaggelismos General Hospital, Greece, 5Center for Diabetes and Endocrine 
Research, University of Toledo, United States
Purpose: Population-based studies identified an association between serum HDL con-
centrations and bone mineral density (BMD). We designed this study to examine all lipids 
association with BMD in a population with a history of fractures.Methods: We prospec-
tively enrolled adult subjects of both genders with history of fracture(s) (anytime during 
their lifetime), not on lipids-altering medications, at our practice in Patras, Greece, between 
2014-2018. We recorded patients’ age, menopause status and tobacco use. We performed a 
fasting lipid panel and BMD measurements at >=2 sites, with a GE Lunar DEXA device. 
We split our subjects’ BMD, based on the lowest T/Z-score in “Normal” (>-1.0), “low bone 
mass” (LBM) (-2.5) and “Osteoporosis” (OST) (<=-2.5). We classified them according to 
gender, smoking status, age and lipids concentrations. Ratios were compared with χ2 test; 
continuous variables were compared with one-way ANOVA; correlations were estimated 
with Spearman’s rank correlation coefficient; p<0.05 was deemed significant.Results: We 
screened 3596 consecutive patients and enrolled 332 subjects with history of fractures; 
70.5% of them had abnormal BMD (OST or LBM). Subjects with BMI>=25kg/m2 had high-
er mean T/Z score compared to those with BMI<25kg/m2 in men >50 years old and in all 
women’s subgroups. HDL correlated negatively with the lowest T/Z score (r=-0.19, p=0.01) 
and this association remained significant independent of tobacco use (smokers: r=-0.20, non 
smokers: r=-0.15, p=0.03 for both). Individuals with OST had the highest mean HDL-C 
concentration (p=0.04) compared to LBM and Normal BMD. In subjects of age >50, the 
lowest T/Z score correlated positively with LDL (r=0.17, p=0.02) and triglycerides (r=0.22, 
p=0.002) concentrations. Triglycerides were higher in those with normal, compared to those 
with abnormal BMD (p=0.001). OST was more prevalent in subjects with normal compared 
to those with elevated triglycerides [p=0.004, OR 2.7(1.4-5.4)]. Lower triglycerides were 
found in individuals with recurrent fractures, compared to those with one fracture (p=0.03). 
LDL-C was higher in postmenopausal women with normal T/Z score compared to those 
with abnormal BMD (p=0.003). Total cholesterol concentration was higher in individuals 
>50 with history of hip fracture, compared to those with other fracture sites.Conclusions: 
Our analysis identified a strong association between bone mass and lipids concentrations, 
implying that these metabolic parameters might play a - yet not fully elucidated - role in 
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bone metabolism and BMD. Since the interactions between the liver, adipose and skeletal 
metabolism are very complex, further studies are required to address this issue.
Disclosures: Charilaos Chourpiliadis, None
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A Tailored Education Program Can Increase Bone Health Knowledge in 
Older Black Adults *Nicole Wright1, Ventrice Shillingford-Cole1, Ama Lee2, 
Ann Wingate3, Kathleen Cody3. 1University of Alabama at Birmingham, United 
States, 2BonesNBalance, United States, 3American Bone Health, United States
Purpose: Previous studies report that osteoporosis and bone health knowledge is lower 
in Black and other women of color compared to White women. However, osteoporosis edu-
cational efforts have infrequently targeted populations of color, taken place in their commu-
nities, or have been led by someone from the community. Our study evaluated if a peer-edu-
cator led bone health educational program tailored for Black women increases osteoporosis 
knowledge. Methods: We tailored an American Bone Health community presentation for 
Black women to increase knowledge and awareness about bone health, osteoporosis, and 
fractures. The 60-minute program, “Why Healthy Bones Matter” covered the importance of 
the musculoskeletal system, data about bone health in the Black community, and provided 
four elements designed to encourage action including: understanding baseline bone health, 
identifying factors that increase bone loss, engaging in protective bone health activities, 
and becoming proactive about bone health. Participants completed a pre- and post-survey, 
including the Osteoporosis & You Knowledge scale, which we evaluated pre and post pro-
gram.  Results: To date, 16 participants with a mean (SD) age of 61.1 (13.5) years attended 
one virtual session. Three (19%) of the participants had a prior fracture, but only one report-
ed having a DXA scan. When asked what the greatest obstacle was in taking care of their 
bones, the majority reported that they rarely thought about bone health (42.9%) or were 
more concerned with other health issues (42.9%). The mean (SD) pre-osteoporosis knowl-
edge score was 7.6 (2.0) out of 10, which increased to 9.4 (0.70) post program. The greatest 
change pre- and post- program was observed in the “bones cannot be rebuilt once they thin 
from osteoporosis” question. Similar results were seen among those with pre- and post- data 
(n=9). All participants (100%) said that they planned to make changes in their life based on 
something they learned from the program.Conclusions: Despite global circumstances re-
sulting in a virtual format, in our sample of community-dwelling Black adults, we observed 
increases in bone health knowledge with a tailored educational program. Given where the 
largest change was observed and the reports of plans to change, our program indicates an 
intention to act around bone health. This is the first step needed to see if increasing knowl-
edge leads to activation and changes in behaviors regarding bone health in Black women.
Disclosures: Nicole Wright, Amgen, Grant/Research Support, Pfizer, Other Financial or 
Material Support
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A RETROSPECTIVE OBSERVATIONAL STUDY TO ESTIMATE 
PREVALENCE OF FRAGILITY FRACTURES IN SPANISH PRIMARY 
CARE (PREFRAOS STUDY): INTERIM ANALYSIS *Cristina Carbonell1, 
Daniel Martínez-Laguna2, José-Carlos Bastida3, Milagros González4, Rafael 
M Micó-Pérez5, Francisco Vargas6, Mónica Balcells-Oliver7, Laura Canals7. 11 
Health Center Vía Roma, Barcelona. 2 GREMPAL Investigation Group, IDIAP 
Jordi Gol, Spain, 22 GREMPAL Investigation Group, IDIAP Jordi Gol.3. Health 
Center Sant Martí de Provençals, Barcelona 4. CIBERFes 3, Spain, 35. Health 
Center of Marín, Pontevedra, Spain, 46 Health Center of Montesa, Madrid, 
Spain, 57. Health Center of Fontanars dels Alforins, EAP Ontinyent, Valencia, 
Spain, 68. Health Center Dr. Guigou, Santa Cruz de Tenerife, Spain, 79. Medical 
Department, Amgen Europe, Spain
Purpose: Some studies suggest underdiagnosis and inadequate treatment of osteopo-
rosis (OP) among elderly patients in Spanish Primary Care (PC) settings. Recent data on 
the prevalence of fragility fractures in this population is lacking. The purpose of this study 
was to estimate the prevalence of fragility fractures among subjects >=70 years old seen in 
Spanish PC centers and describe the main characteristics of OP in subjects with at least one 
fragility facture.Methods: This is an observational, retrospective chart review in Spanish PC 
centers. The study is divided into two phases (A and B). Phase A comprises subjects >=70 
years old listed in the participating center´s medical records from November 2018-Febru-
ary 2020. Phase B includes approximately 20 consecutive consented subjects per center 
with a recorded fragility (osteoporotic) fracture (defined as a ‘low energy‘ trauma) and prior 
consultation at the center for any reason. Phase A will estimate the prevalence of fragility 
fractures in the PC setting and Phase B will describe the main characteristics of OP (risk 
factors, diagnosis and non-pharmacological /pharmacological interventions) in subjects with 
at least one fragility facture. We report data from an interim analysis of Phase A (data cut-off 
dated February 26,2020).Results: 32 PC centers across 15 Spanish Regions participated. Of 
47,472 medical records reviewed in Phase A, 20.2% (9,586) subjects were >=70 years old. 
The majority of these eligible patients were female (5,731/9,586 [59.8%]). The prevalence 
of fragility fractures is summarised in Table 1.Conclusions: Prevalence of fragility fractures 
in subjects >=70 years old seen in Spanish PC centers is 17.1%, being higher in women 
(23.4% had at least one fragility fracture) and vertebral the most common fracture type. 
The prevalence of fragility fractures in all locations assessed was higher among women 
compared with men.
Disclosures: Cristina Carbonell, AMGEN Europe, Consultant
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Pelvic Ring Fragility Fractures:  A Debilitationg Fracture Occurring in 
Elderly Ambulatory Patients with Monoclonal Gammopathy of Uncertain 
Significance, Pernicious Anemia, Hyponatremia, and Associated with High 
Mortality *Michael Lovy1. 1Desert Oasis Healthcare, United States
PURPOSE: To study the clinical characteristics and course of a cohort of patients 
presenting with pelvic ring fragility fractures(PFF).METHODS:  A retrospective chart re-
view of 43 patients with PFF seen over a 4 year period in a community based outpatient 
fracture clinic was conducted.  A complete history and physical, review of medical records 
and x-rays, CBC, chemistry profile, TSH, urinalysis, vitamin B12, 25-OH vitamin D, PTH, 
and immunofixation(IMF) was done in all patients.  Antiparietal cell(APA) and intrinsic 
factor(IF) antibody and SPE was done in select cases. Comorbidity including history of 
solid tumor, diabetes, COPD, cardiac and neurologic disorder were tabulated.RESULTS: 
There were 38 females and 5 males ranging in age 55-95 years(mean 82.3). 23 patients 
had a previous major osteoporotic fracture and 8 a total hip replacement.  17 had received 
previous osteoporosis treatment.  40 patients were living at home and 22 were still driving 
within 3 months prior to the fall causing the PFF.  13 were using ambulatory aids.  Patients 
had 0-3(mean 0.93) comorbid conditions:  COPD-11, cardiac-11, cancer-7, neurologic-6, 
and diabetes-5.  2 patients had previous radiation therapy to the pelvic area.  The BMI was 
20< in 9 patients and 19 had peripheral neuropathy(PN). CT or MRI confirmed the PFF in 37 
patients and showed fractures of the sacrum-17, acetabulum-7, and both sacrum and acetab-
ulum-5 in addition to the pelvic rami.  Monoclonal protein was found with IMF in 17(42%) 
patients:  IgG-7, IgG-6, and light chains-4.  M-spike was found in 8.  5(14%) patients had 
low vitamin B12 and either APA or IF.  3 patients had vitamin D levels 20<ng/ml and 7 
had hyponatremia. Alkaline phosphatase was elevated in 12 patients. 29 patients required 
rehabilitation in a nursing home.  During follow up (mean 20.7 months) 12(31%) patients 
died,10 within 1 year after PFF from causes unrelated to the fracture.CONCLUSIONS:  PFF 
occurs predominantly in female, elderly, independent and active patients with few comorbid 
conditions and is associated with significant morbidity.  PFF may be a prelude to mortality 
within 1 year of occurrence.  CT or MRI scans are necessary to define the full extent of injury 
to the pelvis.  Although the clinical characteristics may differ between PFF, hip, and vertebral 
fracture patients, they all share age related conditions such as low BMI, PN, MGUS, perni-
cious anemia and hyponatremia that predispose to falling and bone fragility.
Disclosures: Michael Lovy, None
P-563
VERTEBRAL  FRACTURES IN LIVING DONOR LIVER TRANSPLANT: 
STUDY FROM A TERTIARY CARE CENTRE IN INDIA *Shalin Shah1, 
Beena Bansal1, Sunil Kumar Mishra1, Mohammad Shafi Kucchay1, A S Soin1, Jai 
Prakash Sharma1, Ambrish Mithal1. 1Medanta The Medicity, India
Objective:To determine the prevalence of radiological vertebral fractures in living do-
nor liver transplant recipients.  Methods:84 consecutive patients visiting the liver transplant 
clinic from December 2017 to October 2018, aged >18 years, were included in the study. 
These patients had undergone liver transplant between 2010 to 2017. Vertebral fractures 
were assessed semi-quantitatively from lateral spine X-rays using Genant scoring. Re-
sults:The mean age of the patients was 50.7+/-10.1 years with 76 males and 8 females. The 
median duration from liver transplantation was 5 months (range 1.4-96.1 months). Vertebral 
fractures were recorded in 39/84 (46.4%) patients, out of which only one was symptomatic. 
Thoracic fracture was seen in 22 (26.2%) patients (Grade 1- 14.3 %, Grade 2- 8.3%, Grade 
3- 3.6 %) and lumbar fractures in 24 (28.6%) patients (Grade 1- 22.6%, Grade 2- 4.8%, 
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Grade 3- 1.2%). There was a significant difference in the age of the patients with and without 
fracture, with fracture rates being highest in patients aged more than 60 years. There was no 
significant difference in the prevalence of fracture in patients with history of diabetes, smok-
ing, alcohol, previous history of vertebral or upper limb fractures or those receiving calcium 
and vitamin D supplementation. Serum levels of calcium (9.73 vs 9.69 mg/dl), phosphorus 
(3.54 vs 3.57 mg/dl), PTH (50.8 vs 58.5 pg/ml) and 25 (OH) D (21.2 vs 20.4 ng/ml) were 
not different between the two groups. We looked at the relationship of vertebral fractures 
with the etiology of chronic liver disease (CLD). Vertebral fractures were found in 8/10 
patients with NAFLD (Non Alcoholic Fatty Liver Disease), 8/14 patients with hepatitis B 
associated CLD, 15/30 patients with alcoholic liver disease, 2/6 patients with autoimmune 
CLD, 3/11 patients with cryptogenic CLD, and 1/6 patients with HCV CLD. No fractures 
were found in patients with Wilson’s disease (0/4) and Budd-Chiari syndrome (0/3).Verte-
bral fractures were more prevalent in patients who had undergone transplant in the previous 
one year.  Conclusions:Asymptomatic vertebral fractures are a common occurrence in living 
donor liver transplant recipients in India. Liver transplant recipients should be evaluated 
for vertebral fractures prior and within one year after transplantation. Strategies to optimize 
bone mass prior to transplant and prevention of further bone loss in the early post-transplant 
period need to be implemented uniformly.
Disclosures: Shalin Shah, None
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Changes in Bone Mineral Density and Trabecular Bone Score in Chinese 
HIV-Infected Individuals One Year after Initiation of Antiretroviral 
Therapy *Wenmin Guan1, Wei Pan2, Wei Yu3, Xiaojing Song2, Yanling Li2, 
Taisheng Li2, Evelyn Hsieh4. 1Department of Radiology, Peking Union Medical 
College Hospital, Chinese Academy of Medical Sciences & Peking Union 
Medical College, China, 2Department of Infectious Diseases, Peking Union 
Medical College Hospital, Chinese Academy of Medical Sciences, China, 
3Department of Radiology, Peking Union Medical College Hospital, Chinese 
Academy of Medical Sciences, China, 4Rheumatology, Yale School of Medicine, 
United States
PurposeHIV infection and antiretroviral therapy (ART) have been associated with 
reduced bone mineral density (BMD) in persons with HIV (PWH). BMD measured by 
dual-energy X-ray absorptiometry (DXA) provides information only about bone mineral 
quantity but not bone microarchitecture. Trabecular bone score (TBS) is a noninvasive tool 
that estimates bone microarchitecture from lumbar spine DXA images. No prior studies have 
measured changes in TBS among Chinese PWH.MethodsWe conducted a retrospective chart 
review of adult Chinese PWH seen at a large tertiary care hospital. Patients with a DXA 
scan prior to ART initiation, and again 48 weeks later were included. Information regarding 
demographic and clinical history, HIV treatment history, BMD and TBS were collected. We 
analyzed differences in BMD and TBS over 48 weeks in the overall group, and by exposure 
to three types of antiviral drugs [tenofovir disoproxil fumarate (TDF), lopinavir/ritonavir 
(LPV/r) and efavirenz (EFV)]. Associations between key risk factors and changes in BMD 
and TBS were analyzed using linear regression.ResultsOur study included 233 PWH (mean 
age = 36.6+/-11.1 years). Patients treated with regimens containing TDF (Figure 1) or LPV/r 
showed greater percent decreases in BMD than those on regimens without those agents. 
The differences in TBS were not significant in any of the groups. Higher baseline HIV viral 
load and TDF exposure were associated with larger decreases in BMD at each site. The use 
of LPV/r was only associated with decreased total hip BMD [β (95% CI): -0.213 (-0.373, 
-0.053), p=0.009]. Lower BMI [0.250 (0.008, 0.492), p=0.043] and higher baseline CD4+ 
cell count [-0.005 (-0.010, 0.000), p=0.032] were associated with larger decreases in TBS. 
No associations were found between TBS changes and specific antiretroviral exposure.Con-
clusionBoth BMD at each site and TBS decreased one year after ART initiation. Although 
BMD decreases were observed in patients treated with TDF- and PI-containing regimens, 
change in TBS was not statistically significant. Lower BMI and higher baseline CD4+ cell 
count were associated with greater declines in TBS.
Disclosures: Wenmin Guan, None
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Dentists’knowledge about osteoporosis and the ability to identify the disease 
*Renato Ferreira1, Suely Roizenblatt1, Vera Szejnfeld1. 1UNIFESP/Escola 
Paulista de Medicina, Brazil
Objective: to evalute the knowledge of general dentists about osteoporosis and verify 
their ability to identify these patients by applying mandibular cortical width (MCW) and 
mandibular cortical index (MCI) on panoramic dental radiographs using a simple visual 
method. Methods: A questionnaire regarding the diagnosis and prevention of osteoporosis 
was administered via e-mail to 20773 dentists. These proofessionals indication was obtained 
from the database provided by the Regional Council of Dentistry of the State of Sao Paulo. 
The dentists who completed the questionnnaire were selected and, after receiving mandibu-
lar radiomorphometric training via internet, analysed MCI and MCW of 114 panoramic ra-
diographs of postmenopausal women who were submitted to both panoramic radiograph and 
bone densitometry of the spine and femur. Based on radiomorphometric indices, and without 
knowledge of densitometry results, the dentists decided if they would or not indicate bone 
density for these patients. Results: Overall, 485 dentists completed the questionnaire, and 50 
evaluated panoramic radiographs using MCW and MCI. Although all of them answered that 
they had some knowledge about osteoporosis, 41.6% responded that osteoporosis is “lack of 
calcium in bones”, demonstrating the misleading concept of the disease. About 90%reported 
minimal or no access to this information during graduation and only 27% had adequate ex-
posure to the theme during postgraduate training. About 70.7% expressed the desire to learn 
more about osteoporosis prevention and 99% expressed interest in learning how to apply 
the radiomorphometric indices on panoramic radiographs. The application of the MCW and 
MCI indices by dentists resulted in 52.9% sensitivity and 64% specificity for the detection of 
low mineral density. Conclusions: Dentists have insufficient knowledge about osteoporosis 
and their ability to detect osteopenia or osteoporosis, by applying radiomorphometric indi-
ces, is lower than described in the literature.  
Disclosures: Renato Ferreira, None
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The study of risk factors for fractures in sports veterans *Elena Tenyaeva1, 
Elena Turova2, Golovach Albina2, Irina Articulova2. 1Turova E.A., Golovach 
A.V., Articulova I.N., Russian Federation, 2membership, Russian Federation
The purpose of the study was to research the metabolic parameters of bone metabolism 
in sports veterans depending on the type of physical activity and their relationship with the 
probability of developing osteoporotic fractures.Metabolic parameters of bone metabolism 
were studied in 50 sports veterans aged 51 to 82 years, the average age of athletes was 
67 years. Athletes previously engaged in such sports as swimming, cross-country skiing, 
cycling, jumping, light and heavy athletics, football, hockey, speed skating, figure skating, 
and martial arts. Of the examined sports veterans, 9 people (in 18% of cases) had fractures 
of the radius, hip neck or spine.Statistical analysis showed a significant negative correlation 
of vitamin D level with age (r= -0.25, p<0,05), parathyroid hormone level (r= -0.23,p<0,05 
), probability of fracture development (r= -022,p<0,05 ) and positive with body mass index 
(r=0.32, p<0,05), osteocalcin level (r=0.16,p<0,05 ) and testosterone (r=0.22, p<0,05). The 
probability of developing fractures did not depend on the level of osteocalcin and b-cross-
laps.There was a negative correlation of testosterone levels, regardless of the gender of ath-
letes, with the probability of developing fractures (K= -0.27,p<0,05 ) and also a negative 
correlation of insulin levels with the probability of developing fractures (r= -0.23, p<0,05).
When analyzing sports depending on the Olympic classification, it was found that sports 
veterans who were engaged in cyclical and speed-power sports had lower levels of testos-
terone, vitamin D and osteocalcin than athletes who were previously engaged in martial arts 
and weightlifting (p<0,05), which is probably due to high levels of bone and muscle mass 
under these sports loads.Thus, it was found that sports veterans who previously engaged in 
martial arts or weightlifting, the probability of osteoporotic fractures is lower than in cyclic, 
game and speed-power sports, due to higher levels of vitamin D, testosterone and higher 
muscle mass
Disclosures: Elena Tenyaeva, None
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The Silent Wreck – Prevalence and risk factors of Atraumatic Osteoporotic 
Vertebral Compression Fractures *Saikrishna Gadde1, Sudhir Ganesan1, 
Ajay Gowtham1, Shriraam Mahadevan1, Adlyne Reena Asirvatham1, Vignesh 
Jeyabalan1, Karthik Kailash Kannan1. 1Sri Ramachandra Medical College and 
Research Institute, India
Background: Osteoporosis emerged to be a major contributor for the rise in morbidity 
among elderly population along with other chronic medical diseases. It is a skeletal disorder 
characterised by compromised bone strength, predisposing a person to an increased risk of 
fragile fractures. The presentation of a vertebral compression fracture may vary from being 
asymptomatic to complete paraplegia and disability. These fragile vertebral compression 
fractures are not always caused due to trauma, shifting the focus over to the concept of skel-
etal endocrinology.Purpose: The main purpose of this study is to find the prevalance and risk 
factors associated with atraumatic vertebral compression fractures of thoracolumbar spine 
in an emerging country where the socioeconomic conditions do not encourage aggressive 
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screening.Methodology: This is a cross sectional study conducted on 700 individuals aged 
above 50 years at Sri Ramachandra Medical Centre, Chennai from 2017-2019 and their plain 
radiographs of the thoracolumbar spine were assessed. Reduction in the vertebral height of 
more than 25% was considered as a fracture. Patients with history of previous spinal surgery 
and deformities were excluded. Questionnaire containing information regarding age, gender, 
height, weight, Body Mass Index, comorbid conditions, chronic drug usage, vision prob-
lems, previous and family history of fragile fractures were filled by them. Data was assessed 
using FRAX scoring system and statistical analysis was done. Bone Mineral Density was 
not calculated.Results: 19% of the subjects had vertebral compression fractures and 9.4% of 
the study population had atraumatic vertebral compression fractures. 45.28% of the subjects 
are at increased risk of hip fractures and 19.98% are at increased risk of major osteoporotic 
fractures.Conclusion: Old age, female gender, history of fragile fracture are major risk fac-
tors contributing to sustain a new fracture. There need not always be a history of trauma for 
fractures to occur. These risk factors identification may target prevention of these fractures, 
early diagnosis and intervention in order to reduce the disability, morbidity and mortality due 
to osteoporotic atraumatic vertebral compression fractures.Keywords: Osteoporosis, Atrau-
matic Vertebral Compression fractures, FRAX scoring system
Disclosures: Saikrishna Gadde, None
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Estimation of Bone Fracture Risk Using FRAX Model in Two Regions of 
Jalisco (México) *Jose Francisco Torres-Naranjo1, Edgar Saul Tejeda Chavez7, 
Martha Yadira Perez Avalos0, Roberto Gabriel González-Mendoza4, Hugo 
Gutiérrez-Hermosillo5, Claudia Martinez-Cordero6, Juan Ricardo López-Taylor4, 
Ricardo Garcia Gaeta0. 1Centro de Investigación Ósea y de la Composición 
Corporal, CIO, Mexico, 7Servicios de Salud Jalisco, Centro Universitario del 
Norte de la Universidad de Guadalajara, Mexico, 0 Centro Universitario del 
Norte de la Universidad de Guadalajara Profesor de Tiempo Completo del 
Centro Universitario del Norte de la Universidad de Guadalajara, Mexico, 
4Institute of Applied Sciences for Physical Activity and Sport, Department of 
Human Movement Sciences, Education, Sport,Recreation and Dance, University 
Health Sciences Center, University of Guadalajara, Mexico, 5Hospital Aranda 
de la Parra, Mexico, 6HRAEB Hospital Regional de Alta Especialidad del Bajio, 
Mexico, 0Departamento de Medicina Preventiva de los Servicios de Salud 
Jalisco, Mexico
Purpose: To estimate the absolute risk of major osteoporotic and hip fractures in an 
urban and rural population of some Jalisco regions using Mexico-specific FRAX® mod-
el.Material and methods: Representative samples of the population without social security 
from an urban and a rural community included 693= Mexican residents (505 women and 
188 men) aged 50-80 years (mean age 70.84 +/- 7.92 years). The absolute risk of fractures 
was calculated without BMD using the batch processing of data. High fracture risk fracture 
was fixed to a probability of 20% a 3% for MOF and HF, respectively. Results: The average 
absolute risk of major osteoporotic fractures (MOF) was 12.81% (14.78% in women and 
7.52% in men, p=0,0001), hip fractures (HF)  5.36% (6.12% in women and 3.31% in men, 
p=0.0001). The absolute risk of MOF and HF increased with age both in men and women. In 
women, the absolute risk of MOF and HF was higher in all age groups across than in men. 
There were significant differences in the absolute risk of fracture between urban and rural 
populations. MOF 10.54% and 20.70%; HF 3.97% and 10.17%, in urban and rural popula-
tions, respectively, p=0.0001). The proportion of individuals who reported a previous fragil-
ity fracture was 13.56%, and only 57% of them were classified as high-risk of fracture using 
the prespecified cut off points. Conclusion: The absolute risk of MOF and HF increased with 
age and were significantly higher among the female population. Differences were observed 
between urban and rural scenarios. Only a proportion of participants with previous fragility 
fractures were classified as high fracture risk of fracture, according to FRAX, which may 
imply a low sensibility for those patients.
Disclosures: Jose Francisco Torres-Naranjo, None
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Prevalence of Osteoporosis in Armenia and Relationship to Vitamin D 
Level *Nicholas Hutchings1, Varta Babalyan4, Annemieke Heijboer3, Sisak 
Baghdasaryan4, Mushegh Qefoyan4, Mariëtte T Ackermans3, Arus Ivanyan5, 
Anna Formenti6, Andrea Giustina6, John P Bilezikian7. 1University of California, 
Irvine, United States, 4Osteoporosis Center of Armenia, Armenia, 3Vrije 
Universiteit Medisch Centrum, Netherlands, 4Osteoporosis Center of Armenia, 
United States, 5Yerevan State Medical University, Armenia, 6Università Vita-
Salute San Raffaele, Italy, 7Columbia University, United States
Osteoporosis is a leading cause of morbidity among older women. The prevalence and 
thus the burden of the disease in Armenia is unknown. In addition, the relationship between 
vitamin D level, as measured by 25-hydroxyvitamin D (25-OH D), and bone mineral density 
(BMD) remains a matter of discussion. This study sought to identify the prevalence of oste-
oporosis and characterize the relationship between 25-OH D and T-score in post-menopausal 
community dwelling adults in Armenia. As part of a larger study investigating vitamin D 
insufficiency in the country, 265 participants underwent BMD testing, from a roughly geo-
graphically proportional distribution. BMD was evaluated by DXA of the lumbar spine, 
femoral neck, total hip, and forearm. Osteoporosis, as determined by a T-score < -2.5, in at 
least one of the anatomical regions evaluated, was detected in 46% of participants. Osteo-
penic values were detected in 31%. Only 23% had normal T-scores throughout. The mean 
25-OH D levels of osteoporotic and osteopenic individuals were not significantly different 
from those without abnormal BMD. However, we noted a trend towards lower 25-OH D 
in association with lower T-scores: participants in the lowest tertile of 25-OH D had lower 
mean T-scores in all regions than the other tertiles. We conclude that osteoporosis and os-
teopenia are prevalent in Armenia, and, given its high morbidity, addressing this disease 
should remain a high priority for clinicians and public health programs. The extent to which 
vitamin D deficiency is playing a role, given its high prevalence in the population, remains 
to be elucidated.
Disclosures: Nicholas Hutchings, None
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Low Awareness of and Knowledge About Osteoporosis Among Women in 
Armenia *Nicholas Hutchings1, Varta Babalyan2, Sisak Baghdasaryan2, Mushegh 
Qefoyan2, Arus Ivanyan3, Annemieke Heijboer4, Mariëtte T Ackermans4, Anna 
Formenti5, Andrea Giustina5, John P Bilezikian6. 1University of California, 
Irvine, United States, 2Osteoporosis Center of Armenia, Armenia, 3Yerevan State 
Medical University, Armenia, 4Vrije Universiteit Medisch Centrum, Netherlands, 
5Università Vita-Salute San Raffaele, Italy, 6Columbia University, United States
Assessing current knowledge of osteoporosis and understanding of the disease among 
the population is necessary in order to design programs to increase awareness. Such pro-
grams to disseminate knowledge are the first steps towards implementing proactive mea-
sures to prevent the disease. To that end, we conducted an assessment of knowledge and 
attitudes towards osteoporosis among post-menopausal women in Armenia. As part of a 
larger study investigating vitamin D in the country, 591 postmenopausal women (mean age 
63) completed questionnaires about osteoporosis, a subset not different from the larger popu-
lation. A majority of the participants had heard little about osteoporosis. In addition, the ma-
jority could not identify characteristics of or risk factors for the disease. Overall, participants 
from Armenia scored markedly worse than participants of a 2006 survey of women in North 
America and Europe. The results of this survey reveal a substantial knowledge gap among 
those most at risk for developing osteoporosis. This information should serve as an impetus 
for country-wide programs to be established among clinicians and public health officials to 
raise awareness of the disease and improve community-wide preventive measures.
Disclosures: Nicholas Hutchings, None
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The Fragility Hip Fracture: Not only a Marked Burden of Disease, but also 
a Significant Predictor of Subsequent Hip Fracture Risk *Emil Schemitsch1, 
Jonathan D. Adachi2, Jacques P. Brown3, Jean-Eric Tarride4, Natasha Burke5, 
Thiago Oliveira5, Lubomira Slatkovska5. 1Division of Orthopaedics, Department 
of Surgery, Western University, Canada, 2St Joseph’s Healthcare, McMaster 
University, Canada, 3CHU de Québec Research Centre, Laval University, 
Canada, 4Department of Health Research Methods, Evidence and Impact, 
McMaster University, Canada, 5Amgen Canada Inc., Canada
Purpose: Hip fracture is one of the most common and burdensome fragility fractures 
caused by osteoporosis. We describe the contribution of hip fractures to fragility fracture 
burden in older adults in Ontario, Canada.Method: This retrospective observational study 
used de-identified health services data generated from the publicly funded healthcare system 
in Ontario, Canada. The cohort included men and women aged >65 years with an index 
fragility fracture between January 1, 2011 and March 31, 2015, identified using ICD-10 
codes from hospital admissions, emergency and ambulatory care. Patients were followed to 
a cutoff date of March 31, 2017. Results: The cohort consisted of 115,776 patients with an in-
dex fragility fracture. The median age (interquartile range) was 81 (74–87) years and 72.3% 
were female. Hip fracture was the most common index fracture (27.3%, n=31,613), and 
32.4% (n=10,254) of index hip fractures occurred in patients <=80 years of age. Proportion 
of index fractures that were hip fractures by age was: ages 66-70, 12.1% (n=2,179); ages 71-
75, 17.3% (n=3,092); ages 76-80, 24.2% (n=4,983); ages 81-86, 31.2% (n=7,524); and ages 
86+, 39.3% (n=13,835). Hip fracture was also the most common second fracture (27.8%, 
n=5,745). It occurred as the second fracture in >=19% of cases for all index fracture sites ex-
amined; occurring most often after hip (33.0%) or pelvic (32.3%) index fractures, and least 
often after tibia/fibula/knee (23.3%) or radius/ulna (19.4%) index fractures. Among patients 
requiring surgery related to their index fracture (n=44,949) and those experiencing compli-
cations 30 days post-surgery (n=8,868), respectively, 64.1% and 71.9% had a hip fracture. 
One-year mortality (due to any cause) was 26.2% after hip index fracture and 15.9% in the 
entire cohort; hip fracture had the highest mortality rate of all index fracture sites examined, 
followed by femur (21.9%). Total mean (+/- standard deviation) healthcare cost per patient 
(in 2017 Canadian dollars) in the first year after index fracture was the second highest for 
hip index fracture ($62,793 +/- 44,438), after femur index fracture ($65,490 +/- 54,116).
Conclusion: These data highlight the significant morbidity, mortality and financial burden of 
hip fragility fractures in adults aged >65 and the urgent need to initiate secondary fracture 
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prevention measures after a fragility fracture occurring at any site to help reduce subsequent 
hip fracture and associated burden.
Disclosures: Emil Schemitsch, Amgen; Biocomposites; Smith & Nephew, Grant/
Research Support, Acumed, LLC; Amgen; Implants for Trauma Surgery; Pentopharm; 
Sanofi-Aventis; Smith & Nephew; Stryker; Swemac, Consultant, DePuy; Saunders/Mosby-
Elsevier; Smith & Nephew; Springer; Stryker; Zimmer, Other Financial or Material 
Support
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Associations Between Health Service Use and Quality of Life 12-Months 
Following a Non-Hip Osteoporotic Fracture: Analyses of the International 
Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) 
*Jason Talevski1, Kerrie Sanders1, Ljoudmila Busija2, Alison Beauchamp2, 
Catherine Connaughton1, Gustavo Duque3, Karen Lim4, Fredrik Borgström5, 
John Kanis6, Axel Svedbom7, Amanda Stuart8, Sharon Brennan-Olsen8. 1The 
University of Melbourne, Australia, 2Monash University, Australia, 3Australian 
Institute for Musculoskeletal Science (AIMSS), Australia, 4Australian Catholic 
University, Australia, 5Quantify Research, Sweden, 6University of Sheffield, 
United Kingdom, 7ICON Plc, Sweden, 8Deakin University, Australia
Objectives: While it is well-documented that hip fractures are the most severe type of 
fracture, imposing the greatest burden on health-related quality of life (HRQoL) and physi-
cal disability, fractures at other osteoporotic sites – vertebrae, wrist and humerus – are also 
associated with a significant burden on patients and the healthcare system. There is limited 
knowledge of which types of health services are associated with improved HRQoL in older 
adults after a non-hip major osteoporotic fracture (MOF). This study aimed to identify spe-
cific combinations of health service use that facilitate the recovery of HRQoL 12-months 
following non-hip MOF.Methods: The analyses included 2,469 adults aged >=50 years with 
a non-hip MOF participating in the International Costs and Utilities Related to Osteopo-
rotic Fractures Study (ICUROS) – a multinational observational study (Australia, Austria, 
France, Italy, Lithuania, Mexico, Russia, Spain, UK). HRQoL at pre-fracture and 12-months 
post-fracture was measured using the EQ-5D-3L survey. Health service use data was collect-
ed by patient interviews and medical record reviews including in-hospital care; outpatient 
care; community services and medication use. The data analyses involved two stages: 1) 
latent class analyses to identify different combinations of health service use (“classes”); 
and 2) logistic regression to assess effects of classes on HRQoL recovery (adjusted and un-
adjusted analyses).Results: Overall, 1,439 participants (58.3%) recovered to their pre-frac-
ture HRQoL at 12-month follow-up. The number of classes ranged from two to five across 
countries. We identified several distinct, country-specific classes that were associated with 
improved HRQoL recovery across individual countries. Across all countries, increased 
odds of HRQoL recovery at 12-months was commonly characterized by a combination of 
emergency department presentations without hospitalization; outpatient department visits; 
general practitioner or primary care centre visits; allied health visits (e.g. physiotherapy, 
occupational therapy); vitamin D/calcium supplementation; and/or non-opioid analgesic 
use.Conclusion: Understanding country-specific health services that are associated with 
greater recovery of HRQoL, and that are not routinely accessed in other countries, could 
improve post-fracture care on a global scale. Future research should focus on determining 
the cost-utility of these care pathways.
Disclosures: Jason Talevski, None
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A prospective cohort study of patient characteristics, bone health measures 
and clinical outcomes following low trauma wrist fracture *Maire Rafferty1, 
James Bernard Walsh2, Kevin McCarroll1. 1St James Hospital, Ireland, 2Sj James 
Hospital, Ireland
IntroductionPatients with lower BMD are at increased risk of fragility fracture. We 
aimed to explore characteristics of patients with wrist fractures and to identify whether 
bone health parameters might also influence patient reported outcome measures (PROMs).
MethodsPatients aged > 50 years who had a new x-ray diagnosis of a low trauma wrist 
fracture were recruited into our study between January and October 2018. Assessments were 
performed within 12 weeks and at 6 and 12 months. Data were collected regarding patient 
characteristics and results of DXA, Clinical Frailty Scale (CFS) and PROMs including the 
Short Form 12, Patient Rated Wrist Evaluation (PRWE) and Disabilities of the Arm, Shoul-
der and Hand (DASH). Statistical analysis was performed using SPSS v26.Results133 pa-
tients attended for initial assessment and 113 had at least one follow up visit. 91.9% were 
female and median age was 69.0. The majority (68.9%) were not frail (CFS <4 ) and were 
on <5 medications (59.7%). The biggest risk factor for fracture was a history of previous 
fracture (45.9%) followed by premature menopause (39.3%) (<45 yrs), low dietary calci-
um (39.3%), a family history of osteoporosis (29.6%), recurrent falls (23.0%) and smoking 
(17.8%). 41% had osteoporosis using DXA criteria. Better outcomes in PCS12 (p=0.046), 
PRWE (p<0.001) and DASH (P=0.001) were identified within the first 12 weeks. There 
were continued improvements in PCS-12 (P<0.001), MCS-12 ( P<0.001), PRWE (P<0.001) 
and DASH (P<0.001) over 12 months. We also found that lower BMD at the spine was 
associated with poorer scores on the PRWE (p=0.006) and DASH (p=0.018) at 6 months, 
which remained at 12 months for PRWE (p= 0.043) and also present for MCS12 (p=0.02). 
Similarly there were associations at 12 months between neck of femur BMD and PRWE 
(p=0.008) and DASH (p=0.018).Other factors shown to negatively impact outcomes includ-
ed dominant hand fracture (all measures) and gender (DASH) though there was no affect of 
age on disability or function (DASH or PRWE).ConclusionsThis study shows an association 
between lower BMD and poorer patient reported outcomes following wrist fractures. This is 
to our knowledge the first time this finding has been reported though associations have been 
found between BMD and radiographic features of severity and other clinical outcomes. Age 
did not affect disability or function suggesting that other factors independent of age such as 
frailty are more important.
Disclosures: Maire Rafferty, None
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Joining Forces for Bone Health: Lessons from a Bone Health Campaign 
with Susan G. Komen *Kathleen Cody1, Lisa Qualls2. 1kathleen@
americanbonehealth.org, United States, 2American Bone Health, United States
Objective:To extend the reach of bone health messages beyond a traditional audience 
by collaborating with a larger advocacy organization in a mutually beneficial education and 
awareness campaign.Methods and Materials:The campaign was designed to 1) determine the 
extent of participants’ bone health knowledge, and 2) empower walkers with information to 
develop a personal bone health plan as measured by post-event surveys and focus groups.
American Bone Health provided content, tools and resources for use by Susan G. Komen, 
the world’s leading breast cancer charity, at its 3-Day walks and races. The material was used 
to educate and empower participants to take steps to protect their bone health, particularly 
during and after treatment for breast cancer. This educational campaign included:- A digital 
phase of emails, blog posts and online articles about a variety of bone health topics.- An 
onsite phase with learning experiences. The races included a personal bone health quiz and 
the American Bone Health Fracture Risk Calculator, and the 3-Day walks also had an inter-
active game.Results:Total Reach: >58,000 digital; 17,050 onsiteTotal Activations:Digital: 
292• Those 292 users account for 532 sessions on the landing pages.• The average duration 
of sessions was 434% longer than the average session on American Bone Health webpages 
during the same time.• The largest traffic spike corresponds with the blog post and email 
around the topic of exercise and bone health.Onsite: 1,157• 798 people (age 45+) used the 
American Bone Health Fracture Risk Calculator to learn their risk in the next 10 years: with 
39% being at moderate or high risk.• 359 (people under 45) people took Bone Health Quiz.
Conclusion:Collaborating with a larger advocacy organization can amplify bone health mes-
sages and provide bone health awareness to an audience not traditionally reached.
Disclosures: Kathleen Cody, None
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Stronger Together: The Asia Pacific Fragility Fracture Alliance (APFFA) 
*Yoonah Choi1, Angie Roddick2, Kirsten Bruce3, Ding-Cheng (Derrick) Chan4, 
Jacqueline Close5, Joon Kiong Lee6, Paul Mitchell7, Robert D Blank8. 1Evidencia 
Medical Communications Pty Ltd, Australia, 2APFFA Secretariat, New Zealand, 
3Viva! Communications Pty, Australia, 4National Taiwan University Hospital 
Chu Tung Branch, Taiwan, Province of China, 5Prince of Wales Hospital, 
University of New South Wales, Australia, 6Beacon Hospital, Petaling Jaya, 
Malaysia, 7Synthesis Medical NZ Ltd, New Zealand, 8Garvan Institute of 
Medical Research, Australia
The Asia Pacific Fragility Fracture Alliance (APFFA) is a collaborative forum for Asia 
Pacific regional organisations and global organisations that focus on osteoporosis and frac-
tures. APFFA was launched in November 2018 and comprises the following member organ-
isations: Asian Federation of Osteoporosis Societies, Asia-Oceanian Society of Physical and 
Rehabilitation Medicine, Asia Pacific Geriatric Medicine Network, Asia Pacific Orthopaedic 
Association, Fragility Fracture Network, International Osteoporosis Foundation and Inter-
national Society for Clinical Densitometry.The primary purpose of APFFA is to drive policy 
change, improve awareness and change political and professional mindsets to facilitate op-
timal fragility fracture management across the Asia Pacific region. Aligned with the Global 
Call to Action, the clinical focus of APFFA is to improve acute care for people in the Asia 
Pacific region who sustain fragility fractures, and optimise subsequent rehabilitation and 
secondary fracture prevention.To actualize the mission and vision of APFFA, three working 
groups have been established and a strategic plan has been developed, which includes a 
detailed communications plan.The Hip Fracture Registry Working Group aims to:provide 
practical tools and resources that outline key steps in setting-up and rolling-out national hip 
fracture registries in each countryraise awareness of the problems relating outcomes of hip 
fracture across the regionadvocate for national professional organizations to collaborate to 
establish national quality improvement initiatives, and lobby governments for policy change 
and fundingThe Education Working Group aims to:identify a range of educational resourc-
es from member organisations that will be shared through an Education Directorycreate new 
resources to fill the gaps for key stakeholder groupsdevelop an approach to distribute the 
educational content, including use of conference presentationscustomise educational content 
to address differing concerns of distinct segments of our audienceThe Evidence Generation 
Working Group aims to:identify evidence gaps relating to the vision and mission of APF-
FAdesign research collaborations with partners to use real-world data share the new under-
standing through publication and other knowledge-sharing activitiesidentify and promote 
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any findings that would be considered practice-changing to improve patient outcomesFur-
ther information at:  https://apfracturealliance.org
Disclosures: Yoonah Choi, Amgen, Other Financial or Material Support
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Calcifediol Soft Gelatin Capsules Have a Superior Efficacy and a More 
Rapid Response than Cholecalciferol for the Management of Vitamin D 
Deficiency in Postmenopausal Women: Calcifediol Must be Considered in 
Therapeutic Guidelines *Jose Luis Pérez-Castrillón1, Antonio Dueñas-Laita2, 
Carlos Gómez-Alonso3, Gonzalo Hernández-Herrero4, Nieves Fernández-
Hernando4, Sandra Pamela Chinchilla4. 1Hospital Universitario Río Hortega, 
Internal Medicine Department, Spain, 2Hospital Universitario Río Hortega, 
Clinical Toxicology Unit, Spain, 3Hospital Universitario Central de Asturias, 
Bone Mineral Metabolism Department, Spain, 4Faes Farma, R&D and Innovation 
Department, Spain
BackgroundVitamin D deficiency has a high prevalence worldwide, with relevance in 
specific diseases and stages of life. Few guidelines assess the optimal dosing in the general 
population however, levels above 20 ng/mL are necessary to obtain benefits on bone metab-
olism.ObjectiveTo assess the efficacy of calcifediol in the treatment of vitamin D deficiency, 
compared with therapeutic guidelines recommendations for cholecalciferol in postmeno-
pausal women.MethodsPhase III-IV, double blind, randomised, controlled, multicentre su-
periority clinical trial. Postmenopausal women with baseline levels of 25(OH)D < 20 ng/mL 
were randomised to three arms: 266 mcg of calcifediol/month for 4 or 12 months (approved 
SmPC and test regimes), or to cholecalciferol 25000 IU/month for 12 months (as per ther-
apeutic guidelines).Main analysis performed upon completion of 4 months of treatment are 
presented and reported without unblinding study treatments (interim analysis).The trial has 
been approved by ethics committees and national competent authorities.Results298 women 
were included in the ITT analysis. The average age was 63.4 +/- 8.2 years, mean BMI 29.3 
+/- 6 kg/m2 and received treatment, 25% of the population had 25(OH)D levels <10ng/mL. 
All demographic characteristics and risk factors for osteoporosis were balanced amongst 
groups.13.5% and 35% of women in the calcifediol group reached values of 25(OH)D > 
30ng/mL at 1 and 4 months, respectively, compared to 0% and 8.2% in the cholecalciferol 
group (p<.0001). Calcifediol achieved target levels more rapidly (Figure 1, highlights 20ng/
mL which is a widely accepted minimum therapeutic level). Mean increase in 25(OH)D 
levels in calcifediol v. cholecalciferol arms were 9.7 ng/mL v. 5.1 ng/mL; p<.0001 (month 
1) and 14.9 ng/mL v. 9.9 ng/mL; p<.0001(month 4).No relevant safety issues were reported 
for the present analysis.ConclusionsCalcifediol shows a greater efficacy and a more rapid 
effect than cholecalciferol regime (as recommended in therapeutic guidelines), for the treat-
ment of vitamin D deficiency in postmenopausal women, which could impact osteoporosis 
treatment. Cholecalciferol fails to achieve 25(OH)D recommended levels in a significant 
proportion of this population.AcknowledgementsPrincipal investigators and their teams: F 
Cereto, ML Brandi, E Jodar, J del Pino-Montes, JM Quesada-Gómez, JM Olmos-Martínez, 
MA Colmenero-Camacho, R Alhambra, B Galarraga
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The impact of vitamin D supplementation on fractures: an umbrella review 
of systematic reviews and meta-analyses of randomized controlled trials 
*Marlene Chakhtoura1, Charbel Gharios1, Sara Ajjour1, Mariam Assaad1, Dania 
Saleh Bacha1, Yara Jabbour1, Francesca Kahale1, Aya Bassatne1, Stephanie 
Antoun1, Elie A Akl1, Ghada El-Hajj Fuleihan1. 1American university of Beirut, 
Lebanon
Introduction: Despite recent conflicting evidence on the benefits of vitamin D supple-
mentation on skeletal outcomes, calcium and vitamin D (CaD) provide the basis for most 
primary and secondary fracture prevention recommendations. We reviewed all systematic 
reviews of randomized controlled trials assessing the effect of vitamin D supplementation 
on the risk of fractures in adults.Methods: We searched MEDLINE, PubMed, Embase, and 
Cochrane databases (2010 -2020). Two independent reviewers assessed studies against the 
following eligibility criteria: 1) meta-analyses of randomized controlled trials, 2) comparing 
vitamin D, alone or in combination with calcium (CaD), 3) to placebo or control, 4) in adults 
>= 50 years old, and 5) reporting fracture as an outcome. We assessed the quality of the 
systematic reviews in duplicate and independently using the AMSTAR-2 tool. Registration: 
CRD42019129540.Results: Out of 13,621 captured citations, we included 22 eligible me-
ta-analyses. Four were of moderate quality, 6 were of low quality, and the remaining 12 were 
of critically low quality. Seven out of 13 meta-analyses reported a significant reduction in 
the risk of hip fractures with CaD supplementation (400-800 UI/d + 0.5-1.2 mg/d); risk re-
duction range 16-39% (Figure). Similarly, CaD significantly reduced the risk of fractures at 
any skeletal site, by 5-19%, in 7 out of 14 meta-analyses. Vitamin D alone did not reduce the 
risk of hip nor any other fractures in any meta-analysis. In one review of moderate quality, 
subgroup analysis by residency found that the relative risk of hip and of any fracture with 
CaD was significantly lower in institutionalized individuals but not in community dwelling 
individuals. This finding was not consistent in lower-quality meta-analyses performing the 
same subgroup analysis. Meta-analyses that only included trials of community dwelling in-
dividuals did not show any significant fracture risk reduction.Conclusion: Supplementation 
with CaD, but not vitamin D alone, most consistently decreased the risk of hip and of any 
fractures, in several meta-analyses. Assessment of the overlap in trials included, of statis-
tical methods used, and a focus on higher quality meta-analyses, may identify the patients 
who would benefit the most from CaD supplementation (by baseline fracture and vitamin 
D status).
Disclosures: Marlene Chakhtoura, None
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The effect of exercise intensity on postmenopausal BMD: a meta-analysis 
*Melanie Fischbacher1, Benjamin K Weeks1, Beck Belinda R 1. 1Menzies Health 
Institute Queensland, Griffith University, Gold Coast campus, Gold Coast, 
Queensland, Australia, Australia
Background: Previous reviews have concluded that exercise has only modest effects on 
aBMD in postmenopausal women. Despite the well-recognised strong positive relationship 
between load magnitude and bone response observed from animal research, the majority 
of human trials have examined the effects of only low to moderate intensity exercise on 
bone. We speculated that meta-analysing according to intensity may reveal a more potent 
exercise effect at higher intensity.Objectives: To determine the effects of low, moderate and 
high intensity exercise on aBMD at the spine and hip in postmenopausal women.Methods: 
Electronic databases and reference lists were searched for RCTs that examined the effect 
of exercise compared to control on DXA-derived lumbar spine, femoral neck or total hip 
aBMD in healthy postmenopausal women. Interventions were classified as low, moderate or 
high intensity and pooled based on classification. Mean differences (MD) were calculated 
using random effects models and a risk of bias analysis was undertaken.Results: Fifty-one 
trials, testing 61 interventions (17 low, 38 moderate, 5 high intensity) were included. At the 
lumbar spine, high intensity exercise yielded greater aBMD effects (MD = 0.025 g/cm2 95% 
CI [0.007, 0.043], p = 0.007) than moderate (MD = 0.013 g/cm2 95% CI [0.008, 0.018], p 
< 0.001) and low intensity (MD = 0.010 g/cm2 95% CI [0.005, 0.015], p < 0.001). Low and 
moderate intensity exercise was equally effective at the femoral neck (low: 0.012 g/cm2 95% 
CI [0.006, 0.017], p < 0.001; moderate: 0.011 g/cm2 95% CI [0.007, 0.016], p < 0.001), but 
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no effect of high-intensity exercise was observed. Moderate intensity exercise increased total 
hip BMD (0.007 g/cm2 95% CI [0.003, 0.010], p < 0.001), but low intensity did not. There 
were insufficient data to meta-analyse the effect of high intensity exercise at the total hip. 
Risk of bias was mainly low or unclear due to insufficient information reported.Conclusion: 
High intensity exercise is a more effective stimulus for lumbar spine aBMD than low or 
moderate intensity, but not the femoral neck, however, the latter may be due to lack of power. 
While data from high-intensity exercise interventions are limited, the current comprehensive 
meta-analysis demonstrates the same positive relationship between load magnitude and bone 
response in humans as observed from animal research. Findings have implications for opti-
mal exercise prescription for osteoporosis in postmenopausal women.
Disclosures: Melanie Fischbacher, None
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Influence of race/ethnic background on tibial bone microarchitecture 
changes following 8 weeks of US Army Basic Combat Training *Kristin 
Popp1, Julie Hughes1, Kathryn Taylor1, Katelyn Guerriere1, Nathaniel Smith1, 
Susan Proctor1, Stephan Foulis1, Mary Bouxsein2. 1Military Performance 
Division, United States Army Research Institute of Environmental Medicine, 
United States, 2Center for Advanced Orthopedic Studies, Beth Israel Deaconess 
Medical Center, United States
Risk of stress fracture (SF) increases during periods of heightened physical activity, 
such as U.S. Army Basic Combat Training (BCT), with highest incidence rates among those 
of White racial/ethnic background. We previously showed bone adaptation, which may mit-
igate SF risk, in both men and women in response to BCT.  However, it is unknown whether 
these changes differ according to race/ethnicity.  PURPOSE:  To determine whether chang-
es in tibial bone microarchitecture following 8 weeks of BCT differ by racial/ethnic back-
ground.  METHODS:  In an on-going prospective study of risk factors for SF among Army 
trainees, we will enroll 4,000 subjects and measure cortical (Ct) and trabecular (Tb) bone 
density and microarchitecture by HR-pQCT of the distal tibia pre- and post-BCT.  Here, we 
present data from 995 men and 525 women who completed BCT. Subjects were of White 
non-Hispanic (WNH: 466M, 173W), White Hispanic (WH: 112M, 63W), Black non-His-
panic (B: 215M, 164W) and Other/mixed (176M, 110W) racial/ethnic backgrounds.  We 
used linear mixed models to determine, within each sex: 1) pre- to post-BCT differences 
in bone parameters controlling for age, height, and weight and 2) whether changes differ 
by race/ethnic groups controlling for age, height, weight, and baseline bone values. RE-
SULTS:  Men (21.0+/-3.8yrs) and women (20.3+/-3.5) were of similar age. Ct.thickness, 
Tb.thickness, Tb.BV/TV, and total, Ct. and Tb.vBMD increased significantly from baseline 
(all p<0.001) in both men and women. Tb.separation decreased among both sexes (p<0.001), 
whereas Tb.number increased among men (p=0.002), but not women. Changes were largely 
similar among race/ethnic groups, with few meaningful differences.  B men had slightly 
greater increases in total (0.88%) and Tb. (0.80%) vBMD compared to WNH men (0.64%, 
0.58%, respectively; p<0.05). WNH women had greater decreases in Tb.separation com-
pared to B women (p=0.02). B women, however, had a greater increase in total vBMD 
(1.12%) than WNH women (0.87%; p=0.08), though these differences were not statistically 
significant.  There were no other differences between racial/ethnic groups for men or women. 
CONCLUSION: Eight weeks of BCT led to significant changes in bone density and micro-
structure in both men and women. Overall, bone changes in response to BCT did not vary 
markedly by race/ethnic group, suggesting that mechanisms beyond differential adaptive 
response to BCT contribute to racial/ethnic disparities in SF risk during BCT.
Disclosures: Kristin Popp, None
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Accelerometer-measured physical activity in relation to bone mineral 
density: a Mendelian randomization study *Ruizhuo Li1, Pengfei Wu2, Bing 
Wang3, Kun Xia2. 1Fifth Affiliated Hospital of Sun Yat-sen University, China, 
2School of Life Sciences, Central South University, China, 3Second Xiangya 
Hospital, Central South University, China
Background: The potential beneficial effect of physical activity in improving bone 
mineral density (BMD) has long been postulated. Emerging observational studies and ran-
domized controlled trials have yielded inconsistent results. Traditional physical activity 
measurement based on self-report exercise patterns is prone to be confounded or biased, 
leading to unconvincing conclusions.Methods: We conducted a two-sample Mendelian ran-
domization (MR) analysis to infer the causal effects of physical activity on BMD in the 
European ancestry. To identify instrumental variables associated with objectively measured 
physical activity, we selected 5 genetic variants reaching genome-wide significance (P < 5 × 
10-8) from the largest meta-analysis of 91,105 UK Biobank participants. Summary statistics 
for BMD based on dual-energy X-ray absorptiometry scans, incorporating lumbar spine (n 
= 28,498), femoral neck (n = 32,735), forearm (n = 8143), and total body BMD (n = 66,628) 
were released by the Genetic Factors for Osteoporosis consortium. The inverse-variance 
weighted MR was employed as the primary analysis, while MR-PRESSO, weighted median, 
and MR-Egger test were implemented in sensitivity analyses. Effects were expressed as 
standard deviation (SD) changes in BMD per 1-SD increment in physical activity (~8 mil-
ligravities per 5-second-epoch). All statistical analyses were performed in R version 3.6.1. 
Statistical significance was set at Bonferroni corrected P = 0.0125.Results: MR results did 
not support a role for genetically-proxied higher physical activity in the BMD accrual. In 
the main MR analyses, 1-unit increase in accelerometer-measured physical activity was not 
causally associated with lumbar spine (-0.42, 95% confidence interval [CI]: -0.88 to 0.04; P 
= 0.07), femoral neck (-0.06, 95% CI: -0.59 to 0.48, P = 0.84), forearm (-0.05, 95% CI: -0.62 
to 0.52, P = 0.86), or total body BMD (0.17, 95% CI: -0.11 to 0.45, P = 0.24). No evidence 
of horizontal pleiotropy was detected by MR-Egger regression; consistency and robustness 
of primary results were verified through sensitivity analyses.Conclusion: This study suggests 
that genetically predicted physical activity is not causally associated with BMD. Provided 
that genetic structures and molecular mechanisms for BMD regulation are still largely un-
raveled, further studies are warranted to shed verify whether the physical activity should be 
promoted as an effective strategy for improving bone health.
Disclosures: Ruizhuo Li, None
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Feasibility, safety and effectiveness of a pilot 16-week home-based, high-
impact exercise intervention in post-menopausal women with low bone 
mineral density *Carrie-Anne Ng1, Lachlan McMillan1, Ludovic Humbert2, 
Peter Ebeling1, David Scott1. 1Department of Medicine, School of Clinical 
Sciences at Monash Health, Monash University, Australia, 2Musculoskeletal 
Unit, Galgo Medical, Barcelona, Spain, Spain
OBJECTIVE: High-impact exercise may improve bone health, but the feasibility and 
efficacy of home-based exercise in postmenopausal women with low bone mineral density 
(BMD) is unclear. We aimed to determine feasibility and safety, and changes in BMD, bone 
microarchitecture, physical function, and bone turnover markers, following a pilot 16-week 
home-based, high-impact exercise intervention in postmenopausal women with low BMD. 
METHODS: 50 community-dwelling postmenopausal women with BMD T-scores < -1.0 
participated in 16-weeks of home-based high-impact exercise progressively increasing to 50 
multi-directional unilateral hops on each leg for 7 days a week. Bone density and structure 
was assessed by lumbar spine and total hip dual-energy X-ray absorptiometry (DXA), 3D 
modelling algorithms (3D-SHAPER) of hip DXA scans, and distal tibial high-resolution 
peripheral quantitative computed tomography scans (HR-pQCT). Physical performance was 
assessed by repeated chair stand time and stair climb time. RESULTS: 44 women (mean+/-
SD age 64.5+/-7.5 years) completed the intervention, with adherence to exercise sessions of 
84.7+/-18.0%. Six (12%) women did not complete the study due to related soreness (n=2), 
unrelated injury (n=1) and loss of interest (n=3). Femoral neck areal BMD significantly 
increased by 1.13+/-3.76% (p=0.048). Trabecular volumetric BMD of the total hip and fem-
oral neck estimated by 3D-SHAPER significantly increased (2.27+/-7.03%; p=0.038 and 
3.20+/-5.39%; p<0.001, respectively). Additionally, femoral neck integral (trabecular plus 
cortical) volumetric BMD increased by 1.81+/-4.33% (p=0.010). At the distal tibia, total vol-
umetric BMD significantly increased by 0.32+/-0.88% (p=0.032) and cortical cross-section-
al area significantly increased by 0.55+/-1.54% (p=0.034). Chair stand and stair climb time 
significantly improved by 2.3+/-1.88s (p<0.001) and 0.27+/-0.49s (p<0.001), respectively. 
CONCLUSION: A pilot 16-week home-based, high-impact exercise intervention was both 
feasible and effective in improving femoral neck areal BMD, total hip and distal tibial vol-
umetric BMD, and physical function in postmenopausal women. Home-based, high-impact 
exercise interventions may reduce risk factors for fracture in older populations with limited 
access to clinic- or gym-based exercise programs.
Disclosures: Carrie-Anne Ng, None
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Longitudinal population vitamin D sufficiency is increasing and associated 
with less BMD loss over 10 years *Michael Thompson1, Graeme Jones1, Saliu 
Balogun2, Dawn Aitken1. 1Menzies Research Institute Tasmania, Australia, 
2Australian National University, Australia
IntroductionVitamin D deficiency is a prevalent, modifiable determinant of osteoporotic 
fracture risk. Efforts to improve population vitamin D have intensified. There are limited 
data that examine the longitudinal change in population 25-hydroxyvitamin D (25OHD) 
and none that evaluate the skeletal outcomes of longitudinal vitamin D sufficiency. Meth-
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odsCommunity-dwelling adults aged 50-80 years had 25OHD assessed by radioimmunoas-
say at baseline (n=1096), 2.5 (n=870) and 10 (n=565) years. Sun exposure was quantified 
by questionnaire, supplement use at clinic review, BMD by DXA and physical activity by 
pedometer. 25OHD <50nmol/L was considered deficient. ResultsOver 10 years 25OHD 
increased (52.4+/-18.7 vs 62.5+/-23.5 nmol/L, p<0.001) and the percentage of vitamin D 
deficient participants decreased (45.4% vs 31.0%, p<0.001). Participants with baseline 
deficiency had larger 25OHD increases than baseline sufficient participants (19.2+/-25.3 
vs 1.6+/-23.3 nmol/L, p<0.001). Longitudinal change in 25OHD was associated with vita-
min D and calcium supplement use, baseline and change in BMI, physical activity and sun 
exposure. The proportion of participants taking vitamin D (2.3% vs 37.1%, p<0.001) and 
calcium (7.3% vs 18.8%, p<0.001) supplements increased. Longitudinal vitamin D suffi-
ciency was associated with less BMD loss at lumbar spine (-0.016+/-0.08 vs 0.012+/-0.09 
g/cm2, p=0.006), total hip (-0.054+/-0.08 vs -0.034+/-0.07 g/cm2, p=0.046), femoral neck 
(-0.031+/-0.08 vs -0.012+/-0.06 g/cm2, p=0.034) and total body (-0.013+/-0.06 vs 0.005+/-
0.10 g/cm2, p=0.047).ConclusionsCohort 25OHD concentration increased over 10 years and 
longitudinal vitamin D sufficiency was associated with less BMD loss. This suggests popula-
tion vitamin D status can improve and that persistent sufficiency may ameliorate age-related 
BMD loss.
Disclosures: Michael Thompson, None
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Plasma Vitamin C Sufficiency is Related to Higher Bone Mineral Density: 
The Boston Puerto Rican Osteoporosis Study *Kelsey Mangano1, Sabrina 
Noel1, Bess Dawson-Hughes2, Katherine Tucker1. 1University of Massachusetts, 
Lowell, United States, 2Jean Mayer USDA Human Nutrition Research Center on 
Aging, United States
There is evidence that vitamin C is important for bone health, but few studies have 
evaluated plasma vitamin C status. The purpose of this study was to investigate the relation 
of bone mineral density (BMD) with 1) dietary vitamin C (diet and supplements) and 2) 
plasma vitamin C (an established biomarker) among Puerto Rican adults. In this cross-sec-
tional study of 902 adults aged 46-78y, from the Boston Puerto Rican Osteoporosis Study 
(BPROS), BMD was measured using DXA at the hip and spine. Usual dietary intakes and 
supplement use were assessed with a food frequency questionnaire. The association between 
dietary, supplemental (yes/no) and plasma vitamin C with BMD was assessed by multi-
variable linear regression. Least squares mean BMD was compared across energy adjusted 
tertile categories of dietary vitamin C (median intake: 36 mg/d (lowest); 64 mg/d; 106 mg/d 
(highest)) and plasma vitamin C status (deficiency (<20 µmol/dL, 20% of sample); sub-
clinical deficiency (20-50µmol/dL, 36%); adequate status (>=50 µmol/dL, 44%)). Interac-
tions by sex and smoking status (never, former, current) were examined, but not significant. 
Covariates included age, sex, education, menopause, smoking status, alcohol consumption, 
physical activity score, height, BMI, calcium intake, plasma vitamin D (ng/mL), C-reac-
tive protein (mg/dL) and diabetes (yes/no). Greater vitamin C from dietary intake was not 
associated with BMD at any site (P-range=0.34-0.90). Supplemental vitamin C intake ap-
proached a positive association with BMD at the femoral neck (FN, P=0.07) and total femur 
(TF, P=0.08). A significant linear association between plasma vitamin C and BMD was ob-
served at the trochanter (TR, β=0.0004, P=0.05) and the association approached significance 
at the TF (β=0.0004, P=0.08). Mean TR and TF BMD among individuals with vitamin C 
deficiency (0.820+/-0.012g/cm2, 1.022+/-0.013g/cm2 respectively) was significantly low-
er than among those vitamin C sufficient (0.847+/-0.010g/cm2, P=0.02; 1.050+/-0.011g/
cm2, P=0.03). In this sample, Puerto Rican adults with plasma vitamin C concentration 
below 20 µmol/dL had significantly lower BMD at the hip compared to those with sufficient 
plasma vitamin C, after controlling for confounders. Replication in other cohorts is needed 
to confirm these results and to develop dietary recommendations of vitamin C sufficiency 
for optimal bone health among older adults. This is important, as a large percentage of the 
population may not meet these guidelines.
Disclosures: Kelsey Mangano, None
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Muscle Strength and Muscle Area Independently Predict Bone Strength 
at the Tibia and Radius in Women at Risk of Fracture *Suelen M. Goes1, 
Bradley Bigsby1, Philip Chilibeck1, James D. Johnston2, Saija Kontulainen1. 
1University of Saskatchewan - College of Kinesiology, Canada, 2University of 
Saskatchewan - Department of Mechanical Engineering, Canada
Background/Purpose: Muscle size and strength, physical function and physical activ-
ity can contribute to fracture prediction by reducing fall risk; however, their role in deter-
mining bone strength and areal bone mineral density (aBMD) in women at high risk of 
fracture is unknown. Our objective was to assess if muscle size and strength, physical per-
formance, daily moderate-to-vigorous physical activity (MVPA), and impact counts would 
independently predict bone strength and aBMD in women at risk of fracture.Methods: We 
included 45 women (mean age 74, SD 8.6y) with osteoporosis, hyperkyphosis, or history of 
vertebral fracture. We estimated bone strength to resist compression (BSIc) at the distal sites 
and torsion (SSIp) at the shaft sites of tibia and radius and recorded muscle area at the lower 
leg and forearm using pQCT. We measured aBMD at the femoral neck and lumbar spine as 
well as total body lean mass using DXA, physical performance by 30-second sit-to-stand and 
grip strength tests, and daily minutes of MVPA and impact counts using tri-axial accelerom-
eters over seven days. We performed hierarchical linear regression (adjusted for body mass 
index and age) to assess if muscle outcomes (muscle area and total lean mass), physical per-
formance, daily MVPA, and daily impacts would independently predict bone strength and 
aBMD.Results: Lower leg muscle area was an independent predictor of BSIc at the distal 
tibia [β=0.01, CI95% 0.001;0.02, p<0.05]. However, when the 30-second sit-to-stand perfor-
mance was added to the model, this muscle strength measure took place as an independent 
predictor of BSIc at the distal tibia [β=1.9, CI95% 0.05;3.9, p<0.05]. Forearm muscle area 
was an independent predictor of SSIp at the radial shaft [β=0.07, CI95% 0.03;0.13, p0.05). 
Daily MVPA and impact counts did not independently predict bone strength or aBMD at any 
site (p>0.05).Conclusion: These findings suggest that muscle size and strength measures, 
rather than time spent in MVPA or number of daily impact counts, might be critical for 
maintaining bone strength at the tibia and radius in women at risk of fracture. 
Disclosures: Suelen M. Goes, None
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In  a clinical trial of vitamin D there was no effect on physical performance 
*Lynette Smith1, J Chris Gallagher2. 1University Nebraska Medical center, 
United States, 2Creighton University, United States
Introduction: The effect of vitamin D supplementation on physical performance is con-
troversial. Longitudinal cohort studies show very low levels of serum 25OHD (< 15- 20ng/
ml) are associated with lower physical performance. There are few clinical trials of the effect 
of vitamin D on physical performance and results are mixed.Design: 163 independent living 
women entered a 12-month double blind randomized dose ranging study of daily vitamin 
D,400,800,1600,2400,3200,4,000,4800IU or placebo together with calcium supplement as 
needed for a total intake ~1200mg and mean diet vitamin D of 114 IU. Inclusion criteria: 
total serum 25OHD <= 20ng/ml (Diasorin RIA); no known disease or drugs affecting calci-
um or bone metabolism. Physical performance tests were performed at baseline and end as 
described in the Short physical performance battery (SPPB) that included Balance, Timed 
walk, Chair rising test. Additional tests included Timed up and Go, Grip strength and Bal-
ance (Biodex). Fall history was recorded at baseline and at 3-monthly visits. Serum 25OHD 
was measured by Diasorin RIA and LCMS,Free 25OHD was measured by Elisa (Future 
Diagnostics).Changes in physical performance and fallers were analyzed by dose groups and 
by quintiles of serum 25OHD(46 ng/ml). This was a secondary analysis using Intent to treat 
and statistical analysis used Chi square and ANOVA for association between dose, quintiles 
and tests.Results: Age range 57-87 years, mean age 66.2 years (SD 7.3), mean BMI 30.3 kg/
m2 (SD 5.9). Compliance, measured every 3 months, was 94% for vitamin D and 91% cal-
cium. 147 women completed study. There was no significant effect of vitamin D dose on any 
physical performance test. When data was examined according to serum total or free 25OHD 
quintiles there was no association between serum levels of 25OHD and change in any phys-
ical performance test. The relation between vitamin D dose and serum 25OHD and falls 
followed a U-shaped curve as previously published with a 45 percent reduction in fallers in 
the serum middle quintile 32-41ng/ml compared to quintiles 1 and 5, p<0.001 (1).Conclu-
sions: There was no effect of vitamin D on physical performance. There was a U-shaped re-
sponse on vitamin D with a significant reduction in falls in the serum 25OHD range 30-40ng/
ml.There is no correlation between physical performance, fallers and non- fallers.1Smith 
LM, Gallagher JC, Suiter C. J Steroid Biochem Mol Biol. 2017 Oct; 173:317-322.
Disclosures: Lynette Smith, None
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Moderate Blueberry Consumption Increased Net Bone Calcium Retention 
in Healthy Postmenopausal Women: A Randomized Crossover Trial *Joanna 
K. Hodges1, Sisi Cao1, Pamela J. Lachcik2, Munro Peacock3, George P. McCabe4, 
Linda D. McCabe4, Dennis P. Cladis4, Mario G. Ferruzzi5, Berdine R. Martin4, 
Connie M. Weaver4. 1The Ohio State University, United States, 2Bioanalytical 
Systems, Inc., United States, 3Indiana University School of Medicine, United 
States, 4Purdue University, United States, 5North Carolina State University, 
United States
Objectives: Preclinical studies suggest that blueberry consumption is associated with 
improved bone health. This study quantified changes in urinary excretion of the long-lived 
calcium radioisotope 41Ca to assess the effect of blueberries on bone loss in postmeno-
pausal women. We hypothesized that blueberry consumption would reduce bone loss in 
a dose-dependent manner.Methods: Healthy women at least 4 years past menopause were 
dosed with 41Ca and completed a 5-mo equilibration period for 41Ca deposition in bone, 
a 6-wk control period, and 3 alternating rounds of 6-wk intervention and washout periods. 
During the interventions, participants consumed a low (17.5 g/d), medium (35 g/d), or high 
(70 g/d) dose of freeze-dried blueberry powder equivalent to 0.75, 1.5, or 3 cups of fresh 
blueberries. The blueberry powder was consumed daily as part of granola bars, spread, and 
drinks. Urinary 41Ca:Ca ratio was measured by accelerator mass spectrometry in 24-h urine 
collected weekly during intervention and every 3 wk during washout periods. Serum bone 
biomarkers (P1NP, CTX, OPG, RANKL, and Sclerostin) and urinary polyphenols were mea-
sured at the end of control and each intervention period. Serum 25-hydroxyvitamin D and 
calcium concentrations were measured prior to each intervention. Data were analyzed using 
a linear mixed model and repeated measures ANOVA.Results: Fourteen healthy non-oste-
oporotic (baseline mean bone mineral density t-score: -1.3) women completed the study. 
Net bone calcium retention increased by 6% during the low (p < 0.01) and 4% during the 
medium (p < 0.05) dose intervention compared with the control and washout periods. The 
high dose had no significant effect on net bone calcium retention (p = 0.19). Serum RANKL 
was significantly lower during the medium dose intervention (p < 0.05), while serum P1NP 
was significantly lower during the low and medium dose interventions (p < 0.01) compared 
with the control period. Urinary excretion of hippuric acid was significantly higher during 
the high dose intervention compared with the control period (p < 0.01). No significant chang-
es were found in serum 25-hydroxyvitamin D or calcium during the study.Conclusions: A 
hormetic response was observed, whereby daily consumption of foods containing 17.5-35 
g, but not 70 g, of freeze-dried blueberry powder increased net bone calcium retention. 
Moderate consumption of blueberries may be an effective strategy to attenuate bone loss in 
healthy postmenopausal women.
Disclosures: Joanna K. Hodges, None
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Bovine colostrum improves bone microstructure in ovariectomized and 
orchidectomy rats via VEGFA signaling *Eirini Kydonaki1, Laura Freitas1, 
Bruno Fonseca1, Henrique Reguengo1, Carlos Simón2, Ana Bastos3, Raphaël 
Canadas3, Joaquim Oliveira4, Vitor Correlo4, Rui Reis4, Yiannis Koutedakis5, Rui 
Pinto6, Franklim Marques1, Tânia Amorim1. 1UCIBIO/REQUIMTE, Faculty of 
Pharmacy, University of Porto, Porto, Portugal, Portugal, 2Centro de Estudios 
Superiores de la Industria Farmacéutica (CESIF, SA). Madrid, Spain, Spain, 
33B’s Research Group, I3Bs - Research Institute on Biomaterials, Biodegradables 
and Biomimetics, University of Minho, Guimarães, Portugal; ICVS/3B’s, Braga/
Guimarães, Portugal, Portugal, 4The Discoveries Centre for Regenerative and 
Precision Medicine, University of Minho, Guimarães, Portugal., Portugal, 
5Faculty of Education, Health and Wellbeing, University of Wolverhampton, 
Walsall, United Kingdom; School of Sports and Exercise Sciences, University of 
Thessaly, Trikala, Greece, Greece, 6iMed.UL, Faculty of Pharmacy, University of 
Lisbon, Lisbon, Portugal; JCS, Dr. Joaquim Chaves, Miraflores Algés, Portugal, 
Portugal
IntroductionResearch has shown that components of bovine colostrum (BC), as lacto-
ferrin, induce bone anabolic effects. However, the effects of BC supplementation as a whole 
in bone microarchitecture and the mechanisms through which BC may induce bone anabolic 
effects is relatively unclear. The aim of this study was to evaluate the effects of different 
BC doses supplementation in ovariectomized (OVX) and orchidectomy (ORX) rat-mod-
els and to identify the pathways that may mediate the action of BC on bone.MethodsAfter 
baseline measurements of bone microarchitecture (μCT), twenty-seven-month-old female 
(OVX, n=32) and male (ORX, n=32) Wistar rats were randomly assigned to the following 
groups: a) placebo b) BC dose 1 (0.5g/day/females; 1.0g/day/males), c) BC dose 2 (1g/
day/females; 1.5g/day/males) and d) BC dose 3 (1.5g/day/females; 2g/day/males). After 4 
months of supplementation, bone microarchitecture was re-assessed. Gene expression of 
VEGFA, FGF2, TATA, OPG, RANK and RANKL were measured by qRT-PCR. The study 
was approved by the National Ethics Committee for the Use of Animals in Research.Re-
sultsRegarding male rats, BC dose 1 significantly improved bone microarchitecture, as these 
rats not only revealed significantly less cortical porosity (41.9%, p<0.05) and cortical pore 
size (25.7%, p<0.05) compared to placebo group, but also significantly increased cortical 
volume (89.7%, p<0.05), cortical BMD (134.9%, p<0.01), trabecular thickness (37.3%, 
p<0.01), trabecular volume (24.6%, p<0.001) and trabecular BMD (7.5%, p<0.01). BC dose 
2 induced the same effects as dose 1 for male rats, and significantly reduced trabecular po-
rosity (8.1%, p<0.01), while dose 3 reduced trabecular separation (29.3%, p<0.05). As for 
female rats, BC dose 1 did not induce positive effects on bone microarchitecture. However, 
BC dose 2 and 3 decreased cortical porosity (placebo: 65.75+/-4.22; dose 2: 25.16+/-8.83; 
dose 3: 25.22+/-8.54%, p<0.01) and improved trabecular thickness (placebo: 12.22+/-0.99; 
dose 2: 21.11+/-3.28; dose 3: 18.39+/-2.45μm, p<0.01) compared to placebo. BC dose 3 
significantly increased mRNA expression of VEGFA (2.37+/-1.83, p<0.05).ConclusionBC 
preserves bone mass of OVX and ORX rats by stimulating bone formation. Indeed, as bone 
is a high vascularized organ and VEGFA plays important roles in vascular development and 
angiogenesis, it seems that VEGFA is influencing skeletal development and osteogenesis in 
OVX and ORX rats.
Disclosures: Eirini Kydonaki, None
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The Impact of Exercise on Bone Health in the Transmenopause Period: 
Helpful or Harmful? *Laura Flores1, Nancy Waltman2, Kevin Kupzyk1, Joan 
Lappe3, Laura Bilek4. 1University of Nebraska Medical Center, United States, 
2University of Nebraska Medical Center College of Nursing- Lincoln Division, 
United States, 3Creighton University, United States, 4University of Nebraska 
Medical Center- College of Allied Health Professions, United States
Introduction: Transmenopause, the period immediately following menopause, is a time 
of rapid bone loss. The most rapid decline in bone mineral density (BMD) is seen early 
following menopause with a modest decline thereafter. These changes increase osteoporosis 
risk and should be mitigated. Interventions including vitamin D and calcium supplementa-
tion and weight-bearing exercise are often recommended for maintenance of bone health. 
As transmenopause is a time of tremendous bone loss, establishing appropriate and timely 
interventions is necessary to prevent osteoporosis. Thus, we evaluated the effect of time 
since onset of menopause on change in BMD of the spine and hip in persons participating in 
lifestyle interventions for bone health.Methods: Data are from postmenopausal women with 
low bone mass who completed the Heartland Osteoporosis Prevention Study and were ran-
domized to 12 months of control [Ca and vit D] or exercise + Ca and vit D. BMD of the total 
hip and lumbar spine were assessed at baseline and 12 months using DXA. Women within 
6 years of menopause diagnosis with 12 month data were included in analysis. Time from 
menopause was self-reported, and groups were divided into 24 months since the last men-
strual cycle (Late Menopause). The within group (exercise and control) and between group 
effect of time from menopause on BMD were analyzed.Results: There were 72 women (22 
Early Menopause; 50 Late Menopause) in the exercise group with a mean age of 54.7(3.0). 
The control group had 77 (18 Early Menopause, 59 Late Menopause) women with an aver-
age age of 54.3(3.3). In the exercise group, within group analysis demonstrated a significant 
difference in lumbar spine BMD between early and late menopause groups (p=0.021) with 
those in the early menopause group having greater bone loss relative to those the late meno-
pause group. A similar trend was observed for hip BMD within the exercise group (p=0.06). 
There were no significant differences in BMD changes of the hip or spine between women of 
early and late menopause in the control group.Conclusion: While lifestyle (exercise, calcium 
and vitamin D supplementation) for bone health is important, the ability of these interven-
tions to maintain BMD may depend on the time elapsed since a women’s last menstrual 
cycle. This result should be evaluated further in terms of bone strength and structure.
Disclosures: Laura Flores, None
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Vitamin D level and functional recovery after hip fracture *Sneha Mohan1, 
Pam Holte1, Brandon Yuan1, Andrew Sems1, Ann Kearns1. 1Mayo Clinic, United 
States
Background: Vitamin D deficiency is common in patients presenting with low energy 
hip fractures. The relationship between Vitamin D levels at the time of a fracture and long 
term functional outcomes has not been studied. Identifying a benefit to recovery with ade-
quate vitamin D would support supplementation in elderly patients at risk for hip fracture.
Methods: A retrospective cohort of patients >/= 50 years, who were treated surgically for low 
energy hip fracture between July 1 2016 and June 30 2018 were identified. The correlation 
between Vitamin D levels and functional recovery, assessed using the time up and go (TUG) 
test, survival at 3 months and 1 year, and readmission within 3 months was examined.  The 
Charlson comorbidity index (CCI) at baseline was also assessed.Results: A total of 216 pa-
tients were treated for a hip fracture. A majority was female (134, 62%), mean age 80 years 
(+/-12) and mean CCI 5.98 (+/- 2.6).  52 (24%) individuals died within a year of surgery, 
among whom 23 (44.2% of 52) passed away within 3 months. 45 (20.8%) were readmitted 
within 3 months of surgery and 20 (9.2%) sustained a second fracture within a year.174 pa-
tients had Vitamin D level measured at presentation and were included for analysis. Vitamin 
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D <20 ng/ml was seen in 39 (22.4%) patients and all received appropriate supplementation. 
The correlation of Vitamin D levels, taken as a continuous variable, to outcomes, was ana-
lyzed using logistic regression. No  significant relationships  between  higher Vitamin D and 
death within 3 months (OR=0.995, p=0.8), death within 1 year (OR=1.008, p=0.62), read-
mission within 3 months (OR=1.001, p=0.96), second fracture within 1 year (OR=1.017, 
p=0.33) and failure to recover (OR=1.002, 0.86). After adjusting for age, gender and CCI, 
Vitamin D levels were non-significantly inversely associated with both TUG 1 and TUG2, 
with every 1 unit higher Vitamin D associated with a TUG lowered by 0.15 seconds, p=0.42 
and 0.44. Vitamin D was poorly correlated to CCI with correlation coefficient of 0.02, p = 
0.71.Conclusions: Our results indicate that Vitamin D levels at the time of a hip fracture 
do not correlate with patients’ functional outcomes. It is possible that replacing vitamin D 
eliminated the possible negative impact on functional recovery.
Disclosures: Sneha Mohan, None
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The Impact of a Nutritional Intervention on Indices of Bone Health in 
Exercising Women with Menstrual Disturbances *Mary Jane De Souza1, 
Emily Southmayd1, Rebecca Mallison1, Nancy Williams1. 1Penn State University, 
United States
Exercising women with low energy availability (EA) and menstrual dysfunction are 
at risk for poor bone health. REFUEL was a 52-wk randomized controlled trial designed to 
improve energy status, restore menses, and improve bone health in exercising women with 
menstrual disturbances. Women (n=62, 18-30 yrs) with oligo/amenorrhea were randomized 
to increase energy intake 20-40% above baseline energy requirements (+Cals, n=32) or 
maintain baseline energy intake (Control, n=30) for 52 weeks. Bone mineral density (BMD, 
total body (TB), lumbar spine (LS), femoral neck (FN), and total hip (TH)) was assessed by 
DXA at baseline, wk21, and wk53 (post). Markers of bone formation (P1NP) and resorption 
(sCTx) were measured at baseline and weeks 5, 9, 21, 33, and 53 to assess bone forma-
tion index, resorption index, and balance (formation index/resorption index). The impact of 
group, time, and group*time for BMD and bone turnover were assessed with linear mixed 
models. Twenty-nine women completed the intervention (+Cals, n=15; Control, n=14). Per-
cent changes described below include only those that completed. Energy intake (EI) in-
creased +448 kcal/day (24%) and body weight increased 3.0 kg (5.6%) by wk53 in the +Cals 
group compared with a change in EI of -42 kcal/day and BW of 0.5 kg in the Control group 
(p<0.05). Women in the +Cals group were more likely to experience menses compared with 
the Control group (p0.05). In exercising women with low EA and menstrual dysfunction, a 
modest increase in energy intake for 53 weeks increased body weight and improved men-
strual regularity but was not sufficient to significantly improve BMD. Sustained and/or more 
substantial increases in energy intake that improve bone formation relative to resorption are 
likely needed to improve BMD in oligo/amenorrheic exercising women.
Disclosures: Mary Jane De Souza, None
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Assessing the Efficacy of Herbal Teas on Bone Health in an Osteopenic 
Population: OsTea *Fahima Munmun1, Alyssa Linden2, Sa’ed Al-Olimat2, 
Jacquelyn Madler2, Hunter Hanlon2, Hannah Enderby3, Paula Witt-Enderby1. 
1Duquesne University Graduate School of Pharmaceutical, Administrative and 
Social Sciences, United States, 2Duquesne University School of Pharmacy, 
United States, 3Duquesne University Bayer School of Natural and Environmental 
Sciences, United States
The purpose of the OsTea (Herbal Teas on Bone Health in an Osteopenic Population; 
NCT03480126) RCT was to assess the efficacy of herbal teas (tulsi, rooibos, oolong) com-
pared to placebo (coriander) in an osteopenic population. In this study, the effects of these 
teas were assessed on markers of bone health, inflammation, melatonin, and the microbiome 
. Quality of life was also assessed using validated questionnaires and diary logs.  Participants 
were asked to drink 3 cups of tea per day for 90 days. Mechanistic studies were also per-
formed on hMSC to determine tea effects on viability and osteoblast differentiation. Overall, 
it was observed that out of the four groups, rooibos and tulsi demonstrated the most signif-
icant effects. Specifically, rooibos consumption significantly decreased urinary CTX levels 
and this was associated with a decrease in urinary bone turnover marker activity (i.e., de-
creased P1NP:CTX ratio); an increase (p=0.06) in nocturnal melatonin levels; an increase in 
the morning: evening salivary cortisol ratio; a decrease in serotonin-producing microbes in 
the gut; a trend (p=0.09) towards an improvement in emotional parameters in QUALIOST; 
and a significant increase in the hMSC differentiation into osteoblasts under normal and 
oxidative stress conditions revealed through alizarin red staining. For tulsi, consumption pri-
marily affected subjective measures related to stress, anxiety, and bone health. Specifically, 
consumption of tulsi over 3 months significantly improved scores of PSS, STAI-trait anxiety 
and osteoporosis/osteopenia-related parameters in QUALIOST. These improvements in sub-
jective measures were associated with an increase in the morning: evening salivary cortisol 
ratio; and a decrease in urinary bone turnover marker activity (i.e., decreased P1NP:CTX 
ratio).  Tulsi tea also protected hMSC viability (i.e., significantly increased osteoblast dif-
ferentiation) under oxidative stress conditions. Although no clinical effects of oolong were 
observed, oolong tea was found to protect hMSCs under oxidative stress conditions reflected 
by an increase in hMSC viability and osteoblast differentiation, similar to tulsi. These find-
ings provide both clinical and mechanistic support for the use of herbal teas, particularly 
rooibos and tulsi, for improving quality of life and bone health.
Disclosures: Fahima Munmun, None
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Vitamin D Insufficiency is Widespread in Armenia *Nicholas Hutchings1, 
Varta Babalyan2, Annemieke Heijboer3, Sisak Baghdasaryan2, Mushegh 
Qefoyan2, Mariëtte T Ackermans3, Arus Ivanyan4, Anna Formenti5, Andrea 
Giustina5, John P Bilezikian6. 1University of California, Irvine, United States, 
2Osteoporosis Center of Armenia, Armenia, 3Vrije Universiteit Medisch 
Centrum, Netherlands, 4Yerevan State Medical University, Armenia, 5Università 
Vita-Salute San Raffaele, Italy, 6Columbia University, United States
Vitamin D plays a critical role in skeletal development and in its maintenance. Thus, 
vitamin D sufficiency is an important goal for public health programs. Given the absence 
of any foods fortified in vitamin D in the land-locked country of Armenia, we hypothesized 
that vitamin D insufficiency would be widespread. To test this hypothesis, we conducted a 
random modified cluster model survey of vitamin D status of women in the country. We em-
ployed a dried blood spot (DBS) assay, a convenient and accurate method which lends itself 
to representative sampling throughout a country like Armenia: sampling entails obtaining a 
small volume of blood, applying it to filter paper, and then transporting it to the laboratory 
for LC/MS analysis. We also utilized a questionnaire to assess lifestyle factors which may 
influence vitamin D levels. In summer, we sampled 1206 participants from 40 randomly 
selected communities in Armenia, covering the entire country. Mean 25-hydroxyvitamin 
D (25-OH D) level among women aged 18-24 was 19.63 ng/mL (SD 7.61); among women 
aged 25-64 was 20.76 ng/mL (SD 7.39); and among women > 65 was 18.39 ng/mL (SD 
7.51). The country-wide mean of the entire population was 19.76 ng/mL (SD 7.55).  A ma-
jority of the population (> 54%) had 25-OH D levels < 20 ng/mL with nearly 13% having 
25-OH D levels < 12 ng/mL. Participants who reported calcium, vitamin D, or multivitamin 
supplementation had statistically higher levels of 25-OH D (p-values 0.004, 0.0002, and 0.03 
respectively) as did pre- vs post-menopausal women (p = 0.01), pregnant vs non-pregnant 
women (p = < 0.0001) and women who had experienced a sunburn in the past year (p = 
0.004). There was no statistically significant relationship between the 25-OH D level and 
acknowledged smoking, alcohol use, sun exposure, physical activity, or dietary intake of 
foods rich in vitamin D. In Armenia, the results show a strikingly high prevalence of vitamin 
D insufficiency, providing much-needed data to inform and bolster public health directives 
to address this pervasive threat to optimal skeletal health.
Disclosures: Nicholas Hutchings, None
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Different impact of running, soccer and rugby trainings on diaphyseal 
tibia and fibula architecture, with different dependence on cortical tissue 
mineralization. *Sergio Luscher1, Leandro Pisani2, Nicolas Pilot2, Leandro 
Mackler1, Joern Rittweger3, Alex Ireland4, Jose Luis Ferretti1, Ricardo Francisco 
Capozza1, Gustavo Roberto Cointry1. 1Center for P-Ca Metabolism Studies 
(CEMFoC), Natl Univ of Rosario and Arg NRC (CONICET), Argentina, 2Unit of 
Musculoskeletal Biomechanics Studies (UDEBOM), CUADI, Universidad del 
Gran Rosario, Argentina, 3Institute of Aerospace Medicine, German Aerospace 
Center (DLR); Department of Pediatrics and Adolescent Medicine, University 
of Cologne, Germany, 4School of Healthcare Science, Manchester Metropolitan 
University, United Kingdom
Some differences between pQCT indicators of cortical tibia and fibula design between 
athletes trained in disciplines involving a different use of the foot with respect to untrained 
controls have been observed. This study aims to analyze these differences and assess their 
possible dependence on cortical tissue deformability (a relevant feature to mechanostat con-
trol of bone design). To that purpose, we compared the pQCT-assessed, anterior-posterior 
and lateral bending moments of inertia (xMI, yMI) in 18 serial scans taken at every 5% of 
the dominant-tibia length of 13 long-distance runners (LDR, in whom the foot is not trained 
in rotation/eversion), 28 soccer players and 19 rugbiers (S,R, in which foot rotation/eversion 
are intensively solicited), and 15 untrained controls (C). We correlated both MI values with 
the cortical vBMD (vCtD) at every site as a surrogate of bone tissue stiffness.Tibia MIs 
were significantly but moderately larger in R, S and LDR that in C, in that decreasing or-
der (p<0.001), especially in the proximal region. In contrast, in the fibulae, xMI was much 
larger in R, S and DLR than in C (p<0.001) throughout, and yMI was similar to C in LDR 
and much higher in R and S (p<0.001), with differences increasing proximally. The vCtD 
was significantly but mildly lower in R, S and LDR tan in C, with differences increasing 
proximally. The negative, hyperbolic MI/vCtD relationships for both MI’s were more signif-
icant in the tibiae (r=0.61-0.81, always p<0.001) than in the fibulae (r=0.11-0.39, not always 
significant) in all groups.Results show a contrasting behavior of both MI’s between both 
bones and disciplines. In the tibiae, the MI’s varied ‘canonically’ (significantly larger values 
in LDR, S or R than in C throughout), regardless of foot behavior. In the fibulae, however, 
the MI’s varied in parallel with the degree of predominance of foot rotation/eversion on 
training and showed some site-specificity. Moreover, in the tibiae, the MI/vCtD relation-
ships followed the ‘natural’, negative relationship observed in previous studies, while in 
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the fibulae they were much less significant if any. This suggests that the strikingly larger MI 
(especially, yMI) values in R and especially F than in LDR or C should have taken place 
‘despite of’ the natural limitations of mechanostat input imposed by the intrinsic stiffness of 
cortical tissue. These observations are consonant with some phylogenetical features related 
to Natural Selection of leg bones.
Disclosures: Sergio Luscher, None
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Blueberry Polyphenols do not Improve Bone Mechanical Properties in 
Ovariectomized Rats *Dennis P Cladis1, Elizabeth A Swallow2, Matthew 
R Allen2, Kathleen M Hill Gallant1, Mario G Ferruzzi3, Connie M Weaver4. 
1Department of Nutrition Science, Purdue University; Department of Food 
Science and Nutrition, University of Minnesota, United States, 2Department of 
Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, 
United States, 3Plants for Human Health Institute, North Carolina State 
University, United States, 4Department of Food Science, Purdue University, 
United States
           Postmenopausal women are at increased risk of osteoporosis and osteoporotic 
fractures. Bisphosphonates are commonly prescribed to mitigate osteoporotic bone loss, but 
some are hesitant to use them because of potential side effects. In light of this, alternative 
treatment options have been sought, including the use of fruit and vegetable-derived poly-
phenols. Previous in vitro experiments have demonstrated beneficial effects of polyphenols 
on bone health, leading to the increased use of polyphenol-rich herbal and botanical di-
etary supplements for bone health. We examined the efficacy of this strategy using blueberry 
polyphenols in a rat model of postmenopausal bone loss.            Five-month old, ovariec-
tomized, Sprague-Dawley rats (n=10/gp) were orally gavaged for 90 days with either a pu-
rified extract of blueberry polyphenols (0, 50, 250, or 1000 mg total polyphenols/kg bw/d) 
or lyophilized blueberries (50 mg total polyphenols/kg bw/d, equivalent to 1-2 cups fresh 
blueberries/d in humans). Upon completion of the dosing regimen, right femur, right tibia, 
and L1-L4 vertebrae were harvested. Bone mineral density (BMD) was assessed at all three 
sites by PIXImus. Micro-architecture and mechanical properties of femora were determined 
using micro-CT and three-point bending, respectively, with standard equations used to cal-
culate material properties.            Total polyphenol content of lyophilized blueberries and 
the purified extract were 3.5% and 27% (w/w), respectively. No differences were observed 
in BMD at any of the sites analyzed. Bone mechanical properties, including ultimate force, 
total displacement, stiffness, and total work, were not different across treatment groups. For 
material-level biomechanical properties, ultimate stress was higher in the 1000 mg group as 
compared to the 250 mg group (p=0.042), although no other differences were noted across 
treatment groups for total strain, modulus, or toughness.            These results indicate that 
consuming blueberry polyphenols in the whole fruit or as an extract had little impact on 
BMD or bone mechanical properties in an animal model of estrogen deficiency-induced 
bone loss.
Disclosures: Dennis P Cladis, None
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The Dried Blood Spot Assay: Successful Application of a Methodology to 
Conduct a Country-Wide  Survey of Vitamin D Status *Nicholas Hutchings1, 
Annemieke Heijboer2, Varta Babalyan3, Sisak Baghdasaryan3, Mushegh 
Qefoyan3, Mariëtte T Ackermans2, Anna Formenti4, Andrea Giustina4, John P 
Bilezikian5. 1University of California, Irvine, United States, 2Vrije Universiteit 
Medisch Centrum, Netherlands, 3Osteoporosis Center of Armenia, Armenia, 
4Università Vita-Salute San Raffaele, Italy, 5Columbia University, United States
Information about nutrients throughout a population is critical not only to quantify nu-
tritional status but also to establish a foundation for public health recommendations and 
interventions. Obtaining reliable and robust data for a large and geographically diverse 
population is a major challenge of conducting such studies. In our country-wide survey of 
vitamin D nutrition in Armenia, we developed and applied a replicable and accurate method 
for randomized, representative participant selection and sampling. Using citizen registration 
data from the Ministry of Health in Armenia, we randomly selected 40 health clinics and 
then randomly selected 35 individuals registered to each clinic in a representative age distri-
bution. From 1206 participants, using a finger prick, we obtained a drop of blood which was 
applied to and dried on filter cards (dried blood spot [DBS] cards). We also obtained point-
of-care hematocrit and questionnaires. DBS cards were subsequently analyzed for 25-OH 
D via liquid chromatography mass spectrometry (LC-MS/MS). This well-standardized LC-
MS/MS method shows a strong correlation between DBS and serum-obtained measurements 
of 25-OH D (R = 0.98) and DBS measurements were calibrated against serum measure-
ments, thereby assuring the accuracy of the data. The results, provided in another abstract, 
represent the most comprehensive survey of any similarly important health index among 
the population of Armenia. The DBS methodology can be adapted to the measurement of 
other nutrients in Armenia or other countries. Using dried blood spots, such studies can be 
conducted conveniently, accurately, and in a cost-effective manner.
Disclosures: Nicholas Hutchings, None
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Correlations between dietary patterns of Mediterranean-type and Dietary 
Approaches to Stop Hypertension style and bone health status in adults 
*Yi-Chin Lin1, Jia-Yu Lin1. 1Department of Nutrition, Chung Shan Medical 
University, Taiwan, Province of China
Osteoporosis is an asymptomatic disease characterized by low bone mass and microar-
chitectural deterioration that would consequently increase bone fragility and the risk of 
fracture. According to the results from 2013-2016 Nutrition and Health Survey in Taiwan 
(NAHSIT), the prevalence rates of osteoporosis in those aged 50 years and older were 8.6% 
in men and 15.5% in women, respectively, and the prevalence increases with age. Previous 
studies have shown that both DASH (Dietary Approaches to Stop Hypertension) diet and the 
Mediterranean diet are associated with improved health. We thus hypothesized that adults 
with higher adherence to these diets would have better bone health status. The subjects were 
289 adults (141 males and 148 females) aged 20 years and older who were originally recruit-
ed for two independent observational studies on adult bone health. Adherence to DASH diet 
was assessed by calculating the Mellen‘s index based on the intake of 9 nutrients according 
to the 24-h dietary recalls of the subjects, whereas the adherence to the Mediterranean diet 
was assessed by calculating the MMDS (modified Mediterranean Diet score) according to 
the intake of 5 beneficial components (vegetables, fruits and nuts, legumes, cereals, and fish) 
and 2 components presumed to be detrimental (meat and poultry products, and dairy prod-
ucts). These diet scores were then evaluated for the association with bone health measure-
ments, including BMC and BMD at total body, lumbar spine and femoral neck.The results 
showed that only low to fair adherence to both diets in the subjects though the adherence to 
DASH diet seemed to increase with age (p<0.0001 for both genders). There were positive 
correlations, of borderline significance, between MMDS and BMC at total body (b=70.22; 
p=0.0591), lumbar spine (b=2.98; p=0.0585), and femoral neck (b=0.15; p=0.0559) and be-
tween MMDS and BMD at lumbar spine (b=0.04; p=0.0759) in males aged 65 years and 
older. DASH diet score, however, was negatively correlated with BMD in males and fe-
males, but positively correlated with lean mass in males (b=4.26; p=0.0264). It appears that 
adhere to DASH diet may be beneficial for maintaining lean mass in males, whereas higher 
adherence to diet of Mediterranean type may be associated with better bone health status in 
males aged 65 years or older.
Disclosures: Yi-Chin Lin, None
P-597
Time Restricted Eating for 12 Weeks Does Not Adversely Alter Bone Mineral 
Content and Bone Metabolism in Overweight Adults *Andrea Lobene1, 
Satchindananda Panda2, Douglas Mashek3, Kathleen Hill Gallant4, Lisa Chow5. 
1Department of Nutrition Science, Purdue University, United States, 2Salk 
Institute for Biological Studies, United States, 3Department of Biochemistry, 
Molecular Biology and Biophysics and Department of Medicine, Division of 
Diabetes, Endocrinology and Metabolism, University of Minnesota, United 
States, 4Department of Nutrition Science, Purdue University; Department of Food 
Science and Nutrition, University of Minnesota, United States, 5Department of 
Medicine-Division of Diabetes, Endocrinology, and Metabolism, University of 
Minnesota, United States
Time-restricted eating (TRE), shortening the daily eating window to 8-10 hours, has 
been investigated as a potential strategy for weight loss and improving cardiometabolic 
health. However, the effect of TRE on bone health has not yet been determined. The aim 
of our study was to assess the effect of TRE on bone mineral content and bone metabolism. 
This study was a secondary analysis of a feasibility study which assessed the effect of TRE 
on weight, body fat, and cardiometabolic outcomes (Chow et al. Obesity 2020). Overweight 
and obese participants with a documented eating window >=14 hours (age=45+/-12 years) 
were randomly assigned to either TRE (n=11) or non-TRE (n=9). TRE participants were 
instructed to maintain a self-selected 8-hour ad libitum window for the 12-week intervention 
period, while non-TRE participants maintained their usual eating habits. Total body bone 
mineral content (BMC) and bone mineral density (BMD) were assessed pre- and post-inter-
vention by DXA. Pre- and post-intervention serum samples were used to assess NTX and 
P1NP by ELISA, and intact PTH by EIA. Data were non-normally distributed and were 
log-transformed. Bone outcomes did not differ between groups at baseline. Linear mixed 
model analyses were conducted to assess the effect of time, treatment, and the interaction 
between treatment and time on the measured bone-related outcomes. There was an interac-
tion between treatment and time for BMC (p=0.02) such that BMC increased in the TRE 
group but decreased in the non-TRE group over the 12 weeks, though the changes were 
<20g each. P1NP decreased in both treatment groups (p=0.04) with a larger decrease in the 
non-TRE group such that the interaction between treatment and time approached signifi-
cance (p=0.07). PTH increased in both groups, though the change did not reach statistical 
significance (p=0.09). There were no significant differences in BMD or NTX over time or 
between groups. Changes in bone outcomes were not correlated with changes in weight or 
BMI in either group. Our results suggest 12 weeks of TRE does not negatively affect BMC, 
BMD, or markers of bone metabolism. Given the prevalence of overweight/obesity, and the 
importance of implementing weight-loss interventions in this population, it is important to 
understand the impacts on long-term bone health. Therefore, future studies should include 
a longer intervention period with clinically important measures such as site-specific BMD, 
bone microarchitecture, or fracture risk.
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Predominant Effects of Inducible Deletion of ERα in Osteocytes as 
Compared to Osteoclasts in Reducing Bone Mass in Adult Female Mice 
*David Monroe1, Madison Doolittle1, Joshua Farr1, Megan Weivoda2, Jennifer 
Rowsey1, Brittany Eckhardt1, Daniel Fraser1, Sundeep Khosla1. 1Mayo Clinic, 
United States, 2University of Michigan, United States
The skeleton has long been recognized as a major target for estrogen (E) action, how-
ever major gaps still exist in our fundamental knowledge of how E and E receptors (ERs) 
regulate bone metabolism. Previous studies have shown that global deletion of ERα (ERα-
KO) results in increased bone mass, however this is confounded by high circulating E levels. 
Specific osteocyte/osteoblast ERα-KO resulted in conflicting findings, perhaps confounded 
by ERα effects on growth and development versus on the adult skeleton. By contrast, spe-
cific osteoclast ERα-KO throughout life has fairly consistently resulted in decreased bone 
mass through an increase in osteoclasts. Thus, in order to directly evaluate E effects on 
the adult skeleton, we developed two novel mouse models that express the tamoxifen-in-
ducible Cre deleter, CreERT2, in either osteocytes or osteoclasts using the Dmp1(8kb) and 
Ctsk promoters, respectively. We crossed these models with an ERα-flox mouse and treated 
with tamoxifen using a predetermined regimen at 4 months of age to create the ERαΔOcy/
CreERT2 and ERαΔOcl/CreERT2 adult-deleted models and analyzed the bone phenotype at 
5 months. Female, but not male, ERαΔOcy/CreERT2 mice exhibited a significant decrease 
in trabecular BV/TV (-20.1%, P = 0.004; Panel A) and Tb.Th (-9.7%, P = 0.014) at the spine, 
clearly establishing a key role for osteocytic ERα in regulating the skeleton in adult female 
mice. Periosteal expansion (+65.6%, P = 0.004) and endocortical resorption (+64.1%, P 
= 0.003) were higher in ERαΔOcy/CreERT2 mice compared to control mice at the tibial 
diaphysis, with no change observed in Ct.Th., demonstrating an action of E through ERα 
to inhibit periosteal apposition and promote endocortical formation. An increase in Sdf1/
Cxcl12 mRNA (1.38-fold, P = 0.002) was observed in trabecular bone at the spine, as well as 
an increase in the Wnt-inhibitor Sost (2.1-fold, P = 0.015), consistent with previous reports 
that E suppresses Sost levels in mice and humans. Interestingly, a decreasing trend in trabec-
ular BV/TV (-10.2%, P = 0.084; Panel B) was observed in the female ERαΔOcl/CreERT2 
adult-deleted model, along with a concomitant increase in serum Ctx (2.1-fold, P = 0.005). 
These findings thus establish that osteocytic ERα, and to a lesser extent osteoclastic ERα, is 
critical for E action in female, but not male, adult bone metabolism and that these effects may 
differ from mechanisms of E action during early growth and development.
Disclosures: David Monroe, None
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Identification of a new circulating cellular biomarker from patients with 
postmenopausal osteoporosis *Kaichi Kaneko1, Deniece Menez1, Steven 
Zeng1, Peter Sang Park1, Haemin Kim1, Hao Chen1, Seyeon Bae1, Sehwan Mun1, 
Eugenia Giannopoulou1, Emily Stein2, Richard Bockman2, Linda A Russell3, 
Joseph Lane4, Jessica Starr2, Patricia Donohue2, Kyung-Hyun Park-Min1. 
1Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics 
Research Center, Hospital for special surgery, United States, 2Endocrine Service, 
Hospital for Special Surgery, United States, 3Rheumatology, Hospital for Special 
Surgery, United States, 4Orthopedic surgery, Hospital for Special Surgery, United 
States
Osteoporosis is a metabolic bone disorder characterized by compromised bone mass, 
quality, and strength, resulting in an increased risk of fracture. More than 25% of the mid-
dle-age population has low bone mass and most remain unaware of their growing risk for 
fracture. Although considerable work has been done to improve diagnostic standards and 
tools to identify low bone mass, early detection of the predicate causes of osteoporosis does 
not exist. Therefore, discovering new diagnostic markers that closely correlate with early 
osteoporosis disease activity is imperative. Here, we describe a new cellular marker that 
closely correlates with increased osteoclast activity, a prime underlying cause responsi-
ble for pathological bone loss.We describe a new circulating cell population from human 
blood—osteoclast-enhancing cells (OECs). OECs enhance human osteoclastogenesis and 
express essential osteoclast-specific receptors such as CSF1R and RANK, but do not express 
CD66b, CD3, and CD19. OECs also express CD14, but the morphology of OECs differs 
from CD14+monocytes. To further characterize OECs, we performed RNA-sequencing and 
identified that the expression of 2697 genes was significantly (p 1.5) changed between OECs 
and monocytes. Ingenuity Pathway Analysis identified that the differentially expressed genes 
are enriched in key regulatory pathways for osteoclastogenesis including oxidative stress 
and interferon signaling pathways.We then hypothesized that the number of circulating 
OECs could act as a marker for increased osteoclastic activity in bone. To test this, we deter-
mined the frequency of OECs in blood from postmenopausal women with no treatment and 
compared the number of OECs with lumbar spine and total hip bone mineral density (BMD) 
from DXA and serum bone turnover markers. Of the 44 participants, 16 women (36%) had 
osteoporosis (mean age +/- SD: 67.3 +/- 8.8), 19 (43%) had osteopenia (66.8 +/- 8.8), and 9 
(20%) had normal BMD (66.1 +/- 9.5). Correlation analysis showed a significant correlation 
between the number of OECs and BMD (p = 0.0008, r = -0.4960), and between the number 
of OECs and CTX (p = 0.0185, r = 0.4585).  In summary, a circulating population of OECs 
with high osteoclastogenic activity is described and significantly increased OECs have been 
found in subjects with the lowest BMD values. We conclude that OECs could potentially 
serve as a prognostic marker for patients with low and falling bone mass.
Disclosures: Kaichi Kaneko, None
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The Role of Tmem263 in the Regulation of Bone Mass and Micro-
architecture in Mice *Imranul Alam1, Rita Gerard-O’Riley1, Dena Acton1, Sara 
Hardman1, Madeline Murphy1, Caylin Billingsley1, Michael Econs1. 1Indiana 
University School of Medicine, United States
Previously, several genome-wide association studies (GWAS) discovered a list of 
genes important in genetic variation of BMD and risk of fracture. One locus on chro-
mosome 12q23.3 harboring the gene TMEM263 was strongly associated with hip BMD 
(p<9.6x10-10). Recently, we discovered a unidirectional allelic imbalance in TMEM263 
mRNA expression in human bone. Also, we found Tmem263 mRNA was highly expressed 
in osteoblasts and osteocytes compared to osteoclasts. These data suggest that Tmem263 
might play important roles in bone homeostasis predominantly through osteoblasts. Current-
ly, very little is known about the TMEM263 gene as it is not part of an established protein 
family and most publications about this gene document the identification of open reading 
frame or cDNA sequences. To further identify the role of Tmem263 in bone biology, in this 
study, we created osteoblast-specific conditional Tmem263 knockout male and female mice 
using 2.3-kb α1 type 1 collagen promoter (Col2.3-α1-Tmem263) and measured bone density 
and micro-architecture, evaluated serum biochemistry and biomarkers of bone metabolism 
in growing (8 weeks) and adult (16 and 24 weeks) age. We found that Col2.3-α1-Tmem263 
mice were smaller in size compared to their WT and heterozygote littermates at 8, 16 and 
24 weeks of age. In addition, compared to WT and heterozygote mice, Tmem263 knockout 
mice exhibited significantly lower whole body aBMD and BMC in growing and adult age, 
and significantly lower femur and spine (L1-5) aBMD and BMC at 24 weeks of age in 
both male and females (Figure 1). Micro-CT analysis of trabecular bone at distal femur also 
revealed lower BV/TV in male and female Tmem263 knockout mice at all time points com-
pared to the age-matched WT and heterozygote mice (Figure 1). Cortical analysis at femur 
midshaft showed lower cortical area and thickness in the Tmem263 homozygote knockout 
mice compared to the other genotypes at 24 weeks of age in female. In addition, we did not 
observe any significant differences for serum biochemistry (Ca, P, BUN and Creatinine) at 
any age as well as no differences for serum CTX, TRAP and P1NP levels at 24 weeks of age 
among different genotypes. Further, only Tmem263 knockout mice displayed spontaneous 
tail fractures at various ages. Our study demonstrates that Tmem263 plays a critical role in 
the regulation of bone mass and micro-architecture in mice.
Disclosures: Imranul Alam, None
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ENPP1 regulates bone mass via an unidentified catalytically independent 
mechanism *Demetrios Braddock1, Ralf Oheim2, Kristin Zimmerman1, 
Simon v. Kroge2, Paul Stabach1, Dillon Kavanagh1, Steven Tommasini3, 
Thomas Carpenter4. 1Yale University, Department of Pathology, United States, 
2Department of Osteology and Biomechanics, University Medical Center 
Hamburg-Eppendorf, Germany, 3Department of Orthopædics and Rehabilitation, 
Yale University School of Medicine, United States, 4Department of Pediatrics at 
Yale University School of Medicine, United States
Heterozygous ENPP1 deficiency is associated with early onset osteoporosis, a pheno-
type faithfully reproduced in murine models. ENPP1 hydrolyzes extracellular nucleotide 
triphosphates to generate nucleotide monophosphates and pyrophosphate (PPi), however 
the mechanism of ENPP1 associated osteoporosis is not readily apparent given that PPi is a 
strong inhibitor of mineralization. Current murine models reduce both Enpp1 catalytic ac-
tivity and protein expression via disruption of protein folding and stability. A single catalytic 
site, a Threonine at position 238 in Enpp1, is responsible for the hydrolysis of the high-en-
ergy nucleoside phosphate bond via an SN2 reaction mechanism. Accordingly, we  convert-
ed the Threonine nucleophile to an Alanine in C57BL/6 mice using Crispr/Cas techniques 
to eliminate Enpp1 catalytic activity without disrupting protein folding or expression, and 
compared the skeletal and tissue mineralization phenotype in Enpp1T238A/T238A mice 
with WT sibling pairs, and to Enpp1asj/asj mice which exhibit disrupted protein expression 
and catalysis. Similar to Enpp1asj/asj mice, Enpp1T238A/T238A mice exhibited markedly 
decreased plasma PPi (13% of WT), increased intact FGF23 (180% of WT), phosphate wast-
ing (70% of WT), and increased extra-skeletal calcifications in the soft tissues and joints. 
Of note, bone mass in Enpp1T238A/T238A mice was better preserved than in Enpp1asj/
asj mice at both 10 and 23 wks of age, with normal trabecular bone volume and trabecular 
number (by both microCT and histomorphometry). Moreover, Enpp1T238A/T238A mice 
had a consistently more favorable biomechanical profile (stiffness, maximum load, and total 
work in tibias on 4-point bending) than Enpp1asj/asj mice.  Furthermore, in contrast to Enp-
p1asj/asj mice, Enpp1T238A/T238A mice exhibited no evidence of osteomalacia – MAR 
and MLT were normal at both 10 and 23 weeks. Finally, similar to Enpp1asj/asj mice, qBEI 
analysis demonstrated decreased osteocyte lacunar area at both time points. Overall, this 
constellation of findings suggests that Enpp1 contributes to skeletal mass through an uniden-
tified mechanism independent of its catalytic activity.
Disclosures: Demetrios Braddock, Inozyme Pharma, Grant/Research Support
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A decrease in NAD+ contributes to the loss of osteoprogenitors and bone 
mass in aged mice *Ha-Neui Kim1, Filipa Ponte1, Aaron Warren1, Maria 
Almeida1. 1University of Arkansas for Medical Sciences, United States
Age related osteoporosis results in part from a deficit in osteoblasts. The forkhead 
box O (FoxO) transcription factors attenuate Wnt/β-catenin signaling and thereby decrease 
bone formation. The NAD+ dependent Sirtuin 1 (Sirt1) deacetylates FoxOs and β-catenin 
in osteoblast progenitors and increases bone mass. NAD+ is recycled from nicotinamide 
via activity of nicotinamide phosphoribosyltransferase (Nampt). Although the number of 
osteoblast progenitors greatly decrease with age, it remains unknown whether dysregulation 
of the Sirt1/FoxO/β-catenin pathway contributes to this effect and to age-related bone loss. 
We found that the levels of NAD+ decrease in osteoblast progenitor cultures from old mice, 
associated with increased acetylation of FoxO1 and with decreased levels of Nampt – a 
critical enzyme of the NAD salvage pathway. Addition of the NAD+ precursor nicotinamide 
riboside (NR) to the cultures abrogated FoxO1 and β-catenin acetylation and increased the 
osteoblastogenic capacity of cells from old mice. We next administered NR (via the drink-
ing water) to 12 month-old C57BL/6 female mice or TdRFP;Osx1-Cre mice, to achieve 
a dose of 400 mg/kg of body weight/day, for 8 months. NR administration increased the 
levels of NAD+ in liver and fat, and in cultured bone marrow-derived stromal cells. The 
number of TdRFP;Osx1 osteoprogenitors, present in the bone marrow, was also increased 
as determined by flow cytometry. Furthermore, NR attenuated the loss of cortical bone as 
determined by micro-CT in femur. This was associated with increased mineralizing surface 
while osteoclast numbers were unaffected. We next examined whether a decrease in NAD in 
bone cells could mimic the effects of aging. To this end, we generated mice haploinsufficient 
for Nampt in the mesenchymal lineage targeted by Prx1-Cre (Namptfl/+;Prx1-Cre). At 2 mo 
Namptfl/+;Prx1-Cre mice had no detectable bone phenotype but at 8 mo had decreased cor-
tical thickness when compared to Namptfl/+ littermate controls, as determined by micro-CT. 
In addition, bone marrow derived osteoblastic cell cultures from Namptfl/+;Prx1-Cre mice 
had decreased NAD+ and increased FoxO1 and β-catenin acetylation, and decreased levels 
of β-catenin and osteoblastogenic capacity.  Together, these findings suggest that the de-
crease in bone formation with old age is due to a decrease in NAD+ and dysregulated Sirt1/
FoxO/β-catenin pathway in osteoblast progenitors.
Disclosures: Ha-Neui Kim, None
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Loss of Osteogenic Dickkopf-1 Ameliorates Cortical and Trabecular Bone 
Loss by Suppressing Bone Resorption in Male Mice With Type 1 Diabetes 
Mellitus *Souad Daamouch1, Juliane Coldtitz1, Nick Hildebrandt1, Sylvia 
Thiele1, Lorenz C. Hofbauer1, Martina Rauner1. 1Department of Medicine III and 
Center for Healthy Aging, Technische Universität, Germany
Patients with type 1 diabetes mellitus (T1D) have decreased bone mass and increased 
susceptibility to fractures. The underlying molecular mechanisms, however, remain incom-
pletely understood. Studies have shown that patients suffering from T1D have an increased 
expression of Dickkopf-1 (Dkk-1), a potent inhibitor of the pro-osteogenic Wnt signaling 
pathway. Here, we investigated the role of Dkk1 in a mouse model of T1D-induced bone 
loss.T1D was induced in 10-week-old male mice with Dkk1-deficiency in osteoblasts/osteo-
cytes (Dkk1f/f; Dmp1-Cre, cKO) by 5 subsequent injections of streptozotocin (40 mg/kg). 
Control groups received citrate buffer. Four weeks later, the bone phenotype was analyzed 
using µCT and dynamic histomorphometry. Each group contained 8-10 mice. We measured 
the blood glucose level and body weight twice per week throughout the experiment. Further, 
a glucose tolerance test (GTT) was performed.During the experiment, diabetic mice did not 
gain body weight compared to control mice and further lost their perigonadal and subcuta-
neous fat pads. There were no differences between Dkk1-cKO and control mice. Diabetic 
mice had highly elevated serum glucose levels and impaired glucose tolerance; however, 
this was regardless of Dkk1.T1D led to a 36% decrease in trabecular bone volume in control 
animals, whereas Dkk1 cKO mice only lost 16% of bone volume. Moreover, trabecular 
number was decreased and trabecular separation increased in T1D control mice, whereas it 
remained unchanged in T1D Dkk1 cKO mice. Moreover, Dkk1 cKO mice were completely 
protected from T1D-induced cortical bone loss. T1D suppressed the bone formation rate, the 
number of osteoblasts in trabecular bone, and serum levels of P1NP in both, Dkk1-deficient 
and sufficient mice. This may be explained by the increase in serum sclerostin levels in both 
genotypes. In contrast, the number of osteoclasts and TRAP serum levels only increased in 
diabetic control mice, but not in Dkk1 cKO mice.In summary, Dkk1 derived from osteogenic 
cells does not influence the development of T1D, but plays a crucial role in T1D-induced 
bone loss in male mice by regulating osteoclast numbers.
Disclosures: Souad Daamouch, None
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Cathepsin D regulates bone mass through distinct mode of actions in the 
autophagy pathway in osteoblasts and osteoclasts *Chao Wan1, Fengjie 
Zhang1, Wing Pui Tsang1, Qiling He2. 1Key Laboratory for Regenerative Medicine, 
Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, 
The Chinese University of Hong Kong, Hong Kong SAR, China., Hong Kong, 
2Department of Microbiology, University of Alabama at Birmingham, AL 35294, 
USA., United States
Insufficiency in nutrient and oxygen availability, oxidative stress, and autophagy failure 
are fundamental factors for the decline of bone mass and strength with aging. Accumulating 
evidence indicates that these factors affect normal autophagosomal or lysosomal activities 
which are the major force in clearance of aggregated or damaged proteins. Cathepsin D 
(CtsD), the principal lysosomal aspartate protease and a main endopeptidase, functions in 
the normal activity of autophagosome and lysosome. It is indicated that CtsD exists in the 
skeletal tissue during development or injury. However, the molecular and cellular mecha-
nisms of CtsD mediated autophagosome or lysosome function in the skeletal homeostasis 
remain unclear. In the present study, we showed that global knockout of CtsD dramatically 
decreased bone mass in the 3-week old mutant mice compared with their control littermates 
as indicated by decreased BV, BV/TV, BS, trabecular number, trabecular thickness and in-
crease trabecular separation in the microCT analysis. Histomorphometry analysis revealed 
that the phenotype was characterized by decreased osteoblast numbers, osteoblast surface/
bone surface and mineral apposition rate, increased osteoclast numbers, osteoclast surface/
bone surface and erosion surface/bone surface. At molecular level, siRNA medicated inacti-
vation of CtsD in MC3T3E1 cells attenuated osteoblastic differentiation and downregulated 
LC3B expression, which was accompanied by decreased levels of P62, p-Akt and p-GSK-
3beta in osteoblasts. Intriguingly, inactivation of CtsD in RAW264.7 cells increased osteo-
clast differentiation with decreased LC3B expression but upregulated P62 level. This was 
accompanied by alterations in the formation of autophagosome and differential gene profiles 
associated with the autophagy pathway during the differentiation of osteoblasts and osteo-
clasts. The results suggest that CtsD mediated autophagy pathway plays important roles in 
regulation of bone mass and homeostasis through distinct mode of actions in osteoblasts and 
osteoclasts, fine tuning of CtsD activity may serve as a potential therapeutic target for the 
maintenance of bone mass.  
Disclosures: Chao Wan, None
P-605
Glycosaminoglycan and Pyridinoline content at forming trabecular 
surfaces are strongly associated with fracture incidence independent of 
clinical diagnosis and estimated fracture risk based on BMD. *Eleftherios P. 
Paschalis1, Sonja Gamsjaeger1, Stamatia Rokidi1, David Dempster2, Hua Zhou2, 
Elizabeth Shane2, Adi Cohen2, John P. Bilezikian2, Mishaela Rubin2, Carolina 
Moreira3, Vicente F.C. Andrade3, Socrates Papapoulos4, Erik F. Eriksen5, Klaus 
Klaushofer1. 1Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital 
of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department, 
Hanusch Hospital, Vienna, Austria, Austria, 2Medicine and Pathology, College 
of Physicians and Surgeons of Columbia University, New York, New York, USA, 
United States, 3Endocrinology Division (SEMPR), Federal University of Parana, 
Curitiba, Brazil, Brazil, 4Center for Bone Quality, Leiden University Medical 
Center, Leiden, The Netherlands, Netherlands, 5Oslo University Hospital and 
Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Norway
Background: Bone fragility is attributed to low BMD as well as altered structure and 
material properties. In the present work we tested the hypothesis that organic matrix quality 
at actively forming trabecular surfaces is associated with fragility fracture incidence (Fx) 
independent of BMD and clinical diagnosis.Methods: We used Raman microspectroscopy 
to analyze iliac crest biopsies from females who belonged any of three groups: 1. Healthy 
(HC; ages 1.5 – 59 yrs, N = 124) 2. Women sustaining Fx irrespective of clinical diagnosis 
and BMD (Fx; ages 2 – 74 yrs, N = 92) 3. Women with altered BMD values but without Fx 
(NC; ages 23-74 yrs, N = 79). The measured indices were: mineral/matrix (MM; affecting 
stiffness and brittleness), glycosaminoglycan (GAG; negative modulators of mineral ho-
meostasis; involved in collagen fibrilogenesis), and pyridinoline (Pyd; associated with fiber 
stiffness, ultimate stress and post-yield energy and strength, and bending strength) contents 
at forming cancellous surfaces. Spectra were obtained between the second fluorescent label 
and the mineralizing front (TA1), between the two labels (TA2), and right behind the first 
label (TA3). Individual patient data were considered as a function of patient- and tissue-age. 
Additionally, lumbar spine (LS) and femoral neck (FN) Z-scores were available for all sub-
jects except healthy females aged 1-19 years. LS, FN, and total hip (TH) T-scores were avail-
able for all subjects except healthy females aged 1-19 years, as well as children diagnosed 
with mild osteogenesis imperfecta.To evaluate differences in BMD, and bone quality related 
spectroscopic parameters between the 3 groups, 2-way analysis of covariance (ANCOVA) 
was applied with age as a continuous covariate and tissue age as categorical cofactor. Sidák´s 
post-hoc test was used for pairwise comparisons amongst levels of skeletal health status. 
Differences were considered significant at p<0.05.Findings: ANCOVA indicated that BMD 
Z- and T-scores discriminated between HC and either Fx or NC groups but not between Fx 
and NC. On the other hand, unlike MM, GAGs and Pyd contents discriminated between 
patients in the 3 groups (Table 1).Interpretation: The results indicate that GAG and Pyd 
contents identify patients sustaining fragility fractures irrespective of clinical diagnosis and 
commonly employed clinical screening tools. Thus, they provide new insight into the patho-
genesis of skeletal diseases characterized by fragility fractures.
Disclosures: Eleftherios P. Paschalis, None
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Exaggerated Bone Microarchitecture Defects and Osteopenia After 
Splenectomy in a Thalassemia Mouse Model *Hui Sun1, Ling Wang2, 
Matthew Sherrier1, Mark Gladwin2, Hongshuai Li1. 1Musculoskeletal Growth 
& Regeneration Laborotary, Department of Orthopaedics Surgery, University of 
Pittsburgh, United States, 2Pittsburgh Heart, Lung, and Blood Vascular Medicine 
Institute, Department of Medicine, University of Pittsburgh, United States
Thalassemia bone disease (TBD) is a common and severe complication in β-thalas-
semias for which there is limited prevention or treatment options. Clinical manifestations 
of TBD include osteoporosis, fragility fractures, and pain. The etiology of low bone mass is 
multifactorial with ineffective erythropoiesis, iron overload, chelation, and endocrine dys-
function all being implicated. Splenectomy, a common surgical procedure to help maintain 
hemoglobin levels, is strongly correlated with increased risk of osteoporosis in thalassemic 
patients. However, little is known about the mechanism of TBD progression after splenec-
tomy. In this study, we characterize the effects of splenectomy on bone abnormalities in 
a thalassemic mouse model and explore the possible mechanisms. A heterozygous mouse 
model of β0-thalassemia (Hbbth3/+), which demonstrates moderate anemia and severe sple-
nomegaly was used. Th3/+ mice were found to have cranial bone enlargement, decreased 
BV/TV, Tb. N, and Tb. Th on trabecular bone of spine and proximal tibia, decreased cortical 
bone thickness, bone area, and increased marrow area (mid-shaft femur) when compared 
to WT controls. Osteopenia and bone microstructural defects were present in both male 
and female th3/+ mice, although more severe in males. Splenectomy at age 4 weeks sig-
nificantly worsened the geometric parameters in trabecular and cortical bone in both male 
and female th3/+ mice when compared with th3/+ sham surgery controls. Splenectomy had 
no significant influence on bone geometric parameters in WT controls. Histomorphometric 
analyses demonstrated decreased bone formation and increased resorption in th3/+ mice, 
which was exaggerated after splenectomy. To explore the mechanism, iron metabolism was 
tested. When compared to WT controls, Pearl’s staining in th3/+ mice revealed progressive 
iron accumulation in liver and spleen, but less so in bone marrow. Following splenectomy 
in th3/+ mice, there was a significant increase in hepatic iron accumulation but significantly 
decreased iron content in bone marrow. This study demonstrates accelerated bone loss after 
splenectomy in a thalassemic animal model, which represents clinical observations seen in 
human patients. The worsened bone loss after splenectomy is due to further decreased bone 
formation and increased bone resorption. Splenectomy exaggerates the hepatic iron overload 
and conversely causes iron deficiency in the bone marrow, which may accelerate the pro-
gression of the bone abnormalities in thalassemia.
Disclosures: Hui Sun, None
P-607
Abaloparatide Promotes Bone Repair of Vertebral Defects in an 
Ovariectomized Rat Model of Osteoporosis *Akito Makino1, Tomoka 
Hasegawa2, Hideko Takagi1, Yoshimasa Takahashi1, Naoki Hase1, Norio 
Amizuka2. 1Pharmacology Research Department, Teijin Pharma Limited, Japan, 
2Developmental Biology of Hard Tissue, Graduate School of Dental Medicine, 
Hokkaido University, Japan
Objective: Osteoporotic vertebral fractures (OVF) are associated with morbidity and 
mortality. This study was examined to investigate the effects of abaloparatide, a bone ana-
bolic agent for the treatment of severe osteoporosis, on bone repair in ovariectomized (OVX) 
rats with vertebral defects.Material and Methods: Female Sprague-Dawley rats (7-8 weeks 
old) were subjected to OVX or sham surgery. After 32 +/- 4 days of bone depletion period, 
bone defects were created in OVX animals at L4-L6 vertebral bodies using a 1.5 mm diame-
ter dental drill. OVX animals were given once-daily subcutaneous injection of abaloparatide 
at a dose of 30 μg/kg or vehicle for maximum 6 weeks from the day of the vertebral defect 
surgery (Day 0). Animals weresequentially sacrificed at Day 3, Week 1, Week 2, Week 4, 
and Week 6, followed by collecting defected (L4-L6) and non-defected (L3) vertebrae. Bone 
mass and trabecular structural parameters (BV/TV, Tb.Th, Tb.N, and Tb.Sp) of the vertebrae 
were measured by DXA and micro-CT. Bone strength was measured by a vertebral body 
compression test.Results: OVX animals showed significantly lower lumbar BMD than sham 
animals at the end of the bone depletion period. At the defected site of vertebrae, abaloparati-
de showed significantly higher BMC than vehicle at Week 2, Week 4, and Week 6. Trabec-
ular structure parameters were significantly improved by abaloparatide administration after 
Week 2. Abaloparatide showed significantly greater increases in bone strength of defected 
vertebrae than vehicle at Week 2, Week 4, and Week 6. Histological analysis revealed that 
alkaline phosphatase and cathepsin K positive cells were abundant on the surface of new 
bone by abaloparatide administration, suggesting that bone remodeling is highly promoted 
at the defected site. Abaloparatide also showed significantly higher BMD and bone strength 
at non-defected vertebrae. There was no significant change in serum calcium concentrations 
by abaloparatide during the administration period.Conclusion: Abaloparatide promoted bone 
repair of defected vertebrae with an increase in bone strength in OVX rats. Abaloparatide 
also improved BMD and bone strength at non-defected vertebrae. These results suggest that 
abaloparatide is a promising therapeutic option for the treatment of severe osteoporosis with 
OVF.
Disclosures: Akito Makino, None
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Loss of glucocorticoid rhythm induces an osteoporotic phenotype in mice 
*Maaike Schilperoort1, Jan Kroon2, Sander Kooijman2, Kathrin Mletzko3, Leo 
vanRuyven4, Felix Schmidt3, Bjorn Busse3, Alberto Pereira2, Natasha Appelman-
Dijkstra5, Nathalie Bravenboer6, Patrick Rensen2, Onno Meijer2, Elizabeth 
Winter5. 1Department of Medicine, Division of Endocrinology, Einthoven 
Laboratory for Experimental Vascular Medicine, Netherlands, 2Department of 
Medicine, Division of Endocrinology, Einthoven Laboratory for Experimental 
Vascular Medicine, Netherlands, 3Department of Osteology and Biomechanics 
(IOBM), University Medical Center Hamburg-Eppendorf, Germany, 
4Department of Functional Anatomy, Academic Centre for Dentistry Amsterdam 
(ACTA), Netherlands, 5Department of Medicine, Division of Endocrinology, 
Center for Bone Quality, Einthoven Laboratory for Experimental Vascular 
Medicine, Netherlands, 64Department of Clinical Chemistry, Vrije Universiteit 
Amsterdam, Amsterdam Movement Sciences, Netherlands
Glucocorticoid (GC)-induced osteoporosis is a widespread health problem that is ac-
companied with increased fracture risk. Detrimental effects of GC therapy on bone have 
been ascribed to the excess in GC exposure, but it is unknown whether disruption of the 
endogenous GC rhythm inherent to GC therapy also plays a role. To investigate this, we 
subcutaneously implanted female C57Bl/6J mice with either vehicle pellets or slow-releas-
ing corticosterone (CORT) pellets to blunt CORT rhythm without inducing hypercortisolism 
(n=10 mice/group). This experiment was approved by the Central Animal Experiments 
Committee. Flattening of the CORT rhythm for 7 weeks reduced cortical and trabecular 
bone volume (-8.1%, P=0.0009 and -25.5%, P=0.017 respectively), cortical and trabecular 
thickness (-6.9%, P<0.0001 and -8.7%, P=0.03 respectively), and cortical BMD (-3.4%, 
P=0.032), as determined by micro-CT analysis. Furthermore, TRAP levels were increased 
(+42%, P=0.008) while P1NP levels were decreased (-37%, P<0.0001) in plasma of mice 
with a flattened CORT rhythm compared to vehicle, indicative of a negative balance in bone 
remodelling. Double calcein labeling of bone in vivo revealed a reduced bone formation, 
as reflected by a reduced mineral apposition rate (MAR; -20%, P=0.018), mineralizing sur-
face per bone surface (MS/BS; -23%, P=0.014) and bone formation rate per bone surface 
(BFR/BS; -39%, P=0.002). Collectively, these perturbations in bone turnover and structure 
decreased bone strength (-14.7%, P=0.003) and stiffness (-11.1%, p=0.003), as determined 
by mechanical testing. In conclusion, we demonstrate for the first time that flattening of the 
GC rhythm results in an osteoporotic phenotype in mice. Our findings indicate that at least 
part of the fracture risk associated with GC therapy may be the consequence a disturbed GC 
rhythm, rather than an excess in GC dose alone. 
Disclosures: Maaike Schilperoort, None
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The bone Quality Index of Mineral Maturity / Crystallinity at forming 
trabecular surfaces and its potential role in the bone mineral loss evident 
in postmenopausal osteoporosis *Sonja Gamsjaeger1, Klaus Klaushofer1, 
Eleftherios Paschalis1. 1Ludwig Boltzmann Institute for Osteology, Austria
Bone formation consists of two phases: the initial formation of mineral crystals and the 
subsequent mineral accumulation.In the present study, we used Raman microspectroscopic 
analysis of iliac crest biopsies from healthy females (HC; N = 108) and postmenopausal 
osteoporosis patients (PMOP) receiving placebo (N = 66) to test the hypothesis that at form-
ing trabecular surfaces, mineral maturity / crystallinity (MMC) of the youngest crystallites 
associates with the amount of subsequent mineral accumulation. Surfaces were chosen based 
on the presence of fluorescent double labels, allowing measurements at three tissue ages: be-
tween the second label and the mineralizing front, between the two labels, and right behind 
the first one.The mineral content was estimated from the ratio of the v2PO4 band (410–460 
cm−1) integrated area to the spectral slice 494-509 cm-1 (PMMA). MMC was approximated 
from the inverse of the full width at half height (FWHH) of the v1PO4 (930–980 cm−1) 
band.Individual patient values were considered as a function of age and tissue age. To eval-
uate differences in bone mineral content and MMC between the levels of skeletal health sta-
tus, 2-way analysis of covariance (ANCOVA) was applied with biological age as continuous 
covariate and tissue age as categorical cofactor, followed by Sidák´s post-hoc test. Differ-
ences were considered significant at p<0.05.The results (Fig. 1) indicated that there were no 
differences in amount of initial mineral formed between healthy females and postmenopaus-
al osteoporosis patients, while PMOP had larger crystallites and decreased mineral content 
compared to healthy females at the two older tissue ages considered.This can affect bone as 
follows:i)                   affect the mechanical properties of bone as larger crystallites have been 
shown to result in compromised mechanical attributes.ii)                 increased homogeneity 
in the distribution of MMC values.iii)               larger crystallites grow slower compared to 
smaller ones due to decreased crystallite specific surface area. Thus, it is conceivable that 
the decelerated mineral accumulation in PMOP is in part due to the larger crystallites that 
are initially formed, compounding the bone mineral loss due to increased bone resorption 
in PMOP patients.In conclusion, the results of the present analysis indicate that increased 
MMC of the youngest formed mineral may contribute to the bone mineral loss evident in 
PMOP and the accompanying increased fracture risk independently of bone turnover rate.
237





Disclosures: Sonja Gamsjaeger, None
P-611
Bilirubin increases the viability of osteoclasts: An in vitro study *Susana 
Jurado1, Núria Guañabens2, Pilar Peris2, Andreu Combalia2, Ana Monegal2, 
Albert Pares2. 1CIBERehd, Spain, 2Hospital Clinic, University of Barcelona, 
Spain
Introduction Osteoporosis is a complication of primary biliary cholangitis (PBC), a 
liver disease resulting in cholestasis with increased circulating bile acids and bilirubin. Bili-
rubin and litocholic acid (LCA) have harmful effects on osteoblasts and osteocytes in vitro. 
Ursodeoxycholic acid (UDCA), which is used in the treatment of PBC patients, neutralizes 
these deleterious actions. The effects of bilirubin and LCA on osteoclasts have not been 
analyzed, although there is evidence of increased bone resorption, especially in cholestatic 
end-stage disease. Objective To analyze the effects of bilirubin, LCA and UDCA on the 
viability of osteoclast cells obtained from differentiated RAW 264.7 cells. Methods The 
murine macrophage cell line RAW 264.7 was seeded in 96 well plates at a density of 8,000 
cells per well and cultured in α-MEM with 10% FBS and 30 ng/mL of RANKL for 7 days. 
Differentiation into osteoclasts was assessed by TRAP stain. FBS in media was reduced to 
2% and cells were treated for 24 hours with: bilirubin (10 μM, 50 μM and 100 μM), LCA 
(10 μM, 100 μM and 500 μM) and UDCA (10 μM, 100 μM and 500 μM), as well as com-
binations of LCA 10 μM and/or bilirubin 50 μM with UDCA 10 μM or 100 μM. Controls 
were an untreated group and a positive control group treated with Camptothecin (CAM, 0.5 
μM) to potentiate cell death. Cell viability was measured using the WST-1 assay. In each 
experiment, three replicates were made per condition and experiments were performed 6 
times. Results Treatment with bilirubin increased osteoclast viability when compared with 
the untreated control group. Although there was a slight decrease in cell viability at 10 μM 
(10%), a progressive increase was observed at bilirubin concentrations of 50 μM (35%) and 
100 μM (80%; p<0.007). By contrast, cell viability decreased significantly with CAM, LCA 
and UDCA (500 μM) (59%, 53% and 77%). Combination treatments showed that bilirubin 
50 μM with UDCA 10 μM or LCA 10 μM increased viability by 37% and 60%, respectively. 
LCA 10 μM plus UDCA 100 μM decreased cell viability by 35%. Conclusions Bilirubin 
increases viability of differentiated osteoclasts from RAW 264.7 cells. This effect of bili-
rubin counteracts the deleterious actions of litocholic and ursodeoxycholic acids, favoring 
viability even in the presence of these substances. Therefore, bilirubin at concentrations 
found in patients with severe cholestasis may contribute to increased bone resorption and the 
development of osteoporosis.
Disclosures: Susana Jurado, None
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The Regulatory Role of PiRNA-63049 in Pathogenesis of Osteoporosis via 
Targeting Wnt2b *Gaoyang Chen1, Shang Wang1, Songlin Peng1. 1The Second 
Clinical Medical College of Jinan University, China
Purpose: Osteoporosis is an age-related metabolic osteopathy, which leads to bone fra-
gility and increased risk of fracture. The bone marrow stromal cells (BMSCs) play critical 
roles in the process of osteoporosis. However, the osteogenic differentiation ability of os-
teoporotic BMSCs was significantly decreased, leading to the decrease of bone formation. 
Recent studies have shown that piwi-binding RNA (piRNA) was involved in the occurrence 
of diseases at post transcriptional level. However, to the best of our knowledge, the role 
and regulatory mechanism of piRNA in bone and joint diseases remains unclear.Methods: 
The differential expression profile of piRNA in BMSCs of osteoporotic rats was detected 
using RNA sequencing, and then verified by quantitative real time PCR. The piRNA-mRNA 
networks were conducted to predict the potential targets of differentially expressed piRNAs. 
The hub piRNA-mRNA axis was screened out based on bioinformatics analysis and correla-
tion analysis. The luciferase report gene assay was carried out to verify the binding sites of 
piR-63049 and Wnt2b. PiR-63049 mimics and inhibitor were transfected into BMSCs to 
evaluate the effect of knocking-down and over-expressing piR-63049 on osteogenic differ-
entiation of BMSCs. Antagomir of piR-63049 was used to evaluate the effect of piR-63049 
on prevention and treatment of osteoporosis via the tail vein injection in ovariectomized 
rats.Results: Our study showed a novel non-coding RNA, piR-63049, may play import-
ant roles in bone metabolism in osteoporosis. The expression of piR-63049 was signifi-
cantly increased in of osteoporotic rats and peripheral blood mononuclear cells of patients 
with osteoporosis, while negative linear with the osteogenic differentiation of BMSCs. The 
further bioinformatics and luciferase study showed that Wnt2b was the potential target of 
piR-63049. Furthermore, Wnt2b is a positive regulator in Wnt/beta-catenin signaling during 
bone formation. Over-expressing piR-63049 could attenuate the osteogenic differentiation 
of BMSCs, while knocking down piR-63049 could promote the osteogenic differentiation 
of BMSCs. In vivo experiment further verified the stimulating effect of knocking-down piR-
63049 on bone formation.Conclusion: Our study revealed the differential expression profile 
of piRNA in osteoporotic BMSCs and screened out piR-63049 as the hub piRNA, which 
might play critical role in osteogenic differentiation of BMSCs and bone metabolism in 
osteoporosis via targeting Wnt2b.
Disclosures: Gaoyang Chen, None
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Alendronate suppresses initiation of bone formation in cortical bone in 
postmenopausal osteoporosis *Xenia G Borggaard1, Jean-Paul Roux2, Jean-
Marie Delaisse1, Pascale Chavassieux2, Christina M Andreasen1, Thomas L 
Andersen1. 1Molecular Bone Histology Team, Clinical Cell Biology, Research 
Unit of Pathology, Dept. of Clinical Research, University of Southern Denmark 
and Dept. of Pathology, Odense University Hospital, Denmark, 2INSERM UMR 
1033, Université de Lyon, France
In cortical bone, the age-induced and osteoporosis-related porosity is attributed to ac-
cumulation of enlarged eroded pores, reflecting a delayed bone formation. This study focus 
on the cortical effect of alendronate treatment within postmenopausal osteoporotic (PMO) 
women. Intracortical pores were measured and categorized according to their surface (erod-
ed, eroded-formative, formative or quiescent) on 89 transiliac biopsies obtained from the In-
ternational Phase III study of alendronate.  Biopsies collected from PMO women after either 
two years of treatment with alendronate (n = 9) or placebo (n = 26) or after three years of 
treatment with alendronate (n = 15) or placebo (n = 39) were investigated as pooled (placebo 
vs. treatment). The cortical porosity (%) and pore density (#/T.Ar) was unaffected by alen-
dronate treatment in PMO. Cortical porosity, but not pore density, correlated positively with 
pore diameter in both alendronate and placebo (r2=0.77, p<0.0001 and r2=0.74, p<0.0001, 
respectively) and mainly reflected non-quiescent pores. In alendronate compared to placebo 
a significantly higher percentage of the cortical porosity reflected eroded pores (p<0.001) 
and a significantly lower percentage reflected eroded-formative pores (p0.01). This was ev-
ident, although fractions (%) of eroded and eroded-formative pores did not change with 
treatment. Interestingly, although the contribution of eroded and eroded-formative pores cor-
relates negatively and positively (respectively) with the degree of porosity in placebo, these 
correlations disappear upon alendronate treatment. Additionally, the prevalence of formative 
pores and their contribution to cortical porosity decreased significantly in the alendronate 
treatment compared to placebo (p < 0.01 and p < 0.05, respectively), whereas pore size and 
mean wall thickness did not change significantly.Overall, the ratio between eroded pores and 
pores with initiated formation was significantly higher for alendronate treatment (p < 0.001), 
while the wall thickness reflecting the magnitude of bone previously formed in quiescent 
osteons was not statistically different comparing alendronate and placebo. Collectively, this 
study shows that alendronate further inhibit the initiation of bone formation in cortical bone, 
rather than affecting the magnitude of bone formed when initiated.
Disclosures: Xenia G Borggaard, None
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Effects of Spaceflight on Cancellous and Cortical Bone in Proximal Femur 
in Rats *Lara Sattgast1, Amanda Gamboa1, Dawn Olson1, Adam Branscum2, 
Urszula Iwaniec1, Russell Turner1. 1Skeletal Biology Laboratory, Oregon State 
University, United States, 2Oregon State University, United States
Bone loss is common in astronauts during long-duration spaceflight missions with se-
vere bone loss often occurring in the proximal femur, a region not typically investigated in 
animal models. We recently evaluated bone microarchitecture in the femoral head in rapidly 
growing male Sprague Dawley rats subjected to a 4-day spaceflight aboard STS-41. Com-
pared to ground controls, cancellous bone volume fraction (bone volume/tissue volume, 
BV/TV) was dramatically lower in the flight animals. Because the effects of spaceflight 
on the rodent skeleton can vary with age, duration of flight, and potentially strain and sex, 
we evaluated bone in the femoral head from two additional missions: a 10-day mission 
(STS-57) using growing male Fisher rats, and a 14-day mission (STS-62) using growing 
ovariectomized (ovx) Fisher 344 rats. Cancellous microarchitecture and cortical thickness 
were assessed using microcomputed tomography. In male rats, BV/TV was lower in flight 
animals compared to flight controls but differences were not significant compared to base-
line, suggesting that osteopenia was due in part to reduced bone accrual. In ovx rats, BV/
TV was lower in flight animals compared to flight controls and tended to be lower (p=0.06) 
compared to baseline. Whereas BV/TV was lower in flight animals compared to flight con-
trols in all studies, changes in bone microarchitecture (connectivity density, trabecular thick-
ness, number, and separation) in response to spaceflight were not uniform among studies. 
Cortical thickness did not differ among groups in any of the studies. Taken together, these 
findings support the conclusion that spaceflight results in cancellous osteopenia in femoral 
head of growing rats. Fractures in humans occur at several locations in the femoral neck, 
including intertrochanteric, transcervical neck, subcapital neck, and subtrochanteric region. 
Fractures occurring through the femoral head are more commonly associated with trauma 
and are particularly difficult to manage. That being said, traumatic injury would be the most 
likely cause of a fracture during a spaceflight mission and a microgravity-induced reduction 
in bone volume fraction at this site would likely reduce the magnitude of trauma required 
for fracture. We therefore conclude that future studies performed in more skeletally mature 
animals should carefully evaluate this site.
Disclosures: Lara Sattgast, None
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Synthesis and in vitro evaluation of a bispecific aptamer targeting both 
Sclerostin and Dickkopf-1 *Zhenjian Zhuo1, Shuaijian Ni2, Zongkang Zhang1, 
Ning Zhang1, Yuanyuan Yu2, Aiping Lu2, Ge Zhang2, Bao-Ting Zhang1. 1The 
Chinese University of Hong Kong, Hong Kong, 2Hong Kong Baptist University, 
Hong Kong
Synthesis and in vitro evaluation of a bispecific aptamer targeting both Sclerostin and 
Dickkopf-1Zhenjian Zhuo1,5*, Shuaijian Ni2,3,4,5*, Zongkang Zhang1, Ning Zhang1, 
Yuanyuan Yu2,3,4, Aiping Lu2,3,4, Ge Zhang2,3,4 & Bao-Ting Zhang11School of Chi-
nese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 
SAR, China,2Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint 
Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, 
China,3Institute of Integrated Bioinformedicine and Translational Science, School of Chi-
nese Medicine, Hong Kong Baptist University, Hong Kong SAR, China,4Guangdong-Hong 
Kong-Macao Greater Bay Area International Research Platform for Aptamer-based Trans-
lational Medicine and Drug Discovery, Hong Kong, China,5Aptacure Therapeutics Limit-
ed, Kowloon, Hong Kong SAR, China*Contributed equally.Abstract: Sclerostin antibody 
treatment has been reported to promote bone formation, whereas the promotion wanes over 
time due to the increased Dickkopf-1 as a negative feedback. It is desirable to co-inhibit both 
Sclerostin and Dickkopf-1. However, immunogenicity, production, and stability are the ma-
jor concerns of antibody. Aptamers are non-naturally oligonucleotides with high specificity 
and affinity to proteins without the above concerns. We have obtained an aptamer against 
Sclerostin, and an aptamer against Dickkopf-1 from published study. We first synthesized 
bispecific aptamer candidates targeting both Sclerostin and Dickkopf-1 by coupling of 5’ an 
amine-functionalized aptamer1 with N-hydroxysuccinimide-activated PEG (PEG3/PEG6/
PEG9/PEG24) and 3’ a thiol-functionalized aptamer2 with maleimide bound to the other 
end of bivalent PEG (PEG3/PEG6/PEG9/PEG24) linker (F-1). Aptbis03, aptbis04, aptbis07 
and aptbis08 with higher binding specificity to Sclerostin and Dickkopf-1 were chosen for 
affinity characterization (F-2). Aptbis03 and aptbis07 with low nM level of affinity to both 
Sclerostin and Dickkopf-1 were chosen for activity characterization (F-3). The inhibition 
potency of the aptamer candidates on antagonistic effects of both Sclerostin and Dickkopf-1 
in Wnt signaling in vitro was further examined. Aptbis03 with the best inhibition potency 
was identified (F-4). This work develops a bispecific aptamer targeting both Sclerostin and 
Dickkopf-1. Acknowledgments: This study was supported by the Innovation & Technology 
Fund (UIM/328) and General Research Fund (14108816).
Disclosures: Zhenjian Zhuo, None
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Kynurenine Promotes Age-Related Bone Loss via Upregulating RANKL–
Induced Osteoclastogenesis and Inhibiting Bone Marrow Mesenchymal 
Stem Cells Osteogenesis *Nada Eisa1, Sakamuri Reddy2, Ahmed Elmansi3, 
Galina Kondrikova1, Dmitry Kondrikov3, Xing-Ming Shi4, Chad Novince5, 
Mark Hamrick6, Meghan McGee-Lawrence7, Carlos Isales8, Sadanand Fulzele9, 
William Hill3. 1Dept. Pathology, Medical University of South Carolina, United 
States, 2Dept. Pediatrics, Medical University of South Carolina, United States, 
3Dept of Pathology, Medical University of South Carolina, United States, 
4Department of Neuroscience and Regenerative Medicine, Augusta University, 
United States, 5College of Dental Med / Oral Health Sciences, Medical University 
of South Carolina, United States, 6Dept of Cellular Bio & Anatomy, Augusta 
University, United States, 7Dept Cellular Bio & Anatomy, Augusta University, 
United States, 8Sec Endocrinology, Augusta University, United States, 9Dept of 
Orthopedic Surgery, Augusta University, United States
Aging is associated with a decrease of bone mass that increases the risk for osteoporosis 
and fractures to the spine and extremities. While accumulating evidence from diverse studies 
show the involvement of kynurenine (KYN) - an oxidized, or IDO-1, tryptophan metabolite 
- in aging related bone loss, the direct effect of KYN on osteoclast formation has not been 
studied. We have previously reported that KYN contributes to aging-related bone loss via 
reducing in vivo and in vitro osteogenic differentiation potential of bone marrow mesenchy-
mal stem cells. Further, we showed that in vivo treatment with KYN significantly increased 
the number of osteoclasts on bone surfaces suggesting that in addition to inhibiting bone 
formation it could drive increased bone resorption. Here, we report the direct effect of KYN 
on receptor activator of nuclear factor kappa B ligand (RANKL)-induced in vitro osteoclas-
togenesis. We show that treating RAW 264.7 macrophages cells with KYN results in dose 
dependent enhancement of RANKL-induced osteoclast differentiation. This was evident by 
the significant increase in number of multinucleated TRAP positive osteoclasts, significant 
increase in hydroxyapatite bone resorptive activity and significant upregulation of osteo-
clast differentiation genes including c-Fos, CTSK and DC-STAMP. Mechanistically the aryl 
hydrocarbon receptor (AhR), which is a known KYN receptor, is a negative regulator of 
bone mass. Indeed, our results show that treating RAW 264.7 cells with 3′,4′-dimethoxy-
flavone [DMF] (an AhR inhibitor) significantly decreased KYN mediated enhancement of 
osteoclastogenesis as evident by significant decrease in number of multinucleated TRAP 
positive osteoclasts. Altogether, our results suggest that KYN can act as positive regulator 
of RANKL-mediated osteoclast differentiation. Whether kynurenine acts solely via direct 
activation of AhR or through additional pathways, or downstream metabolites, needs to be 
further investigated. Due to the dual activity of KYN on both osteogenic and osteoclas-
togenic differentiation in bone, it could provide a potential clinical intervention target for 
prevention and treatment of osteoporosis.
Disclosures: Nada Eisa, None
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Bone mineral density and shifts in plasma estradiol concentrations 
throughout the menstrual cycle in young female oral contraceptive users 
versus non-users *Jenna Laughlin1, Mark Kern2, Shirin Hooshmand 1. 1San 
Diego State University, United States, 2San Diego State University, United States
Purpose: Oral contraceptives (OCs) may negatively affect bone health of young women. 
One potential mechanism of this is suppressed endogenous estrogen levels. The objective of 
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this study was to compare bone mineral density (BMD) and hormone concentrations during 
the menstrual cycle between oral contraceptive users and non-users. Methods: Sixteen wom-
en, aged 18-25 y, either taking oral contraceptives (n=8) or not taking any hormones (n=8) 
were recruited. Women in the OC group were required to have used their current regimen 
consistently for at least 1 year prior to starting the study. Anthropometric measurements, 
Block Food Frequency Questionnaire (FFQ), physical activity and habitual calcium and vi-
tamin D intake were evaluated at baseline to detect any differences between groups. Bone 
density scans were performed at baseline including lumbar spine (L1-L4), hip, forearm, 
and whole body BMD using DXA. Plasma estradiol levels were evaluated from samples 
collected on menstrual cycle days 1, 4, 11, and 21. Results: The groups did not significantly 
differ in height, weight, and body mass index (BMI), which is important as excess body fat 
can impact estrogen levels. Intake of calcium and vitamin D, two important nutrients for 
bone metabolism were nearly identical between the two groups. BMD measurements and 
T-scores for each group were similar and in the normal range. There was a significant main 
effect of cycle day on plasma estradiol level (p<.05) and a significant interaction between 
group (OC vs. non-OC) and cycle day (p<.5) with estradiol increasing throughout the men-
strual cycle in non-users and remaining relatively unchanged in users. The largest difference 
between groups occurred on cycle day 21 (p<.05). Conclusion: Women taking OCs maintain 
relatively static estradiol concentrations across the menstrual cycle while women not taking 
any hormonal contraceptives experience fluctuations in estradiol levels across the menstrual 
cycle. These results confirm that taking OCs interferes with estrogen levels, which according 
to some research may have negative effects on bone health, predisposing young women to 
osteopenia or osteoporosis.
Disclosures: Jenna Laughlin, None
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CT-derived bone mineral density is the main determinant of prevalent 
vertebral fractures in cirrhotic patients awaiting liver transplantation. 
*Clément Nachef1, Valérie Bousson2, Nadia Belmatoug3, Martine Cohen-Solal4, 
Valérie Vilgrain5, François Durand6, Thomas Funck-Brentano1. 1Department of 
Rheumatology, Hôpital Lariboisière, APHP.Nord, Université de Paris, France, 
2Department of Radiology, Hôpital Lariboisière, APHP.Nord, Université de 
Paris, France, 3Department of internal medicine, Hôpital Beaujon, APHP.Nord, 
Université de Paris, France, 4Bioscar INSERM U1132, Université de Paris, 
Paris, France, France, 5Department of Radiology, Hôpital Beaujon, APHP.Nord, 
Université de Paris, France, 6Department of Hepatology, Hôpital Beaujon, APHP.
Nord, Université de Paris, France
Background: Candidates for liver transplantation (LT) with cirrhosis are at high risk of 
fragility fractures. However, screening for osteoporosis may be suboptimal due to limited 
access to DXA and lack of awareness. The primary objective of the study was to identi-
fy the determinants of vertebral fractures using opportunistic CT screening at candidates’ 
registration on OLT waiting list. The secondary objective was to identify the determinants 
of CT-derived bone mineral density (CT-derived BMD).Methods: Consecutive cirrhotic pa-
tients placed on waiting list for LT in an academic center from March 2004 to June 2018 
were included in the study. Prevalent vertebral fractures (VF) were identified on sagittal and 
coronal reconstructions of thoraco-abdominal CT scans performed at evaluation. CT-derived 
BMD (mean Hounsfield unit) was measured in an elliptic region of interest of an axial sec-
tion of the vertebral body of L1. Skeletal muscle index (SMI) was defined as the axial psoas 
muscle area divided by height squared.Results: Among the 381 consecutive candidates, 376 
had available thoraco-abdominal CT scans, and were included in the final analysis (75% 
males; mean age 55 +/- 8 years; mean BMI 26.3 +/- 4.6 kg/m²; 42% alcoholic cirrhosis, 
40% viral hepatitis cirrhosis). A total of 139 VF in 55 (14.6%) patients were identified. The 
prevalence of VF was greater in alcoholic (22.6%) and non-alcoholic steatohepatitis cirrho-
sis (19.0%) compared to viral hepatitis cirrhosis (7.9%). Patients with VF were older (56.9 
55 +/- 7.2 vs 54.3 +/- 8.5 years, P=0.034) and had lower CT-derived BMD (86.3 +/- 30.3 
vs 137.6 +/- 40.2 HU, P<0.001). In logistic regression models including age, sex, BMI and 
alcoholic cirrhosis, low CT-derived BMD was the only determinant of prevalent VF (for 
each SD decrease, OR=6.76 95%CI[3.94 to 11.63]; AUC for ROC curve = 0.86, Figure). 
A CT-derived BMD < 100 HU was associated with increased prevalence of VF (OR=8.7 
95%CI[4.5 to 16.6]). The association between SMI and CT-derived BMD was significant, 
but the correlation was modest (Pearson’s coefficient=0.30; variance explained r2=9%). In 
linear regression models, determinants of low CT-derived BMD were high age, alcoholic 
cirrhosis and low SMI (P<0.001 for all).Conclusions: Low CT-derived BMD is the major 
determinant of vertebral fractures in cirrhotic patients awaiting LT and should be routinely 
assessed to screen patients at high risk of fragility fractures.
Disclosures: Clément Nachef, None
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Effects of Zoledronic Acid and Ambulation on Hip Bone Mineral Density 
after Acute Spinal Cord Injury: Year 1 of a Randomized Controlled Trial 
*Ifaz Haider1, Narina Simonian2, Joana Barroso3, W. Brent Edwards1, Thomas 
Schnitzer2. 1University of Calgary, Canada, 2Northwestern University Feinberg 
School of Medicine, United States, 3Universidade do Porto, Portugal, Portugal
Spinal cord injury (SCI) is associated with a significant decline in bone mineral density 
(BMD) and increased risk of fracture at sublesional locations. Losses in BMD occur rapidly 
after SCI, plateauing 2 to 5 years after injury [1]. Zoledronic acid (ZOL) has been shown to 
effectively attenuate bone loss in individuals with recent SCI [2]. However, the durability of 
treatment is unclear, as are the effects of potential covariates such as ambulation. Here, we 
report results from the first year of a prospective double-blind clinical trial (NCT02325414), 
assessing the durability of ZOL for the prevention of bone loss in individuals with acute SCI 
(i.e., < 4 months post-injury). Sixty individuals were randomized to receive an IV infusion of 
placebo (PBO; n=30) or 5 mg ZOL (n=30). Areal bone mineral density (aBMD) at the total 
hip (TH) and femoral neck (FN) was measured at baseline and after 6 and 12 months of treat-
ment as was ambulation ability using the Walking Index for Spinal Cord Injury II (WISCI). 
Linear mixed modeling analysis was applied with baseline aBMD, visit and WISCI score 
as covariates to examine the effects of treatment group on % change from baseline in total 
hip (TH) and femoral neck (FN) aBMD. Interaction effects for treatment group*visit and 
treatment group*WISCI score were also included. There were no significant differences in 
age, gender, BMI, WISCI, or ASIA scores between treatment groups at baseline.  Significant 
differences were found for % change in TH and FN aBMD between groups at both the 6 
mo and 12 mo time points, p<0.001 for all. (TH data shown in Fig.1: ZOL and PBO groups 
LS means % change +/-SE in aBMD at 6 months and 12 months; -1.3+/-1.4 vs -10.4+/-1.4 
and -3.0+/-1.4 vs -14.9+/-1.4, respectively, p<0.001 for both comparisons). WISCI had a 
significant effect on % change in both TH and FN aBMD, p=0.004 and 0.028, respectively. 
Although both treatment and WISCI had a positive effect on % change in aBMD, the in-
teraction term between these variables was not significant. Further analyses of this cohort, 
over 2 years of treatment, is ongoing and will include assessment of treatment durability and 
computed tomography of bone mineral at the knee. However, these initial data support the 
notion that one-year treatment with ZOL can effectively attenuate bone loss after SCI, with 
benefits of treatment observed regardless of ambulatory ability. [1] Haider, Osteoporosis Int. 
2018. [2] Goenka, Spinal Cord. 2018.
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Aromatase Inhibitor Induced Bone Loss in Postmenopausal Women with 
Breast Cancer: A Systematic Review and Meta-analysis of Randomized 
Controlled Trials *Abir Bou Khalil1, Aya Bassatne1, Marlene Chakhtoura1, 
Asma Arabi1, Catherine Van Poznak2, Ghada El-Hajj Fuleihan 1. 1American 
University of Beirut, Lebanon, 2University of Michigan, United States
Aromatase inhibitors (AIs) suppress estrogen levels, leading to accelerated bone loss 
and fractures. In this systematic review and meta-analysis of randomized controlled trials 
(RCTs), we assess the effect of anti-resorptive therapy in postmenopausal women with ear-
ly breast cancer (BCa), receiving AIs, on Bone Mineral Density (BMD), fracture risk and 
bone turnover markers (BTM). We conducted the search in 4 databases from inception until 
December 6, 2019. We completed title/abstract and full text screening in duplicate and inde-
pendently. The primary outcome is % change at lumbar spine (LS) or total hip (TH) BMD 
at 12 months and secondary outcomes include % change in BMD, fracture incidence and 
change in BTM, at different intervals. For BMD we report the % change mean weighted 
differences, and for any fracture we report the risk ratio (RR), with corresponding 95% CI. 
Only trials with data on BMD and estimated standard deviations were analyzed. Analysis 
of BTM is ongoing. We identified 19 RCTs. Participants had mean age of > 55 years, mean 
BMI of 23.08-31 kg/m2, and were followed up to 5 years. The mean weighted difference 
in LS BMD in patients on intravenous zoledronate (ZOL) with placebo, when combining 
3 trials (N=2194), were 5.30 [4.36, 6.24], 7.27 [6.13, 8.42] and 8.03 [6.92, 9.13], at 1, 2 
and 3 years respectively. Similarly, the % mean weighted difference at LS in 4 ZOL trials 
(N= 2745) was 9.43 [8.85, 10.00] at 5 years. Corresponding numbers at the TH were 3.33 
[3.09, 3.57], 4.65 [4.35, 4.94], 5.06 [4.71, 5.42] and 6.37 [5.68, 7.07], at 1, 2, 3 and 5 years. 
Combining data from 4 oral bisphosphonate trials, N=383, revealed % mean weighted dif-
ferences at LS of 3.05 [1.03, 5.07] and 4.78 [3.83, 5.73], and at TH of 2.36 [0.81, 3.90] and 
3.75 [2.85, 4.65], at 1 and 2 years respectively. There was a decrease in clinical fracture, RR 
0.93 [0.50, 1.70], 0.90 [0.59, 1.39], and 0.89 [0.61, 1.30] with ZOL vs. placebo at 1, 2 and 
3 years, respectively. In 1 trial, denosumab decreased clinical fracture with a RR of 0.47 
[0.36, 0.61] vs. placebo at 3 years. Combining parenteral data from ZOL and denosumab 
trials showed a RR of 0.68 [0.41, 1.13], vs. placebo at 3 years. I2 in 5 out of 6 of LS BMD 
analyses was > 50% and <50% in 4 out of 6 of TH BMD analyses. Use of anti-resorptive 
therapy in women with early BCa receiving AIs is effective at preventing bone loss and 
decreasing fracture risk.
Disclosures: Abir Bou Khalil, None
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Androgen Deprivation Therapy Differentially Impacts Bone and Muscle 
in the Short Term in Physically Active Men with Prostate Cancer *Naim 
Maalouf1, Orhan Oz1, Avneesh Chhabra1, Dwight Towler1, Jason Zafereo1, 
Ross Querry1, Joseph Frankl1, May Xac1, Craig Rubin1. 1University of Texas 
Southwestern Medical Center, United States
Background: Androgen Deprivation Therapy (ADT) is a cornerstone of therapy in ad-
vanced prostate cancer (PCa). Its use is associated with a loss of bone mineral density (BMD) 
and a greater risk of falls and osteoporotic fractures. Androgen receptors are expressed on 
myocytes, and ADT-related fall and fracture risk may be in part due to early changes in 
muscle and body composition. The well-described crosstalk between bone and muscle led us 
to test the hypothesis that a decline in muscle strength precedes the decline in bone strength 
in men initiating ADT for PCa.Methods: Men with PCa were enrolled and evaluated at 3 
time points: immediately before (Week 0), and 6 and 24 weeks after ADT initiation. Study 
measures included fasting blood (for markers of muscle and bone metabolic activity), MRI 
and QCT imaging (for muscle volume and composition, and bone density and architecture), 
and validated clinical tests of muscle strength and gait.Results: Sixteen men (13 Caucasian,3 
African American) completed all study visits. At baseline, median (25th, 75th percentile) age 
was 67 (65, 68) years, BMI 29.8 (27.9, 31.3) kg/m2, and PSA 4.6 (0.9, 7.3) ng/ml. The men 
were considered physically active, exercising a median of 3 (2, 6) times/week throughout 
the duration of the study, but still experienced weight gain (+2.2 kg at week 24 vs. week 0, 
p=0.004). Biochemically, all men sustained dramatic reductions in sex hormones at 6 weeks 
post-ADT that persisted at 24 weeks, along with a progressive and significant increase in 
serum CTX (by +88% at week 24 vs. week 0). There was a trend for rise in serum sclerostin 
(p=0.09) and IL-6 (p=0.08), but no significant change in serum myostatin (p=0.99). Volu-
metric BMD by QCT declined significantly at the femoral neck (-4.4% at week 24 vs. week 
0), particularly at the trabecular compartment (-5.7% at week 24 vs. week 0). On MRI, there 
were no significant changes in gluteal and thigh muscle volume or fat fraction. On physical 
testing, men developed weaker grip strength, but no change in lower extremity and lumbar 
spine muscle strength (Hip abduction/adduction, and hip/knee/lumbar flexion/extension), or 
functional tests of gait (step velocity and length at self-selected and fast speed).Conclusions: 
In physically active men, ADT for 24 weeks results in a significant increase in bone turnover 
and reduction in BMD, but no significant change in pelvic/thigh muscle volume and quality 
(on imaging) or strength and gait (on functional testing).
Disclosures: Naim Maalouf, None
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Feasibility of Risedronate to Prevent Bone Loss after Sleeve Gastrectomy: 
a Pilot Randomized Controlled Trial *Kristen Beavers1, Daniel Beavers2, 
Aldofo Fernandez2, Ashley Weaver2, Jamy Ard2. 1Wake Forest University, United 
States, 2Wake Forest School of Medicine, United States
Purpose: Mounting evidence implicates bariatric surgery in increased skeletal fragility 
and fracture risk. Bisphosphonate therapy reduces osteoporotic fracture risk and may be 
effective in minimizing bone loss associated with bariatric surgery.Methods: The main ob-
jective of this pilot randomized controlled trial (RCT; NCT03411902) was to determine the 
feasibility of recruiting, treating, and following 24 older sleeve gastrectomy (SG) patients in 
a 6 month RCT examining the efficacy of 150 mg once monthly risedronate (versus placebo) 
in the prevention of surgical weight loss associated bone loss. Feasibility was defined as: (1) 
>30% recruitment yield; (2) >80% retention; (3) >80% pills taken; (4) 80% participant sat-
isfaction. Secondary outcomes include 6 month change in dual energy x-ray absorptiometry 
(DXA) acquired regional bone mineral density (BMD) and trabecular bone score (TBS). 
Primary outcomes were estimated using descriptive measures, and secondary group treat-
ment effects were estimated using a general linear model adjusted for baseline values of each 
outcome. Sensitivity analyses included stratification by menopausal status and adjustment 
for total weight change.Results: 70 participants were referred, with 24 randomized (34% 
yield) to risedronate (n=11) or placebo (n=13). Average age was 56+/-7 years, 83% were 
female (75% postmenopausal), and 21% were black. The risedronate group had a higher 
baseline body mass index than placebo (48.1+/-7.2 vs 41.9+/-3.8 kg/m2). 10-year fracture 
risk was low (6.0% major osteoporotic fracture, 0.4% hip fracture); however, three individ-
uals (12%, all risedronate group) were osteopenic at baseline. 21 participants returned for 
6 month follow up testing (88% retention) with all (n=3) loss to follow up occurring in the 
risedronate group. Average pills taken among completers was 5.9+/-0.4 and 6.0+/-0.0 in rise-
dronate and placebo groups, respectively (p=0.21), with all active participants taking >80% 
of allotted pills. Four AEs (134 contacts; 3% AE rate) were reported; one definitely related, 
one possibly related, and none serious. All participants reported being highly satisfied with 
participation in the study. Treatment effect estimates revealed preserved BMD at all sites in 
the risedronate group versus placebo, with significant effects observed at the femoral neck 
[mean: 0.005 (95% CI: -0.028, 0.038) vs -0.043 (-0.069, -0.017) g/cm2] and lumbar spine 
[0.024 (-0.007, 0.055) vs -0.028 (-0.052, -0.005) g/cm2]; both p<=0.03 (see Figure 1). BMD 
results did not differ when stratified by menopausal status or after adjusting for total weight 
change. No differences in TBS were observed.Conclusion: Risedronate treatment in the 6 
months following SG appears feasible. Preliminary treatment effects suggest risedronate use 
minimizes short-term BMD loss, particularly at weight bearing sites, following SG.
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Bone Quality is Associated with Fragility Fracture in Patients with 
Hemoglobinopathies *Ellen Fung1, Lisa Calvelli1, Melissa Cervantes1, 
Kaylianna Cadena1, Ashutosh Lal1. 1UCSF Benioff Children’s Hospital Oakland, 
United States
Introduction: Low bone mass has been described in up to 70% of adults with thalas-
semia (Thal) and sickle cell disease (SCD). DXA assessment is part of routine clinical prac-
tice, though bone quality has been inadequately characterized.  Trabecular bone score (TBS), 
a textural analysis of bone quality from spine DXA scan, is predictive of fracture in adults 
without hemoglobinopathies. We evaluated the prevalence of abnormal bone quality and its 
relationship to fracture in patients with Thal or SCD.  Methods: A retrospective chart review 
was conducted in patients with Thal or SCD who weighed >40 kg and had >1 spine bone 
mineral density (BMD) scan performed on a Hologic Horizon scanner in the past 10 yrs. 
The most recent scan was reanalyzed for bone quality using TBS Insight (Medimaps v 3.0.2, 
Geneva, CH) and abnormal bone quality was defined as TBS <1.20. Fracture prevalence was 
determined by patient report at time of DXA. TBS results were compared with data obtained 
from healthy controls. Statistical analysis was performed using STATA, v16. Results: Data 
from 352 individuals with mean (SD) 28+/-13 years of age were abstracted that included 
58% female and 62% were over 21 years. There were 131 patients with Thal, 154 with SCD, 
and 67 controls. Thal group had greater deficits in spine BMD Z-score (-2.2+/-1.2, range 
1.3 to -5.7), compared with SCD (-1.4+/-1.5, 4.8 to -4.9) and control (-0.1+/-0.8) groups 
(p<0.01). There was a higher prevalence of abnormal TBS (25%) in Thal compared with 
SCD (10%), or control (5%, p<0.01). More Thal had hypogonadism (31% vs. 1% in SCD) 
and diabetes (9% vs. 3% in SCD); however, there was no difference in fracture prevalence 
between the two groups. TBS was positively correlated with BMD (r=0.7) and negatively 
with age (r=-0.3). After controlling for age and hypogonadism, abnormal TBS was asso-
ciated with a Thal diagnosis (p=0.01). Although abnormal TBS was not related to overall 
fracture prevalence, it was associated with fragility type fracture, regardless of diagnosis 
(RR: 8.9, p=0.013).  Conclusions: These data support the relationship between reduced bone 
mass and bone quality in adolescent and adult patients with hemoglobinopathies. TBS may 
be a valuable tool in differentiating risk of fragility fractures in this group of inactive patients 
with extremely low BMD. There is a need to develop models that include both BMD and 
TBS for prediction of fracture risk in patients with hemoglobinopathies who might benefit 
from anti-resorptive therapies.
Disclosures: Ellen Fung, None
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Low Serum Osteocalcin Levels are Associated with the Presence of Diabetes 
Mellitus in Glucocorticoid Treated Patients *Helena Florez1, José Hernández-
Rodríguez 2, Josep Lluis Carrasco3, Sergio Prieto-González 2, Xavier Filella4, 
Ana Monegal1, Núria Guañabens1, Pilar Peris1. 1Metabolic Bone Diseases Unit. 
Department of Rheumatology. Hospital Clinic, University of Barcelona, Spain, 
2Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital 
Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August 
Pi i Sunyer (IDIBAPS), Barcelona, Spain., Spain, 3Biostatistics, Department 
of Basic Clinical Practice, University of Barcelona, Barcelona, Spain., Spain, 
4Biochemistry and Molecular Genetics Department. Hospital Clinic, University 
of Barcelona, Spain
Increasing evidence indicates that osteocalcin (OC) is involved in the regulation of 
glucose homeostasis. Glucocorticoid (GC) treatment is associated with impaired osteoblast 
function and decreased OC levels and also with the development of CG-induced diabetes 
mellitus (GIDM). However, whether decreased OC levels in GC-treated subjects contribute 
to GIDM is not well known.Purpose: To analyse whether OC levels in GC-treated patients 
are associated with the presence of GIDM.Methods: 127 patients (aged 62+/-18years, 63% 
women) on GC treatment for autoimmune diseases (>=5mg/day,>3 months) were included. 
Clinical and anthropometric data were analysed, including the GC dose and treatment dura-
tion, presence of GIDM, fragility fractures, densitometric osteoporosis and bone formation 
(OC, bone alkaline phosphatase [BAP], PINP) and resorption markers (urinary NTX, serum 
CTX). The cut-offs of each bone marker for the presence of GIDM were estimated and 
optimized with the Youden index and included in the logistic regression analysis (adjusted 
for BMI, age and GC doses).Results: 17.3% of patients presented GIDM. Diabetic subjects 
were older (70.5+/-12.2 vs. 59.6+/-18.4, p=0.001) and had a higher BMI than non-diabetics 
(30+/-5.2 vs. 26+/-4.2, p=0.002). No differences were observed in GC dose, disease duration 
or in the presence of vertebral fractures. Diabetics showed lower levels of OC (7.57+/-1.01 
vs. 11.56+/-1; p<0.001), PINP (21.48+/-1.01 vs. 28.39+/-1; p=0.0048), NTx (24.91+/-1.01 
vs. 31.7+/-1; p=0.036) and CTX (0.2+/-1.01 vs. 0.3+/-1; p=0.0016) with similar BAP val-
ues. The best discriminating cut-offs for GIDM presence were: <9.25ng/mL for OC, <24ng/
mL for PINP, <27.5nMol/mM for NTX and <0.25ng/mL for CTX. On multivariate analysis 
OC (<9.25) was the only marker related to the presence of GIDM (OR 6.1; CI95% 1.87-
19.89; p=0.001).Conclusions: Decreased OC levels in GC-treated patients are associated 
with an increased risk of GIDM, a finding that was not observed with other bone turnover 
markers, further confirming the involvement of OC in the glucose homeostasis regulation 
in this entity.
Disclosures: Helena Florez, None
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Bone Mineral Density, Trabecular Bone Score and proximal Femur 3D-DXA 
Analysis in Psoriatic Diseases. *Eric Toussirot1, Renaud Winzenrieth2, Maxime 
Desmarets3, Francois Aubin4, Gilles Dumoulin5. 1INSERM CIC-1431 CHU 
de Besançon, France, 2 Galgo Medical, Spain, 3INSERM CIC-1431 CHU 
de Besançon, France, 4Dermatologie CHU de Besançon, France, 5Biochimie 
Médicale CHU de Besançon, France
Purpose: current data regarding areal bone mineral density (aBMD) in patients with 
psoriasis (PsO) or psoriatic arthritis (PsA) are conflicting. Results on Trabecular Bone Score 
(TBS) in these patients are lacking. 3D-analysis of cortical and trabecular bone from hip 
DXA is a new method for non-invasive bone structure assessment, providing separate assess-
ment of the cortical layer and trabecular macrostructure. Patients and methods: Case-con-
trol study (NCT02849795) in which 52 PsO and 52 PsA cases (CASPAR criteria) were 
each paired to a control subject matched for age, sex and body mass index (BMI). aBMD 
measurements at (L2-4) lumbar spine (LS), femoral neck (FN) and total hip (TH) were 
performed using DXA, Lunar GE. TBS was calculated from antero-posterior L2-L4 BMD 
image using TBS iNsight V1.8 (Med-Imaps, Pessac, France). 3D-SHAPER software (ver-
sion 2.10, Galgo Medical S.L, Barcelona, Spain) was used to derive a 3D analysis from the 
hip DXA scans. Results: LS and TH aBMD measurements did not differ between patients 
with PsO or PsA and their respective controls (Table 1). Left FN BMD was higher in patients 
with PsO compared to controls (p = 0.028), a difference not observed on the right FN. TBS 
was similar in PsA patients and their controls while decreased values were observed in PsO 
patients (p = 0.04). In 3D analysis, none of the parameters differed between patients with 
PsA and their controls. For patients with PsO, no difference was found with the controls 
for 3D-DXA parameters from the right FN, while total hip cortical surface BMD (sBMD) 
of the left FN was higher in PsO compared to their controls (p = 0.037). Similarly, cortical 
thickness (Cth) of the intertrochanteric and shaft regions of the left FN was also higher in 
PsO (p = 0.032 and p = 0.033). Finally, analysis by region (neck, intertrochanteric and shaft) 
showed higher values for cortical sBMD from each region of the left FN in the patients with 
PsO (all p <0.05).Conclusion: Our results showed comparable aBMD, TBS and 3D proximal 
femur parameters in patients with PsA and controls. This supports that PsA population is 
not at increased risk of osteoporosis. In patients with PsO, while LS bone microarchitecture 
seems impaired, FN displayed better cortical parameters than the controls. Although these 
results seem marginal, they support the fact that patients with PsO are not at high risk for 
osteoporosis and hip fracture.
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Association of bone and plasma microRNA levels in patients with Cushing’s 
disease. *Zhanna Belaya1, Tatiana Grebennikova1, Alexey Nikitin2, Alexandr 
Solodovnikov3, Andrey Grigoriev1, Galina Melnichenko1. 1The National Medical 
Research Centre for Endocrinology, Russian Federation, 2Federal Research 
and Clinical Center FMBA of Russia, Russian Federation, 3Ural State Medical 
Academy, Russian Federation
MicroRNA (miR) are considered promising osteoporosis biomarkers but current under-
standing of the relationship between miR levels in bone tissue and circulation is limited.Ob-
jective: to estimate if there is an association between miR levels in bone and plasma samples 
of patients with active Cushing’s disease (CD).Methods: Bone and plasma samples were ob-
tained from patients with clinically and biochemically-evident CD. Morning fasting blood 
samples were collected and centrifugated twice at a temperature of +5C at 3000 rpm. Plasma 
samples were frozen and stored at -80C. Bone samples were obtained during transsphenoidal 
adenomectomy from the base of the sella turcica. Differences between miR levels in bone 
samples of CD vs control group were previously estimated [1]  in the following miRs : 
miR- 100-5p; miR-10b-5p; miR-122-5p; miR-125b-5p; miR-133a-5p; miR-135a-5p; miR-
148a-3p; miR-155-5p; miR-188-3p; miR-199a-5p; miR-203a-5p; miR-21-3p; miR-21-5p; 
miR-211-5p; miR-22-3p; miR-26a-5p; miR-27a-3p; miR-27a-5p; miR-31-5p; miR-320a; 
miR-328-3p; miR-34a-5p; miR-550a-5p; miR-550b-2-5p; miR-7g-5p; miR-9-5p; miR-96-
5p. These miRs were measured in plasma samples by qPCR on the same patients with CD. 
Twenty-four hours urine free cortisol (24hUFC) was measured by an immunochemilumi-
nescence assay on a Vitros ECi.Results: Patients with Cushing’s disease (n=14 (13 females 
and 1 male); age 38 (95%CI 32-44) years) had elevated levels of 24hUFC – 1230 (95%CI 
748-1711) nmol/24h (reference range 60-413 nmol/24h). We observed statistically signifi-
cant correlations between three miRs levels in bone and plasma samples: miR-203a-5p ρo = 
0.555 p=0.047; miR-21-3p ρo = -0.635 p = 0.015 and miR-96-5p ρo = -0.63 p = 0.021. MiR-
203a-5p, miR-21-3p were previously shown to be upregulated whereas miR-96-5p was un-
changed in bone samples of patients with CD [1].  Plasma levels of miR- 203a-5p (ρo = 0.560 
p=0.046), miR-96-5p (ρo = 0.786 p=0.001); and miR-35-5p (ρo = 0.703 p=0.007)  correlat-
ed with 24hUFC levels.Conclusions: Hypercortisolism due to CD changes miR levels both 
in bone and circulation. The plasma levels of MiR-203a-5p and miR-96-5p are associated 
with their levels in bone and with 24hUFC. 1) Belaya ZE, Grebennikova TA, Melnichenko 
GA, Nikitin AG, Solodovnikov AG, Brovkina OI, Grigoriev AU, Rozhinskaya LY, Dedov 
II. Effects of endogenous hypercortisolism on bone mRNA and microRNA expression in 
humans. Osteoporos Int. 2018 Jan;29(1):211-221. doi: 10.1007/s00198-017-4241-7
Disclosures: Zhanna Belaya, None
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Anti-depressant Use is Associated with Cortical Bone Deficits and Reduced 
Physical function *Carmen Germosen1, Sanchita Agarwal1, Mariana Bucovsky1, 
John Williams1, Mishaela Rubin1, Elizabeth Shane1, Marcella Walker1. 1Columbia 
University Irving Medical Center, United States
Recent work suggests anti-depressants, particularly selective serotonin reuptake inhib-
itors, are associated with an increased risk of fracture. The mechanism is unclear and may 
be due to effects on bone metabolism, muscle strength, falls or other factors. We compared 
musculoskeletal health between anti-depressant (ever) users vs. never users from a popula-
tion-based multiethnic cohort study of adults >= 65 yrs old in New York, the Washington 
Heights-Inwood Community Aging Project. Musculoskeletal health was assessed using dual 
x-ray absorptiometry (DXA), trabecular bone score (TBS), vertebral fracture assessment 
(VFA), high resolution peripheral quantitative computed tomography (HRpQCT), body 
composition, grip strength and impact microindentation (IMI). The analysis was limited 
to women (n=195, mean age 76.3+/-6.1 yrs). The cohort was 35.6% black, 22.3% white 
and 42.1% mixed race. Anti-depressant users were more likely to be white than non-white 
(OR 3.6, 95% CI 1.6-8.2) and were shorter vs. non-users, but there was no difference in 
age, weight, BMI, physical activity, calcium/vitamin D intake, falls or self-rated health. 
There was a trend toward more historical fractures in users vs. non-users (62.1% vs. 42.9%, 
p=0.07), particularly pelvic fractures. Age- and weight-adjusted T-score by DXA was lower 
in users at the 1/3-radius (-1.8+/-1.4 vs. -1.0+/-1.3, p=0.006), but not other sites. There was 
no difference in TBS (p=0.09), the frequency of vertebral fractures by VFA (p=0.77) or fat/
lean mass by DXA, but grip strength was 14.4% lower in users vs. non-users (p=0.03). 
By HRpQCT, age- and weight-adjusted cortical (Ct.) volumetric BMD (vBMD) was 5.9% 
lower in users vs. non-users at the 4% radius (p=0.006), but stiffness in a subset (n=49) did 
not differ (p=0.13). There were no differences in trabecular indices, tibial microstructure, 
or IMI in a subset (n=10). When the analysis was limited to non-white women (n=153), 
results were similar. Age- and weight-adjusted 1/3-radius T-score (-1.7+/-1.4 vs. -0.9+/-1.2, 
p=0.03), Ct. vBMD (754+/-66 vs. 808+/-66 mgHA/cm3, p=0.001), Ct. thickness (0.712+/-
0.16 vs. 0.806+/-0.16 mm, p=0.03) at the radius and grip strength were lower in users vs. 
non-users. In summary, anti-depressant use was associated with cortical, but not trabecular, 
skeletal microstructural deficits and reduced physical function. These findings indicate that 
taking anti-depressants may contribute to the increased risk of fracture in older adults.
Disclosures: Carmen Germosen, None
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Association Between Sleep Duration and Bone Mineral Density in Midlife 
Women *Christine Swanson1, Patrick Blatchford1, Wendy Kohrt1, Kenneth 
Wright, Jr.2, Howard Kravitz3, Ellen Gold4, Katie Stone5, Martica Hall6, Jane 
Cauley6. 1University of Colorado, United States, 2University of Colorado 
at Boulder, United States, 3Rush University Medical Center, United States, 
4University of California Davis, United States, 5University of California, San 
Francisco, United States, 6University of Pittsburgh, United States
Accelerated bone mineral density (BMD) loss occurs across the menopausal transition 
when sleep disturbance often occurs, but the rate of loss varies between individuals, and 
reasons for more rapid bone loss are largely unknown. Self-reported short and long sleep 
durations have been associated with lower BMD in women, but the association between 
objectively assessed sleep duration and BMD in women across the menopausal transition is 
unknown. We used objective measures of sleep duration (wrist actigraphy) and BMD (DXA) 
from the Study of Women’s Health Across the Nation (SWAN) Sleep Study to determine the 
cross-sectional association between sleep duration and BMD in midlife women. Sleep dura-
tion was analyzed as both a continuous and dichotomous variable using NIH sleep duration 
recommendations to categorize women as recommended (7-8 h/night, N = 18) or short (<6 
h/night, N = 92) sleepers. Covariates were incorporated into adjusted models if their group 
differences were either clinically or statistically significant. Three linear regression models 
were used.  Model A was unadjusted. Model B adjusted for age, race, BMI and clinical site. 
Model C additionally adjusted for calcium/vitamin D use, depressive symptoms, self-report-
ed health, menopausal status, hormone use and days between actigraphy and DXA visit. On 
average, women were 52.6 +/- 2.37 years old, with a BMI of 29.0 +/-6.67 kg/m2, and 43.6% 
were Caucasian. Menopausal status included: unknown due to hormone use (8.2%), pre- 
(6.4%), peri- (73.6%), and postmenopausal (11.8%).  In the unadjusted model only, femoral 
neck BMD was higher in short sleepers compared to women with the recommended sleep 
duration (p = 0.027).  This was likely driven by BMI differences as it was not significant 
in the minimally and fully adjusted models.  BMD at the L-spine or total hip did not differ 
significantly between recommended and short sleepers in any model (all p >= 0.15).  When 
sleep duration was analyzed as a continuous variable (N = 183), BMD at the femoral neck 
and total hip were non-significantly lower in women with shorter sleep duration in the fully 
adjusted model only (total hip BMD 0.013 g/cm2 higher for each hour of sleep, p = 0.21). In 
conclusion, BMD was not associated with objectively-determined sleep duration in midlife 
women.  However, the cohort was small, actigraphy and BMD were obtained, on average, 
92 +/- 62 days apart, and sleep durations >=7 h/night were under-represented.
Disclosures: Christine Swanson, None
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Assessment of bone mineral density, cortical bone thickness and bone 
marrow fat at the proximal femur in HIV-infected subjects *Julio Carballido-
Gamio1, Magdalena Posadzy2, Po-Hung Wu2, Thomas Link2, Phyllis Tien3, 
Roland Krug2, Galateia Kazakia2. 1Department of Radiology, University of 
Colorado Anschutz Medical Campus, United States, 2Department of Radiology 
and Biomedical Imaging, University of California, San Francisco, United States, 
3Department of Medicine, University of California, San Francisco, United States
Purpose. Increased fracture risk is increasingly recognized as a significant comorbid-
ity of HIV infection and treatment. While low bone mineral density and deteriorated bone 
quality has been reported at the extremities in HIV-infected individuals, data at the proximal 
femur –an important anatomical site for fracture– is limited. The purpose of this work was 
to quantify differences in volumetric bone mineral density (vBMD), cortical bone thickness, 
and bone marrow fat content (BMF) between HIV-infected patients and uninfected controls.
Methods. Forty HIV-infected patients and 26 age-matched uninfected controls were includ-
ed in this study. Using quantitative computed tomography (QCT) and quantitative mag-
netic resonance imaging (MRI), proximal femur maps of volumetric bone mineral density 
(vBMD), cortical bone thickness (Ct.Th), and BMF were generated. Using linear regression, 
differences in vBMD, Ct.Th. and BMF between HIV-infected patients and uninfected con-
trols were investigated for different volumes of interest: total hip, femoral head, femoral 
neck and trochanter. The linear models were adjusted for age, body mass index (BMI), sex 
and race.Results. There were no significant differences in age and BMI between HIV-infect-
ed patients (58+/-5 years and 26+/-4 kg/m2) and uninfected controls (58+/-5 years and 25+/-
4 kg/m2). Thirty percent in the HIV-infected group, and 54% in the uninfected control group 
were females; and 65% of the participants were white in both groups. Significantly lower 
values were identified in HIV-infected patients compared to uninfected controls for: 1) in-
tegral (cortical + trabecular) vBMD at the total hip, femoral neck and trochanter (P<0.05); 
and 2) trabecular vBMD at the femoral neck and trochanter (P<0.006). Significantly higher 
BMF values were identified in HIV-infected patients compared to uninfected controls at the 
femoral neck (P<0.007). Cortical vBMD and cortical bone thickness were not significantly 
different between the two groups. Discussion. Results of this study indicate that the trabec-
ular bone and not the cortical bone is compromised in HIV-infected patients at the proximal 
femur. Lower vBMD at the femoral neck and trochanter, and higher BMF at the femoral 
neck –both fracture prone regions– are indicators of lower bone strength, partly explaining 
the higher risk of fracture in HIV-infected patients.
Disclosures: Julio Carballido-Gamio, None
P-630
Characterization of bone involvement in early Parkinson’s Disease patients: 
a pilot cross-sectional study *Antimo Moretti1, Sara Liguori1, Marco Paoletta1, 
Matteo Bertone1, Giovanni Iolascon1. 1Department of Medical and Surgical 
Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, 
Italy, Italy
PurposeBone involvement in early stages of Parkinson’s disease (PD) is poorly investi-
gated. We aim to evaluate the qualitative and quantitative alteration of bone in patients with 
early PD and the associations among BMD, Trabecular Bone Score (TBS), and physical 
performance in the same population.MethodsIn our cross-sectional study, we enrolled PD 
patients with Hoehn & Yahr stage <=2 without fragility fracture. In this population, we 
assessed the following outcomes: BMD of left femoral neck (l-FN), lumbar spine (LS) mea-
surement by GE Lunar i-DXA, and TBS by TBS iNsight™ software; muscle performance 
using Short Physical Performance Battery (SPPB) to identify a “poor performance” group 
A (SPPB score <= 8), and “high performance” group B (SPPB >8). Distribution of all vari-
ables was tested using Shapiro-Wilk test. All variables were normally distributed; intergroup 
comparisons were made using t-test for independent variables. Continuous variables are 
presented as mean +/- standard deviation (SD), and categorical variables as counts and per-
centage (%).ResultsWe included 13 PD patients (7 men, 6 women) aged 65.8 +/- 6.1 years, 
with a BMI of 27.6 +/- 3.9 kg/m2 and duration of PD 4.2 +/- 1.2 years.The DXA examination 
showed the following results: L1-L4 BMD = 1.19 +/- 0.160 g/cm2, T-score =-0.67 +/- 1.23 
SD; l-FN BMD=0.825 +/- 0.134 g/cm2, T-score =-1.62 +/- 1.04 SD. The mean value of 
TBS was 1.311 +/- 0.14. Bone microarchitecture was degraded in 4 patients (30.8%) and 
partially degraded in 3 patients (23.1%). Age was not statistically significant associated with 
low BMD (<-1 SD at LS or l-FN, p=0.337), whereas it was statistically significant associ-
ated with low TBS (<1.350, p=0.032). The SPPB mean score was 8.8 +/- 2.3. Five patients 
(38.5%) included in group A and 8 patients (61.5%) in group B. For densitometric values, 
there are no statistically significant differences between the two groups (BMD LS vs SPPB 
p=0.587; BMD l-FN vs SPPB p=0.958); otherwise, for the qualitative evaluation, statis-
tically significant between-group difference is observed (p <0.0063).ConclusionOur data 
suggest that TBS might identify bone involvement earlier than BMD in initial stages of PD, 
confirming the experimental findings of an early bone microarchitectural alteration due to 
dopaminergic depletion regardless of motor impairment. On the other side, it seems that the 
worsening of physical performance is associated with poor bone microarchitecture instead 
of low bone density in early PD patients.
Disclosures: Antimo Moretti, None
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Changes in Bone and Fat derived hormones are correlated with BMD and 
Body Fat at 12 months after initiation of antiretroviral therapy in men 
with HIV. *Arnold Olali1, Ryan Ross1, Elizabeth Shane2, Michael Yin2. 1Rush 
University Medical Center, United States, 2Columbia University Medical Center, 
United States
Low bone mineral density (BMD) is commonly observed in people living with HIV 
(PLWH), especially after initiation of combination antiretroviral therapy (cART). cART ini-
tiation is also associated with lipodystrophy, which is characterized by body fat redistribu-
tion. Although previous studies have reported an association between cART initiation and 
change in bone and fat mass, the mechanisms remain unclear. There is growing evidence that 
bone and fat cells produce hormones that influence the function of one another. Therefore, 
in the current study, we tested the hypothesis that cART initiation induces changes in the 
circulating levels of the bone-derived hormones, undercarboxylated osteocalcin (ucOCN), 
and lipocalcin-2 sclerostin, and the fat-derived hormones, leptin and adiponectin, and that 
these changes are associated with BMD and fat mass. Serum samples were collected from a 
small cohort of men with HIV (n=15) initiating fixed dose tenofovir disoproxil fumarate/em-
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tricitabine/efavirenz at baseline, prior to cART initiation, and at 12-months after initiation. 
BMD at the lumbar spine (LS) and femoral neck (FN), as well as, trunk fat was evaluated 
using dual energy x-ray absorptiometry (DXA) 12 months after initiation. Serum ucOCN, 
sclerostin, leptin, adiponectin and lipocalcin-2 were measured using enzyme-linked immu-
nosorbent assays (ELISAs). Baseline and 12-month hormones levels were compared using 
paired t-test or a Wilcoxon rank test. The correlation between change in hormone levels and 
BMD and body fat was evaluated using Spearman’s rank order correlation analysis. There 
was a significant reduction in LS BMD (p<0.05) and FN (p=0.003). There was a significant 
increase in lipocalin-2 (p=0.012), and no significant changes in ucOCN, leptin, adiponectin, 
and sclerostin between baseline and 12-months. Change in sclerostin between baseline and 
12-months was positively associated with LS (r=0.649, p=0.012) and FN BMD (r=0.548, 
p=0.043). Change in ucOCN was negatively associated with trunk fat (r=0.538, p=0.047) 
and change in adiponectin was negatively associated with LS BMD (r=-0.600, r=0.023). Our 
findings support previously published work demonstrating the association between circulat-
ing sclerostin and bone mass . The associations noted between the bone-derived hormone, 
ucOCN, and trunk fat and the fat-derived hormone, adiponectin, and lumbar spine BMD are 
supportive of bone-fat hormonal cross-talk in PLWH treated with ART.
Disclosures: Arnold Olali, None
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Hip Fracture risk in Type 2 Diabetes in an elderly population of three 
Communities of Central Spain **Federico Hawkins1, Guillermo Martínez Díaz-
Guerra1, David Lora1, Felix Bermejo Pareja1. 1Research Institute i+12,University 
Hospital 12 de Octubre, Spain
Background.Type 2 Diabetes (T2D) affects approximately one-third of those aged 65 
and older. Data on Hip Fracture (HF) risks in T2D are inconsistent.The reported risk fac-
tors(RFs) for these fractures are under discussion. We have performed a study to analyze 
RFs in elderly patients with and withoutHF and T2D.Design and Methods.We have studied 
the association ofHFwithT2D in the NEDICES cohort survey.Subjects were selected by the 
local census. A questionnary and a detailed face-to-face interview for the evaluation of T2D 
was performed in people aged  >=65 years from three areas:1)Lista (professional class);2)
Las Margaritas (workingarea);3) Arévalo (agriculture zone).This areas were selected be-
cause there were approximately 2000 inhabitants, facilities of computer-based registry med-
ical data, and represented different socioeconomic geographic communities of central Spain.
Results. There were initially 5278 screening patients, 42.3%were men and 67.6% wom-
en.Of these 874 were T2D; prevalence of T2D was higher in women respect men (18.5% 
vs. 1.4%). Age was similar in T2D (74+/-6 yrs) and non-DM  (74.4+/-7). HF was present 
in 21 T2D (2.4%)and in 145 non-diabetics (3.3%).BMI was significantly higher in T2D 
vs.non-DM(28.2+/-8 vs. 27.2+/-5,p<0.001). Smoking(12.4%vs.9.6%),alcohol ingestion 
(35.1%vs.24.3%),p=<0.001)were higher in non-DM, while diagnosis of osteoporosis and 
serum cholesterol levels were similar.Hypertension was significantly higher in T2D (63% vs. 
48%, p=<0.001).Other RFs were cataracts (39.9%vs.29%,p<0.001),CVD (14.5% vs.9.2%, 
p<0.001).Patientswith HF were older and there were more females (81%) and mostly diag-
nosed of osteoporosis (46.9 vs,15%,p<0.001).T2D was not significantly different in patients 
with/without HF. Charlson and Carey indexes were higher in areas 2 and 3(p<0.001).There 
was a higher percent of illiterates and lower higher studies in T2D and in patients with 
HF.Percentage of HF was lower in zone 3(rural) compared with 1 and 2 (22.3%,39.2% & 
38.5%, p<0.001).Conclusions. Our study provides information regard the associations of HF 
and T2D in a large cohort of community-dwelling elderly subjects. Cataracts, hypertension, 
CVD, comorbidites, and lower cultural levels are more frequent in T2D, while in patients 
with HF, osteoporosis, cataracts,female sex and  differences in socioeconomic areas has to 
be considered.
Disclosures: Federico Hawkins, None
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Is Hypocitraturia Associated with Reduced Bone Mineral Density? *Anusha 
Veeravanallur Appuswamy1, Frederick Hance2, Stephen Knohl3, Donald Cibula4, 
Scott Wiener5, Ruban Dhaliwal6. 1Division of Endocrinology, Diabetes and 
Metabolism - SUNY Upstate Medical Univeristy, United States, 2College of 
Medicine, SUNY Upstate Medical University, United States, 3Division of 
Nephrology, SUNY Upstate Medical Univeristy, United States, 4Department of 
Public Health and Preventative Medicine, SUNY Upstate Medical University, 
United States, 5Division of Urology- SUNY Upstate Medical Univeristy, United 
States, 6Division of Endocrinology, Diabetes and Metabolism - SUNY Upstate 
Medical Univeristy, United States
Purpose:Hypercalciuria is a known risk factor for bone mineral density (BMD) loss. 
Hypocitraturia (HC), a metabolic alteration that facilitates the formation of kidney stones, 
is commonly observed with hypercalciuria. The objective of this study was to determine 
the effect of hypocitraturia on bone mineral density as an independent risk factor and in the 
presence of hypercalciuria.  Methods:In total, 211 patients were included in the study of four 
groups:  group A – 42 patients with HC without hypercalciuria, group B – 98 patients with 
hypercalciuria without HC, group C – 40 patients with HC and hypercalciuria, and group D – 
31 controls. Parameters of phospho-calcium metabolism, bone metabolism and bone densi-
tometry were assessed. The intergroup differences in BMD were analyzed by one-way ANO-
VA with multiple comparisons. Hochberg’s T2 comparisons were used for variables with ho-
mogeneous variance among groups; Games-Howell comparisons were used when the equal 
variance assumption was not met.Results:Baseline characteristics (weight, body mass index, 
serum intact parathyroid hormone and 25-hydroxy vitamin D levels) were similar between 
groups. Mean age was lower in group C compared to group D (44.7 +/- 13.7 vs 53.9 +/- 14.2 
years, p<0.05). Twenty-four-hour urine calcium was higher in groups B and C (subjects with 
hypercalciuria) than in groups A or D (p<0.05). Twenty-four-hour urine citrate was lowest 
in group A compared to all other groups (all p values <0.05).  Mean lumbar spine BMD was 
lower in group C (1.074 +/- 0.144) compared to groups A, B and D (1.102 +/- 0.160, 1.113 
+/- 0.198 and 1.118 +/- 0.180 respectively), but did not differ significantly between groups 
(p=0.67). Adjusting for age had no effect on this comparison.Conclusion:Despite younger 
age of patients in group C (with hypocitraturia and hypercalciuria), this group had the lowest 
BMD. The lack of statistical significance was likely a consequence of small sample size. 
Hypocitraturia, similar to hypercalciuria, may be a risk factor for bone loss, independent of 
age. Hypocitraturia may also accentuate bone loss in the presence of hypercalciuria. Larger 
studies are needed to ascertain whether individuals with hypocitraturia and hypercalciuria 
have a higher risk of osteopenia and osteoporosis.
Disclosures: Anusha Veeravanallur Appuswamy, None
P-634
Factors Contributing to Fracture in Pernicious Anemia Patients Presenting 
with Symptomatic Subacute Vertbral Compression Fractures *Nir Ben-
Shlomo1, Michael Lovy2. 1University of Iowa Medial School, United States, 
2Desert Oasis Healthcare, United States
PURPOSE:  Pernicious anemia has been associated with both low spine BMD and 
increased fracture risk in retrospective cohort studies.  The cause of these observations is 
obscure.  The purpose of this study is to describe and compare the clinical details of a cohort 
of pernicious anemia patients who presented with subacute vertebral compression fractures 
(SVCF) to one without pernicious anemia.METHODS:  A retrospective cohort study was 
conducted from a population of 173 patients presenting with SVCF to an outpatient fracture 
clinic.  The clinical characteristics of 38 pernicious anemia patients diagnosed at the time of 
presentation, based low vitamin B12 levels and either intrinsic factor (IF) or antiparietal cell 
antibodies (APCA), was compared to the remaining 135 without pernicious anemia.  A com-
plete history and physical exam including review of past medical records and current and 
past radiographs was performed.  CBC, sedimentation rate, chemistry profile, TSH, urinaly-
sis, vitamin B12, PTH, 25-OH vitamin D, and serum protein electrophoresis was done in all 
patients.RESULTS:  There were 27 female and 11 male pernicious anemia patients, ranging 
in age from 66-96 (mean 79.5 years) with a BMI of 15-31 (mean 25.3).  17 patients were 
taking thyroid hormone and 16 were on protein pump inhibitors (PPIs) .  19 had previous 
fractures.  Fractures occurred after falling in 28, lifting in 3, and were spontaneous in 6.  The 
location of the fracture was between T-11 and L-2 in 58% of cases and 10 patients presented 
with multiple fractures.  31 out of the 38 patients had evidence of peripheral neuropathy.  IF 
was present in 21 patients, APCA in 7, and 10 had both.  25-OH vitamin D was 65 pg/ml 
in 10.  A monoclonal gammopathy of undetermined significance (MGUS) was found in 7. 
There was an increased incidence of peripheral neuropathy (p<0.0001), 25-OH vitamin D 
<20ng/dl (p< 0.0003), use of PPIs (p 65 ng/dl (p=0.00001), thyroid disease (p=0.04), and 
MGUS (p=0.064) in the patients with pernicious anemia.  Age, gender, previous fractures, 
diabetes, BMI, fracture location, mechanism of fracture, and occurrence multiple fractures 
did not differ between the two cohorts.CONCLUSIONS:  This cohort of SVCF patients with 
pernicious anemia had a higher incidence of peripheral neuropathy, vitamin D deficiency, 
hyperparathyroidism, thyroid disease and MGUS than SVCF patients without pernicious 
anemia.  These observations may explain the higher incidence of fractures and low BMD 
found in previous studies of pernicious anemia patients.
Disclosures: Nir Ben-Shlomo, None
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Denosumab for preoperative management of severe hypercalcemia due to 
primary hyperparathyroidism *Anna Eremkina1, Julia Krupinova1, Ekaterina 
Bibik1, Anna Gorbacheva1, Natalia Mokrysheva1. 1Endocrinology Research 
Centre, Moscow, Russian Federation
Intoduction: Denosumab is widely used and approved for hypercalcemia of malignan-
cy. But data on its applying in patients with primary hyperparathyroidism (PHPT) is lim-
ited.Aim: We present 2 cases of PHPT patients that received denosumab prior to surgery.
Material and methods. The values are: «albumin-adjusted» serum calcium (Ca, RR 2.15-
2.55 mmol/l), phosphate (P, RR 0.74-1.52 mmol/l), intact parathyroid hormone (iPTH, RR 
15-65 pg/ml) concentrations, glomerular filtration rate (GFR, ml/min/1.73m2); dual energy 
X-ray  absorptiometry (DXA).Case 1. Female 40-year old patient with no significant past 
medical history presented with pathological fracture of the femur and osteoporosis on DXA 
(total hip –3.9 SD, total radius –5.4SD, L1-L4 -1.2SD in Z-score). Laboratory data revealed 
Ca 3.99 mmol/l, P 0.56 mmol/L, GFR 68, iPTH 1120 pg/ml. Considering the increase in neu-
rological symptoms, the denosumab 60 mg was administred in combination with cinacalcet 
30 mg and rehydration therapy. Normocalcemia (2.46 mmol/l) was achieved on the 9th day, 
cinacalcet was discontinued. After curative parathyroid surgery Ca dropped to 1.75 mmol/l. 
Active vitamin D and calcium supplements were prescribed. Histopathological examination 
confirmed parathyroid adenoma.Case 2. 61 year-old man with previous history of PHPT, 
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osteoporosis (total hip -2.5SD, total radius -4.5SD, no change in L1-L4 in T-score), chronic 
cardiovascular and kidney disease (GFR 13) presented with severe hypercalcemia: Ca 4.11 
mmol/l, P 1.18 mmol/l, iPTH 2146 pg/ml. To prevent the hypercalcemic crisis and stabilize 
renal function denosumab 60 mg, saline infusion and cinacalcet 120 mg were administred. 
Follow-up Ca levels were: day 3rd– 3.5 mmol/l, 7th – 2.82 mmol/l with complete normaliza-
tion on the 10th day, then cinacalcet was gradually discontinued . Right lower (55 mm) and 
upper left (15 mm) parathyroid glands tumors were removed, Ca decreased to 1,72 mmol/l 
the day after resection. The histological examination confirmed parathyroid carcinomas. The 
therapy with active vitamin D and calcium supplements was carried out to manage postop-
erative hypocalcemia.Conclusion. Denosumab interferes with RANKL signaling, inhibits 
bone resorption and thereby reduces calcium level.  Thus, it could be useful to control severe 
hypercalcemia in patients with PHPT and bone impairment before surgery. Benefits include 
no restrictions of Denosumab use in patients with concomitant CKD.
Disclosures: Anna Eremkina, None
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Infection among Denosumab and Alendronate Users for Osteoporosis 
*Jiannong Liu1, Haifeng Guo1, kimberly Niewan1. 1Hennepin Healthcare 
Research Institute, United States
Denosumab (Prolia, DEN) was approved to treat osteoporosis with a warning of serious 
infection risk. Studies on infection risk for DEN have been conducted based on clinical trial 
data or case reports. We assessed serious infection risk for DEN, compared with alendronate 
(ALN), in real-world practice.We used 2011-2017 Medicare 20% database and included 
patients who initiated DEN or ALN for osteoporosis 2012-2016, were aged >=66 years and 
covered by Medicare for >=1 year pre-initiation; patients with cancer were excluded. Pa-
tients were followed from medication initiation to the earliest of death, Medicare coverage 
loss, 90 days after medication discontinuation, or 12/31/2017. Outcomes included any se-
rious infection (hospitalization due to cellulitis, infectious endocarditis, gastroenteritis, di-
verticulitis, labyrinthitis, osteomyelitis, urinary tract infection, or respiratory infection) and 
cause-specific serious infections (hospitalization due to one of the above). Adjusted 2-year 
infection probability was calculated for DEN users and ALN users separately to compare 
infection risk between DEN and ALN use; the probability was adjusted for patient demo-
graphics, previous zoledronic acid use, and previous infections (serious and mild [non-hos-
pitalized], separately). Analysis was also performed separately for men and women.In total, 
73,750 DEN and 103,790 ALN users were included. DEN users were older (mean age 78.1 
vs 76.7 years); more were female (93.3% vs 89.7%) and white (87.2% vs 80.5%). Previous 
serious infection rates were similar (8.7% vs 8.8%), but DEN users had more previous mild 
infections (59.1% vs 53.9%,). During the mean follow-up of 20.9 and 19.2 months for DEN 
and ALN users, respectively, 5.9% of DEN and 4.9% of ALN users had serious infections. 
Adjusted 2-year infection probability was 6.8% (95% CI: 6.50-7.05) for DEN vs 6.3% (95% 
CI: 6.13-6.55) for ALN users. Adjusted probability of cause-specific serious infection varied 
by cause (Table 1). Due to a small number/percent of male users, results for women were 
almost identical to those for all and estimates for men are not stable. We found low serious 
infection risk among DEN and ALN users. Estimate of adjusted infection probability was 
slightly higher for DEN users, but the difference was not clinically significant and varied 
slightly by cause. As with other observational studies, despite adjustment for demographics 
and previous infection, results might be biased due to unmeasured confounders.
Disclosures: Jiannong Liu, None
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Factors associated with vertebral fractures after Denosumab. A 
retrospective study of 797 cases. *Olivier Lamy2, Peter Burckhardt0, Thierry 
Buclin1, Mohamed Faouzi3, Daniel Aeberli4, Fabio Cattaneo4, Jean Dudler4, 
markus Felder4, Diana Frey4, paul hasler4, Hans Jörg Häuselmann4, Sigrid 
Jehle-Kunz4, Ina Krull4, Thomas Lehmann4, Kurt Lippuner4, Christian Meier4, 
Urs Moser4, Martin Oehri4, Andreas Rohrer4, Franco Tanzi4, Martin Toniolo4, 
Brigitte Ubelhart4, Lukas Wildi4, Dagmar Wildpaner4. 2University Hospital 
CHUV, Switzerland, 0Clinique Hirslanden, Switzerland, 1University Hospital 
CHUV, Switzerland, 3university, Switzerland, 4Swiss Denosumab Study Group, 
Switzerland
PURPOSE: Search of factors influencing the occurrence of vertebral fractures (VF) 
after Denosumab Treatment (DMAB).METHODS: 22 specialists in Switzerland collected 
data of 861 randomly chosen women, in whom DMAB was interrupted, by a questionnaire 
for the periods before, during and after DMAB.RESULTS: We excluded 64 cases with miss-
ing data, and analyzed 797 cases (134 breast cancer). Mean age was 65.3 years (27-92). 
91 patients experienced VF after discontinuation of DMAB, in average 2.6 VF (1-5), 15.6 
months (median 12) after the last dose of DMAB. DMAB was given for +35 months (5-120) 
and the follow-up after DMAB was +25.7 months (1-78). The incidence of VF was 19.8% 
before, 2.3% during, and 11.4% after DMAB. Lumbar spine BMD (T-score) increased sign.
by 26% during DMAB, and decreased sign. by 14% thereafter. Fem. neck and total hip BMD 
changed accordingly. TBS improved sign.by 4.0% during DMAB, and did not decline there-
after.Patients with VF after DMAB discontinuation had no higher resorption markers (ResM) 
measured before DMAB than those without VF. But they had more previous VF (HR=1.8, 
p=0.009) and were less often previously treated with bisphosphonates (BP) (HR=0.35, 
p<0.001). Their total hip BMD was lower before DMAB (HR=0.71, p=0.06), during DMAB 
(HR=0.62, p=0.004), and after DMAB (HR=0.69, p=0.01). After DMAB, their femoral neck 
BMD was lower (HR=0.61, p=0.005), and their ResM were higher (HR=1.71, p<0.001). 
They experienced sign. more non-vertebral fractures after DMA discontinuation (6.6% 
vs 1.4%).Patients without VF after DMAB discontinuation received more often BP after 
DMAB than women who fractured (68.7% vs 48.3%, IRR=0.41, p<0.001), and BP were 
given earlier: 9.1 mos after the last DMAB dose vs 16.5 mos (HR=1.06, p<0.0001).The 
number of VF after DMAB discontinuation (NbVF) did not correlate with risk factors for 
osteoporosis, neither with the number of DMAB injections, nor with the pre-DMAB lumbar 
spine and femoral neck BMD. But it correlated negatively with total hip and femoral neck 
BMD after DMAB (both p=0.02), and positively with ResM measured after DMAB (IRR=2, 
p=0.001). It was decreased by a treatment with BP before DMAB (IRR=0.26, p<0.001), and 
after DMAB (IRR=0.52, p=0.03). The changes in BMD during and after DMAB had no 
sign. influenceCONCLUSION: This retrospective study describes the factors favoring an in-
crease of VF after DMAB cessation, esp. prevalent VF, low BMD, high resorption markers, 
no treatment with bisphosphonates.
Disclosures: Olivier Lamy, None
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Evaluation of Relugolix Combination Therapy to Maintain Bone Mass in 
Women with Uterine Fibroids Through 52 Weeks: LIBERTY Long-Term 
Extension Study *Michael R. McClung1, Arthur Santora2, Ayman Al-Hendy3, 
Laura McKain4, Yulan Li4, Rachel B. Wagman4. 1Oregon Osteoporosis Center, 
United States, 2Kinexum Services LLC, United States, 3Department of Obstetrics 
and Gynecology, University of Illinois/Chicago, United States, 4Myovant 
Sciences Inc., United States
Purpose: Relugolix combination therapy (Rel-CT), a once-daily, orally active, non-pep-
tide, gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol (E2), and nore-
thindrone acetate (NETA), reduced menstrual blood loss and pain in women with uterine 
fibroids and was well tolerated with preservation of bone mineral density (BMD) through 24 
weeks (Al Hendy, 2019). We assessed the effects of Rel-CT on BMD for up to 52 weeks of 
treatment in the LIBERTY extension study.Methods: Patients with heavy menstrual bleeding 
associated with uterine fibroids who were enrolled in 24-week double-blind, placebo-con-
trolled LIBERTY 1 and 2 trials were randomized to receive Rel-CT, delayed Rel-CT (relugo-
lix 40 mg monotherapy for 12 weeks followed by Rel-CT for 12 weeks), or placebo. Women 
who completed those trials who met all entry criteria were eligible to enroll in a 28-week 
study extension in which all women received once-daily treatment with open-label Rel-CT. 
BMD was assessed by dual-energy X-ray absorptiometry of the lumbar spine (L1–L4) and 
proximal femur at baseline, at Weeks 12 and 24 in LIBERTY, and Weeks 36 and 52 in the 
extension. Percent change from LIBERTY baseline was summarized by location according 
to original treatment assignment using a mixed-effect model with repeated measures adjust-
ed for region, visit, and selected baseline characteristics.Results: Of the 610 women who 
completed LIBERTY 1 and 2 studies, 477 (78%) were enrolled in the extension, of which 
363 (76%) completed. Least squares mean % change BMD from baseline to Week 52 in 
lumbar spine and total hip for Rel-CT was –0.80% and –0.15%, respectively (Figure). These 
values were relatively unchanged from Week 12 and were similar to values for the placebo 
group that transitioned to Rel-CT at Week 24. In the delayed Rel-CT group, which showed 
significant bone loss after 12 weeks of relugolix monotherapy, BMD remained stable upon 
transitioning to Rel-CT through 52 weeks. Similar patterns of change in total hip BMD 
were observed.Conclusion: The combination of relugolix with E2/NETA maintained BMD 
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through 52 weeks of treatment. Rel-CT represents a potential long-term treatment for wom-
en with symptomatic uterine fibroids, providing therapeutic benefit while preserving BMD.
Disclosures: Michael R. McClung, Amgen, Speakers’ Bureau, Amgen and Myovant, 
Consultant
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Cardiovascular Risk in Patients Treated with Romosozumab: 
Disproportional Meta-Analysis *Abdulhafez Selim1, Omar Selim2, Paula 
Karabelas3. 1PCOM, United States, 2University of Maryland, Baltimore, United 
States, 3Independent Scientist, United States
Background: Osteoporosis and cardiovascular (CV) diseases are closely correlated. 
Wnt signaling pathway is implicated in the pathogenesis of both osteoporosis and CV dis-
eases. Romosozumab (ROMO), a sclerostin inhibitor, was FDA-approved in 2019 for the 
treatment of osteoporosis in postmenopausal women at high risk for fracture. Romosozum-
ab works through Wnt signaling manipulation via the anti-sclerostin antibody mechanism. 
Sclerostin inhibition may enhance CV risk by increasing arteriosclerosis through boosted 
mineralization as well as lipid accumulation. We, therefore, aimed to investigate the risk of 
CV outcomes in patients with primary osteoporosis treated with ROMO.Methods: MED-
LINE’s PubMed, Cochrane Library, and EMBASE commercial databases were systemati-
cally searched from the inception dates to March 18, 2020. We included randomized clinical 
trials comparing ROMO versus active comparators (alendronate or teriparatide) or placebo 
for at least 6 months, in patients diagnosed with primary osteoporosis or osteopenia. Two 
investigators independently extracted data for study characteristics and outcomes of interest 
in accordance with PRISMA guidelines. For data analysis, we used the approach of dispro-
portional analysis, which is a known tool to generate hypotheses on possible causal relations 
between drugs and adverse effects. We examined the following endpoints: composite CV 
outcome; three-point major adverse CV event (3P-MACE); 4P-MACE; myocardial infarc-
tion (MI); stroke; heart failure (HF); death or CV death; congestive heart disease (CHD); 
and atrial fibrillation (AF).Results: Six relevant studies with a total of 12,219 subjects 
were included. These subjects were as follows: 6,116 ROMO; 3,770 placebo (PBO); 268 
teriparatide (TERI); and 2,065 alendronate (ALEN). A Disproportional analysis compar-
ing ROMO subjects (6,116) to all other treatments combined (6,103 subjects) showed nu-
merically higher risk ratios (mean and median values) in all endpoints (Table 1). However, 
statistical significance was only seen in 4P-MACE endpoint (Risk Ratio: 1.4 with 95.0% 
CI of 1.002 to 1.928).Conclusion: These data demonstrated a trend of higher rates in CV 
events in patients treated with ROMO. Additionally, a statistically significant risk was seen 
in the 4P-MACE endpoint. This causal relationship appears likely considering these data, 
as well as the biological plausibility. These findings highlight the importance of weighing 
risk versus benefits when treating patients with osteoporosis who have pre-existing CV risk 
factors. Additionally, our data demonstrated the need for extensive post-marketing studies 
aiming CV risk assessment.
Disclosures: Abdulhafez Selim, None
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Relugolix Combination Therapy Preserves Bone Mass in Patients with 
Uterine Fibroids: Results from Phase 3 LIBERTY Program *Michael R. 
McClung1, Arthur Santora2, Ayman Al-Hendy3, Laura McKain4, Yulan Li4, Rachel 
B. Wagman4. 1Oregon Osteoporosis Center, United States, 2Kinexum Services 
LLC, United States, 3Department of Obstetrics and Gynecology, University of 
Illinois/Chicago, United States, 4Myovant Sciences Inc., United States
Purpose: Relugolix is a once-daily, orally active, non peptide gonadotropin releasing 
hormone (GnRH) receptor antagonist being developed in combination with estradiol (E2) 
and norethindrone acetate (NETA) for the treatment of heavy menstrual bleeding (HMB) 
associated with uterine fibroids (UF). The purpose of adding E2 to relugolix is to prevent 
the bone loss anticipated with relugolix monotherapy. The efficacy and safety of treatment 
was evaluated in replicate Phase 3 LIBERTY 1 and 2 trials. Relugolix combination therapy 
(Rel-CT [once-daily relugolix 40 mg, E2 1 mg, NETA 0.5 mg]) significantly reduced men-
strual blood loss and pain in women with UF and was well tolerated (Al-Hendy, 2019). In 
these studies, we assessed the effects of Rel-CT vs relugolix monotherapy on bone mineral 
density (BMD).Methods: Premenopausal women (age 18–50 years) with HMB were ran-
domized 1:1:1 to receive Rel-CT for 24 weeks, relugolix 40 mg alone for 12 weeks followed 
by Rel-CT for 12 weeks (delayed Rel-CT), or placebo for 24 weeks. BMD was assessed 
by dual-energy X-ray absorptiometry of the lumbar spine (L1–L4), total hip and femoral 
neck at baseline, and Weeks 12 and 24. Treatment comparisons were performed on pooled 
data from the LIBERTY 1 and 2 studies. Percent change from baseline was summarized 
by location for each treatment group using a mixed-effect model with repeated measures 
adjusted for region, visit, and selected baseline characteristics.Results: Evaluation included 
768 patients. Least squares (LS) mean percent changes from baseline to Week 12 and 24 in 
lumbar spine BMD were comparable for Rel-CT vs placebo (Week 12: –0.63% vs 0.34%; 
Week 24: –0.23% vs 0.18%, respectively) (Figure). For patients who received 12 weeks of 
relugolix alone, % change from baseline at Week 12 was –1.96%, which stabilized with 
transition to Rel-CT at –1.97% at Week 24. Rel-CT was statistically superior to relugolix 
alone at Week 12 with a difference of 1.34% (p < 0.0001). Findings at the proximal femur 
were consistent with those at the lumbar spine and comparable between Rel-CT and placebo 
groups.Conclusion: Compared with relugolix alone, Rel-CT prevented bone loss over 12 
weeks of treatment: this benefit was maintained over 24 weeks. Initiating treatment for with 
relugolix combined with E2/NETA represents a potential method for preserving BMD while 
providing therapeutic benefit for women with symptomatic UF.
Disclosures: Michael R. McClung, Myovant, Consultant, Amgen, Speakers’ Bureau, 
Amgen, Consultant
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Romosozumab After Denosumab Improves Lumbar Spine and Maintains 
Total Hip Bone Mineral Density in Postmenopausal Women with Low 
Bone Mass *MR McClung1, MA Bolognese2, JP Brown3, J-Y Reginster4, BL 
Langdahl5, N Ruiz-Santiago6, Y Shi6, M Rojeski6, J Timoshanko7, C Libanati7, 
H Kassahun6, M Oates6. 1Oregon Osteoporosis Center, United States, 2Bethesda 
Health Research Center, United States, 3Laval University and CHU de Québec 
(CHUL) Research Centre, Canada, 4University of Liège, Belgium, 5Aarhus 
University Hospital, Denmark, 6Amgen Inc., United States, 7UCB Pharma, 
Belgium
Objective: Romosozumab, an anti-sclerostin antibody that increases bone formation 
while decreasing bone resorption, reduces fracture risk within 12 months. Here we evaluate 
the effects of transitioning from denosumab to romosozumab in treatment-naïve patients.
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Materials and Methods: This phase 2 trial (NCT00896532) enrolled postmenopausal wom-
en with a lumbar spine, total hip, or femoral neck T-score <= –2.0 and >= –3.5. Patients 
were randomized to placebo or various doses of romosozumab monthly or every 3 months 
from baseline to month (M) 24, were rerandomized to 12 months of denosumab 60 mg 
every 6 months or placebo (M24–36), and then all were to receive romosozumab 210 mg 
monthly for 12 months (M36–48). Results for the overall population have been previously 
published (McClung et al, J Bone Miner Res 2018; Kendler et al, Osteoporos Int 2019). 
Here we present data from a subset of patients who were randomized to placebo for 24 
months, denosumab (n = 16) or placebo (n = 12) for 12 months, and then romosozumab for 
12 months.Results: In patients who were randomized to placebo followed by denosumab, 
romosozumab treatment for 12 months maintained BMD gained during denosumab treat-
ment at the total hip (mean change from end of denosumab treatment, 0.9%) and further 
increased BMD gains at the lumbar spine (mean change from end of denosumab treatment, 
5.3%) (Table). As expected, P1NP and CTX levels decreased with denosumab. Upon tran-
sition to romosozumab (M36–48), P1NP levels initially increased and gradually returned to 
baseline by M48 while CTX gradually increased to baseline levels.In patients who transi-
tioned to romosozumab after 36 months of placebo, BMD increased at the lumbar spine and 
total hip (Table). P1NP levels initially increased with romosozumab and gradually returned 
to baseline by M48 while median CTX level remained below baseline with romosozumab 
treatment.Conclusions: BMD response in the placebo to romosozumab group was similar to 
that observed in other studies. Transitioning to romosozumab after 12 months of denosumab 
further improves lumbar spine BMD and maintains total hip BMD.
Disclosures: MR McClung, Myovant, Consultant, Amgen Inc., Speakers’ Bureau, Amgen 
Inc., Consultant
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Heterogeneity in the Cortical Response to Abaloparatide and Teriparatide 
in the Proximal Femur by DXA-Based 3D Modeling *Renaud Winzenrieth1, 
Michael S. Ominsky2, Yamei Wang2, Ludovic Humbert1, Richard J. Weiss2. 
1Galgo Medical, Barcelona, Spain, Spain, 2Radius Health, Inc., Waltham, MA, 
United States
Differences in the effects of abaloparatide (ABL) and teriparatide (TPTD) on cortical 
bone density were previously reported based on 3D modeling of proximal femur DXA im-
ages. These changes were further examined in the femur neck (FN), intertrochanteric (IT), 
and shaft (S) subregions to determine heterogeneity and impact on bone strength indices.
Baseline, 6 month (M), and 18 M hip DXA scans from 750 patients, 250 in each group 
(PBO, ABL, TPTD), from the ACTIVE trial were subjected to DXA-based 3D modeling 
(3D-SHAPER v2.10.1, Galgo Medical, Spain). Changes from baseline were calculated 
for each subregion for cortical thickness (Ct.Th), cortical volumetric BMD (Ct.vBMD), 
cross-sectional moment of inertia (CSMI), and section modulus (Z). Regions in the proxi-
mal femur that lost vBMD from baseline during treatment were further evaluated to quantify 
the % of total volume and average vBMD loss. Comparisons to baseline were made using 
paired t-tests; pairwise group comparisons were made for % change from baseline data using 
P-values derived from contrast tests based on an MMRM model.For each subregion at 18 
M, ABL and TPTD similarly increased Ct.Th from baseline (1.4-2.1%; all P<0.05), while 
only ABL significantly increased Ct.vBMD from baseline (1.4-1.8%; all P<0.05). Ct.vB-
MD improvement with ABL was associated with greater increases in the density-weighted 
strength indices CSMI and Z than with TPTD, particularly at the more cortical subregions 
(FN: 7.2-7.7% vs 4.5-5.0%; S: 2.7-3.2% vs 0.4-0.5%, all P<0.001 ABL vs TPTD). Analysis 
of the anatomical distribution of average changes in vBMD revealed areas within the proxi-
mal femur where vBMD decreased at 6 and 18 M, as shown in the Figure. At 6 M, treatment 
with TPTD, and to a lesser extent ABL, resulted in focal declines in vBMD, primarily in 
the cortical shaft. At 18 M, the % volume with vBMD decline was persistent in the TPTD 
group (6.11%) but mostly reversed in the ABL group (0.14%).Both ABL and TPTD resulted 
in increased positive changes in Ct.Th and bone strength indices across the proximal hip 
by DXA-based 3D modeling after 18 M. The greater ABL-mediated increases in Ct.vBMD 
were associated with lesser focal losses than with TPTD, with vBMD losses having resolved 
after 18 M of ABL.  Future research may investigate the mechanisms by which these differ-
ences in cortical vBMD occur and estimate their impact on hip strength.
Disclosures: Renaud Winzenrieth, Galgo Medical, Other Financial or Material Support, 
Radius Health, Consultant
P-644
Geographic Variation in Prevalence of Osteoporosis Diagnosis and 
Utilization of Anti-Osteoporosis Therapies in United States Female Medicare 
Fee-for-Service Beneficiaries with Fragility Fractures *E. Michael Lewiecki1, 
Andrea J. Singer2, Pallavi B. Rane 3, Anne Shah4, Allison Petrilla4, Kris Norris 4, 
Michele McDermott3, Shravanthi R. Gandra3. 1University of New Mexico Health 
Sciences Center, United States, 2MedStar Georgetown University Hospital, 
United States, 3Amgen Inc., United States, 4Avalere Health, United States
Background: There is limited real-world evidence on geographic variation in preva-
lence of fragility fractures among postmenopausal women in the US, and in osteoporosis 
diagnosis or treatment rates in such women.Objective: To describe geographic variations 
in distribution of fragility fractures among female Medicare Fee-for-Service (FFS) benefi-
ciaries at the sub-national level, and to describe osteoporosis diagnosis and treatment rates 
among these women.Methods: This retrospective cohort study utilized the 100% Medicare 
FFS Part A, B, & D claims data. Female beneficiaries aged >=66 years were identified on 
the first occurrence of a fragility fracture of hip, vertebra, or non-hip non-vertebral in the 
hospital or outpatient setting (based on diagnosis and procedure codes on medical claims), 
between Jan 1, 2011 – Dec 31, 2017. Fracture-related measures in the year preceding and 
following fracture included: diagnosis of osteoporosis (medical claim with ICD9/10 diag-
nosis code for age-related or other osteoporosis), use of anti-resorptive or anabolic agents, 
receipt of bone mineral density (BMD) testing, and subsequent fracture events.Results: 
Among the 26,104,783 women who met study eligibility criteria, 1,026,295 (3.9%) had >=1 
fragility fractures (mean[SD] age= 82.2[8.5] years; 91.2% were Caucasian and 38.8% were 
from southern regions, with mean[SD] Charlson comorbidity index score= 1.9[2.3]). The 
most commonly occurring index fracture were hip (38.2%), followed by non-hip non-ver-
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tebral (37.0%), and vertebral (24.8%), with 74.6% of all index fractures reported in a hos-
pital setting. In the 1-year pre-index fracture period, 10.2% of women received a BMD 
test, 15.2% had a diagnosis of osteoporosis, and 17.5% were receiving any anti-resorptive 
or anabolic agents. Despite having sustained fractures, these values increased to 12.8%, 
36.2%, and 20.3%, respectively; and 10.0% of women had a subsequent fragility fracture in 
the 1-year follow-up period. There was geographic variation in different US states for frac-
ture-related measures as described in Table 1; Hawaii had the lowest prevalence of fracture 
and subsequent fracture and the highest utilization of anti-resorptive or anabolic agents.
Conclusion: Osteoporosis is underdiagnosed and undertreated in elderly US women with 
fragility fractures, and geographic variation is observed across different states in the US for 
fragility-fracture related measures.
Disclosures: E. Michael Lewiecki, Amgen Inc., Consultant
P-645
Spaceflight-Induced Osteoporosis in Non-Weight-Bearing Bone and 
Treatment with BP-NELL-PEG *Timothy Liu1, Diana-Beatrix Velicu2, Stella 
Dong2, Luan Tran2, Shahin Setoudeh Maram2, Josiah Low1, Jiayu Shi2, Kang 
Ting2, Chia Soo1, Jin Hee Kwak2. 1David Geffen School of Medicine, University 
of California, Los Angeles, United States, 2School of Dentistry, University of 
California, Los Angeles, United States
Purpose: Spaceflight induces osteoporosis by mechanical unloading. Interestingly, re-
cent studies report that microgravity directly affects osteoblasts (OB) and osteoclasts (OC) in 
vitro, by upregulating OC activity and disrupting the OB cytoskeleton. Non-weight-bearing 
bones, such as those in the temporomandibular joint (TMJ), provide important insight into 
cellular-level effects of microgravity in vivo. NELL-1 is a novel osteogenic growth factor, 
which upon PEGylation (NELL-PEG) demonstrates enhanced pharmacokinetics and prom-
ising potential as a systemic therapy for osteoporosis in mice. To test NELL-PEG systemic 
therapy in spaceflight-induced osteoporosis, we have collaborated with CASIS and NASA 
through the Rodent Research 5 (RR-5) mission. This study is a branch of the RR-5 mission 
and, for the first time, focuses on the TMJ to investigate how space microgravity and NELL-
1-based treatment affect non-load-bearing bones in vivo. Methods: To meet the mission’s 
technical demands, we conjugated NELL-PEG with bioinert bisphosphonate as a bone-tar-
geting molecule (BP-NELL-PEG, or ‘BP-NP’) to enhance NELL-PEG’s pharmacokinetics 
and safety. Eight-month-old female BALB/c mice (n=10/group) were randomly assigned to 
4 groups: (1) Flight + PBS, (2) Flight + BP-NP, (3) Ground + PBS, and (4) Ground + BP-NP. 
Flight and Ground groups were housed in the International Space Station and the Kennedy 
Space Center, FL, respectively, for 9 weeks. Mice received 10mg/kg BP-NP or PBS via 
intraperitoneal injection every 2 weeks. At 9 weeks, TMJ were analyzed with micro-CT 
and histology.  Results: Micro-CT of subchondral bone of mandibular condyle showed in-
creased porosity and decreased bone mineral density in Flight + PBS, compared to Ground + 
PBS. BP-NP treatment showed significantly increased subchondral bone in both Ground and 
Flight groups. Histology revealed significant changes in condylar cartilaginous zones (Fig. 
1). Polymorphic zone thickness was significantly decreased in Flight + PBS compared to 
Ground + PBS. Strikingly, BP-NP treatment showed a 3-fold increase in thickness of the cal-
cified hypertrophic zone in Ground and Flight groups. Treatment also showed an increased 
mature zone thickness in Flight group. Conclusion: Spaceflight induces osteoporotic chang-
es in the TMJ, a non-weight-bearing joint, suggesting that microgravity has direct effects on 
OB and OC. In addition, BP-NP systemic therapy has demonstrated potent chondrogenic and 
osteogenic effects in the TMJ.
Disclosures: Timothy Liu, None
P-646
Estimating Relative Fracture Reduction of Romosozumab versus 
Teriparatide for Postmenopausal Osteoporosis Using Bone Mineral 
Density Outcomes *Benjamin Johnson1, Michael McClung2, Stuart Silverman3, 
Shravanthi Gandra4, Jennifer Timoshanko5, Björn Stollenwerk6. 1Amgen Ltd, 
United Kingdom, 2Oregon Osteoporosis Center, United States, 3Cedars Sinai, 
United States, 4Amgen Inc., United States, 5UCB Pharma Ltd, United Kingdom, 
6Amgen GmbH, Switzerland
Introduction: When modelling the cost-effectiveness of osteoporosis therapies, relative 
treatment efficacy is typically informed by fracture outcomes. However, for the comparison 
of romosozumab versus teriparatide, no direct evidence exists on relative fracture incidence. 
Indirect comparisons of these treatments would require synthesis of studies with substantial 
heterogeneity in trial populations, sequential therapies, and follow-up times. Consequential-
ly, estimates obtained would be prone to uncertainty and bias. Therefore, the aim of this study 
was to use direct bone mineral density (BMD) outcomes for romosozumab versus teriparati-
de to estimate relative risks (RRs) of fracture in postmenopausal women with osteoporosis. 
The approach is justified by the significant linear relationship between percentage total hip 
BMD change from baseline and RRs of hip and vertebral fracture on the log scale shown by 
a meta-regression conducted by the Foundation for the National Institutes of Health (FNIH).
Methods: The STRUCTURE trial provides a 3.4% difference in total hip BMD change from 
baseline at 12 months for romosozumab versus teriparatide in patients previously treated 
with bisphosphonates. This value was translated into RRs of hip, vertebral, and nonvertebral 
fracture using slopes from the FNIH meta-regression. Uncertainty around resulting estimates 
was derived by error propagation. As a sensitivity analysis, BMD efficacy for romosozumab 
versus teriparatide was taken from a phase II trial (2.8% difference in total hip BMD change 
from baseline) to explore outcomes for a treatment-naïve population.Results: In the base 
case, RRs of fracture (with 95% confidence intervals) for romosozumab versus teriparatide 
were 0.75 (0.60 to 0.95), 0.53 (0.37 to 0.76), and 0.90 (0.78 to 1.03) for hip, vertebral, and 
nonvertebral fracture, respectively. The sensitivity analysis using phase II trial data yielded 
RRs of 0.79 (0.64 to 0.97), 0.59 (0.43 to 0.82), and 0.91 (0.81 to 1.03) for hip, vertebral, and 
nonvertebral fracture. Validation of the approach using romosozumab trials reporting both 
BMD and fracture outcomes at 12 months (FRAME, ARCH) showed consistency between 
BMD-predicted and observed RRs of fracture.Conclusion: Results indicate that the BMD 
benefit of romosozumab versus teriparatide translates into clinically meaningful fracture 
reductions for bisphosphonate pre-treated and treatment naïve patients.
Disclosures: Benjamin Johnson, Employee: Amgen, Other Financial or Material Support, 
Amgen, Major Stock Shareholder
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Sequential Therapy with Denosumab After Teriparatide Leads to Large 
Increases in Spine and Hip BMD in Premenopausal Women with Idiopathic 
Osteoporosis (IOP) *Adi Cohen1, Stephanie Shiau2, Mafo Kamanda-Kosseh1, 
Mariana Bucovsky1, John M. Williams1, Sanchita Agarwal1, Robert R. Recker3, 
Joan M. Lappe3, Julie Stubby3, Jennifer Larsen3, Elizabeth Shane1. 1Columbia 
University Irving Medical Center, United States, 2Rutgers School of Public 
Health, United States, 3Creighton University Medical Center, United States
We have previously reported that teriparatide (TPTD; 20 mcg daily for 24 months) is as-
sociated with substantial increases in BMD at the lumbar spine (LS), total hip (TH) and fem-
oral neck (FN) in premenopausal women with IOP (PreMenIOP), all severely affected with 
low trauma vertebral and/or non-vertebral fractures and/or very low BMD.After completing 
TPTD, 33 women enrolled in an open label, FDA-funded phase 2b study of denosumab 
(Dmab; 60mg SC q6M) and 32 completed 12M of Dmab. BMD was measured annually 
and bone turnover markers (BTMs) at baseline, 3, 6 and 12M: osteocalcin (OC), N-terminal 
propeptide of type I procollagen (PINP), C-telopeptide (CTX). On average, these 32 women 
had experienced large BMD increases on TPTD of 14.2+/-8.1% at LS, 5.3+/-4.3% at the TH 
and 5.1+/-5.2% at the FN, while BMD declined by -2.2+/-3.1% at the distal radius (DR; all 
p<0.001). Three were TPTD NonResponders (12M change in LS BMD <0.026g/cm2).After 
12M of Dmab, BMD increased a further 5.2+/-2.6% at the LS, 2.9+/-2.4% at the TH, 3.0+/-
3.8% at the FN (all p<0.001) and 0.9+/-2.5% at the DR (p<0.05). BMD increases on Dmab 
were similar in TPTD-Responders and NonResponders at all sites (p=NS). BTMs decreased 
by 75-80% from baseline by 3M and remained suppressed (Figure). Change in TH BMD at 
12M was inversely related to change in all BTMs at all timepoints (r=-0.44-0.63; p<=0.01 
for all). Change in FN BMD was inversely related to change in OC at 6 and 12M and CTX 
at 6M (r=-0.37-0.38; p200 pg/mL after 6M of Dmab, the 12M BMD response to Dmab did 
not differ from the rest of the group. Increases after 24M of TPTD + 12M of Dmab totaled 
20.1+/-7.5% at the LS, 8.4+/-5.3% at the TH and 8.3+/-6.2% at the FN (all p<0.0001). DR 
remained below baseline by -1.4+/-3.2% (p<0.05).In summary, a 12M course of Dmab after 
a 24M course of TPTD led to further BMD gains in PreMenIOP, even those in whom BMD 
did not increase on TPTD. The substantial gains in TH BMD after 24M of TPTD + 12M of 
Dmab are encouraging, as change in BMD at this site has been recently reported to be the 
strongest predictor of fracture risk reduction in postmenopausal women. We conclude that 
sequential therapy with TPTD followed by Dmab markedly improves spine and hip BMD in 
severely affected premenopausal women with IOP.
Disclosures: Adi Cohen, None
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Hormone therapy reduces the risk of fracture regardless of baseline 
FRAX probability or prior falls – results from the Women’s Health 
Initiative hormone therapy trials *Mattias Lorentzon1, Helena Johansson2, 
Nicholas Harvey3, Enwu Liu4, Liesbeth Vandenput5, Carolyn Crandall6, Eugene 
McCloskey7, John Kanis8. 1Geriatric Medicine, Institute of Medicine, Sahlgrenska 
Academy, University of Gothenburg, Gothenburg, Sweden and Mary McKillop 
Institute for Health Research, Australian Catholic University, Melbourne, 
Australia, Sweden, 2Mary McKillop Institute for Health Research, Australian 
Catholic University, Melbourne, Australia and Centre for Metabolic Bone 
Diseases, University of Sheffield, Sheffield, UK, Australia, 3MRC Lifecourse 
Epidemiology Unit, University of Southampton, Southampton, UK and NIHR 
Southampton Biomedical Research Centre, University of Southampton and 
University Hospital Southampton NHS Foundation Trust, Southampton, UK, 
United Kingdom, 4Mary McKillop Institute for Health Research, Australian 
Catholic University, Melbourne, Australia, Australia, 5Mary McKillop Institute 
for Health Research, Australian Catholic University, Melbourne, Australia and 
Geriatric Medicine, Institute of Medicine, Sahlgrenska Academy, University of 
Gothenburg, Gothenburg, Sweden, Australia, 6Department of Medicine, David 
Geffen School of Medicine at the University of California, Los Angeles, US, 
United States, 7Mellanby Centre for bone research, Department of Oncology 
and Metabolism, University of Sheffield and Centre for Integrated research 
in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research, 
University of Sheffield, Sheffield, UK, United Kingdom, 8Mary McKillop 
Institute for Health Research, Australian Catholic University, Melbourne, 
Australia and Centre for Metabolic Bone Diseases, University of Sheffield, 
Sheffield, UK, Australia
Objective The objective of the present analysis was to determine if the anti-fracture 
efficacy of menopausal hormone therapy (HT) was dependent on baseline falls history or 
FRAX fracture probability in a combined analysis of the two Women’s Health Initiative 
(WHI) HT trials.Material and methods25,389 postmenopausal women aged 50-79 years 
were randomized to receive HT (n=12,739) or matching placebo (n=12,650). At baseline, 
questionnaires were used to collect information on falls history, within the last 12 months, 
and clinical risk factors. FRAX 10-year probability of major osteoporotic fracture (MOF) 
was calculated without BMD. Incident clinical fractures, other than fractures of the skull, 
face, fingers, toes, ribs, sternum, and cervical vertebrae, were verified using medical re-
cords. An extension of Poisson regression was used to investigate the relationship between 
treatment and fractures in 1) the whole cohort; 2) those with prior falls; and 3) those with-
out prior falls. The effect of baseline FRAX probability on efficacy was investigated in the 
whole cohort. ResultsOver 4.3+/-2.1 years (mean+/-SD), in the whole population, HT (vs. 
placebo) significantly reduced the risk of any clinical fracture (Hazard Ratio [HR] 0.72 [95% 
CI, 0.65-0.78]), MOF (HR 0.60 [95% CI, 0.53-0.69]) and hip fracture (0.66 [95% CI, 0.45-
0.96]). Treatment was effective in reducing the risk of any clinical fracture (Figure 1), MOF 
and hip fracture in women regardless of baseline FRAX MOF probability, with no evidence 
of an interaction between HT and FRAX (p>0.30 for the interaction term for all fracture 
outcomes). Similarly, there was no interaction (p>0.30) between HT and prior falls. HT was 
effective in reducing the risk of any clinical fracture and MOF both in those with prior falls 
(any fracture HR 0.74 [95% CI, 0.63-0.85] and MOF HR 0.57 [95% CI, 0.46-0.70]) and 
in those without prior falls (any fracture HR 0.70 [95% CI, 0.62-0.79] and MOF HR 0.62 
[95% CI, 0.53-0.73]).ConclusionsHT reduces fracture risk regardless of FRAX probabili-
ty and falls risk in postmenopausal women. FundingThe National Heart, Lung, and Blood 
Institute, National Institutes of Health, U.S. Department of Health and Human Services 
through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, 
HHSN268201600003C, and HHSN268201600004C. WHI project:3572
Disclosures: Mattias Lorentzon, None
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Efficacy of low dose Denosumab in maintaining bone mineral density 
in postmenopausal women with osteoporosis: a real world, prospective 
observational study *Aliya Khan1, Hajar Abu Alrob1, M’Hiri Iman2, Hosay 
Said1, Romanovschi Mihai2, Sharjil Hussain 2, Heather Zariffeh2, Ismail Hweija1, 
Salman Iqbal 2, Shawn Davison3. 1McMaster University, Canada, 2Bone Research 
and Education Centre, Canada, 3Trilogy Writing & Consulting, Canada
Introduction: Denosumab, a fully human monoclonal antibody to RANK-ligand, has 
been shown to increase bone mineral density (BMD) and reduce the risk of hip, vertebral and 
non-vertebral fractures in postmenopausal women with osteoporosis (1,2). Varying doses of 
denosumab including 30mg/3months have demonstrated a decrease in bone remodelling in 
a dose-dependent manner (3,4,5). The primary objective of this study is to evaluate the effi-
cacy of low dose denosumab (30mg/6 months) in postmenopausal women with osteoporosis 
who are reluctant to consider or continue the full dose of denosumab due to adverse events 
(AE) or concerns of potential AE.Methods: Following informed consent, postmenopausal 
women with a T-score of <= -2.5 at the lumbar spine (LS) or at the total hip (TH) received 
denosumab 30mg/6months. Patients with an additional skeletal disorder, prior fragility frac-
ture, or on oral steroids (daily in the past 12 months) were excluded. The primary endpoint 
was the percent change in BMD at the lumbar spine (LS), total hip (HP), femoral neck (FN) 
and 1/3 radius (1/3R) at 12 months. Secondary outcomes were 1) percent change in BMD 
at the LS, TH, FN, and 1/3R at 24 months and 2) AE.Results: We enrolled 183 patients. The 
mean age was 69 years (SD= 7.07), 80% of patients had a moderate fracture risk (CAROC 
tool), 3% were current smokers and 9% consumed alcohol daily. 14.4% of patients were 
on SSRI/SNRI, 9.6% were on PPI, and no patient was on an aromatase inhibitor. At 12 
months (n=125), the mean BMD significantly increased by +2.0% (95% CI 2.8%-1.3%) at 
the LS (p<0.001). There was no significant change in BMD at the FN, TH, or 1/3R site. At 
24 months (n=65), the percent change in BMD was +3.4% (95% CI 4.8%-2.0%: p<0.001) 
at the LS, +1.5% (95% CI 2.9%-0.15%: p=0.031) at the FN, +1.9% (95% CI 3.5%-0.24%: 
p=0.025) at the 1/3R. There was no significant change in BMD at the TH.Conclusion: Low 
dose denosumab appears to be effective in maintaining BMD in postmenopausal women 
with a moderate fracture risk and may be of benefit in individuals who are experiencing 
side effects or have concerns of side effects. This may also be a potential treatment option 
following 10 yrs of denosumab therapy.
Disclosures: Aliya Khan, Shire, Grant/Research Support, Ultragenyx, Speakers’ Bureau, 
Amgen, Grant/Research Support, Alexion, Grant/Research Support
P-650
Randomized Study to Evaluate a Secondary Prevention Program for 
Women with Osteoporotic Fractures *Cori Blauer-Peterson1, Alon Yehoshua2, 
Maureen Carlyle1, Valery Walker1, Shravanthi Gandra2. 1Optum, United States, 
2Amgen Inc., United States
Purpose: To assess the impact of an intensive outreach program in post-menopausal 
osteoporosis patients (pts) over 3, 6, and 12 months (mos).Methods: Medicare Advantage 
female members (age 67–85y) with pharmacy and medical coverage and evidence of a 
fragility fracture (fx) (index date=date of fx) from 15 Apr 2016–27 Jan 2017 and 23 Oct 
2017–27 Nov 2017 were eligible. Pts had no history of fx 60 days pre-index and continuous 
enrollment 12 mos pre-index. Pts with BMD test during 24 mos pre-index, osteoporosis 
medication 12 mos pre-index, Paget’s, or fxs of finger, toe, and skull were excluded. Ran-
domization was to a current health plan program (standard-of-care [SOC]), or an intensive 
outreach intervention designed to increase post-fx care coordination and communication 
between pts and providers. In addition to SOC, it included an educational mailing to pts, 
post–heel scan follow-up phone calls to pts and providers, and an informational fax and 
phone call to providers. Study endpoints were: 1) composite of DXA monitoring and/or 
osteoporosis medication fill, 2) DXA monitoring, 3) osteoporosis medication fill, and 4) sub-
sequent fxs. Endpoints 1–3 were evaluated at 3, 6, and 12 mos, and endpoint 4 at 12 mos.
Results:The 12-mo follow-up included 3,720 pts (1,847 intervention; 1,873 SOC). Only 98 
(5.3%) pts and 678 (36.7%) providers were eligible for phone outreach and successfully 
contacted. The results were consistent across mos 3, 6, and 12. At 12 mos, the intervention 
group had a statistically significant greater proportion of DXA monitoring and/or osteopo-
rosis medication fill vs. SOC (32.7% vs. 29.5%; p=0.036) and a greater proportion of DXA 
monitoring alone vs. SOC (29.9% vs. 26.1%; p=0.009). No significant differences between 
intervention and SOC were found for medication fill alone (10.5% vs. 10.1%, respectively; 
p=0.759) or subsequent fxs (21.0% vs. 21.7%; p=0.591). The overall osteoporosis medica-
tion fill for all pts was 6.8% within 6 mos and 10.3% within 12 mos. Further, 21.4% of all pts 
experienced an additional fx, and 4.4% experienced multiple fxs.Conclusion: An intensive 
outreach program increased post-fx DXA monitoring vs. SOC, with no differences between 
groups in medication fill or subsequent fxs. Addressing the barriers encountered in this study 
to increase contact with pts and providers may be needed to increase osteoporosis moni-
toring and use of osteoporosis medication and reduce subsequent fxs during post-fx care.
Disclosures: Cori Blauer-Peterson, Optum, Other Financial or Material Support
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A simple-to-use nomogram for identifying individuals at high risk of 
denosumab-associated hypocalcemia in postmenopausal osteoporosis: a 
real-world cohort study *Kyoung Jin Kim1, Namki Hong1, Seunghyun Lee1, 
Yumie Rhee1. 1Department of Internal Medicine, Severance Hospital, Endocrine 
Research Institute, Yonsei University College of Medicine, Republic of Korea
Denosumab, a fully-humanized monoclonal antibody against receptor activator of nu-
clear factor-kappa B ligand (RANKL), has been increasingly prescribed based on its potent 
anti-resorptive action. Although denosumab-associated hypocalcemia was infrequent in pre-
vious randomized trials, data on incidence and risk factors of hypocalcemia in the general 
population is limited. This study was aimed to identify risk factors and develop a helpful 
nomogram for identifying individuals at risk for hypocalcemia after denosumab injection. 
In this retrospective cohort, 790 consecutive female patients received denosumab 60 mg 
between November 2016 and September 2017 were analyzed after excluding patients with 
metastatic cancer, liver cirrhosis, or hypoparathyroidism. Mild hypocalcemia and moderate 
hypocalcemia were defined as albumin-corrected serum calcium levels of <8.5 mg/dL and 
<8.0 mg/dL and observed in 8.2% (65; range 5.4-8.4 mg/dL) and 1.0% (8; range 5.4-7.9 mg/
dL) patients, respectively. The median time to hypocalcemia was 6.3 months (interquar-
tile range 5.3 to 7.4). Patients who developed mild hypocalcemia had lower baseline cCa 
(8.9 vs. 9.3 mg/dL), lower estimated glomerular filtration rate (eGFR; 75.0 vs. 83.2 mL/
min/1.73m2), and more frequent loop diuretics use (10.8% vs. 4.4%; p<0.05 for all). In a 
multivariate model, low baseline cCa (OR 0.78, 95% CI: 0.72-0.84) and chronic kidney 
disease stage 4-5 increased the risk of mild and moderate hypocalcemia (OR 4.27, 95% CI: 
1.55-11.80 and OR 13.56, 95% CI:2.28-80.71, respectively). The use of loop diuretics was 
associated with modest hypocalcemia (OR 2.61, 95% CI: 1.11-6.18 and OR 12.43, 95% 
CI:2.86-54.07) independent of baseline cCa and CKD stage. Based on these three indepen-
dent risk factors, we constructed a nomogram for predicting the probability of denosumab 
induced hypocalcemia in Korean female patients with osteoporosis. A nomogram approach 
identified four risk groups: 1) cCa < 8.5 mg/dL; 2) cCa 8.5-8.9 mg/dL with loop diuretics 
use or 3) with CKD 4-5; 4) cCa 9.0-9.4 mg/dL with CKD 4-5. In conclusion, the incidence 
of moderate hypocalcemia after denosumab injection was low in real world-settings, which 
was reassuring. This simple-to-use nomogram identified high-risk groups for hypocalcemia 
after denosumab treatment in postmenopausal osteoporosis, which may enable the individ-
ualized monitoring strategy.
Disclosures: Kyoung Jin Kim, None
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Bisphosphonate protects cortical bone at key locations of the femur in 
aromatase-inhibitor associated bone loss: a 3D cortical bone mapping study 
*Namki Hong1, Graham Treece2, Kyungjin Kim1, Seunghyun Lee1, Heajeong 
Park1, Yumie Rhee1. 1Yonsei University College of Medicine, Republic of Korea, 
2University of Cambridge, United Kingdom
Aromatase inhibitor treatment in hormone-sensitive breast cancer is associated with 
accelerated bone loss and increased risk of fracture. Bisphosphonates (BP) are the mainstay 
treatment of aromatase inhibitor associated bone loss (AIBL), which might improve femoral 
bone at key locations prone to fracture. To test this hypothesis, we performed 3D cortical 
bone mapping based on QCT scans in postmenopausal women with early breast cancer re-
ceiving aromatase inhibitors. In Severance Hospital early breast cancer cohort, Korea, data 
of subjects who had both baseline and at least one time of follow-up QCT between 2005 
and 2015 were analyzed (BP user, n=93; non-user, n= 203). After excluding BP users with 
low medication persistence (proportion of days covered 0.05 for all). At follow-up, BP use 
prevented AIBL in LSvBMD (+7.2% vs. -3.8%, p<0.001), FNaBMD (+1.3% vs. -2.7%, 
p<0.001), and THaBMD (-0.3% vs. -2.5%, p=0.024). BP had protective effect on cortical 
parameters of femoral bone: estimated cortical thickness (CTh), +3.3% vs. +0.1%, p=0.007; 
cortical mass surface density (CMSD, cortical mass per unit surface area calculated by mul-
tiplying cortical BMD × CTh), +3.4% vs. -0.3%, p<0.001. CMSD increased by up to 15% 
at key locations including superior part of femoral neck and lateral femoral trochanter. BP 
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prevented the thinning of average CTh of femoral neck (-1.4% vs. -6.1%, p<0.001), partic-
ularly at superior anterior quadrant of femoral neck (absolute difference +12.8% vs. non-us-
ers in linear regression model with the adjustment for age and baseline BMD). Compared 
to non-users, BP users had improved cross-sectional moment of inertia (+4.4% vs. -0.7%, 
p=0.001) and less increase in buckling ratio (+1.3% vs. +7.5%, p<0.001). BP use prevented 
cortical bone loss in AIBL at key locations of proximal femur.
Disclosures: Namki Hong, None
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Overcoming the adherence gap through specialized osteological care - Data 
from the DVO Osteoporosis Registry *Christina Westphal1, Lars Joeres2, Tanja 
Heidbrede2, Hans-Christof Schober3, Alexander Defèr4. 1Max-Planck-Institut für 
demografische Forschung, Germany, 2UCB Pharma GmbH, Germany, 3Klinikum 
Südstadt Rostock, Germany, 4Outpatient Centre for bone diseases, Germany
Introduction: Osteoporosis and associated fractures are serious health issues.Even 
though effective therapy options are now available, there are still significant deficits in the 
care of outpatients and compliance to osteoporosis medications has been shown to be poor 
after 2 years (S. Morell 2017; J. Morley, 2019). Moreover, the question if specialized oste-
ological care improves the intake of medication compared to standard care has not yet been 
clarified. This study assessed persistence in patients using osteoporosis medications with-
in the DVO registry, a German patient registry assessing clinical outcomes and reflecting 
specialized care, and in a German-wide prescription database provided by Insight health, 
reflecting standard care.Methods: Selected patients from the DVO registry had at least 2 
observations and documented continuous treatment with the respective drugs. From the 
prescription database, patients with initiation of respective medications (index date) from 
01.01.2017 – 30.06.2017 and with a medication free period of 12 months prior to index 
date were selected. Age and gender matched distribution per respective medication groups 
according to the distribution provided by DVO registry was applied. Persistence was cal-
culated as being still on treatment with the respective drug on month 12 and month 24, 
divided by all patients starting the respective treatment.Results: The DVO registry contains 
data from approx. 17.000 patients, where of 6.346 were selected according to the selection 
parameters. (ALN: 2.698, RIS: 1.548, ZOL: 239, TPD: 30, IBN: 601, DNB:1230). 11.64% 
of patients were male; 88.35% female. Persistence overall after 12/24 months was 98.11% 
and 92.70% respectively. The Insight health prescription dataset covers around 60 million 
patients, which equals to 77% of the German statutory insured population. Of those 96.459 
patients were prescribed with medication according to the selection parameters (ALN: 
46.704, RIS: 14.896, ZOL: 4.451, TPD: 164, IBN: 6.725, DNB: 23.519). 12.76% of patients 
were male; 87.23% female. Persistence overall after 12/24 months was 48.69% and 33.46%, 
respectively.Conclusion: A continuous, specialized osteological care leads to a considerable 
improvement in therapy persistence. 92,7% of patients from the DVO registry still followed 
the prescription after two years. Only 33,46% of patients in standard care did ex aequo to the 
Morley work. Limiting is the lack of diagnosis codes in the prescription database.
Disclosures: Christina Westphal, None
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Clinical Features of 99 Patients with Vertebral and Non-Vertebral Fractures 
after Denosumab Discontinuation: an International Cohort *Elena Gonzalez 
Rodriguez1, Maria Belen Zanchetta2, Pilar Peris3, Elisa Fernández Fernández4, 
Stergios A Polyzos5, Maria Carolina Ballarino2, José Luis Mansur6, Polyzois 
Makras7, Helena Florez3, Pilar Aguado Acin4, Berengere Aubry-Rozier1, 
Athanasios D Anastasilakis8, Olivier Lamy1. 1Center of Bone Diseases, Bone and 
Joint Department, University of Lausanne and Lausanne University Hospital, 
Switzerland, 2Cátedra de Osteología y Metabolismo Mineral, Universidad del 
Salvador, Argentina, 3Department of Rheumatology. Hospital Clinic, University 
of Barcelona, Spain, 4Servicio de Reumatología, Hospital Universitario La 
Paz, Spain, 5First Laboratory of Pharmacology, School of Medicine, Aristotle 
University of Thessaloniki, Greece, 6Centro de Endocrinologia y Osteoporosis 
La Plata, Argentina, 7Department of Endocrinology and Diabetes and Department 
of Medical Research, 251 Hellenic Air Force & VA General Hospital, Greece, 
8Department of Endocrinology, 424 General Military Hospital, Greece
PurposeDenosumab (DMAb) discontinuation (DD) induces an increase of bone turn-
over above baseline for up to 2 years and a loss of the BMD gain, associated with an 1 to 
10% of spontaneous clinical vertebral fractures (SCVF). Risk factors for SCVF and the in-
cidence of other fractures are not known.MethodsBetween Mars 2013 and November 2018, 
99 women were evaluated in 5 international tertiary hospitals because of new fractures at-
tributed to DD. We report the anthropometric, clinical and biological characteristics obtained 
from clinical records.ResultsWomen were 68.7+/-9.0 years and had received 6.6+/-2.7 (2 to 
14) DMAb doses; in 14 cases it was given for aromatase-inhibitor (AI) bone-loss prevention. 
DMAb was mostly omitted (26), delayed (14) or stopped (13) by the patients themselves. 
Ninety-eight women developed SCVF [of which 11 also had non-vertebral fractures (Non-
VF)], and one no SCVF but 4 Non-VF. They had 3.4+/-2.3 (range: 1-13) SCVF, and 2.0+/-
1.4 (range: 1-4) Non-VF, following 11.6+/-4.0 months from the last DMAb injection. At the 
time of SCVF 3 women were under bisphosphonates (BP) for 2 to 14 months, and 1 had a 
DMAb dose 1 month before. Mean serum ß-crosslaps (sCTX) value was 1034+/-564 g/l 
(Normal < 573). Following SCVF, 20 women had 3.4+/-1.8 vertebroplasties, and 6 of them 
presented 1 to 8 new SCVF.In the 2 years prior DMAb initiation, 23 women had received a 
BP, and 10 other anti-osteoporotic agents. From the 47 (47.5%) women with prevalent frac-
tures, 31 had vertebral ones (mean 1.8+/-1.3). During DMAb treatment, 3 women suffered a 
VF and 7 a Non-VF.SCVF number was not associated with treatment in the 2 previous years, 
prevalent or incident fractures, or any T-score value at DMAb initiation or at the time of frac-
tures. SCVF number was inversely correlated with age at DMAb initiation, and at the time 
of fracture, with more SCVF in younger patients (4.2+/-2.8 vs 2.8+/-1.8, 65 years, p=0.004), 
but was not correlated with CTX values at the time of fracture. The higher the number of 
DMAb doses, the higher the CTX at SCVF (R2=0.14, p=0.01), and the shorter the time to 
fracture (R2=0.04, p=0.04). There was no factor associated to Non-VF occurrence.Conclu-
sionFractures occur in patients who discontinue DMAb mostly for non-medical reasons. 
About 10% of patients also develop Non-VF. The number of SCVF is higher in younger pa-
tients, and they occur earlier in patients with longer treatment. A close follow-up for 2 years 
after DD is necessary. Further studies are needed to improve the identification of patients at 
risk for SCVF and the most adequate transition treatment after DD.
Disclosures: Elena Gonzalez Rodriguez, None
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Potential cases of missed hypophosphatasia in an Osteoporosis Clinic? 
Low ALP as a signal for hypophosphatasia *Elisabeth Ng1, Claudia Ashkar1, 
Shoshana Sztal-Mazer1. 1Alfred Health, Australia
Purpose: To evaluate alkaline phosphatase (ALP) levels in patients referred to an Os-
teoporosis Clinic and describe the prevalence of subnormal values which may signal low 
ALP enzymatic activity and, potentially, hypophosphatasia (HPP).Background: HPP is a 
rare condition that can masquerade as osteoporosis. Caused by impaired tissue-non-specific 
alkaline phosphatase (TNSALP) production, it can manifest at any age with varying clinical 
severity and can be mild in adults such that it evades suspicion. Fragility fractures and low 
bone mineral density are common to both adult HPP and osteoporosis, hence HPP can be 
misdiagnosed as the latter, more prevalent condition. The risk of this is use of bisphospho-
nate therapy, which is first line in osteoporosis but harmful in HPP due to the effect of excess 
pyrophosphate in the setting of ALP deficiency, which can further inactivate TNSALP and 
impair mineralization, posing a heightened fracture risk. Furthermore, atypical femoral frac-
tures, a hallmark of adult HPP, can occur in long term bisphosphonate therapy, confounding 
the misdiagnosis. Diagnosis is confirmed with DNA sequencing, but reduced ALP enzymatic 
activity can be a clue to potential underlying HPP.Methods: We retrospectively audited all 
adult patients seen in the Osteoporosis Clinic of a metropolitan tertiary center from its incep-
tion in 2012 up until 2020. Pathology results from 2008 onwards were reviewed and clinical 
notes interrogated in those with an ALP level below the lower limit of normal, 30 IU/L.
Results: 1866 patients were identified, and 27 excluded due to no recorded ALP level (see 
Figure 1). 168 patients (9.1%) had an ALP level < 30 IU/L, with the median number of tests 
per patient being 76. 158 of these patients (94%) had at least 20 ALP tests, with a median 
ALP of 56 IU/L. Seven (4.2%) patients had over 50% of their ALP levels < 30 IU/L, with the 
median ALP in this group being 25 IU/L. Two had already undergone ALPL genetic testing 
confirming a pathogenic variant. The other five patients will receive further workup for HPP. 
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We also evaluated circumstances surrounding transiently low ALP values.Conclusion: Adult 
HPP should not be forgotten as a differential diagnosis in those presenting with fractures and 
osteoporosis. We highlight the value of testing and analyzing the ALP level in individuals 
referred for osteoporosis management to ensure consideration of HPP before antiresorptive 
therapy is initiated.
Disclosures: Elisabeth Ng, None
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KER-012, A NOVEL ACTIVIN RECEPTOR TYPE II LIGAND TRAP 
INCREASES BONE IN MICE VIA A UNIQUE MECHANISM OF 
ACTION *Keith Babbs1, Christopher Materna1, ffolliott Fisher1, Jasbir Seehra1, 
Jennifer Lachey1. 1Keros Therapeutics, United States
Osteoporosis is a bone disorder affecting over 200 million people worldwide and is 
characterized by low bone mineral density, reduced bone strength, deterioration of bone, 
and high risk of bone fracture leading to increased mortality. TGFß superfamily ligands, 
including activin A and B, are negative regulators of bone remodeling suppressing bone 
growth. KER-012 is a modified Activin receptor II ligand trap designed to bind and inhibit 
activins and SMAD 2/3 signaling. Our aims were to test the efficacy of KER-012 in increas-
ing bone and to investigate the mechanism of action of KER-012 in mice. To investigate the 
mechanism of KER-012’s effects, adult male mice (n=10/grp) were administered 20 mg/
kg KER-012 or vehicle (VEH) twice weekly for 5 weeks. Ex vivo analysis demonstrated 
that, relative to VEH-dosed mice, KER-012-dosed mice had 82.0% greater bone volume 
(p<0.001), 28.8% higher bone volume fraction (p<0.001), and 33.5% greater trabecular 
number (p<0.01). Additionally, in KER-012 treated mice, relative to VEH, we observed 
reductions in trabecular eroded surface ratio (-42.2%; p<0.001) and osteoclast number 
(-45.8%; p<0.01), as well as increased mineralizing surface (+63.4%; p<0.01), mineral ap-
position rate (+29.9%; p<0.05), and bone formation rate (+107.7%; p<0.01), suggesting at-
tenuated catabolism and enhanced anabolism. Together, these results suggest that KER-012 
potentially acts through a differentiated mechanism to increase bone in mice by reducing 
bone resorption and enhancing formation. This suggests that KER-012 could potentially 
treat conditions resulting in bone loss.
Disclosures: Keith Babbs, Keros Therapeutics, Grant/Research Support
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Sclerostin loop3: a potential target for developing a next generation 
sclerostin inhibitor for bone anabolic therapy with low cardiovascular 
concern *Yuanyuan Yu1, Luyao Wang2, Shuaijian Ni1, Zhenjian Zhuo3, Hang 
Yin Chu4, Ning Zhang3, Dijie Li1, Jin Liu1, Aiping Lyu1, Bao Ting Zhang3, Ge 
Zhang1. 1Law Sau Fai Institute for Advancing Translational Medicine in Bone 
and Joint Diseases (TMBJ), School of Chinese Medicine, Hong Kong Baptist 
University, Hong Kong, 2Guangdong-Hong Kong-Macao Greater Bay Area 
International Research Platform for Aptamer-based Translational Medcine and 
Drug Discovery, Hong Kong, 3School of Chinese Medicine, Faculty of Medicine, 
The Chinese University of Hong Kong, Hong Kong, 4Aptacure Therapeutics 
Limited, Hong Kong
Sclerostin is an antagonist of bone anabolic Wnt signaling pathway. Antibody against 
sclerostin for postmenopausal osteoporosis has been approved by US FDA, with a boxed 
warning for potential cardiovascular risk. Therefore, it is desirable to develop a next gener-
ation sclerostin inhibitor with low cardiovascular concern.Sclerostin has a protective role in 
cardiovascular system by inhibiting the proinflammatory cytokines to prevent aortic aneu-
rysm and atherosclerosis development in ApoE-/- mice induced by angiotensin II (AngII). 
Sclerostin has three loops within its central region. We found sclerostin regulated skeletal 
and cardiovascular system via different loops (Fig 1a). Loop2 and/or loop3 played important 
roles in inhibiting Wnt signaling and osteogenic potential in MC3T3-E1 cells (Fig 1b). Either 
loop2&3 deficiency by genetic truncation or loop2&3 inhibition by sclerostin antibody could 
attenuate the suppression effects of sclerostin on the expression of inflammatory cytokines 
and chemokines in macrophages and VSMCs, whereas loop3 deficiency by genetic trunca-
tion maintained the above suppression effects of sclerostin in macrophages and VSMCs with 
AngII infusion in vitro (Fig 1c&d). Therefore, we hypothesized that specifically targeting 
sclerostin loop3 could promote bone formation and maintain sclerostin loop3-independent 
cardiovascular protective effect. We have tailored screened an ssDNA aptamer aptscl56 
which selectively targeting human sclerostin loop3 by using full length sclerostin as the 
positive target, and loop3 deficient sclerostin as the negative target (Fig 2). The aptamer had 
a high inhibition effect to sclerostin’s antagonistic effect on Wnt signaling in vitro, but had 
no effect on the expression of inflammatory cytokines and chemokines in macrophages and 
VSMCs, with AngII infusion in vitro (Fig 1&2). Furthermore, by mutation studies, we found 
residues R114, Q116, R117, V118, Q119, E126, P128, K132, V133, and R134 on sclerostin 
loop3 were the functional sites in antagonizing Wnt signaling.Residues D111, R112, Y113, 
L120, L121 and C122 on loop3, and nucleotides T13C14G15, C23T24T25 and T30G31G32 
on the aptamer could be the binding sites between sclerostin and the aptamer. This study 
could help to understand the functional mechanism of sclerostin and provide a strong basis 
for the development of the next generation sclerostin inhibitor specifically targeting loop3 to 
promote bone formation with a low cardiovascular concern.
Disclosures: Yuanyuan Yu, None
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Six-month Study of Early Clinical Effects and Drug Interactions in 
Romosozumab Treatment *Ayako Tominaga1, Keiji Wada1, Ken Okazaki1, 
Yoshiharu Kato2. 1Tokyo Women’s Medical University, Japan, 2Kita Shinagawa 
3rd Hospital, Japan
Purpose: Romosozumab first appeared as a new osteoporosis medication in Japan in 
2019. This drug is an anti-sclerostin antibody that increases bone formation and suppresses 
bone resorption. We aimed to assess its actual clinical effects and whether other anti-oste-
oporosis pre-treatments affect romosozumab treatment.Methods: We analyzed 185 patients 
treated with romosozumab for six months. We measured bone mineral density (BMD) be-
fore and after six months of romosozumab treatment. We also performed blood tests before 
romosozumab treatment and after one, three, and six months. We set tartrate-resistant acid 
phosphatase 5b (TRACP-5b) as the bone resorption marker and type ? procollagen N-ter-
minal propeptide (P1NP) as the bone formation marker. We grouped patients according to 
anti-osteoporosis treatment before romosozumab, as follows: non pre-treatment group (Non, 
n = 71), change from Teriparatide group (TPD, n = 35), change from denosumab G1 group 
(DMAB G1, n = 13), change from denosumab G2 group (DMAB G2, n = 21), and change 
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from bisphosphonate group (BIS, n = 39). As denosumab is a long-acting drug, we named 
the group that started romosozumab within three months after using denosumab for G1 and 
the group that started after four months for G2.Results: There were no new fractures during 
treatment. As the percent changes in spine and total hip BMD from the baseline were 6.34% 
and 1.53% after six months of treatment (Figure 1A), this treatment was effective on spine 
osteoporosis. In terms of spine BMD with pre-treatment, all groups showed a therapeutic 
effect that was higher than the least significant change. Compared with the anabolic windows 
provided by bone resorption and formation markers (Figure 1B–F), the anabolic windows 
in the Non and TPD group were closed after six months of treatment with romosozumab, 
whereas in the DMAB G1 and BIS groups, the windows remained open after six months of 
treatment. DMAB G2 had a much narrower anabolic window than did other groups.Conclu-
sion: Romosozumab was effective in preventing fractures and useful for increasing spine 
BMD. At present, no significant difference in spine BMD was observed, but the anabolic 
window had characteristic movements for each anti-osteoporosis pre-treatment before romo-
sozumab treatment. The effect may be diminished if romosozumab is started more than four 
months after the last denosumab treatment.
Disclosures: Ayako Tominaga, None
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Comparison of the therapeutic effects of teriparatide and denosumb in 
distributing lumbar spine bone mineral density: Differing effects using 
QCT and finite element analysis *Soji Tani1, Koji Ishikawa1, Koki Tsuchiya1, 
Takako Negishi-Koga1, Takashi Nagai1, Tomoaki Toyone1, Katsunori Inagaki1. 
1Department of Orthopaedic Surgery, Showa University School of Medicine, 
Japan
IntroductionTeriparatide and denosumab are promising treatments for patients with 
osteoporosis who have a high risk of fractures. The anabolic agent teriparatide stimulates 
osteoblasts while denosumab targets osteoclast-mediated bone resorption. Despite these 
drugs having opposite effects on the bone, their effects on fracture reduction of the lumbar 
spine are equal.The aim of this study was to determine the effects of osteoporosis medica-
tions teriparatide and denosumab on the distribution of lumbar spine bone density.MethodIn 
this study, we retrospectively analyzed with postmenopausal osteoporosis who were initially 
treated with either teriparatide (n = 14) or denosumab (n = 14). Between the two groups, 
the mean age, mean lumbar spine bone mineral density (LS-BMD) at baseline, and mean 
percent change of LS-BMD after treatment were compares. At baseline and at 12 months, 
we divided the lumbar body into eight sections and measured the volumetric BMD (vBMD) 
using quantitative computed tomography. The compression forces of the lumbar vertebrae 
were also measured using computed tomography-based finite element analysis.ResultIn the 
teriparatide group, the vBMD was significantly increased in all sections of the vertebral 
body. In contrast, in the denosumab group, limited sections of the vBMD were increased. 
The percent change of vBMD at the vertebral body was greater in the teriparatide group than 
in the denosumab group. However, the compression forces of both groups were significantly 
increased. No significant difference was noted between two groups.ConclusionThe present 
study revealed that teriparatide was more effective on the trabecular bone than was denosum-
ab. Both treatments, however, reduced the risk of vertebral fractures. These results suggested 
that the effect of fracture prevention was different for teriparatide and denosumab.
Disclosures: Soji Tani, None
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Romosozumab Treatment Lowers The Incidence Of New Vertebral 
Fractures Across All Fracture Severity Grades Among Postmenopausal 
Women With Osteoporosis *Robert Feldman1, Piet Geusens2, Mary Oates3, 
Thierry Thomas4, Polyzois Makras5, Franz Jakob6, Bente Langdahl7, Wenjing 
Yang3, Maria Rojeski3, Cesar Libanati8. 1Senior Clinical Trials, Inc, United 
States, 2Maastricht University Medical Center, Netherlands, 3Amgen Inc., 
United States, 4Department of Rheumatology, Hôpital Nord, CHU Saint-Etienne, 
France, 5Department of Endocrinology & Diabetes, 251 Hellenic Air Force 
General Hospital, Greece, 6University of Würzburg, Germany, 7The Department 
of Endocrinology and Diabetes, Aarhus University Hospital, Denmark, 8UCB, 
Belgium
Vertebral fractures (VFx) are the most common fracture in postmenopausal osteopo-
rosis (PMO), carry the highest subsequent fracture rate of fragility fractures, and are asso-
ciated with significant morbidity regardless of severity. Genant grading classifies VFx as 
mild (grade 1), moderate (grade 2), or severe (grade 3), based on the degree of compression 
visible on spinal x-rays. Here, we assessed the incidence of new VFx by Genant grading in 
the romosozumab (Romo) vs placebo (Pbo) or alendronate (ALN) arms of the FRAME and 
ARCH studies, respectively.In FRAME, 7180 women with PMO were randomized 1:1 to 
Romo 210mg or Pbo SC QM (12 months) followed by denosumab (DMAb) 60mg Q6M 
(Romo→DMAb or Pbo→DMAb) (12 months). In ARCH, 4093 women with PMO and >=1 
fracture were randomized 1:1 to Romo 210mg QM or ALN 70mg PO QW (12 months) 
followed by ALN 70mg PO QW (Romo→ALN or ALN→ALN) (>=12 months). In both 
studies, lateral spinal radiographs were assessed by Genant grading for the presence and 
severity of VFx at baseline,12, and 24 months post-treatment.In both studies, incidence of 
new VFx was significantly lower among patients who received Romo. Over 12 months, 
incidence of new VFx was 0.5% Romo vs 1.8% Pbo (P<0.001) in FRAME and 3.2% Romo 
vs 5.0% ALN (P=0.008) in ARCH. Over 24 months, incidence of new VFx was 0.6% Ro-
mo→DMAb vs 2.5% Pbo→DMAb (P<0.001) in FRAME and 4.1% Romo→ALN vs 8.0% 
ALN→ALN (P<0.001) in ARCH. Fewer new VFx were observed in the Romo arm of both 
studies across severity grades. In FRAME, incidence of mild VFx was 0.2% Romo vs 0.4% 
Pbo (12 months) and 0.2% Romo→DMAb vs 0.6% Pbo→DMAb (24 months); incidence 
of moderate VFx was 0.1% Romo vs 0.9% Pbo (12 months) and 0.2% Romo→DMAb vs 
1.4% Pbo→DMAb (24 months); and incidence of severe VFx was 0.2% Romo vs 0.5% 
Pbo (12 months) and 0.2% Romo→DMAb vs 0.6% Pbo→DMAb (24 months). In ARCH, 
incidence of mild VFx was 0.5% Romo vs 1.0% ALN (12 months) and 0.4% Romo→ALN 
vs 1.4% ALN→ALN (24 months); incidence of moderate VFx was 1.3% Romo vs 2.1% 
ALN (12 months) and 1.8% Romo→ALN vs 3.4% ALN→ALN (24 months); and incidence 
of severe VFx was 1.5% Romo vs 1.9% ALN (12 months) and 1.9% Romo→ALN vs 3.3% 
ALN→ALN (24 months). Thus, Romo administered over 12 months to women with PMO 
resulted in VFx reduction across severity grades compared with Pbo and standard-of-care 
ALN. This effect continued after transitioning to an antiresorptive agent. These data may 
foster treatment decisions in postmenopausal women at high risk for VFx.
Disclosures: Robert Feldman, Amgen, Biogen, AB Biogenesis, GSK, TTP, Grant/Research 
Support, Amgen, Consultant, Amgen, Other Financial or Material Support, Amgen, Merck, 
Speakers’ Bureau
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Smad4-dependent transforming growth factor-β family signaling regulates 
the differentiation of dental epithelial cells in adult mouse incisors *Aiko 
Machiya1, Sho Tsukamoto2, Satoshi Ohte3, Mai Kuratani2, Naoto Suda4, 
Takenobu Katagiri2. 1Division of Oral Rehabilitation of Sciences, Department of 
Restorative and Biomaterials Sciences, Meikai University School of Dentistry, 
Japan, 2Division of Biomedical Sciences, Research Center for Genomic 
Medicine, Saitama Medical University, Japan, 3Microbial Chemistry Laboratory, 
Graduate School of Pharmaceutical Sciences, Kitasato University, Japan, 
4Division of Orthodontics, Department of Human Development and Fostering, 
Meikai University School of Dentistry, Japan
Teeth consist of two major tissues, enamel and dentin, which are formed during devel-
opment by epithelial and mesenchymal cells, respectively. Rodent incisors are useful exper-
imental models for studying the molecular mechanisms of tooth formation because they are 
simultaneously growing in not only embryos but also adults. Members of the transforming 
growth factor-β (TGF-β) family regulate epithelial-mesenchymal interactions through an es-
sential coactivator, Smad4. In the present study, we established Smad4 conditional knockout 
(cKO) mice and examined phenotypes in adult incisors. Smad4 cKO mice died with severe 
anemia within one month. Phosphorylated Smad1/5/9 and Smad2/3 were detected in epi-
thelial cells in both control and Smad4 cKO mice. Disorganized and hypoplastic epithelial 
cells, such as ameloblasts, were observed in Smad4 cKO mice. Moreover, alkaline phospha-
tase expression and iron accumulation were reduced in dental epithelial cells in Smad4 cKO 
mice. These findings suggest that TGF-β family signaling through Smad4 is required for the 
differentiation and functions of dental epithelial cells in adult mouse incisors.
Disclosures: Aiko Machiya, None
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Effects of Denosumab, Alendronate, or Denosumab after Alendronate on 
Humeral Bone Mineral Density and Finite Element Predicted Strength 
in Ovariectomized Cynomolgus Monkeys *Ifaz Haider1, Paul Kostenuik2, 
Steven Boyd1, W. Brent Edwards1. 1University of Calgary, Canada, 2Amgen Inc; 
University of Michigan (Adjunct), United States
Proximal humeral fragility fractures are common in older women with postmenopausal 
osteoporosis (PMO) and are associated with high health care costs, disability, and a reduction 
in perceived health status1,2. Denosumab was recently shown to reduce the rate of humeral 
fractures in this population3. Several studies show that denosumab increases radius BMD 
in postmenopausal women who are treatment-naïve or transitioning from bisphosphonate 
therapy, but there are no human or nonclinical data on the effects of denosumab on humeral 
BMD. We therefore assessed BMD in harvested humeri from ovariectomized cynomolgus 
monkeys after 12 monthly injections of s.c. vehicle (VEH; n = 10), s.c. denosumab (DMAb; 
25 mg/kg, n  = 9), or the bisphosphonate alendronate i.v. (ALN; 50 μg/kg, n = 10). Other 
groups received 6 months of VEH followed by 6 months of DMAb (VEH-DMAb; n = 7) or 
6 months of ALN followed by 6 months of DMAb (ALN-DMAb; n = 9). Harvested humeri 
were imaged with computed tomography (CT) to quantify integral, trabecular, and cortical 
bone mineral density (Int.vBMD, Tb.vBMD, Ct.vBMD) at the ultra-proximal and proximal 
regions and Ct.vBMD at the 1/5 proximal and midshaft regions, as defined by fixed per-
centages of humeral length (Fig). CT-based finite element (FE) models were used to predict 
stiffness and strength in axial compression, torsion, and 3-point bending. Bone was mod-
eled as an elastic perfectly-plastic, transversely isotropic material, with elastic moduli based 
on apparent density. Ct.vBMD at the ultra-proximal region was significantly higher with 
DMAb and ALN-DMAb vs. VEH (p <= 0.014; Fig). Ct.vBMD at the 1/5 proximal, region 
and midshaft were higher in all active treatment groups vs. VEH (p <= 0.011). There were 
no significant between-group differences for ultra-proximal and proximal Int.vBMD and 
Tb.vBMD. FE predictions of stiffness and strength were not significantly different between 
groups (Fig). In summary, antiresorptive treatments were associated with higher Ct.vBMD 
in most humeral regions, and 12 months of denosumab or 6 months of denosumab after 6 
months of alendronate was associated with higher Ct.vBMD in all humeral regions. These 
findings support the hypothesis that BMD gains in the humeral cortex contribute to reduced 
humeral fracture rates in denosumab-treated women with PMO3.1. van Eck, Ann Joint 2019; 
2. Calvo, J Shoulder Elbow Surg 2011; 3. Bilezikian Osteoporos Int 2019.
Disclosures: Ifaz Haider, Amgen, Grant/Research Support
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Probability of Achieving T-scores Goals Above -2.5 With Alendronate 
or Romosozumab Followed by Alendronate or Denosumab *Steven 
Cummings1, Cesar Libanati2, Celeste Hamilton3, Zhigang Yu3, Wenjing Yang3, 
Serge Ferrari4, Jens-Erik Beck Jensen5, Pilar Peris Bernal6, Francesco Bertoldo7, 
Eric Lespessailles8, Eric Hesse9, Felicia Cosman10. 1San Francisco Coordinating 
Center, United States, 2UCB Pharma, Belgium, 3Amgen Inc., United States, 
4Geneva University Hospital, Switzerland, 5Copenhagen University Hospital, 
Denmark, 6University of Barcelona, Spain, 7University of Verona, Italy, 
8Centre Hospitalier Régional d’Orléans, France, 9University Hospital, Ludwig-
Maximilians-University, Germany, 10Columbia University, United States
Background: Increases in bone mineral density (BMD) reduce fracture risk in patients 
receiving treatment for osteoporosis. Goal-directed Treatment (also called ‘Treat-to-Tar-
get’) recommends that selection of initial treatment (anti-resorptive agent or bone-forming 
agent) for patients with a T-score <−2.5 should be based on the probability of achieving a 
goal BMD T-score >=−2.5.Objective: To compare the probability of achieving a T-score of 
>=−2.5 at the total hip or lumbar spine after 3 years of treatment with alendronate (ALN) 
only; or the treatment sequences of 12 months of romosozumab (ROMO) followed by 2 
years of ALN (ROMO/ALN) or denosumab (ROMO/DMAB).Methods: Female participants 
in the ARCH trial received ALN for 3 years or ROMO for 1 year followed by ALN for 
2 years. Those in the FRAME trial received ROMO for 1 year followed by DMAB for 
2 years. For participants with initial BMD T-scores <–2.5 at total hip or spine, we calcu-
lated the probability of achieving a T-score >=–2.5 with the three treatments.Results: The 
probabilities of achieving a T-score >=–2.5 depended on baseline T-score and treatment. At 
year 3, those with baseline spine T-scores of >=–3.0 had a >=55.3% probability with ALN, 
>=80.7% with ROMO/ALN and >=92.8% with ROMO/DMAB. Participants with a spine 
T-score of –3.5 had a 11.2% probability with ALN, 46.3% with ROMO/ALN, and 68.1% 
with ROMO/DMAB. The probabilities of reaching a T-score >=–2.5 were lower for the total 
hip but trended similarly by treatment sequence. While >=50% of participants with an initial 
T-score of >=–2.7 achieved a T-score >=–2.5 with any of the treatments at both sites, those 
with a hip T-score of >=–3.0 had a >=10.2% probability with ALN, >=39.2% with ROMO/
ALN, and >=62.1% with ROMO/DMAB. Participants with a total hip T-score of –3.5 had a 
very low probability of reaching a T-score >=–2.5 after 3 years of any treatment.Conclusion: 
Women with a baseline T-score >=–3.0 at the spine or >=–2.7 at the hip have at least a 50% 
chance to achieve a T-score >=–2.5 with any of the three regimens. In contrast, those with a 
T-score below –3.0 at the spine, or –2.7 to –3.5 at the total hip, have a substantially greater 
probability of achieving T-scores >=–2.5 when using a bone-forming agent first (i.e. ROMO/
ALN or ROMO/DMAB vs. ALN alone). Those with hip T-scores <=–3.5 may require more 
than 3 years of treatment that continues to improve BMD. These probabilities should be 
considered when selecting initial treatment.
Disclosures: Steven Cummings, Amgen, Radius, Myovant, Consultant, Amgen, Grant/
Research Support
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The Effect of Teriparatide Treatment on the Risk of Clinical 
Fragility Fractures in Postmenopausal Women with Osteoporosis: Results 
from the Asian and Latin America Fracture Observational Study 
(ALAFOS) *Huilin Yang1, Nadia Al Ali2, Lale Altan3, Joao Borges4, Alan 
Brnabic15, Noemi Casas6, Chung-Hwan Chen7, Abdulaziz Elsalmawy8, Sirel 
Gurbuz15, Sophia Ish-Shalom10, Seung-Jae Lim11, Fernando Marin15, Thomas 
Moll15, Imre Pavo15, Sandra Florez15. 1Department of Orthopedics, The First 
Affiliated Hospital of Soochow University, Suzhou, People’s Republic of 
China, China, 2Endocrinology Unit, Amiri Hospital, MOH, Kuwait, Kuwait, 
3Department of Physical Medicine and Rehabilitation, Uludağ University 
School of Medicine, Bursa, Turkey, Turkey, 4Faculty of Medicine, Universidade 
Católica de Brasília, Brasilia, Brazil, Brazil, 15Eli Lilly and Company, Australia, 
6Riesgo de Fractura CAYRE, Bogotá, Colombia, Colombia, 7Department of 
Orthopedics and Orthopedic Research Center, Kaohsiung Municipal Ta-Tung 
Hospital and Kaohsiung Medical University Hospital, College of Medicine, 
Kaohsiung Medical University, Kaohsiung City, Taiwan, Taiwan, Province of 
China, 8Department of Trauma and Orthopedic Surgery, Al Noor Specialized 
Hospital, Makkah, Saudi Arabia, Saudi Arabia, 15Eli Lilly and Company, United 
States, 10Lin Endocrine Research Center, Haifa, Israel, Israel, 11Department 
of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University 
School of Medicine, Seoul, South Korea, Republic of Korea, 15Eli Lilly and 
Company, Spain, 15Eli Lilly and Company, Switzerland, 15Eli Lilly and Company, 
Austria, 15Eli Lilly and Company, Colombia
Purpose: To evaluate new clinical vertebral and nonvertebral fragility fractures in rela-
tion to time on teriparatide therapy, up to 24 months, in real-world clinical practice. Meth-
ods: Prospective, site-based, observational study in postmenopausal women with osteoporo-
sis from 20 countries across Asia, Latin America, the Middle East, and Russia. Teriparatide 
was initiated according to local prescription practices. Fractures were collected at each fol-
low-up visit. Generalized linear models, adjusted for clinically relevant baseline covariates, 
were used to assess the rate of patients with one or multiple fractures over 6-month intervals. 
Odds ratios (OR), incident rate ratios (IRR), and 95% confidence intervals (95% CI) are 
presented.Results: In total, 3098 postmenopausal patients (mean [SD] age 72.4 [10.4] years) 
recruited at 152 sites were analyzed. At baseline, 63.2% had at least one pre-existing osteo-
porotic fracture, with 28.8% having >=2. Mean (SD) bone mineral density T-scores at base-
line were -3.07 (1.39) and -2.59 (1.05) at the lumbar spine and femoral neck, respectively. 
For those 3054 patients who started teriparatide therapy, median treatment duration was 18.7 
months, and treatment adherence at 12, 18 and 24 months was 68.2%, 53.5% and 31.0%, 
respectively. Over the 24-months, 111 patients (3.6%) sustained 126 clinical fractures (2.98 
fractures/100 patient-years; 39 vertebral and 87 nonvertebral, including 25 hip fractures). Of 
these 111 patients, 97 sustained a single fracture while 13 patients sustained 2 fractures and 
1 patient 3 fractures. In the adjusted analyses, compared with the first 6-month treatment 
period, the rate of new clinical fragility fractures decreased by 37% (IRR 0.63; 95% CI: 
0.40-0.99; p=0.0434), 64% (IRR 0.36; 95% CI: 0.20-0.65; p6-12, >12-18 and >18-24-month 
treatment periods, respectively. After adjustments, odds of first fracture was also statistically 
significantly reduced at every time period compared with the first 6 months (Table 1). Simi-
lar results were obtained in the unadjusted analyses.  Conclusions: Results from this observa-
tional study suggest that postmenopausal women with osteoporosis, treated with teriparatide 
up to 24 months in standard clinical practice across a broad geographic area, experience a 
greater reduction of osteoporotic fractures over time.
Disclosures: Huilin Yang, None
P-665
Dual-target effect of tanshinone IIA sulphate on osteoclast-osteoblast 
activity: A time-lapse study *PREETY PANWAR1, Jean-Marie Delaisse2, 
Kent Soe2, Dieter Bromme1. 1UBC, Canada, 2University of Southern Denmark, 
Denmark
Bone homeostasis is maintained by osteoclasts (OCs) and osteoblasts (OBs) in a cou-
pling process. In this study, we used specific markers and time-lapse analyses to monitor 
the action of antiresorptive and anabolic compounds. OCs were generated from human 
CD14+ peripheral blood monocytes, while OBs were outgrowths obtained from human 
trabecular bone specimens. We compared the efficacy of bisphosphonate (zoledronic acid) 
(BP), odanacatib (ODN, active site cathepsin K inhibitor), tanshinone IIA sulphate (T06, 
ectosteric cathepsin K inhibitor), and cladrin (anabolic compound) in in-vitro cell assays. 
In accordance with OC mono culture time-lapse results, we found under control conditions 
elongated trenches generated by OCs moving rapidly over the bone surface while resorbing. 
However, clusters of small round pits reflecting intermittent bone resorption were observed 
during T06 and ODN treatments. Bisphosphonate abolished the resorption by targeting OCs, 
however, cladrin showed only minor effect on resorption by interrupting the formation of 
longer trenches. More interestingly, in co-culture between OCs and OBs, BP, T06, and ODN 
significantly reduced the release of the cathepsin K-specific collagen type I degradation 
marker, CTx1, but only T06 and cladrin enhanced the deposition of mineralized matrix as 
seen by EDX analysis and corroborated by increased alkaline phosphatase (ALP) activity in 
OBs. In addition, time-lapse results of human OC/OB co-cultures revealed a higher affinity 
of OBs towards pits compared to trenches. Here, significantly more OBs approached the 
pits and occupied these cavities for longer periods of time under T06 treatment when com-
pared to their length of stay in trenches under untreated conditions where rapid migration of 
OBs was common. Immunofluorescence microscopy analysis of OC and OB morphology in 
terms of nuclei, actin fibres and actin-ring formation was not changed during T06 treatment. 
In conclusion, T06 showed both antiresorptive and anabolic properties and is acting as a 
dual-targeting compound and may represent a novel and more effective approach to treat 
osteoporosis.
Disclosures: PREETY PANWAR, None
P-666
The Case for Limiting Teriparatide Treatment to One Year *Clay Larkin1, 
Florence Lima1, Margaret Lund1, Madhumathi Rao1. 1University of Kentucky, 
United States
Background: Treatment with anabolic agents such as teriparatide is generally recom-
mended for 18-24 months, and not to exceed the latter. However, emerging data suggests 
that the maximal effect on bone formation is seen in the first year. In this study we compared 
the effect of teriparatide in the first and second years of treatment on bone density (BMD), 
trabecular bone scores (TBS) and bone turnover markers (BTM) - serum levels of bone spe-
cific alkaline phosphatase, n-telopeptide and osteocalcin, to assess the incremental value of 
the second year of treatment vs risk of forearm bone loss. Patients and methods: We studied 
117 patients receiving teriparatide for treatment of osteoporosis who underwent serial bone 
density measurements of the axial skeleton, as well as forearm measurements. Time trends 
of BMD and BTM changes were analyzed using repeated measures ANOVA. Results: The 
mean age of patients at onset of therapy was 62+/-11 years and 84 % were female. Lumbar 
spine (LS) BMD increased by 7.1%, forearm BMD declined by 4.4%, (p<0.01 for both) and 
TBS did not change significantly during treatment. The increase in LS BMD was signifi-
cantly higher during year 1 than year 2 (p=0.03); the decline in forearm BMD did not differ 
significantly between years 1 and 2 of treatment (p=0.11) (figure 1). BMD did not change 
significantly at other axial sites. All three BTMs showed a uniform increase over the first 
year with either decline or plateau in the second year, despite continued treatment with teri-
paratide (p value for interaction <0.05) (figure 1). Conclusions: Teriparatide induces gains 
in axial BMD that are maximal in the first year with non-significant incremental value in the 
second year. This observation is consistent with the downtrend in BTMs during the second 
year despite continued treatment with teriparatide, suggesting a less evident effect on bone 
turnover. Decline in forearm BMD appears to continue monotonically during the second 
year of treatment. These observations suggest that treatment could potentially be limited to 
one year, potentially as a basis for cyclic therapy with anti-resorptive agents or allowing the 
opportunity for later use of anabolic therapy if the need arose.
Disclosures: Clay Larkin, None
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Safety and efficacy of zoledronic acid for prevention of bone loss after 
gastric bypass: pilot study *Yi Liu1, Michael Cheney2, Maya Cote2, Katherine 
Lindeman2, Claire Rushin2, Elaine Yu2. 1Lahey Hospital and Medical Center, 
United States, 2Endocrine Unit, Massachusetts General Hospital, United States
Purpose: Roux-en-Y gastric bypass (RYGB) inadvertently causes bone loss and in-
creased fracture risk. To date, there have been no studies examining whether pharmacologic 
treatments can prevent bone loss after RYGB. We sought to examine the preliminary safety 
and efficacy of zoledronic acid (ZOL) to suppress bone turnover markers and prevent de-
clines in bone mineral density (BMD) after RYGB.Methods: Postmenopausal women older 
than 50 years with obesity who were planning RYGB were recruited for this open-label pilot 
study (n=4). A single dose of ZOL 5 mg was given intravenously prior to RYGB. BMD 
was obtained at the spine and hip by dual-energy x-ray absorptiometry and at the trabecular 
spine by quantitative CT at baseline and 24 weeks. Serum bone biochemistries including 
C-telopeptide (CTX) were measured. Results were compared against pre-operative baseline 
and against historical RYGB controls (n=10).Results: Baseline characteristics of ZOL and 
control groups were similar (mean +/-SD: age 59 +/-9 years, BMI 42 +/-4 kg/m^2), and post-
RYGB weight loss at 24 weeks was similar in both groups (59 +/- 22 lbs). By 24 weeks after 
RYGB, participants receiving ZOL had a significant increase in CTX above pre-operative 
baseline (+0.228 +/-0.117 ng/dL, p=0.030) but this CTX rise was less than that observed in 
the controls (+0.601 +/-0.307 ng/dL, p=0.042 between groups).  There was a suggestion that 
the ZOL group was protected against trabecular spine volumetric bone loss as compared to 
the control group (+4.8+/-8.0% vs. -5.9+/-7.0%, p=0.075 between groups). Despite ZOL, 
participants had significant areal BMD loss at the total hip as compared to pre-operative 
baseline (-4.2+/-1.5%, p=0.012) that was similar in magnitude to total hip BMD loss in the 
controls (-5.5+/-3.9%, p=0.005).  Serum calcium, 25-hydroxyvitamin D, and parathyroid 
hormone did not change in either group.  No hypocalcemia, change in renal function, or sig-
nificant adverse events were observed after ZOL.Conclusion: In patients receiving RYGB, 
zoledronic acid was safe and appeared to mitigate but not fully prevent high bone turnover 
in the acute postoperative period. Our preliminary data suggest that ZOL may preserve tra-
becular bone density at the spine, but was not sufficient to prevent bone loss at the hip at 24 
weeks. Prospective controlled studies are needed to confirm our findings and to identify the 
best strategies for preventing bone loss and lowering fracture risk in this bariatric population.
Disclosures: Yi Liu, None
P-668
Generation of humanized RANKL mice to study rebound resorption after 
discontinuation of Denosumab *Qiang Fu1, Cecile Bustamante-Gomez1, 
Anveshi Guha1, Igor Gubrij1, Charles O’Brien1. 1University of Arkansas for 
Medical Sciences, United States
Discontinuation of long-term administration of Denosumab results in a dramatic de-
crease in bone mass unless anti-resorptive treatment is resumed. After discontinuation, 
bone resorption increases to levels above those observed prior to Denosumab treatment, 
a phenomenon that has been referred to as rebound resorption. The molecular mechanisms 
responsible for rebound resorption are unknown, therefore we sought to develop a murine 
model to study it. Because murine RANKL is not inhibited by Denosumab, the region of 
the protein bound by the antibody must be replaced using the human sequence. Amgen had 
previously accomplished this by replacing the coding region of exon 5 of the Tnfsf11 gene, 
which encodes RANKL, with the coding sequence of the human gene. Because these mice 
are not widely available, we used gene-editing in mice to change exon 5 to match the human 
sequence only in the region encoding the epitope bound by Denosumab, which was recently 
identified. We tested the ability of Denosumab to inhibit resorption in these mice by weekly 
injection of 10 mg Denosumab/kg body weight for 3 weeks into adult males homozygous 
for the humanized gene. Wildtype C57BL/6 mice were injected as controls. Seven days after 
the final injection, blood was collected and markers of bone resorption were quantified. 
Denosumab had no effect on CTX-1 or TRAP5b in wildtype mice but potently suppressed 
these markers in humanized RANKL mice. We next determined whether discontinuation of 
Denosumab would lead to rebound resorption in these mice. Adult mice homozygous for 
the humanized gene were injected once per week with vehicle or Denosumab for 10 weeks. 
Blood was collected at day 0, on the last day of injection, and at 2 and 4 weeks after the last 
injection. Analysis of BMD by DXA 2 weeks after final injection revealed that bone mass 
was elevated in Denosumab-treated mice versus vehicle-treated mice. Consistent with this, 
circulating TRAP5b was much lower after 10 weeks of Denosumab injection compared with 
vehicle injection. However, 2 weeks after the last injection, TRAP5b levels were similar 
in both groups and 4 weeks after the last injection, they were much higher in Denosum-
ab-treated mice versus vehicle-treated mice. These results demonstrate that discontinuation 
of Denosumab in our humanized RANKL mice leads to rebound resorption that mimics the 
human condition. These mice should be useful in identifying the molecular mechanisms 
underlying rebound resorption.
Disclosures: Qiang Fu, None
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Cost-effectiveness of Romosozumab versus Teriparatide for Severe 
Postmenopausal Osteoporosis in Japan *Hiroshi Hagino1, Kiyoshi Tanaka2, 
Michael McClung3, Stuart Silverman4, Shravanthi Gandra5, Mata Charokopou6, 
Kenji Adachi7, Benjamin Johnson8, Björn Stollenwerk9. 1Tottori University, 
Japan, 2Kobe Gakuin University, Japan, 3Oregon Osteoporosis Center, United 
States, 4Cedars Sinai, United States, 5Amgen Inc., United States, 6UCB BioPharma 
SPRL., Belgium, 7Amgen K.K., Japan, 8Amgen Ltd., United Kingdom, 9Amgen 
GmbH, Switzerland
Objective: To assess the cost-effectiveness of romosozumab versus teriparatide, both 
sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis from 
the perspective of the Japanese healthcare system.Methods: A published Markov cohort 
cost-effectiveness model was adapted to a Japanese setting using country-specific data. 12 
months of romosozumab was compared with 24 months of teriparatide, with both treat-
ments sequenced to alendronate to make up a total treatment duration of 60 months. The 
population comprised postmenopausal women with severe osteoporosis (T-score <= -2.5 
and a history of fragility fracture) with a mean age of 78 years. The analysis used a Japanese 
public healthcare and long-term care system perspective, a lifetime horizon, and a discount 
rate of 2% per annum for costs and health outcomes. Direct osteoporosis-related healthcare 
costs and costs of long-term institutional care were included. Based on the bone mineral 
density (BMD) superiority of romosozumab compared with teriparatide, two scenarios were 
assessed: a scenario where the BMD advantage of romosozumab was translated into fracture 
reduction benefits, and a conservative scenario where it was assumed that both regimens 
were equally efficacious. Costs were assessed in 2019 US dollars and Japanese yen, and 
health outcomes in quality-adjusted life years (QALYs).Results: Romosozumab/alendronate 
dominated teriparatide/alendronate (i.e. it was cost saving and more or equally effective). 
Cost savings were $4,961 (¥533,491) and $4,401 (¥473,270) under the superior and equal 
efficacy scenarios, respectively, with 0.042 QALYs gained in the superior efficacy scenario.
Conclusion: Cost-effectiveness model outcomes indicate that treating women with severe 
postmenopausal osteoporosis with 12 months of romosozumab produces a greater number of 
QALYs at a lower cost than 24 months of teriparatide, when both treatments are sequenced 
to alendronate.
Disclosures: Hiroshi Hagino, Asahi Kasei Pharma, Astellas, Chugai, Eisai, Mitsubishi 
Tanabe Pharma, Pfizer Japan, Taisho Toyama, Teijin Pharma, Grant/Research Support, 
Speaking Fees : Astellas-Amgen, Asahi Kasei Pharma, Astellas, Chugai, Eisai, Eli 
Lilly Japan, Mitsubishi Tanabe Pharma, Mochida, MSD, Pfizer Japan, Taisho Toyama, 
Teijin Pharma, UCB Japan, Other Financial or Material Support, Asahi Kasei Pharma, 
Consultant
P-670
Relative Potency of Calcifediol vs Cholecalciferol *Salvatore Minisola1, 
Jessica Pepe1, Luciano Colangelo1, Luciano Nieddu2, Franco Mazzei3, Cristiana 
Cipriani1. 1Department of Clinical, Internal, Anesthesiologic and Cardiovascular 
Sciences, Sapienza University of Rome, Italy, 2Faculty of Economics, UNINT 
University of Rome, Italy, 3Department of Chemistry and Technology of Drugs, 
Sapienza University of Rome, Italy
There is a long standing debate on the relative potency of calcifediol versus cholecalcif-
erol. We analyzed investigations in which calcifediol was utilized to reach vitamin D suffi-
ciency and compared with most recent and important studies that utilized cholecalciferol to 
reach sufficiency. There were two main “a priori” selection criteria: the first was represented 
by basal 25(OH)D values less than 30 ng/mL; the second was the duration of treatment of at 
least 10 weeks. Since there are many more studies with cholecalciferol than with calcifediol, 
we chose the most recent and the most cited. A total population of 402 subjects for calcife-
diol studies and 1086 subjects for cholecalciferol investigations, was included.Concerning 
the rise in serum 25(OH)D as a function of daily oral input, we found significant correlations 
for both calcifediol and cholecalciferol (r=0.788, p<0.001 ; r=0.779, p<0.001, respective-
ly). However, the slope values of the correlations between the daily dose ingested and the 
final 25(OH)D value was steeper for calcifediol (1.59 +/- 0.32) compared to cholecalciferol 
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(0.25+/-0.01) and significantly different (p<0.001 ). This observation is confirmed, consid-
ering the average values of the induced metabolic effect for the same dose concentration 
ranges (as daily mcg) used in the administration of the two drugs (Figure 1). Furthermore, 
the difference of calcifediol potency in respect to cholecalciferol increases as a function of 
daily oral input.No correlations were found between the delta, final minus basal 25(OH)
D value, for each study and initial 25(OH)D values considering all studies and those with 
calcifediol or cholecalciferol, separately. However, the slope of the curve (albeit not signifi-
cantly different) was positive considering cholecalciferol studies and negative taking into 
account calcifediol studies.Considering mean BMI of the population studied and the delta 
of 25(OH)D values adjusted for the treatment period, we found statistical significance cor-
relations considering studies as a whole (r=-0.404, p=0.013) and no statistical significance 
with cholecalciferol data; in contrast, data pertaining calcifediol were significant (r=-0.528, 
p=0.029).We showed on a large data base that 1) calcifediol has a variable greater relative 
potency in respect to cholecalciferol depending on the dose administered; 2) the inverse 
correlation found between BMI and calcifediol suggests that fat mass might be negatively 
involved in the CYP2R1 regulation.
Disclosures: Salvatore Minisola, Abiogen, Amgen, Bruno Farmaceutici, Diasorin, Eli 
Lilly, Shire, Sandoz, Takeda, Speakers’ Bureau, Abiogen, Kyowa Kirin, Pfizer, UCB, Other 
Financial or Material Support
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Abaloparatide, A Novel Selective Agonist for PTH/PTHrP Receptor, 
Effectively Improved Hip Geometry and Biomechanical Properties Assessed 
by Hip Structural Analysis in Elderly Osteoporotic Patients - Results of the 
Japanese Phase 3 Trial (ACTIVE-J)- *Teruki Sone1, Kazuhiro Ohnaru2, Maki 
Mihoya3, Tetsuo Inoue4, Toshio Matsumoto5. 1Department of Nuclear Medicine, 
Kawasaki Medical School, Japan, 2Department of Orthopedic Surgery, Kawasaki 
Medical School, Japan, 3Clinical Development Administration Department, 
Teijin Pharma Limited, Japan, 4Aoyama General Hospital, Japan, 5Fujii Memorial 
Institute of Medical Science, Tokushima University, Japan
Background and Objectives: Abaloparatide (ABL) is a selective agonist for PTH/
PTHrP receptor, which significantly increased bone mineral density (BMD) and lowered the 
risk of osteoporosis-related vertebral and non-vertebral fractures in the international phase 
3 ACTIVE trial. In Japan, ABL also demonstrated potent increases in BMD at the lumbar 
spine, total hip, and femoral neck, in a randomized, double blind, multi-center, placebo-con-
trolled phase 3 trial, ACTIVE-J. To evaluate the effect of ABL on hip geometry and bio-
mechanical properties, hip structural analysis (HSA) was performed based on dual-energy 
X-ray absorptiometry (DXA) scans from ACTIVE-J. Subjects: A total of 213 patients (193 
postmenopausal women and 20 men) aged 55 or older with lumbar spine (LS) BMD less 
than T-score -1.77 and one or more vertebral fractures, BMD T-score less than -3.0 without 
fractures, or aged 65 years or older with BMD less than T-score -2.5 were randomly assigned 
to daily subcutaneous injection of 80 µg ABL or placebo (PBO) for 18 months in a 2:1 ratio. 
Methods: Hip DXA scans were performed at baseline, 3, 6, 12 and 18 months. Cross-sec-
tional geometrical parameters at the narrowest segment of the femoral neck (NN), the inter-
trochanteric region (IT), and the proximal shaft (PS) were analyzed using APEX 3.0 soft-
ware (Hologic, Inc.). Geometrical parameters and derived strength indices included average 
cortical thickness (CT), bone cross-sectional area (CSA), cross-sectional moment of inertia 
(CSMI), section modulus (SM), and buckling ratio (BR). Change from baseline in these 
indices in the ABL group were compared with PBO at the NN, IT and PS regions. Results: 
Compared with the PBO group (n=65) after 18 months, the ABL group (n=128) showed 
higher CT, CSA, CSMI, and SM at both the NN and IT regions. And lower BR was observed 
in the ABL group at the IT region. No expansion of periosteal diameter was observed at these 
regions. There were no differences in CSMI and BR at the PS region. Conclusion: These 
results indicate that overall structural strength in the proximal femur increased compared 
to placebo, suggesting that 18-months of ABL treatment effectively reverses changes in hip 
geometry and strength with aging.
Disclosures: Teruki Sone, Teijin Pharma, Consultant, Shimadzu Corporation, Consultant, 
Teijin Pharma, Grant/Research Support
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Real-world bone turnover marker use: Impact on treatment decisions and 
fracture *Nancy E. Lane1, Kenneth Saag2, Tyler J. O’Neill3, Megan Manion4, 
Roma Shah3, Ursula Klause5, Richard Eastell6. 1Department of Internal Medicine, 
UC Davis Health, United States, 2Department of Medicine, Division of Clinical 
Immunology and Rheumatology, University of Alabama at Birmingham, 
United States, 3Data Science and Services, Diagnostics Information Solutions, 
Roche Diagnostics, United States, 4Roche Diagnostics, United States, 5Roche 
Diabetes Care, Roche Diagnostics, United States, 6Department of Oncology and 
Metabolism, University of Sheffield, United Kingdom
Purpose: 1) To characterise bone turnover marker (BTM) testing patterns in patients 
with osteoporosis in a large, heterogeneous practice setting using a retrospective claims 
database. 2) To estimate potential BTM clinical utility in treatment decision-making and 
fragility fracture risk following BTM use.Methods: Data from patients aged >=50 years with 
newly diagnosed osteoporosis enrolled in the Truven MarketScan® Commercial Claims and 
Encounters and Medicare Supplemental and Co-ordination of Benefits databases from 1 Jan 
2008–30 Jun 2018 were included. Osteoporosis was ascertained by explicit claims, or fra-
gility fracture events associated with osteoporosis, or prescribed anti-resorptive or anabolic 
therapy. Patients with metabolic or genetic diseases associated with low bone mineral densi-
ty and those with neoplasia were excluded. Eligible BTMs (osteocalcin, bone-specific alka-
line phosphatase, collagen cross-links) tested patients were 1:1 propensity score matched to 
those untested following diagnosis. Generalised estimating equation models with logit links 
and independent correlation structures were performed to estimate odds ratios (ORs) and 
95% confidence intervals (CIs) for testing versus no testing on both treatment decision-mak-
ing (categorised following a BTM test according to days of coverage or supply) and fragil-
ity fracture.Results: Of 457,829 patients with osteoporosis, 6,075 were identified with >=1 
BTM test claims on/following diagnosis; of these patients, 1,345 had a unique treatment 
decision made <=30 days of BTM testing. During the study period, the proportion of patients 
receiving BTM tests increased significantly each year (average annual % change=+8.1%; 
95% CI=5.6–9.0; p=0.01) despite a stable average testing of 2.2 tests (standard deviation 
[SD]=2.0) per patient (Figure). On matching 6,075 BTM tested to 6,075 untested patients, 
those tested were significantly more likely to have a treatment decision (OR=1.14; 95% 
CI=1.13–1.15), and testing was associated with lower odds of fracture, versus those untested 
(OR=0.87; 95% CI=0.85–0.88).Conclusions: In this large, heterogeneous population of pre-
sumed osteoporotic patients, BTM testing was associated with treatment decision-making, 
likely leading to fragility fracture reduction following use. Further investigation is needed 
to validate our findings and understand what drives test ordering, but our evidence provides 
further value of monitoring osteoporotic patients with BTMs.Figure: Annual period prev-
alence (per 100 persons) of bone turnover marker testing and average testing per patient 
among osteoporotic patients enrolled in Truven MarketScan® Commercial Claims and En-
counters and Medicare Supplemental and Co-ordination of Benefits databases, 2008–2018.
Disclosures: Nancy E. Lane, Roche, Consultant
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Factors associated with adherence to osteoporosis medications among male 
Veterans *Nicole Sagalla1, Richard Lee1, Richard Sloane1, Kenneth Lyles1, 
Cathleen Colón-Emeric1. 1Duke University, United States
Purpose: To determine adherence rates and factors associated with adherence to osteo-
porosis medications among male Veterans. Methods: We conducted a secondary analysis of a 
national cohort of male Veterans with a prescription for an oral bisphosphonate or Calcitonin 
between 2000-2010. We identified demographic, comorbid and fracture-related risk factors 
by their ICD9 and CPT codes and used multivariable logistic regression to evaluate their 
association with adherence as measured by medication possession ratio (MPR) over 5 years 
starting at the time of their first prescription during the study period and censoring at death 
or end of study period. Results: Of 135,306 men identified with at least 1 prescription for 
an osteoporosis medication during the study period, 90,406 (67%) were non-adherent (MPR 
< 0.80). The median duration of therapy was 3.2 years (IQR=1.7, 5.0). In the fully adjusted 
model, the odds of adherence were lower in those < 65 years (OR=0.87; 95% CI: 0.84,0.89), 
with no copay (OR=0.78; 0.76,0.80), dementia (OR=0.87; 0.83,0.91), anxiety/depres-
sion (OR=0.93; 0.90,0.95), tobacco use (OR=0.91; 0.89,0.94), alcohol abuse (OR=0.91; 
0.89,0.94), rheumatoid arthritis (OR=0.91; 0.87,0.96), and on androgen deprivation therapy 
(OR=0.89; 0.83,0.95). The odds of adherence were higher in whites (OR=1.14; 1.11,1.17), 
with a prior screening colonoscopy (OR=1.12; 1.09, 1.15), on Alendronate vs. other agents 
(OR=1.60; 1.55,1.66), with a DXA (OR=1.14; 1.11,1.17), and on glucocorticoids (OR=1.08; 
1.02,1.14). Conclusion: Adherence to oral bisphosphonates/Calcitonin for osteoporosis/os-
teopenia is poor, with particular subgroups at greatest risk. These findings may help tailor 
approaches for supporting adherence in men prescribed osteoporosis medications.
Disclosures: Nicole Sagalla, None
P-674
Sclerostin Mutant with Selective Binding to LRP4 Activates Wnt Pathway 
and Promotes Bone Anabolic Functions *Svetlana Katchkovsky1, Niv Papo1, 
Noam Levaot1. 1Ben Gurion University of the Negev, Israel
The Wnt signaling pathway plays an essential role in bone homeostasis and is finely 
tuned by a complex interplay between Wnt ligands, receptors, activators and inhibitors. Wnt 
induction of bone formation is inhibited upon binding of sclerostin, a glycoprotein produced 
by osteocytes, to the Wnt receptors LRP5/6. Binding of sclerostin to additional receptor 
LRP4 is required to facilitate optimal inhibition. Herein, we show that a sclerostin mutant 
(sclerostinN93A) with high binding affinity to LRP4 but not LRP5/6 antagonizes wild-type 
sclerostin (sclerostinWT) inhibition of Wnt signaling pathway in vitro in osteoblast cultures. 
In order to increase retention of sclerostinN93A  we fused the Fc domain of immunoglobulin 
G to the C-terminal of sclerostinN93A (sclerostinN93AFc). We show that this modification 
does not interfere with its ability to antagonize sclerostinWT. Finally, we show that bi-week-
ly subcutaneous injections of sclerostinN93AFc for two weeks significantly increase tra-
becular volumetric bone fraction and bone length in developing mice. Our data suggest that 
compounds that target sclerostin LRP4 binding interface could serve as a potential strategy 
to promote bone anabolic functions.
Disclosures: Svetlana Katchkovsky, None
P-675
Autonomy begets adherence: Patients stick with their decisions to initiate 
osteoporosis pharmacotherapy after attending an osteoporosis group 
‘educonsult’ program which emphasizes shared decision-making *Maddie 
Wilton-Clark1, Lynn Feasel2, Greg Kline1, Emma Billington1. 1University of 
Calgary, Canada, 2Alberta Health Services, Canada
Many individuals recommended for osteoporosis pharmacotherapy do not start treat-
ment, and persistence at one year is only 50% among those who do. Patients do not al-
ways agree with physician-set treatment thresholds, and low uptake and persistence may 
reflect lack of confidence in the treatment recommendations provided by physicians. In this 
prospective study, we assessed patterns in pharmacotherapy use in patients who attended a 
group ‘educonsult’ program for osteoporosis that focuses on shared decision-making. Par-
ticipants were women referred to our specialty clinic for age-associated osteoporosis who 
attended a 2-hour group educonsult in lieu of one-on-one specialist consultation. The edu-
consult is facilitated by a specialist physician and nurse, and involves estimation of ten-year 
major osteoporotic fracture risk (FRAX) and extensive education regarding fracture con-
sequences and potential advantages and disadvantages of pharmacotherapy. Post-consult, 
patients make autonomous decisions regarding treatment intent and follow-up with their pri-
mary care provider to enact their preferred plan. We assessed treatment intent post-consult, 
and treatment status 3 and 12 months later. Treatment status at 3 months was considered to 
reflect each individual’s final treatment decision, and treatment status at 12 months indicated 
congruence with the final (3 month) decision. Persistence was defined as the proportion of 
treated participants at 3 months who remained treated at 12 months. Among 101 partici-
pants, mean(SD) age was 62.7(5.8) years, and median(IQR) FRAX 10.7(8.3-17.6)%; 18 
patients (17.8%) were considered high-risk using a common physician-set threshold (FRAX 
>=20%). Treatment status at 3 and 12 months is shown in Figure 1. Immediately post-con-
sult, 27 intended to initiate treatment. At 3 months, 23 (22.8%) were on treatment and 25 
(24.8%) were on treatment at 12 months. At 12 months, treatment status was congruent in 
94 (93.1%), and 21/23 (91.3%) were persistent with therapy. Of 94 respondents to a 3 month 
survey, 80 (85.1%) reported being confident in their final treatment decision, and 85/89 
(95.5%) respondents reported confidence at 12 months. When individuals with age-associat-
ed osteoporosis are encouraged to make autonomous decisions regarding pharmacotherapy 
use, final treatment decisions may differ from initial intentions, but these decisions are made 
with high confidence and result in much better persistence than previously reported in the 
literature.
Disclosures: Maddie Wilton-Clark, None
P-676
Effect of bisphosphonates for secondary prevention of fracture in frail older 
adults *Sarah Berry1, Dae Kim1, Gahee Oh2, Natalia Gouskova2, Douglas Kiel1. 
1Hebrew SeniorLife & BIDMC, United States, 2Hebrew SeniorLife, United 
States
Background: Osteoporosis treatment is often withheld in frail, older adults after the oc-
currence of a hip fracture given the uncertainty as to whether these drugs are safe and effec-
tive in this vulnerable population. Our objective was to determine whether the effect of oral 
bisphosphonates on secondary fracture prevention differed in frail, older adults.Methods: 
To minimize between-person confounding, we conducted a nested case-control study using 
an augmented 5% sample of Medicare beneficiaries in 2014-2015. Using Part A claims, we 
identified subjects aged >= 65 yrs with a hospitalized incident hip fracture (7/2014-12/2015). 
We excluded subjects with a claim for Hospice or any osteoporosis medication in the 6 
months before fracture (remaining n=16,725). Cases were subjects with a second hip frac-
ture at least 100 days following the incident hip fracture and through 12/2016. We matched 
four controls for each case using risk-set sampling and based on age, sex, and date of inci-
dent hip fracture. Exposure was duration of oral bisphosphonate use (no more than 30 days 
versus > 30 days) following the incident fracture and ascertained by Medicare Part D claims. 
A frailty index (range 0-1 with 1 most frail) was calculated using a validated algorithm from 
Medicare claims in the 6 months before the incident hip fracture. An index of >=0.2 was 
defined as frail.  Conditional logistic regression was used to calculate the odds ratio and 95% 
confidence intervals of second hip fracture according to bisphosphonate exposure. In ad-
justed models, we included the number of medications in the model. Models were stratified 
by frailty status.Results: Cases included 752 subjects with a second hip fracture (mean age 
82yrs, 76% female) and 3,008 matched controls. 396 cases were frail prior to the incident hip 
fracture. Only 26.7% of BP users received 6 months or more of the drug.  As shown in the ta-
ble, bisphosphonate use appeared to decrease the risk of second fracture in non-frail persons, 
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whereas it had no effect in frail persons; however, none of the odds ratios were statistically 
significant.   Conclusions: Although our results were not significant, our findings suggest the 
efficacy of bisphosphonates may differ according to frailty status. 
Disclosures: Sarah Berry, None
P-677
Compliance with the Administration of Denosumab Injections during 
COVID-19 Pandemic. *Ejaz Mahmood1, Alexis Richardson2, Maria Meirzon1, 
Catherine Anastasopoulou1. 1Einstein Medical Center, United States, 2Department 
of Endocrinology, Einstein Medical center., United States
Purpose: Denosumab is a monoclonal antibody to the receptor activator of nuclear fac-
tor kappa-B ligand (RANKL). It inhibits osteoclast formation which decreases bone resorp-
tion, increases bone mineral density and reduces the risk of fracture. It has been established 
that stopping or omitting Denosumab is associated with increased fracture risk.[1] Its admin-
istration is approved to be provided by a healthcare professional.[2] Our study aims to assess 
the compliance with Denosumab injection during COVID-19 pandemic when elective ser-
vices were limited.Methods:A retrospective chart review of all the patients with osteoporosis 
who were due to receive Denosumab Injection in an endocrine practice between 03/01/2020 
and 05/22/2020 was conducted. The patients who received the scheduled Denosumab were 
categorized based on the type of visit.Results:A total of 89 patients were identified. 14 pa-
tients (15.7%) refused to get Denosumab injection during this pandemic. 2 patients (2.3%) 
had to be rescheduled due to logistic needs of infusion center. 73 patients (82%) received 
scheduled dose of Denosumab in different ways; 23 patients (25.8%) attended a scheduled 
office visit to get the injection, 46 patients (51.7%) received the medication on a home visit 
by a registered nurse of the practice and 4 patients (4.5%) also got their injections by the reg-
istered nurse via a drive through arrangement.Conclusion:The current COVID-19 pandemic 
has a significant effect on the health care facilities by limiting direct access to non-emergent 
care to the patients. It also has an impact on patients’ behavior of utilizing the medical ser-
vices and on their perception of how they want to get their care delivered in a safe manner.
Continuation of Denosumab injection is time sensitive and delay in administration is asso-
ciated with worse outcomes. By actively identifying the patients and offering them different 
options of logistics including office visits, home visits or drive through injections, a high 
percentage of adherence to the scheduled Denosumab was achieved during the early phase 
of the COVID-19 pandemic. References:Cummings SR, Ferrari S, Eastell R, et al. Vertebral 
Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized 
Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-
198. doi:10.1002/jbmr.3337Johnson, Gretchen L. “Denosumab (prolia) for treatment of 
postmenopausal osteoporosis.” Am Fam Physician 2012; 85(4): 334-336
Disclosures: Ejaz Mahmood, None
P-678
Trends in Medication Prescribing for Primary Osteoporosis Using the 
Korea National Health Insurance Database, 2006-2015 *Nami Lee1, Jaeyong 
Shin1, Yong Jun Choi1, Yunhwan Lee1, Dae Jung Kim1, Yoon-Sok Chung1. 1Ajou 
University School of Medicine, Republic of Korea
Osteoporosis has emerged as a significant health problem, contributing to socioeconom-
ic burdens due to the rapidly growing elderly population worldwide, including South Korea 
[1, 2]. However, adherence to medications for osteoporosis is relatively low because there 
are seldom symptoms until the patient develops osteoporotic fractures, leading to increased 
morbidity and mortality [3-5]. We investigated the prescribing pattern of anti-osteoporotic 
drugs (AODs) with government health insurance reimbursement guideline, especially bis-
phosphonates and selective estrogen receptor modulators (SERMs), in South Korea during 
the recent ten-year period.We used the Korea National Health Insurance Service – National 
Sample Cohort (NHIS-NSC) data from January 1, 2006 to December 31, 2015. We selected 
patients 50 years of age or older, diagnosed with osteoporosis.The mean age at the time of 
diagnosis for osteoporosis was 69.9 years (means +/- SD; 61.3~78.6 years). The proportion 
of women among total osteoporotic patients was 88%. One-half of osteoporotic patients 
received AOD prescriptions.Over the 10-year period, oral bisphosphonates (oral BP, 90.2%) 
were the most frequently prescribed AOD in South Korea (Table 1). The proportion of oral 
BP prescription decreased steadily from about 95% to 77.9%, though it still was the most 
commonly used AOD. In the mid-2000s, the intravenous bisphosphonates (IV BP) were 
scarcely prescribed, but it gradually increased to 12.1% in 2015. Moreover, this trend stood 
out at 24.9% among hospitalized patients in 2015. SERMs were prescribed 6.2% in 2006, 
but as of 2011, its proportion decreased to 2.9%. After that, the prescription of SERMs 
increased to 9.9% in 2015.Bisphosphonate was still the mostly preferred AOD, a pattern 
similar to that of other countries. However, the prescription pattern has changed according 
to the administration route of bisphosphonates. The proportion of IV BP increases while oral 
BP decreases. This trend is probably due in part to patient’s medication adherence. SERMs 
are approved drug to treat osteoporosis only for women in several Asian countries, including 
South Korea. It is the relatively preferred AOD mainly because of the safety concern. More 
recently since 2016, the prescription of denosumab and teriparatide has increasing due to 
advanced osteoporosis observed in aged patients.
Disclosures: Nami Lee, None
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Comparison of Femoral Neck Shortening and Outcomes between In Situ 
Fixation and Fixation after Reduction for Severe Valgus Impacted Femoral 
Neck Fractures *Youngchang Park1, Kyuhyun Yang2. 1Catholic Kwandong 
University, Republic of Korea, 2Yonsei university, Republic of Korea
Purpose: To compare femoral neck shortening (FNS) and outcomes between in situ 
fixation and fixation after reduction for severe valgus impacted femoral neck fractures (AO/
OTA classification 31-B1.1) in patients aged 65 years or younger.  Methods: This retrospec-
tive study included 55 patients who underwent internal fixation with three parallel screws for 
severe valgus impacted femoral neck fracture between January 2006 and December 2018. 
Twenty-eight patients were treated with in situ fixation (in situ group), and 27 underwent 
fixation after reduction (reduction group). In the reduction group, reduction using lateral 
traction with a Schanz pin was performed before internal fixation. The independent t-test and 
chi-square or Fisher exact test were used for data analysis. Results: Bone union was achieved 
in all patients; avascular necrosis occurred in two patients each in both groups. There was no 
significant difference in the preoperative characteristics between the groups. FNS at 1 year 
postoperatively was significantly smaller and FNS >5 mm was significantly less in the re-
duction group than in the in situ group (11% versus 75%). The mean Harris Hip Score (HHS) 
at 1 year postoperatively was significantly higher in the reduction group than in the in situ 
group. FNS and HHS were negatively correlated; the mean HHS was significantly higher in 
none/mild shortening (<5 mm) than in moderate/severe shortening (>=5 mm).  Conclusion: 
In patients aged 65 years or younger, internal fixation after reduction for severe valgus im-
pacted femoral neck fractures is safe and effective for restoring the femoral neck length and 
achieving successful bone union.
Disclosures: Youngchang Park, None
P-680
Short-term of clinical efficacy of romosozumab in patients with rheumatoid 
arthritis and primary osteoporosis *Yasuhide Kanayama2, Taichi Tsuji0, 
Naohisa Futamura0, Kyotaro Ota0, Yui Adachi0, Ryosuke Sugimoto0, Kei 
Terasawa0, Kento Maeda0. 2Orthopedic Surgery and Rheumatology, Toyota 
Kosei Hospital, Japan, 0Orthopedic Surgery, Toyota Kosei Hospital, Japan
[Background] Romosozumab (ROM), a monoclonal antibody that binds sclerostin, in-
creases bone formation and decreases bone resorption.And although it is a novel therapeutic 
agent for osteoporosis, which has shown high effects of increasing bone density and inhibit-
ing fragile fracture in overseas clinical trials. However the clinical efficacy in daily clinical 
practice is unknown.[Objectives] To evaluate the early clinical efficacy of ROM in patients 
with osteoporosis between rheumatoid arthritis (RA-OP) and primary osteoporosis (P-OP) 
for 6 months.[Methods] RA patients diagnosed according to the 2010 ACR/EULAR criteria. 
RA-OP and P-OP patients met at least one of the following criteria were eligible; a bone 
mineral density T score of -2,5 or less at the lumber spine or total hip and either one or more 
moderate or severe vertebral fractures or two or more mild vertebral fractures. All patients 
were initiated ROM from between March and September, 2019. The total number of patients 
was 26 cases, including 11 RA-OP and 15 P-OP. All patients received continuous ROM 
therapy more than 6 months. The ROM dose was 210mg at once every 1 months. In all cases 
native or activated vitamin D has been used. We reviewed the results for 6 months about the 
increase and decrease of bone mineral density (BMD) of lumbar spine(LS) and total hip(TH) 
by DEXA and bone turnover markers, intact n-terminal propeptide type I procollagen(PINP) 
and tartrate-resistant acid phopshatate form 5b(TRACP-5b).[Results] The gender was 25 
female and 1 male. The mean age was 70.7 +/- 11.2; disease duration of RA-OP patients 
was 19.4 +/- 15.0 years; the body mass index was 19.4 +/- 3.6 and the FRAX was 31.1 
+/- 15.3. Clinical findings related to RA-OP at baseline were as follows; CRP 1.51 +/- 1.73; 
DAS-CRP 3.57 +/- 0.98; HAQ 1.60 +/- 1.03 in RA-OP patients and in the all patients, bone 
turnover markers and bone mineral density at baseline were as follows ; P1NP 57.6 +/- 42.3; 
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TRACP-5b 434 +/- 232 ; LS-BMD and T-score 0.81 +/- 0.17 g/cm2 and -2.62 +/- 1.13 and 
TH-BMD 0.57 +/- 0.08 g/cm2 and -3.07 +/- 0.62 g/cm2. The rate of increased P1NP from 
baseline to 1, 3 and 6 months were each 119.8 +/- 90.0% at 1 month, 108.4 +/- 98.6% at 3 
month and 79.4 +/- 133.6% at 6 month and decreased TRAC-5b were -17.5 +/- 23.8% at 
1 month, -49.9 +/- 44.9% at 3 month and 0.5 +/- 53.1% at 6 month. The rate of increased 
LS-BMD from baseline to 6 months were 9.3 +/- 7.1% and TH-BMD were 4.4 +/- 4.5%.
[Conclusion] Short-term of clinical efficacy of ROM for RA-OP and P-OP was extremely ef-
fective and has the high potential to be an important option in the treatment of osteoporosis.
Disclosures: Yasuhide Kanayama, None
P-681
Evaluation of a Multidisciplinary Team Approach to Improve Osteoporosis 
Management *Violet Lagari1, Gracielena Rodriguez1, Maribel Garcia1, Sue 
Kwok1, Martha Salazar1, Silvina Levis1. 1Miami VA Healthcare System, United 
States
The Veterans Health Administration (VHA) provides care for 9 million veterans, of 
which 64% are men older than 55. In 2012, the Office of the Inspector General determined 
that 42% of veterans with osteoporotic fractures received appropriate evaluation and treat-
ment. We evaluated the impact of a multidisciplinary team on osteoporosis management 
at one of the largest VA facilities.The multidisciplinary team (3 clinical pharmacists and 
2 endocrinologists) began working in May 2015 to compare outcomes prior to program 
implementation (5/2014 – 5/2015) and after implementation (11/2017 - 11/2018). Abnormal 
bone mineral density (BMD) test results were defined as either 1) T-score diagnosis of os-
teoporosis, 2) Osteopenia with high fracture risk as determined by FRAX score, 3) history 
of a low-trauma fracture noted on the BMD intake. Thirty days after abnormal BMD results 
were reported to the ordering physician, a clinical pharmacist performed a chart review to 
identify patients who did not receive an appropriate prescription for an osteoporosis medi-
cation. Recommendations included 1) a follow-up phone call to obtain more information, 2) 
patient referral for further work-up in the endocrinology clinic, or 3) anti-osteoporosis ther-
apy initiation. The primary outcome was osteoporosis management as defined by initiation 
of anti-osteoporosis medications, endocrinology referral or patient contact for osteoporosis 
management discussion.The pre-intervention group consisted of 89 patients and intervention 
group consisted of 176 patients. Baseline characteristics were similar between groups. Oste-
oporosis management was provided to 53.9% of patients in the pre-intervention group and 
to 95.5% of patients in the intervention group. Anti-osteoporosis medications were initiated/
continued in 44.9% of patients in the pre-intervention group, and in 72.2% of patients in 
the intervention group. Of the patients in the pre-intervention group, 44% had sustained 
a low-trauma fracture and, of those, 46% had received osteoporosis management. In the 
intervention group, 22% had sustained a low trauma fracture and, of those, 89% received 
osteoporosis management.A greater proportion of patients received osteoporosis manage-
ment, inclusive of anti-osteoporosis medications, in the intervention group. Having a multi-
disciplinary team approach that includes clinical pharmacists as part of a multidisciplinary 
team-based approach improves osteoporosis management.
Disclosures: Violet Lagari, None
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The urgent need of strategies to improve secondary fracture prevention 
in Spain: A call to action *Cristina Carbonell1, José Carlos Bastida2, Josep 
Blanch3, Enrique Casado4, José Luis Pérez Castrillón5, Laura Canals6, Luis 
Lizán7. 1Primary care, Catalan Health Institute (ICS), Spain, 2Family Medicine, 
Marín Health Centre, Spain, 3Department of Rheumatology, Hospital del Mar, 
Spain, 4Department of Rheumatology, Hospital Universitari Parc Taulí (UAB), 
Spain, 5Department of Internal Medicine, Hospital Universitario “Rio Hortega”, 
Spain, 6Amgen (Europe) GmBH, Spain, 7Outcomes’10, Spain
PurposeSeveral scientific organizations have called for an improvement in fragility 
fracture management to prevent subsequent fractures. This study aims to establish a con-
sensus among health professionals regarding the strategies to promote secondary prevention 
of osteoporotic fractures in Spain.MethodsA literature review and a working group with 
experts (n=12) were performed to identify the main barriers for secondary fracture preven-
tion. Twenty improvement strategies were compiled in a 43-item questionnaire, reviewed 
by a committee (2 rheumatologists, 2 primary care (PC) physicians, 1 internist physician). 
Questions were approached from 3 perspectives: current (C: current situation), desire (D: 
what is wanted to happen) and prognosis (P: what will really happen in 5 years); and rated 
on a 7-point scale (1=total disagree; 7=total agree). A total of 102 professionals from 14 
scientific societies were invited to participate in a 2-round Delphi consultation. Consensus 
was established (D and P perspectives) when at least 75% of the answers were in the range 
of disagreement (points 1-3) or agreement (points 5-7). Items that did not reach consensus 
in the 1st round were included in the 2nd round.ResultsA total of 75 and 69 multidisci-
plinary healthcare professionals participated in the 1st and 2nd rounds, respectively. All 
the strategies reached consensus from D perspective and 58.1% from P perspective. Sec-
ondary prevention strategies identified as not widespread and requiring improvement, but 
with low probability of implementation, were (% of agreement): clinical report standardiza-
tion (C:8.0%, D:93.3%, P:33.3%), PC-hospital communication via case manager (C:8.0%, 
D:92.0%, P:47.8%) or telephone/e-mail (C:13.3% D:85.3% P:47.8%), quality of life ques-
tionnaires use (C:9.3%, D:81.3%, P: 18.8%), treatment compliance monitoring (C:13.3%, 
D:96.0%, P:55.1%), health managers involvement in educational campaigns (C:9.3%, 
D:92.0%, P:23.2%), treat-to-target strategy application (C:12.0%, D:78.7%, P:53.6%), and 
social support promotion (C:17.3%, D:90.7%, P:43.5%).ConclusionsA multidisciplinary 
panel of healthcare experts has reached consensus on the strategies to improve secondary 
prevention of fragility fractures in Spain. Although all the strategies proposed were consid-
ered necessary, some of them are considered difficult to implement in the mid-term. Greatest 
attention should focus on those strategies with the largest divergences between the D and 
P perspectives.
Disclosures: Cristina Carbonell, Amgen, Rubió, Consultant
P-683
The Florence Text Messaging System Can Improve Patient Concordance 
with  Osteoporosis Medications and Treatment Plans *Eamonn Brankin1, 
Margaret Yates2, Anne Lickrish2, Morag Hearty3, Robin Munro2. 1NHS 
Lanarkshire Osteoporosis Service / University of Glasgow/ Glasgow Caledonian 
University, United Kingdom, 2NHS Lanarkshire Osteoporosis Service, United 
Kingdom, 3NHS Lanarkshire Technology Enabled Care Team, United Kingdom
Florence (Flo) is a novel telehealth text messaging service  evolving  in the UK Na-
tional Health Service (NHS)  which sends patients reminders and health ideas tailored to 
their individual situation. It was named after Florence Nightingale, the founder of modern 
nursing practice. The NHS Lanarkshire telehealth monitoring service has been funded by 
a Scottish Government initiative called Technology Enabled Care which   aims to increase 
the number of people receiving telehealth at home.Health Care professionals  can adjust the 
settings on Flo for each patient, deciding  when  to send messages, what information is being 
asked  for and how the system should respond. With appropriate patient consent, Flo then 
sends regular text messages to patients  as an aide to help them to monitor their own health, 
sharing any information sent back by the patient with the health professional  managing their 
care. Patients receive instruction on and leaflets about how the system works.This system 
was introduced as a pilot to the NHS Lanarkshire Osteoporosis service in autumn 2019 as an 
aid to medication concordance and to identify those who may therefore benefit from 2nd line 
treatments. Text questions ascertain if the patient is currently taking their bisphosphonate, 
if they are taking it correctly on an empty stomach and avoiding other food/medications, if 
the patient is experiencing any side effects from this and if the patient leaves 4hrs between 
their weekly bisphosphonate and calcium and vitamin D supplements. It allows for patients 
to flag and discuss any concerns. It has run over a 9 month period so far.In the first 9 months, 
so far 95 patients have opted into  the system, 37 have not responded and been removed 
and 83 are in regular touch with the system. 250 e-mails have been generated to/from pa-
tients subsequent to their involvement and patient care updated as required. Appropriately 
identified  patients are referred for an updated DEXA scan then review by an osteoporosis 
nurse specialist or physician and alternative therapy offered as required. By adding in this 
text facility to the fracture liaison service (FLS) we have improved medication concordance, 
improved communication  with patients otherwise currently disengaged from the service and 
offered them further opportunities to discuss their disease and treatment and with improve-
ments in appropriately taken treatment, reduced  their risk of further fragility fracture in a 
more patient centred way.
Disclosures: Eamonn Brankin, None
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Clinical Utility of Trabecular Bone Score (TBS) *Stuart Silverman1, Alan 
Chien2. 1Cedars-Sinai Medical Center, David Geffen School of Medicine at 
UCLA, OMC Clinical Research Center, United States, 2OMC Clinical Research 
Center, United States
Purpose: The Trabecular Bone Score or TBS is a clinical risk factor for fracture, which 
is partially independent of areal bone density (aBMD) at the lumbar spine/proximal femur, 
and the FRAX® algorithm. We assessed the clinical utility of TBS in determining osteopo-
rosis (OP) treatment in a retrospective chart review.   Methods: We performed a retrospective 
chart review on 100 consecutive patients seen 2018 and 2019 for whom FRAX and trabec-
ular bone score (TBS) was ordered in a bone clinic with institutional affiliation. The mean 
age was 64 years old. Nineteen of the 100 patients were male. We recorded indications for 
TBS use, BMD of spine and hip, FRAX score before and after TBS adjustment, and patient 
willingness to take medication for osteoporosis after discussion of the TBS adjusted FRAX 
score with a clinician.  Results: TBS was ordered for one of five reasons: 21% of the orders 
were to decide if therapy was needed, 60% to help choose an appropriate therapy (anabolic 
or antiresorptive), 10% to optimize bone health prior to surgery, 2% to explain a fracture in 
the setting of normal bone density, and 7% to decide if medications should be continued by 
comparing TBS scores to baseline. Twenty-one percent of patients had a TBS score in the top 
third (TBS>=1.3), 41% of the patients in the middle third (1.2<TBS<1.3), and 38% of pa-
tients in the bottom third (TBS<=1.2). Of the patients with TBS in the top third, 43% (9/21) 
did not receive therapy. Nineteen percent (4/21) received an oral bisphosphonate. Of the 
patients with TBS in the bottom third, 47% (18/38) of patients received an anabolic. In this 
group, 11% (4/38) of patients deferred starting osteoporosis therapy. Conclusion: TBS may 
have clinical utility for an osteoporosis clinician to help choose a therapy, decide whether a 
therapy is needed, or optimize bone health. Some patients, at high risk of fracture by FRAX 
with a TBS in the bottom third, were still not willing to take OP medication. These patients, 
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despite being informed about their OP risk, chose to defer OP therapy. We recognize patients 
may choose to defer therapies based on their perception of risks and benefits.  While TBS 
risk information is understood by clinicians, it is not clear how well it is understood by pa-
tients. Further prospective research is needed to fully understand whether TBS information 
increases osteoporosis prescription fulfillment and/or adherence.
Disclosures: Stuart Silverman, None
P-685
Improving Access with Nurse-Led Telephone Follow-up after Bisphosphonate 
Initiation: Saving time and travel *Kathryn Dinh1, Magdalena Wojtowicz2, 
Katherine Wysham3, Radhika Narla1. 1Division of Metabolism, Endocrinology, 
and Nutrition, Department of Medicine, University of Washington School of 
Medicine, United States, 2Geriatric Research, Education, and Clinical Center 
(GRECC), Veteran Affairs Puget Sound Health Care System, United States, 
3Department of Rheumatology, Veteran’s Affairs Puget Sound Health Care 
System, United States
Purpose: Veterans Administration’s (VA) Puget Sound Health Care System has a 
multi-disciplinary osteoporosis clinic aimed at fracture prevention, serving all of Wash-
ington state. An expanding referral base and aging population has increased demand for 
tailored bone health care resulting in lengthy wait for new referrals and limited follow-up 
availability. With the goals of optimizing clinic access, ensuring medication adherence, and 
decreasing Veteran travel, we implemented a nurse (RN)-led telephone initiative to provide 
three-month follow-up in place of a physician (MD) visit for patients initiated on a bis-
phosphonate.Method: Patients started on bisphosphonate therapy from 5/1-12/31/2019 were 
enrolled for a RN telephone visit in three months and MD follow-up in 12 months. The call 
assessed adherence to bisphosphonate and prescribed supplements, side effects, new falls, 
and changes in clinical status. MDs were alerted to patient or RN concerns, and face-to-
face visits were scheduled when necessary. Distance Veteran travels to clinic, comorbidities, 
therapy referrals, and patient reported mobility changes were also recorded.Results: Five 
patients on alendronate (ALN) and nine patients on zoledronic acid (ZA) had telephone 
follow-up with the Osteoporosis Clinic RN by 5/1/2020. The patients were majority male 
(71%) and 93% had Charlson comorbidity index higher than 3 (average 5.1) which was nu-
merically higher in the ZA group (5.7 vs 4.0). Adherence was 100% for ALN and all patients 
received ZA as prescribed. One patient on ZA had a fracture (11%) and four had new falls 
(44%); no falls or fractures occurred in those on ALN. MD was alerted to side effects, patient 
questions, or mobility changes for seven patients (50%) while clinic visits were needed for 
only three patients (21%), all on ZA. This intervention saved 11 follow-up visits and spared 
Veterans, on average, $40 USD and 96 minutes in travel. The average call took 17 minutes, 
ranging from 12-25.Conclusion: In a VA Osteoporosis Clinic, RN-led telephone follow-up 
at three months for Veterans initiated on a bisphosphonate increased clinic access, identified 
patients with side effects, new falls or fractures necessitating MD evaluation while allowing 
for five new consultations and preserving Veteran travel costs. This intervention appears to 
balance principles of high-quality care delivery, even in patients with significant comorbidi-
ties, while improving clinic availability and saving Veteran time. 
Disclosures: Kathryn Dinh, None
P-686
Results of a Multidisciplinary Clinic to Prevent Second Fragility Fracture 
*Nariman Saba Khazen1, Miri Steier2, Ronit Wollstein3. 1Carmel and Lin 
Medical Center, Haifa, Israel, Israel, 2Carmel and Lin Medical Center, Israel, 
3NYU School of Medicine, United States
Purpose: Identifying and treating patients with fragility fractures may be effective in 
prevention of consequent fractures since a first fragility fracture predicts a second fracture. 
Since fracture liaisons have been shown to be effective in preventing fracture occurrence, a 
multidisciplinary anti-osteoporotic clinic designed for patients with prior distal radius fra-
gility fractures (DRF) was formed. The purpose of this study was to evaluate the outcome of 
this clinic. We hypothesized that targeting this early fracture may be effective in prevention 
of a second fracture.Methods:A retrospective case-control study. Cases included patients 
treated surgically for a DRF fragility fracture, assigned to a tertiary, multidisciplinary, frac-
ture prevention clinic.  Controls constituted a series of similarly treated patients in the same 
health system that did not attend the clinic. Our main outcome was a second fracture during 
the follow-up period.Results:Average follow-up period was 42 months in the treated group 
and 85 months in the untreated group. The treated group was treated significantly more for 
osteoporosis than the control group. There was one new fracture in the treated group, and 6 
new fractures in the control group. Using multivariate analysis, follow-up period was not a 
significant factor in new fracture occurrence. There was no significant difference in fracture 
occurrence between the groups.Conclusion:The evidence from this study supports imple-
mentation of the multidisciplinary anti-osteoporotic clinic in treating osteoporosis but not 
in reducing subsequent fractures. Despite a significant difference in treatment, there was no 
difference in fracture occurrence. Though it is possible that we were underpowered to detect 
a difference in fracture incidence and that longer follow-up is needed, it is also possible that 
our treatment is not effective enough. 
Disclosures: Nariman Saba Khazen, None
P-687
Extent of and Reasons for Osteoporosis Medication Non-Adherence Among 
Veterans and Feasibility of a Pilot Text Message Reminder Intervention 
*Nicole Sagalla1, Richard Lee1, Kenneth Lyles1, Julie Vognsen2, Cathleen Colón-
Emeric1. 1Duke University, United States, 2Durham VA, United States
Purpose:To evaluate the extent of and reasons for non-adherence to oral bisphospho-
nates among Veterans and to assess the acceptability and feasibility of a pilot text message 
reminder application.  Methods:We surveyed 105 Veterans initiating oral bisphosphonates 
for osteoporosis/osteopenia within the prior 18 months utilizing a validated self-report mea-
sure adapted for osteoporosis. Additionally, we conducted a pilot text message reminder ap-
plication for 12 patients who were initiating or were currently non-adherent to oral bisphos-
phonates. Patients were surveyed on their experience/satisfaction. Medication adherence 
measured with MPR (medication possession ratio) was an exploratory outcome.  Results:Of 
the 43 (40.9% response rate) completed surveys, the most common reasons for non-adher-
ence were “I forgot” (37.5%), “I had other medications to take” (20.5%), “my bones are not 
weak” (18.4%), “I felt well” (18.4%), and “I worried about taking them for the rest of my 
life” (17.9%). Median MPR for the 49 (46.7%) non-adherent (MPR< 0.80) veterans was 
0.35 (IQR 0.21-0.64). Of patients offered a weekly automated text message reminder, 12 
(50%) accepted.  Nine of these 12 patients reported the text message reminders did “very 
well” at reminding them to take their medication and would recommend the application to 
other patients/family/friends. The median 6-month MPR for the reminder group was 0.96 
(IQR 0.54 – 1.00) and median 3 to 9-month MPR for the comparison group was 0.67 (0.39–
1.00), p = 0.50. Conclusion:Half the patients in our sample were taking insufficient doses 
of oral bisphosphonates to attain the full benefit of fracture risk reduction. Reasons for poor 
adherence included forgetfulness, polypharmacy, and misconceptions about osteoporosis. A 
pilot text message reminder intervention targeted to the most commonly cited reason was 
found to be acceptable and feasible among veterans. 
Disclosures: Nicole Sagalla, None
P-688
Treatment with Zoledronic Acid in Patients with Osteoporosis who Have 
Various Characteristics: Results in 12 months *Yuji Hirano1, Jyunya 
Hasegawa2, Hironobu Kosugiyama3, Daisuke Kihira3, Kyosuke Hattori3. 
1Rheumatology, Toyohashi Munucipal Hospital, Japan, 2Rheumatology, 
Toyohashi Municipal Hospital, Japan, 3Orthopaedic Surgery, Nagoya University, 
Japan
Background : Zoledronic acid (ZOL) is an intravenous bisphosphonate administered 
yearly. Although ZOL was permitted for clinical use to treat osteoporosis (OP) in the United 
States and Europe in 2006, it was permitted in Japan only in 2016. Hence, data on the effica-
cy and safety of ZOL in Japanese clinical practice is still insufficient. Patients with OP have 
various backgrounds, comorbidities, and concomitant drugs. Differences in such characteris-
tics could affect the effect and safety of ZOL. Objectives: The aim of this retrospective study 
was to investigate the efficacy of ZOL in daily clinical practice in patients with OP who have 
various characteristics. Methods: This retrospective study included 53 women with OP who 
were treated with ZOL for >12 months. The time courses of bone mineral density (BMD) in 
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the lumbar spine (LSBMD) and total hip (THBMD) and of bone turnover markers (BTM) 
and the frequency of acute phase reaction (APR) were investigated. The patients were clas-
sified by disease (OP background; category 1) and by the drug used before ZOL for OP 
treatment (category 2). In category 1, we compared patients with rheumatoid arthritis (RA) 
without taking prednisolone (PSL) (RAOP-N), patients with RA taking PSL (RAOP-GC), 
patients with postmenopausal OP (PMOP), and patients with glucocorticoid-induced OP 
(GIOP). In category 2, we compared patients with bisphosphonate pretreatment (BP), pa-
tients without pretreatment apart from vitamin D (DN), and patients with denosumab pre-
treatment (DMB). Results: The mean age of all the patients was 72 years, and 43% of them 
had a history of a previous fracture. The number of patients categorized in each group was 
as follows: category 1 RAOP-N (n = 23), RAOP-GC (n = 6), PMOP (n = 19), and GIOP (n = 
5); category 2 BP (n = 26), DN (n = 19), DMB (n = 7). In all the patients, LSBMD and THB-
MD increased significantly by +3.8% and +1.1%, respectively, at 12 months, whereas BTM 
decreased significantly. At 12 months, LSBMD and THBMD increased by +4.9% and +1.9% 
in RAOP-N, +3.9% and +1.4% in RAOP-GC, +2.8% and +0.0% in PMOP, and +2.3% and 
+0.4% in GIOP, respectively, in category 1 and by +3.6% and +0.7% in BP, +5.1% and 
+2.8% in DN, and +0.1% and −2.0% in DMB, respectively, in category 2; most APRs were 
mild. Conclusions: ZOL was comparatively effective for RAOP-N, PMOP, BP, and DN with 
respect to LSBMD and for RAOP-N and DN with respect to THBMD. BMD decreased with 
DMB, and most APRs were mild but frequent.
Disclosures: Yuji Hirano, None
P-689
Bone metabolism markers change in the initial 4 months after switching 
from Denosumab to Romozosumab *yoichi kishikwa1. 1kishikawa orthopedic 
clinic, Japan
Backgrounds                                                                            Romozosumab(RZMb) is 
a biological antibody which suppresses Sclerostin. It promotes Wint /β catenin signals, and 
makes strong bones by means of activating bone formation and suppressing bone resorption. 
On the other hand, Denosumab(DSMb) has a problem of bone metabolismovershoot when 
it is discontinued. It has been reported that switching from DSMb to Teriparatide results in a 
loss of BMD in the femoral neck, a very undesirable affect. To date, there has been no report 
of the effect on bone metabolism when switching from DSMb to RZMb. Purpose and meth-
od                                                                                                In cases where no increase of BMD 
or incidence of new fractures occurred under administration of DSMb, I chose to switch 
from DSMb to RZMb in 25 subjects. I compared these 25 subjects to 21 subjects, whom I 
switched from bisphosphonates(BPs) to RZMb.                                                               Subjects 
were retrospectively observed and statistically demonstrated from the point of bone metabo-
lism markers (TRACP5b, OC, ucOC ) and BMD (Femoral neck and total) for 4 months after 
switching to RZMb. The initial blood samples were taken 6 months after the last administra-
tion of DSMb. Results                                                                                                               OC, 
ucOC, ucOC/ OC increased significantly in both groups after 4 months of switching from 
BPs or DSMb(P<0.001).                                                    TRACP5b decreased when 
switching from BPs (P<0.001), but increased when switching from DSMb(P<0.001). 
When looking at the data on an individual subject basis, TRACP5b decreased in 2 cases 
when initial TRACP5 were high above 700 mu/dl although in the other 20 cases it increased 
when initial TRACP5 were under 500 mu/dl.        This phenomenon might mean an over-
shoot of bone metabolism overrides the original effect of RZMb when DSMb is discontin-
ued.                           Further careful observation must be needed to investigate how bone 
metabolism markers change after 12 months when switching from DSMb to RZMb.  BMD 
didn’t change significantly in either group after 4 months. It is said that Serum Calcium 
may drop down no less than 8 mg/ml after 2 weeks upon administration of RZMb. This 
phenomenon was not observed under concordant use of activated vitamin D in any of these 
cases.  Discussion                                                                                                       When 
switching from DSMb to RZMb, bone formation is activated as OC increased (P<0.001), 
but bone resorption is activated too as TRACP5b increased DSMb(P<0.001) after 4 months.
Disclosures: yoichi kishikwa, None
P-690
Pearls for Creating and Sustaining a Successful Fragility Fracture Liaison 
Program *Susan Williams-Judge1, Teresa Sherman1, Julie L. Carkin1. 1University 
of Washington Northwest, United States
Osteoporosis remains a silent, underappreciated and under-treated disease. One of the 
most successful ways to break the fragility fracture cycle is to implement fragility fracture 
liaison programs; yet there are a dearth of programs nationwide, and many programs fail 
due to a plethora of issues including program costs, personnel retention and recruitment, 
and addressing critical issues and therapy disconnections in a timely manner.Five years into 
establishing a successful fragility fracture liaison program, the Strong Bones Program at the 
University of Washington Medical Center Northwest campus in Seattle, Washington felt 
it was important to share major pearls that will serve as a basis for implementation and 
sustainment in creating a successful fragility fracture program regardless of geographic or 
clinical service boundaries. Information will include the four stages of creating a successful 
interdisciplinary program, how to avoid common pitfalls and major roadblocks, creating and 
sustaining a successful, well-balanced inpatient and outpatient referral center at no extra 
cost to the institution, and with considerable benefit to the aging community in preventing 
potential future fractures resulting in an improved quality of life.
Disclosures: Susan Williams-Judge, None
P-691
Denosumab (Dmab):  Long Inter-Injection Interval (III) without Apparent 
Adverse Effects *Elliott Schwartz1, Patricia Schwartz1, Clinten P. Edmondson2. 
1Northern California Institute for Bone Health, Inc., United States, 2Northern 
California Institute for bone Health, Inc, United States
Dmab is a fully human monoclonal antibody to the receptor activator of nuclear factor 
Kβ ligand (RANKL) that inhibits development and activity of osteoclasts. Dmab was ap-
proved in the US in 2009 utilizing data from 30 clinical trials and 12,000 subjects.Results 
of “rebound” phenomena in bone turnover markers (BTM) after discontinuing indicated 
increased bone resorption (BR), bone loss and VCFxs. At the 6-month mark, BR should 
return to 45 % of baseline (BSL) from its nadir at 1 month. Subsequently, reports of a “cri-
sis” or “gap” in treatment of OP became prominent. Patients were concerned with increased 
AEs where decrease in bone turnover (BTO) may play a role. In order to monitor BTO 
more closely, we began a program consisting of BSL BTM, BTM 1 month post-injection 
(post-Prolia lab), BTM at 6 months post -injection (pre-Prolia lab) and BTM at subsequent 3 
month intervals if the patient was deemed “not ready” for their next dose by the 45 % “rule.” 
We followed 17 patients who, because of different issues (persistent decrease in BTM, dental 
work, non-compliance, etc.) had long III (shortest 11 months, longest 56 months). No VCFxs 
occurred monitored by VFA or other imaging.Additional risk factors for the occurrence or 
non-occurrence of VCFxs after Dmab discontinuation need to be explored and may include 
persistent decrease in BTM.
Disclosures: Elliott Schwartz, None
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Molecular and cellular analyses of BMP-dependent coupling signals between 
osteoclasts and osteoblasts during bone remodeling *Maiko Omi1, Laura 
Ortinau2, Dongsu Park0, Yuji Mishina1. 1Department of Biologic and Materials 
Sciences & Prosthodontics, University of Michigan School of Dentistry, United 
States, 2Department of Molecular Human Genetics, Baylor College of Medicine, 
United States, 0Department of Molecular Human Genetics, Baylor College of 
Medicine, United States
The balance between bone resorption and bone formation is regulated by a mechanism 
called coupling that includes communication between osteoclasts (OCLs) and osteoblasts 
(OBs). We reported that OCL-specific disruption of a BMP receptor encoded by Bmpr1a 
(Bmpr1afx/fx;Ctsk-Cre) leads to increased bone mass associated with increased bone for-
mation. In vitro studies have shown that conditioned media from Bmpr1a mutant OCLs 
promote OB mineralization compared to those from control OCLs, while OCLs inhibit OB 
differentiation in a direct co-culture system, suggesting that OCLs regulate OB activity via 
two distinct modes. Interestingly, OCLs physically interact with OBs thorough tunneling 
nanotubes (TNTs), actin-based long cell protrusions, and Bmpr1a mutant OCLs exhibit a 
decrease in TNT-mediated OCL-to-OB interaction, suggesting that TNT-mediated cellular 
communication is a downstream event of BMP signaling. In this study, we further investigat-
ed how TNT-mediated OCL-to-OB interaction contributes to OB-mediated bone formation 
both in vitro and in vivo.The in vitro studies showed that (1) OBs co-cultured with OCLs 
exhibited increased Annexin V expression. In addition, (2) OBs interacted with OCLs via 
TNTs displayed typical morphological changes of cells undergoing apoptosis, and (3) those 
OBs highly expressed Bax, a proapoptotic marker, suggesting that OCLs induce OB cell 
death through TNTs. To address the in vivo function of TNTs, we established an intravi-
tal imaging system of mouse calvaria tissues, in which bone marrow cells from Ctsk-Cre/
tdTomato mice were transplanted into sublethally irradiated Osteocalcin-GFP mice. Using 
intravital microscopy, we were able to show that (4) OCLs physically interact with OBs via 
TNTs in live calvaria. Additionally, (5) OBs interacted with OCLs via TNTs exhibited ab-
normal cell shape in the fixed femur samples, suggesting that OCLs may regulate cell death 
of OBs via TNTs.Taken together, our data suggest that OCLs have two distinct functions 
during bone remodeling; OCLs induce OB cell death via TNTs when and where they re-
sorb bone matrix, while they promote OB activity via secreted factors to initiate subsequent 
bone formation, which may be important for regulating spatial and temporal coupling of 
bone formation and bone resorption. Our findings also suggest that those direct and indirect 
OCL-to-OB interaction are the potential targets of BMP signaling providing new therapeutic 
opportunities for bone mass-related diseases.
Disclosures: Maiko Omi, None
P-693
Mmp13 deletion in cells of the mesenchymal lineage decreases osteoclast 
number, increases cortical and trabecular bone mass, and may attenuate 
the cortical bone loss caused by estrogen deficiency in mice *Filipa Ponte1, 
Ha-neui Kim1, Srividhya Iyer1, Aaron Warren1, Li Han1, Erin Mannen1, Horacio 
Gomez-Acevedo1, Maria Almeida1, Stavros Manolagas1. 1UAMS, United States
Estrogens attenuate the resorption of trabecular and cortical bone via estrogen receptor 
alpha (ERα), mediated actions on cells of the hematopoietic and mesenchymal lineages, 
respectively. To identify estrogen target genes that regulate osteoclast number via actions 
on cells of the mesenchymal  lineage, we performed microarray analysis of GFP-sorted 
Osx1+ cells without or with ERα, derived from the calvaria of ERαDGFP:Osx1mice or 
GFP:Osx1-Cre controls. Among 510 up-regulated transcripts in ERα deleted cells (cut off 
p=0.01) the highest, 9-fold increase, encoded the matrix metalloproteinase 13 (MMP13). 
The microarray findings were confirmed by qPCR and reproduced in ERα-deleted Prx1 
cells derived from the calvaria of ERαDPrx1. Additionally, the protein levels of the active 
form of MMP13 were 4-fold higher in the BM plasma of ovariectomized C57BL/6J mice, 
as compared to sham controls. To obtain functional evidence for the role of mesenchymal 
cell-derived MMP13 in bone resorption we next generated mice with Mmp13 deletion in 
Prx1 expressing cells (Mmp13DPrx1). Mmp13f/f control littermates and Mmp13DPrx1 
mice where either ovariectomized (OVX) or sham-operated at 5 months of age and eutha-
nized 1 month later. Relative Mmp13 mRNA expression in femur shafts of Mmp13DPrx1 
mice was decreased by 50-fold, as compared to the controls. Total body and uterine weight 
were no different, but femur and tibia length was decreased. Cortical thickness at the dis-
tal metaphysis and diaphysis, trabecular bone volume and trabecular number and thickness 
in the femur and tibia, measured by micro-CT, as well as bone strength (yield, ultimate 
stress and modulus of elasticity) were increased in the sham-operated female Mmp13DPrx1 
mice. These phenotypic changes were accompanied by a decrease in osteoclast number, as 
determined by dynamic histomorphometry of undecalcified endocortical sections. Mineral 
apposition rate, mineralizing surface, and bone formation rate, on the other hand, were un-
affected by the Mmp13 deletion. OVX decreased both femoral and tibia cortical thickness 
in the control mice and this effect was attenuated in the Mmp13DPrx1 mice; whereas the 
effect of OVX on cancellous bone was not affected by the Mmp13 deletion. These findings 
suggest an important role of mesenchymal cell–derived MMP13 on osteoclast number, bone 
resorption, and bone mass; as well as a contributory role in the cortical, but not trabecular, 
bone loss caused by estrogen deficiency.
Disclosures: Filipa Ponte, None
P-694
Stem Cell Marker and Wnt-associated Protein Lgr6 is Dispensable for 
Development and Intramembranous Bone Formation but Required for 
Endochondral Fracture Healing *Laura Doherty1, Daniel Youngstrom1, Sanja 
Novak1, Kurt Hankenson2, Ivo Kalajzic1, Archana Sanjay1. 1UConn Health, 
United States, 2University of Michigan, United States
Because of its essential role in osteoblast function, the Wnt pathway is a current target 
of clinical trials to treat bone diseases including osteoporosis. Leucine-rich repeat-contain-
ing G protein-coupled receptor 6 (Lgr6) potentiates Wnt signaling and has been identified 
as a putative osteochondral stem cell marker in vitro and in vivo. However, its function in 
the context of fracture healing is undefined. Hypothesizing a requirement for Lgr6 in bone 
regeneration, we ablated endogenous Lgr6 expression using homozygous knock-in Lgr6EG-
FP-ires-CreERT2 mice (Lgr6-null). In contrast to Lgr5-null and Lgr4-null mice, which ex-
hibit severe skeletal abnormalities and neonatal lethality, Lgr6-null mice develop normally 
with no overt skeletal phenotype. We performed femoral fractures in Lgr6-null mice and 
wild-type controls, and analyzed the calluses at 14 and 28 days post-fracture. Lgr6-null mice 
experience significant delays in mineralization during repair. While overall callus size at 14 
days post-fracture is comparable among groups, Lgr6-null bones have significantly reduced 
callus bone volume relative to controls (46% reduction in BV/TV, p=0.038). The calluses are 
characterized by large unmineralized voids shown by μCT, and retain significant amounts of 
cartilage as shown by safranin O staining, suggesting a defect in endochondral bone healing. 
28 days post-fracture, Lgr6-null calluses display aberrant morphology compared to controls, 
with significantly higher retained callus volume (115% larger callus TV, p=0.033), and few-
er, thinner areas of newly formed cortical bone. Periosteal progenitors isolated from Lgr6-
null mice show significant delays in in vitro mineralization compared to controls following 
21 days of exposure to differentiation media, further validating in vivo results. To understand 
the role of Lgr6 in intramembranous ossification as opposed to endochondral ossification, 
we performed bone marrow ablation studies, and analyzed the intramedullary femur 7 days 
post-injury. Strikingly, Lgr6-null mice regenerate significantly more trabecular bone follow-
ing marrow ablation compared to controls (158% increased BV/TV 7 days post-ablation, 
p=0.003). Our results suggest that Lgr6 is an essential, yet context-specific, component of 
skeletal regeneration. Its divergent function in endochondral and intramembranous bone 
formation, including cellular and molecular mechanisms within the broader context of Wnt 
signaling, are the subject of ongoing investigation.
Disclosures: Laura Doherty, None
P-695
Role of Sfrp4-dependent Non-canonical Wnt Regulation in Bone Repair and 
Regeneration *Chiho Ahn1, Ruiying Chen1, Kun Chen1, Shawn Berry1, Roland 
Baron2, Francesca Gori1. 1Division of Bone and Mineral Research, Harvard 
Medical School and Harvard School of Dental Medicine. Department of Oral 
Medicine, Infection and Immunity, Harvard School of Dental Medicine., United 
States, 2Division of Bone and Mineral Research, Harvard Medical School and 
Harvard School of Dental Medicine. Department of Oral Medicine, Infection and 
Immunity, Harvard School of Dental Medicine. Endocrine Unit, Massachusetts 
General Hospital., United States
Sfrp4 (Secreted Frizzled Receptor Protein 4) functions as a decoy receptor for the 
Wnt ligands and, differently from other well-known Wnt antagonists, such as sclerostin 
(Sost) that binds to Lrp5/Lrp6 and block canonical (c)Wnt signaling, Sfrp4 suppresses both 
cWnt and non-cWnt cascades. Loss of function mutations in SFRP4 are the cause of Pyle’s 
disease, a rare skeletal disease that leads to limb deformity and fragility fractures. Sfrp4 
deletion in mice causes skeletal deformities closely mimicking those seen in individuals 
with Pyle’s disease: long bones with wide metaphyses, increased trabecularization and thin 
cortex. Using these mice, we uncovered that cortical thinning is due to decreased periosteal 
bone formation as well as uncoupled remodeling on the endosteal surface, largely due to the 
activation of the non-cWnt/Jnk cascade. Given that the periosteum contains a niche of stem 
cells which contributes to the response to injury to support new bone formation, we asked 
whether activation of both cWnt and non-cWnt signaling (Sfrp4-/- mice)  may alter bone 
repair and regeneration. To this end, we created both calvarial critical-sized defects (which 
don’t heal spontaneously) and subcritical-sized defects (which heal spontaneously). We used 
Sost-/- mice as a model for cWnt signaling activation. We demonstrated that while cWnt 
signaling is equally activated in calvarial bones of Sost-/- and Sfrp4-/- mice, the non-cWnt 
cascade is activated only in Sfrp4-/- calvarial bones. Confirming previous findings, activa-
tion of cWnt signaling (Sost deletion) favors bone regeneration (measured as BV/TV%) 
within the initial critical defect (14%+1.7 in wt vs 29%+12.4 in Sost-/- mice, p<0.01) 6 wk 
after surgery. In contrast, deletion of Sfrp4 did not (13%+1.1 in wt vs 13.1%+0.44 in Sfrp4-
/- mice, NS). In the subcritical defects, while activation of cWnt signaling (Sost-/- mice) led 
to accelerated bone regeneration (38.3%+7.7 in wt vs 57.5%+3 in  Sost-/- mice, p<0.05), 
Sfrp4-/- mice showed only a response similar to wt mice (31.5%+2 in wt vs 31.2%+2.3 in 
Sfrp4-/- mice, NS). These findings demonstrate once again how Wnt signaling fine-tuning 
is critical to achieve proper bone responses. Given that activation of cWnt signaling in the 
calvaria is similar in both Sost and Sfrp4 null mice, we hypothesize that activation of non-
cWnt signaling might be responsible for improper function of stem cells within the sutures 
and/or progenitors in the periosteum.
Disclosures: Chiho Ahn, None
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Interleukin-6 Trans Signaling Enhances the Chondrogenic Response of 
Human Bone Marrow Stromal Cells to Bone Morphogenetic Proteins 
*Landon Gatrell1, Hong Wu1, Elisabeth Ferreira2, Ryan Porter2. 1University of 
Arkansas for Medical Sciences, Department of Internal Medicine, United States, 
2University of Arkansas for Medical Sciences, Departments of Internal Medicine 
and Orthopaedic Surgery, United States
Bone fractures typically heal through endochondral ossification, involving formation 
and remodeling of a cartilaginous callus. For larger defects, this endochondral repair path-
way is compromised. Preclinical studies have demonstrated that cartilage templates engi-
neered in vitro from bone marrow-derived mesenchymal stem/stromal cells (BMSCs) can 
stimulate the repair of large bone defects. Directing BMSC chondrogenesis within the bone 
injury site would be a more practical alternative to tissue engineering; however, pro-in-
flammatory cytokines upregulated in response to skeletal injury have been shown to inhibit 
BMSC chondrogenesis induced by transforming growth factor (TGF)-β. Less has been re-
ported about chondroinduction by BMPs, which have distinct potency on BMSCs compared 
to the TGF-β isoforms. When screening pro-inflammatory cytokines for their impact on 
BMSC chondrogenesis using a differentiation-conditional luciferase reporter, interleukin 
(IL)-6 was observed to enhance reporter activity in response to BMPs, in contrast to the 
other cytokines tested. This effect required co-stimulation with the soluble IL-6 receptor 
(i.e., trans signaling), though sIL-6R had negligible independent effects. IL-6 trans signaling 
enhanced proteoglycan deposition and chondrogenic gene expression stimulated by BMPs 
-2, -4, and -7, but not TGF-β1. Cell sorting demonstrated that the CD146-positive subpop-
ulation of BMSCs was responsive to IL-6 enhancement of BMP-induced chondrogenesis. 
Gene expression analysis of the TGF-β superfamily and related signaling mediators revealed 
minimal effects of IL-6/sIL-6R – as opposed to IL-1β challenge. Instead, members of the 
Wnt signaling pathway were differentially expressed by IL-6 trans signaling in a pattern sug-
gesting enhanced canonical Wnt signaling. These data demonstrate that the pro-inflamma-
tory cytokines are not uniformly refractory to BMSC chondrogenesis; rather, IL-6 through 
a trans signaling pathway can potently enhance their chondroinductive response to multiple 
bone morphogenetic proteins known to promote endochondral bone formation.
Disclosures: Landon Gatrell, None
P-697
PDGF Regulation of BMP2-Mediated Osteogenesis *Josip Madunic1, Laura 
Shum1, MIlan Vucetic1, Sanja Novak1, Ivo Kalajzic1. 1UConn Health, United 
States
Bone healing consists of complex cell interactions regulated by growth factors. Re-
combinant BMP2 is used in orthopedic treatments to induce bone formation. However, the 
supraphysiological doses used can cause serious side-effects. PDGF, a mitogenic growth 
factor highly expressed during bone healing, has also been used to induce bone formation 
in some clinical applications. Despite the individual abilities of PDGF and BMP2 to in-
duce bone, our previous work showed that PDGF inhibits BMP2-induced osteogenesis in 
periosteal progenitor cells in vitro. The purpose of the current study was to determine the 
in vivo role of PDGF on BMP2-mediated osteogenesis. We used critical-sized long bone 
defects in αSMA9/Col2.3GFP transgenic mice. These mice express the red reporter tdToma-
to in αSMA+ mesenchymal progenitor cells allowing for analysis of progenitor expansion. 
Col2.3GFP is expressed in mature osteoblasts and is an indicator of osteogenesis. Criti-
cal-sized femoral defects (3 mm) stabilized by external fixation were made in 5-month-old 
male mice. Growth factors PDGF-BB (2 µg) and BMP2 (0.5 µg or 5 µg), individually or 
in combination, were applied on the collagen-based material “Infuse” in the defect. αS-
MA-driven Cre activity was induced by injecting tamoxifen. We assessed defect healing at 
2 and 9 weeks using histological analyses. µCT-based morphometry was quantified 9 weeks 
after defect surgeries. We observed expansion of αSMA+ progenitor cells into the defect 
following BMP2 treatment and a more pronounced effect with the higher dose. This effect 
was significantly decreased when the higher dose of BMP2 was combined with PDGF, as 
quantified by αSMA+ area (p<0.01). At 9 weeks of healing, PDGF and BMP2 individual-
ly stimulated osteoblast differentiation, as evidenced by the increase in Col2.3GFP signal 
corresponding to the areas of new bone formation. However, these effects were inhibited 
when the growth factors were combined. Although 5 µg BMP2 had biggest impact on bone 
bridging and bone volume within the defect area, PDGF treatment alone also increased bone 
volume. Furthermore, μCT data showed that PDGF had inhibited BMP2-induced bone for-
mation, demonstrated by the decrease in bone volume in the defect area (p<0.01). Our in 
vivo data shows evidence that individual treatments by BMP2 and PDGF-BB induced bone 
formation, while PDGF exerted negative effects on the osteogenic action of BMP2.
Disclosures: Josip Madunic, None
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ENDOTHELIAL CELL PHYSIOLOGY IN A MICROFLUIDIC DEVICE 
AND THEIR RESPONSE TO MESENCHYMAL STROMAL CELLS 
*Shuang Zhang1, Bastiaan Tuk2, Marijke Koedam1, Pouyan E. Boukany3, Georg 
Pesch3, Gert-Jan Kremers4, Johan W. van Neck2, Johannes P.T.M. van Leeuwen1, 
Bram C.J. van der Eerden1. 1Internal Medicine, Erasmus University Medical 
Center, Netherlands, 2Plastic and Reconstructive Surgery, Erasmus University 
Medical Center, Netherlands, 3Chemical Engineering, Delft University of 
Technology, Netherlands, 4Optical Imaging Center, Erasmus University Medical 
Center, Netherlands
Introduction: Fracture healing involves a complex sequence of physiological events. 
A functional vascular system is a prerequisite for bone repair as disturbed angiogenesis of-
ten causes nonunions. Paracrine factors derived from bone mesenchymal stromal cells have 
angiogenic effects on endothelial cells. However, whether this paracrine step participates in 
blood flow dynamics within bone capillaries remains poorly understood.Objective: Study 
the effect of human bone marrow-derived mesenchymal stromal cells (hBMSCs) secretome 
on endothelial cell behaviour in blood capillary physiology-mimicking microfluidic models.
Methods: Conditioned medium was collected from hypoxic hBMSCs (hBMSC-CM), and 
cytokines were detected by angiogenic protein array. The effect of hBMSC-CM on endothe-
lial cell proliferation (Ki-67 immunostaining) was monitored in a microfluidic model under 
physiological shear stress. A second microfluidic wound-healing model was generated to 
mimic endothelial cell disruption following injury-induced hypoxia. Differently sized fluo-
rescence-labelled dextrans were used to mimic chemotactics of proteins in the hBMSC-CM. 
By analyzing wound healing over time, the mechanotactic effect of shear stress and chemo-
tactic effects of hBMSCs on endothelial cell migration were evaluated.Results: Different 
angiogenic-related factors including platelet-derived growth factor (PDGF-BB; 10-fold) and 
vascular endothelial growth factor (VEGF; 15-fold), were elevated in hBMSC-CM versus 
control medium. hBMSC-CM introduction in the microfluidic single channel model induced 
endothelial cell proliferation (2-fold) as assessed by ki67 staining and cell number counts. In 
the microfluidic-based endothelium rupture model, a wound was generated by introducing 
three parallel fluid streams in the channel, of which the middle one contained the protease 
trypsin. A stable diffusion gradient of differently sized dextrans was measured in the chan-
nel implicating that chemotactics takes place in the model. Indeed, hBMSC-CM infusion 
at physiologically relevant shear stress-inducing flow rates increased the endothelial cell 
migration rate (1.5-fold) versus control medium.Conclusion: Trophic factors released by 
hBMSCs enhanced angiogenic properties in microfluidic models mimicking endothelial cell 
physiology including injury, hypoxia, shear stress and chemotaxis. This platform provides a 
novel in vivo-like microenvironmental approach to study fracture healing-related processes.
Disclosures: Shuang Zhang, None
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Muscle-derived lumican stimulates bone formation via integrin α2β1 and the 
downstream ERK signal *Jin Young Lee1, So Jeong Park1, Da Ae Kim1, Beom-
Jun Kim2. 1Asan Institute for Life Sciences, Asan Medical Center, University of 
Ulsan College of Medicine, Republic of Korea, 2Division of Endocrinology and 
Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 
Republic of Korea
Skeletal muscle and bone are highly interrelated, and previous proteomic analyses sug-
gest that lumican is one of muscle-derived factors. To further understand the role of lumican 
as a myokine affecting adjacent bone metabolism, we investigated the effects of lumican on 
osteoblast biology. Lumican expression was significantly higher in the cell lysates and con-
ditioned media (CM) of myotubes than those of undifferentiated myoblasts, and the known 
anabolic effects of myotube CM on osteoblasts were reduced by excluding lumican from the 
CM. Lumican stimulated preosteoblast viability and differentiation, resulting in increased 
calvaria bone formation. The expression of osteoblast differentiation markers was consis-
tently increased by lumican. Lumican increased the phosphorylation of ERK, whereas ERK 
inhibitors completely reversed lumican-mediated stimulation of Runx2 and ALP activities in 
osteoblasts. Results of a binding ELISA experiment in osteoblasts show that transmembrane 
integrin α2β1 directly interacted with lumican; and an integrin α2β1 inhibitor attenuated the 
stimulation of ERK and ALP activities by lumican. Taken together, the results indicate that 
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muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream 
ERK signal, indicating that this is a potential therapeutic target for metabolic bone diseases.
Disclosures: Jin Young Lee, None
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Fluoxetine Exposure during the Peripartal Period Has Sex-Specific Impacts 
on Adult Bone Health in Mice *Hannah Fricke1, Chandler Krajco1, Celeste 
Sheftel1, Julia Charles2, Laura Hernandez1. 1University of Wisconsin - Madison, 
Department of Animal and Dairy Sciences, United States, 2Harvard Medical 
School, Department of Orthopedic Surgery, United States
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class 
of antidepressants during pregnancy and lactation. SSRIs decrease bone mineral density 
(BMD) across all ages and sexes. Lactation is also characterized by increased bone resorp-
tion to mobilize calcium and achieves this via a serotonin-induced hormonal cascade. This 
serotonin-mediated bone loss is normally restored after weaning but is persistent when an 
SSRI is administered during the peripartum period. Previous research in our lab has shown 
that peripartal fluoxetine (FLX) exposure is associated with increased serum serotonin 
content, decreased femoral length, lower BMD, and lower trabecular bone volume/tissue 
volume (BV/TV) in the exposed offspring at weaning. We hypothesize that peripartal FLX 
exposure has a negative impact on long bone growth and BMD that persists into adulthood. 
Female C57BL/6J between 6-8 weeks of age were randomized to receive the SSRI fluox-
etine hydrochloride (20 mg/kg) or saline daily via intraperitoneal (IP) injection from the 
beginning of pregnancy (E0) through the end of lactation (D21). At weaning, the offspring 
were then separated into the following groups: Saline-exposed female (SF) and male (SM) 
and FLX-exposed female (FF) and male (FM). Dual-energy X-ray absorptiometry (DEXA) 
was used to measure a baseline BMD at 6 weeks of age, and a baseline weight was taken as 
well. BMD was measured periodically, and daily weights were taken until 12 weeks of age. 
At 12 weeks, all groups were euthanized, and the femurs were collected for gene expression 
analysis via RT-PCR. The total body BMD of the FM group was significantly lower than SM 
across the treatment period (p=0.0119), but there was no difference between the SF and FF 
(p=0.4991) groups. There was an increase in the ratio of gene expression between RANKL 
and OPG in the FLX groups (p=0.0287) and an increase in RANK expression in FM com-
pared to SM (p=0.0364). There was no difference in weight gain between 6 and 12 weeks of 
age between the SF and FF (p=0.8699) groups or the SM and FM (p>0.9999) groups. Bone 
microarchitecture will be measured via micro-computed tomography (micro CT) to further 
analyze the impact of developmental FLX exposure. We conclude that peripartum FLX ex-
posure has a sex-dependent impact on adult bone health in mice.
Disclosures: Hannah Fricke, None
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Effects of Peripartal Sertraline on Maternal and Fetal Bone Health *Celeste 
M. Sheftel1, Luma C. Sartori1, Robbie Manuel1, Hannah Fricke1, Julia Charles2, 
Laura L. Hernandez1. 1University of Wisconsin-Madison, United States, 2Harvard 
Medical School, United States
Lactation is taxing on mothers’ bone health, causing them to lose up to 10% of their 
bone mass to supply milk calcium. Selective serotonin reuptake inhibitor antidepressants 
(SSRIs) are commonly used during pregnancy and lactation but decrease maternal bone 
mass independent of lactation. We have previously demonstrated that both maternal and 
offspring bone densities were compromised by maternal treatment with the SSRI fluoxetine 
throughout pregnancy and lactation.In this study, we examined whether sertraline would 
similarly compromise maternal and offspring bone like observations with treatments of flu-
oxetine. Female C57BL/6 dams (n=20/group) were treated with sertraline (10mg/kg/d) or 
a vehicle (DMSO) from pregnancy day 1 through 21 (weaning). Pups were euthanized at 
weaning. Dams were euthanized at weaning (n=10/group) or three months post-weaning 
(n=10/group) for analysis.Compared to control, sertraline treatment reduced the expression 
of parathyroid hormone related protein, (p<0.1), and the calcium transport proteins Orai1 
and Serca2 (p<0.05) in the mammary gland at weaning. However, circulating calcium was 
not altered during lactation in either group. Circulating procollagen type I N-terminal pro-
peptide, a marker of bone formation, was not altered in sertraline-treated dams on the first 
day of lactation or at weaning, contrary to results observed due to fluoxetine treatment. Ser-
traline treatment altered gene expression in maternal femoral bone, with a tendency towards 
increased Mmp13 expression at weaning (p<0.1), and an increase in Mcp1, a bone resorption 
gene, at three months postpartum (p<0.05); however, no other bone resorption or formation 
marker was affected at either timepoint. Circulating calcium was similarly unaffected in the 
pups at weaning, suggesting an adequate supply of calcium in the milk from the dam. In 
utero exposure to sertraline reduced litter size (5.4 vs 6.8 pups/dam, p<0.01) and increased 
pup mortality (20% vs 5% dead pups/litter, p<0.01) during the first 24 hours postpartum 
compared with controls.These data suggest that sertraline has a milder impact on maternal 
bone and calcium trafficking than fluoxetine but may induce a failure to thrive in the off-
spring. Bones will be analyzed by micro-computed tomography to measure sertraline-medi-
ated changes to maternal bone microarchitecture at weaning and 3 months post-weaning in 
the dams and in the offspring at weaning.
Disclosures: Celeste M. Sheftel, None
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Very low doses of sclerostin and Dkk1 neutralizing antibody are strongly 
anabolic if administered at the optimal ratio *Roy Choi1, Alexander Robling1. 
1Indiana University School of Medicine, United States
Sclerostin is an attractive target for targeted bone therapies due to its selectivity to 
bone cells and its prominent effects on bone mass. Recently, sclerostin antibody(Evenity™) 
was approved for clinical use in the US to treat bone disorders. Curiously, targeting other 
Wnt inhibitors such as Dkk1 fails to induce significant osteoanabolic response. However, 
Dkk1 antibody(Dkk1-mAb) is highly osteoanabolic in Sost KO mice, suggesting that Sost 
might restrain the otherwise anabolic action of Dkk1 inhibition. Moreover, co-treatment of 
both sclerostin antibody(Scl-mAb) and Dkk1-mAb showed synergistic osteoanabolic action, 
where the anabolic response was greater than either, Scl-mAb or Dkk1-mAb alone, and well 
beyond additive effects. The strength of the response promoted us to explore whether the 
proportions of Scl-mAb and Dkk1-mAb could be optimized to elicit maximal osteoanabolic 
activity. At a previous ASBMR meeting, we presented that a 3:1 ratio was found to be the op-
timal formulation. In the current experiments, we sought to determine the minimal total dose 
of 3:1 antibody treatment that could maintain equal efficay as the Scl-mAb alone at 25mg/
kg, or 25,19,12, or 6mg/kg of 3:1 antibody mixture. The 25mg/kg 3:1 mixture was able to 
generate significantly increased cancellous properties in the both distal femur and lumbar 
spine compared to 25mg/kg Scl-mAb alone, with stepwise reduction according to total dose. 
However, the loweset 3:1 dose (6.2mg/kg), was able to generate similar bone anabolic action 
as the 25mg/kg Scl-mAb alone group, at roughly one quarter of the total dose. In conclusion, 
the optimal 3:1 ratio of Scl-mAb and Dkk1-mAb can significantly increase cancellous bone 
properties and provide equal anabolic action as 4X the amount of Scl-mAb alone.
Disclosures: Roy Choi, None
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Prophylactic treatment of rapamycin ameliorates naturally developing 
and episode - induced heterotopic ossification in mice expressing human 
mutant ACVR1 *Hirotsugu Maekawa1, Shunsuke Kawai1, Sanae Nagata1, 
Nishio Megumi2, Yonghui Jin2, Hiroyuki Yoshitomi3, Shuichi Matsuda3, Junya 
Toguchida1. 1Department of Cell Growth and Differentiation, Center for iPS Cell 
Research and Application, Kyoto University, Japan, 2Department of Regeneration 
Sciences and Engineering, Institute for Frontier Life and Medical Sciences, 
Kyoto University, Japan, 3Department of Orthopaedic Surgery, Graduate School 
of Medicine, Kyoto University, Japan
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal-dominant disease char-
acterized by heterotopic ossification (HO) in soft tissues and caused by a mutation of the 
ACVR1A/ALK2 gene, which encodes a type I receptor for bone morphogenetic protein 
(BMP). Activin-A is a key molecule for initiating the process of HO via the activation of 
mTOR, while rapamycin, an mTOR inhibitor, effectively inhibits the Activin-A-induced 
HO. However, few reports have verified the effect of rapamycin on FOP in clinical per-
spectives.We investigated the effect of rapamycin for different clinical situations by using 
mice conditionally expressing human mutant ACVR1A/ALK2 gene (FOP-ACVR1 mice). 
We also compared the effect of rapamycin between early and episode-initiated treatments 
for each situation.First of all, we investigated the effect of rapamycin on spontaneous HO 
which developed without any known triggers in FOP-ACVR1 mice. Continuous, episode-in-
dependent administration of rapamycin reduced the incidence and severity of HO in the 
natural course of FOP-ACVR1 mice. In addition, rapamycin also improved the survival rate 
of FOP-ACVR1 mice during observation period.Next, we evaluated the effect of rapamycin 
on HO induced by a physical skeletal muscle damage in FOP-ACVR1 mice. To imitate the 
clinical situation, FOP-ACVR1 mice received pinch-injury to lower hindlimbs. Pinch-injury 
induced HO in FOP-ACVR1 mice not only at the injured sites, but also in the contralateral 
limbs and provoked a prolonged production of Activin-A in inflammatory cells. Although 
both early and injury-initiated treatment of rapamycin suppressed HO in the injured sites, 
the former was more effective at preventing HO in the contralateral limbs. In addition, we 
confirmed that rapamycin suppressed infiltration of inflammatory cell at the injured site in 
the inflammatory stage of HO.Finally, we investigated whether rapamycin can suppress the 
recurrent HO formation after resection. Rapamycin was also effective at reducing the vol-
ume of recurrent HO after the surgical resection of injury-induced HO, for which the early 
treatment was more effective.Our study suggested that rapamycin inhibit HO formation not 
only at chondrogenic stage but also at inflammatory stage and prophylactic treatment will be 
a choice of method for the clinical application of rapamycin for FOP.
Disclosures: Hirotsugu Maekawa, None
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Small molecule inhibition of TGFβ-activated kinase (TAK1) results in 
reduced heterotopic ossification *Amy Strong1, Philip Spreadborough2, Chase 
Pagani1, Ryan Haskins2, Devaveena Dey2, Patrick Grimm2, Keiko Kaneko1, 
Simone Marini1, Amanda Huber1, Charles Hwang1, Kenneth Westover3, Yuji 
Mishina1, Matthew Bradley4, Benjamin Levi1, Thomas Davis4. 1University of 
Michigan, United States, 2Uniformed Services University of the Health Sciences, 
United States, 3University of Texas Southwestern Medical Center, United States, 
4Uniformed Services University of the Health Sciences, United States
Heterotopic ossification (HO) is defined as ectopic bone formation around joints and 
in soft tissue following trauma, particularly blast-related extremity injury or thermal injury, 
or following orthopedic surgery or neurological injury, leading to increased pain and di-
minished quality of life. Current treatment options include non-steroidal anti-inflammatory 
drugs, radiotherapy, or surgical excision, but these treatments have limited efficacy and have 
associated complication profiles. In contrast, small molecule inhibitors have been shown to 
have more favorable specificity and less systemic cytotoxicity. Previous studies have shown 
that downstream non-canonical BMP signaling of TGF-β activated kinase-1 (TAK1) con-
tributes to HO. In the current study, small molecule inhibition of TAK1 (NG-25) was evalu-
ated for its efficacy in limiting ectopic bone formation following a rat blast lower extremity 
injury model and a murine burn tenotomy injury model. A significant decrease in total HO 
volume in the rat blast injury model was observed by microCT, with no systemic compli-
cations following NG-25 therapy. Furthermore, rat tissue-resident mesenchymal progenitor 
cells (MPCs) harvested from animals treated with NG-25 demonstrated decreased prolifer-
ation, osteogenic differentiation capacity, and reduced gene expression of Tac1, Col10a1, 
Ibsp, Smad3, and Sox2. Single cell RNA-sequencing of murine cells harvested from the 
injury site in a burn tenotomy injury model showed increased expression of these genes in 
murine MPC during stages of chondrogenic differentiation. Additional in vitro cell cultures 
of murine tissue-resident MPCs and osteochondrogenic progenitor cells (OCPs) treated with 
NG-25 demonstrated reduced chondrogenic differentiation by 10.2-fold and 133.3-fold, re-
spectively as well as associated reduction in chondrogenic gene expression. Induction of 
HO in Tak1 knockout mice demonstrated a 7.1-fold and 2.7-fold reduction in chondrogenic 
differentiation in murine MPCs and OCPs, respectively, with reduced chondrogenic gene 
expression. Together, our in vivo models and in vitro cell culture studies demonstrate the 
importance of TAK1 signaling in chondrogenic differentiation and HO formation and sug-
gest that small molecule inhibition of TAK1 is a promising therapy to limit the formation 
and progression of HO.
Disclosures: Amy Strong, None
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Nerve modulation therapy: targeting galectin-1 expression from dorsal 
root ganglia alleviates osteoarthritis *Jingtian Mei1, Feng Zhou1, Hanjun Li1, 
Tingting Tang1. 1Shanghai Key Laboratory of Orthopaedic Implants, Department 
of Orthopaedic Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong 
University School of Medicine, Shanghai, PR China, China
Osteoarthritis (OA) is the most common and debilitating type of arthritis, causing a 
large societal and economic burden. During OA development, all joint components are af-
fected, resulting in significant subchondral bone remodelling and osteochondral neovascu-
larisation that occur prior to articular cartilage degeneration [1]. In this process, pathological 
sensory nerve sensitation and its innervation into normally aneural tissues mostly causes 
pain. Tanezumab, the β nerve growth factor (β NGF) targeting drug, has been proven effi-
caciously in reducing pain for OA patients, while data demonstrated increased incident of 
rapidly progressive OA (RPOA) with dose and duration [2]. It suggests the significant role of 
peripheral nerve in the progression of OA. In addition, sensory nerves of dorsal root ganglia 
(DRG) in OA innervating into bone and synovium mediate joint pain and may affect other 
joint components by secreting neurotrophic factor. Here, RNA-Seq screened out the up-reg-
ulated Galectin-1 (Gal-1) in primary DRG cells within inflammatory environment. We found 
that DRG-derived Gal-1 promoted angiogenesis and osteoclastogenesis, which was further 
examined in experimental OA rats as the local injection of lentiviral vectors expressing Gal-
1 short hairpin RNA significantly attenuated articular cartilage degeneration, subchondral 
bone angiogenesis, and remodelling. Also, Gal-1 levels in subchondral bone were higher in 
patients with more severe osteoarthritis. Subsequently, we screened the most effective small 
molecular compound Kaempferol (Kae) that could suppress Gal-1 expression both in DRG 
cell bodies and peripheral nerve fibres via inhibiting the NF-κB, JNK and ERK pathways, 
thereby inhibiting downstream c-Fos, c-Jun, and ΔFosB expression as well as AP-1 binding 
activity to the Gal-1 promoter. Nerve fibres of less Gal-1 expression innervated the sub-
chondral bone, consequently exerting a protective effect on OA including less cartilage de-
generation, ameliorated hypersensitivity, reduced subchondral bone remodelling and H-type 
angiogenesis. These results suggest a more intimate connection between the nervous system 
and OA progression mediated by DRG-derived Gal-1. Thus, targeting up-regulated Gal-1 
expression in DRG by Kae provides novel insights for future OA research in both disease 
modifying and pain alleviation.1, Chen Y, et al. Bone Research. 5: 17034,2017.2, Schnitzer 
TJ, et al. Ann Rheum Dis. 74: 1202,2015.
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Blocking CCN2 Preferentially Inhibits Osteoclastogenesis Induced by 
Repetitive High Force Bone Loading *Mary F Barbe1, Mamta Amin1, Anne 
Gingery2, Alex G Lambi3, Steven N Popoff1. 1Lewis Katz School of Medicine, 
Temple University, United States, 2Mayo Clinic, United States, 3University of 
California, Los Angeles David Geffen School of Medicine, United States
We recently found that blocking CCN2 signaling using a monoclonal antibody (FG-
3019, from Fibrogen, Inc) may be a novel therapeutic strategy for reducing overuse-induced 
tissue fibrosis. Since CCN2 plays roles in osteoclastogenesis, and persistent performance of 
a high repetition high force (HRHF) lever pulling task results in a loss in trabecular bone 
volume in the radius, our aim was to determine if blocking CCN2 signaling would reduce 
the early catabolic effects of performing a HRHF task for 3 weeks. The experiment was 
approved by the the Institutional Animal Care and Use Committee in compliance with NIH 
guidelines for the humane care and use of laboratory animals. Studies were conducted on 40 
young adult, female, Sprague-Dawley rats. Twenty-five rats were randomly chosen to under-
go an initial operant shaping period for 6 wks to learn a high force lever pulling task, before 
then going on to perform an operant HRHF lever pulling task for 3 weeks (pulling a lever bar 
at 50% of their maximum pulling force, 1.27 Newtons, 4 reaches/min for a food reward, for 
2 hrs/day, in 30 min intervals with 1.5 hr rest breaks between, 3 days/wk) HRHF rats were 
randomly divided into subcohorts that were untreated (HRHF Untreated), treated with an 
anti-CCN2 monoclonal antibody (HRHF+FG-3019, 40 mg/kg body wt, i.p.; 2x per wk for 2 
wks), or with a human IgG as a vehicle control (HRHF+IgG), ), while continuing to perform 
the task. Non task control rats  (n=15) were left untreated. In distal metaphyseal trabeculae 
of the radius, HRHF Untreated rats showed increased osteoblast numbers and other indices 
of bone formation, compared to controls, yet decreased trabecular bone volume, increased 
osteoclast numbers, and increased serum CTX-1 (a serum biomarker of bone resorption). 
HRHF+FG-3019 rats also showed increased osteoblast numbers and bone formation, but in 
contrast to HRHF Untreated rats, showed higher trabecular bone volume, and reduced osteo-
clast numbers and serum CTX-1 levels (statistically similar to Control levels). In conclusion, 
HRHF loading increased bone formation in each task group, yet blocking CCN2 dampened 
trabecular bone catabolism by reducing osteoclast numbers and activity.
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Abaloparatide is more effective than PTH in restoring bone formation, but 
both agents correct the impaired bone structural and material properties 
and citrate content in mice with Type 1 Diabetes *Serra Ucer Ozgurel1, 
Amy Y. Sato2, Kevin McAndrews3, David Halladay3, Meloney Cregor3, Alma 
Villasenor 4, Maricruz Marmani-Huanca5, Coral Barbas4, Arancha Gortazar6, 
Teresita Bellido2. 1Department of Anatomy, Cell Biology and Physiology, Indiana 
University School of Medicine, Richard L. Roudebush Veterans Administration 
Medical Center, Indianapolis, IN, United States, 2Department of Anatomy, Cell 
Biology and Physiology, Indiana University School of Medicine, Indianapolis, 
IN, Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, IN, 
United States, 3Department of Anatomy, Cell Biology and Physiology, Indiana 
University School of Medicine, Indianapolis, IN, Richard L. Roudebush Veterans 
Administration Medical Center, Indianapolis, IN, United States, 4Centre for 
Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad 
San Pablo-CEU, CEU Universities, Campus Monteprincipe, 28925 Alcorcón, 
Madrid, Spain, 54Centre for Metabolomics and Bioanalysis (CEMBIO), 
Faculty of Pharmacy, Universidad San Pablo-CEU, CEU Universities, Campus 
Monteprincipe, 28925 Alcorcón, Madrid, Spain, 6Bone Physiopathology 
laboratory, Applied Molecular Medicine Institute (IMMA), Universidad San 
Pablo-CEU, CEU Universities, Campus Monteprincipe, 28925 Alcorcón, 
Madrid, Spain
Pharmacologic approaches to treat skeletal fragility induced by diabetes are needed. We 
compared the effects on bone of 12 pmoles/g/d of hPTH(1-34) (PTH, 50ng/g/d) or abalop-
aratide (ABL, 47.5ng/g/d, Radius Health), FDA approved bone anabolic agents. Agents or 
vehicle (veh) were administered for 28d to 19wk old C57BL/6J male mice with established 
bone disease induced by streptozotocin, a preclinical model of type 1 diabetes (T1D). We 
showed earlier that ABL was superior than PTH in increasing or restoring bone mass (BMD 
and µCT) in control (C) or T1D mice, respectively, and that ABL induced a longer-lasting 
increase in bone remodeling compared to PTH. We now report that T1D mice exhibited 
reduced trabecular (t) and periosteal (p) bone formation rate (BFR) (38% and 49% below 
C, respectively). ABL increased t and pBFR to a greater extent than PTH under physiologic 
and T1D conditions. Thus, ABL increased tBFR 70% and 194% over veh, and pBFR 110% 
and 372% over veh in C and T1D mice, respectively. In contrast, PTH did not significantly 
alter BFR in C mice; and increased tBFR only 92% over veh and did not increase pBFR in 
T1D mice. We next evaluated bone strength by femoral 3-point-bending. Structural (extrin-
sic) bone indexes: ultimate force and energy to failure were decreased in T1D. Only ABL 
increased ultimate force in C and T1D mice. T1D mice treated with ABL or PTH exhibited 
similar ultimate force and energy to failure when compared to respective C mice, indicating 
bone strength restoration. Material (intrinsic) properties: toughness and Young’s modulus 
were decreased or increased, respectively, in T1D mice vs C; whereas no differences were 
detected between T1D and C mice treated with ABL/PTH, indicating restoration. In ad-
dition, though T1D mice did not exhibit changes vs C in ultimate stress, another intrinsic 
property, both agents increased it in T1D mice. We next measured by capillary electropho-
resis/MS bone content of citrate, an innate component of hydroxyapatite crystals that im-
parts nanocrystal stability, bone strength, and resistance to fracture. Bones from T1D mice 
displayed 46% less citrate than C mice; and, similar to the effects on toughness, bones from 
T1D mice treated with ABL or PTH displayed similar citrate content to their corresponding 
C mice. In conclusion, ABL is more effective than PTH in restoring bone formation, but both 
ABL and PTH have the ability to correct the impaired bone extrinsic and intrinsic properties 
in T1D mice.
Disclosures: Serra Ucer Ozgurel, None
P-708
Genotypic and Phenotypic Characterization of CRISPR/Cas9 Mediated 
Fluorescent Osteoclast Reporter Mice *Dilara Yilmaz1, Yannick Fischer2, 
Ralph Müller2, Esther Wehrle2. 1ETH Zurich, Switzerland, 2ETH Zurich, 
Switzerland
Several transgenic BAC or Cre based fluorescent mouse models have been developed 
to understand the function of bone cells during adaptation and regeneration, however, these 
methods remain ineffective and costly. By employing CRISPR/Cas9 genome editing, our 
lab recently developed fluorescent osteoclast reporter mice. To validate the model, we aimed 
to identify fluorescent osteoclasts and by combining single-cell mechanomics, we will track 
them dynamically in mouse bone and investigate the molecular response to changes in 
mechanics in their 3D local in vivo environment (LivE). Osteoclasts were labeled linking 
mCherry with acid phosphatase type 5 (Acp5). PCR genotyping and Sanger sequencing 
were performed. Specific endogenous signals of osteoclasts were confirmed with fluorescent 
(ELF-97) and histological TRAP stainings. Bone histomorphometry parameters such as the 
number of osteoclasts per bone surface (N.Oc/BS) were assessed and data were expressed as 
mean+/-standard deviation (SD). Unpaired Student’s two-tailed t-test was used to evaluate 
statistical differences. Wild type mice were used as a control to confirm the specificity of 
fluorescent protein expression in osteoclasts. Our results displayed complete integration of 
all targets at the intended loci through PCR and Sanger sequencing. We observed distinct 
fluorescence signals around the resorption pits in femurs and vertebrae of 4 and 20 week-
old homozygous mice (Acp5-mCherry). This was confirmed by co-localization of endoge-
nous mCherry signals with histological and fluorescent osteoclast specific TRAP stainings. 
Moreover, mean N.Oc/BS was quantified (n=4) as 4.43+/-0.89/mm for homozygous and 
4.61+/-0.43/mm for wild type mice. Statistical analysis did not reveal a significant difference 
between the groups (p=0.716). Furthermore, sequential stainings and imaging enabled us to 
co-localize fluorescent (Calcein Blue) and histological (Toluidine Blue) signals from a single 
section (Fig.1).In this study, we generated fluorescent reporter mice through CRISPR/Cas9 
technology to identify osteoclasts fluorescently and validated the function of the fluorescent 
protein through genotyping, sequencing, and histology. Furthermore, by combining fluores-
cent and histological stainings, we were able to obtain extensive molecular information from 
the same section. In the near future, these fluorescent reporter mice will serve to investigate 
spatially resolved in vivo single-cell mechanomics of bone adaptation and regeneration. 
Disclosures: Dilara Yilmaz, None
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A Simultaneous Bone and Muscle Surgical Injury Model Reveals Age/
Gender Differences in Musculoskeletal Healing *Claudia Cristina Biguetti1, 
Ana Claudia Rodrigues Silva6, João Shindo3, Marco Antonio Hungaro Duarte3, 
Jesus Carlos Andreo3, Lynda Bonewald4, Zhiying Wang1, Marco Brotto5, Mariza 
Matsumoto6. 1Bone-Muscle Research Center, CONHI, The University of Texas 
at Arlington, United States, 6School of Dentistry, São Paulo State University, 
UNESP, Brazil, 3School of Dentistry, University of São Paulo, USP, Brazil, 
4Indiana Center for Musculoskeletal Health, Indiana University, United States, 
5Bone-Muscle Research Center, CONHI,The University of Texas at Arlington, 
United States, 6School of Dentistry, São Paulo State University, UNESP, United 
States
Most if not all in vivo models of musculoskeletal (MSK) injury, evaluate recovery from 
injury in only one tissue at a time. We created a new tool for bone-muscle and MSK crosstalk 
studies, using a simultaneous surgical injury in the vastus lateralis (VA) muscle and the fe-
muri of 129/SvEv mice. Mice were ethically anesthetized, and a 1mm micro punch was used 
to create a muscle defect to a depth of 1.5mm until reaching the femoral bone, which was 
drilled using a 0.50mm drill to produce a subjacent monocortical bone defect in a maximum 
depth of 1mm. Only subcutaneous tissue was sutured to allow natural healing. After one day 
of surgery, male (M) and female (F), young (3 months), and aged (18 months) mice were 
able to properly ambulate. Mice were euthanatized at 7 and 14 days post-surgery to evalu-
ate MSK healing, utilizing microCT, histology, and immunohistochemistry for MuRF1 and 
MyoD. Non-injured skeletal muscles were used for targeted lipidomics analyses. Data were 
evaluated for statistical significance (p<0.05) by two-way ANOVA followed by Bonferroni 
correction. At 7 days, a decreased bone formation (BV/TV, %) was observed in the femurs 
of aged M and F mice (7.7+/-4.1 and 5.6+/-2.4) compared to young M and F (22+/-1.8 
and 25+/-1.9). At day 14, the aged F group presented increased inflammation compared to 
young F, in both injured tissues; adipose and connective tissue was observed in the central 
area of muscle injury in both M and F aged mice, while young controls displayed myoblasts 
surrounded by connective tissue fibers. At day 14, a decreased cross-sectional area (μm2) 
of muscle fibers was noted adjacent to the injury in aged F (505+/-101) compared to the 
young F (1127+/-446). At day 7, MuRF1 was significantly increased in injured muscles of 
aged animals, while MyoD was significantly higher in young mice, with no gender differ-
ences. Lipidomics revealed that 6-keto-PGF1α was increased in aged F compared to young 
F mice, while the levels of 11,12-EET were increased in aged F compared to aged M. We 
conclude that MSK healing is influenced by age and gender, with major changes observed 
in aged F. Changes in skeletal muscle levels of AA derived lipid mediators may contribute 
to MSK healing differences in older females. We are now employing pharmacological and 
molecular-genetic approaches to investigate mechanisms contributing to these differences in 
older females. Our new model will be useful to advance the understanding of bone-muscle 
crosstalk with injury during aging.
Disclosures: Claudia Cristina Biguetti, None
P-710
Dyrk1a-Related Down Syndrome Bone Defects Abrogated by Temporally-
Targeted Pharmacological Intervention *Jonathan LaCombe1, Matthew 
Blackwell1, Kourtney Sloan1, Randall Roper1. 1IUPUI, United States
All individuals with Down syndrome (DS) have skeletal defects and experience an 
earlier onset of osteoporosis as compared to the general population. Skeletal abnormalities 
characteristic of DS emerge early and are developmental in nature. Trisomy of chromosome 
21 (T21) causes a gene dosage imbalance of almost 300 genes, leading to negative effects 
on skeletal development, maturity, and maintenance. Of the many genes triplicated in T21, 
DYRK1A has been shown to have pathogenic effects in Alzheimer’s disease, neural devel-
opment, and skeletal maintenance. The Ts65Dn mouse model is the most studied model of 
DS. It has a extra freely segregating chromosome containing about 50% of the genes homol-
ogous to human chromosome 21, including Dyrk1a, and recapitulates the skeletal phenotype 
of DS. Genetic normalization of Dyrk1a in otherwise trisomic Ts65Dn male mice improved 
trabecular bone measure at six weeks of age, suggesting that trabecular phenotypes are re-
lated to Dyrk1a overexpression and pharmacological inhibition of DYRK1A may improve 
trabecular bone measures. Gene expression and microcomputed tomography (μCT) analysis 
revealed that Dyrk1a overexpression at P24 precedes the emergence of trabecular deficits 
at P30  in male Ts65Dn mice. We hypothesized that pharmacologically targeting the over-
expression of Dyrk1a in a critical developmental window would prevent the emergence of 
Dyrk1a-related skeletal defects. Male Ts65Dn mice were treated with a DYRK1A inhibitor 
from P21-P29. Femurs were obtained at P30 and subjected to μCT analysis. In DS mod-
el mice receiving treatment, pharmacological intervention improved percent bone volume, 
trabecular separation, and trabecular number, similar to measurements observed in euploid 
controls. These data suggest  that a pharmacological intervention during a developmental 
window that is sensitive to Dyrk1a overexpression prevents the emergence of Dyrk1a-relat-
ed skeletal phenotypes and suggests that other Dyrk1a-related phenotypes can be targeted 
in a similar manner. Future experiments aim to determine the molecular mechanisms that 
Dyrk1a overexpression dysregulates to produce characteristic Dyrk1a-related appendicular 
skeletal phenotypes. This work will contribute to improving the overall health, quality of 
life, and longevity of individuals with DS.
Disclosures: Jonathan LaCombe, None
P-711
Single-cell RNASeq analysis of developing bones in a G610C mouse model 
of osteogenesis imperfecta *Laura Gorrell1, Elena Makareeva1, Shakib Omari1, 
Sergey Leikin1. 1NICHD, NIH, United States
Abnormal osteoblast differentiation and function have been reported in several mouse 
models of osteogenesis imperfecta (OI). We previously introduced and characterized a 
G610C mouse model, in which a Gly610 to Cys substitution in the triple helical region of the 
α2(I) chain causes a moderately severe OI. We demonstrated that accumulation of misfolded 
procollagen in the osteoblast ER caused cell stress and resulted in osteoblast malfunction, 
but the molecular mechanisms of the cell stress and osteoblast adaptation to it remained 
unclear. To identify these molecular mechanisms, here we performed single-cell RNASeq 
analysis of calvaria, femur, and tibia in E18.5 embryos of wild type, heterozygous and ho-
mozygous G610C mice. We found that the mutation significantly affects gene expression 
only in hypertrophic chondrocytes and osteoblasts. We confirmed our earlier qPCR findings 
of significant cell stress, which was not accompanied by activation of canonical unfolded 
protein response (UPR). Instead of increased Hspa5 and Atf4 transcription expected in UPR, 
scRNASeq revealed upregulation of their paralogs Hspa9 and Atf5 in mature osteoblasts 
and Atf3 in hypertrophic chondrocytes, indicating activation of unexpected cell stress path-
ways, which we are currently investigating. In mature osteoblasts, most changes occurred in 
mRNA transcripts of genes involved in regulating different aspects of cellular homeostasis 
and osteoblast function. However, we also observed significant changes in transcription of 
some extracellular matrix proteins, e.g. decorin and several types of collagen. Overall, our 
findings not only support the concept of osteoblast cell stress and malfunction as an im-
portant factor in OI pathophysiology but also reveal underlying molecular pathways and 
potential therapeutic targets.
Disclosures: Laura Gorrell, None
P-712
The role of osteoblasts in skeletal abnormalities of Down syndrome male 
and female mice *Jared Thomas1, Randall J. Roper1. 1IUPUI, United States
Individuals with Down syndrome (DS) have lower bone mineral density (BMD) that is 
present in adolescence and persists until adulthood. In adults with DS, here is an age-related 
decline in BMD in individuals with DS leading to an increased risk of osteoporosis and 
fracture. Trisomy 21 is the cause of DS and increased gene dosage disrupts bone develop-
ment and homeostasis and occurs in both males and female, but at different times. Skeletal 
anomalies observed postnatally may be the result of a cellular defect, resulting in reduced 
bone formation and/or low bone turnover. DYRK1A is found in three copies in humans 
with DS and Ts65Dn DS model mice, and has been linked to cognitive impairments and 
skeletal abnormalities. Previous studies in Ts65Dn male mice at 6 weeks revealed decreased 
osteoblast number, activity and significantly decreased bone formation. Reduction of Dyr-
k1a copy number to normal levels from conception in all cells in otherwise trisomic mice 
rescues postnatal skeletal abnormalities and cellular deficits. We hypothesized reduction 
of Dyrk1a copy number in osteoblasts would improve osteoblast proliferation, activity and 
mineralization thereby normalizing trabecular architecture, cortical geometry and mechani-
cal strength in Ts65Dn mice.Ts65Dn mice with a floxed Dyrk1a gene (Ts65Dn, Dyrk1afl/+) 
were bred to Osx1-GFP::Cre+ mice to generate Ts65Dn animals with a reduced copy of Dyr-
k1a in mature osteoblast cells. Our preliminary data indicate that Ts65Dn,Dyrk1a+/+/+ and 
Ts65Dn,Dyrk1a+/+/-male and female mice display significant defects in both trabecular and 
cortical architecture. Ultimate force was reduced in female trisomic animals, suggesting 
whole bone and tissue level properties are not adversely affected by Dyrk1a copy num-
ber in female trisomic mice. Based on our preliminary data, trisomic Dyrk1a may not alter 
osteoblast cellular activity in a cell-autonomous manner in trisomic animals. Three cop-
ies of Dyrk1a could influence cellular signaling pathways involved in bone remodeling, 
mineralization, and proliferation independent of osteoblast expression of Dyrk1a. Alterna-
tively, Dyrk1a expression in osteoclasts could highlight cell autonomous or non-cell auton-
omous mechanisms related to skeletal defects and possible alterations in DS bone homeo-
stasis.  Identifying the genetic and developmental etiology of skeletal phenotypes associated 
with DS could help to design therapies to rescue skeletal deficiencies seen in DS.
Disclosures: Jared Thomas, None
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Support for a new therapeutic approach of using a low-dose FGFR tyrosine 
kinase inhibitor (infigratinib) for achondroplasia *Benoit Demuynck1, Justine 
Flipo1, Gary Li2, Carl Dambkowski2, Laurence Legeai-Mallet1. 1Université de 
Paris, Imagine Institute, INSERM UMR, France, 2QED Therapeutics Inc., 
United States
Background: Fibroblast growth factor receptor 3 (FGFR3) plays a crucial role in bone 
elongation, demonstrated by FGFR3 gain-of-function mutations in individuals with achon-
droplasia (ACH). We evaluated a therapeutic strategy targeting all pathways downstream of 
FGFR3, hypothesizing that a very low dose of the oral selective FGFR1–3 tyrosine kinase 
inhibitor (TKI) infigratinib (BGJ398) could improve defective bone elongation and have 
greater potency at lower concentrations in a human chondrocyte cell line than a C-type 
Natriuretic Peptide (CNP) analog (vosoritide).Methods: A mouse model (Fgfr3Y367C/+) 
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mimicking ACH was treated with subcutaneous infigratinib daily (0.2 or 0.5 mg/kg/d) or 
intermittently (1 mg/kg q3d) for 15d (PND1–15). In vivo results were compared with ve-
hicle-treated mutant mice. TAN 4-18-chondrocytes, a human chondrocyte line expressing a 
heterozygous Y373C FGFR3 mutation, were treated with multiple concentrations of infig-
ratinib and vosoritide and MAPK levels were measured.Results: We observed a significant 
improvement of the upper (humerus +7%, ulna +11%) and lower (femur +11%, tibia +16%) 
limbs at 0.5 mg/kg/d, and improvement in the foramen magnum. The effect of infigratinib 
on bone elongation was reduced with a lower dose (0.2 mg/kg), confirming a dose-response 
relationship. With intermittent injections of infigratinib (1 mg/kg q3d), gain of growth was 
significant for all long bones (+7%) and foramen magnum size was increased. Modification 
of the growth plate structure, displaying better organization, was also seen. Compared with 
FGF18-treated TAN 4-18-chondrocytes, infigratinib at 10-6M to 10-10M led to statistically 
significant (p<0.05) improvements. With vosoritide, a concentration of 10-4M led to statisti-
cally significant improvements vs FGF18-treated chondrocytes (p<0.05), although this was 
not seen at 10-5M.Conclusions:In vitro data demonstrate that infigratinib has superior activ-
ity over a CNP analog, suggesting that inhibition of multiple key pathways downstream of 
FGFR3 controlling either proliferation or differentiation of the chondrocytes leads to better 
efficacy vs MAPK inhibition alone. In vivo data demonstrate that low, as well as intermit-
tent, doses of infigratinib promote growth in this ACH mouse model. No apparent toxicity 
of infigratinib was observed. These results suggest that, at low doses, infigratinib has the 
potential to be a valuable and relevant therapeutic option for children with ACH.
Disclosures: Benoit Demuynck, None
P-714
Effects of Alzheimer’s Disease on Bone Quality in the 5xFAD Transgenic 
Mouse Model *Joan LLabre1, Blanca Barquera2, Bernard Possidente3, Deepak 
Vashishth4. 1Department of Biomedical Engineering, Rensselaer Polytechnic 
Institute, United States, 2Department of Biological Sciences, Rensselaer 
Polytechnic Institute, United States, 3Department of Biology, Skidmore 
College, United States, 4Center for Biotechnology and Interdisciplinary Studies, 
Rensselaer Polytechnic Institute, United States
Alzheimer’s disease (AD), an irreversible brain disorder that occurs with aging is one 
of the most common causes of dementia affecting an estimated 35 million people world-
wide. Interestingly, skeletal fragility has been found to be a comorbidity of AD with patients 
exhibiting reduced mineralization, increased risk of osteoporosis, and a 2-fold risk for fragil-
ity fractures. Here we used the established 5xFAD transgenic mouse model to better under-
stand the effects of AD on bone quality. Five-week old 5xFAD mice (34840-JAX, The Jack-
son Laboratory) and their wildtype (WT) littermate controls (n=10/group; 50% Female/50% 
Male) were used in this study. 5xFAD mice overexpress mutant human Abprecursor protein 
(APP695) with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) famil-
ial AD (FAD) mutations, along with human PS1 harboring 2 FAD mutations, M146L and 
L286V. As an indicator of cognitive ability, their nesting behavior was assessed throughout 
the study. This behavior was quantified by measuring the weight of a cotton roll before and 
after being placed atop the mice cages for 5 days. 5xFAD mice showed a statistically sig-
nificant and consistent decline in their ability to build nests by 6 months onwards (Fig. 1A). 
To measure bone quality, femoral samples were harvested (age 12 months) and analyzed via 
μCT (VivaCT40, Scanco) with high-resolution scans (70kVp, 114mA, 10.5mm voxel size, 
301ms integration time). μCT analysis of the femoral mid-diaphysis revealed significant de-
creases in cortical thickness (9.6%), BMD (12.4%, Fig. 1B), and cortical bone area fraction 
(12.8%, Fig. 1C) in 5xFAD female mice compared to WT. Similarly, analysis of the distal 
femoral epiphysis revealed a decrease in BV/TV (8.5%), trabecular number (16.8%, Fig. 
1D), as well as an increase in trabecular separation (12.5%), trabecular thickness (10.4%), 
and SMI (3.2%) in 5xFAD female mice compared to WT. These results suggest degradation 
of bone quality for female 5xFAD mice as the reduction in trabecular number correlates to 
an 80% loss strength. However, as the male 5xFAD mice did not show these same findings 
it is likely that the results seen here are attributable to genotype and gender interactions. 
Overall, 5xFAD female mice showed poorer bone quality and typical signs of osteoporosis 
compared to WT. 
Disclosures: Joan LLabre, None
P-715
Association between endogenous oxidative stress and muscle atrophy in 
the elastase-induced pulmonary emphysema mouse model *Yosuke Mano1, 
Manabu Tsukamoto1, Ke-Yong Wang3, Kenji Kosugi1, Takafumi Tajima1, 
Yoshiaki Yamanaka1, Eiichiro Nakamura1, Tamiji Nakashima0, Quian Zhou4, 
Kagaku Azuma4, Yun-shan Li5, Kazuaki Kawai5, Kazuhiro Yatera6, Akinori 
Sakai1. 1Department of Orthopaedic Surgery, University of Occupational and 
Environmental Health, Japan, Japan, 3Shared-Use Research Center, University of 
Occupational and Environmental Health, Japan, Japan, 0Department of Human, 
Information and Life Sciences, University of Occupational and Environmental 
Health, Japan, Japan, 4Department of Anatomy, University of Occupational and 
Environmental Health, Japan, Japan, 5Department of Environmental Oncology, 
University of Occupational and Environmental Health, Japan, Japan, 6Department 
of Respiratory Medicine, University of Occupational and Environmental Health, 
Japan, Japan
Background; Chronic obstructive pulmonary disease (COPD) causes skeletal muscle 
atrophy. Although exogenous oxidative stress (OS) due to smoking and endogenous OS 
due to chronic inflammation are considered as the factors of muscle atrophy, the details are 
not clear. In a previous study, bone loss and type I muscle fiber atrophy were observed in 
elastase-induced pulmonary emphysema (PE) mice, and we hypothesized that endogenous 
OS was involved in the phenotype. The purpose of this study was to investigate the rela-
tionship among PE, endogenous OS, and muscle atrophy.Methods; 12-week-old male mice 
were treated with intratracheal administration of 0.1 U porcine pancreatic elastase (PPE 
group) dissolved in saline or saline alone (control group). We analyzed the percentage of 
low-attenuation area (%LAA) in the lungs as the PE parameter on micro CT images. Mice 
were euthanized 12 weeks after administration, and the lungs and leg muscles were obtained. 
8-hydroxy-2’-deoxyguanosine (8-OHdG) levels in the urine, lung and muscle tissues were 
analyzed. We measured the muscle weight and examined mRNA/protein expression levels 
in the muscle. Morphological evaluations were also performed on the muscle.Results; We 
obtained the following four findings. First, the OS marker in PE mice was elevated sys-
temically. In the urine, lung and muscle tissues, the 8-OHdG levels in the PPE group were 
significantly higher than those in the control group. In addition, 8-OHdG levels in each 
tissue were positively correlated with the %LAA. Second, mitochondrial dysfunction due 
to OS was suggested in PE mice. Mitochondrial swelling, which are signs of mitochondri-
al dysfunction, were observed in the PPE group using electron microscopy. Furthermore, 
the mitochondria-specific superoxide dismutase levels were significantly lower. Third, the 
mRNA/protein expression levels of phospho-MKK3/6, phospho-p38, and FoxO1, which are 
the muscle atrophy-related signaling pathways caused by OS, were elevated in the muscles 
of PE mice. Fourth, PE mice showed significant muscle weight loss in only the soleus, in 
which type I muscle fibers are richly contained.Conclusion, In PE mice, OS was elevated in 
the muscle, resulting in mitochondrial dysfunction and activation of muscle atrophy-related 
signaling pathways caused by OS. Since PE mice showed dominantly type I muscle fiber 
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atrophy, endogenous OS may be strongly involved in COPD-related skeletal muscle atrophy, 
especially type I muscle fiber atrophy.
Disclosures: Yosuke Mano, None
P-716
Characterization of a Pediatric Lateral Meningocele Syndrome Mouse 
Model *Haydee Torres1, Ashley VanCleave2, Tania Rodezno2, Malini Mukherjee3, 
Jennifer Westendorf4, Jianning Tao5. 1Cancer Biology & Immunotherapies Group 
at Sanford Research; Department of Chemistry and Biochemistry, South Dakota 
State University, United States, 2Cancer Biology & Immunotherapies Group 
at Sanford Research, United States, 3Functional Genomics and Bioinformatics 
Core at Sanford Research, United States, 4Department of Orthopedic Surgery, 
Mayo Clinic, Rochester, MN, USA; Department of Biochemistry & Molecular 
Biology, Mayo Clinic, Rochester, MN, USA, United States, 5Cancer Biology 
& Immunotherapies Group at Sanford Research; Department of Pediatrics at 
Sanford School of Medicine at the University of South Dakota; Department of 
Biomedical Engineering, University of South Dakota, United States
Notch signaling is an evolutionarily conserved signaling pathway involved in cell fate 
decisions and cell renewal of multiple systems, including skeletal and muscle homeostasis. 
Recently, whole exome sequencing of family-related or unrelated patients with Lateral Me-
ningocele Syndrome (LMS) revealed truncating mutations in the last exon of NOTCH3. To 
understand the gap in our knowledge of LMS and NOTCH3, we are characterizing a mouse 
model (N3LMS) of the human disease, specifically the causing role of NOTCH3 activation 
in osteosclerosis and kyphosis, a phenotype resulting from changes of either bone shape 
(e.g. abnormal thoracic vertebrae) or muscle integrity (e.g. truncal hypotonia). Our central 
hypothesis is that NOTCH3 gain-of-function (GoF) perturbs either osteoblast or myocyte 
differentiation, inducing the osteosclerosis and other abnormal characteristics of LMS in 
our model. We performed Sanger Sequencing, revealing that the heterozygous N3LMS mice 
contain a G to A point mutation (G to A) in the first base pair of the splice donor site in intron 
31 of Notch3, which mimics truncating NOTCH3 mutations found to occur in human LMS 
patients. The homozygous N3LMS mutant mice developed kyphosis by 5 weeks of age, and 
we observed a difference in their weights at p14. qRTPCR analysis shows mutant mRNA is 
highly expressed in N3LMS mice. Preliminary trabecular bone MicroCT analysis of N3LMS 
homozygous mice indicates that these mutant mice may exhibit osteosclerosis by 2 months. 
On the other hand, mutant mice show a decrease in TA muscle weight and lower gripping 
strength in our behavior analysis of N3LMS mice, the latter suggesting normal embryonic 
muscle development but dramatic defects in postnatal muscle growth and function. Ongoing 
studies, including BASEscope and RNA-seq transcriptomic analysis on bone and muscle, 
will further elucidate gene expression pattern and potential pathways that lead to disease. 
Because there is currently no treatment available, a thorough biological understanding of this 
novel mouse model may point to new treatments to reduce the morbidity of LMS patients.
Disclosures: Haydee Torres, None
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Congenic myostatin (GDF8) deficiency increases skeletal bone volume in 
Col1a2 G610C osteogenesis imperfecta mouse model. *Catherine Omosule1, 
Victoria Gremminger1, Ashley Aguillard1, Youngjae Joeng1, Ferris Pfeiffer1, 
Laura Schulz1, Charlotte Phillips1. 1University of Missouri, United States
Bone fragility is a hallmark of osteogenesis imperfecta (OI), a rare genetic connective 
tissue disorder with no known cure. OI is phenotypically and clinically heterogeneous and 
occurs due to greater than 1500 known mutations. Mild to moderate human OI is modeled 
in the established G610C (Col1a2tm1.1Mcbr) OI mouse model that is due to a glycine to 
cysteine substitution in the Col1a2 gene.Muscle and bone cross-talk reflect both physical 
and biochemical reciprocity. Myokines like myostatin, a TGF-β superfamily member, po-
tently regulate muscle. The absence of myostatin results in increases in muscle fiber num-
ber and size in mice. We had previously shown that congenic myostatin deficiency in mild 
heterozygous OI murine (Col1a2oim/+) mice (due to a functional null of Col1a2 gene) im-
proved skeletal phenotype in adulthood.  Ligands which trap myostatin (sActRIIB) have also 
successfully increased muscle mass and bone integrity in heterozygote G610C (+/G610C) 
mice, while improving muscle mass but not skeletal integrity in Col1a2oim/oim or Col1a-
1Jrt/+ mouse models of OI. In addition, sActRIIB, which binds multiple additional ligands, 
caused adverse effects in humans.To further delineate how the loss of myostatin impacts 
skeletal integrity in OI, we generated double heterozygous myostatin and G610C mice (+/
mstn +/G610C, Dbl.Het) and compared their musculoskeletal properties to those of their 
littermates [wildtype (Wt), +/mstn, +/G610C, Dbl.Het] at 16 weeks of age. The +/G610C 
mice had inferior femoral biomechanical properties and reduced body weights relative to Wt 
offspring. Myostatin deficiency was verified in the Dbl.Het offspring and they showed 32.7% 
and 14.3% decreases in circulating myostatin relative to Wt and +/G610C, respectively. 
Dbl.Het offspring were substantially heavier, with increases in muscle mass relative to +/
G610C mice and rivaling +/mstn offspring weights. Femoral cortical and trabecular bone 
microarchitecture was significantly improved in Dbl.Het compared to +/G610C although 
biomechanical strength was unaffected.Our study further confirms myostatin’s regulatory 
role in muscle. We are unable to confirm whether the improved microarchitecture in the 
Dbl.Het offspring is a result of mechanosensation via increased muscle loading or direct 
biochemical signaling on bone. However, our results suggest that increasing muscle mass 
by decreasing circulating myostatin can improve bone microarchitecture and may improve 
skeletal integrity in OI.
Disclosures: Catherine Omosule, None
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Skeletal and Systemic Phenotype of a Combined Model of Type 1 Diabetes 
and Chronic Kidney Disease in Mice *John Damrath1, Corinne Metzger2, 
Jennifer Hatch3, Elizabeth Swallow2, Matthew Allen2, Joseph Wallace3. 1Purdue 
University, United States, 2Indiana University School of Medicine, United States, 
3Indiana University - Purdue University at Indianapolis, United States
INTRODUCTION: Chronic Kidney Disease (CKD) affects 15% of Americans and dra-
matically increases fracture risk. However, 45% of CKD patients have diabetes listed as 
their primary cause of CKD, another condition that alters bone strength and quality. While 
these conditions have been studied independently, there is a great clinical need to understand 
the interactive effects of these diseases on the skeleton. Here, we report a rodent model, 
combining type 1 diabetes (T1D) and CKD, that demonstrates the effects of these conditions 
on bone microarchitecture.METHODS: Eight-week old male C57BL/6 mice (n=4) received 
daily streptozotocin injections (STZ, 50 mg/kg) for 5 days to induce T1D with blood glucose 
(BG) analyzed weekly. T1D was defined as BG >= 250 mg/dl. At 10 weeks of age, STZ-in-
jected mice were fed a casein-based diet (0.9% P, 0.6% Ca) with 0.2% adenine diet (AD) to 
induce CKD. At 16 weeks of age, STZ+AD mice were switched to a casein control diet with 
maintained calcium and phosphorus ratios. A control cohort without T1D or CKD (n=4) was 
fed the casein control diet. All mice were sacrificed at 20 weeks. At harvest, serum was col-
lected for biochemistries while femora and vertebrae were collected to assess microarchitec-
ture and bone mineral density. Data were analyzed by Student’s t-test.RESULTS: STZ+AD 
mice demonstrated varying degrees of T1D based on glucose tolerance tests performed one 
day before sacrifice. Blood urea nitrogen (BUN) was 170% higher and parathyroid hor-
mone (PTH) was 506% higher in STZ+AD mice vs. control. BUN was highest in the most 
diabetic animal. Micro-CT of the femur demonstrated 3,355% higher cortical porosity with 
40% lower cortical thickness (Ct.Th) in STZ+AD mice. In femora, trabecular bone volume 
fraction (BV/TV) and trabecular thickness (Tb.Th) were 39% and 26% lower, respectively. 
In vertebrae, trabecular BV/TV, Tb.Th, trabecular number (Tb.N), and tissue mineral density 
(TMD) were 46%, 16%, 36%, and 10% lower, respectively (p < 0.05 for all). Ct.Th, BV/TV, 
and Tb.Th were lowest in the most diabetic animal.DISCUSSION: This study demonstrated 
that a spectrum of T1D can be induced in mice alongside CKD. Importantly, we found that 
biochemical and skeletal outcomes that are typically abnormal in CKD, such as BUN and 
cortical geometry/porosity are preserved with T1D. Future studies will incorporate larger co-
horts to investigate the independent and combined effects of T1D and CKD on the skeleton.
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Mechanical Ventilation-Induced Myopathy is Accompanied by Significant 
Trabecular Bone Loss *Zbigniew Gugala1, Gordon Klein1, Lars Larsson2. 
1University of Texas Medical Branch, United States, 2Karolinska Institutet, 
Sweden
Mechanical ventilation is the mainstay treatment for critically ill patients with respi-
ratory distress. However, through the course of ventilator therapy, these patients routinely 
develop severe muscle wasting with preferential loss of myosin not attributable to immo-
bility. Systemic inflammation triggered by lung mechanical injury with subsequent cytokine 
storm and upregulation of catabolic pathways likely contribute to this myopathy, although 
the exact mechanisms are unknown. We have developed a rat model of ventilator-induced 
muscle wasting and established its feasibility and clinical validity. This model involves phar-
macologic muscle paralysis, parenteral nutrition, and continuous mechanical ventilation up 
to 10d, and represents the respiratory setup used clinically, In this study we hypothesized that 
deterioration of skeletal muscle on mechanical ventilation is accompanied by bone changes. 
The aim was to determine the rate, nature and extent of changes in the femora and spines 
of rats subjected to ventilator for 0 (control), 2,5,8, and 10d. (N=20). In addition to routine 
muscle analyses, we performed microCT and bone biomechanical tests.  Following ventila-
tor exposure,animals were euthanized at the designated time points. MicroCT demonstrated 
progressive decline in femoral trabecular bone volume (p=0.0001-.0077), mineral densi-
ty (p=0.0071-.0086), trabecular number (p=0.002-.011), connectivity density (p=0.0012-
.0043), and increased porosity (p=0.0009-.018), beginning at day 8 of mechanical ventilation 
and correlated with loss of muscle mass and myosin/actin ratio (r2=0.64, p<0.0001). Bio-
mechanical 3 point bending revealed a decrease in flexural stiffness (p=0.0078) and strength 
(p=0.0383) at day 10, coincidental with muscle decline. The femoral cortical bone and the 
trabecular bone of the lumbar vertebrae did not show statistically significant changes. Re-
sults indicate that mechanical ventilation leads to quantitative and qualitative deterioration 
of distal femoral trabecular bone  correlating with severe skeletal muscle loss and involving 
reduction in bone mechanical integrity. Simultaneous loss of muscle and bone provide a 
fracture risk for survivors of ventilator therapy. Preventing or impeding this loss maylty 
improve post-ventilator functional recovery. Our rat model of ventilator-induced muscle and 
bone loss allows us to gain insight into muscle-bone interactions and to establish therapeutic 
targets to combat post-ventilator frailty and bone loss
Disclosures: Zbigniew Gugala, None
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Thrombopoietic Agents Improve Angiogenesis during Fracture Healing 
*Ushashi Dadwal1, Paul Childress1, Jeffery Nielsen2, Aamir Tucker1, Alexander 
Brinker1, Kelli Jestes3, Krista Jackson0, Rachel Blosser1, Roman Natoli 1, Stewart 
Low4, Philip Low2, Todd McKinley1, Jonathan Lowery 0, Melissa Kacena 1. 
1Department of Orthopaedic Surgery, Indiana University School of Medicine, 
IN, USA, United States, 2Departments of Medicinal Chemistry and Molecular 
Pharmacology, Purdue University, West Lafayette, Indiana, USA, United States, 
3Division of Biomedical Science, Marian University College of Osteopathic 
Medicine, Indianapolis, Indiana, USA, United States, 0Division of Biomedical 
Science, Marian University College of Osteopathic Medicine, Indianapolis, 
Indiana, USA, United States, 4Department of Chemistry, Purdue University, West 
Lafayette, Indiana, USA, United States
Achieving bone union remains a significant clinical dilemma. Osteoinductive agents 
such as BMPs are used clinically, but have significant side effects. Thus, identifying novel 
bone healing agents is critical. First, we demonstrate the robust bone healing capabilities 
of the main megakaryocyte growth factor, thrombopoietin (TPO) and/or second generation 
TPO agents in mice, rats, and pigs. This bone healing activity is shown by X-ray, µCT, 
histology, and biomechanical testing in two fracture models (critical sized defect and closed 
fracture) and with local or systemic administration. Second, we began to dissect the mech-
anisms by which TPO improves bone healing. To accomplish this, we treated collagenase 
digested bone cells and bone marrow from mouse femurs with BMP-2 (100ng/mL), TPO 
(200ng/mL), or saline for 48 hours and collected total RNA for microarray analysis. Our 
data revealed that TPO treatment resulted in the upregulation of more growth factors and 
cytokines than BMP-2 treatment, implicating enhanced angiogenesis. To test the effect of 
TPO on endothelial cells (ECs), we examined several cellular parameters using validated 
2D culture assays. TPO significantly increased proliferation and the length of vessel-like 
structures from human cord blood-derived ECs. Additionally, TPO-treated mice had in-
creased numbers of ECs within the fracture callus. Next, we completed multianalyte phos-
pho-profiling arrays of protein from the fracture callus of mice treated with saline, TPO 
(5µg), or BMP-2 (5µg). Our data revealed broader regulation of effector phosphorylation 
status with TPO as compared to BMP-2, with increased expression of proteins important 
in regulation of actin cytoskeletal dynamics and motility as well as cytokines and growth 
factors, including Angiopoietin 1.  We then determined TPO treatment of megakaryocytes 
significantly increased Angiopoietin 1 mRNA expression (3.4-fold increase). Together, our 
data suggest that TPO acts to increase angiogenesis at the fracture site, improving fracture 
healing. Although additional preclinical safety studies are required before the FDA would 
approve use of thrombopoietic agents for bone healing in humans, our rodent and pig studies 
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are promising. Thus, expanding the therapeutic potential of this axis to include bone healing 
is an attractive possibility.
Disclosures: Ushashi Dadwal, None
P-721
Improved Bone Fracture Repair through Targeted Delivery of Angiogenic 
Agents *Jeffery Nielsen1, Stewart Low1, Philip Low1, Chris Chen1, Ephriam 
Mbachu1. 1Purdue University, United States
PURPOSE: Delayed fracture healing is a major health issue, and strategies to improve 
repair will improve patient outcomes and lower healthcare costs. Revascularization of frac-
ture is an essential step in fracture healing, low vascularization delays healing. Our lab has 
developed a system based on acidic oligopeptides whereby a targeted therapeutic agent can 
be administered SC distally and it will accumulate on the exposed hydroxyapatite at the 
bone fracture. We sought to develop a new class of bone fracture targeted angiogenic drug 
to improve bone fracture healing. These would be able to stimulate a targeted revascular-
ization of the tissue adjacent to the exposed mineral surface of the bone fracture and thus 
providing oxygen, nutrients, progenitor cells, and minerals for cell survival and proliferation 
in order to result in successful healing.METHODS: Targeted conjugates of anabolic frag-
ments or memetics of VEGF(QK)1, SPARC (SPARC 113)2, and PDGF-BB(PBA2-1c )3 
were synthesized using standard Fmoc solid-phase peptide synthesis. Once the activity of 
the conjugates was confirmed, they were tested in an Einhorn method midshaft-stabilized 
femur fracture model in 12-week-old Swiss Webster mice with and without STZ induced 
type 1 diabetes. The mice(n=10) were dosed SC daily for 3 weeks. Healing was assessed 
using µCT. Fractured femurs were tested for strength in a four-point bend to failure. Sta-
tistical analysis was performed using a one-way ANOVA (α=0.05). All animal experiments 
were performed in accordance with protocols approved by Purdue University’s Institutional 
Animal Care and Use Committee.RESULTS: Targeted angiogenic fragments demonstrated 
significant improvements in bone fracture healing both structurally and mechanically. The 
VEGF memetic QK had the greatest improvement with a 180% increase in callus BV/TV, 
and a 242% increase in max load after 17 days of treatment. No side effects were observed, 
even at very high doses. Significant healing responses were seen in both healthy and in slow 
healing diabetic mice.CONCLUSIONS:The targeted angiogenic agents rapidly improved 
fracture healing and, and the attachment of a targeting ligand allowed angiogenic agents 
to be noninvasively administered. QK shows promise as a future drug as it significantly 
improved the healing of bone fractures in repeated in vivo models of normal and delayed 
healing by promoting earlier revascularization. This could reduce the time a patient spends 
suffering with immobility
Disclosures: Jeffery Nielsen, None
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Effects of Treatment with Bone-Targeted Prostaglandin E2 Receptor 4 
Agonist prodrug, C3 (Mes-1007), in a Mouse Model of Severe Osteogenesis 
Imperfecta *Iris Boraschi-Diaz1, Jonathan Polak2, Gang Chen2, Robert N 
Young2, Frank Rauch1. 1Shriners Hospital for Children-Canada, Canada, 
2Department of Chemistry, Simon Fraser University, Canada
Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that is typically 
caused by mutations in COL1A1 or COL1A2, the genes encoding collagen type I. Bisphos-
phonates are widely used to decrease fracture rate but are only partially effective. Prostaglan-
din E2 (PGE2) and PGE2 receptor 4 (EP4) agonists have been shown to be bone anabolic in 
vivo and treatment with EP4 agonists may bring additional benefits. In this study, we tested 
a novel bone-targeted EP4 agonist prodrug, C3 (Mes-1007), in Jrt mice, a model of severe 
OI. Male 8-week old wild-type and OI mice were randomly assigned to 4 weeks of three 
intraperitoneal injections per week with C3 (5 or 25 mg/kg body weight), control injections, 
zoledronate (5 μg/kg), and a combination treatment of zoledronate (5 μg/kg) and C3 (25 mg/
kg). MicroCT analysis at the distal femoral metaphysis showed that treatment with zoledro-
nate alone or with both C3 and zoledronate led to a significant increase in trabecular bone 
volume. C3 had an additive effect on trabecular bone volume in zoledronate-treated wild 
type mice that was due to increased trabecular thickness. In OI mice, C3/zoledronate combi-
nation treatment was associated with higher trabecular thickness but the difference in bone 
volume was not significant. At the femoral midshaft, C3/zoledronate combination treatment 
increased cortical thickness in both genotypes and led to higher periosteal diameter in OI 
mice. Three-point bending tests of femurs showed that zoledronate increased the stiffness 
in wild type but not in OI mice. L4 vertebral body microCT revealed that C3/zoledronate 
combination treatment had an additive effect on trabecular bone volume, which in OI mice 
was due to an increase in both trabecular number and thickness. Trabecular bone volume 
in OI mice that received combination treatment was similar to untreated wild type mice 
(p-value = 0.25). In conclusion, adding C3 to zoledronate amplified the effect of zoledronate 
in this severe model of OI.
Disclosures: Iris Boraschi-Diaz, None
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The role of nonhuman primates as a model for diabetes pathophysiology 
*Roberto J. Fajardo1, Todd L. Bredbenner2, Ellen E. Quillen3. 1Clinical and 
Applied Science Education, University of the Incarnate Word School of 
Osteopathic Medicine, United States, 2Department of Mechanical and Aerospace 
Engineering, University of Colorado Colorado Springs, United States, 3Section 
on Molecular Medicine and Center for Precision Medicine, Wake Forest School 
of Medicine, United States
In vivo associations between glycemic control and skeletal characteristics in humans 
and animal models remain unclear. At the cellular level, hyperglycemia decreases bone for-
mation. However, identifying relationships between HbA1c and systemic indicators of bone 
health, such as bone mineral density (aBMD) and bone biomarkers, such as osteoprotegerin 
(OPG), osteocalcin (OCN), sclerostin (SOST), and parathyroid hormone (PTH), remain 
somewhat elusive. We investigated the relationship between HbA1c, imaging, and serum 
based skeletal health indicators in a baboon animal model. Due to pathophysiologic similar-
ity with humans, nonhuman primates represent an ideal model of obesity and diabetes pro-
gression, but almost nothing is known about how bone traits co-vary with glycemic control 
in this animal model. To evaluate the relationship between diabetes and bone traits, we eval-
uated 17 female baboons, 18-27 years of age (54-81 human-equivalent years) with elevated 
HbA1c levels (>5%) for several years prior to death and 17 age- and weight-matched healthy 
controls. Weight-matching was included to minimize the influence of obesity on bone.  Pan-
els of circulating bone biomarkers were run in triplicate using the Milliplex MAP Human 
Bone Magnetic Bead Panel. L2 vertebral bodies were imaged using microCT (53 mm), and 
tissue mineral density (TMD), vertebral shell thickness (VS.t), and thickness of the pedicle 
(cortical) shell (PS.t) were determined. HbA1c ranged between 3.2% and 6.1%. Linear re-
gression indicated that HbA1c was positively associated with PS.t (adj R2 = 0.185, p=0.006) 
and OPG levels (adj R2 = 0.098, p=0.051, Figure 1). OCN and PTH showed non-significant 
inverse relationships with HbA1c (p=0.154 and p=0.186, respectively). TMD, aBMD, and 
SOST were not significantly related to HbA1c, despite approximately a two-fold variation in 
the sample, suggesting ample dynamic ranges. While our results support a role for OPG and 
cortical shell thickness in increased fracture risk among individuals with poorer glycemic 
control and diabetes, the mechanisms that underlie these associations and metrics that reli-
ably predict diabetic fracture risk are unclear. Although nonhuman primates are an excellent 
model of human obesity and diabetes pathophysiology, more needs to be learned about the 
relationship between glycemic control and skeletal traits in these animals.
Disclosures: Roberto J. Fajardo, None
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Effect of TNFα Inhibition on Synovial Joint Inflammation and Subchondral 
Bone Healing Following Intraarticular Fracture in a Rat PTOA Model 
*Michael Valerio1, Sarah Franco1, Connor Dolan1, Naveena Janakarim1, 
Benjamin (Kyle) Potter2, Christopher Dearth1, Stephen Goldman1. 11 DoD-VA 
Extremity Trauma & Amputation Center of Excellence, Fort Sam Houston, TX 2 
Department of Surgery, Uniformed Services University of the Health Sciences & 
Walter Reed National Military Medical Center, Bethesda, MD, United States, 22 
Department of Surgery, Uniformed Services University of the Health Sciences & 
Walter Reed National Military Medical Center, Bethesda, MD 3 Department of 
Orthopaedic Surgery, Walter Reed National Military Medical Center, Bethesda, 
MD, United States
Intraarticular fractures (IAF) lead to a particularly aggressive form of post-traumatic os-
teoarthritis (PTOA) occurring primarily in younger populations, costing the healthcare sys-
tems billions of dollars annually. TNFα, an early acting pro-inflammatory cytokine, has been 
implicated in the development of PTOA and has been shown to persist in traumatized syno-
vial joints well past the inflammatory phase of healing. Infliximab (INX), a monoclonal an-
tibody against TNFα, inhibits its action and may protect against the development of PTOA. 
The aim of this study was to test the effects of TNFα inhibition via INX on inflammation 
and long-term osteochondral healing. IAF were induced in male Lewis rats via a 5J blunt 
impact to the lateral aspect of the left hindlimb knee. Osmotic pumps delivering INX at rate 
of 10mg/kg/day or saline (control) were implanted for 2 weeks. Blood was drawn at days -1, 
0, 1, 3, 7, 14, 28 and 56 relative to injury. At days 14 and 56 post-injury, hindlimbs were im-
aged and synovial fluid (SF) and limbs were harvested. Multiplex and target-specific ELISA 
kits were used to detect relevant soluble factors and INX from serum and SF. µCT analysis 
was conducted on cortical and trabecular regions from isolated tibial plateau head, femoral 
head and proximal tibial bones. IAF were mainly classified as full articular fractures (41C, 
33C), with some extra-articular avulsion (41A, 33A) and were mostly comminuted. Serum 
[INX] was shown to increase after pump implantation and remained elevated (>2500ng/
mL) through Day 28. Plasma soluble factor analysis showed that at Day 14, TNFα, IL-1β 
and IL-13 values were reduced by ~ 42, 53, and 49% respectively, in the INX treated group 
vs control (n=3/group). Analysis of SF at 14 days showed a near six-fold reduction in in-
flammatory cytokines;TNFα, IFNγ, IL1α, IL1β, IL2, IL12, IL13 and IL17A (p<0.001, each) 
and chemokines; IP10 and MCP3 (p<0.01) in the INX treated group compared to control. 
µCT analysis revealed no differences in subchondral bone morphometry between groups 
but increased bone mineral density (BMD, p<0.02) in INX treated relative to control. These 
results suggest that INX effectively damps the local pro-inflammatory microenvironment 
following IAF which is associated with an increased BMD of the subchondral bone. As such, 
INX represents a clinically available therapy that may have additional utility for mitigating 
the particularly aggressive form of PTOA that typically follows IAF.Acknowledgements: 
This study was aided by a grant from the Orthopaedic Trauma Association (Grant#2819).
Disclaimer: The contents of this publication are the sole responsibility of the author(s) and 
do notnecessarily reflect the views, opinions or policies of Uniformed Services University 
of the HealthSciences (USUHS), the Department of Defense (DoD), the Departments of the 
Army, Navy, or Air Force.Mention of trade names, commercial products, or organizations 
does not imply endorsement by the U.S.Government.
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Novel Osteomyelitis Model Development Utilizing Clinical Isolates of 
Staphylococcus aureus *Philip Roper1, Linda Cox1, Yael Alippe1, Gabriel 
Mbalaviele1, Deborah Veis1. 1Washington University School of Medicine, United 
States
Osteomyelitis (OM) is the debilitating infection of bone, and Staphylococcus aureus is 
the predominant causative organism. We developed two separate OM models in our labora-
tory - an intratibial injection model mimicking direct deposition of bacteria after injury or 
surgery and a tail vein injection model mimicking hematogenous OM more common in chil-
dren - employing 5 clinical isolates from pediatric OM. All isolates were transformed with a 
Lux operon to become bioluminescent. Infected mice were monitored for four or five weeks, 
during which bioluminescent imaging (BLI) was performed to longitudinally track bacterial 
burden, followed by microCT and histological analyses of femora and tibiae. All 5 isolates 
produced an infection by BLI, and in all cases, once an infection developed, it persisted 
without much change to the BLI intensity, suggesting a balance between host and pathogen. 
We also found that BLI signal correlated with the extent of trabecular bone loss as measured 
by microCT. There were, however, differences in the infectivity of isolates as measured by 
the percentage of infected legs by BLI. Two isolates that best highlight this difference are 
6416W and 6473W2, as they consistently had the lowest and highest infection incidence, 
respectively, across trials and models. This suggested an inherent difference in these isolates, 
which was borne out by histology. 6416W consistently had a predilection for producing a 
joint centered infection with 100% of bioluminescent legs showing joint inflammation in the 
intratibial model, and 75% in the hematogenous model. Conversely, 6416W only displayed 
bone involvement in 25% and 37% of bioluminescent legs in the respective models, and any 
bone involvement seemed to be secondary to the joint infection, occurring exclusively in the 
epiphyses. 6473W2 predominantly localized to the long bones, primarily femurs, producing 
abscesses in metaphysis and/or diaphysis, often associated with bacterial colonies. Bony 
changes with 6473W2 included loss of trabeculae in the metaphysis, sometimes extending 
through the growth plate into the epiphysis.In bioluminescent legs, 6473W2 produced bone 
centered infection in 80% of hematogenous and 87% of intratibial samples, with only 18% 
of hematogenous samples displaying minor joint inflammation. These distinct mouse models 
of S. aureus bone infection initiated by hematogenous spread and direct deposit will catalyze 
further study of OM pathogenesis and treatment.
Disclosures: Philip Roper, None
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Fibroblast growth factor receptor (FGFR)-selective tyrosine kinase 
inhibitors (TKI), such as infigratinib, show potency and selectivity for 
FGFR3 at pharmacologically relevant doses for the potential treatment of 
achondroplasia (ACH) *Katherine Dobscha1, Ge Wei1, Carl Dambkowski1, 
Daniela Rogoff1. 1QED Therapeutics Inc., United States
Background: Germline mutations in FGFR genes 1–3 can cause skeletal dysplasias and 
craniosynostoses. ACH, the most common form of disproportionate short stature, is caused 
primarily by an autosomal dominant G380R substitution in FGFR3. Infigratinib (BGJ398), 
a potent and selective FGFR1–3 TKI, demonstrated preclinical efficacy at low doses in an 
ACH mouse model. The objective of this analysis is to evaluate the dose dependency and 
toxicity profiles of FGFR-selective TKIs like infigratinib in preclinical skeletal dysplasia 
models.Methods: A review of the literature was performed to investigate non-clinical data 
from studies of infigratinib and other FGFR-selective TKIs relevant to FGFR-driven skele-
tal dysplasias. Major databases (e.g. PubMed, Medline [NLM Catalog]) were searched for 
relevant articles from the past 10 years and conference archives (e.g. ENDO, ESPE, ISDS, 
ASHG, ASBMR) for relevant abstracts from the past 5 years. Full text was included where 
possible. Keywords included in the searches were: achondroplasia, FGFR inhibition, infig-
ratinib, BGJ398, AZD4547, PD173074, tyrosine kinase inhibitor.Results: Of the 683 publi-
cations identified, 10 relevant articles and 2 abstracts were selected for review. Due to direct 
relevance, 2 additional articles were included (total 14 publications). Infigratinib was the 
most commonly identified TKI. In vitro data showed inhibition of FGFR1–3 activity at con-
centrations of 5 to 100 nM, including reversal of established growth arrest in chondrocytes 
at 7 nM. In vivo studies revealed dose-dependent improvements in foramen magnum and 
long bone length in Fgfr3Y367C/+ mice at doses of 0.2–2 mg/kg/day. No studies reported a 
survival disadvantage and one showed a significant survival advantage for infigratinib-treat-
ed mice. For other FGFR TKIs, one study showed that AZD4547 decreased survival in mice 
treated at doses of 1x106 to 2x106 nM; another showed limb malformation in chicken em-
bryos treated with PD173074 at doses of 1x106 to 50x106 nM. While one study suggested 
toxicity with FGFR-selective TKIs, the results were not generated at pharmacologically rel-
evant doses for ACH, nor were they replicated in the literature. Furthermore, in vivo mice 
studies with low doses of infigratinib did not result in any of the abnormal findings observed 
in this study.Conclusions: Given the totality of evidence, low-dose infigratinib appears to be 
a potentially safe option for further development in children with ACH.
Disclosures: Katherine Dobscha, QED Therapeutics Inc., Other Financial or Material 
Support
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Mutant Mouse BMD Phenotypes for 509 Genes from the Mouse Mutant 
Informatics (MGI) Database *Robert Brommage1. 1BoneGenomics, United 
States
Mouse models of human skeletal diseases contribute to understanding mechanisms and 
developing therapies for osteoporosis and rare human genetic skeletal diseases. Skeletal 
analyses of mutant mice often include dual-energy X-ray absorptiometry (DXA) measure-
ments of bone mineral density (BMD).The Mouse Genome Database (MGD; http://www.
informatics.jax.org) of the Mouse Genome Informatics (MGI) resource summarizes mutant 
mouse phenotypes . Data are derived from published papers and direct data submissions 
from the International Mouse Phenotyping Consortium (IMPC). The April 2020 database 
(MGI 6.15) provides 62,884 mutant alleles in 14,823 genes. Alleles showing BMD pheno-
types include QTL loci (72), transgenes (24), spontaneous mutations (32), radiation-induced 
mutants (2), ENU chemical mutagenesis mutants (51), and engineered mutations employing 
gene-targeting (505), gene trap (11), and CRISPR/Cas9 (64) technologies. There are three 
long noncoding RNAs and two microRNAs.There are certainly unidentified false-positive 
phenotypes. Low body BMD is frequently observed in small-sized mice (often unhealthy 
from pleiotropic gene actions) and a limitation of body DXA scans is that measured body 
BMD is artifactually reduced in obese mice. BMD phenotypes can result from disrupting 
genes having pleiotropic actions in multiple tissues or from genes acting specifically in bone 
cells.These BMD mutant alleles comprise 509 unique genes, with 350 low BMD, 147 high 
BMD and 12 complex BMD phenotypes. Mutations in 61 homologous human genes result 
in human genetic skeletal disorders characterized by the International Skeletal Dysplasia 
Society. The IMPC high-throughput body BMD screen (http://www.mousephenotype.org) 
identified 173 low BMD and 81 high BMD mutant lines, with 2 lines showing opposite 
BMD phenotypes in males and females. Phenotypes consistent with small body size were 
present in 117 (68%) of the IMPC low BMD mutants. Elevated lean body mass occurs in 21 
(26%) of the high BMD lines. The MGD also provides links to mutants having various skel-
etal structural abnormalities, including osteomalacia, osteopetrosis, osteogenesis imperfecta, 
craniofacial defects and spontaneous fractures. This summary provides a 2020 snapshot of 
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our knowledge and ignorance on the genetics of BMD and skeletal abnormalities in mouse 
models of human diseases. 
Disclosures: Robert Brommage, None
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Low-dose infigratinib treatment does not lead to changes in phosphorus 
in preclinical animal studies *Maribel Reyes1, Uma Sinha2, Gary Li1, David 
Martin1. 1QED Therapeutics Inc., United States, 2BridgeBio Pharma, United 
States
Background: Infigratinib (BGJ398) is a potent and selective FGFR1–3 inhibitor under 
evaluation for the treatment of achondroplasia (ACH), the most common form of dispropor-
tionate short stature. Low doses of infigratinib were effective in improving skeletal abnor-
malities in a mouse model of ACH [Demuynck et al. 2019; Komla-Ebri et al. 2016]. At high-
er doses in adults (e.g. 10–100-fold the dose shown to have efficacy in preclinical models of 
achondroplasia), infigratinib appears to be associated with elevation in phosphorus, an effect 
known to be associated with FGFR1 inhibition. Specifically, FGFR1 inhibition leads to de-
creases in FGF23 which, in turn, leads to decreased excretion of phosphate by the kidneys. 
We sought to understand the relationship between lower doses of infigratinib and changes 
in phosphorus in preclinical animal models.Methods: Changes in phosphorus were tested at 
multiple doses in three different species – mouse, rat, and dog – across five different studies. 
Infigratinib was given orally at doses ranging from 0.03 mg/kg to 30 mg/kg. Both PK and PD 
(i.e., phosphorus) data was available in all species. Measurement days ranged from day 10 
to week 12, although PK/PD measurements occurred within 1 day of each other. All animals 
were treated in accordance with AVMA guidelines.Results: No significant dose-phosphorus 
relationship was observed in animals treated with doses of infigratinib ranging from 0.03 
mg/kg to 5 mg/kg. A dose-phosphorus and exposure (AUC0-24)-phosphorus relationship 
was observed at doses of infigratinib >=10 mg/kg across transgenic mouse, rat, and dog 
studies. At low doses, the exposure (AUC0-24)-phosphorus relationship showed a shallow 
slope with linear regression analysis in rats and mice.Conclusions: These findings from five 
studies in three different species indicate that the exposure-phosphorus relationship is con-
sistent. Importantly, no relationship was observed between dose and phosphorus levels in 
rats and mice treated with infigratinib at or below 5 mg/kg (human equivalent dose of 0.41 
mg/kg based on mouse to human conversion). Despite hyperphosphatemia being an early 
on-target toxicity expected with infigratinib, this study suggests that low doses of infigratinib 
(shown previously to improve skeletal abnormalities in an ACH mouse model) do not result 
in meaningful changes in phosphorus. Infigratinib (planned dose of 0.016 mg/kg) will be 
evaluated in global clinical studies in children with ACH in 2020.
Disclosures: Maribel Reyes, QED Therapeutics Inc., Other Financial or Material Support, 
BridgeBio, Major Stock Shareholder, QED Therapeutics Inc., Major Stock Shareholder, 
Gilead Sciences, Major Stock Shareholder
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Characterization of Brittle Mechanical Phenotype in Amish G610C Model 
of Osteogenesis Imperfecta *Rachel Kohler1, Carli Tastad2, Amy Creecy2, 
Joseph Wallace2. 1Purdue University, United States, 2Indiana University Purdue 
University Indianapolis, United States
Osteogenesis imperfecta (OI) is a hereditary bone disease where gene mutations affect 
collagen formation resulting in osteopenia and increased fracture risk. There are several es-
tablished mouse models of OI, but these are often severe, resulting in spontaneous fractures 
or early animal death leading to significant specimen loss in preclinical studies. The Amish 
G610C mouse model is a newer, more moderate OI model that shows potential for use in 
intervention studies including those applying external mechanical loading. One limitation of 
this model to date is that it has been bred on several different inbred mouse strains so the data 
available in the literature regarding its bone phenotype are inconsistent. This study is the first 
comprehensive mechanical and architectural characterization of the bone quality of Amish 
mice based on a pure C57BL/6 inbred strain, and will provide a baseline for future treatment 
studies. Male and female wild-type (WT) and heterozygous (G610C) mice were euthanized 
at 10 and 16 weeks (n = 13-16). Harvested tibiae, femurs, and L4 vertebrae were scanned via 
micro-computed tomography (10 mm resolution), and analyzed for cortical and trabecular 
architectural properties. Right femurs and tibiae were then tested to failure in 3 or 4-point 
bending, respectively. G610C mice were found to have less bone but more highly mineral-
ized cortical and trabecular tissue than their sex- and age-matched WT counterparts, with 
cortical cross-sectional area, thickness, and mineral density, and trabecular bone volume, 
mineral density, spacing and number all differing significantly as a function of genotype 
(2 Way ANOVA with main effects of sex and genotype at each age). In addition, mechan-
ical yield force, ultimate force, displacement, strain, and toughness were all significantly 
lower in G610C vs. WT, resulting in a highly brittle phenotype. Importantly, there were no 
spontaneous fractures noted in any bones harvested from the Amish mice. This characteriza-
tion demonstrates that despite being a moderate OI model, the Amish G610C mouse model 
maintains a distinctly brittle phenotype and is well-suited for use in treatment, loading, and 
mechanical analysis studies.
Disclosures: Rachel Kohler, None
P-730
Mild Traumatic Brain Injury (TBI) in Mice-induces Releases of Osteogenic 
Growth Factors into Serum: A Potential Mechanism for Neurological 
Heterotopic Ossification *Subburaman Mohan1, Chandrasekhar Kesavan 1. 
1VALLHS, United States
Heterotrophic ossification (HO) is a serious disorder of an extra-skeletal bone forma-
tion in soft connective tissues that occurs as a common complication of trauma or in rare 
genetic disorders.   It is now well established that patients who suffered from bone fracture 
combined with TBI are at significantly increased risk of HO (exceeds 50%).  Although the 
pathophysiology of HO after TBI is poorly understood, recent findings of central nervous 
system control of bone mass by factors such as leptin, serotonin and neuropeptide Y sug-
gest an important role for humoral factors from injured brain in contributing to peripheral 
osteogenesis at HO sites.  To test for the hypothesis that TBI induces release of osteogenic 
molecules into serum, we tested the biological activity of serum samples collected from mice 
that were subjected to mild TBI or control anesthesia.  Eight-week-old mice were subjected 
to mild TBI using an established weight drop model for four consecutive days and serum 
collected 24 hours after the last impact.  Control mice were subjected to sham anesthesia 
without an injury to the brain.  The effects of TBI and control sera on proliferation and 
differentiation of osteogenic cells were tested under serum-free conditions.  We found that 
TBI serum promoted cell proliferation to a greater extent (20%, P<0.05) than control sera 
in both established mouse osteoblast cell line, MC3T3-E1, as well as primary cultures of 
osteoblasts-derived from calvaria of 7-day old mice.   To determine if TBI-induced factors 
promoted differentiation, we measured alkaline phosphatase activity, a measure of osteoblast 
differentiation, after treatment with sera from mild TBI and control mice.  We found that sera 
from TBI mice increased ALP activity by 50-100% (P<0.05) compared to control sera in 
MC3T3 and in ST2 stromal cell lines. In conclusion, our in vitro data demonstrate that TBI 
induced factors in serum stimulate both proliferation and differentiation of osteoblast lineage 
cells, thereby providing a potential mechanism for neurological HO.
Disclosures: Subburaman Mohan, None
P-731
Assessment of bone microarchitecture and mineralization changes in 
an animal model of inflammatory bowel disease using high-resolution 
synchrotron-based microCT *Damian Myers1, Christopher Hall2, Ahmed Al 
Saidi3, Ali Ghasem Zadeh1, Shilpa Sharma3, Sara Vogrin3, Rhiannon Filippone4, 
Anton Maksimenko2, Daniel Häusermann5, Kulmira Nurgali6, Gustavo Duque1. 
1University of Melbourne and the Australian Institute for Musculoskeletal 
Science, Australia, 2Australian Nucelar Science Technology Organisation, 
Australia, 3University of Melbourne, Australia, 4Victoria University, Australia, 
5Australian Synchrotron, Australia, 6Victoria University and the Australian 
Institute for Musculoskeletal Science, Australia
Background: The Winnie-muc2 mouse (C57BL/6 background) exhibits pathophysiolo-
gy of inflammatory bowel disease and other organ system changes, providing an opportunity 
to study bone loss related to malabsorption and other factors. We hypothesized that both 
bone microstructure and mineralization may differ in Winnie-muc2 mice so performed tem-
poral studies using high-resolution synchrotron-based microCT (HR-S-μCT).Aim: To char-
acterize cortical and trabecular metrics in Winnie-muc2 vs C57BL/6 mice including bone 
volume (BV), bone mineral density (BMD) and other ultrastructural parameters.Methods: 
Male and female animals (4-7/group) were euthanized after cardiac perfusion (4% PFA) at 
6, 14 and 24wks and tibiae harvested then stored in 10% formol saline. MicroCT images 
were acquired at the Australian Synchrotron (25keV beam, 1800 projections, 6.82 μ3 isotro-
pic volumes, at 2-3 mm below condyls). Volumes were reconstructed using XTRACTTM 
(CSIRO), trimmed using Image-J and processed using the BMA module in Analyze14.0 
(Mayo Clinic).Results:• In Winnie-muc2 males (vs C57BL/6), whole BV was 26% lower 
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at 24 wks (0.99 mm3, IQR 0.82-1.16 vs 1.34 mm3, IQR 1.28-1.39 p=0.021) and in Win-
nie-muc2 females (vs C57BL/6 females) whole BV was less at 14 and 24wks (21%, p=0.11 
and 9%, p=0.021, respectively) with both female groups decreasing over time.• Tb vBMD 
was sustained over time for all groups but Tb Tissue vBMD (Tb+IntraTb) was lower at 
14 and 24 wks in Winnie-muc2 males (vs C57BL/6 males, p=0.047 and 0.021) and at 14 
wks in females (vs C57BL/6 females; p=0.033).• Tb Tissue BMD in Winnie-muc2 males 
(vs C57BL/6 males) was 21% less at 14 wks (155 mg/cc, IQR 131-173 vs 203 mg/cc, IQR 
175-215 p=0.043) and 32% less at 24 wks (116 mg/cc, IQR 105-128 vs 174 mg/cc, IQR 
168-175 p=0.021). In females, both C57BL/6 and Winnie-muc2 showed similar temporal 
decreases over 6 to 24 wks (both p=0.021).• Whilst Tb BMD was sustained in Winnie-muc2 
and C57BL/6 males, C57BL/6 females showed an increase from 6 to 24 wks (p=0.021), 
however, the Winnie-muc2 group did not change over time (p>0.05), indicating compro-
mised mineralization of trabeculae in female Winnie-muc2.Conclusion: HR-S-μCT analysis 
reveals microarchitectural and BMD changes in the Winnie-muc2 that highlight the value 
of this model to study bone microarchitecture. This model exhibits severe bone loss and 
altered mineralization and will aid in the study of mechanisms and potential treatments for 
bone lytic diseases.
Disclosures: Damian Myers, None
P-732
Direct Four-Dimensional Assessment of Cortical Bone Basic Multicellular 
Unit Longitudinal Erosion Rate in PTH-Dosed Rabbits: A Novel Synchrotron 
X-Ray Imaging Approach *Kim Harrison1, Erika Sales1, Beverly Hiebert1, 
Arash Panahifar2, Ning Zhu2, Terra Arnason3, Peter Pivonka4, Kurtis Swekla5, 
David Cooper1. 1Department of Anatomy, Physiology, and Pharmacology, 
College of Medicine, University of Saskatchewan, Canada, 2BioMedical 
Imaging and Therapy Beamline, Canadian Light Source, Canada, 3Department 
of Medicine, College of Medicine, University of Saskatchewan, Canada, 4School 
of Mechanical, Medical, and Process Engineering, Queensland University of 
Technology, Australia, 5Research Services and Ethics Office, Office of the Vice-
President of Research, University of Saskatchewan, Canada
Basic Multicellular Units (BMUs) remodel cortical bone through the creation of sec-
ondary osteons via spatio-temporal coupling of osteoclastic and osteoblastic activities. Cur-
rent understanding of BMU behavior has been developed largely from fluorochrome-based 
2D histomorphometry. While effective at measuring bone formation, this approach cannot 
directly assess resorption rates, including the progression of the resorptive phase (cut-
ting-cone) of BMUs - their Longitudinal Erosion Rate (LER). LER has only been inferred 
in classical studies of dogs from the rate at which the formative phase (closing-cone) of 
BMUs advance (~39 µm/day). A 3D imaging approach deployed longitudinally (4D) would, 
for the first time, enable direct measurement of LER; though, radiation dose and resolution 
limitations have presented significant challenges. Synchrotron-based X-ray phase contrast 
micro-CT presents an opportunity to overcome these challenges through superior detection 
of cortical porosity with improved radiation dose efficiency. Our objective was to develop 
and deploy a method for direct 4D measurement of LER in a rabbit model of elevated corti-
cal bone remodeling induced by Parathyroid Hormone (PTH). In-line X-ray phase contrast 
micro-CT at the Canadian Light Source synchrotron was used to detect BMU-related re-
sorption spaces (13 µm voxel size), in vivo, in the right tibiae of New Zealand White rabbits 
(n=5/group) at approximately 1, 2.5 and 5 Gy, 2 weeks after the initiation of PTH dosing 
(30 µg/kg/day). After 2 more weeks of PTH dosing, post-mortem ex vivo desktop micro-CT 
(5 µm voxel size) scans were performed and co-registered with the in vivo scans to directly 
assess LER via 3D landmarking. 3D (cortical porosity, canal diameter and cortical thickness) 
and 2D (total area, marrow area and cortical area) parameters compared between the irradi-
ated and non-irradiated limbs revealed no differences, suggestive of no significant radiation 
impacts for all dose groups. LER was successfully assessed from 186 BMUs from 12 rabbits 
(4/group, ~ 12.4 BMUs/rabbit) and did not vary significantly by dose group. Pooled LER 
was 23.79 +/- 1.83 um/day. This study represents the first direct assessment of LER in 4D 
in an animal model. Imbalanced BMU activity is the root of osteoporotic bone loss and thus 
this novel platform holds great promise in the study of remodeling regulated bone adaptation 
and disease including consideration of BMU 4D spatio-temporal behavior.
Disclosures: Kim Harrison, None
P-733
Altered Endochondral Ossification and Primary Cilia in a Hypothyroid 
Swine Model *Ashley Mohrman1, Erica Reber2, Fayez Safadi2, Mark 
Adamczyk1. 1Akron Children’s Hospital, United States, 2Northeast Ohio Medical 
University, United States
Hormonal defects in children are known to affect bone development, and specifical-
ly hypothyroidism (HypoTH) delays lengthening at the physis. A reversible, experimental 
HypoTH swine model was used to study primary cilia and differentiation of chondrocytes 
during endochondral ossification. Six male Sinclair mini-swine age 10 wk were evenly split 
into HypoTH and control (CTL) groups. HypoTH mini-swine were dosed orally with prop-
ylthiouracil for 15 wk while CTL animals received a placebo. Hindlimb endochondral sam-
ples were split for multiple analyses. Decalcified paraffin slides were stained with Safranin 
O and IHC staining for collagen type II (Col2) and type X (ColX) is underway. Individual 
zones and total growth plate (GP) height were quantitated using ImageJ. Thicker sections 
were dual-stained for acetylated tubulin and a cilia surface marker. Measures of primary cilia 
length and angle of emergence are underway. RNA was extracted and reverse transcribed 
from gene expression samples. Real-time PCR was used to assay markers of GP regula-
tion (Col2; ColX; Sox9; aggrecan, Acan; matrix metalloproteinase 13, Mmp13; vascular 
endothelial factor, Vegf) as well as hedgehog signaling (Indian hedgehog, Ihh; patched; Gli 
transcription factor 2, Gli2). Differences between GP organization and cellularity are easily 
observed between CTL and HypoTH mini-swine (Figure 1A). Glycosaminoglycan staining 
did not demonstrate qualitative differences in matrix composition; however, trabeculae distal 
to the physes appear thicker in HypoTH samples than CTL and contained more undigested 
cartilage matrix. HypoTH physes have a significantly smaller hypertrophic fraction com-
pared to CTL (p<0.5) (Figure 1B,C). Cilia have been identified in the GP of both groups, 
and measures of the angle of emergence and primary cilia length are underway. PCR results 
of key physeal regulators are shown in Figure 1D. Col2 and Ihh mRNA are significantly 
decreased in HypoTH physes compared to CTL. Though ColX mRNA appears greatly re-
duced in the HypoTH group, it is not statistically significant between groups. Lack of Ihh 
may indicate disruption of signaling through primary cilia. The hedgehog receptor, patched, 
and Gli2 will be assayed by PCR to confirm signaling deficits in the Ihh pathway. HypoTH 
physes showed reduced hypertrophy and Ihh expression, which is expected to correlate with 
reduced primary cilia function.
Disclosures: Ashley Mohrman, None
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NaQuinate Protects Against Ovariectomy-Induced Changes in Cortical 
Bone Mass and Architecture Through a Regionally Targeted Mechanism 
*Amy Lock1, Stephanie Gohin1, Behzad Javaheri1, Mark Hopkinson1, Ruby 
Chang1, Robin Soper2, Andrew Pitsillides1, Stephen Hodges1. 1Royal Veterinary 
College, United Kingdom, 2Haoma Medica Ltd, United Kingdom
Background: Current therapies for osteoporosis have limited long-term use and create a 
gap for new anti-osteoporosis agents with greater safety margins. NaQuinate, a naphthoqui-
none carboxylic acid, increases cortical cross-sectional area (CSA) in the tibia of ovariecto-
mized (OVX) rats. These beneficial effects on bone mass were targeted to specific cortical 
regions, modifying architecture to increase predicted resistance to torsion (J). A minimum 
effective NaQuinate dose of 250ug/Kg/day for tibial skeletal changes and 1500ug/Kg/day 
for increased femoral fracture resistance have been determined. The mechanism by which 
NaQuinate acts remains to be determined.Aims: To gain further insight into the skeletal mass 
and architectural effects of NaQuinate at the minimum effective dose in rat tibia of OVX rats 
in a confirmatory study by improved whole-bone, high-resolution micro-computed tomog-
raphy analysis.Methods: Sham-operated (SO) and OVX rats were dosed daily (ip) for 6wks 
with either vehicle (5% EtOH in PBS) or NaQuinate (250µg/Kg/day). Whole tibiae were 
scanned by ex-vivo high-resolution micro-CT (9um resolution), manually segmented into 
whole-bone trabecular and cortical compartments and analysed along the entire tibial length 
for mass and architectural bone parameters.Results:  NaQuinate exerted minimal changes in 
mass and architecture along the tibia in SO rats. In contrast, NaQuinate increased midshaft 
regional cortical CSA and J in OVX rats, confirming earlier findings and extending to a wid-
er spatial range. There was an increase in CSA from 30-60% (P<0.05) and 80-90% (P<0.05) 
of the tibial length, indicating both diaphyseal mid-shaft and distal beneficial effects. There 
was an increase in cortical thickness in the midshaft tibial region of OVX rats (48-60%; 
P<0.05), with increases in the second moment of area around minor (Imin) and major axes 
(Imax) as well as J suggesting an increase in resistance to torsion. Both Imin and Imax were 
also significantly greater in the distal region (65-90%; P<0.05), again culminating in an 
overall increase in predicted resistance to torsion.Conclusions: Highly targeted and regional 
tibial increases in bone mass and shape in OVX rats by NaQuinate treatment were confirmed 
in this study. The findings have been extended to show changes in previously unexplored 
regions of the tibial cortex, suggesting that the observed skeletal changes may hold clues to 
a novel mechanism of action.
Disclosures: Amy Lock, None
P-735
3D volumetric analysis is more sensitive than 1D linear analysis to detect 
bone loss in the ligature-induced periodontitis model. *Mizuho Kittaka1, 
Marcus Levitan2, Tetsuya Yoshimoto1, Yasuyoshi Ueki1. 1Department of 
Biomedical Sciences and Comprehensive Care, Indiana University School of 
Dentistry, Indianapolis, United States, 2Indiana University School of Dentistry, 
Indianapolis, United States
The ligature-induced periodontitis model in mice is widely used to study the mech-
anism of bone loss in periodontitis. In this model, the distance between cementoenamel 
junction (CEJ)-alveolar bone crest (ABC) is preferentially used to assess the bone loss. 
This preference is based on the assumption that ABC is the primary site for osteoclastic 
bone resorption. However, many previous reports show that the induction of TRAP-positive 
osteoclasts occurs in more in-depth and broader areas of the alveolar bone beyond ABC. 
Therefore, we hypothesized that bone reduction is a 3-dimensional (3D) volumetric event 
rather than a 1-dimensional (1D) linear event in periodontitis and that sensitivity for detect-
ing bone loss is different between 1D and 3D analysis.The maxillary left second molar of 
10-week-old C57BL/6 mice was ligated with a silk suture to induce periodontitis. The right 
second molar was left un-ligated to serve as a control. After 5, 7, and 10 days maxilla was 
CT-scanned. Bone erosion was evident at all time points, but we observed periosteal reaction 
suggesting bone formation at day 7 and 10. Therefore, we performed a microCT analysis on 
day 5 to exclude the influence of bone formation. In the 1D analysis, total CEJ-ABC distance 
underneath the four cusps of the second molar was measured. To determine the net increase 
in the CEJ-ABC distance, we subtracted an increase in the periodontal ligament width at the 
apical root from the CEJ-ABC distance. In the 3D analysis, bone volume (BV/TV) between 
two buccal roots of the second molar, which is 140 µm of width, was measured.The CEJ-
ABC measurement identified 10.7 +/- 7.0 and 19.0 +/- 8.5% differences, while the BV/TV 
measurement identified 28.6 +/- 9.6 and 26.3 +/- 8.5% differences in males and females, 
respectively, suggesting that the difference in BV/TV is more significant than that in CEJ-
ABC. Furthermore, the BV/TV analysis detected the restoration of bone loss by antibiotics 
treatment in both genders, while the CEJ-ABC analysis failed to detect it.In conclusion, the 
3D volumetric analysis showed superior sensitivity to the 1D linear analysis in detecting 
a bone loss in the ligature-induced periodontitis model. Measurement and assessment of 
multiple parameters will be required to prevent overlooking site- and stage-specific delicate 
alveolar bone loss.
Disclosures: Mizuho Kittaka, None
P-737
Locally applied basic fibroblast growth factor promotes osseointegration of 
loosely inserted screw in rodent long bone: A preliminary study for salvage 
of failed screw fixation *Chikara Ushiku1, Soki Kato1, Hisashi Hashimoto1, 
Masataka Okabe1, Kazuhito Morioka2, Shoshi Akiyama1, Mitsuru Saito1. 
1The Jikei University School of Medicine, Japan, 2University of California, 
San Francisco (UCSF) Orthopaedic Trauma Institute (OTI) Zuckerberg San 
Francisco General Hospital and Trauma Center (ZSFG), United States
Background:Screw fixation is a frequently used technique in orthopaedic and dental 
surgery, but one of the most common troubles that may occur with this fixation method is 
intraoperative screw loosening, in other word, iatrogenic loosening. Despite the widespread 
use of screw fixation in the management of fracture treatment, very few papers have looked 
at revision screw strategies. Purpose:To evaluate the local reaction of the screw hole which 
become bigger than screw size induced by basic fibroblast growth factor (bFGF) released 
from a gelatin hydrogel put on the top of screw for the purpose of osseointegration for sal-
vage of a failed screw in the long bone. Methods:8-12-weeks-old female Sprague–Dawley 
rats were used. A hole was made in the tibia diaphysis with a 14G needle (outer diameter, 
2.1 mm) as the screw hole. A stainless screw with 1.43 mm outer diameter of threads and 
3.0 mm of the screw head was installed in the hole. Gelatin-based hydrogel contained either 
saline (control group) or 10 μg bFGF (bFGF group) was applied onto the top of the screw 
head. Samples were examined histologically at 1 and 6 weeks after surgery. Results:A gap 
between the screw and bone was not filled with a new bone at 1 week in the both control 
and bFGF groups. Six weeks after the surgery, in the bFGF group, massive new bone for-
mation was found in the area adjacent to the screw where the gap between screw and bone 
was originally seen. The mean bone implant contact ratio in the control group at 6 weeks 
was 17.543% +/- 4.241%, whereas it was 19.745 +/- 4.722% in the rh-FGF2 group at 6 
weeks. Conclusion:We investigated whether local application of gelatin-hydrogel contained 
bFGF might improve osseointegration in a developed rat model of screw loosening. Histo-
logical observations indicated that new bone formation at the area close to the screw was 
higher in the bFGF group compared to the control group.
Disclosures: Chikara Ushiku, None
P-738
In Vitro Osteoclast Assay as a Predictor of Zoledronate Response In Vivo 
*Jukka Rissanen1, Katja Fagerlund1, ZhiQi Peng1, Jukka Morko1. 1Pharmatest 
Services, Finland
Bisphosphonates (BP) are used to treat a number of bone diseases including osteopo-
rosis, cancer bone metastases and rare bone diseases such as osteogenesis imperfecta. Pre-
clinical evaluation of drug candidates for treating bone diseases often utilize clinically used 
drug, such as BP’s, as a reference compound to demonstrate in vitro or in vivo test system 
potency. However, there is no universal conversion formula from in vitro to in vivo dose and, 
therefore, dose conversion is determined based on experimental data. In this study, dose-re-
sponse of a nitrogen containing bisphosphonate zoledronate (ZOL) was determined in in 
vitro human osteoclast assay and obtained dose-response was used as a predictor of ZOL 
response in vivo in adult ovariectomized (OVX) rat model of human postmenopausal oste-
oporosis. In the osteoclast assay, human CD34+ osteoclasts were cultured on bovine bone 
slices in the presence of ZOL (1-1000 μM). C-terminal cross-linked telopeptides of type 
I collagen (CTX-I) was measured from the culture medium to quantitate bone resorption. 
Based on the EC50 value in osteoclast assay 20 μg/kg dose was selected for in vivo study 
with 6-month-old female OVX rats. The selected 20 μg/kg (sc) ZOL single dose completely 
prevented OVX induced osteopenia in trabecular bone as assessed by peripheral quantitative 
computed tomography (pQCT) and histomorphometry during 8-week follow-up period. By 
using ZOL as an example of commonly used bone disorder drug, this study demonstrated 
dose conversion of ZOL from in vitro osteoclast assay to in vivo rat OVX model and typical 
effective doses in those studies.  
Disclosures: Jukka Rissanen, None
P-739
Greater Activation of Modeling-Based Bone Formation and Improvement in 
Bone Microarchitecture by Intermittent PTHrP vs. PTH in Ovariectomized 
(OVX) Rats *Tala Azar1, Wenzheng Wang1, Wei-Ju Tseng1, Hongbo Zhao1, 
Nathaniel Dyment1, Xiaowei Sherry Liu1. 1University of Pennsylvania, United 
States
Similar to parathyroid hormone (PTH), PTH-related protein analog (PTHrP), an FDA 
approved treatment for postmenopausal osteoporosis, exhibits anabolic effect when admin-
istered intermittently. However, the effects of PTH and PTHrP at the trabecular level, includ-
ing microarchitecture and types of bone formation (BF) induced, have not been compared. 
Modeling-based BF (MBF - BF on quiescent surfaces) and remodeling-based BF (RBF - BF 
coupled with resorption by osteoclasts), are important mechanisms by which anabolic agents 
improve bone mass. We hypothesized that different levels of MBF and RBF induced by 
PTHrP vs. PTH may lead to different degrees of improvement in bone microarchitecture.
We injected calcein (green, G), alizarin complexone (red, R), and tetracycline (yellow, Y) 
277





fluorochrome labels in a G-R-Y-G sequence on days -2, 5, 12, and 19 (treatment initiated 
on day 0) with euthanasia on day 21 in 5-mo-old OVX rats. In VEH-, PTH- (20 μg/kg), and 
PTHrP-treated (20 μg/kg) samples (n=6/group, Fig A-C), fluorochrome labels and cement 
lines on cryo-sections of tibial trabecular bone were used to identify MBF (smooth cem ent 
line, Fig D) or RBF (scalloped cement line, Fig E) sites. Compared to VEH, both PTH and 
PTHrP groups had significantly greater MBF- and RBF-induced mineralizing surface (MS/
BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS, Fig F-H). Compared 
to PTH, PTHrP activated 55% and 50% greater MBF-induced MS/BS and BFR/BS, respec-
tively. MAR did not differ between PTH and PTHrP, indicating similar rates of mineral 
deposition at each BF site. Conversely, there were similar increases of RBF-induced MS/
BS, MAR, and BFR/BS in response to PTH vs. PTHrP.In vivo μCT at wks 0 and 3 (Fig I) 
demonstrated that PTH and PTHrP (40 μg/kg, n=7-9/group) improved bone volume fraction 
(BV/TV), thickness (Tb.Th), and number (Tb.N) of tibial trabecular bone, and yielded more 
plate-like trabeculae indicated by reduced structure model index (SMI, Figs J-M). Compared 
to PTH, PTHrP led to greater improvement in BV/TV (78% vs. 54%), more plate-like tra-
beculae (-0.8 vs. -0.6 in SMI), and less reduction in Tb.N (-1% vs. -14%). Increases in Tb.Th 
did not differ between PTH and PTHrP. In conclusion, compared to PTH, PTHrP treatment 
better improved trabecular bone volume and microarchitecture in estrogen deficient rats. 
This may be due to greater activation of new MBF sites that most efficiently enhance struc-
tural integrity of the trabecular network.
Disclosures: Tala Azar, None
P-740
A synbiotic treatment protects from ovariectomy-induced trabecular 
bone loss and correlates with microbiome pathway enrichment for fiber 
degradation, and SCFA and vitamin K2 production *Lina Lawenius1, Karin 
L. Gustafsson1, Jianyao Wu1, Karin H. Nilsson1, Sofia Movérare-Skrtic1, Eric 
M. Schott2, Maria J. Soto-Giron2, Gerardo V. Toledo2, Klara Sjögren1, Claes 
Ohlsson1. 1Centre for Bone and Arthritis Research, Institute of Medicine, 
Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 
Sweden, 2Solarea Bio, Cambridge, Massachusetts, USA, United States
As fear of side effects of current osteoporosis therapeutics have led to low treatment 
rates and adherence to medication, a safer, more natural alternative is needed. Recent reports 
have shown that certain strains of Lactobacillus can protect against bone loss induced by 
estrogen deficiency in both rodents and humans. To date, no study has shown whether a 
combinatorial effect of a synbiotic product (probiotic bacteria and prebiotic fibers), or other 
microbes including fungi could expand available bone-sparing probiotics.The aim with this 
project was to develop a novel synbiotic intervention at an optimal dose to prevent bone loss 
in ovariectomized (ovx) mice. We hypothesized that microbes naturally occurring in fresh 
or fermented fruits and vegetables might provide beneficial health effects. To test this, we 
isolated and sequenced the genomes of >4,000 bacterial and fungal strains from these food 
sources. Using genomic, ecological, and functional insights, we prioritized the synbiotic 
consortium SBD111, with the greatest capacity to produce short chain fatty acids (SCFA) 
from plant fibers and code for vitamin K2 biosynthesis compared to other combinations. 
SBD111 consists of lactic acid bacteria, gammaproteobacteria, yeast, and prebiotic plant 
fibers.To determine if SBD111 protects from ovx-induced bone loss, 10 week-old-mice were 
ovx and treated by daily oral gavage with vehicle, the prebiotic fibers of SBD111 or three 
doses of SBD111 (low 5x108; medium 5x109; or high 1.5x1010 total CFU/dose) with pre-
biotic fibers for 4 weeks. Both the medium (trabecular BMD, +14.1%; p<=0.01) and high 
(+17.1%; p<=0.01) dose of SBD111 protected from ovx-induced trabecular bone loss in 
the distal femur compared to vehicle treatment. Both the low (trabecular BMD, +9.9%; 
p<=0.01) and medium (+11.4%; p=0.01) dose protected from ovx-induced trabecular bone 
loss in vertebra L5 and a similar trend was observed for the high dose (+7.2%; p=0.06). 
No effect of the prebiotic fiber alone was observed. To connect the bone protective pheno-
type with functional changes in the microbiome, fecal samples were analyzed using shot-
gun metagenomics. We observed an enrichment in the relative gene abundance of pathways 
related to fiber degradation, and SCFA and vitamin K2 production in SBD111-treated ovx 
mice.In conclusion, using a novel strategy targeting specific pathways within the micro-
biome, we have developed a synbiotic treatment that protects from bone loss caused by 
estrogen deficiency.
Disclosures: Lina Lawenius, None
P-741
Effects of Teriparatide and Low-Intensity Aerobic Exercise on Osteopenia 
and Muscle Atrophy in Type 2 Diabetes Mellitus Model Rats *Kazunobu 
Abe1, Naohisa Miyakoshi1, Yuji Kasukawa1, Koji Nozaka1, Hiroyuki Tsuchie1, 
Chiaki Sato1, Hikaru Saito1, Ryo Shoji1, Yoichi Shimada1. 1Akita university 
graduate school of medicine, Japan
Purpose: In patients with type 2 diabetes mellitus (T2DM), bone fragility and sarcope-
nia increase the risk of fractures and falls. Teriparatide (TPTD) increases bone strength by 
promoting bone formation. On the other hand, exercise therapy has been shown to increase 
bone mineral density (BMD), prevent falling, and promote muscle remodeling and hyper-
trophy effects. However, there have been few reports on their combined effects on bone and 
skeletal muscle. In this study, we examined the effects of TPTD and exercise therapy on 
bone and skeletal muscle in T2DM rats. Methods: Thirty-week-old T2DM model rats (Ot-
suka Long-Evans Tokushima Fatty) were divided into four groups: Control (vehicle-treated, 
sedentary, hereafter referred to as Cont), TPTD (30 μg/kg subcutaneously injected, 3 times/
week), Exercise (treadmill exercise, 10 m/min, 60 min/day, 5 times/week, hereafter referred 
to as Exe), and Combined (TPTD-treated and treadmill exercise combined, hereafter referred 
to as Comb) groups. Long-Evans Tokushima Otsuka (LETO) rats were used as a nondiabetic 
control (n=9-10 per group). At 5 weeks after treatment, blood glucose levels, BMD of the 
lumbar spine and the femur, bone strength of the middle shaft and the distal metaphysis of 
the femur, and wet weight of the tibialis anterior (TA) and soleus muscles were assessed. Re-
sults: Blood glucose levels in the Cont group were significantly higher in the T2DM model 
rats than in the LETO rats (p < 0.01), but there was no significant difference between the four 
intervention groups. BMDs of the lumbar spine and the femur were significantly higher (p < 
0.01) only in the Comb group compared to the Cont group. In the three-point bending test of 
the middle shaft of the femur, the maximum load in the Comb group was significantly higher 
than in the Cont and Exe groups (p < 0.01). In the compression test of the distal metaphysis 
of the femur, the maximum loads in the TPTD and Comb groups were significantly higher 
than in the Cont and Exe groups (p < 0.01). On the other hand, the wet weight of the TA and 
soleus muscles in the Cont group was significantly lower than in the LETO rats (respectively 
p < 0.001 and p < 0.01), but neither were significantly different among the four intervention 
groups. Conclusions: The combination of TPTD and treadmill exercise increased BMD and 
bone strength of the lumbar spine and the femur in T2DM model rats. On the other hand, 
there was no effect on muscle wet weight in either the TA or the soleus.
Disclosures: Kazunobu Abe, None
P-742
Effects of Low and High Dietary Phosphorus and Acute High Dietary 
Phosphorus on Intestinal Phosphorus Fractional Absorption in 
Nephrectomized Male Rats *Kendal Schmitz1, Dennis Cladis1, Colby Vorland2, 
Ying Dong3, Meryl Wastney3, Sharon Moe4, Kathleen Hill Gallant1. 1Department 
of Nutrition Science, Purdue University; Department of Food Science and 
Nutrition, University of Minnesota, United States, 2Department of Applied 
Health Science, Indiana University School of Public Health-Bloomington, 
United States, 3Department of Nutrition Science, Purdue University, United 
States, 4Department of Medicine-Division of Nephrology, Indiana University 
School of Medicine, United States
Dietary phosphorus (P) restriction and phosphate binder medications are common ther-
apies for patients with chronic kidney disease (CKD). The goal of these therapies is to reduce 
intestinal P absorption to slow the development of CKD-mineral and bone disorder. How-
ever, bouts of non-adherence to these interventions could cause unintended consequences of 
spikes in P absorption and serum P due to increased intestinal P absorption efficiency. This 
has been observed in healthy rats using in vitro methods for assessing intestinal P uptake 
but has not been evaluated in CKD rats nor with in vivo absorption testing methods. This 
study aimed to determine the effects of dietary P level in CKD and normal rats using a 2x3 
factorial design. Male Sprague-Dawley rats with 5/6 nephrectomy (n=36) or sham operation 
(n=36) were block randomized to one of three diets: low P (LP, 0.1%), high P (HP, 1.2%), or 
low P followed by acute high P (LPHP, 0.1% then 1.2%) (n=12/group) and were fed for 4h/d 
for 7 days. LPHP rats were fed the LP diet on days 1-6 and the HP diet on day 7. Following 
the final feeding period, rats underwent an in vivo intestinal P absorption test using 33P 
radioisotope administered either by oral gavage or IV. Fractional P absorption was deter-
mined from the ratio of area under the oral and IV plasma 33P curves (AUCPO/AUCIV) 
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from serial blood draws over 2 hours. A linear mixed model was used to determine main 
effects of diet and disease and the interaction. Results show a main effect of diet (p=0.03), no 
effect of disease (p=0.31), and no interaction effect (p=0.98). LP rats had higher fractional P 
absorption (0.13 +/- 0.01) compared to HP rats (0.08 +/- 0.01, p(diff)=0.046) or LPHP rats 
(0.08 +/- 0.01, p(diff)=0.049). Fractional P absorption was not different between HP and 
LPHP (p(diff)=0.999). These results are consistent with prior studies using in vitro methods 
showing an increase in P uptake efficiency with P restriction. The lack of statistical differ-
ence for P absorption efficiency between CKD and sham rats aligns with other emerging 
reports that CKD does not reduce P absorption efficiency. Importantly, these results show a 
rapid response to reduce intestinal P absorption efficiency when an acute high P load is given 
following a week of dietary P restriction. This is evidence against the notion that dietary 
P restriction causes an unintended harm of increased absorption efficiency during dietary 
non-adherence.
Disclosures: Kendal Schmitz, None
P-743
Reconstitution of the Host Holobiont Acutely Increases Bone Growth of 
the Gnotobiotic Rat *Piotr Czernik1, Rachel M Golonka1, Saroj Chakraborty1, 
BengSan Yeoh1, Saha Piu1, Abdullah Ahmed1, Blair Mell1, Y Tian2, AD 
Patterson0, Bina Joe1, Matam Vijay-Kumar0, Beata Lecka-Czernik3. 1University 
of Toledo, Microbiome Consortium, College of Medicine and Life Sciences, 
Dept. Physiology and Pharmacology, United States, 2The Pennsylvania State 
University, Dept. Veterinary and Biomedical Sciences, United States, 0The 
Pennsylvania State University, Dept. Veterinary and Biomedical Sciences, 
United States, 0University of Toledo, Microbiome Consortium, College of 
Medicine and Life Sciences, Dept. Physiology and Pharmacology, United States, 
3University of Toledo, College of Medicine and Life Sciences, Dept. Orthopaedic 
Surgery, United States
In recent years there has been growing evidence regarding the influence of microbiota 
on the skeletal growth and homeostasis in humans and rodents. Here we present for the first 
time an accelerated longitudinal and radial bone growth in response to short-term exposure 
of germ-free rats to newly established gut microbiota. In our study, 7 week-old germ-free 
male rats were colonized with microbiota through co-housing with conventional rats of the 
same sex and age. Changes in bone mass and structure were analyzed 10 days post coloni-
zation and revealed unprecedented acceleration of bone accrual in cortical and trabecular 
compartments, increased bone tissue mineral density, improved proliferation and hypertro-
phy of growth plate chondrocytes, bone lengthening, and preferential deposition of perios-
teal bone in tibia diaphysis.  It is widely accepted that short-chain fatty acids (SCFA, e.g. 
acetate, propionate and butyrate) produced by gut microbiota act as regulatory metabolites, 
and affect bone growth through a variety of molecular mechanisms. The observed changes in 
bone status were paralleled with a dramatic increase in cecal concentration of all three SCFA 
and increased hepatic Igf-1 expression implicating an involvement of the somatotropic axis. 
Increased serum levels 25-OH vitamin D and alkaline phosphatase pointed towards active 
process of bone formation. Our studies demonstrate that gut microbiotal metabolic products 
can deliver powerful signals to the skeleton and accelerate bone expansion resembling ad-
olescent growth spurt. Our findings may help in developing microbiota-based therapeutics 
to combat bone related disorders resulting from the microbiotal dysbiosis-associated with 
hormonal defects and malnutrition in children.
Disclosures: Piotr Czernik, None
P-744
The effects of a phosphate-enriched diet on the progression of chronic 
kidney disease in an experimental 5/6-nephrectomy model in C57BL/6 
mice *Judith Radloff1, Nejla Latic1, Ulrike Pfeiffenberger1, Claudia Bergow1, 
Reinhold Erben1. 1Veterinary University of Vienna, Austria
Surgical removal of functional kidney mass is a commonly used experimental mod-
el to study pathophysiological processes in chronic kidney disease (CKD). C57Bl/6 mice 
are known to be rather resistant to the development of CKD after 5/6-nephrectomy (NX). 
Because it is known that increased phosphate intake aggravates the progression of renal 
injury, we sought to characterize the development of CKD and its cardiac and skeletal se-
quelae during the first three months after experimental CKD induction in C57Bl/6 mice on 
a phosphate-enriched diet. CKD was surgically induced by two-step 5/6-nephrectomy in 
12-week-old male C57BL/6 mice. Age- and sex-matched animals underwent Sham surgery. 
All mice were maintained on a diet enriched with phosphate, calcium and lactose. Intra-ar-
terial blood pressure measurements were performed 4, 8 and 12 weeks post-surgery. Serum 
concentrations of aldosterone, intact FGF23 and intact PTH were measured by immunoas-
says. Skeletal phenotyping included bone histomorphometry and assessment of bone mass 
by peripheral quantitative computed tomography (pQCT) in lumbar vertebrae and tibiae. 
Picrosirius red staining of renal and cardiac paraffin sections was performed to assess fibro-
sis. Serum creatinine and urea levels significantly increased in NX mice when compared to 
Sham controls. Serum levels of aldosterone, FGF23 and PTH were increased in NX mice at 
all time points. In line with decreased volumetric bone mineral density in lumbar vertebrae 
and tibiae, serum alkaline phosphatase activity as well as osteoclast numbers and mineral-
ization lag time were increased in NX mice. Furthermore, cortical thickness of the tibial 
shaft was decreased in NX mice at 12 weeks after 5/6-Nx, relative to Sham controls. His-
tological assessment of kidney paraffin sections revealed increasing interstitial fibrosis with 
time postsurgery in NX mice. Moreover, NX mice showed elevated mean arterial pressure 
and pulse pressure, relative to Sham mice at 12 weeks after 5/6-Nx, but not at earlier time 
points. Collectively, our data show that 5/6-Nx in BL/6 mice on a phosphate-rich diet leads 
to increased serum creatinine and urea levels, tubulointerstitial fibrosis, progressive cortical 
bone loss, impaired bone mineralization, and the development of hypertension, all hallmarks 
of clinical CKD. Therefore, our model may be useful for gaining further insights into the 
pathophysiology of cardiovascular and bone disorders associated with CKD.
Disclosures: Judith Radloff, None
P-745
Treatment with a Chimeric Long-Acting CSF1 Molecule Enhances Fracture 
Healing *Lena Batoon2, Susan Millard2, Kyle Williams2, Wenhao Sun2, 
Cheyenne Sandrock2, Andy Wu3, Martin Wullschleger4, Katharine Irvine2, Vaida 
Glatt5, Liza Raggatt2, David Hume2, Allison Pettit2. 2Mater Research Institute-The 
University of Queensland, Australia, 2Mater Research Institute-The University of 
Queensland, Singapore, 3Translational Research Institute, Australia, 4Gold Coast 
University Hospital, Australia, 5University of Texas Health Science Center San 
Antonio, United States
Macrophage colony-stimulating factor 1 (CSF1) controls the proliferation, differentia-
tion and function of osteoclasts and macrophages. Exogenous CSF1 has been shown to have 
anabolic effects on multiple tissues, including the ability to promote bone repair. Clinical 
and pre-clinical CSF1 applications have been constrained by its short circulating half-life. 
This limitation was overcome by engineering a chimeric CSF1 molecule, CSF1-Fc, to by-
pass renal clearance, facilitating a more potent and long-acting CSF1-receptor signaling. 
We tested weekly and biweekly CSF1-Fc treatment regimens over a 4-week period in adult 
12-16-week-old female and male mice. Histomorphometric analysis showed F4/80+ osteal 
macrophage number was unchanged after either regimen, while TRAP+ osteoclast surface/
trabecular bone surface was significantly increased only after biweekly CSF1-Fc treatment 
(p=0.0071) irrespective of gender. Hence, weekly CSF1-Fc treatment had minimal impact 
on bone-related myeloid cell populations under homeostatic conditions. To assess whether 
this non-myeloproliferative CSF1-Fc regimen primed regenerative mechanisms, we inves-
tigated the therapeutic potential in bone regeneration using the MouseFix internally plated 
femoral fracture model. Weekly CSF1-Fc treatment for 4 weeks post-fracture significantly 
increased bone marrow macrophages as examined by flow cytometry (p<0.0001) but did 
not alter osteoclast surface/trabecular bone surface on the contralateral/unfractured limb. 
Torsional strength testing of the fractured femora revealed CSF1-Fc treatment significantly 
increased fracture maximum torque (+44%). Collectively, our results indicate that targeting 
macrophages using a weekly CSF1-Fc treatment regimen is a promising fracture therapeutic 
to promote bone regeneration.
Disclosures: Lena Batoon, None
P-746
Iron deficiency does not impact femoral bone properties in young female rats 
following 12-weeks of high-intensity running *Jonathan Scott1, Yasmin Mejia-
Guevara2, Elizabeth Swallow3, Corinne Metzger3, Alexander Stacy3, Matthew 
Allen3, Heath Gasier4. 1Department of Military and Emergency Medicine, 
Uniformed Services University, United States, 2Henry M. Jackson Foundation 
f or the Advancement of Military Medicine, United States, 3Department of 
Anatomy and Cell Biology, Indiana University School of Medicine, United 
States, 4Department of Anesthesiology, Duke University, United States
Purpose: Up to 20% of females sustain stress fractures during initial military training, 
and ~1/3 of female recruits who finish training develop iron deficiency. Iron is a cofactor 
in bone collagen formation, thus we hypothesized iron deficiency is contributing to altered 
bone structure and mechanics during periods of increased mechanical loading.Methods: 
Three-week old female Sprague-Dawley rats were assigned to one of four groups (n = 10/
group): iron adequate sedentary (IAS), iron deficient sedentary (IDS), iron adequate exer-
cise (IAE), and iron deficient exercise (IDE). IDS and IDE rats consumed a modified AIN-
93G diet containing no added iron, whereas IAS and IAE consumed a control diet. Energy 
and macronutrient composition were similar between diets. IAE and IDE rats performed 54 
min of high-intensity running three times/week. After 12-weeks, rats were euthanized and 
blood and whole femora were collected. Blood and serum were used to measure iron status 
and biomarkers of bone formation and resorption. Microcomputed tomography was used to 
measure cortical geometry and cancellous microarchitecture. Four-point bending tests were 
used to measure mechanical properties. All animal procedures were approved by the Uni-
formed Services University Institutional Animal Care and Use Committee. Analyses were 
completed using a two-way repeated measures ANOVA.Results: Body weight was similar 
between groups at the end of the 12-weeks. An iron deficient diet led to reductions in He-
moglobin (Hb), hematocrit, mean corpuscular Hb (MCH), MCH concentration, and red cell 
distribution width. Iron deficiency increased tartrate-resistant acid phosphatase 5b (TRAcP 
5b) (11%) and CTx (50%) levels compared to IAS rats. Exercise (IAE + IDE) increased 
CTx (51%) and osteocalcin (14%) levels compared to IAS rats. IDE increased the levels 
of TRAcP 5b (17%) and P1NP (6%) compared to IAS rats. Independent of diet, exercise 
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increased Ct.Th (5%), BV/TV (22%), and Tb.Th (9%) and maximum load (7%) compared to 
sedentary rats.Conclusion: These data show femoral bone geometry and mechanics are un-
affected by diet-induced iron deficiency during 12-weeks of high-intensity running in young 
growing female rats.
Disclosures: Jonathan Scott, None
P-747
Analysis of bone and muscle in a adenine-induced chronic kidney disease 
model rats *Hikaru Saito1, Miyakoshi Naohisa1, Yuji Kasukawa1, Koji Nozaka1, 
Hiroyuki Tsuchie1, Chiaki Sato1, Kazunobu Abe1, Ryo Shoji1, Yoichi Shimada1. 
1Department of Orthopedic Surgery, Akita University Graduate School of 
Medicine, Japan
[Background]Patients with chronic kidney disease (CKD) are at increased risk of falls 
and fractures due to decreased bone and muscle strength. However, there is insufficient 
evidence about how bone loss and muscle weakness progresses in patients with advanced 
CKD. In the present study, we generated adenine-induced CKD model rats and examined 
the changes in bone and muscle.[Methods]Eight-week-old male Wistar rats were treated 
with a 0.75% adenine diet for 4 weeks, followed by a regular diet to generate CKD model 
rats (CKD group). The CKD and Sham groups were sacrificed at 12, 16, and 20 weeks of 
age, and the following parameters were evaluated. Bone was evaluated by bone mineral 
density (BMD) of whole body by dual energy X-ray absorptiometry, bone strength testing 
by the three-point bending test of femoral shaft and compression test of distal femoral me-
taphysis, and bone structural analysis and BMD of the distal femur using micro-computed 
tomography (micro-CT). Muscle wet weights of the tibialis anterior and soleus muscles were 
measured to assess the muscle. Blood urea nitrogen (BUN), serum creatinine (Cre), phos-
phorus (P), and calcium (Ca) were measured as serologic assessments. Renal tissue sections 
were stained with Elastica Masson to evaluate the kidney and the area of fibrotic interstitium 
was measured.[Results]In the CKD group, whole body BMD was reduced at 12, 16 and 20 
weeks of age (P < 0.05). In addition, micro-CT at 20 weeks of age in the CKD group showed 
decreased trabecular BMD, cortical BMD, cortical bone area, and cortical bone thickness (P 
< 0.05). Breaking energy and maximum load by the bone strength testing in the CKD group 
were significantly decreased compared with the sham group at 20 weeks of age (P < 0.05). 
At 20 weeks of age in the CKD group, tibialis anterior and soleus muscle wet weights were 
smaller (P < 0.05), but there was no significant difference in their percentage relative to body 
weight. BUN, Cre and serum P levels at 20 weeks of age in the CKD group were significant-
ly higher than those in the sham group (P < 0.05). Renal tissue sections from the CKD group 
showed a greater rate of interstitial fibrosis (P < 0.05).[Conclusion] CKD model rats induced 
by adenine diet revealed serologically CKD stage 4. This CKD model rats also presented 
decreased BMD, bone microstructural deterioration in the cortical bone, and decreased bone 
strength, although the muscle wet weight as a percentage of body weight did not change.
Disclosures: Hikaru Saito, None
P-748
Pharmacokinetics and Biodistribution of Bone Fracture Targeted 
Abaloparatide *STEWART LOW1, Jeffery Nielsen1, Philip Low1. 1Purdue 
University, United States
PURPOSE:Previously we have demonstrated the efficacy of a fracture targeted abalo-
paratide. Following systemic injection, the targeted bone anabolic accumulates selectively 
on a bone fracture surface and improves the rate of fracture repair as well as the quality of 
the bone. Here we seek to understand the pharmacokinetics (PK) and elucidate the mini-
mal dosing frequency while maintaining therapeutic concentrations of drugMETHODS:To 
achieve the above objective, we synthesized a modified abaloparatide. On the C-terminus 
of the abalo we conjugated a bone mineral-(hydroxyapatite-) targeting acidic oligopeptide 
forming NOV004.Murine in vivo experiments were conducted on female Swiss Webster 
mice (3 per group). Femoral fractures stabilized by locking nail. Two weeks post fracture, 
mice were dosed with 0.03 nmol/kg/dose of radiolabeled NOV004 or non-conjugated (free) 
radiolabeled abalo.  Mice were euthanized at time points 1 h, 2 h, 4 h, 8 h, 16 h, 24 h, 36 h, 
48 h, 72 h, 120 h, and 168 h. Blood, heart, lung, liver, spleens, kidney, skin(injection site), 
healthy femur, and fracture femur samples were collected from each mouse and counted on 
a gamma counter.  SPECT/CT imaging mice were euthanized at 16h and were imaged on a 
SPEC II CT (MiLabs).RESULTS SECTION:In SPECT/CT imaging studies we observed a 
marked increase fracture callus accumulation. Small off target accumulation was noted in ar-
eas of high cancellous bone. However, accumulation at the fracture site was over 10-fold the 
accumulation per unit volume of any of the off target skeletal sites.No significant differences 
between NOV004 and abalo were observed in the blood PK half-life (4.2h and 3.7h respec-
tively). In addition, area under the curve (AUC), a measurement of whole-body exposure 
were 24.5 and 28.02 for NOV004 and abalo respectively. When comparing the fracture sites 
11-fold increase in AUC of NOV004 to abalo and an half-life improvement of 66.6 h and 8.8 
h occurred.Conclusions:Previously we observed improved and accelerated fracture repair 
from NOV004 over abalo or saline during daily dosing over a wide therapeutic range.  In this 
study we observe that less frequent dosing is likely possible due to the long half-life in the 
fractured bone.  Futhermore, we do not observe extra systemic exposures when compared 
to abalo. Considering this data, it we can reduce dosing frequency to twice a week or fewer 
without losing efficacy or increasing side effects, making this drug easier for the patient.
Disclosures: STEWART LOW, Novosteo INC., Major Stock Shareholder
P-749
Intermittent Tryptophan Withdrawal Over a Three-month Period Avoids 
Severe Weight Loss While Preserving Bone Mass *Kehong Ding1, Wendy 
Bollag2, Meghan McGee-Lawrence1, Debra L Irsik1, Xingming Shi1, William 
Hill3, Sadanand Fulzele1, Mohamed Awad1, Mark Hamrick1, Carlos Isales1. 
1Augusta University, United States, 2Augusta University; Charlie Norwood 
VA Hospital, United States, 3Medical University of South Carolina/Ralph H. 
Johnson VAMC, United States
We have previously shown that kynurenine (kyn), a tryptophan (Trp) oxidation product, 
accumulates with age and contributes to age-induced bone loss. Thus, measures to lower kyn 
levels could be of benefit in preserving bone mass. One potential approach would be to re-
strict dietary Trp thus lowering kyn levels. Trp is an essential amino acid used in protein syn-
thesis, serotonin or melatonin synthesis or rapidly broken down to kynurenine through in-
doleamine 2,3 dioxygenase. Similar to caloric restriction, dietary Trp restriction results in in-
creased lifespan but with detrimental side effects. Dietary Trp restriction results in rapid and 
sustained weight loss in both human and animal subjects. We have previously shown that in 
C57BL/6 mice on Trp deficient diet lose about 20% of their body weight within three weeks 
of initiating this diet, thus limiting its usefulness. We hypothesized that feeding the mice a 
Trp deficient diet in an intermittent fashion might be better tolerated. In an IACUC-approved 
protocol using aged (21-month-old) C57BL/6 mice, we fed one group an alternating (one-
week interval) 0 or 0.2% (standard) Trp-containing diets (AD) vs the control (Crt) group 
which was fed a standard (0.2%) Trp containing diet for twelve weeks. There was a small 
but significant decrease in body weight in the mice fed the 0/0.2% alternating tryptophan diet 
compared to controls at the end of the twelve week period (Ctr: 32.0.+/-1.5 vs 32.8+/-1.6 vs 
AD: 31.8+/-2.5 vs 28.8+/-3.0 gm, (Means+SD, Ctr vs AD p=0.005, n=10/group). Intermit-
tent removal of Trp from the diet did not have a detrimental effect on bone mineral density 
(BMD). Total BMD: (Ctr: 0.0524+/-0.0009 vs 0.522+/-0.0024 vs AD: 0.0518+/-0.0019 vs 
0.0515+/-0.0015, Means+SD, Ctr vs AD at beginning and end of 12-week period). Femoral 
or Spinal BMD did not change. Thus, intermittent dietary Trp restriction avoided the marked 
weight loss seen with continuous Trp restriction and preserved BMD.
Disclosures: Kehong Ding, None
P-750
The major components of the widely consumed medium-chain triglyceride 
ketogenic diet have differential effects on bone *Divya Vohora1, Shreshta Jain2. 
1Jamia Hamdard, India, 2Jamia Hamdard, New Delhi, India
Purpose: Ketogenic diet consists of high fat, low carbohydrates with a moderate pro-
tein intake. The diet has been modified over the years, with modified Atkin’s diet and the 
incorporation of medium-chained triglycerides (MCT). Commonly, the MCT diet is asso-
ciated with weight loss, fat loss and reduction in body composition referred from clinical 
and meta-analysis studies performed. They are also endorsed globally as a dietary treatment 
against neurodegenerative disorders such as refractory epilepsy and Alzheimer’s disease, 
both of which have been associated with bone deficits. To the best of our knowledge, we 
evaluated for the first time, the role of two major components of MCT ketogenic diet, Ca-
prylic acid and Capric acid to ascertain effects on bone after in vivo administration.Methods: 
Swiss albino mice were administered oral suspensions of caprylic acid (1100mg/kg, po) and 
capric acid (1700 mg/kg, po) for 4 weeks. Bone-specific alkaline phosphatase (ALP) and 
tartrate-resistant acid phosphatase (TRAP5b) along with the microarchitectural parameters, 
using micro-computed tomography, of the trabecular region of femur and tibia bones, bone 
mineral density and biomechanical strength were analyzed. Urinary ketone levels were also 
measured.Results: Remarkable alterations of the trabecular bone microarchitecture, reduced 
ALP and elevated TRAP5b levels were observed in the caprylic acid treated groups. Inter-
estingly, when used in combination with capric acid, the deteriorating effects on bone were 
less significant. While the exact mechanisms remain unknown, the role of ketone bodies 
appears unlikely from our results.Conclusion: We suggest significant negative effects on 
bone health by caprylic acid. The findings are significant and calls for further validation and 
dietary modification of the MCT- ketogenic diet composition.Acknowledgement: We thank 
Dr. Divya Singh and Ms Reena Rai for helping carrying out microarchitecture and biome-
chanical strength studies at CDRI, Lucknow. 
Disclosures: Divya Vohora, None
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The Role of Pre-existing Infection/Inflammation and Oncology Doses 
of Zoledronic Acid in the Development of Osteonecrosis of the Jaw after 
Tooth Extraction in Rice Rats *Evelyn Castillo1, Abel Abraham1, Summer 
Croft1, Gabriella Gonzalez-Perez1, Jessica Jiron1, Samantha Thomas1, Indraneel 
Bhattacharyya1, Donald Kimmel1, J. Ignacio Aguirre0. 1University of Florida, 
United States, 0University of Florida, United States
Osteonecrosis of the jaw (ONJ) is an adverse event affecting osteoporosis and cancer 
patients taking powerful anti-resorptives (pAR; e.g., zoledronic acid [ZOL]). Local factors 
(e.g., tooth extraction, periodontitis [PD]) combined with systemic factors (e.g., pARs, etc.) 
are required for ONJ to occur. ONJ pre-clinical studies using tooth extraction have given 
inconsistent outcomes and rarely considered the role of infection/inflammation associated 
with teeth being extracted. We hypothesized that in rice rats receiving an oncologic dose 
of ZOL, extraction of a periodontally-involved molar causes greater ONJ prevalence than 
extraction of a periodontally-healthy molar.At age 4-wks, 55 female rats were fed a standard 
(STD) diet, and administered either saline (VEH) intravenously (IV) or ZOL (80 μg/Kg IV 
[oncology dose]) q4wks. STD diet induces localized PD at the maxillary molar (M) M2M3 
interdental space in ~60% of rice rats by age 16wks. At age 17+/-3 wks, rats were anes-
thetized, orally-examined for grossly-visible localized PD (LPD) in the M2M3 interdental 
space and randomized into four groups of 12-15: 1) VEH rats with no LPD; 2) VEH rats 
with LPD; 3) ZOL rats with no LPD, and 4) ZOL rats with LPD. Rats were anesthetized and 
one maxillary second molar was extracted from each rat. ZOL treatment continued until the 
day of necropsy. Rats were euthanized at 56 days post extraction (PE) to determine ONJ 
prevalence. Maxillae were fixed, decalcified, embedded in paraffin, and serially-sectioned 
parasagitally at 4µm thickness through the extraction site. Sections were stained with H&E. 
The whole extraction site and surrounding region was evaluated for necrotic, exposed bone, 
the hallmark of ONJ.Histopathologic evaluation for ONJ prevalence by group showed: 1) 
0% (0/14) in VEH/no LPD rats; 2) 0% (0/12) in VEH/LPD rats; 3) 87% (13/15) in ZOL/no 
LPD rats; and 4) 79% (11/14) in ZOL/LPD rats. Fisher’s Exact Test showed that the ZOL 
groups differed significantly from both VEH groups (P<.0001), but not from each other. ONJ 
occurred only in ZOL rats; its prevalence was not influenced by grossly-detectable localized 
PD at the time/site of tooth extraction. Radiographic examination of grossly-visible local-
ized PD lesions will be considered in future studies to verify the accuracy of localized PD 
diagnosis. We conclude that tooth extraction in rice rats, as in humans, is an oral risk factor 
for ONJ in rats treated with a systemically-administered oncology dose of ZOL.
Disclosures: Evelyn Castillo, None
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Magnesium Inhibits Periodontitis Progression via Reducing Expression of 
Tumor Necrosis Factor-α and Promoting Subperiosteal Bone Formation 
*Wei He1, Hai Zhang2, Jiaxuan Qiu3, Danfeng Xue1. 1Nanchang University, 
China, 2School of Dentistry, University of Washington, United States, 3The First 
Affiliated Hospital of Nanchang University, China
Purpose: Periodontitis causes alveolar bone destruction leading to tooth loss. Increased 
tumor necrosis factor α (TNF-α) in periodontal tissues promotes inflammatory cell recruit-
ment and inhibits bone growth. Magnesium (Mg) was shown to reduce inflammation and 
promote osteogenesis. The objectives of this study were to determine therapeutic effects 
of Mg on periodontitis in a rat model, and to elucidate its mechanisms related to TNF-α 
and bone growth in vivo and in vitro.Methods: Pure Mg rods (Φ1.4mm×5 mm) were im-
planted in sockets (located under the mandibular first molars) immediately after SD rat in-
cisors were extracted. Titanium rods with same dimensions were used as control (n=6 per 
group). Periodontitis models were established simultaneously at first molars by ligature. 
Inflammatory cell infiltration and alveolar bone around first molars were analyzed by his-
tology and micro-CT respectively at 2 and 6 weeks post-operation. In the meantime local 
Mg content was measured by scanning electron microscopy–energy-dispersive spectroscopy 
(SEM-EDS). TNF-α concentration in periodontal tissue was semi-quantitatively analyzed 
by immunohistochemistry. Osteogenic effects of MgCl2 (0.8, 1.8, 5, 10, 20mM) on peri-
osteum-derived cells (PDCs) under TNF-α treatment were evaluated by proliferation (1-3 
days) and qRT-PCR of osteogenic genes (2 weeks) assays. Data were statistically analyzed 
(ANOVA followed by post hoc t-test, α=0.05).Results: H&E staining showed significantly 
less inflammatory cell infiltration and large amount of new bone formation under periosteum 
in Mg-implanted rats. Marginal bone loss was significantly lower and alveolar bone volume 
was significantly higher in Mg group at both time points by micro-CT. SEM-EDS revealed 
remarkably higher Mg concentration on the surface of alveolar crest in Mg group. TNF-α 
concentration in gingiva was significantly lower in Mg-implanted group. The proliferation 
of PDCs was significantly increased at 10 and 20mM MgCl2 groups (p<0.05). The expres-
sion of Alp, Col 1 and Opn was significantly higher in PDCs with 5, 10mM MgCl2 and the 
existence of 5ng/ml TNF-α (p<0.05)Conclusions: Mg implant inhibits progression of exper-
imental periodontitis in rats. This may partially attribute to the suppressive effect of Mg on 
TNF-α expression and inflammation, as well as stimulation of subperiosteal osteogenesis by 
Mg. This study provides foundations of a potential therapeutic modality against periodontitis 
by localized application of Mg.
Disclosures: Wei He, None
P-753
Effects of Infigratinib, a Selective FGFR1-3 Tyrosine Kinase Inhibitor, on 
Dentoalveolar Development *Sarah Aitken1, Omar Glover1, Zachary Michel2, 
Emily Chu1, Francesca Avogadri3, David Martin3, Susan Moran4, Michael 
Collins2, Martha Somerman1. 1National Institute of Arthritis and Musculoskeletal 
and Skin Diseases (NIAMS), National Institutes of Health (NIH), United States, 
2National Institute of Dental and Craniofacial Research (NIDCR), National 
Institutes of Health (NIH), United States, 3QED Therapeutics Inc, United States, 
4QED Therapeutics Inc., United States
Fibroblast Growth Factor-Receptor-3 (FGFR3) gain-of-function mutations are linked 
to achondroplasia in humans. Infigratinib (formerly known as BGJ398) is a tyrosine kinase 
inhibitor of FGFRs 1-3 and has been shown to improve skeletal growth in an achondroplasia 
mouse model. However, infigratinib effects on tooth development have not been studied. 
Existing data demonstrates that multiple FGFs and their receptors have critical roles within 
the tooth organ. We hypothesized that infigratinib affects dentoalveolar development in a 
dose-dependent manner. Beginning on postnatal day (PND) 7, male and female Wistar rats 
received a daily dose of either vehicle, 0.1mg/kg infigratinib (low dose), or 1.0mg/kg infig-
ratinib (high dose). Rats were euthanized at PND21 or 37, and heads were fixed in formalin. 
Mandibles were dissected and hemisected sagittally. Micro-computed-tomographic (µCT) 
scans of heads and hemi-mandibles were conducted using a Scanco-µCT-50 Scanner. Quali-
tative and quantitative 3D µCT analyses were performed using AnalyzePro software. Quan-
titative data were analyzed using one-way ANOVA with post-hoc Tukey-test for pairwise 
comparisons, where p<0.05 was considered statistically significant. We report high dose 
infigratinib (1mg/kg) affects the formation of dentoalveolar tissues and that female rats were 
more sensitive to infigratinib compared to males.  Most notably, in comparison to the other 
groups, high-dose PND37 female rat molars and surrounding bone exhibited: reduced dentin 
volume (9-12%); increased dentin densities (2-3%); reduced pulp volume (10-20%) and re-
duced alveolar bone volume (10-13%). These differences were not detected in PND37 male 
rats, or in any rats at PND21. Infigratinib did not affect enamel volume or density or alveolar 
bone density at any timepoint. Mandibular 3rd molars exhibited aberrant crown and root 
morphology in 100% of high dose female rats and in 80% of high dose male rats at PND37 
and PND21.  Since the infigratinib doses proposed for achondroplasia treatment are signifi-
cantly lower than 1.0mg/kg, no effect on dental structures would be anticipated.  To better 
elucidate underlying mechanisms of the effects of infigratinib on dentoalveolar tissues, fu-
ture studies should include histological analyses, analyses of associated genes/proteins, and 
dental phenotyping of achondroplasia animal models and patients.  These additional studies 
will inform the best dosing for patients.
Disclosures: Sarah Aitken, None
P-754
Neonatal severe hyperparathyroidism: New analysis causes new guideline. 
Stephen J. Marx, Ninet Sinaii. Office of the Scientific Director, Section on 
Genetics and Endocrinology, NICHD/NIH, Bethesda MD 20892 *Stephen 
Marx1. 1NICHD, United States
Context: Neonatal severe hyperparathyroidism (NSHPT) is a rare and life-threatening 
emergency. It includes generalized hyperparathyroid bone disease and respiratory distress 
from combinations among a narrowed thorax, rib fractures, hypotonia, and biochemical 
disturbances. Neuromotor retardation may persist after otherwise successful therapy. Ear-
ly intervention seems critical. NSHPT is usually caused by homozygous or heterozygous 
pathogenic variant(s) of the CASR. Homozygotes and heterozygotes are often not distin-
guished. In theory, their management should differ. Optimum treatment in homozygotes is 
early total parathyroidectomy. Optimal management of heterozygotes varies from careful 
observation without surgery, to bisphosphonates and/or calcimimetics, and/or to subtotal 
parathyroidectomy. Evidence Acquisition: Each case met strict criteria for “severe” disease. 
To compare different immunoassays, PTH was analyzed as a ratio (thus without units) of the 
raw data divided by the upper limit of its normal range. This is a major extension on a recent 
report (JCEM April 2020). We now include many variables about presentation and therapy. 
Evidence Synthesis: There were 98 cases with homozygous pathogenic CASR variants and 
35 cases with heterozygous pathogenic or likely pathogenic variants. Maximal serum cal-
cium was far higher in homozygotes 5.8 +/- 1.5 versus 3.2 +/- 0.2 (P<.001) (normal 2.2-2.6 
mM). Maximal serum PTH as a ratio was also far higher in homozygotes 17 +/- 12 versus 
8 +/- 9 (P=.003) (normal ratio 0.3-1.0). We defined extreme hypercalcemia empirically as 
any calcium value above 4.5 mM. No heterozygote had a maximal calcium above 3.7 mM; 
however, 30 of 36 (83%) of the homozygotes had maximal calcium above the conservative 
cutoff of 4.5 mM. A more aggressive cutoff of 4.0 mM would capture 95% of homozygotes 
and no heterozygotes. The linear regression of the highest levels of extreme hypercalcemia 
versus day number confirmed frequent clustering of recognition in the first 10 days. Conclu-
sions: Extreme hypercalcemia greater than 4.5 mM was newly identified as a conservative 
cutoff that was 100% predictive of homozygosity for pathogenic CASR variants. Extreme 
hypercalcemia in NSHPT is an early, facile, rapid, and inexpensive determinant of homo-
zygosity. It should be sought and used as a guideline to promote early and definitive total 
parathyroidectomy in homozygotes.
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P-755
Efficacy of burosumab in older adults with X-linked hypophosphataemia 
(XLH): A subgroup analysis of a randomized, double-blind, placebo-
controlled, phase 3 study *Richard Keen1, Karl Insogna2, Wei Sun3, Julian 
Howell4, Susan Wood4. 1Royal National Orthopaedic Hospital, United 
Kingdom, 2Yale University School of Medicine, United States, 3Kyowa Kirin 
Pharmaceutical Development, United States, 4Kyowa Kirin International, United 
Kingdom
XLH (X-linked hypophosphataemia) is a rare, chronic and progressive disease. In adults 
with XLH, acquired bone deformities from childhood, together with ongoing chronic hypo-
phosphataemia and osteomalacia, may lead to substantial musculoskeletal and functional 
morbidities. Data have shown that treatment with burosumab in adults leads to sustained 
improvement in biochemical measures, as well as key symptoms and functional impair-
ments. This exploratory post-hoc subgroup analysis of data from CL303 (NVT02526160) 
assesses how biochemical and clinical outcomes in patients over 50 years of age treated with 
burosumab compare with younger patients.CL303 is a phase 3 multicentre, randomized, 
double-blind, placebo-controlled study evaluating the efficacy and safety of burosumab in 
adults with XLH. Adults were randomly allocated (1:1) to burosumab (1.0mg/kg, SC Q4 
Weekly) or placebo (SC Q4 Weekly) for 24 weeks; followed by 24 weeks of open label buro-
sumab. This subgroup analysis examines responses at Week 24 in age-based patient cohorts 
(>50 years and <50 years) to the primary endpoint of correction of serum phosphate, the key 
secondary endpoints of pain, stiffness and physical function and exploratory endpoint of 
(pseudo)-fracture healing.134 subjects were randomized (68 in burosumab and 66 in place-
bo); 65% female; median age 41 years [18–65 years]; 26 patients were aged >50 years (16 
burosumab; 10 placebo); and 108 <50yrs (52 burosumab; 56 placebo). Baseline symptom-
atology was similar between age and treatment groups.Results at Week 24 are shown in the 
table. Patients >50yrs treated with burosumab responded at least as well as those <50yrs and 
better than placebo, for all endpoints.Despite decades of progressive disease, both age co-
horts of adult patients with XLH treated with burosumab responded similarly well and better 
than placebo, improving biochemical markers, symptoms and (pseudo)-fracture healing. In 
adult patients with symptomatic XLH, advanced age should not be a factor when considering 
initiation of burosumab treatment.
Disclosures: Richard Keen, Kyowa Kirin International, Consultant
P-756
Real-world evidence of the progressive and cumulative morbidity arising 
from X-linked hypophosphatemia (XLH) over the adult life course *Kassim 
Javaid1, Erik Imel2, Rafael Pinedo-Villanueva1, Angela Rylands3, Angela 
Williams3, Karl Insogna4, Leanne Ward5. 1University of Oxford, United Kingdom, 
2Indiana University of Medicine, United States, 3Kyowa Kirin International, 
United Kingdom, 4Yale School of Medicine, United States, 5University of 
Ottawa, Canada
X-linked hypophosphatemia (XLH) is a rare, genetic phosphate-wasting disorder. 
Musculoskeletal deficits and dental abnormalities begin in childhood, becoming more pro-
nounced and numerous with age. This analysis aimed to explore the disease sequelae of 
XLH in adulthood according to age groups, using patient-reported data from a multinational 
online survey.Adults with self-reported XLH were recruited via clinicians and XLH patient 
advocacy networks to complete the survey. Burosumab-naive adults with XLH were ana-
lyzed by age group: 18–29, 30–39, 40–49, 50–59, and >=60 years. Specific manifestations 
(see Table) were investigated, including musculoskeletal, non-musculoskeletal, and conven-
tional therapy-related sequelae.Data were analyzed from 209 adults (63% United States, 
24% Europe, 13% rest of world; mean+/-SD age 45.5+/-13.0 years; 77% women; 38% cur-
rently not on therapy). 98% of adults reported >=1 sequelae, with a median of 4 sequelae 
per person (range 0–11). The proportion experiencing >=5 sequelae increased nearly 9-fold 
from the youngest to eldest group (8% to 71%, respectively).The proportion experiencing 
>=1 musculoskeletal sequelae increased from 50% in the 18–29-year group to 77–94% in all 
older groups. Fracture history prevalence increased across the age groups from 27% in the 
18–29-year group, to ~40% in the 30–59-year groups, and 68% in the >=60-year group. The 
most common fracture site was the femur (19%). Osteoarthritis was reported by 23% of the 
18–29-year group, increasing to 71% in the >=60-year group. Other comorbidities increased 
with age; in the 18–29-year group, osteophytes occurred in 19%, enthesopathy in 4%, and 
spinal stenosis in 4%, increasing in frequency with age to 52%, 45%, and 39%, respectively, 
in the >=60-year group.Non-musculoskeletal sequelae were highly prevalent at all ages, 
increasing from 85% in the 18–29-year group to 94% in the >=60-year group, driven by the 
presence of dental abscess in most adults (87%). 46% of the 18–29-year-olds reported >=1 
conventional therapy-related sequelae, increasing gradually to 65% in the >=60-year group. 
Of note, hyperparathyroidism was reported by 29% of adults, with prevalence increasing 
with age from 8% in the 18–29-year group to 61% in the >=60-year group.This analysis of 
patient-reported data indicates that XLH is a life-long, cumulative, and progressive disease. 
Important disease manifestations present in early adulthood, and frequency sharply increases 
after 30 years of age.
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A Natural History Study In Patients With ENPP1 Deficiency or Severe 
ABCC6 deficiency *Frank Rutsch1, Yvonne Nitschke1, Kristina Kintzinger1, 
Mary Hackbarth2, Ulrike Botschen1, Sisi Wang3, Rachel Gafni4, Kerstin Mueller3, 
Gus Khursigara5, Pedro Huertas5, William Gahl2, Carlos Ferreira2. 1Muenster 
University Children’s Hospital, Germany, 2National Human Genome Research 
Institute, National Institutes of Health, United States, 3ICON plc, Canada, 
4National Institute of Dental and Craniofacial Research, National Institutes of 
Health, United States, 5Inozyme Pharma, United States
We report on an interim analysis of a retrospective, cross-sectional natural history 
study (based on chart reviews) in patients diagnosed with generalized arterial calcification 
of infancy (GACI) or autosomal recessive hypophosphatemic rickets type 2 (ARHR2). The 
National Institutes of Health (NCT03478839) and Münster University Children’s Hospital 
(NCT03758534) contributed medical data for the study. The study collected full medical 
data from 127 patients of whom 115 patients were diagnosed with GACI, 36 patients were 
diagnosed with ARHR2, including 25 patients diagnosed with both GACI and ARHR2. Of 
109 probands with genetic confirmation, 88 had mutations in ENPP1 and 21 in ABCC6. 
Deaths in ENPP1 and ABCC6 subjects were 35 and 4, respectively. Consistent with past 
observations, arterial calcification (88%, 95%), joint calcification (64%, 33%), hypertension 
(65%, 67%) and short stature (stature-for-age less than third centile; 42%; 33%) were prev-
alent in ENPP1 and ABCC6 cohorts, respectively. Organ calcification (78%; 85%) cardiac 
dysfunction (78%, 85%), renal dysfunction (47%: 40%) and gastrointestinal dysfunction 
(63%; 58%) were also observed in both ENPP1 and ABCC6 cohorts, respectively. A higher 
prevalence of neurological complications was observed in the ABCC6 cohort (58% to 40%) 
while hearing loss (53%; 7%) and rickets (48%; 17%) were higher in the ENPP1 cohort. The 
data demonstrate similar clinical manifestation between ENPP1 and ABCC6 deficient pa-
tients. Significant mortality during infancy, calcification of multiple arteries, organ dysfunc-
tion and skeletal abnormalities are reported in both ENPP1 and ABCC6 deficient patients. 
The overlap of patients diagnosed with both GACI and ARHR2 suggests they may not be 
distinct conditions. Further analysis will further support and elucidate the progression of the 
disease. ENPP1 and ABCC6 deficiences are genetic conditions caused by loss-of-function 
mutations in either the ENPP1 or ABCC6 genes which may manifest in infants as GACI, 
a life-threatening disorder. Infants present with arterial calcifications, stenoses and cardiac 
complications. Approximately 50% of GACI infants do not survive the first 6 months of life. 
Patients with ENPP1 deficiency also manifest hearing loss and ARHR2, characterized by 
short stature, bone deformities and pain in pediatric and young adults. ABCC6 deficiency 
also manifests as Pseudoxanthoma elasticum in adults. Disclosure: Grant support and con-
sulting fees from Inozyme Pharma.
Disclosures: Frank Rutsch, Inozyme Pharma, Grant/Research Support, Inozyme Pharma, 
Consultant
P-758
Inhibition of Activin A with Garetosmab Improved Parameters of Lung 
Function in Patients with FOP *Cynthia Portal-Celhay1, Eduardo Forleo-
Neto1, Gregory P. Geba1, Marcella Ruddy1, Robert J Pignolo2, Richard Keen3, 
Maja Di Rocco4, Mona Al Mukaddam5, Philippe Orcel6, Christian Roux7, 
Jacek Tabarkiewicz8, Javier Bachiller-Corral9, Angela M. Cheung10, Kathryn 
M. Dahir11, Thomas Funck-Brentano6, Sami Kolta7, Annalisa Madeo4, Judith 
S Bubbear3, Małgorzata Szczepanek8, Esmée Botman12, Neena Sarkar1, Peijie 
Hou1, Scott Mellis1, Andrew J Rankin1, Aris Economides1, Dinko Gonzales 
Trotter1, Gary Herman1, David M. Weinreich1, George D. Yancopolous1, E. 
Marelise W. Eekhoff12, Frederick S. Kaplan5. 1Regeneron Pharmaceuticals, 
United States, 2Department of Medicine, Mayo Clinic, United States, 3Centre 
for Metabolic Bone Disease Royal National Orthopaedic Hospital NHS Trust, 
United Kingdom, 4Department of Pediatrics, Unit of Rare Diseases, IRCCS 
Istituto Giannina Gaslini, Italy, 5Departments of Orthopaedics, Medicine and the 
Center for Research in FOP & Related Disorders, University of Pennsylvania 
Perelman School of Medicine, United States, 6Service de Rhumatologie - 
DMU Locomotion, AP-HP.Nord - Université de Paris, France, 7Department 
of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, 
France, 8Rzeszów University, Rzeszów, Poland, 9Hospital Universitario Ramón 
y Cajal, Spain, 10University Health Network, University of Toronto, Canada, 
11Vanderbilt University Medical Center, United States, 12Department of Internal 
Medicine section Endocrinology, Amsterdam Bone Center, Amsterdam UMC, 
Vrije Universiteit, Netherlands
Background: Fibrodysplasia ossificans progressiva (FOP) is characterized by soft tissue 
inflammation (flare-ups) and cumulative heterotopic ossification (HO) resulting in skeletal 
deformity, progressive immobility and early mortality. Progressively-diminished chest wall 
mobility is common and thoracic insufficiency syndrome is the leading cause of death in 
FOP. LUMINA-1 evaluated safety and efficacy of garetosmab (GAR), a monoclonal anti-
body (mAb) inhibitor of Activin A, in adults with FOP. Pulmonary function was evaluated 
as an exploratory outcome.Methods: In LUMINA-1 (NCT03188666), subjects were ran-
domized to IV GAR 10 mg/kg (n=20) or placebo (PBO; n=24) every 4 weeks (Q4w) for 28 
weeks and then continued in open-label treatment. Primary efficacy was assessed by 18F-so-
dium fluoride positron emission tomography (PET) and whole-body low-dose computerized 
tomography (CT). Spirometry (FVC, FEV1, FEV1/FVC) was performed at baseline and 
week 28.Results: Pulmonary function of 41 adults (mean age [SD], 27.6 [8.5] years; 43% 
male overall) in GAR and PBO groups were comparable at study initiation (in L, FEV mean 
[SD], 1.84 [0.64] and 1.90 [0.80] and FVC, 1.96 [0.69] and 2.12 [0.94], respectively). All 
exhibited restrictive ventilatory defect at baseline shown by low % predicted FVC and high 
FEV1/FVC. By week 28, there was a trend toward improved % predicted FVC (mean [SD] 
baseline: GAR 48.03 [15] vs. PBO 49.81 [18.5]; 28 weeks: GAR 54.67 [20.3] vs, PBO 50.64 
[18.2]; change 13.8% GAR vs. 1.6% PBO), or as an improvement in PBO-adjusted absolute 
change (L) of FVC (GAR, 0.29 [14.7%] vs PBO, 0.05 [2.4%]) of 12.3%, and a statistically 
significant improvement in % predicted FEV1 (0.32 vs.-1.824; P=0.004) and % change in L 
FEV1 (7.6% vs 0%; P=-0.003) (Figure).Conclusions: GAR resulted in meaningful increases 
in lung function parameters with statistically significant improvement in FEV1 and a clin-
ically important increase in FVC. We hypothesize that the chest wall restriction in FOP is 
mediated in part by soft tissue inflammation and is reversible by inhibiting Activin A with 
garetosmab. These results may have important implications for the long-term health of indi-
viduals living with FOP and should be studied further.Fig:
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P-759
A Global Natural History Study of Fibrodysplasia Ossificans Progressiva 
(FOP): 12-Month Outcomes *Mona Al Mukaddam1, Robert J Pignolo2, 
Geneviève Baujat3, Matthew A Brown4, Carmen De Cunto5, Maja Di Rocco6, 
Edward C Hsiao7, Richard Keen8, Kim-Hanh Le Quan Sang3, Andrew Strahs9, 
Rose Marino9, Frederick S Kaplan10. 1Departments of Orthopaedic Surgery & 
Medicine, The Center for Research in FOP and Related Disorders, Perelman 
School of Medicine, University of Pennsylvania, United States, 2Department 
of Medicine, Mayo Clinic, United States, 3Département de Génétique, Institut 
IMAGINE and Hôpital Universitaire Necker-Enfants Malades, France, 4Guy’s 
& St Thomas’ NHS Foundation Trust and King’s College London NIHR 
Biomedical Research Centre, United Kingdom, 5Pediatric Rheumatology 
Section, Department of Pediatrics, Hospital Italiano de Buenos Aires, Argentina, 
6Unit of Rare Diseases, Department of Pediatrics, Giannina Gaslini Institute, 
Italy, 7Division of Endocrinology and Metabolism, UCSF Metabolic Bone 
Clinic, Institute of Human Genetics, and UCSF Program in Craniofacial Biology, 
Department of Medicine, University of California-San Francisco, United States, 
8Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital, 
United Kingdom, 9Ipsen, United States, 10Departments of Orthopaedic Surgery 
& Medicine, The Center for Research in FOP and Related Disorders, Perleman 
School of Medicine, University of Pennsylvania, United States
Background: FOP is an ultra-rare, severely disabling genetic disorder characterized by 
cumulative heterotopic ossification (HO), often preceded by episodic flare-ups, leading to 
physical disability and early death. FOP is diagnosed and managed by multiple healthcare 
professionals, including bone specialists.Objective: A prospective, 36-month, global natural 
history study (NCT02322255) was designed to investigate the progression of FOP, HO, and 
impact on physical function. Results are described for the first 12 months.Methods: Individ-
uals with FOP aged <=65 years with documented ACVR1R206H mutation were eligible. 
HO volume was assessed by low-dose whole-body computed tomography (WBCT; exclud-
ing the head) interpreted at a blinded, central laboratory using pre-specified procedures. 
Physical function was evaluated using the Cumulative Analogue Joint Involvement Scale 
(CAJIS; total score 0–30 represents degree of ankylosis across 15 joints) and the FOP Phys-
ical Function Questionnaire (FOP-PFQ; % total score); higher scores indicate more severe 
limitations. Changes from Baseline (BL) in HO volume, CAJIS and FOP-PFQ at Month 12 
were evaluated.Results: Of 114 participants with BL data, 99 (aged 4–56 years at enrollment, 
mean 17 years; 56% male) had a Month 12 assessment and 93 had evaluable WBCT HO data 
at BL and Month 12. Over 12 months, 40% (37/93) developed new HO and 48% (48/99) 
reported >=1 flare-up. Of participants with new HO, 65% (24/37) reported >=1 flare-up 
(mean 2.3 flare-ups/year) and 35% (13/37) reported no flare-up. Of participants with no new 
HO, 43% (24/56) reported >=1 flare-up (mean 1.8 flare-ups/year). Among all participants, 
mean new HO volume in those who reported flare-ups was 39,718 mm3 (SD: 91,969 mm3; 
n=48) vs 5,081 mm3 (SD: 14,582 mm3; n=45) in those who did not. Mean changes from BL 
in CAJIS and FOP-PFQ were minimal (CAJIS: 0.6 [SD: 2.4; median: 1.0; n=99]; FOP-PFQ: 
4.4% [SD: 11.2%; median: 3.7%; n=90]) and similar across participants with or without new 
HO.Conclusions: In participants with FOP, WBCT HO volume increased over 12 months. 
Among those who experienced new HO, this was not preceded by a flare-up in over one 
third of cases. Among all participants, mean new HO volume in those who reported flare-ups 
was ~8 times higher than in those who did not. CAJIS and FOP-PFQ were not sufficiently 
sensitive to assess FOP disease progression over 12 months. Measuring HO may be a viable 
way to monitor changes in FOP over short periods of time.
Disclosures: Mona Al Mukaddam, Biocryst, Blueprint, Daiichi Sankyo, Keros, Consultant, 
Research investigator: Clementia/Ipsen, Regeneron; Advisory board (all voluntary): 
IFOPA Registry Medical Advisory Board, International Clinical Council on FOP, Other 
Financial or Material Support
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Long-term trajectory of bone mineral density in pregnancy and lactation-
associated osteoporosis with or without bisphosphonate use after teriparatide 
*Seunghyun Lee1, Kyoung Jin Kim1, Namki Hong1, Yumie Rhee1. 1Department 
of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei 
University College of Medicine, Republic of Korea
Pregnancy- and lactation- associated osteoporosis(PLO) is a rare and devastating dis-
order that leads to limited activity and pain during pregnancy and lactation due to multiple 
compression fractures. Previous studies showed that teriparatide(TPTD) might be helpful in 
patients with severe PLO in terms of bone mineral density(BMD) recovery and subsequent 
fracture risk reduction.[i] However, it is unclear whether TPTD can be discontinued without 
sequential treatments with anti-resorptives such as bisphosphonates(BP) in premenopausal 
women with PLO, as recommended in postmenopausal women. In this study, we inves-
tigated the changes in BMD in PLO patients treated with TPTD 20 mcg daily injection 
for one year, with and without sequential BP use. Forty-three premenopausal patients with 
PLO between 2007 and 2015 in Severance hospital were retrospectively analyzed. Among 
them, 37 women were treated with TPTD (TPTD with sequential BP treatment, n=17; TPTD 
without sequential BP treatment, n=20). All subjects maintained regular menstruation cycles 
after pregnancy and lactation. At baseline, BP users and non-BP users after TPTD were not 
different in age (31 vs. 32 years), body mass index (20.0 vs. 20.9 kg/m2), duration of TPTD 
treatment (14.1 vs. 12.6 months), lumbar spine(LS) BMD (0.670 vs. 0.725 g/cm2) and femo-
ral neck(FN) BMD (0.595 vs. 0.550 g/cm2; p > 0.05 for all). Median duration of BP use was 
21 months (12 to 26 months) in BP users after TPTD. In overall subjects, average increase in 
LSBMD was 15.2%, 22.4%, 22.0% after 1,2,3 years from baseline, respectively (P 0.05 for 
all time points). Similar results were observed for THBMD, with an average increase of up 
to 4.05%, 7.38%, and 7.37% for 1,2,3 year time points after initiation of TPTD (p<0.05 for 
each treatment group, at all time points). In conclusion, BMD gain by TPTD use in patients 
with PLO was well maintained without sequential BP treatment, showing a similar long-
term trajectory to that of sequential BP users.[i] Namki Hong, Yumie Rhee et al. Comparison 
of Efficacy of Pharmacologic Treatments in Pregnancy- and lactation-associated osteoporo-
sis. Clinical Reviews in Bone and Mineral Metabolism (2019) 17:86-93
Disclosures: Seunghyun Lee, None
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Lesional Sodium Fluoride uptake decreases on PET-CT scan in patients with 
Fibrous Dysplasia/McCune Albright syndrome treated with Denosumab. 
*Wouter van der Bruggen1, Dennis Vriens1, Maartje E. Meier1, Frits Smit1, P. 
D. Sander Dijkstra1, Liesbeth E.M. Winter1, Lioe-Fee de Geus-Oei1, Natasha M. 
Appelman-Dijkstra1. 1Leiden University Medical Center (LUMC), Netherlands
Despite the recently described correlation between fibrous dysplasia (FD) disease bur-
den measured with [18F]NaF PET-CT (NaF-PET) and bone turnover markers, the effect 
of treatment on lesional NaF-uptake in patients with fibrous dysplasia (FD) is unknown. 
[99mTc]-HDP uptake does not change after bisphosphonate treatment. We retrospectively 
studied fifteen FD/MAS-patients who underwent NaF-PET scans (37 scans) and received 
antiresorptive treatment. Baseline and follow-up NaF parameters of healthy bone and FD-le-
sions and serum markers of bone turnover around treatment with denosumab (n=8) or on bis-
phosphonates (n=7) were assessed. Individualized patient healthy bone cut-offs on NaF-PET 
ensured adequate normalization and did not change after denosumab (p=0.237) or bisphos-
phonates (p=0.575) treatment, reassuring the hypothesis that sites with increased turnover 
receive the highest dose of treatment. Volumetric parameters of FD-burden on NaF-PET 
(FTV) showed significant decrease after start of denosumab, median FTV 199 cm3 on base-
line scan to 97 cm3 during follow-up, p=0.030. However, FTV did not change in patients re-
ceiving bisphosphonates (p=0.249). FTV correlated positively with serum markers Alkaline 
Phosphatase (ALP) (rSpearman=0.406; p=0.006; n=37) and with P1NP (rSpearman=0.730; 
p<0.001; n=36). Relative changes in FTV and both serum biomarkers of bone turnover cor-
related positively (DFTV versus DALP and DP1NP, r Spearman=0.518 and 0.489; p=0.024 
and 0.032, respectively). In several patients, either ALP or P1NP (n=5) or both (n=3) showed 
normal serum levels, still FTV adequately quantified disease and response to antiresroptive 
treatment, as measured by pain scores, and possibility to reduce pain medication. Changes 
in serum markers of bone turnover correlate with FD-disease burden measured with FTV on 
NaF-PET. Therefore NaF-PET could be used as an objective local parameter of treatment 
response in FD in addition to serum biomarkers of bone turnover, pinpointing location and 
extension of FD-burden. NaF might be of extra importance in patients with normal(ized) 
serum markers and clinical complaints.
Disclosures: Wouter van der Bruggen, None
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Infigratinib Therapy in Tumor-Induced Osteomalacia *Iris R. Hartley1, Kelly 
L. Roszko1, Karen Pozo1, Jamie Streit1, Jaydira del Rivero2, Roo Vold3, Susan 
Moran3, Michael T. Collins4, Rachel I. Gafni1. 1National Institute of Dental and 
Craniofacial Research, National Institutes of Health, United States, 2National 
Cancer Institute, National Institutes of Health, United States, 3QED Therapeutics, 
United States, 4National Institute of Dental and Cranial Facial Research, National 
Institutes of Health, United States
Tumor-induced osteomalacia (TIO) is a rare disorder caused by fibroblast growth factor 
23 (FGF23)-producing phosphaturic mesenchymal tumors (PMTs). Resultant phosphaturia 
and suppressed 1,25-(OH)2 vitamin D (1,25D) leads to hypophosphatemia, osteomalacia, 
and fractures. Fibronectin- fibroblast growth factor receptor 1 (FN1-FGFR1) fusions have 
been identified in up to 40% of PMTs. Infigratinib is a selective FGFR1-3 tyrosine kinase 
inhibitor with observed anti-tumor activity in phase 2 trials of cancers with FGFR genetic 
alterations. A previous infigratinib trial, that included 2 TIO patients, normalized FGF23 
and phosphate in both, with decreased metastatic PMT burden in one.Four patients (2m, 
2f; 26-41y) with TIO due to non-localized or non-resectable PMTs were enrolled in a 24w 
open-label phase 2 trial of oral infigratinib with the goal of inducing persistent biochemical 
remission after drug discontinuation. The starting dose was 75 mg/d, which was adjusted to 
25-125 mg/d based on biochemical changes and tolerability.Three patients completed 24w 
of infigratinib; 2 had dose interruptions due to adverse events (AEs). The 4th subject com-
pleted 17w of infigratinib, which was then held due to an AE and not restarted because of 
rising C-terminal FGF23 levels on therapy. Biochemical parameters improved in all patients 
while on infigratinib including decrease in intact FGF23, and an increase in blood phosphate 
and 1,25D (Fig). After drug discontinuation, values returned to baseline, indicating a lack 
of persistent biochemical remission. 68Ga-DOTATATE scans at 24w in the 2 subjects with 
identified PMTs showed a decrease in PMT activity but not size. After study end, 3 subjects 
pursued other therapies, and 1 received infigratinib for an additional 42d.All subjects ex-
perienced mild to moderate treatment-related, dose-limiting AEs but no serious AEs. The 
study closed early due to a greater than expected incidence of ocular AEs, possibly due to 
the continuous daily dosing regimen, and evidence from these first 4 subjects that permanent 
remission was unlikely on infigratinib.Infigratinib suppression of PMT activity with meta-
bolic remission confirmed the role of FGFR signaling in PMT pathogenesis, consistent with 
an autocrine feed-forward physiology. Because persistent remission was not achieved with 
discontinuation, and treatment-related, primarily ocular, AEs were significant, infigratinib 
should only be considered in those with life-limiting metastatic TIO.
Disclosures: Iris R. Hartley, QED Therapeutics, Grant/Research Support
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A Phase 1 PK/PD Study of Once vs Twice Daily Administration of 
rhPTH(1-84) in Patients With Hypoparathyroidism: Final Analysis *Steven 
Wai Ing1, Richard D Finkelman2, Ping He3, Aliya A. Khan4, Michael Mannstadt5, 
Lars Rejnmark6, Ivy Song3, István Takács7. 1Division of Endocrinology, Diabetes 
and Metabolism, Ohio State University, United States, 2Shire Human Genetic 
Therapies, Inc., a Takeda company, Lexington, MA, USA, United States, 3Shire 
Human Genetic Therapies, Inc., a Takeda company, Lexington, MA, USA, 
United States, 4McMaster University, Canada, 5Endocrine Unit, Massachusetts 
General Hospital and Harvard Medical School, United States, 6Department 
of Clinical Medicine, Aarhus University Hospital, Denmark, 7Department of 
Medicine, Faculty of Medicine, Semmelweis University, Hungary
Introduction: In the US, recombinant human parathyroid hormone, rhPTH(1-84), is 
indicated as an adjunct to calcium (Ca) and active vitamin D (vitD) once daily (QD) to 
control hypocalcemia in patients with hypoparathyroidism (HypoPT). In a phase 1 study, 
we compared PTH pharmacokinetics (PK) and pharmacodynamic (PD) effects (serum Ca 
[S-Ca], urinary Ca [U-Ca] excretion) between QD and twice daily (BID) administration over 
a single day.Methods: Patients with chronic HypoPT (n=34; 30 [88.2%] female; 33 com-
pleters) were sequentially enrolled into 1 of 4 rhPTH(1-84) treatment cohorts in a crossover 
study design. All received single-dose (100 µg QD) plus one of two BID doses (25 µg BID 
or 50 µg BID) of rhPTH(1-84); without oral Ca (cohorts 1 & 2) or with oral Ca (cohorts 3 
& 4). Cohort 1: 25µg BID or 100µg QD, no Ca (n=9). Cohort2: 50µg BID or 100µg QD, no 
Ca (n=8). Cohort 3: 25µg BID or 100µg QD, with Ca (n=9). Cohort 4: 50µg BID or 100µg 
QD, with Ca (n=8). Within each cohort, patients were randomized 1:1 to sequence order: 
QD→ BID vs BID→QD. All received their usual conventional therapy (oral Ca/active vitD) 
on Day –1, prior to rhPTH(1-84) dose (Day 1). Active vitD was withheld on Day 1. After a 
washout period, patients crossed over to the opposite rhPTH(1-84) treatment (QD or BID). 
S-Ca and U-Ca were obtained on Days –1 and 1. Data were summarized using descriptive 
statistics.Results: S-Ca responses were generally similar among treatments, although S-Ca 
tended to be numerically higher where treatment included adjunctive oral Ca. Compared 
with conventional therapy (Day –1), rhPTH(1-84) treatment at 100µg QD, 50µg BID, or 
25µg BID markedly reduced 24-h U-Ca excretion in cohorts without oral Ca (1 & 2) by 
32.0%, 49.6%, and 47.6%, respectively and in cohorts with oral Ca (3 & 4) by 18.4%, 
17.7%, and 31.1%, respectively (Figure). Overall, 18 (52.9%) patients experienced 58 treat-
ment-emergent adverse events (TEAEs), 26 considered treatment-related. All but 2 TEAEs 
were resolved. No serious TEAEs were reported.Conclusions: S-Ca was not different among 
the three rhPTH(1-84) regimens. Treatment with rhPTH(1-84) led to a decrease in U-Ca 
excretion compared with oral Ca/active vitD. With respect to BID administration, U-Ca ex-
cretion was reduced incrementally compared with QD but less so  when treatment included 
adjunctive oral Ca. No new safety findings were observed with rhPTH(1-84) whether QD or 
BID. Data reflect a single day of dosing.
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P-764
Calcium and Phosphate Homeostasis in Patients With Chronic 
Hypoparathyroidism on Conventional Therapy *Olulade Ayodele1, Lars 
Rejnmark2, Allison Briggs3, Kristina Chen4, Clara Monleón Bonet5, Angela Lax3, 
Fan Mu3, Nicole Sherry6, Elvira Gosmanova7. 1Shire Human Genetic Therapies, 
Inc., Global Evidence and Outcomes, Data Sciences Institute, United States, 
2Aarhus University and Aarhus University Hospital, Denmark, 3Analysis Group, 
Inc., United States, 4Former, Shire Human Genetic Therapies, Inc., Global 
Evidence and Outcomes, Data Sciences Institute, Research and Development; 
Current, Arena Pharmaceuticals, United States, 5Shire International GmbH, 
Switzerland, 6Shire Human Genetic Therapies, Inc., United States, 7Albany 
Medical College, United States
Objective: To evaluate longitudinal albumin-corrected serum calcium (Ca), serum 
phosphate (P), and calcium-phosphate product (Ca × P) levels in patients (pts) with chronic 
hypoparathyroidism (HypoPT) receiving conventional therapy.Methods: Pts with chronic 
HypoPT were identified from the Explorys electronic medical record database (Jan 2007–
Aug 2019) in the US. Index date was the day after first calcitriol prescription. Ca analysis 
included pts with >=1 pair of serum albumin and serum Ca values reported on the same 
date during the 6 mo before index and during 5 years (y) (+/-6 mo) follow up. P and Ca 
× P analyses were conducted among pts in the Ca analysis sample with >=1 available P 
value on the same date as their Ca measurement. Pt characteristics before index date were 
evaluated. Mean proportion of measurements per pt within specified ranges throughout the 
5-y period after the index date was assessed using the following ranges for Ca (target range 
[2.00–2.25 mmol/L], normal range [2.15–2.55 mmol/L], mild hypocalcemia [1.875–2.00 
mmol/L], moderate-severe hypocalcemia [2.55 mmol/L]), P (normal range: >=0.81–<=1.45 
mmol), and Ca × P (normal range: <=4.4 mmol2/L2).Results: There were 143 pts with 
available Ca data; mean +/- SD age was 55.3+/-14.9y. Pts had a mean +/- SD (range) of 
41.4%+/-24.62% (0–100.00%) of Ca measurements within target range, 28.5%+/-27.06% 
(0–100.00%) of measurements above target range but within normal range, and 10.4%+/-
12.75% (0–50.00%) of measurements within the mild hypocalcemia range (Figure). Also, 
15.1%+/-22.34% of Ca measurements were in the moderate-severe hypocalcemia range and 
4.7%+/-9.30% were in the hypercalcemia range. The P and Ca × P analysis sample included 
31 pts (mean +/- SD age 56.1+15.0y). These pts had a mean +/- SD (range) of 58.8%+/-
25.59% (4.55–100.00%) of P measurements and 96.7%+/-6.16% (76.47–100.00%) of Ca 
× P measurements within normal range.Conclusions: Despite the paramount importance of 
normal Ca and P homeostasis for health-related outcomes in HypoPT, pts treated with con-
ventional therapy had sub-optimal control of Ca, with wide fluctuations in Ca and P during 
the 5-y period. Having Ca and/or P measurements outside the target range has been shown 
to be associated with poor long-term outcomes in pts with HypoPT, including increased risk 
of renal and cardiovascular complications.
Disclosures: Olulade Ayodele, Takeda, Other Financial or Material Support
P-765
Clinical responses in adult XLH patients not achieving consistent serum 
phosphate normalization: A subgroup analysis of a randomized, double-
blind, placebo-controlled, Phase 3 study (CL303 NCT02526160) *Maria 
Luisa Brandi1, Susan Wood2, Mark Nixon3, Jennifer Liu3, Robin Lachmann4. 
1Azienda Ospedaliero Universitaria Careggi, Italy, 2Kyowa Kirin International, 
United Kingdom, 3Chilli Consultancy, United Kingdom, 4Charles Dent Metabolic 
Unit National Hospital for Neurology and Neurosurgery, United Kingdom
X-linked hypophosphataemia (XLH) is characterised by excess Fibroblast growth 
factor 23 (FGF23) activity and chronic hypophosphataemia. Burosumab, a fully human 
anti-FGF23 antibody, restores phosphate homeostasis, thus improving musculoskeletal 
symptoms and physical function.CL303 is a phase 3 multicentre, randomized, double-blind, 
placebo-controlled study that evaluated the efficacy and safety of burosumab in adults with 
XLH. Adults were randomized (1:1) to SC administration of burosumab (1.0mg/kg) or pla-
cebo, Q4W for 24 weeks. 92.6% of the burosumab group achieved a mean serum phosphate 
concentration above the lower limit of normal (LLN) across the midpoints of the dose in-
tervals through W24, compared with only 7.6% of the placebo group (p < 0.0001). This 
exploratory analysis compared clinical outcomes at W24 in subjects with phosphate levels 
>=LLN for the majority of their visits in the first 24 weeks (>=6/12 ) (Pi 6+) versus those 
with fewer (Pi 5-) and was performed in subjects with complete data for both serum phos-
phate and TmP/GFR measurements.Most subjects treated with burosumab (39/79.6%) had 
serum phosphate >=LLN for 6 or more visits (Pi6+) versus only 2 (4%) of placebo-treated 
subjects. Patients treated with burosumab achieved a mean increase in serum phosphate 
of at least 30% from baseline. All burosumab subjects achieved TmP/GFR measurements 
>=LLN.  Clinical outcomes at Week 24 are shown in the table. Data are not shown for the 2 
patients in the placebo Pi 6+ group as small sample size renders results not meaningful.Bu-
rosumab consistently improved serum phosphate levels with XLH. Clinical outcomes were 
improved in subjects treated with burosumab, including those who achieved LLN at less 
than half of their study visits. A sustained improvement of serum phosphate is a good indica-
tor of clinical effect in these patients even if individual measurements fall short of the LLN.
Disclosures: Maria Luisa Brandi, Kyowa Kirin, Consultant
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Mild X-linked hypophosphatemia (PHEX c.*231A>G): Normalization 
of serum phosphorus levels with low-dose burosumab therapy *Gary 
Gottesman1, Valerie Wollberg1, Steven Mumm2, Michael Whyte1. 1Shriners 
Hospitals for Children-St. Louis, United States, 2Washington University School 
of Medicine, United States
X-linked hypophosphatemia (XLH), from deactivating mutations of PHEX, is the most 
common heritable disorder featuring renal phosphate (Pi) wasting.  Elevated circulating lev-
els of phosphatonin FGF23 cause hypophosphatemia in affected children leading to rickets 
with skeletal deformity and reduced linear growth.  In 2015, we reported uniquely mild 
XLH in American children and mothers carrying the non-coding PHEX 3’-UTR mutation 
c.*231A>G.  At last year’s ASBMR meeting, we reported that a duplication of PHEX exons 
13 – 15 was present in 3’-UTR patients.   Hence, the 3’-UTR change may represent a molec-
ular marker for this mild XLH phenotype.  This year, our retrospective age- and sex-matched 
1:1 case-control publication contrasted clinical, biochemical, and DXA findings of 30 people 
harboring the 3’-UTR mutation versus 30 individuals with classic XLH.  We demonstrated 
the 3’-UTR group had mild XLH, especially the females who were often undiagnosed and 
untreated.  In XLH, burosumab, the fully-human monoclonal antibody targeting FGF23 (ap-
proved by the FDA in 2018), improves Pi homeostasis and rickets in children and osteomala-
cia in adults. Herein, we report our experience treating four children (1 boy, 3 girls) with the 
3’-UTR defect who required only low-dose (0.3 mg/kg/dose) burosumab therapy given sub-
cutaneously every two weeks to normalize their serum Pi levels and improve their reported 
symptoms.  For another girl with a family history of XLH, we had started her on a standard 
burosumab dose of 0.8 mg/kg every 2 weeks (rounded per initial FDA-approved Prescribing 
Information).  She became hyperphosphatemic requiring a reduced dose.  Subsequently, 
PHEX molecular analysis revealed a 3’-UTR mutation. The 3’-UTR PHEX genotype is 
presently the single known etiology of mild XLH, although  our experience with greater than 
350 XLH children and their families indicates other PHEX alterations cause mild disease. 
Identifying XLH patients with this PHEX 3’-UTR variant, or other mild phenotypes, has 
implications for safe treatment with burosumab or calcitriol and phosphate.  Molecular diag-
nosis of the 3’-UTR PHEX genotype will help guide safe and appropriate therapy.  
Disclosures: Gary Gottesman, None
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Characterization of Comorbidity in X-linked Hypophosphatemia: A 
Prospective Parallel Cohort Study Using the UK CPRD *Samuel Hawley1, 
Nick Shaw2, Antonella Delmestri1, Daniel Prieto-Alhambra1, Cyrus Cooper3, 
Rafael Pinedo-Villanueva1, M. Kassim Javaid1. 1University of Oxford, United 
Kingdom, 2Birmingham Women’s and Children’s NHS Foundation Trust, United 
Kingdom, 3University of Southampton, United Kingdom
Background and objective: X-linked hypophosphatemia (XLH) is a rare multisystemic 
disease of mineral homeostasis that has a prominent skeletal phenotype. We have previously 
demonstrated an unexpected increase in mortality in patient with XLH. We here aimed to 
describe comorbidity in patients with XLH and compare this to general population controls.
Material and methods: The Clinical Practice Research Datalink (CPRD) GOLD was used 
to identify a cohort of XLH patients (1995-2016), along with a non-XLH cohort matched 
(1:4) on age, gender and GP practice at date of first XLH diagnosis (index date). Previously 
published phenotyping algorithms openly available from the online CALIBER portal were 
used to identify the first primary care diagnosis (and associated age) of 273 defined comorbid 
conditions during any eligible patient follow-up. For primary analysis, the individual con-
ditions were merged into 15 major disease categories and the proportion of patients having 
>=1 diagnosis in each category was compared between cohorts using univariable logistic 
regression. In secondary analysis individual conditions were compared. Only categories/
conditions affecting >=10% of either cohort were included in these comparisons given the 
large number of comorbidities screened relative to a limited sample size. Bonferroni cor-
rected P-values were used to account for multiple testing.Results: There were 64 and 256 
patients in the XLH and non-XLH cohort, respectively. Of these, 45% were aged over 16 
years at index date and 70.5% were female. Average follow-up per patient was 10.2 years. 
Recorded comorbidities (categorized) are presented in the table (below). In secondary anal-
yses of individual conditions, eight were recorded in at least 10% of XLH patients which 
in age ascending order were: acne, dermatitis, asthma, rhinitis, migraine, depression, enthe-
sopathy and hypertension. Four conditions were at least twice as likely to be present in the 
XLH relative to non-XLH cohort, but only depression met the Bonferroni threshold: odds 
ratio= 2.95 [95%CI: 1.47 to 5.92]; p=0.0023.Conclusion: Findings suggest XLH patients 
have elevated levels of comorbidity broadly defined as endocrinological and neurological, 
in addition to nearly three times the occurrence of depression. These findings should raise 
awareness of the non-skeletal effects of this rare bone disease.
Disclosures: Samuel Hawley, None
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A qualitative thematic analysis of the burden of illness of x-linked 
hypophosphatemia across the life course *Juddith Bubbear1, Angela J 
Rylands2, Angela Williams2, Karen Bailey3, Jacqui Bernarde3, Moira Cheung4. 
1Royal National Orthopaedic Hospital NHS Trust, United Kingdom, 2Kyowa 
Kirin International, United Kingdom, 3OPEN VIE, United Kingdom, 4Evelina 
London Children’s Hospital, United Kingdom
X-linked hypophosphatemia (XLH) is a rare, genetic phosphate-wasting disorder. 
Bone, muscular and dental problems begin early in childhood, widening to include multiple 
complications and symptoms in adulthood. This qualitative analysis aimed to explore the 
symptoms or complications from XLH that interfere most with life using a sub-set of data 
from burosumab-naïve participants completing a large multinational online patient survey. 
Responses to two open-ended questions from adults (n=209) and children (n=86 via proxy 
report) with self-reported XLH (59% US, 24% EU, 17% Rest of World) were analysed by 
age group (1-4, 5-11, 12-17, 18-29, 30-39, 40-49, 50-59, 60+ years) using hybrid deduc-
tive and inductive thematic analysis. Two researchers independently coded and analysed 
the responses, with any differences settled in consensus with a multifaceted research group. 
Dominant themes, across the life course, were identified according to the most frequently 
applied codes, and grouped into three categories. The categories were: 1. “clinical signs and 
symptoms”, 2. “impact of signs and symptoms” and 3. “negative treatment experiences”. 
Within category 1, ‘pain’ was the most dominant theme across the life course, with frequent 
reports of ‘joint pain’ in adults and ‘bone pain’ in children, ‘bone and joint pathology’ inter-
fered with life most frequently in children. ‘Dental problems’ were problematic across life, 
beginning in early years, with ‘stiffness’ emerging as a symptom in early adulthood. For 
category 2, interference with ‘movement and physical exertion’ was a major theme across 
all age groups. Impact on ‘emotional wellbeing’ was widely reported, in particular ‘depres-
sion’ and ‘worries about the future’ in adults and ‘frustration’ and ‘lack of self-esteem’ in 
children. ‘Social impacts’ was an important theme, largely due to ‘feeling different from 
peers’ for teenagers and ‘social isolation’ for adults. For category 3, ‘medication frequency’ 
was most burdensome for children, with adult groups focussing more on lack of ‘access to 
appropriate treatment’. This qualitative analysis highlights that symptoms and complications 
of XLH can be physical, emotional and social in nature, presenting throughout the lifetime, 
although the symptoms or complications that interfere most notably vary between children, 
adolescents and adults. Findings contribute new insights to age-specific impacts of XLH, 
illustrating the need for age-appropriate multidisciplinary care.
Disclosures: Juddith Bubbear, Kyowa Kirin International, Consultant
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A Clinical Trial to Assess Safety and Efficacy of Burosumab in Cutaneous 
Skeletal Hypophosphatemia Syndrome (CSHS) *Rachel Gafni1, Andrea 
Estrada2, Alison Boyce1, Mirini Kim3, Lindsay Weigley3, Elmer Rajah3, Austin 
Gillies3, Laura Tosi3. 1Skeletal Disorders and Mineral Homeostasis Section, 
National Institute of Dental and Craniofacial Research, National Institutes of 
Health, United States, 2Division of Endocrinology and Diabetes, Children’s 
National, United States, 3Bone Health Program, Division of Orthopaedics & 
Sports Medicine, Children’s National, United States
Purpose:CSHS is a rare multi-lineage mosaic disorder due to somatic gain-of-function 
RAS variants, manifesting with skin lesions, skeletal dysplasia, neoplasms, and FGF23-me-
diated hypophosphatemia. Conventional therapy includes phosphate and active vitamin D, 
but the regimen is often poorly tolerated and associated with complications. Burosumab is a 
fully human monoclonal antibody against FGF23 approved for X-linked hypophosphatemia. 
As FGF23 levels are elevated in CSHS, we initiated a 52-week investigator-sponsored trial 
evaluating burosumab in an 18-year-old skeletally-mature woman with debilitating CSHS.
Methods: Oral calcitriol and phosphate were stopped 1 week prior to the 1st dose. Burosum-
ab was given q4w (starting at 0.3mg/kg), with biochemistries q2-4w. The dose was titrated 
to keep trough Pi levels normal. Additional results including skeletal imaging, fitness testing, 
and patient-reported outcomes are pending completion of 52 weeks.Results:Data reflects 36 
weeks of treatment. Screening FGF23 was 224 RU/ml (normal < 180). At baseline, fasting 
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Pi was 1.6 mg/dL (2.5-4.5), 1,25 (OH)2-Vitamin D 16 pg/mL (1,25D,18-72), TmP/GFR 1.4 
mg/dL (2.5-4.2). Two weeks after the 1st dose, all 3 rose into the normal range to 3 mg/dL, 
68 pg/mL, and 3.2 mg/dL, respectively, consistent with FGF23 blockade. Burosumab was 
increased to 0.6 mg/kg with the 3rd injection, when the trough Pi was 2.1 mg/dL; Pi, 1,25D, 
TmP/GFR, alkaline phosphatase, Ca, and PTH remained in the normal range on this dose 
(Figure). Of note, the patient had a history of primary hyperparathyroidism with nephrolithi-
asis; curative resection of a parathyroid adenoma occurred 1 year prior to study enrollment. 
Renal ultrasound at screening demonstrated small asymptomatic nephroliths without neph-
rocalcinosis however, after 7w of burosumab, she passed several calcium oxalate kidney 
stones, without concurrent hypercalciuria. It is unclear if burosumab promoted new stone 
formation or simply led to mobilization of pre-existing stones. Otherwise, burosumab has 
been well-tolerated and the patient reports subjective reduction in fatigue and improvement 
in strength.Conclusion: 36 weeks of burosumab normalized Pi, 1,25D, and TmP/GFR in an 
adult with FGF23-mediated hypophosphatemia due to CSHS, similar to patients with XLH. 
While the increased passage of kidney stones was documented, relationship to the drug 
remains unclear. These early data suggest burosumab may be a safe and effective treatment 
for CSHS.
Disclosures: Rachel Gafni, Ultragenyx Pharmaceutical, Grant/Research Support
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Persistent Hypophosphatasemia and its Musculoskeletal Repercussion 
*Ariela Kitaigrodsky1, Luisa Plantalech1, Sebastian Marciano1, Maria Diehl1, 
Graciela Jimenez1. 1Hospital Italiano de Buenos Aires, Argentina
Introduction: Low alkaline phosphatase (ALP) or hypophosphatasemia due to hypo-
phosphatasia or to secondary causes; although rare and probably underdiagnosed, could 
have clinical implications. The aim of this report is to estimate the hypophosphatasemia 
prevalence and describe our clinical findings in adults with persistent hypophosphatasemia.
Methods: An electronic medical record search of adult members of our health care system 
between 2013 and 2017 was made. Those members with two or more ALP <= 30 IU/l, no 
ALP > 30 IU/l, and no diagnosis of secondary causes were selected. Clinical reports and 
available complementary studies were analyzed. The categorical variables were expressed as 
absolute number and percentage, the numerical ones in median and interquartile range 25% 
-75% (RIC). Results: Persistent hypophosphatasemia was detected in 0.07% (0.06-0.09) of 
105.925 members. One patient was excluded because of celiac disease as a secondary cause, 
77 cases were included; 61.1% were women, with a median age of 44 (34-56) years old, ALP 
was 24 (20-27) IU/l and phosphatemia 4.1 (3.8-4.6) mg/dl. Osteoarthritis, vascular calcifi-
cations and fractures were detected in 45, 13 and 12 patients respectively; nephrolithiasis, 
diffuse idiopathic skeletal hyperostosis (DISH), tooth loss and seizures were less frequently 
reported. At least one of those clinical manifestations was observed in 63.6% of the cases, 
but in only 5.2% of them hypophosphatasemia had been registered in their clinical record. 
Densitometric analysis showed osteopenia or osteoporosis in 76.2%. The majority of the 19 
fractures observed were of the radius, with no gender predominance. Four patients received 
bisphosphonates, with low ALP before starting them. No atypical fractures were observed, 
one patient presented with multiple fractures (pelvis, olecranon and wrist) after antiresorp-
tive treatment. Conclusions: The prevalence of hypophosphatasemia was 0.07%. Findings in 
medical records were not taken into account in most cases, but far from being asymptomatic, 
varied clinical manifestations were observed, similar to what had been previously reported 
in other hypophosphatasemia and adult hypophosphatasia series. In the presence of hypo-
phosphatasemia without a secondary cause, adult hypophosphatasia should be suspected. 
An adequate diagnosis of hypophosphatasia is relevant due to its clinical and therapeutical 
implications (antiresorptives should be avoided) as well as for genetic counseling.
Disclosures: Ariela Kitaigrodsky, None
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Whole Exome Sequencing (WES) Reveals Likely Pathogenic Variants in 
a Small Subset of Premenopausal Women with Idiopathic Osteoporosis 
*Adi Cohen1, Joseph Hostyk2, Evan H. Baugh2, Christie M. Buchovecky2, 
Vimla S. Aggarwal2, Robert R. Recker3, Joan M. Lappe3, Mafo Kamanda-
Kosseh1, Mariana Bucovsky1, Julie Stubby3, David B. Goldstein2, Elizabeth 
Shane1. 1Columbia University Irving Medical Center, United States, 2Columbia 
University Institute for Genomic Medicine, United States, 3Creighton University 
Medical Center, United States
Premenopausal women with idiopathic osteoporosis diagnosed in adulthood (Preme-
nIOP) have profound bone structural deficiencies and commonly report both adult and child-
hood fractures (Fx) and family history (FH) of osteoporosis. Some have very low bone 
formation rates suggesting osteoblast dysfunction. These features led us to investigate po-
tential genetic etiologies of bone fragility.In 75 PremenIOP, we performed WES using our 
variant analysis pipeline to select candidate variants. All had transiliac bone biopsies after 
tetracycline labeling of bone forming surfaces. The variant analysis pipeline highlights rare 
(<= 6.29e-5 allele frequency) and novel genotypes likely to affect known disease genes, 
including known pathogenic variants, compound heterozygous variants, protein-truncating 
variants in susceptible genes, and other novel variants absent from our in-house variant 
database and external control reference samples.We ran burden analyses both on all genes 
individually and on a set of implicated osteoporosis genes. For LRP5 in particular, we also 
assessed the frequency of all (including common) variants in subjects vs controls (reference 
cohort, n=18,746 without a diagnosis of osteoporosis).59 women had adult low trauma Fx 
and 16 had low BMD but no adult Fx. No novel genotype was identified. The cases had no 
increased burden of common LRP5 variants when compared to controls. Our cohort-wide 
collapsing results showed that no gene had genome-wide significance between rates of cases 
and controls with qualifying variants. The variant analysis pipeline did not highlight variants 
in COL1A1, COL1A2, WNT, or ALPL. The pipeline identified 4 heterozygous variants in 
LRP5 and PLS3 (encoding Plastin 3) that confidently contribute to osteoporosis. All 4 were 
either protein-truncating/loss-of-function variants or occurred at sites within the protein that 
have known pathogenic variants in ClinVar or HGMD. All 4 women had adult Fxs, and 3 had 
multiple Fxs, childhood Fxs and a FH of osteoporosis. Two presented during pregnancy or 
lactation. Tissue level bone formation rate was below normal in 3 and just above the lower 
normal limit in one.In summary, WES revealed likely pathogenic variants in LRP5 and PLS3 
in only 4 of 75 women with PreMenIOP. All 3 LRP5 variants were highlighted as rare. In the 
rest of the group, the LRP5 variant rate was similar to controls. Further functional studies are 
planned to investigate phenotypic effects of the identified variants.
Disclosures: Adi Cohen, None
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Vitamin B6 Sufficiency In Children With Hypophosphatasia *Michael P. 
Whyte1, Fan Zhang2, Deborah Wenkert2, Karen E. Mack2, Karen L. Ericson3, 
Vinieth N. Bijanki2, Stephen P. Coburn4. 1Center for Metabolic Bone Disease and 
Molecular Research, Shriners Hospitals for Children-St. Louis; and Div. of Bone 
and Mineral Diseases, Dept. of Internal Medicine, Washington University School 
of Medicine at Barnes-Jewish Hospital, United States, 2Center for Metabolic 
Bone Disease and Molecular Research, Shriners Hospitals for Children-St. 
Louis, United States, 3Department of Chemistry, Purdue University-Fort Wayne, 
United States, 4Dept. of Chemistry, Purdue University-Fort Wayne, United States
Hypophosphatasia (HPP) is the metabolic bone disease caused by loss-of-function 
mutation(s) of the ALPL gene that encodes the tissue non-specific isoenzyme of alkaline 
phosphatase (TNSALP).  In HPP, autosomal dominant and autosomal recessive inheritance 
from among ~ 400 usually missense defects located throughout ALPL largely explains the 
broad-ranging severity of this inborn-error-of-metabolism.  TNSALP is a cell-surface phos-
phohydrolase expressed especially in the skeleton, liver, and developing teeth.  Thus, in 
HPP its substrates accumulate extracellularly and include pyridoxal 5′-phosphate (PLP), the 
principal circulating form of vitamin B6 (B6).  In neonates and babies with life-threatening 
HPP, markedly compromised dephosphorylation of PLP by TNSALP can lower circulating 
pyridoxal (PL), the B6 metabolite capable of cell entry, and thereby cause B6-dependent 
seizures.  For milder HPP, our initial findings from relatively few patients showed circulating 
PL levels were not low and thereby indicated B6 homeostasis was intact.  Then in 2015 our 
25-year experience with 173 affected children and adolescents expanded the clinical nosol-
ogy for pediatric HPP to include, by increasing severity, odonto HPP, mild childhood HPP, 
severe childhood HPP, infantile HPP, and perinatal HPP.  In 2018, having used our cation-ex-
change high-pressure liquid chromatography method since 1985 to study this cohort, we 
documented invariably elevated plasma PLP that reflected HPP severity in all 150 patients 
tested.  Herein, from that study, we show both plasma PL and the vitamin B6 degradation 
product 4-pyridoxic acid (PA) were normal or elevated, but not low:  PL mean (SD) 66.7 
(59.0) nmol/L [control 39.2 (41.0)] (p = 0.1293), and PA 40.2 (25.1) nmol/L [control 39.4 
(33.9)] (p = 0.8152).  Furthermore, L-tryptophan challenge of 5 children with HPP revealed 
no evidence of B6 deficiency.  Thus, in children and adolescents with non-life-threatening 
HPP, B6 sufficiency is intact, including PL, the form of B6 capable of cell entry.
Disclosures: Michael P. Whyte, None
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High Bone Mass From Mutation Of Low-Density Lipoprotein Receptor-
Related Protein 6 (LRP6) *María Lorena Brance1, Lucas R. Brun2, Nicolás 
M. Cóccaro3, Andrés Aravena 4, Shenghui Duan5, Steven Mumm6, Michael 
P. Whyte7. 1Reumatología y Enfermedades Óseas. Rosario. Argentina; Bone 
Biology Laboratory. School of Medicine, Rosario National University, 
Argentina; National Council of Scientific and Technical Research (CONICET), 
Argentina, Argentina, 2Bone Biology Laboratory. School of Medicine, Rosario 
National University, Argentina; National Council of Scientific and Technical 
Research (CONICET), Argentina, Argentina, 3Servicio de Diagnóstico por 
Imágenes, Sanatorio Británico. Rosario. Argentina, Argentina, 4Bone Biology 
Laboratory. School of Medicine, Rosario National University, Argentina, 
Argentina, 5Division of Bone and Mineral Diseases, Department of Internal 
Medicine, Washington University School of Medicine at Barnes-Jewish Hospital, 
United States, 6Division of Bone and Mineral Diseases, Department of Internal 
Medicine, Washington University School of Medicine at Barnes-Jewish Hospital; 
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals 
for Children-St. Louis, United States, 7Center for Metabolic Bone Disease and 
Molecular Research, Shriners Hospitals for Children-St. Louis; Division of Bone 
and Mineral Diseases, Department of Internal Medicine, Washington University 
School of Medicine at Barnes-Jewish Hospital, United States
Background: Wnt-signaling is important for skeletal development and health. Eleven 
heterozygous gain-of-function missense mutations within the first β-propeller of LRP5 are 
known to cause the autosomal dominant disorder called high bone mass (HBM). Recently, 
the HBM phenotype was identified in two American families harboring different heterozy-
gous LRP6 missense mutations.Case report:  A 19-year-old Argentinian man was referred for 
“osteopetrosis” with nine years of generalized, medium-intensity bone pain and arthralgias 
of both knees. His jaw and nasal bridge were broad and several teeth were missing (Figure 
A). Routine biochemical testing, including of mineral homeostasis, was normal. Urinary 
deoxypyridinoline and serum CTX were slightly increased. Radiographic skeletal survey 
showed diffusely increased radiodensity (Figure B). DXA revealed substantially elevated 
BMD Z-scores. Digital orthopantomography confirmed agenesis of maxillary and man-
dibular lateral incisors and the second left superior premolar. Cranial magnetic resonance 
imaging showed diffuse thickening of the calvarium and skull base, dilation of the sheath 
of the optic nerves containing increased fluid and associated with subtle stenosis of the 
optic canal, and narrow internal auditory canals. Mutation analyses identified a heterozy-
gous missense mutation in exon 4 of LRP6 leading to a 6-nucleotide/2-amino acid deletion 
(c.678T>Adel679-684, p.His226Gln-del227-228ProPhe) compromising the first β-propeller 
of LRP6.  Notably, LRP6 HBM seemed distinguishable from LRP5 HBM solely by mutation 
analysis, except in LRP6 HBM there is distinctive absence of adult lateral incisors.
Disclosures: María Lorena Brance, None
P-774
Clinical, Biochemical and Genetic Study in Patients with 
Odontohypophosphatasia in Japan *Takuo Kubota1, Yasuhisa Ohata1, Yasuki 
Ishihara2, Makoto Fujiwara2, Shinji Takeyari1, Kenichi Yamamoto1, Yukako 
Nakano1, Taichi Kitaoka1, Hirofumi Nakayama1, Chieko Yamada1, Takeshi 
Ishimi1, Rena Okawa3, Kazuhiko Nakano3, Tomoyuki Akiyama4, Haruna 
Kakimoto5, Shunsuke Araki6, Shinichiro Sano7, Tsutomu Ogata8, Keiichi Ozono1. 
1Department of Pediatrics, Osaka University Graduate School of Medicine, Japan, 
2Department of Pediatrics, Osaka University Graduate School of Medicine; The 
first Department of Oral and Maxillofacial Surgery, Osaka University Graduate 
School of Dentistry, Japan, 3Department of Pediatric Dentistry, Osaka University 
Graduate School of Dentistry, Japan, 4Department of Child Neurology, Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Japan, 5Department of Pediatrics, Kagoshima University Hospital, 
Japan, 6Department of Pediatrics, University of Occupational and Environmental 
Health, Japan, 7Department of Pediatrics, Hamamatsu Medical Center, Japan, 
8Department of Pediatrics, Hamamatsu University School of Medicine, Japan
Hypophosphatasia (HPP) is characterized by defective mineralization of bone and/or 
teeth in the presence of low serum alkaline phosphatase (ALP) activity and caused by muta-
tions in the ALPL gene encoding tissue-nonspecific ALP. Odontohypophosphatasia (odonto 
HPP) is characterized by dental complications without abnormalities of the skeleton system. 
However, the clinical course and biochemical and genetic features of odonto HPP are lim-
ited. Thus, we aimed to investigate clinical, biochemical and genetic features in patients 
with odonto HPP in Japan. We analyzed 16 unrelated Japanese patients with odonto HPP. 
The median (min.–max.) duration of follow-up was 2.2 (0.1–12.9) years. The first primary 
tooth loss occurred at the age of 1.8 (0.7–4.0) years. The age of referral to the department of 
pediatrics was 3.9 (1.7–11.4) years. Height SDS and weight SDS at the first visit was −0.12 
(−2.57 to +1.51) and 0.29 (−1.92 to +1.77), respectively. Serum ALP levels were decreased, 
259 (66–361) U/L (The normal range at the age of 3 years is 420 to 1200 [male] or 1130 
[female] U/L). Urine phosphoethanolamine (PEA) levels were elevated, 644 (166–1853) 
nmol/mgCr. In 9 patients, serum levels of pyridoxal 5’-phosphate (PLP) and pyridoxal (PL) 
were measured. PLP levels were high, 322.7 (132.6–706.7) nmol/L. PL levels were 32.4 
(10.8–70.1) nmol/L. PLP/PL ratio was high, 10.7 (6.3–32.5). Ages at the first primary tooth 
loss were not associated with ALP levels and PLP/PL ratio. ALP levels were negatively 
correlated with PEA levels and PLP/PL ratio. PEA levels were positively correlated with 
PLP/PL ratio. The ALPL gene analysis showed 12 patients with a heterozygous mutation and 
3 with compound heterozygous mutations, including two novel mutations. ALP and PEA 
levels in patients with compound heterozygous mutations were decreased and increased, 
respectively, compared to those with a heterozygous mutation. Two patients began to exhibit 
skeletal symptoms such as bone pain and muscle weakness during elementary school and 
then were diagnosed with childhood HPP. Our study in Japan showed that odonto HPP, the 
mildest form of HPP, has the biochemical characteristics of HPP and that serum ALP levels 
are negatively correlated its substrate levels. Genotype-phenotype analysis indicated that 
compound heterozygous mutations result in more profound biochemical abnormalities than 
a heterozygous one. Patients with odonto HPP may develop childhood HPP as they grow.
Disclosures: Takuo Kubota, Alexion Pharmaceuticals, Grant/Research Support
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Hypophosphatasia: ALPL c.1133A>T, p.D378V and c.1250A>G, p.N417S 
are the most prevalent dominant American mutations *Steven Mumm1, Gary 
Gottesman2, Shenghui Duan1, Gabriel Haller1, Karen Mack2, Valerie Wollberg2, 
Sarah Loving2, Vinieth Bijanki2, Fan Zhang2, C. Charles Gu1, Christina Gurnett1, 
Michael P. Whyte2. 1Washington University School of Medicine, United States, 
2Shriners Hospitals for Children-St. Louis, United States
Hypophosphatasia (HPP) is the rare inborn-error-of-metabolism featuring the conse-
quences of impaired skeletal mineralization caused by loss-of-function mutation(s) in the 
gene ALPL that encodes the tissue non-specific isoenzyme of alkaline phosphatase. HPP 
manifests with dental disease, sometimes with rickets in infants and children or osteomala-
cia in adults. Severity ranges from neonatal lethality to asymptomatic carrier status in adult 
life. HPP is inherited as an autosomal dominant or recessive trait. Generally, recessive HPP 
disease is more severe. To better understand the molecular basis and inheritance of HPP, we 
performed mutation analysis of ALPL in >300 HPP probands over the past 32 years, primar-
ily individuals from North America. Typically using leukocyte DNA and advancing methods 
of mutation analysis, one ALPL missense mutation, c.1133A>T, p.D378V was found in 39 
probands without a second ALPL mutation, making this defect the most prevalent dominant 
ALPL mutation in our cohort. Co-segregation of the mutation with HPP findings in the 
large kindreds, confirmed dominant inheritance. Genealogy thus far has not disclosed a com-
mon ancestor among these families, who all have early American heritage, although limited 
haplotype analysis suggests p.D378V in our cohort reflects a shared founder. The patients 
generally have mild disease (ranging from odonto, mild or severe childhood, to adult HPP). 
HPP can manifest in carriers as they age. There are literature reports of severe or lethal cases 
when p.D378V is compound heterozygous with a second ALPL mutation. The other prev-
alent dominant ALPL mutation, c.1250A>G, p.N417S, was identified in 26 families, and 
causes relatively mild HPP disease (odonto, mild or severe childhood, or adult HPP) with 
significant clinical variation among patients when inherited singly, but more severe HPP 
when inherited with a second ALPL defect. Therefore, surprisingly broad clinical expression 
of HPP occurs in these 65 families with either of these single dominant ALPL mutations. Ad-
ditional genetic or environmental factors likely contribute to their HPP phenotype. Exome 
sequencing to identify modifier genes to help explain this variation is underway.
Disclosures: Steven Mumm, None
P-776
Longitudinal rhPTH(1-84) Data From the Observational PARADIGHM 
Registry of Patients With Chronic Hypoparathyroidism *Bart Clarke1, 
Sigridur Björnsdottir2, Maria Luisa Brandi3, Pascal Houillier4, Aliya A. Khan5, 
Michael Levine6, Michael Mannstadt7, Lars Rejnmark8, Tamara Vokes9, Stefanie 
Hahner10, Lorenz Hofbauer11, Dolores Shoback12, John Germak13, Claudio 
Marelli14, Pinggao Zhang13, Neil Gittoes15. 1Mayo Clinic Rochester, United States, 
2Karolinska Institutet, Sweden, 3University Hospital of Careggi, Italy, 4Centre de 
Recherche des Cordeliers, INSERM, Sorbonne Université, France, 5McMaster 
University, Canada, 6Children’s Hospital of Philadelphia, United States, 
7Massachusetts General Hospital and Harvard Medical School, United States, 
8Aarhus University and Aarhus University Hospital, Denmark, 9University of 
Chicago, United States, 10University Hospital Würzburg, Germany, 11Technische 
Universität Dresden, Germany, 12San Francisco Veterans Affairs Medical Center; 
University of California, San Francisco, United States, 13Shire Human Genetic 
Therapies, Inc., a Takeda company, United States, 14Shire International GmbH, 
a Takeda company, Switzerland, 15University of Birmingham, United Kingdom
This is the first report of longitudinal data from PARADIGHM, an actively recruit-
ing, prospective, observational registry collecting data for >=10 years per patient with 
chronic hypoparathyroidism (NCT01922440/EUPAS16927). Monitoring key disease-spe-
cific parameters will chart the effectiveness of recombinant human parathyroid hormone, 
rhPTH(1-84), treatment and conventional therapy (CT; oral calcium and active vitamin D) in 
patients under routine clinical care. We present 2-year longitudinal data of adult patients who 
had values for each measured parameter at baseline, 12-months, and 24-months as of August 
31 2019. Registry inclusion criteria are patients with hypoparathyroidism for >6 months 
and receiving CT, rhPTH(1-84) plus CT, or rhPTH(1-84). Baseline was defined as the value 
entered at the time of enrollment; for rhPTH(1-84)-treated patients, baseline was the most 
recent value before the first dose of rhPTH(1-84). Only patients who had data at baseline 
per definition were included in this analysis. The variability in patient numbers across pa-
rameters is due to data availability. Patients with outlier data were excluded: serum calcium 
20 mg/dL; serum phosphate 8 mg/dL; serum creatinine 10 mg/dL; eGFR no lower limit/
except negative values excluded, >200 mL/min/1.73 m2.Median and mean data are shown 
in the Table. Both patient groups had stable serum calcium. There was an apparent trend for 
serum phosphate decline in patients treated with rhPTH(1-84) contrasting with no change 
in patients receiving CT. There was no differential trend apparent in serum creatinine and 
eGFR consistent with the short period of observation. Limitations are small sample size and 
short observation time. Additional years of longitudinal data should result in robust future 
analyses and demonstrate the growing utility of the PARADIGHM registry for assessing the 
effectiveness and safety of routine clinical care of patients with chronic hypoparathyroidism 
treated with rhPTH(1-84) and CT.
Disclosures: Bart Clarke, Shire, Grant/Research Support, Shire, Consultant
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Clinical Characteristic of Pregnancy and Lactation Associated Osteoporosis 
(PLO): Results from an Online Survey *Mafo Kamanda-Kosseh1, John M. 
Williams1, Mariana Bucovsky1, Ivelisse Colon1, Elizabeth Shane1, Adi Cohen1. 
1Columbia University Irving Medical Center, United States
PLO is a rare form of early-onset osteoporosis in which young women experience spon-
taneous or low trauma fractures(Fx), most commonly multiple vertebral Fx, during late preg-
nancy or lactation. Although cohort studies have described this condition, the pathogenesis 
is poorly understood.Between 5/2018 and 1/2020, we recruited women who self-identified 
with PLO from our clinical practice and PLO online support groups. Participants completed 
an anonymized Qualtrics survey with questions on reproductive, nutrition, exercise and fam-
ily history, and medical conditions/medication exposures that could potentially be related to 
PLO.Responses were received from 126 women aged (mean+/-SD) 37.5+/-8.2, BMI 22.1+/-
4.9 kg/m2; 94% reported white race, 7% Latina ethnicity.Only 5% had a history of osteo-
porosis before the PLO Fx. 48% reported family history of osteoporosis and 46% reported 
childhood Fx.Among responders,113(91%) reported vertebral Fx. Of these, age at Fx was 
32.9+/-6.5 and 105(93%) reported multiple vertebral Fx (mean,3.5+/-2.5). In 99(88%), the 
Fx occurred during lactation.Another 8 women(6%) reported hip Fx.Among these, age at Fx 
was 35.1+/-8.5, 2 had bilateral Fx, and in 7, the Fx occurred during pregnancy.With regard to 
history of conditions associated with bone fragility, 53 women(43%) reported none, 9(7%) 
had celiac disease, 5(4%) had anorexia nervosa, 4(3%) had exercise induced amenorrhea, 
4(3%) had hyperthyroidism and 9 (7%) had nephrolithiasis. In 28(23%), physical activity 
had been restricted prepartum. Use of medications associated with bone fragility included 
14(11%) with history of glucocorticoid exposure>=3 wks, 14(11%) on thyroid hormone, 
36(29%) on progestin-only OCP and 22(18%) with history of heparin or low molecular 
weight heparin therapy during pregnancy.Use of thyroid hormone and heparins was more 
frequent than expected based on recent reports of prevalence among pregnant women. Wom-
en with these exposures did not differ by age, ht, wt, type or timing of Fx.These survey data 
indicate that a substantial proportion of women with PLO have a history suggestive of or 
leading to underlying bone fragility. Particularly common were family history, a Fx that 
antedated pregnancy, diseases or medications known to be associated with bone loss and 
Fx. This leads us to hypothesize that genetic or developmental factors may contribute to 
susceptibility to PLO, and that conditions and medications affecting bone metabolism may 
also contribute to risk.
Disclosures: Mafo Kamanda-Kosseh, None
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Premature manifestation and accumulation of musculoskeletal-related 
diseases in adults with X-linked hypophosphatemia (XLH): an analysis of 
baseline medical history clinical trial data *Kassim Javaid1, Leanne Ward2, 
Rafael Pinedo-Villanueva1, Angela Rylands3, Angela Williams3, Karl Insogna4, 
Erik Imel5. 1University of Oxford, United Kingdom, 2University of Ottawa, 
Canada, 3Kyowa Kirin International, United Kingdom, 4Yale School of Medicine, 
United States, 5Indiana University of Medicine, United States
X-linked hypophosphatemia (XLH) is a rare, genetic, phosphate-wasting disease caus-
ing chronic hypophosphatemia and characterized in childhood by short stature, lower-limb 
deformities, and dental defects. These deficits persist into adulthood, compounded by further 
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complications from XLH and its treatment. This analysis uses baseline XLH medical history 
data from an international, phase 3, randomized controlled trial of burosumab versus placebo 
in adults with XLH (NCT02526160) to explore complications across age groups.Adults with 
XLH and a Brief Pain Inventory “worst pain” score >=4 at screening were grouped by age: 
18–29, 30–39, 40–49, and >=50 years. Five prespecified musculoskeletal manifestations 
(fracture, osteoarthritis [OA], osteophytes, enthesopathy, and spinal stenosis) and associ-
ated orthopedic surgeries were investigated (see Table).Data were analyzed for 127 adults 
(mean+/-SD age 39.8+/-12.3 years [range 18.5–65.5]; 66% women). 90% of adults had re-
ceived oral phosphate and/or active vitamin D therapy before enrolment, with 70% taking 
the therapy within 2 years of study baseline. In each age cohort, >65% of adults reported >=1 
musculoskeletal manifestation. Those with >=3 manifestations increased from 23% in the 
18–29-year group to 58% in the >=50-year group.Overall, 43% of patients reported a history 
of fractures (37% of the 18–29-year group; 30% of the 30–39-year group and 51–54% of 
those >=40-years). Fractures were predominantly in the lower limbs (26% femoral). OA 
was reported by 37% of 18–29-year-olds, increasing to 74–77% in those >=30-years of 
age. A medical history of osteophytes increased with age from 26% (18–29-year group) to 
42% (>=50-year group). A history of enthesopathy was noted in 23% of 18–29-year-olds, 
which gradually increased with age to 54% in the >=50-year group. Spinal stenosis history 
was reported in none of the 18–29-year-olds compared with 11% of the 30–39-year-olds, 
and in a third of adults aged >=40 years. Hip or knee replacements were recorded in 9% 
of all adults, with none in those <39 years. Hip replacements were reported in 13% in the 
40–49-year group and in 8% of the >=50-year group. Knee replacements were reported in 
5% in the 40–49-year group and in 19% of the >=50-year group.In this trial population of 
adults with XLH and moderate to severe baseline pain, musculoskeletal sequelae that are 
usually associated with ageing in the general population developed in early adulthood, with 
progressive accrual with age.
Disclosures: Kassim Javaid, Kyowa Kirin International, Grant/Research Support, Kyowa 
Kirin International, Speakers’ Bureau, Kyowa Kirin International, Consultant
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X-Linked Hypophosphatemia: HR-pQCT and Finite Element Analysis 
Uniquely Show Benefits from Burosumab Therapy in Fraternal Twins 
Crossing Puberty *Vinieth N. Bijanki1, Hiram D. Stahl2, Valerie Wollberg3, 
William H. McAlister4, Steven Mumm5, Gary S. Gottesman6, Michael P. Whyte7. 
1Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals 
for Children - St. Louis; Clinical Research Department, Shriners Hospitals for 
Children - St. Louis, United States, 2Radiology Department, Shriners Hospital 
for Children - St. Louis, United States, 3Center for Metabolic Bone Disease and 
Molecular Research, Shriners Hospitals for Children - St. Louis, United States, 
4Mallinckrodt Institute of Radiology, Washington University School of Medicine 
at St. Louis Children’s Hospital, United States, 5Division of Bone and Mineral 
Diseases, Department of Internal Medicine, Washington University School of 
Medicine at Barnes-Jewish Hospital; Center for Metabolic Bone Disease and 
Molecular Research, Shriners Hospitals for Children - St. Louis, United States, 
6Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals 
for Children - St. Louis, United States, 7Center for Metabolic Bone Disease 
and Molecular Research, Shriners Hospitals for Children - St. Louis; Division 
of Bone and Mineral Diseases, Department of Internal Medicine, Washington 
University School of Medicine at Barnes-Jewish Hospital, United States
X-linked hypophosphatemia (XLH) features rickets during growth and osteomalacia in 
adults due to renal phosphate (Pi) wasting caused by mutations in PHEX leading to increased 
FGF23 expression. For decades, standard of care medical therapy for XLH was oral Pi and 
active vitamin D. In 2018, burosumab, a fully human anti-FGF23 monoclonal antibody, 
became available to treat XLH. Clinical trials for burosumab involved validated scales of 
rickets severity: the radiographic global impression of change (RGI-C) and the Thacher rick-
ets severity score (RSS). Both scales require open growth plates. High resolution peripheral 
quantitative computed tomography (HR-pQCT) precisely delineates bone quality, typically 
at the distal radius and distal tibia. The HR-pQCT standard evaluation assesses skeletal den-
sity, structure, and geometry in detail, while finite element analysis (FEA) predicts bone 
quality by calculating strength, strain, and stress. Here, we document benefits from buro-
sumab therapy in 14.7-year-old fraternal twin brothers with XLH following conversion from 
conventional calcitriol and Pi treatment. Calcitriol and Pi supplementation had improved 
their rickets radiographically, more so for twin 1 than twin 2. Nine months after the change 
to burosumab therapy, rickets assessed radiographically improved in both patients. Addition-
ally, the HR-pQCT evaluation analysis and FEA both documented substantial improvement. 
In the tibia, twin 1 increased total volumetric bone mineral density (Tt.vBMD) from 261.5 to 
309.3 mg HA/cm3 and twin 2 from 245.1 to 331.7 mg HA/cm3 (18.3% and 35.3% increases, 
respectively). For both twins, FEA revealed increased failure load and stiffness in both the 
radius and the tibia. In the tibia, failure load (absolute value) and stiffness increased in twin 
1 by 34.7% (10206.1 N to 13755.9 N) and 37.7% (188605.8 N/mm to 259724.5 N/mm), 
respectively. Remarkably in the tibia of twin 2, failure load and stiffness increased by 59.4% 
(7710.8 N to 12290.5 N) and 58.1% (145907.7 N/mm to 230615.0 N/mm), respectively. 
Assessment of radiographic changes in XLH has primarily involved the physes, which close 
at the end of puberty. HR-pQCT evaluation with FEA now provides a sensitive and robust 
tool for evaluating treatment of pediatric XLH including crossing puberty.
Disclosures: Vinieth N. Bijanki, None
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Incidence of osteophyte, spinal ligament ossification, enthesopathy, 
nephrocalcinosis, dental disease, and hearing impairment in 25 adult 
X-linked hypophosphatemic rickets *Minae Koga1, Hajime Kato1, Nobuaki 
Ito1. 1Department of Nephrology and Endocrinology, The University of Tokyo, 
Japan
?Background?X-linked hypophosphatemia (XLH) is the inherited disorders related 
to loss of function mutations in the phosphate-regulating endopeptidase (PHEX). Loss of 
function in PHEX leads to inappropriately increased serum fibroblast growth factor 23 with 
hypophosphatemia. Clinical manifestations of XLH can vary but most patients present with 
rickets. Adult XLH develops complications including common treatment related adverse 
events, which are osteophytes around large joints, ossification in spinal ligament, enthe-
sopathy, nephrocalcinosis, dental disease and hearing impairment. However, these mani-
festations have not been systemically reviewed and the prevalence and severity remains 
uncertain. ?Method?The present study includes 25 adult XLH. The clinical records of the 
participants were retrospectively reviewed. ?Results?The participants consisted of 13 males 
and 12 females from 21 families, with a median age of 40.3 (18-72) years. 20 patients (80 %) 
developed ossification of spinal ligament (ossification of the anterior longitudinal ligament/
posterior longitudinal ligament/ligamentum flavum (OALL/OPLL/OLF)). The median score 
of OA/OP/OF/OS index were 3.3 (0-20), 1.6 (0-11), 1.7 (0-12) and 6.7 (0-28), independent-
ly. 18 cases (82 %) developed enthesopathy. Osteophytes around hip and knee joints were 
reported in all cases (100%) and 20 cases (80 %), respectively. The average KL grade was 3 
in hip joint and 2 in knee joint. 13 patients (52 %) had O-shaped deformity, and 5 patients (20 
%) had X-shaped deformity in the legs. Ultrasound revealed nephrocalcinosis in 18 patients 
(72%). Median number of residual tooth and intact tooth were 25.4 (15 - 32) and 14.6 (0 
- 32), respectively. Hearing impairment developed in seven cases (30 %) and was all in sen-
sorial pattern.?Discussion?Osteophytes around the joint and ossification of spinal ligament 
were more severe and frequent than in the general population with the reported incidence of 
hip/knee osteophyte and spinal ligament ossification being 46 – 68 % and 1.5 - 6.0 %, re-
spectively. Because XLH is relatively common inherited disorder (1/20,000) and the isolated 
cases are not uncommon, there might be not a few undiagnosed cases of XLH included in the 
patients with OALL/OPLL/OLF and severe hip/knee OA patients. The clarification of un-
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derlying cause of ectopic ossification in some inherited FGF23rHR is intriguing unresolved 
research agenda possibly leading to the development of treatment for these comorbidities.
Disclosures: Minae Koga, None
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Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency 
Appears to be Associated with an Evolving Skeletal Dysplasia in Addition 
to Ectopic Calcifications and Rickets *Deborah Wenkert1, William McAlister2. 
1Wenkert & Young, LLC, United States, 2Department of Pediatric Radiology, 
Mallinckrodt Institute of Radiology at St. Louis Children’s Hospital, Washington 
University School of Medicine, United States
Introduction:  Recessive, loss-of-function mutations in the gene encoding ectonucle-
otide pyrophosphatase/phosphodiesterase 1, (ENPP1) result in Generalized Arterial Calcifi-
cation of Infancy (GACI) (OMIM # 208000) and Autosomal Recessive Hypophosphatemic 
Rickets type 2 (ARHR2) (OMIM # 613312).  Dominant inheritance has been reported as 
associated with osteoporosis in adults.  Among the >200 publications describing patients 
with these disorders, the radiographic descriptions understandably focus on the prominent 
findings that help a clinician make the diagnosis (e.g., ectopic calcification and/or the signs 
of rickets). Published radiographs, however, display a number of other ENPP1 deficiency 
(ENPP1-D) associated skeletal features. We undertook a review of all available published 
plain x-rays of patients with ENPP1-D disorders as a first step in developing a rating scale 
to be used in establishing the natural history of the skeletal features of the disorder.Methods: 
The following terms were searched in PubMed: [ENPP1] or [GACI] or [Generalized arterial 
calcification of infancy] or [autosomal recessive hypophosphatemic rickets] or [Ectonucle-
otide pyrophosphatase/phosphodiesterase I] AND [x-ray] or [radiograph]. Additional radio-
graphs were identified searching Google images using the same search strategy.Results: A 
unique combination of >10 radiographic skeletal abnormalities affected patients who had not 
been previously treated with bisphosphonates (table). Metaphyseal tongues of radiolucency 
and craniosynostosis were only seen in patients who had received etidronate.Conclusions: 
Our review of published skeletal radiographs of patients with ENPP1-D, uncovered >10 
abnormalities including some that have not, and others that have only rarely, been mentioned 
before. Many abnormalities, were apparent only in radiographs of older children implying 
ENPP1-D is an evolving dysplasia. In addition, although rickets is known to appear in survi-
vors of GACI, we also found rickets in the radiographs of infants with ENPP1-D associated 
GACI. Thus, rather than being two distinct disorders, GACI and ADHR2 appear to represent 
stages of the natural evolution of ENPP1-D. Ascertaining the prevalence of all of the skeletal 
features of ENPP1-D and the natural history of their evolution will be important to under-
stand the response to treatment being developed for ENPP1-D.
Disclosures: Deborah Wenkert, Inozyme Pharma, Consultant
P-782
Addressing a Knowledge Gap: Characterizing the Physical, Functional, 
and Cognitive Performance in Adults with Hypophosphatasia *Christina 
Dourrough1, Kathryn Dahir2. 1Vanderbilt Pi Beta Phi Rehabilitation Institute, 
Nashville, TN, United States, 2Vanderbilt University Medical Center, United 
States
Introduction: Limited data exist regarding physical and cognitive functioning of adults 
with hypophosphatasia (HPP), and no guidelines for evaluation by physical therapists (PT), 
occupational therapists (OT), or speech-language pathologists (SLP) exist. We evaluated 
physical, functional, and cognitive performance among adults with HPP through compre-
hensive assessments and patient reported outcome tools. Methods: Fifteen subjects with HPP 
(median age 42 (32.5-50.5) yrs, 73% female, 100% Caucasian, 50% on enzyme replacement 
therapy) completed standardized assessments of mobility, balance, fine motor, activities of 
daily living, cognition, and self-reported measures of health-related quality of life, fatigue, 
depression and anxiety. This study was conducted in accordance with the Declaration of 
Helsinki and approved by the IRB. Results: Compared with normative data from community 
dwelling adults, subjects traveled less distance on a Six-Minute Walk Test (1,376 +/- 431** 
ft vs 1873+/-299) and had slower gait on a 10-Meter Walk Test (1.04+/-0.21 vs 1.39-1.46m/
s). Subjects were slower to respond on the Nine Hole Peg Test (20.6+/-2.4s** for right & 
21.7+/-2.4s** for left hand vs 16.5s to 18.5s), and 2 had an abnormally slow reaction time 
via Dynavision (0.9s* [0.85,0.96], functional speed is <1.15s). 20% scored in the low aver-
age/borderline range of performance on the Repeatable Battery for the Assessment of Neuro-
psychological Status (RBANS), suggestive of cognitive impairment. On the Short Form-36 
(SF36), 75% reported limitations in their ability to fulfill life roles due to physical problems 
(25%+/-39%ile**), 75% reported below average energy (30%+/-23ile**), and 100% rated 
their health as unlikely to improve (32%+/-15%ile**). Fatigue Severity Scale scores were 
well above the median for a healthy population (47 [34,60.5]* vs 2.3). Median scores for De-
pression, Anxiety, and Stress (DASS) were within the normal range, but severe depression 
was reported by 4 subjects. Subjects reported moderate (4), severe (1), or extremely severe 
(1) anxiety; and 4 reported severe (2) or extremely severe (2) stress. Conclusions: Objective 
functional assessments indicate mild deficits, but subjects’ self-reported significant limita-
tions due to physical dysfunction, indicating that current objective testing is inadequate in 
the HPP population. Impaired reaction time may indicate potential safety concerns with 
driving or certain occupations, and screening may be indicated. A subgroup of subjects was 
significantly affected by depression, stress, and/or anxiety. Guidelines and additional assess-
ment tools should be created to further evaluate physical and cognitive functioning among 
adults with HPP. The use of PT, OT, and SLP specialists can aid in establishing baseline as-
sessment of impairment and developing treatment plans with objective metrics for assessing 
efficacy of treatment. *median **mean
Disclosures: Christina Dourrough, None
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Medications Used by Individuals with Fibrodysplasia Ossificans Progressiva 
(FOP): Data from a Global Natural History Study *Richard Keen1, Mona Al 
Mukaddam2, Geneviève Baujat3, Carmen De Cunto4, Edward C Hsiao5, Robert 
J Pignolo6, Kathleen Harnett7, Rose Marino7, Frederick S Kaplan2. 1Centre for 
Metabolic Bone Disease, Royal National Orthopaedic Hospital, United Kingdom, 
2Departments of Orthopaedic Surgery & Medicine, The Center for Research 
in FOP and Related Disorders, Perelman School of Medicine, University of 
Pennsylvania, United States, 3Département de Génétique, Institut IMAGINE and 
Hôpital Universitaire Necker-Enfants Malades, France, 4Pediatric Rheumatology 
Section, Department of Pediatrics, Hospital Italiano de Buenos Aires, Argentina, 
5Division of Endocrinology and Metabolism, UCSF Metabolic Bone Clinic, 
Institute of Human Genetics, and UCSF Program in Craniofacial Biology, 
Department of Medicine, University of California-San Francisco, United States, 
6Department of Medicine, Mayo Clinic, United States, 7Ipsen, United States
Background: FOP is an ultra-rare genetic disorder characterized by episodic progres-
sive heterotopic ossification (HO) and flare-ups, causing cumulative disability and early 
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death. There are no established disease-modifying therapies to prevent HO in FOP. Howev-
er, treatment guidelines for the symptomatic relief of FOP have recently been published by 
the International Clinical Council on FOP (ICC).1Objective: To report use of medications to 
manage symptoms of FOP in a natural history study (NHS), as per standard clinical practice.
Methods: Individuals with FOP aged <=65 years with a documented ACVR1R206H muta-
tion were eligible to participate in a 36-month, prospective, global NHS (NCT02322255). 
This analysis reports interim data on medication use during that observational study (data 
cut 31 August 2019). Use of medications (acute and chronic) was assessed at Baseline (BL), 
by telephone at Weeks 1–3 and every 3 months thereafter, and at clinic visits (Months 12, 
24, and 36). Medication prescribed for symptomatic treatment of reported flare-ups was re-
corded on flare-up Days 1, 42, and 84. Data were collected using a standardized list and are 
summarized here by preferred term (PT).Results: 73/114 (64.0%) participants were taking 
prior medications that were ongoing at BL in the NHS. The most common medications on-
going at BL by PT were prednisone (25.4%), ibuprofen (22.8%), and montelukast (19.3%), 
all of which are included in the ICC guidelines (Table). Pain relief medications ongoing at 
BL also included (among others): paracetamol (11.4%), naproxen (8.8%), and celecoxib 
(7.9%). Most participants (91/114; 79.8%) initiated treatment with new medications during 
the NHS. The most frequent newly-initiated medications by PT were prednisone (31.6%), 
ibuprofen (28.1%), and paracetamol (21.9%). Glucocorticoids were commonly administered 
upon onset of flare-ups (155/217; 71.4%), in accordance with ICC guidelines.Conclusions:-
To manage their symptoms during this NHS, individuals with FOP used various medica-
tions, which were generally consistent with current ICC guidelines. Although the objective 
of this study was not to evaluate efficacy or safety of medications used, it highlights the need 
for disease-modifying therapies to treat or prevent the symptomatic progression of FOP.Ref-
erence: 1. Kaplan FS. ICC FOP Treatment Guidelines. Available at: http://www.iccfop.org/
dvlp/wp-content/uploads/2020/03/Guidelines_January-2020.pdf [Accessed: 14 May 2020]. 
Disclosures: Richard Keen, Research investigator: Clementia/Ipsen, Kyowa Kirin, 
Regeneron; Advisory board: IFOPA FOP Registry Medical Advisory Board, International 
Clinical Council on FOP, Other Financial or Material Support
P-784
Use of Assistive Devices and Adaptations by Individuals with Fibrodysplasia 
Ossificans Progressiva (FOP): Data from a Global Natural History Study 
*Edward C Hsiao1, Mona Al Mukaddam2, Geneviève Baujat3, Carmen De 
Cunto4, Richard Keen5, Robert J Pignolo6, Kathleen Harnett7, Rose Marino7, 
Frederick S Kaplan8. 1Division of Endocrinology and Metabolism, the UCSF 
Metabolic Bone Clinic, the Institute of Human Genetics, and the UCSF Program 
in Craniofacial Biology, Department of Medicine, University of California-San 
Francisco, United States, 2Departments of Orthopaedic Surgery & Medicine, 
The Center for Research in FOP and Related Disorders, Perelman School of 
Medicine, University of Pennsylvania, United States, 3Département de Génétique, 
Institut IMAGINE and Hôpital Universitaire Necker-Enfants Malades, France, 
4Pediatric Rheumatology Section, Department of Pediatrics, Hospital Italiano de 
Buenos Aires, Argentina, 5Centre for Metabolic Bone Disease, Royal National 
Orthopaedic Hospital, United Kingdom, 6Department of Medicine, Mayo Clinic, 
United States, 7Ipsen, United States, 8Deparments of Orthopaedic Surgery & 
Medicine, The Center for Research in FOP and Related Disorders, Perelman 
School of Medicine, University of Pennsylvania, United States
Background: FOP is an ultra-rare, severely disabling genetic disorder of progressive 
heterotopic ossification (HO). HO is episodic, causing cumulative disability. Most indi-
viduals with FOP are confined to a wheelchair by the third decade of life.Objective: To 
characterize the use of assistive devices and adaptations (ADA) in individuals with FOP 
in a natural history study (NHS).Methods: Individuals with FOP aged <=65 years with a 
documented ACVR1R206H mutation were eligible to participate in a prospective, 36-month 
NHS (NCT02322255). This analysis describes the use of ADA at Baseline (BL) and new 
ADA reported annually. Participants indicated which ADA they were using via a list grouped 
into 12 categories. The proportion of participants using >=1 ADA in each category was 
stratified by age group and analyzed using descriptive statistics.Results: Data on ADA usage 
were available for 111/114 participants, and use of new ADA for 84/99 participants with any 
assessment at Month 12. The most common ADA categories used overall at BL (N=111) 
were personal care tools/aids (82.9%), bedroom aids and devices (75.7%), care attendants 
(73.0%), eating tools (66.7%), and mobility aids (65.8%). The same devices were used at 
Month 12 (n=97) by 84.5%, 75.3%, 72.2%, 62.9%, and 70.1% of participants, respectively. 
In younger participants, use of school adaptations was similar (2–7 years: 81.3% [13/16]; 
8–14 years: 79.4% [27/34]). A relatively high proportion of participants aged 8–14 years 
used medical therapies for daily living (79.4% [27/34]) compared with other age groups. 
Several categories of ADA were used more frequently in older versus younger age groups 
including mobility aids, personal care tools/aids, bathroom and bedroom aids/devices, and 
home adaptations. The most common new ADA at Month 12 across age groups were per-
sonal care tools/aids, care attendants, bathroom and bedroom aids/devices, and home adap-
tations; there was a notable rise in the use of new ADA from these categories in participants 
aged >=25 years (Figure).Conclusions: At least 83% of participants in the NHS used >=1 
ADA to manage their disabilities at Baseline and at least 40% used >=1 new ADA at Month 
12. Specific types of ADA used varied across age groups and over 12 months; however, 
longer follow-up to capture the increase in number and complexity of ADA is needed to 
further demonstrate the physical and financial burden of FOP, and the rate of progression 
of ADA use.
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Impaired Bone Microarchitecture in patients with Tumor Induced 
Osteomalacia assessed by HR-pQCT *maria belen zanchetta1, Cesar Bogado1, 
Selva Nuñez1, Yamile Morcalbel 2, Analía Pignatta2, Natalia Elias3, Adriana 
Diaz2, Carlos Vigovich 4, Carolina Cohen 2, Celeste Balonga1, Sofia Gonzalez5, 
jose ruben zanchetta1. 1IDIM, Universidad del Salvador, Argentina, 2Hospital 
de Clínicas, Argentina, 3Hospital Británico, Argentina, 4Hospital Gobernador 
Centeno, Argentina, 5Hospital Churruca, Argentina
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by 
persistent hypophosphatemia. Hypophosphatemia is caused by increased renal phosphate 
wasting consequent to elevated levels of circulating fibroblast growth factor 23 (FGF23).
Besides causing phosphaturia, FGF23 inhibits renal 1α-hydroxylase, resulting in low levels 
of 1,25-dihydroxy vitamin D. This pathophysiology leads to deter mineralization of the os-
teoid matrix causing bone pain, fragility fractures, muscle weakness and severe bone quality 
impairment. Deterioration of bone microarchitecture parameters in patients presenting os-
teomalacia has been described by histomorphometric analysis of bone biopsies samples.The 
aim of this study was to assess the status of bone microarchitecture parameters in patients 
with TIO using high-resolution pQCT (HR-pQCT), a non-invasive procedure.We studied 8 
TIO patients (5 female, 3 male) consulting or referred to our bone clinic. Mean age was 47.4 
+/-12.6 (SD) years, range 28.5-64 years. Bone microarchitecture parameters were assessed 
at the distal radius and tibia by HR-pQCT using Xtreme CT (Scanco Medical AG, Bassers-
dorf, Switzerland). Results were compared with a group of 16 healthy subjects (10 female, 
6 male) obtained from our data base, paired by age and sex in a 2:1 ratio. Mean age of the 
control group was 47.3 +/-12.2 (SD) years, range 28.8-68 years. Mean percent difference 
between the patients and control groups was calculated and the results are depicted in Table 
1.In the radius, cortical thickness was 24.7% lower in patients than controls (0.61 +/- 0.28 
vss 0.81 +/- 0.18 mm) and trabecular density was 31 % lower ( 128.4 +/- 56.7 vss 186.7 +/- 
53.6 mg HA/cm3). In the tibia, cortical thickness was  41% lower in patients than controls 
(0.72 +/- 0.42 vss 1.22 +/- 0.32 mm) and trabecular density was 52.5 % lower (83.0 +/- 62.4 
vss.174.7 +/- 50.5 mg HA/cm3)The results confirm severe bone microarchitecture deterio-
ration in patients with TIO. Deterioration of bone microarchitecture was more evident at the 
distal tibia, most probably due to impaired mobility as a result of severe muscle weakness.
HR-pQCT is a suitable method for the evaluation of bone microarchitecture in patients with 
TIO and can be a useful tool to evaluate the degree of deterioration and eventually follow 
the response to treatment.
Disclosures: maria belen zanchetta, ultragenyx, Grant/Research Support
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Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized 
High Turnover Bone Phenotype, High s RANKL and Responds to 
Denosumab *Ravit Regev1, Ronald Laxer1, Kristi Whitney-Mahoney2, 
Yesmino Elia1, Kornelia Filipowski2, Damien Noone1, Amer Shammas1, Reza 
Vali1, Etienne Sochett1. 1The Hospital for Sick Children, University of Toronto, 
Canada, 2The Hospital for Sick Children, Canada
Background: MCTO is a rare disorder, caused by mutations in the MABF gene, a neg-
ative regulator of RANKL. Manifestations include carpal tarsal osteolysis and renal failure. 
Pathophysiology is poorly understood, and no effective treatment is available. Clinical case: 
A 5y old boy presented with R wrist pain and diffuse swelling. MRI showed pan-carpal 
synovitis with joint effusion. Plain films showed central loss of the proximal row of car-
pal bones. His mother was followed as an adolescent with presumed juvenile rheumatoid 
arthritis. Genetic testing confirmed MAFB gene mutation (c.206C>T,p.Ser69Leu) in both. 
At 7y, skeletal survey showed diffuse osteopenia and mild height loss in T1. DXA (L1-4) 
Z-score -0.7. Calcium phosphate metabolism indices were within reference ranges. Bone 
Specific Alk Pi was modestly increased and C-telopeptide markedly increased. He received 
Denosumab (0.5-0.75 mg/Kg) 4-monthly for two years and had less pain with improved 
R wrist function. Osteolysis stabilized and none was noted in the L wrist or ankles. BMD 
Z-score was -0.2. Following each treatment C-telopeptide showed a significant decrease, 
while bone specific alkaline phosphatase remained stable. (fig. 1) At 13y, radiology showed 
R knee osteopenia, R wrist almost complete destruction of the carpal bones. Neither ankle 
nor L wrist showed osteolysis. BMD Z-score was -1.2. Serum calcium, 25(OH)Vitamin D 
and PTH were normal. Bone specific alkaline phosphatase and C-Telopeptide were elevated. 
eGFR 150 ml/min/1.73m2, ACR 6.6 ([normal< 3.5] mg/mmol), no hypercalciuria or neph-
rocalcinosis. High resolution peripheral quantitative computerized tomography (HRpQCT) 
of the L distal radius and distal tibia compared with 7 age-matched healthy males showed 
reduced total volumetric BMD (186.4;198.2-306.4), normal trabecular volumetric BMD and 
markedly reduced cortical volumetric BMD (320.4;636.5-792.5). HRpQCT measurements 
of the R wrist and tibia were similar. Consecutive sRANKL levels at 6 weeks and 12 weeks 
after Denosumab were markedly increased in both undiluted (35.4, 26.62 pmol/L) and av-
eraged diluted samples (83.73, 58.98 pmol/L) when compared with healthy age-matched 
children (0.21-0.41pmol/L).Clinical Lessons: The MAFB, mutation c.206C>T,p.Ser69Leu), 
has a generalized high turnover osteoporosis, likely driven by very high levels of sRANKL. 
Denosumab is a targeted treatment for the osteoporosis associated with this form of MCTO.
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Long-term effectiveness of Asfotase Alfa in adults with pediatric-onset 
Hypophosphatasia in routine clinical practice *Franca Genest1, Dominik 
Rak1, Anna Petryk2, Lothar Seefried1. 11Orthopaedic Clinic King-Ludwig-
Haus, University of Würzburg, Würzburg, Germany, Germany, 22Alexion 
Pharmaceuticals, Inc., Boston, MA, USA, United States
Introduction: Hypophosphatasia (HPP) is a rare, inherited, metabolic disorder caused 
by low tissue nonspecific alkaline phosphatase activity. Heterogeneous presentation in 
adults includes musculoskeletal symptoms, impaired physical function, and reduced 
health-related quality of life (HRQoL). We evaluated real-world, long-term effectiveness 
of asfotase alfa, on physical function and HRQoL among adults with pediatric-onset HPP 
(NCT03418389). Methods: Adults aged >=18 years (y) receiving care at the Orthopedic In-
stitute of the Julius-Maximilians-University of Wu¨rzburg (Germany) were treated with As-
fotase Alfa for >=24 months (mo). Physical function evaluation included the 6-Minute Walk 
Test (6MWT), Timed Up-and-Go (TUG) test, Lower Extremity Functional Scale (LEFS), 
and Short Physical Performance Battery (SPPB). HRQoL was assessed with the 36-item 
Short-Form Health Survey, version 2 (SF-36v2); pain was also evaluated. Safety data were 
collected throughout the study. Results: The study included 14 (11 women, 3 men) patients, 
with a median (min, max) age of 53 (20, 78) y for women and 46 (19, 57) y for men at treat-
ment initiation. All had compound heterozygous ALPL gene variants, >=1 HPP bone mani-
festation and history of >=1 fracture. We previously reported score changes from baseline to 
12 mo; here, we report changes from 12–24 mo. Improvements were observed over the first 
12 mo on treatment and maintained another 12 mo. Median (min, max) 6MWT distance was 
similar at 12 mo (320 [0, 605] m) and 24 mo (316 [60, 600] m) (n=13; P=0.115). An increase 
in median time to complete the TUG test from 11.3s–13.75s was not statistically signifi-
cant (n=7; P=0.382). Specific SPPB component results were stable. Decreases in median 
4m usual gait speed from 1.12m/s–1.02m/s (n=9; P=0.61) and median repeated chair rise 
time from 12.53s–12.48s (n=8; P=0.398) were not statistically significant. Improvements in 
LEFS (n=10) and SF-36v2 Physical Component Summary (n=9) scores were seen early at 
3 and 6 mo and remained stable over 24 mo. Changes in pain level (n=5) were variable be-
tween 12 and 24 mo. No new safety signals were identified. Conclusions: These data suggest 
adults with pediatric-onset HPP treated with asfotase alfa in real-world settings have marked 
improvements in clinical and functional outcomes, which were observed within the first 12 
mo and sustained over 24 mo of treatment.
Disclosures: Franca Genest, Alexion, Other Financial or Material Support
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Safety and Efficacy of Burosumab in Cutaneous Skeletal Hypophosphatemia 
Syndrome (CSHS) *Thomas Carpenter1, Laila Tabatabai2, Diana Luca3, Mary 
Scott Roberts3, Dale Hamilton2. 1Yale University School of Medicine, United 
States, 2Houston Methodist Hospital and Research Institute; WCM Affiliate, 
United States, 3Ultragenyx Pharmaceutical Inc., United States
CSHS is a rare syndrome caused by somatic RAS mutations often in a mosaic pat-
tern. CSHS is characterized by epidermal and/or melanocytic nevi, skeletal dysplasia, and 
excess FGF23, resulting in chronic hypophosphatemia, renal phosphate wasting, impaired 
1,25(OH)2D synthesis, and rickets/osteomalacia. Current medical management is oral phos-
phate and/or active vitamin D analogs, but these have limited efficacy. Burosumab is a fully 
human monoclonal antibody against FGF23 approved to treat X-linked hypophosphatemia 
(XLH) and is being investigated in tumor-induced osteomalacia (TIO) and CSHS, all char-
acterized by excess FGF23. An ongoing, open-label, phase 2 trial of burosumab safety and 
efficacy (NCT02304367) enrolled 17 adults with TIO or CSHS. Primary endpoints were 
changes in serum phosphorus and osteomalacia. Here we focus on the subject with CSHS 
with data through week 144.The 20-yr-old white male had multiple linear nevi, skeletal 
dysplasia, and chronic FGF23-mediated hypophosphatemia and suffered from bone pain, 
distal lower extremity valgus deformities, left femur varus deformity, leg length discrep-
ancy, and multiple fractures. He had been treated with oral phosphate and active vitamin D 
for 16 yrs prior to study entry.The subject was maintained on the burosumab starting dose 
(0.3 mg/kg SC Q4W) throughout the study, which resulted in normalization of serum phos-
phorus through W144. TmP/GFR and 1,25(OH)2D also increased with burosumab (table). 
The baseline bone biopsy lacked sufficient integrity for accurate measures of osteomalacia. 
However at W48, osteoid surface/bone surface was 16%, osteoid thickness was 8.7 µm, 
and mineralization lag time was 12.2 days, indicative of no osteomalacia. The subject had 
19 areas of increased uptake on baseline radionucleotide bone scan, indicative of fractures/
pseudofractures. All were fully (68.4%) or partially (31.6%) healed by W144. Bone turnover 
markers decreased over the study (table).Changes in patient-reported pain and fatigue were 
variable and inconclusive. No changes in sit-to-stand repetitions were seen.The subject had 
19 treatment-emergent adverse events; all mild or moderate, none serious, and none consid-
ered related to burosumab.In conclusion, burosumab normalized phosphorus homeostasis 
and improved fracture/pseudofracture healing in this subject with CSHS. Improvements 
were maintained through W144. Adverse events were tolerable, and efficacy was similar to 
the broader study population with TIO.
Disclosures: Thomas Carpenter, Ultragenyx, Inozyme, Tegeneron, Kyowa Kirin, 
Consultant, Ultragenyx Pharmaceutical Inc, Grant/Research Support, Ultragenyx, 
Inozyme, Other Financial or Material Support
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Clinical characteristics, therapeutic outcome and follow up of 66 patients of 
Paget Disease from South India *Krishna Mori1, Adlyne Reena Asirwatham1, 
Shriraam Mahadevan1, Karthik Balachandran1, Amulya Yalamanchi1, Sathish 
Kumar1. 1Sri Ramchandra Medical College, India
Introduction: Paget disease of bone (PDB) is a disorder of altered bone remodeling 
mainly characterized by increased osteoclastic activity. While the exact Indian prevalence 
remains unknown, a clustering of published cases suggests South Indian predominance.Ob-
jective: To study the clinico-biochemical profile and therapeutic response of patients with 
PDB and briefly review the epidemiology of PDB from an Indian perspective.Methods: Ret-
rospective data was collected from the charts of patients who have been seen in Endocrine 
out-patient clinics in Tamilnadu over a 12 year period. Published literature on PDB from 
India was reviewed.Results: A total of 66 patients (71% males) predominantly from Tamil-
nadu were studied. Mean age at presentation was 67+/-8 years. Polyostotic involvement 
was seen in 89% and familial occurrence of PDB in 5 patients. Symptoms at presentation 
mainly included bone pain (51%) and skeletal deformities (18%). Scalp vein sign (21%) and 
sensorineural hearing loss (64%) were also noted. Incidental PDB detection by raised serum 
alkaline phosphatase (SAP) levels was observed in 17% and by abnormal FDG-PET scan in 
6% of cases. Mean SAP at presentation was 606+438 IU/L (Normal, 76-140). Major skeletal 
site involvement includes pelvis (62.1%) and spine (34.8%). Mean (range) follow up of the 
cohort was 3.4 years (1-12 years). From the cohort, 64 subjects received zoledronate and two 
received alendronate and mean (SD) SAP at 1-year was 73+/-42 IU/L. All but two showed 
remission at the end of 1 year. Two had pathological fractures and two had sarcomas. Review 
of epidemiology of PDB in Indian literature clearly showed a south Indian predilection for 
unclear reasons.Conclusion: PDB was considered rare in Asians, especially Indians. Most of 
the case series and other studies were mainly from Caucasians in UK or the migrant English 
population in Australia. However, in little over a decade, there were several case studies and 
two case series from India, suggesting that PDB is not uncommon in India. Hence, in this 
retrospective study, we intend to present the clinical and therapeutic aspects of 66 patients 
with PDB from Tamilnadu and provide a focused review of the epidemiology of this disorder 
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from an Indian perspective. Interestingly, most of the cases reported are exclusively from 
South India and this needs more exploration.Keywords: Paget disease of bone; South India, 
Alkaline phosphatase; Zoledronate
Disclosures: Krishna Mori, None
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X-Linked Hypophosphataemic Rickets: Description of 16 Cases in the 
Adulthood in Argentina *Tatiana Martinez1, Laura Maria Schiro1, Patricia 
Rodriguez1, Evangelina Giacoia1. 1Hospital Nacional Prof. A. Posadas, Argentina
Introduction: X-linked hypophosphatemic rickets (XLH) is an inherited disorder that 
results from an inactivating mutation of the PHEX gene. The familiar form comprises most 
cases. Its incidence is 4.8 per 100000 persons1. XLH is characterized by bowed or bent 
legs, short stature, tooth abscesses, hearing loss, joint pain and impaired mobility, which 
can alter quality of life.Aim: To describe clinical characteristics, laboratory and imaging 
findings of XLH adult patients attending to our hospital; to evaluate physical function and 
impact on the quality of life; to estimate adherence to conventional treatment. Methods: A 
retrospective, observational study from 16 XLH patients’ medical records was performed. 
Age, sex, BMI, age at diagnosis, number of fractures, bone deformities, corrective surgeries, 
biochemical and genetic profile were evaluated. Physical functionality, pain and stiffness 
were measured with WOMAC and PROMIS scale; and quality of life (QOL) with SF36. 
Adherence to treatment was assessed with the CQR questionnaire. Renal ultrasound and 
brain CT scan were performed.Results: 16 patients were evaluated 14 (88%) female, 2 (12%) 
male, with a mean (?) age 40.06 years (+/-12.4), Age at diagnosis ?:12.68 years (SD+/-
18.37), BMI ?:38.5 kg/m2 (13.07), stature ?:129.9 cm (+/-33.9), fractures 8/16 (50%) and 
skeletal deformities 16/16 (100% ), number of corrective surgeries required 15/16 (94%), 
pseudofractures 13/16 (81%), kyphoscoliosis 8/16 (50%). Laboratory: calcemia ?:9.5mg/
dl (+/-0.37) phosphatemia ?:2.07mg/dl (+/-0.41), PTH ?:88.31 pg/ml (+/- 36.1), 25OHD 
?:26.77 ng/ml (+/-11.48), RTP?:76.76% (+/-11.19), FAO ?:37.08 (+/-26.94), CTX ?:1646 
(+/-1119), FGF23 ?:58.85pg/ml (+/-27.7). Genetic profile: 1/14 had a definitely pathogen-
ic not previously described in the literature mutation. 14/16 (88%) patients showed NOT 
to adhere to conventional treatment. Application of WOMAC function scale ?:47.87 (+/-
25.23); PROMIS ?:31.5 questionnaire (+/-9.23); SF36 ?:34.95 (+/- 8.5). Renal ultrasound 
abnormalities 2/16 (13%) nephrocalcinosis and 3/16 (19%) renal lithiasis; no brain calcifica-
tions in the CT were described. Conclusion: The high percentage of patients not adherent to 
conventional treatment leads to marked impaired physical function with important skeletal 
deformities, fractures and pseudofractures, bone pain and altered QOL. Early diagnosis, 
adequate treatment and follow-up by a multidisciplinary team will avoid complications and 
improve the patient’s quality of life.
Disclosures: Tatiana Martinez, None
P-791
Bone Turnover and Mineral Metabolism in Adult Patients With Pediatric-
Onset Hypophosphatasia (HPP) Treated With Asfotase Alfa *Lothar 
Seefried1, Dominik Rak1, Anna Petryk2, Franca Genest1. 1Orthopedic Clinic 
König-Ludwig-Haus, Julius-Maximilians-Universität Würzburg, Germany, 
2Alexion Pharmaceuticals, Inc., United States
Introduction: Evaluate changes in bone turnover markers in adults with pediatric-onset 
HPP who were treated with asfotase alfa.Methods:Observational study of adult patients (age 
>=18 years [y]) with pediatric-onset HPP who were treated with asfotase alfa for 12 months 
(mo) as part of routine care at 1 center (NCT03418389).Results: Data from 14 patients, 
ages 19-78y (median 52y), with compound heterozygous ALPL mutations and histories of 
skeletal (at least 1 fracture) and other HPP manifestations, were analyzed. Levels of Para-
thyroid Hormone 1-84 (PTH), mostly in the lower normal range before treatment, exhibited 
a transient increase at 3 mo of treatment, returning back towards baseline levels at 3 and 6 
mo. This effect was not accompanied by changes in calcium or phosphate levels. Significant 
transient increases were observed regarding procollagen type 1 N-propeptide (PINP) at 3 mo 
and osteocalcin at 3 and 6 mo; both reverted to near baseline by 12 mo (Table). Numeric tem-
porary increases in N-telopeptide of type 1 collagen (NTx) and tartrate-resistant acid phos-
phatase 5b (TRAP 5b) were not statistically significant. Serum concentrations of pyridoxal 
5’-phosphate (PLP) were elevated at baseline with a  median of 286ng/mL and decreased 
significantly (n=12, P=0.005) after12 mo of treatment to 8.5ng/mL (normal: 5-30). Similarly, 
significant reductions occurred in urine phosphoethanolamine (PEA)/creatinine ratio (n=11, 
P=0.008), with a decrease from 54.9mmol/mol creatinine at baseline to 22.4mmol/mol creat-
inine at 12 mo (normal: 2.3-11.3).Conclusions: This is the first systematic evaluation of bone 
turnover markers during asfotase alfa treatment. Results of this study suggest that beyond 
significantly reducing PLP and PEA, improvements in bone mineralization may be reflected 
by specific changes in biochemical markers, indicating facilitated bone remodeling during 
treatment with asfotase alfa.
Disclosures: Lothar Seefried, Alexion Pharmaceuticals, Inc., Consultant
P-792
Flawed Fractures: Are some fractures pathognomonic for non-accidental 
injury? *Amy Bobyn1, Oana Caluseriu2, Breanne Frohlich3, Mary Jetha4, 
Chelsey Grimbly5. 1University of Alberta, Canada, 2Department of Medical 
Genetics, University of Alberta, Canada, 3Division of General and Community 
Pediatrics, Department of Pediatrics, University of Albert, Canada, 4Division 
of Pediatric Endocrinology, Department of Pediatrics, University of Alberta, 
Canada, 5Department of Pediatrics, Division of Endocrinology, University of 
Alberta, Canada
Introduction: Non-accidental injury (NAI) is a diagnosis of exclusion in children pre-
senting with multiple unexplained fractures. Features highly suggestive of NAI include me-
taphyseal corner fractures and posterior rib fractures. Osteogenesis Imperfecta (OI) is a rare 
monogenic class of disorders with vast clinical and genetic heterogeneity characterized by 
multiple fractures and additional features. OI is often included in the differential diagnosis 
of NAI. We present a case of siblings with metaphyseal corner fractures and rib fractures 
due to FKBP10 mutations, a rare cause of OI (MIM 259450; 610960). We performed a lit-
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erature review to address the overlap between OI and NAI fractures. We aim to demonstrate 
that OI requires careful consideration in cases being investigated for NAI. Cases: A healthy 
18-month-old male born to nonconsanguineous parents presented with asymmetric shoulder 
alignment. Xrays showed multiple fractures of varying healing stages including rib, bilateral 
ulnar, and metaphyseal corner fractures leading to investigations for NAI. He had isolated 
gross motor delay and no family history of recurrent fractures. Physical exam showed short 
stature (Height Z score -2.0), mildly blue sclera, joint hyperlaxity, and kyphosis. There was 
no dentinogenesis imperfecta (DI) or contractures. Genetic testing showed compound het-
erozygous likely pathogenic variants in FKBP10, and parents were confirmed carriers. The 
mother was pregnant at the time, and there was no suspicion of OI through multiple fetal 
ultrasounds; fetal growth tracked between 25th -50th centile. However, a skeletal survey at 
birth showed multiple rib fractures, metaphyseal corner fractures and long bone fractures. 
Genetic testing confirmed the same FKBP10 variants as in the sibling. A literature review 
identified 191 articles describing fracture patterns in NAI and OI. Thirteen articles reported 
79 children investigated for NAI, later found to have OI; 75 children had clinical and radio-
logical signs of OI. Thirty-seven cases proceeded to legal trial and 38 children were removed 
from family care due to suspicion of NAI. Conclusion: This report highlights that there 
are no pathognomonic fractures in NAI. OI can present with metaphyseal corner fractures, 
posterior rib fractures, and fractures at various stages of healing. Our work supports the im-
portance of exploring a diagnosis of OI in cases suspected of NAI with multiple implications 
for patient and family management.
Disclosures: Amy Bobyn, None
P-793
Quality of Life and Stigma Outcomes in the Surgical Treatment of 
Craniofacial Fibrous Dysplasia *Andrea Burke1, Brian Leroux2, Amanda 
Konradi3. 1University of Washington School of Dentistry, United States, 
2University of Washington, United States, 3Loyola University Maryland, United 
States
Purpose: Craniofacial fibrous dysplasia (CFD), a rare disease of bone marrow stromal 
cells, may distort facial features, cause functional/esthetic problems or pain. Our work has 
shown that quality of life (QoL) outcomes in CFD, as measured by the SF-36, were not 
significantly different in subjects treated operatively vs. non-operatively. Given the variable 
severity of CFD and important psychosocial implications, the purpose of this study was 
to measure the association between operative treatment and QoL measures, when taking 
into account demographic/disease variables and stigma. Methods: This is a retrospective 
cross-sectional study of subjects enrolled in the Fibrous Dysplasia Foundation Patient Reg-
istry, July 2016-December 2018. The primary predictor variable was operative treatment 
(no surgery, one surgery, more than one surgery); covariates included diagnosis (monostotic 
FD, polyostotic FD, McCune-Albright Syndrome), lesion location, and demographic data. 
Outcome variables were QoL and stigma measures obtained from the validated SF-36, 
HADS anxiety/depression scale, Brief Pain Inventory, and NeuroQoL survey. Multiple lin-
ear regression was conducted for the eight SF-36 domains, anxiety, depression, impact of 
pain, and experienced/internalized stigma to assess associations (p<0.05). Since stigma may 
influence both demographic/disease variables and QoL outcomes, the models were rerun 
with stigma as a control variable. Results: The sample was composed of 117 CFD adult 
subjects, with mean age 40 years, 84% female. Forty-nine subjects (41%) had at least one 
surgical treatment, of which 78% had an operation on facial bones. The number of cranio-
facial operations was not associated with physical and psychosocial QoL outcomes in any 
model. Higher disease burden (McCune-Albright Syndrome/polyostotic disease) was asso-
ciated with worse physical function and pain, before and after adjustment for stigma. Body 
pain, general health and vitality were worse in females. Subjects who reported greater levels 
of stigma had significantly worse outcomes for all QoL measures, including pain. Those 
reporting internalized stigma significantly experienced anxiety and depression.  Conclusion: 
Experienced and internalized stigma may play a role in the relationships between disease 
severity and QoL measures. Along with surgery, treatment of CFD should address the social 
effects of the disease.
Disclosures: Andrea Burke, None
P-794
STOPFOP: A Phase II Clinical Trial of Saracatinib (AZD0530) in FOP 
*Bernard J Smilde1, Richard Keen2, Clemens Stockklausner3, Dong Liu4, Alex 
Bullock5, Annette von Delft5, Natasja M van Schoor6, Paul B Yu7, E Marelise 
W Eekhoff1. 1Department of Internal Medicine, Amsterdam University Medical 
Center, Netherlands, 2Department of Rheumatology, Royal National Orthopaedic 
Hospital, United Kingdom, 3Department of Paediatrics, Klinikum Garmisch-
Partenkirchen, Germany, 4BioPharmaceuticals R&D, AstraZeneca, United States, 
5Nuffield Department of Medicine, University of Oxford, United Kingdom, 
6Department of Epidemiology and Biostatistics, Amsterdam University Medical 
Center, Netherlands, 7Department of Medicine, Brigham and Women’s Hospital, 
United States
Background: Fibrodysplasia Ossificans Progressiva (FOP) is an autosomal dominant, 
debilitating disorder marked by severe heterotopic ossifications (HO), progressive loss of 
mobility and early death. There are currently no approved treatments.Classic FOP is caused 
by a gain-of-function mutation (Acvr1[R206H]), resulting in a mutated ALK2-Kinase. 
AZD0530 (saracatinib) was identified by our team as a potent inhibitor of ALK2-kinase 
and was effective in preventing heterotopic ossification in FOP mouse models. The pur-
pose of this study is to investigate the repositioning of AZD0530, originally designed for 
ovarian cancer treatment, to treat patients with FOP. This study is funded by the Innovative 
Medicines Initiative (IMI).Methods: The Saracatinib Trial to Prevent FOP (STOPFOP) is a 
phase 2a, multicentre, 6-month double blind randomized controlled trial of AZD0530 versus 
placebo, followed by a 12 month open-label trial comparing extended AZD0530 treatment 
with historical data. We will include 20 otherwise healthy FOP patients, aged 18-65 years, 
with the classic FOP mutation. Endpoints are an objective change in heterotopic bone vol-
ume measured by low-dose whole-body computer tomography (CT), [18F] NaF PET activ-
ity and patient reported outcome measures such as the FOP-IADL assessment.Discussion: 
Drug repositioning - using existing, previously researched but unapproved drugs for the 
treatment of a different disease - is especially useful in rare diseases with limited study 
populations. It represents an ideal solution for limiting risks in early clinical studies. Using 
existing pre-clinical and clinical knowledge may also allow more effective use of resources.
With positive study outcome, AZD0530 may provide a rapidly translatable therapy for FOP 
due to the availability of extensive safety data from over 600 patients in more than 28 reg-
istered clinical trials using AZD0530.Trial registration: NCT04307953 / EudraCT number 
2019-003324-20
Disclosures: Bernard J Smilde, None
P-795
Reduced Trabecular Bone Score is Associated with Non-Vertebral Fractures 
and Nephrolithiasis in Transfusion-Dependent Thalassemia *Nisal 
Punchihewa1, Anne Trinh2, Zane kaplan3, Madhuni Herath3, Frances Milat2, 
Phillip Wong2. 1Monash University, Australia, 2Hudson Institute, Australia, 
3Monash Health, Australia
Although hypercalciuria, osteoporosis, fractures and nephrolithiasis are well described 
in thalassemia, there is limited literature to guide clinical surveillance of the renal-bone 
disease in this group. Bone mineral density as assessed by dual-energy x-ray absorptiometry 
(DXA) is cannot adequately capture the microarchitectural changes seen in thalassaemia 
bone disease. The trabecular bone score (TBS), derived from the lumbar spine using DXA 
provides a surrogate measures of bone microarchitecture. There is limited information avail-
able on the utility of TBS for fracture risk assessment in the thalassemia cohort. In this 
cross-sectional study of 71 subjects with transfusion-dependent thalassemia, the relationship 
between TBS, BMD, fractures, nephrolithiasis and biochemical parameters were investigat-
ed. TBS was significantly associated with non-vertebral fractures (OR 1.99 [95% CI 1.28 
- 3.09]) and nephrolithiasis (OR 1.98 [1.33, 2.95]). Nephrolithiasis was highly prevalent 
(40.6%) and common in men (60%). Conventional DXA parameters were not significantly 
associated with nephrolithiasis but were associated with all types of fracture. This study 
demonstrates the potential use of TBS in predicting non-vertebral fractures and nephrolithi-
asis in transfusion-dependent thalassemia. The association between TBS and nephrolithiasis 
deserves further study.
Disclosures: Nisal Punchihewa, None
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Skeletal Abnormalities Confirmed by Chest Radiography in Childhood 
Could Provide a Clue to Diagnose Gorlin Syndrome *Makoto Fujiwara1, 
Takuo Kubota1, Taichi Kitaoka1, Yasuhisa Ohata1, Hirofumi Nakayama1, Shinji 
Takeyari1, Yukako Nakano1, Kenichi Yamamoto1, Chieko Yamada1, Takeshi 
Ishimi1, Tomonao Aikawa2, Mikihiko Kogo2, Akinori Takeshita3, Narikazu 
Uzawa3, Keiichi Ozono1. 1Department of Pediatrics, Osaka University Graduate 
School of Medicine, Japan, 2The first Department of Oral and Maxillofacial 
Surgery, Osaka University Graduate School of Dentistry, Japan, 3Department 
of Oral and Maxillofacial Surgery 2, Osaka University Graduate School of 
Dentistry, Japan
Background: Gorlin syndrome, also called basal cell nevus syndrome, is a disorder 
characterized by malformations of the skin, nerves, eyes, and bones. Heterozygous muta-
tions of PTCH1, PTCH2, or SUFU which are involved in the SHH-PTCH1 pathway cause 
the syndrome, and de novo mutations account for 20 to 30% of cases. Because the pa-
tients with Gorlin syndrome have a predisposition to various tumors including basal cell 
carcinoma (BCC) and keratocystic odontogenic tumor (KCOT), early diagnosis is of great 
importance. Although the major criteria including BCC and KCOT are often not evident 
until the childhood, the radiological manifestations of various skeletal abnormalities may 
contribute to make early diagnosis. Especially, rib anomalies such as bifid ribs, whose over-
all prevalence is estimated lower than 3% in general population, are common with high 
specificity in Gorlin syndrome.Objectives: The aim of this study was to verify the usefulness 
of occasional chest X-ray to detect skeletal abnormalities in pediatric patients with Gorlin 
syndrome.Methods: We retrospectively assessed the chest X-ray films of Gorlin syndrome 
patients aged under15 year old who have been followed at Osaka University Medical and/
or Dental Hospital since 2001.Results: Six patients (2 males and 4 females) were analyzed. 
Family history was found in 3 patients. All patients showed calcification of the falx cerebri, 
two patients presented cleft lip and palate, and one patient revealed cardiac fibroma. All 
patients have developed KCOT and the resection was performed. Genetic analysis was per-
formed in 3 patients, in all of whom heterozygous PTCH1 mutations were detected. All chest 
X-ray photographs were taken as a preoperative examination at 6.6 – 14.2 years old (average 
11.3 years old). Rib abnormalities were found in 3 patients, and vertebral anomalies were 
identified in 2 patients. Previous chest X-ray could be traced in two patients and all of them 
showed the same skeletal abnormalities. Two patients were diagnosed with Gorlin syndrome 
by the rib abnormalities.Conclusion: Patients with Gorlin syndrome exhibit skeletal anom-
alies in their childhood at high rates, which could be detected by chest X-ray and provide a 
clue to the diagnosis. Therefore, it is worth considering Gorlin syndrome even when bone 
abnormalities in chest radiography are observed by chance.
Disclosures: Makoto Fujiwara, None
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Erdheim-Chester disease - Unusual presentation with isolated skeletal 
lytic lesions *Amulya Yalamanchi1, Adlyne Reena Asirwatham1, Karthik 
Balachandran1, Shriraam Mahadevan1, Sathish Kumar1, Krishna Mori1. 1Sri 
Ramachandra medical college, India
Background: Erdheim Chester disease (ECD) is a rare, non-langerhans cell histiocy-
tosis characterized by CD68+ and CD1a- foamy histiocytes with multisystem involvement 
and characteristic sclerotic musculoskeletal lesions. First case was described as “lipogranu-
lomatosis” by Jakob Erdheim and William Chester in 1930. Since then only 650 cases have 
been reported so far.Case report: A 48-year-old peri-menopausal women, presented with 
persistent headache and tender swelling of the left shoulder and hip joint for 5 years and with 
difficulty in walking for 18 years due to multiple long bone fractures. Roentograms showed 
large mixed expansile lytic sclerotic lesions involving left humerus and acetabulum. Tech-
netium 99m bone scan showed discrete hot spots in the skull, right humerus, left humerus, 
left femur and iliac crests. MRI brain showed multiple lytic lesions in the skull vault. Biopsy 
from humeral lesion showed characteristic histologic findings: clusters of foamy histiocytes 
positive for vimentin, CD68 and negative for S-100 and CD1a, typical of ECD histiocytes.
Conclusion: Symmetrical long bone osteosclerosis is the most specific radiological finding 
for ECD whereas in Langerhans cell histiocytosis (LCH), bone involvement is mostly os-
teolytic and do not involve long bones. Only 5-8% of the patients with ECD have osteolytic 
lesions either on the flat bones, or long bones. As our patient has overlapping features of 
Langerhans cell histiocytosis as well as Erdheim Chester disease, it lead to misdiagnosis 
for about 20 years. This case represents the unusual presentation of the spectrum of ECD.
Keywords: Erdheim Chester disease; Osteosclerosis; non-langerhans cell histiocytosis; Lyt-
ic bone lesions;
Disclosures: Amulya Yalamanchi, None
P-798
The Role of Lysine Specific Demethylase 1 in Osteoclast Differentiation 
*Kristina Astleford1, Kim Mansky1. 1University of Minnesota, United States
Changes in gene expression help bone respond to developmental, repair and remod-
eling cues in a rapid manner. Healthy skeletal growth and maintenance requires carefully 
coordinated cycles of bone formation and resorption. Osteoclasts are large, multinucleat-
ed cells that are responsible for bone degradation by secreting acids and proteolytic en-
zymes to dissolve bone mineral and extracellular matrix. Increased activity of osteoclasts 
has a detrimental effect on the skeleton and therefore, have become a therapeutic target 
for many skeletal diseases including osteoporosis. Progression from multipotent progeni-
tors into specialized, terminally differentiated cells involves carefully regulated patterns of 
gene expression to control lineage specification and development of the cellular phenotype. 
This process requires synchronized action of transcription factors with co-activators and 
co-repressors to initiate proper activation and inhibition of gene expression. Lysine-specific 
demethylase 1 (LSD1 or KDM1A) is a member of the histone demethylases which is a group 
of transcriptional co-repressors/co-activators known for regulating gene expression via re-
moval of mono- and di-methyl groups from histone 3 lysine 4 (H3K4 and histone 3 lysine 
9 (H3K9). Demethylation of H3K4 represses transcription while demethylation of H3K9 
activates transcription. The mechanism by which LSD1 regulates osteoclast differentiation 
is currently unknown. As measured by RNA and protein, LSD1 is expressed throughout 
osteoclast differentiation. Treatment of bone marrow macrophages with the LSD1 chem-
ical inhibitor S2101, enhances osteoclast differentiation and mono-methylation of H3K4. 
Furthermore, shRNA knockdown of LSD1 exhibits a similar phenotype with an increase 
in the osteoclast gene markers, Nfatc1, Dcstamp and Cathepsin K. Furthermore, shRNA 
knockdown of LSD1 results in an increase in multiple osteoclast fusion genes including 
Adam8 and Oscar, suggesting that osteoclast fusion may be regulated by LSD1. Lastly, 
knockdown of LSD1 enhances osteoclast resorptive ability. Currently, we are investigating 
LSD1’s epigenetic role in regulating osteoclast differentiation and activity using mice who 
are conditionally deleted for LSD1 in osteoclasts by determining their in vivo skeletal and 
in vitro osteoclast phenotype.
Disclosures: Kristina Astleford, None
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Melorheostosis: Successful Pain Management with Medical Marijuana 
*Anjali Manavalan1, Donna Lee1, Julia Arnsten2, Vafa Tabatabaie1. 1Division 
of Endocrinology, Montefiore Medical Center, Albert Einstein College of 
Medicine, United States, 2Division of General Internal Medicine and Psychiatry, 
Montefiore Medical Center, Albert Einstein College of Medicine, United States
Background: Melorheostosis is a rare bone disorder first recognized in 1922. It is char-
acterized by osteosclerosis of cortical bone and adjacent soft tissue. Pain is the most com-
mon symptom and correlates with periosteal bone formation. Involvement of the surround-
ing soft tissue or joint capsule may result in deformities. Localized, asymmetric lesions may 
help distinguish it from other conditions that are radiologically similar. Sporadic somatic 
mutations in MAP2K1, SMAD 3 and the RAS pathway have been implicated in isolated 
melorheostosis (1). Treatment is focused on pain control. The utility of medical marijuana 
for pain control in patients with melorheostosis has not been described previously.Clinical 
Case: A 25-year-old man presented to our metabolic bone clinic for the management of 
worsening melorheostosis that had been diagnosed by bone biopsy at an outside hospital. 
Genetic testing was unavailable but no family history suggestive of bone disease was report-
ed. Physical exam uncovered tender sites in the left lower extremity without deformity or 
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joint involvement. Progression of sclerosis was noted on imaging. Vitamin D deficiency and 
secondary hyperparathyroidism were treated with supplementation. Suboptimal analgesia 
with opiates led to a referral to the medical cannabis clinic. Pain improved significantly and 
opiates were weaned. Laboratory Results: Calcium 9.7mg/dl (8.5-10.5), Creatinine 1.1mg/dl 
(<1.5), Vitamin D 25-OH 30), Intact Parathyroid hormone 73.5pg/ml (15-65), TSH 1.04uU/
ml (0.4-4.60), C-Telopeptide 704pg/ml, Osteocalcin 27ng/ml (9-38). Prior Skeletal Survey: 
Cortical thickening involving the left femoral shaft and iliac bone, consistent with melor-
heostosis. Current X-Ray Tibia and Fibula: Flowing ossifications in the left distal femur, 
fibular shaft and calcaneus, compatible with melorheostosis. Conclusion: Treatment of me-
lorheostosis is centered on symptom management. Non-steroidal analgesics may be inade-
quate and opiates are fraught with the development of tolerance, side effects and potential 
for addiction and abuse. Bisphosphonates and denosumab may be used but can increase the 
risk of atypical fractures. Medical marijuana has proven efficacy in the management of pain 
and anxiety and could represent a safe and effective approach to analgesia in patients with 
melorheostosis.References:1)P. Wordsworth and M.Chan;Melorheostosis and Osteopoikilo-
sis: A Review of Clinical Features and Pathogenesis;Calcified Tissue International volume 
104,530–543(2019)
Disclosures: Anjali Manavalan, None
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The developmental phenotype of the great toe in fibrodysplasia ossificans 
progressiva *Will Towler1, Eileen Shore1, Fred Kaplan1. 1University of 
Pennsylvania, United States
Fibrodysplasia ossificans progressiva (FOP) is a genetic disorder in which extensive 
heterotopic ossification begins to form during early childhood and continues to progress 
throughout life. Although heterotopic bone formation does not occur during embryonic de-
velopment, children who carry the ACVR1R206H mutation that causes most cases of FOP 
characteristically exhibit malformation of their great toes at birth, indicating that the muta-
tion also alters skeletal formation. Despite the prevalence of the great toe malformation in 
the FOP population, it has received relatively little attention due to its apparently clinically 
benign nature. In this study, we examined radiographs from a cohort of 41 FOP patients 
ranging from 2 months to 48 years of age to provide a detailed analysis of the developmental 
features, progression, and variability of the great toe malformation of FOP, which include 
absent skeletal structures, malformed epiphyses, ectopic ossification centers, malformed first 
metatarsals and phalangeal fusion.
Disclosures: Will Towler, None
P-801
Tumor-induced Osteomalacia under treatment with burosumab *Daniel 
Salica1, Ariel Sanchez2. 1School of Medicine. National University of Cordoba. 
Argentina, Argentina, 2Center of Endocrinology, Argentina
Introduction:Tumor-induced Osteomalacia (TIO) is a rare paraneoplastic syndrome, 
related to excessive production of FGF-23 by tumors of mesenchymal origin. This report is 
about a patient with TIO whose tumor relapsed after surgery in 2008; she started treatment 
with burosumab, a fully human monoclonal antibody to FGF23, a year ago.Clinical Case:A 
51-year-old woman started in 2004 with muscle weakness, progressive muscle and bone 
pain, prostration and multiple fractures in vertebrae, both hips, humerus and left shoulder. 
X-rays studies revealed a tumor in the left ischiopubic bone. The biopsy revealed a mesen-
chymal tumor. Surgery was performed in 2008, with removal of the affected bone; patholog-
ical studies suggested fibrous dysplasia. Symptoms improved and eventually disappeared; 
the patient remained asymptomatic until 2011, when her clinical picture recurred, causing 
disability and prostration; she also presented lumbosacral radicular compression syndrome. 
Treatment with burosumab (started in May 2019), at the current dose of 60 mg per month, 
increased serum phosphate levels, and decreased pain and fatigue, improving her quality of 
life,.Laboratory tests before burosumab were: serum calcium 9.1 mg/dl, serum phosphate 
1.2 mg/dl, FGF-23 1127.5 pg/dl  (NR 0-134); serum alkaline phosphatase 235 IU/l (NR 
60-120), serum calcitriol 15.4 pg/ml (NR 19-54);  ionic calcium (pH 7,40) 1.21 mmol/l (NR 
1.10-1.28); serum PTH 271 pg/ml (NR 10-65); 25-hydroxyvitamin D 38 ng/ml (NR 30-
150) urine calcium 200 mg/24 h; tubular reabsorption of phosphate 52% (normal >83).The 
medical imaging (CT scans, FDG-PET) was negative for tumor, but showed multiple uptake 
in bone areas attributed to increased remodelling and bone fractures.Laboratory tests during 
treatment with burosumab were: serum calcium 8.9 mg/dl; ionized calcium 4.76 mg/dl; se-
rum phosphate 2.9 mg/dl; serum alkaline phosphatase 301 IU/l; 25-hydroxyvitamin D 27 
ng/ml; serum PTH 269 pg/ml; urine calcium 90 mg/24 h.Conclusion:Burosumab treatment 
in this case of TIO increased serum phosphate levels, improved mobility, pain and fatigue 
during 12 months of follow-up, without adverse events.
Disclosures: Daniel Salica, None
P-802
Orbital Fibrous Dysplasia: Visual Loss Due To New Lesion 50 Years After 
Initial Diagnosis *Abhilasha Singh1, Vishnu Sundaresh1, Massiell German1. 
1University of Utah, United States
IntroductionFibrous dysplasia (FD) is a rare bone disorder in which normal bone is re-
placed by fibro-osseous tissue resulting in pathological fractures. It is monostotic in 75-80% 
of cases, while remaining are polyostotic. Craniofacial involvement is 10-27% in monostotic 
and 50% in the polyostotic form. Of these, orbital lesions occur in about 20-39%. Majority 
of craniofacial lesions occur within 3.4 years of diagnosis. We describe a patient presenting 
with new progressive lesions 5 decades after initial diagnosis.CaseA 56-year-old white fe-
male was referred to our clinic by ophthalmology after being evaluated for progressive loss 
of vision in the left eye over 4 months. Medical history included polyostotic fibrous dyspla-
sia diagnosed at age 14 years when she presented with multiple fractures with onset at age 
5 years. History of lobectomy for a benign goiter. Magnetic resonance imaging (MRI) brain 
reported mass effect on left optic nerve at the orbital apex. Oral and IV prednisone was not 
helpful. Examination revealed only finger counting in the left eye, with restricted superior 
and inferior temporal fields. Right eye was normal. No signs of hypercortisolism, acromega-
ly, and skin lesions. Labs revealed normal calcium, albumin, phosphorus, magnesium levels 
with PTH: 27 (15-65 pg/ml), Vit D: 57 (30-80 ng/ml), BUN: 13 (8-24 mg/dl), Cr: 0.74 
(0.57-1.11 mg/dl), TSH: 0.29 (0.35-4.94 mU/l), FT4: 1.4 (0.8-1.7 ng/dl), TSI: 104 (<122%), 
PRL: 5.6 (2.8-26 pg/ml), IGF-1: 95 (48-235 ng/ml), Alkaline phoshatase: 156 (38-126 U/L), 
BSAP: 26.5 (7.0 - 22.4 ug/L), and C-telopeptide: 619 (104-1008 pg/mL). Tc99m Bone scan 
reported osteoblastic activity in the right calvarium including parietal, temporal, skull base, 
humeri, pelvis, and femur. Decompressive surgery for the left eye or prophylactic surgery 
in the right eye was deemed not to be beneficial. Zoledronate was recommended.Discus-
sionMost cases of FD are identified in early childhood and lead to deformity of the involved 
bone over time making them prone to fractures. Although, patients develop complications in 
pre-existing lesions decades after diagnosis, it is extremely rare to present with new lesions. 
We report the development of new progressive lesions 50 years after initial diagnosis. We 
suggest to follow these patients lifelong to monitor for new lesions. Timely diagnosis and 
intervention may reduce fractures, visual and hearing loss, and rarely malignant transforma-
tion, with improved quality of life.
Disclosures: Abhilasha Singh, None
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Uncommon disease presenting with common symptom-Tumoral calcinosis 
presenting as bilateral pedal edema *ASHOK VENKATANARASU1, 
RAMAN BODDULA2, CHIMUTAI CHINTE2, VIDYA TICKOO3, PRANITH 
RAM MAMIDI3. 1SANJEEVANI THYROID, SUGAR AND HORMONES 
CLINIC, India, 2Yashoda hospital, India, 3YASHODA HOSPITAL, India
Introduction:Tumoral calcinosis (TC) is a rare metabolic disorder characterized by 
ectopic calcification (periarticular or dermal) that results from abnormality in phosphate 
homeostasis due to an increase in renal phosphate reabsorption, often associates with normal 
calcitriol. Commonly presents as periarticular soft tissue mass or rarely as calcinosis cutis. 
Here we are reporting such case that presented with bilateral symmetrical pedal edema, 
which is uncommon presentation.Clinical caseA 55 years old gentleman who is known case 
of type 2 diabetes mellitus presented with swelling of feet and legs on both sides since 2 
years. It was associated with stiffness, pain and hardness of legs. There was no history of red-
ness of skin over swelling, fever or localized swellings elsewhere in the body. Similar history 
is present in his mother and younger brother. His parent’s and grandparent’s marriage was 
consanguineous marriage.  On examination, there was symmetrical bilateral pedal edema 
that extending upto below knee of the legs and stony hard on palpation. There were no signs 
of vascular insufficiency and local infection. X- Ray of both legs showed diffuse subcuta-
neous calcification on both sides(X-ray picture).Laboratory tests revealed, serum calcium- 
10.0mg/dL, serum phosphorous-6.2mg/dL, serum creatinine -1.1mg/dL, TMP-GFR-6.014, 
serum parathyroid hormone-24.5pg/mL, 25 (OH)2 Vitamin D3-22ng/mL, 1,25(OH)2 Vita-
min D3- 100pmol/L, fibroblast growth factor 23 (FGF-23, C-terminal)- 1038 RU/mL (upto 
150) (ELISA) and HbA1C -6.7%.  His mother laboratory reports also revealed that serum 
calcium-10.6, serum phosphorous -6.8, serum albumin 4.1g/dL and serum creatinine-1mg/
dL. Genetic work up revealed a homozygous missense variation in exon 6 of the GAL-
NT3 gene, with amino acid substitution of Arginine for Leucine at codon 366 (c.1097 T>G 
(p.Leu366Arg)). FGF-23 levels are high as it was C- terminal (inactive FGF-23) estimation, 
expected to be high in this case. Diagnosis of familial tumoral calcinosis made and started 
on phosphate-restricted diet along with Sevelamer. After 4months, there were improvement 
noted clinically and also in lab parameters, serum calcium-9.6, serum phosphorous-5.4mg/
dL.Conclusion-Familial tumoral calcinosis, which is a rare disease, presented with common 
general symptom as pedal edema. Sevelamer and phosphate restricted diet showed improve-
ment in presented symptoms and serum phosphorous levels.
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P-804
Delayed Administration of a Selective ALK2 Inhibitor, VU002, Reduces 
Injury-Induced Endochondral Heterotopic Ossification (HO) by Stopping 
HO Expansion in Fibrodysplasia Ossificans Progressiva (FOP) Mice *Jessica 
Pierce1, Shivangi Dave2, Paulo Melo2, Cody Elkins1, Huili Lyu1, C. Henrique 
Serezani2, Daniel Perrien1. 1Emory University, United States, 2Vanderbilt 
University Medical Center, United States
Expression of aberrantly active variants of ACVR1/ALK2 in muscle-resident cells is re-
quired for flare initiation and endochondral HO (EHO) in FOP. Daily treatment with clinical-
ly-relevant small molecule ALK2 inhibitors started at the time of injury or 2 days post-injury 
(dpi) can block EHO in FOP mice. However, the role of ALK2 at later stages of flare devel-
opment and the ability of ALK2 inhibitors to reduce EHO when treatment is further delayed 
are unclear.  Since the trigger for FOP-flares in patients is often unknown, it is important to 
understand the stages during which ALK2 inhibitor treatments are effective.  Muscle injury 
in tamoxifen-inducible ALK2R206H-FlEx/wt (tamFOP) mice causes hyperinflammation 
detectable at 2-6 dpi, cartilage formation by 6-8 dpi, and radiographically detectable miner-
alization by 7-11 dpi.  Thus, we hypothesized that oral delivery of a highly potent and selec-
tive small-molecule ALK2 inhibitor (VU002) in tamFOP mice would block HO formation 
when treatment is delayed up to 7 dpi.  Following tamoxifen-induced permanent expression 
of ALK2R206H, 33-35 day old tamFOP mice received bilateral pinch injuries of lower hind-
limb muscles.  Mice remained untreated (CON) or received 20 mg/kg VU002 b.i.d. by oral 
gavage starting immediately at the time of injury (D0), or 5-, 7-, or 14-dpi (n=3-6 per group), 
and treatment continued daily until sacrifice at 35 dpi.  As expected, CON mice developed 
extensive EHO by 14 dpi which continued to expand until 35 dpi, and this was completely 
prevented in mice that received VU002 starting at the time of injury (d0-35 p<0.0001). Mice 
in the d5-35 and d7-35 groups also developed HO by 14 dpi (64+/-16 p<0.05 and 45+/-18 
p<0.01, respectively), but this was significantly less than in CON mice (103+/-16).  Further, 
the amount of EHO in d5-35 and d7-35 groups did not expand from 14-35 dpi.  In contrast, 
starting treatment at 14 dpi (d14-35 group) did not alter HO area vs. Untreated mice at any 
timepoint.  Surprisingly, immature intramuscular cartilage and mature EHO were present in 
histological sections of legs from mice treated with VU002 at d5-35 and d7-35, suggesting 
that ALK2-inhibition may block cartilage maturation and mineralization.  Mechanistically, 
these data suggest that expansion of mineralized HO in FOP mice may be independent of 
ALK2 signaling.  This also indicates the window to initiate oral ALK2 kinase inhibitor treat-
ment may be limited to the inflammatory, prechondrogenic phase of a flare.
Disclosures: Jessica Pierce, None
P-805
New Ifitm5 S42L mouse model for atypical type VI Osteogenesis Imperfecta 
recapitulates patient phenotype. *Gali Guterman Ram1, Ghazal Hedjazi2, Chris 
Stephan3, Stéphane Blouin2, Victoria Schemenz4, Wolfgang Wagermaier4, Jochen 
Zwerina2, Peter Fratzl4, Kenneth M Kozloff3, Nadja Fratzl-Zelman2, Joan C 
Marini5. 1Section on Heritable Disorders of Bone and Extracellular Matrix, Eunice 
Kennedy Shriver National Institute of Child Health and Human Development, 
National Institutes of Health, United States, 2Ludwig Boltzmann Institute 
of Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre 
Meidling, 1st Medical Department, Hanusch Hospital, Austria, 3Department 
of Orthopaedic Surgery, University of Michigan, United States, 4Max Planck 
Institute of Colloids and Interfaces, Dept. of Biomaterials, Germany, 5Section on 
Heritable Disorders of Bone and Extracellular Matrix, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, United States
Osteogenesis Imperfecta (OI) is a type I collagen-related bone dysplasia. Type V OI, 
caused by a recurrent dominant mutation in IFITM5/BRIL, and type VI OI, caused by re-
cessive null mutations in SERPINF1/PEDF, each have distinctive features. IFITM5 S40L, 
reported in 9 patients, causes severe dominant OI with phenotype, bone histology and de-
creased cellular PEDF secretion similar to type VI OI, rather than type V. Our aim is to 
understand the role of the pathways connecting IFITM5 and SERPINF1 in bone develop-
ment.We generated an Ifitm5 S42L knock-in mouse model with NICHD-ACUC approval. 
Mice were analyzed by X-Ray, aBMD, qBEI, µCT, bone mechanics, serum chemistry and 
in-vitro OB differentiation.Newborn Ifitm5 S42L mice, both heterozygous (HET) and homo-
zygous (HMZ), are non-lethal, have flared rib cage, shoulder and knee dislocations; HMZ 
pups also have rib fractures. On x-Rays, HET mice exhibit »50% humeral fractures at 1,2-
and 6-months, while HMZ incur fractures in 96% of humerii, femora and pelvis. Like aVI 
OI patients, young HET males have increased serum ALP and normal serum PEDF level 
(p<0.01) vs. WT. Mechanical testing of 2-month HET and HMZ show reduced stiffness, 
yield and ultimate load, with markedly increased brittleness. Biomechanics are not explained 
by bone size, suggesting material differences. On µCT, HET mice have decreased Ct.Th, but 
increased BV/TV and Tb.N, as well as increased vascular pore volume/BV. Whole-body 
DXA-aBMD was significantly decreased in 1,2-and 6-month-old mice with a step effect, 
suggesting HMZ are more severe than HET(p<0.01). qBEI of cortical bone revealed hy-
permineralization in 1-and 2-month HET vs. WT males, with increased CaMean, CaPeak 
(all, p<0.01) and CaHigh (p=0.0133, p=0.0027 respectively); 2-month HET show increased 
density and decreased area (both p<0.001) of osteocyte lacunar sections. Second harmonic 
generation florescence microscopy revealed bones from HET mice contain mostly disor-
dered matrix (60% vs 20% WT, p<0.0001). Cultured calvarial osteoblasts from HET mice 
deposit increased mineralization by alizarin red staining (p<0.05). HET mice have increased 
expression of osteoblast differentiation markers, including Ifitm5; OB BRIL level is normal 
on western blot.We demonstrated our mouse model recapitulates patient phenotype and re-
vealed differences in bone fragility, mineralization, vascularity, matrix organization. Con-
tinuing investigation will reveal cellular mechanisms involving Ifitm5 and Serpinf1.
Disclosures: Gali Guterman Ram, None
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Skeletal and Epidermal Contributons of FGF23 Excess in Cutaneous 
Skeletal Hypophosphatemia Syndrome *Zachary Michel1, Diana Ovejero2, 
Amanda Saikali1, Christophe Cataisson3, Stuart Yuspa3, Michael Collins1, Luis 
Fernandez de Castro1. 1Skeletal Disorders and Mineral Homeostasis Section, 
National Institute of Dental and Craniofacial Research, National Institutes of 
Health, Bethesda, Maryland, United States, 2Musculoskeletal Research Unit, 
Hospital del Mar Institute of Medical Investigation (IMIM), Barcelona, Spain, 
Spain, 3Laboratory of Cancer Biology and Genetics, National Cancer Institute, 
National Institutes of Health, Bethesda, Maryland, United States
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a rare, mosaic genetic 
disease caused by gain-of-function RAS mutations during embryogenesis. It prominently 
affects skin and bone, causing skeletal dysplasia and a variety of skin lesions. It is associated 
with elevated circulating FGF23, an osteocyte-derived phosphaturic hormone, resulting in 
hypophosphatemia and often osteomalacia and rickets. Early studies suggested skin lesions 
are the source of a “phosphaturic factor” causing osteomalacia. Consequently, some patients 
still undergo painful resections of lesional skin, despite no improvement in hypophosphate-
mia. Previous studies indicate that skin lesions do not express FGF23 but failed to prove that 
RAS mutated bone cells are the source of FGF23 excess.We hypothesized that the origin of 
FGF23 excess in CSHS is RAS-mutated bone, not skin. To test this, we studied two mouse 
models with mosaic-like expression of human HRAS G12 gain-of-function mutations: one 
restricted to the appendicular skeleton and cranial areas (by a Prrx1 promoter), and doxycy-
cline-inducible (Bone HRAS G12V); and another with an orthotopic graft of keratinocytes 
transduced with a mutant HRAS (Epidermal HRAS G12R). Both models result in constitu-
tive HRAS signaling restricted to bone or squamous papilloma, respectively. In both models, 
we measured blood levels of active FGF23 (intact, iFGF23) and total FGF23 (iFGF23 plus 
its inactivated c-terminal fragment, cFGF23), as well as vertebral bone volume by micro-CT 
analysis of the L5 vertebral bone to assess for possible osteomalacia due to FGF23 ex-
cess.Bone HRAS G12V mice exhibited dramatically increased total FGF23 and iFGF23 
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(approximately 17-fold and 30-fold higher than WT, respectively), and decreased vertebral 
trabecular bone volume. Epidermal HRAS G12R mice showed elevated total FGF23 (3-fold 
change) but no significant change in iFGF23. Epidermal HRAS G12R did not show bone 
loss, but L5 vertebrae showed trabecular thinning.In this study, we demonstrated marked 
excess of active iFGF23 and vertebral bone loss in mice with mosaic-like bone HRAS G12V 
expression. We are currently investigating the cause of inactive cFGF23 excess and the 
moderate bone microarchitecture changes observed in epidermal HRAS G12R mice, e.g. 
systemic inflammation. Further studies will also assess vertebral osteomalacia by histomor-
phometry, serum phosphate levels, and Fgf23 expression in bone and skin in both models.
Disclosures: Zachary Michel, None
P-807
Skeletal defects in Rps19+/- models of Diamond Blackfan anemia are 
mediated in part by failure of the meschymal lineage *Jimmy Hom1, Hiren 
Patel1, Mushran Khan1, Douglas J Adams2, Lydie M Da Costa3, Luanne L Peters4, 
Cheryl L Ackert-Bicknell2, Jeffrey M Lipton1, Lionel Blanc1. 1Feinstein Institute 
for Medical Research, United States, 2Departament of Orthopedics, University 
of Colorado Anschutz Medical Campus, United States, 3Service dHématologie 
Biologique, Hôpital Robert Debré, France, 4The Jackson Laboratory, United 
States
Diamond Blackfan Anemia (DBA) is a bone marrow failure syndrome characterized 
by red cell aplasia, craniofacial defects, and abnormalities of the forelimbs. Causative mu-
tations for DBA are often found in genes encoding ribosomal proteins, most commonly 
RPS19. In a 37-week gestation stillborn RPS19+/- DBA patient, we observed decreased tra-
becular bone and an expanded hypertrophic zone in the ribs. To study this mutation further, 
2 mouse models were generated, each with Rsp19 haploinsufficiency: an embryonic stem 
cell (mESC) line harboring a gene trap in Rps19 and an in vivo model using Prrx1-Cre with 
a floxed Rps19 allele. Rps19+/- mESCs differentiated into osteoblasts showed decreased 
ability to form mineralized nodules compared to controls. In these cells at day 23 post differ-
entiation we saw decreased expression of Bmp2 (fold = -4.00, p<0.001) and Runx2 (fold = 
-6.91, p<0.001), and an increase in the osteoclast stimulating factor Tnfsf11 (RANK Ligand, 
fold = 8.66, p<0.001). As we reported previously, Prrx1-Cre;Rps19fl/+ mice were born with 
dysmorphic forelimbs, and shortened hindlimbs. We now show that these growth defects are 
concurrent with an expanded and disorganized hypertrophic chondrocyte zone in the distal 
femur. We observed an increase in apoptosis in the pre-hypertrophic zone and a decrease in 
the hypertrophic zone. The decreased hypertrophic chondrocyte apoptosis may in part be 
explained by an observed reduction of SOX9 expression. Femur length was reduced at 10 
weeks of age in males (p<0.001). We also saw a reduction in trabecular bone volume fraction 
(BV/TV) in the distal femur and an increase in TRAP+ cells in the metaphysis. Patients with 
DBA present with increased TRP53 activation in erythroid progenitors. As we reported pre-
viously, when TRP53 levels were reduced by crossing Trp53fl/fl with Prrx1-Cre;Rps19fl/+ 
mice to generate animals with loss of 1 or 2 alleles of Trp53, the forelimbs defects resolved 
in a dose-dependent manner.  We now report that RUNX2 expression at the metaphysis 
and the femoral growth plate disorganization were both resolved upon Trp53 deletion. Tra-
becular bone was increased in the Rps19+/-,Trp53-/- 10 week old male mice compared to 
Rps19+/-,Trp53+/+. These data suggest a fundamental role for Rps19 in skeletal biology that 
are associated with alterations in TRP53 levels and that skeletal defects seen in DBA patients 
appear due to RPS19 action in the mesenchymal cells.
Disclosures: Jimmy Hom, None
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Gnas heterozygous inactivation in a mouse model of Albright hereditary 
osteodystrophy differentially affects cortical bone formation based upon 
parental inheritance of mutation *Patrick McMullan1, Peter Maye2, David 
Rowe2, Emily Germain-Lee3. 1Depts of Pediatrics and Center for Regenerative 
Medicine and Skeletal Development, UConn Health, United States, 2Center 
for Regenerative Medicine and Skeletal Development, UConn Health, United 
States, 3Depts of Pediatrics and Center for Regenerative Medicine and Skeletal 
Development, UConn Health and Division of Pediatric Endocrinology, 
Connecticut Children’s, United States
Albright hereditary osteodystrophy (AHO) is caused by heterozygous inactivation 
of GNAS, which encodes the α-stimulatory subunit (Gαs) of GPCRs. AHO skeletal signs 
include adult short stature, brachydactyly and subcutaneous ossifications. AHO patients 
with maternally-derived GNAS mutations develop pseudohypoparathyroidism type 1A and 
are obese with resistance to hormones requiring Gαs (eg., PTH, TSH and GHRH) due to 
tissue-specific paternal imprinting of GNAS. Paternally-derived GNAS mutations cause 
pseudopseudohypoparathyroidism in which patients have AHO skeletal features but do not 
develop severe obesity or hormonal resistanceThis study aimed to identify if bone formation 
is affected within Gnas+/- adult (12 wk) mice, and if the parental inheritance of the Gnas 
mutation differentially affects bone formation. We utilized our AHO mouse model creat-
ed by targeted disruption of exon 1 of Gnas, resulting in global heterozygous inactivation 
of Gnas+/- (bred on a pure 129/SvEv background). Previous reports identified adult PPHP 
(Gnas+/-p) mice had reduced cortical bone quality compared to PHP1A (Gnas+/-m) due to 
elevated endosteal resorption; no evaluation of bone formation was performed in adults.1We 
assessed bone formation in vivo by serum P1NP ELISA and dynamic histomorphometry. 
Statistical analyses include data from male and female mice. Serum P1NP was significantly 
elevated in Gnas+/-m mice compared to both Gnas+/-p and WT mice. Osteoblast activity 
(MAR) was also significantly elevated in Gnas+/-m on trabecular and endosteal surfaces 
compared to Gnas+/-p mice. BMSCs from 6-8 week Gnas+/-m mice treated with osteo-
genic-inducing media for 14 days demonstrated a significant increase in Bglap1 expression 
by RT-PCR compared to Gnas+/-p and WT BMSCs. Bglap1 expression was significantly 
decreased in flushed tibia specimens from Gnas+/-p mice compared to WT. Bglap1 expres-
sion in Gnas+/-m specimens was comparable to WT but trended higher than Gnas+/-pThis 
work identifies distinct phenotypic differences within cortical bone formation between adult 
Gnas+/-p and Gnas+/-m mice caused by increased osteoblast activity in Gnas+/-m mice. 
These data provide an additional explanation for the phenotypic differences in cortical bone 
parameters in adult Gnas+/- mice and suggest imprinting may be involved in bone remod-
eling1.Ramaswamy,G. et al. Gsα Controls Cortical Bone Quality by Regulating Osteoclast 
Differentiation via cAMP/PKA and β-Catenin Pathways.Sci. Rep7,1–11(2017)
Disclosures: Patrick McMullan, None
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Bone Tissue and Osteoblasts from X-linked type XVIII OI with defects in 
Regulated Membrane Proteolysis have Distinct Features *Allahdad Zarei1, 
Nadja Fratzl-Zelman2, An Dang Do3, Megan Glassford4, Mark Hannibal4, Paul 
W Esposito5, Kristin Lindstrom6, Jochen Zwerina2, Marianne Knue3, Sara 
Talvacchio3, Joan C. Marini1. 1Section on Heritable Disorders of Bone and 
Extracellular Matrix, National Institute of Child Health and Human Development, 
National Institutes of Health, United States, 2Ludwig Boltzmann Institute of 
Osteology at the Hanusch Hospital of OEGK and AUVA Trauma Centre, Austria, 
3Office of Clinical Director, Eunice Kennedy Shriver National Institute of Child 
Health and Human Development, National Institutes of Health, United States, 
4Division of Genetics, Department of Pediatrics and Communicable Diseases, 
University of Michigan Medical School, United States, 5Department of Pediatric 
Orthopaedic Surgery University of Nebraska Medical Center, United States, 
6Division of genetics and Metabolism, Phoenix Childern’s Hospital, United 
States
Background: Site-2 protease (S2P), encoded by MBTPS2, is a Golgi transmembrane 
proprotein convertase of membrane-bound transcription factors, well-known for its role in 
cholesterol metabolism. We previously identified an X-linked recessive form of osteogenesis 
imperfecta (type XVIII OI) with defects in S2P metal ion coordination site. These mutations 
cause impaired regulated intramembrane proteolysis (RIP) of SREBP, ATF6 and OASIS, 
with decreased secretion of type I collagen and increased LP/HP collagen crosslink ratio.
Methods: We identified the 3rd and 4th probands with type XVIII OI: a 2yr4m boy with S2P 
p.N459S, as in prior Thai pedigree, and a 1yr5mos boy with a novel p.L455Q (c.1364T>A) 
mutation. Bone and primary osteoblasts (OB) with p.N459S were investigated with qBEI, 
histomorphometry, qPCR and RNAseq.Results: The new S2P mutation is associated with 
short stature, blue sclerae, limb fractures and deformity, undertubulated long bones with LE 
rhizomelia, multiple vertebral compression fractures, and L1-L4 DXA z-score= -7.36. Bone 
turnover markers were elevated: total ALP 1574 (ref range 104-345IU/L), bone specific 
ALP 420 (25-221mcg/L), osteocalcin 68.9 (7.3-38.5ng/ml). OASIS processing in fibroblasts 
with p.L455Q mutation showed decreased 50kD S1P/S2P cleavage product, and increased 
55kDa S1P cleavage band. A cortical bone sample obtained as surgical discard from the S2P 
p.N459S had notable marrow fibrosis and was not hypermineralized on qBEI, as found in 
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classical OI. Histomorphometric analysis of cortical bone revealed increased osteoblast sur-
face per bone surface (Ob.S/BS=14.1%,Tb ref range 8.5+/-4.1), and osteoid surface per bone 
surface (OS/BS=46.8%, Tb ref range: 34.0+/-6.7). In vitro, the hemizygous S2P p.N459S 
mutation hampered osteoblastogenesis.  Early osteoblast markers, OSX, RUNX2, COL1A1, 
COL1A2, SPARC were downregulated in proband vs age-matched normal primary OB, 
whereas, late osteoblast/early osteocyte markers, SPP1, BGLAP, DMP1 and MEPE were 
upregulated in proband OB. In vitro mineralization was severely delayed in proband primary 
OB.  Transcript profiling revealed that p.N459S alters expression of genes that are constit-
uents of ECM and involved in ECM organization.Conclusions: These MBTPS2 missense 
mutations further support a critical role of RIP in normal bone development. Analysis of 
proband bone tissue and OB identifies distinctive features of type XVIII OI, and will reveal 
insights into the tissue-specific mechanism of RIP.
Disclosures: Allahdad Zarei, None
P-810
Response of the ENPP1 -deficient skeletal phenotype to oral phosphate 
supplementation and/or enzyme replacement therapy: Comparative studies 
in Humans and Mice. *Demetrios Braddock1, Carlos Ferreira2, Ralf Oheim3, 
Kristin Zimmerman1, Dillon Kavanagh1, Paul Stabach1, Bjorn Busse3, Thorsten 
Schinke3, Simon van Kroge3, Michael Levine4, Thomas Carpenter5, Mark 
Horowitz6. 1Yale University, Department of Pathology, United States, 2Medical 
Genomics and Metabolic Genetics Branch, National Human Genome Research 
Institute, National Institutes of Health, United States, 3Department of Osteology 
and Biomechanics, University Medical Center Hamburg-Eppendorf, Germany, 
4Department of Pediatrics, University of Pennsylvania Perlman School of 
Medicine, United States, 5Department of Pediatrics at Yale University School of 
Medicine, United States, 6Department of Orthopædics and Rehabilitation, Yale 
University School of Medicine, United States
Human ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP1) deficiency can 
result in early-onset osteoporosis (EOOP) in heterozygous deficiency and Autosomal Re-
cessive Hypophosphatemic Rickets (ARHR2) in homozygous deficiency. ARHR2 patients 
are frequently treated with phosphate supplementation to ameliorate the rachitic phenotype, 
but elevating plasma Pi concentrations in ENPP1 deficiency increases the risk of ectopic 
calcifications and nephrocalcinosis. To determine the efficacy of ENPP1 enzyme replace-
ment to ameliorate these risks, we treated Enpp1asj/asj mice on a high phosphate diet with 
recombinant murine Enpp1-Fc and examined the effects on the skeletal and renal phenotype. 
Similar to Enpp1asj/asj mice on normal chow, 5-week Enpp1asj/asj mice on a diet high in 
phosphate and low in magnesium (acceleration diet) exhibit markedly lower trabecular bone 
mass (Tb. BV/TV 70%, Tb.Sp 125%, and TbN 82% of wild type, WT), reduced cortical 
bone mass (Ct. BV/TV 90%, Ct. Thickness 72% of WT), and higher bone fragility (maxi-
mum load and stiffness was 52% and 45% of WT, respectively, and total work-to-fracture 
was 27% of WT). Treating the Enpp1asj/asj mice with Enpp1-Fc between weeks 2-5 of age 
normalized trabecular bone mass, normalized or improved bone biomechanical properties 
(significant improvement in stiffness and total work-to-fracture, and maximum load normal-
ized compared to WT), and prevented the development of nephrocalcinosis and renal failure. 
Evaluation of a cohort of patients with biallelic ENPP1 deficiency demonstrated low bone 
mineral density in all adults analyzed and in one adolescent, whose bone mineral density 
exhibited progressive decline while on conventional treatment with oral phosphate and cal-
citriol. Medullary nephrocalcinosis occurred in half the patients treated with oral phosphate 
and calcitriol supplementation, which improved the rickets phenotype but did not prevent 
progressive reductions in bone mineral density in a closely-followed adolescent. Overall, 
these data confirm the validity of the Enpp1asj/asj mouse model for the study of skeletal and 
renal complications of human ENPP1 deficiency and suggest that ENPP1 enzyme replace-
ment therapy may address the aberrant skeletal phenotype present in ENPP1 deficiency.
Disclosures: Demetrios Braddock, Inozyme Pharma, Grant/Research Support
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NFAM1 Regulates SAPK/JNK Signaling to Enhance Osteoclast 
Differentiation and Bone Resorption in Paget’s Disease of Bone *Purushoth 
Ethiraj1, Yuvaraj Sambandam2, Sakamuri Reddy3. 1Darby Childens Research 
Institute, United States, 2Northwestern University, United States, 3Darby 
Childrens Research Institute, MUSC, United States
Paget’s disease of bone (PDB) is marked by focal activity of abnormal osteoclasts 
(OCLs) with excess bone resorption. We previously detected measles virus nucleocapsid 
protein (MVNP) transcripts in OCLs from patients with PDB. In addition, MVNP stimu-
lates pagetic OCL formation in vitro and in vivo. MVNP transduced normal human PBMC 
showed an increased NFAT activating protein with ITAM motif 1 (NFAM1) mRNA expres-
sion without RANKL treatment. Further, bone marrow cells from patients with PDB demon-
strated elevated levels of NFAM1 mRNA expression. We have also demonstrated NFAM1 
signaling enhances OCL formation/bone resorption activity in the PDB, however, the mo-
lecular mechanisms underlying the NFAM1 regulation of OCL differentiation and bone re-
sorption are unclear. Here, we showed that the activation of receptor activator of nuclear 
factor-B ligand (RANKL) enhances NFAM1 expression in preosteoclast cells. Conditioned 
media obtained from RANKL stimulated RAW264.7 NFAM1 knock-down (NFAM1-KD) 
stable cells showed a significant inhibition in the levels of IL-6 (2.5-fold), TNF-α (2.2-fold) 
and CXCL-5 (3-fold) compared to control (WT) cells. Further, RANKL stimulation sig-
nificantly increased p-STAT6 expression (5.5-fold) in WT cells, but no significant effect 
was observed in NFAM1-KD cells. However, no changes were detected in STAT3 levels in 
either of cell groups. Interestingly, NFAM1-KD suppressed the RANKL stimulated c-fos, 
p-c-Jun expression and c-Jun N-terminal kinase (JNK) activity in preosteoclast cells. We 
further showed that the suppression of JNK activity is through inhibition of p-SAPK/JNK in 
these cells. In addition, the expression of NFATc1, a key transcription factor associated with 
OCL differentiation is significantly inhibited in NFAM1-KD preosteoclast cells. NFAM1 
inhibition suppressed the OCL formation/bone resorption activity in mouse bone marrow 
cell cultures. We also demonstrated inhibition of TRAP expression in RANKL stimulated 
NFAM1-KD preosteoclast cells. Collectively, our results suggest that MVNP modulation of 
the NFAM1 regulates SAPK/JNK signaling to enhance OCL formation and bone resorption 
in Paget’s disease.
Disclosures: Purushoth Ethiraj, None
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Measuring Outcomes in Ultra-Rare Bone Diseases: Methodology of 
the Palovarotene Fibrodysplasia Ossificans Progressiva (FOP) Clinical 
Development Program *Robert J Pignolo1, Geneviève Baujat2, Matthew 
A Brown3, Carmen De Cunto4, Maja Di Rocco5, Edward C Hsiao6, Richard 
Keen7, Mona Al Mukaddam8, Andrew Strahs9, Donna R Grogan9, Rose Marino9, 
Frederick S Kaplan8. 1Department of Medicine, Mayo Clinic, United States, 
2Département de Génétique, Institut IMAGINE and Hôpital Universitaire Necker-
Enfants Malades, France, 3Guy’s & St Thomas’ NHS Foundation Trust and 
King’s College London NIHR Biomedical Research Centre, United Kingdom, 
4Pediatric Rheumatology Section, Department of Pediatrics, Hospital Italiano 
de Buenos Aires, Argentina, 5Unit of Rare Diseases, Department of Pediatrics, 
Giannina Gaslini Institute, Italy, 6Division of Endocrinology and Metabolism, 
UCSF Metabolic Bone Clinic, Institute of Human Genetics, and UCSF Program 
in Craniofacial Biology, Department of Medicine, University of California-San 
Francisco, United States, 7Centre for Metabolic Bone Disease, Royal National 
Orthopaedic Hospital, United Kingdom, 8Departments of Orthopaedic Surgery 
& Medicine, The Center for Research in FOP and Related Disorders, Perelman 
School of Medicine, University of Pennsylvania, United States, 9Ipsen, United 
States
Background: FOP is an ultra-rare genetic disorder characterized by heterotopic ossifica-
tion (HO) of soft and connective tissues (often preceded by flare-ups), cumulative disability, 
and early mortality. Palovarotene (PVO) is a selective retinoic acid receptor gamma agonist 
under investigation for treatment of FOP. Conducting trials in FOP has multiple challenges, 
including the low number of confirmed cases worldwide, a limited understanding of disease 
progression, and the need to identify disease-specific biomarkers and optimize assessment of 
HO progression.Objective: To develop a methodological approach addressing the challenges 
of conducting clinical trials in underexplored rare bone diseases.Methods: Here, we describe 
the methodology of: a non-interventional, prospective, protocol-specified, longitudinal nat-
ural history study (NHS; NCT02322255); a multicenter, randomized, double-blind, place-
bo-controlled phase II trial (NCT02190747); an ongoing open-label extension (OLE) to the 
phase II trial (NCT02279095) (Table). Studies were designed adaptively. PVO doses were 
administered episodically (high dose for 2 or 4 weeks, followed by low dose for 4 or >=8 
weeks, from flare-up onset) or chronically (daily). In the double-blind period of the phase 
II trial, participants were randomized in two cohorts: 0:3:1 (aged >=15 years) or 3:3:2 (>=6 
years) to PVO 5/2.5 mg, PVO 10/5 mg or placebo, episodically for 2 weeks (high dose) then 
4 weeks (low dose). HO incidence and volume are assessed annually by standardized low 
dose whole-body computed tomography and/or at 12 weeks during the course of flare-ups 
(defined as >=2 [>=1 in OLE Part C] of pain, swelling, stiffness, decreased range of motion, 
redness, or warmth). Other clinical, functional and patient-reported outcomes are assessed 
using FOP-specific measures of physical function, including the Cumulative Analogue Joint 
Involvement Scale (CAJIS) and FOP Physical Function Questionnaire (FOP-PFQ). Studies 
were approved by independent ethics committees. 151 unique participants were enrolled. 
Learnings informed the design of the ongoing phase III MOVE trial (NCT03312634; 107 
enrolled participants).Conclusions: Novel methodological approaches are needed to expe-
dite availability of disease-modifying treatments for serious, ultra-rare diseases. HO is the 
main cause of disability in patients with FOP. This program could be used as an example to 
inform development of new treatments in rare bone diseases.
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Disclosures: Robert J Pignolo, Research investigator: Clementia/Ipsen, Regeneron; 
Advisory board: President of the International Clinical Council on FOP; Chair of the 
Publications Committee for the IFOPA Registry Medical Advisory Board, Other Financial 
or Material Support
P-813
Sclerostin-antibody Effect on Dental Pathologies in Hyp Mice *Kelsey 
Carpenter1, Elizabeth Guirado2, Yinghua Chen2, Anne George2, Ryan Ross1. 
1Rush University, United States, 2University of Illinois at Chicago, United States
X-linked hypophosphatemia (XLH) is the most common form of inherited rickets, 
affecting approximately 1 in 20,000 people. XLH is caused by an inactivating mutation 
in the phosphate regulating neutral endopeptidase on the X-chromosome (PHEX). This 
mutation leads to elevated fibroblast growth factor 23 (FGF23) levels, which subsequent-
ly impair phosphate reabsorption in the kidney and inhibit skeletal mineralization. Dental 
abnormalities are also common in patients with XLH and include tooth fractures, abscess-
es, and periodontal disorder. Our previous study demonstrated that sclerostin anti-body 
(Scl-Ab) improves phosphate metabolism and increases endochondral bone mass in Hyp 
mice (XLH murine model). This study aims to investigate the efficacy of Scl-Ab on the 
dentin-alveolar bone phenotype in Hyp mice.Male hemizygous and female heterozygous 
Hyp mice and wild type littermates (37 male; 45 female) were used for this study. Mice 
were randomly assigned to biweekly subcutaneous injections of 25 mg/kg Scl-Ab or vehicle 
(saline) treatment starting at 12-weeks of age until sacrifice at 20 weeks of age. Left and 
right hemi-mandibles were collected at sacrifice. Left hemi-mandibles were analyzed with 
micro-computed tomography (μCT) for assessing phenotypic changes in alveolar bone, den-
tin, and periodontal ligament (PDL) space.  Right hemi-mandible were decalcified, paraffin 
embedded, stained with Hemotoxylin-Eosin (H&E), and compared for the presence of os-
teoid and osteocytic halos.Consistent with our previous data in the femur, Scl-Ab treatment 
significantly increased bone volume over total volume (BV/TV) in the alveolar bone region 
(p=0.001 males; p=0.002 females). Gross comparison of H&E stained alveolar bone shows 
a decrease in osteoid and osteocytic halos. There was no Scl-Ab treatment effect on dentin 
thickness or the volume of the periodontal ligament space.The current study demonstrates 
that Scl-Ab treatments improve alveolar bone mass and mineralization in 20-week old Hyp 
mice. These findings suggest that Scl-Ab treatment may help to improve some of the alveolar 
bone phenotypes of XLH patients. While no significant dentin or PDL improvements were 
detected with μCT analyses, future studies are needed to investigate further, such as PDL 
fiber-orientation and gene expression analysis.
Disclosures: Kelsey Carpenter, None
P-814
Osteoblasts and osteoclasts communicate through a chemokine self-
amplifying positive feedback loop in sporadic lesions of Paget’s Disease of 
Bone *Britta Petersen1, Cynthia Alander1, Hannah Hardy1, Joseph Lorenzo2, 
Marc F. Hansen1. 1Center for Molecular Oncology, UConn School of Medicine, 
United States, 2Division of Endocrinology and Metabolism, Department of 
Medicine, UConn School of Medicine, United States
            Paget’s Disease of Bone (PDB) is a focal disorder characterized by an exagger-
ated form of bone remodeling affecting 1.5 million people in the United States. Despite the 
frequency of PDB, its pathogenesis remains elusive. Sequestosome 1 (SQSTM1) mutations 
and measles virus nucleocapsid protein (MVNP) are commonly associated with PDB. Our 
lab has previously found that a subset of osteoblasts (OB) within a somatic PDB lesion pos-
sess the SQSTM1 mutation. To elucidate how SQSTM1 mutations impact OB chemokine 
expression, mRNA analysis was performed on PBD OB isolated by laser capture microdis-
section. We found substantial fold increases in the expression of chemokines, CCL5 (3.0 
+/- 0.2) and CXCL6 (6.5 +/- 0.5) (p< 0.05 for both). In vitro experiments comparing a 
pagetic stromal cell line possessing a heterozygous SQSTM1 mutation (PSV10) to a nor-
mal osteogenic cell line (hFOB1.19) treated with 15nM 1α,25-(OH)2D3 and 1mg/mL LPS 
found increased fold mRNA expression for CCL5 and CXCL6  (5.5 +/-0.25 and 5.7 +/-0.3 
respectively, p <0.05 for both) and protein expression (30 fold +/-15 and 3 fold +/-1, respec-
tively, p <0.05 for both) in the PSV10 cells and in the PSV10 culture media. Transfection of 
hFOB1.19 with a SQSTM1 mutation increased mRNA expression of the chemokines (7.5 
+/-2.0 and 6.0 +/-1.0 fold respectively, p <0.001) compared to wildtype hFOB1.19 cells 
following 1α,25-(OH)2D3 treatment. Analysis of gene expression data found in the Ge-
nome Expression Omnibus (GEO) (GEO Data Series GSE29106) of MVNP-transduced, 
RANKL and M-CSF stimulated human bone marrow derived non-adherent cells (BMM) 
found that BMMMVNP expressed greater levels of the CCL5 and CXCL6 receptors, CCR5 
(6.0 fold) and CXCR1 (5.0 fold), compared to similarly treated SQSTM1P392L-transduced 
BMMs (GEO data series GSE29107) (p< 0.001 for both). Immunostaining of pagetic lesion 
samples found robust CXCR1 expression in the pagetic osteoclasts (OC). GEO data anal-
ysis also revealed that BMMMVNPexpressed greater levels of the chemokine, CXCL5 (70 
fold, p< 0.001), compared to BMMP392L. CXCL5 is known to facilitate recruitment of OB 
and OC. Given this information, we propose a model of sporadic PDB wherein a somat-
ic SQSTM1 mutation in an OB upregulates chemokine expression to recruit MVNP-contain-
ing OC precursors. Together, they form a self-amplifying positive feedback loop to facilitate 
recruitment of normal OB and OC to the growing pagetic lesion in a growth-by-recruitment 
model.
Disclosures: Britta Petersen, None
P-815
Development of a 3D bioprinted human-based bone model using patient-
derived cells *Anke de Leeuw1, Jianhua Zhang1, Pei Jin Lim2, Matthias Rüger3, 
Marianne Rohrbach2, Cecilia Giunta2, Ralph Müller1, Marina Rubert1. 1Institute 
for Biomechanics, ETH Zurich, Switzerland, 2Connective Tissue Unit, Division 
of Metabolism and Children’s Research Center, University Children’s Hospital 
Zurich, Switzerland, 3Department of Pediatric Orthopaedics and Traumatology, 
University Children’s Hospital Zurich, Switzerland
The current gold standard for understanding bone biology and pathology involves the 
use of animal models. While extremely valuable, the generation of transgenic animals re-
mains a costly and inefficient process, which is ultimately not representative of human bone 
pathophysiology. We aim to establish personalized and clinically relevant in vitro bone mod-
els to study bone pathophysiology of rare bone disorders such as osteogenesis imperfecta 
(OI) by developing novel 3D bioprinted bone models using patient-derived cells. Human 
bone specimens (n = 2) were obtained from pediatric patients undergoing subtractive os-
teotomies. Cells were isolated based on tissue culture plastic adherence. After expansion, 
cells were combined with alginate-gelatine (0.8-4.1% w/v) hydrogels and bioprinted to 3D 
cell-laden scaffolds (n = 3) to mimic the trabecular bone structure (Zhang, 2019). 3D bi-
oprinted scaffolds were cultured in static bioreactors for 6 or 7 weeks under osteogenic 
conditions. Live/dead assays were performed to determine cell viability after bioprinting. 
Weekly micro-CT scans were taken non-invasively to assess mineral volume. Osteoblast 
and osteocyte cell phenotypes of the 3D bioprinted scaffolds were assessed by histology, 
immunohistochemistry and gene expression analysis after 6 or 7 weeks of culture. Scaffolds 
were compared to human bone tissues to demonstrate resemblance to in vivo bone archi-
tecture and phenotype. Over 90% of patient-derived cells survived the bioprinting process. 
Alizarin Red S staining showed a high degree of mineralization after 6 weeks of culture 
and micro-CT data revealed an average mineral volume of 53.6 +/- 4.3 mm3 in our 3D bi-
oprinted scaffolds. Cells resided in cavities in the mineralized bone-like tissue (Figure 1A), 
resembling the morphology of osteocytes embedded in lacunae (Figure 1B). Osteocalcin 
expression in 3D bioprinted scaffolds was similar to this of bone explants. Furthermore, the 
upregulation of PHEX showed that our 3D bioprinted bone models support cell differenti-
ation towards the osteocyte lineage. These results are a proof of concept for 3D bioprinted 
organotypic bone model using patient-derived cells supporting co-existence and bioactivity 
of both osteoblastic and osteocytic cells. The established 3D bioprinted bone model will be 
an especially powerful tool to elucidate pathomechanisms in OI and other rare human bone 
diseases and facilitate the development and testing of advanced therapies on a patient-spe-
cific level.
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P-816
Mice heterozygous for the Clcn7G213R mutation display osteopetrosis and 
compromised bone biomechanics *Wenping Song1, Benjamin Greene1, Wei 
Fan1, Megan Cox1, Alexander Verbitsky1, Xiaoyou Ying1, Robert Fogle1, Jennifer 
Johnson1, Sue Ryan1, Sheila Cummings1, Dinesh Bangari1, Markella Katidou1, 
Mostafa Kabiri1, Yves Sabbagh1, Stefano Zanotti1. 1Sanofi, United States
Autosomal dominant osteopetrosis type II (ADO2) is a severe rare disease that mani-
fests with generalized bone accumulation and susceptibility to fragility fractures of the ap-
pendicular skeleton. ADO2 is characterized by a high number of osteoclasts and elevated 
tartrate-resistant acid phosphatase (TRAP)5b serum levels, without an increase in collagen 
type I cross-linked C telopeptide (CTXI). The disorder is caused by dominant mutations in 
CLCN7, which encodes a homodimeric Cl-/H+ antiporter required for osteoclastic bone 
resorption. The most common disease-causing CLCN7 mutation leads to a Gly to Arg sub-
stitution at position 215. To investigate the mechanisms by which heterozygosity for the 
CLCN7G215R allele causes bone fragility, we generated the homologous Clcn7G213R mu-
tation in mice by Cas9-directed mutagenesis of 129SvJ single-cell embryos. Initial efforts 
led to precise editing of both Clcn7 alleles, thereby generating Clcn7G213R homozygotes 
that did not survive beyond one month of age due to severe osteopetrosis. Optimization 
of editing conditions allowed creation of Clcn7G213R heterozygotes, which appeared nor-
mal and fertile. Analysis of areal bone mineral density and skeletal microarchitecture by 
dual-energy X-ray absorptiometry and microcomputed tomography, respectively, revealed 
generalized and marked osteopetrosis in heterozygous mutants. Cancellous bone volume 
was more than doubled in femurs and lumbar 6 vertebrae from heterozygous Clcn7G213R 
mice of both sexes due to increased trabecular number, connectivity density, and trabecular 
thickness. Three-point-bending analysis indicated that femurs from Clcn7G213R heterozy-
gotes had a reduced capacity to absorb energy before failure, secondary to increased brit-
tleness and stiffness. Conversely, compression testing demonstrated that lumbar vertebrae 
from mutant females required higher maximum force to failure than bones from wild type 
littermates, although this is consistent with the observation that ADO2 rarely presents with 
vertebral compression fractures. These findings were complemented by elevated TRAP5b 
serum levels without a corresponding increase in CTXI, which indicated presence of a high 
number of osteoclasts with a reduced ability to resorb bone. The phenotype was sustained in 
6-month-old mice but did not worsen with aging. In conclusion, heterozygous Clcn7G213R 
mice recapitulate the clinical features of ADO2 and are an ideal translational model for the 
human condition.
Disclosures: Wenping Song, Snofi, Grant/Research Support
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A noncanonical focal adhesion pathway initiated by LAMA5 regulates 
skeletogenesis and produces a distinct bent bone dysplasia *Ivan Duran1, 
Maya Barad2, Deborah Krakow2, Fabiana Csukasi2. 1University of Malaga/
CIBER-BBN, Spain, 2University of California Los Angeles, United States
In addition to its structural role in skeletogenesis, the extracellular matrix (ECM) fa-
cilitates communication with intracellular signaling pathways and cell to cell interactions 
to control differentiation, proliferation, migration and survival. Alterations in extracellular 
proteins cause a number of skeletal disorders and one attributed mechanism results from the 
deleterious effects of mutated proteins on ECM structure. Yet, the consequences of abnor-
mal ECM on cellular communication remains less well understood. Herein, we describe an 
unclassified distinct form of bent bone dysplasia caused by recessively inherited mutations 
in gene LAMA5. This finding uncovered a mechanism of disease driven by ECM-cell in-
teractions between alpha5-containing Laminins, and Integrin mediated focal adhesion sig-
naling within the skeleton, particularly in cartilage. Loss of LAMA5 altered b1 Integrin 
signaling through the non-canonical and tissue specific pathway regulated by PYK2 and the 
specific-SRC kinase FYN. Loss of LAMA5 negatively impacted WNT signaling, tying focal 
adhesion complexes to key skeletal signaling molecules. This newly described mechanism 
underlies the role of a LAMA5-b1 Integrin-PYK2-FYN focal adhesion complex regulat-
ing skeletogenesis and when dysregulated produces a distinct bent bone skeletal disorder.
Disclosures: Ivan Duran, None
P-818
Consistent Dental Defects Associated with ALPL Mutations in Humans 
and Sheep with Hypophosphatasia *Joshua Bertels1, Michael Chavez2, Alyssa 
Falck1, Shannon Huggins1, Kaitrin Kramer2, Charles Long1, Larry Suva1, Brian 
Foster2, Dana Gaddy1. 1Texas A&M University, United States, 2Ohio State 
University, United States
TheALPL gene encodes tissue non-specific alkaline phosphatase (TNAP), an enzyme 
expressed primarily in bones, teeth, liver, and kidney. Loss-of-function mutations in ALPL 
are the cause of hypophosphatasia (HPP), an inborn error-of-metabolism that produces skel-
etal and dental mineralization defects that can affect all dental hard tissues: enamel, den-
tin, and cementum. However, it is unclear how dental defects correlate to specific genetic 
mutations. Therefore, a large animal model of HPP was created using sheep to define the 
structural nature of HPP dental defects. The HPP sheep model was created based on a female 
child (proband) diagnosed with HPP and compound heterozygous for ALPL mutations (exon 
5: c.346G>A, p.A116T; exon 10: c.1077C>G, p.I359M). The corresponding human exon 10 
mutation of ALPL was introduced into the Rambouillet sheep genome. Dental effects in the 
primary dentition of the proband and HPP sheep were analyzed by radiography, high-res-
olution micro-computed tomography (micro-CT), and histology. We hypothesized that all 
dental mineralized tissues would exhibit effects of HPP and aimed to establish quantita-
tive measurements of dental tissues in HPP. Both sheep and the proband exfoliated primary 
teeth prematurely, increased retained root length and mantle dentin mineralization defects. 
In addition, the proband had lack of functional cementum on some but not all teeth. In the 
proband, enamel density and thickness were not adversely affected by HPP; however, densi-
ty variation was greater vs. control teeth. HPP sheep teeth featured decreased crown dentin 
density, but no difference in root dentin density compared to controls. Histology supported 
the micro-CT analysis, revealing little to no cementum and altered periodontal ligament 
fiber organization in HPP teeth. The characterization of mantle dentin defects provides novel 
insights into the mechanisms of dental pathology in HPP. These data implicate the ALPL 
mutation in exon 10 (c.1077C>G, p.I359M) as the responsible mutation driving the dental 
manifestations observed in the proband. Continued examination of the HPP sheep will in-
form ongoing studies of etiopathologies and therapeutic interventions to improve the mus-
culoskeletal and dental anomalies in HPP.
Disclosures: Joshua Bertels, None
P-819
Introduction to a Multinational, Long-term, Prospective Outcomes Disease 
Monitoring Program (DMP) in Patients With X-linked Hypophosphatemia 
*Thomas Carpenter1, Leanne Ward2, Marise Lazaretti-Castro3, Hamilton 
Cassinelli4, Alison Skrinar5, Christine Wang5, Linda Rees5, Erik Imel6. 1Yale 
University School of Medicine, United States, 2University of Ottawa, Canada, 
3Instituto de Medicina Avancada, Brazil, 4Hospital de Niños Ricardo Gutiérrez, 
Argentina, 5Ultragenyx Pharmaceutical Inc., United States, 6Indiana University 
School of Medicine, United States
In X-linked hypophosphatemia (XLH), excess FGF23 causes hypophosphatemia, lead-
ing to chronic debilitating musculoskeletal impairments. XLH treatment options include a 
combination of oral phosphate and active vitamin D, or burosumab, a fully-human monoclo-
nal antibody to FGF23 approved to treat patients with XLH.The XLH Disease Monitoring 
Program (XLH-DMP) is a prospective, multinational, outcomes study examining the longi-
tudinal progression of clinical, radiographic, and biochemical features of XLH. This 10-year 
study is collecting real-world safety and effectiveness data of both conventional therapy and 
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burosumab and includes patients irrespective of age or treatment modality. Enrollment is 
targeted at >= 500 patients with a confirmed clinical diagnosis of XLH, of whom >= 200 will 
be children < 18 years.As of 29 February 2020, we have enrolled 566 patients (age range: 1 
month to 76 years), including 334 adults and 232 pediatric patients. Of these, 34% (114/334) 
of adult patients and 36% (83/232) of pediatric patients completed the year 1 visit as of the 
analysis cutoff date. Overall, 28% of patients (89 adults, 67 children) had previously partic-
ipated in burosumab clinical trials and were continuing this therapy (Group 1), 37% were 
non-trial patients (102 adults, 109 children) who initiated burosumab by prescription before 
or during the XLH-DMP (Group 2), and 35% of patients (143 adults, 56 children) never re-
ceived burosumab (Group 3). At XLH-DMP enrollment, 53% (176/334) of adults reported a 
history of enthesopathy/bone spurs/osteophytes, and 22% (74/334) of adults reported spinal 
stenosis or cord compression. Bowing of the legs was reported in 79% (184/232) of pediatric 
patients. Burosumab-related adverse events were reported in 13% (25/191) of adult and 10% 
(17/176) of pediatric patients and were consistent with the known safety profile of buro-
sumab. To date, there have been no burosumab-related serious adverse events. XLH-DMP 
enrollment is ongoing.The XLH-DMP is establishing a comprehensive real-world dataset in 
one of the largest populations of this rare disease studied to date. Results from this ongoing 
10-year study will improve understanding of the natural history of XLH. These results, and 
the added potential to link XLH-DMP outcomes with previous clinical trial assessments, will 
provide further insight into the long-term safety and effectiveness of XLH therapy.
Disclosures: Thomas Carpenter, Ultragenyx Pharmaceutical Inc., Consultant, Ultragenyx 
Pharmaceutical Inc., Grant/Research Support
P-820
Hypophosphatemia Gene Panel Sponsored Program:  A High Yield of 
Molecular Diagnoses from Clinically Confirmed XLH and Suspected 
Genetic Hypophosphatemia *Kathryn Dahir1, Eric Rush2, Daniel Beltran3, Scott 
Eisenbeis4, Britt Johnson3, Prameela Ramesan4, Soodabeh Sarafrazi4, Rebecca 
Truty3, Nicole Miller4. 1Vanderbilt University Medical Center (VUMC), United 
States, 2Department of Internal Medicine, University of Kansas Medical Center, 
United States, 3Invitae Corporation, United States, 4Ultragenyx Pharmaceutical 
Inc., United States
X-linked hypophosphatemia (XLH), a dominant disorder caused by a disease-associ-
ated variant in the PHEX gene, affects males and females of all ages. Rickets and osteo-
malacia may be present along with short stature, lower limb deformity, muscle pain and/
or weakness/fatigue, bone pain, joint pain/stiffness, hearing difficulty, enthesopathy, osteo-
arthritis and dental abscesses. Patients with XLH have below-normal serum phosphate and 
elevated serum FGF23. XLH is one of multiple etiologies of hypophosphatemia; depending 
on genetic cause, management may differ. Acquired hypophosphatemia (e.g. tumor induced 
osteomalacia) is non-genetic in nature. The program provides a no-charge test to confirm a 
clinical XLH diagnosis or to aid suspected genetic hypophosphatemia diagnosis. Program 
eligibility: >/= 6 months and either clinical XLH diagnosis or suspicion of genetic hypo-
phosphatemia as evidenced by 2 or more clinical signs/symptoms. The next generation se-
quencing panel includes 13 genes: ALPL, CLCN5, CYP2R1, CYP27B1, DMP1, ENPP1, 
FAH, FAM20C, FGF23, FGFR1, PHEX, SLC34A3 and VDR. Copy number variant (CNV) 
detection was performed. Results704 individuals (671 unrelated probands) have been tested 
as of 3/24/2020. Of 704 samples received, 510 (72.4%) had a PHEX variant: 47 (9.2%) were 
variants of uncertain significance (VUS) and 463 (90.8%) were either pathogenic or likely 
pathogenic (P/LP). Of the 194 cases (27.6%) where no PHEX variant was found, 29 (15%) 
had molecular diagnoses associated with other genes/disorders: 3 had a variant (P/LP) in 
FGF23 (autosomal dominant [AD] hypophosphatemic rickets), 2 had two variants (P/LP) 
in CYP27B1 (autosomal recessive [AR] vitamin D dependent rickets), 1 had P/LP variants 
in ENPP1 (AR hypophosphatemic rickets Type 2). There were 20 cases with single P or LP 
variants in ALPL (AD hypophosphatasia, HPP); 3 cases carried two variants (P/LP) in ALPL 
(AR form). Of 203 unique P/LP PHEX variants detected: 53 were deletions, duplications or 
insertions; 35 were CNVs; 42 were splicing; 73 were single nucleotide variants. Additional 
family member testing/clinical information resulted in 38 cases having VUS reclassified to 
P/LP, highlighting the value of family testing/clinical information to resolve VUS. RNA 
analyses to resolve VUS/unidentified variants may further improve molecular diagnostic 
yield. Program results demonstrate a high diagnostic yield for XLH/ genetic hypophospha-
temia and new insight into XLH-associated PHEX variants.
Disclosures: Kathryn Dahir, Ultragenyx Pharmaceutical Inc, Consultant, Regeneron, 
Grant/Research Support, Mereo, Grant/Research Support, SoftBones Hypophosphatasia 
Research Grant, Grant/Research Support, Alexion, Grant/Research Support, Alexion, 
Consultant, Ultragenyx Pharmaceutical Inc, Grant/Research Support
P-821
Impaired Mitochondrial Respiration and Altered Fiber Type in 
Hypophosphatasia Sheep Skeletal Muscle *Joshua Bertels1, Alyssa Falck1, 
Shannon Huggins1, Sarah White1, Charles Long1, Larry Suva1, Dana Gaddy1. 
1Texas A&M University, United States
Hypophosphatasia (HPP) is a rare inherited disorder of mineral metabolism, the re-
sult of inactivation of the tissue-nonspecific alkaline phosphatase (TNSALP) gene (ALPL) 
characterized by decreased mineralization and profound muscle weakness in humans. Since 
murine genetic models have not demonstrated the muscle phenotype of HPP, a large ani-
mal model of HPP using Rambouillet sheep was generated. Based upon a novel compound 
heterozygous female child diagnosed with HPP, (exon 5: c.346G>A, p.A116T; exon 10: 
c.1077C>G, p.I359M) the Isoleucine -> Methionine (c.1077 C>G) mutation of ALPL was 
introduced into the sheep genome. Characterization of founder (F0) HPP sheep skeletal mus-
cle demonstrated aberrant mitochondrial cristae and variable muscle fiber size. To better 
characterize the muscle defects observed in HPP sheep, gluteus medius (GM) fiber type was 
determined in 6-mo-old F1 sheep expressing the wild-type (WT; n = 3), heterozygous (Het; 
n = 1), and homozygous (Hom; n = 2) genotypes for the ALPL mutation by immunofluo-
rescence. The percentage of myosin heavy chain (MyHC) Type 1 and 2a fibers was greater 
in Hom compared to WT sheep (P<0.05) at the expense of MyHC Type 2x fibers. At 1 yr of 
age, GM samples from the same sheep were analyzed for mitochondrial characteristics. Mi-
tochondrial volume density (citrate synthase activity; CS) was numerically decreased in Het 
and Hom compared to WT, but low power prevented statistical significance. Mitochondrial 
function (cytochrome c oxidase activity) was similar between all groups but Hom had ap-
proximately 50% lower integrative (relative to tissue wet weight) oxidative phosphorylation 
(OXPHOS) capacity with complex I+II (PCI+II) compared to WT (P=0.04). After normal-
izing to CS activity, intrinsic PCI+II was similar between groups, indicating the decrement 
in capacity was likely due to lower CS activity. However, the flux control ratio of PCI+II, an 
indicator of the coupling efficiency of mitochondrial electron transfer with ATP production 
was lower in Het and Hom compared to WT (P0.02). Overall, HPP sheep exhibited lower 
skeletal muscle OXPHOS capacity, likely due to decreased mitochondrial volume density, 
despite an increase in oxidative fiber type populations. Further, HPP sheep had lower mito-
chondrial coupling efficiency, which may lead to excess production of damaging interme-
diates (e.g. reaction oxygen species) during respiration. Collectively, these data provide a 
mechanistic basis for muscle weakness in HPP.
Disclosures: Joshua Bertels, None
P-822
RNA-based bone histology and histomorphometry *Elena Makareeva1, Laura 
Gorrell1, Shakib Omari1, Edward Mertz1, Sergey Leikin1. 1NICHD, NIH, United 
States
Traditional histological staining identifies many cell types in bone sections, but subjec-
tive morphological evaluation of these cells limits the information content and ambiguity 
of such analysis. To develop a more objective approach to bone histopathology and charac-
terize cell differentiation, functional state, and crucial molecular pathways, we replaced the 
traditional staining with fluorescent labeling of RNA transcripts. We adapted commercial 
tape-transfer cryo-sectioning (Section Lab) and fluorescent RNA labeling (RNAScope™) 
technologies for simultaneous imaging of multiple transcripts in the same cryosection of a 
fully mineralized mouse bone. We developed automated analysis procedures for counting 
different bone cells and evaluating relative expression of key RNA transcripts within these 
cells. For instance, we identify active osteoclasts and osteoblasts as bone surface cells with 
high Ctsk and Col1a1 expression, respectively. We characterize osteoblast differentiation 
by visualizing expression of Bglap, Dmp1, Sost, and other transcripts relative to Col1a1. 
To test this approach, we utilized a G610C mouse model of osteogenesis imperfecta (OI). 
RNA-based histological analysis combined with RNA-based histomorphometry demonstrat-
ed altered differentiation of G610C osteoblasts and resolved multiple inconsistencies be-
tween histopathological, micro-CT, and biomechanical measurements in this animal model. 
We found that reduced mineral apposition rate in G610C mice is likely caused by deficient 
osteoblast maturation. The animals appear to compensate for this deficiency and normal-
ize their bone formation rate by recruiting additional osteoblasts without an accompany-
ing increase in the number of active osteoclasts, explaining an otherwise puzzling increase 
in trabecular thickness. We are currently developing approaches to identifying molecular 
mechanisms of bone cell pathology by combining single cell transcriptomic analysis with 
visualization of key RNA transcripts in histological sections.
Disclosures: Elena Makareeva, None
P-823
In Vivo Binding of Fluorescence-Labeled Asfotase Alfa to Sites of 
Physiological Mineralization and Ectopic Calcification *Flavia Amadeu de 
Oliveira1, Sonoko Narisawa1, Massimo Bottini1, José Luis Millán1. 1Sanford 
Burnham Prebys Medical Discovery Institute, United States
A mineral-targeted form of recombinant tissue-nonspecific alkaline phosphatase 
(TNAP), asfotase alfa, was approved multinationally as an enzyme replacement therapy for 
hypophosphatasia in 2015. Two reports to date have shown evidence of binding of this drug 
to mineralizing tissues using histochemistry1 and immunohistochemistry2. Here, we sought 
to expand on those earlier studies by directly visualizing the in vivo binding of asfotase alfa 
conjugated with AnaTag HiLyte Fluor 750 or Alexa Fluor 647 fluorescent dye to sites of 
skeletal/dental mineralization and ectopic calcification. We utilized 40-day-old Tagln-Cre; 
HprtALPL/Y mice3, a model of severe medial vascular calcification; Tie2-Cre; Hpr-
tALPL/Y mice4, a model of severe intimal calcification; and sibling WT HprtALPL/Y mice, 
devoid of soft-tissue calcification. A single dose of 8 mg/kg labeled asfotase alfa was inject-
ed via the retro-orbital route. Skeletal tissues and soft organs were imaged ex vivo 2 days 
after the injection. Strong fluorescence signal was observed in all skeletal tissues (calvaria, 
vertebra, long bones, jaw, and mandibles) from mutant and WT mice. Fluorescence analysis 
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of histological sections from bones revealed strong binding of asfotase alfa. Asfotase alfa 
binding to sites of ectopic calcification in the heart, aorta, and renal artery were found in both 
the Tagln-Cre; HprtALPL/Y and Tie2-Cre; HprtALPL/Y mice but not in WT mice. In ad-
dition, asfotase alfa binding was also found in the kidney stroma and brain of the Tie2-Cre; 
HprtALPL/Y mice. Our results show that fluorescence-labeled asfotase alfa administered in 
vivo binds not only to sites of skeletal and dental mineralization but also to sites of ectopic 
calcification in these animal models5. 1 Millán JL et al. 20082 Yadav MC et al. 20123 Sheen 
CR et al. 20154 Savinov AY et al. 20155 Amadeu de Oliveira F et al. 2020
Disclosures: Flavia Amadeu de Oliveira, None
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Partial Depletion of Ccr2+ Myeloid Cells Reduces Endochondral Heterotopic 
Ossification without Inhibiting Muscle Repair in Fibrodyplasia Ossificans 
Progressiva Mice *Cody M Elkins1, Nikash Hari2, Joshua R Johnson2, Daniel 
S Perrien1. 1Emory University, United States, 2Vanderbilt University Medical 
Center, United States
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder caused by point 
mutations in Type 1 BMP receptor ACVR1/ALK2 and is characterized by episodes of endo-
chondral heterotopic ossification (EHO) in skeletal muscle known as “flares”. Unfortunately, 
there is no approved therapy for FOP. Inflammation is strongly implicated in FOP flares, and 
depletion of phagocytic macrophages (MΦs) was previously shown to reduce, but not elim-
inate, EHO in FOP mice. However, the role of non-phagocytic MΦs has not been described. 
Thus, we sought to determine the effects of extensive depletion of the entire MΦ lineage on 
EHO and muscle repair in FOP mice. Ccr2DTR mice, in which administration of diphtheria 
toxin (DT) selectively depletes Ccr2+ cells, were crossed with tamoxifen-inducible FOP 
mice to create Ccr2DTR/wt;ALK2FlEx-R206H/wt;R26creERt2/creERt2 (Ccr2DTRFOP) 
mice. In separate studies, DT was injected at 50ng/g of bodyweight then tapered to 10ng/g 
every 3 days or given at 10ng/g throughout. FACs analysis revealed the higher dose protocol 
depleted 90% of F4/80+CD11b+ MΦs (full depletion), while the lower dose depleted 20% 
(partial depletion), in Ccr2DTR mice. Ccr2DTRFOP and Ccr2wtFOP mice received DT 
from 3-5 days before muscle injury until sacrifice. Data were analyzed by Mann-Whitney U 
test. Partial MΦ depletion significantly reduced EHO in Ccr2DTRFOP mice vs Ccr2wtFOP 
mice as measured in radiographs (p<0.01), μCT (p<0.02), and histology (p<0.01) at d21 
post-injury. Areas of necrotic or regenerating myofibers and cartilage weren’t significantly 
affected by partial MΦ depletion. Full MΦ depletion also decreased EHO in Ccr2DTR FOP 
vs Ccr2wtFOP mice by all three measurements (p<0.001 for all) and cartilage area (p<0.02). 
However, full depletion also reduced body weight (p<0.01), decreased regenerating myo-
fiber area (p<0.0001), and increased necrotic myofiber area (p<0.03) vs Ccr2wtFOP mice. 
Importantly, significant areas of intramembranous dystrophic heterotopic bone (p=0.0002 vs 
Ccr2wt FOP) were found in injured muscles of fully depleted mice. Hence, while 90% de-
pletion of Ccr2+ cells reduced EHO by 94%, it also inhibited muscle repair and induced dys-
trophic heterotopic bone formation. However, inclusion of non-phagocytic MΦs allowed a 
relatively mild 20% MΦ depletion to achieve 75% EHO reduction without inhibiting muscle 
repair, suggesting that targeting non-phagocytic MΦs may be a viable therapeutic strategy.
Disclosures: Cody M Elkins, None
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Bone compartments respond differently to short- and long-term sclerostin 
antibody treatment in Brtl/+ osteogenesis imperfecta mouse during growth 
*Christopher Stephan1, Anne Ryan1, Camden Felgner1, Katie Ferguson1, Ernesto 
Quiroz1, Michelle Caird1, Kurt Hankenson1, Kenneth Kozloff1. 1University of 
Michigan Department of Orthopaedic Surgery, United States
Romosozumab, a sclerostin antibody (SclAb), is an FDA-approved anabolic for treat-
ment of osteoporosis in postmenopausal women at high risk of fracture. Potential additional 
applications include osteogenesis imperfecta (OI), which due to high fracture rates through 
adolescence, require long-term treatment options. Continuous use of Romosozumab in adults 
is limited due to waning anabolic effects over time, yet the effects of treatment duration and 
age on anabolic efficacy have not been fully explored in OI. The purpose of this study was to 
determine if extended SclAb exposure shows attenuated bone-forming effects during bone 
growth. Male wildtype (WT) and Brtl/+ OI mice received anti-sclerostin therapy (SclAb VI 
Amgen and UCB; 25mg/kg) or vehicle 2x/wk over a short 2wk duration at three different 
ages (3-5, 7-9 or 13-15wks) and were compared to endpoint-matched long-term treatment 
groups (3-9 or 3-15wks). Sample sizes ranged from 2-10/group. 2wks of SclAb had similar 
increases in trabecular BV/TV (Fig 1) across all ages driven by both thickness (TbTh) and 
number (TbN). Gains in TbN vs. age-matched controls were strongest when 2wk SclAb 
started at young, not older ages, while extending treatment duration further increased gains. 
In contrast, TbTh gains were strongest when 2wk treatment started at mid- and late, but not 
young ages, or with extended treatment. In Brtl/+ diaphyses, 2wk SclAb at any age reduced 
marrow area, but increased treatment duration actually increased marrow area expansion. 
CFU-F from marrow harvested at sacrifice demonstrate a reduction in progenitors after 6 
wks SclAb compared to age-matched mice treated for 2 wks. Conversely, total cortical area 
increased in a treatment duration-dependent manner with 2wk delayed treatments having no 
effect, while 6 and 12 wk treatments resulted in profound periosteal expansion. In summary, 
extended SclAb exposure induces different effects at different sites compared to short term 
treatments. Early and extended treatments preserve TbN, while TbTh is enhanced with in-
creased drug exposure. Contrasting duration effects in the endosteal and periosteal diaphysis 
suggest the endosteum is more sensitive to treatment attenuation, possibly due to progenitor 
cell depletion, but that the periosteum remains responsive. These findings emphasize the 
need to understand mechanisms responsible for SclAb attenuation in pediatric applications 
such as OI which require long-term sustained treatment for therapeutic benefit. 
Disclosures: Christopher Stephan, None
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Semaphorin-3F, a potential biomarker for Lymphatic Anomalies and Bone 
Cell Function *Ernesto Solorzano1, Fayez Safadi1, Michael Kelly1. 1NEOMED, 
United States
Lymphatic anomalies (LA) are rare conditions characterized by abnormal vascular-
ization of lymphatic vessels (lymphangiogenesis). Gorham-Stout Disease (GSD) is an ag-
gressive type of LA which invades cortical bone and makes it “disappear”. There is little 
evidence elucidating the etiology of GSD and its osteolytic tendencies due to the rarity of 
the disease. In addition, there are no biomarkers capable of predicting GSD progression 
or treatment outcome. Normal bone does not have lymphatic vessels. It is believed that in 
GSD lymphatic endothelial cells (LEC) undergo genetic changes early in development that 
facilitate their migration and vessel formation in bone. LECs and their secretome are likely 
both crucial to lymphatic migration into bone and the cortical destruction seen in GSD. In 
this study, we focused on the LEC secretome with the goal of identifying proteins capable of 
modifying LEC and bone cell interactions. We initially assessed the effects of normal LEC 
conditioned media (LEC-CM) on bone cell differentiation and function in vitro and found 
that LEC-CM stimulates osteoclast differentiation. Next, we subjected LEC-CM to mass 
spectrometry and over 500 proteins were identified. One of these proteins, Semaphorin-3F 
(SEMA3F), effectively inhibits lymphangiogenesis in part, by competing with vascular en-
dothelial growth factor-C (VEGF-C), for binding to the neuropilin-2 (Nrp2) receptor. We 
measured mRNA expression of both SEMA3F and VEGF-C in untreated and Rapamycin 
treated LECs, a clinically effective therapy for patients with lymphatic anomalies (LA). 
SEMA3F mRNA expression was upregulated while VEGF-C was downregulated in Rapa-
mycin treated versus untreated LEC cultures. We next assessed the effects of exogenous 
SEMA3F on LEC viability and on osteoblast differentiation and function. We found that 
SEMA3F reduced LEC viability in a dose-dependent fashion. In addition, SEMA3F inhibit-
ed osteoblast differentiation and function independent of its effects on osteoblast viability or 
proliferation. Experiments are currently underway to determine the expression/localization 
of SEMA3F, VEGF-C and Nrp2 in LA tissues obtained from pediatric patients. We expect 
that SEMA3F expression will be downregulated while VEGF-C will be upregulated in LA 
compared to normal lymphatics. In summary, our data suggest that SEMA3F might be a 
possible biomarker for patient with LA conditions or contributes to their pathogenesis.
Disclosures: Ernesto Solorzano, None
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Mutation of PFN1 Gene Causes an Early Onset, Polyostotic Paget’s-like 
Disease Less Responsive to Amino-bisphosphonate Treatment *Daniela 
Merlotti 1, Maria Materozzi 1, Simone Bianciardi 1, Vito Guarnieri2, Domenico 
Rendina3, Luca Volterrani1, Cristiana Bellan4, Christian Mingiano1, Tommaso 
Picchioni1, Alessandro Frosali1, Ugo Orfanelli 5, Simone Cenci5, Luigi Gennari1. 
1Department of Medicine, Surgery and Neurosciences, University of Siena, 
Italy, Italy, 2Medical Genetics Service, IRCCS “Casa Sollievo della Sofferenza” 
Hospital, San Giovanni Rotondo (FG), Italy, Italy, 3Department of Clinical 
and Surgical Medicine, Federico II University Medical School, Naples, Italy, 
Italy, 4Department of Medical Biotechnologies, University of Siena, Italy, Italy, 
5Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, 
Italy;, Italy
Purpose. Paget’s disease of bone (PDB) is a focal, metabolic bone disease whose ge-
netic cause remains unknown in up to 50% of familial cases. Our aim was to investigate the 
underlying genetic defect in a four generations pedigree with a severe, early onset, auto-
somal dominant form of PDB for which mutations in all known genes involved in PDB or 
PDB-like diseases had been excluded.Methods. Whole exome sequencing was performed in 
5 affected and 5 unaffected family members, across 3 generations. Then mutation screening 
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was extended to a sample of 41 PDB cases with early-onset, polyostotic PDB without mu-
tations in SQSTM1 or other known PDB-related genes, selected from a large cohort of 893 
unrelated PDB patients.Results. We identified a frameshift D107Rfs*3 mutation in PFN1 
(encoding for profilin1, a highly conserved regulator of actin-polymerization and cell mo-
tility) causing the truncation of the C-terminal part of the protein. The mutation was also 
detected in a 17-yrs old asymptomatic family member, that upon biochemical and radiolog-
ical analyses was indeed found to be affected. Sequencing of the entire PFN1 coding region 
in unrelated PDB cases identified the same mutation in one patient. All mutation carriers 
had a reduced response to bisphosphonates such as intravenous pamidronate or neridronate, 
and required multiple zoledronate infusions (up to 5) to control bone pain and achieve bio-
chemical remission over a long term. Moreover, the skeletal distribution of lesions was less 
focal than generally described in PDB (involving the skull, vertebral bodies and the lower 
limbs in most cases) and the radionuclide bone scans showed a patched-like pattern of  tracer 
uptake at affected bones rather than the uniform uptake typically described in PDB. These 
features, together with the very early onset of the lesions (possibly arising in adolescence) 
suggest that the disease affecting this pedigree is distinct from classical PDB. In vitro osteo-
clastogenesis in PBMCs from mutation carriers showed a higher number of osteoclasts with 
PDB-like features. A similar phenotype was observed upon PFN1 silencing in murine bone 
marrow-derived monocytes, suggesting  that the frameshift PFN1 mutation confers a loss of 
function in profilin 1 activity that induces PDB-like features in the osteoclasts, likely due 
to enhanced cell motility and actin ring formation.Conclusions. Our findings indicate that 
PFN1 mutation causes a severe, early onset, polyostotic PDB-like disorder.
Disclosures: Daniela Merlotti, None
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Urine Phosphoethanolamine (PEA) Is An Underutilized Biomarker For 
Hypophosphastasia (HPP) *Nadia Ayala-Lopez1, Zahra Shajani-Yi2, Margo 
Black1, Kathryn Dahir2. 1Vanderbilt University Medical Center, United States, 
2Vanderbilt University School of Medicine, United States
  HPP is a rare disease caused by a loss-of-function mutation in the ALPL gene leading 
to a deficiency in the tissue-non-specific isoenzyme alkaline phosphatase (ALP) and excess 
of extracellular inorganic pyrophosphate (PPi) and pyridoxal 5’phosphate (PLP). HPP has a 
widely variable clinical phenotype, from neonatal seizures and hypomineralization to isolat-
ed dental or musculoskeletal disease in adults leading to significant diagnostic challenges, 
particularly in those with minor disease manifestations. Patients present with ALP activity 
levels below their age-adjusted reference interval and elevations in PLP.  Biomarkers for 
diagnosing HPP and monitoring patients on enzyme replacement therapy (ERT) are limited. 
Low ALP activity is not specific for HPP; it can be low in other conditions including un-
treated hypothyroidism, and other skeletal dysplasias. Accurate PLP assessment is limited 
in patients on ERT due to hydrolysis of the substrate. PEA is a substrate hydrolyzed by ALP 
and elevated levels of PEA may be observed in HPP, supporting the diagnosis of HPP, but 
have been reported to be non-specific. We hypothesized that urine PEA levels could be used 
to diagnose HPP and as a surrogate marker for ERT compliance. We performed a retro-
spective analysis on 85 adult patients (64F: 21M) presenting for investigation or follow-up 
of HPP from 7/1/2014 to 1/7/2020. Urine was sent to the Children’s Hospital in Colora-
do for PEA testing. Patients were diagnosed with HPP if they had of all of the following: 
ALP levels persistently below the age-adjusted reference interval, an ALPL gene mutation/ 
family history of HPP and had musculoskeletal/dental symptoms pathology. Patients were 
negative for HPP if ALP was not persistently low, vitamin B6 levels were normal without 
supplementation, and when tested negative for ALPL variants, and either had absence of 
musculoskeletal/dental symptoms or explained by an alternative disease state. PEA levels 
were not considered for diagnosis. The following was collected from the EMR: PEA re-
sults, diagnosis, and ERT status. PEA levels were higher in patients with HPP not on ERT 
(median=126.0, N=51) vs. those negative for HPP (median=20.5, N=16, p<0.0001). The 
receiver operator curve for PEA in diagnosing HPP had an AUC of 0.95 (SE=0.026, p53.5 
ng/ml (sensitivity=82.35%) with an NPV of 66.6% and PPV of 100%. Initial PEA values in 
patients with HPP and not on ERT were higher (median 126.0, N=51) than patients on ERT 
(median 65.0, N=16, p=0.004). Patients who began ERT had a decline in PEA levels after 
treatment (mean decrease 68.1%). PEA is a specific diagnostic marker for HPP in patients 
undergoing investigation for HPP and may be used as a surrogate marker to monitor ERT 
compliance. Future studies are necessary to evaluate the association between PEA levels and 
functional performance.   
Disclosures: Nadia Ayala-Lopez, None
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Differences in static and dynamic cortical bone histomorphometry between 
patients with typical osteoporotic and BP-induced atypical femoral fractures 
*Shijing Qiu2, George Divine2, Elizabeth Warner2, Mahalakshi Honasoge2, Ruban 
Dhaliwal3, Sudhaker Rao2. 2Henry Ford Health System, United States, 2Henry 
Ford Health System, Uruguay, 3SUNY Upstate Medical University, United States
Bisphosphonates (BPs) are commonly used for the prevention and treatment of typical 
osteoporotic fractures (TOF). However, long-term BP treatment is prone to cause atypi-
cal femoral fracture (AFF) in cortical-rich femoral diaphysis. Compromised cortical bone 
quality would increase the risk of both TOF and AFF.  To date, there is little information on 
the differences in cortical bone structure and turnover between patients with TOF and AFF.
Trans-iliac bone biopsies were obtained after double tetracycline labeling from 79 post-
menopausal women with TOF (aged 66.3 +/- 6.18) and 73 postmenopausal women with 
>=2y of alendronate treatment; 57 without AFF (non-AFF, aged 68.2 +/- 7.4y) and 16 with 
AFF (aged 67.6 +/- 7.7y). The mean duration of BP treatment was 7.3 +/- 4.7y in non-AFF 
and 11.1 +/- 5.0y in AFF patients. Bone histomorphometry was performed in intracortical 
and endocortical envelopes and results are combined. The variables included bone volume 
(BV/TV), cortical thickness (Ct.Th, µm) wall thickness (W.Th, µm), erosion surface (ES/
BS, %), osteoclast surface (Oc.S/BS, %), osteoid surface (OS/BS, %), osteoid thickness 
(O.Th, µm), osteoblast surface (Ob.S/BS, %), mineralizing surface (MS/BS, %), mineral 
apposition rate (MAR, μm/day), and bone formation rate (BFR/BS, μm3/μm2/year).There 
was no significant difference in BV/TV among the 3 groups. Ct.Th was significantly thicker 
in non-AFF and AFF patients compared to TOF patients, but it had no significant difference 
between the BP treated groups (Table 1).  Notably, W.Th decreased progressively from TOF 
to non-AFF to AFF patients (Table 1). Other bone remodeling-related variables, including 
OS/BS, ES/BS, MS/BS, MAR and BFR/BS were significantly higher in TOF group than in 
non-AFF and AFF groups, but did not show significant differences between the BP treated 
groups (Table 1).Our results indicate that BP treatment substantially increases Ct.Th by in-
hibiting bone resorption and remodeling, which increases bone mass (and presumably bone 
strength), and reduces the risk of TOF. The decreases in ES/BS and W.Th in BP-treated 
patients indicates that both the extent and depth of bone resorption are reduced after long-
term BP treatment.  Moreover, W.Th is significantly thinner in AFF vs non-AFF patients, 
suggesting that decreased resorption depth is an independent risk factor for AFF. We propose 
that decreased resorption depth would increase the volume of aged interstitial bone that is 
vulnerable to fatigue failure.
Disclosures: Shijing Qiu, None
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Effect of Parathyroid Hormone (1-34) on Gross ONJ-like Lesions in Rice 
Rats Treated with Oncology Doses of Zoledronic Acid *Evelyn Castillo1, 
Jessica Jiron1, Gabriella Gonzalez-Perez1, Samantha Thomas1, Summer Croft1, 
Indraneel Bhattacharyya1, Donald Kimmel1, J. Ignacio Aguirre1. 1University of 
Florida, United States
Osteonecrosis of the jaw (ONJ) is a severe adverse event occurring in osteoporosis 
and cancer patients taking powerful anti-resorptives, including nitrogen-containing bisphos-
phonates, such as zoledronic acid (ZOL). Multiple clinical case series describe successful 
treatment of ONJ with surgical and non-surgical approaches. Parathyroid hormone (PTH 
[1-34]) has been used off-label clinically to treat ONJ in uncontrolled trials and pre-clinically 
in a few small experiments. We hypothesize that administration of PTH in an osteoporo-
sis-like regimen reduces the size and severity of gross ONJ-like lesions. At age 4wks, 64 
rice rats (32 M/32 F) were fed a standard (STD) diet and given oncologic doses of ZOL 
(80µg/kg IV q4wks), to induce maxillary gross ONJ-like lesions. From age 10wks until the 
end of the experiment, biweekly oral exams of the maxillary molar (M) M2M3 interdental 
space and surrounding region were used to assign an in vivo gross quadrant grade (GQG, 
0-4) that reflected lesion severity. Previous studies in rice rats showed that GQG>=2 lesions 
are usually histologically-positive for ONJ. Therefore, forty rats (22M, 18F) having one 
maxilla with GQG>=2 entered study after 30+/-10 (All data=Mean+/-SD) weeks of ZOL. 
Rats were randomized by GQG and body weight into two groups (N=20 each) of match-
ing gender ratio. As ZOL continued, one group received saline subcutaneously (SC) 3X/wk 
(ZOL+VEH) and the other received 40μg/kg of PTH (Bachem) SC 3X/wk (ZOL+PTH). Af-
ter 6 wks, rats were euthanized, high resolution (HR) photographs were taken, and jaws were 
fixed for histopathologic analyses. Using the HR photograph, a treatment-blinded operator 
measured gross lesion area (GL.Ar) and total maxilla area (TMx.Ar) with the Axiovision 
software. GL.Ar/TMx.Ar (expressed as a percentage) in the ZOL+PTH group (8.1+/-4.6%) 
was significantly smaller compared to the ZOL+VEH group (14.4+/-5.4%) (P=0.003, t-test 
of means). T-test of pairs showed that during treatment, GQG in the ZOL+PTH group fell 
from 2.55+/-0.51 at enrollment to 2.35+/-0.49 (P<0.04), while GQG in the ZOL+VEH group 
rose from 2.35+/-0.49 at enrollment to 2.65+/-0.49 (P<0.01), resulting in a net improvement 
in GQG of 0.50+/-0.47 with PTH (P<0.002). We conclude that six weeks of PTH improved 
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established gross ONJ-like lesions, as reflected by reduced severity and smaller lesion size. 
Histopathologic analyses are currently ongoing to evaluate the amount of necrotic bone in 
present in oral lesions and wound healing end-points.
Disclosures: Evelyn Castillo, None
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Studies of OI Patient and Murine Osteoblasts to Investigate Phenotypic 
Variability of Dominant Osteogenesis Imperfecta *Milena Jovanovic1, 
Apratim Mitra2, Ryan K Dale 3, Joan C Marini1. 1Section on Heritable Disorders 
of Bone and Extracellular Matrix, National Institute of Child Health and Human 
Development, National Institutes of Health, United States, 2Bioinformatics and 
Scientific Programming Core, National Institute of Child Health and Human 
Development, National Institutes of Health, United States, 3Bioinformatics and 
Scientific Programming Core, National Institute of Child Health and Human 
Development, National Institutes of Health, Bethesda, United States
Introduction: Osteogenesis Imperfecta (OI) is a heterogeneous group of bone disorders 
characterized by bone fractures, growth deficiency and skeletal defects. An important and 
unexplained feature of OI and many dominant disorders is phenotypic variability with the 
same mutation. We present the first comparative study of osteoblast differentiation from 
normal pediatric controls vs OI patients with phenotypic variability. In addition, phenotypic 
variability in OI mouse models focused on comparison of COL1A1 G349C mice with new 
G349S.Methods: Differentiated osteoblasts (OB) cultured from healthy pediatric donor sur-
gical discard and OI patients were subjected to transcriptome profiling by RNA-Seq. Min-
eralization of OB was evaluated by Alizarin Red. Collagen chain modification, folding and 
fibrils were studied by 3H steady-state assay, 14C intracellular folding assay, and electron 
microscopy. Murine X-rays and BMD were examined by Faxitron. Whole mount skeletal 
staining was done on P1 pups.Results: We focused on COL1A1 mutations Gly352Ser and 
Gly589Ser, each in two unrelated patients differing in phenotypic severity. Patient OB cell 
layer and secreted collagen was overmodified, indicating delayed folding; quantitative com-
parison of Hyl is ongoing. Patient OB deposit significantly less mineral in vitro than con-
trols, while severe patient OB deposit significantly less mineral than mild patients. RNA-Seq 
transcriptomics showed proteasomal protein degradation, autophagy, and vesicle organiza-
tion pathways upregulation vs controls, while protein translation was downregulated. OB 
from both severe patients have upregulation of pathways related to ubiquination vs controls. 
In parallel, we study the effect of the collagen glycine substituting residue on murine skeletal 
phenotype, comparing our Brtl(Cys) mouse (COL1A1 Gly349Cys) and a new model with 
Gly349Ser. Both mice are small but Brtl(Ser) has a more severe phenotype with rib fractures, 
limb bowing, flared ribcage, kyphosis and skeletal undermineralization by BMD. Brtl(Ser) 
calvarial osteoblasts have slower collagen folding, lower secreted collagen and lower min-
eral deposition than wt. Brtl(Ser) dermal collagen fibrils are smaller in diameter than wt or 
Brtl(Cys).Conclusion: This combined human/mouse approach will lead to novel insights 
into OI osteoblast differentiation, the roles of OB and matrix in phenotypic variability and 
the effect of substituting residue and position along the collagen helix.
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The Safety of Withdrawal from Denosumab Therapy in Fibrous Dysplasia 
and McCune Albright Syndrome *Maartje Meier1, Stance Clerkx 1, Liesbeth 
Winter1, Sander Dijkstra2, Michiel Van de Sande1, Natasha Appelman-Dijkstra1. 
1Leiden University Medical Center, Netherlands, 2Leiden University Medical 
Center, Netherlands
Introduction: In fibrous dysplasia/McCune Albright Syndrome (FD/MAS) Denosumab 
(Dmab) suppresses the RANKL-mediated increased bone resorption. In a FD mouse model 
RANKL-inhibition reduced lesional growth, but after withdrawal the lesions reoccurred. 
In humans Dmab has been used in case of bisphosphonate resistant FD/MAS but data on 
withdrawal in humans are scarce, with only one pediatric case with a massive rebound phe-
nomenon including hypercalcemia, increased markers of bone turnover (BTMs) and lesional 
growth. Therefore we aimed to study the safety of Dmab withdrawal in adults with FD/
MAS treated in our hospital.Methods: All FD/MAS patients using and taken off Dmab were 
included. Health records were screened for fractures, lesional growth, pain flares and serum 
levels of calcium, alkaline phosphatase (ALP), procollagen type 1 N-terminal propeptide 
(P1NP) and β-crosslaps (CTX). Values during treatment (baseline, BL) were compared with 
values at 3, 6 and 12 months after the last injection. Data were calculated as median (IQR).
Results: 14 patients were included, 2 had only 1 injection and 12 had multiple injections for a 
median of 1.6 (+/-IQR 1.2) years. Reasons for stopping were: no effect on pain (n=9, 64.3%), 
side effects (n=4, 28.6%), child wish (n=1, 7.1%) or other (n=3, 14.3%). Median follow up 
after treatment was 3.4 (+/-2.2) years, wherein no fractures, lesional growth or pain flares 
occurred. Calcium remained normal in all but 1 patient who had a mild asymptomatic hyper-
calcemia of 2.73 mmol/L 5 months after therapy withdrawal. In 9/10 patients (90%) at least 
one BTM exceeded pretreatment values. ALP exceeded the upper limit of normal (ULN) in 
20% of the patients (n=2), rose in 50% (n=5) beyond pretreatment values, from 64 (+/-29) 
to 124 (+/-89) U/L at 6 months, but returned to BL levels at 12 months. P1NP passed the 
ULN in 6 patients (60%), increased in 4 patients (40%) above pretreatment values, from 24 
(+/-22) to 80 (+/-157) ng/ml at 3 months and stabilized thereafter. CTX followed an identical 
curve. CTX transcended the ULN in in 30% (n=3) and rose in 80% of the patients (n=8) 
above pretreatment values.Conclusion: These results show that in adults, pretreated with 
bisphosphonates, withdrawal from Dmab causes a biochemical, asymptomatic rebound phe-
nomenon mainly after treatment with multiple injections. Yet, a longer treatment does not 
seem to induce a stronger rebound. Further studies on the safety of Dmab and of withdrawal 
are needed and currently ongoing.
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Human and Murine Dentin Anomalies in Loeys Dietz Syndrome *Priyam 
Jani1, Cyrus Keyvanfar1, Quynh Nguyen1, Olivier Duverger1, Natasha Curry1, 
Marian Young2, Janice Lee1. 1Craniofacial Anomalies and Regeneration Section, 
National Institute of Craniofacial and Dental Research, National Institutes of 
Health, United States, 2Molecular Biology of Bones and Teeth Section, National 
Institute of Craniofacial and Dental Research, National Institutes of Health, 
United States
Objectives: Loeys–Dietz syndrome (LDS), a multisystemic autosomal dominant rare 
connective tissue disorder, is caused by mutations in the TGF-β signaling pathway genes. 
Major manifestations include vascular tortuosity, aneurysms and craniofacial anomalies. We 
previously reported and characterized significant enamel defects in a cohort of 40 patients 
diagnosed with LDS. However, it is not clear if dentin and the surrounding bone, connec-
tive tissue derivatives, are also affected in LDS. We, therefore, compared teeth and alveolar 
bone obtained from a patient and mouse model of LDS-2.Methods: Shed deciduous teeth 
were obtained from a patient with LDS Type-2 (LDS-2) having a heterozygous mutation 
in the TGFBR2 gene (TGFBR2 p.M457K). Mandibles and teeth were harvested from Tgf-
br2G357W/+ mice recapitulating LDS-2. Human and Murine teeth were characterized using 
X-ray radiography, micro-CT, histology, scanning electron microscopy, and second harmon-
ic generation. Micro-indentation was performed to assess the hardness of the dentin tissue. 
Shed deciduous teeth from a healthy donor were used as control for human teeth and age and 
gender matched littermates were used as controls for murine teeth.Results: X-ray radiogra-
phy showed increased alveolar bone loss in mandibles of Tgfbr2G357W/+ mice. Micro-CT 
analysis revealed a decrease in the volume of dentin in Tgfbr2G357W/+ mice compared 
to controls and confirmed a significant decrease in the alveolar bone volume surrounding 
the teeth in Tgfbr2G357W/+ mice. Human teeth from a patient with LDS-2 also showed 
decreased dentin volume. Confocal imaging of FITC stained dentinal tubules showed sparse 
and irregular dentinal tubules in Tgfbr2G357W/+mice. SEM imaging showed disorganiza-
tion of collagen fibers surrounding the tubules and excess mineral deposition in both human 
and murine teeth. Dentin was harder in Tgfbr2G357W/+ mice and LDS-2 human teeth com-
pared to control teeth.Conclusion: Dentin structure is altered in both human and murine teeth 
with LDS-2. Changes in dentinal tubules and disorganization of collagen were striking in 
SEM and confocal imaging. Increased hardness of dentin may suggest excess mineral depo-
sition and further biomechanical changes which will need further investigation. These data 
indicate, for the first-time, that dentin and alveolar bone are affected by the abnormal TGF-b 
signaling in Loeys-Dietz syndrome.
Disclosures: Priyam Jani, None
P-834
A patient-derived in vitro disease model for Muenke Syndrome reveals 
defects in neural crest development. *Fahad Kidwai1, Pamela Robey1, Janice 
Lee1. 1NIH, United States
Craniofacial malformation, including macrocephaly, craniosynostosis, midfacial hypo-
plasia, high arch palate, and temporal bossing is associated with rare craniofacial diseases. 
One of the most common inherited forms of craniofacial malformation is Muenke syndrome 
(MS), which is caused by a p.Pro250Arg (c.749C>G) gain-of-function mutation in fibro-
blast growth factor receptor 3 (FGFR3). Bone deformities in MS patients, in contrast to pa-
tients with other FGFR mutations, are mostly limited to the facial neural crest (NC)-derived 
bones with mild axial and appendicular skeletal abnormalities. NC gives rise to craniofacial 
bone, whereas mesoderm gives rise to the rest of the skeletal. Bone deformities limited 
to the craniofacial region in MS leads to the question: By what mechanism does FGFR3 
p.Pro250Arg disrupts neural crest-derived craniofacial bone or suture development while 
sparing axial and appendicular skeletal growth? For this, we aimed to track the effect of 
FGFR3 p.Pro250Arg gain-of-function mutation on neural crest differentiation by establish-
ing human induced pluripotent stem cells (hiPSCs) derived from MS patients as an in vitro 
disease model. First, we have successfully created hiPSCs lines from two unrelated MS pa-
tients (MUT-MS-hiPSCs) as verified by using standard characterization methods including 
colony morphology, p.Pro250Arg mutation confirmation, nuclear staining for expression of 
OCT4 and NANOG, karyotype analysis, Short Tandem Repeat (STR) analysis, and terato-
ma formation assay. Interestingly, we found higher endogenous FGF1 in MUT-MS-hiPSCs 
compared with the control cell line (WT-hiPSCs). These data suggest that FGFR3 can ini-
tiate its own positive feedback loop, suggesting that FGF1-FGFR3 p.Pro250Arg signaling 
may cause earlier and higher expression of both ligand and receptor. Second, to study the ef-
fect of the mutation causing MS in neural crest differentiation, we integrated a SOX10-GFP 
reporter into both MS-hiPSCs and WT-hiPSCs to track the neural crest cells. Interestingly, 
the MUT-MS-hiPSCs-SOX10 population displayed higher SOX10 levels as compared with 
WT suggesting FGFR3 p.Pro250Arg mutation plays a role in neural crest differentiation. 
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Ongoing studies aim to further characterize the molecular mechanism causing MS and may 
also reveal a novel mechanism through which FGFR-linked pathologies arise.
Disclosures: Fahad Kidwai, None
P-835
Angiogenesis Inhibitors (AgIs) and Chemotherapy Drugs Associated with 
Osteonecrosis of the Jaw Exhibit In Vivo Anti-resorptive Activity *Evelyn 
Castillo1, Summer Croft1, Gabriella Gonzalez-Perez1, L. Shannon Holliday1, 
Lorraine Perciliano de Faria0, J. Ignacio Aguirre1, Donald Kimmel1. 1University 
of Florida, United States, 0University of Florida, United States
Introduction: Osteonecrosis of the jaw (ONJ) is an adverse event linked to powerful 
anti-resorptives (pARs) (e.g., zoledronic acid [ZOL] and anti-RANKL antibodies) in oste-
oporosis and cancer patients. Angiogenesis inhibitors (AgIs) (e.g., anti-vascular endothelial 
growth factor A ([VEGFA] antibodies, anti-VEGFA) and tyrosine kinase inhibitors (TKIs) 
(e.g., sunitinib [SU], dasatinib [DA]) are also associated with ONJ in cancer patients in the 
absence of pARs. Though pARs’ mechanism is very specific for blocking osteoclast activity 
in vivo and AgIs are best known for their ability to inhibit angiogenesis, AgIs have more 
off-target activities than pARs. For instance, certain AgIs inhibit osteoclast differentiation 
and/or activity in vitro. Similar effects have been described for chemotherapy drugs (CHE-
MOs) (e.g., cisplatin [CP], paclitaxel [PTX]) that are co-administered with AgIs to cancer 
patients. We hypothesized that AgIs and CHEMOs inhibit bone resorption in vivo.Research 
Design and Methods: We tested the bone resorption effects of the above AgIs and CHEMOs 
in rapidly growing rats (Schenk Assay). 100 male SD rats aged 6 wks were randomized into 
12 groups (N=8-12). Vehicle (VEH) rats received either saline intravenously (IV), IgG IV, 
or DMSO/PEG by oral gavage (OG) daily. ZOL rats received 80 µg/kg IV ZOL on Day 1. 
Anti-VEGFA rats received 3 or 10 mg/kg IV B20-4.1.1 (Genentech) on Days 1, 4, and 7. 
SU rats received 6 or 20 mg/kg daily by OG. DA rats received 3 or 10 mg/kg daily by OG. 
CP rats received 1.2 or 4mg/kg IV on Days 1 and 8. PTX rats received 1.5 or 5 mg/kg IV on 
Days 1 and 8. Rats were euthanized and serum TRAcP5b was assessed. Femurs were fixed 
for histomorphometric analysis of calcified cartilage volume (Ca.V/TV) and other endpoints 
in the distal femoral metaphysis. Group differences were tested by ANOVA+Tukey’s T-test 
post-hoc test (P<0.05).Results: Serum TRAcP5b was lower than VEH with ZOL, anti-VEG-
FA10, DA10, and SU20. Ca.V/TV was higher than VEH in rats given ZOL, anti-VEGFA3, 
SU6, SU20, DA10, CP1.2, CP4, and PTX1.5. Trabeculae were thicker than VEH in rats 
given ZOL, anti-VEGFA10, and SU20. Osteoclast number was lower than VEH in rats given 
ZOL, anti-VEGFA10, SU20, DA3, and PTX5. The effect of AgIs and CHEMOs was always 
much less than ZOL.Conclusion: Our data indicate that AgIs and CHEMOs have moderate 
in vivo anti-resorptive activity that may play a role in their association with ONJ in the 
absence of pARs.
Disclosures: Evelyn Castillo, None
P-836
Real-World Practices and Perceptions on X-Linked Hypophosphatemia 
Care Among Interdisciplinary Teams in Four Large US Healthcare Systems 
*Namrata Dass1, Rasha Alam2, Cherilyn Heggen2, Jeffrey Carter2, Tamar Sapir2. 
1Premier Endocrinology, United States, 2PRIME Education, LLC, United States
Early identification and treatment of patients with x-linked hypophosphatemia (XLH) is 
critical to prevent or delay life-long disability, yet system-, team-, and individual-level bar-
riers may challenge optimal care. In a quality improvement initiative, we assessed referral, 
diagnosis, and care coordination perceptions and practices among 55 interdisciplinary team 
members providing care to patients with XLH through surveys conducted between 2/2020 
and 4/2020 across 4 US academic systems. To address identified barriers, teams participated 
in audit-feedback sessions to develop action plans. Survey participants comprised 4 met-
abolic bone specialists, 25 endocrinologists, 10 nephrologists, 4 pediatricians, 1 primary 
care physician, 2 nurse practitioners, 4 nurses, and 5 other healthcare providers. Over half 
of respondents (57%) estimated that the average length of time between symptom onset and 
referral to their center exceeded 2 years for adults; 25% estimated over 2 years for pediatric 
patients. Top barriers were identified as referring providers’ lack of knowledge about XLH 
(71% of respondents), belief that symptoms are related to other health problems (45%), and 
uncertainty about where to refer patients (42%). Survey findings also revealed gaps related 
to genetic risk and testing. Although 75% of respondents believed that XLH family mem-
bers should be tested for hypophosphatemia, only 60% reported often/always discussing 
family history and genetics of XLH with patients and only 25% believed that XLH patients 
understand genetic risks for family members. Only 47% agreed/strongly agreed that patients 
understand their XLH and available treatment options. On 5-point Likert scales, providers 
reported being fairly/extremely satisfied on the following XLH care processes: timely refer-
rals of patients with XLH to their center (53%), timely receipt of testing results to confirm 
diagnosis (42%), counseling patients on the role of family history (55%), appropriate appli-
cation of pharmacologic therapy (53%), and team-based coordination of care (44%). During 
audit-feedback sessions, teams identified and formulated action plans for implementation 
of improved referral processes, care coordination, genetic testing, shared decision making 
practices, and patient and provider education. These findings can inform additional initia-
tives to improve timely and appropriate referral, diagnosis, treatment, and care coordination 
to optimize outcomes for patients with XLH.
Disclosures: Namrata Dass, None
P-837
Development of a New Therapeutic Modality for Bisphosphonate-Related 
Osteonecrosis of the Jaw *Hiroko Okawa1, Akishige Hokugo1, Takeru Kondo1, 
Jesus J. Campagna2, Varghese John2, Shuting Sun3, Frank H. Ebetino3, Charles 
E. McKenna4, Ichiro Nishimura1. 1UCLA School of Dentistry, United States, 
2Department of Neurology, David Geffen School of Medicine at UCLA, United 
States, 3BioVinc, United States, 4Department of Chemistry, University of 
Southern California, United States
Antiresorptive therapy has been reported to be associated with a rare but serious oral 
morbidity characterized by jawbone necrosis, often with pain and infection. Bisphospho-
nate-related osteonecrosis of the jaw (BRONJ) represents the largest population of such 
oral complications, particularly in cancer patients. We previously found that bisphosphonate 
(BP) adsorption to bone mineral can be reversed by a subsequent application of other BPs. 
The objective of this research was to develop a trans-oral epithelial formulation of a low 
potency BP, and to test its efficacy for the prevention and treatment of BRONJ in a mouse 
model.A fluorescent-BP or MHDP was encapsulated in microfluidics-derived nanoparticles 
to develop deformable nano-scale vesicles (fBP-DNV and MHDP-DNV). Trans-oral epithe-
lial drug delivery was demonstrated using an in vitro human oral epithelial model (EpiGin-
gival, MatTek Corp) and in mouse maxilla in vivo using fBP-DNV. BRONJ-like symptoms 
were experimentally induced in C57Bl6/J mice (female, 8-wo) with a bolus IV injection 
of zoledronate followed by maxillary first molar extraction. In this model, MHDP-DNV 
was topically applied on the palatal gingiva, prior to or 1 week after the left maxillary first 
molar extraction. Two weeks after extraction, mouse maxillary tissues were harvested for 
standardized photography, microCT and decalcified histology.fBP-DNV (170+/-10 nm di-
ameter and +34 +/-4 mV zeta potential) demonstrated greater trans-oral epithelial delivery 
of BP than without DNV, in vitro, and as detected by the fluorescent signal on the underlin-
ing alveolar bone after a topical application in vivo. Mice receiving a ZOL administration 
followed by tooth extraction, consistently exhibited ONJ-like lesions. Pre-treatment with 
MHDP-DNV eliminated alveolar bone exposure and reduced gingival swelling. MicroCT 
images demonstrated significantly better socket healing in the MHDP-DNV topical appli-
cation group. Separately, after ONJ-like lesions were established at week 1 (ONJ-like le-
sion prevalence: 100%), MHDP-DNV was topically applied. All MHDP-DNV treated mice 
exhibited a closed oral wound. By contrast, 83% of untreated control mice exhibited ONJ 
symptoms with an open oral wound at week 2, which was also still observed in 33% of mice 
at week 4.This study suggests an efficient treatment of BRONJ by topical application of an 
MHDP-DNV trans-oral epithelial drug formulation, creating the possibility of a translat-
able therapy in clinical dentistry.Supported by NIH/NIDCR R01DE022552, R44DE025524, 
NIH/NCRR C06RR014529
Disclosures: Hiroko Okawa, None
P-838
Establishing a Critical-Sized Segmental Defect in a Mouse Model of 
Osteogenesis Imperfecta *Kyle Kavaseri1, David Bertrand1, Frank Rauch1, 
Reggie Hamdy1, Bettina M. Willie1. 1McGill University, Shriners Hospital for 
Children Research Centre, Canada
Purpose: Osteogenesis Imperfecta (OI) is a rare bone fragility disorder, typically caused 
by mutations in COL1A1 or COL1A2. Bisphosphonates are given during growth to prevent 
fractures. Although fractures appear to heal normally, osteotomies often result in non-union 
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or delayed healing.1 Osteotomies are performed to correct limb deformities. No studies have 
investigated osteotomy or defect healing in mouse models of OI. The aim of our study was 
to establish a critical size femoral segmental defect stabilized under controlled mechanical 
conditions in the osteogenesis imperfecta murine (oim) model. Methods: Female oim -/-, 
oim -/+, oim +/+ mice (n=7-8 mice/genotype) were injected with 0.05 mg/kg zoledronic acid 
from weeks 5-9 of age. At 10 weeks of age, a double osteotomy was performed to create 
a 2mm segmental defect in the left femoral midshaft using a gigli saw. The osteotomy was 
stabilized with a unilateral external fixator. The defect was filled with a bovine collagen 
scaffold, saturated with saline. Healing at the osteotomy defect was assessed using in vivo 
µCT on days 0, 7, 14, 21 and 28 (8-µm voxel size) and histology on day 28. The effects of 
scan day, genotype and interactions were assessed by ANOVA and post hoc t-tests (α=0.05).
Results: Stabilization of the osteotomy was not possible in oim -/- mice due to fracture at 
the pin sites, but was successful in the oim -/+ and oim +/+ mice. Osteotomy defects in both 
oim -/+ and oim +/+ did not achieve bony bridging over 28 days (Fig1A). All µCT-based 
microstructural parameters of the callus (BV, BV/TV, vTMD, TMC) were not significantly 
affected by either scan day or genotype (Fig1B). TV was the exception, but demonstrated 
no significant difference between oim -/+ and oim +/+ on day 28. Histological analysis con-
firmed these findings.Conclusions: We show that 2mm is a critical sized femoral segmental 
defect in the oim -/+ and wild-type mice treated with bisphosphonates. Even with bisphos-
phonate treatment, the bones of oim -/- mice are too fragile to support an external fixator. 
The established osteotomy defect model stabilized under controlled mechanical conditions 
will allow for investigation of novel cell-based therapies and/or biomaterial scaffolds to 
treat non-unions in oim -/+ mice.References: 1- Anam et al. JBMR. 30:1362-1368. 2015. 
2- Munns et al. JBMR. 19:1779-1786. 2004.
Disclosures: Kyle Kavaseri, None
P-839
Longitudinal and Flare-Up-Specific Biomarkers in Fibrodysplasia 
Ossificans Progressiva (FOP): Data from a Global Natural History Study 
*Robert J Pignolo1, Mona Al Mukaddam2, Geneviève Baujat3, Carmen De 
Cunto4, Edward C Hsiao5, Richard Keen6, Kathleen Harnett7, Rose Marino7, 
Frederick S Kaplan2. 1Department of Medicine, Mayo Clinic, United States, 
2Departments of Orthopaedic Surgery & Medicine, The Center for Research 
in FOP and Related Disorders, Perelman School of Medicine, University of 
Pennsylvania, United States, 3Département de Génétique, Institut IMAGINE and 
Hôpital Universitaire Necker-Enfants Malades, France, 4Pediatric Rheumatology 
Section, Department of Pediatrics, Hospital Italiano de Buenos Aires, Argentina, 
5Division of Endocrinology and Metabolism, UCSF Metabolic Bone Clinic, 
Institute of Human Genetics, and UCSF Program in Craniofacial Biology, 
Department of Medicine, University of California-San Francisco, United States, 
6Centre for Metabolic Bone Disease, Royal National Orthopaedic Hospital, 
United Kingdom, 7Ipsen, United States
Background: FOP is an ultra-rare, severely debilitating genetic disorder characterized 
by episodic heterotopic ossification (HO) and flare-ups. Identification of biomarkers would 
be useful to predict flare-ups and monitor FOP disease progression, and to identify when in-
terventions are warranted and assess responses to these interventions. Objective: To evaluate 
putative serum and urine biomarkers at Baseline (BL), annually, and during the course of 
flare-ups in a longitudinal FOP natural history study (NHS).Methods: Individuals with FOP 
aged <=65 years with a documented ACVR1R206H mutation were eligible to participate in 
a prospective, 36-month NHS (NCT02322255) investigating the longitudinal progression 
of FOP. This analysis evaluated biomarker data at BL and Month 12, and during flare-ups. 
Blood and urine samples were collected at BL and annual study visits, and at Days 1, 42, 
and 84 of imaged flare-ups to measure biomarkers of inflammation, angiogenesis, and bone/
cartilage turnover. Low-dose whole-body computed tomography (WBCT, excluding the 
head) was performed to assess HO at Months 12, 24, and 36; flare-up HO volumes were 
assessed by CT at the flare-up sites. Magnetic resonance imaging (MRI) or ultrasound was 
used to assess flare-ups for the presence of edema. Data were analyzed using descriptive 
statistics.Results: BL and Month 12 assessments were completed for 99/114 participants; 93 
had evaluable WBCT HO at both timepoints, of whom 37 (39.8%) had new HO at Month 
12. Overall, biomarker values did not change substantially from BL to Month 12, and mean 
values were similar between participants with versus those without new HO at Month 12 
(Table). A total of 52 flare-ups were CT-imaged, of which 14 (26.9%) resulted in new HO at 
Day 84. Out of 42 flare-ups assessed at Day 1 by MRI or ultrasound, 29 (69.0%) had edema; 
of these, 10 (34.5%) had new HO at Day 84 (versus 19 [65.5%] with no new HO). No serum 
biomarker was identified that was predictive of flare-ups with BL edema or that resulted in 
development of new HO.Conclusions: The identification of biomarkers to predict disease 
progression could greatly benefit the clinical management of FOP. As results from this NHS 
did not identify a signal for a longitudinal or flare-up-specific biomarker for FOP, potentially 
due to the limited panel of biomarkers tested, a narrow sampling window, and/or missing 
data for some participants, further research is required.
Disclosures: Robert J Pignolo, Research investigator: Clementia/Ipsen, Regeneron; 
Advisory board: President of the International Clinical Council on FOP; Chair of the 
Publications Committee for the IFOPA Registry Medical Advisory Board, Other Financial 
or Material Support
P-840
Impact on osteoblasts/osteocytes in vitro of a novel genetic variant of the 
OFD1 gene linked to X-linked osteoporosis, dental/facial hypoplasia and 
spontaneous adult-onset multiple long bone insufficiency fractures similar 
to atypical femur fractures *Laetitia Michou1, Marie-Eve Boisvert1, Emile 
Couture1, Rachel Laframboise2, Frederic Fournier1, Suzanne N Morin3, Edith 
Gagnon1, Claudia Gagnon1, Fabrice Mac-Way1, Mahmoud Rouabhia4, Louis-
Georges Ste-Marie 5, Arnaud Droit1, Jacques P Brown1. 1CHU de Québec-
Université Laval Research Centre, Canada, 2CHU de Québec-Université Laval, 
Canada, 3McGill University, Canada, 4Faculté de médecine dentaire, Université 
Laval, Canada, 5Centre de recherche du CHUM, Universite de Montreal, Canada
Purpose – We identified a novel variant, p.Ala642Asp, of the OFD1 gene in a 
French-Canadian family in which eleven relatives have X-linked osteoporosis and/or dental 
and facial hypoplasia and/or adult-onset multiple long bone insufficiency fractures. In bone 
biopsies from this variant carriers a profound tissular and cellular osteoblastic depression 
was observed. Mutations of the OFD1 gene are linked to the oral-facial-digital syndrome, 
belonging to genetic disorders of the primary cilia. We reported another OFD1 variant in a 
woman with bisphosphonate (BP)-associated atypical femur fracture (AFF). We aimed to 
investigate the functional effects of the p.Ala642Asp variant, in silico predicted to be patho-
genic, on osteoblasts/osteocytes cell lines in vitro.Methods – We reproduced the murine 
equivalent of this variant using PCR-directed mutagenesis in a lentiviral vector containing 
the murine ofd1 gene. These vectors, containing the p.Ala642Asp variant or a wild-type 
vector were transfected into murine cell lines: MC3T3-E1 (pre-osteoblast) and MLO-Y4 
(osteocyte-like). Osteoblasts were differentiated over three weeks, before assessing the im-
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pact on osteoblasts proliferation and bone formation abilities using alizarin red. The pro-
liferation of osteocytes and length of primary cilia were quantified in both rare variant and 
wild-type vectors. To explore the effect of BP on these in vitro experiments, we treated the 
two cell lines with 10-12 M of alendronate, equivalent of a short-term therapeutic exposure 
in humans. One-way Anova and Tuckey’s post hoc tests were performed.Results – In pres-
ence of the p.Ala642Asp variant, there was a significant (p<0.01) decrease of osteoblastic 
proliferation as compared to the wild-type osteoblasts (Fig 1). As expected, the proliferation 
of wild-type osteoblasts was higher under BP (142 cells versus 217 with BP). Although the 
mineralization significantly increased in wild-type osteoblasts treated by BP (p<0.01), no 
increase was observed in osteoblast carriers of the variant. The osteocytes proliferation was 
not modified by the variant (Fig 1). However, the length of primary cilia was significantly 
(P<0.0001) decreased in presence of this variant (4 versus 1.5 μm).Conclusions - Our results 
are consistent with a pathogenic effect of this OFD1 rare variant on osteoblast proliferation 
and osteocyte cilia length in vitro, and may be linked to the pathogenesis of long bone insuf-
ficiency fractures in oral-facial-digital syndrome.
Disclosures: Laetitia Michou, None
P-841
The Diagnostic Journey in Fibrodysplasia Ossificans Progressiva: Insights 
from the FOP Registry *L. Adam Sherman1, Kin Cheung1, Carmen De 
Cunto2, Sammi Kile1, Robert Pignolo3, Frederick Kaplan4. 1International FOP 
Association, United States, 2Department of Pediatrics, Hospital Italiano de 
Buenos Aires, Argentina, 3Department of Medicine, Mayo Clinic School of 
Medicine, Mayo Clinic, United States, 4Perelman School of Medicine, The 
University of Pennsylvania, c/o Department of Orthopaedic Surgery, Penn 
Musculoskeletal Center, United States
Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare, disabling genetic disease 
that causes bone to form in muscle, tendons, ligaments, and other connective tissues.  One 
of the hallmark characteristics of FOP is the malformation of the great toes, which is pres-
ent in nearly all individuals with FOP. The great toe malformation, along with heterotopic 
ossification, are early signposts for a definitive clinical diagnosis. However, given its rarity, 
a diagnosis of FOP is often missed at birth and delayed for years.The International FOP 
Association (IFOPA), a global patient association, developed the FOP Registry to advance 
our understanding of FOP. Data from the FOP Registry shows that the mean age of symptom 
onset is 6.2 years (range, 0 – 45), whereas the mean age at correct diagnosis is 8.3 years 
(range, 0 – 48). Diagnosis takes longer for patients who have the non-classical versus the 
classical FOP mutation (18.6 vs. 7.0 years). The diagnostic journey has shortened over the 
last five years, taking on average 1.5 years to receive a correct diagnosis after first symp-
tom, compared to 2.2 years.Prior to receiving a correct diagnosis, patients see on average 
3.3 physician specialties (range, 1 – 10); this average has remained remarkably stable over 
time. Misdiagnosis occurred in 52.5% of Registry participants, with the most common mis-
diagnoses noted: cancer (29%), juvenile fibromatosis (13%), myositis ossificans (10%), and 
Klippel-Feil Syndrome (4%).Orthopedists (25.5%), geneticists (25.1%), and pediatricians 
(13.7%) are the most common physician specialties providing a definitive diagnosis for FOP. 
When first symptom onset occurs after the age of 12, rheumatologists (19.0%) play a larger 
role in making the correct diagnosis. Several physician specialties have high rates of misdi-
agnosis as a ratio of correct diagnoses given. General physicians are 8.9 times more likely 
to make an incorrect diagnosis for every correct diagnosis given, followed by pediatricians 
(5.5), orthopedists (2.5), rheumatologists (1.9) and geneticists (0.9).Patient registries can 
help medical communities better understand the diagnostic journey taken to make the cor-
rect diagnosis, which is critical to ensuring that patients receive the proper clinical care and 
support services. With a misdiagnosis rate over 50%, greater disease awareness is essential 
to increase clinicians’ index of suspicion for FOP.
Disclosures: L. Adam Sherman, None
P-842
Uncontrolled Serum Calcium and Phosphate Levels and Risk of 
Cardiovascular Disease in Patients With Chronic Hypoparathyroidism *Lars 
Rejnmark1, Kristina Chen2, Olulade Ayodele3, Clara Monleón Bonet4, Nicole 
Sherry5, Emma Billmyer6, Erin Cook6, Elyse Swallow6, Elvira Gosmanova7. 
1Aarhus University and Aarhus University Hospital, Denmark, 2Former, Shire 
Human Genetic Therapies, Inc., Global Evidence and Outcomes, Data Sciences 
Institute, Research and Development; Current, Arena Pharmaceuticals, United 
States, 3Shire Human Genetic Therapies, Inc., Global Evidence and Outcomes, 
Data Sciences Institute, United States, 4Shire International GmbH, Switzerland, 
5Shire Human Genetic Therapies, Inc., United States, 6Analysis Group, Inc., 
United States, 7Albany Medical College, United States
Objective: This study evaluated the association of albumin-corrected serum calcium 
(Ca), serum phosphate (P), and calcium-phosphate product (Ca × P) with risk of developing 
cardiovascular (CV) events in patients (pts) with chronic hypoparathyroidism (HypoPT).
Methods: A nested case-control study using the Explorys electronic medical record database 
(Jan 2007–Aug 2019) was conducted among US adults with chronic HypoPT (>=2 diagnosis 
codes for HypoPT occurring >=6 mo apart) on conventional therapy. Index date was the day 
after first calcitriol prescription. Baseline (BL) period was the 6 mo before the index date 
and exposure window was the time between the index date and development of a CV event. 
Pts with a CV event (defined as >=1 diagnosis code for cerebrovascular disease, coronary 
artery disease, heart failure, or peripheral vascular disease) before the index date, and those 
receiving parathyroid hormone, were excluded. Controls without a CV event were matched 
1:1 to cases with a CV event based on age+/-5y, index date+/-1y, exposure duration, and sex. 
Associations between levels of Ca, P, and Ca × P and odds of developing CV events were as-
sessed in adjusted logistic regression analyses.Results: Analyses included 264 matched pairs 
with Ca, and 100 matched pairs with P or Ca × P. Overall, cases and controls had similar BL 
characteristics, except cases had more comorbidities than controls. Mean age was 59y for 
the Ca pairs (76% women); mean follow-up 3.0y. Mean age was 57y for cases and 56y for 
controls for the P and Ca × P pairs (73% women); mean follow-up 2.6y. In the adjusted anal-
yses, compared with pts with <33% of Ca measurements outside the target range, pts with 
>=67% of measurements outside the target range had 1.94 times higher odds of developing 
a CV event (P<0.05) (Table), but there was no statistically significant association between 
having 33%–<67% of Ca measurements outside the target range and developing a CV event. 
Having any P measurements above the target range, or Ca × P outside the target range was 
associated with higher odds of developing a CV event than pts without any measurements 
above or outside the target range (OR 3.86, P<0.01; OR 4.21, P<0.05; Table).Conclusions: 
In pts with chronic HypoPT treated with conventional therapy, a higher proportion of Ca or 
Ca × P measurements outside the target range, or any P measurements above the target range 
was associated with higher odds of developing a CV event.
Disclosures: Lars Rejnmark, Shire, a Takeda company, Consultant, Shire, a Takeda 
company, Speakers’ Bureau, Shire, a Takeda company, Grant/Research Support
P-843
Characterization of the skeletal phenotype of a new mouse model for Smith-
McCort dysplasia *Milena Dimori1, Irina Pokrovskaya1, Qiang Fu1, Vladimir 
Lupashin1, Brian Storrie1, Roy Morello1. 1University of Arkansas for Medical 
Sciences, United States
Smith-McCort (SMC) and Dyggve-Melchior-Clausen (DMC) dysplasia are rare, auto-
somal recessive, severe osteochondrodysplasias that share identical radiologic features and 
cartilage histology. Skeletal defects present after birth, between 12 and 36 months of age and 
are progressive resulting in significant deformities. The first genetic locus for Smith-McCort 
dysplasia-1 (SMC1) was identified on chromosome 18q21 and associated with homozygous 
or compound heterozygous mutations in the DYM gene (encoding for Dymeclin, a novel 
intracellular protein involved in Golgi organization and intracellular vesicle trafficking). 
Mutations in the same gene also cause Dyggve-Melchior-Clausen disease, making SMC and 
DMC allelic disorders. A second locus for Smith-McCort dysplasia-2 (SMC2) was identi-
fied on chromosome 4q31 where homozygous or compound heterozygous mutations in the 
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RAB33B gene were identified. RAB33B encodes a small GTP-binding protein that also 
plays important roles in Golgi organization, vesicular transport, endocytosis pathway and 
autophagy. Based on the roles of the Golgi apparatus in protein processing, glycosylation 
and secretion and the importance of the extracellular matrix (ECM) to bone development, 
we hypothesize that the underlying disease mechanism is defective Golgi-dependent pro-
tein processing/glycosylation leading to defective accumulation of ECM/cell surface pro-
tein(s). To study this we generated a new mouse model using CRISPR/Cas9 technology 
and designed it to mimic a RAB33B 136A>C (p.K46Q) human mutation into the mouse 
ortholog gene. This mutation was described to change the conserved lysine residue in the 
guanine nucleotide-binding domain, lead to protein deficiency and cause SMC2. Heterozy-
gous Rab33b+/A136C mice were generated and mated to obtain homozygous mice. Skeletal 
phenotyping at 6 weeks of age indicated reduced BMD and BMC in male Rab33bA136C /
A136C mice (but not females) compared to WT littermate controls. MicroCT scanning of 
the male Rab33bA136C /A136C mice showed a trend towards reduction in BV/TV at the 
femur and spine with concurrent reduction of trabecular thickness. Ongoing studies aim to 
elucidate the potential consequences of this Rab33b mutation on the glycosylation patterns 
of cell surface and secreted glycoproteins that are important to bone biogenesis.
Disclosures: Milena Dimori, None
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Zoledronate Treatment Improves Trabecular Bone without Affecting 
Bone Biomechanical Properties in +/G610C Mouse Model of Osteogenesis 
Imperfecta *Jukka Morko1, Jaakko Lehtimäki1, Jukka P Rissanen1, Jukka 
Vääräniemi1. 1Pharmatest Services, Finland
Human Osteogenesis Imperfecta (OI) is a group of genetic disorders that results in 
heterogeneous symptoms ranging from low bone mass and occasional fractures to perinatal 
lethality. The clinical management of OI aims to maximize bone strength and minimize 
injuries. Bisphosphonate therapy has been shown to increase bone mass in OI patients. In 
most cases, human OI is caused by autosomal dominant mutations in type I collagen genes. 
Accordingly, most animal models of OI are gene-modified mice mimicking these genetic 
disorders. One animal model is ‘Amish variant’ mouse with a dominant negative G610C mu-
tation in Col1a2 gene. Previously, we have demonstrated that young adult heterozygous (+/
G610C) mice are an excellent animal model of mild-to-moderate OI and that treatment with 
zoledronate increases the amount of their trabecular bone. In this study, we characterized 
the bone phenotype of young adult +/G610C male mice in more detailed and investigated 
the effects of zoledronate treatment on their bone biomechanical properties. At 2 months 
of age, the tibia of +/G610C and wild-type (+/+) male mice was analyzed by in vivo mi-
cro-computed tomography (µCT). Then, +/G610C mice were treated with zoledronate (25 
µg/kg, s.c.) or vehicle, and +/+ mice with vehicle once a week for 2 months. At 4 months of 
age, the mice were terminated, and their femora, tibiae and lumbar vertebrae were harvested 
for ex vivo µCT, peripheral quantitative computed tomography (pQCT), dual-energy X-ray 
absorptiometry (DXA), and biomechanical testing. At 2 months of age, +/G610C mice were 
lighter, and had smaller tibia and less trabecular bone than +/+ mice. At 4 months of age, 
+/G610C mice were still lighter, and had smaller tibia, femur and lumbar vertebral body, 
and less trabecular bone. As functional consequences of G610C mutation, femoral neck ex-
hibited smaller maximum load and work-to-fracture in cantilever bending test, and tibial 
diaphysis demonstrated smaller post-yield displacement and work-to-fracture in three-point 
bending test. Treatment with zoledronate increased the amount of trabecular bone in femur, 
tibia and lumbar vertebral body. However, the anti-catabolic zoledronate treatment was not 
sufficient to improve bone biomechanical properties in young adult +/G610C male mice. 
This study supports the use of young adult +/G610C mice as the excellent animal model of 
mild-to-moderate OI and indicates that the improvement of bone strength is a major chal-
lenge in the therapy of human OI.
Disclosures: Jukka Morko, None
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The fibrodysplasia ossificans progressiva-causing ACVR1[R206H] and 
ACVR1[R258G] mutations exhibit distinct skeletal phenotypes in neonatal 
mice. *John Lees-Shepard1, Sarah Hatsell1, Nyanza Rothman1, Saathyaki 
Rajamani1, Ron Deckelbaum2, Lily Huang2, Lili Wang2, Aris Economides1, 
Andrew Murphy2, Kalyan Nannuru2, Vincent Idone2, Qian Zhang1. 1Regeneron, 
United States, 2regeneron, United States
Gain of function mutations in the intracellular domain of the type I BMP receptor 
ACVR1 are associated with fibrodysplasia ossificans progressiva (FOP), a rare but cata-
strophically debilitating disease of ectopic intramuscular bone formation.  Although the 
vast majority of FOP cases are caused by a R206H mutation the GS domain of ACVR1 
(ACVR1[R206H]), FOP-causing mutations occur throughout the GS and the kinase 
domain of ACVR1. Of particular note, all three reported cases of a R258G mutation in 
the ACVR1 kinase domain exhibited more severe developmental skeletal and non-skel-
etal defects than are observed for ACVR1[R206H] bearing FOP patients. In an effort to 
model this phenotypic variance, we engineered a Cre-regulated ‘conditional-ON’ allele 
of ACVR1[R258G] in the mouse (Acvr1[R258G]FlEx/+), similar to the previously de-
scribed Acvr1[R205H]FlEx/+mouse (Hatsell, Idone et al. 2015). As observed in the pre-
viously published Acvr1[R206H]FlEx/+;Gt(ROSA26)SorCreERT2/+  mouse, body-wide 
activation of the FOP allele in adult Acvr1[R258G]FlEx/+;Gt(ROSA26)SorCreERT2/+mice 
resulted in heterotopic ossification, which was entirely ameliorated by treatment with an 
Activin A blocking antibody. When recombination was driven by early-embryonic expres-
sion of Cre-recombinase, both ACVR1[R206H] and ACVR1[R258G] muteins exhibited 
skeletal deformities and neonatal lethality.  Detailed skeleletal and soft-tissue imaging via 
iodine-contrast micro-CT confirmed that the skeletal phenotype presented more severely 
in ACVR1[R258G] mice than ACVR1[R206H] mice, consistent with the increased rarity 
and severity of ACVR1[R258G] relative to ACVR1[R206H] within the human FOP patient 
population. Indeed, ACVR1[R258G] mice presented with novel fusions and overgrowths 
in craniofacial and axial skeletal elements that were not observed in ACVR1[R206H] 
mice. Further, although ACVR1[R258G] mice are born alive and respond to stimulus, ad-
vanced imaging revealed that the lungs of ACVR1[R258G] mice were uninflated, indicating 
that ACVR1[R258G] likely die due to failure to breathe.  Experiments are presently under-
way to determine whether Activin A neofuction contributes to the embryonic phenotype of 
either the ACVR1[R258G] or ACVR1[R206H] mice and if the increased severity of the 
ACVR1[R258G] phenotype is due to enhanced ligand dependent signaling, ligand indepen-
dent signaling, and/or neoresponsivess to TGF-β or BMP family ligands. 
Disclosures: John Lees-Shepard, Regeneron, Grant/Research Support
P-846
BIOCHEMICAL ALGORITHM TO IDENTIFIFY INDIVIDUALS 
WITH ALPL VARIANTS BETWEEN SUBJECTS WITH PERSISTENT 
HYPOPHOSPHATASAEMIA *C. Tornero1, V. Navarro-Compán1, J. A 
Tenorio2, S. García-Carazo1, A. Buño3, I. Monjo1, C. Plasencia-Rodriguez1, 
J.M Iturzaeta3, P. Lapunzina4, K.E Heath5, A. Balsa6, P. Aguado6. 1Department 
of Rheumatology. La Paz University Hospital., Spain, 2Institute of Medical 
and Molecular Genetics (INGEMM). La Paz University Hospital., Spain, 
3Department of Clinical Biochemistry. La Paz University Hospital., Spain, 
4Institute of Medical and Molecular Genetics (INGEMM. La Paz University 
Hospital., Spain, 5Institute of Medical and Molecular Genetics (INGEMM). 
La Paz University Hospital, Spain, 6Department of Rheumatology. La Paz 
University Hospital, Spain
BACKGROUND: Studies show a long diagnostic delay in Hypophosphatasia (HPP) 
and the accessibility for the genetic testing is not always possible. Our previous cross-sec-
tional study (Tornero et al. OJRD (2020) 15:51) revealed alkaline phosphatase (ALP) levels 
< 25 IU/L seemed to be useful to identify individuals with ALPL variants among subjects 
with persistent hypophosphatasaemia. These data highlight the importance of establishing 
a specific biochemical profile and the value of including TNSALP substrates is a matter of 
interest.OBJECTIVES: First, to confirm our previous results in a one-year follow-up of a 
longitudinal study. Second, to determine the value of including TNSALP substrates (serum 
pyridoxal phosphate-PLP-and urinary phosphoetanolamine-PEA) in a specific biochemical 
profile to detect variants in ALPL in individuals with persistent low ALP levels.METHODS: 
Biochemical parameters of subjects included in a prospective longitudinal study conducted 
at La Paz Hospital were employed. Subjects were divided into two groups according to their 
genetics (+ GT or -GTgroup). Substrates were determined at baseline and at one-year visit 
and ALP levels also at six-months. To confirm the threshold, diagnostic utility measures 
were calculated at the 3 visits. ROC curves were employed to determine PLP and PEA 
best cut-off levels. Hierarchical binary logistic regression analysis was used to determine 
how well the different models fit (Nagelkerke R2). Finally, diagnostic utility measures for 
each model were calculated.RESULTS: Using ALP data from the three visits, Specificity (E) 
ranged between 84-91%; positive predictive value (PPV), 76-87% and +LR 3-6.1%. The 
ROC curves revealed cut-off PLP levels with the best combination of S and E for PLP were 
180 nmol/L (S: 72%, E:86%) and for PEA, 35 (S:58%, E89%) umol/g creat. The regression 
model showed an OR (95% IC) for ALP180 and PEA>35 of 6.52 (1.07-39.6), 8.06 (2.2-
29.9) and 4.4 (1.03-18.9). Compared to the model just including ALP, R2 improved (0.161 
to 0.526) when substrates were added (E and PPV:100% and S:22%), especially when PLP 
was included (Table 1).CONCLUSION: This study confirms that ALP levels <25 IU/L could 
be useful to identify individuals displaying ALPL variants. Additionally, the combination of 
this threshold with the proposed cut-off levels of its substrates, especially PLP, have shown 
a very high specificity to detect the disease and could help vigorously in the diagnostic 
work-up of HPP.
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Validity and Reliability of the Fibrodysplasia Ossificans Progressiva 
Physical Function Questionnaire (FOP-PFQ), a Patient-Reported, Disease-
Specific Measure *Robert J Pignolo1, Miriam Kimel2, John Whalen4, Ariane 
Kawata2, Dennis Revicki2, Rose Marino4, Frederick S Kaplan5. 1Department 
of Medicine, Mayo Clinic, United States, 2Evidera, United States, 4Ipsen, 
United Kingdom, 4Ipsen, United States, 5Departments of Orthopaedic Surgery 
& Medicine, The Center for Research in FOP and Related Disorders, Perelman 
School of Medicine, University of Pennsylvania, United States
Background: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic dis-
order characterized by heterotopic ossification (HO), leading to progressive disability and 
functional limitations in joint mobility. To measure the ability of individuals with FOP to 
conduct activities of daily living, age-specific versions of the FOP physical function ques-
tionnaire (FOP-PFQ) were designed based on FDA guidance on patient-reported outcome 
(PRO) development.Objective: To evaluate the reliability and validity of the FOP-PFQ.
Methods: Test-retest reliability was evaluated by comparing scores between Baseline and 
Week 1–3 visits in an FOP natural history study (NHS; NCT02322255); participants’ clini-
cal status was expected to remain stable during this time. Convergent validity was assessed 
by comparing scores with the Cumulative Analogue Joint Involvement Scale (CAJIS; a 
whole-body joint function measure), the Patient-Reported Outcomes Measurement Infor-
mation System Global Health Scale (PROMIS; a quality of life measure), and whole-body 
HO volume assessed by computed tomography; the validation used pooled FOP-PFQ data 
from the NHS, an FOP patient registry (NCT02745158), and phase II trials evaluating palo-
varotene for individuals with FOP (NCT02190747; NCT02279095).Results: Test-retest 
reliability was high, with correlation coefficients >0.90 for all age-specific versions, well 
above the 0.70 threshold, indicating that FOP-PFQ scores were stable over the 1–3 week 
interval between questionnaires. In convergent validity assessments, adult FOP-PFQ scores 
were highly correlated with CAJIS (Spearman coefficient: 0.71, p<0.0001), indicating that 
loss of joint function has a significant impact on the ability to conduct activities of daily 
living as measured by the FOP-PFQ. Lower correlations were observed with the PROMIS 
physical health subscore (–0.49, p<0.0001) and HO volume (0.33, p<0.05). Findings for 
the pediatric versions of the FOP-PFQ were generally similar to the adult version, but were 
limited by small sample sizes, particularly for those aged 2–4 years (n=11).Conclusions: The 
FOP-PFQ is the first validated PRO developed specifically for FOP, and performed well on 
test-retest reliability and convergent validity, although some evaluations were inconclusive 
for pediatric versions, which had small sample sizes. The FOP-PFQ may help individuals 
with FOP and clinicians better understand the impact of FOP on physical function in trials 
and clinical practice.
Disclosures: Robert J Pignolo, Research investigator: Clementia/Ipsen, Regeneron; 
Advisory board: President of the International Clinical Council on FOP; Chair of the 
Publications Committee for the IFOPA Registry Medical Advisory Board, Other Financial 
or Material Support
P-848
Bone Health in Children and Youth with Autism Spectrum Disorder: A 
Systematic Review and Meta-Analysis *Mahdi Rostami Haji Abadi1, Saija 
Kontulainen1. 1University of Saskatchewan, Canada
A higher risk of fracture reported in individuals with autism spectrum disorder (ASD) 
may relate to poor bone health and development in childhood and adolescence. We aimed 
to systematically review studies comparing imaged bone outcomes between children and 
youth with ASD and typically developing children and youth, and perform a meta-analysis 
to compare commonly reported bone outcomes. We searched articles published between Jan-
uary 1991 and December 2018 from PubMed, Cochrane Library, Web of Science, EMBASE 
and Scopus databases. We included studies comparing areal bone mineral density (aBMD) 
between children with ASD and typically developing children in the meta-analysis, and eval-
uated other imaged bone outcomes qualitatively. We assessed the quality of included studies 
using the modified version of the National Heart, Lung and Blood Institute’s Quality Assess-
ment Tool. We used random-effects models with an inverse variance method to pooled effect 
sizes (ES) of included studies. We estimated publication bias visually by re-displayed funnel 
plots after Duval and Tweedie’s Trim and Fill adjustment for those measures reported in 
three or more studies. Seven publications were identified for the systematic review, and four 
studies were included in the meta-analysis. Studies had a fair (n=6) and poor (n=1) quality 
rating. The meta-analysis indicated that aBMD of the total body (ES=-0.77; 95% CI, -1.26 
to -0.28; n=2), lumbar spine (-0.69; -1.00 to -0.39; 4), total hip (-1.00; -1.82 to -0.17; 3) and 
femoral neck (-1.07; -1.54 to -0.60; 3) were lower in children with ASD compared to typical-
ly developing children (Figure 1). There was no evidence of publication bias. Based on our 
qualitative review, limited evidence suggested 13% lower total body bone mineral content 
and 10-20% lower cortical and trabecular thickness (distal radius), cortical area and bone 
strength (distal radius and tibia) in children with ASD. Meta-analysis indicated that children 
and youth with ASD have lower aBMD at total body, lumbar spine, hip and proximal femur 
compared to typically developing children. Limited evidence also suggested deficits in bone 
mineral content, microarchitecture and strength in children and youth with ASD. Future 
studies are warranted to complement the preliminary findings of bone microarchitecture and 
strength deficits in children and youth with ASD.
Disclosures: Mahdi Rostami Haji Abadi, None
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Functional characterization of a unique mutant of ALK2, p.K400E, that is 
associated with a skeletal disorder, diffuse idiopathic skeletal hyperostosis 
*Sho Tsukamoto1, Mai Kuratani2, Takenobu Katagiri2. 1Division of Biomedical 
Sciences, Research Center for Genomic Medicine, Saitama Medical University, 
Japan, 2Division of Biomedical Sciences, Research Center for Genomic 
Medicine, Saitama Medical Universityity, Japan
Bone morphogenetic protein (BMP) signaling regulates the physiological and patho-
logical development of skeletal tissues. Activin receptor-like kinase 2 (ALK2) is a BMP 
type I transmembrane serine/threonine kinase receptor. Recently, a p.K400E mutation was 
found in ALK2 in a patient with diffuse idiopathic skeletal hyperostosis (DISH), which is a 
disorder characterized by calcification and ossification of spinal ligaments and entheses. We 
report here the functional characterization of ALK2 p.K400E in vitro. Cells overexpressing 
ALK2 p.K400E activated BMP signaling in response to osteogenic BMP ligands. However, 
ALK2 p.K400E was not activated by a nonosteogenic ligand, Activin A. BMP signaling 
through ALK2 p.K400E was further enhanced by the coexpression of a BMP type II recep-
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tor. The type II receptor increased the phosphorylation level of ALK2 p.K400E, suggesting 
that ALK2 p.K400E is a hypersensitive mutant to the BMP type II receptor kinases. Our 
findings suggest that pathological calcification and ossification in DISH are caused by over-
activated BMP signaling through ALK2 p.K400E enhanced by type II receptors in response 
to osteogenic BMPs rather than Activin A.
Disclosures: Sho Tsukamoto, None
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Stem Cell Therapy for Osteogenesis Imperfecta: A Systematic Review and 
Meta-analysis of Preclinical Studies using Mouse Models *Lauren Battle1, 
Shoshana Yakar 2, Alessandra Carriero1. 1The City College of New York, United 
States, 2New York University College of Dentistry, United States
Osteogenesis imperfecta (OI) is a genetic collagen-related disease characterized by 
poor bone quality, osteopenia and increased fracture risk1. Bisphosphonates and other exist-
ing treatments can only partially correct the bone phenotype, providing symptomatic relief 
but not addressing the underlying genetic defect. Stem cell therapy is a promising treatment 
as it holds potential to correct the bone phenotype at the cellular level by utilizing genetically 
healthy cells early in their development to improve the quality and increase the quantity of 
OI bone. Here, we conduct a meta-analysis to investigate the efficacy of stem cell thera-
py on mouse models of OI.  A literature review was performed to identify studies treating 
mouse models of OI with stem cells, including bone marrow, mesenchymal stem cells, and 
human fetal stem cells. Effect size of fracture incidence, maximum load, stiffness, cortical 
thickness, BV/TV, and raw engraftment rates were pooled in a random-effects meta-analy-
sis. Moderator analyses were run to estimate the influence of variables including cell type, 
cell number, injection route, mouse age, irradiation, anatomical bone, and follow-up time.
Consistent with clinical case studies2, bone fracture incidence greatly decreased with stem 
cell therapy, although the small raw engraftment rate. Cell therapy had a beneficial effect on 
maximum load, with follow-up time and anatomical bone having an influence on it. Stiff-
ness, cortical thickness and BV/TV were not affected by cell therapy in mouse models of 
OI.This study demonstrates the promising potential of stem cell therapy to reduce fractures 
in OI despite the low cell engraftment. The mechanism of stem cell engraftment and its 
participation in bone modeling and remodeling is yet to be understood. Results support the 
hypothesis that transplanted cells produce beneficial effects by secreting paracrine factors 
and other soluble molecules3. It was not possible to investigate further parameters due to 
the lack of standards of investigation between the studies. Being bone fracture the primary 
symptom of OI, there is a critical need to measure the fracture toughness of OI bone treated 
with stem cells to assess the actual efficacy of the treatment to rescue OI bone brittleness. 
Understanding the mechanism of cellular therapy on bone (re)modeling as well as its actual 
efficacy on enhancing the strength and toughness of OI bone is crucial for the successful 
implementation of this therapy in the clinic.Van Dijk FS, Sillence DO. Am J Med Genet 
A. 164A(6), 2014.Horwitz EM, Prockop DJ, Gordon PL, et al. Blood. 97(5), 2001.Prockop 
DJ. Cytotherapy.19(1), 2017.
Disclosures: Lauren Battle, None
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The Association Between STX16 and the Imprinting of GNAS in the 
Pathogenesis of Pseudohypoparathyroidism *Cagri Aksu1, Monica Reyes1, 
Claire Remillard1, Qing He1, Murat Bastepe1. 1Massachusetts General Hospital, 
United States
Autosomal dominant pseudohypoparathyroidism type-Ib is characterized by renal para-
thyroid hormone resistance, with resultant hypocalcemia and hyperphosphatemia. This dis-
order is associated with an isolated loss of methylation at GNAS exon A/B and most patients 
carry maternal microdeletions in the neighboring STX16 gene. The shortest deletion overlap 
is a 1.2-kb region spanning STX16 exon 4 and thought to harbor a cis-acting element reg-
ulating GNAS A/B methylation. However, ablation of the orthologous mouse region does 
not recapitulate the patient findings and no functional data exists supporting the association 
between the STX16 gene and GNAS imprinting. The A/B methylation is established in the 
female germline and maintained throughout the development in somatic cells. We thus in-
vestigated the role of the 1.2-kb STX16 region in the maintenance of A/B methylation, em-
ploying HCT116 cells, a near-diploid human cell line derived from colorectal carcinoma. To 
delete this region, we used CRISPR/Cas9 and suitable guide-RNAs targeting upstream and 
downstream of exon 4. We first generated HCT116 cells stably expressing Cas9 and intro-
duced the guide-RNAs into those cells by lentiviral delivery. After antibiotic enrichment of 
the transduced cells, the presence of a 2.1-kb deletion spanning STX16 exon 4 and flanking 
intronic regions was confirmed by PCR, followed by TA-cloning and Sanger sequencing of 
the products. Multiplex ligation-dependent probe amplification (MLPA) indicated a modest 
reduction in the STX16 exon 4 copy number, suggesting that the deletion was present only 
in a subset of cells. Methylation specific-MLPA analysis, which was performed in non-clonal 
cells, indicated normal methylation status at GNAS exon A/B, and this finding was con-
firmed by the combined bisulfite restriction analysis. Thus, our initial findings suggest that 
the putative cis-acting element within STX16 does not regulate the maintenance of exon A/B 
methylation. To further confirm these results, we are in the process of selecting and analyz-
ing clonal HCT116 cells homozygous or heterozygous for this deletion. In addition, we are 
introducing the same deletion into human ES cells, so that we can determine its impact on 
GNAS imprinting during early development.
Disclosures: Cagri Aksu, None
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Histochemical Quantification of FGF23 Expression in the Bone with 
Phosphor Integrated Dot Nanoparticles *Minae Koga1, Hajime Kato1, 
Nobuaki Ito1. 1The University of Tokyo Hospital, Japan
Background: Tumor-induced osteomalacia (TIO) is a fibroblast growth factor 23 (FG-
F23)-related hypophosphatemic disorder caused by FGF23 producing tumors. TIO rep-
resents bone pain, fracture/pseudofracture, muscle weakness, etc. which could sometimes 
lead a patient bedridden. TIO is completely cured only by the removal of the tumor, but 
localization of the tumor is occasionally challenging as the tumor could be very tiny, could 
develop in any part of the bones or the soft tissue. In our hospital, seven out of 43 cases 
missed the identified tumor.              In TIO patients, FGF23 production in normal bone 
tissue is expected to be suppressed due to low serum phosphate. Therefore, in those patients 
with the clinical diagnosis of TIO with an unidentified tumor, it is possible to determine if 
they actually possess FGF23 producing tumor or suffer from other conditions with over-
production of FGF23 in the bone by confirming the expression level of FGF23 in the bone. 
However, conventional immunostaining methods are not sensitive enough to confirm the 
suppression of FGF23 due to relatively low physiological expression levels of FGF23. Also, 
it is difficult to confirm the local FGF23 production by PCR or Western blotting due to the 
complexity of extracting mRNA or protein from the tough bone tissue.              Phosphor 
Integrated Dot nanoparticles staining (PID) was developed to detect the target proteins with 
extremely high sensitivity and quantifiability. Therefore, here we exploit this method to con-
firm FGF23 suppression in suspected patients with TIO.Methods: The bone samples from 
13 patients (STD-bone) and 2 dialysis patients (HD-bone) were collected on the event of hip 
arthroplasty. Also, the bone samples from 2 patients with FGF23 producing bone tumor were 
collected during the removal of the tumors (TIO-bone). FGF23 immunostaining using PID 
was performed for each sample, and the average number of PID particles within 5.5 μm from 
the cell nucleus for each nucleus was counted with the attribution method.Result: The mean 
number of PID particles per nucleus was 153.7 in STD-bone, 357.7 in HD-bone, and 19.0 
in TIO-bone, with a significant difference between the STD-bone and TIO-bone (P<0.001).
Discussion: PID method undoubtedly revealed physiological suppression of FGF23 expres-
sion in the bone from TIO patients. This method allows us to clearly differentiate the etiolo-
gy of acquired FGF23 related hypophosphatemic rickets/osteomalacia patients.
Disclosures: Minae Koga, None
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Association of Biochemical Parameters With Chronic Kidney Disease 
in Chronic Hypoparathyroidism Using Electronic Medical Record Data 
*Elvira Gosmanova1, Kristina Chen2, Olulade Ayodele3, Clara Monleón Bonet4, 
Nicole Sherry5, Erin Cook6, Fan Mu6, Joshua Young6, Lars Rejnmark7. 1Albany 
Medical College, United States, 2Former, Shire Human Genetic Therapies, 
Inc., Global Evidence and Outcomes, Data Sciences Institute, Research and 
Development; Current, Arena Pharmaceuticals, United States, 3Shire Human 
Genetic Therapies, Inc., Global Evidence and Outcomes, Data Sciences Institute, 
United States, 4Shire International GmbH, Switzerland, 5Shire Human Genetic 
Therapies, Inc., United States, 6Analysis Group, Inc., United States, 7Aarhus 
University and Aarhus University Hospital, Denmark
Objective: This study evaluated the association of albumin-corrected serum calcium 
(Ca), serum phosphate (P), and calcium-phosphate product (Ca × P) with risk of developing 
chronic kidney disease (CKD; defined as >=1 diagnosis code for CKD stage 3–5 or >=2 
outpatient estimated glomerular filtration rate values <60 mL/min/1.73 m2 >3 mo apart) in 
patients (pts) with chronic hypoparathyroidism (HypoPT).Methods: A nested, case-control 
study using the Explorys electronic medical record database (Jan 2007–Aug 2019) was con-
ducted among US adults with chronic HypoPT (>=2 diagnosis codes for HypoPT occurring 
>=6 mo apart) on conventional therapy. Index date was the day after first calcitriol prescrip-
tion, baseline (BL) period was the 6 mo before the index date, and exposure window was 
the time between the index date and development of CKD. Pts with CKD before the index 
date and those receiving parathyroid hormone were excluded. Controls without CKD were 
matched 1:1 to cases with CKD based on age+/-5 y, index date+/-1 y, exposure duration, and 
sex. Associations between longitudinal levels of Ca, P, and Ca × P product and odds of devel-
oping CKD were assessed in adjusted logistic regression analyses.Results: The analyses in-
cluded 150 matched pairs with Ca, and 40 matched pairs with P or Ca × P. Overall, cases and 
controls had similar BL characteristics. Mean age was 58 y for the Ca pairs (83% women); 
mean follow-up 2.8 y. Mean age was 57 y for cases and 58 y for controls for the P or Ca × P 
pairs (83% women); mean follow-up 2.5 y. In the adjusted analyses, compared with pts with 
<33% of Ca measurements outside the target range, pts with >=67% of Ca measurements 
outside, above, or below the target range had 3.46, 2.85, and 2.68 significantly increased 
odds, respectively, of developing CKD. Pts with 33%–<67% of Ca measurements above or 
outside the target range had increased odds of developing CKD, but the associations were 
not statistically significant (Table). There were no statistically significant associations be-
tween developing CKD and any P measurements above the target range, or Ca × P measure-
ments outside the target range (Table).Conclusions: In pts with chronic HypoPT treated with 
conventional therapy a higher proportion of Ca measurements outside, above, or below the 
target range was associated with higher odds of developing CKD. Future studies are needed 
to evaluate the effects of calcium fluctuations and risk of CKD in pts with chronic HypoPT.
Disclosures: Elvira Gosmanova, Shire, a Takeda company, Consultant
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Design of primers for direct sequencing of nine coding exons in the human 
ACVR1 gene *Masaru Matsuoka1, Sho Tsukamoto2, Yuta Orihara1, Rieko 
Kawamura1, Mai Kuratani2, Nobuhiko Haga3, Kenji Ikebuchi1, Takenobu 
Katagiri4. 1Department of Clinical Laboratory, Saitama Medical University, 
Japan, 2Division of Biomedical Sciences, Research Center for Genomic 
Medicine, Saitama Medical University, Japan, 3Department of Rehabilitation 
Medicine, Graduate School of Medicine, The University of Tokyo, Japan, 
4Division of Biomedical Sciences, Research Center for Genomic Medicine, 
Saitama Medical University, Japan
The human ACVR1 gene encodes a transmembrane protein consisting of 509 amino 
acids called activin A receptor, type I (ACVR1) or activin receptor-like kinase 2 (ALK2) and 
has nine coding exons. The ALK2 protein functions as a signaling receptor for ligands of the 
transforming growth factor-β family. In the human ACVR1 gene, approximately 20 types of 
heterozygotic mutations in the coding exons have been associated with congenital disorders 
and a somatic cancer, such as fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic 
pontine glioma, diffuse idiopathic skeletal hyperostosis and some congenital heart disorders. 
In the present study, we designed primers for direct sequencing of the nine coding exons 
in the human ACVR1 gene. The reliability of the primers was examined by PCR and DNA 
sequencing using genomic DNA prepared from peripheral blood or swab samples of three 
patients with FOP who had different mutations in the ACVR1 gene. A single nucleotide het-
erozygotic mutation was identified in each genomic sample without additional mutations in 
other regions. Therefore, the primers designed for the nine coding exons of the ACVR1 gene 
could be useful for the genetic diagnosis of patients who may have disorders associated with 
mutations in the ACVR1 gene.
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Sarcopenic obesity according to the EWGSOP II criteria and four different 
concepts of obesity in regards to physical frailty in Brazilian older adults: 
data from the SARCOS study. *Alberto Frisoli Jr1, Sheila Ingham1, Jairo 
Borges1, Angela Paes1, Valdir Ambrosio1. 1Universidade Federal Sao Paulo, 
Brazil
Sarcopenic obesity has been linked to impaired physical capacity, functional loss and 
incidence of frailty. However, its diagnosis is not yet defined due to the diversity of criteria 
for obesity (overweight or over regional body fat). Aim: To assess which phenotype of sarco-
penic obesity has the greatest association with physical frailty. Method: cross-sectional anal-
ysis of the SARCopenia and OSteoporosis in 369 community-dwelling older adults from an 
outpatient clinic. Appendicular skeletal lean mass and regional fat were assessed by DXA. 
Frailty was defined by Fried’s criteria. The phenotypes were composed by the presence of 
sarcopenia, that was diagnosed according to recommendations given by EWGSOP II, and 
obesity, which was diagnosed by four different criteria: BMI >=30 kg/m2 (BMI obesity); ap-
pendicular fat percentage ³ 30% (Appendicular obesity); percentage of total body fat ³ 35% 
women and ³25% men (Total body obesity); and trunk fat percentage ³ 30% (Trunk obesity). 
The phenotypes were then separated into 4 groups: sarcopenic obesity, sarcopenia, obesity 
and controls. Then, we evaluated the association of each group with physical frailty. Results: 
Mean age of 78.45 (+/- 7.2) years old with 53.2% (n=189) women, 67.3% Caucasians. Phys-
ical frailty was diagnosed in 38.5%. Sarcopenia EWGSOP II was present in 19.8%, BMI 
obesity in 23.6%, trunk obesity in 88.4%, total body obesity in 81.9% and appendicular 
obesity in 66.1%. The prevalence of sarcopenic obesity due to BMI obesity was 1.6% (n 
= 6), 13.3% (n = 49) due to appendicular obesity, 15.6% (n = 58) due to trunk obesity and 
14.2% (n = 53) for total body obesity. Sarcopenia without BMI obesity occurred in 18.2%, 
6.5% without appendicular obesity, 5.4% without trunk obesity and 4% by total body obe-
sity. Adjusted regression analyzes are shown in figure 1.Conclusion: Sarcopenic obesity di-
agnosed by regional obesity was more associated with physical frailty, compared to obesity 
sarcopenic by BMI obesity, which did not reach a significant association.Sarcopenia of all 
phenotypes was less associated with physical frailty compared to sarcopenic obesity
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Skin autofluorescence, a non-invasive biomarker for advanced glycation 
end-products, is associated with Sarcopenia: The Rotterdam study *Komal 
Waqas1, Jinluan Chen2, Katerina Trajanoska2, M. Arfan Ikram2, Fernando 
Rivadeneira2, Andre G Uitterlinden2, M. Carola Zillikens1. 1Department of 
Internal Medicine, Erasmus Medical Centre, Netherlands, 2Department of 
Epidemiology, Erasmus Medical Centre, Netherlands
Accumulation of advanced glycation end-products (AGEs) in skeletal muscle might be 
related to sarcopenia development and its components namely appendicular skeletal mass 
index (ASMI), hand grip strength (HGS) and gait speed (GS). No studies have so far investi-
gated skin AGEs in relation to sarcopenia in a general population of European background.In 
a cross-sectional analysis, 2,744 participants were included from the Rotterdam Study with 
a mean age of 74.1 years (56% females, 13% diabetics). Skin AGEs were measured using 
AGE readerTM as Skin autofluorescence (SAF), ASMI with iDXA (GE-Lunar), HGS with 
a hydraulic hand dynamometer and GS measured on an electronic walkway in a subgroup 
(n=2,079). We defined probable sarcopenia (low HGS) and sarcopenia (low HGS + low 
ASMI) based on European working group on Sarcopenia in older people revised criteria 
(EWGSOP2). Multivariate linear and logistic regression analysis were performed adjusting 
for age, sex, body fat percentage, height, renal function, diabetes and smoking status. Data 
was also analyzed in sex-stratified, age-adjusted SAF quartiles for literature comparison.
Prevalence of low ASMI was 7.7%, of probable sarcopenia 19%, of low GS 2.9% and of 
sarcopenia 3.5%. SAF was consistently inversely associated with ASMI (β=-0.064, p=3E-5), 
HGS (β=-0.054, p=2E-5) and GS (β=-0.077, p=3E-4). SAF was an independent predictor of 
low ASMI (odds ratio per SAF SD, [OR]= 1.98, 95% confidence interval [CI] 1.47-2.67), 
probable sarcopenia OR=1.34 (95% CI: 1.07-1.67) and sarcopenia OR=1.98 (95% CI: 
1.30-3.03) in fully adjusted models using EWGSOP2 cut-offs. As compared to the bottom 
three SAF quartiles combined (Q1-3), individuals in the Q4 had higher odds of low ASMI 
(OR=1.62 (95% CI: 1.18-2.23), probable sarcopenia (OR=1.16 (95% CI: 0.91-1.47) and sar-
copenia (OR=1.67 (95% CI: 1.06-2.65).Higher skin AGEs are associated with low muscle 
mass, strength and performance which is in line with the hypothesis that AGEs play a role 
in age-related sarcopenia.
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Pro-inflammatory Diet is Associated with Higher Odds of Frailty in Middle-
aged and Older Adults *Courtney Millar1, Daniel Habtemariam1, Alyssa 
Dufour1, Marian Hannan1, Nitin Shivappa2, James Hebert2, Joanne Murabito3, 
Emelia Benjamin3, Shivani Sahni1. 1Hebrew Senior Life, Harvard Medical 
School, United States, 2University of South Carolina, United States, 3Boston 
University, School of Medicine; Framingham Heart Study, United States
Systemic inflammation, a key determinant of frailty, is highly modifiable by diet. The 
dietary inflammatory index (DII) estimates the inflammatory potential of diet (higher scorers 
indicate a more pro-inflammatory diet). Our objective was to determine whether a pro-in-
flammatory diet was associated with higher odds of frailty in middle-aged and older adults 
from the Framingham Heart Study Offspring Cohort. This prospective study included non-
frail individuals with baseline diet assessment from a food frequency questionnaire (FFQ) 
in 1998-2001 and a follow-up frailty measurement in 2011-2014. DII scores were calculated 
from foods and nutrients (e.g. macronutrient, vitamin, mineral intake) from the FFQ. Frail-
ty was defined as fulfillment of 3 or more Fried frailty phenotype criteria of unintentional 
weight loss, exhaustion, low physical activity, slowness (of gait speed), and weakness (of 
grip strength). Participants with missing gait/grip tests due to physical limitation were as-
sumed to be slow (n=14) or weak (n=21), respectively. Logistic regression was used to 
calculate odds ratios (OR) and 95% confidence intervals (95% CI) for frailty onset adjusting 
for baseline age, sex, energy intake, current smoking, treatment for diabetes and/or cardio-
vascular disease, and non-melanoma cancers. Of the 1,805 non-frail individuals at baseline 
(mean age: 59 (SD=8) years, range: 33 – 81; 44% male), 174 individuals became frail over 
~16 years. Mean DII for all participants was -0.10 (SD=1.8; range: -4.5 – 4.8). Mean DII in 
frail individuals was 0.02 (SD=1.8; range: -3.8 – 3.9), while in non-frail individuals it was 
-0.11 (SD=1.8; range: -4.5 – 4.8). In the model adjusted for age and sex, a one unit difference 
in DII was associated with 11% higher odds of developing frailty (p=0.02). The associations 
became strong after further adjustments for energy intake and current smoking (Table). Ad-
ditional adjustments for disease indicators did not further change the association. In this 
cohort of middle-aged and older adults, a pro-inflammatory diet was associated with higher 
odds of frailty onset over follow-up. Thus, dietary modification may be a useful strategy for 
frailty prevention.
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Association of D3Cr muscle mass with short term declines in BMD and bone 
strength in older men in late life: The MrOS Study *Peggy Cawthon1, Steven 
Cummings1, Andrew Burghardt2, Lisa Langsetmo3, Kristine Ensrud3, Jane 
Cauley4, Kristen Beavers5, Ashley Weaver5, William Evans6, Mary Bouxsein7, 
Eric Orwoll8. 1California Pacific Medical Center, Research Institute, United 
States, 2University of California, San Francisco, United States, 3University of 
Minnesota, United States, 4University of Pittsburgh, United States, 5Wake Forest 
University, United States, 6University of California, Berkeley, United States, 
7Harvard University, United States, 8Oregon Health and Sciences University, 
United States
Men with low muscle mass by D3-creatine dilution (D3Cr muscle mass) have a higher 
risk of fractures and lower volumetric bone mineral density (vBMD) and estimated failure 
load (FL) at the distal radius and tibia (as assessed by high resolution peripheral quantita-
tive computed tomography, HR-pQCT). Whether D3Cr muscle mass is also associated with 
decline in BMD is unknown. We tested the hypotheses that low D3Cr muscle mass (or low 
weight) are associated with greater short term declines in BMD and FL by HR-pQCT, and 
areal (aBMD) by dual energy x-ray absorptiometry (DXA) in community dwelling men in 
late life.MrOS men (mean age 77+/-3.8 yrs) had D3Cr muscle mass, HR-pQCT imaging 
of the distal radius and tibia, and hip DXA assessed at the Year 14 exam. An average of 
1.6 years (SD=0.2) later, a subset (N=235) returned for HR-pQCT and DXA. Generalized 
linear models calculated age- and weight- adjusted mean percent change in BMD and FL, 
by quartile of D3Cr muscle mass. We also calculated mean percent change by quartiles of 
weight (adjusted for age and D3Cr muscle mass). Longitudinal changes were measured in 
common co-registered images for both HR-pQCT and DXA, and included: total vBMD (Tt.
BMD), cortical BMD (Ct.BMD) trabecular vBMD (Tb.BMD), and FL at the distal radius 
and tibia; and aBMD at the femoral neck and total hip.Mean percent change was -1.4%+/-2.4 
for distal radius Tt.BMD; -1.1%+/-1.7 for distal tibia Tt.BMD; -1.6%+/-6.0 for distal radius 
FL, -1.5%+/-4.5 for distal tibia FL, -0.4%+/-3.8 for femoral neck aBMD, and -0.9%+/-2.6 
for total hip aBMD. Men with higher levels of D3Cr muscle mass at the Year 14 visit had 
smaller declines in Tt.BMD and Ct.BMD at the distal radius and distal tibia than men with 
lower levels of D3Cr muscle mass (p for trend<0.05, Figure). Patterns of change in FL were 
similar but did not reach statistical significance; D3Cr muscle mass appeared unrelated to 
change in Tb.BMD. D3Cr muscle mass was not significantly associated with change in total 
hip or femoral neck aBMD. Weight was not associated with change in BMD or FL at any 
site.In summary, men with higher D3Cr muscle mass had smaller declines in vBMD at distal 
sites, particularly in cortical vBMD, than men with lower levels of D3Cr muscle mass. D3Cr 
muscle mass was not significantly related to change in trabecular vBMD at distal sites, or 
aBMD at the hip. Weight was unrelated to change in BMD. Low muscle mass may influence 
vBMD declines at distal sites.
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A Longitudinal Study of Sarcopenia in Older Community Dwelling Women 
*Hampus Ekstubbe1, Patrik Bartosch1, Fiona McGuigan1, Kristina E. Akesson1. 
1Lund University, Department of Clinical Sciences Malmö, Sweden
Background: Musculoskeletal ageing is a worldwide public health concern. Loss of 
muscle mass and strength (sarcopenia) contributes to the decline into frailty and to numerous 
adverse outcomes, including osteoporosis and fracture.Purpose: To longitudinally investi-
gate prevalence of sarcopenia in a population-based cohort of community-dwelling older 
women, and its overlap with frailty and body composition. We also investigated the asso-
ciation between sarcopenia, frailty and mortality.Methods: The OPRA cohort were all 75y 
at inclusion (n=1044); and reassessed at 80y (n=715) and 85y (n=382). Extensive data was 
collected, including measures of muscle strength (hand grip strength (HGS); knee exten-
sion, Biodex), muscle mass (DXA), physical function (gait speed) and body composition; 
a frailty index (FI) was also available. Based on low muscle strength (HGS <16kg or knee 
<175 Nms); low mass (<5.5 kg/m2), low gait speed (<=0.8m/s) and total body fat (>40%), 
individuals were categorized as having Probable Sarcopenia, Sarcopenia and Severe Sar-
copenia as outlined by the 2018 European Working Group on Sarcopenia in Older People. 
Frail was defined as FI>0.25.Results: Sarcopenia prevalence increased from 3.3% at 75 to 
5.1% and 10.1% at 80 and 85. Proportionally, sarcopenia with obesity was 0.8%, 1.6%, 5.4% 
respectively.A substantial increase in frailty was also apparent with increasing severity of 
sarcopenia; having probable sarcopenia at 75y increased the odds (OR) of being frail at 80y 
(OR 3.77, CI 2.18-6.49). By age 85 three quarters of all women were both sarcopenic and 
frail.The odds of death at 5yrs was increased already among those with probable sarcopenia 
(4.07, CI 2.28-7.28), and higher again when combined with low body fat mass (OR: 6.02, 
CI 2.48-14.62). It was not increased in those with higher fat mass (OR: 0.54, CI 0.07-4.10). 
In those with probable sarcopenia in combination with frailty the odds of death were highest 
(6.33, 3.15-12.75).Conclusion: With the loss of muscle mass, strength and function that typ-
ifies musculoskeletal aging, comes an elevated risk of frailty and mortality. Evaluation for 
sarcopenia may facilitate intervention to maintain musculoskeletal competence; as a way of 
reducing falls, a major cause of fractures in the elderly.
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Adjusting Fracture Probability for Prior Falls: A Registry-Based Cohort 
Study. *William Leslie1, Suzanne Morin2, Lisa Lix1, Eugene McCloskey3, 
Helena Johansson3, Nicholas Harvey4, John Kanis3. 1University of Manitoba, 
Canada, 2McGill University, Canada, 3University of Sheffield, United Kingdom, 
4University of Southampton, United Kingdom
BACKGROUND: FRAX® estimates 10-year fracture probability from multiple risk 
factors but does not currently consider the risk associated with falls. FRAX has been shown 
to underestimate fracture risk in those with one or more falls in the preceding 12 months, 
and the magnitude of this underestimation increases the greater the number of number of 
prior falls.OBJECTIVE: To derive a simple adjustment to FRAX probability based upon 
the number of falls in the preceding 12 months and assess its impact on risk reclassification.
METHODS: Using the population-based Manitoba Bone Mineral Density (BMD) Program 
registry, we identified women and men age 40 years or older with baseline BMD and FRAX 
measures. Number of self-reported falls in the prior 12 months was collected from Septem-
ber 1, 2012 onwards. We identified incident major osteoporotic fractures (MOF) and hip 
fracture (HF) to March 31, 2018 from population-based healthcare data. We compared the 
effect of applying a simple risk adjustment to FRAX that varied from +10% to +100% per 
fall in steps of 10%. Cox regression analysis was used to determine the optimal adjustment 
that minimized the residual effects of falls (model Chi-square). We computed categorical net 
reclassification improvement (NRI) using 20% MOF and 3% HF intervention thresholds, 
and integrated discrimination improvement  (IDI).RESULTS: The study population consist-
ed of 20,767 individuals (age 65.7 +/- 10.1 years; 85% women). After mean 2.6 years of ob-
servation there were incident MOF in 640 and HF in 146. HR for MOF (adjusted for FRAX 
with BMD) progressively increased with the number of number of prior falls: 1.53 (95% CI 
1.25-1.86) for one fall, 1.91 (1.43-2.55) for two falls, 2.57 (1.95-3.38) for 3+ falls (referent 
no falls). Adjusted HRs were slightly greater for HF (one fall 1.59 [95% CI 1.07-2.38], two 
falls 1.99 [1.12-3.52], 3+ falls 3.05 [1.80-5.15]). Model Chi-square for falls was minimized 
for an adjustment to FRAX of +70% per fall for MOF and +50% per fall for HF (FIGURE). 
Applying the lower FRAX adjustment of +50% per fall reclassified MOF risk in 6.1% and 
improved MOF prediction (total NRI +0.071; IDI +0.003; both p<0.001); reclassified HF 
risk in 3.4% and improved HF prediction (total NRI +0.021; IDI +0.003; both p<0.001).
CONCLUSIONS: A simple risk adjustment to FRAX based upon the number of falls in the 
preceding 12 months significantly improves MOF and HF risk prediction, and reclassifies a 
moderate proportion of individuals.
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Dairy food intake is not associated with frailty in adults *Shivani Sahni1, 
Alyssa Dufour1, Courtney Millar1, Douglas Kiel1, Paul Jacques2, Marian 
Hannan1. 1Marcus Institute, Hebrew SeniorLife and Harvard Medical School, 
United States, 2Jean Mayer USDA HNRCA, Tufts University School of 
Nutrition, United States
Dietary protein is associated with lower risk of frailty, which occurs in 10-15% of com-
munity-living older adults. Yet, little evidence exists for the consumption of dairy foods (a 
good source of high quality protein) being related to the risk of frailty. It is unclear if high-fat 
dairy foods have a protective role in frailty given that anorexia and low-calorie intakes are 
often seen in frail individuals. The aim of this study was to determine the association of dairy 
food intake [milk, yogurt, cheese, total dairy (milk+yogurt+cheese), low-fat, and high-fat 
dairy, servings/week] with the odds of frailty in older adults from the Framingham Offspring 
study.In this cross-sectional study, 2,888 men and women completed food frequency ques-
tionnaires (FFQ) and had frailty assessments using Fried’s frailty phenotype (1998-2001). 
Average intake of each dairy food was calculated from FFQs in 1998-2001, 1995-1998, and 
1990-1995. Fried’s frailty phenotype was defined as presence of >=3 criteria for unintention-
al weight loss, exhaustion, slowness (gait speed), low physical activity, and weakness (grip 
strength). Logistic regression was used to calculate odds ratios and 95% confidence intervals 
adjusting for age, sex, energy intake (residual analysis), current smoking, multivitamin use, 
self-reported health status (excellent, good, fair/poor), and presence of disease indicators 
(cognitive impairment, type 2 diabetes treatment, cardiovascular disease, non-skin cancer, 
and chronic kidney disease).Mean age (+/-SD) was 61y (+/-9, range 33-87y), and 54% were 
female. Mean dairy food intakes [(+/-SD), servings/week] were 5.7 (+/-5) (total milk), 1.0 
(+/-1.6) (yogurt), 2.8 (+/-2.8) (cheese), 9.5 (+/-6.4) (total dairy), 6.1 (+/-5.7) (low-fat dairy), 
and 4.4 (+/-3.9) (high-fat dairy), Prevalent frailty was 2.3%. In age and sex adjusted models, 
yogurt was associated with 4% lower odds of frailty and high-fat dairy intake was associ-
ated with 3% higher odds of frailty (Table). These association became non-significant after 
adjustment for other variables. Further adjustment for disease indicators did not change the 
associations (data not shown).In this study of adults with wide age-range, dairy food intake 
was not associated with frailty. These analyses were limited by low number of frail indi-
viduals (n=67). The observed trend for a deleterious association with high-fat dairy intake 
should be re-examined in longitudinal studies with frailty assessed over time, particularly 
in older adults.
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Global Balance of the Spine, an Independent Contributor to Physical 
Function and Falls in Older Adults: the SAFE Cohort Study *Melany Hars1, 
Antonio Faundez2, Jacques Fechtenbaum3, Karine Briot3, Christian Roux3, 
Francois Herrmann4, Serge Ferrari1, Stephane Genevay5, Sana Boudabbous6, 
Andrea Trombetti7. 1Division of Bone Diseases, Department of Medicine, 
Geneva University Hospitals and Faculty of Medicine, Switzerland, 2Hôpital La 
Tour & Division of Orthopaedics and Trauma Surgery, Department of Surgery, 
Geneva University Hospitals and Faculty of Medicine, Switzerland, 3Department 
of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, 
France, 4Division of Geriatrics, Department of Readaptation and Geriatrics, 
Geneva University Hospitals and Faculty of Medicine, Switzerland, 5Division 
of Rheumatology, Department of Medicine, Geneva University Hospitals 
and Faculty of Medicine, Switzerland, 6Division of Radiology, Department 
Diagnostic, Geneva University Hospitals and Faculty of Medicine, Switzerland, 
7Division of Bone Diseases, Department of Medicine & Division of Geriatrics, 
Department of Readaptation and Geriatrics, Geneva University Hospitals and 
Faculty of Medicine, Switzerland
Purpose: Falls are common among older adults and remain the leading cause of frac-
tures. They may result from several intrinsic and extrinsic risk factors. Among them, the 
role of the global balance of the spine has never been fully established. We conducted a 
preliminary cross-sectional analysis to determine the association between global balance 
of the spine, physical function and falls in community-dwelling older adults.Material and 
Methods: The SAFE study is an ongoing prospective, longitudinal cohort study conducted in 
Geneva (Switzerland) among community-dwelling adults aged >=65 years without history 
of instrumented spinal surgery. All subjects underwent a comprehensive assessment battery 
including: full skeleton 2D/3D radiographs in the standing position by EOS® low-dose bi-
plane X-ray imaging system, DXA imaging, clinical examination, fall history in the past 
12 months, and physical function tests. Spino-pelvic parameters collected included, among 
others, the spino-sacral angle (SSA) and the C7-central sacral line (C7-CSL) distance for 
sagittal and coronal balance, respectively.Results: 50 subjects (mean age, 74 years; 76% 
female) were included. Among them, 18 (36%) reported one or more falls in the past 12 
months, 19 (38%) reported a history of low-trauma fracture, 15 (30%) were osteoporotic, 
while 12 (24%) had a Short Physical Performance Battery (SPPB) score <=9. Global sag-
ittal balance was independently associated with physical performances after controlling for 
potential confounders (adjusted regression coefficient for SPPB score and SSA= 0.09, 95% 
CI [0.03, 0.16]; p=0.007), as well as some sagittal pelvic and lumbar curve measures. In 
addition, imbalanced subjects or balanced subjects thanks to compensations had more falls 
as compared to balanced subjects with no compensation (IRR=1.46, 95% CI [0.13, 2.79; 
p=0.031]). After controlling for age, sex, comorbidities, vertebral fractures and SPPB score, 
increased C7-CSL distance was independently associated with increased fall risk (OR=2.28, 
95% CI [1.06, 4.92]; AUC=0.79, 95% CI [0.65, 0.92]).Conclusions: The findings of this 
study suggest that global balance of the spine is an independent contributor to physical im-
pairments and falls in older adults. Further analysis from this longitudinal cohort study will 
reveal the role of compensating mechanisms in the sagittal plane, and should help to clarify 
whether global balance of the spine relates to incident falls and fractures in older adults.
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Decreased Lower-extremity Muscle Performance is Associated with 
Decreased Hip Bone Mineral Density and Increased Fracture Risk in 
Community-dwelling Postmenopausal Women *Dexing Dai1, Feng Xu1, 
Ruoman Sun1, Yali Ling1, Zhongjian Xie1. 1National Clinical Research Center 
for Metabolic Diseases, Hunan Provincial Key Laboratory for Metabolic Bone 
Diseases, and Department of Metabolism and Endocrinology, The Second 
Xiangya Hospital of Central South University, China
Abstract: Postmenopausal women are at high risk for osteoporotic fractures. It has 
been shown that decreased lower-extremity muscle performance is associated with oste-
oporotic fractures. The purpose of this study was to investigate the relationship between 
lower-extremity muscle performance and bone mineral density (BMD) or fracture risk in 
community-dwelling postmenopausal women. A total of 247 postmenopausal women aged 
50-85 years old (age = 65.9; SD = 8.6 years) participated in this study. The short physical 
performance battery (SPPB) tool including the chair stand test (CST), gait speed test (GST) 
and balance test (BT) was used to determine lower-extremity functioning and the CST, GST, 
BT and SPPB total scores were recorded. The BMD of lumbar spine (LSBMD), femoral 
neck (FNBMD) and total hip (THBMD) were measured by dual-energy X-ray absorptiom-
etry (DXA) and the vertebral fracture was confirmed by lateral spine X-rays radiographs. 
In addition, patients’ 10-years major osteoporotic fracture risk and hip fracture risk were 
assessed by the Fracture Risk Assessment Tool (FRAX). Linear regression analysis was used 
to analyze the association between muscle performance and BMD. The results showed that 
the CST, GST and SPPB total scores were positively associated with LSBMD, THBMD, 
and FNBMD before adjustment for age, height, and weight. Besides, the SPPB total scores 
were positively associated with FNBMD and THBMD, but not with LSBMD after adjust-
ment for age, height, and weight. However, the BT score was positively associated with 
FNBMD and THBMD, but not with LSBMD before and after adjustment for age, height, 
and weight. Moreover, the CST, GST, BT and SPPB scores were negatively associated with 
the FRAX score. These data suggest that decreased lower-extremity muscle performance 
is associated with decreased hip BMD and increased fracture risk in community-dwelling 
postmenopausal women with BMD.Nothing to Disclosures: DD, FX, RS, YL, ZX. Sources 
of Research Support: The National Natural Science Foundation of China (No. 81072219, 
81272973, 81471055, and 81672646)
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Prevalence of Frailty and Associated Factors in a National Observational 
Cohort of Rheumatic Diseases. *Katherine D. Wysham1, Joshua F. Baker2, 
Kristin Wipfler3, Patricia P. Katz4, Kaleb Michaud5. 1VA Puget Sound Health Care 
System/University of Washington, United States, 2University of Pennsylvania, 
United States, 3The National Databank for Rheumatic Diseases, United States, 
4University of California, San Francisco, United States, 5University of Nebraska/
National Databank for Rheumatic Diseases, United States
Purpose: Frailty is associated with poor outcomes in the general population and recent-
ly studies have highlighted its importance in rheumatic musculoskeletal diseases (RMDs). 
Self-reported measures of frailty are validated in the general population but have not been 
studied in RMDs. We aimed to describe the prevalence of self-reported frailty across RMDs 
and associated factors in a large observational cohort. Methods: Data were from participants 
in FORWARD, The National Databank for Rheumatic Diseases, the largest patient reported 
RMD research databank in the US, with biannual questionnaires from 1998. The January 
2020 questionnaire included a 5-item validated patient-reported frailty scale querying fa-
tigue, ability to walk several blocks, climb ten stairs, weight loss and 11 comorbidities. 
Those meeting >=3 of the 5 criteria were listed as frail. 1422 responses were collected as of 
May 21st, 2020 which represents 28% of the total cohort. Multivariable logistic regression 
analysis was performed to identify factors independently associated with frailty.Results: Top 
RMDs were rheumatoid arthritis (RA) (N=901, 63%) and osteoarthritis (OA) (N=213, 15%). 
Those categorized as frail (N=420, 30%) were older, had longer disease duration, a higher 
pain scale, a higher percentage of obese participants and more historical fractures than those 
who were not frail (Table 1). Systemic lupus erythematosus (SLE) had the highest propor-
tion of frailty (40%) despite being the youngest group (61+/-12 years). The top three factors 
contributing to frailty scores were inability to walk several blocks, inability to climb 10 
stairs and >=5/11 comorbidities (Table 1). In the multivariable model age, disease duration, 
pain scale and prior fracture were associated with elevated odds ratios of frailty (ORs 1.04, 
1.01, 1.23 and 2.02 respectively, all p<0.05). Within RMDs, using OA as the referent, SLE 
was associated with 2.74-fold increased odds of frailty (p=0.002). Using normal weight 
as the referent, overweight and obesity were also associated with increased high odds of 
frailty (ORs 1.98 and 4.92, p<0.001).Conclusion: Self-reported frailty was prevalent in a 
third of participants with RMDs with the highest rate in those with SLE. SLE, prior fracture 
and obesity had the greatest odds of frailty in the multivariable model. Future longitudinal 
analyses to determine factors associated with incident frailty and fractures are needed in this 
high-risk population.
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Neither Baseline Nor Change in Leg Muscle Strength and Balance Are 
Associated with the Incidence of Falls in Middle-aged Women: A 5-year 
Population-based Prospective Study *Mengmeng Wang1, Feitong Wu1, 
Michele Callisaya2, Graeme Jones1, Tania Winzenberg1. 1Menzies Institute for 
Medical Research, University of Tasmania, Australia, 2Menzies Institute for 
Medical Research, University of Tasmania; Peninsula Clinical School, Central 
Clinical School, Monash University, Australia
Objective: Muscle strength and balance are major modifiable factors of falls in older 
adults, but their associations with falls in middle-aged adults are under investigated. We 
aimed to examine the association of baseline and change in leg muscle strength (LMS) and 
balance with the incidence of falls in a cohort of middle-aged women.Material and Methods: 
This was a five-year follow-up of a population-based sample of 273 women aged 36-57 
years at baseline (2011-2012). Data on LMS (by dynamometer) and balance (timed up and 
go test [TUG], step test [ST], functional reach test [FRT], and lateral reach test [LRT]) were 
obtained at baseline and five years later (2017-2018). After five years, falls were recorded 
monthly for one year by questionnaire (2017-2019). Negative binomial/Poisson and log bi-
nomial regressions were used as appropriate to assess associations of baseline and change 
in LMS and balance with any falls, injurious falls and multiple falls.Results: Over one-
year, 115 participants (42%) reported at least one fall. Neither baseline nor 5-year change 
in LMS and balance measures were associated with the risk of any falls, injurious falls, or 
multiple falls five years later, with or without adjusting for potential confounders at baseline 
(incidence rate ratio/relative risk ranging from 0.91 to 1.14, 0.94 to 1.16, and 0.88 to 1.23, 
respectively; P>0.05 for all).Conclusion: Baseline or change in LMS and balance measures 
are not associated with incident falls among middle-aged women. These findings suggest 
that risk factor profiles for falls in middle-aged women may be different from those in older 
adults. Upon further confirmation of these findings different preventive strategies for falls 
may be needed in this population.
Disclosures: Mengmeng Wang, None
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Grip Strength Reference Values to Identify Sarcopenia in Youth *Fátima 
Baptista1, Kathleen F Janz2, Pedro St Maurice3, Elena Letuchy4, Luis Gracia-
Marco5, Enrique G Artero6, Francisco Ortega7, Jonatan R Ruiz8, Luis A 
Moreno5, German Vicente-Rodriguez5, Steven M Levy 9. 1CIPER, Faculdade 
de Motricidade Humana, Universidade de Lisboa, Portugal, 2Department of 
Health and Human Physiology, University of Iowa, United States, 3Metabolic 
Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National 
Cancer Institute, NIH, United States, 4Department of Epidemiology, University 
of Iowa, United States, 5University of Zaragoza, Spain, 6SPORT Research Group 
(CTS-1024), University of Almería, Spain, 7School of Sport Sciences, University 
of Granada, Spain, 8University of Granada, Spain, 9Department of Epidemiology; 
Department of Preventive and Community Dentistry, College of Dentistry, The 
University of Iowa, United States
Purpose Sarcopenia is a condition characterized by loss of skeletal muscle mass and 
strength. In adults it is diagnosed via the assessment of grip strength (identification) and the 
assessment of muscle mass index (confirmation). In adults, the cut-off values for the lower 
limits of grip strength and muscle mass index are 2.5 standard deviations (SD) and 2.0 SD 
below the peak of the average of healthy adults, respectively. Sarcopenia is not, however, 
exclusive to adults; it also manifests itself in children and adolescents due to various clinical 
conditions and lifestyle. The recognition of sarcopenia in youth is comprised by the lack of 
reference values. This study aimed to determine and validate handgrip strength reference 
values of for the identification of sarcopenia in adolescents.Methods The sample consisted 
of 880 participants divided into 2 sub-samples: a sub-sample for the development of grip 
strength cut-off values that included 525 healthy youth from Iowa (USA) (14.1 +/-2.3yrs) 
and a validation sub-sample comprising 355 healthy adolescents from Zaragoza, Spain (14.9 
+/-1.2yrs). Handgrip strength was measured with a dynamometer and whole-body lean mass 
index (LBMI, kg/m2) without bone was determined using dual-energy x-ray absorptiometry. 
Grip strength performance was used to discriminate decreased LBMI of 2 SD and also of 1 
SD (for primary prevention purposes). By gender, statistical analysis included the area under 
the curve (AUC), sensitivity (Se), specificity (Sp), and predictive odds ratios.Results The 
AUC varied from 0.72 to 0.81 for grip strength cut points with values for Se and Sp between 
53.7 to 82.9% in the development sample. Results were similar in the validation sample. 
Those not meeting the grip strength cut points were 3 to 13 times more likely to have de-
creased LBMI, depending on gender, and the cut point being considered (LBMI < -2 SD vs. 
< -1 SD). Grip strengths of -1.1 SD for males and - 1.2 SD for females were associated with 
a -2 SD LBMI decrease.Conclusions Grip strength is a valid marker for the identification of 
sarcopenia in adolescents. We propose the adoption of grip strength of -1.1 SD in males and 
-1.2 SD in females for the identification of sarcopenia in 10 -18 yrs old.
Disclosures: Fátima Baptista, None
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Recent Fall and High Imminent Risk of Fracture *Kyoungmin Kim1, Li-Yung 
Lui1, Marcia L Stefanick2, Steven R Cummings1. 1San Francisco Coordinating 
Center, California Pacific Medical Center Research Institute, United States, 
2Stanford Prevention Research Center, School of Medicine, Stanford University, 
United States
Purpose: We tested the hypothesis that a recent fall predicts a high risk of fracture in 
the next year.Methods: We used data from the prospective SOF and MrOS studies. SOF en-
rolled 9704 women and MrOS, 5994 men age >= 65 years and participants were asked every 
4 months about falls or fractures (FXs) in the preceding 4 months. FXs were validated by 
x-rays reports and follow-up for FXs and falls was > 90% complete over 14.8 years for SOF 
and 12.6 years for MrOS. 34% in women and men had history of falls within the previous 
1 year and about half of those subjects in both sexes had fallen in the preceding 4 months. 
Non-spine FXs occurred in 4257 (43.9%) women and 1280 (21.4%) men and hip FX in 1444 
(14.8%) women and 340 (5.7%) men, respectively. Total hip bone mineral density (BMD) 
was measured at baseline and every follow-up visit. Multivariate logistic models included 
history of falls and FXs during preceding 4 or 12 months, age, sex, and total hip BMD to 
predict over 1, 2 and 3 years.Results: In women and men, falls within 4 months indicated 
a high risk of non-spine and of hip fractures in the next year that was greater than the risk 
conferred by fall in the past year (Figure). In women, a recent fall carries an 8.1% risk of a 
non-spine FX within 1 year, a 2.5-fold greater risk than women without falls, and 2.5% risk 
of hip FX, a 3-fold increased risk. Those risks of FX diminished in 2nd and 3rd years after 
the fall (5.0% in 2nd year and 4.4% in 3rd year for non-spine FX and 1.6% in 2nd year and 
1.4% in 3rd year for hip FX). In the multivariate models, in both women and men, recent 
history of fall, in the preceding 4 or 12 months, indicated a greater increase in 1-year risk of 
FX than did a history of FX during the same intervals: A fall within 4 months indicated a 2.3-
fold (95% C.I. = 2.2-2.4) increased risk of non-spine FX while a FX indicated only 1.2-fold 
(1.1-1.3) increased risk. A fall within 4 months indicated a 2.7-fold [2.5-2.9] increased risk 
of hip FX while a FX in that period was not significantly associated with an increased risk of 
hip FX (odds ratio =1.0 [0.8-1.2]).Conclusions: A fall, especially within 4 months, indicates 
a high risk of fracture in the next 12 months. In multivariate models, a recent fall predicts 
non-spine and hip FXs more strongly than does a recent FX. Older women and men with 
recent falls warrant measures to prevent falls and should be considered for drug treatment to 
reduce their imminent risk of fracture.
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Evaluating the Muscle-Bone Unit in Severe Obesity with and without Type 
2 Diabetes *Alessandra Amato1, Jenna C. Gibbs2, Claudia Gagnon3, Anne-
Frédérique Turcotte3, Guy Hajj Boutros4, Fabrice Mac-Way3, Mylène Aubertin-
Leheudre5, Vanessa Tardio6, Suzanne N. Morin7. 1Department of Kinesiology and 
Physical Education, McGill University, Canada, 2Department of Kinesiology 
and Physical Education, McGill University; Research Institute of the McGill 
University Health Centre, Canada, 3Endocrinology and Nephrology Research 
Axis, CHU de Quebec Research Centre; Department of Medicine, Université 
Laval, Canada, 4Research Institute of the McGill University Health Centre, 
Montréal, Canada, 5Department of Exercise Science, Université du Québec 
à Montréal, Canada, 6Division of Endocrinology and Metabolism, McGill 
University Health Centre, Canada, 7Research Institute of the McGill University 
Health Centre; Department of Medicine – Division of General Internal Medicine, 
McGill University Health Centre, Canada
Background: Individuals with severe obesity and type 2 diabetes (T2D) are at a higher 
risk of fracture despite having higher areal bone mineral density (aBMD). Obesity is an 
important risk factor for T2D and has negative effects on bone health due to inflammation, 
higher visceral adipose tissue, functional limitations, and muscle fat infiltration. Muscle-re-
lated force production protects against T2D but also increases bone strength by stimulating 
bone turnover rates. However, data comparing the muscle-bone unit in severe obesity with 
and without T2D are lacking.Purpose: To describe and compare the associations between 
measures of muscle quality, bone quality, and physical performance in obese adults with and 
without T2D.Methods: We aim to recruit obese men and women (age >= 18 y, BMI >35 kg/
m2) with (n=20) and without T2D (n=20) for one-time measures in two university research 
centres. Quantitative computed tomography (QCT) will be used to determine bone quality 
parameters at the lumbar spine (total and trabecular volumetric BMD (vBMD)), proximal 
femur, tibia and radius (total, trabecular and cortical vBMD; cortical thickness) using the 
Mindways QCTPro software. Cross-sectional analysis of the lean and fat soft tissue from 
these sections will be performed using the Tissue Composition Module of the QCTPro soft-
ware. Peripheral QCT (pQCT) will also be performed for a subset of participants to compare 
the bone and muscle data with those of QCT. Handgrip and knee extensor muscle strength 
will be measured using validated Jamar and Biodex Pro3 dynamometer protocols. Perfor-
mance-based tests of mobility, balance, and submaximal aerobic capacity, and biochemical 
analyses of hormones involved in bone metabolism will also be performed (Table 1). Inde-
pendent t-tests will be used to compare outcomes between groups (T2D versus non-T2D 
participants). Pearson/Spearman correlation and multivariable linear regression analyses 
adjusting for potential confounders including, age, sex, and T2D status will be conducted.
Expected Results: Greater muscle quality (cross-sectional area, handgrip, and knee extensor 
strength) will be associated with better bone quality and physical performance. Conclusions: 
Our research will provide new knowledge on the muscle-bone unit in severe obesity and 
T2D and inform future multimodal intervention studies to enhance muscle and bone health 
and prevent falls and fractures in these high-risk populations.
Disclosures: Alessandra Amato, None
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